nct_id,title,official_title,primary_drug,all_drug_names,drug_count,study_type,phases,primary_phase,primary_purpose,primary_condition,all_conditions,keywords,overall_status,why_stopped,start_date,completion_date,primary_outcomes,secondary_outcomes,outcome_count,min_age,max_age,sex,healthy_volunteers,lead_sponsor,sponsor_class,collaborator_count,enrollment_count,enrollment_type,collected_date,api_version,is_interventional,has_drug_interventions,is_completed,is_failed,has_safety_outcomes,failure_reason
NCT00249002,Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis,"A Pilot Phase II Trial Of ABI-007 (A Cremophor El-Free, Protein Stabilized, Nanoparticle Paclitaxel) For The Prevention Of Vascular Access Graft Failure In Patients Undergoing Hemodialysis",ABI-007,"['ABI-007', 'Abraxane®', 'paclitaxel']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Hemodialysis Graft Dysfunction,['Hemodialysis Graft Dysfunction'],"['Vascular Access Graft Failure', 'Venous Neointimal Hyperplasia(VNH)', 'Hemodialysis']",TERMINATED,Terminated due to pipeline prioritization,2005-11-01,2007-11-01,"[{'measure': 'Percentage of Participants With Discontinued, Delayed or Interrupted Therapy', 'description': 'Percentage of participants who had discontinued therapy or had a delayed dose or an interrupted (omitted) dose due to toxicities/adverse events.', 'timeFrame': 'up to week 21'}, {'measure': 'Percentage of Participants Without Graft Failure or Need for Intervention', 'description': 'Graft failure is defined as graft thrombosis, loss of vascular access function, or \\>50% stenosis of the index lesion at the time of a regularly scheduled angiographic assessment.', 'timeFrame': '24 weeks'}, {'measure': 'Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 12', 'description': 'Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.', 'timeFrame': '12 weeks'}, {'measure': 'Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 24', 'description': 'Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.', 'timeFrame': '24 weeks'}, {'measure': 'Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 9', 'description': 'Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.', 'timeFrame': '9 months'}, {'measure': 'Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 12', 'description': 'Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.', 'timeFrame': '12 months'}, {'measure': 'Stenosis (%) of a Non-index Lesion Using Angiography at Week 12', 'description': 'Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.', 'timeFrame': '12 weeks'}, {'measure': 'Stenosis (%) of a Non-index Lesion Using Angiography at Week 24', 'description': 'Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.', 'timeFrame': '24 weeks'}, {'measure': 'Stenosis (%) of a Non-index Lesion Using Angiography at Month 9', 'description': 'Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.', 'timeFrame': '9 months'}, {'measure': 'Stenosis (%) of a Non-index Lesion Using Angiography at Month 12', 'description': 'Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.', 'timeFrame': '12 months'}]","[{'measure': 'Participants With Arthrosclerotic Cardiovascular Complications', 'description': 'Counts of participants who had treatment-emergent arthrosclerotic cardiovascular complications, specifically myocardial infarction, arterial thromboses, or cerebrovascular events.', 'timeFrame': 'up to week 25'}, {'measure': 'Kaplan Meier Estimates for Time to Graft Failure or Intervention', 'description': 'The time to graft failure or intervention was defined as the time from first dose of study drug to the first time graft failure or intervention. Participants who did not have graft failure or intervention at the end of the study were censored at the last known time that the participant had angiography.', 'timeFrame': 'up to 12 months'}, {'measure': 'Percentage of Participants With Patency of Index and Non-Index Lesions at 24 Weeks', 'description': 'The patency (unblocking) for index lesions is defined as \\<50% of stenosis and no PFTE graft thrombosis at 24 weeks. The patency for non-index lesions is defined as \\<50% of stenosis and no new non-index lesions at 24 weeks.', 'timeFrame': '24 weeks'}]",13,18 Years,,ALL,False,Celgene,INDUSTRY,0,9.0,ACTUAL,2025-09-01T16:18:15.902973,v2_robust,True,True,False,True,True,Terminated due to pipeline prioritization
NCT00000102,Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets,,Nifedipine,['Nifedipine'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Congenital Adrenal Hyperplasia,['Congenital Adrenal Hyperplasia'],[],COMPLETED,,,,[],[],0,14 Years,35 Years,ALL,False,National Center for Research Resources (NCRR),NIH,0,,,2025-09-01T16:18:15.903009,v2_robust,True,True,True,False,False,
NCT02425202,Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome (OSAS) After Tonsillectomy,Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome After Tonsillectomy: A Randomized Controlled Trial,Ketamine,"['Ketamine', 'Ketalar']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Obstructive Sleep Apnea Syndrome,['Obstructive Sleep Apnea Syndrome'],"['pediatric', 'obstructive sleep apnea', 'tonsillectomy', 'analgesia']",COMPLETED,,2014-12,2018-05-03,"[{'measure': 'Measurement of post-operative opioid requirements after tonsillectomy in obstructive sleep apnea (OSA) patients', 'description': 'Influence of low-dose continuous ketamine infusion on post-operative opioid requirements after tonsillectomy in OSA patients.', 'timeFrame': '24 hrs'}]","[{'measure': 'Documentation of respiratory morbidity after tonsillectomy in OSA patients', 'description': 'Influence of low-dose ketamine infusion on respiratory morbidity after tonsillectomy in OSA patients', 'timeFrame': '24 hrs'}]",2,1 Year,17 Years,ALL,True,University of Manitoba,OTHER,0,36.0,ACTUAL,2025-09-01T16:18:15.903063,v2_robust,True,True,True,False,False,
NCT05749302,Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins,Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins,Al18F-NOTA-FAPI,"['18F-FAPI', 'Al18F-NOTA-FAPI']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Malignancy,['Malignancy'],['malignant tumors expressing fibroblast-activated proteins'],RECRUITING,,2023-01-08,2026-01-08,"[{'measure': 'Diagnostic value', 'description': 'Sensitivity and Specificity of Al18F-NOTA-FAPI PET/CT for Malignant Tumors Expressing Fibroblast-activated Proteins', 'timeFrame': 'through study completion, an average of 1 year'}]",[],1,18 Years,,ALL,False,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",OTHER,0,500.0,ESTIMATED,2025-09-01T16:18:15.903126,v2_robust,True,True,False,False,False,
NCT01266902,A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1,An Open-label Trial With TMC278 25 mg q.d. in Combination With a Background Regimen Containing 2 N(t)RTI's in HIV-1 Infected Subjects Who Participated in TMC278 Clinical Trials and Were Still Benefitting From Treatment With TMC278,Rilpivirine,['Rilpivirine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,HIV-1 Infection,['HIV-1 Infection'],"['HIV-1 Infection', 'HIV-1', 'HIV', 'TMC278-TiDP6-C222', 'TMC278-C222', 'TMC278', 'Rilpivirine']",COMPLETED,,2011-02,2020-02,"[{'measure': 'Number of Participants With Adverse Events (AEs)', 'description': 'An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.', 'timeFrame': 'Up to 7 years'}, {'measure': 'Number of Participants With Grade 3/4 Events of Rash Irrespective of Causality', 'description': 'Number of participants with grade 3/4 events of rash irrespective of causality were assessed. A grade 3 rash defined as diffuse macular, maculopapular or morbilliform rash with vesicles or limited number of bullae or; rash with superficial ulcerations of mucous membranes limited to 1 anatomical site or; rash with at least one of the following: elevations in aspartate aminotransferase (AST)/alanine aminotransferase (ALT) more than 2\\*baseline value and at least 5 times upper limit of normal; fever greater than (\\>) 38 degree celsius or 100 degree fahrenheit; eosinophils \\> 1000/millimeter (mm)\\^3; serum sickness-like reaction. A grade 4 rash defined as the following: extensive or generalized bullous lesions or; Stevens-Johnsons Syndrome (SJS) or ulceration of mucous membrane involving 2 or more distinct mucosal sites or toxic epidermal necrolysis.', 'timeFrame': 'Up to 7 years'}]","[{'measure': 'Time to Virologic Rebound', 'description': 'Time to virologic rebound was time to (first) human immunodeficiency virus type1 (HIV-1) ribonucleic acid (RNA) greater than or equal to (\\>=) 50 or \\>=200 copies/milliliter (copies/mL). The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.', 'timeFrame': 'Up to Week 360'}, {'measure': 'Time To Treatment Failure', 'description': 'Time to treatment failure was defined as time to virologic rebound (time to first HIV-1 RNA \\>= 50 or \\>= 200 copies/mL) or discontinuation for reason other than RPV having become commercially available in the participating country, whichever came first, calculated as the time (in days) from baseline until treatment failure. The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.', 'timeFrame': 'Up to Week 360'}, {'measure': 'Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count for Observed Case Approach Until Week 336', 'description': 'The immunologic assessment was determined by change from baseline in CD4+ cell count for observed case approach.', 'timeFrame': 'Baseline up to weeks 96, 192, 288, 336'}, {'measure': 'Change From Baseline in CD4+ Cell Count for Non-Completer Equals Failure (NC=F) Approach Until Week 336', 'description': 'Change from baseline in CD4+ cell count were reported for NC=F approach (participants who discontinued because RPV became commercially available or could be accessed through another source or because the participants switched to other local \\[RPV-based\\] treatment options or local standard of care, were censored at that time; other participants after discontinuation had their CD4+ values imputed with baseline value. Intermittently missing values were imputed with a last observation carried-forward approach).', 'timeFrame': 'Baseline up to weeks 96, 192, 288, 336'}, {'measure': 'Number of Participants With Serious Adverse Events (SAEs)', 'description': 'A SAE is any untoward medical occurrence that at any dose: results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect.', 'timeFrame': 'Up to 7 years'}, {'measure': 'Number of Participants With AEs Related to Rilpivirine (RPV)', 'description': 'Number of participants with AEs related to RPV were assessed. An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.', 'timeFrame': 'Up to 7 years'}]",8,18 Years,,ALL,False,Janssen R&D Ireland,INDUSTRY,0,482.0,ACTUAL,2025-09-01T16:18:15.903142,v2_robust,True,True,True,False,True,
NCT01313702,Single Pill to Avert Cardiovascular Events,Effect of Polipill on Patients at High Cardiovascular Risk : a Randomized Controlled Trial,polipillV1,"['polipillV2', 'polipillV1', 'lisinopril', 'simvastatin', 'acetylsalicilic acid', 'atenolol', 'hidrochlorotiazide', 'no other name', 'usual care']",9,INTERVENTIONAL,['PHASE3'],PHASE3,,Cardiovascular Disease,['Cardiovascular Disease'],"['polypill, compliance, cardiovascular disease']",WITHDRAWN,,2012-10,2014-07,"[{'measure': 'compliance with treatment', 'timeFrame': '18 months'}, {'measure': 'changed in blood pressure', 'timeFrame': '18 months'}, {'measure': 'changes in LDL-cholesterol levels', 'timeFrame': '18 months'}]","[{'measure': 'the main reason for non compliance with treatment', 'timeFrame': '18 months'}, {'measure': 'safety of poli pill measures by laboratorial tests', 'description': 'hemogram and blood platelets count, liver function tests (ALT, AST), renal function tests (creatinine).', 'timeFrame': '18 months'}, {'measure': 'combined outcome', 'description': 'compound of cardiovascular and total mortality, major cardiovascular events and cholesterol levels.', 'timeFrame': '18 months'}]",6,18 Years,,ALL,True,Hospital do Coracao,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:15.903172,v2_robust,True,True,False,True,True,
NCT06730802,Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII),Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII),PCSK9 inhibitor,"['Statin', 'PCSK9 inhibitor']",2,INTERVENTIONAL,['NA'],,,Myocardial Ischaemic Syndrome,"['Myocardial Ischaemic Syndrome', 'Coronary Heart Disease']","['inflammation', 'CABG']",NOT_YET_RECRUITING,,2025-01-01,2026-12-31,"[{'measure': 'Major Adverse Cardiovascular and Cerebrovascular Events', 'description': 'Major Adverse Cardiovascular and Cerebrovascular Events include cardiac death, reinfarction, emergency coronary revascularization and stroke', 'timeFrame': '6 months after surgery'}]","[{'measure': 'C-reactive protein', 'description': 'Peripheral blood C-reactive protein', 'timeFrame': '6 months after surgery'}]",2,18 Years,,ALL,False,Nanjing Medical University,OTHER,2,400.0,ESTIMATED,2025-09-01T16:18:15.903184,v2_robust,True,True,False,False,True,
NCT01304953,Tropisetron on Postoperative Pain,Tropisetron on Postoperative Pain in Women After Gynaecological Laparoscopy,Group P+P,"['Group P+P', 'Group S+T', 'Group S+P', 'Group P+T']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pain, Postoperative","['Pain, Postoperative']","['General anaesthetics', 'gynaecological laparoscopy', 'anaesthetic i.v.', 'propofol', 'anaesthetic volatile', 'evoflurane', 'antiemetics', 'reopisetron', 'postoperative pain']",COMPLETED,,2010-01,2010-12,"[{'measure': 'Postoperative pain at rest', 'description': 'The primary outcome was the postoperative pain at rest assessed by numeric analog score (NAS, where 0 indicates no pain, and 10 indicates the most severe pain) immediately after awaking.', 'timeFrame': 'At 0.5 postoperative hour'}]","[{'measure': 'Postoperative pain at rest', 'description': 'The patients were instructed to give the number that represented the pain level at rest soon after awakening, the first 30 min postoperatively, and every 2 hours within the first 24 postoperative hours.', 'timeFrame': 'At 2,4,6,8,10,12,14,16,18,20,22,24 postoperative hours'}, {'measure': 'Intraoperative hemodynamic values', 'description': 'Heart rate and mean arterial pressure (MAP) every 5 min within 30 min after induction and 30 min before last suture', 'timeFrame': 'At 5, 10,15,20,25,30 min after induction and 30, 25, 20, 15,10,5 min before last suture'}, {'measure': 'Postoperative shivering', 'description': 'The incidence of shiver within 24 h was recorded.', 'timeFrame': 'At 24 hour postoperativelly'}, {'measure': 'The incidence of postoperative nausea and vomiting (PONV)', 'description': 'The incidence of postoperative nausea and vomiting (PONV) was recorded at 24 h after surgery.', 'timeFrame': 'At 24 hour postoperativelly'}, {'measure': 'Quality of Recovery Score 40', 'description': 'Quality of Recovery Score 40 was determined at 24 hours postoperativelly', 'timeFrame': 'At 24 postoperative hour'}]",6,18 Years,50 Years,FEMALE,False,Huazhong University of Science and Technology,OTHER,0,296.0,ACTUAL,2025-09-01T16:18:15.903235,v2_robust,True,True,True,False,False,
NCT00163553,Neuraxial Pethidine After Lumbar Surgery Trial,Neuraxial Pethidine After Lumbar Surgery Trial,Pethidine,"['Placebo', 'Pethidine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Sciatica,['Sciatica'],"['spinal surgery', 'pethidine', 'analgesia']",UNKNOWN,,2004-12,,"[{'measure': 'Cumulative 24-hour pethidine consumption', 'timeFrame': '24 hours'}]","[{'measure': 'Patient data:'}, {'measure': 'Age'}, {'measure': 'Gender'}, {'measure': 'Body mass index'}, {'measure': 'Current medications'}, {'measure': 'Preoperative opioid analgesic use (none, low, high - high dose being > 300 mg codeine or dextropropoxyphene daily or oral morphine or parenteral opioid use)'}, {'measure': 'Compensable status (HNC, TAC, WCV or PMI/SUR) 22'}, {'measure': 'Surgical data:'}, {'measure': 'Anatomical extent of surgery (number of spinal levels)'}, {'measure': 'Highest anatomical surgical level'}, {'measure': 'Experience level of primary surgeon (trainee or consultant)'}, {'measure': 'Anatomical level of epidural tip (identified from postoperative X-Ray when taken as routine care only)'}, {'measure': 'Dural tear at the time of surgery (yes/no)'}, {'measure': 'Spinal instrumentation (yes/no)'}, {'measure': 'Other end-points (all at 1, 4, 24 and 48 hours unless stated):'}, {'measure': 'Cumulative pethidine dose'}, {'measure': 'Cumulative morphine dose'}, {'measure': 'VAS scores for pain at rest and during movement'}, {'measure': 'Sedation score (1 - 4) 16'}, {'measure': 'VAS scores for nausea, pruritis'}, {'measure': 'Other adverse events: agitation, tremor, hallucinations, seizure'}, {'measure': 'Patient satisfaction scale for pain control during study (48 hours)', 'timeFrame': '48 hours'}, {'measure': '(very dissatisfied, dissatisfied, neutral, satisfied, very satisfied) 17'}, {'measure': 'Plasma pethidine and norpethidine levels (24 hours)', 'timeFrame': '24 hours'}, {'measure': 'Physiotherapy assessment of ability to deep breathe & cough (unable, poor, adequate, good)'}, {'measure': 'Length of inpatient stay'}]",27,18 Years,,ALL,False,Austin Health,OTHER_GOV,0,60.0,ESTIMATED,2025-09-01T16:18:15.903285,v2_robust,True,True,False,False,True,
NCT02108353,Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers,"Multicenter, Randomized, Double-blind, Placebo Controlled Trial of 2 mg Melatonin for Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers",Melatonin 2mg,"['Circadin®', 'Melatonin 2mg', 'None active substances', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,"Sleep Disorders, Circadian Rhythm","['Sleep Disorders, Circadian Rhythm']","['Type 2 Diabetes', 'metabolic control', 'Metabolomics', 'Circadian Rhythm', 'Melatonin', 'Biomarker', 'Clock Gene', 'PBMC', 'Cardiovascular function', 'Epigenetic modification', 'Lifestyle Intervention']",COMPLETED,,2015-01,2017-03-29,"[{'measure': 'Efficacy (AUC)', 'description': 'The change in the area under the curve (AUC) of blood glucose during an oral glucose tolerance test between baseline and 12 weeks of intervention.', 'timeFrame': 'baseline and 12 weeks'}]","[{'measure': 'Efficacy BMI', 'description': 'The change in body weight, BMI, abdominal circumference, biomarkers and vascular function between baseline and 12 weeks of intervention and between week 12 and 24.', 'timeFrame': 'baseline, 12 weeks and 24 weeks'}, {'measure': 'Efficacy expression pattern of clock genes', 'description': 'The change in the gene expression patterns of Clock genes in peripheral blood monocytic cells (PBMC) between baseline and 12 weeks of intervention and between week 12 and 24.', 'timeFrame': 'baseline, 12 weeks and 24 weeks'}, {'measure': 'Efficacy glucose homeostasis (HOMA-index)', 'description': 'The change in the HOMA-index (Homeostasis Model Assessment) between baseline and 12 weeks of intervention and between week 12 and 24.', 'timeFrame': 'baseline, 12 weeks and 24 weeks'}, {'measure': 'Efficacy glucose homeostasis (QUICKI-index)', 'description': 'The change in the QUICKI-index (quantitative insulin sensitivity check index) between baseline and 12 weeks of intervention and between week 12 and 24.', 'timeFrame': 'baseline, 12 weeks and 24 weeks'}, {'measure': 'Efficacy glucose homeostasis (Stumvoll ISI-index)', 'description': 'The change in HbA1c between baseline and 12 weeks of intervention and between week 12 and 24.', 'timeFrame': 'baseline, 12 weeks and 24 weeks'}, {'measure': 'Efficacy glucose homeostasis (HbA1c)', 'description': 'The change in the Stumvoll ISI (Stumvoll insulin sensitivity index) between baseline and 12 weeks of intervention and between week 12 and 24.', 'timeFrame': 'baseline, 12 weeks and 24 weeks'}, {'measure': 'Efficacy epigenetic profiles', 'description': 'The differences in epigenetic profiles of genes involved in circadian rhythm between the study groups after 12 weeks of intervention and between week 12 and 24.', 'timeFrame': '12 weeks and 24 weeks'}, {'measure': 'Efficacy biomarkers', 'description': 'The differences in plasma and serum biomarkers between baseline and 12 weeks of intervention and between week 12 and 24.', 'timeFrame': 'baseline, 12 weeks and 24 weeks'}, {'measure': 'Efficacy AUC Insulin 24 weeks', 'description': 'The change in the area under the curve (AUC) of blood insulin during an oral glucose tolerance test between week 12 and week 24 (= after 12 weeks without intervention).', 'timeFrame': '12 weeks and 24 weeks'}, {'measure': 'Efficacy AUC glucose 24 weeks', 'description': 'The change in the area under the curve (AUC) of blood glucose during an oral glucose tolerance test between week 12 and week 24 (= after 12 weeks without intervention).', 'timeFrame': '12 weeks and 24 weeks'}, {'measure': 'Efficacy AUC insulin 12 weeks', 'description': 'The change in the area under the curve (AUC) of blood insulin during an oral glucose tolerance test between baseline and 12 weeks of intervention.', 'timeFrame': 'baseline and 12 weeks'}]",12,18 Years,,ALL,True,Universitätsklinikum Hamburg-Eppendorf,OTHER,0,46.0,ACTUAL,2025-09-01T16:18:15.903311,v2_robust,True,True,True,False,False,
NCT00920153,Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma,"Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma",ABVD regimen,"['ABVD regimen', 'dacarbazine', 'doxorubicin hydrochloride', 'ifosfamide', 'gemcitabine hydrochloride', 'methylprednisolone', 'vincristine sulfate', 'melphalan', 'mitoguazone', 'cytarabine', 'carmustine', 'dexamethasone', 'cisplatin', 'etoposide', 'vindesine', 'vinorelbine tartrate']",16,INTERVENTIONAL,['PHASE3'],PHASE3,,Lymphoma,['Lymphoma'],"['stage I adult Hodgkin lymphoma', 'stage II adult Hodgkin lymphoma', 'stage III adult Hodgkin lymphoma', 'stage IV adult Hodgkin lymphoma']",TERMINATED,Other new drugs,2008-05,2016-03,"[{'measure': 'Event-free survival', 'description': 'event free survival', 'timeFrame': 'treatments evaluation'}]",[],1,18 Years,65 Years,ALL,False,French Innovative Leukemia Organisation,OTHER,0,442.0,ACTUAL,2025-09-01T16:18:15.903401,v2_robust,True,True,False,True,False,Other new drugs
NCT06517953,Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations,"A Phase II Study to Assess Befotertinib and Icotinib as First-Line Treatment in Patients With Locally Advanced or Metastatic NSCLC and Uncommon EGFR Mutation(IcomBine, GASTO-10114)",Icotinib,"['Conmana', 'Befotertinib', 'D-0316', 'Icotinib']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-small Cell Lung Cancer Metastatic,"['Non-small Cell Lung Cancer Metastatic', 'EGFR G719X', 'EGFR L861Q', 'EGFR S768I']",[],RECRUITING,,2024-07-17,2027-12-24,"[{'measure': 'Objective Response Rate （ORR）', 'description': 'ORR, per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR).', 'timeFrame': '24 months'}]","[{'measure': 'Progression-free survival（PFS）', 'description': 'PFS, defined as time from study drug administration to progression or death due to any cause.', 'timeFrame': '12 months'}, {'measure': 'Disease control rate（DCR）', 'description': 'DCR, defined as proportion of complete response, partial response, and disease stabilization to the proportion of patients with evalueable tumors.', 'timeFrame': '12 months'}, {'measure': 'Overall survival （OS）', 'description': 'OS, defined as the time from study drug administration until the date of death due to any cause.', 'timeFrame': '24 months'}]",4,18 Years,,ALL,False,Sun Yat-sen University,OTHER,0,23.0,ESTIMATED,2025-09-01T16:18:15.903420,v2_robust,True,True,False,False,False,
NCT00279253,Effects of Intravenous Clonidine on Ocular Blood Flow and Intraocular Pressure,,clonidine (drug) intravenously,['clonidine (drug) intravenously'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Physiology,['Physiology'],"['clonidine', 'glaucoma']",COMPLETED,,2004-03,2005-01,[{'measure': 'ocular blood flow'}],[],1,19 Years,35 Years,MALE,True,Medical University of Vienna,OTHER,0,12.0,,2025-09-01T16:18:15.903444,v2_robust,True,True,True,False,False,
NCT02755753,A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis,"A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)",Lansoprazole,"['Lansoprazole', 'Rebamipide-placebo', 'Rebamipide', 'Lanston', 'Mucosta-placebo', 'Mucosta']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Gastroesophageal Reflux,['Gastroesophageal Reflux'],['Rebamipide'],COMPLETED,,2014-01,2016-04,"[{'measure': 'Endoscopic healing rate', 'description': 'The ratio of the endoscopically completely healed (normal or minimal change) patients per groups', 'timeFrame': '4 weeks'}]","[{'measure': 'Histologic change', 'description': 'Histologic change defined with Hematoxylin and eosin (H\\&E) stain', 'timeFrame': '4 weeks'}, {'measure': 'Change in inflammatory cytokines', 'description': 'Change in the tissue level of Platelet activating factor (PAF) and Interleukin-8 (IL-8)', 'timeFrame': '4 weeks'}, {'measure': 'Time to complete symptom relief', 'description': ""Interval between inital medication and the first time of symptom relief judged by subject's diary"", 'timeFrame': 'every 2 week, up to 4 week'}, {'measure': 'Overall symptom relief', 'description': 'The proportion of relieved subjects at the end of treatment', 'timeFrame': 'every 2 week, up to 4 week'}, {'measure': 'Adverse events profile', 'description': ""patient's symptoms, physical findings, abnormal laboratory values, vital signs, and ECG findings"", 'timeFrame': 'every 2 week, up to 4week'}]",6,20 Years,70 Years,ALL,False,YongChan Lee,OTHER,1,143.0,ACTUAL,2025-09-01T16:18:15.903452,v2_robust,True,True,True,False,True,
NCT05671653,"A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range","A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF TWO STEADY-STATE DOSE LEVELS OF PF-07081532 ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, OMEPRAZOLE AND AN ORAL CONTRACEPTIVE, AND THE EFFECT OF STEADY-STATE SEMAGLUTIDE ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, IN OBESE ADULT FEMALE PARTICIPANTS",PF-07081532,"['PF-07081532', 'Wegovy, Ozempic', 'Semaglutide']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Obesity,['Obesity'],"['Midazolam', 'Omeprazole', 'PF-07081532']",TERMINATED,The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.,2023-01-19,2023-11-03,"[{'measure': 'Cohort 1: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Midazolam in Periods 1, 4 and 7', 'description': 'Midazolam was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for midazolam pharmacokinetic (PK) at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Omeprazole in Periods 1, 4 and 7', 'description': 'Omeprazole was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for omeprazole PK at the preset time points described in the Time Frame. AUClast calculated area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to omeprazole dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: AUClast of Levonorgestrel (LE) in Periods 2, 5,and 8', 'description': 'LE was given on Day 1 in Period 2, 5, 8 of Cohort 1 and blood samples were collected for LE PK at the preset time points described in the Time Frame. AUClast calculated area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.', 'timeFrame': 'For Cohort 1 Periods 2, 5, and 8: At 0 (prior to LE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period'}, {'measure': 'Cohort 1: AUCinf of Ethinyl Estradiol (EE) in Periods 2, 5,and 8', 'description': 'EE was given on Day 1 in Period 2, 5, 8 of Cohort 1 and blood samples were collected for EE PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.', 'timeFrame': 'For Cohort 1 Periods 2, 5, and 8: At 0 (prior to EE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period'}, {'measure': 'Cohort 2: AUCinf of Midazolam in Period 1 and 3', 'description': 'Midazolam was given on Day 1 in Period 1 and 3 of Cohort 2 and blood samples were collected for midazolam pharmacokinetic (PK) at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.', 'timeFrame': 'For Cohort 2 Periods 1 and 3: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}]","[{'measure': 'Cohort 1: Number of Participants With All-Causality and Treatment-Related TEAEs', 'description': 'An adverse event (AE) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events were events between first dose of study treatment and up to approximately 35 days that were absent before treatment or that worsened relative to pretreatment state.', 'timeFrame': 'From first dose (Day 1) to follow-up telephone contact (Days 153 to 160) in Cohort 1'}, {'measure': 'Cohort 1: Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)', 'description': 'Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria.', 'timeFrame': 'From first dose (Day 1) to follow-up telephone contact (Days 153 to 160) in Cohort 1'}, {'measure': 'Cohort 1: Percentage of Change From Baseline in Body Weight by Period 9 Day 1', 'description': 'Percentage of changes from Baseline in body weight of the participants were measured.', 'timeFrame': 'From baseline (last pre-dose measurement in Period 1) to Period 9 Day 1 (Day 124)'}, {'measure': 'Cohort 1: Number of Participants With Completed Suicide, Suicide Attempt, Preparatory Acts Towards Imminent Suicidal Behavior, Suicidal Ideation, or Self-Injurious Behavior of No Suicidal Intent As Assessed on the C-SSRS', 'description': 'The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS items were mapped to the following categories: completed suicide, suicide attempt, preparatory acts towards imminent suicidal behavior, suicidal ideation, and self-injurious behavior of no suicidal intent. Number of participants with completed suicide, suicide attempt, preparatory acts towards imminent suicidal behavior, suicidal ideation, or self-injurious behavior of no suicidal intent as assessed on the C-SSRS are reported below.', 'timeFrame': 'Screening, Study Day -1 (D-1) (ie, Period 1 Day -1 [P1D-1]), D7 (P3D1), D21 (P3D15), D35 (P4D1), D54 (P6D14), D68 (P6D28), D82 (P6D42), D96 (P6D56), D103 (P6D63), D110 (P8D6) and at follow up visit D132-135'}, {'measure': 'Cohort 1: Patient Health Quessionare-9 (PHQ-9) Total Scores', 'description': 'The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The PHQ-9 is completed by participants and reviewed by site staff at the pre-defined time points. The total score is derived by adding the corresponding values of responses to each item. The total score ranges from 0 to 27, with the following interpretation: 1-4: Minimal depression; 5-9: Mild depression; 10-14: Moderate depression; 15-19: Moderately severe depression; 20-27: Severe depression.', 'timeFrame': 'Screening, Study Day -1 (D-1) (ie, Period 1 Day -1 [P1D-1]), D7 (P3D1), D21 (P3D15), D35 (P4D1), D54 (P6D14), D68 (P6D28), D82 (P6D42), D96 (P6D56), D103 (P6D63), D110 (P8D6) and at follow up visit D132-135'}, {'measure': 'Cohort 1: AUCinf of Midazolam in Period 9', 'description': 'Midazolam was given on Day 1 in Period 9 of Cohort 1 and blood samples were collected for midazolam pharmacokinetic (PK) at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.', 'timeFrame': 'For Cohort 1 Period 9: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1'}, {'measure': 'Cohort 1: Maximum Observed Concentration (Cmax) of Midazolam in Period 1, 4, 7', 'description': 'Midazolam was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for midazolam PK at the preset time points described in the Time Frame. Cmax was defined as maximum observed concentration and was observed directly from data.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: Time for Cmax (Tmax) of Midazolam in Period 1, 4, 7', 'description': 'Midazolam was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for midazolam PK at the preset time points described in the Time Frame. Tmax was defined as time for Cmax and was observed directly from data.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: Apparent Clearance (CL/F) of Midazolam in Period 1, 4, 7', 'description': 'Midazolam was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for midazolam PK at the preset time points described in the Time Frame. CL/F was defined as apparent clearance and was calculated as dose/AUCinf.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: Apparent Volume of Distribution (Vz/F) of Midazolam in Period 1, 4, 7', 'description': 'Midazolam was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for midazolam PK at the preset time points described in the Time Frame. Vz/F was defined as apparent volume of distribution and was calculated as dose/(AUCinf\\*kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: Terminal Half-Life (t1/2) of Midazolam in Period 1, 4, 7', 'description': 'Midazolam was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for midazolam PK at the preset time points described in the Time Frame. t1/2 was defined as terminal half life and was calculated as loge(2)/kel.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: Cmax of Omeprazole in Period 1, 4, 7', 'description': 'Omeprazole was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for omeprazole PK at the preset time points described in the Time Frame. Cmax was defined as maximum observed concentration and was observed directly from data.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to omeprazole dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: Tmax of Omeprazole in Period 1, 4, 7', 'description': 'Omeprazole was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for omeprazole PK at the preset time points described in the Time Frame. Tmax was defined as time for Cmax and was observed directly from data.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to omeprazole dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: CL/F of Omeprazole in Period 1, 4, 7', 'description': 'Omeprazole was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for omeprazole PK at the preset time points described in the Time Frame. CL/F was defined as apparent clearance and was calculated as dose/AUCinf.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to omeprazole dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: Vz/F of Omeprazole in Period 1, 4, 7', 'description': 'Omeprazole was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for omeprazole PK at the preset time points described in the Time Frame. Vz/F was defined as apparent volume of distribution and was calculated as dose/(AUCinf\\*kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to omeprazole dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: t1/2 of Omeprazole in Period 1, 4, 7', 'description': 'Omeprazole was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for omeprazole PK at the preset time points described in the Time Frame. Vz/F was defined as apparent volume of distribution and was calculated as dose/(AUCinf ×kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to omeprazole dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: Cmax of LE in Period 2, 5, 8', 'description': 'LE was given on Day 1 in Period 2, 5, 8 of Cohort 1 and blood samples were collected for LE PK at the preset time points described in the Time Frame. Cmax was defined as maximum observed concentration and was observed directly from data.', 'timeFrame': 'For Cohort 1 Periods 2, 5, and 8: At 0 (prior to LE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period'}, {'measure': 'Cohort 1: Tmax of LE in Period 2, 5, 8', 'description': 'LE was given on Day 1 in Period 2, 5, 8 of Cohort 1 and blood samples were collected for LE PK at the preset time points described in the Time Frame. Cmax was defined as maximum observed concentration and was observed directly from data.', 'timeFrame': 'For Cohort 1 Periods 2, 5, and 8: At 0 (prior to LE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period'}, {'measure': 'Cohort 1: CL/F of LE in Period 2, 5, 8', 'description': 'LE was given on Day 1 in Period 2, 5, 8 of Cohort 1 and blood samples were collected for LE PK at the preset time points described in the Time Frame. Cmax was defined as maximum observed concentration and was observed directly from data.', 'timeFrame': 'For Cohort 1 Periods 2, 5, and 8: At 0 (prior to LE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period'}, {'measure': 'Cohort 1: Vz/F of LE in Period 2, 5, 8', 'description': 'LE was given on Day 1 in Period 2, 5, 8 of Cohort 1 and blood samples were collected for LE PK at the preset time points described in the Time Frame. Vz/F was defined as apparent volume of distribution and was calculated as dose/(AUCinf\\*kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.', 'timeFrame': 'For Cohort 1 Periods 2, 5, and 8: At 0 (prior to LE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period'}, {'measure': 'Cohort 1: t1/2 of LE in Period 2, 5, 8', 'description': 'LE was given on Day 1 in Period 2, 5, 8 of Cohort 1 and blood samples were collected for LE PK at the preset time points described in the Time Frame. t1/2 was defined as terminal half life and was calculated as loge(2)/kel.', 'timeFrame': 'For Cohort 1 Periods 2, 5, and 8: At 0 (prior to LE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period'}, {'measure': 'Cohort 1: Cmax of EE in Period 2, 5, 8', 'description': 'EE was given on Day 1 in Period 2, 5, 8 of Cohort 1 and blood samples were collected for EE PK at the preset time points described in the Time Frame. Cmax was defined as maximum observed concentration and was observed directly from data.', 'timeFrame': 'For Cohort 1 Periods 2, 5, and 8: At 0 (prior to EE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period'}, {'measure': 'Cohort 1: Tmax of EE in Period 2, 5, 8', 'description': 'EE was given on Day 1 in Period 2, 5, 8 of Cohort 1 and blood samples were collected for EE PK at the preset time points described in the Time Frame. Tmax was defined as time for Cmax and was observed directly from data.', 'timeFrame': 'For Cohort 1 Periods 2, 5, and 8: At 0 (prior to EE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period'}, {'measure': 'Cohort 1: CL/F of EE in Period 2, 5, 8', 'description': 'EE was given on Day 1 in Period 2, 5, 8 of Cohort 1 and blood samples were collected for EE PK at the preset time points described in the Time Frame. CL/F was defined as apparent clearance and was calculated as dose/AUCinf.', 'timeFrame': 'For Cohort 1 Periods 2, 5, and 8: At 0 (prior to EE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period'}, {'measure': 'Cohort 1: Vz/F of EE in Period 2, 5, 8', 'description': 'EE was given on Day 1 in Period 2, 5, 8 of Cohort 1 and blood samples were collected for EE PK at the preset time points described in the Time Frame. Vz/F was defined as apparent volume of distribution and was calculated as dose/(AUCinf\\*kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.', 'timeFrame': 'For Cohort 1 Periods 2, 5, and 8: At 0 (prior to EE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period'}, {'measure': 'Cohort 1: t1/2 of EE in Period 2, 5, 8', 'description': 'EE was given on Day 1 in Period 2, 5, 8 of Cohort 1 and blood samples were collected for EE PK at the preset time points described in the Time Frame. t1/2 was defined as terminal half life and was calculated as loge(2)/kel.', 'timeFrame': 'For Cohort 1 Periods 2, 5, and 8: At 0 (prior to EE dose), 0.75, 2, 4, 8, 12, 24, 48, 72, 96 and 120 hours post LE dose on Day 1 of each period'}, {'measure': 'Cohort 1: Metabolite/Parent Ratio for AUCinf (MRAUCinf) of 1-Hydroxy Midazolam in Period 1, 4, 7', 'description': 'Midazolam was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for midazolam (parent) and and its metabolite 1-Hydroxy Midazolam PK at the preset time points described in the Time Frame. MRAUCinf was calculated as (AUCinf, metabolite/AUCinf, parent) \\* (MWparent/MWmetabolite). MW = molecular weight.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: MRAUCinf of 5-Hydroxy Omeprazole in Period 1, 4, 7', 'description': 'Omeprazole was given on Day 1 in Period 1, 4, 7 of Cohort 1 and blood samples were collected for omeprazole (parent) and and its metabolite 5-Hydroxy omeprazole PK at the preset time points described in the Time Frame. MRAUCinf was calculated as (AUCinf, metabolite/AUCinf, parent) \\* (MWparent/MWmetabolite). MW = molecular weight.', 'timeFrame': 'For Cohort 1 Periods 1, 4, and 7: At 0 (prior to omeprazole dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 1: Area Under the Plasma Concentration-Time Profile From Time 0 to 24 Hours (AUC24) of PF-07081532 in Period 3 and 6', 'description': 'PF-07081532 was given titrated to 80 mg QD on Day 1-28 of Period 3, and titrated to 260 mg QD on Day 1-63 of Period 6 in Cohort 1, and blood samples were collected for PF-07081532 PK at the preset time points described in the Time Frame. AUC24 was defined as area under the plasma concentration-time profile from time 0 to 24 hours and was determined using the linear/log trapezoidal method.', 'timeFrame': 'For Cohort 1 Periods 3 and 6: At 0 , 0.5, 1, 2, 4, 6, 8, 10, 14, and 24 hours post PF-07081532 dose on Day 28 of Period 3 and Day 63 of Period 6'}, {'measure': 'Cohort 1: Cmax of PF-07081532 in Period 3 and 6', 'description': 'PF-07081532 was given titrated to 80 mg QD on Day 1-28 of Period 3, and titrated to 260 mg QD on Day 1-63 of Period 6 in Cohort 1, and blood samples were collected for PF-07081532 PK at the preset time points described in the Time Frame. Cmax was defined as maximum observed concentration and was observed directly from data.', 'timeFrame': 'For Cohort 1 Periods 3 and 6: At 0 , 0.5, 1, 2, 4, 6, 8, 10, 14, and 24 hours post PF-07081532 dose on Day 28 of Period 3 and Day 63 of Period 6'}, {'measure': 'Cohort 1: Tmax of PF-07081532 in Period 3 and 6', 'description': 'PF-07081532 was given titrated to 80 mg QD on Day 1-28 of Period 3, and titrated to 260 mg QD on Day 1-63 of Period 6 in Cohort 1, and blood samples were collected for PF-07081532 PK at the preset time points described in the Time Frame. Tmax was defined as time for Cmax and was observed directly from data.', 'timeFrame': 'For Cohort 1 Periods 3 and 6: At 0 , 0.5, 1, 2, 4, 6, 8, 10, 14, and 24 hours post PF-07081532 dose on Day 28 of Period 3 and Day 63 of Period 6'}, {'measure': 'Cohort 2: Number of Participants With All-Causality and Treatment-Related TEAEs', 'description': 'An adverse event (AE) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events were events between first dose of study treatment and up to approximately 35 days that were absent before treatment or that worsened relative to pretreatment state.', 'timeFrame': 'From first dose (Day 1) to follow-up telephone contact (Days 193 to 200) in Cohort 2'}, {'measure': 'Cohort 2: Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)', 'description': 'Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria.', 'timeFrame': 'From first dose (Day 1) to follow-up telephone contact (Days 193 to 200) in Cohort 2'}, {'measure': 'Cohort 2: Percentage of Change From Baseline in Body Weight by Period 4 Day 1', 'description': 'Percentage of changes from Baseline in body weight of the participants were measured.', 'timeFrame': 'From baseline (last pre-dose measurement in Period 1) to Period 4 Day 1 (Day 165)'}, {'measure': 'Cohort 2: Number of Participants With Completed Suicide, Suicide Attempt, Preparatory Acts Towards Imminent Suicidal Behavior, Suicidal Ideation, or Self-Injurious Behavior of No Suicidal Intent As Assessed on the C-SSRS', 'description': 'The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS items were mapped to the following categories: completed suicide, suicide attempt, preparatory acts towards imminent suicidal behavior, suicidal ideation, and self-injurious behavior of no suicidal intent. Number of participants with completed suicide, suicide attempt, preparatory acts towards imminent suicidal behavior, suicidal ideation, or self-injurious behavior of no suicidal intent as assessed on the C-SSRS are reported below.', 'timeFrame': 'Screening, D-1 (P1D-1), P2 Week 5 [W5], P2W9, P2W13, P2W17, D150 (P3D2), at follow up visit (Day 172-175)'}, {'measure': 'Cohort 2: PHQ-9 Total Scores', 'description': 'The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The PHQ-9 is completed by participants and reviewed by site staff at the pre-defined time points. The total score is derived by adding the corresponding values of responses to each item. The total score ranges from 0 to 27, with the following interpretation: 1-4: Minimal depression; 5-9: Mild depression; 10-14: Moderate depression; 15-19: Moderately severe depression; 20-27: Severe depression.', 'timeFrame': 'Screening, D-1 (P1D-1), P2 Week 5 [W5], P2W9, P2W13, P2W17, D150 (P3D2), at follow up visit (Day 172-175)'}, {'measure': 'Cohort 2: AUCinf of Midazolam in Period 4', 'description': 'Midazolam was given on Day 1 in Period 4 of Cohort 2 and blood samples were collected for midazolam pharmacokinetic (PK) at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.', 'timeFrame': 'For Cohort 2 Period 4: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14 and 24 hours post midazolam dose on Day 1'}, {'measure': 'Cohort 2: Cmax of Midazolam in Period 1 and 3', 'description': 'Midazolam was given on Day 1 in Period 1 and 3 of Cohort 2 and blood samples were collected for midazolam pharmacokinetic (PK) at the preset time points described in the Time Frame. Cmax was defined as maximum observed concentration and was observed directly from data.', 'timeFrame': 'For Cohort 2 Periods 1 and 3: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 2: Tmax of Midazolam in Period 1 and 3', 'description': 'Midazolam was given on Day 1 in Period 1 and 3 of Cohort 2 and blood samples were collected for midazolam pharmacokinetic (PK) at the preset time points described in the Time Frame. Tmax was defined as time for Cmax and was observed directly from data.', 'timeFrame': 'For Cohort 2 Periods 1 and 3: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 2: CL/F of Midazolam in Period 1 and 3', 'description': 'Midazolam was given on Day 1 in Period 1 and 3 of Cohort 2 and blood samples were collected for midazolam pharmacokinetic (PK) at the preset time points described in the Time Frame. CL/F was defined as apparent clearance and was calculated as dose/AUCinf.', 'timeFrame': 'For Cohort 2 Periods 1 and 3: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 2: Vz/F of Midazolam in Period 1 and 3', 'description': 'Midazolam was given on Day 1 in Period 1 and 3 of Cohort 2 and blood samples were collected for midazolam pharmacokinetic (PK) at the preset time points described in the Time Frame. Vz/F was defined as apparent volume of distribution and was calculated as dose/(AUCinf\\*kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.', 'timeFrame': 'For Cohort 2 Periods 1 and 3: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 2: t1/2 of Midazolam in Period 1 and 3', 'description': 'Midazolam was given on Day 1 in Period 1 and 3 of Cohort 2 and blood samples were collected for midazolam pharmacokinetic (PK) at the preset time points described in the Time Frame. t1/2 was defined as terminal half life and was calculated as loge(2)/kel.', 'timeFrame': 'For Cohort 2 Periods 1 and 3: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}, {'measure': 'Cohort 2: MRAUCinf of 1-Hydroxy Midazolam in Period 1, 3, 4', 'description': 'Midazolam was given on Day 1 in Period 1, 3, 4 of Cohort 2 and blood samples were collected for midazolam (parent) and and its metabolite 1-Hydroxy Midazolam PK at the preset time points described in the Time Frame. MRAUCinf was calculated as (AUCinf, metabolite/AUCinf, parent) \\* (MWparent/MWmetabolite). MW = molecular weight.', 'timeFrame': 'For Cohort 2 Periods 1 and 3: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24 hours post midazolam dose on Day 1 of each period'}]",48,18 Years,,FEMALE,True,Pfizer,INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:15.903488,v2_robust,True,True,False,True,True,The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.
NCT04161053,Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy,Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy,Rifaximin,"['Nitazoxanide', 'Gastrobiotic, Trencedia', 'Rifaximin', 'Nanazoxid']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Hepatic Encephalopathy,['Hepatic Encephalopathy'],[],RECRUITING,,2018-11-01,2028-12,"[{'measure': 'Number of encephalopathy episodes during treatment', 'description': 'The number of encephalopathy episodes during treatment', 'timeFrame': '6 months'}]",[],1,20 Years,65 Years,ALL,False,Tanta University,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:15.903522,v2_robust,True,True,False,False,False,
NCT02420353,Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears,Evaluation of Recombinant Growth Hormone Therapy to Prevent Muscle Atrophy in Patients With Anterior Cruciate Ligament Tears,Somatropin,"['Placebo', 'Somatropin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Rupture of Anterior Cruciate Ligament,['Rupture of Anterior Cruciate Ligament'],"['muscle atrophy', 'growth hormone', 'ACL tear']",COMPLETED,,2015-05,2018-10,"[{'measure': 'Normative Isokinetic Knee Extension Strength, Measured in Newton Meters (Nm) at 26 Weeks Post-op', 'description': 'Isokinetic knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isokinetic measurements were performed at a speed of 60º/sec from a range of 0º to 90º of knee flexion. Normalized values were calculated by dividing the value from the injured limb by the value from the contralateral, uninjured leg prior to surgery. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at 26 wks post-op'}]","[{'measure': 'Normative Isokinetic Extension (Nm) at Pre-op (Baseline)', 'description': 'Isokinetic knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isokinetic measurements were performed at a speed of 60º/sec from a range of 0º to 90º of knee flexion. Normalized values were calculated by dividing the value from the injured limb by the value from the contralateral, uninjured leg prior to surgery. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Normative Isokinetic Flexion (Nm) at Pre-op (Baseline)', 'description': 'Isokinetic knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isokinetic measurements were performed at a speed of 60º/sec from a range of 0º to 90º of knee flexion. Normalized values were calculated by dividing the value from the injured limb by the value from the contralateral, uninjured leg prior to surgery. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Normative Isokinetic Flexion (Nm) at 26 Weeks Post-op', 'description': 'Isokinetic knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isokinetic measurements were performed at a speed of 60º/sec from a range of 0º to 90º of knee flexion. Normalized values were calculated by dividing the value from the injured limb by the value from the contralateral, uninjured leg prior to surgery. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'Normative Isometric Extension (Nm) at Pre-op (Baseline)', 'description': 'Isometric knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isometric measurements were performed at 45º of knee flexion. Normalized values were calculated by dividing the value from the injured limb by the value from the contralateral, uninjured leg prior to surgery. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Normative Isometric Extension (Nm) at 26 Weeks Post-op', 'description': 'Isometric knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isometric measurements were performed at 45º of knee flexion. Normalized values were calculated by dividing the value from the injured limb by the value from the contralateral, uninjured leg prior to surgery. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'Normative Isometric Flexion (Nm) at Pre-op (Baseline)', 'description': 'Isometric knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isometric measurements were performed at 45º of knee flexion. Normalized values were calculated by dividing the value from the injured limb by the value from the contralateral, uninjured leg prior to surgery. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Normative Isometric Flexion (Nm) at 26 Weeks Post-op', 'description': 'Isometric knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isometric measurements were performed at 45º of knee flexion. Normalized values were calculated by dividing the value from the injured limb by the value from the contralateral, uninjured leg prior to surgery. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'Absolute Isokinetic Extension (Nm) at Pre-op (Baseline)', 'description': 'Absolute Isokinetic knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isokinetic measurements were performed at a speed of 60º/sec from a range of 0º to 90º of knee flexion. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Absolute Isokinetic Extension (Nm) at 26 wk Post-op', 'description': 'Absolute Isokinetic knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isokinetic measurements were performed at a speed of 60º/sec from a range of 0º to 90º of knee flexion. Strength values were calculated by comparing the affected limb of each subject across study group. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at 26 wk post-op'}, {'measure': 'Absolute Isokinetic Flexion (Nm) at Pre-op (Baseline)', 'description': 'Absolute Isokinetic knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isokinetic measurements were performed at a speed of 60º/sec from a range of 0º to 90º of knee flexion. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Absolute Isokinetic Flexion (Nm) at 26 Weeks Post-op', 'description': 'Absolute Isokinetic knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isokinetic measurements were performed at a speed of 60º/sec from a range of 0º to 90º of knee flexion. Strength values were calculated by comparing the affected limb of each subject across study group. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'Absolute Isometric Extension (Nm) at Pre-op (Baseline)', 'description': 'Isometric knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isometric measurements were performed at 45º of knee flexion. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Absolute Isometric Extension (Nm) at 26 Weeks Post-op', 'description': 'Absolute Isometric knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isometric measurements were performed at 45º of knee flexion. Strength values were calculated by comparing the affected limb of each subject across study group. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'Absolute Isometric Flexion (Nm) at Pre-op (Baseline)', 'description': 'Isometric knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isometric measurements were performed at 45º of knee flexion. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Absolute Isometric Flexion (Nm) at 26 Weeks Post-op', 'description': 'Absolute Isometric knee flexion and extension strength measurements were obtained in a System 3 dynamometer (BioDex, Shirley, New York). Isometric measurements were performed at 45º of knee flexion. Strength values were calculated by comparing the affected limb of each subject across study group. For each measurement, the highest force from a series of 5 repetitions was used.', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'VR12 Health Survey: Physical Health Summary Measure Score at Pre-op (Baseline)', 'description': 'The VR-12 includes 12 questions that do not give an overall score but yield a physical and mental component score. PCS and MCS summary scores are standardized using a t-score transformation and normalized to the U.S. population of a score of 50 and a standard deviation of 10. Higher PCS and MCS scores indicate better health. Medical Expenditure Panel Survey (MEPS) collected between 2000 and 2002 standard norms range as followed PCS maximum: 72.11; minimum: 0.59.', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'VR12 Health Survey: Physical Health Summary Measure Score at 26 Weeks Post-op', 'description': 'The VR-12 includes 12 questions that do not give an overall score but yield a physical and mental component score. PCS and MCS summary scores are standardized using a t-score transformation and normalized to the U.S. population of a score of 50 and a standard deviation of 10. Higher PCS and MCS scores indicate better health. Medical Expenditure Panel Survey (MEPS) collected between 2000 and 2002 standard norms range as followed PCS maximum: 72.11; minimum: 0.59.', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'VR12 Health Survey: Mental Health Summary Measure Score at Pre-op (Baseline)', 'description': 'The VR-12 includes 12 questions that do not give an overall score but yield a physical and mental component score. PCS and MCS summary scores are standardized using a t-score transformation and normalized to the U.S. population of a score of 50 and a standard deviation of 10. Higher PCS and MCS scores indicate better health. Medical Expenditure Panel Survey (MEPS) collected between 2000 and 2002 standard norms range as followed MCS Maximum: 76.09; Minimum: -2.47.', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'VR12 Health Survey: Mental Health Summary Measure Score at 26 Weeks Post-op', 'description': 'The VR-12 includes 12 questions that do not give an overall score but yield a physical and mental component score. PCS and MCS summary scores are standardized using a t-score transformation and normalized to the U.S. population of a score of 50 and a standard deviation of 10. Higher PCS and MCS scores indicate better health. Medical Expenditure Panel Survey (MEPS) collected between 2000 and 2002 standard norms range as followed MCS Maximum: 76.09; Minimum: -2.47.', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'International Knee Document Committee (IKDC) at Pre-op (Baseline)', 'description': 'The IKDC percentage score is a subjective patients reported outcome measure (PROM) that scores a participants over all score. The PROM looks at 3 categories: symptoms, sports activity, and knee function. Scores range from 0 to 100, the final score given is interpreted as a measure of function with higher scores representing higher levels of function.', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'International Knee Documentation Committee (IKDC) up to 26 wk Post-op', 'description': 'The IKDC percentage score is a subjective patients reported outcome measure (PROM) that scores a participants over all score. The PROM looks at 3 categories: symptoms, sports activity, and knee function. Scores range from 0 to 100, the final score given is interpreted as a measure of function with higher scores representing higher levels of function.', 'timeFrame': 'up to 26 wk post-op'}, {'measure': 'The Knee Injury and Osteoarthritis Outcome Score (KOOS): Patient Reported Outcome Measure: ADL at 26 Weeks Post-op', 'description': 'KOOS Function in daily living (ADL) (17 items). A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. An aggregate total score is not calculated since it is regarded desirable to analyze and interpret the five dimensions separately.\n\nMaximum score 100% / Minimum score 0%. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as is common in orthopaedic assessment scales and generic measures', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'KOOS Patient Reported Outcome Measure: ADL at Pre-op (Baseline)', 'description': 'KOOS Function in daily living (ADL) (17 items). A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. An aggregate total score is not calculated since it is regarded desirable to analyze and interpret the five dimensions separately.\n\nMaximum score 100% / Minimum score 0%. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as is common in orthopaedic assessment scales and generic measures', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'KOOS Patient Reported Outcome Measure: Pain at 26 Weeks Post-op', 'description': 'KOOS Pain (9 items) A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. An aggregate total score is not calculated since it is regarded desirable to analyze and interpret the five dimensions separately.\n\nMaximum score 100% / Minimum score 0%. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as is common in orthopaedic assessment scales and generic measures', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'KOOS Patient Reported Outcome Measure: Pain at Pre-op (Baseline)', 'description': 'KOOS Pain (9 items) A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. An aggregate total score is not calculated since it is regarded desirable to analyze and interpret the five dimensions separately.\n\nMaximum score 100% / Minimum score 0%. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as is common in orthopaedic assessment scales and generic measures', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'KOOS Patient Reported Outcome Measure: Quality of Life at 26 Weeks Post-op', 'description': 'KOOS Quality of Life (QoL) (4 items) A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. An aggregate total score is not calculated since it is regarded desirable to analyze and interpret the five dimensions separately.\n\nMaximum score 100% / Minimum score 0%. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as is common in orthopaedic assessment scales and generic measures', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'KOOS Patient Reported Outcome Measure: Quality of Life at Pre-op (Baseline)', 'description': 'KOOS Quality of Life (QoL) (4 items) A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. An aggregate total score is not calculated since it is regarded desirable to analyze and interpret the five dimensions separately.\n\nMaximum score 100% / Minimum score 0%. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as is common in orthopaedic assessment scales and generic measures', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'KOOS Patient Reported Outcome Measure: Sport and Recreation at 26 Weeks Post-op', 'description': 'KOOS Sport and Recreation (Sport/Rec) (5 items) A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. An aggregate total score is not calculated since it is regarded desirable to analyze and interpret the five dimensions separately.\n\nMaximum score 100% / Minimum score 0%. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as is common in orthopaedic assessment scales and generic measures.', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'KOOS Patient Reported Outcome Measure: Sports and Recreation at Pre-op (Baseline)', 'description': 'KOOS Sport and Recreation (Sport/Rec) (5 items) A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. An aggregate total score is not calculated since it is regarded desirable to analyze and interpret the five dimensions separately.\n\nMaximum score 100% / Minimum score 0%. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as is common in orthopaedic assessment scales and generic measures.', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'KOOS Patient Reported Outcome Measure: Symptoms at 26 Weeks Post-op', 'description': 'KOOS Symptoms (7 items) A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. An aggregate total score is not calculated since it is regarded desirable to analyze and interpret the five dimensions separately.\n\nMaximum score 100% / Minimum score 0%. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as is common in orthopaedic assessment scales and generic measures', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'KOOS Patient Reported Outcome Measure: Symptoms at Pre-op (Baseline)', 'description': 'KOOS Symptoms (7 items) A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. An aggregate total score is not calculated since it is regarded desirable to analyze and interpret the five dimensions separately.\n\nMaximum score 100% / Minimum score 0%. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as is common in orthopaedic assessment scales and generic measures', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Absolute Quadriceps Volume (L) at Pre-op (Baseline)', 'description': 'Bilateral MRI scans were obtained at specific time points to assess the muscle volume of the quadriceps and hamstring muscle groups will be calculated using GE ImagePACS software (FDA cleared software which is the standard software used to read and analyze imaging studies in the UMHS).', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Absolute Quadricep Volume (L) at 26 Week Post-op', 'description': 'Bilateral MRI scans were obtained at specific time points to assess the muscle volume of the quadriceps and hamstring muscle groups will be calculated using GE ImagePACS software (FDA cleared software which is the standard software used to read and analyze imaging studies in the UMHS).', 'timeFrame': 'at 26 week post-op'}, {'measure': 'Absolute Hamstring Volume (L) at Pre-op (Baseline)', 'description': 'Bilateral MRI scans were obtained at specific time points to assess the muscle volume of the quadriceps and hamstring muscle groups will be calculated using GE ImagePACS software (FDA cleared software which is the standard software used to read and analyze imaging studies in the UMHS).', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Absolute Hamstring Volume (L) at 26 Weeks Post-op', 'description': 'Bilateral MRI scans were obtained at specific time points to assess the muscle volume of the quadriceps and hamstring muscle groups will be calculated using GE ImagePACS software (FDA cleared software which is the standard software used to read and analyze imaging studies in the UMHS).', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'Normalized Quadriceps Volume (L) at Pre-op (Baseline)', 'description': 'Normalized volume relative to the pre-op measurements of the uninjured limb, used to assess the muscle volume of the quadriceps and hamstring muscle groups will be calculated using GE ImagePACS software (FDA cleared software which is the standard software used to read and analyze imaging studies in the UMHS).', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Normalized Quadriceps Volume (L) at 26 Weeks Post-op', 'description': 'Normalized volume relative to the pre-op measurements of the uninjured limb, used to assess the muscle volume of the quadriceps and hamstring muscle groups will be calculated using GE ImagePACS software (FDA cleared software which is the standard software used to read and analyze imaging studies in the UMHS).', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'Normalized Hamstring Volume (L) at Pre-op (Baseline)', 'description': 'Normalized volume relative to the pre-op measurements of the uninjured limb, used to assess the muscle volume of the quadriceps and hamstring muscle groups will be calculated using GE ImagePACS software (FDA cleared software which is the standard software used to read and analyze imaging studies in the UMHS).', 'timeFrame': 'at pre-op (baseline)'}, {'measure': 'Normalized Hamstring Volume (L) at 26 Weeks Post-op', 'description': 'Normalized volume relative to the pre-op measurements of the uninjured limb, used to assess the muscle volume of the quadriceps and hamstring muscle groups will be calculated using GE ImagePACS software (FDA cleared software which is the standard software used to read and analyze imaging studies in the UMHS).', 'timeFrame': 'at 26 weeks post-op'}, {'measure': 'Insulin Like Growth Factor (IGF1) at -1 and 5 Weeks Post-op', 'description': 'IGF1 was measured from serum using an IMMULITE 2000 system (Siemens).', 'timeFrame': 'Area under the curve between -1 and 5 weeks post-op'}, {'measure': 'Myostatin at -1 and 5 Weeks Post-op', 'description': 'Myostatin was measured from plasma using ELISAs (R\\&D Systems, Minneapolis, MN) following manufacturer recommendations.', 'timeFrame': 'Area under the curve between -1 and 5 weeks post-op'}, {'measure': 'MMP3 at -1 and 5 Weeks Post-op', 'description': 'Matrix metalloproteinase-3 (MMP3) was measured from serum using ELISAs (R\\&D Systems, Minneapolis, MN) following manufacturer recommendations.', 'timeFrame': 'Area under the curve between -1 and 5 weeks post-op'}, {'measure': 'Hyaluronic Acid at -1 and 5 Weeks Post-op', 'description': 'Hyaluronic acid was measured from plasma using ELISAs (R\\&D Systems, Minneapolis, MN) following manufacturer recommendations.', 'timeFrame': 'Area under the curve between -1 and 5 weeks post-op'}]",44,18 Years,35 Years,MALE,False,University of Michigan,OTHER,1,20.0,ACTUAL,2025-09-01T16:18:15.903578,v2_robust,True,True,True,False,False,
NCT03109353,Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease,Modification of Extracorporeal Photopheresis Technology With 5-aminolevulinic Acid in Patients With Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease - A Proof-of-concept Study,ECP with 5-aminolevulinic acid,"['5-ALA', 'ECP with 5-aminolevulinic acid']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Cutaneous T-Cell Lymphoma, Unspecified","['Cutaneous T-Cell Lymphoma, Unspecified', 'Chronic Graft Versus Host Disease in Skin']","['Photopheresis', '5-aminolevulinic acid', 'Extracorporeal Circulation']",COMPLETED,,2017-09-20,2022-12-31,"[{'measure': 'Treatment safety: Monitored through recordings of ECG, vital signs and safety laboratory measurements including haematology, clinical chemistry and urinalysis.', 'description': 'Monitored through recordings of ECG, vital signs and safety laboratory measurements including haematology, clinical chemistry and urinalysis.', 'timeFrame': 'up to 1 year'}]","[{'measure': 'Main efficacy for CTCL', 'description': 'Response of skin disease and reduction in immunosuppression. Response will be evaluated with study baseline as reference as: complete response, partial response, minimal response, stable disease, progressive disease or maximal response based on set definitions.', 'timeFrame': 'up to 1 year'}, {'measure': 'Main efficacy for cGvHD', 'description': 'Response of skin disease and reduction in immunosuppression. Response will be evaluated with study baseline as reference as: complete response, partial response, minimal response, stable disease, progressive disease or maximal response based on set definitions.', 'timeFrame': 'up to 1 year'}]",3,18 Years,,ALL,False,St. Olavs Hospital,OTHER,2,7.0,ACTUAL,2025-09-01T16:18:15.903805,v2_robust,True,True,True,False,True,
NCT03635853,Identification of Compound Isolated From Cock's Comb and Its Effect on Arsenical Palmar Keratosis,Identification of Compound Isolated From Cock's Comb and Its Effect on Arsenical Palmar Keratosis,drug containing extract from cock's comb,"[""drug containing extract from cock's comb""]",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Improvement of Keratotic Nodular Size,['Improvement of Keratotic Nodular Size'],[],UNKNOWN,,2017-09-16,2019-02,"[{'measure': 'changes in keratotic nodular size', 'description': 'palmar arsenical keratosis will be measured before and after applying interventions', 'timeFrame': 'three months'}]",[],1,18 Years,60 Years,ALL,False,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:15.903822,v2_robust,True,True,False,False,False,
NCT05132153,Effect of Nebulized Milrinone on Right Ventricular Hemodynamics in Adult Cardiac Surgery,Effect of Nebulized Milrinone on Right Ventricular Hemodynamics in Adult Cardiac Surgery,Milrinone,"['Milrinone', 'Normal saline']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Anesthesia,['Anesthesia'],[],UNKNOWN,,2021-10-17,2022-09-20,"[{'measure': 'Effect of inhaled milrinone on improvement of right ventricular function', 'description': 'The right ventricle function will be assessed by Fractional area change ( Change in area between systole and diastole by echocardiograph ( intraoperative and postoperative)', 'timeFrame': 'After 15 minutes of inhaled milrinone intraoperative and repeated after 12, 24 hours in intensive care unit'}]",[],1,18 Years,,ALL,False,Ain Shams University,OTHER,0,70.0,ESTIMATED,2025-09-01T16:18:15.904019,v2_robust,True,True,False,False,False,
NCT00379353,The Effects of Thalidomide on Symptom Clusters,The Effects of Thalidomide on Symptom Clusters,Thalidomide,"['Thalidomide', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Cancers,['Advanced Cancers'],"['Advanced Cancers', 'Anorexia', 'Fatigue', 'Thalidomide', 'Placebo']",COMPLETED,,2006-09,2013-01,"[{'measure': 'Change in Symptoms as Measured by Edmonton Symptom Assessment Scale (ESAS)', 'description': 'ESAS assessment of appetite (symptom) where the severity at the time of assessment is rated from 0 to 10 on a numerical scale; with 0 meaning that the symptom is absent and 10 that it is the worst possible severity. Evaluated at baseline \\[± 3 days\\], 2 weeks\\[± 3 days\\] and 4 weeks \\[± 3 days\\]', 'timeFrame': 'Baseline to Day 29'}]","[{'measure': 'Functional Assessment of Anorexia/Cachexia Therapy (FAACT)', 'description': ""12-item symptom-specific subscale of the FACT-G designed to measure participants' additional concerns about their anorexia/cachexia during the previous 7 days. Participant rates concerns from 0 to 4 (0= not at all, 4= very much), combined are the 12 items subscales for a total of 0 to 48 where the higher number would represent greater concern."", 'timeFrame': 'Baseline to Day 29'}, {'measure': 'Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)', 'description': 'The FACIT-F consists of 27 general quality of life questions divided into 4 domains (physical, social, emotional and functional), plus a 13-item fatigue subscore. The participant rates the intensity of fatigue and its related symptoms on a scale of 0-4 (0= not at all, 4= very much) where the 13-item fatigue subscore totals are combined for a total of 0 to 52, with the higher number representing greater fatigue.', 'timeFrame': 'Baseline to Day 29'}, {'measure': 'Hospital Anxiety and Depression Scale (HADS) HADS-A (Anxiety)', 'description': 'The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0-3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21). The higher the score The higher the score, the more likely the patient is showing signs of anxiety and as a result may benefit from a counseling/supportive session.', 'timeFrame': 'Baseline to Day 29'}, {'measure': 'Hospital Anxiety and Depression Scale (HADS) HADS-D (Depression)', 'description': 'The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0-3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21). The higher the score, the more likely the patient is showing signs of depression and as a result may benefit from a counseling/supportive session.', 'timeFrame': 'Baseline to Day 29'}, {'measure': 'Pittsburgh Sleep Quality Index (PSQI)', 'description': 'PSQI measures the quality and patterns of sleep. It differentiates poor from good sleep by measuring subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. A participant indicates how frequently each item was experienced on a scale from 0 to 3. The 7 component scores are then summed to obtain a global sleep score that can range from 0 to 21. A score of \\>/= 5 indicates poor sleepers.', 'timeFrame': 'Baseline to Day 29'}, {'measure': 'Change in Body Composition as Measured by Body Mass Index (BMI)', 'description': ""BMI, commonly used to measure overweight and obesity, is a measure of body fat based on a person's weight and height."", 'timeFrame': 'Baseline to Day 29'}, {'measure': 'Change in Serum Cytokines and Receptors', 'description': 'Cytokines Levels of IL-1β and its receptor IL RA, IL-6 its receptor IL-6R, and TNF-α and its receptors (i.e. tumor necrosis factor receptor (TNFR)) of TNFR1, TNFR2, IL-10, IL-8(serum) measured at baseline, Days 15 and 29. Multiplex bead Immunoassay used to measure serum/plasma levels of IL-1, IL-6, TNF-α, IL-10, IL-8 and their receptors where assay sensitivity for the cytokines was 3-6 pg/mL. Serum IL-10, IL-1β, IL-1RA, IL-6R, sTNF-RI, sTNF-R2 were also analyzed using an enzyme-linked immunosorbent assay device. Lowering cytokine levels can decrease fatigue, increase appetite and decrease anxiety and depression.', 'timeFrame': 'Baseline to Day 15'}]",8,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,32.0,ACTUAL,2025-09-01T16:18:15.904068,v2_robust,True,True,True,False,False,
NCT00704353,Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia,"A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of a Single Dose of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Subjects Who Are Not Dialysis Dependent",Ferric Carboxymaltose,"['Standard Medical Care (SMC)', 'Ferric Carboxymaltose', 'Ferrous Sulfate, Venofer, Ferrlecit, Infed, Dexferrum']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Anemia,['Anemia'],[],COMPLETED,,2008-06,2011-03,"[{'measure': ""Number of Participants With Treatment-emergent Serious Adverse Events (SAE's)"", 'timeFrame': 'through 30 days after the last dose of study drug (FCM or SMC for the treatment of IDA)'}]",[],1,18 Years,,ALL,False,"American Regent, Inc.",INDUSTRY,0,735.0,ACTUAL,2025-09-01T16:18:15.904128,v2_robust,True,True,True,False,True,
NCT07128953,Study on the Mechanism of Zuoqing San Promoting Postoperative Wound Healing of Anal Fistula by Inhibiting ROS-dependent NETosis,The First Affiliated Hospital of Anhui University of Chinese Medicine,Solution of Zuoqing San for fumigation and washing of the postoperative wound of anal fistula,['Solution of Zuoqing San for fumigation and washing of the postoperative wound of anal fistula'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Anal Fistula,['Anal Fistula'],['Anal fistula'],ENROLLING_BY_INVITATION,,2025-08-01,2026-02-01,"[{'measure': 'Wound healing time', 'description': 'The number of days from the day after the operation until the wound surface is completely covered by epithelium (as observed by the naked eye, there is no exudation, and upon palpation, the scar is smooth).', 'timeFrame': 'From postoperative day 1 until wound healing is achieved (assessed daily during hospitalization and weekly after discharge, up to 8 weeks)'}]",[],1,18 Years,,ALL,False,The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:15.904137,v2_robust,True,True,False,False,False,
NCT05394337,Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma,Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma,Atezolizumab,"['Tiragolumab', 'TECENTRIQ', 'Atezolizumab', 'MPDL3280A']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Metastatic Malignancy,['Metastatic Malignancy'],[],RECRUITING,,2023-02-23,2025-12-31,"[{'measure': 'To evaluate relapse-free survival (RFS)', 'timeFrame': 'Through study completion, an average of 1 year'}, {'measure': 'To evaluate overall survival (OS).', 'timeFrame': 'Through study completion, an average of 1 year'}]",[],2,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,10.0,ESTIMATED,2025-09-01T16:18:15.904199,v2_robust,True,True,False,False,False,
NCT06786637,Investigating the Protective Impact of LY-2940094 on Stress-induced Depression- and Anxiety-related Phenotypes in Humans,A Combined Investigation of the Protective Impact of the NOF/Q Antagonist LY-2940094 on Stress-induced Depression- and Anxiety-related Phenotypes in Humans,Nociceptin Receptor Antagonist (LY-2940094),"['Nociceptin Receptor Antagonist (LY-2940094)', 'Nociceptin Receptor Antagonist (C220614004-FP)', 'Nociceptin Receptor Antagonist (BTRX-246040)']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Depression - Major Depressive Disorder,"['Depression - Major Depressive Disorder', 'Anxiety', 'Stress']",[],NOT_YET_RECRUITING,,2025-06,2026-08,"[{'measure': 'Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (SCID-5)', 'description': 'The Structured Clinical Interview for DSM-5 (SCID-5) is a clinician-administered diagnostic tool used to assess and diagnose mental disorders based on DSM-5 criteria. The SCID-5 categorically identifies the presence or absence of specific diagnoses and does not provide numerical minimum/maximum values.', 'timeFrame': 'Baseline'}, {'measure': 'Childhood Trauma Questionnaire (CTQ)', 'description': 'The Childhood Trauma Questionnaire (CTQ) is a self-report tool assessing childhood emotional abuse, physical abuse, sexual abuse, emotional neglect, and physical neglect. Scores on each subscale range from 5 to 25, with a total score ranging from 25 to 125; higher scores indicate greater severity of childhood trauma.', 'timeFrame': 'Baseline'}, {'measure': 'List of Threatening Experiences Questionnaire (LTE)', 'description': 'The List of Threatening Experiences Questionnaire (LTE) is a self-report measure assessing the occurrence of stressful life events, such as bereavement, illness, or job loss, over a specified period. Scores range from 0 to 12, representing the number of endorsed events, with higher scores indicating a greater number of stressful experiences.', 'timeFrame': 'Baseline'}, {'measure': 'Combined Cue-Context Fear Conditioning Task: Subjective Fear Ratings', 'description': 'The combined cue-context fear conditioning task is a paradigm to assess fear learning and extinction in response to discrete cues as well as different contexts. Subjective ratings of fear are collected via visual analog scales throughout the task. Higher ratings mean higher expression of fear towards cues and contexts (min-max: 0-100).', 'timeFrame': 'Baseline'}, {'measure': 'Probabilistic Reward Task (PRT)', 'description': ""The Probabilistic Reward Task (PRT) is a behavioral measure assessing reward sensitivity and reinforcement learning. It evaluates participants' ability to modulate behavior based on probabilistic feedback associated with correct responses. The primary outcome is the response bias score, which ranges from negative values to positive values. Higher scores indicate a stronger bias toward the more frequently rewarded response, reflecting greater reward sensitivity and reinforcement learning. Lower or negative scores suggest impaired reward responsiveness, which is often associated with anhedonia or mood disorders."", 'timeFrame': 'Baseline'}, {'measure': 'Perceived Stress Scale', 'description': 'The Perceived Stress Scale (PSS) is a self-report measure assessing the degree to which situations in life are perceived as stressful over the past month. Scores range from 0 to 40, with higher scores indicating greater perceived stress.', 'timeFrame': 'Baseline'}, {'measure': 'Combined Cue-Context Fear Conditioning Task: Skin Conductance Responce (SCR)', 'description': 'The combined cue-context fear conditioning task is a paradigm to assess fear learning and extinction in response to discrete cues as well as different contexts. Skin conductance response (SCR) is a psychophysiological measure assessing objective levels of arousal. Skin conductance is measured in microsiemens (µS) and will be processed to quantify amplitude changes in response to task stimuli. Higher amplitudes indicate higher arousal levels in response to task stimuli (min: 0, max: none).', 'timeFrame': 'Baseline'}, {'measure': 'Combined Cue-Context Fear Conditioning Task: Fear-Potentiated Startle (FPS)', 'description': 'The combined cue-context fear conditioning task is a paradigm to assess fear learning and extinction in response to discrete cues as well as different contexts. Fear-potentiated startle (FPS) is a psychophysiological measure assessing objective levels of fear responses. FPS is a difference score between threat stimuli and neutral stimuli, both measured in microvolts (µV) and processed to quantify amplitude changes, in response to task stimuli. Higher FPS scores indicate higher fear levels towards the threat stimuli (min: none, max: none).', 'timeFrame': 'Baseline'}]",[],8,18 Years,,ALL,True,Mclean Hospital,OTHER,1,50.0,ESTIMATED,2025-09-01T16:18:15.904244,v2_robust,True,True,False,False,False,
NCT00962637,Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Open-Label, Active-Controlled Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism",Androxal,"['AndroGel', 'Enclomiphene citrate', 'Androxal', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Secondary Hypogonadism,['Secondary Hypogonadism'],['Secondary Hypogonadism'],COMPLETED,,2006-03,2007-05,"[{'measure': 'Evaluate the safety of Androxal™ administered in men with secondary hypogonadism', 'timeFrame': 'Six months'}]","[{'measure': 'Demonstrate that treatment of men with secondary hypogonadism with Androxal™ was non-inferior to treatment with the active control, AndroGel®', 'timeFrame': 'Six months'}]",2,18 Years,68 Years,MALE,False,Repros Therapeutics Inc.,INDUSTRY,0,194.0,ACTUAL,2025-09-01T16:18:15.904297,v2_robust,True,True,True,False,True,
NCT01994837,A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML),A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML),ABT-199,"['ABT-199', 'ABT-199 also known as venetoclax']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Myelogenous Leukemia,"['Acute Myelogenous Leukemia', 'AML', 'Acute Myeloid Leukemia']","['GDC-0199', 'Acute Myelogenous Leukemia', 'AML', 'ABT-199', 'Acute Myeloid Leukemia', 'Myeloid Leukemia']",COMPLETED,,2013-11,2014-12,"[{'measure': 'Objective Remission Rate', 'description': 'The objective remission rate (ORR) was defined as the percentage of participants who achieved complete remission (CR), complete remission with incomplete bone marrow recovery (CRi), or partial remission (PR) per the International Working Group criteria for AML. Complete remission (CR) was defined as peripheral neutrophils at least 10˄3/μL, platelets ≥ 10˄5/μL and normocellular bone marrow with ≤ 5% blasts. Complete remission with incomplete bone marrow recovery (CRi) was defined as bone marrow with less than 5% blasts, with peripheral neutrophils of at least 10˄3/μL or platelets ≥ 10˄5/μL. Partial remission (PR) was defined as normalization in peripheral blood neutrophil and platelet counts with at least a 50% decrease in blasts persisting in bone marrow versus baseline.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}]","[{'measure': 'Complete Remission Rate', 'description': 'The complete remission (CR) rate was defined as the percentage of participants who achieved CR per the International Working Group criteria for AML. Complete remission was defined as peripheral neutrophils at least 10˄3/μL, platelets ≥ 10˄5/μL and normocellular bone marrow with ≤ 5% blasts.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Duration of Remission', 'description': 'Duration of remission was defined as the number of days from the date of first remission (CR, CRi, or PR) per the International Working Group criteria for AML to the earliest recurrence or progressive disease (PD). In this study, the duration of remission analysis was not performed because of the low remission rate, per the Statistical Analysis Plan.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Time to Progression', 'description': 'Time to progression was defined as the number of months from the date of enrollment to the date of earliest disease progression. If a participant did not experience disease progression, then the data for that participant was censored at the date of the last disease assessment.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Progression-free Survival', 'description': 'Progression-free survival was defined as the number of months from the date of enrollment to the date of earliest progression or death. If a participant did not experience disease progression or death, then the data was censored at the date of the last disease assessment.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Overall Survival', 'description': 'Overall survival was defined as the number of months from the date of enrollment to the date of death for all dosed participants. For participants who did not die, their data were censored at the date of last study visit or the last known date to be alive, whichever was later.', 'timeFrame': 'Measured up to 2 years after the last subject had enrolled in the study.'}, {'measure': 'Percentage of Participants Who Received Subsequent Stem Cell Transplant', 'description': 'The percentage of participants who received a subsequent allogenic (from a healthy donor) stem cell transplant was summarized.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Rate of Minimal Residual Disease (MRD) Negativity', 'description': 'The rate of minimal residual disease (MRD) response was defined as the percentage of participants who had MRD negative status. Only participants with a reported MRD assessment (negative or positive) from the local laboratory at the investigator site were used in the calculation of MRD response rate.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Complete Remission With Incomplete Marrow Recovery (CRi) Rate', 'description': 'The complete remission with incomplete bone marrow recovery (CRi) rate was defined as the percentage of participants who achieved CRi per the International Working Group criteria for AML. Complete remission with incomplete bone marrow recovery was defined as bone marrow with less than 5% blasts, with peripheral neutrophils of at least 10˄3/μL or platelets ≥ 10˄5/μL.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Complete Remission Rate and Complete Remission With Incomplete Marrow Recovery (CRi) Rate', 'description': 'The complete remission rate and the complete remission with incomplete marrow recovery rate (Cri) was defined as the percentage of participants who achieved complete remission (CR) or complete remission with incomplete bone marrow recovery (CRi), per the International Working Group criteria for AML. Complete remission (CR) was defined as peripheral neutrophils at least 10˄3/μL, platelets ≥ 10˄5/μL and normocellular bone marrow with ≤ 5% blasts. Complete remission with incomplete bone marrow recovery (CRi) was defined as bone marrow with less than 5% blasts, with peripheral neutrophils of at least 10˄3/μL or platelets ≥ 10˄5/μL.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}]",10,18 Years,99 Years,ALL,False,AbbVie,INDUSTRY,1,32.0,ACTUAL,2025-09-01T16:18:15.904313,v2_robust,True,True,True,False,False,
NCT00715637,Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study,Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study,Daunorubicin and Cytarabine,"['Daunorubicin and Cytarabine', 'Amonafide and Cytarabine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Secondary Acute Myeloid Leukemia (Secondary AML, sAML)","['Secondary Acute Myeloid Leukemia (Secondary AML, sAML)']","['AML', 'Leukemia', 'MDS', 'Amonafide', 'Cytarabine', 'Daunorubicin', 'Lymphatic disorders']",UNKNOWN,,2007-06,,"[{'measure': 'Rate of CR + CRi (which includes CRc and CRd) will be determined by assessing the proportion of patients who achieved CR or CRi among all evaluable patients.', 'timeFrame': 'Course 1/Course 2 Day 37 bone marrow assessments and confirmation bone marrow 30 days later'}]","[{'measure': 'Median duration of remission and median duration of disease free survival.', 'timeFrame': 'Follow-up visits following post-remission therapy'}]",2,18 Years,,ALL,False,Antisoma Research,INDUSTRY,0,420.0,ESTIMATED,2025-09-01T16:18:15.904459,v2_robust,True,True,False,False,False,
NCT04268537,Immunoregulatory Therapy for 2019-nCoV,Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients,PD-1 blocking antibody+standard treatment,"['Thymosin+standard treatment', 'PD-1 blocking antibody+standard treatment']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"2019 nCoV, PD-1","['2019 nCoV, PD-1']","['2019-ncov', 'immunotherapy', 'PD-1', 'respiratory failure']",UNKNOWN,,2020-02-10,2020-10-31,"[{'measure': 'lung injury score', 'description': 'proportion of lung injury score decreased 1 or more points', 'timeFrame': '7 days'}]","[{'measure': 'absolute lymphocyte counts', 'description': 'lymphocyte counts at day 7, 14 and 28 after randimization', 'timeFrame': '7, 14 and 28 days'}, {'measure': 'serum level of CRP, PCT and IL-6', 'description': 'serum level of CRP, PCT and IL-6 at day 3,7 and 14 after randimization', 'timeFrame': '3, 7 and 14 days'}, {'measure': 'SOFA score', 'description': 'SOFA score at Day 7, with scores range from 0 to 24 and higher score means worse outcome', 'timeFrame': '7 days'}, {'measure': 'all cause mortality rate', 'description': 'died at day 28', 'timeFrame': '28 days'}, {'measure': 'ventilation free days', 'timeFrame': '28 days'}, {'measure': 'ICU free days', 'timeFrame': 'up to 28 days'}]",7,18 Years,,ALL,False,"Southeast University, China",OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:15.904470,v2_robust,True,True,False,False,False,
NCT06426537,Colchicine's Efficacy in MI Patients: Comparing PCI and Non-Reperfusion Approaches,A Comparative Study of Colchicine's Role in Reducing Cardiac Fibrosis in Acute Myocardial Infarction Patients: Evaluating Outcomes With Percutaneous Coronary Intervention Versus Without Reperfusion,Colchicine 0.5 MG Oral Tablet,"['Colchicine Tablets', 'Colchicine 0.5 MG Oral Tablet', 'Colchicine Oral Administration', 'Generic Colchicine']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,ST-Elevation Myocardial Infarction,['ST-Elevation Myocardial Infarction'],[],COMPLETED,,2022-10-20,2023-11-20,"[{'measure': 'mpact of Colchicine on Ventricular Remodeling in Acute ST-Elevation Myocardial Infarction (STEMI) Patients Post-PCI', 'description': 'This study assesses the impact of colchicine on ventricular remodeling by measuring changes in the expression of NLRP3 inflammasome, TGF-β, and galectin-3. These biomarkers are indicative of inflammation and fibrotic activity affecting ventricular structure and function in acute STEMI patients post-PCI or without reperfusion therapy', 'timeFrame': 'Baseline and 1 month post-intervention'}]",[],1,18 Years,,ALL,True,University of Brawijaya,OTHER,0,63.0,ACTUAL,2025-09-01T16:18:15.904486,v2_robust,True,True,True,False,False,
NCT02783937,Filgrastim for Premature Ovarian Insufficiency,Filgrastim for Treatment of Premature Ovarian Insufficiency: Randomized Clinical Trial,Saline,"['Saline', 'placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Premature Ovarian Failure,['Premature Ovarian Failure'],"['Premature', 'Ovarian', 'Failure', 'Filgrastim']",COMPLETED,,2016-11,2021-06,"[{'measure': 'Return of menses', 'description': 'Return of menses in patients with amenorrhea of at least 4 months', 'timeFrame': '6 months'}]","[{'measure': 'Pregnancy', 'description': 'Occurrence of pregnancy as diagnosed by positive serum B-hCG and/or ultrasound', 'timeFrame': '6 months'}, {'measure': 'serum Estradiol', 'description': 'Normalization of serum Estradiol as tested bi-weekly', 'timeFrame': '6 months'}, {'measure': 'serum Anti-mullarian Hormone (AMH)', 'description': 'Normalization of serum AMH in patients with AMH level less than 0.9 ng/mL', 'timeFrame': '6 months'}, {'measure': 'serum FSH', 'description': 'Normalization of serum FSH in patients with FSH level above 25 IU/L', 'timeFrame': '6 months'}, {'measure': 'Follicular growth', 'description': 'Growth of follicle to size at least 18 mm as monitored by transvaginal ultrasound', 'timeFrame': '6 months'}, {'measure': 'endometrial thickness', 'description': 'increase of endometrial thickness in women with thin endometrium (less then 8 mm)', 'timeFrame': '6 months'}]",7,16 Years,40 Years,FEMALE,False,South Valley University,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:15.904542,v2_robust,True,True,True,False,False,
NCT03970837,Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs),"A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs",Tofacitinib,"['Placebo', 'Tofacitinib']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Arthritis, Rheumatoid","['Arthritis, Rheumatoid']","['Rheumatoid Arthritis', 'GSK3196165', 'Otilimab', 'Tofacitinib', 'Placebo', 'DMARDs']",TERMINATED,Only Asia cohort is early terminated.Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.,2019-06-05,2023-01-18,"[{'measure': 'Percentage (%) of Participants With 20% Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo (Global Cohort)', 'description': ""ACR20 is calculated as a 20% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 20% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) \\[visual analogue scale (VAS) with values from 0=best to 100=worst\\], Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant \\[high sensitivity C-reactive Protein milligram per liter (mg/L) (hsCRP)\\]. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage (%) of Participants With 20% Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 (Asia Cohort)', 'description': ""ACR20 is calculated as a 20% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 20% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) \\[visual analogue scale (VAS) with values from 0=best to 100=worst\\], Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant \\[high sensitivity C-reactive Protein milligram per liter (mg/L) (hsCRP)\\]. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms. Percentage values are rounded off."", 'timeFrame': 'Week 12'}]","[{'measure': 'Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Total Score Less Than or Equal to (<=)10 [CDAI Low Disease Activity (LDA)] at Week 12 (Global Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score \\<=10. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms."", 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Global Cohort)', 'description': 'HAQ-DI is a 20-question instrument that assesses the degree of difficulty of a participant in accomplishing tasks in eight functional areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Overall HAQ-DI score was computed as sum of the domain scores divided by the number of domains answered. The total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Percentage of Participants Achieving 20% Improvement in ACR20 at Week 24: Non-inferiority Comparison With Tofacitinib (Global Cohort)', 'description': ""ACR20 is calculated as a 20% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 20% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) \\[visual analogue scale (VAS) with values from 0=best to 100=worst\\], Physician Global Assessment of Arthritis Disease Activity (PhGA) (VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant \\[high sensitivity C-reactive Protein milligram per liter (mg/L) (hsCRP)\\]."", 'timeFrame': 'Week 24'}, {'measure': 'Percentage of Participants Achieving CDAI Total Score <=10 (CDAI LDA) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score \\<=10."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving CDAI Total Score <=10 (CDAI LDA) at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score \\<=10."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving CDAI Total Score <=2.8 (CDAI Remission) at Week 12 (Global Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. CDAI remission is achieved when CDAI total score \\<=2.8. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms"", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving CDAI Total Score <=2.8 (CDAI Remission) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. CDAI remission is achieved when CDAI total score \\<=2.8."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving CDAI Total Score <=2.8 (CDAI Remission) at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. CDAI remission is achieved when CDAI total score \\<=2.8."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving 50%/70% Improvement in American College of Rheumatology Criteria(ACR50/70) at Week 12 (Global Cohort)', 'description': ""ACR50/70 is calculated as a 50%/70% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 50%/70% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale (VAS) with values from 0=best to 100=worst), Physician Global Assessment of Arthritis Disease Activity (PhGA) \\[VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP)\\]. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving ACR50/70 at Week 24 and ACR20/50/70 Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': ""ACR20/50/70 is calculated as a 20%/50%/70% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 20%/50%/70% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale (VAS) with values from 0=best to 100=worst), Physician Global Assessment of Arthritis Disease Activity (PhGA) \\[VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP)\\]."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving ACR50/70 at Week 24 and ACR20/50/70 Week 52 for Placebo Switched Arms (Global Cohort)', 'description': ""ACR20/50/70 is calculated as a 20%/50%/70% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 50%/70% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale (VAS) with values from 0=best to 100=worst), Physician Global Assessment of Arthritis Disease Activity (PhGA) \\[VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP)\\]."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving Disease Activity Score Using 28 Joint Count and C-Reactive Protein (DAS28-CRP) <=3.2 (DAS28-CRP LDA) at Week 12 (Global Cohort)', 'description': ""The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP greater than or equal to (\\<=)3.2. A negative change from baseline in DAS28-CRP indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving DAS28 Erythrocyte Sedimentation Rate (ESR) <=3.2 (DAS28-ESR LDA) at Week 12 (Global Cohort)', 'description': ""The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in millimeter \\[mm\\]/hour\\[hr\\]), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-ESR\\<=3.2. A negative change from baseline in DAS28-ESR indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving DAS28-CRP <=3.2 (DAS28-CRP LDA) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': ""The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP greater than or equal to (\\<=)3.2. A negative change from baseline in DAS28-CRP indicates an improvement."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28-ESR <=3.2 (DAS28-ESR LDA) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': ""The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in millimeter \\[mm\\]/hour\\[hr\\]), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-ESR\\<=3.2. A negative change from baseline in DAS28-ESR indicates an improvement."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28-CRP <=3.2 (DAS28-CRP LDA) at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': ""The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP greater than or equal to (\\<=)3.2. A negative change from baseline in DAS28-CRP indicates an improvement."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28-ESR <=3.2 (DAS28-ESR LDA) at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': ""The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in millimeter \\[mm\\]/hour\\[hr\\]), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-ESR\\<=3.2. A negative change from baseline in DAS28-ESR indicates an improvement."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 12 (Global Cohort)', 'description': ""The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-CRP less than (\\<)2.6. A negative change from baseline in DAS28-CRP indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving DAS28 ESR <2.6 (DAS28-ESR Remission) at Week 12 (Global Cohort)', 'description': ""The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-ESR \\<2.6. A negative change from baseline in DAS28-ESR indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': ""The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-CRP less than (\\<)2.6. A negative change from baseline in DAS28-CRP indicates an improvement."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28 ESR <2.6 (DAS28-ESR Remission) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': ""The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-ESR \\<2.6. A negative change from baseline in DAS28-ESR indicates an improvement."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': ""The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-CRP less than (\\<)2.6. A negative change from baseline in DAS28-CRP indicates an improvement."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28 ESR <2.6 (DAS28-ESR Remission) at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': ""The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-ESR \\<2.6. A negative change from baseline in DAS28-ESR indicates an improvement."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving a Good/Moderate (European League Against Rheumatism) EULAR Response at Week 12 (Global Cohort)', 'description': 'DAS28-CRP and DAS28-ESR scores were categorized using EULAR response criteria. Response at a given time point was defined based on the combination of current DAS28 score and the improvement in the current DAS28 score relative to Baseline. The definition of no response, moderate response and good response was as; DAS28\\<=3.2 and DAS28 decrease from Baseline (\\>1.2: good response),(\\>0.6 to \\<=1.2: moderate response) and (\\<=0.6: no response); DAS28 \\>3.2 to \\<=5.1 and DAS28 decrease from Baseline (\\>1.2: moderate response),(\\>0.6 to \\<=1.2: moderate response) and (\\<=0.6: no response) and DAS28\\>5.1 and DAS28 decrease from Baseline (\\>1.2: moderate response),(\\>0.6 to \\<=1.2: no response) and (\\<=0.6: no response).If the post-Baseline DAS28-CRP score was missing, then the corresponding EULAR category was set to missing. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving a Good/Moderate EULAR Response at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'DAS28-CRP and DAS28-ESR scores were categorized using EULAR response criteria. Response at a given time point was defined based on the combination of current DAS28 score and the improvement in the current DAS28 score relative to Baseline. The definition of no response, moderate response and good response was as; if current DAS28 \\<=3.2 and DAS28 decrease from Baseline (\\>1.2: good response), (\\>0.6 to \\<=1.2: moderate response) and (\\<=0.6: no response); if current DAS28 \\>3.2 to \\<=5.1 and DAS28 decrease from Baseline value (\\>1.2: moderate response), (\\>0.6 to \\<=1.2: moderate response) and (\\<=0.6: no response) and if current DAS28 \\>5.1 and DAS28 decrease from Baseline value (\\>1.2: moderate response), (\\>0.6 to \\<=1.2: no response) and (\\<=0.6: no response). If the post-Baseline DAS28-CRP score was missing, then the corresponding EULAR category was set to missing.', 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving a Good/Moderate EULAR Response at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'DAS28-CRP and DAS28-ESR scores were categorized using EULAR response criteria. Response at a given time point was defined based on the combination of current DAS28 score and the improvement in the current DAS28 score relative to Baseline. The definition of no response, moderate response and good response was as; if current DAS28 \\<=3.2 and DAS28 decrease from Baseline (\\>1.2: good response), (\\>0.6 to \\<=1.2: moderate response) and (\\<=0.6: no response); if current DAS28 \\>3.2 to \\<=5.1 and DAS28 decrease from Baseline value (\\>1.2: moderate response), (\\>0.6 to \\<=1.2: moderate response) and (\\<=0.6: no response) and if current DAS28 \\>5.1 and DAS28 decrease from Baseline value (\\>1.2: moderate response), (\\>0.6 to \\<=1.2: no response) and (\\<=0.6: no response). If the post-Baseline DAS28-CRP score was missing, then the corresponding EULAR category was set to missing.', 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Number of Participants Achieving ACR/EULAR Remission at Week 12 (Global Cohort)', 'description': ""Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) \\<= 1, Swollen Joint Count 66 (SJC66) \\<= 1, high sensitivity C-reactive Protein (hsCRP) \\<= 1mg/dl and patient's global assessment of disease activity (PtGA) \\<= 10. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms."", 'timeFrame': 'Week 12'}, {'measure': 'Number of Participants Achieving ACR/EULAR Remission at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': ""Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) \\<= 1, Swollen Joint Count 66 (SJC66) \\<= 1, high sensitivity C-reactive Protein (hsCRP) \\<= 1mg/dl and patient's global assessment of disease activity (PtGA) \\<= 10."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Number of Participants Achieving ACR/EULAR Remission at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': ""Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) \\<= 1, Swollen Joint Count 66 (SJC66) \\<= 1, high sensitivity C-reactive Protein (hsCRP) \\<= 1mg/dl and patient's global assessment of disease activity (PtGA) \\<= 10."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving no Radiographic Progression Van Der Heijde Modified Total Sharp Scores (mTSS) <= 0.5) at Week 12 (Global Cohort)', 'description': 'Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. No radiographic progression is defined as a change from Baseline in van der Heijde mTSS score of \\<=0.5. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving no Radiographic Progression (mTSS <= 0.5) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. No radiographic progression is defined as a change from Baseline in van der Heijde mTSS score of \\<=0.5.', 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving no Radiographic Progression (mTSS <= 0.5) at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. No radiographic progression is defined as a change from Baseline in van der Heijde mTSS score of \\<=0.5.', 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Change From Baseline in CDAI Total Score at Week 12 (Global Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (PtGA and PhGA VAS with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score \\<=10. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms."", 'timeFrame': 'Baseline (Day 1) and week 12'}, {'measure': 'Change From Baseline in CDAI Total Score at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score \\<=10. Baseline was defined as the latest pre-dose assessment with a non-missing value (NMV), including those from unscheduled visits. Change from Baseline (CB) was calculated by subtracting the post dose (PD) visit value from the Baseline value (BV)."", 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in CDAI Total Score at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score \\<=10. Baseline was defined as the latest pre-dose assessment with a non-missing value (NMV), including those from unscheduled visits. Change from Baseline (CB) was calculated by subtracting the post dose (PD) visit value from the Baseline value (BV). For efficacy assessments baseline is interpreted as Day 1."", 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in DAS28-CRP/DAS28-ESR at Week 12 (Global Cohort)', 'description': ""DAS28-CRP and DAS28-ESR are measure of RA disease activity calculated using Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), high sensitivity C-reactive Protein (hsCRP in mg/L)/Erythrocyte sedimentation rate (ESR) \\[ESR in milimeter/hour (mm/hr)\\] and patient's global assessment of disease activity (PtGA) transformed to a 0-10 scale. Total score approximate range 0-9.4, with higher scores indicating more disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value (NMV), including those from unscheduled visits. Change from Baseline (CB) was calculated by subtracting the post dose (PD) visit value from the Baseline value (BV)."", 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in DAS28-CRP/DAS28-ESR at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': ""DAS28-CRP and DAS28-ESR are measure of RA disease activity calculated using Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), high sensitivity C-reactive Protein (hsCRP in mg/L)/Erythrocyte sedimentation rate (ESR) \\[ESR in milimeter/hour (mm/hr)\\] and patient's global assessment of disease activity (PtGA) transformed to a 0-10 scale. Total score approximate range 0-9.4, with higher scores indicating more disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value (NMV), including those from unscheduled visits. Change from Baseline (CB) was calculated by subtracting the post dose (PD) visit value from the Baseline value (BV)."", 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in DAS28-CRP/DAS28-ESR at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': ""DAS28-CRP and DAS28-ESR are measure of RA disease activity calculated using Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), high sensitivity C-reactive Protein (hsCRP in mg/L)/Erythrocyte sedimentation rate (ESR) \\[ESR in milimeter/hour (mm/hr)\\] and patient's global assessment of disease activity (PtGA) transformed to a 0-10 scale. Total score approximate range 0-9.4, with higher scores indicating more disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value (NMV), including those from unscheduled visits. Change from Baseline (CB) was calculated by subtracting the post dose (PD) visit value from the Baseline value (BV). For efficacy assessments baseline is interpreted as Day 1."", 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Van Der Heijde mTSS at Week 12 (Global Cohort)', 'description': 'Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Van Der Heijde mTSS at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score ranges from 0 to 448 for mTSS with higher values representing higher disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Van Der Heijde mTSS at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score ranges from 0 to 448 for mTSS with higher values representing higher disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value (NMV), including those from unscheduled visits. Change from Baseline (CB) was calculated by subtracting the post dose (PD) visit value from the Baseline value (BV). For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in HAQ-DI at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'HAQ-DI is a 20-question instrument that assesses the degree of difficulty of a participant in accomplishing tasks in eight functional areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Overall HAQ-DI score was computed as sum of the domain scores divided by the number of domains answered. The total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in HAQ-DI at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'HAQ-DI is a 20-question instrument that assesses the degree of difficulty of a participant in accomplishing tasks in eight functional areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Overall HAQ-DI score was computed as sum of the domain scores divided by the number of domains answered. The total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value (NMV), including those from unscheduled visits. Change from Baseline (CB) was calculated by subtracting the post dose (PD) visit value from the Baseline value (BV). For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1) and Week 52'}, {'measure': 'Change From Baseline in Arthritis Pain VAS at Week 12 (Global Cohort)', 'description': 'For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at ""0"" (no pain) and ""100"" (most severe pain). A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Arthritis Pain VAS at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at ""0"" (no pain) and ""100"" (most severe pain). A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 24 and Week 52'}, {'measure': 'Change From Baseline in Arthritis Pain VAS at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at ""0"" (no pain) and ""100"" (most severe pain). A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value (NMV), including those from unscheduled visits. Change from Baseline (CB) was calculated by subtracting the post dose (PD) visit value from the Baseline value (BV). For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1) and Week 24 and Week 52'}, {'measure': 'Change From Baseline in Short Form (SF)-36 Physical Component Scores at Week 12 (Global Cohort)', 'description': 'SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning(PF),bodily pain(BP),role limitations due to physical/emotional problems,general health(GH),mental health,social functioning,vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.PCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health.PCS is primarily derived from 4 domains(PF,role-physical,BP,GH) representing overall physical health.Positive change from baseline, reported using T-score change, indicates improvement in overall physical health.Quality Metric software was used for scoring.Baseline=latest pre-dose assessment with NMV, including those from unscheduled visits.CB=subtracting PD visit value from BV.For purpose of all analyses up to week12, placebo arms were pooled into single arm to primarily serve as reference for comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in SF-36 Mental Component Scores at Week 12 (Global Cohort)', 'description': 'SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning,bodily pain,role limitations due to physical/emotional problems,general health,mental health(MH),social functioning(SF),vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.MCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. MCS is primarily derived from 4 domains (SF,vitality,MH,role-emotional) representing overall mental health.Positive change from baseline, reported using T-score change, indicates improvement in overall mental health.Quality Metric software was used for scoring.Baseline=latest pre-dose assessment with NMV, including those from unscheduled visits.CB=subtracting PD visit value from BV.For purpose of all analyses up to week12, placebo arms were pooled into single arm to primarily serve as reference for comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in SF-36 Domain Scores at Week 12 (Global Cohort)', 'description': 'Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The MCS consists of 4 domains (social functioning, vitality, mental health, and role-emotional domains) and PCS consists of 4 domains (physical functioning, role-physical, bodily pain and general health). The individual question items are first summed for each item under the various sections. Then, those domain scores are weighted to a scale between 0 to 100, where higher score represents better health. A positive change from baseline indicates an improvement. Quality Metric software was used for scoring for SF-36. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in SF-36 Physical Component Scores at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning(PF),bodily pain(BP),role limitations due to physical/emotional problems,general health(GH),mental health,social functioning,vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.PCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health.PCS is primarily derived from 4 domains(PF,role-physical,BP,GH) representing overall physical health.Positive change from baseline, reported using T-score change, indicates improvement in overall physical health.Quality Metric software was used for scoring. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in SF-36 Mental Component Scores at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning,bodily pain,role limitations due to physical/emotional problems,general health,mental health(MH),social functioning(SF),vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.MCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. MCS is primarily derived from 4 domains (SF,vitality,MH,role-emotional) representing overall mental health.Positive change from baseline, reported using T-score change, indicates improvement in overall mental health.Quality Metric software was used for scoring. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in SF-36 Domain Scores at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The MCS consists of 4 domains (social functioning, vitality, mental health, and role-emotional domains) and PCS consists of 4 domains (physical functioning, role-physical, bodily pain and general health). The individual question items are first summed for each item under the various sections. Then, those domain scores are weighted to a scale between 0 to 100, where higher score represents better health. A positive change from baseline indicates an improvement. Quality Metric software was used for scoring for SF-36. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in SF-36 Physical Component Scores at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning(PF),bodily pain(BP),role limitations due to physical/emotional problems,general health(GH),mental health,social functioning,vitality. Each of 8 domains is scored using average, 0-100; higher score represents better health. PCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. PCS is primarily derived from 4 domains (PF,role-physical,BP,GH) representing overall physical health. Positive change from baseline, reported using T-score change, indicates improvement in overall physical health. Quality Metric software was used for scoring. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in SF-36 Mental Component Scores at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning,bodily pain,role limitations due to physical/emotional problems,general health,mental health(MH),social functioning(SF),vitality. Each of 8 domains is scored using average, 0-100; higher score represents better health. MCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. MCS is primarily derived from 4 domains (SF,vitality,MH,role-emotional) representing overall mental health. Positive change from baseline, reported using T-score change, indicates improvement in overall mental health. Quality Metric software was used for scoring. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in SF-36 Domain Scores at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning(PF), bodily pain(BP), role limitations due to physical and emotional problems, general health(GH), mental health(MH), social functioning(SF), vitality. The MCS consists of 4 domains (SF, vitality, MH, role-emotional) and PCS consists of 4 domains (PF, role-physical, BP, GH). The individual question items are first summed for each item under the various sections. Then, those domain scores are weighted to a scale between 0 to 100, where higher score represents better health. A positive change from baseline indicates an improvement. Quality Metric software was used for scoring for SF-36. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue at Week 12 (Global Cohort)', 'description': 'The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. A positive change from baseline in FACIT-fatigue indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in FACIT-Fatigue at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. A positive change from baseline in FACIT-fatigue indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in FACIT-Fatigue at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. A positive change from baseline in FACIT-fatigue indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) (Global Cohort)', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms. Fifteen participants in Placebo group received active treatment of Tofacitinib mistakenly from Week 4 instead of Week 12 as planned. They were added with the Tofacitinib arm in safety analysis.', 'timeFrame': 'Up to Week 59'}, {'measure': 'Change From Baseline in Hematology Parameter of White Blood Cell (WBC) Count, Platelet Count, Neutrophils, Lymphocytes at Week 12 (Giga Cells Per Liter) (Global Cohort)', 'description': 'Blood samples were collected for the assessment of change from baseline in hematology parameters including WBC count, platelet count, neutrophils, lymphocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Hematology Parameter of WBC Count, Platelet Count, Neutrophils, Lymphocytes at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of change from baseline in hematology parameters including WBC count, platelet count, neutrophils, lymphocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Hematology Parameter of WBC Count, Platelet Count, Neutrophils, Lymphocytes at Week 24 and Week 52 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of change from baseline in hematology parameters including WBC count, platelet count, neutrophils, lymphocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Hematology Parameter of Hemoglobin at Week 12 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of change from baseline in hematology parameters hemoglobin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Hematology Parameter of Hemoglobin at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of change from baseline in hematology parameters hemoglobin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Hematology Parameter of Hemoglobin at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'Blood samples were collected for the assessment of change from baseline in hematology parameters hemoglobin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma-Glutamyl Transpeptidase (GGT) at Week 12 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameters including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP) and gamma-glutamyl transferase (GGT) levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of AST, ALT, AP, GGT at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameters including AST, ALT, AP and GGT levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of AST, ALT, AP, GGT at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameters including AST, ALT, AP and GGT levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin at Week 12 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameter total bilirubin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameter total bilirubin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameter total bilirubin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Albumin at Week 12 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameter albumin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Albumin at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameter albumin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Albumin at Week 24 and Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameter albumin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 12 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 24 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 24 for Placebo Switched Arms (Global Cohort)', 'description': 'Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12) and Week 24'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 52'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For lipid profile assessments, baseline is interpreted as Week 4.', 'timeFrame': 'Baseline (Week 4) and Week 52'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol at Week 12 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, HDL Cholesterol at Week 24 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, HDL Cholesterol at Week 24 for Placebo Switched Arms (Global Cohort)', 'description': 'Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12) and Week 24'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, HDL Cholesterol at Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 52'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, HDL Cholesterol at Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For lipid profile assessments, baseline is interpreted as Week 4.', 'timeFrame': 'Baseline (Week 4) and Week 52'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 12 (Global Cohort)', 'description': 'Blood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 24 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Blood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 24 for Placebo Switched Arms (Global Cohort)', 'description': 'Blood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12) and Week 24'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Global Cohort)', 'description': 'Blood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 52'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 52 for Placebo Switched Arms (Global Cohort)', 'description': 'TBlood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For lipid profile assessments, baseline is interpreted as Week 4.', 'timeFrame': 'Baseline (Week 4) and Week 52'}, {'measure': 'Number of Participants With National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE)>=Grade 3 Hematological/Clinical Chemistry Abnormalities (Global Cohort)', 'description': 'Number of participants with NCI-CTCAE \\>=Grade 3 hematological/clinical chemistry abnormalities were summarized. Hematological and Clinical chemistry parameters were summarized according to the NCI-CTCAE, version 5.0: Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling. Higher grade indicates more severity. Data is presented for only those parameters for which participants had worst case \\>=Grade 3 shifts from Baseline. Fifteen participants in Placebo group received active treatment of Tofacitinib mistakenly from Week 4 instead of Week 12 as planned. They were added with the Tofacitinib arm in safety analysis.', 'timeFrame': 'Up to Week 59'}, {'measure': 'Concentrations of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) Autoantibody (Global Cohort)', 'description': 'Blood samples were collected for markers which may influence rheumatoid arthritis. Concentrations of GM-CSF autoantibodies was determined.', 'timeFrame': 'At baseline'}, {'measure': 'Number of Participants With Anti-GSK3196165 Antibodies (Global Cohort)', 'description': ""Serum samples were collected for the determination of anti- GSK3196165 antibodies (ADA) using a validated electrochemiluminescence (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Confirmed positive ADA samples were further characterized in the titration assay to quasi-quantitate the amount of ADA in the sample. Additionally, confirmed positive ADA samples were also tested in a validated neutralizing antibody assay to determine the potential neutralizing activity of the ADA."", 'timeFrame': 'Up to Week 52'}, {'measure': 'Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Total Score Less Than or Equal to (<=)10 [CDAI Low Disease Activity (LDA)] at Week 12 (Asia Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score \\<=10. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms. Percentage values are rounded off."", 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Asia Cohort)', 'description': 'HAQ-DI is a 20-question instrument that assesses the degree of difficulty of a participant in accomplishing tasks in eight functional areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Overall HAQ-DI score was computed as sum of the domain scores divided by the number of domains answered. The total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Percentage of Participants Achieving CDAI Total Score <=10 (CDAI LDA) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score \\<=10. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving CDAI Total Score <=10 (CDAI LDA) at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score \\<=10. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving CDAI Total Score <=2.8 (CDAI Remission) at Week 12 (Asia Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. CDAI remission is achieved when CDAI total score \\<=2.8. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms. Percentage values are rounded off."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving CDAI Total Score <=2.8 (CDAI Remission) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. CDAI remission is achieved when CDAI total score \\<=2.8. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving CDAI Total Score <=2.8 (CDAI Remission) at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. CDAI remission is achieved when CDAI total score \\<=2.8. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving 50%/70% Improvement in American College of Rheumatology Criteria(ACR50/70) at Week 12 (Asia Cohort)', 'description': ""ACR50/70 is calculated as a 50%/70% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 50%/70% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale (VAS) with values from 0=best to 100=worst), Physician Global Assessment of Arthritis Disease Activity (PhGA) \\[VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP)\\]. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms. Percentage values are rounded off."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving ACR20/50/70 at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': ""ACR20/50/70 is calculated as a 20%/50%/70% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 20%/50%/70% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale (VAS) with values from 0=best to 100=worst), Physician Global Assessment of Arthritis Disease Activity (PhGA) \\[VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP)\\]. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving ACR20/50/70 at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': ""ACR20/50/70 is calculated as a 20%/50%/70% improvement from Baseline in Tender Joint Count 68 (TJC68) and Swollen Joint Count 66 (SJC66) and a 50%/70% improvement in 3 of the following 5 measures: Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale (VAS) with values from 0=best to 100=worst), Physician Global Assessment of Arthritis Disease Activity (PhGA) \\[VAS with values from 0=best to 100=worst), Patient Assessment of Arthritis Pain (VAS with values from 0=no pain and 100=most severe pain), Health Assessment Questionnaire-Disability Index (HAQ-DI) (ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty) and an acute-phase reactant (high sensitivity C-reactive Protein mg/L (hsCRP)\\]. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving Disease Activity Score Using 28 Joint Count and C-Reactive Protein (DAS28-CRP) <=3.2 (DAS28-CRP LDA) at Week 12 (Asia Cohort)', 'description': ""The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP greater than or equal to (\\<=)3.2. A negative change from baseline in DAS28-CRP indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms. Percentage values are rounded off."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving DAS28 Erythrocyte Sedimentation Rate (ESR) <=3.2 (DAS28-ESR LDA) at Week 12 (Asia Cohort)', 'description': ""The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in millimeter \\[mm\\]/hour\\[hr\\]), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-ESR\\<=3.2. A negative change from baseline in DAS28-ESR indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms. Percentage values are rounded off."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving DAS28-CRP <=3.2 (DAS28-CRP LDA) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': ""The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP greater than or equal to (\\<=)3.2. A negative change from baseline in DAS28-CRP indicates an improvement. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28-ESR <=3.2 (DAS28-ESR LDA) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': ""The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in millimeter \\[mm\\]/hour\\[hr\\]), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-ESR\\<=3.2. A negative change from baseline in DAS28-ESR indicates an improvement. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28-CRP <=3.2 (DAS28-CRP LDA) at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': ""The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Low disease activity (LDA) is achieved when DAS28-CRP greater than or equal to (\\<=)3.2. A negative change from baseline in DAS28-CRP indicates an improvement. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28-ESR <=3.2 (DAS28-ESR LDA) at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': ""The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in millimeter \\[mm\\]/hour\\[hr\\]), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. Low disease activity (LDA) is achieved when DAS28-ESR\\<=3.2. A negative change from baseline in DAS28-ESR indicates an improvement. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 12 (Asia Cohort)', 'description': ""The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-CRP less than (\\<)2.6. A negative change from baseline in DAS28-CRP indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms. Percentage values are rounded off."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving DAS28 ESR <2.6 (DAS28-ESR Remission) at Week 12 (Asia Cohort)', 'description': ""The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-ESR \\<2.6. A negative change from baseline in DAS28-ESR indicates an improvement. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms. Percentage values are rounded off."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': ""The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-CRP less than (\\<)2.6. A negative change from baseline in DAS28-CRP indicates an improvement. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28 ESR <2.6 (DAS28-ESR Remission) at at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': ""The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-ESR \\<2.6. A negative change from baseline in DAS28-ESR indicates an improvement. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28-CRP <2.6 (DAS28-CRP Remission) at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': ""The DAS28-CRP is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), C-reactive protein (CRP) (in mg/L), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28- CRP scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-CRP less than (\\<)2.6. A negative change from baseline in DAS28-CRP indicates an improvement. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving DAS28 ESR <2.6 (DAS28-ESR Remission) at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': ""The DAS28-ESR is a measure of RA disease activity calculated using Tender Joint Count 28 (TJC28), Swollen Joint Count 28 (SJC28), Erythrocyte sedimentation rate (ESR) (in mm/hr), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst). DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicates less disease activity. Remission is achieved when DAS28-ESR \\<2.6. A negative change from baseline in DAS28-ESR indicates an improvement. Percentage values are rounded off."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving a Good/Moderate European League Against Rheumatism (EULAR) Response at Week 12(Asia Cohort)', 'description': 'DAS28-CRP and DAS28-ESR scores were categorized using EULAR response criteria. Response at a given time point was defined based on the combination of current DAS28 score and the improvement in the current DAS28 score relative to Baseline. The definition of no response, moderate response and good response was as; DAS28\\<=3.2 and DAS28 decrease from Baseline (\\>1.2: good response),(\\>0.6 to \\<=1.2: moderate response) and (\\<=0.6: no response); DAS28 \\>3.2 to \\<=5.1 and DAS28 decrease from Baseline (\\>1.2: moderate response),(\\>0.6 to \\<=1.2: moderate response) and (\\<=0.6: no response) and DAS28\\>5.1 and DAS28 decrease from Baseline (\\>1.2: moderate response),(\\>0.6 to \\<=1.2: no response) and (\\<=0.6: no response).If the post-Baseline DAS28-CRP score was missing, then the corresponding EULAR category was set to missing. Percentage values are rounded off.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving a Good/Moderate EULAR Response at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'DAS28-CRP and DAS28-ESR scores were categorized using EULAR response criteria. Response at a given time point was defined based on the combination of current DAS28 score and the improvement in the current DAS28 score relative to Baseline. The definition of no response, moderate response and good response was as; if current DAS28 \\<=3.2 and DAS28 decrease from Baseline (\\>1.2: good response), (\\>0.6 to \\<=1.2: moderate response) and (\\<=0.6: no response); if current DAS28 \\>3.2 to \\<=5.1 and DAS28 decrease from Baseline value (\\>1.2: moderate response), (\\>0.6 to \\<=1.2: moderate response) and (\\<=0.6: no response) and if current DAS28 \\>5.1 and DAS28 decrease from Baseline value (\\>1.2: moderate response), (\\>0.6 to \\<=1.2: no response) and (\\<=0.6: no response). If the post-Baseline DAS28-CRP score was missing, then the corresponding EULAR category was set to missing. Percentage values are rounded off.', 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving a Good/Moderate EULAR Response at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'DAS28-CRP and DAS28-ESR scores were categorized using EULAR response criteria. Response at a given time point was defined based on the combination of current DAS28 score and the improvement in the current DAS28 score relative to Baseline. The definition of no response, moderate response and good response was as; if current DAS28 \\<=3.2 and DAS28 decrease from Baseline (\\>1.2: good response), (\\>0.6 to \\<=1.2: moderate response) and (\\<=0.6: no response); if current DAS28 \\>3.2 to \\<=5.1 and DAS28 decrease from Baseline value (\\>1.2: moderate response), (\\>0.6 to \\<=1.2: moderate response) and (\\<=0.6: no response) and if current DAS28 \\>5.1 and DAS28 decrease from Baseline value (\\>1.2: moderate response), (\\>0.6 to \\<=1.2: no response) and (\\<=0.6: no response). If the post-Baseline DAS28-CRP score was missing, then the corresponding EULAR category was set to missing. Percentage values are rounded off.', 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Number of Participants Achieving ACR/EULAR Remission at Week 12 (Asia Cohort)', 'description': ""Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) \\<= 1, Swollen Joint Count 66 (SJC66) \\<= 1, high sensitivity C-reactive Protein (hsCRP) \\<= 1mg/dl and patient's global assessment of disease activity (PtGA) \\<= 10. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms."", 'timeFrame': 'Week 12'}, {'measure': 'Number of Participants Achieving ACR/EULAR Remission at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': ""Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) \\<= 1, Swollen Joint Count 66 (SJC66) \\<= 1, high sensitivity C-reactive Protein (hsCRP) \\<= 1mg/dl and patient's global assessment of disease activity (PtGA) \\<= 10."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Number of Participants Achieving ACR/EULAR Remission at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': ""Boolean-based ACR/EULAR remission is achieved if all of the following requirements are met at the same timepoint: Tender Joint Count 68 (TJC68) \\<= 1, Swollen Joint Count 66 (SJC66) \\<= 1, high sensitivity C-reactive Protein (hsCRP) \\<= 1mg/dl and patient's global assessment of disease activity (PtGA) \\<= 10."", 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving no Radiographic Progression Van Der Heijde Modified Total Sharp Scores (mTSS) <= 0.5) at Week 12 (Asia Cohort)', 'description': 'Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. No radiographic progression is defined as a change from Baseline in van der Heijde mTSS score of \\<=0.5. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms. Percentage values are rounded off.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Achieving no Radiographic Progression (mTSS <= 0.5) at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. No radiographic progression is defined as a change from Baseline in van der Heijde mTSS score of \\<=0.5. Percentage values are rounded off.', 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Percentage of Participants Achieving no Radiographic Progression (mTSS <= 0.5) at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. No radiographic progression is defined as a change from Baseline in van der Heijde mTSS score of \\<=0.5. Percentage values are rounded off.', 'timeFrame': 'Week 24 and Week 52'}, {'measure': 'Change From Baseline in CDAI Total Score at Week 12 (Asia Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of sum of Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (PtGA and PhGA VAS with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score \\<=10. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms."", 'timeFrame': 'Baseline (Day 1) and week 12'}, {'measure': 'Change From Baseline in CDAI Total Score at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score \\<=10. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value."", 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in CDAI Total Score at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': ""Clinical Disease Activity Index (CDAI) total score is a composite score consisting of the sum of Swollen Joint Count 28 (TJC28), Tender Joint Count 28 (TJC28), Patient's Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with values from 0=best to 100=worst) and Physician Global Assessment of Arthritis Disease Activity (PhGA) (visual analogue scale with values from 0=best to 100=worst). PtGA and PhGA are transformed to a 0-10 scale before computing the CDAI total score. CDAI total score ranges from 0 to 76 with higher values representing higher disease activity. Low disease activity (LDA) is achieved when CDAI total score \\<=10. Baseline was defined as the latest pre-dose assessment with a non-missing value (NMV), including those from unscheduled visits. Change from Baseline (CB) was calculated by subtracting the post dose (PD) visit value from the Baseline value (BV). For efficacy assessments baseline is interpreted as Day 1."", 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in DAS28-CRP and DAS28-ESR at Week 12 (Asia Cohort)', 'description': ""DAS28-CRP and DAS28-ESR are measure of RA disease activity calculated using Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), high sensitivity C-reactive Protein (hsCRP in mg/L)/Erythrocyte sedimentation rate (ESR) \\[ESR in milimeter/hour (mm/hr)\\] and patient's global assessment of disease activity (PtGA) transformed to a 0-10 scale. Total score approximate range 0-9.4, with higher scores indicating more disease activity. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms."", 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in DAS28-CRP and DAS28-ESR at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': ""DAS28-CRP and DAS28-ESR are measure of RA disease activity calculated using Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), high sensitivity C-reactive Protein (hsCRP in mg/L)/Erythrocyte sedimentation rate (ESR) \\[ESR in milimeter/hour (mm/hr)\\] and patient's global assessment of disease activity (PtGA) transformed to a 0-10 scale. Total score approximate range 0-9.4, with higher scores indicating more disease activity. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value."", 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in DAS28-CRP/DAS28-ESR at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': ""DAS28-CRP and DAS28-ESR are measure of RA disease activity calculated using Swollen Joint Count 28 (SJC28), Tender Joint Count 28 (TJC28), high sensitivity C-reactive Protein (hsCRP in mg/L)/Erythrocyte sedimentation rate (ESR) \\[ESR in milimeter/hour (mm/hr)\\] and patient's global assessment of disease activity (PtGA) transformed to a 0-10 scale. Total score approximate range 0-9.4, with higher scores indicating more disease activity. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1."", 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Van Der Heijde mTSS at Week 12 (Asia Cohort)', 'description': 'Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Van Der Heijde mTSS at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Van Der Heijde mTSS at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'Van der Heijde mTSS is utilized for scoring radiographs of hands and feet in rheumatoid arthritis. This method includes 16 areas of erosions, and 15 areas for joint space narrowing (JSN) in each hand, and 6 areas for erosions and 6 areas JSN in each foot. The total mTSS score is the sum of erosion (maximum of 280) and JSN (maximum of 168) scores. The score range from 0 to 448 for mTSS with higher values representing higher disease activity. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in HAQ-DI at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'HAQ-DI is a 20-question instrument that assesses the degree of difficulty of a participant in accomplishing tasks in eight functional areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Overall HAQ-DI score was computed as sum of the domain scores divided by the number of domains answered. The total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. A negative change from baseline indicates an improvement. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in HAQ-DI at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'HAQ-DI is a 20-question instrument that assesses the degree of difficulty of a participant in accomplishing tasks in eight functional areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Overall HAQ-DI score was computed as sum of the domain scores divided by the number of domains answered. The total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. A negative change from baseline indicates an improvement. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1) and Week 52'}, {'measure': 'Change From Baseline in Arthritis Pain VAS at Week 12 (Asia Cohort)', 'description': 'For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at ""0"" (no pain) and ""100"" (most severe pain). A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Arthritis Pain VAS at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at ""0"" (no pain) and ""100"" (most severe pain). A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 24 and Week 52'}, {'measure': 'Change From Baseline in Arthritis Pain VAS at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'For the Arthritis Pain VAS, participants assess the severity of their current arthritis pain using a continuous visual analogue scale (VAS) with anchors at ""0"" (no pain) and ""100"" (most severe pain). A negative change from baseline indicates an improvement. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1) and Week 24 and Week 52'}, {'measure': 'Change From Baseline in Short Form (SF)-36 Physical Component Scores at Week 12 (Asia Cohort)', 'description': 'SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning(PF),bodily pain(BP),role limitations due to physical/emotional problems,general health(GH),mental health,social functioning,vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.PCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health.PCS is primarily derived from 4 domains(PF,role-physical,BP,GH) representing overall physical health.Positive change from baseline, reported using T-score change, indicates improvement in overall physical health.Quality Metric software was used for scoring.Baseline=latest pre-dose assessment with NMV, including those from unscheduled visits.CB=subtracting PD visit value from BV.For purpose of all analyses up to week12, placebo arms were pooled into single arm to primarily serve as reference for comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in SF-36 Mental Component Scores at Week 12 (Asia Cohort)', 'description': 'SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning,bodily pain,role limitations due to physical/emotional problems,general health,mental health(MH),social functioning(SF),vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.MCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. MCS is primarily derived from 4 domains (SF,vitality,MH,role-emotional) representing overall mental health.Positive change from baseline, reported using T-score change, indicates improvement in overall mental health.Quality Metric software was used for scoring.Baseline=latest pre-dose assessment with NMV, including those from unscheduled visits.CB=subtracting PD visit value from BV.For purpose of all analyses up to week12, placebo arms were pooled into single arm to primarily serve as reference for comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in SF-36 Domain Scores at Week 12 (Asia Cohort)', 'description': 'Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The MCS consists of 4 domains (social functioning, vitality, mental health, and role-emotional domains) and PCS consists of 4 domains (physical functioning, role-physical, bodily pain and general health). The individual question items are first summed for each item under the various sections. Then, those domain scores are weighted to a scale between 0 to 100, where higher score represents better health. A positive change from baseline indicates an improvement. Quality Metric software was used for scoring for SF-36. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in SF-36 Physical Component Scores at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning(PF),bodily pain(BP),role limitations due to physical/emotional problems,general health(GH),mental health,social functioning,vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.PCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health.PCS is primarily derived from 4 domains(PF,role-physical,BP,GH) representing overall physical health.Positive change from baseline, reported using T-score change, indicates improvement in overall physical health.Quality Metric software was used for scoring. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in SF-36 Mental Component Scores at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning,bodily pain,role limitations due to physical/emotional problems,general health,mental health(MH),social functioning(SF),vitality.Each of 8 domains is scored using average, 0-100; higher score represents better health.MCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. MCS is primarily derived from 4 domains (SF,vitality,MH,role-emotional) representing overall mental health.Positive change from baseline, reported using T-score change, indicates improvement in overall mental health.Quality Metric software was used for scoring. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in SF-36 Domain Scores at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning, bodily pain, role limitations due to physical and emotional problems, general health, mental health, social functioning, vitality. The MCS consists of 4 domains (social functioning, vitality, mental health, and role-emotional domains) and PCS consists of 4 domains (physical functioning, role-physical, bodily pain and general health). The individual question items are first summed for each item under the various sections. Then, those domain scores are weighted to a scale between 0 to 100, where higher score represents better health. A positive change from baseline indicates an improvement. Quality Metric software was used for scoring for SF-36. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in SF-36 Physical Component Scores at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning(PF),bodily pain(BP),role limitations due to physical/emotional problems,general health(GH),mental health,social functioning,vitality. Each of 8 domains is scored using average, 0-100; higher score represents better health. PCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. PCS is primarily derived from 4 domains (PF,role-physical,BP,GH) representing overall physical health. Positive change from baseline, reported using T-score change, indicates improvement in overall physical health. Quality Metric software was used for scoring. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in SF-36 Mental Component Scores at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'SF-36 is health-related survey that assesses quality of life covering 8 domains:physical functioning,bodily pain,role limitations due to physical/emotional problems,general health,mental health(MH),social functioning(SF),vitality. Each of 8 domains is scored using average, 0-100; higher score represents better health. MCS was aggregated across the domains and scaled to T-score with mean of 50 and SD of 10; higher score represents better health. MCS is primarily derived from 4 domains (SF,vitality,MH,role-emotional) representing overall mental health. Positive change from baseline, reported using T-score change, indicates improvement in overall mental health. Quality Metric software was used for scoring. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in SF-36 Domain Scores at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'Short-Form 36 (SF-36) is a health-related survey that assesses quality of life covering 8 domains: physical functioning(PF), bodily pain(BP), role limitations due to physical and emotional problems, general health(GH), mental health(MH), social functioning(SF), vitality. The MCS consists of 4 domains (SF, vitality, MH, role-emotional) and PCS consists of 4 domains (PF, role-physical, BP, GH). The individual question items are first summed for each item under the various sections. Then, those domain scores are weighted to a scale between 0 to 100, where higher score represents better health. A positive change from baseline indicates an improvement. Quality Metric software was used for scoring for SF-36. Baseline was defined as latest pre-dose assessment with non-missing value, including from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue at Week 12 (Asia Cohort)', 'description': 'The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. A positive change from baseline in FACIT-fatigue indicates an improvement. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in FACIT-Fatigue at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. A positive change from baseline in FACIT-fatigue indicates an improvement. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in FACIT-Fatigue at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue is a validated patient-reported measure of 13 statements regarding the feeling of fatigue. The total score ranges from 0 to 52 with higher values representing a lower fatigue and a better quality of life. A positive change from baseline in FACIT-fatigue indicates an improvement. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For efficacy assessments baseline is interpreted as Day 1.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) (Asia Cohort)', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death.', 'timeFrame': 'Up to Week 59'}, {'measure': 'Change From Baseline in Hematology Parameter of White Blood Cell (WBC) Count, Platelet Count, Neutrophils, Lymphocytes at Week 12 (Giga Cells Per Liter) (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of change from baseline in hematology parameters including WBC count, platelet count, neutrophils, lymphocytes. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Hematology Parameter of WBC Count, Platelet Count, Neutrophils, Lymphocytes at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of change from baseline in hematology parameters including WBC count, platelet count, neutrophils, lymphocytes. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Hematology Parameter of WBC Count, Platelet Count, Neutrophils, Lymphocytes at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of change from baseline in hematology parameters including WBC count, platelet count, neutrophils, lymphocytes. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Hematology Parameter of Hemoglobin at Week 12 (Asia Cohort)', 'description': 'Blood samples was collected for the assessment of hematology parameters. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Hematology Parameter of Hemoglobin at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Blood samples was collected for the assessment of hematology parameters. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Hematology Parameter of Hemoglobin at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'Blood samples was collected for the assessment of hematology parameters. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma-Glutamyl Transpeptidase (GGT) at Week 12 (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameters including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP) and gamma-glutamyl transferase (GGT) levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of AST, ALT, AP, GGT at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameters including AST, ALT, AP and GGT levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of AST, ALT, AP, GGT at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameters including AST, ALT, AP and GGT levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin at Week 12 (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameter total bilirubin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameter total bilirubin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameter total bilirubin level. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Albumin at Week 12 (Asia Cohort)', 'description': 'Blood samples was collected for the assessment of clinical chemistry parameter albumin. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Albumin at Week 24 and Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Blood samples was collected for the assessment of clinical chemistry parameter albumin. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value.', 'timeFrame': 'Baseline (Day 1), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Clinical Chemistry Parameter of Albumin at Week 24 and Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'Blood samples was collected for the assessment of clinical chemistry parameter albumin. Baseline was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting post dose visit value from Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12), Week 24 and Week 52'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 12 (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 24 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 24 for Placebo Switched Arms (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12) and Week 24'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 52'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Total Cholesterol at Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of lipid profile of total cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For lipid profile assessments, baseline is interpreted as Week 4.', 'timeFrame': 'Baseline (Week 4) and Week 52'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol at Week 12 (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, HDL Cholesterol at Week 24 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, HDL Cholesterol at Week 24 for Placebo Switched Arms (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12) and Week 24'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, HDL Cholesterol at Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 52'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of LDL Cholesterol, HDL Cholesterol at Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'Blood samples were collected for the assessment of fasting lipid profile including LDL cholesterol, HDL cholesterol levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For lipid profile assessments, baseline is interpreted as Week 4.', 'timeFrame': 'Baseline (Week 4) and Week 52'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 12 (Asia Cohort)', 'description': 'Blood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For the purpose of all analyses up to week 12, the placebo arms were pooled into a single placebo arm to primarily serve as a reference for the comparison of active treatment arms.', 'timeFrame': 'Baseline (Day 1) and Week 12'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 24 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Blood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 24 for Placebo Switched Arms (Asia Cohort)', 'description': 'Blood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For safety assessments baseline is interpreted as Week 12.', 'timeFrame': 'Baseline (Week 12) and Week 24'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 52 for Treatment Arms Who Started Study Intervention From Day 1 (Asia Cohort)', 'description': 'Blood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.', 'timeFrame': 'Baseline (Day 1) and Week 52'}, {'measure': 'Change From Baseline in Lipid Profile Parameter of Triglycerides at Week 52 for Placebo Switched Arms (Asia Cohort)', 'description': 'Blood samples was collected for the assessment of change from baseline in fasting lipid profile triglycerides levels. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. For lipid profile assessments, baseline is interpreted as Week 4.', 'timeFrame': 'Baseline (Week 4) and Week 52'}, {'measure': 'Number of Participants With National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE)>=Grade 3 Hematological/Clinical Chemistry Abnormalities (Asia Cohort)', 'description': 'Number of participants with NCI-CTCAE \\>=Grade 3 hematological/clinical chemistry abnormalities were summarized. Hematological and Clinical chemistry parameters were summarized according to the NCI-CTCAE, version 5.0: Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling. Higher grade indicates more severity. Data is presented for only those parameters for which participants had worst case \\>=Grade 3 shifts from Baseline.', 'timeFrame': 'Up to Week 59'}, {'measure': 'Concentrations of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) Autoantibody (Asia Cohort)', 'description': 'Blood samples were collected for markers which may influence rheumatoid arthritis. Concentrations of GM-CSF autoantibodies was determined.', 'timeFrame': 'At baseline'}, {'measure': 'Number of Participants With Anti-GSK3196165 Antibodies (Asia Cohort)', 'description': ""Serum samples were collected for the determination of anti- GSK3196165 antibodies (ADA) using a validated electrochemiluminescence (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Confirmed positive ADA samples were further characterized in the titration assay to quasi-quantitate the amount of ADA in the sample. Additionally, confirmed positive ADA samples were also tested in a validated neutralizing antibody assay to determine the potential neutralizing activity of the ADA."", 'timeFrame': 'Up to Week 59'}, {'measure': 'Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) for Placebo Switched Arms (Global Cohort)', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death.', 'timeFrame': 'Week 12 to Week 59'}, {'measure': 'Number of Participants With National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE)>=Grade 3 Hematological/Clinical Chemistry Abnormalities for Placebo Switched Arms (Global Cohort)', 'description': 'Number of participants with NCI-CTCAE \\>=Grade 3 hematological/clinical chemistry abnormalities were summarized. Hematological and Clinical chemistry parameters were summarized according to the NCI-CTCAE, version 5.0: Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling. Higher grade indicates more severity. Data is presented for only those parameters for which participants had worst case \\>=Grade 3 shifts from Baseline.', 'timeFrame': 'Week 12 to Week 59'}, {'measure': 'Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) for Placebo Switched Arms (Asia Cohort)', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is any untoward medical occurrence that, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity and/or can result in death.', 'timeFrame': 'Week 12 to Week 59'}, {'measure': 'Number of Participants With National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE)>=Grade 3 Hematological/Clinical Chemistry Abnormalities for Placebo Switched Arms (Asia Cohort)', 'description': 'Number of participants with NCI-CTCAE \\>=Grade 3 hematological/clinical chemistry abnormalities were summarized. Hematological and Clinical chemistry parameters were summarized according to the NCI-CTCAE, version 5.0: Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling. Higher grade indicates more severity. Data is presented for only those parameters for which participants had worst case \\>=Grade 3 shifts from Baseline.', 'timeFrame': 'Week 12 to Week 59'}]",189,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,1,1764.0,ACTUAL,2025-09-01T16:18:15.904625,v2_robust,True,True,False,True,True,Only Asia cohort is early terminated.Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.
NCT07028645,Uroflowmetry and Nocturnal Enuresis,Is Uroflowmetry Useful in Assessing Response to Pharmacological Treatment in Enuresis,desmopressin melt form 120 μg,"['Propiverine tablet', 'Desmopressin lyophilisate (Melt)', 'desmopressin melt form 120 μg']",3,OBSERVATIONAL,[],,,"Enuresis, Nocturnal","['Enuresis, Nocturnal']","['Uroflowmetry', 'Enuresis']",ACTIVE_NOT_RECRUITING,,2022-08-20,2025-12-30,"[{'measure': 'Number of days without bedwetting', 'description': 'Achievement of bedwetting in one or less night of a month', 'timeFrame': '1 month'}]",[],1,5 Years,17 Years,ALL,False,Furkan Adem Canbaz,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:15.904998,v2_robust,False,True,False,False,False,
NCT01082445,Effects of N-acetylcysteine on Diabetic Foot Oxygenation,Effects of Prolonged N-acetylcysteine Administration on Foot Ulcer Oxygenation in Diabetic Patients,N-acetylcysteine,"['Fluimucil (R) 600 mg, tablets', 'N-acetylcysteine', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Foot Ulcer, Diabetic","['Foot Ulcer, Diabetic']","['stage C', 'grade 0 (Texas University)']",COMPLETED,,2009-08,2010-11,"[{'measure': 'Tissue oxygenation improvement', 'timeFrame': 'Basal (time 0) and after 3 months of treatment/observation'}]","[{'measure': 'Improvement of the endothelial function', 'description': 'nitrites/nitrates - ICAM - VCAM - PAI-1', 'timeFrame': 'Basal (time 0) and after 3 months of treatment/observation'}, {'measure': 'Oxidation status reduction', 'description': '8-iso PGF-2alpha assessment', 'timeFrame': 'Basal (time 0) and after 3 months of treatment/observation'}]",3,45 Years,70 Years,ALL,False,"University of Turin, Italy",OTHER,0,100.0,ACTUAL,2025-09-01T16:18:15.905030,v2_robust,True,True,True,False,False,
NCT00297245,Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass,,cognitive function,['cognitive function'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Cognitive Decline,['Cognitive Decline'],['gastrodin'],UNKNOWN,,2006-02,2006-05,[{'measure': 'Gastrodin markedly prevents cognitive decline related to cardiopulmonary bypass'}],[{'measure': 'neuropsychological tests'}],2,18 Years,65 Years,ALL,False,Huazhong University of Science and Technology,OTHER,0,200.0,,2025-09-01T16:18:15.905041,v2_robust,True,True,False,False,False,
NCT00357045,Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine,Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine; THE HEPDEP II STUDY,Paroxetine,['Paroxetine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Major Depression,['Major Depression'],[],COMPLETED,,,,[],[],0,18 Years,,ALL,,Portland VA Medical Center,FED,2,,,2025-09-01T16:18:15.905171,v2_robust,True,True,True,False,False,
NCT04589845,Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study,Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial,Entrectinib,"['Trastuzumab emtansine', 'Gavreto (US)', 'Divarasib', 'Rozlytrek', 'Kadcyla', 'Alecensa', 'GDC-0077', 'Alectinib', 'Tecentriq', 'Inavolisib', 'Belvarafenib', 'Pralsetinib', 'Atezolizumab', 'Camonsertib', 'GDC-6036', 'Entrectinib', 'Ipatasertib']",17,INTERVENTIONAL,['PHASE2'],PHASE2,,Solid Tumors,['Solid Tumors'],[],RECRUITING,,2021-01-18,2032-09-25,"[{'measure': 'All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)', 'description': 'Confirmed objective response indicates ≥4 weeks after initial documentation of response.', 'timeFrame': 'Approximately up to 12 years'}]","[{'measure': 'All Cohorts: IRC-assessed Duration of Response (DOR) per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'All Cohorts: IRC-assessed Clinical Benefit Rate (CBR) per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'All Cohorts: IRC-assessed Progression-free Survival (PFS) per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'All Cohorts: Investigator (INV)-assessed ORR per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'All Cohorts: INV-assessed DOR per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'All Cohorts: INV-assessed CBR per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'All Cohorts: INV-assessed PFS per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'All Cohorts: IRC- and INV-assessed Time to Central Nervous System (CNS) Progression per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'All Cohorts: Overall Survival (OS)', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-ORR per Response Assessment in Neuro-oncology (RANO)', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-DOR per RANO', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-CBR per RANO', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-PFS per RANO', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: INV-assessed CNS-ORR per RANO', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: INV-assessed CNS-DOR per RANO', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: INV-assessed CNS-CBR per RANO', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: INV-assessed CNS-PFS per RANO', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed ORR per International Neuroblastoma Response Criteria (INRC)', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed DOR per INRC', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed CBR per INRC', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed PFS per INRC', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed ORR per INRC', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed DOR per INRC', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed CBR per INRC', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed PFS per INRC', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: IRC-assessed Intracranial (IC)-ORR per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: IRC-assessed IC-DOR per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: IRC-assessed IC-CBR per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: IRC-assessed IC-PFS Rate per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: INV-assessed IC-ORR per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: INV-assessed IC-DOR per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: INV-assessed IC-CBR per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A, B, C, D, I, J, K: INV-assessed IC-PFS Rate per RECIST v1.1', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A and B: Percentage of Participants With Confirmed Deterioration as Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)', 'description': 'The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points.', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A and B: Change From Baseline in the EORTC-QLQ-C30 Total Score', 'description': 'The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points.', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A and B: Percentage of Participants With a Clinical Meaningful Change on the Global Health Status, Physical Functioning, and Role Functioning Scores From the EORTC QLQ-C30', 'description': 'The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points.', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'Cohorts A and B: Time to Confirmed Symptom Onset or Worsening From Tumor-related Symptom Scores From the EORTC QLQ-C30 and EORTC Item Library 71 (IL71)', 'description': 'The EORTC Item library includes stand-alone symptoms scales and an overall assessment of treatment bother to provide additional information not currently captured in the EORTC QLQ-C30. The scales use the same rating scale and recall period of previous week as the symptom scales in the EORTC QLQ-C30.', 'timeFrame': 'Approximately up to 12 years'}, {'measure': 'All Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'AE severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5 (NCI CTCAE v5.0.)', 'timeFrame': 'Approximately up to 12 years'}]",39,,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,920.0,ESTIMATED,2025-09-01T16:18:15.905195,v2_robust,True,True,False,False,True,
NCT01806272,Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis,"A Open,Randomized Phase II Trial Comparing Local Use of rhGM-CSF and Compound Vitamin B12 Solution to Compound Vitamin B12 Solution Alone Treating Chemoradiotherapy-induced Oral Mucositis in Patients With Primary Nasopharyngeal Carcinoma",rhGM-CSF,"['贯新克', 'Compound Vitamin B12', '特尔立', 'rhGM-CSF']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Nasopharyngeal Cancers,['Nasopharyngeal Cancers'],"['rhGM-CSF', 'Oral Mucositis', 'Primary Nasopharyngeal Cancers', 'Chemoradiotherapy']",UNKNOWN,,2013-03,2014-08,"[{'measure': 'The incidence of grade II and less oral mucositis at the end of treatment', 'description': 'Using the criteria of NCI CTCAE v3.0', 'timeFrame': '7 weeks'}]","[{'measure': 'Pain', 'description': 'Cumulative incidence and time of different grade,using the criteria of WHO,NRS', 'timeFrame': '12 weeks'}, {'measure': 'Cumulative incidence and time of grade III and more oral mucositis', 'description': 'Using the criteria of NCI CTCAE v3.0', 'timeFrame': '7 weeks'}, {'measure': 'Dysphagia', 'description': 'Cumulative incidence and time of different grade,using NCI CTCAE v3.0', 'timeFrame': '12 weeks'}, {'measure': 'Tumor response to chemoradiotherapy', 'description': 'Using the criteria of Response Evaluation Criteria in Solid Tumors1.1(RECIST1.1)', 'timeFrame': '12 weeks'}]",5,18 Years,65 Years,ALL,False,Wei LUO,OTHER,0,160.0,ESTIMATED,2025-09-01T16:18:15.905263,v2_robust,True,True,False,False,False,
NCT05590572,A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma,A Study of Etoposide and Ifosfamide Combined With or Without Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma,Sulfatinib,"['Etoposide', 'Isophosphamide', 'Sulfatinib']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Osteosarcoma,['Osteosarcoma'],"['Refractory or Relapsed osteosarcoma', 'Sulfatinib', 'Tyrosine kinase inhibitors', 'Etoposide', 'Ifosfamide']",NOT_YET_RECRUITING,,2023-01,2027-12,"[{'measure': '4 months progression-free survival', 'description': 'The proportion of patients who had no objective tumor progression or death from the start of treatment to 4 months of follow-up.', 'timeFrame': '4 months'}, {'measure': 'Efficacy evaluation in solid tumors', 'description': 'Complete response (CR), all target and non-target lesions (non-lymph nodes) disappear, and the diameter of all pathologic lymph nodes (both target and non-target) must be reduced to \\<10 mm; Partial response (PR), using baseline total diameter as reference, reduced the total diameter of target lesions by at least 30%.', 'timeFrame': '2 months'}]","[{'measure': 'Best of response,BOR', 'description': 'From the date of the first administration of the study drug to disease progression or death, whichever occurs first.', 'timeFrame': '4 months'}, {'measure': 'Duration of Remission (DOR)', 'description': 'Complete response (CR)/ partial response (PR) was first recorded until disease progression was first recorded until the data cutoff date.', 'timeFrame': '2 years'}]",4,2 Years,25 Years,ALL,False,"Second Affiliated Hospital, School of Medicine, Zhejiang University",OTHER,5,148.0,ESTIMATED,2025-09-01T16:18:15.905285,v2_robust,True,True,False,False,False,
NCT00718172,Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C,Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C,Peginterferon &amp; Ribavirin for Hepatitis C,"['Pre-treatment Ribavirin', 'Peginterferon &amp; Ribavirin for Hepatitis C']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Hepatitis C, Chronic","['Hepatitis C, Chronic']","['Ribavirin Pretreatment', 'Gene Expression', 'Peginterferon', 'Hepatitis C', 'Liver Biopsy', 'HCV']",COMPLETED,,2008-07-11,2014-08-19,[{'measure': 'Improved viral kinetics with ribavirin pretreatment.'}],"[{'measure': 'Changes in gene expression during peginterferon and/or ribavirin thereapy, effect of treatment on NK cell function.'}]",2,18 Years,,ALL,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,0,81.0,ACTUAL,2025-09-01T16:18:15.905303,v2_robust,True,True,True,False,False,
NCT02205372,"Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy","A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 (Low Dose) in Subjects With Diabetic Nephropathy",MT-3995,"['MT-3995', 'Placebo']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Diabetic Nephropathy,['Diabetic Nephropathy'],['Diabetic Nephropathy'],COMPLETED,,2014-07,2015-08,"[{'measure': 'Frequency and nature of treatment-emergent adverse events and serious adverse events.', 'timeFrame': '20 weeks'}]","[{'measure': 'Plasma concentrations of MT-3995', 'timeFrame': '20 weeks'}, {'measure': 'Plasma concentrations of major metabolite of MT-3995', 'timeFrame': '20 weeks'}, {'measure': 'Change from baseline in Urine albumin-to-creatinine ratio (UACR)', 'timeFrame': '20 weeks'}, {'measure': 'Change from baseline in blood pressure', 'timeFrame': '20 weeks'}]",5,20 Years,75 Years,ALL,False,Mitsubishi Tanabe Pharma Corporation,INDUSTRY,0,31.0,ACTUAL,2025-09-01T16:18:15.905341,v2_robust,True,True,True,False,True,
NCT06332872,"Comparison Effectiveness of Oral Ivermectin , 1% Permethrin Shampoo and 4% Dimeticone Liquid Gel in the Treatment of Pediculosis Capitis Among School Children in Chachoengsao Province, Thailand","Comparison Effectiveness of Oral Ivermectin , 1% Permethrin Shampoo and 4% Dimeticone Liquid Gel in the Treatment of Pediculosis Capitis Among School Children in Chachoengsao Province, Thailand",Oral Ivermectin,"['4% dimenticone liquid gel', 'Oral Ivermectin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Pediculus Capitis Infestation,"['Pediculus Capitis Infestation', 'Permethrin Adverse Reaction', 'Dimethicone Adverse Reaction', 'Permethrin Allergy', 'Dimethicone Allergy', 'Ivermectin', 'School-age Children']","['Pediculosis capitis', 'head lice', 'pediculicides', 'School', 'Children', 'Permethrin', 'Shampoo', 'Ivermectin', 'Dimenticone', 'gel', 'liquid gel', 'pediculosis']",ACTIVE_NOT_RECRUITING,,2023-12-15,2024-05,"[{'measure': 'Comparison effectiveness of Oral ivermectin , 1% Permethrin shampoo and 4% Dimeticone liquid gel in the treatment of Pediculosis capitis', 'description': 'Treatment of Pediculosis capitis was considered effective by the absence of live lice', 'timeFrame': 'From enrollment to the end of treatment at 28 days'}]","[{'measure': 'Prevalence of head louse infestation among school children in Chachoengsao Province, Thailand', 'description': 'Determined with a fine-toothed de-lousing comb to detect living head lice under natural sunlight by combing the hair 20 times in each portion of hair and visual observation above the ears and along the nape of the neck. The detection of viable nits (louse eggs) and nymphs is also considered positive.', 'timeFrame': 'From enrollment to the end of screening at 28 days'}, {'measure': 'Side effects of Oral ivermectin , 1% Permethrin shampoo and 4%Dimeticone liquid gel', 'description': 'collected by post-treatment questionnaire about symptoms and allergic reactions after receive the treatment; oral Ivermectin, 4% Dimenticone liquid gel, or 1% Permethrin shampoo', 'timeFrame': 'From enrollment to the end of treatment at 28 days'}, {'measure': 'The association factor of head lice infestation among school children in Chachoengsao Province, Thailand', 'description': 'Collected by pre-treatment questionnaire about factors that may be related to lice infection. The parents of the subjects will complete the questionnaire because the subjects were under 14 years of age.', 'timeFrame': 'From the enrollment to the end of treatment at 28 days'}]",4,6 Years,13 Years,ALL,False,Phramongkutklao College of Medicine and Hospital,OTHER,0,117.0,ESTIMATED,2025-09-01T16:18:15.905438,v2_robust,True,True,False,False,False,
NCT03090672,"Cellular & Biocellular Regenerative Therapy in Musculoskeletal Pain, Dysfunction,Degenerative or Inflammatory Disease","Use of Cellular and Biocellular Therapy in Musculoskeletal Pain, Dysfunction, Degenerative or Inflammatory Disease",Normal Saline,['Normal Saline'],1,INTERVENTIONAL,['NA'],,,Osteoarthritis,"['Osteoarthritis', 'Rheumatoid Nodule', 'Degenerative Joint Disease', 'Tendinopathy', 'Tendinosis', 'Back Pain']","['Arthritis', 'Degenerative', 'Tendinosis', 'Jont disease', 'Low back pain']",UNKNOWN,,2017-03-11,2022-12-31,"[{'measure': 'Participants with complications', 'description': 'Adverse and Severe Adverse Events Reports', 'timeFrame': '1 month'}]","[{'measure': 'Change from baseline quality of life level (QoL Questionnaire)', 'description': 'QoL Questionnaire', 'timeFrame': '6 months, 12 months'}, {'measure': 'Change from baseline visual analog pain score', 'description': 'Changes of Visual Analog Pain Score (VAS) 1-10', 'timeFrame': '6 months, 1 year, 2 year'}, {'measure': 'Change from baseline of limitation of activities (Functional analysis of range of motion)', 'description': 'Functional analysis of range of motion compared from baseline', 'timeFrame': 'baseline, 6 months, 1 year'}, {'measure': 'Change from baseline of imaging if required for study entry', 'description': 'imaging', 'timeFrame': 'baseline, 1 year'}]",5,18 Years,90 Years,ALL,False,"Robert W Alexander, MD",OTHER,2,300.0,ESTIMATED,2025-09-01T16:18:15.905456,v2_robust,True,True,False,False,True,
NCT01801072,Seizure Prophylaxis in Aneurysm Repair,Seizure Prophylaxis in Aneurysm Repair,Levetiracetam,"['Levetiracetam', 'Keppra']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Intracranial Aneurysms,"['Intracranial Aneurysms', 'Seizure']",[],COMPLETED,,2013-02,2023-10-06,"[{'measure': 'Incidence of Seizure', 'description': 'Incidence of seizure reported as number of participants who had at least one seizure within the relevant date range. Data collected at hospital discharge, 1-2 months, 4-6 months, 6-12 months, and 5 years. Data is not cumulative. Counts reflect the number of participants who experienced a seizure since their previous check-in.', 'timeFrame': '5 years from procedure'}]","[{'measure': 'Duration of Seizure', 'description': 'Duration of seizure', 'timeFrame': 'To compare duration of seizure in each randomization group'}]",2,18 Years,,ALL,False,University of Michigan,OTHER,0,82.0,ACTUAL,2025-09-01T16:18:15.905464,v2_robust,True,True,True,False,False,
NCT05261672,Regional Midazolam in Quadratus Lumborum Block,Midazolam as an Adjuvant to Bupivacaine in Quadratus Lumborum Block After Caesarean Section; Does it Offer Better Pain Control? a Randomized Double Blind Clinical Trial,Midazolam/ bupivaciane,"['Bupivacain', 'Midazolam/ bupivaciane']",2,INTERVENTIONAL,['NA'],,,Postoperative Pain,['Postoperative Pain'],"['Midazolam', 'Bupivacaine']",RECRUITING,,2022-03-15,2024-01-20,"[{'measure': 'rescue analgesia', 'description': 'Time to rescue analgesia in the post operative period', 'timeFrame': '24 hours'}]","[{'measure': 'Visual analog scale', 'description': 'Pain Visual analog scale during the 1st 24 hours', 'timeFrame': '2, 4, 6, 8, 12, 16, 20, 24 hours'}]",2,24 Years,40 Years,FEMALE,False,Assiut University,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:15.905499,v2_robust,True,True,False,False,False,
NCT05045872,Assessment of Renal Vasculature and Function with Ferumoxytol-enhanced Magnetic Resonance Imaging,Clinical Study of Domestic Polysaccharide Superparamagnetic Iron Oxide Nanoparticle Injection for Renal Contrast-enhanced Magnetic Resonance Imaging,domestic polysaccharide superparamagnetic iron oxide nanoparticle,"['domestic polysaccharide superparamagnetic iron oxide nanoparticle', 'ferumoxytol']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Kidney Diseases,['Chronic Kidney Diseases'],"['Ultrasmall Superparamagnetic Particles of Iron Oxide', 'Contrast-Enhanced Magnetic Resonance', 'Renal Artery Stenosis']",COMPLETED,,2021-09-17,2024-09-03,"[{'measure': 'the degree of renal artery stenosis', 'description': 'Degree of renal artery stenosis assessed by Magnetic Resonance Imaging and renal angiography', 'timeFrame': 'baseline and after intervention'}, {'measure': 'quantitative cortical T2* value', 'description': 'the quantitative T2\\* value of the renal cortex will be measured bilaterally at the upper and lower poles by drawing six equal-sized, non-overlapping operator-dependent regions of interest (ROI) to calculate average quantitative T2\\* values.', 'timeFrame': 'baseline and after intervention'}, {'measure': 'change of hemoglobin level', 'description': 'hemoglobin examination of patients before and after examination to evaluate anemia.', 'timeFrame': 'baseline,72 hours,30 days,3 months'}, {'measure': 'serum creatinine', 'description': 'serum creatinine examination of patients before and after examination to evaluate kidney function.', 'timeFrame': 'baseline,72 hours,30 days,3 months'}, {'measure': 'Urine routine', 'description': 'Urine routine examination of patients before and after examination to evaluate kidney function.', 'timeFrame': 'baseline,72 hours,30 days,3 months'}, {'measure': '24-hour urine biochemistry', 'description': '24-hour urine biochemistry examination of patients before and after examination to evaluate kidney function.', 'timeFrame': 'baseline,72 hours,30 days,3 months'}, {'measure': 'Retinol binding protein', 'description': 'Retinol binding protein examination of patients before and after examination to evaluate kidney function.', 'timeFrame': 'baseline,72 hours,30 days,3 months'}, {'measure': 'Neutrophil gelatinase-associated lipocalin', 'description': 'Neutrophil gelatinase-associated lipocalin examination of patients before and after examination to evaluate kidney function.', 'timeFrame': 'baseline,72 hours,30 days,3 months'}, {'measure': 'Serum iron', 'description': 'Determination of serum iron before and after MRA to evaluate the changes of iron content in peripheral blood.', 'timeFrame': 'baseline,72 hours,30 days,3 months'}, {'measure': 'Ferritin', 'description': 'Determination of serum ferritin before and after MRA to evaluate the changes of iron content in peripheral blood.', 'timeFrame': 'baseline,72 hours,30 days,3 months'}, {'measure': 'Transferrin', 'description': 'Determination of serum transferrin before and after MRA to evaluate the changes of iron content in peripheral blood.', 'timeFrame': 'baseline,72 hours,30 days,3 months'}, {'measure': 'serum cystatin C', 'description': 'Determination of serum cystatin C before and after examination to evaluate the changes of renal function.', 'timeFrame': 'baseline,72 hours,30 days,3 months'}]",[],12,18 Years,75 Years,ALL,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,1,44.0,ACTUAL,2025-09-01T16:18:15.905509,v2_robust,True,True,True,False,False,
NCT04349072,A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy",Mavacamten,"['Mavacamten', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"HOCM, Hypertrophic Obstructive Cardiomyopathy","['HOCM, Hypertrophic Obstructive Cardiomyopathy']",[],COMPLETED,,2020-07-06,2024-05-20,"[{'measure': 'Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16', 'description': 'Participants who decided to proceed with SRT or were eligible for SRT at week 16. Participants with missing assessments were classified as meeting the primary endpoint (did not improve).\n\nSRT eligibility using the New York Heart Association Functional Class (NYHA) and left ventricular outflow tract (LVOT) assessments per the 2011 ACCF/AHA guideline clinical and hemodynamic criterion are below:\n\n* NYHA Class III or IV/ NYHA Class II with exertion-induced syncope/near syncope, AND\n* Dynamic LVOT gradient at rest or with provocation \\>= 50 mmHg.\n\nNYHA Class II at week 16, the following rules will be applied:\n\n* NYHA Class II with history of exertional syncope/ syncope at baseline and at W16 is still NYHA Class II, they remain SRT eligible IF their maximal LVOT gradient is ≥ 50mmHg\n* NYHA Class III/IV at baseline and at W16 has improved to Class II, they are no longer SRT eligible UNLESS they have AE of exertional syncope or pre-syncope during the 16 weeks.', 'timeFrame': 'Week 16'}]","[{'measure': 'Number of Participants With at Least One Class Improvement From Baseline in New York Heart Association (NYHA) Class at Week 16', 'description': 'The NYHA functional classification of heart failure assigns participants to 1 of 4 categories based on the participants symptoms. Baseline values are defined generally as the last available value before the first administration of study drug of analysis interest. Participants with missing NYHA class assessments are treated as no improvement.\n\nClass 1: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).\n\nClass 2: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).\n\nClass 3: Marked limitation of physical activity. Comfortable at rest. Less-than ordinary-activity causes fatigue, palpitation, or dyspnea. Class 4: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.', 'timeFrame': 'Baseline and week 16'}, {'measure': 'Change From Baseline to Week 16 in Kansas City Cardiomyopathy Questionnaire 23-item Version, Clinical Summary Score (KCCQ-23, CSS)', 'description': ""The KCCQ-23 is a 23-item, self-administered questionnaire that measures the impact of a participant's cardiovascular disease or its treatment on 6 distinct domains using a 2-week recall period: symptoms/signs, physical limitation, quality of life (QoL), social limitations, self-efficacy, and symptom stability. The KCCQ 23 Clinical Summary Score (CSS) is derived from the Total Symptom Score (TSS) and the Physical Limitations (PL) score of the KCCQ 23. The CSS, TSS, and the PL score range from 0 to 100 with higher scores representing less severe symptoms and/or physical limitations. The CSS is a mean of the TSS and the PL score."", 'timeFrame': 'Baseline and week 16'}, {'measure': 'Change From Baseline to Week 16 in N-Terminal Pro-b-Type Natriuretic Peptide (NT-proBNP)', 'description': 'A geometric mean ratio was used to assess the change from baseline to Week 16 in N-Terminal Pro-b-Type Natriuretic Peptide (NT-proBNP). Baseline values are defined as the last non-missing value prior to the first dose of study drug unless specified otherwise.', 'timeFrame': 'Baseline and week 16'}, {'measure': 'Change From Baseline to Week 16 in Cardiac Troponin', 'description': 'A geometric mean ratio was used to assess the change from baseline to week 16 in cardiac troponin. Baseline values are defined as the last non-missing value prior to the first dose of study drug unless specified otherwise.', 'timeFrame': 'Baseline and week 16'}, {'measure': 'Change From Baseline to Week 16 in Post-Exercise Left Ventricular Outflow Tract (LVOT) Gradient', 'description': 'Change from baseline to week 16 in post-exercise left ventricular outflow tract (LVOT) gradient. Baseline values are defined as the last non-missing value prior to the first dose of study drug unless specified otherwise.', 'timeFrame': 'Baseline and week 16'}]",6,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,112.0,ACTUAL,2025-09-01T16:18:15.905613,v2_robust,True,True,True,False,False,
NCT00325572,Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism,Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism,oral zinc and vitamin C supplements,['oral zinc and vitamin C supplements'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Autism,"['Autism', 'Pervasive Developmental Disorder']",[],TERMINATED,Lack of efficacy to proceed to Phase 2,2006-11,2011-12,"[{'measure': 'Copper/Zinc Ratio of Children With Autism Compared to Typically Developing Children Phase 2: Change in Copper/Zinc Ratio With Supplementation of Zinc and Vitamin C', 'description': 'Phase 2 was not initiated; no data was collected.', 'timeFrame': '16 weeks'}]",[],1,3 Years,8 Years,ALL,True,Milton S. Hershey Medical Center,OTHER,1,89.0,ACTUAL,2025-09-01T16:18:15.905770,v2_robust,True,True,False,True,False,Lack of efficacy to proceed to Phase 2
NCT06865872,Alcohol and Sexual Communication Among Couples in the Laboratory,Alcohol and Sexual Communication Among Couples in the Laboratory,Alcohol (Ethanol),['Alcohol (Ethanol)'],1,INTERVENTIONAL,['NA'],,,Alcohol Intoxication,"['Alcohol Intoxication', 'Sexual Communication', 'Intimate Partner Violence (IPV)']",[],RECRUITING,,2025-04-18,2028-02,"[{'measure': 'Sexual Violence Perpetration as Measured by the Sexual Imposition Paradigm', 'description': 'The Sexual Imposition Paradigm measures sexual violence perpetration. Possible scores are 0 (no perpetration) to 1 (perpetration).', 'timeFrame': 'up to 1 hour post beverage consumption'}, {'measure': 'Sexual Violence Perpetration Length of Time as Measured by the Sexual Imposition Paradigm', 'description': 'The Sexual Imposition Paradigm measures sexual violence perpetration length of time. Scores range from 0 to 120 seconds, with higher scores indicating longer perpetration.', 'timeFrame': 'up to 1 hour post beverage consumption'}]",[],2,21 Years,65 Years,ALL,True,"University of Colorado, Denver",OTHER,1,480.0,ESTIMATED,2025-09-01T16:18:15.905778,v2_robust,True,True,False,False,False,
NCT02159872,Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure,A Phase II Study of Omacetaxine (OM) in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure,Omacetaxine,"['Omacetaxine', 'Homoharringtonine', 'Synribo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Leukemia,['Leukemia'],"['Leukemia', 'Myelodysplastic Syndrome', 'MDS', 'Omacetaxine', 'Synribo', 'Homoharringtonine']",COMPLETED,,2015-05-18,2020-04-14,"[{'measure': 'Overall Survival (OS)', 'description': 'Overall survival defined as the time from treatment start to the time of death. Overall survival continuously monitored using the Bayesian method.', 'timeFrame': 'Up to 2.5 Years'}, {'measure': 'Number of Participants With a Response', 'description': 'Response is Complete Response (CR) + Partial Response (PR) + Hematologic Improvement (HI). CR is the normalization of the peripheral blood and bone marrow with \\</= 5% bone marrow blasts, a peripheral blood granulocyte count \\>/= (1.0x10\\^9/L, and a platelet count \\>/= 100x10\\^9/L). PR is the same as CR except for the presence of 6-15% marrow blasts, or 50% reduction if \\<15% at start of treatment. HI meets all of the criteria for CR except for platelet recovery to \\>/=100x10\\^9L.', 'timeFrame': 'Up to 2 years'}]",[],2,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,48.0,ACTUAL,2025-09-01T16:18:15.905789,v2_robust,True,True,True,False,False,
NCT00052572,Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders,A Multicenter Phase II Study Of BMS 247550 (Epothilone B Analogue) In Indolent Lymphoproliferative Disorders,ixabepilone,['ixabepilone'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Leukemia,"['Leukemia', 'Lymphoma']","['refractory chronic lymphocytic leukemia', 'B-cell chronic lymphocytic leukemia', 'recurrent grade 1 follicular lymphoma', 'recurrent grade 2 follicular lymphoma', 'recurrent grade 3 follicular lymphoma', 'Waldenström macroglobulinemia', 'recurrent marginal zone lymphoma', 'recurrent small lymphocytic lymphoma', 'recurrent mantle cell lymphoma', 'extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue', 'nodal marginal zone B-cell lymphoma', 'splenic marginal zone lymphoma']",COMPLETED,,2002-10,2007-07,"[{'measure': 'Safety'}, {'measure': 'Efficacy'}]","[{'measure': 'Progression-free survival'}, {'measure': 'Mean and median duration of response'}, {'measure': 'Mean and median duration of progression-free and overall survival'}, {'measure': 'Probability of polymerase chain reaction negativity after treatment'}]",6,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,35.0,ESTIMATED,2025-09-01T16:18:15.905921,v2_robust,True,True,True,False,True,
NCT00764595,Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor,Phase II Multicenter Clinical Trial on Imatinib Treatment for Patients With Resectable Hepatic Metastasis From Gastrointestinal Stromal Tumors (GISTs),imatinib mesylate,['imatinib mesylate'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastrointestinal Stromal Tumor,"['Gastrointestinal Stromal Tumor', 'Metastatic Cancer']","['gastrointestinal stromal tumor', 'liver metastases']",COMPLETED,,2008-10,2016-03,"[{'measure': 'Progression-free survival', 'description': 'Progression-free survival is defined as time from date of starting protocol treatment until date of comfirmation of progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 or death from any cause, whichever comes first.', 'timeFrame': '7.5 years'}]","[{'measure': 'Tumor response', 'description': 'Tumor response is defined as best overall response by RECIST v1.0 from date of starting protocol treatment until 48 weeks after starting protocol treatment.', 'timeFrame': '48 weeks'}, {'measure': 'Overall survival', 'description': 'Overall survival is defined as time from date of starting protocol treatment until date of death from any cause.', 'timeFrame': '7.5 years'}, {'measure': 'Types and severities of adverse events', 'description': 'Types and severities of adverse events from date of starting protocol treatment until 30 days after date of finishing the treatment are evaluated according to Japanese version of the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) by Translational Research Informatics Center.', 'timeFrame': '7.5 years'}]",4,20 Years,,ALL,False,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",OTHER,1,5.0,ACTUAL,2025-09-01T16:18:15.905978,v2_robust,True,True,True,False,True,
NCT04680195,Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding,"Prospective, Open Clinical Trial of Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding",Thalidomide,['Thalidomide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Radiation Proctitis,['Chronic Radiation Proctitis'],"['Thalidomide', 'Bleeding', 'Chronic radiation proctitis']",UNKNOWN,,2020-12-14,2022-12-30,"[{'measure': 'Remission rate of rectal bleeding one month after thalidomide treatment', 'description': 'Remission of rectal bleeding was defined as the score of Subjective Objective Management Analysis system (SOMA) for retcal bleeding at least 1 grade lower and the hemoglobin level at least 10g/L higher than that before treatment. The SOMA score for hematochezia was ranged from 1 to 4, with the higher the score, the more serious.', 'timeFrame': 'the first month after thalidomide treatment'}]","[{'measure': 'Remission rate of rectal bleeding one month during thalidomide treatment', 'description': 'Remission of rectal bleeding was defined as the score of Subjective Objective Management Analysis system (SOMA) for retcal bleeding at least 1 grade lower and the hemoglobin level at least 10g/L higher than that before treatment. The SOMA score for hematochezia was ranged from 1 to 4, with the higher the score, the more serious.', 'timeFrame': 'the first month during thalidomide treatment'}, {'measure': 'Remission rate of rectal bleeding two months during thalidomide treatment', 'description': 'Remission of rectal bleeding was defined as the score of Subjective Objective Management Analysis system (SOMA) for retcal bleeding at least 1 grade lower and the hemoglobin level at least 10g/L higher than that before treatment. The SOMA score for hematochezia was ranged from 1 to 4, with the higher the score, the more serious.', 'timeFrame': 'the second month during thalidomide treatment'}, {'measure': 'Remission rate of rectal bleeding three months during thalidomide treatment', 'description': 'Remission of rectal bleeding was defined as the score of Subjective Objective Management Analysis system (SOMA) for retcal bleeding at least 1 grade lower and the hemoglobin level at least 10g/L higher than that before treatment. The SOMA score for hematochezia was ranged from 1 to 4, with the higher the score, the more serious.', 'timeFrame': 'the third month during thalidomide treatment'}, {'measure': 'Remission rate of rectal bleeding four months during thalidomide treatment', 'description': 'Remission of rectal bleeding was defined as the score of Subjective Objective Management Analysis system (SOMA) for retcal bleeding at least 1 grade lower and the hemoglobin level at least 10g/L higher than that before treatment. The SOMA score for hematochezia was ranged from 1 to 4, with the higher the score, the more serious.', 'timeFrame': 'the fourth month during thalidomide treatment'}, {'measure': 'Remission rate of rectal bleeding three months after thalidomide treatment', 'description': 'Remission of rectal bleeding was defined as the score of Subjective Objective Management Analysis system (SOMA) for retcal bleeding at least 1 grade lower and the hemoglobin level at least 10g/L higher than that before treatment. The SOMA score for hematochezia was ranged from 1 to 4, with the higher the score, the more serious.', 'timeFrame': 'the third month after thalidomide treatment'}, {'measure': 'Remission rate of rectal bleeding six months after thalidomide treatment', 'description': 'Remission of rectal bleeding was defined as the score of Subjective Objective Management Analysis system (SOMA) for retcal bleeding at least 1 grade lower and the hemoglobin level at least 10g/L higher than that before treatment. The SOMA score for hematochezia was ranged from 1 to 4, with the higher the score, the more serious.', 'timeFrame': 'the sixth month after thalidomide treatment'}, {'measure': 'Endoscopic score one month during thalidomide treatment', 'description': 'Endoscopic score was performed using Vienna rectoscopy Score (VRS). VRS was ranged 1 to 5. A higher score indicated a more severe lesion.', 'timeFrame': 'the first month during thalidomide treatment'}, {'measure': 'Endoscopic score four months during thalidomide treatment', 'description': 'Endoscopic score was performed using Vienna rectoscopy Score (VRS). VRS was ranged 1 to 5. A higher score indicated a more severe lesion.', 'timeFrame': 'the fourth month during thalidomide treatment'}, {'measure': 'Endoscopic score one month after thalidomide treatment', 'description': 'Endoscopic score was performed using Vienna rectoscopy Score (VRS). VRS was ranged 1 to 5. A higher score indicated a more severe lesion.', 'timeFrame': 'the first month after thalidomide treatment'}, {'measure': 'Endoscopic score three months after thalidomide treatment', 'description': 'Endoscopic score was performed using Vienna rectoscopy Score (VRS). VRS was ranged 1 to 5. A higher score indicated a more severe lesion.', 'timeFrame': 'the third month after thalidomide treatment'}, {'measure': 'Endoscopic score six months after thalidomide treatment', 'description': 'Endoscopic score was performed using Vienna rectoscopy Score (VRS). VRS was ranged 1 to 5. A higher score indicated a more severe lesion.', 'timeFrame': 'the sixth month after thalidomide treatment'}, {'measure': 'Quality of life of the patient one month during thalidomide treatment', 'description': 'Quality of life of the patient was evaluated by the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 is a 30-item questionnaire composed of multi-item scales and single items that reflect the multidimensionality of the quality-of-life. It incorporated five functioning subscales (physical, role, cognitive, emotional, and social), nine symptom subscales (pain, fatigue, nausea and vomiting, appetite loss, constipation, diarrhea, dyspnea, insomnia, financial difficulties), and one global quality of life subscale, and the scores were ranged 0 to 100. Higher scores for functional subscales and global quality of life subscale indicated the better functional status and quality of life. But the higher scores for symptom subscales indicated the poorer quality of life.', 'timeFrame': 'the first month during thalidomide treatment'}, {'measure': 'Quality of life of the patient two months during thalidomide treatment', 'description': 'Quality of life of the patient was evaluated by the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 was a 30-item questionnaire composed of multi-item scales and single items that reflecting the multidimensionality of the quality-of-life. It incorporated five functioning subscales (physical, role, cognitive, emotional, and social), nine symptom subscales (pain, fatigue, nausea and vomiting, appetite loss, constipation, diarrhea, dyspnea, insomnia, financial difficulties), and one global quality of life subscale, and the scores were ranged 0 to 100. Higher scores for functional subscales and global quality of life subscale indicated the better functional status and quality of life. But the higher scores for symptom subscales indicated the poorer quality of life.', 'timeFrame': 'the second month during thalidomide treatment'}, {'measure': 'Quality of life of the patient three months during thalidomide treatment', 'description': 'Quality of life of the patient was evaluated by the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 was a 30-item questionnaire composed of multi-item scales and single items that reflecting the multidimensionality of the quality-of-life. It incorporated five functioning subscales (physical, role, cognitive, emotional, and social), nine symptom subscales (pain, fatigue, nausea and vomiting, appetite loss, constipation, diarrhea, dyspnea, insomnia, financial difficulties), and one global quality of life subscale, and the scores were ranged 0 to 100. Higher scores for functional subscales and global quality of life subscale indicated the better functional status and quality of life. But the higher scores for symptom subscales indicated the poorer quality of life.', 'timeFrame': 'the third month during thalidomide treatment'}, {'measure': 'Quality of life of the patient four months during thalidomide treatment', 'description': 'Quality of life of the patient was evaluated by the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 was a 30-item questionnaire composed of multi-item scales and single items that reflecting the multidimensionality of the quality-of-life. It incorporated five functioning subscales (physical, role, cognitive, emotional, and social), nine symptom subscales (pain, fatigue, nausea and vomiting, appetite loss, constipation, diarrhea, dyspnea, insomnia, financial difficulties), and one global quality of life subscale, and the scores were ranged 0 to 100. Higher scores for functional subscales and global quality of life subscale indicated the better functional status and quality of life. But the higher scores for symptom subscales indicated the poorer quality of life.', 'timeFrame': 'the fourth month during thalidomide treatment'}, {'measure': 'Quality of life of the patient one month after thalidomide treatment', 'description': 'Quality of life of the patient was evaluated by the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 was a 30-item questionnaire composed of multi-item scales and single items that reflecting the multidimensionality of the quality-of-life. It incorporated five functioning subscales (physical, role, cognitive, emotional, and social), nine symptom subscales (pain, fatigue, nausea and vomiting, appetite loss, constipation, diarrhea, dyspnea, insomnia, financial difficulties), and one global quality of life subscale, and the scores were ranged 0 to 100. Higher scores for functional subscales and global quality of life subscale indicated the better functional status and quality of life. But the higher scores for symptom subscales indicated the poorer quality of life.', 'timeFrame': 'the first month after thalidomide treatment'}, {'measure': 'Quality of life of the patient three months after thalidomide treatment', 'description': 'Quality of life of the patient was evaluated by the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 was a 30-item questionnaire composed of multi-item scales and single items that reflecting the multidimensionality of the quality-of-life. It incorporated five functioning subscales (physical, role, cognitive, emotional, and social), nine symptom subscales (pain, fatigue, nausea and vomiting, appetite loss, constipation, diarrhea, dyspnea, insomnia, financial difficulties), and one global quality of life subscale, and the scores were ranged 0 to 100. Higher scores for functional subscales and global quality of life subscale indicated the better functional status and quality of life. But the higher scores for symptom subscales indicated the poorer quality of life.', 'timeFrame': 'the third month after thalidomide treatment'}, {'measure': 'Quality of life of the patient six months after thalidomide treatment', 'description': 'Quality of life of the patient was evaluated by the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 was a 30-item questionnaire composed of multi-item scales and single items that reflecting the multidimensionality of the quality-of-life. It incorporated five functioning subscales (physical, role, cognitive, emotional, and social), nine symptom subscales (pain, fatigue, nausea and vomiting, appetite loss, constipation, diarrhea, dyspnea, insomnia, financial difficulties), and one global quality of life subscale, and the scores were ranged 0 to 100. Higher scores for functional subscales and global quality of life subscale indicated the better functional status and quality of life. But the higher scores for symptom subscales indicated the poorer quality of life.', 'timeFrame': 'the sixth month after thalidomide treatment'}, {'measure': 'Incidence of adverse events four months during thalidomide treatment', 'description': 'Including adverse reactions of thalidomide and other adverse events', 'timeFrame': 'the fourth month during thalidomide treatment'}, {'measure': 'Incidence of adverse events six months after thalidomide treatment', 'description': 'Including adverse reactions of thalidomide and other adverse events', 'timeFrame': 'the sixth month after thalidomide treatment'}]",21,18 Years,75 Years,ALL,False,"Sixth Affiliated Hospital, Sun Yat-sen University",OTHER,0,62.0,ESTIMATED,2025-09-01T16:18:15.906045,v2_robust,True,True,False,False,True,
NCT00785395,Up-Down Oxytocin Infusion,Up-down Determination of the ED90 of Oxytocin Infusions for the Prevention of Postpartum Uterine Atony in Parturients Undergoing Cesarean Delivery,Oxytocin infusion,['Oxytocin infusion'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Uterine Atony,['Uterine Atony'],[],COMPLETED,,2008-06,2008-08,"[{'measure': 'The primary outcome measure is the response of effective uterine contraction as either satisfactory or unsatisfactory as determined by the obstetrician blinded to the oxytocin infusion dose.', 'timeFrame': '3 minutes'}]","[{'measure': 'Secondary outcomes will include need for additional uterotonics, calculated intra-operative blood loss and presence of oxytocin related adverse effects.', 'timeFrame': '2 days'}]",2,18 Years,,FEMALE,False,IWK Health Centre,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:15.906123,v2_robust,True,True,True,False,True,
NCT02303795,RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial,"A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER",Rivaroxaban,"['Warfarin', 'Rivaroxaban']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Valvular Heart Disease,['Valvular Heart Disease'],"['bioprosthetic mitral valve', 'valvular heart disease', 'anticoagulant agents', 'NOACs', 'rivaroxaban', 'warfarin']",COMPLETED,,2015-08,2020-08,"[{'measure': 'Major Clinical Events', 'description': 'Combined Endpoint of major clinical events as defined by strokes (CVA), transient ischemic attack (TIA), major bleeding, all-cause death, valve thrombosis and non-CNS systemic embolism, hospitalization due to cardiac failure.', 'timeFrame': '12 months'}]","[{'measure': 'Major bleeding', 'description': 'Clinically overt bleeding associated with: fatal outcome, involving a critical site, or clinically overt bleeding associated with a fall in hemoglobin concentration of ≥2 g/dL, or leading to transfusion of ≥2 units of packed red blood cells or whole blood.', 'timeFrame': '12 months'}, {'measure': 'Combined endpoint of nonfatal stroke (CVA), transient ischemic attack (TIA), systemic embolism, valve thrombosis, venous thromboembolism and vascular causes death.thrombosis, and vascular death', 'description': 'Stroke: sudden, focal neurologic deficit from a presumed cerebrovascular cause, not reversible within 24 hours and not due to na identifiable cause.\n\nNon-CNS systemic embolism: abrupt vascular insufficiency associated with clinical or radiologic evidence of arterial occlusion.\n\nValve thrombosis: any thrombus attached to or near an implanted valve that occludes part of the blood flow, interferes with function or warrant treatment.\n\nMortality: Deaths any cause. Venous thromboembolism: verification by definitive diagnostic evaluation. Deep Vein Thrombosis: abnormal compression ultrasound or intraluminal filling defect on venography or autopsy.\n\nPulmonary embolism: at least one: 1) intraluminal filling defect on CT scan; 2) intraluminal filling defect on pulmonary angiogram; 3) high- probability on v/p lung scan; 4)inconclusive spiral CT, pulmonary image with demonstration of DVT in the lower extremities; 5) autopsy', 'timeFrame': '12 months'}]",3,18 Years,,ALL,False,Hospital do Coracao,OTHER,0,1005.0,ACTUAL,2025-09-01T16:18:15.906134,v2_robust,True,True,True,False,False,
NCT00850395,Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection,Non-Interventional Study Of Celsentri® In Treatment Experienced Patients Infected With CCR5 Tropic HIV-1,maraviroc,"['maraviroc', 'Selzentry, Celsentri']",2,OBSERVATIONAL,[],,,HIV-1,['HIV-1'],"['HIV-1', 'non-interventional', 'CCR-5 tropic virus', 'therapy experienced patients']",COMPLETED,,2009-07,2011-10,"[{'measure': 'Change From Baseline in Log 10 Transformed Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) at Month 3', 'timeFrame': 'Baseline, Month 3'}, {'measure': 'Change From Baseline in Log 10 Transformed Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) at Month 6', 'timeFrame': 'Baseline, Month 6'}, {'measure': 'Change From Baseline in Log 10 Transformed Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) at Month 12', 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Counts at Month 3', 'timeFrame': 'Baseline, Month 3'}, {'measure': 'Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Counts at Month 6', 'timeFrame': 'Baseline, Month 6'}, {'measure': 'Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Counts at Month 12', 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Number of Participants With Centers for Disease Control and Prevention (CDC) Classification at Month 3', 'description': 'Participants were classified based on the severity as mild (Category A), moderate (Category B), and severe (Category C).', 'timeFrame': 'Month 3'}, {'measure': 'Number of Participants With Centers for Disease Control and Prevention (CDC) Classification at Month 6', 'description': 'Participants were classified based on the severity as mild (Category A), moderate (Category B), and severe (Category C).', 'timeFrame': 'Month 6'}, {'measure': 'Number of Participants With Centers for Disease Control and Prevention (CDC) Classification at Month 12', 'description': 'Participants were classified based on the severity as mild (Category A), moderate (Category B), and severe (Category C).', 'timeFrame': 'Month 12'}]","[{'measure': 'Change From Baseline in Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials Group (ACTG) Symptom Distress Module (SDM) Overall Score at Months 6 and 12', 'description': ""SDM consists of the 20 items questionnaire, each item rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health). A positive change from baseline indicates a decline in a participant's quality of life over that period."", 'timeFrame': 'Baseline, Months 6, 12'}, {'measure': 'Number of Participants With Human Immunodeficiency Virus (HIV) Response', 'description': 'Response was defined as a HIV-1 RNA count of less than 50 copies/mL.', 'timeFrame': 'Month 12'}, {'measure': ""Physician's Assessment of Efficacy"", 'description': 'Number of participants with each grade of efficacy as assessed by the physician was reported on the 5 point categorical scale: excellent, very good, good, fair, poor.', 'timeFrame': 'Month 12'}, {'measure': 'Number of Participants Taking Concomitant Therapy', 'description': 'Participants taking HIV/AIDS concomitant medication at Month 12, at Baseline and Month 12 were reported. It included Emtricitabine/tenofovir disoproxil fumarate(FTC/TDF),Raltegravir(RAL), Ritonavir (RTV), Darunavir(DRV), Kaletra, Atazanavir sulfate(ATV), Abacavir sulfate/lamivudine(ABC/LAM), Tenofovir disoproxil fumarate(TDF), Etravirine(ETR), Lamivudine (LAM), Zidovudine W/lamivudine(ZDV W/LAM), Nevirapine(NVP), Saquinavir mesilate(SQV), Trizivir(TZV), Zidovudine(ZDV), Abacavir sulfate(ABC), Emtricitabine(FTC),Entecavir(ETV).', 'timeFrame': 'Baseline, Month 12'}]",13,18 Years,,ALL,False,ViiV Healthcare,INDUSTRY,1,79.0,ACTUAL,2025-09-01T16:18:15.906248,v2_robust,False,True,True,False,False,
NCT00741195,Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer,"Docetaxel Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC",Docetaxel,"['Avastin', 'Docetaxel', 'Bevacizumab', 'Taxotere']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-small-cell Lung Cancer,['Non-small-cell Lung Cancer'],"['Cancer', 'NSCLC', 'Docetaxel', 'Bevacizumab']",COMPLETED,,2008-04,2016-10,"[{'measure': 'Progression Free Survival', 'timeFrame': '1 year'}]","[{'measure': 'Overall response rate', 'timeFrame': 'Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)'}, {'measure': 'Overall Survival', 'timeFrame': '1 year'}, {'measure': 'Quality of life assessment', 'timeFrame': 'Assessment every two cycles'}, {'measure': 'Toxicity profile', 'timeFrame': 'Assessment every two cycles'}]",5,18 Years,,ALL,False,Hellenic Oncology Research Group,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:15.906338,v2_robust,True,True,True,False,False,
NCT05998395,JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease,Single Patient Study of JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease,Ruxolitinib,['Ruxolitinib'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Kohlmeier Degos Disease With Neurologic Involvement,['Kohlmeier Degos Disease With Neurologic Involvement'],"['Rare Small Vessel Vasculopathy Of Unknown Etiology', 'Kohlmeier Degos Disease With Neurologic Involvement']",COMPLETED,,2023-09-28,2025-02-28,"[{'measure': 'To test the hypothesis that JAK/STAT inhibition by ruxolitinib will delay progression of neuroradiological manifestations of our one patient with neurological involvement of K-D disease.', 'description': 'The primary endpoint is stability or regression of existing enhancing lesions or no development of new enhancing lesions in the brain and spine observed in MRI evaluation after 13 weeks and up to 73 weeks of ruloxitinib (10 mg BID) compared to pre-treatment MRI images.', 'timeFrame': '6 months'}]",[],1,18 Years,100 Years,ALL,False,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,0,1.0,ACTUAL,2025-09-01T16:18:15.906395,v2_robust,True,True,True,False,False,
NCT02315495,Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes,Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes,Saxagliptin,"['Saxagliptin', 'Onglyza', 'Acarbose', 'Glucobay']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Type 2 Diabetes,['Type 2 Diabetes'],[],COMPLETED,,2015-04-03,2016-08-26,"[{'measure': 'Blood glucose concentrations at pre-defined intervals', 'timeFrame': '-60,-10,0,30,60,90,120,180min'}]","[{'measure': 'Plasma concentrations of incretin hormones at pre-defined intervals', 'timeFrame': '-60,-10,0,30,60,90,120,180min'}, {'measure': 'Plasma concentrations of insulin at pre-defined intervals', 'timeFrame': '-60,-10,0,30,60,90,120,180min'}, {'measure': 'Plasma concentrations of C-peptide at pre-defined intervals', 'timeFrame': '-60,-10,0,30,60,90,120,180min'}, {'measure': 'Plasma concentrations of glucagon at pre-defined intervals', 'timeFrame': '-60,-10,0,30,60,90,120,180min'}, {'measure': 'half-emptying time (T50)', 'timeFrame': '0-180min'}]",6,18 Years,70 Years,ALL,False,Zilin Sun,OTHER,0,22.0,ACTUAL,2025-09-01T16:18:15.906438,v2_robust,True,True,True,False,False,
NCT02031939,Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer,Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer,"Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)","['Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)']",1,INTERVENTIONAL,['PHASE3'],PHASE3,,Advanced Rectal Cancer,['Advanced Rectal Cancer'],"['Rectal cancer', 'neoadjuvant chemoradiotherapy', 'optimization']",ACTIVE_NOT_RECRUITING,,2014-01,2025-12,"[{'measure': 'overall survival', 'timeFrame': '5 years'}]","[{'measure': 'disease free survival', 'timeFrame': '3 years'}, {'measure': 'Disease free survival', 'timeFrame': '5 years'}, {'measure': 'Respond rate', 'timeFrame': 'One week after surgery'}]",4,18 Years,75 Years,ALL,False,Sun Yat-sen University,OTHER,0,556.0,ESTIMATED,2025-09-01T16:18:15.906470,v2_robust,True,True,False,False,False,
NCT04886739,CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea,"Safety and Effectiveness of CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea: A Randomized, Double-Blind, Vehicle-Controlled Proof of Concept Study",CGB-400,"['Vehicle Gel', 'CGB-400']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Rosacea,['Rosacea'],[],COMPLETED,,2021-05-07,2021-12-22,"[{'measure': 'Inflammatory Lesion Count', 'description': 'Numerical count of inflammatory lesions (pustules and papules)', 'timeFrame': 'Week 12'}, {'measure': 'Investigator Global Assessment (IGA)', 'description': '* 0 - Clear; No inflammatory lesions present; at most mild erythema\n* 1 - Almost clear; Very mild erythema present. Very few small papules/pustules\n* 2 - Mild; Mild erythema. Several small papules/pustules\n* 3 - Moderate; Moderate erythema. Several small or large papules/pustules\n* 4 - Severe; Severe erythema. Numerous small and/or large papules/pustules', 'timeFrame': 'Week 12'}]","[{'measure': 'Inflammatory Lesion Count', 'description': 'Numerical count of inflammatory lesions (pustules and papules)', 'timeFrame': 'Weeks 2, 4, and 8'}, {'measure': 'Investigator Global Assessment (IGA)', 'description': '* 0 - Clear; No inflammatory lesions present; at most mild erythema\n* 1 - Almost clear; Very mild erythema present. Very few small papules/pustules\n* 2 - Mild; Mild erythema. Several small papules/pustules\n* 3 - Moderate; Moderate erythema. Several small or large papules/pustules\n* 4 - Severe; Severe erythema. Numerous small and/or large papules/pustules', 'timeFrame': 'Weeks 2, 4, and 8'}, {'measure': 'Rosacea Quality of Life (RosaQoL) Questionnaire', 'description': 'Patient Reported Outcome', 'timeFrame': 'Week 12'}]",5,18 Years,,ALL,False,CAGE Bio Inc.,INDUSTRY,1,78.0,ACTUAL,2025-09-01T16:18:15.906480,v2_robust,True,True,True,False,False,
NCT00650039,"Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction","A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg QD And Valdecoxib 20 Mg BID Compared To Placebo Over Multiple Days For Management Of Acute Postsurgical Pain In Patients Undergoing Anterior Cruciate Ligament Reconstruction",placebo,"['valdecoxib', 'placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Pain,['Pain'],"['Post surgical pain', 'Anterior Cruciate ligament reconstruction', 'Arthroscopy', 'Perioperative pain']",COMPLETED,,2004-03,2005-02,"[{'measure': 'Summed Pain Intensity (categorical) through 24 hours (SPI 24)', 'timeFrame': 'Day 2 and Day 3'}, {'measure': ""Patient's Global Evaluation of Study Medication (PGESM)"", 'timeFrame': 'Day 2 and Day 3'}]","[{'measure': 'Average Pain Intensity (derived from the mBPI-sf) on each study day', 'timeFrame': 'Days 2 to 5'}, {'measure': 'Worst Pain Intensity (derived from the Modified Brief Pain Inventory Short Form [mBPI-sf]) on each study day', 'timeFrame': 'Days 2 to 5'}, {'measure': 'Symptom Distress Scale Questionnaire', 'timeFrame': 'Days 2 to 5'}, {'measure': 'Patient Satisfaction Questionnaire for each study day', 'timeFrame': 'Days 2 to 5'}, {'measure': 'Time-specific pain intensity (PI) (categorical) on each study day', 'timeFrame': 'Days 2 to 5'}, {'measure': 'SPI 24 (Visual Analog Scale [VAS]) on each study day', 'timeFrame': 'Days 2 to 5'}, {'measure': 'Time-specific PI (VAS) on each study day', 'timeFrame': 'Days 2 to 5'}, {'measure': ""Patient's Global Evaluation of Study Medication"", 'timeFrame': 'Day 4 and Day 5'}, {'measure': 'Time to first dose of rescue medication (supplemental analgesia) on each study day', 'timeFrame': 'Days 2 to 5'}, {'measure': 'Percent of subjects who took rescue medication (supplemental analgesia) on each study day', 'timeFrame': 'Days 2 to 5'}, {'measure': 'Amount of rescue medication (supplemental analgesia) taken on each study day', 'timeFrame': 'Days 2 to 5'}, {'measure': 'Individual and Composite Pain Interference With Function score (derived from the mBPI-sf) on each day', 'timeFrame': 'Days 2 to 5'}, {'measure': 'Time between doses of study medication on each study day', 'timeFrame': 'Days 2 to 5'}, {'measure': 'Post-Discharge Recovery Experience for each study day', 'timeFrame': 'Days 2 to 5'}, {'measure': 'SPI 24 (categorical)', 'timeFrame': 'Day 4 and Day 5'}]",17,18 Years,75 Years,ALL,False,Pfizer,INDUSTRY,0,488.0,ACTUAL,2025-09-01T16:18:15.906501,v2_robust,True,True,True,False,False,
NCT00124839,Naltrexone in Borderline Personality Disorder,Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder,Naltrexone,['Naltrexone'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Borderline Personality Disorder,['Borderline Personality Disorder'],"['Dissociation', 'Flashbacks', 'Self-injurious behavior']",TERMINATED,Difficulties in recruiting enough subjects,2005-10,2008-03,"[{'measure': 'Reduction of dissociative symptoms', 'timeFrame': 'End of 3rd week treatment of naltrexon'}]","[{'measure': 'Reduction of flashbacks', 'timeFrame': 'End of 3rd week treatment of naltrexone'}, {'measure': 'Reduction of self-injurious behavior', 'timeFrame': 'End of 3rd week treatment of naltrexone'}, {'measure': 'Reduction of psychopathology (depression, anxiety, anger, borderline symptoms)', 'timeFrame': 'End of 3rd week treatment of naltrexone'}, {'measure': 'Safety regarding liver enzyme elevation', 'timeFrame': 'End of 3rd week treatment of naltrexone'}]",5,18 Years,50 Years,FEMALE,False,"Central Institute of Mental Health, Mannheim",OTHER,0,48.0,ESTIMATED,2025-09-01T16:18:15.906688,v2_robust,True,True,False,True,True,Difficulties in recruiting enough subjects
NCT04665739,Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors,Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors,Everolimus,"['Everolimus', '177 Lu-DOTA-Tyr3-Octreotate', 'RAD001', 'Certican', '177Lu-DOTA0-Tyr3-Octreotate', 'RAD 001', 'Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate', 'Lutetium (177Lu) Oxodotreotide', 'Votubia', 'Lutathera', 'Lutetium Lu 177 Dotatate', 'Lutetium Oxodotreotide Lu-177', 'Afinitor', 'RAD-001', '177 Lu-DOTA-TATE', 'Zortress', 'Lutetium Lu 177-DOTA-Tyr3-Octreotate', '42-O-(2-Hydroxy)ethyl Rapamycin', 'lutetium Lu 177-DOTATATE']",19,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Lung Neuroendocrine Tumor,"['Advanced Lung Neuroendocrine Tumor', 'Functioning Lung Neuroendocrine Tumor', 'Locally Advanced Lung Neuroendocrine Neoplasm', 'Lung Neuroendocrine Neoplasm', 'Lung Neuroendocrine Tumor G1', 'Lung Neuroendocrine Tumor G2', 'Metastatic Lung Neuroendocrine Neoplasm', 'Metastatic Lung Neuroendocrine Tumor', 'Non-Functioning Lung Neuroendocrine Tumor', 'Recurrent Lung Neuroendocrine Neoplasm', 'Unresectable Lung Neuroendocrine Neoplasm', 'Unresectable Lung Neuroendocrine Tumor']",[],RECRUITING,,2023-02-03,2033-01-16,"[{'measure': 'Median progression-free survival (PFS)', 'description': 'Will be compared between patients with a bronchial neuroendocrine tumor receiving lutetium Lu 177 dotatate to those receiving everolimus. The distribution of PFS will be estimated using the Kaplan Meier method. Will be tested using a one-sided stratified log rank test. The median PFS, along with 90% confidence intervals (CIs), will be estimated for the two treatment groups.', 'timeFrame': 'From randomization until either radiographic progression confirmed by central radiology review or death, assessed up to 5 years from study registration'}]","[{'measure': 'Overall survival (OS)', 'description': 'The distribution of OS will be estimated using the method of Kaplan-Meier. The median OS, along with 90% CIs, will be estimated by the two treatment groups. OS will be compared between the two between treatment arms using the stratified log-rank test at a one-sided 10% level of significance.', 'timeFrame': 'From randomization until death due to any cause, with patients censored at the last date known to be alive or last contact date, assessed up to 5 years from study registration'}, {'measure': 'Overall response rate (ORR)', 'description': 'Defined as the proportion of patients in each arm whose best response is either complete response (CR) or partial response (PR). Will be estimated using point estimates and 95% CIs according to the methods in Duffy and Santner.', 'timeFrame': 'Up to 5 years from study registration'}, {'measure': 'Incidence of adverse events', 'description': 'Will evaluate and compare the toxicity profile of lutetium Lu 177 dotatate and everolimus. As per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, the term toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to the study treatment.', 'timeFrame': 'Up to 5 years from study registration'}]",4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,70.0,ESTIMATED,2025-09-01T16:18:15.906704,v2_robust,True,True,False,False,True,
NCT01705639,Melatonin and Glucose Tolerance Among Individuals With a Variant of the MTNR1B Gene,Does Melatonin Treatment Affect Glucose Tolerance Among Individuals With a Variant (rs10830963) of the Melatonin Receptor 1B (MTNR1B) Gene?,Melatonin,"['Circadin', 'Melatonin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Diabetes,"['Diabetes', 'Glucose Tolerance']","['diabetes', 'melatonin', 'glucose tolerance', 'sleep']",COMPLETED,,2012-11,2014-08,"[{'measure': 'Glucose tolerance', 'description': 'Glucose tolerance is measured in OGTT: 0,30,60,90 and 120 minute values of glucose and insulin.', 'timeFrame': '3 months'}]","[{'measure': 'sleep', 'description': 'monitoring of sleep with questionnaires and activity monitoring', 'timeFrame': '3 months'}, {'measure': 'Activity', 'description': 'Activity and sleep of the subjects is recorded with Actigraph at 0 and 3 months', 'timeFrame': '3 months'}]",3,18 Years,75 Years,ALL,True,University of Helsinki,OTHER,2,45.0,ACTUAL,2025-09-01T16:18:15.906788,v2_robust,True,True,True,False,False,
NCT06598839,Immuno-effect of Tα1 for Stage I NSCLC,Assessment of the Efficacy of Immunomodulatory Therapy With Thymosin Alpha 1 (Tα1) Following Surgical Resection in Patients With Stage I Non-Small Cell Lung Cancer,Thymosin Alpha1,"['Thymosin Alpha1', 'Thymalfasin', 'Tα1']",3,INTERVENTIONAL,['NA'],,,Non Small Cell Lung Cancer,['Non Small Cell Lung Cancer'],"['NSCLC', 'Thymosin alpha1', 'CTC', 'Immunosenescence']",RECRUITING,,2024-06-30,2025-12-30,"[{'measure': 'Number of CTCs', 'description': 'Number of peripheral blood circulating tumor cells after Tα1 treatment', 'timeFrame': '4 months after sugery'}]","[{'measure': 'Number of immune cells', 'description': 'Number of TERT+ immnue cells after Tα1 treatment', 'timeFrame': '4 months after sugery'}, {'measure': 'Peripheral blood immune cells profile', 'description': 'Number of immune cells profile, including but limited to CD4+, CD8+, T cells', 'timeFrame': '4 months after sugery'}, {'measure': 'AE', 'description': 'the safety profile of the Tα1 treatment', 'timeFrame': 'within 4 months after sugery'}]",4,18 Years,75 Years,ALL,False,Yousheng Mao,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:15.906800,v2_robust,True,True,False,False,True,
NCT00236639,A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity",topiramate,['topiramate'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Obesity,['Obesity'],"['Obesity', 'Hypertension', 'Hyperlipidemia', 'Type 2 Diabetes Mellitus', 'Body Mass Index']",COMPLETED,,2000-07,2002-06,[{'measure': 'The percent change in body weight from the baseline (randomization) to Week 60 (after one year of maintenance therapy).'}],"[{'measure': 'Changes from either baseline to Week 60 and/or Week 112, or enrollment to Week 60 and/or Week 112 in absolute body weight, Body Mass Index (BMI), body measurements, fasting lipid profile.'}]",2,18 Years,75 Years,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,1293.0,ACTUAL,2025-09-01T16:18:15.906818,v2_robust,True,True,True,False,False,
NCT06516939,The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin,The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin,bFGF,"['bFGF', 'Bovine Basic Gel']",2,INTERVENTIONAL,['NA'],,,Sensitive Skin,['Sensitive Skin'],[],RECRUITING,,2024-06-10,2024-07-18,"[{'measure': 'erythema index', 'description': 'The change rate in lesion clearance of face at 1 month after treatment will be measured as the primary outcome', 'timeFrame': '0、1、2、4 week'}]",[],1,18 Years,60 Years,ALL,False,Shanghai Dermatology Hospital,OTHER,0,28.0,ESTIMATED,2025-09-01T16:18:15.906828,v2_robust,True,True,False,False,False,
NCT06004739,Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection,Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection,Start Antibiotics / Continue Antibiotics for treatment of bacteriuria,['Start Antibiotics / Continue Antibiotics for treatment of bacteriuria'],1,INTERVENTIONAL,['NA'],,,Infectious Disease,['Infectious Disease'],"['Delirium', 'Antibiotics', 'Older adults', 'Urinary Tract Infection']",RECRUITING,,2024-05-18,2027-09,"[{'measure': 'Delirium at day 7 or at day of hospital discharge, whichever is earliest', 'description': 'Delirium will be assessed using Confusion Assessment Method (CAM). CAM assesses 4 delirium features: \\[1\\] inattention, \\[2\\] acute and fluctuating level of consciousness, \\[3\\] disorganized thinking and \\[4\\] altered mental status. For a diagnosis of delirium by CAM, the patient must display feature \\[1\\] AND \\[2\\], AND EITHER \\[3\\] or \\[4\\].', 'timeFrame': 'Delirium will be assessed at the first of day 7 or discharge'}]","[{'measure': 'Length of hospitalization', 'timeFrame': 'Up to 30 days'}, {'measure': 'Number of participants with bacteremia (bacteria isolated in blood culture)', 'timeFrame': 'Up to 7 days'}, {'measure': 'Number of participants who were transferred to Intensive Care Unit (ICU)', 'timeFrame': 'Up to 7 days'}, {'measure': 'Number of participants who had a fall', 'timeFrame': 'Up to 7 days'}, {'measure': 'Number of participants who were physically restrained', 'timeFrame': 'Up to 7 days'}, {'measure': 'Number of participants who received antipsychotics', 'timeFrame': 'Up to 7 days'}, {'measure': 'Days of antibiotics', 'timeFrame': 'Up to 7 days'}, {'measure': 'Number of participants with C. difficile infection', 'description': 'C. difficile will be defined as a combination of a positive microbiological test for C. difficile (if still hospitalized at the time of diagnosis), or self-reported diagnosis of C. difficile (provided the patient reported diarrhea and receipt of an antibiotic to treat C. difficile)', 'timeFrame': 'By 30 days'}, {'measure': 'Number of participants who died', 'timeFrame': 'By 30 days'}, {'measure': 'Number of participants who died', 'timeFrame': 'By 365 days'}, {'measure': 'Number of participants who were readmitted to hospital', 'timeFrame': 'By 365 days'}, {'measure': 'Number of participants who were readmitted to hospital', 'timeFrame': 'By 30 days'}]",13,60 Years,,ALL,False,"Mount Sinai Hospital, Canada",OTHER,5,550.0,ESTIMATED,2025-09-01T16:18:15.907010,v2_robust,True,True,False,False,False,
NCT03828539,Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine,"Head-to-head Study of Erenumab Against topiRamate-a Double-blind, Double Dummy Migraine Study to Assess Tolerability and Efficacy in a patiEnt -Centered Setting",Topiramate,"['Topiramate matching placebo', 'Topamax', 'Topiramate']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Migraine,['Migraine'],"['Migraine', 'Episodic migraine', 'Chronic migraine', 'Headache', 'erenumab', 'topiramate', 'CAMG 334', 'Calcitonin Gene-related Peptide', 'CGRP', 'CGRP receptor agonist', 'monoclonal antibody', 'treatment failure']",COMPLETED,,2019-02-22,2020-07-29,"[{'measure': 'Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE)', 'description': 'The primary objective was to demonstrate the tolerability of 70 mg and 140 mg erenumab compared to topiramate in the highest tolerated dose assessed by the rate of patients discontinuing treatment due to AE during the double-blind epoch of the study.', 'timeFrame': '24 Weeks'}]","[{'measure': 'Number of Patients With at Least 50% Reduction From Baseline in Monthly Migraine Days (MMD) Over the Last Three Months (Month 4, 5, and 6)', 'description': ""The secondary objective of this study was to evaluate the effect of erenumab compared to topiramate on the proportion of patients with at least 50% reduction from baseline in MMDs. The Baseline period was defined as the period between Week -4 and the day prior to first dose. This was analyzed by logistic regression over the last 3 months (months 4, 5, and 6) of treatment. All the subjects' data collected regarding 50% response in MMD was used in the analysis regardless of whether subjects discontinue study treatment or not. Subjects with missing response information on this endpoint were imputed as non-response (non-responder imputation)."", 'timeFrame': 'Baseline, Last three months (month 4, 5, and 6)'}]",2,18 Years,65 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,777.0,ACTUAL,2025-09-01T16:18:15.907075,v2_robust,True,True,True,False,True,
NCT06527677,Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects,"Phase 1, Open-Label, Non-Randomized, Single-Center, Single-Dose Study to Assess the Pharmacokinetics & Safety of ANT3310 Combined With Meropenem Administered as a Single Intravenous Infusion to Adult Subjects With Renal Function Impairment",ANT3310,"['Meropenem', 'ANT3310']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Renal Impairment,['Renal Impairment'],[],COMPLETED,,2024-07-19,2025-07-10,"[{'measure': 'Maximum Plasma Concentrations (Cmax) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Area under the curve from 0 to infinity (AUC0-inf) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Time from dosing to maximum observed concentration (tmax) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Apparent terminal elimination half-life (t1/2λz) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Area under the curve from time 0 to time of last measurable concentration (AUC0-last) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Area under the curve from time 0 to 48h (AUC0-48h) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Percentage of AUC0-inf obtained by extrapolation (AUCext) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Total body clearance (CL) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Non-renal clearance (CLNonR) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in plasma and urine.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Apparent volume of distribution during the terminal phase after administration (Vz) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Mean residence time (MRT) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Amount of ANT3310 and Meropenem that is eliminated in urine from 0 to infinity (Ae0-inf) after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in urine.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Renal clearance (CLR) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in urine.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Fraction of dose recovered in urine (fe) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in urine.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Amount of ANT3310 and Meropenem that is eliminated in urine from 0 to 48h (Ae0-48h) after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in urine.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Fraction of dose recovered in urine from 0 to 48 hours (fe0-48h) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in urine.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Renal clearance from 0 to 48 hours (CLR[0-48h]) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in urine.', 'timeFrame': 'From pre-dose to Day 3'}, {'measure': 'Dialysis clearance (CLD) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem in dialysed subjects', 'description': 'Pharmacokinetic parameter of ANT3310 and Meropenem in dialysate and plasma.', 'timeFrame': 'during dialysis'}]","[{'measure': 'Number and severity of treatment-emergent adverse event (TEAE) to evaluate the safety and tolerability of ANT3310 and meropenem after a single i.v. infusion of a combination of ANT3310 and meropenem.', 'description': 'Percentage of participants experiencing ≥ one treatment-emergent adverse event (TEAE) by seriousness, intensity, and relatedness from baseline to end of study (EoS) or early withdrawal.', 'timeFrame': '0 hours to Day 9'}, {'measure': 'Number of participants who discontinue due to a TEAE.', 'description': 'Percentage of participants who discontinue due to a TEAE.', 'timeFrame': '0 hours to Day 9'}, {'measure': 'Number of participants who meet the clinically significant abnormal criteria for safety laboratory tests at least once after start of dosing.', 'description': 'Percentage of participants who meet the clinically significant abnormal criteria for safety laboratory tests at least once after start of dosing.', 'timeFrame': '0 hours to Day 9'}, {'measure': 'Number of participants meeting the clinically significant abnormal criteria for vital signs measurements at least once after start of dosing.', 'description': 'Percentage of participants meeting the clinically significant abnormal criteria for vital signs (blood pressure, pulse rate, respiratory rate, and body temperature) measurements at least once after start of dosing.', 'timeFrame': '0 hours to Day 9'}, {'measure': 'Number of participants who meet the clinically significant abnormal criteria for ECG (Electrocardiogram) parameters.', 'description': 'Percentage of participants who meet the clinically significant abnormal criteria for ECG parameters.', 'timeFrame': 'Day-1 to Day 9'}, {'measure': 'Number of infusion site reactions to assess local venous tolerability', 'timeFrame': 'From pre-dose on Day 1 to Day 3'}]",24,18 Years,80 Years,ALL,True,Antabio,INDUSTRY,1,41.0,ACTUAL,2025-09-01T16:18:15.907305,v2_robust,True,True,True,False,True,
NCT06363877,Diluted Aqueous Povidone-Iodine Compared to Saline to Decrease Surgical Site Infections,Wound Irrigation and Peritoneal Lavage With Diluted Aqueous Povidone-Iodine Compared to Saline to Decrease Surgical Site Infections,Povidone-Iodine,"['Povidone-Iodine', 'Normal Saline']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Surgical Site Infection,['Surgical Site Infection'],"['Intraoperative Wound Irrigation', 'Intraoperative Peritoneal Lavage', 'Povidone-Iodine', 'Normal Saline', 'Exploratory Laparotomy', 'Clean Contaminated Wounds', 'Contaminated Wounds']",RECRUITING,,2024-06-03,2025-11,"[{'measure': 'Surgical Site Infection', 'description': 'Subjects in each study arm will be assessed for presence of surgical site infection using a composite measurement based on the CDC/NHSN Guidelines for Surgical Site Infection (SSI) Event (January 2024).\n\nThe presence of one or more of the following will constitute a surgical site infection:\n\n1. purulent drainage from the superficial incision, deep incision or the drain in an organ/space\n2. organism(s) identified from an aseptically-obtained specimen from the superficial incision, subcutaneous tissue, deep soft tissues, or fluid or tissue in the organ space by a culture or nonculture based microbiologic testing method\n3. an incision that is deliberately opened by a provider AND patient has at least one of the following signs or symptoms: localized pain or tenderness; localized swelling; erythema; or heat\n4. an abscess or other evidence of infection involving the deep incision or organ/space detected on gross anatomical exam, histopathologic exam, or imaging test', 'timeFrame': 'Between date of initial operation and post-operative follow up visit (up to 30 days post-operatively)'}]","[{'measure': 'Readmission', 'description': 'Subjects in each study arm will be assessed for the number of times the subject has been readmitted into the hospital for any cause. This will be tracked by chart review and follow-up until 30 days after the initial operation.', 'timeFrame': 'Between date of surgery and 30 days post-operatively'}, {'measure': 'Return to the Operating Room', 'description': 'Subjects in each study arm will be assessed for the number of times the subject returns to the operating room for any cause. This will be tracked throughout the hospital stay and post-discharge by chart review and follow-up until 30 days after the initial operation.', 'timeFrame': 'Between date of surgery and 30 days post-operatively'}, {'measure': 'Ileus', 'description': 'Subjects in each study arm will be assessed for the development of an ileus. This will be diagnosed by lack of bowel function, physical examination (i.e. abdominal distention, tympany) and KUB x-ray to assess for distended loops of bowel with no transition point identified.', 'timeFrame': 'Between date of surgery and 30 days post-operatively'}, {'measure': 'Small Bowel Obstruction', 'description': 'Subjects in each study arm will be assessed for the development of a small bowel obstruction. This will be diagnosed by lack of bowel function, physical examination (i.e. abdominal distention, tympany) and KUB x-ray to assess for distended loops of bowel with a transition point identified. Additional testing including an upper gastrointestinal series (e.g. small bowel follow through) can be used in a case-by-case if medically necessary for diagnosis.', 'timeFrame': 'Between date of surgery and 30 days post-operatively'}]",5,18 Years,80 Years,ALL,False,Loma Linda University,OTHER,0,1100.0,ESTIMATED,2025-09-01T16:18:15.907365,v2_robust,True,True,False,False,False,
NCT01019577,Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant,Phase II Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant,Ixabepilone,"['BMS-247550', 'Ixabepilone', 'Ixempra']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Breast Cancer,['Metastatic Breast Cancer'],[],COMPLETED,,2005-10,2007-07,"[{'measure': 'To assess the tumor response using RECIST Criteria to determine the best overall response and response rate', 'timeFrame': 'For a maximum of 9 3-week cycles or until unacceptable toxicity'}]","[{'measure': 'To evaluate safety of BMS-247550 (AEs, SAEs, Deaths, treatment related AEs) using CTC Criteria', 'timeFrame': 'Every cycle'}, {'measure': 'To evaluate the duration of achieved responses', 'timeFrame': 'For a maximum of 9 3-week cycles or until unacceptable toxicity'}, {'measure': 'To evaluate time to progression (TTP)', 'timeFrame': 'For a maximum of 9 3-week cycles or until unacceptable toxicity'}]",4,20 Years,,FEMALE,False,R-Pharm,INDUSTRY,0,54.0,ESTIMATED,2025-09-01T16:18:15.907398,v2_robust,True,True,True,False,True,
NCT05388877,E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma,Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System (CNS) Metastases From BRAF V600-Mutated Metastatic Melanoma,Dabrafenib,"['BRAF Inhibitor GSK2118436', 'E6201', 'E-6201', 'GSK-2118436', 'Dabrafenib', 'GSK2118436', 'GSK-2118436A', 'MEK-1/MEKK-1 Inhibitor E6201']",8,INTERVENTIONAL,['PHASE1'],PHASE1,,Clinical Stage IV Cutaneous Melanoma AJCC v8,"['Clinical Stage IV Cutaneous Melanoma AJCC v8', 'Metastatic Malignant Neoplasm in the Brain', 'Metastatic Malignant Neoplasm in the Central Nervous System', 'Metastatic Melanoma']",[],TERMINATED,Financial issues,2022-10-20,2025-06-02,"[{'measure': 'Maximum tolerated dose', 'timeFrame': 'Up to end of cycle 1 (1 cycle = 28 days)'}]","[{'measure': 'Overall intracranial response rate', 'description': 'Defined as the number of patients who have achieved CR or PR per Response Assessment in Neuro-oncology (RANO) for brain metastases criteria during treatment with E6201 plus dabrafenib divided by total number of evaluable patients. Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall extracranial response rate', 'description': 'Defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Systemic response by RECIST 1.1 criteria for extracranial disease will be estimated using systemic response rate (SRR) - where SRR is defined as the number of evaluable patients achieving a response (partial response or complete response per RECIST 1.1) during treatment with study therapy divided by the total number of evaluable patients. Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Incidence of adverse events', 'description': 'The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Time to first progression', 'description': 'Will be summarized descriptively.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival', 'description': 'Will be summarized descriptively.', 'timeFrame': 'Up to 2 years'}]",6,18 Years,,ALL,False,Mayo Clinic,OTHER,0,13.0,ACTUAL,2025-09-01T16:18:15.907431,v2_robust,True,True,False,True,True,Financial issues
NCT02862977,Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine and Caffeine in Osteomuscular Treatment,"Phase III, National, Multicenter, Randomized, Double-blind, Double-masked, Compare the Efficacy of Ketoprofen, Cyclobenzaprine and Caffeine Association Versus Cyclobenzaprine and Caffeine (Miosan Caf®) in the Treatment of Osteomuscular Pain in Adults",ketoprofen and cyclobenzaprine association with caffeine,"['ketoprofen and cyclobenzaprine association with caffeine', 'Cyclobenzaprine with caffeine', 'Miosan Caf®', 'EMS association']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Musculoskeletal Pain,['Musculoskeletal Pain'],[],COMPLETED,,2017-11-10,2019-12-20,"[{'measure': 'Efficacy of osteomuscular treatment based on proportion of participants who achieve the 2, 3 or 4 points in the pain scale.', 'timeFrame': '48 hours'}]","[{'measure': 'Safety will be evaluated by the adverse events occurrences', 'timeFrame': 'Maximal experiment duration: 9 days'}]",2,18 Years,65 Years,ALL,False,EMS,INDUSTRY,0,414.0,ACTUAL,2025-09-01T16:18:15.907469,v2_robust,True,True,True,False,True,
NCT03460977,"Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma","A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)",Mervometostat (PF-06821497),"['Xtandi', 'EZH2i', 'Mervometostat (PF-06821497)', 'Enzalutamide']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Metastatic Castration Resistant Prostate Cancer (mCRPC),"['Metastatic Castration Resistant Prostate Cancer (mCRPC)', 'Small Cell Lung Cancer (SCLC)', 'Follicular Lymphoma (FL)']","['EZH2', 'enhancer of zeste homolog 2', 'castrate resistant prostate cancer', 'prostatecancer-study.com', 'mCRPC', 'efficacy', 'safety', 'pharmacokinetics', 'pharmacodynamics', 'dose escalation', 'dose expansion', 'open-label', 'small cell lung cancer', 'SCLC', 'follicular lymphoma', 'FL', 'relapsed', 'refractory']",RECRUITING,,2018-04-17,2026-03-19,"[{'measure': 'Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)', 'description': 'First cycle DLTs will be utilized to determine the MTD', 'timeFrame': 'Baseline up to 90 days'}, {'measure': 'Overall safety profile including adverse events', 'description': 'Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version \\[4.03\\])', 'timeFrame': 'Baseline up to approximately 2 years'}, {'measure': 'Preliminary efficacy determination as evaluated by disease specific response criteria', 'description': 'Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC.', 'timeFrame': 'Through study completion, approximately 2 years past last patient first visit.'}, {'measure': 'Overall safety profile including laboratory abnormalities', 'description': 'Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version \\[4.03\\]), and timing.', 'timeFrame': 'Baseline up to approximately 2 years'}, {'measure': 'Overall safety profile including vital signs', 'description': 'Vital sign changes from baseline including blood pressure, heart rate, ECG changes.', 'timeFrame': 'Baseline up to approximately 2 years'}, {'measure': 'Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival', 'description': 'PCWG3', 'timeFrame': 'Baseline until disease progression or death or through study completion (approx 2 years)'}]","[{'measure': 'Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.', 'description': 'Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC)', 'timeFrame': 'Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.'}, {'measure': 'Evaluate overall survival', 'description': 'Median time to death proportion of patients alive at 6 months, 1 year, and 2 years.', 'timeFrame': 'Baseline up to approximately 2 years'}, {'measure': 'Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)', 'description': 'Single dose and multiple dose PK will be calculated as data permits', 'timeFrame': 'At specific timepoints from Cycle 1 day 1 to End of Treatment visit'}, {'measure': 'Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'description': 'Single dose and multiple dose PK will be calculated as data permits', 'timeFrame': 'At specific timepoints from Cycle 1 day 1 to End of Treatment visit'}, {'measure': 'Pharmacokinetic Parameters: Area Under the Curve (AUC)', 'description': 'Single dose and multiple dose PK will be calculated as data permits', 'timeFrame': 'At specific timepoints from Cycle 1 day 1 to End of Treatment visit'}, {'measure': 'Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)', 'description': 'Single dose and multiple dose PK will be calculated as data permits', 'timeFrame': 'At specific timepoints from Cycle 1 day 1 to End of Treatment visit'}, {'measure': 'Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)', 'description': 'Single dose and multiple dose PK will be calculated as data permits', 'timeFrame': 'At specific timepoints from Cycle 1 day 1 to End of Treatment visit'}, {'measure': 'Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)', 'description': 'Singe dose and multiple dose PK will be calculated as data permits', 'timeFrame': 'At specific timepoints from Cycle 1 day 1 to End of Treatment visit'}, {'measure': 'Evaluate the impact of mevrometostat on patient reported outcomes.', 'description': 'Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P.', 'timeFrame': 'At specific time-points from Cycle 1 Day 1 to End of Treatment visit.'}, {'measure': 'Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity', 'description': 'Questionnaire customized from PRO-CTCAE.', 'timeFrame': 'At specific time points from Cycle1 Day 1 to end of treatment'}]",16,18 Years,,ALL,False,Pfizer,INDUSTRY,0,343.0,ESTIMATED,2025-09-01T16:18:15.907477,v2_robust,True,True,False,False,True,
NCT00857077,Intermittent Preventive Treatment for Malaria in Infants in Navrongo Ghana,Evaluation of the Safety and Effectiveness of EPI-linked Malaria Intermittent Chemotherapy and Iron Supplementation,Sulfadoxine-pyrimethamine,"['Sulfadoxine-pyrimethamine', 'Placebo']",2,INTERVENTIONAL,['NA'],,,Anaemia,"['Anaemia', 'Malaria']",['incidence of anaemia'],COMPLETED,,2000-09,2004-06,[{'measure': 'incidence of anaemia'}],"[{'measure': 'incidence of clinical malaria'}, {'measure': 'incidence of severe disease and mortality'}, {'measure': 'prevalence of anaemia and parasitaemia'}, {'measure': 'incidence of adverse events'}]",5,2 Months,24 Months,ALL,True,London School of Hygiene and Tropical Medicine,OTHER,4,2485.0,ACTUAL,2025-09-01T16:18:15.907497,v2_robust,True,True,True,False,True,
NCT06419777,Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes,Strict Versus Permissive Threshold for Initiation of Pharmacotherapy in Gestational Diabetes Mellitus (GDM) With Glucometer Use - A Randomized Control Trial (START1),Insulin,"['Lantus', 'Lispro', 'Levemir', 'Insulin', 'Humalog', 'NPH']",6,INTERVENTIONAL,['NA'],,,Gestational Diabetes,"['Gestational Diabetes', 'Pregnancy Related']","['gestational diabetes', 'pregnancy', 'insulin', 'Initiation of medication']",RECRUITING,,2024-09-01,2026-05,"[{'measure': 'Neonatal Composite Outcome', 'description': 'neonatal composite including the following measures: large for gestational age (LGA) of neonate defined as birth weight \\>90th percentile for gestational age using the Fenton growth chart, hypoglycemia o defined as glucose \\<40 mg/dL \\<48 hours after birth or glucose, hyperbilirubinemia, stillbirth or neonatal death, birth trauma', 'timeFrame': 'First 28 days of birth'}]","[{'measure': 'Neonatal Outcome: Gestational Age of Birth', 'description': 'Gestational age at delivery in weeks and days', 'timeFrame': 'Delivery Time'}, {'measure': 'Neonatal Outcome: APGAR Score', 'description': 'Scoring system provided a standardized assessment for infants after delivery from 0-10', 'timeFrame': 'At 1 minute of life and at 5 min of life'}, {'measure': 'Neonatal Outcome: Birthweight', 'description': 'Birthweight in grams, Macrosomia (birthweight \\>4000g, Small for gestational age (\\<10th percentile based on Fenton Growth Charts)', 'timeFrame': 'Delivery Time'}, {'measure': 'Neonatal Outcome: Brachial Plexus Injury', 'description': 'Brachial plexus nerves in neonate are torn, stretched, or compressed at delivery', 'timeFrame': 'Delivery Time'}, {'measure': 'Neonatal Outcome: Respiratory distress', 'description': 'Breathing difficulties after birth requiring supplemental oxygen, mask, intubation, and/or surfactant', 'timeFrame': 'Within first 24 hours after delivery'}, {'measure': 'Neonatal Outcome: Admission to Neonatal intensive Care Unit', 'description': 'Admission to neonatal intensive care unit (NICU)', 'timeFrame': 'From delivery to discharge from NICU'}, {'measure': 'Maternal Outcomes: Maternal hypoglycemia', 'description': 'Maternal episode of hypoglycemia \\< 60 mg/dL throughout the pregnancy', 'timeFrame': 'Initiation of insulin to delivery'}, {'measure': 'Maternal Outcomes: Shoulder Dystocia', 'description': ""An obstetric emergency where the anterior fetal shoulder becomes stuck on the maternal pubic symphysis, delaying the birth of the baby's body."", 'timeFrame': 'At Delivery'}, {'measure': 'Maternal Outcomes: Obstetric anal sphincter injury (OASIS)', 'description': '3rd degree and 4th degree perineal injuries', 'timeFrame': 'At Delivery'}, {'measure': 'Maternal Outcomes: Operative Delivery', 'description': 'Vacuum-assisted and Forcep-assisted vaginal Delivery', 'timeFrame': 'At Delivery'}, {'measure': 'Maternal Outcomes: Cesarean Delivery', 'description': 'Cesarean birth', 'timeFrame': 'At Delivery'}, {'measure': 'Maternal Outcomes: Postpartum hemorrhage', 'description': 'Defined as cumulative blood loss ≥1000 mL, or bleeding associated with signs/symptoms of hypovolemia within 24 hours of the birth process', 'timeFrame': 'Within 24 hours of delivery'}, {'measure': 'Maternal Outcomes: Hypertensive Disorders of Pregnancy', 'description': 'Hypertensive disorders of pregnancy: gestational hypertension, Preeclampsia without severe features, Pre-eclampsia with severe features, severe range blood pressures defined as (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥110 mmHg), symptoms of central nervous dysfunction, thrombocytopenia with Platelet count \\<100,000 platelets/microL, hepatic abnormalities, kidney impairment, and or pulmonary edema', 'timeFrame': 'From gestational age of 20 weeks during pregnancy to 6 weeks postpartum'}]",14,18 Years,,FEMALE,True,Thomas Jefferson University,OTHER,1,430.0,ESTIMATED,2025-09-01T16:18:15.907549,v2_robust,True,True,False,False,False,
NCT00003777,"Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer",A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma,amifostine trihydrate,"['amifostine trihydrate', 'fluorouracil', 'cisplatin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Head and Neck Cancer,['Head and Neck Cancer'],"['stage III lip and oral cavity cancer', 'stage IV lip and oral cavity cancer', 'recurrent lip and oral cavity cancer', 'stage III hypopharyngeal cancer', 'stage IV hypopharyngeal cancer', 'recurrent hypopharyngeal cancer', 'stage III laryngeal cancer', 'stage IV laryngeal cancer', 'recurrent laryngeal cancer', 'stage III paranasal sinus and nasal cavity cancer', 'stage IV paranasal sinus and nasal cavity cancer', 'recurrent paranasal sinus and nasal cavity cancer', 'stage III oropharyngeal cancer', 'stage IV oropharyngeal cancer', 'recurrent oropharyngeal cancer']",TERMINATED,PI left institution,1998-12,2001-04-20,[],[],0,18 Years,120 Years,ALL,False,Abramson Cancer Center at Penn Medicine,OTHER,0,35.0,ESTIMATED,2025-09-01T16:18:15.907599,v2_robust,True,True,False,True,False,PI left institution
NCT00303277,Do HMG CoA Reductase Inhibitors Affect Abeta Levels?,Do HMG CoA Reductase Inhibitors Affect Abeta Levels?,simvastatin,"['simvastatin', 'Lipitor', 'Zocor', 'pravastatin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Alzheimer's Disease,"[""Alzheimer's Disease"", 'Aging']","[""Alzheimer's disease"", 'beta-amyloid', 'statins']",COMPLETED,,2002-08,2005-04,"[{'measure': 'CSF abeta levels', 'timeFrame': 'baseline and 12 weeks'}]","[{'measure': 'CSF biomarkers', 'timeFrame': 'baseline and 12 weeks'}]",2,18 Years,90 Years,ALL,False,Seattle Institute for Biomedical and Clinical Research,OTHER,0,35.0,ACTUAL,2025-09-01T16:18:15.907605,v2_robust,True,True,True,False,False,
NCT00333775,A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer,"A Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Docetaxel in Comparison With Docetaxel Plus Placebo, as First Line Treatment for Patients With HER2 Negative Metastatic and Locally Recurrent Breast Cancer.",Docetaxel,"['Avastin', 'Docetaxel', 'Bevacizumab', 'Placebo to bevacizumab']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],[],COMPLETED,,2006-03,2013-10,"[{'measure': 'Progression-free Survival', 'description': 'Progression-free survival was evaluated using Response Evaluation Criteria In Solid Tumors (RECIST 1.0). Progression-free survival was defined as the time from randomization to the time of the first documented disease progression or death, whichever occurred first. Disease progression was defined as ≥ 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions, or appearance of new lesion(s).', 'timeFrame': 'Baseline to the 15 Sep 2008 cut-off date (up to 2 years, 6 months)'}]","[{'measure': 'Percentage of Participants With a Complete Response or a Partial Response', 'description': 'Responses were evaluated using the Response Evaluation Criteria in Solid Tumors. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.', 'timeFrame': 'Baseline to the 15 Sep 2008 cut-off date (up to 2 years, 6 months)'}, {'measure': 'Duration of Response', 'description': 'Duration of response was defined as the time from the first documented complete response or partial response to disease progression or death. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were evaluated using the Response Evaluation Criteria in Solid Tumors.', 'timeFrame': 'Baseline to the 15 September 2008 cut-off date (up to 2 years, 6 months)'}, {'measure': 'Time to Treatment Failure', 'description': 'Time to treatment failure was defined as time from randomization to the date of disease progression, death, or withdrawal of treatment due to an adverse event, withdrawal of informed consent, insufficient therapeutic response, refusal of treatment/failure to co-operate, or failure to return, whichever occurred first.', 'timeFrame': 'Baseline to the 15 September 2008 cut-off date (up to 2 years, 6 months)'}, {'measure': 'Overall Survival', 'description': 'Overall survival was defined as the time from randomization to death from any cause.', 'timeFrame': 'Baseline to the 15 Sep 2008 cut-off date (up to 2 years, 6 months)'}]",5,18 Years,,FEMALE,False,Hoffmann-La Roche,INDUSTRY,0,736.0,ACTUAL,2025-09-01T16:18:15.907710,v2_robust,True,True,True,False,True,
NCT00138775,Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia,D-Serine Adjuvant Pharmacotherapy for the Treatment of Schizophrenia,D-serine,['D-serine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Schizophrenia,"['Schizophrenia', 'Schizoaffective Disorder']","['D-serine', 'Negative symptoms', 'Cognition', 'Schizophrenia', 'Amino acid']",UNKNOWN,,2004-10,2007-10,"[{'measure': 'SANS - Scale for the Assessment of Negative Symptoms - weeks 0, 8 and 16'}, {'measure': 'Measurement and Treatment Research for Cognition in Schizophrenia (MATRICS) battery - visit weeks 0, 8 and 16'}]","[{'measure': 'Positive and Negative Syndrome Scale of Schizophrenia (PANSS) positive, negative, general and total score - weeks 0, 8 and 16'}, {'measure': 'Simpson-Angus Scale (SAS) total score - weeks 0, 8 and 16'}, {'measure': 'Clinical Global Impressions (CGI) score - weeks 0, 8 and 16'}, {'measure': 'Calgary Depression Scale for Schizophrenia (CDSS) score - weeks 0, 8 and 16'}, {'measure': 'Side effect check list'}]",7,18 Years,64 Years,ALL,False,Sheba Medical Center,OTHER_GOV,1,200.0,,2025-09-01T16:18:15.907749,v2_robust,True,True,False,False,False,
NCT00481975,Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients,"A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving",rimonabant (SR141716),['rimonabant (SR141716)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Obesity,"['Obesity', 'Eating Disorders']","['binge eating', 'eating disorders', 'obesity']",COMPLETED,,2004-08,2005-08,[{'measure': 'Change in body weight from baseline to Day 180 visit'}],"[{'measure': 'Efficacy: binge eating episodes, BES score, TFEQ dimensions, waist circumference, Body Mass Index'}, {'measure': 'Safety: clinical examination, vital signs, adverse events, Hospital Anxiety and Depression (HAD) scale'}]",3,18 Years,70 Years,ALL,False,Sanofi,INDUSTRY,0,289.0,ACTUAL,2025-09-01T16:18:15.907762,v2_robust,True,True,True,False,True,
NCT01438775,Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH),Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart,NX-1207,['NX-1207'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Benign Prostatic Hyperplasia,['Benign Prostatic Hyperplasia'],"['Benign prostatic hyperplasia', 'BPH', 'Enlarged prostate', 'Lower urinary tract symptoms', 'LUTS', 'LUTS secondary to BPH', 'LUTS/BPH', 'Benign prostatic obstruction', 'BPO', 'Bladder outlet obstruction', 'BOO']",COMPLETED,,2011-09,2013-01,"[{'measure': 'Safety', 'description': 'Safety parameters as determined by Adverse Events, clinical laboratory test results, vital signs, physical exam and electrocardiogram (ECG).', 'timeFrame': '180 days'}]","[{'measure': 'Symptomatic Improvement', 'description': 'Symptomatic improvement as measured by the change in American Urological Association (AUA) Symptom Index from baseline at 90 days. The AUA Symptom Index is a standardized questionnaire that uses seven questions relating to associated BPH symptoms to provide an assessment of symptom severity on a scale from 0 (no symptoms) to 35 (most severe).', 'timeFrame': '90 days'}, {'measure': 'Prostate Volume Change', 'description': 'Change in prostate volume from baseline to 90 days as measured by transrectal ultrasonography', 'timeFrame': '90 days'}, {'measure': 'Change in Urinary Peak Flow', 'description': 'Change in Urinary Peak Flow (Qmax) from baseline to 90 days as determined by urinary flow-rate recording (uroflowmetry).', 'timeFrame': '90 days'}, {'measure': 'Symptomatic Improvement', 'description': 'Symptomatic improvement as measured by the change in AUA Symptom Index from baseline at 180 days.', 'timeFrame': '180 days'}]",5,45 Years,,MALE,False,Nymox Corporation,INDUSTRY,0,192.0,ACTUAL,2025-09-01T16:18:15.907783,v2_robust,True,True,True,False,True,
NCT01103375,Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma,A Phase I Single Arm Open Label Study of Erlotinib and 13-cis-Retinoic Acid (CRA) in Patients With Recurrent Malignant Gliomas,erlotinib hydrochloride,"['OSI-774', 'erlotinib', 'Sotret', '13-CRA', 'Amnesteem', 'CP-358,774', 'erlotinib hydrochloride', 'Cistane', 'Claravis', 'isotretinoin']",10,INTERVENTIONAL,['PHASE1'],PHASE1,,Adult Anaplastic Astrocytoma,"['Adult Anaplastic Astrocytoma', 'Adult Anaplastic Oligodendroglioma', 'Adult Diffuse Astrocytoma', 'Adult Giant Cell Glioblastoma', 'Adult Glioblastoma', 'Adult Gliosarcoma', 'Adult Mixed Glioma', 'Adult Oligodendroglioma', 'Recurrent Adult Brain Tumor']",[],TERMINATED,Slow accrual,2010-05,2013-03,"[{'measure': 'Recommended phase II doses of erlotinib hydrochloride and isotretinoin', 'description': 'At least 3 patients will be treated at each dose level and the maximum tolerated dose (MTD) will be determined. Patients will be evaluated for dose-limiting toxicity (DLT) in the first 3 weeks on protocol.', 'timeFrame': '3 weeks'}]","[{'measure': 'Toxicity as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression-free survival', 'timeFrame': 'At 6 months'}, {'measure': 'Overall survival', 'timeFrame': 'At 6 months'}, {'measure': 'Response rates (complete or partial response)', 'timeFrame': 'Up to 2 years'}, {'measure': 'EGFRvIII, PTEN, cyclin D1, cyclin E, and RARbeta1 expression in tumor samples', 'timeFrame': 'Pre-study'}]",6,18 Years,,ALL,False,Wake Forest University Health Sciences,OTHER,1,5.0,ACTUAL,2025-09-01T16:18:15.907793,v2_robust,True,True,False,True,True,Slow accrual
NCT01937975,The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050),An Open-Label Study to Investigate the Pharmacokinetics of MK-5172 and MK-8742 in Subjects With Renal Insufficiency,Grazoprevir,"['Elbasvir', 'Grazoprevir']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Hepatitis C,"['Chronic Hepatitis C', 'Renal Impairment']",[],COMPLETED,,2013-09-06,2013-12-17,"[{'measure': 'Area Under the Concentration-time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Grazoprevir', 'description': 'Blood for determination of Grazoprevir concentration was collected predose and 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 12, 16, and 24 hours postdose on Day 9 (ESRD participants only) or Day 10 (all participants)', 'timeFrame': 'Up to 24 hours postdose'}, {'measure': 'Plasma Concentration at 24 Hours Postdose (C24hr) of Grazoprevir', 'description': 'Blood for determination of Grazoprevir concentration was collected at 24 hours postdose on Day 9 (ESRD participants only) or Day 10 (all participants)', 'timeFrame': '24 hours postdose'}, {'measure': 'Maximum Plasma Concentration (Cmax) of Grazoprevir', 'description': 'Blood for determination of Grazoprevir concentration was collected predose and 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 12, 16, 24, 32, 48, 72, 96, and 120 hours postdose on Day 10 (all participants) and only up to 24 hours for ESRD participants on Day 9', 'timeFrame': 'Up to 120 hours postdose'}, {'measure': 'Time of Maximum Plasma Concentration (Tmax) of Grazoprevir', 'description': 'Blood for determination of Grazoprevir concentration was collected predose and 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 12, 16, 24, 32, 48, 72, 96, and 120 hours postdose on Day 10 (all participants) and only up to 24 hours for ESRD participants on Day 9', 'timeFrame': 'Up to 120 hours postdose'}, {'measure': 'Apparent Terminal Half-life (T1/2) of Grazoprevir', 'description': 'Blood for determination of Grazoprevir concentration was collected predose and 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 12, 16, 24, 32, 48, 72, 96, and 120 hours postdose on Day 10', 'timeFrame': 'Up to 120 hours postdose'}, {'measure': 'Apparent Clearance After Extravascular Administration (CL/F) of Grazoprevir', 'description': 'Blood for determination of Grazoprevir concentration was collected predose and 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 12, 16, and 24 hours postdose on Day 9 (ESRD participants only) or Day 10 (all participants)', 'timeFrame': 'Up to 24 hours postdose'}, {'measure': 'Apparent Volume of Distribution After Extravascular Administration (Vz/F) of Grazoprevir', 'description': 'Blood for determination of Grazoprevir concentration was collected predose and 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 12, 16, and 24 hours postdose on Day 10', 'timeFrame': 'Up to 24 hours postdose'}, {'measure': 'Area Under the Concentration-time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Elbasvir', 'description': 'Blood for determination of Elbasvir concentration was collected predose and 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 12, 16, and 24 hours postdose on Day 9 (ESRD participants only) or Day 10 (all participants)', 'timeFrame': 'Up to 24 hours postdose'}, {'measure': 'Plasma Concentration at 24 Hours Postdose (C24hr) of Elbasvir', 'description': 'Blood for determination of Elbasvir concentration was collected at 24 hours postdose on Day 9 (ESRD participants only) or Day 10 (all participants)', 'timeFrame': '24 hours postdose'}, {'measure': 'Maximum Plasma Concentration (Cmax) of Elbasvir', 'description': 'Blood for determination of Elbasvir concentration was collected predose and 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 12, 16, 24, 32, 48, 72, 96, and 120 hours postdose on Day 10 (all participants) and only up to 24 hours for ESRD participants on Day 9', 'timeFrame': 'Up to 120 hours postdose'}, {'measure': 'Time of Maximum Plasma Concentration (Tmax) of Elbasvir', 'description': 'Blood for determination of Elbasvir concentration was collected predose and 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 12, 16, 24, 32, 48, 72, 96, and 120 hours postdose on Day 10 (all participants) and only up to 24 hours for ESRD participants on Day 9', 'timeFrame': 'Up to 120 hours postdose'}, {'measure': 'Apparent Terminal Half-life (T1/2) of Elbasvir', 'description': 'Blood for determination of Elbasvir concentration was collected predose and 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 12, 16, 24, 32, 48, 72, 96, and 120 hours postdose on Day 10', 'timeFrame': 'Up to 120 hours postdose'}, {'measure': 'Apparent Clearance After Extravascular Administration (CL/F) of Elbasvir', 'description': 'Blood for determination of Elbasvir concentration was collected predose and 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 12, 16, and 24 hours postdose on Day 9 (ESRD participants only) or Day 10 (all participants)', 'timeFrame': 'Up to 24 hours postdose'}, {'measure': 'Apparent Volume of Distribution After Extravascular Administration (Vz/F) of Elbasvir', 'description': 'Blood for determination of Elbasvir concentration was collected predose and 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 12, 16, and 24 hours postdose on Day 10', 'timeFrame': 'Up to 24 hours postdose'}]",[],14,18 Years,80 Years,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:15.907803,v2_robust,True,True,True,False,False,
NCT01086475,D-Cycloserine and Social Skills Training in Autism Spectrum Disorders,"A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders",D-cycloserine,"['Seromycin', 'Placebo', 'Sugar pill', 'D-cycloserine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Autistic Disorder,"['Autistic Disorder', ""Asperger's Disorder"", 'Pervasive Developmental Disorder NOS']","['Autism Spectrum Disorder', 'D-cycloserine', 'Social Skills Training']",COMPLETED,,2010-03,2014-01,"[{'measure': 'Social Responsiveness Scale (SRS) Change', 'description': 'The 65-item SRS is a standardized measure of the core symptoms of autism. Each item is scored on a 4-point Likert scale. The score of each individual item is summed to create a total raw score. A total scores results are as follows:\n\n0-62: Within normal limits 63-79: Mild range of impairment 80-108: Moderate range of impairment 109-149: Severe range of impairment', 'timeFrame': 'Completed at Baseline and Week 11'}, {'measure': 'Social Responsiveness Scale (SRS) at Follow-Up', 'description': 'The 65-item SRS is a standardized measure of the core symptoms of autism. Each item is scored on a 4-point Likert scale. The score of each individual item is summed to create a total raw score. A total scores results are as follows:\n\n0-62: Within normal limits 63-79: Mild range of impairment 80-108: Moderate range of impairment 109-149: Severe range of impairment', 'timeFrame': 'Completed at Week 22'}]","[{'measure': 'Clinical Global Impressions Improvement Scale Responder Analysis', 'description': 'The CGI Global Improvement (CGI-I) is a clinician-rate scale designed to take into account all factors to arrive at an assessment of severity and response to treatment, including parent report, parent-rated measures, teacher-rated measures, and clinician-rated measures. The CGI-I is rated from 1 to 7 (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) at a single time-point. The CGI-I was completed at each visit, but only at week 11 were those subjects classified as ""much"" or ""very much improved"" defined as responders and all other classifications will be regarded as non-responders.', 'timeFrame': 'Week 11'}]",3,5 Years,11 Years,ALL,True,Indiana University,OTHER,1,68.0,ACTUAL,2025-09-01T16:18:15.907885,v2_robust,True,True,True,False,False,
NCT02459457,A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer,"A Comparison of Paclitaxel in Combination With Cisplatin(TP), Carboplatin(TC) or Fluorouracil(TF) Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Squamous Cell Carcinoma: A Three-Arm Randomized Phase III Trial",Paclitaxel and Cisplatin,"['TF', 'Paclitaxel and Fluorouracil', 'TP', 'Paclitaxel and Carboplatin', 'TC', 'Paclitaxel and Cisplatin']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Stage III Esophageal Squamous Cell Carcinoma,['Stage III Esophageal Squamous Cell Carcinoma'],"['esophageal squamous cell carcinoma', 'concurrent chemoradiotherapy', 'paclitaxel', 'cisplatin', 'carboplatin', 'fluorouracil']",COMPLETED,,2015-07-01,2022-02,"[{'measure': 'overall survival', 'timeFrame': '3 years'}]","[{'measure': 'progression free survival', 'timeFrame': '1year, 2 years, 3 years'}, {'measure': 'adverse event', 'timeFrame': '3 years'}]",3,18 Years,75 Years,ALL,False,Fudan University,OTHER,7,321.0,ACTUAL,2025-09-01T16:18:15.907968,v2_robust,True,True,True,False,True,
NCT01875757,Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life,Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life,Vitamin D3,"['Vitamin D3', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Acute Bronchitis,"['Acute Bronchitis', 'Upper Respiratory Tract Infection', 'Acute Bronchiolitis']","['Vitamin D', 'Acute bronchitis', 'Upper respiratory tract infection', 'Recurrent bronchitis', 'Acute bronchiolitis', 'Infants']",COMPLETED,,2013-11,2016-12,"[{'measure': 'Percentage of children with acute bronchitis', 'description': 'Check that the administration of a vitamin D dose of 1,000 U / day decreases the percentage of children with acute bronchitis during the first year of life', 'timeFrame': '1 year'}]","[{'measure': 'Number of episodes of upper respiratory infections reported by parents in the first year of life', 'description': 'Check that the supplementation of vitamin D of 1,000 units / day decreases the number of upper respiratory infections', 'timeFrame': '1 year'}]",2,,19 Days,ALL,False,Hospital Universitari Vall d'Hebron Research Institute,OTHER,0,200.0,ACTUAL,2025-09-01T16:18:15.907977,v2_robust,True,True,True,False,False,
NCT01163357,"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma",Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With High Risk Multiple Myeloma,bortezomib,"['sirolimus', 'bortezomib', 'SILA 9268A', 'Rapamune', 'Advagraf', 'fludarabine phosphate', 'RAPA', 'Prograf', 'Fludara', 'Protopic', 'MLN341', 'AY 22989', 'SLM', 'PS-341', '2-F-ara-AMP', 'LDP 341', 'Beneflur', 'rapamycin', 'tacrolimus', 'VELCADE', 'FK 506']",21,INTERVENTIONAL,['PHASE1'],PHASE1,,Autologous Hematopoietic Stem Cell Transplant Recipient,"['Autologous Hematopoietic Stem Cell Transplant Recipient', 'Loss of Chromosome 17p', 'Plasma Cell Leukemia', 'Recurrent Plasma Cell Myeloma', 'Refractory Plasma Cell Myeloma']",[],COMPLETED,,2011-01-28,2024-05-20,"[{'measure': 'Maximum tolerated dose of bortezomib as defined as the highest dose tested in which none or only one patient experiences dose limiting toxicity attributable to the study regimen', 'description': 'Assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Dose-limiting toxicity will be defined using Bearman Scale for events that occur.', 'timeFrame': '6 weeks post transplant'}, {'measure': 'Feasibility of escalating doses of bortezomib with or without TMI in combination with FLU and MEL as preparative regimen for allogeneic hematopoietic stem cell transplant in patients with high risk multiple myeloma', 'timeFrame': '5 years post transplant'}]","[{'measure': 'Frequency of clinical response (i.e., complete, partial, or very good partial response)', 'description': 'Response is evaluated based on a new International myeloma working group uniform response criteria.', 'timeFrame': 'At 6 months and 1 year post transplant'}, {'measure': 'Frequency of primary and secondary engraftment failure', 'timeFrame': '6 weeks post transplant and 4 years post transplant'}, {'measure': 'Time to neutrophil and platelet engraftment', 'timeFrame': '100 days post transplant'}, {'measure': 'Progression-free survival', 'description': 'Time from day 0 of transplant to the first observation or relapse or death due to any cause, assessed up to 4 years', 'timeFrame': '4 years post transplant'}, {'measure': 'Incidence of acute and chronic graft-versus-host disease', 'timeFrame': 'At 6 months and 1 year post transplant up to 4 years post transplant'}, {'measure': 'Overall survival', 'description': 'Time from first day of treatment to time of death due to any cause, assessed up to 4 years', 'timeFrame': '4 years post transplant'}, {'measure': 'Minimal residue disease', 'description': 'Assessed by flow cytometry', 'timeFrame': 'At 6 months and 1 year post transplant'}]",9,18 Years,70 Years,ALL,False,City of Hope Medical Center,OTHER,1,18.0,ACTUAL,2025-09-01T16:18:15.908046,v2_robust,True,True,True,False,True,
NCT03104257,The Neural Correlates of Cannabis Use,The Neural Correlates of Cannabis Use,[11-C]OMAR,['[11-C]OMAR'],1,OBSERVATIONAL,[],,,Cannabis Dependence,"['Cannabis Dependence', 'Healthy']","['Healthy Control, Cannabis, Dependence']",COMPLETED,,2016-12,2022-04-27,"[{'measure': 'CB1R availability using [11-C]OMAR PET imaging', 'description': 'Change in CB1R availability (e.g. volume distribution).', 'timeFrame': 'Change in CB1R availability from baseline to 48 hours and 28 days'}]","[{'measure': 'Changes in Cognition during withdrawal using a computerized battery', 'description': 'Changes in cognitive functions such as attention, memory, motor functioning, and processing speed.', 'timeFrame': 'Change in CB1R availability from baseline to 48 hours and 28 days'}, {'measure': 'Changes in brain rhythms measured by Electroencephalography', 'description': 'Changes in electroencephalographic (EEG) brain rhythms related to information processing.', 'timeFrame': 'Change in CB1R availability from baseline to 48 hours and 28 days'}]",3,18 Years,55 Years,ALL,True,Yale University,OTHER,1,162.0,ACTUAL,2025-09-01T16:18:15.908055,v2_robust,False,True,True,False,False,
NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,"Betaferon Prospective Study on Adherence, Coping and Nursing Support","Interferon beta-1b (Betaseron, BAY86-5046)","['Interferon beta-1b (Betaseron, BAY86-5046)']",1,OBSERVATIONAL,[],,,Relapsing Remitting Multiple Sclerosis (RRMS),['Relapsing Remitting Multiple Sclerosis (RRMS)'],['Clinically Isolated Syndrome (CIS)'],COMPLETED,,2008-06,2014-10,"[{'measure': 'Proportion of patients adhering to treatment', 'timeFrame': '6, 12, 18 and 24 months'}]","[{'measure': 'Rate of early treatment termination', 'timeFrame': '6, 12, 18 and 24 months'}, {'measure': 'Rate of study dropout', 'timeFrame': '6, 12, 18 and 24 months'}, {'measure': 'Predictive value of BL parameters, WCQ, HADS, RODQ', 'timeFrame': '12 and 24 months'}, {'measure': 'WCQ (Ways of Coping Questionnaire)', 'timeFrame': '6, 12, 18 and 24 months'}, {'measure': 'HADS (Hospital Anxiety and Depression Scale)', 'timeFrame': '6, 12, 18 and 24 months'}, {'measure': 'RODQ (Risk of Dropout Questionnaire)', 'timeFrame': 'Monthly over 6 months; every other month thereafter'}, {'measure': 'EDSS (Expanded Disability Status Scale)', 'timeFrame': '6, 12, 18 and 24 months'}, {'measure': 'Relapse rate', 'timeFrame': '6, 12, 18 and 24 months'}]",9,12 Years,,ALL,False,Bayer,INDUSTRY,0,1723.0,ACTUAL,2025-09-01T16:18:15.908149,v2_robust,False,True,True,False,False,
NCT04396457,Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901,Phase 2 Study of Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-squamous Non-small Cell Lung Cancer With PD-L1 Tumor Proportion Score of Less Than 50%: CJLSG1901,Pembrolizumab,"['Pembrolizumab', 'Alimta Injection', 'Pemetrexed', 'KEYTRUDA Injection']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-squamous Non-small-cell Lung Cancer,"['Non-squamous Non-small-cell Lung Cancer', 'Cancer, Lung']",[],UNKNOWN,,2020-05-25,2024-11,"[{'measure': 'Overall response rate', 'description': 'Overall response rate', 'timeFrame': 'Up to approximately 3 years'}]","[{'measure': 'Progression free survival', 'description': 'Progression free survival', 'timeFrame': 'Up to approximately 3 years'}, {'measure': '1 year progression free survival rate', 'description': '1 year progression free survival rate', 'timeFrame': '1 year'}, {'measure': 'Overall survival', 'description': 'Overall survival', 'timeFrame': 'Up to approximately 3 years'}, {'measure': 'Adverse event', 'description': 'Adverse event', 'timeFrame': 'Up to approximately 3 years'}]",5,75 Years,,ALL,False,National Hospital Organization Nagoya Medical Center,OTHER,2,50.0,ESTIMATED,2025-09-01T16:18:15.908164,v2_robust,True,True,False,False,True,
NCT00002157,Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome,Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome,Thalidomide,['Thalidomide'],1,INTERVENTIONAL,['NA'],,,HIV Infections,"['HIV Infections', 'HIV Wasting Syndrome']","['Acquired Immunodeficiency Syndrome', 'Cachexia', 'Thalidomide']",COMPLETED,,,,[],[],0,18 Years,,ALL,False,Celgene Corporation,INDUSTRY,0,,,2025-09-01T16:18:15.908241,v2_robust,True,True,True,False,False,
NCT01923857,Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function,"A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function",Androxal 25 mg,"['Androxal 25 mg', 'enclomiphene citrate']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Secondary Hypogonadism,['Secondary Hypogonadism'],[],COMPLETED,,2013-08,2014-08,"[{'measure': 'Pharmacokinetic parameters', 'description': 'Pharmacokinetic parameters calculated as a ratio in subjects with mild or moderate renal impairment to normal after a single dose of 25 mg Androxal.', 'timeFrame': '24 hours'}]",[],1,18 Years,80 Years,MALE,True,Repros Therapeutics Inc.,INDUSTRY,0,26.0,ACTUAL,2025-09-01T16:18:15.908327,v2_robust,True,True,True,False,False,
NCT02607657,Pharmacokinetics of Eplerenone Tablet,"Phase I Trial Comparing Eplerenone Pharmacokinetics (Tablet) in Different Dosages: 25mg, 50mg,100 mg Per Day and 100 mg (One 50 mg Tablet Every 12 Hours).",Eplerenone 25 mg,"['Eplerenone 50 mg twice a day', 'Eplerenone 25 mg', 'Eplerenone 100 mg', 'Eplerenone 50 mg', 'Eplerenone 25 mg twice a day']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],WITHDRAWN,,2016-05,,"[{'measure': 'Area under the curve(0-last)', 'timeFrame': '24 hours'}, {'measure': 'Area under the curve(0-all)', 'timeFrame': '24 hours'}, {'measure': 'Area under the curve(0-inf)', 'timeFrame': '24 hours'}, {'measure': 'Half-life (t1/2)', 'timeFrame': '24 hours'}, {'measure': 'Elimination rate constant (Ke)', 'timeFrame': '24 hours'}, {'measure': 'Maximum serum concentration (Cmax)', 'timeFrame': '24 hours'}, {'measure': 'Time to reach maximum (peak) plasma concentration following drug administration (tmax)', 'timeFrame': '24 hours'}, {'measure': 'Time of the last measurable (positive) concentration (tlast)', 'timeFrame': '24 hours'}, {'measure': 'Area under the first moment of the plasma concentration-time curve extrapolated from time zero to infinity as a percentage of total AUC', 'timeFrame': '24 hours'}]","[{'measure': 'Number of adverse events', 'timeFrame': '30 days'}, {'measure': 'Intensity of adverse events', 'timeFrame': '30 days'}]",11,18 Years,50 Years,ALL,True,Biolab Sanus Farmaceutica,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:15.908354,v2_robust,True,True,False,True,True,
NCT00193557,Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma,Phase I Trial of Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma,Bortezomib,['Bortezomib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,['Multiple Myeloma'],[],COMPLETED,,2004-05,2009-01,[{'measure': 'objective response rate'}],"[{'measure': 'progression-free survival'}, {'measure': 'overall survival'}, {'measure': 'Safety'}]",4,18 Years,,ALL,False,"SCRI Development Innovations, LLC",OTHER,1,40.0,,2025-09-01T16:18:15.908370,v2_robust,True,True,True,False,True,
NCT01515657,Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients,"A Randomized, Actively Controlled, Crossover Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Patients With Type II Diabetes",PL2200 Aspirin Capsules,"['Enteric-coated aspirin caplets', 'PL2200 Aspirin Capsules', 'Immediate-Release Aspirin Tablets']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2012-01,2012-06,"[{'measure': 'Time to 99% Inhibition of Serum Thromboxane (TxB2)', 'description': ""Aspirin's antiplatelet activity is measured by the capacity of platelets to generate serum thromboxane (a surrogate marker for inhibition of COX-1 by aspirin). Inhibition of serum thromboxane is a key marker of antiplatelet efficacy."", 'timeFrame': '4 days'}]",[],1,21 Years,79 Years,ALL,False,PLx Pharma,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:15.908388,v2_robust,True,True,True,False,False,
NCT00089557,An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain,An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain,Capsaicin Dermal Patch,['Capsaicin Dermal Patch'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Herpes Zoster,"['Herpes Zoster', 'Neuralgia', 'Pain', 'HIV Infections', 'Peripheral Nervous System Diseases', 'Diabetic Neuropathies', 'Diabetes Mellitus', 'Polyneuropathies']","['Dermal assessment', 'Pain assessment', 'Diary', 'Analgesics', 'Capsaicin', 'Herpes zoster', 'Neuralgia', 'Pain', 'HIV Infections', 'Peripheral Nervous System Diseases', 'Diabetic Neuropathies', 'Diabetes Mellitus', 'Polyneuropathies', 'Complementary Therapies']",TERMINATED,,,,[],[],0,18 Years,,ALL,False,NeurogesX,INDUSTRY,0,,,2025-09-01T16:18:15.908397,v2_robust,True,True,False,True,False,
NCT05179057,Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation,"Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, With Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation",Posoleucel,"['Posoleucel', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Adenovirus Infection,['Adenovirus Infection'],"['Allogeneic Hematopoietic Cell Transplant', 'Adenoviremia', 'Adenovirus', 'Stem Cell Transplant', 'Posoleucel', 'ALVR105', 'Bone Marrow Transplant']",TERMINATED,Study discontinued as DSMB determined it was futile. No safety concerns were noted.,2022-04-26,2024-01-31,"[{'measure': 'Number of Participants With Undetectable Adenovirus Infection', 'description': 'Viral load of adenovirus was measured at the central laboratory using quantitative polymerase chain reaction (qPCR) from blood and stool samples at each study visit and on Day 29 from a nasopharyngeal swab. There was a 14-day window for participants who crossed over from posoleucel to placebo; and for participants who crossed over from placebo to posoleucel, the pre-dose cross-over Day 1 viral load was used. Participants missing the primary endpoint but having undetectable viremia before Day 29 and after Day 43 were imputed as successes. Undetectable adenovirus viremia was less than the lower limit of quantification (LLOQ).', 'timeFrame': 'Day 29 through Day 43 (Day 29 + 14 days; up to 43 days post-first infusion)'}, {'measure': 'Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)', 'description': 'A TEAE was defined as an adverse event (AE) with a start date and time on or after the first dose of study treatment. A serious AE (SAE) was an AE that met at least one of the following serious criteria: fatal, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or other important medical event. TEAEs of special interest (AESI) included acute or chronic graft versus host disease, cytokine release syndrome, infusion-related reactions, and graft failure or rejection. Treatment-related refers to the assessment of a relationship between study treatment and the event by the investigator.', 'timeFrame': 'Up to 34 weeks'}]","[{'measure': 'Number of Participants With Overall Disease Progression', 'timeFrame': 'From Day 29 up to Week 10'}, {'measure': 'Area Under the Curve (AUC) Adenovirus Viral Load', 'timeFrame': 'Pre-dose and Day 29'}, {'measure': 'Number of Participants Who Achieved Adenovirus Viremia <400 Copies/mL at Day 29', 'timeFrame': 'Day 29'}, {'measure': 'Time to Undetectable Adenovirus Viremia (Less Than LLOQ)', 'timeFrame': 'Pre-dose to 34 weeks'}, {'measure': 'Number of Participants With Adenovirus Disease Recurrence', 'timeFrame': '34 weeks'}]",7,,,ALL,False,AlloVir,INDUSTRY,0,57.0,ACTUAL,2025-09-01T16:18:15.908427,v2_robust,True,True,False,True,True,Study discontinued as DSMB determined it was futile. No safety concerns were noted.
NCT02224157,A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma,A Clinical Study Comparing Symbicort 'as Needed' With Pulmicort Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma,budesonide/formoterol 'as needed' + budesonide placebo bid,"[""budesonide/formoterol 'as needed' + budesonide placebo bid"", ""budesonode bid + terbutaline 'as needed'""]",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Asthma,['Asthma'],[],COMPLETED,,2014-11-28,2017-08-16,"[{'measure': 'Annual Severe Asthma Exacerbation Rate - Non-inferiority Analysis', 'description': 'Severe asthma exacerbations over the randomised treatment period, negative binomial model for non-inferiority test evaluation', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Annual Severe Asthma Exacerbation Rate - Superiority Analysis', 'description': 'Severe asthma exacerbations over the randomised treatment period, negative binomial model for superiority test evaluation', 'timeFrame': 'up to 52 weeks'}]","[{'measure': 'Number of Participants Experiencing at Least One Severe Asthma Exacerbation', 'description': 'A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids.', 'timeFrame': 'Day 1 up to 52 weeks'}, {'measure': 'Average Change From Baseline in Pre-bronchodilator FEV1', 'description': 'The average change from baseline (baseline defined by measurement at week 0, prior to first dose of IP) to the treatment period average assessed over the entire treatment period in pre-bronchodilator FEV1 was derived by computing a contrast for the mean across the post-randomisation visits (week 17, 34, 52) from the MMRM (mixed model repeated measures) analysis.', 'timeFrame': 'Study weeks 0,17, 34, 52'}, {'measure': 'Number of Participants With Study Specific Asthma Related Discontinuation', 'description': 'The following two criteria lead to discontinuation from the IP due to asthma related events: A severe asthma exacerbation with duration for more than 3 weeks, and/or three severe asthma exacerbations during 6 months.', 'timeFrame': 'Day 1 up to 52 weeks'}, {'measure': ""Average Change From Baseline in 'as Needed' Use"", 'description': ""'As-needed' use change from baseline over the randomised treatment period. Baseline was defined as the last 10 days of the run-in period. 'As needed' use was calculated as the cumulative doses of 'as-needed' medication over the randomised treatment period divided by the follow-up time (number of days - 1). ie, average number of inhalations per day."", 'timeFrame': 'Week 0 up to 52 weeks'}, {'measure': ""Change From Baseline in Percent of 'as Needed' Free Days"", 'description': ""'As needed' free days (%) change from baseline during randomised treatment period. An 'as-needed' free day was defined as a day and night with no use of 'as needed' medication. Variable analysed is the percentage (%) of 'as-needed' free days during the randomised treatment period. Baseline is defined by the last 10 days of the run-in period."", 'timeFrame': 'Week 0 up to 52 weeks'}, {'measure': 'Percentage of Controller Use Days', 'description': ""ICS controller use days (%) during the randomised treatment period is calculated as the cumulative days when any controller medication (containing ICS) was taken including maintenance (Pulmicort bid group) and 'as needed' medication (Symbicort 'as needed' group) and additional prescribed ICS for asthma (all treatment groups), divided by the number of days in the randomised treatment period."", 'timeFrame': 'Week 0 up to 52 weeks'}, {'measure': 'Average Change From Baseline in Asthma Control Questionnaire (5-item Version) - ACQ-5 Score', 'description': ""ACQ questionnaire contains five questions on patients' symptoms, which are assessed on a 7-point scale from 0 (representing good control) to 6 (representing poor control). The score is the mean score of all questions for which responses are provided. The average change from baseline to treatment period average in ACQ-5 was derived by computing a contrast for the mean across all post-randomisation visits (week 17, 34, 52) from the MMRM (mixed model repeated measures) analysis."", 'timeFrame': 'Study weeks 0, 17, 34, 52'}, {'measure': 'Average Change From Baseline in Asthma Quality of Life Questionnaire Standardised Version - AQLQ(S) Score', 'description': 'AQLQ(S) consists of 32 questions in 4 domains. Each question is assessed on a 7-point scale from 1 to 7, with higher values indicating better health-related quality of life. The overall score is calculated as the mean score of all 32 items. The average change from baseline to treatment period average in AQLQ(S) overall score was derived by computing a contrast for the mean across all post-randomisation visits (week 17, 34, 52) from the MMRM (mixed model repeated measures) analysis.', 'timeFrame': 'Study weeks 0,17, 34, 52'}]",10,12 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,0,4215.0,ACTUAL,2025-09-01T16:18:15.908445,v2_robust,True,True,True,False,False,
NCT03539601,"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD","A PHASE 3B/4, MULTICENTER, RANDOMIZED, ASSESSOR BLINDED, VEHICLE AND ACTIVE (TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR) CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY, SAFETY, AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT, 2% IN PEDIATRIC AND ADULT SUBJECTS (AGES 2 YEARS AND OLDER) WITH MILD TO MODERATE ATOPIC DERMATITIS","Crisaborole ointment, 2%","['Eucrisa', 'Locoid 0.1%', 'Elidel', 'Crisaborole Vehicle', 'Hydrocortisone butyrate cream, 0.1%', 'Crisaborole ointment, 2%', 'Pimecrolimus cream, 1%']",7,INTERVENTIONAL,['PHASE4'],PHASE4,,Atopic Dermatitis,['Atopic Dermatitis'],"['Atopic Dermatitis, Crisaborole ointment 2%, TCS, TCI']",TERMINATED,This decision was made for business reasons only and is not related to any safety concerns regarding crisaborole.,2018-04-27,2020-12-11,"[{'measure': 'Percent Change From Baseline in the Eczema Area and Severity Index (EASI) Total Score at Day 29', 'description': ""EASI quantifies severity of participant's AD (excluded scalp) based on lesion severity and percent (%) body surface area (%BSA) affected. Lesion severity included erythema (E), induration/papulation (I), excoriation (Ex), lichenification (L) scored for 4 regions (head and neck \\[h\\], upper limbs \\[u\\], trunk \\[t\\] \\[including axillae, groin\\], lower limbs \\[l\\] \\[including buttocks\\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score (A) based upon %BSA with AD in body region: 0 (0%), 1 (\\>0 to \\<10%), 2 (10 to \\<30%), 3 (30 to \\<50%), 4 (50 to \\<70%), 5 (70 to \\<90%), 6 (90 to 100%). Total EASI score (aged \\>=8 years) =0.1\\*Ah\\*(Eh + Ih + Exh + Lh) + 0.2\\*Au\\*(Eu + Iu + Exu + Lu) + 0.3\\*At\\*(Et + It +Ext + Lt) + 0.4\\*Al\\*(El + Il + Exl + Ll); for aged 2 to \\<8 years =0.2\\*Ah\\*(Eh + Ih + Exh + Lh) + 0.2\\*Au\\*(Eu + Iu + Exu + Lu) + 0.3\\*At\\*(Et +It + Ext + Lt) + 0.3\\*Al\\*(El + Il + Exl + Ll). Total score ranges from 0.0 to 72.0, higher scores indicated greater AD severity."", 'timeFrame': 'Baseline, Day 29'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Discontinuations Due to AEs and SAEs', 'description': 'An AE is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. TEAEs are events between the first dose of study drug up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A SAE is any untoward medical occurrence at any dose that: results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event.', 'timeFrame': 'From Baseline up to 28 days after last dose of study treatment (maximum up to 60 Days)'}, {'measure': 'Number of Participants With Local Tolerability Adverse Events (AEs)', 'description': 'Local tolerability AEs included application and instillation site reactions, application site discharge, application site erythema, application site exfoliation, application site pain, application site pruritus, application site swelling, dermatitis and eczema, dermatitis atopic, dermatitis contact, eczema, skin irritation, telangiectasia and related conditions, and urticarias.', 'timeFrame': 'From Baseline up to 28 days after last dose of study treatment (maximum up to 60 Days)'}, {'measure': 'Number of Participants With Clinically Significant Changes in Vital Signs', 'description': 'Vital sign measurements included temperature, respiratory rate, pulse rate, and blood pressure. Temperature, respiratory rate, pulse rate, and blood pressure were taken in the seated or supine position, after the participant has been sitting or lying calmly for a minimum of 5 minutes (when possible for younger children). Position of recording was consistent within participant through-out the study.', 'timeFrame': 'Screening up to Day 29'}, {'measure': 'Number of Participants With Clinically Significant Abnormal Laboratory Parameters', 'description': 'Hematology parameters included with criteria greater than (\\>) 1.2\\*upper limit of normal (ULN): leukocytes (10\\^3 per cubic millimeter \\[10\\^3/mm\\^3\\]), lymphocytes (10\\^3/mm\\^3), lymphocytes/leukocytes (%), neutrophils (10\\^3/mm\\^3), neutrophils/leukocytes (%), basophils/leukocytes (%), eosinophils (10\\^3/mm\\^3), eosinophils/leukocytes (%), monocytes (10\\^3/mm\\^3), monocytes/leukocytes (%). Clinical chemistry included parameters: aspartate aminotransferase (units per liter \\[U/L\\]) (\\>3.0\\* ULN), alanine aminotransferase (U/L) (\\>3.0\\* ULN), alkaline phosphatase (U/L) (\\>3.0\\* ULN), creatinine (milligram per deciliter \\[mg/dL\\]) (\\>1.3\\* ULN), potassium (milliequivalent per liter \\[mEq/L\\]) (\\>1.1\\* ULN), bicarbonate (mEq/L) (\\>1.1\\* ULN).', 'timeFrame': 'Screening up to Day 29'}]","[{'measure': 'Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Day 8, 15 and 22', 'description': ""EASI quantifies severity of participant's AD (excluded scalp) based on lesion severity and %BSA affected. Lesion severity included erythema (E), induration/papulation (I), excoriation (Ex), lichenification (L) scored for 4 regions (head and neck \\[h\\], upper limbs \\[u\\], trunk \\[t\\] \\[including axillae, groin\\], lower limbs \\[l\\] \\[including buttocks\\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score(A) based upon %BSA with AD in body region: 0 (0%), 1 (\\>0 to \\<10%), 2 (10 to \\<30%), 3 (30 to \\<50%), 4 (50 to \\<70%), 5 (70 to \\<90%), 6 (90 to 100%). Total EASI score (aged \\>=8 years) =0.1\\*Ah\\*(Eh + Ih + Exh + Lh) + 0.2\\*Au\\*(Eu + Iu + Exu + Lu) + 0.3\\*At\\*(Et + It +Ext + Lt) + 0.4\\*Al\\*(El + Il + Exl + Ll); for aged 2 to \\<8 years =0.2\\*Ah\\*(Eh + Ih + Exh + Lh) + 0.2\\*Au\\*(Eu + Iu + Exu + Lu) + 0.3\\*At\\*(Et +It + Ext + Lt) + 0.3\\*Al\\*(El + Il + Exl + Ll). Total score ranges from 0.0 to 72.0, higher scores indicated greater AD severity."", 'timeFrame': 'Baseline, Day 8, 15 and 22'}, {'measure': ""Number of Participants Who Achieved Success in the Investigator's Static Global Assessment (ISGA) (ISGA Score of Clear [0] or Almost Clear [1] With At-least a 2-Grade Improvement From Baseline) at Day 8, 15, 22 and 29"", 'description': ""ISGA is a five point global assessment scale of AD severity, used to characterize participants' overall disease severity across all treatable AD lesions (excluding the scalp). ISGA score ranged from 0 to 4: where 0= clear (minor residual hypo/hyperpigmentation; no erythema or induration/papulation; no oozing/crusting), 1= almost clear (trace faint pink erythema, with barely perceptible induration/papulation and no oozing/crusting), 2= mild (faint pink erythema with mild induration/papulation and no oozing/crusting), 3= moderate (pink-red erythema with moderate induration/papulation with or without oozing/crusting), 4= severe (deep or bright red erythema with severe induration/papulation and with oozing/crusting). Higher scores indicated greater severity of AD."", 'timeFrame': 'Day 8, 15, 22 and 29'}, {'measure': ""Number of Participants Who Achieved Investigator's Static Global Assessment (ISGA) Score of Clear (0) or Almost Clear (1) at Day 8, 15, 22 and 29"", 'description': ""ISGA is a five point global assessment scale of AD severity, used to characterize participants' overall disease severity across all treatable AD lesions (excluding the scalp). ISGA score ranged from 0 to 4: where 0 = clear (minor residual hypo/hyperpigmentation; no erythema or induration/papulation; no oozing/crusting), 1= almost clear (trace faint pink erythema, with barely perceptible induration/papulation and no oozing/crusting), 2= mild (faint pink erythema with mild induration/papulation and no oozing/crusting), 3= moderate (pink-red erythema with moderate induration/papulation with or without oozing/crusting), 4= severe (deep or bright red erythema with severe induration/papulation and with oozing/crusting). Higher scores indicated greater severity of AD."", 'timeFrame': 'Day 8, 15, 22 and 29'}, {'measure': 'Number of Participants Who Achieved Greater Than or Equal to (>=) 75 Percent (%) Improvement From Baseline in Eczema Area and Severity Index (EASI) Total Score at Day 8, 15, 22 and 29', 'description': ""EASI quantifies severity of participant's AD (excluded scalp) based on lesion severity and %BSA affected. Lesion severity included erythema (E), induration/papulation (I), excoriation (Ex), lichenification (L) scored for 4 regions (head and neck \\[h\\], upper limbs \\[u\\], trunk \\[t\\] \\[including axillae, groin\\], lower limbs \\[l\\] \\[including buttocks\\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score(A) based upon %BSA with AD in body region: 0 (0%), 1 (\\>0 to \\<10%), 2 (10 to \\<30%), 3 (30 to \\<50%), 4 (50 to \\<70%), 5 (70 to \\<90%), 6 (90 to 100%). Total EASI score (aged \\>=8 years) =0.1\\*Ah\\*(Eh + Ih + Exh + Lh) + 0.2\\*Au\\*(Eu + Iu + Exu + Lu) + 0.3\\*At\\*(Et + It +Ext + Lt) + 0.4\\*Al\\*(El + Il + Exl + Ll); for aged 2 to \\<8 years =0.2\\*Ah\\*(Eh + Ih + Exh + Lh) + 0.2\\*Au\\*(Eu + Iu + Exu + Lu) + 0.3\\*At\\*(Et +It + Ext + Lt) + 0.3\\*Al\\*(El + Il + Exl + Ll). Total score ranges from 0.0 to 72.0, higher scores indicated greater AD severity."", 'timeFrame': 'Day 8, 15, 22 and 29'}, {'measure': 'Time to First Improvement From Baseline in Eczema Area and Severity Index (EASI) Total Score of Greater Than or Equal to (>=) 75%', 'description': ""EASI quantifies severity of participant's AD (excluded scalp) based on lesion severity and %BSA affected. Lesion severity included erythema (E), induration/papulation (I), excoriation (Ex), lichenification (L) scored for 4 regions (head and neck \\[h\\], upper limbs \\[u\\], trunk \\[t\\] \\[including axillae, groin\\], lower limbs \\[l\\] \\[including buttocks\\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score(A) based upon %BSA with AD in body region: 0 (0%), 1 (\\>0 to \\<10%), 2 (10 to \\<30%), 3 (30 to \\<50%), 4 (50 to \\<70%), 5 (70 to \\<90%), 6 (90 to 100%). Total EASI score (aged \\>=8 years) =0.1\\*Ah\\*(Eh + Ih + Exh + Lh) + 0.2\\*Au\\*(Eu + Iu + Exu + Lu) + 0.3\\*At\\*(Et + It +Ext + Lt) + 0.4\\*Al\\*(El + Il + Exl + Ll); for aged 2 to \\<8 years =0.2\\*Ah\\*(Eh + Ih + Exh + Lh) + 0.2\\*Au\\*(Eu + Iu + Exu + Lu) + 0.3\\*At\\*(Et +It + Ext + Lt) + 0.3\\*Al\\*(El + Il + Exl + Ll). Total score ranges from 0.0 to 72.0, higher scores indicated greater AD severity."", 'timeFrame': 'Baseline up to Day 43'}, {'measure': 'Change From Baseline in Percent Body Surface Area (%BSA) at Day 8, 15, 22 and 29', 'description': ""Four body regions were evaluated: head and neck, upper limbs, trunk (including axillae) and lower limbs (including buttocks) excluding scalp. BSA was calculated using handprint method. Number of handprints (size of participant's full palmer hand in a closed position) fitting in affected area of a body region was estimated. Maximum number of handprints were: 10 for head, neck (20 for \\<8 years age), 20 for upper limbs, 30 for trunk, 40 for lower limbs (30 for \\<8 years age). Surface area (SA) of body region equivalent to 1 handprint: 10% for head, neck (5% for \\<8 years age), 5% for upper limbs, 3.33% for trunk, 2.5% for lower limbs (3.33% for \\<8 years age). Overall %BSA for a body region = total number of handprints in a body region \\* % SA equivalent to 1 handprint. % BSA for an individual: mean of % BSA of all 4 body regions, range =0-100%, higher values = greater AD severity."", 'timeFrame': 'Baseline, Day 8, 15, 22 and 29'}, {'measure': 'Change From Baseline in Peak Pruritus Numerical Rating Scale (NRS) in Participants Aged Greater Than or Equal to (>=) 12 Years at Day 8, 15, 22 and 29', 'description': 'The severity of itch (pruritus) due to AD was assessed using the peak pruritus NRS for participants aged \\>=12 years. Participants at specified time points were asked the following question: ""how would you rate your itch at the worst moment during the previous 24 hours?"" The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.', 'timeFrame': 'Baseline, Day 8, 15, 22 and 29'}, {'measure': 'Change From Baseline in Participant Reported Itch Severity Scale in Participants Aged 6-11 Years at Day 8, 15, 22 and 29', 'description': 'The severity of itch (pruritus) due to AD was assessed using the five-category participant reported itch severity scale for participants aged 6-11 years. Participants at specified time points were asked to ""circle the face that shows how itchy your skin has been today"". The scale ranged from 0 to 4, where 0= no itch and 4= very itch. Higher scores indicated worse itch.', 'timeFrame': 'Baseline, Day 8, 15, 22 and 29'}, {'measure': 'Change From Baseline in Observer Reported Itch Severity Scale in Participants Aged Less Than (<) 6 Years at Day 8, 15, 22 and 29', 'description': 'The severity of itch (pruritus) due to AD was assessed using the participant reported itch severity scale for participants aged \\<6 years. Participant\'s caregivers at specified time points were asked the following question ""how would you rate your observation of your child\'s itch (scratching, rubbing) at the worst moment during the previous 24 hours?"". The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.', 'timeFrame': 'Baseline, Day 8, 15, 22 and 29'}, {'measure': 'Time to Greater Than or Equal to (>=2) Point Improvement From Baseline in Peak Pruritus Numeric Rating Scale (NRS) in Participants Aged Greater Than (>) 12 Years', 'description': 'The severity of itch (pruritus) due to AD was assessed using the peak pruritus NRS for participants aged \\>12 years. Participants at specified time points were asked the following question: ""how would you rate your itch at the worst moment during the previous 24 hours?"" The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.', 'timeFrame': 'Baseline up to Day 29'}, {'measure': 'Time to >= 3 Point Improvement From Baseline in Peak Pruritus Numeric Rating Scale (NRS) in Participants Aged Greater Than (>)12 Years', 'description': 'The severity of itch (pruritus) due to AD was assessed using the Peak Pruritus NRS for participants aged \\>12 years. Participants at specified time points were asked the following question: ""how would you rate your itch at the worst moment during the previous 24 hours?"" The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.', 'timeFrame': 'Baseline up to Day 29'}, {'measure': 'Time >=2 Point to Improvement From Baseline in Observer Reported Itch Severity Scale in Participants Aged Less Than (<) 6 Years', 'description': 'The severity of itch (pruritus) due to AD was assessed using the patient reported itch severity scale for participants aged \\<6 years. Participant\'s caregivers at specified time points were asked the following question ""how would you rate your observation of your child\'s itch (scratching, rubbing) at the worst moment during the previous 24 hours?"". The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.', 'timeFrame': 'Baseline up to Day 29'}, {'measure': 'Time to >=3 Point Improvement From Baseline in Observer Reported Itch Severity Scale in Participants Aged Less Than (<) 6 Years', 'description': 'The severity of itch (pruritus) due to AD was assessed using the Patient Reported Itch Severity Scale for participants aged \\<6 years. Participant\'s caregivers at specified time points were asked the following question ""how would you rate your observation of your child\'s itch (scratching, rubbing) at the worst moment during the previous 24 hours?"". The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.', 'timeFrame': 'Baseline up to Day 29'}, {'measure': 'Number of Participants Who Achieved >=2 Point Improvement From Baseline in Peak Pruritus Numeric Rating Scale (NRS) in Participants Aged Greater Than or Equal to (>=) 12 Years at Day 8, 15, 22 and 29', 'description': 'The severity of itch (pruritus) due to AD was assessed using the peak pruritus NRS for participants aged \\>=12 years. Participants at specified time points were asked the following question: ""how would you rate your itch at the worst moment during the previous 24 hours?"" The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.', 'timeFrame': 'Day 8, 15, 22 and 29'}, {'measure': 'Number of Participants Who Achieved >=3 Point Improvement From Baseline in Peak Pruritus Numeric Rating Scale (NRS) in Participants Aged Greater Than or Equal to (>=) 12 Years at Day 8, 15, 22 and 29', 'description': 'The severity of itch (pruritus) due to AD was assessed using the Peak Pruritus NRS for participants aged \\>=12 years. Participants at specified time points were asked the following question: ""how would you rate your itch at the worst moment during the previous 24 hours?"" The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.', 'timeFrame': 'Day 8, 15, 22 and 29'}, {'measure': 'Number of Participants Who Achieved Greater Than or Equal to (>=) 2 Point Improvement From Baseline in Observer Reported Itch Severity Scale in Participants Aged Less Than (<) 6 Years at Day 8, 15, 22 and 29', 'description': 'The severity of itch (pruritus) due to AD was assessed using the Patient Reported Itch Severity Scale for participants aged \\<6 years. Participant\'s caregivers at specified time points were asked the following question ""how would you rate your observation of your child\'s itch (scratching, rubbing) at the worst moment during the previous 24 hours?"". The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.', 'timeFrame': 'Day 8, 15, 22 and 29'}, {'measure': 'Number of Participants Who Achieved Greater Than or Equal to (>=) 3 Point Improvement From Baseline in Observer Reported Itch Severity Scale in Participants Aged Less Than (<) 6 Years at Day 8, 15, 22 and 29', 'description': 'The severity of itch (pruritus) due to AD was assessed using the Patient Reported Itch Severity Scale for participants aged \\<6 years. Participant\'s caregivers at specified time points were asked the following question ""how would you rate your observation of your child\'s itch (scratching, rubbing) at the worst moment during the previous 24 hours?"". The scale ranged from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.', 'timeFrame': 'Day 8, 15, 22 and 29'}, {'measure': 'Change From Baseline in Dermatology Life Quality Index (DLQI) in Participants Greater Than or Equal to (>=) 16 Years at Day 8, 15, 22 and 29', 'description': 'DLQI is a 10-item questionnaire that measures the impact of skin disease on participants aged \\>=16 years. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participant.', 'timeFrame': 'Baseline, Day 8, 15, 22 and 29'}, {'measure': ""Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) in Participants Aged 4-15 Years at Day 8, 15, 22 and 29"", 'description': ""The CDLQI was a 10-item questionnaire that measures the impact of skin disease on children's (aged 4 to 15 years) quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The CDLQI total score was the sum of individual scores of question 1-10 and ranged from 0 (not at all) to 30 (very much): 0-1 = no effect on the child's life; 2-6 = small effect; 7-12 = moderate effect; 13-18 = very large effect; 19-30 = extremely large effect. Higher scores indicated more impact on quality of life of children."", 'timeFrame': 'Baseline, Day 8, 15, 22 and 29'}, {'measure': 'Change From Baseline in Dermatitis Family Impact Questionnaire (DFI) in Participants Aged 2-17 Years at Day 8, 15, 22 and 29', 'description': 'The DFI was a 10-item disease questionnaire that measures the impact of having a child (aged 2-17 years) with AD on family quality of life. It was completed by parent/legal guardian of the child (affected by AD), based on recall over the past week. Each question was scored on a 4-point scale ranging from 0 (not at all) to 30 (very much): where higher scores indicated worst quality of life of family. The DFI total score was the sum of individual scores of the 10 questions and ranged from 0 (no impact on life of family) to 30 (maximum effect on life of family), where higher DFI scores indicated maximum effect on life of family.', 'timeFrame': 'Baseline, Day 8, 15, 22 and 29'}]",25,2 Years,,ALL,False,Pfizer,INDUSTRY,0,237.0,ACTUAL,2025-09-01T16:18:15.908494,v2_robust,True,True,False,True,True,This decision was made for business reasons only and is not related to any safety concerns regarding crisaborole.
NCT01563601,Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer,"A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer","Obatoclax Mesylate, Carboplatine and Etoposide","['Obatoclax Mesylate, Carboplatine and Etoposide', 'Etoposide: Eposin, Neoposid, Vepesid, Etopophos', 'Carboplatin and Etoposide', 'Carboplatin: Paraplatin', 'Obatoclax: CEP-41601']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Extensive-stage Small Cell Lung Cancer,['Extensive-stage Small Cell Lung Cancer'],[],WITHDRAWN,Business Decision,2012-08,2018-01,"[{'measure': 'Overall survival (OS): Time to Death', 'description': 'After 570 death events have been observed (Interim Analysis after 171 death events)or 24 months from last patient enrolled', 'timeFrame': '24 months from last patient enrolled'}]","[{'measure': 'Progression-Free Survival (PFS)', 'description': 'Randomization to Date of First Documented Disease Progression or Death for up to 24 months from last patient enrolled', 'timeFrame': '24 months from last patient enrolled'}, {'measure': 'Duration of Response', 'description': 'First Response to Disease Progression or Death up to 24 months from last patient enrolled', 'timeFrame': '24 months from last patient enrolled'}, {'measure': 'Objective Response Rate (Complete Response or Partial Response)', 'timeFrame': '37 months'}, {'measure': 'Quality of Life', 'description': 'This is assessed with the European Organization for Research and Treatment of Cancer(EORTC)QLQ-C30 and EORTC QLQ-LC13 questionnaires', 'timeFrame': '37 months'}]",5,18 Years,,ALL,False,Cephalon,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:15.908521,v2_robust,True,True,False,True,False,Business Decision
NCT00561301,Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma,Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma,GemDOx,['GemDOx'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Lymphoma,['Lymphoma'],[],UNKNOWN,,2006-11,2009-10,"[{'measure': 'objective response rate', 'timeFrame': '10/2009'}]","[{'measure': 'toxicities, progression-free survival, overall survival, ASCC efficacy, rate for proceeding to ASCT', 'timeFrame': '10/2009'}]",2,15 Years,65 Years,ALL,False,Cooperative Study Group A for Hematology,NETWORK,0,43.0,ESTIMATED,2025-09-01T16:18:15.908550,v2_robust,True,True,False,False,False,
NCT01128101,Effects of Spironolactone in Dialysis,Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients,Spironolactone,['Spironolactone'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Renal Failure,['Renal Failure'],"['spironolactone', 'chronic kidney disease', 'dialysis', 'LHV']",UNKNOWN,,2011-03,2013-12,"[{'measure': 'Reduction of Left Ventricular Hypertrophy', 'description': 'The reduction of left ventricular hypertrophy will be measured by echocardiography, blood pressure monitoring residential and pulse wave velocity.', 'timeFrame': '12 months'}]","[{'measure': 'To evaluate the safety and efficacy of the use of spironolactone at a dose of 25mg in patients with chronic kidney disease on hemodialysis.', 'description': 'Measurement of serum potassium and other routine laboratory parameters pertaining to the hemodialysis unit of the Hospital of the Medical School of Botucatu - UNESP.', 'timeFrame': '12 months'}]",2,18 Years,80 Years,ALL,False,UPECLIN HC FM Botucatu Unesp,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:15.908558,v2_robust,True,True,False,False,True,
NCT01970501,Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure,GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure,bucindolol hydrochloride,"['metoprolol succinate', 'Toprol-XL', 'bucindolol', 'bucindolol hydrochloride', 'metoprolol']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Current or Recent History of Atrial Fibrillation,['Current or Recent History of Atrial Fibrillation'],"['atrial fibrillation', 'atrial flutter', 'heart failure', 'reduced left ventricle ejection fraction', 'electrical cardioversion', 'GENETIC-AF', 'Medtronic', 'bucindolol', 'pharmacogenetic', 'ARCA', 'Toprol', 'Toprol-XL', 'Metoprolol', 'Metoprolol succinate']",COMPLETED,,2014-04,2017-12-28,"[{'measure': 'Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24].', 'description': ""Time-to-event is calculated as the date of the event minus the date of initiation of efficacy follow-up, with 1 added in order to include both the start date and end date of the interval. Cox's proportional hazards model will be used to calculate estimated hazard ratios and 95% confidence intervals. The calculations will be performed with the SAS PHREG procedure, with the stratification variables specified in the STRATA statement and the treatment group comparator and any covariates being examined specified in the MODEL statement. For the primary endpoint, the appropriateness of assuming proportional hazards will be explored by the graphing of log (-log(survival function)) over follow-up for each treatment group."", 'timeFrame': 'end of treatment week 24'}]","[{'measure': 'Time to First Event of Symptomatic or Asymptomatic AF/AFL or ACM During the 24-week Follow-up Period After Establishment of Stable SR on Study Drug [End of Treatment Week 24]', 'description': 'Number of days on study medication before participant experienced symptomatic or asymptomatic atrial fibrillation, atrial flutter, or all-cause mortality during the 24 week follow up period.', 'timeFrame': 'end of treatment week 24'}, {'measure': 'Number of Patients With Adequate Ventricular Rate Control During the 24-week Follow-up Period', 'description': 'Number of patients with adequate ventricular rate control following the start of medication during the 24-week Follow-up Period', 'timeFrame': 'end of treatment week 24'}, {'measure': 'Total Number of Hospitalization Days Per Patient (All-cause) During the Total Study Period (24 Weeks)', 'description': 'Total number of hospitalization days per patient (all-cause) following the start of study medication during the Total Study Period (24 weeks). Hospitalization was defined by a hospital admission (note that same day admit and discharge equates to 0 days duration), ER visits were not counted as events.', 'timeFrame': '24 weeks'}]",4,18 Years,85 Years,ALL,False,"ARCA Biopharma, Inc.",INDUSTRY,1,267.0,ACTUAL,2025-09-01T16:18:15.908568,v2_robust,True,True,True,False,False,
NCT01562301,Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC),"A Phase I Study of the Combination of Carboplatin, Docetaxel, and Increasing Doses of Sublingual Anvirzel (Nerium Oleander) in Advance Non-Small Cell Lung Cancer",Carboplatin,"['Nerium oleander', 'Anvirzel', 'Carboplatin', 'Taxotere', 'Paraplatin', 'Docetaxel']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Chemotherapeutic Agent Toxicity,"['Chemotherapeutic Agent Toxicity', 'Lung Cancer']","['chemotherapeutic agent toxicity', 'recurrent non-small cell lung cancer', 'stage IIIA non-small cell lung cancer', 'stage IIIB non-small cell lung cancer', 'stage IV non-small cell lung cancer', 'carboplatin', 'Paraplatin', 'docetaxel', 'Taxotere', 'Anvirzel', 'nerium oleander', 'Advanced Non-Small Cell Lung Cancer', 'NSCLC']",WITHDRAWN,,2014-06,,"[{'measure': 'Maximum Tolerated Dose (MTD) of sublingual (SL) dosing of Anvirzel in combination with chemotherapy', 'timeFrame': '21 Day Cycle'}, {'measure': 'Pharmacokinetics of carboplatin and docetaxel when administered concurrently with SL Anvirzel', 'description': 'Pharmacokinetic studies evaluate plasma concentrations over a 24 hour period prior to administration of chemotherapy, using high performance liquid chromatographic and electron ion-spray mass spectrometry', 'timeFrame': '24 hours'}]","[{'measure': 'Anti-inflammatory effects of SL Anvirzel during carboplatin and docetaxel chemotherapy', 'timeFrame': 'Up to four 21 day cycles (84 days)'}, {'measure': 'Immunomodulatory effects of SL Anvirzel during carboplatin and docetaxel chemotherapy', 'timeFrame': 'Up to four 21 day cycles (84 days)'}, {'measure': 'Symptoms and quality-of-life outcomes based on MDASI-LC and SF-12 scores', 'timeFrame': 'Up to four 21 day cycles (84 days)'}, {'measure': 'Grade 3-4 toxicities at each course according to NCI Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0', 'timeFrame': 'Up to four 21 day cycles (84 days)'}]",6,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,2,0.0,ACTUAL,2025-09-01T16:18:15.908613,v2_robust,True,True,False,True,True,
NCT00576901,A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.,"""An Open Label Study to Assess the Effect of Neoadjuvant Treatment With Docetaxel + Xeloda + Avastin on Pathological Response Rate in Inflammatory or Locally Advanced Breast Cancer""",bevacizumab [Avastin],"['Xeloda', 'Docetaxel', 'bevacizumab [Avastin]']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],[],TERMINATED,The sample for statistical analysis of results could not be recruited within the specified timeframe upon retirement of the original principal investigator.,2007-11,2009-06,"[{'measure': 'Percentage of Participants Achieving Pathological Complete Response (pCR)', 'description': 'pCR was defined as the absence of viable tumor cells, as determined by standard histologic procedure, in the tumor specimen (including regional lymph nodes) obtained at surgery. In order to minimize evaluation bias, tumor specimens were analyzed by both a central and local pathologist. The number of participants with pathological tumor stage 0 (pT0) and regional lymph nodes stage 0 (pN0) at surgery was determined. pCR was defined as the number of participants with pT0 and pN0 at surgery divided by the total number of participants with pathological tumor stage data collected.', 'timeFrame': 'At time of surgery, after receiving up to 6 cycles of treatment (average of 12 to 18 weeks)'}]","[{'measure': 'Percentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR)', 'description': 'The percentage of participants with a best overall response of CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \\[\\<\\]10 millimeters \\[mm\\]). No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short aixs was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.', 'timeFrame': 'Day 1 of Cycles 1-6'}, {'measure': 'Progression-Free Survival', 'description': 'Progression-free survival was defined as the time from the date of informed consent until the date disease progression was identified, or the date of death from disease progression, whichever occurred first.', 'timeFrame': 'Cycles 1-6'}, {'measure': 'Overall Survival', 'description': 'Overall survival was defined as the time from the date of informed consent until the date of death due to any cause.', 'timeFrame': 'Cycles 1-6'}, {'measure': 'Percentage of Participants Undergoing Breast-Conserving Surgery', 'description': 'The percentage of participants who were able to undergo breast-conserving surgical procedures (segmentectomy plus lymphadenectomy or quadrantectomy plus lymphadenectomy) rather than non-breast conserving procedures (radical mastectomy or modified-radical mastectomy) following 4 or more treatment cycles.', 'timeFrame': 'Following Cycle 6'}]",5,18 Years,,FEMALE,False,Hoffmann-La Roche,INDUSTRY,0,23.0,ACTUAL,2025-09-01T16:18:15.908724,v2_robust,True,True,False,True,False,The sample for statistical analysis of results could not be recruited within the specified timeframe upon retirement of the original principal investigator.
NCT02118012,"Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C","Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C",Chlorcyclizine HCl,"['CCZ', 'Chlorcyclizine HCl', 'Ribavirin', 'RBV']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Chronic Hepatitis C,['Chronic Hepatitis C'],"['Chlorcyclizine HCL', 'Direct Acting Antivirals', 'Ribavirin', 'Chronic Hepatitis C']",COMPLETED,,2014-03-20,2016-09-20,"[{'measure': 'Change in Serum HCV RNA Viral Titer From Baseline to 28 Days', 'timeFrame': 'Baseline and 28 days'}, {'measure': 'Number of Participants Who Tolerated the Drug at the Prescribed Dose for the Duration of Therapy', 'timeFrame': '28 days'}]","[{'measure': 'Change in Alanine Aminotransferase (ALT) Levels From Baseline to 28 Days', 'timeFrame': 'Baseline and 28 days'}, {'measure': 'Maximum Chlorcyclizine HCL Weeks 1-4', 'description': 'Chlorcyclizine HCL concentration was measured once a week in the morning. This outcome is the maximum over the four weeks.', 'timeFrame': 'Weeks 1-4'}]",4,18 Years,,ALL,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,0,24.0,ACTUAL,2025-09-01T16:18:15.908876,v2_robust,True,True,True,False,False,
NCT04963712,Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder,A Prospective Single-arm Cohort Study Evaluating the Safety and Efficacy of Thymalfasin (Zadaxin®) in the Treatment of HIV-positive Patients With Immune Reconstitution Disorders,Zadaxin,"['Zadaxin', 'Thymosin α1']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,HIV-1-infection,['HIV-1-infection'],[],COMPLETED,,2021-09-01,2022-08-11,"[{'measure': 'Change in CD4+T cell counts', 'description': 'Peripheral blood', 'timeFrame': 'Measured on week 24'}, {'measure': 'Change in CD4/CD8 ratio', 'description': 'Peripheral blood', 'timeFrame': 'Measured on week 24'}]","[{'measure': 'Change in CD4+T cell count and proportion', 'description': 'Peripheral blood', 'timeFrame': 'Measured on week 0, 4, 8, 12, 24'}, {'measure': 'Change in CD8+T cell count and proportion', 'description': 'Peripheral blood', 'timeFrame': 'Measured on week 0, 4, 8, 12, 24'}, {'measure': 'Change in proportions of T cell subsets', 'description': 'Peripheral blood mononuclear cell', 'timeFrame': 'Measured on week 0, 4, 8, 12, 24'}, {'measure': 'Change in proportions of immune exhausted T cells expressed PD-1 and TIM-3', 'description': 'Peripheral blood mononuclear cell', 'timeFrame': 'Measured on week 0, 4, 8, 12, 24'}, {'measure': 'Change in PBMC sjTREC', 'description': 'Peripheral blood mononuclear cell', 'timeFrame': 'Measured on week 0, 4, 8, 12, 24'}, {'measure': 'Change in HIV-1 RNA', 'description': 'Plasma', 'timeFrame': 'Measured on week 0, 4, 8, 12, 24'}]",8,18 Years,65 Years,ALL,False,Shanghai Public Health Clinical Center,OTHER_GOV,0,20.0,ACTUAL,2025-09-01T16:18:15.908890,v2_robust,True,True,True,False,False,
NCT01085812,Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder,"A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder",Levomilnacipran ER,"['Levomilnacipran ER', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Depression,"['Depression', 'Major Depressive Disorder']",[],COMPLETED,,2010-03,2011-10,"[{'measure': 'Time to Relapse (Days)', 'description': 'Number of days until patients meet relapse criteria. Relapse was defined as 1 or more of the following: 1. MADRS total score of at least 22 at 2 consecutive visits 2. Increase of 2 or more points in CGI-I score compared with the CGI-I score at Visit 9 at 2 consecutive visits 3. Premature discontinuation due to insufficient therapeutic response 4. MADRS item 10 score of at least 4', 'timeFrame': '24 Weeks'}]",[],1,18 Years,65 Years,ALL,False,Forest Laboratories,INDUSTRY,0,734.0,ACTUAL,2025-09-01T16:18:15.908989,v2_robust,True,True,True,False,False,
NCT02657512,Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects,Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects : RICHAR Study,rivaroxaban,"['rivaroxaban and activated charcoal', 'rivaroxaban']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Rivaroxaban, pharmacokinetics, activated charcoal, poisoning']",COMPLETED,,2016-01,2016-04,"[{'measure': 'plasma concentrations of rivaroxaban', 'description': 'rivaroxaban pharmacokinetics', 'timeFrame': 'H0.5, H0.75, H1, H1.5, H2, H2.5, H3, H4, H5, H6, H8, H10, H12, H14, H18 and H24 after rivaroxaban administration'}]",[],1,18 Years,40 Years,MALE,True,Centre Hospitalier Universitaire de Saint Etienne,OTHER,0,12.0,ACTUAL,2025-09-01T16:18:15.909102,v2_robust,True,True,True,False,False,
NCT00824512,Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia,"Efficacy of EGb761 120mg Bid Versus Placebo in Patients Suffering From Friedreich Ataxia. A 3 Month, Phase II, Randomised, Double Blind, Placebo Controlled, Parallel Group Clinical Study.",EGb 761 120 mg,"['EGb 761 120 mg', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Friedreich Ataxia,['Friedreich Ataxia'],[],COMPLETED,,2008-06,2011-10,"[{'measure': 'Creatine Rephosphorylation Rate Post Exercise', 'description': 'Creatine Rephosphorylation Rate post exercise measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy and calculated with correction according to muscular pH.', 'timeFrame': 'Baseline (Week 0) to Week 12'}]","[{'measure': 'Peak Post Exercise Perfusion', 'description': 'Peak post exercise perfusion (mL/mn/100 g of tissue) was assessed using Arterial spin labelling combined with Nuclear Magnetic Resonance imaging.', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Time to Peak Perfusion', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Perfusion-time Integral During the First 9 Minutes Post Exercise.', 'description': ""The integral of 'peak perfusion' over a period of 9 minutes post exercise."", 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Muscle Reoxygenation Rate Post Exercise.', 'description': 'Muscle reoxygenation rate post exercise was assessed using Myoglobin Hydrogen-1 Nuclear Magnetic Resonance spectroscopy.', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Muscle Trophicity: Maximum Cross Section of Muscle', 'description': 'Muscle trophicity measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy and calculated based on maximum cross section of muscle (cm\\^2)', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Developed Force During the Exercise Bout', 'description': 'Developed force during the exercise bout measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Normalised Work Developed During the Exercise', 'description': 'Normalised work developed during the exercise was derived as Work developed during the exercise/(\\[60 X Maximum cross section of muscle\\]-1100).\n\nNormalised work measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy.', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Metabolism Efficacy Index', 'description': 'The metabolism efficacy index was derived as Normalised work x creatine phosphorylation rate (sec-1). \\[Normalised work was derived as Work developed during the exercise/(60 X Maximum cross section of muscle-1100)\\]. Greater values of Metabolism Efficacy index indicate improvement in skeletal muscle energetics while lower values indicate the reverse. Negative values obtained using the formula indicated severe levels of muscle weakness.', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'International Cooperative Ataxia Rating Scale [ICARS] (Total Score)', 'description': 'The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales (i.e. Posture and gait disturbances, Kinetic functions, Speech disorders, \\& Oculomotor disorders). Scores for each subscale quantify the extent of ataxia in each clinically important area and subscale scores are also summed to give a total score ranging from 0 to 100, with 100 indicative of the most severely affected outcome.', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'ICARS (Posture and Gait Disturbance Score)', 'description': 'The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Posture and gait disturbances. Posture and gait disturbances score range from 0 to 34 (Higher scores indicate higher levels of impairment).', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'ICARS (Kinetic Function Score)', 'description': 'The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Kinetic Function. Kinetic Function score range from 0 to 52 (Higher scores indicate higher levels of impairment).', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'ICARS (Speech Disorders Score)', 'description': 'The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Speech Disorders. Speech Disorders Score range from 0 to 8 (Higher scores indicate higher levels of impairment).', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'ICARS (Oculomotor Disorders Score)', 'description': 'The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Oculomotor Disorders. Oculomotor Disorders score range from 0 to 6 (Higher scores indicate higher levels of impairment).', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Timed 25-foot Walk Test', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Nine Hole Peg Test (Dominant Hand)', 'description': 'The nine hole peg test was used to assess cognitive function and in particular, fine motor coordination. The patient was asked to place nine pegs in nine holes and was scored on the amount of time it took to place and remove all nine pegs.', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Nine Hole Peg Test (Nondominant Hand)', 'description': 'The nine hole peg test was used to assess cognitive function and in particular, fine motor coordination. The patient was asked to place nine pegs in nine holes and was scored on the amount of time it took to place and remove all nine pegs.', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Choice Reaction Time Test- Reaction Time', 'description': 'The choice reaction time test was used to assess cognitive functioning. On random presentation of one of six signal lights, the patient was asked to respond as quickly and accurately as possible by removing their index finger of the dominant hand from the bottom key and pressing whichever of the top six keys was indicated by the signal. Reaction time was the time elapsed between the presentation of the stimulus and the release of the finger and movement time was defined as the time elapsed between release of the finger and pressure of the second key.', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Choice Reaction Time Test- Movement Time', 'description': 'The choice reaction time test was used to assess cognitive functioning. On random presentation of one of six signal lights, the patient was asked to respond as quickly and accurately as possible by removing their index finger of the dominant hand from the bottom key and pressing whichever of the top six keys was indicated by the signal. Reaction time was the time elapsed between the presentation of the stimulus and the release of the finger and movement time was defined as the time elapsed between release of the finger and pressure of the second key.', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Visual Assessment Scale (VAS) of Global Impression - Patient', 'description': 'The VAS used a 10-cm scoring scale in which values were reported in mm such that 0=bad and 100=good. Total score range on VAS is from 0 to 100.', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Visual Assessment Scale (VAS) of Global Impression - Parents', 'description': 'The VAS used a 10-cm scoring scale in which values were reported in mm such that 0=bad and 100=good. Total score range on VAS is from 0 to 100.', 'timeFrame': 'Baseline (Week 0) to Week 12'}, {'measure': 'Visual Assessment Scale (VAS) of Global Impression - Investigator', 'description': 'The VAS used a 10-cm scoring scale in which values were reported in mm such that 0=bad and 100=good. Total score range on VAS is from 0 to 100.', 'timeFrame': 'Baseline (Week 0) to Week 12'}]",22,12 Years,22 Years,ALL,False,Ipsen,INDUSTRY,0,22.0,ACTUAL,2025-09-01T16:18:15.909137,v2_robust,True,True,True,False,False,
NCT00286312,Myocardial Infarction Size Reduction With Atorvastatin,Prevention of Reperfusion Damage and Late Left Ventricular Remodelling With Atorvastatin Administered Before Reperfusion Therapy. The REPERATOR Study,Atorvastatin,['Atorvastatin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Myocardial Infarction,"['Myocardial Infarction', 'Reperfusion Injury']","['Acute myocardial infarction', 'Primary angioplasty', 'Reperfusion damage', 'Atorvastatin', 'Placebo', 'Early left ventricular remodelling', 'Late left ventricular remodelling', 'Cardiac MRI', 'Statin', 'Transluminal, Percutaneous Coronary', 'Angioplasty']",COMPLETED,,2006-02,2008-02,[{'measure': 'Left ventricular end systolic volume index as measured by cine magnetic resonance imaging (MRI) at 3 month follow-up'}],"[{'measure': 'Other MRI measurements of global and regional left ventricular function'}, {'measure': 'MRI measurements of infarct size at admission, 1 week, and 3 months, as well as changes in these measures between MRI investigations'}, {'measure': 'Biochemical markers of infarct size'}, {'measure': 'Blush grade'}]",5,18 Years,,ALL,False,R&D Cardiologie,OTHER,1,50.0,ESTIMATED,2025-09-01T16:18:15.909226,v2_robust,True,True,True,False,False,
NCT04477512,Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial),A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial),Cabozantinib,"['Abiraterone acetate', 'Nivolumab', 'Cabozantinib', 'Prednisone']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Metastatic Hormone Refractory Prostate Cancer,['Metastatic Hormone Refractory Prostate Cancer'],[],ACTIVE_NOT_RECRUITING,,2021-02-19,2025-09-11,"[{'measure': 'Frequency of dose-limiting toxicities (DLTs)', 'description': '* Protocol defined hematologic DLTs that occur during the first cycle that are attributed as possibly, probably, or definitely related to study treatment\n* Protocol defined non-hematologic DLTs possibly, probably, or definitely related grade 3 or 4 non-hematologic toxicity that occurs during the first cycle of treatment.', 'timeFrame': 'Completion of 1st cycle of treatment for patients in dose level 1 & dose level 2 (estimated to be 11 months)'}]","[{'measure': 'PSA response rate', 'description': '-Defined by at least 50% decline in PSA level from baseline measured twice at least 3 weeks apart', 'timeFrame': 'Through end of treatment (estimated to be 24 months)'}, {'measure': 'Overall response rate (ORR)', 'description': '-Defined by proportion of patients achieving complete or partial response by RECIST 1.1 or by PCWG3 criteria', 'timeFrame': 'Through end of treatment (estimated to be 24 months)'}, {'measure': 'Overall survival (OS)', 'description': '-Defined as from start of treatment to date of death (all cause) or last follow-up.', 'timeFrame': 'From start of treatment through 1 year of follow-up (estimated to be 36 months)'}, {'measure': 'Progression-free survival (PFS)', 'description': '-Defined from start of treatment to date of progression or death or last follow-up, whichever is earlier.', 'timeFrame': 'From start of treatment through 1 year of follow-up (estimated to be 36 months)'}, {'measure': 'Disease specific survival (DSS)', 'description': '-Defined as from start of treatment to to date of death due to disease or last follow-up.', 'timeFrame': 'From start of treatment through 1 year of follow-up (estimated to be 36 months)'}, {'measure': 'Incidence of adverse events as measured per CTCAE v 5.0', 'timeFrame': 'From time of consent through 100 days after last dose of nivolumab (estimated to be 28 months)'}, {'measure': 'Disease free survival (DFS)', 'description': '-Defined as from date of first PSA response or radiographic complete response to date of recurrence of disease', 'timeFrame': 'From start of treatment through 1 year of follow-up (estimated to be 36 months)'}, {'measure': 'Duration of response (DoR)', 'description': '-Defined from date of first PSA response to date of PSA progression or date of RECIST response to date of radiographic progression.', 'timeFrame': 'From start of first response through 1 year of follow-up (estimated to be 36 months)'}]",9,18 Years,,MALE,False,Washington University School of Medicine,OTHER,2,18.0,ACTUAL,2025-09-01T16:18:15.909269,v2_robust,True,True,False,False,True,
NCT03892512,Dexmedetomidine and Esmolol Early Post Operative Cognitive Dysfunction,"The Effect of Dexmedetomidine and Esmolol on Early Post Operative Cognitive Dysfunction After Middle Ear Surgery Under Hypotensive Technique :Comparative , Randomized Double Blinded Study",Esmolol Hydrochloride,"['Dexmedetomidine', 'esmolol', 'Esmolol Hydrochloride', 'precedex']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Cognitive Dysfunction,['Cognitive Dysfunction'],[],UNKNOWN,,2019-04,2019-12,"[{'measure': 'assess the early cognitive dysfunction after controlled hypotensive anesthesia', 'description': 'mini mental state examination (MMSE) will be used for evaluation of cognitive function Data will be expressed in mean ± SD and were compared using analysis of variance (ANOVA). The significance of non-parametric data was determined using chi-square test. For all comparisons P \\< 0.05 was considered significant.,', 'timeFrame': 'MMS will performed at 1 hour, 6 and 24 hours postoperatively .The mximum score will be 30 points, a decrease of 2 or more will be considered as cognitive function decline. score less than 23 will be considered as cognitive impairmen'}]",[],1,20 Years,50 Years,ALL,False,Beni-Suef University,OTHER,0,58.0,ESTIMATED,2025-09-01T16:18:15.909299,v2_robust,True,True,False,False,False,
NCT00170781,Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout,"A 1-Week, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel Trial Comparing Lumiracoxib (400 mg Once Daily) in Patients With Acute Flares of Gout, Using Indomethacin (50 mg Three Times a Day)",Lumiracoxib,['Lumiracoxib'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Acute Gouty Arthritis,['Acute Gouty Arthritis'],"['Pain, acute gout, arthritis, cyclooxygenase-2 inhibitors, lumiracoxib, indomethacin']",COMPLETED,,2005-06,,[{'measure': 'Pain intensity in the study joint over days 2 to 5 approximately 4h after the first daily dose'}],"[{'measure': 'Safety and tolerability profile'}, {'measure': 'Pain intensity in the study joint over the entire treatment period'}, {'measure': ""Patient's and Physician's global assessment of response to therapy""}, {'measure': ""Physician's assessment of tenderness and swelling of study joint""}, {'measure': 'C-reactive protein level'}, {'measure': 'Proportion of patients who discontinued treatment because of a lack of efficacy'}, {'measure': 'Usage of rescue medication'}, {'measure': 'SF-36 and EQ-5D'}, {'measure': ""Physician's assessment of erythema of study joint""}]",10,18 Years,,ALL,False,Novartis,INDUSTRY,0,234.0,,2025-09-01T16:18:15.909325,v2_robust,True,True,True,False,True,
NCT04380181,Influence of Inotropic Choice on Morbidity and Mortality in Complex Pediatric Heart Surgery,Does the Choice of Perioperative Inotropes Has Influence on the Morbidity and Mortality of Infants Operated for Complex Heart Defects?,dobu,"['milrinone-epinephrine', 'dobu']",2,OBSERVATIONAL,[],,,Pediatric Cardiac Surgery,['Pediatric Cardiac Surgery'],"['pediatric cardiopulmonary bypass', 'milrinone', 'dobutamine', 'epinephrine']",COMPLETED,,2020-05-11,2020-06-10,"[{'measure': 'MODS2 score', 'description': ""Impact of the inotropic plan on the morbi-mortality. Use of the MODS2 score who is defined by death or 2 organ's failures: circulation, respiratory or renal"", 'timeFrame': 'Weaning from cardiopulmonary bypass in the operating room'}]",[],1,,1 Year,ALL,False,Brugmann University Hospital,OTHER,1,250.0,ACTUAL,2025-09-01T16:18:15.909358,v2_robust,False,True,True,False,False,
NCT06539481,"Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.","A Non-randomised, Open-label, Uncontrolled, Multi-centre, Phase IIIb Study Evaluating the Safety and Efficacy of Fluocinolone Acetonide 190 Micrograms Intravitreal Implant in Paediatric Subjects From 6 Years to Less Than 18 Years With Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye",fluocinolone acetonide 190 micrograms,['fluocinolone acetonide 190 micrograms'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Non-infectious Uveitis Affecting the Posterior Segment of the Eye,['Non-infectious Uveitis Affecting the Posterior Segment of the Eye'],[],RECRUITING,,2024-08-31,2028-10-31,"[{'measure': 'Absence of cystoid macular oedema on Optical Coherence Tomography and a decrease from baseline in vitreous haze grade of ≥2 steps, or absence of vitreous haze.', 'description': 'The primary endpoint for evaluating the effect of the implant on non-infectious uveitis affecting the posterior segment of the eye will be based on treatment success, determined at 6 months after administration. Treatment success will be determined based on a composite variable defined as Absence of cystoid macular oedema on Optical Coherence Tomography and a decrease from baseline in vitreous haze grade of ≥2 steps, or absence of vitreous haze.', 'timeFrame': '6 months after administration'}, {'measure': 'Rate of cataract formation and Rate of IOP elevation', 'description': 'The primary endpoint for evaluating the safety of the implant on non-infectious uveitis affecting the posterior segment of the eye will be determined.\n\n* Rate of cataract formation\n* Rate of IOP elevation (Change from baseline in IOP and incidence of significant changes in IOP, including: IOP\\>21 mmHg, IOP\\>25 mmHg, IOP\\>30 mmHg, increases from baseline of 10 mmHg or more).', 'timeFrame': '6 months after administration'}]","[{'measure': 'Changes in vision and incidence of increase in IOP, AE, and uveitis recurrence', 'description': '* Absence of CMO and decrease from baseline in vitreous haze grade of ≥2 steps, or absence of vitreous haze at end of the study\n* Uveitis recurrence rate following treatment, compared to the uveitis recurrence rate over the 12 months prior to enrolment\n* Incidence of recurrence of non-infectious uveitis affecting the posterior segment in the SE and in the FE after receiving study treatment\n* Time to recurrence of non-infectious uveitis affecting the posterior segment\n* Change in macular oedema,\n* Change in BCVA\n* Change in vitreous haze\n* Change in AC cell grade\n* Incidence of secondary increase in IOP and secondary increase in IOP requiring surgical intervention\n* Incidence and onset of secondary lens opacity and extraction\n* Number of adjunctive treatments required to treat recurrences of uveitis\n* Presence of active chorioretinal\n* Presence of retinal vascular lesions\n* Incidence of ocular infection\n* Incidence of AEs\n* Change from baseline in cup-to-disc ratio', 'timeFrame': 'Every 6 months over 3 years'}, {'measure': 'Incidence of secondary increase in IOP, secondary increase in IOP requiring surgical intervention, and ocular and non-ocular AEs.', 'description': 'Mandatory safety measures including IOP checks will be performed every 3 months.\n\nThe following secondary safety endpoints will be assessed at 6 months, 12 months or 36 months\n\n* Incidence of secondary increase in IOP\n* Incidence of secondary increase in IOP requiring surgical intervention\n* Incidence of ocular and non-ocular AEs.', 'timeFrame': '3, 6, 12, and 36 months.'}]",4,6 Years,17 Years,ALL,False,Alimera Sciences,INDUSTRY,0,25.0,ESTIMATED,2025-09-01T16:18:15.909366,v2_robust,True,True,False,False,True,
NCT03007381,Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn,Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn,Ketorolac Tromethamine,"['Normal Saline', 'Ketorolac Tromethamine', 'Toradol']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Breast Cancer Female,['Breast Cancer Female'],[],WITHDRAWN,No funding.,2017-11,2019-06,"[{'measure': 'Length of hospital stay postoperatively', 'description': 'recorded in days beginning post operative day number one', 'timeFrame': 'measured when the patient leaves the hospital, averages between 3-9 days'}]","[{'measure': 'Visual analog scale for pain', 'description': 'Standard for for visual analog scale', 'timeFrame': 'every 6 hours for 72 hours'}, {'measure': 'Narcotic consumption', 'description': 'Total narcotic consumption over first 72 hours converted to morphine equivalence', 'timeFrame': '72 hours'}, {'measure': 'Surgical drain output', 'description': 'Total surgical drain output over first 72 hours', 'timeFrame': '72 hours'}, {'measure': 'Hematoma', 'description': 'Any hematoma requiring management in the operating room', 'timeFrame': 'measured when the patient leaves the hospital, averages between 3-9 days'}, {'measure': 'Adverse events', 'description': 'Any infection requiring antibiotics, or flap complications requiring management in the operating room', 'timeFrame': 'measured when the patient leaves the hospital, averages between 3-9 days'}]",6,18 Years,,FEMALE,False,Nova Scotia Health Authority,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:15.909388,v2_robust,True,True,False,True,True,No funding.
NCT05751681,Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI,Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Patients With Polycystic Ovary Syndrome Undergoing Intra-Cytoplasmic Sperm Injection,"dydrogesterone (Duphaston, Abbott)","['cetrorelix', 'Cetrotide', 'dydrogesterone (Duphaston, Abbott)']",3,INTERVENTIONAL,['NA'],,,Ovary Cyst,"['Ovary Cyst', 'Fertility Issues']","['IVF,ICSI,success rate']",UNKNOWN,,2023-02-20,2025-03-20,"[{'measure': 'Efficacy (Number of MII oocytes retrieved)', 'description': 'this outcome means to measure Percentage (number) of MII oocytes retrieved During our study', 'timeFrame': '3 months'}, {'measure': 'Efficacy (Maturation index)', 'description': 'Maturation index will be calculated: Rate of metaphase-II oocytes (MII) to total oocytes', 'timeFrame': '3 months'}]",[],2,20 Years,40 Years,FEMALE,False,Zagazig University,OTHER_GOV,0,79.0,ESTIMATED,2025-09-01T16:18:15.909468,v2_robust,True,True,False,False,False,
NCT05396781,Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening,Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening: A Clinical Study in Brazil,Proflavine,"['proflavine hemisulfate', 'Proflavine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Suspected or Known Squamous Cell Neoplasia,"['Suspected or Known Squamous Cell Neoplasia', 'Prior History of Squamous Cell Dysplasia and /or Neoplasia']","['Squamous cell neoplasia', 'Proflavine', ""Lugol's chromoendoscopy""]",COMPLETED,,2022-01-13,2022-01-20,"[{'measure': 'Diagnostic yield', 'description': 'The number of neoplastic biopsies/total number of biopsies obtained in patients who received biopsies.', 'timeFrame': 'Day 1'}, {'measure': ""'Patient saved'"", 'description': 'The number of patients who received no biopsies.', 'timeFrame': 'Day 1'}, {'measure': 'Procedure time', 'description': 'Total procedure time added by the HRME imaging.', 'timeFrame': 'During Procedure'}]","[{'measure': 'Clinical impact', 'description': 'The number of cases that a change in clinician plan of action was noted from LCE interpretation only to LCE+HRME interpretation.', 'timeFrame': 'Day 1'}]",4,18 Years,64 Years,ALL,False,"Anandasabapathy, Sharmila, M.D.",INDIV,3,41.0,ACTUAL,2025-09-01T16:18:15.909478,v2_robust,True,True,True,False,False,
NCT00068081,Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia,"A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia",Capsaicin Dermal Patch,['Capsaicin Dermal Patch'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Herpes Zoster,"['Herpes Zoster', 'Neuralgia', 'Pain', 'Peripheral Nervous System Diseases']","['Dermal assessment', 'Pain measurement', 'Diary', 'Analgesics/*therapeutic use', 'Capsaicin/*administration & dosage/adverse effects', 'Herpes zoster/*complication/drug therapy', 'Neuralgia/*drug therapy/etiology', 'Pain', 'Peripheral nervous system diseases/*complications']",COMPLETED,,,,[],[],0,18 Years,,ALL,False,NeurogesX,INDUSTRY,0,150.0,,2025-09-01T16:18:15.909532,v2_robust,True,True,True,False,False,
NCT02963181,Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension,Identifying the Pathophysiology of Neurogenic Orthostatic Hypotension and the Effects of Melatonin on Reducing Supine Hypertension in Peripherally Intact Versus Denervated Post-ganglionic Sympathetic Nerves,Yohimbine,"['DIN:01901885', 'melatonin timed release; 2 or 5 mg', 'Melatonin', 'Yohimbine']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,"Hypotension, Orthostatic","['Hypotension, Orthostatic', 'Hypertension', 'Autonomic Nervous System Diseases']","['Melatonin', 'Yohimbine', 'Anti-hypertensive agents']",TERMINATED,PI leaving,2018-03-01,2019-05-28,"[{'measure': 'Investigation into the integrity of post-ganglionic sympathetic nerves in idiopathic NOH', 'description': 'Markers of post-ganglionic sympathetic function will be examined (i.e. sympathetic blood markers, heart rate, blood pressure, sympathetic nerve activity, etc.)', 'timeFrame': 'Sympathetic markers will be assessed during and immediately following the test. A comparison between healthy participants and NOH patients will be ongoing throughout recruitment and upon completion of study recruitment'}, {'measure': 'Effects of melatonin on supine hypertension in persons with neurogenic orthostatic hypotension', 'description': 'Supine systolic blood pressure', 'timeFrame': '4 weeks'}, {'measure': 'Effects of melatonin on supine hypertension in patients with neurogenic orthostatic hypotension', 'description': 'Change in postural (supine-standing) systolic blood pressure', 'timeFrame': '4 weeks'}]","[{'measure': 'Serum markers of sympathetic activation', 'timeFrame': 'Before and during stimulation of sympathetic nervous system'}, {'measure': 'Carotid artery diameter', 'timeFrame': 'During stimulation of sympathetic nervous system'}, {'measure': 'Sympathetic nerve activation using microneurography', 'timeFrame': 'During stimulation of sympathetic nervous system'}, {'measure': 'Orthostatic symptoms based on standard autonomic symptom questionnaires', 'timeFrame': '30 minutes before testing'}, {'measure': 'Sleep quality assessment using Epworth Sleepiness Scale', 'timeFrame': 'Assessed at pre- and post- melatonin treatment; week 1 and week 5 of melatonin intervention timeframe'}, {'measure': 'Urine and Saliva melatonin levels', 'timeFrame': 'Assessed at pre- and post- melatonin treatment; week 1 and week 5 of melatonin intervention timeframe'}]",9,18 Years,80 Years,ALL,True,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:15.909619,v2_robust,True,True,False,True,False,PI leaving
NCT02073019,"A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers","A Phase I, Two Part Study Exploring the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effect of Ascending Doses of BL-8040 in Healthy Subjects.",BL-8040,"['BL-8040', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB),['Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)'],[],COMPLETED,,2014-08,2015-07,"[{'measure': 'Number of subjects with Adverse Events', 'timeFrame': 'Up to 7 days after treatment comletion'}]",[],1,18 Years,45 Years,MALE,True,"BioLineRx, Ltd.",INDUSTRY,0,33.0,ACTUAL,2025-09-01T16:18:15.909675,v2_robust,True,True,True,False,True,
NCT05716919,Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule,"A Phase I, Double Blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Orally Administered 'Ivaltinostat' Capsule in Healthy Male Volunteers",Ivaltinostat,['Ivaltinostat'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Hematologic Malignancy,"['Hematologic Malignancy', 'Solid Tumor', 'Fibrosis']",[],ACTIVE_NOT_RECRUITING,,2023-03-09,2023-12,"[{'measure': 'Plasma Pharmacokinetic measures (Cmax, Cmax-ss)', 'timeFrame': 'up to 4 weeks'}, {'measure': 'Plasma Pharmacokinetic measures (AUC max, AUCmax-ss)', 'timeFrame': 'up to 4 weeks'}]","[{'measure': 'The Number of Participants Who Experienced Serious or Non-Serious Adverse Events', 'timeFrame': 'Up to 4 weeks for each dosing cohort'}]",3,19 Years,50 Years,MALE,True,"Machaon Biotherapeutics, Inc.",INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:15.909681,v2_robust,True,True,False,False,True,
NCT01484119,"Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis","Multi-center, Double-blind, Double-dummy, Randomized, Placebo-controlled, Active-reference, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-129968 in Adolescent, Adult & Elderly Patients With Seasonal Allergic Rhinitis",ACT-129968,"['Setipiprant', 'Cetirizine', 'ACT-129968', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Seasonal Allergic Rhinitis,['Seasonal Allergic Rhinitis'],['seasonal allergic rhinitis'],COMPLETED,,2011-12,2012-03,"[{'measure': 'The mean change in Daytime Nasal Symptom Score', 'timeFrame': 'baseline to end of treatment period (2 weeks)'}]","[{'measure': 'The mean change in other daytime/nighttime symptom scores of allergic rhinitis', 'timeFrame': 'baseline to end of treatment period (2 weeks)'}]",2,12 Years,76 Years,ALL,False,Idorsia Pharmaceuticals Ltd.,INDUSTRY,0,630.0,ACTUAL,2025-09-01T16:18:15.909779,v2_robust,True,True,True,False,False,
NCT06213519,HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis,"The Efficacy and Safety of Hyperthermic Intraperitoneal Chemotherapy （HIPEC）Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis: A Prospective, Single-arm, Phase II Clinical Study","S-1, Oxaliplatin sintilimab HIPEC","['S-1, Oxaliplatin sintilimab HIPEC']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Peritoneal Metastases,"['Peritoneal Metastases', 'Gastric Cancer']","['gastric cancer', 'peritoneal metastasis', 'HIPEC', 'first-line']",NOT_YET_RECRUITING,,2024-02-20,2027-06-30,"[{'measure': 'Overall survival', 'description': 'Overall survival (OS) is defined as the time from randomization to death', 'timeFrame': 'every 3 month postoperation up to 24 months'}]","[{'measure': 'ORR', 'description': 'Objective Response Rate', 'timeFrame': 'every 3 month postoperation up to 24 months'}, {'measure': 'DCR', 'description': 'disease control rate', 'timeFrame': 'every 3 month postoperation up to 24 months'}, {'measure': 'Progression-free survival', 'description': 'Progression-free survival (PFS) is defined as the time from randomization to diesea progression', 'timeFrame': 'every 3 month postoperation up to 24 months'}, {'measure': 'Safety and Tolerability', 'description': 'Treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': 'every 3 month postoperation up to 24 months'}]",5,18 Years,75 Years,ALL,False,Sichuan University,OTHER,0,69.0,ESTIMATED,2025-09-01T16:18:15.909794,v2_robust,True,True,False,False,True,
NCT01737619,PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer,Prospective Evaluation of Lymph Node Metastasis at the Time of Surgical Staging for High Risk Endometrial Cancer,Indocyanine Green Solution,"['ICG Solution', 'Indocyanine Green Solution', 'IC-GREEN']",3,INTERVENTIONAL,['NA'],,,Endometrial Clear Cell Adenocarcinoma,"['Endometrial Clear Cell Adenocarcinoma', 'Endometrial Mixed Adenocarcinoma', 'Endometrial Serous Adenocarcinoma', 'Grade 3 Endometrial Endometrioid Adenocarcinoma', 'Malignant Mixed Mesodermal (Mullerian) Tumor']",[],ACTIVE_NOT_RECRUITING,,2013-04-03,2025-12-31,"[{'measure': 'False negative rate of positron emission tomography (PET)/computed tomography (CT)', 'description': 'Compared with pathological findings as the gold standard. The false negative rate for the procedure and for the combination of the 2 procedures will be estimated with 90% credible intervals. The posterior probability that the false negative rate is \\> 10% for each procedure and for the combination of the 2 procedures will also be reported.', 'timeFrame': 'Baseline'}, {'measure': 'False negative rate of sentinel lymph node mapping', 'description': 'Compared with pathological findings as the gold standard. The false negative rate for the procedure and for the combination of the 2 procedures will be estimated with 90% credible intervals. The posterior probability that the false negative rate is \\> 10% for each procedure and for the combination of the 2 procedures will also be reported.', 'timeFrame': 'At time of surgery'}]","[{'measure': 'Concordance for each procedure and for the combination of both procedures', 'description': 'The concordance for each procedure and for the combination of the 2 procedures will be estimated with 95% confidence intervals using pathologic findings as the gold standard.', 'timeFrame': 'At time of surgery'}, {'measure': 'Sensitivity of each procedure and for the combination of both procedures', 'description': 'The sensitivity of each procedure and for the combination of the 2 procedures will be estimated with 95% confidence intervals using pathologic findings as the gold standard.', 'timeFrame': 'At time of surgery'}, {'measure': 'Specificity of each procedure and for the combination of both procedures', 'description': 'The specificity of each procedure and for the combination of the 2 procedures will be estimated with 95% confidence intervals using pathologic findings as the gold standard.', 'timeFrame': 'At time of surgery'}, {'measure': 'Positive predictive value (PPV) of each procedure and for the combination of both procedures', 'description': 'The PPV of each procedure and for the combination of the 2 procedures will be estimated with 95% confidence intervals using pathologic findings as the gold standard.', 'timeFrame': 'At time of surgery'}, {'measure': 'Negative predictive value (NPV) of each procedure and for the combination of both procedures', 'description': 'The NPV of each procedure and for the combination of the 2 procedures will be estimated with 95% confidence intervals using pathologic findings as the gold standard.', 'timeFrame': 'At time of surgery'}, {'measure': 'CA-125 levels', 'description': 'Logistic regression methods will be used to model the logit of the probability of metastatic disease at the time of surgical staging as a function of CA-125 level, HE4 level, and other metabolic parameters including tumor intensity, metabolic tumor volume, and total lesion glycolysis. The odds ratio of the association between these factors and metastatic disease will be estimated with a 95% confidence interval. The logit of the probability of locoregional spread as a function of these factors will be similarly modeled. The correlations among these factors will also be estimated.', 'timeFrame': 'Baseline'}, {'measure': 'HE4 levels', 'description': 'Logistic regression methods will be used to model the logit of the probability of metastatic disease at the time of surgical staging as a function of CA-125 level, HE4 level, and other metabolic parameters including tumor intensity, metabolic tumor volume, and total lesion glycolysis. The odds ratio of the association between these factors and metastatic disease will be estimated with a 95% confidence interval. The logit of the probability of locoregional spread as a function of these factors will be similarly modeled. The correlations among these factors will also be estimated.', 'timeFrame': 'Baseline'}, {'measure': 'Metabolic parameters', 'description': 'Logistic regression methods will be used to model the logit of the probability of metastatic disease at the time of surgical staging as a function of CA-125 level, HE4 level, and other metabolic parameters including tumor intensity, metabolic tumor volume, and total lesion glycolysis. The odds ratio of the association between these factors and metastatic disease will be estimated with a 95% confidence interval. The logit of the probability of locoregional spread as a function of these factors will be similarly modeled. The correlations among these factors will also be estimated.', 'timeFrame': 'Baseline'}, {'measure': 'Incidence of intra-operative complications', 'description': 'Morbidity and mortality data will be tabulated, including intra-operative complications.', 'timeFrame': 'At time of surgery'}, {'measure': 'Incidence of post-operative complications', 'description': 'Morbidity and mortality data will be tabulated, including post-operative complications.', 'timeFrame': 'At time of surgery'}]",12,18 Years,,FEMALE,False,M.D. Anderson Cancer Center,OTHER,1,150.0,ESTIMATED,2025-09-01T16:18:15.909875,v2_robust,True,True,False,False,False,
NCT00435019,Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes,An Efficacy and Safety Comparison of Insulin Detemir vs. NPH Insulin in Children and Adolescents Diagnosed With Type 1 Diabetes,insulin detemir,"['insulin detemir', 'insulin NPH', 'insulin aspart']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 1']",[],COMPLETED,,2007-02,2008-09,"[{'measure': 'Glycosylated Haemoglobin A1c (HbA1c)', 'description': 'Glycosylated haemoglobin A1c (HbA1c) measured after 52 weeks of treatment and analysed by central laboratory.', 'timeFrame': 'after 52 weeks of treatment'}]","[{'measure': 'Number of Subjects Reporting Adverse Events', 'description': 'Number of subjects reporting adverse events during the trial (from week -2 to week 52).\n\nFor details, please refer to the adverse events section.', 'timeFrame': 'from week -2 to week 52'}, {'measure': 'Observed Insulin Antibody Values', 'description': 'Observed insulin antibody values for insulin detemir specific antibodies, insulin aspart specific antibodies and insulin detemir/insulin aspart cross-reacting antibodies.', 'timeFrame': 'at 0 and 52 weeks'}]",3,2 Years,16 Years,ALL,False,Novo Nordisk A/S,INDUSTRY,0,348.0,ACTUAL,2025-09-01T16:18:15.909984,v2_robust,True,True,True,False,True,
NCT00683319,Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy,CCLG Observational Study of the Outcome of Ependymoma in Infants Diagnosed Before Their Third Birthday,carboplatin,"['cyclophosphamide', 'vincristine sulfate', 'methotrexate', 'cisplatin', 'carboplatin']",5,OBSERVATIONAL,[],,,Brain and Central Nervous System Tumors,"['Brain and Central Nervous System Tumors', 'Cognitive/Functional Effects', 'Long-term Effects Secondary to Cancer Therapy in Children', 'Ototoxicity']","['long-term effects secondary to cancer therapy in children', 'cognitive/functional effects', 'ototoxicity', 'childhood infratentorial ependymoma', 'childhood supratentorial ependymoma']",ACTIVE_NOT_RECRUITING,,2008-04,,"[{'measure': 'Overall survival'}, {'measure': 'Event-free survival'}, {'measure': 'Response to chemotherapy, if there is residual disease'}, {'measure': 'Requirement for radiotherapy (i.e., residual disease at the completion of chemotherapy, progressive disease during chemotherapy, or recurrent disease during or after completion chemotherapy)'}, {'measure': 'Late effects of treatment (i.e., ototoxicity and nephrotoxicity at the completion of chemotherapy and neurocognitive outcomes at 5, 7, 11, and 16 years of age)'}]",[],5,,2 Years,ALL,False,Children's Cancer and Leukaemia Group,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:15.909997,v2_robust,False,True,False,False,False,
NCT03896230,Ketamine for Pain in the Emergency Department,"Comparison of Ketamine 0.1 mg/kg, 0.2 mg/kg, and 0.3 mg/kg Intravenous Doses for Acute Pain in the Emergency Department: A Prospective, Randomized, Double-blind, Active-controlled, Clinical Trial",Ketamine Injectable Product,['Ketamine Injectable Product'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Acute Pain,['Acute Pain'],"['moderate to severe pain', 'emergency department patient', 'ketamine']",TERMINATED,Due to resource limitations the study was on hold and was then terminated.,2019-05-03,2019-12-20,"[{'measure': 'Pain Score', 'description': 'Pain score using Numerical Rating Scale (NRS) post ketamine infusion. The Numerical Rating Scale (NRS) ranges from 0-to-10 with 0 being no pain and lower numbers representing less pain, so in this case lower numbers will represent better outcomes.\n\nPain scores were reported at baseline and then at 15 min/30 min/60 min/90 min and 120 minutes post-infusion.', 'timeFrame': 'Within 2 hours post infusion completion'}]","[{'measure': 'Adverse Events', 'description': 'Frequency of adverse events secondary to ketamine including fatigue, dizziness, nausea, headache, feeling of unreality, changes in hearing or vision, mood changes, generalized discomfort, and hallucinations, changes in vital signs.\n\nAdverse events were reported at baseline and then at 15 min/30 min/60 min/90 min and 120 minutes post-infusion.', 'timeFrame': 'Within 2 hours post infusion completion'}]",2,21 Years,,ALL,False,Hackensack Meridian Health,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:15.910050,v2_robust,True,True,False,True,True,Due to resource limitations the study was on hold and was then terminated.
NCT01812330,Efficacy and Safety Study of Ticagrelor,The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention,Clopidogrel,"['Brilique', 'Ticagrelor', 'Plavix', 'Clopidogrel']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Acute Coronary Syndrome,['Acute Coronary Syndrome'],"['ACS', 'CR', 'PCI', 'Platelet funtion', 'Ticagrelor']",UNKNOWN,,2013-01,2016-07,"[{'measure': 'PRI', 'description': 'Platelet funtion were tested by flowcytometric vasodilator-stimulated phosphoprotein(VASP) analysis.And a platelet reactivity index (PRI) was calculated.', 'timeFrame': 'post operative 1 month'}]","[{'measure': 'Major adverse cardiac events(MACEs)', 'description': 'cardiovascular death,angiographically conﬁrmed stent thrombosis, recurrent acute coronary syndrome deﬁned by the American College of Cardiology/American Heart Association guidelines,and recurrent revascularization by either coronary angioplasty or bypass surgery', 'timeFrame': 'follow-up for 1 month'}, {'measure': 'major and minor bleeding', 'description': 'Major bleeding was deﬁned as intracranial bleeding or clinically-overt bleeding associated with a decrease in hemoglobin of 50 g/L, according to the Thrombolysis inMyocardial Infarction (TIMI) criteria .Minor bleeding was also deﬁned according to TIMI criteria .', 'timeFrame': 'follow-up for 1 month'}]",3,18 Years,80 Years,ALL,False,General Hospital of Chinese Armed Police Forces,OTHER,0,180.0,ESTIMATED,2025-09-01T16:18:15.910066,v2_robust,True,True,False,False,True,
NCT05311930,Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients,Efficacy and Safety of TPO Receptor Agonists as First-line Drugs in the Treatment of Newly Diagnosed Elderly ITP Patients in China-an Open Label Study,2.5mg/d Hetrombopag,"['2.5mg/d Hetrombopag', 'no use']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Primary Immune Thrombocytopenia,['Primary Immune Thrombocytopenia'],"['hetrombopag', 'Primary Immune Thrombocytopenia', 'platelets']",UNKNOWN,,2022-05-01,2024-12-30,"[{'measure': 'Treatment response', 'description': 'Proportion of subjects with platelet counts ≥50×10\\^9/L after 28 days of treatment', 'timeFrame': '28 days'}]","[{'measure': 'Remission rate', 'description': 'Complete response, effective, ineffective proportion of testers after 28 days of treatment', 'timeFrame': '28 days'}, {'measure': 'Drug efficacy', 'description': 'During treatment, the proportion of subjects, which the platelet count at least once reached ≥50×109/L.', 'timeFrame': '28 days'}, {'measure': 'Evaluation of effectiveness', 'description': 'During treatment, the proportion of subjects, which the platelet count increased at least 2 times compared with baseline.', 'timeFrame': '28 days'}, {'measure': 'Adverse events', 'description': 'Evaluate the incidence and severity of bleeding based on the ITP-BAT bleeding score', 'timeFrame': '6 months from treatment'}, {'measure': 'Adverse events', 'description': 'During treatment, the proportion of subjects, which received at least once rescue', 'timeFrame': '6 months from treatment'}, {'measure': 'Side effects of drugs', 'description': 'Assessing safety through the adverse events,such as liver damage, etc.', 'timeFrame': '1 month from treatment'}]",7,60 Years,100 Years,ALL,False,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",OTHER,1,69.0,ESTIMATED,2025-09-01T16:18:15.910082,v2_robust,True,True,False,False,True,
NCT00169130,ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma,Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma,doxorubicin,"['doxorubicin', 'cyclophosphamide']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,"Lymphoma, Large-Cell, Diffuse","['Lymphoma, Large-Cell, Diffuse']","['lymphoma', 'autologous stem cell transplant', 'chemotherapy', 'BCL2']",COMPLETED,,1999-10,,[{'measure': 'Event free survival.'}],"[{'measure': 'Complete response rate at the end of treatment.'}, {'measure': 'Disease-free survival for complete responders.'}, {'measure': 'Overall survival.'}]",4,18 Years,60 Years,ALL,False,Lymphoma Study Association,OTHER,1,300.0,,2025-09-01T16:18:15.910283,v2_robust,True,True,True,False,False,
NCT06773130,HRS-4642 Combined with Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma,An Exploratory Clinical Study of HRS-4642 Combined with Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma,HRS-4642,"['Nimotuzumab', 'HRS-4642']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Pancreatic Ductal Adenocarcinoma (PDAC),['Pancreatic Ductal Adenocarcinoma (PDAC)'],[],RECRUITING,,2025-02-10,2027-03,"[{'measure': 'RP2D', 'description': 'RP2D will be determined on the basis of evaluation on safety and efficacy data in dose escalation stages.', 'timeFrame': 'Approximately 12 months'}, {'measure': 'ORR', 'description': 'ORR was evaluated by RECIST v1.1.', 'timeFrame': 'Approximately 12 months'}]","[{'measure': 'DCR', 'description': 'Disease control rate (DCR) is assessed by investigators using RECIST 1.1 criteria.', 'timeFrame': '2 years'}, {'measure': 'DoR', 'description': 'Duration of response (DoR) is assessed by investigators using RECIST 1.1 criteria.', 'timeFrame': '2 years'}, {'measure': 'PFS', 'description': 'Progression-free survival (PFS) is assessed by investigators using RECIST 1.1 criteria.', 'timeFrame': '2 years'}, {'measure': 'OS', 'description': 'Overall survival (OS) is assessed by investigators using RECIST 1.1 criteria.', 'timeFrame': '2 years'}, {'measure': 'AEs', 'description': 'AEs are assessed by NCI-CTCAE v5.0', 'timeFrame': '2 years'}]",7,18 Years,75 Years,ALL,False,West China Hospital,OTHER,0,10.0,ESTIMATED,2025-09-01T16:18:15.910292,v2_robust,True,True,False,False,True,
NCT02368730,Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures,Documentation of the Efficacy of Desmopressin (MINIRIN Parenteral 4 Microgram/ml Solution for Injection) Within the Context of Surgical Procedures,desmopressin,"['desmopressin', 'Minirin']",2,OBSERVATIONAL,[],,,Platelet Dysfunction,['Platelet Dysfunction'],[],COMPLETED,,2015-06,2016-07,"[{'measure': 'Change in platelet function pre- and post-administration of desmopressin', 'description': 'As measured by Platelet Function Analyzer (PFA) 100/200', 'timeFrame': 'From baseline up to 7 days'}]",[],1,18 Years,,ALL,False,Ferring Pharmaceuticals,INDUSTRY,0,23.0,ACTUAL,2025-09-01T16:18:15.910298,v2_robust,False,True,True,False,False,
NCT04737330,A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED),"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",Secukinumab,"['AIN457', 'Secukinumab', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Thyroid Eye Disease,"['Thyroid Eye Disease', 'Graves Orbitopathy']","['TED', 'Bulging eyes', 'Exophthalmos']",TERMINATED,Analysis of blinded patient data showed a very low probability of the study meeting the primary efficacy endpoints. No safety concerns were identified,2021-11-29,2023-05-16,"[{'measure': 'Plan A - Percentage of Participants Achieving Overall Response', 'description': 'The percentage of participants achieving overall response was defined as follows: \\>= 2 points reduction in clinical activity score (CAS) AND \\>= 2 mm reduction in proptosis from Baseline in the study eye, provided there was no corresponding deterioration in CAS or proptosis (\\>= 2 point or 2 mm increase, respectively) in the fellow eye after 16 weeks of treatment. Due to premature study discontinuation, purely descriptive analyses were performed for the primary endpoint.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Plan B - Percentage of Participants Achieving Response in Reduction of Proptosis', 'description': 'The percentage of participants achieving response in reduction of proptosis at Week 16 was defined as follows: reduction of \\>= 2 mm from Baseline in the study eye without deterioration (\\>= 2 mm increase) of proptosis in the fellow eye. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the primary endpoint.', 'timeFrame': 'Baseline, Week 16'}]","[{'measure': 'Plan A - Percentage of Participants Achieving Response in Reduction of Clinical Activity Score (CAS)', 'description': 'The percentage of participants achieving response in reduction of clinical activity score (CAS) at Week 16 was defined as follows: reduction of \\>= 2 points from Baseline in the study eye without deterioration (\\>= 2 points increase) of CAS in the fellow eye. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Plan A - Percentage of Participants Achieving Response in Reduction of Proptosis', 'description': 'The percentage of participants achieving response in reduction of proptosis at Week 16 was defined as follows: reduction of \\>= 2 mm from Baseline in the study eye without deterioration (\\>= 2 mm increase) of proptosis in the fellow eye. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Plan A - Percentage of Participants Achieving Response in Diplopia', 'description': 'The percentage of participants achieving response in diplopia at Week 16 was defined as follows: Baseline diplopia \\> 0 and a reduction of \\>= 1 grade with no corresponding deterioration (\\>= 1 grade worsening) in the fellow eye at Week 16. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Plan A - Mean Change From Baseline to Week 16 in Clinical Activity Score (CAS) in the Study Eye', 'description': ""Thyroid Eye Disease (TED) activity was assessed using the CAS at the frequency indicated in the study schedule based on the following signs and symptoms in accordance with the European Group on Graves' Orbitopathy (EUGOGO) guideline:\n\n* Symptoms\n\n  * Spontaneous retrobulbar pain\n  * Pain on attempted upward or downward gaze\n* Signs\n\n  * Redness of eyelids\n  * Redness of conjunctiva\n  * Swelling of caruncle or plica\n  * Swelling of eyelids\n  * Swelling of conjunctiva (chemosis)\n\nFor each item present, 1 point is given. The sum of these points is the CAS score, i.e., minimum score of 0 and maximum score of 7.\n\n* Inactive TED: CAS \\< 3.\n* Active TED: CAS \\>= 3."", 'timeFrame': 'Baseline, Week 2, Week 4, Week 8, Week 12, Week 16'}, {'measure': 'Plan A - Mean Change From Baseline to Week 16 in Millimeters (mm) of Proptosis in the Study Eye', 'description': 'Proptosis measurements were performed at the frequency indicated in the study schedule. The same Hertel instrument, and the same outer intercanthal distance, were to be used for each measurement. The mean of measurements (change from baseline in millimeters (mm) of proptosis, calculated as: (Post-Baseline value - Baseline value) / Baseline value \\* 100)) for each group were presented. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.', 'timeFrame': 'Baseline, Week 2, Week 4, Week 8, Week 12, Week 16'}, {'measure': 'Plan A - Percentage of Participants With Improvement in EUGOGO Disease Severity', 'description': ""Thyroid Eye Disease (TED) activity was assessed using the CAS at the frequency indicated in the study schedule based on the following signs and symptoms in accordance with the European Group on Graves' Orbitopathy (EUGOGO) guideline. Improvement in EUGOGO disease severity was categorized: Mild, Moderate to severe and Sight threatening."", 'timeFrame': 'Baseline, Week 2, Week 4, Week 8, Week 12, Week 16'}, {'measure': ""Plan A - Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 1: Visual Functioning) Over Time"", 'description': ""The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint."", 'timeFrame': 'Baseline, Week 2, Week 4, Week 8, Week 12, Week 16'}, {'measure': ""Plan A - Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 2: Psychosocial Functioning) Over Time"", 'description': ""The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint."", 'timeFrame': 'Baseline, Week 2, Week 4, Week 8, Week 12, Week 16'}, {'measure': 'Plan A - Number of Participants With Adverse Events', 'description': 'The distribution of adverse events during Plan A study treatment period was done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs), through the monitoring of relevant clinical and laboratory safety parameters.', 'timeFrame': 'From first dose of study treatment until Week 16'}, {'measure': 'Plan B - Percentage of Participants Achieving Response in Reduction of Clinical Activity Score (CAS)', 'description': 'The percentage of participants achieving response in reduction of CAS at Week 16 was defined as follows: reduction of \\>= 2 points from Baseline in the study eye without deterioration (\\>= 2 points increase) of CAS in the fellow eye. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Plan B - Percentage of Participants Achieving Overall Response', 'description': 'The percentage of participants achieving overall response was defined as follows: \\>= 2 points reduction in CAS AND \\>= 2 mm reduction in proptosis from Baseline in the study eye, provided there was no corresponding deterioration in CAS or proptosis (\\>= 2 point or 2 mm increase, respectively) in the fellow eye after 16 weeks of treatment. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Plan B - Percentage of Participants Achieving Response in Diplopia', 'description': 'The percentage of participants achieving response in diplopia at Week 16 was defined as follows: Baseline diplopia \\> 0 and a reduction of \\>= 1 grade with no corresponding deterioration (\\>= 1 grade worsening) in the fellow eye at Week 16. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Plan B - Mean Change From Baseline to Week 16 in Clinical Activity Score (CAS) in the Study Eye.', 'description': 'Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Plan B - Mean Change From Baseline to Week 16 in Proptosis in the Study Eye.', 'description': ""Proptosis is the protrusion of the eyeball. Exophthalmos means the same, and this term is usually used when describing proptosis due to Grave's disease. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint."", 'timeFrame': 'Baseline, Week 16'}, {'measure': ""Plan B - Mean Change From Baseline to Week 16 in the Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 1: Visual Functioning)"", 'description': ""The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint."", 'timeFrame': 'Baseline, Week 2, Week 4, Week 8, Week 12, Week 16'}, {'measure': ""Plan B - Mean Change From Baseline to Week 16 in the Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 2: Psychosocial Functioning)"", 'description': ""The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint."", 'timeFrame': 'Baseline, Week 2, Week 4, Week 8, Week 12, Week 16'}, {'measure': 'Plan B - Number of Participants With Adverse Events', 'description': 'Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.', 'timeFrame': 'From first dose of study treatment until Week 16'}]",19,18 Years,80 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,28.0,ACTUAL,2025-09-01T16:18:15.910307,v2_robust,True,True,False,True,True,Analysis of blinded patient data showed a very low probability of the study meeting the primary efficacy endpoints. No safety concerns were identified
NCT06722430,A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants,A Phase 1 Open-label Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Icalcaprant in Healthy Adult Subjects,Icalcaprant,"['Itraconazole (ITZ)', 'Icalcaprant', 'CVL-354', 'ABBV-1354']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteer,['Healthy Volunteer'],"['Healthy Volunteer', 'Icalcaprant', 'Itraconazole', 'ABBV-1354', 'CVL-354']",COMPLETED,,2024-11-13,2025-01-13,"[{'measure': 'Maximum Observed Plasma Concentration (Cmax) of Icalcaprant', 'description': 'Cmax of Icalcaprant', 'timeFrame': 'Up to approximately 14 days'}, {'measure': 'Time to Cmax (Tmax) of Icalcaprant', 'description': 'Tmax of Icalcaprant', 'timeFrame': 'Up to approximately 14 days'}, {'measure': 'Terminal Phase Elimination Rate Constant (Beta) of Icalcaprant', 'description': 'Beta of Icalcaprant', 'timeFrame': 'Up to approximately 14 days'}, {'measure': 'Terminal Phase Elimination Half-Life (t1/2) of Icalcaprant', 'description': 'T1/2 of Icalcaprant', 'timeFrame': 'Up to approximately 14 days'}, {'measure': 'Area under the plasma concentration-time curve (AUC) of Icalcaprant', 'description': 'AUC of Icalcaprant', 'timeFrame': 'Up to approximately 14 days'}, {'measure': 'Area under the plasma concentration-time curve from time 0 until the last measurable Concentration (AUCt) of Icalcaprant', 'description': 'AUCt of Icalcaprant', 'timeFrame': 'Up to approximately 14 days'}, {'measure': 'Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of Icalcaprant', 'description': 'AUCinf of Icalcaprant', 'timeFrame': 'Up to approximately 14 days'}, {'measure': 'Number of Participants with Adverse Events (AEs)', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study', 'timeFrame': 'Up to approximately 47 days'}]",[],8,18 Years,55 Years,ALL,True,AbbVie,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:15.910399,v2_robust,True,True,True,False,True,
NCT02468128,A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management,"A Randomized, Double Blind, Placebo-Controlled, Single Dose Study to Assess The Safety and Efficacy of Intramuscular Sebacoyl Dinalbuphine Ester (SDE) for Post-Hemorrhoidectomy Pain Management",Sebacoyl Dinalbuphine Ester,"['LT1001', 'SDE', 'Sebacoyl Dinalbuphine Ester', 'Placebo', 'Nalbuphine Sebacate']",5,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Analgesia Disorder,"['Analgesia Disorder', 'Pain']","['Analgesic', 'Opioids', 'Pain relief after surgery', 'Dinalbuphine', 'Sebacoyl Dinalbuphine Ester', 'SDE', 'SDN', 'LT1001']",COMPLETED,,2012-12,2015-04,"[{'measure': 'Pain assessment calculated as the area under the curve of VAS pain intensity scores through 48 hours after surgery', 'timeFrame': '1±0.1, 2±0.1, 3±0.1, 4±0.25, 8±0.5, 12±0.5, 16±0.5, 20±0.5, 24±1, 28±1, 32±2, 36±2, 40±2, 44±2, 48±2 h after the surgery'}]","[{'measure': 'Consumption of ketorolac via intravenous Patient- Controlled Analgesia (IV PCA)', 'timeFrame': 'Day 1-2'}, {'measure': 'Pain assessment measured with VAS during Day 3-7 in the morning and evening, as well as during special events such as bowel movements.', 'timeFrame': 'Day 3-7'}, {'measure': 'Time from the end of operation to the first PCA Ketorolac dose', 'timeFrame': 'From the end of operation until the first PCA ketorolac dose used, assessed up to 48 hrs'}, {'measure': 'Brief Pain Inventory (BPI)', 'timeFrame': 'Day 1, 2 and Day 7'}, {'measure': 'Consumption of oral Ketorolac (Day 3-7)', 'timeFrame': 'Day 3-7'}, {'measure': ""Patient satisfaction-Subject will be asked to classify themselves as either: 'highly satisfied', 'satisfied', 'uncertain', 'dissatisfied' or 'very dissatisfied'"", 'timeFrame': 'Day 7'}]",7,20 Years,,ALL,False,"Lumosa Therapeutics Co., Ltd.",INDUSTRY,0,221.0,ACTUAL,2025-09-01T16:18:15.910457,v2_robust,True,True,True,False,False,
NCT02934828,Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer,A Randomized Study of Preoperative Chemotherapy or Postoperative Chemotherapy for Early Triple Negative or Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Operable Breast Cancer,Neoadjuvant Chemotherapy,"['postoperative chemotherapy', 'Neoadjuvant Chemotherapy', 'preoperative chemotherapy', 'Adjuvant Chemotherapy']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],[],UNKNOWN,,2014-10,2018-12,"[{'measure': 'Recurrence-Free Survival (RFS) of neoadjuvant and adjuvant treatment in TNBC and her2 positive breast cancer', 'timeFrame': '5 years'}]",[],1,18 Years,70 Years,FEMALE,False,Chinese Academy of Medical Sciences,OTHER,0,230.0,ESTIMATED,2025-09-01T16:18:15.910484,v2_robust,True,True,False,False,False,
NCT03729128,Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder,The Potential Therapeutic Effects of add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder,dextromethorphan and memantine (DM+MM),"['dextromethorphan and memantine (DM+MM)', 'Placebos']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Stimulants Use Disorder,['Stimulants Use Disorder'],"['amphetamine-type stimulants use disorder', 'dextromethorphan', 'memantine', 'inflammation', 'neurodegeneration']",COMPLETED,,2018-07-24,2020-08-31,"[{'measure': 'Urinary amphetamine tests', 'description': 'The urinary amphetamine tests will be examined during the 12 weeks of treatment period in patients with ATSUD and the results will be compared between the experimental and placebo groups.', 'timeFrame': '12 weeks'}, {'measure': 'Craving severity', 'description': 'The Visual analog scale (VAS) will be measured during the 12 weeks of treatment period in patients with ATSUD. The results will be compared between the experimental and placebo groups. The level of conscious craving was rated from 0 (none) to 100 (very much). Higher scores indicate more severe craving.', 'timeFrame': '12 weeks'}, {'measure': 'Side effects checklists', 'description': 'The investigators will use the self-reported questionnaire, side effects checklists, to evaluate the side effects during the 12 weeks of treatment period in patients with ATSUD. The side effects assessment includes, A) Mental Status/6-item, B) Genito-Urinary/4-item, C) Cardiovascular/4-item, D) Head-Neck/10-item, E) Extremities/9-item, F) Skin/4-item, and G) Gastrointestinal Tract/2-item. The severity of side effects were divided into 4 degrees as follows: 0 = Not present; 1 = Mild or occasional; 2 = Moderate or occurs several times a day; and 3 = Severe or persistent. Scores in each subscale will be summated to get the final total scores. Higher scores indicate more severe side effects. The results of side effects checklists will be compared between the experimental and placebo group.', 'timeFrame': '12 weeks'}]","[{'measure': 'Wisconsin Card Sorting Test (WCST)', 'description': 'The Wisconsin Card Sorting Test (WCST) will be measured in patients with ATSUD at the initial screen period and at the endpoint (after 12 weeks of treatment). We will compare the changes from screen period to the endpoint between experimental and placebo group. Performance on the WCST was scored in terms of the total number of errors (TNE, range form 0-128), perseverative errors (PE, range from 0-118), conceptual level responses (CLRs, range from 0-100%), number of categories completed (NCC, range form 0-12), and trials to complete the first category (TCC, range from 0-128). Higher scores indicate worse performance in TNE, PE, and TCC. Higher scores indicate better performance in CLRs and NCC.', 'timeFrame': '12 weeks'}, {'measure': 'Continuous performance tests (CPT)', 'description': 'The Continuous performance tests (CPT) will be measured in patients with ATSUD at the initial screen period and at the endpoint (after 12 weeks of treatment). We will compare the changes from screen period to the endpoint between experimental and placebo group. The CPT produces a standard set of performance measures that include the number of errors of omission and errors of commission. (1) Errors of omission occur when the participant fails to respond to the target stimulus. The omission errors t-scores are ranged from 20-80 (0-100%). Higher scores indicated worse performance. (2) Errors of commission occur when the participant responds to a non-target (X) stimulus. The commission errors t-scores are ranged from 20-80 (0-100%). Higher scores indicated worse performance.', 'timeFrame': '12 weeks'}, {'measure': 'Wechsler Memory Scale - third edition (WMS-III)', 'description': 'The Wechsler Memory Scale - third edition (WMS-III) will be measured in patients with ATSUD at the initial screen period and at the endpoint (after 12 weeks of treatment). We will compare the changes from screen period to the endpoint between experimental and placebo group. WMS-III composite scores were calculated for the eight standardized primary indices: Auditory Immediate (AIM, range from 50-156), Visual Immediate (VIM, range from 47-162 ), Immediate Memory (IM, range from 40-164 ), Auditory Delayed (ADM, range from 46-162), Visual Delayed (VDM, range from 43-156), Auditory Recognition Delayed (ARDM, range from 55-145), General Memory (GM, range from 40-168), and Working Memory (WM, range from 45-156 ). Higher scores indicate better performance.', 'timeFrame': '12 weeks'}, {'measure': 'Cytokines and neurotrophic factors', 'description': 'The plasma levels of cytokines and neurotrophic factors, tumor necrosis factor α (TNF-α\\[pg/mL\\]), transforming growth factor β1 (TGF-β1 \\[pg/mL\\]), interleukin 6( IL-6\\[pg/mL\\]), interleukin 8(IL-8\\[pg/mL\\]), interleukin 1β (IL-1β\\[pg/mL\\]), and brain-derived neurotrophic factor(BDNF\\[pg/mL\\]), will be measured in patients with ATSUD at the initial screen period, day 1(baseline), week 4, 8, and 12(endpoint). We will compare the changes from screen period to the endpoint between the experimental and placebo group.', 'timeFrame': '12 weeks'}, {'measure': 'C-reactive protein', 'description': 'The plasma levels of C-reactive protein (CRP\\[μg/mL\\]) will be measured in patients with ATSUD at the initial screen period, day 1(baseline), week 4, 8, and 12(endpoint). We will compare the changes from screen period to the endpoint between the experimental and placebo group.', 'timeFrame': '12 weeks'}]",8,20 Years,65 Years,ALL,False,Tzu-Yun Wang,OTHER,1,85.0,ACTUAL,2025-09-01T16:18:15.910502,v2_robust,True,True,True,False,False,
NCT00420628,Pediatric Zylet Safety and Efficacy Study,A Safety and Efficacy Study of Zylet® (Loteprednol Etabonate 0.5% and Tobramycin 0.3% Ophthalmic Suspension) Compared to Vehicle in the Management of Lid Inflammation (Chalazion/Hordeolum) in Pediatric Subjects,loteprednol etabonate/tobramycin opthalmic suspension,"['vehicle', 'loteprednol etabonate/tobramycin opthalmic suspension', 'Zylet']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Chalazion,"['Chalazion', 'Hordeolum']",[],COMPLETED,,2006-11,2009-06,"[{'measure': 'Treatment Emergent Adverse Events', 'description': 'Study eye - Safety Population, At all visits 1,2,3', 'timeFrame': 'day 1, day 8, day 15'}]","[{'measure': 'Investigators Global Assessment of the Clinical Condition', 'description': 'The efficacy endpoints for this study consisted of reduction of inflammation as measured by the IGA of the clinical condition. Changes in clinical condition measured as improved, unchanged or worsened.', 'timeFrame': 'Visit 3, day 8'}, {'measure': 'Assessment of Ocular Signs in the Study Eye - Visit 1', 'description': 'Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.', 'timeFrame': 'Visit 1 (day 1)'}, {'measure': 'Assessment of Ocular Signs in the Study Eye - Visit 2', 'description': 'Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.', 'timeFrame': 'Visit 2 (day 8)'}, {'measure': 'Assessment of Ocular Signs in the Study Eye - Visit 3', 'description': 'Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.', 'timeFrame': 'Visit 3 (day 15)'}]",5,,6 Years,ALL,False,Bausch & Lomb Incorporated,INDUSTRY,0,108.0,ACTUAL,2025-09-01T16:18:17.169197,v2_robust,True,True,True,False,True,
NCT01712828,Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males,"A Phase 1, Open-Label, Two-Part, Fixed-Sequence Crossover Study to Evaluate the Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Male Subjects",Lenalidomide,"['Benadryl', 'Temsirolimus', 'Diphenhydramine', 'Lenalidomide', 'Quinidine']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Lenalidomide,', 'Revlimid,', 'pharmacokinetics,', 'healthy male subjects']",COMPLETED,,2012-10-01,2013-01-01,"[{'measure': 'Lenalidomide PK-AUC (0-24)', 'description': 'Area under the plasma concentration-time curve from time zero to 24 hours post dose', 'timeFrame': 'Up to 21 days'}, {'measure': 'Lenalidomide PK-(Cmax)', 'description': 'Maximum observed plasma concentration', 'timeFrame': 'Up to 21 days (including washout phase)'}, {'measure': 'Lenalidomide PK-(Tmax)', 'description': 'Time to maximum observed plasma concentration', 'timeFrame': 'Up to 21 days'}, {'measure': 'Lenalidomide PK-AUC(0-t)', 'description': 'Area under the plasma concentration-time curve from time zero to time t, where t is the last measurable time point', 'timeFrame': 'Up to 21 days'}, {'measure': 'Lenalidomide PK-AUC(0-∞)', 'description': 'Area under the plasma concentration-time curve from time zero extrapolated to infinity', 'timeFrame': 'Up to 21 days'}, {'measure': 'Lenalidomide PK-(T1/2)', 'description': 'Estimate of the terminal elimination half-life in plasma', 'timeFrame': 'Up to 21 days'}, {'measure': 'Temsirolimus and Sirolimus PK-AUC (0-24)', 'description': 'Area under the plasma concentration-time curve from time zero to 24 hours post dose', 'timeFrame': 'Up to 38 days'}, {'measure': 'Temsirolimus and Sirolimus PK-(Cmax)', 'description': 'Maximum observed plasma concentration', 'timeFrame': 'Up to 38 days'}, {'measure': 'Temsirolimus and Sirolimus PK-(Tmax)', 'description': 'Time to maximum observed plasma concentration', 'timeFrame': 'Up to 38 days'}, {'measure': 'Temsirolimus and Sirolimus PK-(AUC 0-t)', 'description': 'Area under the plasma concentration-time curve from time zero to time t, where t is the last measurable time point', 'timeFrame': 'Up to 38 days'}]","[{'measure': 'Number of participants with adverse events', 'description': 'Safety monitoring will be done by regular adverse event assessment, concomitant medication, clinical laboratory tests, physical exams, ECGs, and vital signs.', 'timeFrame': 'Up to 6 weeks'}]",11,18 Years,65 Years,MALE,True,Celgene,INDUSTRY,1,31.0,ACTUAL,2025-09-01T16:18:17.169236,v2_robust,True,True,True,False,True,
NCT06028828,Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation,Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT),Fludarabine,"['Fludarabine', 'Melphalan']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Allogeneic Hematopoietic Stem Cell Transplantation,"['Allogeneic Hematopoietic Stem Cell Transplantation', 'Allogeneic Stem Cell Transplantation', 'Hematologic Malignancies']","['Allogeneic Hematopoietic Stem Cell Transplantation', 'Allogeneic Stem Cell transplantation', 'AHSCT', 'Hematologic malignancies', 'Melphalan', 'Hematopoietic stem cell transplant -composite risk']",RECRUITING,,2023-09-11,2027-09,"[{'measure': 'Progression-free survival (PFS)', 'description': 'PFS is defined as the time from stem cell infusion to time of disease relapse or death from any cause; data for patients who were alive without relapse will be censored at the date of last contact.', 'timeFrame': 'Up to 48 months'}]","[{'measure': 'Overall survival (OS)', 'description': 'OS is defined as the time from stem cell infusion until death from any cause. Data of patients who were alive without relapse will be censored at the date of last contact.', 'timeFrame': 'Up to 48 months'}, {'measure': 'Cumulative incidence of Graft-Versus-Host-Free, relapse-free survival (GRFS)', 'description': 'GRFS is defined as time from stem cell infusion to time of the first event among acute GVHD grades 3-4, extensive chronic GVHD, relapse, and death. Data of patients who are event-free will be censored at the date of last contact.', 'timeFrame': 'Up to 48 months'}, {'measure': 'Cumulative incidence of relapse', 'description': 'Relapse is defined as re-occurrence of the disease after stem cell infusion. Cumulative incidence of relapse will be measured from date of stem cell infusion to date of disease relapse. Death without disease relapse is considered a competing risk for relapse. Data of patients who are alive without disease relapse will be censored at the date of last contact.', 'timeFrame': 'Up to 48 months'}, {'measure': 'Cumulative incidence of Non-Relapse Mortality (NRM)', 'description': 'NRM is defined as death related to AHSCT during continuous complete remission. Cumulative incidence of NRM will be measured from date of stem cell infusion to date of death. Disease relapse is considered a competing risk for NRM. Data of patients who are alive without disease relapse will be censored at the date of last contact.', 'timeFrame': 'Up to 48 months'}, {'measure': 'Cumulative incidence of acute and chronic graft versus host disease (GVHD)', 'description': 'Acute and chronic GVHD will be measured from date of stem cell infusion to date of the event. Death without GVHD is considered a competing risk for GVHD. Patients who are alive without GVHD will be censored at the date of last contact.', 'timeFrame': 'Up to 48 months'}, {'measure': 'Area Under the Curve (AUC) of Melphalan', 'description': 'AUC will be used to determine the pharmacokinetic of melphalan after the infusion on D-5. Data will be summarized using descriptive statistics.', 'timeFrame': 'From melphalan infusion start time to 22 hours after the infusion.'}]",7,18 Years,70 Years,ALL,False,"University of California, Irvine",OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:17.169447,v2_robust,True,True,False,False,False,
NCT01690065,Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML,Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia,Nilotinib+AD induction,"['Nilotinib+AD induction', 'Tasigna']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Myeloid Leukemia in Myeloid Blast Crisis,"['Chronic Myeloid Leukemia in Myeloid Blast Crisis', 'Untreated Adult Acute Myeloid Leukemia']","['chronic myeloid leukemia', 'myeloid blastic phase', 'bcr-abl(+) acute myeloid leukemia', 'nilotinib']",UNKNOWN,,2012-09,2019-12,"[{'measure': 'Complete remission rate', 'description': 'Primary purpose of this study is to define the efficacy of combined chemotherapy and nilotinib in chronic myeloid leukemia (CML) myeloid blastic phase (MBP) and bcr-abl positive acute myeloid leukemia (AML). The efficacy will be evaluated by complete remission (CR) rate.', 'timeFrame': 'Within 8 weeks after induction therapy'}]","[{'measure': 'Safety', 'description': '* This study will also evaluate the safety of nilotinib and chemotherapy combination therapy.\n* CTCAE ver. 4.03 will be used for safety measurement.', 'timeFrame': 'Within 8 weeks after induction therapy'}, {'measure': 'Time-dependent variables', 'description': '• This study will evaluate the impacts of nilotinib combined with chemotherapy on duration of CR, relapse-free survival (RFS), event-free survival (EFS), and overall survival (OS).', 'timeFrame': 'at least 2 years'}]",3,18 Years,65 Years,ALL,False,Ulsan University Hospital,OTHER,1,46.0,ESTIMATED,2025-09-01T16:18:17.169660,v2_robust,True,True,False,False,True,
NCT01262365,Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease",Epratuzumab,"['Epratuzumab', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Systemic Lupus Erythematosus,['Systemic Lupus Erythematosus'],"['Lupus', 'Monoclonal antibody', 'B-Cell immunotherapy', 'Epratuzumab']",COMPLETED,,2010-12,2015-05,"[{'measure': 'The Percent of Subjects Meeting Treatment Response Criteria at Week 48 According to a Combined Response Index', 'description': ""Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set. The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes."", 'timeFrame': 'At Week 48'}]","[{'measure': 'The Percent of Subjects Meeting Treatment Response Criteria at Week 24 According to a Combined Response Index', 'description': ""Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set. The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes."", 'timeFrame': 'At Week 24'}, {'measure': 'The Percent of Subjects Meeting Treatment Response Criteria at Week 12 According to a Combined Response Index', 'description': ""Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set. The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes."", 'timeFrame': 'At Week 12'}, {'measure': 'The Percent of Subjects Meeting Treatment Response Criteria at Week 36 According to a Combined Response Index', 'description': ""Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set. The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes."", 'timeFrame': 'At Week 36'}, {'measure': 'Change From Baseline in Daily Corticosteroid Dose at Week 24', 'description': 'Subjects with a missing corticosteroid dose at any visit for any reason are counted in the Dose Increased or Missing Data category for that visit.', 'timeFrame': 'At Week 24'}, {'measure': 'Change From Baseline in Daily Corticosteroid Dose at Week 48', 'description': 'Subjects with a missing corticosteroid dose at any visit for any reason are counted in the Dose Increased or Missing Data category for that visit.', 'timeFrame': 'At Week 48'}]",6,18 Years,,ALL,False,UCB Pharma,INDUSTRY,0,793.0,ACTUAL,2025-09-01T16:18:17.169841,v2_robust,True,True,True,False,False,
NCT02475265,Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa,Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa,estradiol 0.045 mg/levonorgestrel 0.015mg,"['estradiol 0.045 mg/levonorgestrel 0.015mg', 'Climara Pro transdermal patch']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Anorexia Nervosa,"['Anorexia Nervosa', 'Osteoporosis']","['Anorexia Nervosa', 'Osteoporosis', 'Eating Disorder', 'Disordered Eating', 'Estrogen', 'Bone']",COMPLETED,,2015-07,2018-07-30,"[{'measure': 'Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA)', 'description': 'Percent change in lumbar spine bone mineral density after six-months. Lumbar spine bone mineral density measured by dual energy x-ray absorptiometry.', 'timeFrame': '6 months'}]",[],1,25 Years,50 Years,FEMALE,False,Massachusetts General Hospital,OTHER,1,11.0,ACTUAL,2025-09-01T16:18:17.169897,v2_robust,True,True,True,False,False,
NCT01016665,Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy,Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study,Anastrozole,['Anastrozole'],1,INTERVENTIONAL,['NA'],,,Breast Cancer,['Breast Cancer'],"['Breast cancer', 'Short Term', 'Homontherapy', 'aromatase inhibitor', 'Short term hormonetherapy in breast cancer']",COMPLETED,,2005-04,2008-06,"[{'measure': 'Expression of progesterone', 'timeFrame': 'end of the study (june 2008)'}]","[{'measure': 'Expression of Ki-67', 'timeFrame': 'end of the study (june 2008)'}]",2,40 Years,90 Years,FEMALE,False,Federal University of São Paulo,OTHER,0,71.0,ACTUAL,2025-09-01T16:18:17.169929,v2_robust,True,True,True,False,False,
NCT04056065,PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock,"A Prospective, Multi-centric, Randomized, Double-blind, Parallel, Saline Controlled Phase II Safety and Efficacy Study of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock to be Used Along With Standard Shock Treatment.",Normal Saline,"['PMZ-2010', 'Normal Saline', 'Vehicle', 'Centhaquine']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Hypovolemic Shock,"['Hypovolemic Shock', 'Blood Loss']","['Resuscitative agent', 'Vasopressor']",COMPLETED,,2017-05-29,2018-10-21,"[{'measure': 'Incidence of PMZ-2010 related adverse events', 'description': 'The primary objective of the study is to determine incidence of drug (PMZ-2010) related adverse events.', 'timeFrame': '28 days'}]","[{'measure': 'Volume of fluid administered', 'description': 'Total volume of fluid administered - Mean through 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Volume of blood products administered', 'description': 'Total volume of blood products administered - Mean through 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Vasopressor(s) infused', 'description': 'Amount of total vasopressor(s) infused - Mean through 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Doses of study drug', 'description': 'Number of doses of study drug administered in first 48 hours post randomization', 'timeFrame': '48 hours'}, {'measure': 'Change in systolic and diastolic blood pressure', 'description': 'Change in systolic and diastolic blood pressure - Mean through 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Change in blood lactate level', 'description': 'Change in blood lactate level - Mean through 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Change in base-deficit', 'description': 'Change in Base-deficit - Mean through 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Change in platelet count', 'description': 'Change in platelet count as part of coagulation parameters mean through 48 hours. Platelets are parts of the blood that helps the blood clot. Average platelet counts are 150,000 to 450,000 number of platelets per microliter.', 'timeFrame': '48 hours'}, {'measure': 'Change in prothrombin time', 'description': 'Change in prothrombin time as part of coagulation parameters mean through 48 hours. Prothrombin time (PT) is a blood test that measures the time it takes for the blood to clot. The average time range for blood to clot is about 10 to 14 seconds.', 'timeFrame': '48 hours'}, {'measure': 'Change in international normalized ratio (INR)', 'description': 'Change in international normalized ratio (INR) as part of coagulation parameters mean through 48 hours. The results of the prothrombin time test vary from laboratory to laboratory, therefore, a ratio called the international normalized ratio (INR) is calculated. It allows for differences in laboratories across the world so that test results become more relevant and can be compared. The average INR range is 0.8 to 1.1.', 'timeFrame': '48 hours'}, {'measure': 'Change in fibrinogen', 'description': 'Change in fibrinogen as part of coagulation parameters mean through 48 hours. Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. The reference range for fibrinogen is 150-400 mg/dL', 'timeFrame': '48 hours'}, {'measure': 'Change in Multiple Organ Dysfunction Syndrome Score', 'description': 'Change in Multiple Organ Dysfunction Syndrome Score (MODS) - Mean through 28 days. MODS is a 5 grade scale from 0 to 4, where 0 is the best and 4 is the worst outcome.', 'timeFrame': '28 days'}, {'measure': 'Change in Acute Respiratory Distress Syndrome', 'description': 'Change in Acute Respiratory Distress Syndrome (ARDS) - Mean through 28 days. ARDS will be determined using Murray Score for Acute Lung Injury which is based upon radiological findings, oxygenation status, ventilation status of the patient. A lower score of 0 is the best and about 2.5 is the worst outcome.', 'timeFrame': '28 days'}, {'measure': 'Change in Glasgow coma score', 'description': 'Change in Glasgow coma score (GCS) - Mean through 28 days. GCS is a 15 point scale to assess the level of consciousness of patients where less than 3 is comatose state and 15 is fully awake.', 'timeFrame': '28 days'}, {'measure': 'Stay in hospital, in ICU and/or on Ventilator', 'description': 'Days in hospital, in ICU and/or on Ventilator - Mean through 28 days', 'timeFrame': '28 days'}, {'measure': 'Incidence of mortality', 'description': 'Proportion of patients with all-cause mortality at 48 hours and 28 days', 'timeFrame': '28 days'}]",17,18 Years,70 Years,ALL,False,"Pharmazz, Inc.",INDUSTRY,0,50.0,ACTUAL,2025-09-01T16:18:17.169973,v2_robust,True,True,True,False,True,
NCT02642367,Stylet Use for McGrath Videolaryngoscope,Comparison of With or Without Use of Stylet for Endotracheal Intubation With McGrath Videolaryngoscope,rocuronium,"['rocumeron', 'rocuronium']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Orotracheal Intubation,['Orotracheal Intubation'],[],COMPLETED,,2016-01,2016-05,"[{'measure': 'intubation time', 'description': 'time the blade passed the lips until endtidal CO2 was detected', 'timeFrame': '2 min after rocuronium injection'}]",[],1,19 Years,70 Years,ALL,False,Ajou University School of Medicine,OTHER,0,140.0,ACTUAL,2025-09-01T16:18:17.170022,v2_robust,True,True,True,False,False,
NCT00672867,A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B,A Open Randomized Clinical Trial Comparing the Efficacy and Safety of Clevudine 30mg Versus Adefovir 10mg in Patients With LC-B,Clevudine,"['Adefovir dipivoxil', 'Levovir', 'Clevudine', 'Hepsera']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Patients With LC-B,['Patients With LC-B'],[],COMPLETED,,2007-12,2014-09,[{'measure': 'Proportion of patients with HBV DNA below 12 IU/mL by Real-Time PCR'}],"[{'measure': 'The change of HBV DNA from the baseline.'}, {'measure': 'Child-Pugh score improvement'}, {'measure': 'MELD score improvement'}, {'measure': 'Biochemical improvement'}, {'measure': 'Proportion of patients with HBeAg loss and/or seroconversion'}]",6,18 Years,,ALL,False,Bukwang Pharmaceutical,INDUSTRY,0,102.0,ESTIMATED,2025-09-01T16:18:17.170063,v2_robust,True,True,True,False,False,
NCT02813967,S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer,"S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus: A Prospective, Randomized, Multi-center Phase-III Study",S-1,['S-1'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Esophageal Cancer,"['Esophageal Cancer', 'Chemoradiation']",[],COMPLETED,,2016-06,2020-08,"[{'measure': 'Overall survival', 'description': '2-year over survival', 'timeFrame': '5 years'}]","[{'measure': 'Progression-free survival', 'timeFrame': '5 years'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': '5 years'}]",3,70 Years,85 Years,ALL,False,Zhejiang Cancer Hospital,OTHER,0,298.0,ACTUAL,2025-09-01T16:18:17.170103,v2_robust,True,True,True,False,True,
NCT03400267,The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor,The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor,Paracetamol,"['Paracetamol', 'Fentanyl']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,STEMI,"['STEMI', 'STEMI - ST Elevation Myocardial Infarction']",[],COMPLETED,,2018-02-16,2019-11-22,"[{'measure': 'platelet reactivity', 'description': 'Platelet reactivity units (PRU) directly post-PCI or 1 hour post-angiography', 'timeFrame': 'directly post-PCI or 1 hour post-angiography'}]",[],1,18 Years,,ALL,False,A.H. Tavenier,OTHER,1,200.0,ACTUAL,2025-09-01T16:18:17.170127,v2_robust,True,True,True,False,False,
NCT01595867,Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo,"A Randomized, Double-Blind, Placebo-Controlled, 3 Way Crossover Study Evaluating The Relative Abuse Potential Of Crushed Embeda Compared To Morphine Sulfate Controlled Release Tablets (Crushed) And Placebo In Non-Dependent, Recreational Opioid Users Following Intranasal Administration",Placebo,"['EMBEDA - morphine sulfate/ naltrexone hydrochloride', 'morphine sulfate CR crushed.', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Narcotic Abuse,"['Narcotic Abuse', 'Opioid-related Disorders', 'Analgesia', 'Chronic Pain']","['abuse liability', 'abuse potential', 'morphine', 'intranasal administration', 'snorting', 'opioid abuse', 'pharmacodynamic', 'recreational drug use']",COMPLETED,,2010-08,2011-01,"[{'measure': 'Drug Liking Visual Analog Scale maximum peak effect (Emax)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Drug Liking Visual Analog Scale Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'High Visual Analog Scale maximum peak effect (Emax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'High Visual Analog Scale Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}]","[{'measure': 'Drug Liking Visual Analog Scale Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Drug Liking Visual Analog Scale Area under the effect curve to 4 hours (AUE0-4h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Drug Liking Visual Analog Scale Area under the effect curve to 8 hours (AUE0-8h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Drug Liking Visual Analog Scale Area under the effect curve to 12 hours (AUE0-12h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Drug Liking Visual Analog Scale Area under the effect curve to 24 hours (AUE0-24h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Drug Liking Visual Analog Scale Area time to maximum effect (TEmax)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'High VVisual Analog Scale Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'High Visual Analog Scale Area under the effect curve to 4 hours (AUE0-4h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'High Visual Analog Scale Area under the effect curve to 8 hours (AUE0-8h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'High Visual Analog Scale Area under the effect curve to 12 hours (AUE0-12h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'High Visual Analog Scale Area under the effect curve to 24 hours (AUE0-24h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'High Visual Analog Scale Area time to maximum effect (TEmax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Any Drug Effects Visual Analog Scale maximum peak effect (Emax)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Any Drug Effects Visual Analog Scale Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Any Drug Effects Visual Analog Scale Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Any Drug Effects Visual Analog Scale Area under the effect curve to 4 hours (AUE0-4h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Any Drug Effects Visual Analog Scale Area under the effect curve to 8 hours (AUE0-8h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Any Drug Effects Visual Analog Scale Area under the effect curve to 12 hours (AUE0-12h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Any Drug Effects Visual Analog Scale Area under the effect curve to 24 hours (AUE0-24h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Any Drug Effects Visual Analog Scale Area time to maximum effect (TEmax)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Good Drug Effects Visual Analog Scale maximum peak effect (Emax)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Good Drug Effects Visual Analog Scale Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Good Drug Effects Visual Analog Scale Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Good Drug Effects Visual Analog Scale Area under the effect curve to 4 hours (AUE0-4h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Good Drug Effects Visual Analog Scale Area under the effect curve to 8 hours (AUE0-8h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Good Drug Effects Visual Analog Scale Area under the effect curve to 12 hours (AUE0-12h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Good Drug Effects Visual Analog Scale Area under the effect curve to 24 hours (AUE0-24h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Good Drug Effects Visual Analog Scale Area time to maximum effect (TEmax)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Bad Drug Effects Visual Analog Scale maximum peak effect (Emax)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Bad Drug Effects Visual Analog Scale Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Bad Drug Effects Visual Analog Scale Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Bad Drug Effects Visual Analog Scale Area under the effect curve to 4 hours (AUE0-4h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Bad Drug Effects Visual Analog Scale Area under the effect curve to 8 hours (AUE0-8h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Bad Drug Effects Visual Analog Scale Area under the effect curve to 12 hours (AUE0-12h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Bad Drug Effects Visual Analog Scale Area under the effect curve to 24 hours (AUE0-24h)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Bad Drug Effects Visual Analog Scale Area time to maximum effect (TEmax)', 'timeFrame': '0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Feel Sick Visual Analog Scale maximum peak effect (Emax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Feel Sick Visual Analog Scale Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Feel Sick Visual Analog Scale Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Feel Sick Visual Analog Scale Area under the effect curve to 4 hours (AUE0-4h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Feel Sick Visual Analog Scale Area under the effect curve to 8 hours (AUE0-8h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Feel Sick Visual Analog Scale Area under the effect curve to 12 hours (AUE0-12h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Feel Sick Visual Analog Scale Area under the effect curve to 24 hours (AUE0-24h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Feel Sick Visual Analog Scale Area time to maximum effect (TEmax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Nausea Visual Analog Scale maximum peak effect (Emax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Nausea Visual Analog Scale Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Nausea Visual Analog Scale Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Nausea Visual Analog Scale Area under the effect curve to 4 hours (AUE0-4h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Nausea Visual Analog Scale Area under the effect curve to 8 hours (AUE0-8h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Nausea Visual Analog Scale Area under the effect curve to 12 hours (AUE0-12h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Nausea Visual Analog Scale Area under the effect curve to 24 hours (AUE0-24h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Nausea Visual Analog Scale Area time to maximum effect (TEmax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Sleepy Visual Analog Scale maximum peak effect (Emax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Sleepy Visual Analog Scale Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Sleepy Visual Analog Scale Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Sleepy Visual Analog Scale Area under the effect curve to 4 hours (AUE0-4h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Sleepy Visual Analog Scale Area under the effect curve to 8 hours (AUE0-8h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Sleepy Visual Analog Scale Area under the effect curve to 12 hours (AUE0-12h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Sleepy Visual Analog Scale Area under the effect curve to 24 hours (AUE0-24h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Sleepy Visual Analog Scale Area time to maximum effect (TEmax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Dizzy Visual Analog Scale maximum peak effect (Emax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Dizzy Visual Analog Scale Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Dizzy Visual Analog Scale Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Dizzy Visual Analog Scale Area under the effect curve to 4 hours (AUE0-4h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Dizzy Visual Analog Scale Area under the effect curve to 8 hours (AUE0-8h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Dizzy Visual Analog Scale Area under the effect curve to 12 hours (AUE0-12h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Dizzy Visual Analog Scale Area under the effect curve to 24 hours (AUE0-24h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Dizzy Visual Analog Scale Area time to maximum effect (TEmax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Pupil Diameter minimum peak effect (Emin)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Pupil Diameter time to minimum peak effect (TEmin)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Pupil Diameter Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Pupil Diameter Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Pupil Diameter Area under the effect curve to 4 hours (AUE0-4h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Pupil Diameter Area under the effect curve to 8 hours (AUE0-8h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Pupil Diameter Area under the effect curve to 12 hours (AUE0-12h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Pupil Diameter Area under the effect curve to 24 hours (AUE0-24h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8,12, and 24 hours post-dose'}, {'measure': 'Take Drug Again Visual Analog Scale maximum peak effect (Emax)', 'timeFrame': '12 and 24 hours post dose'}, {'measure': 'Take Drug Again Visual Analog Scale mean (Emean)', 'timeFrame': '12 and 24 hours post dose'}, {'measure': 'Overall Drug Liking Visual Analog Scale maximum peak effect (Emax)', 'timeFrame': '12 and 24 hours post dose'}, {'measure': 'Overall Drug Liking Visual Analog Scale mean (Emean)', 'timeFrame': '12 and 24 hours post dose'}, {'measure': 'Subject Rating Scale - Need to Blow Nose maximum peak effect (Emax)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Need to Blow Nose Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Need to Blow Nose Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Runny Nose/Nasal Discharge maximum peak effect (Emax)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Runny Nose/Nasal Discharge Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Runny Nose/Nasal Discharge Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Burning maximum peak effect (Emax)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Burning Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Burning Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Facial Pain/Pressure maximum peak effect (Emax)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Facial Pain/Pressure Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Facial Pain/Pressure Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Nasal Congestion maximum peak effect (Emax)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Nasal Congestion Area under the effect curve to 1 hour (AUE0-1h)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Subject Rating Scale - Nasal Congestion Area under the effect curve to 2 hours (AUE0-2h)', 'timeFrame': 'pre dose and 0.5, 1, 1.5, and 2 hours post dose'}, {'measure': 'Plasma morphine - Maximum observed plasma concentration (Cmax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma morphine - Time to maximum observed plasma concentration (Tmax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma morphine - Area under the plasma concentration time curve from time zero to 1 hour (AUC0-1h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma morphine - Area under the plasma concentration time curve from time zero to 2 hours (AUC0-2h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma morphine - Area under the plasma concentration time curve from time zero to 4 hours (AUC0-4h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma 6-ß-naltrexol - Maximum observed plasma concentration (Cmax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma 6-ß-naltrexol - Area under the plasma concentration time curve from time zero to 1 hour (AUC0-1h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma 6-ß-naltrexol - Area under the plasma concentration time curve from time zero to 12 hours (AUC0-12h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma 6-ß-naltrexol - Area under the plasma concentration time curve from time zero to 24 hours (AUC0-24h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma 6-ß-naltrexol - Area under the plasma concentration time curve from time zero to 4 hours (AUC0-4h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma 6-ß-naltrexol - Area under the plasma concentration time curve from time zero to 8 hours (AUC0-8h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma 6-ß-naltrexol - Time to maximum observed plasma concentration (Tmax', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma 6-ß-naltrexol- Area under the plasma concentration time curve from time zero to 2 hours (AUC0-2h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma 6-ß-naltrexol- Area under the plasma concentration time curve from time zero to infinity (AUC0-8), as applicable', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma morphine - Area under the plasma concentration time curve from time zero to 12 hours (AUC0-12h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma morphine - Area under the plasma concentration time curve from time zero to 24 hours (AUC0-24h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma morphine - Area under the plasma concentration time curve from time zero to 8 hours (AUC0-8h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma morphine - Area under the plasma concentration time curve from time zero to infinity (AUC0-8), as applicable', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma naltrexone - Area under the plasma concentration time curve from time zero to 1 hour (AUC0-1h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma naltrexone - Area under the plasma concentration time curve from time zero to 12 hours (AUC0-12h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma naltrexone - Area under the plasma concentration time curve from time zero to 24 hours (AUC0-24h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma naltrexone - Area under the plasma concentration time curve from time zero to 4 hours (AUC0-4h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma naltrexone - Area under the plasma concentration time curve from time zero to 8 hours (AUC0-8h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma naltrexone - Area under the plasma concentration time curve from time zero to infinity (AUC0-8), as applicable', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma naltrexone - Maximum observed plasma concentration (Cmax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma naltrexone - Time to maximum observed plasma concentration (Tmax)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}, {'measure': 'Plasma naltrexone- Area under the plasma concentration time curve from time zero to 2 hours (AUC0-2h)', 'timeFrame': 'pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose'}]",126,18 Years,55 Years,ALL,True,Pfizer,INDUSTRY,0,33.0,ACTUAL,2025-09-01T16:18:17.170157,v2_robust,True,True,True,False,False,
NCT03978767,Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial,Preeclampsia And Nonsteroidal Drugs for Analgesia (PANDA): a Randomized Non Inferiority Trial,Ibuprofen 600 mg,"['Oxycodone', 'Acetaminophen', 'Ketorolac', 'Ibuprofen 600 mg']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Preeclampsia Severe,"['Preeclampsia Severe', 'Preeclampsia Postpartum']","['NSAIDs', 'Ibuprofen']",RECRUITING,,2019-06-10,2025-06-01,"[{'measure': 'postpartum antihypertensive requirements', 'description': 'measurement of anti-hypertensive requirements at time of discharge', 'timeFrame': 'at the end of hospitalization, up to 7 days after randomization'}]","[{'measure': 'Postpartum pain scores', 'description': 'Evaluate the effect of NSAIDs on patient perception of pain', 'timeFrame': 'From randomization to 6 weeks after randomization'}, {'measure': 'Postpartum opioid use', 'description': 'Compare the opioid requirements in each arm', 'timeFrame': 'From randomization to 6 weeks after randomization'}, {'measure': 'Mean arterial blood pressure', 'description': 'Compare peak, average and median MAPs postpartum', 'timeFrame': 'From randomization to 6 weeks after randomization'}, {'measure': 'End organ damage', 'description': 'Evaluate for evidence of renal, hepatic or neurological injury in the poatpartum period', 'timeFrame': 'during hospitalization, an average of 4 days'}, {'measure': 'Hospital readmission', 'description': 'Evaluate the incidence of hospital readmission rate postpartum', 'timeFrame': 'From randomization to 6 weeks after randomization'}, {'measure': 'Continued anti-hypertensive requirement', 'description': 'evaluate the need for antihypertensive medications at 6 weeks postpartum', 'timeFrame': 'up to 6 weeks'}]",7,,,FEMALE,False,Washington University School of Medicine,OTHER,0,286.0,ESTIMATED,2025-09-01T16:18:17.170388,v2_robust,True,True,False,False,False,
NCT03629067,Combination of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects,"A Randomized, Open-label, Single Dose, 3x3 Partial Replicated Crossover Study to Evaluate the Pharmacokinetics and Safety/Tolerability Between BR1010 and Co-administration of BR1010-1 and BR1010-2 in Healthy Volunteers",Treatment T,"['Treatment R', 'Treatment T', 'FAH', 'FA/H']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Pharmacokinetics,['Pharmacokinetics'],['Hypertension'],COMPLETED,,2018-09-13,2018-12-27,"[{'measure': 'Cmax', 'description': 'Maximum Concentration of Fimasartan, Amlodipine, Hydrochlorothiazide in plasma', 'timeFrame': '0~144hours after Medication'}]","[{'measure': 'AUCinf', 'description': '""Area under the plasma concentration versus time curve "" of Fimasartan, Amlodipine, Hydrochlorothiazide', 'timeFrame': '0~144hours after medication'}]",2,19 Years,50 Years,ALL,True,"Boryung Pharmaceutical Co., Ltd",INDUSTRY,0,60.0,ACTUAL,2025-09-01T16:18:17.170409,v2_robust,True,True,True,False,False,
NCT04039867,Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer,Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer,Oxaliplatin with Gemcitabine,"['Oxaliplatin with Gemcitabine', 'Gemzar', 'Eloxatin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,"Carcinoma, Transitional Cell","['Carcinoma, Transitional Cell']","['Carcinoma, Transitional Cell', 'Bladder Cancer', 'oxaliplatin', 'Gemcitabine']",TERMINATED,Trial was terminated due to halt in funding.,2005-01-20,2011-10-06,"[{'measure': 'Number of Participants With Treatment-emergent Adverse Events to Evaluate Tolerability of Oxaliplatin With Gemcitabine', 'description': 'To evaluate the tolerability of administering Oxaliplatin in combination with gemcitabine in patients with recurrent or advanced TCC bladder. Toxicity and adverse events are based on the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0.', 'timeFrame': 'From date of registration until treatment completion, disease progression or other reasons for removal from protocol treatments, whichever came first, an average of 1 year.'}]","[{'measure': 'Overall Response Rate as Assessed by RECIST Criteria of Patients Who Received Gemcitabine and Oxaliplatin', 'description': 'To assess the overall response rate to the combination of gemcitabine and Oxaliplatin in patients with recurrent or advanced TCC bladder. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI. Complete Response (CR) is defined as disappearance of all target lestions. Partial Response (PR) is defined as \\>=30% decrease in the sum of the longest diameter of target lesions. Overall response rate (ORR) is defined as confirmed complete response (CR) and partial response (PR). ORR = CR + PR', 'timeFrame': 'From date of registration until first date of disease progression, toxicity, delay of treatment, or withdrawal of treatment, whichever came first, an average of 1 year.'}, {'measure': 'Overall Survival of Patients Who Received Gemcitabine and Oxaliplatin', 'description': 'To evaluate overall survival in patients with advanced TCC bladder treated with this combination of gemcitabine and Oxaliplatin.', 'timeFrame': 'From date of registration for 5 years or until death from any cause, whichever came first.'}]",3,18 Years,,ALL,False,"University of California, Irvine",OTHER,0,17.0,ACTUAL,2025-09-01T16:18:17.170419,v2_robust,True,True,False,True,True,Trial was terminated due to halt in funding.
NCT06961500,Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A,"A Multicenter, Phase 2, Randomized Trial of Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A (FL)",Obinutuzumab,"['Bendamustine', 'Obinutuzumab', 'CHOP']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Follicular Lymphoma Grade 3A,['Follicular Lymphoma Grade 3A'],[],NOT_YET_RECRUITING,,2025-05-01,2030-11-01,"[{'measure': 'Progression-Free Survival (PFS)', 'description': 'From study entry to the first documented disease progression or death from any cause.', 'timeFrame': 'Assessed up to 5 years.'}]","[{'measure': 'Complete Response (CR)', 'description': 'Defined as the proportion of patients who achieve complete remission at the end of induction therapy.', 'timeFrame': 'Up to 6 cycles (up to 24 weeks).'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'The proportion of patients who achieve complete remission (CR) or partial remission (PR) at the end of induction therapy.', 'timeFrame': 'Up to 6 cycles (up to 24 weeks).'}, {'measure': 'Event-Free Survival (EFS)', 'description': 'From study entry to the first occurrence of any event, including disease progression, discontinuation of treatment, or death for any reason.', 'timeFrame': 'Assessed up to 5 years.'}, {'measure': 'Overall Survival (OS)', 'description': 'From study entry to death from any cause.', 'timeFrame': 'Assessed up to 5 years.'}, {'measure': 'Progression of Disease within 24 months (POD24)', 'description': 'The occurrence of disease progression or relapse within 24 months from the date of enrollment.', 'timeFrame': '24 months.'}]",6,18 Years,,ALL,False,Sun Yat-sen University,OTHER,0,133.0,ESTIMATED,2025-09-01T16:18:17.170540,v2_robust,True,True,False,False,False,
NCT01651000,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency",CTAP101 30 μg capsules,"['CTAP101 30 μg capsules', 'Calcifediol']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Kidney Disease,"['Chronic Kidney Disease', 'Hyperparathyroidism, Secondary', 'Vitamin D Deficiency']","['Parathyroid Diseases', 'Renal Insufficiency', 'Kidney Failure, Chronic', 'Hyperparathyroidism, Secondary', 'Vitamin D', 'Hyperparathyroidism', 'Kidney Diseases', 'Kidney Failure', 'Renal Insufficiency, Chronic']",COMPLETED,,2012-09,2014-07,"[{'measure': 'Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values', 'description': 'Number of subjects in the intent to treat population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of ≥30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders.', 'timeFrame': 'Approximately 6 months'}]","[{'measure': 'Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values', 'description': 'Number of subjects in the per protocol population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of ≥30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders.', 'timeFrame': 'Approximately 6 months'}, {'measure': 'Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D', 'description': 'Subjects in the Intent to Treat Population with normal serum total 25-hydroxyvitamin D (\\>/= 30 ng/dL)', 'timeFrame': 'Approximately 6 months'}, {'measure': 'Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D', 'description': 'Subjects in the Per Protocol Population with normal serum total 25-hydroxyvitamin D (\\>/= 30 ng/mL)', 'timeFrame': 'Approximately 6 months'}]",4,18 Years,,ALL,False,"OPKO IP Holdings II, Inc.",INDUSTRY,0,213.0,ACTUAL,2025-09-01T16:18:17.170583,v2_robust,True,True,True,False,False,
NCT00169000,Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers,Phase I Study of a Novel Schedule of Capecitabine and Docetaxel in Patients With Advanced Solid Tumors,Capecitabine,"['Xeloda', 'Docetaxel', 'Capecitabine', 'Taxotere']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Metastatic Breast Cancer,['Metastatic Breast Cancer'],"['breast cancer', 'capecitabine', 'docetaxel', 'pharmacokinetic/pharmacodynamic', 'bcl-2', 'bax']",COMPLETED,,2003-01,2006-03,"[{'measure': 'To determine the maximum tolerated dose, and dose limiting toxicity of capecitabine when given daily for 14 days with docetaxel given on day 8 of a 21 day cycle', 'timeFrame': '3 weeks'}]","[{'measure': ""To determine the pharmacokinetic profile of capecitabine, 5-fluorouracil, and 5'-deoxy-5-fluorouridine following administration of docetaxel on day 8."", 'timeFrame': '9 days'}, {'measure': 'To determine the expression of Bax, Bcl-2, and phosphorylated Bcl-2 at baseline and again on days 8 and 9 of capecitabine when given at the MTD', 'timeFrame': '9 days'}, {'measure': 'To define pharmacodynamic relationships between observed changes in dihydropyrimidine dehydrogenase (DPD) and altered expression of Bax and Bcl-2 with clinical toxicities and antitumor response', 'timeFrame': '9 days'}]",4,18 Years,,ALL,False,Dartmouth-Hitchcock Medical Center,OTHER,1,12.0,ACTUAL,2025-09-01T16:18:17.170701,v2_robust,True,True,True,False,False,
NCT01537900,A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010),A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Dynamics Following Administration of MK-5172 in Hepatitis C Infected Patients,Grazoprevir,"['MK-5172', 'Grazoprevir']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Hepatitis C,['Hepatitis C'],[],COMPLETED,,2013-10-01,2014-07-31,"[{'measure': 'Estimated Area Under the Liver Concentration-time Curve for 24 Hours Post-dose (AUC[H]0-24hr) of Grazoprevir', 'description': 'Each participant was assigned to undergo Fine Needle Aspiration (FNA) to obtain liver tissue at different time points. Specifically, one participant underwent FNA at 4 hr post-dose only, another participant underwent FNA at 8 hr post-dose only, and a third participant underwent FNA at 24 hr post-dose only. (The fourth participant underwent FNA at 72 hr post-dose and therefore was not included in the calculation of AUC0-24hr.) Therefore, in calculating AUC0-24hr, there were only 3 data points: 1 data point at 4 hr post-dose, 1 data point at 8 hr post-dose, and 1 data point at 24 hr post-dose. The model assumed that drug concentration was at steady-state, and that the concentration at 24 hr post-dose was equal to the concentration at 0 hr post-dose.', 'timeFrame': '4, 8, and 24 hours post-dose on Day 7'}, {'measure': 'Hepatic Concentration of GZR (C[H]Xhr)', 'description': 'C(H)Xhr of GZR was expressed as liver concentration (μmol GZR/L liver) using the concentration of the extracted liver sample (mass of the liver biopsy/0.2 mL solvent), and assuming that liver has the specific gravity of water (1 g/mL). The arithmetic mean C(H)Xhr concentration is based on the means of 4 FNA passes per participant in all 4 participants.', 'timeFrame': '4, 8, 24, and 72 hours post-dose on Day 7'}, {'measure': 'Apparent Terminal Hepatic Half-life (t[H]½ ) of GZR', 'description': 't(H)1/2 is a measure of the time required for the maximum post-dose liver concentration of GZR to decrease by 50%.', 'timeFrame': '4, 8, 24, and 72 hours post-dose on Day 7'}]","[{'measure': 'Plasma AUC[0-24 hr] of GZR', 'description': 'AUC0-24hr is a measure of the mean concentration of drug in plasma after dosing to 24 hours post-dose.', 'timeFrame': 'Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours post-dose on Day 7'}, {'measure': 'Maximum Plasma Concentration (Cmax) of GZR', 'description': 'Cmax is a measure of the maximum plasma concentration post-dose.', 'timeFrame': 'Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours post-dose on Day 7'}, {'measure': 'Lowest Plasma Concentration (Ctrough) of GZR', 'description': 'Ctrough is a measure of drug concentration 24 hours post-dose.', 'timeFrame': 'Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours post-dose on Day 7'}, {'measure': 'Time to Maximum Plasma Concentration (Tmax) of GZR', 'description': 'Tmax is a measure of time to reach maximum post-dose plasma drug concentration.', 'timeFrame': 'Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours post-dose on Day 7'}, {'measure': 'Plasma t½ of GZR', 'description': 't1/2 is a measure of time for the maximum plasma concentration of GZR to decrease by 50%.', 'timeFrame': 'Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours post-dose on Day 7'}]",8,18 Years,65 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,4.0,ACTUAL,2025-09-01T16:18:17.170715,v2_robust,True,True,True,False,False,
NCT06834100,"Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug","Simple Blinded Multicenter Randomized Comparative Study to Assess Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE","polysaccharide conjugated vaccine for prevention of meningococcal infection of serogroups A, C, W, Y","['polysaccharide conjugated vaccine for prevention of meningococcal infection of serogroups A, C, W, Y']",1,INTERVENTIONAL,['PHASE3'],PHASE3,,Infections,"['Infections', 'Meningococcal']",[],RECRUITING,,2025-02-12,2025-12-31,"[{'measure': 'Primary immunogenicity parameter', 'description': 'Proportion (frequency) of subjects with seroconversion to meningococcal serogroups A, C, Y and W135 Seroconversion is defined as (for each serogroup it is determined separately)', 'timeFrame': 'Day 29 ± 1'}]","[{'measure': 'Secondary immunogenicity parameters', 'description': 'The proportion (frequency) of vaccinated subjects with seroprotection', 'timeFrame': 'Day 29 ± 1'}, {'measure': 'Secondary immunogenicity parameters', 'description': 'Geometric mean titers of SBA to antigens of meningococcal serogroups A, C, Y and W135', 'timeFrame': 'Day 29 ± 1'}]",3,3 Years,55 Years,ALL,True,NPO Petrovax,INDUSTRY,0,240.0,ESTIMATED,2025-09-01T16:18:17.170826,v2_robust,True,True,False,False,False,
NCT00057707,Effects of Modafinil on Brain Function in Patients With Schizophrenia,"Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Modafinil on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype",Modafinil,['Modafinil'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Schizophrenia,"['Schizophrenia', 'Schizoaffective Disorder']","['Catecholamines', 'Dopamine', 'fMRI', 'Working Memory', 'Clinical Trial', 'Stabilization', 'Inpatients', 'Placebo', 'Modafinil', 'Normal Volunteers', 'Schizophrenia', 'Schizoaffective Disorder', 'Healthy Volunteer', 'HV']",COMPLETED,,2003-03-26,2017-06-16,[{'measure': 'Genetic differences in working memory testing or fMRI activation'}],"[{'measure': 'Panss, Ham-A, Blood draws for drug levels and liver enzymes'}]",2,18 Years,50 Years,ALL,True,National Institute of Mental Health (NIMH),NIH,0,176.0,ACTUAL,2025-09-01T16:18:17.170925,v2_robust,True,True,True,False,False,
NCT01530607,"Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer","Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer",Standard cyclophosphamide,"['Standard cyclophosphamide', 'Goserelin (Zoladex)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],"['Early Stage Breast Cancer', 'Reduce Ovarian Failure Following Chemotherapy']",COMPLETED,,2009-11,2012-11,"[{'measure': 'The study is to compare the rate of premature ovarian failure at two years following standard adjuvant or neoadjuvant chemotherapy', 'timeFrame': 'Three years'}]",[],1,18 Years,50 Years,FEMALE,False,King Faisal Specialist Hospital & Research Center,OTHER,0,416.0,ACTUAL,2025-09-01T16:18:17.171087,v2_robust,True,True,True,False,False,
NCT04109092,"A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102","INtravesical Phase 1/1b Study of STING Agonist E7766 in NMIBC Including Subjects Unresponsive to BCG Therapy, INPUT-102",E7766,['E7766'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Urinary Bladder Neoplasms,['Urinary Bladder Neoplasms'],"['E7766', 'Non-Muscle Invasive Bladder Cancer', 'Intravesical administration', 'Ta or T1 Papillary Disease', 'Stimulator of Interferon Genes Agonist', 'Carcinoma in situ', 'BCG Unresponsive']",WITHDRAWN,"There was no enrolment of participants.Unscheduled Clinical Study Closure - Eisai Network Company Decision, November 12, 2020.",2020-02-13,2022-09-29,"[{'measure': 'Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs)', 'description': 'DLTs are any of the toxicities occurring during the 6 weeks of the Induction Cycle and assessed by the investigator as related to study drug. Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v.5.0).', 'timeFrame': 'Baseline up to 6 weeks of the Induction Cycle (Cycle length is equal to [=] 6 weeks)'}, {'measure': 'Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'Baseline up to 30 days after the last dose of study drug (approximately 42 months)'}, {'measure': 'Dose Expansion Part: Complete Response Rate (CRR) at 3 Months', 'timeFrame': 'Up to 3 months'}, {'measure': 'Dose Expansion Part: CRR at 6 Months', 'timeFrame': 'Up to 6 months'}, {'measure': 'Dose Expansion Part: CRR at 12 Months', 'timeFrame': 'Up to 12 months'}, {'measure': 'Dose Expansion Part: CRR at 18 Months', 'timeFrame': 'Up to 18 months'}, {'measure': 'Dose Expansion Part: CRR at 24 Months', 'timeFrame': 'Up to 24 months'}]","[{'measure': 'Dose Escalation Part: CRR at 3, 6, 12, 18 and 24 Months', 'timeFrame': 'At Months 3, 6, 12, 18, and 24'}, {'measure': 'DOCR', 'timeFrame': 'From the date of first documented CR until the first documentation of confirmed disease recurrence (approximately 42 months)'}, {'measure': 'Local Recurrence Free Rates', 'timeFrame': 'At Months 6, 12, 18, and 24'}, {'measure': 'Cmax: Maximum Observed Plasma Concentration for E7766', 'timeFrame': 'Dose Escalation: Induction Phase: Day 1: 0-24 hour post dose; Day 15: 0-8 hour post dose; Maintenance Phase: Cycle 1: Day :0- 8 hours post dose; Dose Expansion: Induction Phase: Day 1, Day 15: 0-8 hour post dose (Cycle length is 3 weeks)'}, {'measure': 'Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7766', 'timeFrame': 'Dose Escalation: Induction Phase: Day 1: 0-24 hour post dose; Day 15: 0-8 hour post dose; Maintenance Phase: Cycle 1: Day :0- 8 hours post dose; Dose Expansion: Induction Phase: Day 1, Day 15: 0-8 hour post dose (Cycle length is 3 weeks)'}, {'measure': 'AUC: Area Under the Plasma Concentration Versus Time Curve for E7766', 'timeFrame': 'Dose Escalation: Induction Phase: Day 1: 0-24 hour post dose; Day 15: 0-8 hour post dose; Maintenance Phase: Cycle 1: Day :0- 8 hours post dose; Dose Expansion: Induction Phase: Day 1, Day 15: 0-8 hour post dose (Cycle length is 3 weeks)'}]",13,18 Years,,ALL,False,Eisai Inc.,INDUSTRY,1,0.0,ACTUAL,2025-09-01T16:18:17.171316,v2_robust,True,True,False,True,True,"There was no enrolment of participants.Unscheduled Clinical Study Closure - Eisai Network Company Decision, November 12, 2020."
NCT00123292,Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion,"An Open-label, Ascending-dose, Clinical Trial of Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion",Microplasmin,['Microplasmin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Arterial Occlusive Diseases,['Arterial Occlusive Diseases'],"['arterial occlusion', 'thromboembolism', 'Acute Peripheral Arterial Occlusion']",TERMINATED,Sponsor's decision not to pursue development of uPLi for vascular conditions,2005-03,2009-11,"[{'measure': 'Complete clot-lysis (defined as >95% estimated clot volume reduction compared to baseline angiogram)', 'timeFrame': 'at 4 hours or less (if study drug administration is terminated prior to 4 hours).'}]","[{'measure': 'Proportion of subjects with clot-lysis (complete or partial, defined as any clot volume reduction on angiography)', 'timeFrame': 'At 4 hours or less (if study drug administration is terminated prior to 4 hours).'}]",2,18 Years,80 Years,ALL,False,ThromboGenics,INDUSTRY,0,19.0,ACTUAL,2025-09-01T16:18:17.171336,v2_robust,True,True,False,True,False,Sponsor's decision not to pursue development of uPLi for vascular conditions
NCT03344692,Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes,"Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes : a Randomized, Double-blind, Placebo-controlled, Cross-over Trial""",Alirocumab,['Alirocumab'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Type2 Diabetes,['Type2 Diabetes'],[],COMPLETED,,2019-02-12,2022-04-28,"[{'measure': 'Total area under the post-prandial triglycerides concentration-time curve from meal-time until 8h (AUC0-8h) after standardized high fat meal.', 'description': 'Fifteenth days after the fifth injection of treatment (thus 10 weeks after first injection of treatment), subjects will be reported to investigational site (after a 12 hours overnight fast). Subjects must consume the test meal within 15 min. Upon completion of the meal (T0), sequential postprandial measurements of triglycerides concentrations will be taken. Blood samples will be collected at T-15, every 30 min for the first two hours after meal consumption, thereafter in 60 min intervals from T120 until 240 min and thereafter in 120 min intervals from T240 until 480 min.', 'timeFrame': 'During 8 hours at week 10 after first treatment injection'}]","[{'measure': 'Effect of treatment with alirocumab versus placebo following a standardized high-fat meal on post-prandial lipid metabolism (plasma lipoproteins, apolipoproteins, ...)', 'description': 'Fifteenth days after the fifth injection of treatment (thus 10 weeks after first injection of treatment), subjects will be reported to investigational site (after a 12 hours overnight fast). Subjects must consume the test meal within 15 min. Upon completion of the meal (T0), sequential postprandial measurements of triglycerides concentrations will be taken. Bleed samples will be collected at T-15, every 30 min for the first two hours after meal consumption, thereafter in 60 min intervals from T120 until 240 min and thereafter in 120 min intervals from T240 until 480 min.', 'timeFrame': 'During 8 hours at week 10 after first treatment injection'}, {'measure': 'Effect of treatment with alirocumab versus placebo on fasting lipid metabolism following a standardized high fat meal, using the same biomarkers than those used in the post-prandial state, plus indirect markers of cholesterol absorption and synthesis', 'description': 'Fifteenth days after the fifth injection of treatment (thus 10 weeks after first injection of treatment), subjects will be reported to investigational site after a 12 hours overnight fast. Before ingestion of the high fat meal, blood sample will be removed to perform the analysis.', 'timeFrame': '10 weeks after treatment first injection'}, {'measure': 'Effect of treatment with alirocumab versus placebo on fasting and post-prandial and glucose homeostasis following a standardized high-fat meal', 'description': 'Fasting self-monitored blood glucose test will be obtained before starting the meal and every hour during 8 hours .', 'timeFrame': 'Before and during 8 hours after high fat meal at week 10 after first treatment injection'}]",4,18 Years,75 Years,MALE,False,Nantes University Hospital,OTHER,1,22.0,ACTUAL,2025-09-01T16:18:17.171425,v2_robust,True,True,True,False,False,
NCT03257592,Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease States,PET Imaging of Glial Activation in Psychotic Disease States,[11C]DPA-713,['[11C]DPA-713'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Schizophrenia,"['Schizophrenia', 'Bipolar Disorder']",[],TERMINATED,Lack of funding,2010-08,2018-04,"[{'measure': 'Sensitivity and Specificity of ([11C]DPA)-713 PET brain imaging in patients with recent onset schizophrenia and in patients with recent onset of mania', 'description': 'To determine regional brain uptake of this radioligand in patients with recent onset schizophrenia and in patients with recent onset of mania', 'timeFrame': 'within five years of onset of schizophrenia or within five years of first manic episode'}]","[{'measure': 'PET Imaging of microglial activation', 'description': 'To evaluate changes in activation of microglia in patients with acute schizophrenia and bipolar disorder relative to controls', 'timeFrame': '5 years'}]",2,18 Years,65 Years,ALL,True,Johns Hopkins University,OTHER,0,35.0,ACTUAL,2025-09-01T16:18:17.171459,v2_robust,True,True,False,True,False,Lack of funding
NCT06101992,Mesoglycan for Acute Hemorrhoidal Disease,Randomized Double-blind Controlled Clinical Trial: the Use of Mesoglycan vs Placebo in the Acute Phase of Hemorrhoidal Disease,Mesoglycan,"['MES', 'Mesoglycan']",2,INTERVENTIONAL,['NA'],,,Hemorrhoids,['Hemorrhoids'],[],NOT_YET_RECRUITING,,2024-01-01,2024-09-01,"[{'measure': 'Symptoms relief', 'description': 'According to the validated Hemorrhoidal Disease Symptom Score (from 0: no symptoms to 20: symptoms occurring every day), score reduction will be evaluated', 'timeFrame': '40 days'}]",[],1,18 Years,75 Years,ALL,False,Societa Italiana di Chirurgia ColoRettale,NETWORK,1,50.0,ESTIMATED,2025-09-01T16:18:17.171511,v2_robust,True,True,False,False,False,
NCT06134492,Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL,Effect of Acyclovir Therapy on the Outcome of Ventilated Patients With Lower Respiratory Tract Infection and Detection of Herpes Simplex Virus in Bronchoalveolar Lavage,Acyclovir,"['Acyclovir', 'Aciclovir']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Pneumonia, Viral","['Pneumonia, Viral', 'Ventilator Associated Pneumonia', 'Community-acquired Pneumonia', 'Herpes Simplex', 'Hospital-acquired Pneumonia']","['Pneumonia', 'Herpes Simplex', 'Mechanical Ventilation', 'Aciclovir']",RECRUITING,,2024-02-20,2026-12,"[{'measure': 'mortality (survival status)', 'description': 'survival status', 'timeFrame': 'day 30'}]","[{'measure': 'Ventilation-free days', 'description': 'days without mechanically ventilation via endotracheal tube, incl. tracheostoma', 'timeFrame': 'day 30'}, {'measure': 'Vasopressor-free days', 'description': 'days without continuous vasopressor administration \\> 1h/day', 'timeFrame': 'day 30'}, {'measure': 'Delta SOFA score (Sepsis-related Organ Failure Assessment Score)', 'description': 'Each of six organ systems receive a score ranging from 0 (normal) to 4 (most abnormal), with a minimum SOFA score of 0 and a maximum SOFA score of 24', 'timeFrame': 'Baseline - Day 10 or EOT if this event occurs earlier'}, {'measure': 'Delta SOFA sub-score kidney (Sepsis-related Organ Failure Assessment Score)', 'description': 'Sub-score for kidney function, the score ranges from 0 (normal) to 4 (most abnormal)', 'timeFrame': 'Baseline - Day 10 or EOT if this event occurs earlier'}, {'measure': 'Delta GFR value', 'description': 'GFR value', 'timeFrame': 'Baseline - Day 10 or EOT if this event occurs earlier'}, {'measure': 'Length of stay in ICU', 'description': 'days LOS in ICU', 'timeFrame': 'day 30'}, {'measure': 'Length of stay in Hospital', 'description': 'days LOS in hospital', 'timeFrame': 'day 30'}, {'measure': 'Cost of intervention', 'description': 'ICU and hospitalization days + acyclovir', 'timeFrame': 'up to day 90'}, {'measure': 'Days without delirium/coma', 'description': 'based on CAM-ICU / RASS', 'timeFrame': 'Until day 10 or until EOT if this event occurs earlier'}, {'measure': 'Microbiological cure (EOT)', 'description': 'Percent of participants with HSV eradication (PCR testing negative) in blood and respiratory tract', 'timeFrame': 'At day 10 or day of EOT if this event occurs earlier'}, {'measure': 'mortality (survival status)', 'description': 'survival status', 'timeFrame': '90 days'}, {'measure': 'mortality (survival status)', 'description': 'survival status', 'timeFrame': '180 days'}, {'measure': 'Quality of life (EQ-5D-5L)', 'description': 'EuroQuality of Life Five Dimensions (EQ-5D-5L), the descriptive system comprises five dimensions (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION), with five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems.', 'timeFrame': 'Measurement at day 10 or EOT if this event occurs earlier, day 30, day 90, and day 180'}, {'measure': 'Incidence SAEs', 'description': 'Incidence of serious adverse events', 'timeFrame': 'From time of randomization until day 10 or EOT if this event occurs earlier'}]",15,18 Years,,ALL,False,Jena University Hospital,OTHER,0,616.0,ESTIMATED,2025-09-01T16:18:17.171577,v2_robust,True,True,False,False,True,
NCT04254692,Optimizing Recovery in Abdominoplasty,Randomized Controlled Trial Evaluating Liposomal Bupivacaine Following Abdominoplasty,Liposomal bupivacaine,['Liposomal bupivacaine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Postoperative Pain,['Postoperative Pain'],"['abdominoplasty', 'enhanced recovery after surgery', 'Liposomal bupivacaine']",TERMINATED,division wide research suspension,2021-01-05,2021-01-21,"[{'measure': 'Opioid Use at 24 Hours', 'description': 'Amount of opioids used postoperatively, measured in morphine equivalents', 'timeFrame': '24 hours postoperatively'}]","[{'measure': 'Quality of Recovery-40 (QOR-40) Score', 'description': 'The QOR-40 is a 40 item survey about the quality of recovery with a total possible range of scores from 40 to 200 where the higher the score the higher quality the recovery.', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Pain Score Postoperative Day 1 (POD 1)', 'description': 'The pain survey is scored on a 0-10 scale where 0 is no pain and 10 is the worst possible pain.', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Pain Score 1 Week Postop', 'description': 'The pain survey is scored on a 0-10 scale where 0 is no pain and 10 is the worst possible pain.', 'timeFrame': '1 week postoperatively'}, {'measure': 'Opioid Use at 1 Week', 'description': 'total opioid used, measure in morphine equivalents', 'timeFrame': '1 week postoperatively'}, {'measure': 'Antiemetic Use POD 1', 'description': 'total antiemetic used', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Antiemetic Use 1 Week', 'description': 'total antiemetic used', 'timeFrame': '1 week postoperatively'}, {'measure': 'Number of Participants With Postoperative Nausea and Vomiting', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Number of Participants With Postoperative Complications', 'timeFrame': '1 week postoperatively'}]",9,18 Years,,ALL,True,"University of Wisconsin, Madison",OTHER,0,2.0,ACTUAL,2025-09-01T16:18:17.171651,v2_robust,True,True,False,True,False,division wide research suspension
NCT00006392,S0000 Selenium and Vitamin E in Preventing Prostate Cancer,Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer,Vitamin E,"['Selenium', 'Vitamin E', 'L-selenomethionine', 'alpha tocopherol']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Prostate Cancer,['Prostate Cancer'],['prostate cancer'],COMPLETED,,2001-07,2012-09,"[{'measure': 'Number of Participants With Prostate Cancer', 'description': 'Participants are seen at the study site every six month for an update of medical events. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation.', 'timeFrame': 'Every six months for 7 to 12 years depending on when the participant was randomized.'}]","[{'measure': 'Number of Participants With Lung Cancer', 'description': 'Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.', 'timeFrame': 'Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.'}, {'measure': 'Number of Participants With Colorectal Cancer', 'description': 'Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.', 'timeFrame': 'Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.'}, {'measure': 'Number of Participants With Any Diagnosis of Cancer', 'description': 'Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized.', 'timeFrame': 'Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.'}, {'measure': 'Prostate Cancer Free Survival; Lung Cancer-free Survival, Colorectal Cancer-free Survival, Cancer-free Survival, Overall Survival', 'description': 'Participants are seen at the study site every six month for an update of medical events. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation. Other cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. Follow-up was planned for seven to 12 years depending on when the participant was randomized.', 'timeFrame': 'Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.'}, {'measure': 'Number of Participants With Serious Cardiovascular Events', 'description': 'Participants are seen at the study site every six month for an update of medical events. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Cardiovascular events are based on self-report and are not confirmed. Follow-up was planned for seven to 12 years depending on when the participant was randomized.', 'timeFrame': 'Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.'}]",6,50 Years,120 Years,MALE,True,SWOG Cancer Research Network,NETWORK,4,35533.0,ACTUAL,2025-09-01T16:18:17.171673,v2_robust,True,True,True,False,False,
NCT05819892,"Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer","Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer",Paclitaxel,"['Paclitaxel', 'Dostarlimab', 'Platinol®-AQ', 'Paraplatin®', 'Carboplatin', 'Cisplatin', 'Taxol', 'Platinol®', 'CDDP']",9,INTERVENTIONAL,['PHASE1'],PHASE1,,Endometrial Cancer,['Endometrial Cancer'],[],RECRUITING,,2023-07-17,2028-03-01,"[{'measure': 'Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0', 'timeFrame': 'through study completion; an average of 1 year'}]",[],1,18 Years,,FEMALE,False,M.D. Anderson Cancer Center,OTHER,1,21.0,ESTIMATED,2025-09-01T16:18:17.171714,v2_robust,True,True,False,False,True,
NCT01288092,BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer,"A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer, With or Without PI3K Activated Pathway",BEZ235,['BEZ235'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Breast Cancer,['Metastatic Breast Cancer'],"['Metastatic breast cancer', 'HER2 negative', 'HR positive', 'PI3K pathway', 'no more than 2 prior lines of chemotherapy', 'Metastatic Breast Cancer(MBC)']",WITHDRAWN,,2012-03,,"[{'measure': 'Progression-free survival rate after 16 weeks of treatment', 'timeFrame': '16 weeks after the first BEZ235 administration'}]","[{'measure': 'determine the efficacy of BEZ235 (objective response rate)', 'timeFrame': 'about 6 months'}, {'measure': 'evaluate the clinical benefit rate of BEZ235', 'timeFrame': 'about 6 months'}, {'measure': 'evaluate the time to response', 'timeFrame': 'about 6 months'}, {'measure': 'evaluate the Progression Free Survival Rate at 16-week & 24-week using the Kaplan-Meier method', 'timeFrame': '16-week & 24-week after the first BEZ235 administration'}, {'measure': 'evaluate safety of BEZ235 (frequency and severity of Adverse Events, abnormal laboratory values, other safety data as appropriate)', 'timeFrame': '30-35 days after treatment discontinuation'}]",6,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:17.171769,v2_robust,True,True,False,True,True,
NCT06166992,A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body,Investigation of Pharmacokinetics and Absolute Oral Bioavailability of BI 1291583 Administered as an Oral Dose With an Intravenous Microtracer Dose of [14C]-BI 1291583 in Healthy Male Volunteers,BI 1291583,"['BI 1291583', 'Verducatib', '[14C]-BI 1291583']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2023-12-12,2024-02-07,"[{'measure': 'Area under the concentration-time curve of the analyte over the time interval from 0 extrapolated to infinity (AUC0-∞)', 'timeFrame': 'Up to 10 days'}]","[{'measure': 'Maximum measured concentration of the analyte in plasma (Cmax)', 'timeFrame': 'Up to 10 days'}, {'measure': 'Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable time point (AUC0-tz)', 'timeFrame': 'Up to 10 days'}]",3,18 Years,55 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,14.0,ACTUAL,2025-09-01T16:18:17.171785,v2_robust,True,True,True,False,False,
NCT01012492,Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT,Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant,Abatacept,"['orencia', 'Abatacept']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,AML,"['AML', 'ALL', 'Undifferentiated Leukemia', 'Biphenotypic Leukemia', 'Refractory Anemia', 'Refractory Anemia With Ringed Sideroblasts', 'Refractory Cytopenia With Multilineage Dysplasia', 'Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts', 'Refractory Anemia With Excess Blasts-1 (5-10% Blasts)', 'Refractory Anemia With Excess Blasts-2 (10-20% Blasts)', 'Myelodysplastic Syndrome, Unclassified', 'MDS Associated With Isolated Del (5q)']","['cancer', 'leukemia', 'transplant', 'bone marrow']",COMPLETED,,2009-11,2013-01,"[{'measure': 'Percentage of Participants With Grade III-IV Acute GVHD by Day 100.', 'description': 'Grade III-IV Acute GVHD by Day 100. The incidence of Gr III-IV acute GVHD was measured by the modified Glucksburg scale.', 'timeFrame': 'Day 100 post-transplant'}]","[{'measure': 'Percentage of Participants With Grades III-IV Acute GVHD at 2 Years', 'description': 'The rates of Grades III-IV acute GVHD were measured at 2 years according to standard Glucksberg criteria, which was 10%.', 'timeFrame': '2 years after transplant'}, {'measure': 'Hematologic and Immunologic Reconstitution', 'description': 'Flow cytometric analysis of CD4 t-cell t-cell reconstitution was performed at day +100 post-transplant.', 'timeFrame': 'Day +100 post-transplant'}, {'measure': 'Protective Immunity', 'description': 'Percent of CMV virus binding CD8+ t-cells at day +365 post-transplant', 'timeFrame': 'Day +365 post-transplant'}]",4,12 Years,,ALL,False,Boston Children's Hospital,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:17.171949,v2_robust,True,True,True,False,False,
NCT06979336,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)","A Phase IIb, Multicenter, Double-blind, Placebo-controlled Induction Study With an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients With Moderately to Severely Active Ulcerative Colitis",RO7837195,"['RO7837195', 'RO7837195 Matched Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Ulcerative Colitis,['Ulcerative Colitis'],[],RECRUITING,,2025-09-26,2028-10-31,"[{'measure': 'Percentage of Participants With Clinical Remission at Week 12', 'description': 'Clinical remission is defined as the Modified Mayo Score (mMS) of ≤ 2, including stool frequency subscore of ≤ 1, rectal bleeding subscore of 0, and endoscopy subscore of ≤ 1.', 'timeFrame': 'At Week 12'}]","[{'measure': 'Percentage of Participants With Clinical Response at Week 12', 'description': 'Clinical response is defined as decrease from baseline in the mMS by ≥2 and ≥ 30% reduction from baseline, with either a decrease of ≥1 in the rectal bleeding subscore or an absolute rectal bleeding subscore of ≤1.', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants With Endoscopic Improvement at Week 12', 'description': 'Endoscopic improvement is defined as a Mayo endoscopy subscore of ≤ 1.', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants With Endoscopic Remission at Week 12', 'description': 'Endoscopic remission is defined as a Mayo endoscopy subscore of 0.', 'timeFrame': 'At Week 12'}, {'measure': 'Number of Participants With Adverse Events (AEs)', 'timeFrame': 'Up to Weeks 65'}, {'measure': 'Serum Concentration of RO7837195', 'timeFrame': 'Up to Weeks 65'}, {'measure': 'Percentage of Participants With Anti-drug Antibodies to RO7837195', 'timeFrame': 'Up to Weeks 65'}]",7,18 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,0,224.0,ESTIMATED,2025-09-01T16:18:17.172014,v2_robust,True,True,False,False,True,
NCT01926236,Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers,"A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy.",L-folinic acid,"['Oxaliplatin', 'Folinic acid', 'Eloxatin', '5 FU', 'Fluorouracil', 'L-folinic acid']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Biliary Tract Cancer,"['Biliary Tract Cancer', 'Gallbladder Cancer', 'Cholangiocarcinoma', 'Ampullary Cancer']",[],COMPLETED,,2014-02,2019-01,"[{'measure': 'Overall survival', 'timeFrame': 'Evaluated by monthly follow-up until 12 months after last patient included'}]","[{'measure': 'Progression-free survival', 'description': 'Clinical progression assessed monthly, radiological progression assessed to RECIST criteria every 12 weeks for patients in the chemotherapy arm.', 'timeFrame': 'Evaluated by monthly follow-up until 12 months after last patient included'}, {'measure': 'Response rate (chemotherapy arm only)', 'timeFrame': 'After 12 weeks of treatment'}, {'measure': 'Toxicity (frequency of adverse events and serious adverse events)', 'description': 'Events will be classified according to CTCAE V4.03', 'timeFrame': 'Evaluated monthly until 12 months after last patient included'}, {'measure': 'Quality of life', 'description': 'Assessed from patient completed questionnaire data: QLQ-C30 and QoL BiL', 'timeFrame': 'Evaluated every 3 months until 12 months after last patient included'}, {'measure': 'Costs of health and social care', 'timeFrame': 'Evaluated every 3 months until 12 months after last patient included'}, {'measure': 'Health status (Euroqol)', 'timeFrame': 'Evaluated every 3 months until 12 months after last patient included'}, {'measure': 'Quality adjusted life years (QALYs)', 'description': 'Estimated from Euroqol and survival using published utility tariffs', 'timeFrame': 'Evaluated every 3 months until 12 months after last patient included'}]",8,18 Years,,ALL,False,The Christie NHS Foundation Trust,OTHER,1,162.0,ACTUAL,2025-09-01T16:18:17.172046,v2_robust,True,True,True,False,True,
NCT00786136,Rosuvastatin Prevent Contrast Induced Acute Kidney Injury in Patients With Diabetes,Multicenter Randomized Controlled Study of Rosuvastatin for Prevention of Contrast Induced Acute Kidney Injury in Patients With Diabetes and Slight to Moderate Renal Insufficient,rosuvastatin,['rosuvastatin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetes Mellitus,"['Diabetes Mellitus', 'Chronic Kidney Disease']","['diabetes mellitus', 'chronic kidney disease', 'contrast induced acute kidney injury', 'angiography']",COMPLETED,,2008-12,2011-11,"[{'measure': 'An absolute increase in SCr >=0.5mg/dL（>=44.2μmmol/L）or a >= 25% increase in SCr from baseline to 72h after the procedure', 'timeFrame': '72 h'}]","[{'measure': 'The composite of hospitalization for aggravated renal function, acute renal failure, dialysis or hemofiltration, aggravated at least 1 class of heart function, acute left ventricular failure or death from all causes.', 'timeFrame': '30 d'}]",2,18 Years,75 Years,ALL,False,Shenyang Northern Hospital,OTHER,0,2998.0,ACTUAL,2025-09-01T16:18:17.172165,v2_robust,True,True,True,False,False,
NCT04905836,Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress,Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells,Placebo,['Placebo'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Covid19,['Covid19'],['covid-19'],UNKNOWN,,2021-11-16,2023-03,"[{'measure': 'All-cause mortality rate at Day 28', 'description': 'All-cause mortality rate at Day 28', 'timeFrame': 'Baseline through Day 28'}, {'measure': 'Incidence of all adverse events (AEs) (safety)', 'description': 'Safety as assessed by incidence of AEs by type, frequency, severity, and causality using the Common Terminology Criteria for Adverse Events, Version 5 (CTCAEv5)', 'timeFrame': 'Baseline through study completion at Day 90'}, {'measure': 'Incidence of treatment-emergent adverse events (safety)', 'description': 'Safety as assessed by incidence of treatment-emergent AEs (TEAEs) by type, frequency, severity, and causality using CTCAEv5 criteria', 'timeFrame': 'Baseline through study completion at Day 90'}, {'measure': 'Incidence of severe adverse events (safety)', 'description': 'Safety as assessed by incidence of serious AEs (SAEs) by type, frequency, severity, and causality using CTCAEv5 criteria', 'timeFrame': 'Baseline through study completion at Day 90'}, {'measure': 'Incidence of infusion-related adverse events (safety)', 'description': 'Safety as assessed by incidence of Infusion-related AEs (IrAEs) by type, frequency, severity, and causality using CTCAEv5 criteria over 4 hours', 'timeFrame': 'Baseline to Hour 4'}]","[{'measure': 'All-cause mortality rate at Day 60 and 90', 'description': 'All-cause mortality rate at Day 60 and 90', 'timeFrame': 'Baseline through Day 60 and Day 90'}, {'measure': 'Number of ventilator-free days through Day 28', 'description': 'Number of ventilator-free days through Day 28', 'timeFrame': 'Baseline through Day 28'}, {'measure': 'Number of ICU days through Day 28', 'description': 'Number of ICU days through day 28', 'timeFrame': 'Baseline through Day 28'}, {'measure': 'Change in clinical status', 'description': 'Change in clinical status as assessed using the WHO Clinical Progression Scale (0-10 scale, where lower score means a better outcome) at Day 28', 'timeFrame': 'Baseline to Day 28'}, {'measure': 'Change in oxygenation', 'description': 'Change in oxygenation as assessed using PaO2:FiO2 ratio', 'timeFrame': 'Baseline to Day 14 Day 28, and Day 60'}]",10,18 Years,,ALL,False,"Sorrento Therapeutics, Inc.",INDUSTRY,0,60.0,ESTIMATED,2025-09-01T16:18:17.172187,v2_robust,True,True,False,False,True,
NCT00591136,Phase I Study of Indibulin in Patients With Solid Tumors,Dose-finding and Pharmacokinetic Trial of Orally Administered D-24851 to Patients With Solid Tumors,indibulin,"['ZIO-301', 'indibulin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumors,['Solid Tumors'],[],COMPLETED,,2003-04,2008-09,"[{'measure': 'toxicities', 'timeFrame': '4 months'}]","[{'measure': 'pharmacokinetics', 'timeFrame': '4 months'}]",2,18 Years,,ALL,False,Alaunos Therapeutics,INDUSTRY,0,47.0,ACTUAL,2025-09-01T16:18:17.172227,v2_robust,True,True,True,False,False,
NCT04742036,Capivasertib China PK Study,"A Phase I Open-label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Capivasertib Monotherapy and in Combination With Paclitaxel in Chinese Patients With Advanced Solid Tumours.",Capivasertib,"['AZD5363', 'Paclitaxel', 'Capivasertib']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumours,['Advanced Solid Tumours'],"['Pharmacokinetics', 'Safety', 'Tolerability', 'Capivasertib', 'Chinese']",COMPLETED,,2021-02-22,2022-07-29,"[{'measure': 'Area under the plasma concentration-time curve from time zero to 12 hours post-dose (AUC 0-12) of Capivasertib', 'description': 'AUC0-12 is defined as area under the curve from 0 to 12 hours.', 'timeFrame': 'first dose up to approximately 6 months'}, {'measure': 'Maximum plasma concentration (Cmax) of Capivasertib', 'description': 'Cmax is defined as maximum plasma concentration', 'timeFrame': 'first dose up to approximately 6 months'}, {'measure': 'terminal half-life (t1/2) of Capivasertib', 'description': 't1/2 is defined as terminal half-life', 'timeFrame': 'first dose up to approximately 6 months'}, {'measure': 'Accumulation ratio (Rac) of Capivasertib', 'description': 'Rac is defined as accumulation ratio', 'timeFrame': 'first dose up to approximately 6 months'}]","[{'measure': 'Safety and tolerability of drugs by assessment of AEs/SAEs', 'description': 'Graded according to the National Cancer Institute (NCI CTCAE V5.0)', 'timeFrame': 'From time of signature of the ICF, through study completion, up to 17 months, and including the 30-day follow-up period after discontinuation of study drug'}]",5,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:17.172329,v2_robust,True,True,True,False,True,
NCT00765336,A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.,"A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Minocycline Extended-Release Tablets on Spermatogenesis in Human Males",minocycline extended release,"['Placebo', 'minocycline extended release']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Human Volunteer,['Human Volunteer'],['Spermatogenesis in Healthy Males'],COMPLETED,,2006-11,2009-01,"[{'measure': 'Mean Percent Change From Screening in Sperm Concentration.', 'timeFrame': 'Baseline and 12 Weeks'}]",[],1,18 Years,,MALE,True,Medicis Pharmaceutical Corporation,INDUSTRY,0,180.0,ACTUAL,2025-09-01T16:18:17.172379,v2_robust,True,True,True,False,False,
NCT02629536,Effect on Migraine Frequency of Combined Anti-oxidant Therapy: The MIGRANT Study.,"Effect on Migraine Frequency of Combined Anti-oxidant Therapy: N-acetylcysteine, Vitamin E and Vitamin C (NEC): The MIGRANT Study","N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet","['N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet', 'NEC']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Migraine, Headaches","['Migraine, Headaches']",[],UNKNOWN,,2016-03,2017-03,"[{'measure': 'Difference in mean number of migraine episodes per month between baseline and final four weeks of the study, for both study groups.', 'description': 'Difference in mean number of migraine episodes per month between baseline and final four weeks of the study, for both study groups.', 'timeFrame': '16 weeks'}]","[{'measure': 'Difference in mean migraine duration (hours) per month between baseline and final four weeks of the study, for both study groups', 'description': 'Difference in mean migraine duration (hours) per month between baseline and final four weeks of the study, for both study groups', 'timeFrame': '16 weeks'}, {'measure': 'Difference in mean migraine severity score per month (categorical scale; 0 = nil, 1 = mild, 2 = moderate, 3 = severe) between baseline and final four weeks of the study, for both study groups.', 'description': 'Difference in mean migraine severity score per month (categorical scale; 0 = nil, 1 = mild, 2 = moderate, 3 = severe) between baseline and final four weeks of the study, for both study groups.', 'timeFrame': '16 weeks'}, {'measure': 'Difference in mean MIDAS per month between baseline and final four weeks of the study, for both study groups.', 'description': 'Migraine Disability Assessment Score (MIDAS).', 'timeFrame': '16 weeks'}, {'measure': 'Difference in mean MSQ score per month between baseline and final four weeks of the study, for both study groups. Migraine Specific Quality of Life Questionnaire (MSQ, Version 2.1) score.', 'description': 'Difference in mean MSQ score per month between baseline and final four weeks of the study, for both study groups. Migraine Specific Quality of Life Questionnaire (MSQ, Version 2.1) score.', 'timeFrame': '16 weeks'}, {'measure': 'Difference in mean HRQOL score per month between baseline and final four weeks of the study, for both study groups.Health Related Quality of Life (HRQOL) score', 'description': 'Difference in mean HRQOL score per month between baseline and final four weeks of the study, for both study groups.Health Related Quality of Life (HRQOL) score', 'timeFrame': '16 weeks'}, {'measure': 'Number of treatment adverse events per month Number and type of treatment-related adverse effects per month. Number and type of treatment-related adverse effect', 'description': 'Number of treatment adverse events per month', 'timeFrame': '16 weeks'}, {'measure': 'Difference in mean number of migraine days per month between baseline and final four weeks of the study, for both study groups.', 'description': 'Difference in mean number of migraine days per month between baseline and final four weeks of the study, for both study groups.', 'timeFrame': '16 Weeks'}, {'measure': 'Responder rate: Percentage of subjects reporting ≥ 30% reduction in migraine episodes per month between baseline and final four weeks of the study, for both study groups', 'description': 'Responder rate: Percentage of subjects reporting ≥ 30% reduction in migraine episodes per month between baseline and final four weeks of the study, for both study groups', 'timeFrame': '16 weeks'}]",9,18 Years,65 Years,ALL,True,University of Notre Dame Australia,OTHER,0,90.0,ESTIMATED,2025-09-01T16:18:17.172387,v2_robust,True,True,False,False,True,
NCT00660036,"Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia","Phase I/II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (UPCI 07-154)",Gemtuzumab ozogamicin,"['Etoposide', 'Novantrone®', 'Gemtuzumab ozogamicin', 'ToposarTM', 'Mitoxantrone', 'Mylotarg®']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],"['Acute myeloid leukemia', 'Refractory', 'Relapsed', 'Second line', 'Gemtuzumab ozogamicin', 'Mitoxantrone', 'Etoposide', 'Phase I', 'Phase II']",TERMINATED,due to new safety information,2008-09,2011-04,"[{'measure': 'To evaluate the toxicity and response rate of the combination therapy of mitoxantrone, etoposide and gemtuzumab ozogamicin as second line therapy in patients with acute myeloid leukemia (AML).', 'timeFrame': 'Bone marrow biopsy and aspiration 14 days after gemtuzumab ozogamicin administration, to evaluate response to the study drug regimen.'}]","[{'measure': 'To assess the overall survival in patients with AML treated with the combination of mitoxantrone, etoposide and gemtuzumab ozogamicin.', 'timeFrame': 'Indefinite; subjects are followed for survival.'}]",2,18 Years,70 Years,ALL,False,University of Pittsburgh,OTHER,0,5.0,ACTUAL,2025-09-01T16:18:17.172513,v2_robust,True,True,False,True,False,due to new safety information
NCT02595736,A Study of LY3200327 in Healthy Participants,"A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3200327 in Healthy Subjects",Placebo (SC),"['Placebo (SC)', 'Placebo (IV)', 'LY3200327 (IV)', 'LY3200327 (SC)']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2015-11,2016-08,"[{'measure': 'Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration', 'timeFrame': 'Baseline to study completion (approximately 12 weeks)'}]","[{'measure': 'Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3200327', 'timeFrame': 'Pre-dose up to 84 days post dose'}, {'measure': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3200327', 'timeFrame': 'Pre-dose up to 84 days post dose'}]",3,18 Years,65 Years,ALL,True,Eli Lilly and Company,INDUSTRY,0,52.0,ACTUAL,2025-09-01T16:18:17.172623,v2_robust,True,True,True,False,True,
NCT06917911,"Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, ""7+3"") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)",Phase II Study of Cytarabine + Daunorubicin (7 + 3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7 + 3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Substudy,Cytarabine,"['hP67.6-Calicheamicin', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', 'Aracytine', 'U 19920', 'Alexan', 'RP-13057', 'GDC-0199', 'ARA-cell', 'Gemtuzumab Ozogamicin', 'Venclyxto', 'ABT-0199', '.beta.-Cytosine arabinoside', 'Daunomycin Hydrochloride', 'Daunorubicin.HCl', 'Mylotarg', '1-.beta.-D-Arabinofuranosylcytosine', 'Cerubidin', 'WR-28453', 'Erpalfa', 'Venclexta', 'Cytarbel', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', 'FI-6339', 'Cytosar', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', 'Rubilem', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', 'CHX-3311', 'Cloridrato de Daunorubicina', 'ABT-199', 'ABT199', 'RG7601', 'Daunorubicin Hydrochloride', 'Udicil', 'Venetoclax', 'Ara-C', 'Cytosine Arabinoside', 'gemtuzumab', 'Aracytidine', 'Ondena', 'Cytosine-beta-arabinoside', 'Rubidomycin Hydrochloride', 'WAY-CMA-676', 'Cytosine-.beta.-arabinoside', 'Beta-Cytosine Arabinoside', 'Cytarabinum', 'U-19920', 'GDC0199', 'Arabinofuranosylcytosine', 'Aracytin', 'Cerubidine', 'Daunoblastin', 'Starasid', 'GDC 0199', 'Daunoblastine', 'Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody', '1.beta.-D-Arabinofuranosylcytosine', 'CDP-771', 'Daunoblastina', 'Daunorubicini Hydrochloridum', 'CMA-676', 'Cytarabine', 'Arabinosylcytosine', 'Tarabine PFS', '1-Beta-D-arabinofuranosylcytosine', 'ABT 199', 'Arabine', 'Daunomycin, hydrochloride']",68,INTERVENTIONAL,['PHASE2'],PHASE2,,Core Binding Factor Acute Myeloid Leukemia,['Core Binding Factor Acute Myeloid Leukemia'],[],NOT_YET_RECRUITING,,2025-11-20,2028-07-20,"[{'measure': 'Complete remission without measurable residual disease (CRMRD-)', 'description': 'MRD will be evaluated by Molecular Diagnostics Network flow cytometry and will be defined at a threshold of \\< 10\\^-3.', 'timeFrame': 'At end of induction (Up to 28 days)'}]","[{'measure': 'Rate of complete remission (CR)', 'description': ""Defined as the number of evaluable patients achieving a response of CR per European Leukemia Network (ELN) 2022 criteria at the end of treatment divided by the total number of evaluable patients. Rates of response will be compared between treatment arms using a chi-square test (or Fisher's exact test as needed). Point estimates will be generated for CR rate within each arm along with 95% confidence intervals using the Clopper-Pearson method."", 'timeFrame': 'At the end of treatment (Up to 28 days)'}, {'measure': 'Rate of composite CR', 'description': ""Defined as the number of evaluable patients achieving a response of CR or complete remission with incomplete hematologic recovery (CRi) or complete remission with partial hematologic recovery (CRh) per ELN 2022 criteria at the end of treatment divided by the total number of evaluable patients. Rates of response will be compared between treatment arms using a chi-square test (or Fisher's exact test as needed). Point estimates will be generated for CR rate within each arm along with 95% confidence intervals using the Clopper-Pearson method."", 'timeFrame': 'At the end of treatment (Up to 28 days)'}, {'measure': 'Overall survival (OS)', 'description': 'The distribution of OS will be estimated using method of Kaplan-Meier. The median OS and 95% confidence interval will be reported.', 'timeFrame': 'From registration until death due to any cause, up to 5 years'}, {'measure': 'Event free survival (EVS)', 'description': 'Induction failure is defined as not achieving either CR, CRh or CRi by after induction therapy. The distribution of EFS will be estimated using method of Kaplan-Meier, and compared using log-rank tests. The median EFS and the corresponding 95% confidence interval will be reported.', 'timeFrame': 'From randomization to induction failure, hematologic relapse from CR/CRh/CRi or death from any cause, whichever occurs first, up to 5 years'}, {'measure': 'Cumulative incidence of relapse (CIR)', 'description': 'The distribution of CIR will be estimated using Fine-Gray model and reported via hazard ratios and 95% confidence interval with p values.', 'timeFrame': 'From the date of achievement of a remission until the date of hematologic relapse, up to 5 years'}, {'measure': 'Cumulative incidence of death (CID)', 'description': 'The distribution of CID will be estimated using Fine-Gray model and reported via hazard ratios and 95% confidence interval with p values.', 'timeFrame': 'From the date of achievement of a remission to death without prior relapse, up to 5 years'}, {'measure': 'Rate of early death at 30 days (ED-30)', 'description': ""ED-30 is defined as the total number of patients who died on or before day 30 from randomization divided by the total number of evaluable patients. Rate of early death at day 30 will be compared between treatment arms using a chi-square test (or Fisher's exact test as needed). Point estimates will be generated for ED-30 rate within each arm along with 95% confidence intervals using the Clopper-Pearson method."", 'timeFrame': 'At 30 days'}, {'measure': 'Rate of early death at 60 days (ED-60)', 'description': ""ED-60 is defined as the total number of patients who died on or before day 60 from randomization divided by the total number of evaluable patients. Rate of early death at day 60 will be compared between treatment arms using a chi-square test (or Fisher's exact test as needed). Point estimates will be generated for ED-60 rate within each arm along with 95% confidence intervals using the Clopper-Pearson method."", 'timeFrame': 'At 60 days'}, {'measure': 'Incidence of adverse events', 'description': ""As per national Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. The incidence of severe (grade 3+) adverse events or toxicities will be described for each treatment arm and will also be compared between the arms. Fisher's exact tests will be used to quantitatively compare the incidence of severe as well as specific toxicities of interest between the treatment arms and we will graphically assess differences in maximum grades observed for toxicities between the arms."", 'timeFrame': 'Up to 5 years'}, {'measure': 'Evaluate mutant RAS and mutant KIT as predictive biomarkers for CRMRD- rate', 'description': 'In cohort 1, subgroup analysis will be conducted to evaluate the treatment effect among RAS mutated patients using Kaplan Meier methods and log-rank tests; similar subgroup analysis will be done among KIT mutated patients.', 'timeFrame': 'Up to 5 years'}]",11,18 Years,59 Years,ALL,False,National Cancer Institute (NCI),NIH,0,162.0,ESTIMATED,2025-09-01T16:18:17.172763,v2_robust,True,True,False,False,True,
NCT03514511,Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis,"Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis",LEO 138559,"['LEO 138559 placebo', 'LEO 138559']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Atopic Dermatitis,['Atopic Dermatitis'],[],COMPLETED,,2018-05-07,2021-03-02,"[{'measure': 'Safety of LEO 138559 - numbers of subjects with adverse events', 'timeFrame': 'Day 1 to Day 120'}, {'measure': 'Safety of LEO 138559 - number of adverse events', 'timeFrame': 'Day 1 to Day 120'}, {'measure': 'Tolerability of LEO 138559 - number of local site reactions', 'timeFrame': 'Day 1 to Day 120'}]",[],3,18 Years,55 Years,ALL,True,LEO Pharma,INDUSTRY,0,47.0,ACTUAL,2025-09-01T16:18:17.172847,v2_robust,True,True,True,False,True,
NCT06717711,Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers,Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers,PDE5 inhibitor (tadalafil),['PDE5 inhibitor (tadalafil)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Prostate Carcinoma,"['Prostate Carcinoma', 'Erectile Function', 'Genito Urinary Cancer']","['prostate cancer', 'erectile function', 'rehabilitation', 'genitourinary cancers']",RECRUITING,,2024-08-31,2026-08-31,"[{'measure': 'Erectile Function', 'description': 'To investigate the impact of LiESWT in combination with early PDE5i administration versus early PDE5i alone on the penile rehabilitation of erectile dysfunction (ED) after RARP', 'timeFrame': 'From enrollment to 1 year after treatment'}]","[{'measure': 'Urinary Continence', 'description': 'To evaluate the impact of LiESWT on continence status.', 'timeFrame': 'From enrollment to 1 year after treatment'}, {'measure': 'Adverse effects', 'description': 'To report any adverse effects and classify them according to the Clavien Dindo classification', 'timeFrame': 'From enrollment to 1 year after treatment'}, {'measure': 'Health Related Quality of Life', 'description': 'To compare health-related quality of life (HRQoL) outcomes at 3-, 6- and 12-months (mo) follow-up post-surgery', 'timeFrame': 'From enrollment to 1 year after treatment'}]",4,18 Years,75 Years,MALE,False,Regina Elena Cancer Institute,OTHER,0,158.0,ESTIMATED,2025-09-01T16:18:17.172871,v2_robust,True,True,False,False,True,
NCT02802111,Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults,Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison With Levalbuterol in Healthy Adult Volunteers,Albuterol,"['Albuterol', 'Levalbuterol']",2,INTERVENTIONAL,['NA'],,,Oxygen Consumption,['Oxygen Consumption'],"['Beta Agonists', 'Asthma', 'Albuterol', 'Levalbuterol']",COMPLETED,,2015-06,2017-09,"[{'measure': 'Oxygen Consumption', 'description': 'Oxygen consumption will be measured following for up to 60 minutes beta agonist aerosol', 'timeFrame': '0 to 60 minutes'}]","[{'measure': 'Heart Rate', 'description': 'Vital signs including heart rate will be measured for up to 60 minutes following beta agonist', 'timeFrame': '0 to 60 minutes'}]",2,18 Years,60 Years,ALL,True,Children's Hospital Los Angeles,OTHER,0,24.0,ACTUAL,2025-09-01T16:18:17.172905,v2_robust,True,True,True,False,False,
NCT01623271,Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise),Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise),Gabapentin,"['Gabapentin', 'Gralise']",2,INTERVENTIONAL,['NA'],,,Complex Regional Pain Syndrome I (CRPS I),['Complex Regional Pain Syndrome I (CRPS I)'],['CRPS I'],TERMINATED,Due to limited population of research participants.,2013-05,2014-06,"[{'measure': 'Visual Analog Scale (VAS) at Visit 3', 'description': 'Subjects rated their pain using the VAS at visit 3, which was the last day of their maintenance phase. After this visit, subjects begin to taper the gralise. The VAS is subject reported on a scale of 0-10 with 0 being no pain and 10 being the worst pain they can imagine. Results reported are an average of the 3 subjects who completed visit 3.', 'timeFrame': 'At visit 3'}]",[],1,18 Years,80 Years,ALL,False,Massachusetts General Hospital,OTHER,0,5.0,ACTUAL,2025-09-01T16:18:17.173100,v2_robust,True,True,False,True,False,Due to limited population of research participants.
NCT02880371,A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,"A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors",ARRY-382,"['ARRY-382', 'Pembrolizumab']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],"['Advanced Solid Tumors', 'Pembrolizumab', 'ARRY-382', 'CSF-1R', 'CSF1R', 'cfms']",TERMINATED,Study was halted prematurely due to insufficient efficacy. Not due to safety reasons.,2016-09-01,2019-10-24,"[{'measure': 'Phase 1b, Part A: Number of Participants With Dose-Limiting Toxicities (DLT)', 'description': 'DLT: adverse event (AE) or abnormal laboratory value not clearly attributable to an extraneous cause, such as disease progression, intercurrent illness, or concomitant medications occurring during 21 days of Cycle 1, met 1 of the criteria A) nonhematologic AEs: recurring grade 2 pneumonitis, grade 3 events (irAE, QTcF prolongation, rash; other grade 3/4 except alopecia, nausea, diarrhea, vomiting, tumor flare, pseudoprogression, endocrinopathy); B) hematology AEs/laboratory abnormalities: grade 4 events except lymphopenia, neutropenia, electrolyte imbalances or abnormalities, grade 3 thrombocytopenia, febrile neutropenia, grade 4 AST/ALT elevation, grade 3 AST/ALT elevation lasting \\>7 days, associated with bilirubin levels\\>=2\\*ULN or international normalized ratio \\>1.5, grade 3 bilirubin elevation \\>=3, CK elevation \\>=grade 3 lasting, increase in creatinine \\>=1.5\\*baseline value, dose delay (dose interruption for \\>14 days) or other (inability to receive at least 67% of ARRY-382 doses).', 'timeFrame': 'Cycle 1 (up to 21 days)'}, {'measure': 'Phase 2 Cohorts: Objective Response Rate (ORR)', 'description': 'ORR was defined as the percentage of participants who achieved a best overall response (BOR) of complete response (CR) or partial response (PR) as determined by investigator review of radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. As per RECIST v1.1: CR = disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures less than (\\<) 10 millimeter (mm). PR = at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-progressive disease (PD). The analysis was based on confirmed responses for which CR or PR must be confirmed by repeat disease assessment studies performed no less than 4 weeks after the criteria for response were first met to qualify as CR or PR, respectively.', 'timeFrame': 'From day of first dose to 30 days after last dose (maximum up to 13.5 months)'}]","[{'measure': 'Phase 1b, Part A: Objective Response Rate (ORR)', 'description': 'ORR was defined as the percentage of participants who achieved a BOR of CR or PR as determined by investigator review of radiographic disease assessments per RECIST v1.1. As per RECIST v1.1: CR = disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \\<10 mm. PR = at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD. The analysis was based on confirmed responses for which CR or PR must be confirmed by repeat disease assessment studies performed no less than 4 weeks after the criteria for response were first met to qualify as CR or PR, respectively.', 'timeFrame': 'From day of first dose to 30 days after last dose (maximum up to 34.7 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Duration of Response (DOR)', 'description': 'DOR was defined as the time from the date of the first documented response (CR or PR) to the earliest date of disease progression, or death due to any cause after achieving a response. As per RECIST v1.1: CR = disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \\< 10 mm. PR = at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. PD = at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of \\>= 5 mm or appearance of at least 1 new lesion. Unequivocal progression of existing non-target lesions. DOR was estimated using the Kaplan-Meier method.', 'timeFrame': 'From date of first documented CR or PR up to disease progression or death (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Progression-Free Survival (PFS)', 'description': 'PFS was defined as the time from the date of first dose of study drug to the earliest date of disease progression per RECIST v1.1, or death due to any cause, whichever occurs first. If a participant did not have a PFS event at the time of the analysis cut-off or at the start of any new anticancer therapy, PFS was censored at the date of last adequate tumor assessment. PD = at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of \\>= 5 mm or appearance of at least 1 new lesion. Unequivocal progression of existing non-target lesions.', 'timeFrame': 'From day of first dose until disease progression or death due to any cause or till last tumor assessment date (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Overall Survival (OS)', 'description': 'OS was defined as the time from the start of treatment to the date of death due to any cause. If a death was not observed by the date of the analysis cut-off, OS was censored at the date of last contact. OS was estimated using the Kaplan-Meier method.', 'timeFrame': 'From day of first dose till death due to any cause or date of last contact (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Percentage of Participants With Immune-Related Response Rate (irRR)', 'description': 'irRR was defined as the percentage of participants who achieved immune-related best overall response (irBOR) of immune-related CR (irCR) or immune-related PR (irPR), as determined by the investigator per immune related response criteria (irRC). irBOR was the best response using irRC recorded from the start of study treatment until the end of treatment. irCR was the disappearance of all target lesions, irPR was a decrease in tumor burden by 50% or greater by a consecutive assessment at least 4 weeks after first documentation.', 'timeFrame': 'From day of first dose till up to end of study treatment (for Phase 1b: maximum up to 33.7 months, for Phase 2: maximum up to 12.5 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Immune-Related Progression-Free Survival (irPFS)', 'description': 'irPFS was defined as the time from the start of treatment to the time of first documented progression per irRC, or death due to any cause. irRC criteria for progression for 1) Measurable new lesions: incorporated into the tumor burden (eg, added to the index lesions); do not define progression unless the total measurable tumor burden increases by the required amount (25%); 2) New non-measurable lesions: not considered progression if the total measurable tumor burden is stable or shrinking. For the analysis of irPFS, Kaplan-Meier method was used.', 'timeFrame': 'From the start of treatment to the time of first documented progression, or death (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)'}, {'measure': 'Phase 2 prOVCA: Change From Baseline in Tumor Markers at Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment Discontinuation', 'description': 'Tumor markers were measured for tumor type from serum samples obtained from participants in Phase 2. Mean change from baseline was reported in this outcome measure.', 'timeFrame': 'Baseline, Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, Day 8, 15 of Cycle 1 and Treatment discontinuation (before 13.5 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.', 'timeFrame': 'First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Serum Chemistry Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE) Grade 4.03', 'description': 'Abnormalities: Albumin (hypoalbuminemia),Alkaline phosphatase (ALP increased), Alanine aminotransferase (ALT increased), Aspartate aminotransferase (AST increased),Total bilirubin (TBL increased), Creatinine (increased), Corrected calcium (hypocalcemia/hypercalcemia), Creatine kinase (CK increased), Glucose (hypoglycemia/hyperglycemia), Amylase (increased), Lipase (increased) ,Phosphate (hypophosphatemia), Magnesium (hypomagnesemia/hypermagnesemia), Potassium (hypokalemia/hyperkalemia), Sodium (hyponatremia/hypernatremia). Participants with all grades and grade 3/4 abnormalities were reported. Test abnormalities were graded by CTCAE v4.03 as Grade 1=mild; Grade 2=moderate; Grade 3/Grade 4=severe/life-threatening.', 'timeFrame': 'First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring or Worsening Hematology and Coagulation Laboratory Abnormalities Graded by CTCAE Grade 4.03', 'description': 'Hematology abnormalities: Hemoglobin (anemia/hemoglobin increased), Platelets (count decreased), Leukocytes (count decreased/increased), Neutrophils (count decreased), Lymphocytes (count increased/decreased). Coagulation abnormalities: International Normalized Ratio (INR increased), Partial thromboplastin time(PTT)/Activated partial thromboplastin Time (aPTT, time prolonged). Abnormalities were graded by CTCAE grade 4.03 as Grade 1= mild; Grade 2 = moderate; Grade 3/Grade 4 = severe/life-threatening. Participants with all grades and grade 3/4 abnormalities were reported.', 'timeFrame': 'First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Abnormal Liver Function Tests', 'description': 'Liver function parameters/abnormalities: Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT): \\>3\\* upper limit of normal (ULN), \\>5\\*ULN, \\>8\\*ULN, \\>10\\*ULN, \\>20\\*ULN; Bilirubin \\>1.5\\*ULN, \\>2\\*ULN; Alkaline phosphatase (ALP) \\>2\\*ULN, \\>3\\*ULN.', 'timeFrame': 'First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Shift in Thyroid Panel Severity From Baseline Grade to Post Baseline Grades', 'description': 'Thyroid panel laboratory parameters/abnormalities: thyrotropin, free triiodothyronine (T3), free thyroxine (T4). Shift in thyroid panel severity from baseline grade low, normal, high and missing to the post baseline grades as low, normal, high and missing is reported in this outcome measure.', 'timeFrame': 'Baseline, 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Clinically Significant Urinalysis Finding', 'description': 'Urinalysis laboratory parameters/abnormalities: Decimal logarithm of reciprocal of hydrogen ion activity (pH), specific gravity, protein, glucose, ketones, nitrite, blood, leukocyte esterase, microscopy (if urine tested positive for blood or protein). Clinical significance was judged by investigator.', 'timeFrame': 'First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities', 'description': 'Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, body temperature and weight. Low SBP: less than or equal to (\\<=)90 millimeter of mercury (mmHg) with decrease from baseline of \\>=20 mmHg. High SBP: \\>=160 mmHg with increase from baseline of \\>=20 mmHg. Low DBP: \\<=50 mmHg with decrease from baseline of \\>=15 mmHg. High DBP: \\>=100 mmHg with increase from baseline of \\>=15 mmHg. Low heart rate: \\<=50 beats/min with decrease from baseline of \\>=15 beats/min. High heart rate: \\>=120 beats/min with increase from baseline of \\>=15 beats/min. Low temperature: \\<=36 degree Celsius (C). High temperature: \\>=37.5 degree C. Low Weight: decrease from baseline \\>=20%. High weight: increase from baseline \\>=10%.', 'timeFrame': 'First dose of study drug up to 30 days after last dose (for Phase 1b: maximum up to 34.7 months, for Phase 2: maximum up to 13.5 months)'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of ARRY-382', 'description': 'The lower limit of quantitation (LLOQ) for analyte ARRY-382 was 5.00 nanogram per milliliter (ng/mL).', 'timeFrame': 'Pre dose of ARRY-382 (120 minutes prior to administration): on Day 15 of Cycle 1, on Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9 , 10; 1 hour(hr) (±5 min), 2 hours(hrs) (±10 min), 4 hrs (±20 min) and 8 hrs (±30 min) post dose of ARRY-382 on Day 1 of Cycle 1, 2'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469099', 'description': 'Drug ARRY-382 had its three metabolites AR00469099, AR00469100 and AR00470870. Plasma concentration of metabolite AR00469099 was reported in this outcome measure. The LLOQ for analyte AR00469099 was 1.00 ng/mL.', 'timeFrame': 'Pre dose of ARRY-382 (120 minutes prior to administration): on Day 15 of Cycle 1, on Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9 , 10; 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) post dose of ARRY-382 on Day 1 of Cycle 1, 2'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00469100', 'description': 'Drug ARRY-382 had its three metabolites AR00469099, AR00469100 and AR00470870. Plasma concentration of metabolite AR00469100 was reported in this outcome measure. The LLOQ for analyte AR00469100 was 1.00 ng/mL.', 'timeFrame': 'Pre dose of ARRY-382 (120 minutes prior to administration): on Day 15 of Cycle 1, on Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9 , 10; 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) post dose of ARRY-382 on Day 1 of Cycle 1, 2'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Plasma Concentration Versus Time Profile of Metabolite AR00470870', 'description': 'Drug ARRY-382 had its three metabolites AR00469099, AR00469100 and AR00470870. Plasma concentration of metabolite AR00470870 was reported in this outcome measure. The LLOQ for analyte AR00470870 was 1.00 ng/mL.', 'timeFrame': 'Pre dose of ARRY-382 (120 minutes prior to administration): on Day 15 of Cycle 1, on Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9 , 10; 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) post dose of ARRY-382 on Day 1 of Cycle 1, 2'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Area Under the Plasma Concentration-Time Curve Over a Dosing Interval at Steady-State (AUCtau, ss) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)', 'description': 'AUCtau was defined as area under the plasma concentration-time curve over the dosing interval, where dosing interval was 24 hours.', 'timeFrame': '0 to 24 hrs after administration of ARRY-382 on Day 1 of Cycle 2'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Maximum Observed Plasma Concentration (Cmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)', 'description': 'Cmax was obtained from plasma concentration time curve. Cmax at single dose was reported at Cycle1 Day 1 and Cmax at steady state was reported at Cycle 2 Day 1.', 'timeFrame': 'Pre dose of ARRY-382 (120 minutes prior to administration), 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) after administration of ARRY-382 on Day 1 of Cycle 1 and 2'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Ctrough at Steady State for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)', 'description': 'Measured concentration at the pre-dose at steady-state.', 'timeFrame': 'Pre dose of ARRY-382 (120 minutes prior to administration) on Day 1 of Cycle 2'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Time to Reach Maximum Observed Plasma Concentration (Tmax) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)', 'description': 'Tmax was obtained from plasma concentration time curve. Tmax at single dose was reported at Cycle 1 Day 1 and Tmax at steady state was reported at Cycle 2 Day 1.', 'timeFrame': 'Pre dose of ARRY-382 (120 minutes prior to administration), 1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) after administration of ARRY-382 on Day 1 of Cycle 1 and 2'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Metabolite-to-Parent Ratio (MR) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)', 'description': 'Different MR reported for single dose calculated at Cycle 1 Day 1 were as follows: 1) MRAUClast = ratio of AUClast values of the metabolite compared to parent, corrected for molecular weight, where AUClast was area under the plasma concentration-time curve from zero to the last measurable time point; 2) MRCmax = ratio of Cmax values of the metabolite compared to parent, corrected for molecular weight. Different MR reported for steady state calculated at Cycle 2 Day 1 were as follows: 1) MRAUCtau,ss = ratio of AUCtau,ss values of the metabolite compared to parent, corrected for molecular weight, where AUCtau was area under the plasma concentration-time curve over a dosing interval at steady-state; 2) MRCmax,ss = Ratio of Cmax,ss values of the metabolite compared to parent, corrected for molecular weight.', 'timeFrame': 'Pre dose of ARRY-382 (120 minutes prior to administration),1 hrs (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) after administration of ARRY-382 on Day 1 of Cycle 1 and 2'}, {'measure': 'Phase 1b, Part A and Phase 2 Cohorts: Accumulation Ratio (R) for ARRY-382 and Metabolites (AR00469099, AR00469100, and AR00470870)', 'description': 'Accumulation ratio was calculated and reported for Cmax as RCmax and for AUC as RAUC. RCmax = Cmax at steady-state on Day 1 of Cycle 2 divided by Cmax on Day 1 of Cycle 1. RAUC = AUC from zero to 8 hours after drug administration at steady-state on Day 1 of Cycle 2 divided by AUC from zero to 8 hours after drug administration on Day 1 of Cycle 1.', 'timeFrame': 'Pre dose of ARRY-382 (120 minutes prior to administration),1 hr (±5 min), 2 hrs (±10 min), 4 hrs (±20 min), and 8 hrs (±30 min) after administration of ARRY-382 on Day 1 of Cycle 1 and 2'}]",26,18 Years,,ALL,False,Pfizer,INDUSTRY,0,82.0,ACTUAL,2025-09-01T16:18:17.173134,v2_robust,True,True,False,True,True,Study was halted prematurely due to insufficient efficacy. Not due to safety reasons.
NCT00558571,4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Weeks Treatment With Three Oral Doses of BI 10773 as Tablets in Female and Male Patients With Type 2 Diabetes",BI 10773 low dose,"['placebo to BI 10773', 'BI 10773 medium dose', 'BI 10773 high dose', 'BI 10773 low dose']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2008-01,,"[{'measure': 'Number of Subjects With Drug Related Adverse Events', 'description': 'number of subjects with investigator-defined drug-related adverse events.', 'timeFrame': 'from drug administration up to 6 weeks'}, {'measure': 'Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG', 'description': 'Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.', 'timeFrame': 'from drug administration up to 6 weeks'}]","[{'measure': 'Cmax of Empagliflozin', 'description': 'maximum concentration of the analyte in plasma after first dose (Cmax, Day 1 ) and at steady state over a uniform dosing interval (Cmax,ss, Day 28).', 'timeFrame': '0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 hours(h) after drug administration on day 1 and 28'}, {'measure': 'Tmax of Empagliflozin', 'description': 'time from last dosing to maximum concentration of the analyte in plasma after first dose (Day 1), denoted by tmax; and at steady state (Day 28), denoted by tmax,ss.', 'timeFrame': '0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1 and 28'}, {'measure': 't1/2 of Empagliflozin', 'description': 'terminal half-life of the analyte in plasma after first dose (Day 1), denoted by t1/2; and at steady state (Day 28), denoted by t1/2,ss.', 'timeFrame': '0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1 and 28'}, {'measure': 'AUC0-∞ of Empagliflozin', 'description': 'Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) and over a uniform dosing interval τ at steady state (AUCτ,ss)', 'timeFrame': '0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1'}, {'measure': 'CL/F of Empaglifozin', 'description': 'apparent clearance of the analyte in plasma after first dose (CL/F) and at steady state (CL/F,ss)', 'timeFrame': '0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1 and 28'}, {'measure': 'fe0-24 of Empagliflozin', 'description': 'Fraction of analyte eliminated in urine from time point 0 to 24h after first dose (fe0-24) and at steady state (fe0-24,ss)', 'timeFrame': '0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 h after drug administration on day 1 and 28'}, {'measure': 'LI (Linearity Index).', 'description': 'The linearity index is defined as AUC0-τ divided by AUC0-∞ both at steady state.', 'timeFrame': '0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 after drug administration on day 1 and 28'}, {'measure': 'Ae0-24 of Glucose', 'description': 'Amount of glucose eliminated in urine over the time interval 0 to 24h on day -2, -1, 1, 27 and 28. (Urinary Glucose Excretion)', 'timeFrame': 'Day -2 and 27: -2 to 0, 0 to 5, 5 to 12 and 12 to 24h; Day -1 and 1: 0 to 5, 5 to 12 and 12 to 24; Day 28: 0 to 5, 5 to 12, 12 to 24, 24 to 36, 36 to 48 and 48 to 72h'}, {'measure': 'Fasting Plasma Glucose (FPG)', 'description': 'fasting plasma glucose on day -1 (baseline) and change from baseline to day 28', 'timeFrame': 'in the morning of days -1 and 28'}, {'measure': 'Mean Daily Glucose (MDG) Measured in Blood', 'description': 'change from baseline in MDG on the days 1, 7, 14, 21 and 27. Baseline is defined as day -2.', 'timeFrame': '0:00, 2:30, 5:00, 7:00, 10:00, 12:00, 13:30, 24:00 h after drug administration on day -2. 0:05 h before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00, 13:30, 24:00 h after drug administration on day 1, 7, 14, 21 and 27'}, {'measure': 'Insulin AUEC0-5', 'description': 'change in AUEC0-5 from baseline on day 28. Baseline is defined as day -1.', 'timeFrame': '0:00, 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day -1. 0:05 before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day 28.'}, {'measure': 'Insulin Emax (Maximum Measured Effect)', 'description': 'change in Emax from baseline on day 28. Baseline is defined as day -1', 'timeFrame': '0:00, 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day -1. 0:05 before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day 28.'}, {'measure': 'Fasting Insulin', 'description': 'Change from baseline to the days 1, 7, 14, 21 and 28. Baseline is defined as day -1.', 'timeFrame': 'in the morning of days -1( baseline), 1, 7, 14, 21 and 28'}, {'measure': 'Glucagon Emax (Maximum Measured Effect)', 'description': 'Change from baseline (day -1) in Emax on day 28.', 'timeFrame': '0:00, 2:30, 5:00, 7:00, 10:00, 12:00, 24:00 h after drug administration on day -1. 0:05 before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day 28.'}, {'measure': 'Glucagon AUEC0-5', 'description': 'Change from baseline (day -1) in AUEC0-5 on day 28.', 'timeFrame': '0:00, 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day -1. 0:05 before drug administration and 2:30, 5:00, 7:00, 10:00, 12:00 after drug administration on day 28.'}, {'measure': 'Fructosamine', 'description': 'change from baseline to days 14 and 18. Baseline is defined as day -1.', 'timeFrame': 'day -1 (baseline), 14 and 28'}, {'measure': 'HbA1c', 'description': 'change from baseline on day 28. Baseline is defined as day -1.', 'timeFrame': 'in the morning of days -1 and 28'}]",19,18 Years,70 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,78.0,ACTUAL,2025-09-01T16:18:17.173176,v2_robust,True,True,True,False,True,
NCT06266871,SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer,"SOX Combined With Tislelizumab and Low-dose Radiation Therapy for Neoadjuvant Treatment of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: a Prospective, Multi-center, Single-arm, Phase Ib/II Clinical Trial",SOX+Tislelizumab+LDRT,['SOX+Tislelizumab+LDRT'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Gastric Cancer,['Gastric Cancer'],[],NOT_YET_RECRUITING,,2024-03-10,2026-07-30,"[{'measure': 'pCR rate', 'description': 'defined as the absence of viable tumor cells assessed by histological evaluation criteria after neoadjuvant therapy', 'timeFrame': '5 months after the last subject participating in'}]","[{'measure': 'R0 resection rate', 'description': 'defined as the rate of the complete surgical removal of any residual cancer cells in the tumor bed', 'timeFrame': '5 months after the last subject participating in'}, {'measure': 'MPR rate', 'description': 'defined as tumor residual cells ≤10% in the surgical specimen', 'timeFrame': '5 months after the last subject participating in'}, {'measure': 'ORR', 'description': 'defined as the proportion of patients with the best overall response of complete response (CR) or partial response (PR)) before surgery', 'timeFrame': '5 months after the last subject participating in'}, {'measure': '2-year disease-free survival (DFS) rate', 'description': 'defined as the proportion of patients without disease relapse 2 years after enrolment', 'timeFrame': 'every 3 month postoperation up to 24 months'}, {'measure': '2-year OS rate', 'description': 'defined as the proportion of patients survived 2 years after enrolment', 'timeFrame': 'every 3 month postoperation up to 24 months'}]",6,18 Years,75 Years,ALL,False,West China Hospital,OTHER,0,64.0,ESTIMATED,2025-09-01T16:18:17.173261,v2_robust,True,True,False,False,False,
NCT00307944,Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea,"Randomized, Placebo-Controlled Trial of Pantoprazole for Sleepiness Associated With Acid Reflux and Obstructive Sleep Disordered Breathing",Pantoprazole,['Pantoprazole'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Acid Reflux Disease,"['Acid Reflux Disease', 'Obstructive Sleep Apnea']","['Acid Reflux', 'Obstructive Sleep Apnea', 'Daytime Sleepiness']",COMPLETED,,2004-08,2006-08,[{'measure': 'Difference between treatment groups with regard to change in sleepiness score (ESS)'}],"[{'measure': 'Difference between treatment groups with regard to change in reaction time testing.'}, {'measure': 'Difference between treatment groups with regard to change in total reflux symptom scores.'}, {'measure': 'Difference between treatment groups with regard to change in sleep related QOL (FOSQ).'}]",4,18 Years,,ALL,True,University of Cincinnati,OTHER,1,68.0,,2025-09-01T16:18:17.173357,v2_robust,True,True,True,False,False,
NCT02107144,The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease,"The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease",trimetazidine,"['trimetazidine', 'Vastarel MR', 'Trimetacor', 'Preductal MR']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Coronary Artery Disease,"['Coronary Artery Disease', 'Microcirculation', 'Vascular Resistance']","['trimetazidine', 'microcirculation', 'stenting', 'pressure wire']",COMPLETED,,2014-04,2023-03,"[{'measure': 'index of microcirculatory resistance', 'description': 'Trimetazidine given on day 0 before elective percutaneous coronary intervention would decrease microvascular dysfunction by reducing index of microcirculatory resistance (IMR) measured by thermodilution method using coronary pressure and temperature wire on day 2 during PCI', 'timeFrame': 'On day 2 during percutaneous coronary intervention'}]","[{'measure': 'periprocedural myocardial necrosis', 'description': 'Periprocedural myocardial necrosis will be measured by collecting blood samples for Troponin I, CK and CK-MB at 6, 12 and 24 h after the procedure.', 'timeFrame': 'on day 2 after PCI'}]",2,18 Years,80 Years,ALL,False,Clinical Hospital Center Zemun,OTHER,0,71.0,ACTUAL,2025-09-01T16:18:17.173368,v2_robust,True,True,True,False,False,
NCT01702844,Single Arm on the Tolerability of Weekly Nab-paclitaxel,"LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer",Nab-Paclitaxel,"['Abraxane', 'Nab-Paclitaxel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Non Small Cell Lung Cancer (NSCLC),['Non Small Cell Lung Cancer (NSCLC)'],"['Nab paclitaxel', 'Abraxane', 'First Line', 'Non small cell lung cancer', 'NSCLC', 'Phase II', 'Non-Randomized', 'Elderly', 'Lineberger', 'UNC', 'LCCC 1210']",COMPLETED,,2013-06-25,2019-07-12,"[{'measure': 'Number of Subjects Without Any Adverse Events Grade 3 or Higher', 'description': 'Tolerability of weekly nab-paclitaxel, as measured by occurrence of Grade 3 or worse toxicity after 6 cycles or 3 weeks after discontinuation of treatment, for those who came off treatment earlier as measured by the NCI Common Terminology Criteria for Adverse Events CTCAE, version 4. The CTCAE is a descriptive terminology utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.', 'timeFrame': '168 days after start of treatment (6 cycles) (or 3 weeks after discontinuation of treatment, for those who come off treatment earlier)'}]","[{'measure': 'Median Overall Survival', 'description': 'Overall Survival is defined as the time from day 1 (D1) of treatment until death as a result of any cause', 'timeFrame': 'up to 2 years after end of treatment (treatment lasts up to 168 days (up to 6 cycles of 28 days each))'}, {'measure': 'Median Progression Free Survival', 'description': 'Progression free survival is defined as the time from D1 of treatment until progression or death as a result of any cause. Progressive Disease (PD) is determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. PD is at least a 20% increase in the sum of the longest diameters (LD) of the target lesions taking as reference the smallest sum LD recorded since the treatment started including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters. The appearance of one or more new lesions also constitutes PD.', 'timeFrame': 'up to 2 years after end of treatment (treatment lasts up to 168 days (up to 6 cycles of 28 days each))'}, {'measure': 'Overall Response Rate', 'description': 'Response will be measured by Response Evaluation Criteria In Solid Tumors Criteria (RECIST) version 1.1, indicating if subject experienced a Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions. The Overall Response rate is defined as the percentage of participants with CR or PR', 'timeFrame': '168 days after start of treatment (6 cycles) (or 3 weeks after discontinuation of treatment, for those who come off treatment earlier)'}]",4,70 Years,,ALL,False,UNC Lineberger Comprehensive Cancer Center,OTHER,1,42.0,ACTUAL,2025-09-01T16:18:17.173395,v2_robust,True,True,True,False,True,
NCT02892344,Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma,"A Multi-center, Randomized, 12-week Treatment, Doubleblind Study to Assess the Efficacy and Safety of QMF149 (150/80 Microgram) Compared With MF Twisthaler® (200 Microgram) in Adult and Adolescent Patients With Asthma",QMF149 150/80 μg,"['QMF149 150/80 μg', 'Indacaterol acetate/Mometasone furoate', 'MF 200 μg', 'Mometasone furoate']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Mild Asthma,['Mild Asthma'],"['Phase III, blinded, QMF149, Mometasone furoate (MF), mild asthma, Adolescent, adult']",COMPLETED,,2017-01-16,2018-11-30,"[{'measure': 'Trough FEV1', 'description': 'demonstrate the superiority of QMF149 150/80 microgram o.d. (in the evening) delivered via Concept1 compared with MF 200 microgram o.d. (in the evening) delivered via Twisthaler® in terms of trough FEV1 after 12 weeks of treatment in adults and adolescents. Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured by spirometry.', 'timeFrame': 'week 12'}]","[{'measure': 'ACQ-7', 'description': 'ACQ-7 is an asthma control questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and daily rescue bronchodilator use entered by the patient) validated to evaluate different levels of asthma control. the ACQ-7 was used to assess improvements in asthma symptom control. The ACQ-7, a seven-item disease-specific instrument developed and validated to assess asthma control in patients in clinical trials as well as in individuals in clinical practice, was provided to the site. All seven items were then scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating no control. The questions were equally weighted and the total score was the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the patient while the last question (question 7) was completed by the study investigator using spirometry data generated by the spirometry equipment.', 'timeFrame': 'week 12'}, {'measure': 'Trough FEV1 at Day 2', 'description': 'Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing', 'timeFrame': 'Day 2'}, {'measure': 'Pre-dose FEV1 at Week 4', 'description': 'Pre-dose FEV1 is defined as the mean of -45 min and -15 min FEV1 values pre-evening dose', 'timeFrame': 'week 4'}, {'measure': 'FVC Over 12 Weeks', 'description': 'FVC is the total amount of air exhaled during the FEV test. Forced Vital Capacity (FVC) and Forced Expiratory Flow between 25% and 75% of FVC (FEF25-75) will be measured', 'timeFrame': 'week 12'}, {'measure': 'PEF Over 4 and 12 Weeks', 'description': 'Morning and Evening Peak Expiratory Flow Rate (PEF) will be measured. PEF is the peak expiratory flow, the maximum speed of expiration', 'timeFrame': 'week 12'}, {'measure': 'Percentage of Patients With ACQ-7 MID at Week 12', 'description': 'MID is Minimum Important Difference. ACQ-7 is an asthma control questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and daily rescue bronchodilator use entered by the patient) validated to evaluate different levels of asthma control. Percent of patients achieving the minimal important difference (MID) in ACQ-7 (i.e. at least 0.5 decrease from baseline) will be measured.', 'timeFrame': 'week 12'}, {'measure': 'Daily E-diary Over 12 Weeks', 'description': 'Percentage of asthma symptoms free days, the percentage of nights without nighttime awakenings, and the percentage of mornings without symptoms on awakening as recorded by daily electronic Diary (e-Diary) over 12 weeks of treatment', 'timeFrame': 'week 12'}, {'measure': 'ACQ-7 at Week 4', 'description': 'ACQ-7 is an asthma control questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and daily rescue bronchodilator use entered by the patient) validated to evaluate different levels of asthma control', 'timeFrame': 'week 4'}, {'measure': 'Rescue Medication Use Over 12 Weeks', 'description': 'Rescue salbutamol/albuterol usage (mean daily, nighttime and daytime use) from e-Diary recordings over 12 weeks of treatment', 'timeFrame': 'week 12'}, {'measure': 'Percentage of Rescue Medication Free Days Over 12 Weeks', 'description': 'Percentage of rescue medication free days over 12 weeks of treatment period', 'timeFrame': 'week 12'}, {'measure': 'Quality of Life Assessed by Asthma Quality of Life Questionnaire AQLQ-S 12', 'description': 'The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma. Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks. The overall AQLQ score is the mean response to all 32 questions. Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and \\> 1.5 as marked clinically important differences for any individual domain or for the overall summary score.', 'timeFrame': 'week 12'}, {'measure': 'Number of Patients With Asthma Exacerbation Over 12 Weeks', 'description': 'The exacerbation categories are: mild, moderate, severe and the combination of moderate or severe. Time to first asthma exacerbation by exacerbation category. Annual rate of asthma exacerbations by exacerbation category.', 'timeFrame': 'Week 12'}, {'measure': 'The Number of Asthma Exacerbations (Moderate or Severe) Over the 12 Week Treatment Period', 'description': 'Annual incidence rate of asthma exacerbation by severity of exacerbation. The number of asthma exacerbation is used to calculate annual incidence rate. A severe asthma exacerbation is SCS (Systemic Corticosteroids) use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations', 'timeFrame': 'Week 12'}, {'measure': 'Number of Patients With First Asthma Exacerbations (Moderate or Severe) Over the 12 Week Treatment Period', 'description': 'The annual rate of asthma exacerbations were analyzed using a generalized linear model.', 'timeFrame': 'Week 12'}]",15,12 Years,75 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,802.0,ACTUAL,2025-09-01T16:18:17.173410,v2_robust,True,True,True,False,False,
NCT06979544,A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD,"A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Saftey and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression",LPCN 1154A,"['Brexanolone', 'LPCN 1154A', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Depression, Postpartum","['Depression, Postpartum', 'Depression, Post-Partum', 'Postpartum Depression (PPD)', 'Post-Natal Depression', 'Peripartum Depression', 'Postnatal Depression']",[],RECRUITING,,2025-06-16,2026-05,"[{'measure': 'Change from baseline in HAM-D17 total score compared to placebo', 'description': 'The Seventeen-Item Hamilton Rating Scale for Depression (HAM-D17) contains 17 individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia (initial, middle, and late), work and interests, psychomotor retardation, psychomotor agitation, anxiety (psychic and somatic), gastrointestinal symptoms, general somatic symptoms, sexual interest, hypochondriasis, insight, and weight loss. The total score ranges from 0 to 52, with higher scores indicating more severe depression.', 'timeFrame': 'Baseline to Hour 60'}]","[{'measure': 'Incidence, severity, and causality of AEs and SAEs', 'description': 'Adverse events (AEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'upto Day 30'}, {'measure': 'Change from baseline in HAM-D17 total score', 'description': 'The Seventeen-Item Hamilton Rating Scale for Depression (HAM-D17) evaluates mood, suicide, work and interests, retardation, agitation, gastrointestinal symptoms, somatic symptoms, hypochondriasis, body weight and insight The total score ranges from 0 to 52, with higher scores indicating more severe depression.', 'timeFrame': 'Baseline at Hours 12, and 36, Day 7 and Day 30'}, {'measure': 'HAM-D17 response', 'description': 'Defined as having a 50% or greater reduction from baseline in HAM-D17 total score. The total score ranges from 0 to 52, with higher scores indicating more severe depression.', 'timeFrame': 'Baseline to Hours 12, and 36, 60, Day 7 and Day 30'}, {'measure': 'HAM-D17 remission', 'description': 'Defined as having a HAM-D17 total score ≤7. The total score ranges from 0 to 52, with higher scores indicating more severe depression.', 'timeFrame': 'Hours 12, and 36, 60, Day 7 and Day 30'}, {'measure': 'Patient Global Impression - Change (PGI-C) scale positive response', 'description': 'The PGI-C scale is a 7-point scale that ranges from ""1-very much better"" to ""7-very much worse"" that allows participants to self- report their perception of improvement or decline of overall symptoms since starting treatment.', 'timeFrame': 'Hours 12, and 36, 60, Day 7 and Day 30'}, {'measure': 'Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score', 'description': 'The MADRS is a 10-item assessment that evaluates mood/thoughts, sleep, appetite, tension, concentration The total score ranges from 0 to 60, with higher scores indicating more severe depression.', 'timeFrame': 'Baseline to Hour 60 and Day 30'}, {'measure': 'Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score', 'description': 'The HAM-A is a 14-item assessment that evaluates mood, tension, fear, memory/concentration, sleep, and physical symptoms affecting somatic, sensory, respiratory, cardiovascular, gastrointestinal, genitourinary, and autoimmune systems as it relates to anxiety. The total score ranges from 0 to 56, with higher scores indicating more severe anxiety.', 'timeFrame': 'Baseline to Hours 12, 36, 60 Day 7 and Day 30'}]",8,15 Years,45 Years,FEMALE,False,Lipocine Inc.,INDUSTRY,0,80.0,ESTIMATED,2025-09-01T16:18:17.173515,v2_robust,True,True,False,False,True,
NCT04977544,Virtual Reality Exposure Therapy in the Intensive Treatment of Social Anxiety Disorder,A Randomized Controlled Study of Virtual Reality Exposure Therapy in the Intensive Treatment of Social Anxiety Disorder,Sertraline,['Sertraline'],1,INTERVENTIONAL,['NA'],,,Phobia,['Phobia'],"['phobia', 'VR']",UNKNOWN,,2019-09-01,2022-09-01,"[{'measure': 'the level of anxiety', 'description': 'the score of Hamilton anxiety scale, the minimum and maximum values are 0 and 56, and higher scores mean a worse outcome.', 'timeFrame': '3 months'}, {'measure': 'heart rate of the patients', 'description': 'take the heart rate as a biomarker of fear, the faster heart rate means the participate is more afraid', 'timeFrame': '3 months'}]",[],2,18 Years,45 Years,ALL,False,"Second Affiliated Hospital, School of Medicine, Zhejiang University",OTHER,0,200.0,ESTIMATED,2025-09-01T16:18:17.173589,v2_robust,True,True,False,False,False,
NCT01958944,Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis,"Phase II Prospective, Open Labeled, Multi-Center, Evaluation of the Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Cystic Fibrosis",Nitric oxide,['Nitric oxide'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Cystic Fibrosis,['Cystic Fibrosis'],"['CF', 'Cystic Fibrosis', 'NO', 'nitric oxide', 'inhalation']",COMPLETED,,2013-12,2015-11,"[{'measure': 'Met-Hemoglobin percentage (MetHb)associated with inhaled NO', 'timeFrame': '1 month'}, {'measure': 'Number of participants with adverse events associated with inhaled NO', 'timeFrame': '1 month'}, {'measure': 'Proportion of subjects (%) who prematurely discontinued the study for any reason', 'timeFrame': '1 month'}, {'measure': 'Proportion of subjects (%) who prematurely discontinued the study due to adverse events or serious adverse events', 'timeFrame': '1 month'}]","[{'measure': 'Comparing the FEV1 improvement of ≥10 years old with CF before and after NO treatment', 'timeFrame': '1 month'}]",5,10 Years,,ALL,False,Beyond Air Inc.,INDUSTRY,2,9.0,ACTUAL,2025-09-01T16:18:17.173611,v2_robust,True,True,True,False,True,
NCT03633344,Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form in Patients With Acute Diarrhea,Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form (Carbowhite) in Patients With Acute Diarrhea.,Carbowhite,"['Colloidal Silicon Dioxide', 'Carbowhite placebo', 'Carbowhite', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Diarrhoea;Acute,['Diarrhoea;Acute'],"['Diarrhoea', 'Carbowhite', 'Colloidal silicon dioxide']",COMPLETED,,2016-03-29,2016-10-07,"[{'measure': 'Reduction in Frequency of Defecation to 3 Times Per Day', 'description': 'Percent of patients administered the investigational production who achieved the efficacy endpoint (reduction in frequency of defecation to 3 times per day, absence of loose stool) on Day 5 or earlier', 'timeFrame': 'From randomisation up to 5 days'}]","[{'measure': 'Compliance Rate', 'description': 'Percent of patients administered the investigational production who discontinued the study', 'timeFrame': 'From randomisation up to 5 days'}, {'measure': 'Duration of Treatment', 'description': 'Mean duration of treatment', 'timeFrame': 'From randomisation up to 5 days'}, {'measure': 'Quantity of Used Medication', 'description': 'Mean quantity of tablets per treatment course', 'timeFrame': 'From randomisation up to 5 days'}]",4,18 Years,55 Years,ALL,False,Omnifarma Kiev LLC,INDUSTRY,0,145.0,ACTUAL,2025-09-01T16:18:17.173730,v2_robust,True,True,True,False,False,
NCT05784844,Antimicrobial Revision in Persistent Febrile Neutropenia,"Antimicrobial Revision in Patients With Persistent Febrile Neutropenia: A Prospective, Randomized Trial",Meropenem,"['Meropenem', 'Micafungin', 'Mycamine', 'Merrem']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Febrile Neutropenia,['Febrile Neutropenia'],"['acute myeloid leukemia', 'acute lymphocytic leukemia']",WITHDRAWN,Study was never initiated or activated - Reason was lack of funding,2024-08,2025-04,"[{'measure': 'Global Success Rate', 'description': 'Percentage of study candidates who meet all of the following criteria:\n\n* Defervescence, as defined by a temperature \\< 38°C (100.4°F) sustained for at least 24 consecutive hours, within 72 hours of meropenem or micafungin initiation\n* Absence of signs or symptoms of infection within 72 hours of meropenem or micafungin initiation including but not limited to hypotension, erythema at catheter sites or cellulitis, positive imaging concerning for infection (e.g., pneumonia, osteomyelitis, abscesses etc.), positive cultures or rapid diagnostic tests, positive biomarkers (e.g. galactomannan), dysuria, hypothermia (≤ 35°C or ≤ 95°F) etc.\n* No modification to antimicrobial regimen after initiation of meropenem or micafungin unless the antibiotic modification is considered de-escalation (e.g. discontinuation of vancomycin)', 'timeFrame': 'Hour 72'}]","[{'measure': 'Number of Subjects In-hospital mortality or discharge to hospice', 'description': 'Death during in-hospital admission or discharge from in-hospital admission to hospice care', 'timeFrame': 'From hospital admission to death/discharge to hospice, up to 4 days'}, {'measure': 'Hospital length of stay (days)', 'description': 'Number of days admitted to hospital', 'timeFrame': 'From hospital admission to discharge, up to 4 days'}, {'measure': 'Time to defervescence (hours)', 'description': '* Time of defervescence defined as the beginning of the 24 consecutive hour afebrile period\n* Time to defervescence defined as the time in hours from the initial documented fever to the beginning of the 24 consecutive hour afebrile period', 'timeFrame': 'through study completion, an average of 4 days'}, {'measure': 'Days of therapy of meropenem or micafungin', 'description': '1 antibiotic x the number of days administered, any calendar day in which at least one dose is given counts as a full day of therapy - Time in days from initiation to discontinuation of meropenem or micafungin', 'timeFrame': 'through study completion, an average of 4 days'}, {'measure': 'Rate of Clostridioides difficile infection on meropenem or micafungin', 'description': 'Percentage of patients who develop Clostridioides difficile infection while on meropenem or micafungin', 'timeFrame': 'through study completion, an average of 4 days'}, {'measure': 'Collection of Causes of any proven breakthrough infection while on meropenem or micafungin', 'description': 'Collection of origin of proven breakthrough infection', 'timeFrame': 'through study completion, an average of 4 days'}]",7,18 Years,,ALL,False,Wake Forest University Health Sciences,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:17.173777,v2_robust,True,True,False,True,False,Study was never initiated or activated - Reason was lack of funding
NCT01199744,Relenza® Sentinel Site Monitoring Program in Japan,Collection of Patients' Background InformationRelenza® Sentinel Site Monitoring Program in Japan,zanamivir,['zanamivir'],1,OBSERVATIONAL,[],,,"Influenza, Human","['Influenza, Human']","['Influenza', 'Relenza®', 'SSMP']",COMPLETED,,2009-11,2010-04,"[{'measure': 'Number of Participants With Any Adverse Drug Reaction', 'description': 'An adverse drug reaction is defined as a drug adverse event that a physician has determined to be related to the use of Relenza. A drug adverse event is defined as any unfavorable or unintended sign (including laboratory test abnormalities), symptom, or disease that occurs when a drug is administered, regardless of the relationship to the drug. For a complete list of all adverse drug reactions recorded during the study, see the section entitled ""Other (Non-serious) Adverse Events.""', 'timeFrame': '5 months (November 2009 to March 2010)'}]","[{'measure': 'Number of Participants With Any Serious Adverse Drug Reaction (ADR)', 'description': 'A serious ADR is defined as a serious adverse drug event (ADE) that a physician has determined to be related to the use of Relenza. Serious ADE: death caused by an ADR; an event that is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in severe symptoms requiring treatment so that symptoms do not lead to previously mentioned outcomes, and a congenital anomaly/birth defect. For a complete list of all serious ADRs recorded during the study, see ""Serious Adverse Events"" section.', 'timeFrame': '5 months (November 2009 to March 2010)'}, {'measure': 'Number of Male and Female Participants With Either a Serious or Non-serious Adverse Drug Reaction', 'timeFrame': '5 months (November 2009 to March 2010)'}, {'measure': 'Number of Participants in the Indicated Age Categories With Either a Serious or Non-serious Adverse Drug Reaction', 'timeFrame': '5 months (November 2009 to March 2010)'}, {'measure': 'Number of Participants With Either a Serious or Non-serious Adverse Drug Reaction Categorized by Reason for the Use of Relenza', 'description': 'The dose given for treatment of influenza is 10 mg twice daily for 5days. Prophylaxis is defined as a measure taken for the prevention of a disease or condition. The prophylactic dose of Relenza is 10 mg once daily for 10 days.', 'timeFrame': '5 months (November 2009 to March 2010)'}, {'measure': 'Number of Participants With Either a Serious or Non-serious Adverse Drug Reaction Categorized by Either Having Complications or Having no Complications', 'description': 'A complication is defined as asthma.', 'timeFrame': '5 months (November 2009 to March 2010)'}, {'measure': 'Number of Participants With Either a Serious or Non-serious Adverse Drug Reaction Categorized by Either Having Risk Factors for Influenza or Having no Risk Factors', 'description': 'Risk factors are defined as pregnancy; infancy; being elderly; and having chronic respiratory disease, cardiocirculatory disease, and/or diabetes.', 'timeFrame': '5 months (November 2009 to March 2010)'}, {'measure': 'Number of Participants With Either a Serious or Non-serious Adverse Drug Reaction Who Were Also in the Indicated High-risk Categories', 'description': 'Participants with only hypertension were excluded from the cardiocirculatory disease category. Participants in high-risk categories are at risk for the aggravation of both infection and symptoms.', 'timeFrame': '5 months (November 2009 to March 2010)'}, {'measure': 'Number of Participants With Either a Serious or Non-serious Adverse Drug Reaction Who Were Vaccinated for Influenza', 'timeFrame': '5 months (November 2009 to March 2010)'}, {'measure': 'Number of Participants With Either a Serious or Non-serious Adverse Drug Reaction Who Were Also Taking Concomitant Medications', 'description': 'Concomitant medications are defined as drugs used during the administration of Relenza.', 'timeFrame': '5 months (November 2009 to March 2010)'}]",10,,,ALL,False,GlaxoSmithKline,INDUSTRY,0,1575.0,ACTUAL,2025-09-01T16:18:17.173819,v2_robust,False,True,True,False,True,
NCT00213044,"A Randomized, Controlled, Cross-Over Trial of Safety of Vaginal Use of Carraguard by HIV-Infected Women","A Randomized, Controlled, Double-Blind, Cross-Over Trial of Safety, Effect on Genital Tract HIV Shedding, and Acceptability of Vaginal Use of Carraguard by HIV-Infected Women",Carraguard (PC-515),['Carraguard (PC-515)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,HIV Infections,['HIV Infections'],"['Microbicides', 'HIV prevention', 'HIV-positive women', 'safety', 'carrageenan', 'HIV']",COMPLETED,,2003-03,2004-06,"[{'measure': 'Safety: irritation, effect on vaginal flora, vaginal epithelial disruption determined by visual inspection (Day 7, 14) and colposcopic inspection(Day 7); other adverse effects, which may include UTI or other unforeseen problems (Day 7, 14).'}, {'measure': 'Genital tract HIV: measured using samples collected by CVL (Day 7, 14) and vaginal swab (Day 7, 14).'}, {'measure': 'Acceptability: interview-administered questionnaire (Day 7).'}]",[],3,18 Years,50 Years,FEMALE,False,Population Council,OTHER,8,60.0,,2025-09-01T16:18:17.173830,v2_robust,True,True,True,False,True,
NCT05053334,"Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair","A Randomized Phase I, Double-Blinded, Parallel Comparative Assessment of PK, PD, Safety, and Immunogenicity of BP11 Versus US-Licensed Xolair® and EU Approved-Xolair® Following a Single 150 mg Dose SC Administration in Healthy Male Volunteers",Omalizumab Prefilled Syringe,['Omalizumab Prefilled Syringe'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2022-02-16,2024-01-10,"[{'measure': 'To evaluate pharmacokinetic (PK) similarity of BP11 with US-Xolair and EU-Xolair and between US-Xolair and EU-Xolair', 'description': 'AUC0-inf will be evaluated', 'timeFrame': 'Upto 127 Days'}, {'measure': 'To evaluate PK similarity of BP11 with US-Xolair and EU-Xolair and between US-Xolair and EU-Xolair', 'description': 'Cmax will be evaluated', 'timeFrame': 'Upto 127 Days'}]","[{'measure': 'To assess and compare non-primary PK parameters of BP11 with US-Xolair and EU-Xolair', 'description': 'AUC0-t', 'timeFrame': 'Upto 127 Days'}, {'measure': 'To assess and compare non-primary PK parameters of BP11 with US-Xolair and EU-Xolair', 'description': 'Vd', 'timeFrame': 'Upto 127 Days'}, {'measure': 'To assess and compare non-primary PK parameters of BP11 with US-Xolair and EU-Xolair', 'description': 'Tmax, T½', 'timeFrame': 'Upto 127 Days'}, {'measure': 'To assess and compare pharmacodynamics (PD) of BP11 with US-Xolair and EU-Xolair', 'description': 'Free IgE levels will be assessed', 'timeFrame': 'Upto 127 Days'}, {'measure': 'To assess and compare pharmacodynamics (PD) of BP11 with US-Xolair and EU-Xolair', 'description': 'Total IgE levels will be assessed', 'timeFrame': 'Upto 127 Days'}, {'measure': 'Safety & tolerability of BP11 with US-Xolair and EU-Xolair', 'description': 'Assessment of Vital signs-Blood pressure', 'timeFrame': 'Upto 127 Days'}, {'measure': 'Safety & tolerability of BP11 with US-Xolair and EU-Xolair', 'description': 'Assessment of Vital signs-Pulse rate', 'timeFrame': 'Upto 127 Days'}, {'measure': 'Safety & tolerability of BP11 with US-Xolair and EU-Xolair', 'description': 'Assessment of Vital signs-Body temperature', 'timeFrame': 'Upto 127 Days'}, {'measure': 'Safety & tolerability of BP11 with US-Xolair and EU-Xolair', 'description': 'Assessment of Vital signs-Respiratory rate', 'timeFrame': 'Upto 127 Days'}, {'measure': 'Safety & tolerability of BP11 with US-Xolair and EU-Xolair', 'description': 'Normal 12 Lead ECG (Ventricular rate)', 'timeFrame': 'Screening, Pre-dose (within 1 hour of drug administration) and post dose on day 3)'}, {'measure': 'Safety & tolerability of BP11 with US-Xolair and EU-Xolair', 'description': 'Normal 12 Lead ECG (PR interval)', 'timeFrame': 'Screening, Pre-dose (within 1 hour of drug administration) and post dose on day 3)'}, {'measure': 'Safety & tolerability of BP11 with US-Xolair and EU-Xolair', 'description': 'Normal 12 Lead ECG (QRS complex)', 'timeFrame': 'Screening, Pre-dose (within 1 hour of drug administration) and post dose on day 3)'}, {'measure': 'Safety & tolerability of BP11 with US-Xolair and EU-Xolair', 'description': ""Normal 12 Lead ECG (QT interval and QT interval corrected for heart rate using Bazett's formula)"", 'timeFrame': 'Screening, Pre-dose (within 1 hour of drug administration) and post dose on day 3)'}, {'measure': 'Safety & tolerability of BP11 with US-Xolair and EU-Xolair', 'description': 'Assessment of injection site reaction', 'timeFrame': 'Pre-dose(0hour or within 1 hour prior of drug administration), post dose at 6hours, 12 hours and 24hours.'}]",16,18 Years,55 Years,MALE,True,Syneos Health,OTHER,1,165.0,ACTUAL,2025-09-01T16:18:17.173921,v2_robust,True,True,True,False,True,
NCT03112434,Muscle Elastography in Spastic Cerebral Palsy,Use of Elastography to Quantify Change in Upper Extremity Muscle Spasticity Following Botox Injection in Children With Spastic Cerebral Palsy,Botulinum toxin type A,['Botulinum toxin type A'],1,OBSERVATIONAL,[],,,Unilateral Spastic Cerebral Palsy,['Unilateral Spastic Cerebral Palsy'],[],COMPLETED,,2017-12-14,2020-12-30,"[{'measure': 'Muscle Elasticity', 'description': 'Change in muscle elasticity (in kilopascal )', 'timeFrame': 'From immediate pre-injection to 1 month post-injection.'}, {'measure': 'Muscle Elasticity', 'description': 'Change in muscle elasticity (in m/s)', 'timeFrame': 'From immediate pre-injection to 1 month post-injection.'}]","[{'measure': 'Functional measures', 'description': 'Functional measures (MAS)', 'timeFrame': 'immediately pre- and immediately post-injection, and at 1 month, 3 months and 6 months post-injection.'}, {'measure': 'Functional measures', 'description': 'Functional measures (PROM)', 'timeFrame': 'immediately pre- and immediately post-injection, and at 1 month, 3 months and 6 months post-injection.'}]",4,5 Years,18 Years,ALL,False,"Hospital for Special Surgery, New York",OTHER,1,16.0,ACTUAL,2025-09-01T16:18:17.173941,v2_robust,False,True,True,False,False,
NCT01191034,Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma,Phase I/II Study of Peptide Vaccination Associated With Tumoral Immunomodulation With Proinflammatory Cytokines and Imiquimod in Patients With Advanced Metastatic Melanoma,"Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.","['Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.']",1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Metastatic Melanoma,['Metastatic Melanoma'],[],TERMINATED,Completion after 2 patients then stop due to end of validity of vaccine peptide,2010-08,2012-08-01,"[{'measure': 'To determine whether peptide vaccination associated with local peritumoral treatment with a combination of interleukin-2, interferon-alpha, granulocyte-macrophage colony stimulating factor, and imiquimod, induces tumor responses.', 'description': 'Tumor response will be assessed in accordance with the Modified RECIST version 1.1', 'timeFrame': 'week 11 day 71'}]","[{'measure': 'To document the toxicity of treatment', 'description': 'Laboratory tests, vital sign measurements, physical exams and patient queries will be performed to detect new abnormalities and deteriorations of any pre-existing conditions.\n\nAll clinically significant abnormalities and deteriorations should be recorded in the Case Report Forms as Adverse Events and graded according to the National Cancer Institute CTCAE v3.0.', 'timeFrame': 'at each visit'}, {'measure': 'To document whether this association induces cytolytic T lymphocyte responses to the vaccine antigens', 'description': 'CTL responses will be assessed by comparing either the anti-MAGE-3.A1 or the anti- NA17.A2 CTLp frequency in the pre- and post-immune blood of patients vaccinated with the respective antigen.', 'timeFrame': 'at week 11, day 71'}]",3,18 Years,,ALL,False,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,OTHER,0,2.0,ACTUAL,2025-09-01T16:18:17.173954,v2_robust,True,True,False,True,True,Completion after 2 patients then stop due to end of validity of vaccine peptide
NCT05656534,Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder,Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder,Suvorexant,"['Belsomra', 'Suvorexant']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Alcohol Use Disorder,['Alcohol Use Disorder'],"['suvorexant', 'alcohol use disorder', 'electromyography', 'functional magnetic resonance imaging']",COMPLETED,,2022-11-29,2024-08-01,"[{'measure': 'Startle reactivity to stress with an acute dose of suvorexant.', 'description': 'Changes in acoustic startle electromyographic (EMG) response during stress anticipation following an acute dose of suvorexant.', 'timeFrame': 'Change from baseline to 2 hours post-ingestion of an acute dose of suvorexant.'}, {'measure': 'Startle reactivity to stress with daily use of suvorexant.', 'description': 'Changes in acoustic startle electromyographic (EMG) response during stress anticipation following daily use of suvorexant.', 'timeFrame': 'Change from baseline to post-treatment, up to 1.5-2 months.'}, {'measure': 'Alcohol behavior and daily use of suvorexant.', 'description': 'Changes in proportion of heavy drinking days and drinks per drinking day following daily use of suvorexant.', 'timeFrame': 'Change from baseline to post-treatment, up to 1.5-2 months.'}]","[{'measure': 'Brain change and daily use of suvorexant.', 'description': 'Changes in the anterior insula (aINS) and dorsal anterior cingulate cortex (dACC) reactivity and connectivity during stress anticipation following daily use of suvorexant.', 'timeFrame': 'Change from baseline to post-treatment, up to 1.5-2 months.'}]",4,18 Years,65 Years,ALL,False,Ohio State University,OTHER,0,71.0,ACTUAL,2025-09-01T16:18:17.173967,v2_robust,True,True,True,False,False,
NCT01739634,The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer,The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer,CASAD,"['CASAD', 'Calcium Aluminosilicate Anti-Diarrheal.']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Diarrhea,"['Diarrhea', 'Medullary Thyroid Cancer']","['Diarrhea', 'Medullary thyroid cancer']",UNKNOWN,,2012-11,2013-12,"[{'measure': 'Efficacy in treatment of diarrhea', 'description': 'To evaluate the efficacy of CASAD 3 grams per day in reducing the severity of diarrhea after 1 week of treatment in patients with MTC.', 'timeFrame': '1 week'}]","[{'measure': 'Functional impact of CASAD', 'description': 'To explore the functional impact of CASAD and the relative impact of diarrhea in relation to other symptom issues using MDASI-THY (M.D. Anderson Symptom Inventory-Thyroid, appendix D)', 'timeFrame': '1 week'}, {'measure': 'Effect on thyroid function tests', 'description': 'To explore the effect of CASAD on thyroid function tests, thyroid hormone and calcium absorption', 'timeFrame': '1 week'}, {'measure': 'Changes in MDASI-THY scores', 'description': 'To examine changes in MDASI-THY scores after treatment with CASAD', 'timeFrame': '1 week'}]",4,,,ALL,False,Salient Pharmaceuticals Incorporated,INDUSTRY,0,10.0,ESTIMATED,2025-09-01T16:18:17.173983,v2_robust,True,True,False,False,False,
NCT02354534,Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3),A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3),Artesunate Suppositories,['Artesunate Suppositories'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Cervical Intraepithelial Neoplasia Grade 2/3,"['Cervical Intraepithelial Neoplasia Grade 2/3', 'High-risk HPV (Any Strain)']","['cervical dysplasia', 'HPV', 'Treatment', 'preinvasive', 'cervix', 'vaginal suppository', 'Cornelia Trimble', 'abnormal pap', 'CIN']",COMPLETED,,2015-02,2018-11-06,"[{'measure': 'Number of Participants With Serious Adverse Events', 'description': 'Number of participants with serious adverse events or dose limiting toxicities related to the study intervention assessed using Common Terminology Criteria for Adverse Events (CTCAE) 4.0 criteria.', 'timeFrame': '41 weeks'}]","[{'measure': 'Viral Clearance of HPV', 'description': 'Number of participants whose human papillomavirus (HPV) genotypes present at study entry become undetectable without surgical intervention. HPV genotyping detects strains of HPV present at each timepoint. For this outcome, we evaluated whether strains of HPV detected at study entry became undetectable during the study participation.', 'timeFrame': '41 weeks'}, {'measure': 'Histologic Regression of CIN2/3', 'description': 'Number of participants who had histologic regression from cervical intraepithelial neoplasia (CIN) 2/3 to CIN 1 or less, as assessed by colposcopically-directed biopsies. Histologic regression is defined as disappearance of the high grade lesion (CIN2/3) without surgical intervention.', 'timeFrame': '41 weeks'}]",3,18 Years,,FEMALE,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,1,30.0,ACTUAL,2025-09-01T16:18:17.173997,v2_robust,True,True,True,False,True,
NCT00781534,A Clinical Trial of Ginseng in Diabetes,A Clinical Trial of Ginseng for Glucose Intolerance,Ginseng,"['ginsenoside RE', 'Ginseng']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Diabetes,['Diabetes'],"['Health Supplements', 'Ginseng', 'Diabetes']",COMPLETED,,2003-09,2008-09,[],[],0,18 Years,65 Years,ALL,True,Washington University School of Medicine,OTHER,0,19.0,ACTUAL,2025-09-01T16:18:17.174031,v2_robust,True,True,True,False,False,
NCT00851734,"A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)","A Phase 1 Dose-Escalation Study To Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed By an Open-Label Evaluation of LX214 Ophthalmic Solution in Patients With Keratoconjunctivitis Sicca",voclosporin ophthalmic solution,['voclosporin ophthalmic solution'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Keratoconjunctivitis Sicca,['Keratoconjunctivitis Sicca'],[],COMPLETED,,2009-02,2009-04,"[{'measure': 'ocular irritation', 'timeFrame': '12 hours'}]",[],1,18 Years,55 Years,ALL,True,"Lux Biosciences, Inc.",INDUSTRY,0,35.0,ACTUAL,2025-09-01T16:18:17.174037,v2_robust,True,True,True,False,False,
NCT00259064,Iressa v BSC (Best Supportive Care) in First Line NSCLC,"A Phase II Multicentre Randomised, Parallel Group, Double-Blind, Placebo-Controlled Study of ZD1839 (IRESSATM) (250MG Tablet) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Chemotherapy-Naive Patients With Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status",Gefitinib,['Gefitinib'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,NSCLC,['NSCLC'],[],COMPLETED,,2004-09,2016-04,"[{'measure': 'To compare Iressa v best supportive care in terms of progression free survival', 'timeFrame': 'Progression-free survival'}]","[{'measure': 'To compare Iressa v best supportive care in terms of objective tumour response rate', 'timeFrame': 'Overall objective tumour response rate (CR and PR) according to the RECIST criteria'}, {'measure': 'To compare Iressa v best supportive care in terms of overall survival', 'timeFrame': 'Time to death'}, {'measure': 'To compare Iressa v best supportive care in terms of quality of life', 'timeFrame': 'Improvement in patient-reported functionality as measured by trial outcome index, comprised of the physical and functional well being sections and LCS of FACT-L and quality of life measured by the FACT-L total score'}, {'measure': 'To compare Iressa v best supportive care in terms of tolerability', 'timeFrame': 'Adverse event profile (type, frequency and severity of adverse events); laboratory parameters and vital signs'}]",5,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,0,216.0,ACTUAL,2025-09-01T16:18:17.174076,v2_robust,True,True,True,False,True,
NCT00768664,Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer,CLINICAL PHASE 2 MULTICENTER TRIAL OF PF-00299804 IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK,PF-00299804,['PF-00299804'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Head and Neck Neoplasms,['Head and Neck Neoplasms'],['recurrent or metastatic squamous cell cancer of the Head and Neck; no prior systemic therapy for recurrence'],COMPLETED,,2008-11-04,2012-04-18,"[{'measure': 'Percentage of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR)', 'description': 'Percentage of participants with best OR of confirmed CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST) relative to total number of evaluable participants for response. CR defined as disappearance of all target/non-target lesions. PR defined as at least a 30 percent (%) decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses (CR and PR) were those that persisted on a follow-up imaging assessment greater than or equal to (≥)4 weeks after the initial objective documentation of response.', 'timeFrame': 'Baseline up to 18 months'}]","[{'measure': 'Duration of Response (DR)', 'description': 'Time in weeks from the first documentation of objective tumor response (CR or PR) to progression or death due to progressive disease (PD). DR was calculated as (the date of the first documentation of PD or death due to PD minus the date of the first CR or PR that was subsequently confirmed plus 1). DR was calculated for the subgroup of participants with a confirmed objective tumor response (CR or PR).', 'timeFrame': 'Baseline up to 18 months'}, {'measure': 'Duration of Stable Disease (SD)', 'description': 'Time in weeks from start of treatment to date of objective disease progression (based on RECIST criteria). SD defined as neither sufficient shrinkage for PR nor sufficient increase for PD, taking as a reference the smallest sum of the longest dimensions since treatment start. Participants last known to be alive, not to have started new anticancer treatment, to be progression free, and who had a baseline and at least 1 on-study disease assessment were censored at date of last objective disease assessment that verified lack of PD. Participants who died not due to PD censored on death date.', 'timeFrame': 'Baseline up to 18 months'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'Time in weeks from date of enrollment to first documentation of PD, death due to any cause, symptomatic deterioration, or start of secondary anticancer therapy, whichever occurred first. PFS calculated as (first event date minus enrollment date plus 1). Documentation of progression determined from objective disease assessment based on RECIST criteria. PD defined as at least a 20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since treatment started or the appearance of 1 or more new lesions.', 'timeFrame': 'Baseline up to 18 months'}, {'measure': 'Progression-Free Survival (PFS) at 6 Months and at 1 Year', 'description': 'Probability of being event-free (event defined as PD, death due to any cause, symptomatic deterioration, or start of secondary anticancer therapy) at 26 weeks and 52 weeks after the first dose of study treatment.', 'timeFrame': 'Baseline up to 52 weeks'}, {'measure': 'Overall Survival (OS)', 'description': 'Time in weeks from the start date of enrollment to date of death due to any cause. OS was calculated as (the death date minus the enrollment date plus 1). Participants without death dates, last known to be alive were censored at last contact.', 'timeFrame': 'Baseline up to 18 months'}, {'measure': 'Overall Survival at 6 Months and 1 Year', 'description': 'Probability of survival 26 weeks and 52 weeks after the first dose of study treatment.', 'timeFrame': 'Baseline up to Week 52'}, {'measure': 'Trough Plasma Concentrations (Ctrough) of Dacomitinib After Repeat Dosing', 'description': 'Trough concentrations of dacomitinib in plasma measured as nanograms per milliliter (ng/mL).', 'timeFrame': 'Predose on Day 1 of Cycles 2, 3, and 4 and predose on Day 8 of Cycle 1'}, {'measure': 'Ctrough of Dacomitinib After Repeat Dosing In Participants Requiring Administration of Dacomitinib With a Feeding Tube', 'timeFrame': 'Predose on Day 1 of Cycles 2, 3, and 4 and predose on Day 8 of Cycle 1'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) In Participants Requiring Administration of Dacomitinib With a Feeding Tube', 'timeFrame': 'Cycle 1 Day 1 at predose and 1, 2, 4, 6, 8, 10, and 24 hours postdose'}, {'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) In Participants Requiring Administration of Dacomitinib With a Feeding Tube', 'description': 'Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).', 'timeFrame': 'Cycle 1 Day 1 at predose and 1, 2, 4, 6, 8, 10, and 24 hours postdose'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax) In Participants Requiring Administration of Dacomitinib With a Feeding Tube', 'timeFrame': 'Cycle 1 Day 1 at predose and 1, 2, 4, 6, 8, 10, and 24 hours postdose'}, {'measure': 'Plasma Decay Half-Life (t1/2)', 'description': 'Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.', 'timeFrame': 'Cycle 1 Day 1 at predose and 1, 2, 4, 6, 8, 10, and 24 hours postdose'}, {'measure': 'Correlation Between Biomarkers Status and Best Overall Response', 'description': 'The best overall response was best response recorded from the start of the treatment until disease progression/recurrence. In this outcome measure, biomarkers status and best overall response was reported in terms of correlation coefficient.', 'timeFrame': 'Baseline up to 18 months'}, {'measure': 'H-Score at Baseline and Post-baseline for Paired Biopsy Biomarkers', 'description': 'H-score is a measure of the immunohistochemistry staining positivity. The range for H-score is between 0 and 300. A higher score refers to stronger staining of a particular marker.', 'timeFrame': 'Baseline up to 18 Months'}, {'measure': 'H-Score at Ratio to Baseline for Paired Biopsy Biomarkers', 'description': 'H-score is a measure of the immunohistochemistry staining positivity. The range for H-score is between 0 and 300. A higher score refers to stronger staining of a particular marker.', 'timeFrame': 'Baseline up to 18 Months'}]",16,18 Years,99 Years,ALL,False,Pfizer,INDUSTRY,0,69.0,ACTUAL,2025-09-01T16:18:17.174096,v2_robust,True,True,True,False,False,
NCT02388464,"A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure",A Phase 1 Clinical Pharmacology Study of the Effects of a Single 4 Hour Intravenous Infusion of Bendavia™ (MTP-131) in Subjects With Stable New York Heart Association Class II-III Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction,MTP-131,"['MTP-131', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Congestive Heart Failure,['Congestive Heart Failure'],"['Congestive Heart Failure', 'Bendavia™', 'MTP-131']",COMPLETED,,2014-07,2015-06,"[{'measure': 'Incidence of Adverse Events', 'timeFrame': 'Assessed up to Day 7'}]","[{'measure': 'Left ventricular ejection fraction assessed by 2-D echocardiography', 'timeFrame': 'Assessed up to 24 hours post-infusion start'}]",2,45 Years,80 Years,ALL,False,Stealth BioTherapeutics Inc.,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:17.174266,v2_robust,True,True,True,False,True,
NCT04889664,Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD,Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD: A Pilot Study,Ketamine,['Ketamine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,PTSD,['PTSD'],"['ketamine', 'Written Exposure Therapy', 'PTSD', 'intervention', 'treatment', 'posttraumatic stress disorder']",COMPLETED,,2021-06-04,2023-10-14,"[{'measure': 'CAPS-5', 'description': 'Clinician Administered PTSD Scale for DSM-5 (CAPS-5), assessed at baseline (before the first infusion) and 12 weeks following the start of WET. The Clinician-Administered PTSD Scale (CAPS) is a 30-item structured diagnostic interview designed to measure frequency and intensity of PTSD symptoms. The symptoms are scored in a 0-4 Likert-type scale, total score ranging from 0 to 80, higher score indicates more symptoms', 'timeFrame': 'Baseline and Week 12'}]",[],1,18 Years,70 Years,ALL,False,Icahn School of Medicine at Mount Sinai,OTHER,0,16.0,ACTUAL,2025-09-01T16:18:17.174334,v2_robust,True,True,True,False,False,
NCT06735664,Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation,A Phase I Study of Covalent BTK Inhibitor Zanubrutinib in Combination With a CD3-CD20 Bispecific Antibody Odronextamab in Patients With Richter's Transformation,Zanubrutinib,"['BTK-InhB', 'BGB-3111', 'BGB3111', 'BGB 3111', 'Zanubrutinib', 'Brukinsa']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Recurrent Transformed Chronic Lymphocytic Leukemia,"['Recurrent Transformed Chronic Lymphocytic Leukemia', 'Refractory Transformed Chronic Lymphocytic Leukemia', 'Richter Syndrome', 'Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma']",[],RECRUITING,,2025-08-14,2027-12-13,"[{'measure': 'Dose limiting toxicity (DLT)', 'description': 'All non-hematologic toxicities will be coded and graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Hematologic toxicities will be assessed per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2018. Cytokine release syndrome (CRS)/immune effector cell associated neurotoxicity syndrome (ICANS) will be coded by American Society for Transplantation and Cellular Therapy (ASTCT) grading for CRS/ICANS. DLTs will be summarized by type, severity, and attribution. DLTs will be individually described.', 'timeFrame': 'During the first 2 cycles of protocol therapy (cycle length = 21 days)'}, {'measure': 'Incidence of adverse events (AEs)', 'description': 'All non-hematologic toxicities will be coded and graded according to the NCI CTCAE v 5.0. Hematologic toxicities will be assessed per IWCLL 2018. CRS/ICANS will be coded by ASTCT grading for CRS/ICANS. AEs will be summarized by type, severity, and attribution.', 'timeFrame': 'Up to 28 days after last dose of study treatment'}]","[{'measure': 'Overall response rate (ORR)', 'description': 'ORR will be defined as the proportion of response evaluable patients who achieve a best response of complete response (CR) or partial response (PR) according to Lugano 2014 guidelines on study before any documented disease progression or any subsequent non-Hodgkin lymphoma (NHL) treatment. ORR will be estimated by the binary proportion, along with the 95% exact binomial confidence intervals (CIs).', 'timeFrame': 'Up to 3 years'}, {'measure': 'CR rate', 'description': 'Will be defined as the proportion of response evaluable patients who achieve a best response of complete response according to Lugano 2014 guidelines on study before any documented disease progression or any subsequent NHL treatment. CR rate will be estimated by the binary proportion, along with the 95% exact binomial CIs.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Duration of response (DOR)', 'description': 'Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% CI will be constructed based on log-log transformation. Median DOR will be estimated when available.', 'timeFrame': 'From the first achievement of CR or PR to disease progression/relapse or death due to any cause, whichever is earlier, assessed up to 3 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% CI will be constructed based on log-log transformation. Median PFS will be estimated when available.', 'timeFrame': 'From start of protocol treatment to disease relapse/progression or death due to any cause, whichever is earlier, assessed up to 3 years'}, {'measure': 'Overall survival (OS)', 'description': 'Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% CI will be constructed based on log-log transformation. Median OS will be estimated when available.', 'timeFrame': 'From start of protocol treatment to death due to any cause, assessed up to 3 years'}]",7,18 Years,,ALL,False,City of Hope Medical Center,OTHER,1,23.0,ESTIMATED,2025-09-01T16:18:17.174346,v2_robust,True,True,False,False,True,
NCT05691764,Effect of Cyclosporine and Remote Ischemic Preconditioning in Reperfusion Ischemia Injury on Tetralogy Fallot Patients With Correction Surgery,"Effect of Cyclosporine and Remote Ischemic Preconditioning on MDA, Calcium Cytosol Concentration, and Mitochondrial Edema in Reperfusion Ischemia Injury: Research on Tetralogy Fallot Patients With Correction Surgery",Cyclosporin,"['Placebo', 'Cyclosporin', 'Sandimmun']",3,INTERVENTIONAL,['NA'],,,Myocardial Injury,"['Myocardial Injury', 'Cardiac Surgery']","['RIPC', 'cyclosporine', 'ischemia reperfusion injury', 'MDA', 'calcium cytosol', 'tetralogy Fallot', 'mitochondrial edema', 'infundibulum']",COMPLETED,,2020-09-01,2022-09-01,"[{'measure': 'Malondialdehyde (MDA)', 'description': 'ROS level is determined by measuring MDA concentration (nmol/mL)', 'timeFrame': '1 year'}, {'measure': 'Calcium cytosol concentration', 'description': 'Calcium concentration (nmol/mL) in cytosol is determined by ratiometric analysis on Fura Red- dyed heart cells.', 'timeFrame': '1 year'}, {'measure': 'Mitochondrial edema', 'description': 'Mitochondrial edema (%) is measured by decreasing of optical density that indicates change in mitochondrial matrix volume.', 'timeFrame': '1 year'}]","[{'measure': 'Cardiac index', 'description': 'Examined with echocardiography, unit of measurement is litres per minute per square metre (L/min/m2).', 'timeFrame': '1 year'}, {'measure': 'Troponin I', 'description': 'Measured from venous blood, unit of measurement is nanograms per milliliter (ng/mL).', 'timeFrame': '1 year'}, {'measure': 'Creatine kinase- MB (CKMB)', 'description': 'Measured from venous blood, unit of measurement is units per liter (IU/L).', 'timeFrame': '1 year'}, {'measure': 'Vasoactive inotropic score (VIS)', 'description': 'VIS was calculated as: dopamine dose (μg/kg/min) + dobutamine dose (μg/kg/min) + 100 × epinephrine dose (μg/kg/min) + 10 × milrinone dose (μg/kg/min) + 10 000 × vasopressin dose (unit/kg/min) + 100 × norepinephrine dose (μg/kg/min).', 'timeFrame': '1 year'}]",7,1 Year,6 Years,ALL,False,Indonesia University,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:17.174358,v2_robust,True,True,True,False,False,
NCT04585464,"A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults","A Phase 1, Randomized, Placebo-Controlled, Double-blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and PK of EDG-5506 in Adult Healthy Volunteers and Adults With Becker Muscular Dystrophy",EDG-5506,"['EDG-5506', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteer,"['Healthy Volunteer', 'Becker Muscular Dystrophy']","['Healthy Volunteers', 'Becker Muscular Dystrophy']",COMPLETED,,2020-10-12,2021-12-27,"[{'measure': 'Incidence, frequency, severity and dose-relationship of adverse events', 'timeFrame': 'Up to 42 days of monitoring'}, {'measure': 'Incidence of abnormal laboratory test results (clinical chemistry, hematology, urinalysis, coagulation)', 'timeFrame': 'Up to 42 days of monitoring'}, {'measure': 'Incidence of treatment-emergent clinically abnormal electrocardiogram (ECG)', 'timeFrame': 'Up to 42 days of monitoring'}, {'measure': 'Incidence of abnormal vital signs', 'timeFrame': 'Up to 42 days of monitoring'}, {'measure': 'Incidence of abnormal physical exam findings', 'timeFrame': 'Up to 42 days of monitoring'}]","[{'measure': 'Plasma maximum measured drug concentration (Cmax)', 'timeFrame': 'Up to 42 days of testing'}, {'measure': 'Time of maximum concentration (Tmax)', 'timeFrame': 'Up to 42 days of testing'}, {'measure': 'Area under the concentration-time curve (AUC)', 'timeFrame': 'Up to 42 days of testing'}, {'measure': 'Plasma half-life (T½)', 'timeFrame': 'Up to 42 days of testing'}, {'measure': 'Renal clearance (CLR)', 'timeFrame': 'Up to 42 days of testing'}, {'measure': 'Drug excreted unchanged in urine (Amt0-24)', 'timeFrame': 'Up to 42 days of testing'}, {'measure': 'Fraction excreted in urine (Fe)', 'timeFrame': 'Up to 42 days of testing'}]",12,18 Years,55 Years,ALL,True,"Edgewise Therapeutics, Inc.",INDUSTRY,1,127.0,ACTUAL,2025-09-01T16:18:17.174407,v2_robust,True,True,True,False,True,
NCT05840809,Pharmacokinetics of Drugs Used to Treat Drug Sensitive Tuberculosis in Breastfeeding Mother-infant Pairs,Pharmacokinetics of Drugs Used to Treat Drug-sensitive Tuberculosis in Breastfeeding Mother-infant Pairs: An Observational Pharmacokinetic Study,First line tuberculosis treatment,['First line tuberculosis treatment'],1,OBSERVATIONAL,[],,,Tuberculosis Active,"['Tuberculosis Active', 'Breastfeeding', 'Tuberculosis']","['Breastfeeding', 'Tuberculosis', 'Pharmacokinetic']",ACTIVE_NOT_RECRUITING,,2022-01-20,2026-01-29,"[{'measure': 'Concentration of rifampicin in maternal plasma', 'description': 'Pharmacokinetic', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Concentration of rifampicin in breastmilk', 'description': 'Pharmacokinetic', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Concentration of rifampicin in infant plasma', 'description': 'Pharmacokinetic', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Concentration of isoniazid in maternal plasma', 'description': 'Pharmacokinetic', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Concentration of isoniazid in breastmilk', 'description': 'Pharmacokinetic', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Concentration of isoniazid in infant plasma', 'description': 'Pharmacokinetic', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Concentration of ethambutol in maternal plasma', 'description': 'Pharmacokinetic', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Concentration of ethambutol in breastmilk', 'description': 'Pharmacokinetic', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Concentration of ethambutol in infant plasma', 'description': 'Pharmacokinetic', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Concentration of pyrazinamide in maternal plasma', 'description': 'Pharmacokinetic', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Concentration of pyrazinamide in breastmilk', 'description': 'Pharmacokinetic', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Concentration of pyrazinamide in infant plasma', 'description': 'Pharmacokinetic', 'timeFrame': '0-24 hours after maternal dose'}]","[{'measure': 'Maximum concentration of rifampicin in maternal plasma', 'description': 'Pharmacokinetic measurement', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Maximum concentration of rifampicin in breastmilk', 'description': 'Pharmacokinetic measurement', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Maximum concentration of isoniazid in maternal plasma', 'description': 'Pharmacokinetic measurement', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Maximum concentration of isoniazid in breastmilk', 'description': 'Pharmacokinetic measurement', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Maximum concentration of ethambutol in maternal plasma', 'description': 'Pharmacokinetic measurement', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Maximum concentration of ethambutol in breastmilk', 'description': 'Pharmacokinetic measurement', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Maximum concentration of pyrazinamide in maternal plasma', 'description': 'Pharmacokinetic measurement', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Maximum concentration of pyrazinamide in breastmilk', 'description': 'Pharmacokinetic measurement', 'timeFrame': '0-24 hours after maternal dose'}, {'measure': 'Anxiety in mothers', 'description': 'Generalised anxiety disorder (GAD7 questionnaire)', 'timeFrame': 'During pharmacokinetic study visits (up to 52 weeks postpartum)'}, {'measure': 'Depression in mothers', 'description': 'Patient health questionnaire (PHQ-9)', 'timeFrame': 'During pharmacokinetic study visits (up to 52 weeks postpartum)'}, {'measure': 'Maternal beliefs about medicines', 'description': 'Beliefs about Medicines Questionnaire (BMQ)', 'timeFrame': 'During pharmacokinetic study visits (up to 52 weeks postpartum)'}]",23,18 Years,,FEMALE,False,University of Liverpool,OTHER,1,20.0,ACTUAL,2025-09-01T16:18:17.174484,v2_robust,False,True,False,False,False,
NCT00374309,Experimental Vaccine for Prevention of Ebola Virus Infection,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Ebola Adenoviral Vector Vaccine, VRC-EBOADV018-00-VP, in Healthy Adults",VRC-EBOADV018-00-VP,['VRC-EBOADV018-00-VP'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Ebola Hemorrhagic Fever,"['Ebola Hemorrhagic Fever', 'Ebola Virus Disease', 'Ebola Virus Vaccines', 'Envelope Glycoprotein, Ebola Virus', 'Filovirus']","['Hemorrhagic Fever', 'Healthy', 'Immunity', 'T -Cells', 'Filovirus', 'Healthy Volunteer', 'HV']",COMPLETED,,2006-09-05,2009-05-05,"[{'measure': ""Safety (local and systemic reactogenicity, lab tests, AE's).""}]",[{'measure': 'Immunogenicity (cellular and humoral immune function assays).'}],2,18 Years,50 Years,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,48.0,,2025-09-01T16:18:17.174607,v2_robust,True,True,True,False,True,
NCT04777409,A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus),A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus),Semaglutide,"['Placebo (semaglutide)', 'Semaglutide']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Early Alzheimer´s Disease,['Early Alzheimer´s Disease'],[],ACTIVE_NOT_RECRUITING,,2021-05-18,2026-10-06,"[{'measure': 'Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score', 'description': 'Score on scale (0 to 18)\n\nMeasures the impact of cognitive decline on daily function using the following six domains commonly affected in Alzheimer\'s disease:\n\n* Cognitive domains: memory, orientation, and judgement and problem solving\n* Function domains: community affairs, home and hobbies, and personal care Based on clinical information obtained from the subject and informant, an individual box score ranging from 0 to 3 is determined that represents ""none"" to ""severe"" impairment for each of the six domains.\n\nThe CDR-Sum of Boxes (CDR-SB) score will be derived by adding the individual scores of the six domains at a given time point. The total CDR-SB score ranges from 0 to 18 with higher scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}]","[{'measure': ""Main Phase: Change in the 24-item Alzheimer's Disease Cooperative Study Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-ADL-MCI) score"", 'description': 'Score on scale (0 to 53). An interview-based assessment of information provided by the study partner (informant). The total scores based on 18 items on the scale range from 0 to 53 with lower scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension phase: Change in the ADCS-ADL-MCI score', 'description': 'Score on scale (0 to 53) An interview-based assessment of information provided by the study partner (informant). The total scores based on 18 items on the scale range from 0 to 53 with lower scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Time to progression to Clinical Dementia Rating (CDR) global score greater than or equal to (≥)1.0 among patients with CDR global score equal to (=) 0.5 at baseline', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Extension Phase: Time to progression to Clinical Dementia Rating (CDR) global score greater than or equal to (≥)1.0 among patients with CDR global score equal to (=) 0.5 at baseline', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': ""Main Phase: Change in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog-13) score"", 'description': 'Score on scale (0 to 85) Measures the severity of cognitive impairment in various domains including memory, language, orientation, praxis and executive function. The total scores on the scale range from 0 to 85 with higher scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': ""Extension Phase: Change in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog-13) score"", 'description': 'Score on scale (0 to 85) Measures the severity of cognitive impairment in various domains including memory, language, orientation, praxis and executive function. The total scores on the scale range from 0 to 85 with higher scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the Montreal Cognitive Assessment (MoCA) score', 'description': 'Score on scale (0 to 30) The assessment includes 8 domains of cognitive function with total scores ranging from 0 to 30 and lower scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the Montreal Cognitive Assessment (MoCA) score', 'description': 'Score on scale (0 to 30) The assessment includes 8 domains of cognitive function with total scores ranging from 0 to 30 and lower scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': ""Main Phase: Change in the Alzheimer's Disease Composite Score (ADCOMS)"", 'description': 'Score on scale (0 to 1.97) The ADCOMS is a composite clinical outcome comprising 4 items from the ADAS-Cog-13, 2 items from the MMSE and all 6 items from the CDR-SB.32 The total scores on the scale range from 0 to 1.97 with higher scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': ""Extension Phase: Change in the Alzheimer's Disease Composite Score (ADCOMS)"", 'description': 'Score on scale (0 to 1.97) The ADCOMS is a composite clinical outcome comprising 4 items from the ADAS-Cog-13, 2 items from the MMSE and all 6 items from the CDR-SB.32 The total scores on the scale range from 0 to 1.97 with higher scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the Mini-Mental State Examination (MMSE) score', 'description': 'Score on scale (0 to 30) The MMSE measures orientation, attention, memory, language and visuo-spatial function. The total scores on the scale range from 0 to 30 with lower scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the Mini-Mental State Examination (MMSE) score', 'description': 'Score on scale (0 to 30) The MMSE measures orientation, attention, memory, language and visuo-spatial function. The total scores on the scale range from 0 to 30 with lower scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Time to progression in disease stage based on CDR global score', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Extension Phase: Time to progression in disease stage based on CDR global score', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the composite Z-score based on the three outcome measures CDR-SB, ADCS-ADL-MCI, and ADAS-Cog-13', 'description': 'Score', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the composite Z-score based on the three outcome measures CDR-SB, ADCS-ADL-MCI, and ADAS-Cog-13', 'description': 'Score', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the 10-item Neuropsychiatric Inventory (NPI) score', 'description': '104 Score on scale (0 to 120) The 10-item scale assesses symptoms including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability and aberrant motor activity. For each domain the frequency (4-point scale) and severity (3-point scale) of symptoms is reported. The score for each domain is calculated by multiplying the frequency and severity score. The total 10-item NPI score is 0 to 120 with higher scores indicating a greater symptomatology.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the 10-item Neuropsychiatric Inventory (NPI) score', 'description': '104 Score on scale (0 to 120) The 10-item scale assesses symptoms including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability and aberrant motor activity. For each domain the frequency (4-point scale) and severity (3-point scale) of symptoms is reported. The score for each domain is calculated by multiplying the frequency and severity score. The total 10-item NPI score is 0 to 120 with higher scores indicating a greater symptomatology.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in high sensitivity C-reactive protein level', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in high sensitivity C-reactive protein level', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Number of treatment emergent adverse events (TEAEs)', 'description': 'Number of events', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Extension Phase: Number of treatment emergent adverse events (TEAEs)', 'description': 'Number of events', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Time to first occurrence of major adverse cardiovascular event (MACE) comprising non-fatal myocardial infarction, non-fatal stroke and allcause death', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Time to first occurrence of major adverse cardiovascular event (MACE) comprising non-fatal myocardial infarction, non-fatal stroke and allcause death', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Time to first occurrence of stroke', 'description': 'Weeks', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Time to first occurrence of stroke', 'description': 'Weeks', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the EQ-5D-5L (proxy version) index score', 'description': 'Score The EQ-5D-5L descriptive system comprises mobility, self-care, usual activities, pain/discomfort and anxiety/depression with five response levels each (no problems, slight problems, moderate problems, severe problems, unable to /extreme problems). The EQ-5D-5L proxy version 1 (the study partner is asked to rate how he/she \\[the proxy\\] would rate the subject´s health) will be used in this trial.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the EQ-5D-5L (proxy version) index score', 'description': 'Score The EQ-5D-5L descriptive system comprises mobility, self-care, usual activities, pain/discomfort and anxiety/depression with five response levels each (no problems, slight problems, moderate problems, severe problems, unable to /extreme problems). The EQ-5D-5L proxy version 1 (the study partner is asked to rate how he/she \\[the proxy\\] would rate the subject´s health) will be used in this trial.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Extension phase: Change in the CDR-SB score', 'description': 'Score on scale (0 to 18)\n\nMeasures the impact of cognitive decline on daily function using the following six domains commonly affected in Alzheimer\'s disease:\n\n* Cognitive domains: memory, orientation, and judgement and problem solving\n* Function domains: community affairs, home and hobbies, and personal care Based on clinical information obtained from the subject and informant, an individual box score ranging from 0 to 3 is determined that represents ""none"" to ""severe"" impairment for each of the six domains.\n\nThe CDR-Sum of Boxes (CDR-SB) score will be derived by adding the individual scores of the six domains at a given time point. The total CDR-SB score ranges from 0 to 18 with higher scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}]",30,55 Years,85 Years,ALL,False,Novo Nordisk A/S,INDUSTRY,0,1840.0,ESTIMATED,2025-09-01T16:18:17.174760,v2_robust,True,True,False,False,True,
NCT05925309,Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy,Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy in Biliary Atresia: a Randomized Controlled Trial,"Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem","['Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem', 'Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor']",2,INTERVENTIONAL,['NA'],,,Biliary Atresia,"['Biliary Atresia', 'Cholangitis', 'Anti-Bacterial Agents']",[],RECRUITING,,2023-07-01,2027-07-31,"[{'measure': 'The occurrence of cholangitis (confirmed or suspected) within 6 months after KP', 'description': 'Definition of cholangitis:\n\nA. Clinical elements\n\n1. Fever and/or shivering;\n2. Stool color change;\n3. New/increasing jaundice;\n4. Abdominal discomfort: vomiting, poor, feeding, irritability.\n\nB. Laboratory and imaging elements\n\n1. Inflammatory response (WBC and/or CRP and/or PCT);\n2. Increased/increasing transaminases;\n3. Increased/increasing GGT and/or bilirubin;\n4. Bile lakes.\n\nSuspected cholangitis: one item in A + one item in B. Confirmed cholangitis: two items in A + two items in B or ""suspected cholangitis"" + positive blood culture.\n\nThe diagnosis of cholangitis requires the exclusion of definite infections of other systems.', 'timeFrame': '6 months after KP'}]","[{'measure': 'The occurrence of cholangitis (confirmed or suspected) within 1 year after KP', 'description': 'The definition of cholangitis is the same as primary outcome.', 'timeFrame': '1 year after KP'}, {'measure': 'The occurrence of jaundice clearance within 6 months after KP', 'description': 'Jaundice clearance is defined as total bilirubin (TB) less than 20 μmol/L.', 'timeFrame': '6 months after KP'}, {'measure': 'The occurrence of jaundice clearance within 1 year after KP', 'description': 'Jaundice clearance is defined as TB less than 20 μmol/L.', 'timeFrame': '1 year after KP'}, {'measure': 'The number of cholangitis recurrence within 6 months after KP', 'description': 'The definition of cholangitis is the same as primary outcome.', 'timeFrame': '6 months after KP'}, {'measure': 'The number of cholangitis recurrence within 1 year after KP', 'description': 'The definition of cholangitis is the same as primary outcome.', 'timeFrame': '1 year after KP'}, {'measure': 'The patient survive with native liver or not within 2 years after KP', 'timeFrame': '2 years after KP'}, {'measure': 'The weight gain of the patients from pre-operation to 6 months post KP', 'description': 'Weight for height (length) Z-score is calculated based on the gender, age, and weight reference standards for children in China. The difference in weight for height (length) Z-score between pre-operation and 6 months post KP is regarded as weight gain.', 'timeFrame': 'From pre-operation to 6 months post KP'}, {'measure': 'The weight gain of the patients from pre-operation to 1 year post KP', 'description': 'Weight for height (length) Z-score is calculated based on the gender, age, and weight reference standards for children in China. The difference in weight for height (length) Z-score between pre-operation and 1 year post KP is regarded as weight gain.', 'timeFrame': 'From pre-operation to 1 year post KP'}, {'measure': 'Liver parameters at post-operation month 6', 'description': 'Liver parameters: pediatric end-stage liver disease (PELD) score, liver stiffness measurement.\n\nPELD score = 0.480×ln (total bilirubin) + 1.857×ln (international normalized ratio)-0.687×ln (albumin) + 0.436 × age score + 0.667 × growth arrest\\] × 10. Age score:1 point for age \\< 24 months, 0 for age ≥ 24 months. Growth arrest: 1 point for more than 2 standard deviations below the average, otherwise 0.\n\nLiver stiffness measurement is measured by liver transient elastography.', 'timeFrame': '6 months after KP'}, {'measure': 'Liver parameters at post-operation month 12', 'description': 'Liver parameters: pediatric end-stage liver disease (PELD) score, liver stiffness measurement.\n\nPELD score = 0.480×ln (total bilirubin) + 1.857×ln (international normalized ratio)-0.687×ln (albumin) + 0.436 × age score + 0.667 × growth arrest\\] × 10. Age score:1 point for age \\< 24 months, 0 for age ≥ 24 months. Growth arrest: 1 point for more than 2 standard deviations below the average, otherwise 0.\n\nLiver stiffness measurement is measured by liver transient elastography.', 'timeFrame': '1 year after KP'}, {'measure': 'Changes in intestinal flora from post-operation week 2 to month 3', 'description': 'Fecal samples of 40 patients in each group are collected 2 weeks and 3 months after KP, and frozen at -80℃. 16s-rDNA sequencing is used to find out the changes in intestinal flora.', 'timeFrame': 'From post-operation week 2 to month 3'}, {'measure': 'Changes in intestinal flora from post-operation week 2 to month 6', 'description': 'Fecal samples of 40 patients in each group are collected 2 weeks and 6 months after KP, and frozen at -80℃. 16s-rDNA sequencing is used to find out the changes in intestinal flora.', 'timeFrame': 'From post-operation week 2 to month 6'}]",13,14 Days,90 Days,ALL,False,Children's Hospital of Fudan University,OTHER,0,356.0,ESTIMATED,2025-09-01T16:18:17.174977,v2_robust,True,True,False,False,False,
NCT04598009,Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma,A Phase II Study of Binimetinib in Combination With Imatinib in Patients With Advanced KIT-Mutant Melanoma,Binimetinib,"['Binimetinib', 'Imatinib Mesylate', 'Mektovi', 'ARRY-162', 'Imatinib', 'MEK162', 'Binimetinib Oral']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Melanoma Stage III,"['Melanoma Stage III', 'Melanoma Stage IV']","['KIT-Mutant', 'Unresectable Melanoma', 'Melanoma']",RECRUITING,,2021-03-03,2027-03-31,"[{'measure': 'Objective response rate (ORR)', 'description': 'Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be estimated using the method of Whitehead, and the p-values for testing the null hypothesis at each stage will use the method of Koyama \\& Chen and 90% confidence interval will be reported.', 'timeFrame': 'Up to week 16'}]","[{'measure': 'Proportion of participants with treatment-related adverse events (AE)', 'description': 'Proportion of participants with treatment-related AEs greater than grad2 as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 will be reported by toxicity.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Median duration of response', 'description': 'Will estimate the probability-of-being-in-response function, assuming time to response is exponentially distributed.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Participants with an objective response will be followed for survival from initiation of study treatment until date of disease progression or death from any cause', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival (OS)', 'description': 'Participants will be followed from initiation of study treatment until date of disease progression or death from any cause and estimated using the Kaplan-Meier method to estimate the survival rate (95% CI)', 'timeFrame': 'Up to 2 years'}, {'measure': 'Clinical benefit rate (CBR)', 'description': 'Defined as CR, PR, or stable disease (SD) \\>= 16 weeks by RECIST. CBR will be defined as the proportion of participants with CR, PR, or SD for \\>= 16 weeks.', 'timeFrame': 'Up to 2 years'}]",6,18 Years,,ALL,False,"University of California, San Francisco",OTHER,1,25.0,ESTIMATED,2025-09-01T16:18:17.175091,v2_robust,True,True,False,False,True,
NCT01482299,RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression,A Phase II Trial of RAD001 (Everolimus) for 2nd Line Treatment After Failure of Fluoropyrimidine Plus Platinum Chemotherapy in Patients With Metastatic or Recurrent Gastric Cancer With pS6 Ser 240/4 Expression,RAD001,"['everolimus', 'RAD001']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Stomach Neoplasm,['Stomach Neoplasm'],"['pS6 Ser 240/4', 'RAD001 (everolimus)', 'second-line treatment', 'advanced gastric cancer']",COMPLETED,,2011-11,2014-01,"[{'measure': '4-month progression-free survival', 'description': 'Progression-free survival is defined as the time from the first treatment to the onset of progressive disease per RECIST criteria or to the date of death whichever comes first. For patients who do not experience progressive disease or death, the progression-free survival duration will be right censored on the last disease assessment date.', 'timeFrame': 'up to 3years'}]","[{'measure': 'Response rate', 'description': 'evaluated with abdominal and pelvic dynamic CT scan every 8 weeks, using RECIST version 1.0', 'timeFrame': 'Up to 1year'}, {'measure': 'Number of participants with adverse events', 'description': 'Adverse events will be graded according to Common Terminology Criteria for Adverse events version 4.0', 'timeFrame': 'Monitoring of adverse events will be contineud for at least 28days following the last dose of study treatment'}, {'measure': 'Overall survival', 'description': 'Overall survival duration is calculated as time from the first treatment to the date of death. For patients who are still alive at the cut-off date for statistical reporting, the overall survival duration will be right censored on the last known alive date.', 'timeFrame': 'Up to 3years'}, {'measure': 'Biomarker assessment', 'description': 'Tumor tissues obtained by tumor tissues can be used for immunohistochemistry(IHC) of pS6 Ser 240/4. In patients who did not receive gastrectomy tumor biopsies will be obtained at screening(before everolimus treatment) and after two cycles of treatment. Scoring of all IHC results is based on the percentage of positive cells. The percentage of positive cells is scored as: 0 (0%); 1 (≤10%); 2 (11-33%); 3 (34-66%); 4 (≥67%).', 'timeFrame': '24months'}]",5,20 Years,75 Years,ALL,False,Asan Medical Center,OTHER,0,45.0,ACTUAL,2025-09-01T16:18:17.175203,v2_robust,True,True,True,False,True,
NCT05100199,A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines",OnabotulinumtoxinA X,"['OnabotulinumtoxinA X', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Glabellar Lines,['Glabellar Lines'],"['OnabotulinumtoxinA X', 'BOTOX', 'Glabellar Lines']",COMPLETED,,2021-10-06,2022-12-02,"[{'measure': 'Percentage of Participants with Achievement of ≥ 1-grade improvement from baseline as rated by investigator using the Clinician Glabellar Lines Scale.', 'description': 'The Clinician Glabellar Lines Scale is a four point scale used to assess the severity of Glabellar Lines at maximum contraction ranging from 0 - None to 3 - Severe', 'timeFrame': 'Day 1 to Day 30'}, {'measure': 'Percentage of Participants With Adverse Events (AEs)', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.', 'timeFrame': 'Day 1 to Day 270'}]","[{'measure': 'Percentage of Participants with Achievement of None or Mild as rated by investigator using the Clinician Glabellar Lines Scale.', 'description': 'The Clinician Glabellar Lines Scale is a four point scale used to assess the severity of Glabellar Lines at maximum contraction ranging from 0 - None to 3 - Severe', 'timeFrame': 'Day 1 to Day 30'}, {'measure': 'Percentage of Participants with Achievement of improvement per the Facial Lines Satisfaction Questionnaire Impact domain, among subjects with baseline scores of 14 points or greater.', 'description': 'The Facial Line Satisfaction Questionnaire assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the subject perspective.', 'timeFrame': 'Day 1 to Day 30'}, {'measure': 'Percentage of Participants with Achievement of satisfaction with treatment per the Facial Line Satisfaction Questionnaire Item 5.', 'description': 'The Facial Line Satisfaction Questionnaire assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the subject perspective.', 'timeFrame': 'Day 1 to Day 60'}]",5,18 Years,,ALL,False,Allergan,INDUSTRY,0,328.0,ACTUAL,2025-09-01T16:18:17.175326,v2_robust,True,True,True,False,True,
NCT02234999,Radiolabeled Study of CC-122 in Healthy Subjects,"A Phase 1, Single-center, Open-label Study to Evaluate the Metabolism and Excretion of [14C]-CC-122 in Healthy Male Subjects",CC-122,['CC-122'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['Pharmacokinetics, Healthy Subjects']",COMPLETED,,2014-09-23,2014-10-08,"[{'measure': 'Total [14C]-radioactivity in biological matrices-Pharmacokinetics (PK)', 'description': 'Biological matrices (whole blood, plasma, urine and feces) will be collected and analyzed for total \\[14C\\]-radioactivity', 'timeFrame': 'Up to 12 days'}, {'measure': 'Cumulative excretion of total [14C]-radioactivity in urine and feces (PK)', 'description': 'Urine and feces will be collected and analyzed for measurement of \\[14C\\]-radioactivity', 'timeFrame': 'Up to 12 days'}, {'measure': 'Total [14C]-radioactivity whole blood-to-plasma ratios: PK', 'description': 'Blood samples will be collected and analyzed for measurement of \\[14C\\]-radioactivity', 'timeFrame': 'Up to 8 days'}, {'measure': 'Metabolite profiling/characterization in select biological matrices-PK', 'description': 'Biological matrices (plasma, urine, and fecal samples) will be collected and select samples will undergo metabolite profiling/characterization', 'timeFrame': 'Up to 12 dyas'}, {'measure': 'Peak (maximum) plasma concentration (Cmax) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s), as appropriate PK', 'description': 'Blood samples will be collected and analyzed; Maximum observed plasma or whole blood concentration for up to 168 hours postdose will be calculated and reported as appropriate', 'timeFrame': 'Up to 12 days'}, {'measure': 'Area under the plasma concentration-time curve (AUC) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s), as appropriate', 'description': 'Blood samples will be collected and analyzed; Area under the concentration-time curve from time zero up to 168 hours postdose will be calculated and reported as appropriate', 'timeFrame': 'Up to 12 days'}, {'measure': 'Time to maximum plasma concentration (Tmax) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s), as appropriate', 'description': 'Blood samples will be collected and analyzed; Time to reach the observed maximum (peak) concentration will be calculated and reported as appropriate.', 'timeFrame': 'Up to 12 days'}, {'measure': 'Terminal elimination half-life (t1/2) for total [14C]-radioactivity, [14C]-CC-122, and [14C]-metabolite(s), as appropriate', 'description': 'Blood samples will be collected and analyzed; Terminal half-life will be calculated and reported as appropriate', 'timeFrame': 'Up to 12 days'}]","[{'measure': 'The incidence, type, severity of adverse events (AE)', 'description': ""An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values regardless of etiology"", 'timeFrame': 'Up to 28 days following dose; AEs will be collected and recorded from the time the subjects signs Informed Consent throughthe 28 day period following the of last dose of study drug'}]",9,18 Years,55 Years,MALE,True,Celgene,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:17.175544,v2_robust,True,True,True,False,True,
NCT05561699,Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer,"Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer: A Prospective, Single Arm, Single Center，Exploratory Study",Penpulimab Combined With CRT,['Penpulimab Combined With CRT'],1,INTERVENTIONAL,['NA'],,,Esophageal Squamous Cell Carcinoma,['Esophageal Squamous Cell Carcinoma'],[],UNKNOWN,,2022-09-28,2024-12-31,"[{'measure': 'pathological complete remission（pCR）rate', 'description': 'Proportion of subjects who achieved pathological complete remission (PCR)，PCR was defined as the microscopic absence of tumor cells in the pathological evaluation of excised esophageal cancer lesions and regional lymph node samples after surgery.', 'timeFrame': '3 to 4 months'}, {'measure': 'safety（AE or SAE）', 'description': 'Incidence of adverse events or serious adverse events', 'timeFrame': '2 to 3 years from baseline'}]","[{'measure': 'Tumor regression grade（TRG）', 'description': 'Evaluation of the focus of primary tumor after radiotherapy and chemotherapy', 'timeFrame': '3 to 4 months'}, {'measure': 'R0 resection rate', 'description': 'Proportion of subjects reaching R0 resection. resection was defined as no tumor cells remained within 1mm of the two cutting edges of the esophageal cancer lesions removed during the operation.', 'timeFrame': '3 to 4 months'}, {'measure': 'Event free survival（EFS）', 'description': 'Date of first administration to date of first recording of relevant events', 'timeFrame': '2 to 3 years from baseline'}, {'measure': 'Overall survival（OS）', 'description': 'Date of first administration to date of death due to any cause', 'timeFrame': '2 to 3 years from baseline'}, {'measure': 'Disease free survival（DFS）', 'description': 'Date from the operation to the first recording of relevant events', 'timeFrame': '2 to 3 years from baseline'}]",7,18 Years,75 Years,ALL,False,Shanghai Zhongshan Hospital,OTHER,0,66.0,ESTIMATED,2025-09-01T16:18:17.175636,v2_robust,True,True,False,False,True,
NCT00554099,Asacol Acute Diverticulitis(DIVA)Study,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of a 12 Week Treatment of Acute Diverticulitis With Asacol® 2.4 g/Day (400 mg Mesalamine Tablet), Followed by a 9 Month Treatment-free Observation Period",Mesalamine,"['Align', 'Mesalamine', 'Placebo', 'Antibiotic for Diverticulitis', 'Probiotic']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Diverticulitis,['Diverticulitis'],[],COMPLETED,,2007-11,2010-03,"[{'measure': 'Global Symptom Score (GSS) at Week 12, Primary Efficacy Population', 'description': 'GSS - Abdominal Pain \\& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).', 'timeFrame': '12 Weeks'}]","[{'measure': 'Percentage of Responders at Week 12 - ITT Population', 'description': 'Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain \\& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).', 'timeFrame': '12 Weeks'}, {'measure': 'Percentage of Responders at Week 52 - ITT Population', 'description': 'Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain \\& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).', 'timeFrame': '52 Weeks'}, {'measure': 'Change in GSS From Baseline to Week 12 - ITT Population', 'description': 'GSS - Abdominal Pain \\& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change in GSS From Baseline to Week 52 - ITT Population', 'description': 'GSS - Abdominal Pain \\& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12', 'timeFrame': '12 Weeks'}, {'measure': 'Recurrent Diverticulitis, Percentage, ITT Population, Week 12', 'description': 'At least one report of recurrent diverticulitis since the last visit (prior to the Week 12 visit).', 'timeFrame': '12 Weeks'}, {'measure': 'Recurrent Diverticulitis, Percentage, ITT Population, Week 52', 'description': 'At least one report of recurrent diverticulitis since the last visit (prior to the Week 52 visit).', 'timeFrame': '52 Weeks'}]",8,35 Years,85 Years,ALL,False,Warner Chilcott,INDUSTRY,0,117.0,ACTUAL,2025-09-01T16:18:17.175656,v2_robust,True,True,True,False,False,
NCT00181532,Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC,A Multicentre Randomised Double Blind Placebo-Controlled Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC. An Evaluation of Both Tumor Radiosensitization and Normal Tissue Protection,Celecoxib,['Celecoxib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Non Small Cell Lung Carcinoma,['Non Small Cell Lung Carcinoma'],"['NSCLC', 'cox-2-inhibitor', 'radiosensitizer', 'radiotherapy']",COMPLETED,,2003-05,2008-01,[{'measure': 'tumor response rate'}],"[{'measure': 'local progression free survival 9 months after radiotherapy'}, {'measure': 'radiopneumonitis'}, {'measure': 'lung fibrosis,6 month post radiotherapy'}, {'measure': 'acute esophagitis'}, {'measure': 'quality of life'}, {'measure': 'survival after 1 year'}, {'measure': 'survival after 2 years'}]",8,18 Years,,ALL,False,Maastricht Radiation Oncology,OTHER,1,102.0,,2025-09-01T16:18:17.175896,v2_robust,True,True,True,False,False,
NCT06262932,Effectiveness of Repeated Amiodarone Dosing Regimen Versus Standard Dosing Regimen in Atrial Fibrillation Patient With Rapid Ventricular Response,Effectiveness of Repeated Amiodarone Dosing Regimen Versus Standard Dosing Regimen in Atrial Fibrillation Patient With Rapid Ventricular Response,Amiodarone,['Amiodarone'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Atrial Fibrillation,['Atrial Fibrillation'],[],COMPLETED,,2024-05-01,2024-12-31,"[{'measure': 'Heart rate', 'description': 'Percentage of patients who have Atrial fibrillation with rapid ventricular response, the percentage of patients who have heart rate below 110 bpms at 6 hours after receiving a repeated amiodarone bolus and loading dose regimen to the percentage of patients who have heart rate below 110 bpms at 6 hour after a conventional amiodarone IV loading dose regimen', 'timeFrame': '6-hours after receiving amiodarone bolus'}]","[{'measure': 'Normal sinus rhythm at 24 hours', 'description': 'Percentage of patients who develop Atrial fibrillation with rapid ventricular response, the percentage of patients who have converted to sinus rhythm at 24-hours after receiving a repeated amiodarone bolus and loading dose regimen to the percentage of patients who have converted to sinus rhythm after a conventional amiodarone IV loading dose regimen', 'timeFrame': '24-hours after receiving amiodarone bolus'}, {'measure': 'Heart rate', 'description': 'Percentage of patients who have Atrial fibrillation with rapid ventricular response, the percentage of patients who have heart rate below 110 bpms at 24 hours after receiving a repeated amiodarone bolus and loading dose regimen to the percentage of patients who have heart rate below 110 bpms at 6 hour after a conventional amiodarone IV loading dose regimen', 'timeFrame': '24-hours after receiving amiodarone bolus'}, {'measure': 'Major adverse cardiovascular events', 'description': 'Number of MACE \\[MACE defined as acute myocardial infarction (AMI), stroke, or cardiovascular death\\]', 'timeFrame': '30 days after receiving amiodarone bolus'}, {'measure': 'Phlebitis', 'description': 'Rate of phlebitis complication during amiodarone infusion', 'timeFrame': '24-hours after receiving amiodarone bolus'}, {'measure': 'Changed in heart rate', 'description': 'Compare number of total heart rate induction in patients who received a repeated amiodarone bolus and loading dose regimen and a conventional amiodarone IV loading dose regimen at 24 hrs', 'timeFrame': '24-hours after receiving amiodarone bolus'}]",6,18 Years,,ALL,False,"Police General Hospital, Thailand",OTHER,0,24.0,ACTUAL,2025-09-01T16:18:17.175918,v2_robust,True,True,True,False,True,
NCT06506032,Vancomycin and Negative Pressure Therapy for Post-sternotomy Deep Sternal Wound Infection,Clinical Effect and Wound Penetration of Vancomycin in Open-heart Surgery Patients Receiving Negative Pressure Wound Therapy for Deep Sternal Wound Infection,Intravenous Vancomycin administration,['Intravenous Vancomycin administration'],1,OBSERVATIONAL,[],,,Post-Sternotomy Deep Sternal Wound Infection,['Post-Sternotomy Deep Sternal Wound Infection'],"['Exudate', 'Deep Sternal Wound Infection', 'Negative Pressure Wound Therapy', 'Open-Heart Surgery', 'Vancomycin', 'Wound Penetration']",COMPLETED,,2021-07-30,2023-12-31,"[{'measure': 'Vancomycin penetration into exudate', 'description': 'To determine the vancomycin penetration into the wound during NPWT, the investigators compared the vancomycin total (bound + unbound) average exudate concentration to the vancomycin total (bound + unbound) average serum concentration on the first study day. The same calculation was used to determine the penetration ratio for free (unbound) vancomycin concentrations on the first study day.\n\nFor samples from three consecutive days, the investigators compared the vancomycin total (bound + unbound) through exudate concentrations with the vancomycin total (bound + unbound) through serum concentrations. The same calculation was used to determine the penetration ratio for free (unbound) vancomycin concentrations on three consecutive days.', 'timeFrame': 'repeated measurements for the total of 72 hours'}]","[{'measure': 'Identification of pre-, intra-, and postoperative risk factors for deep sternal wound infection (DSWI) development', 'description': 'The investigators will identify independent risk factors for DSWI by comparing patients with and without DSWI after cardiac surgery.', 'timeFrame': '3 days'}, {'measure': 'Recurrence of DSWI', 'description': 'The investigators will assess the recurrence of DSWI in the study subjects.', 'timeFrame': '1- year follow-up'}, {'measure': 'Determination of mortality', 'description': 'The investigators will assess the in-hospital, 90-day, and all-cause mortality in the study subjects.', 'timeFrame': '1- year follow-up'}]",4,18 Years,,ALL,,University Hospital Ostrava,OTHER,4,10.0,ACTUAL,2025-09-01T16:18:17.175938,v2_robust,False,True,True,False,False,
NCT01220232,Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects,"Open-Label, Fixed-Sequence, Crossover Study To Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects",Abacavir/Lamivudine,"['Lersivirine', 'Abacavir/Lamivudine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['Lersivirine', 'UK-453', '061', 'NNRTI', 'Abacavir', 'Lamivudine', 'Combivir', 'Pharmacokinetics', 'Drug Interaction', 'HIV', 'AIDS']",COMPLETED,,2010-11,2011-01,"[{'measure': 'To estimate the effect of steady state lersivirine 750 mg on the steady state pharmacokinetics of abacavir/lamivudine.', 'timeFrame': '17 days'}]","[{'measure': 'To investigate the safety and tolerability of lersivirine when co-administered with abacavir/lamivudine.', 'timeFrame': '17 days'}]",2,18 Years,55 Years,ALL,True,Pfizer,INDUSTRY,1,14.0,ACTUAL,2025-09-01T16:18:17.176041,v2_robust,True,True,True,False,True,
NCT03219632,Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG,"Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry",Fimasartan,['Fimasartan'],1,OBSERVATIONAL,[],,,Left Ventricular Hypertrophy,"['Left Ventricular Hypertrophy', 'Hypertension']",[],COMPLETED,,2012-06-05,2017-05-30,"[{'measure': 'The change in systolic and diastolic blood pressure, left ventricular hypertrophy in ECG (composite).', 'description': 'Measurements of changes in baseline at 12 months (change in systolic and diastolic blood pressure, left ventricular hypertrophy in ECG)', 'timeFrame': '1 year'}]",[],1,20 Years,80 Years,ALL,False,Seoul National University Bundang Hospital,OTHER,0,72.0,ACTUAL,2025-09-01T16:18:17.176074,v2_robust,False,True,True,False,False,
NCT04058132,Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military,Cerebrovascular Reactivity (CVR) Assessed With Functional Near Infrared Spectroscopy (fNIRS) as a Biomarker of Traumatic Cerebrovascular Injury (TCVI) Measured Longitudinally After Acute TBI in Military Personnel,Sildenafil Citrate 50Mg Tab,"['Gadolinium contrast infusion', 'Viagra®', 'Sildenafil Citrate 50Mg Tab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Traumatic Brain Injury,['Traumatic Brain Injury'],"['traumatic cerebrovascular injury', 'Functional Near Infrared Spectroscopy (fNIRS)']",TERMINATED,"funding ran out after unanticipated length of time ( for IRB approval, CRADA, and start letter",2019-08-09,2020-03-01,"[{'measure': 'Detection of variation of oxyhemoglobin and deoxyhemoglobin concentration using a power analysis between groups during the hypercapnia challenge pre and post a single dose of sildenafil 50 mg at the specified time points after a TBI.', 'description': 'This is a pilot study, whose primary aim is to obtain pilot data that can be used to design a carefullypowered Phase III clinical trial. Thus, a power analysis is only an approximation.This compares favorably with the effect size of 1.3 noted in our preliminary study in chronic TBI (Figs. 2 and 4). For the observed effect size of 1.3, power will be 90%. Since we anticipate that the reduction in CVR will be greater in the acute period than in the chronic period, the proposed study has adequate sample size to measure the evolution of CVR over the subacute period after TBI. Sample size was calculated using GraphPad StatMate, v. 2.0 for Windows (GraphPad Software, San Diego, CA). The following assumptions were made: alpha =0.05, delta = 0.44, sigma = 0.40.', 'timeFrame': '2 years'}, {'measure': 'Longitudinal measure of CVR between groups', 'description': 'For each TBI, we will perform a one way ANOVA test between CVR measure for all the source/detectors pair at the different time point. At each time point of the study, we will also perform a t test on the mean CVR between the TBI group and the HC group.', 'timeFrame': '2 years'}]",[],2,18 Years,55 Years,ALL,True,Uniformed Services University of the Health Sciences,FED,1,1.0,ACTUAL,2025-09-01T16:18:17.176088,v2_robust,True,True,False,True,False,"funding ran out after unanticipated length of time ( for IRB approval, CRADA, and start letter"
NCT06732232,A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma,A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma,CD19/CD20/BCMA CAR-T,['CD19/CD20/BCMA CAR-T'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Relapsed,"['Relapsed', 'Refractory', 'Multiple Myeloma']","['relapsed/refractory multiple myeloma', 'CAR-T', 'CD19', 'CD22', 'BCMA']",RECRUITING,,2024-12-12,2027-12-12,"[{'measure': 'Dose-limiting toxicity(DLT)', 'description': 'Safety', 'timeFrame': '[Time Frame: Day0-Day28]'}, {'measure': 'Maximum tolerated dose (MTD)', 'description': 'Evaluate the incidence, severity, and correlation of SAE Tolerability', 'timeFrame': '[Time Frame: Day0-Day28]'}]","[{'measure': 'Maximum Plasma Concentration(Cmax)', 'description': 'Pharmacokinetics(PK)', 'timeFrame': '[Time Frame: Day0-Day28#Day0-undetectable for CAR positive T cells]'}, {'measure': 'Maximum Plasma Concentration Time (Tmax)', 'description': 'Pharmacokinetics(PK)', 'timeFrame': '[Time Frame: Day0-Day28#Day0-undetectable for CAR positive T cells]'}, {'measure': 'Area Under Curve (AUC)', 'description': 'Pharmacokinetics(PK)', 'timeFrame': '[Time Frame: Day0-Day28#Day0-undetectable for CAR positive T cells]'}, {'measure': 'CAR positive T cells', 'description': 'Pharmacokinetics(PK)', 'timeFrame': '[Time Frame: Day0-Day28#Day0-undetectable for CAR positive T cells]'}, {'measure': 'Cytokines ( IL(interleukin)-2）', 'description': 'Pharmacodynamics (PD)', 'timeFrame': '[Time Frame:Day0-Day28]'}, {'measure': 'Cytokines ( IL(interleukin)-4）', 'description': 'Pharmacodynamics (PD)', 'timeFrame': '[Time Frame:Day0-Day28]'}, {'measure': 'Cytokines ( IL(interleukin)-6）', 'description': 'Pharmacodynamics (PD)', 'timeFrame': '[Time Frame:Day0-Day28]'}, {'measure': 'Cytokines ( IL(interleukin)-8）', 'description': 'Pharmacodynamics (PD)', 'timeFrame': '[Time Frame:Day0-Day28]'}, {'measure': 'Cytokines ( IL(interleukin)-10）', 'description': 'Pharmacodynamics (PD)', 'timeFrame': '[Time Frame:Day0-Day28]'}, {'measure': 'Cytokines ( IL(interleukin)-15）', 'description': 'Pharmacodynamics (PD)', 'timeFrame': '[Time Frame:Day0-Day28]'}, {'measure': 'IFN(interferon)-γ', 'description': 'Pharmacodynamics (PD)', 'timeFrame': '[Time Frame:Day0-Day28]'}, {'measure': 'TNF(tumor necrosis factor)-α', 'description': 'Pharmacodynamics (PD)', 'timeFrame': '[Time Frame:Day0-Day28]'}, {'measure': 'MCP( monocyte chemoattractant protein)-1)', 'description': 'Pharmacodynamics (PD)', 'timeFrame': '[Time Frame:Day0-Day28]'}, {'measure': 'Overall survival (OS)', 'description': 'Based on the analysis of MRD negative rate by researchers according to IMWG standards', 'timeFrame': '[Time Frame: Day28,Month2,Month3,Month6,Month9,Month12,Month15,Month18,Month21,Month24]'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Based on the analysis of MRD negative rate by researchers according to IMWG standards', 'timeFrame': '[Time Frame: Day28,Month2,Month3,Month6,Month9,Month12,Month15,Month18,Month21,Month24]'}, {'measure': 'Minor residual diseases(MRD)', 'description': 'Based on the analysis of MRD negative rate by researchers according to IMWG standards', 'timeFrame': '[Time Frame: Day28,Month2,Month3,Month6,Month9,Month12,Month15,Month18,Month21,Month24]'}]",18,18 Years,75 Years,ALL,False,"Shanghai Cell Therapy Group Co.,Ltd",INDUSTRY,0,12.0,ESTIMATED,2025-09-01T16:18:17.176263,v2_robust,True,True,False,False,True,
NCT02474498,EMD and/or Bone Substitute for the Treatment of Class II Furcations,Enamel Matrix Protein Derivative and/or Synthetic Bone Substitute for the Treatment of Mandibular Class II Buccal Furcation Defects. A 12-month Randomized Clinical Trial,EMD,"['EMD', 'Emdogain']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Periodontal Disease,['Periodontal Disease'],"['Regenerative therapy', 'Randomized clinical trial (RCT)', 'Enamel matrix derivative', 'Hydroxyapatite-beta tricalcium phosphate', 'Buccal furcation']",COMPLETED,,2013-03,2015-06,"[{'measure': 'Relative Horizontal Clinical Attachment Level (RHCAL) at 12 Months', 'description': 'The relative horizontal clinical attachment level (RHCAL) will be measured with the same type of probe (PCP-15 Periodontal Probe - Hu-Friedy - Chicago, IL, USA) as the distance between the deepest point reached by the probe when introduced horizontally into the furcation and the lower border of the stent. This parameter will be evaluated at one specific site at the buccal furcation entrance, determined by a groove made on an individually manufactured acrylic stent and recorded to the nearest 0.5mm.', 'timeFrame': '12 months'}]","[{'measure': 'Relative Vertical Clinical Attachment Level (RVCAL) at 12 Months', 'description': 'The relative vertical clinical attachment level (RVCAL) will be measured with the same type of probe (PCP-15 Periodontal Probe - Hu-Friedy - Chicago, IL, USA) as the distance between the deepest point reached by the probe when introduced vertically into the buccal periodontal pocket. This parameter will be evaluated at one specific site at the buccal furcation entrance, determined by a groove made on an individually manufactured acrylic stent and recorded to the nearest 0.5mm.', 'timeFrame': '12 months'}, {'measure': 'Periodontal Probing Depth at 12 Months', 'timeFrame': '12 months'}, {'measure': 'Relative Gingival Margin Position (RGMP) at 12 Months', 'timeFrame': '12 months'}]",4,18 Years,75 Years,ALL,False,"University of Campinas, Brazil",OTHER,0,41.0,ACTUAL,2025-09-01T16:18:17.176320,v2_robust,True,True,True,False,False,
NCT02553798,Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis,An Open-label Study Assessing Long-term Safety of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis,Glycopyrronium Topical Wipes,"['DRM04', 'Glycopyrronium Topical Wipes']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Hyperhidrosis,['Hyperhidrosis'],[],COMPLETED,,2015-08,2016-12,"[{'measure': 'Long-term Safety Assessed Through Adverse Events and Local Skin Reactions', 'description': 'The Total Participants at risk are based on the Safety population, defined as, Participants who were randomized and received at least one confirmed dose of study drug.', 'timeFrame': 'Day 1 - Week 44'}]",[],1,9 Years,,ALL,False,Journey Medical Corporation,INDUSTRY,0,564.0,ACTUAL,2025-09-01T16:18:17.176343,v2_robust,True,True,True,False,True,
NCT06468098,A Study of IBI363 in Subjects With Advanced Malignancies,"Phase Ib Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of IBI363 Combination Therapy in Subjects With Advanced Malignancies",IBI363 + chemotherapy,"[""IBI363 + Investigator's Choice SOC"", 'IBI363 + chemotherapy']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Malignancies,['Advanced Malignancies'],[],RECRUITING,,2024-06-15,2026-12-31,"[{'measure': 'Adverse Enent (AE)', 'description': 'Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0', 'timeFrame': 'Up to 90 days after the last administration'}, {'measure': 'Treatment-Emergent AE (TEAE)', 'description': 'Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0', 'timeFrame': 'Up to 90 days after the last administration'}, {'measure': 'Adverse Event of Special Interest (AESI)', 'description': 'Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0', 'timeFrame': 'Up to 90 days after the last administration'}, {'measure': 'Serious Adverse Event (SAE)', 'description': 'Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0', 'timeFrame': 'Up to 90 days after the last administration'}, {'measure': 'Objective response rate (ORR)', 'description': 'ORR is defined as the proportion of participants with a complete response (CR) or partial response (PR).', 'timeFrame': 'Through out the study (up to 2 years)'}, {'measure': 'disease control rate (DCR)', 'description': 'DCR is defined as the proportion of participants with a complete response (CR) or partial response (PR) or stable disease(SD)', 'timeFrame': 'Through out the study (up to 2 years)'}, {'measure': 'time to response (TTR)', 'description': 'TTR is defined as the time from the date of first dose of study drug to the date of first documented tumor response (CR/PR)', 'timeFrame': 'Through out the study (up to 2 years)'}, {'measure': 'duration of response (DoR)', 'description': 'DoR is defined as the time from the date of first documented tumor response (CR/PR) until PD/death', 'timeFrame': 'Through out the study (up to 2 years)'}, {'measure': 'progression-free survival (PFS)', 'description': 'PFS is defined as the time from the date of first dose of study drug to the date of the first documented progression or death due to any cause, whichever occurs first', 'timeFrame': 'Through out the study (up to 2 years)'}, {'measure': 'Overall survival (OS)', 'description': 'OS is defined as the time from the date of first dose of study drug until the date of death from any cause.', 'timeFrame': 'Through out the study (an average of 2 years)'}]","[{'measure': 'Plasma concentration (Cmax) of IBI363', 'description': 'PK parameters maximum concentration (Cmax) of IBI363', 'timeFrame': 'Up to 2 years'}, {'measure': 'Area under the curve (AUC) of IBI363', 'description': 'PK parameters area under the curve (AUC)?of IBI363', 'timeFrame': 'Up to 2 years'}, {'measure': 'Half-life (T1/2) of IBI363', 'description': 'PK parameters half-life (t1/2)?of IBI363', 'timeFrame': 'Up to 2 years'}, {'measure': 'Clearance (CL) of IBI363', 'description': 'PK parameters clearance rate of IBI363', 'timeFrame': 'Up to 2 years'}, {'measure': 'Volume of distribution (V) of IBI363', 'description': 'PK parameters apparent volume of distribution(V)?of IBI363', 'timeFrame': 'Up to 2 years'}, {'measure': 'Immunogenicity of IBI363', 'description': 'Incidence of anti-drug (IBI363) antibody', 'timeFrame': 'Up to 2 years'}]",16,18 Years,75 Years,ALL,False,Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,0,556.0,ESTIMATED,2025-09-01T16:18:17.176426,v2_robust,True,True,False,False,True,
NCT04303598,Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients,"A Randomized, Double-blind, Double-simulated, Active-controlled，Phase III Clinical Study Evaluating the Efficacy and Safety of Azvudine Combined With Tenofovir Fumarate and Efavirenz in Hiv-infected Treatment Naive Patients",FNC,"['FNC placebo', '3TC placebo', 'Azvudine placebo', 'FNC', 'EFV', 'Tenofovir Fumarate', 'Lamivudine', 'Azvudine', 'Efavirenz', 'TDF', 'Lamivudine placebo', '3TC']",12,INTERVENTIONAL,['PHASE3'],PHASE3,,HIV-infection/Aids,['HIV-infection/Aids'],"['FNC', 'HIV-infection', 'Aids']",UNKNOWN,,2020-04-01,2022-08-01,"[{'measure': 'Rate of subjects with plasma HIV-1 Ribonucleic acid (RNA) <50 copies/milliliter (c/mL) at Week 48', 'description': 'Rate of participants with a HIV-1 RNA \\< 50 copies per mL .If HIV RNA level is \\< 50 copies per mL at Week 48, it is considered as virologic success as per the snapshot approach.', 'timeFrame': '48 Weeks'}]","[{'measure': 'Rate of subjects with plasma HIV-1 Ribonucleic acid (RNA) <50 copies/milliliter (c/mL) at Week 24 and Week 96', 'description': 'Rate of participants with a HIV-1 RNA \\< 50 copies per mL at Week 24 and Week 96', 'timeFrame': 'Week 24 and Week 96'}, {'measure': 'Rate of subjects with plasma HIV-1 Ribonucleic acid (RNA) <400 copies/milliliter (c/mL) at Week 24 ，Week 48 and Week 96；', 'description': 'Rate of participants with a HIV-1 RNA \\< 50 copies per mL at Week 24，Week 48 and Week 96', 'timeFrame': 'Week 24 and Week 48 and Week 96,'}, {'measure': 'Change of CD4+ cell count from baseline at Week 48 and Week 96', 'description': 'The immunologic change was determined by changes in Cluster of CD4+ cell count. Change from baseline in CD4+ cell count at Weeks 48 and 96 were assessed', 'timeFrame': 'Week 48 and Week 96'}, {'measure': 'Time to achieve virologic failure（HIV-1 RNA<50 copies/ml）', 'description': 'Time to HIV-1 RNA\\<50 copies/ml from baseline', 'timeFrame': 'Baseline and Week 96'}, {'measure': 'Diachronic change of logarithm (log) HIV-RNA reduction from baseline', 'description': 'The Diachronic change of logarithm (log) HIV-RNA change was determined by changes in Cluster of logarithm (log) HIV-RNA count. Change from baseline in logarithm (log) HIV-RNA at Weeks 96 were assessed', 'timeFrame': 'Baseline and Week 96'}, {'measure': 'Diachronic change of CD4+T、 CD8+T cell count from baseline', 'description': 'The immunologic change was determined by changes in Cluster of CD4+ cell count. Change from baseline in CD4+ cell count to Weeks 96 were assessed', 'timeFrame': 'Baseline and Week 96'}, {'measure': 'Safety outcome of subjects at Week 48 and Week 96。', 'description': 'Rate of participants discontinuing therapy due to AEs were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.', 'timeFrame': 'Week 48 and Week 96'}]",8,18 Years,,ALL,False,"Henan Genuine Biotech Co., Ltd.",INDUSTRY,0,720.0,ESTIMATED,2025-09-01T16:18:17.176467,v2_robust,True,True,False,False,True,
NCT04263298,Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer,"A Randomized, Multi-center, Open-label, Phase III Trial of Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer (FAMILY)",Fulvestrant,"['Active Comparator control group', 'Experimental group', 'Fulvestrant', 'Capecitabine Oral Product']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Metastatic Breast Cancer,['Metastatic Breast Cancer'],[],RECRUITING,,2018-05-01,2030-05-01,"[{'measure': 'Progression free survival (PFS)', 'description': 'From enrollment to progression or death (for any reason)', 'timeFrame': 'Estimated 18 months'}]","[{'measure': 'Overall Survival (OS)', 'description': 'From enrollment to death (for any reason)', 'timeFrame': 'Estimated 60 months'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'Ratio of CR and PR in all subjects', 'timeFrame': 'Estimated 18 months'}, {'measure': 'Clinical Benefit Rate (CBR)', 'description': 'Ratio of CR,PR and SD greater than or equal to 24 weeks in all subjects', 'timeFrame': 'Estimated 18 months'}, {'measure': 'Quality Of Life (QOL)', 'description': 'All patients need to fill in the Functional Assessment of Cancer Therapy-Breast (FACT-B), a 44-item self-report instrument designed to measure multidimensional quality of life (QL) in patients with breast cancer.', 'timeFrame': 'Estimated up to 60 months'}, {'measure': 'Adverse Events and Serious Adverse Events', 'description': 'Safety', 'timeFrame': 'From informed consent through 28 days following treatment completion'}]",6,18 Years,75 Years,FEMALE,False,Herui Yao,OTHER,0,210.0,ESTIMATED,2025-09-01T16:18:17.176528,v2_robust,True,True,False,False,True,
NCT07001098,Amino Acids for Cardiac Surgery Associated AKI,Amino Acids for the Infant at Risk for Acute Kidney Injury After Cardiac Surgery: A Pilot Study,Amino Acids,"['Lactated Ringer', 'AA, Trophamine', 'Amino Acids', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Kidney Injury,['Acute Kidney Injury'],['cardiac surgery'],NOT_YET_RECRUITING,,2025-09,2026-11,"[{'measure': 'Number of Participants with Amino acids Related Adverse Events', 'timeFrame': 'Baseline, Daily during infusion upto 48 hours after completion of infusion (upto 5 days)'}]",[],1,1 Day,18 Years,ALL,False,Stanford University,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:17.176546,v2_robust,True,True,False,False,True,
NCT02564198,A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors,"A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors",Ramucirumab,"['IMC-1121B', 'Cyramza', 'Ramucirumab', 'LY3009806']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Pediatric Solid Tumor,"['Pediatric Solid Tumor', 'Refractory Tumor', 'Recurrent Tumor', 'CNS Malignancies']","['relapsed pediatric solid tumors', 'unspecified childhood solid tumor', 'brain and central nervous system tumors']",COMPLETED,,2015-12-11,2019-07-16,"[{'measure': 'Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab', 'description': ""A DLT is defined as an Adverse Event (AE) that is likely related to the study medication or combination, and fulfills any one of the following criteria, graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0:\n\n1\\. Any death not clearly due to the underlying disease or extraneous causes 2. Neutropenic fever 2. Any Grade ≥3 non-hematologic toxicity 3. Grade ≥4 neutropenia or thrombocytopenia \\>7 days 4. Grade ≥3 thrombocytopenia with bleeding 5. Grade ≥3 nausea/vomiting or diarrhea\\>72 hours with adequate antiemetic and other supportive care 6. Grade ≥3 fatigue ≥1 week 7. Grade ≥3 electrolyte abnormality that lasts\\>72 hours, unless the Participant has clinical symptoms, in which case all Grade 3+electrolyte abnormality regardless of duration should count as a DLT.\n\n8\\. Grade ≥3 prolongation of QT interval corrected using the Fridericia formula on 2 separate electrocardiogram readings approximately 5 min apart."", 'timeFrame': 'Baseline to Study Completion (Up to 42 Months)'}, {'measure': 'Population Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab', 'description': 'Population Pharmacokinetics (PK): Minimum observed plasma concentration of Ramucirumab.', 'timeFrame': 'Predose, Cycle 1 Day 1 (end of infusion (EOI), 1 hour after EOI) and Cycle 1 Day 43 (1 hour after EOI)'}, {'measure': 'Number of Participants With Anti-Ramucirumab Antibodies', 'description': 'Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.', 'timeFrame': 'Predose Cycle 1 Day 1 through Follow-Up (Up to 42 Months)'}]","[{'measure': 'Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)', 'description': 'Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.', 'timeFrame': 'Baseline to Date of Objective Disease Progression (Up to 42 Months)'}, {'measure': 'Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD): Disease Control Rate (DCR)', 'description': 'Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.', 'timeFrame': 'Baseline to Date of Objective Disease Progression (Up to 42 Months)'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.', 'timeFrame': 'Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up to 42 Months)'}, {'measure': 'Overall Survival', 'description': 'Overall survival is defined as the time from date of randomization to the date of death (due to any cause). For participants whose last known status is alive at the data cutoff date for the analysis, time will be censored as the last contact date prior to the data cutoff date.', 'timeFrame': 'Baseline to Date of Death from Any Cause (Up to 42 Months)'}]",7,12 Months,21 Years,ALL,False,Eli Lilly and Company,INDUSTRY,1,29.0,ACTUAL,2025-09-01T16:18:17.176586,v2_robust,True,True,True,False,True,
NCT00768963,Ranibizumab for the Inhibition of Neovascularization in Pterygia,Ranibizumab for the Inhibition of Neovascularization in Pterygia,ranibizumab,"['Lucentis', 'ranibizumab']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Pterygium,['Pterygium'],"['ranibizumab', 'pterygium']",COMPLETED,,2008-10,2012-01,"[{'measure': 'The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery.', 'timeFrame': '2 years'}]","[{'measure': 'This study aims to establish the tissue concentration of ranibizumab when delivered via subconjunctival injection and determine the effects of ranibizumab on conjunctival healing, corneal epithelial healing, and wound dehiscence.', 'timeFrame': '2 years'}]",2,18 Years,,ALL,False,University of Miami,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:17.176619,v2_robust,True,True,True,False,True,
NCT01963663,Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients,Comparison of Metformin and Pioglitazone Effects on Serum YKL-40 Concentrations in Patients With Newly Diagnosed Type 2 Diabetes,Metformin,"['Pioglitazone', 'Metformin']",2,INTERVENTIONAL,['NA'],,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],"['YKL-40', 'Chronic low grade inflammation', 'type 2 diabetes mellitus', 'metformin', 'pioglitazone']",COMPLETED,,2012-11,2013-04,"[{'measure': 'Serum concentration of YKL-40', 'timeFrame': '12 weeks'}]",[],1,35 Years,,ALL,False,Tehran University of Medical Sciences,OTHER,0,84.0,ACTUAL,2025-09-01T16:18:17.176627,v2_robust,True,True,True,False,False,
NCT04925063,The Effect of Metformin in Patients With Newly Diagnosed mHSPC,"A Prospective, Randomized Trial Comparing Metformin Plus Androgen Deprivation Therapy (ADT) and Abiraterone With ADT Plus Abiraterone in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer",Metformin,"['Metformin Hydrochloride Sustained Release Tablets', 'Metformin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Prostate Cancer,['Metastatic Prostate Cancer'],['metastatic hormone sensitive prostate cancer; abiraterone; metformin'],NOT_YET_RECRUITING,,2021-06-16,2027-08-31,"[{'measure': 'Castration-resistant prostate cancer free survival', 'description': 'Duration from randomization to time till development of CRPC (Castration-resistant prostate cancer). CRPC is defined by disease progression despite castration level of testosterone and may present as either a biochemical progression and/or radiological progression.', 'timeFrame': '5 years'}]","[{'measure': 'Overall Survival', 'description': 'Overall survival is defined from randomization until death due to any reason.', 'timeFrame': '5 years'}, {'measure': 'Radiographic progression-free survival', 'description': 'Radiographic progression-free survival is defined from randomization until radiographic progression.', 'timeFrame': '5 years'}, {'measure': 'Safety', 'description': 'Adverse events will be assessed according to NCI-CTC AE 5.0.', 'timeFrame': '5 years'}]",4,18 Years,,MALE,False,Sun Yat-sen University,OTHER,0,266.0,ESTIMATED,2025-09-01T16:18:17.176657,v2_robust,True,True,False,False,True,
NCT00389363,Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects,A Phase II-III Trial Assessing the Efficacy and Safety of Three Doses of the ALK HDM Tablet in House Dust Mite Allergic Patients,ALK HDM tablet,['ALK HDM tablet'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Asthma,['Asthma'],[],COMPLETED,,2006-08,2008-04,[{'measure': 'Use of inhaled corticosteroid (ICS).'}],"[{'measure': 'Use of rescue medication and symptoms.'}, {'measure': 'Quality of Life.'}]",3,14 Years,,ALL,False,ALK-Abelló A/S,INDUSTRY,0,800.0,ESTIMATED,2025-09-01T16:18:17.176671,v2_robust,True,True,True,False,False,
NCT03792763,"Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients","Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial ""DEFENCE"" (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE)",Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA],"['Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]', 'Placebo 1.7 ml Subcutaneous Solution']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,['Multiple Myeloma'],"['early multiple myeloma', 'smoldering multiple myeloma', 'SLiM CRAB', 'denosumab', 'Austrian Study Group of Medical Tumour Therapy (AGMT)', 'high risk smoldering myeloma']",COMPLETED,,2019-09-30,2023-09-14,"[{'measure': 'Time to progression', 'description': 'Time from randomization to transformation to symptomatic, active MM (defined as progression to active multiple myeloma according to IMWG diagnosis criteria 2014) or progression of disease according to IMWG response criteria 2016', 'timeFrame': '78 months (the first 6 cycles are 28 days, thereafter each cycle is 3 months for a maximum of 36 months)'}]","[{'measure': 'Percentage of patients transforming in 3 years', 'description': ""Percentage of patients with high-risk SMM and early 'slim CRAB' positive MM transforming to CRAB positive multiple myeloma and/or developing serological progression (as defined by IMWG criteria 2016 for MM) within 3 years"", 'timeFrame': '36 months (the first 6 cycles are 28 days, thereafter each cycle is 3 months)'}, {'measure': 'Overall survival', 'description': 'To determine the overall survival of patients receiving either denosumab or placebo', 'timeFrame': '78 months (the first 6 cycles are 28 days, thereafter each cycle is 3 months for a maximum of 36 months)'}, {'measure': 'Time to first skeletal-related event', 'description': 'To determine the time to first skeletal-related event for patients receiving either denosumab or placebo. • Imaging: low dose wbCT (details will be described in a separate guidance document) or PET-CT mandatory', 'timeFrame': '78 months (baseline and every 6 months thereafter until progression or maximum of 3 years).'}, {'measure': 'Incidence of bone lesions as MM defining events', 'description': 'To determine the incidence of bone lesions as MM defining events. • Imaging: low dose wbCT (details will be described in a separate guidance document) or PET-CT mandatory.', 'timeFrame': '78 months (baseline and every 6 months thereafter until progression or maximum of 3 years).'}, {'measure': 'Time to first anti-myeloma treatment', 'description': 'To determine the time to first anti-myeloma treatment for patients receiving either denosumab or placebo', 'timeFrame': '78 months (the first 6 cycles are 28 days, thereafter each cycle is 3 months for a maximum of 36 months)'}]",6,18 Years,,ALL,False,Arbeitsgemeinschaft medikamentoese Tumortherapie,OTHER,2,8.0,ACTUAL,2025-09-01T16:18:17.176680,v2_robust,True,True,True,False,False,
NCT06200363,A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer,A Clinical Study of Intravenous MVR-T3011 (T3011) in Combination With Oral Regorafenib in Patients With Advanced Colorectal Cancer,T3011,"['T3011', 'Regorafenib']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Colorectal Cancer,['Advanced Colorectal Cancer'],[],RECRUITING,,2023-09-21,2024-11,"[{'measure': 'Adverse event', 'description': 'To evaluate the safety of intravenous T3011 in combination with oral regorafenib in the treatment of patients with advanced colorectal cancer.', 'timeFrame': '28 days after EOT'}]","[{'measure': 'Overall response rate (ORR)', 'description': 'To evaluate the efficacy of intravenous T3011 combined with oral regorafenib in the treatment of patients with advanced colorectal cancer (ORR will be assessed according to RECIST 1.1 \\& iRECIST)', 'timeFrame': 'Every 8 weeks until disease progression, consent withdraw, death or end of study, assessed up to 24 months.'}, {'measure': 'Disease control rate (DCR)', 'description': 'To evaluate the DCR of intravenous T3011 combined with oral regorafenib in the treatment of patients with advanced colorectal cancer (DCR will be assessed according to RECIST 1.1 \\& iRECIST)', 'timeFrame': 'Every 8 weeks until disease progression, consent withdraw, death or end of study, assessed up to 24 months.'}, {'measure': 'Progression-free Survival (PFS)', 'description': 'To evaluate the PFS of intravenous T3011 combined with oral regorafenib in the treatment of patients with advanced colorectal cancer (PFS will be assessed according to RECIST 1.1 \\& iRECIST)', 'timeFrame': 'Every 8 weeks until disease progression, consent withdraw, death or end of study, assessed up to 24 months.'}, {'measure': 'Overall survival (OS)', 'description': 'To evaluate the OS of intravenous T3011 combined with oral regorafenib in the treatment of patients with advanced colorectal cancer', 'timeFrame': '24 months'}, {'measure': 'Quality of life questionnaire (QLQ-C30)', 'description': 'The EORTC Core Questionnaire (QLQ-C30) is widely used to measure quality of life in oncology. For self-reported general health and psychological distress, a higher score indicated worse health.', 'timeFrame': 'Up to 24 months'}]",6,18 Years,75 Years,ALL,False,West China Hospital,OTHER,0,15.0,ESTIMATED,2025-09-01T16:18:17.176767,v2_robust,True,True,False,False,True,
NCT05051163,Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition,"A Randomized Trial to Investigate Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition in Mulago Hospital, Kampala, Uganda",Ceftriaxone Sodium,"['Gentamicin', 'GENTAMICIN INJECTION', 'Ampicillin', 'Ceftriaxone Sodium', 'AMPIMAX-500', 'ZEFONE-1000']",6,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,HIV-1-infection,"['HIV-1-infection', 'Malnutrition, Child']",[],UNKNOWN,,2021-06-14,2024-06-14,"[{'measure': 'In hospital mortality', 'description': 'Cumulative incidence', 'timeFrame': '4 weeks'}]","[{'measure': 'Length of hospitalization', 'description': 'Number of days', 'timeFrame': '90 days'}, {'measure': 'Weight-for-height z-score', 'description': 'Change from baseline', 'timeFrame': '90 days'}, {'measure': 'Weight-for-age z-score', 'description': 'Change from baseline', 'timeFrame': '90 days'}, {'measure': 'Height-for-age z-score', 'description': 'Change from baseline', 'timeFrame': '90 days'}, {'measure': 'Pattern and antimicrobial sensitivity of pathogens', 'description': 'Frequency', 'timeFrame': '7 days'}, {'measure': 'HIV infection', 'description': 'Prevalence', 'timeFrame': 'Baseline'}, {'measure': 'Area under the curve (AUC 0- 12h)', 'description': 'Geometric means', 'timeFrame': '12hours'}, {'measure': 'Maximum concentration (Cmax)', 'description': 'Geometric means', 'timeFrame': '12hours'}, {'measure': 'Concentration at 12hours post dose (C12h)', 'description': 'Geometric means', 'timeFrame': '12hours'}]",10,1 Month,59 Months,ALL,False,Makerere University,OTHER,0,300.0,ESTIMATED,2025-09-01T16:18:17.176776,v2_robust,True,True,False,False,False,
NCT01433263,Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas,"A Randomized, Double-blind, Placebo-controlled Multi-center Study of BYM338 for Treatment of Cachexia in Patients With Stage IV Non-small Cell Lung Cancer or Stage III/IV Adenocarcinoma of the Pancreas",BYM338 active drug,"['Placebo', 'BYM338 active drug']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cachexia,['Cachexia'],"['Wasting syndrome', 'emaciation', 'lung cancer', 'adenocarcinoma', 'pancreatic cancer']",COMPLETED,,2011-08,2014-04,"[{'measure': 'Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 8', 'description': 'Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was no more than or equal to 2% at Week 8 was considered responders.', 'timeFrame': 'Baseline, week 8'}]","[{'measure': 'Percentage Change in Body Weight From Baseline at Week 7 and Week 9', 'description': 'Percentage Change in body weight from baseline in killograms (kg) at week 7 and week 9', 'timeFrame': 'Baseline, Week 7 and Week 9'}, {'measure': 'Maximum Observed Serum Concentration (Cmax)', 'description': 'Blood samples for pharmacokinetic (PK) evaluation were drawn on Day 1 30mg/kg BYM338 (Core)or week 8 Late 30mg/kg BYM338 (when placebo subjects were rolled over to active). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.', 'timeFrame': '0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 1 and Week 8'}, {'measure': 'Time to Reach the Maximum Concentration After Drug Administration (Tmax)', 'description': 'Blood samples for pharmacokinetic (PK) evaluation were drawn on Day 1 30mg/kg BYM338 (Core)or week 8 Late 30mg/kg BYM338 (when placebo subjects were rolled over to active). Tmax was directly determined from the raw serum concentration-time data.', 'timeFrame': '0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 1 and Week 8'}, {'measure': 'Percentage Change From Baseline in Total Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo: at Week 8', 'description': 'total lean body mass (LBM) is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \\[(LBM at Visit - LBM at Baseline) / LBM at Baseline\\] \\* 100.', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Percentage Change From Baseline of Bone Mineral Density (BMD) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo at Week 8', 'description': 'Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \\[(BMD at Visit - BMD at Baseline) / BMD at Baseline\\] \\* 100.', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Number of Steps Taken Compared to Placebo at Week 4 and 7', 'description': 'Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.', 'timeFrame': 'Baseline, Week 4 and Week 7'}, {'measure': 'Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Sedentary Taken Compared to Placebo at Week 4 and 7', 'description': 'Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.', 'timeFrame': 'Baseline, Week 4 and Week 7'}, {'measure': 'Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Standing Compared to Placebo at Week 4 and 7', 'description': 'Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.', 'timeFrame': 'Baseline, Week 4 and Week 7'}, {'measure': 'Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Stepping Compared to Placebo at Week 4 and 7', 'description': 'Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.', 'timeFrame': 'Baseline, Week 4 and Week 7'}]",10,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,57.0,ACTUAL,2025-09-01T16:18:17.176796,v2_robust,True,True,True,False,False,
NCT04888663,"Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)","An Open-label, Multicenter Phase Ib/II Study of Ramucirumab in Combination With Trastuzumab and Weekly Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer",Trastuzumab + Ramucirumab + Paclitaxel,['Trastuzumab + Ramucirumab + Paclitaxel'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Recurrent/Metastatic Gastric Cancer,['Recurrent/Metastatic Gastric Cancer'],[],UNKNOWN,,2018-02-13,2021-09-02,"[{'measure': 'Phase 1b: Maximum tolerated dose of trastuzumab, ramucirumab, and paclitaxel combination treatment in patients with HER2-positive gastric cancer', 'timeFrame': 'Phase 1b: During the first 4 weeks of treatment'}, {'measure': 'Phase 2: Progression-free survival in patients with HER2-positive gastric cancer receiving trastuzumab, ramucirumab, and paclitaxel combination treatment', 'timeFrame': 'Phase 2: At 24 weeks after start of treatment'}]","[{'measure': 'Overall survival', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'Objective response rate according to RECIST 1.1', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'Disease control rate according to RECIST 1.1', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE v4.02', 'timeFrame': 'Throughout the overall study period as well as up to 3 months after the last dose study treatment for each subject'}]",6,19 Years,,ALL,False,Yonsei University,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:17.176862,v2_robust,True,True,False,False,True,
NCT03456063,"A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)","A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody","['Gemzar', 'Carboplatin', 'Placebo Comparator', 'Cisplatin', 'Tecentriq', 'Gemcitabine', 'Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody', 'Nab-paclitaxel', 'Pemetrexed', 'Alimta', 'Abraxane']",11,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-Small-Cell Lung,['Non-Small-Cell Lung'],[],ACTIVE_NOT_RECRUITING,,2018-04-24,2025-12-31,"[{'measure': 'Independent Review Facility (IRF)-Assessed Event Free Survival (EFS)', 'description': 'IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, or death from any cause, whichever occurs first.', 'timeFrame': 'Up to approximately 96 months'}]","[{'measure': 'Pathological Complete Response (pCR)', 'description': 'pCR is defined as the absence of any viable primary tumor cells at the time of surgical resection in the primary tumor and all sampled lymph nodes as assessed by central and local pathology laboratory.', 'timeFrame': 'At time of surgery'}, {'measure': 'Major Pathological Response (MPR)', 'description': 'MPR is defined as ≤ 10% residual viable tumor cells at the time of surgical resection in the primary tumor, as assessed by central and local pathology laboratory.', 'timeFrame': 'At time of surgery'}, {'measure': 'Objective Response (OR)', 'description': 'Objective response is defined as a complete response or partial response, as determined by the investigator according to RECIST v1.1', 'timeFrame': 'Prior to surgery, up to approximately 84 days'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from randomization to death from any cause during the course of the study.', 'timeFrame': 'Up to approximately 96 months'}, {'measure': 'Investigator-Assessed EFS', 'description': 'EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, as assessed by the investigator; or death from any cause, whichever occurs first.', 'timeFrame': 'Up to approximately 96 months'}, {'measure': 'Disease-Free Survival (DFS)', 'description': 'DFS is defined as the time from the first date of no disease to local or distant recurrence (including occurrence of new primary NSCLC) or death due to any cause, whichever occurs first, as determined by the investigator during the adjuvant treatment and observation follow-up', 'timeFrame': 'Up to approximately 96 months'}, {'measure': '2-Year and 3-Year OS', 'description': 'The 2-year and 3-year OS rate is defined as the probability that a participant will be alive 2 years and 3 years after randomization, respectively.', 'timeFrame': 'Up to approximately 96 months'}, {'measure': '2-Year and 3-Year Independent Review Facility-Assessed EFS', 'description': 'EFS is defined as the probability that a participant will be event-free 2 years and 3 years after randomization, respectively, as assessed by the Independent Review Facility.', 'timeFrame': 'Up to approximately 96 months'}, {'measure': '2-Year and 3-Year Investigator-Assessed EFS', 'description': 'EFS is defined as the probability that a participant will be event-free 2 years and 3 years after randomization, respectively, as assessed by the Investigator.', 'timeFrame': 'Up to approximately 96 months'}, {'measure': 'Change from baseline in HRQoL scores', 'description': 'Change from baseline in HRQoL scores as assessed through use of the two-item GHS/HRQoL subscale (Questions 29 and 30) of the EORTC QLQ-C30 at each assessment time point during the study through the completion of adjuvant treatment and observation follow-up assessments', 'timeFrame': 'Up to approximately 96 months'}, {'measure': 'Percentage of Participants With Adverse Events (AEs)', 'timeFrame': 'Up to approximately 96 months'}, {'measure': 'Number and Severity of Surgical Related Adverse Events', 'timeFrame': 'Up to approximately 96 months'}, {'measure': 'Number of Surgical Delays', 'description': 'Number of surgical delays.', 'timeFrame': 'Up to approximately 96 months'}, {'measure': 'Length of Surgical Delays', 'description': 'Length of surgical delays.', 'timeFrame': 'Up to approximately 96 months'}, {'measure': 'Number of Operative and Post-Operative Complications', 'description': 'Number of operative and post-operative complications.', 'timeFrame': 'Up to approximately 96 months'}, {'measure': 'Reasons for Surgical Cancellations', 'description': 'Reasons for surgical cancellations.', 'timeFrame': 'Up to approximately 96 months'}, {'measure': 'Minimum Observed Serum Atezolizumab Concentration (Cmin)', 'description': 'Cmin is the minimum (or trough) concentration that a study drug achieves in the body.', 'timeFrame': 'Pre-dose on Day 1 of Cycles 1 and 3 (each cylce is 21 days) for Neoadjuvant Treatment; pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 (each cycle is 21 days) for Arm A; at treatment or observation follow-up discontinuation (up to approximately 96 months)'}, {'measure': 'Maximum Observed Serum Atezolizumab Concentration (Cmax)', 'description': 'Cmax is the maximum (or peak) concentration that a study drug achieves in the body.', 'timeFrame': 'Pre-dose on Day 1 of Cycles 1 and 3 for Neoadjuvant Treatment; Pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 for Arm A. Each cycle is 21 days; at treatment or observation follow-up discontinuation (up to approximately 96 months)'}, {'measure': 'Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab', 'timeFrame': 'Pre-dose on Day 1 of Cycles 1 and 3 for Neoadjuvant Treatment; Pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 for Arm A. Each cycle is 21 days; at treatment or observation follow-up discontinuation (up to approximately 96 months)'}]",20,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,453.0,ACTUAL,2025-09-01T16:18:17.176977,v2_robust,True,True,False,False,True,
NCT00736463,Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc),"Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein",Simvastatin,"['Simvastatin', 'Atorvastatin 80 mg']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,HDL Cholesterol,['HDL Cholesterol'],"['HDL cholesterol', 'statin', 'inflammation', 'atherosclerosis', 'prevention', 'patients with low baseline HDL cholesterol']",UNKNOWN,,2005-01,,"[{'measure': 'HDL cholesterol', 'timeFrame': '6 weeks'}]","[{'measure': 'HS-CRP, apolipoprotein A1 and B', 'timeFrame': '6 weeks'}]",2,18 Years,,ALL,False,Oregon Health and Science University,OTHER,3,80.0,ESTIMATED,2025-09-01T16:18:17.177095,v2_robust,True,True,False,False,False,
NCT00255463,Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study,"Phase II, Placebo Controlled, Parallel Group, Double Blind, Randomised, Multicentre Trial Comparing the Anastrozole (Arimidex®) Placebo Combination to the Anastrozole - ZD1839 (Iressa™) Combination as Neoadjuvant Treatment in Postmenopausal Women With Stage I-IIIB Breast Cancer and Oestrogen Receptor (ER) and/or Progesterone (PgR) Positive Tumours",Anastrazole,"['Gefitinib', 'Anastrazole']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],[],COMPLETED,,2004-01,2005-11,[{'measure': 'To determine and compare changes in proliferation marker at 16 weeks in the treatment groups'}],"[{'measure': 'Tumour response, safety and tolerability, pharmacokinetics, pharmacokinetics and dynamics, oestradiol levels, mastectomy rate.'}, {'measure': 'Comparison of WHO and RECIST criteria,'}, {'measure': 'Exploratory biomarker studies involving genomics, metabolomics and proteomics.'}]",4,,,FEMALE,False,AstraZeneca,INDUSTRY,0,185.0,,2025-09-01T16:18:17.177117,v2_robust,True,True,True,False,True,
NCT05690087,Lidocaine Infusion on Optic Nerve Sheath Diameter in Laparoscopic Hysterectomy in Trendelenburg Position,Effect of Systemic Lidocaine Infusion on Optic Nerve Sheath Diameter in Patients Undergoing Laparoscopic Hysterectomy in Trendelenburg Position,Lidocaine,"['sodium chloride 0.9% solution', 'Lidocaine']",2,INTERVENTIONAL,['NA'],,,Lidocaine,"['Lidocaine', 'Optic Nerve Sheath Diameter', 'Laparoscopic Hysterectomy', 'Trendelenburg']",[],COMPLETED,,2023-02-01,2024-01-01,"[{'measure': 'Optic Nerve Sheath Diameter (ONSD)', 'description': 'ONSD at 5 min before induction of anesthesia in supine position (T1), 5 min after CO2 pneumoperitoneum in Trendelenburg position (T2), 30 min after CO2 pneumoperitoneum in Trendelenburg position (T3), 60 min after CO2 pneumoperitoneum in Trendelenburg position (T4) and 5 min after the closure of pneumoperitoneum in supine position (T5).', 'timeFrame': '5 min before induction of anesthesia till 5 min after the closure of pneumoperitoneum'}]","[{'measure': 'Heart rate', 'description': 'Heart rate at 5 min before induction of anesthesia in supine position (T1), 5 min after CO2 pneumoperitoneum in Trendelenburg position (T2), 30 min after CO2 pneumoperitoneum in Trendelenburg position (T3), 60 min after CO2 pneumoperitoneum in Trendelenburg position (T4) and 5 min after the closure of pneumoperitoneum in supine position (T5).', 'timeFrame': '5 min before induction of anesthesia till 5 min after the closure of pneumoperitoneum'}, {'measure': 'Mean arterial blood pressure', 'description': 'Mean arterial blood pressure at 5 min before induction of anesthesia in supine position (T1), 5 min after CO2 pneumoperitoneum in Trendelenburg position (T2), 30 min after CO2 pneumoperitoneum in Trendelenburg position (T3), 60 min after CO2 pneumoperitoneum in Trendelenburg position (T4) and 5 min after the closure of pneumoperitoneum in supine position (T5).', 'timeFrame': '5 min before induction of anesthesia till 5 min after the closure of pneumoperitoneum'}, {'measure': 'The incidence of postoperative adverse reactions', 'description': 'The incidence of adverse reactions, such as dizziness, postoperative nausea and vomiting (PONV) and postoperative headache (POHA) within 3 hours after surgery will be recorded in both groups.', 'timeFrame': 'Within 3 hours after surgery'}]",4,35 Years,65 Years,FEMALE,False,Tanta University,OTHER,0,66.0,ACTUAL,2025-09-01T16:18:17.177190,v2_robust,True,True,True,False,True,
NCT05791487,Combination of Diet and Oral Budesonide for Ulcerative Colitis,"Remission With Diet for Ulcerative Colitis Exacerbations: A Single Blinded, International Randomized Controlled Clinical and Translational Trial",Oral Budesonide,['Oral Budesonide'],1,INTERVENTIONAL,['NA'],,,Ulcerative Colitis,"['Ulcerative Colitis', 'Ulcerative Colitis Chronic Mild', 'Ulcerative Colitis Chronic Moderate']","['Ulcerative colitis', 'Diet', 'Partial enteral nutrition', 'Microbiome']",RECRUITING,,2023-12-01,2026-09-01,"[{'measure': 'Steroid free remission', 'description': 'Steroid free intention-to-treat (ITT) remission according to SCCAI\\<3 at week 12\n\n\\*The Simple Clinical Colitis Activity Index (SCCAI). score ranges from 0 to 19. clinical remission will be defined according to SCCAI\\<3', 'timeFrame': 'week 12'}]","[{'measure': 'Clinical response', 'description': '\\*The Simple Clinical Colitis Activity Index (SCCAI). score ranges from 0 to 19 . Clinical response defined as 3-point reduction in SCCAI or remission.', 'timeFrame': 'week 12'}, {'measure': 'Steroids free remission', 'description': 'Steroid free intention-to-treat (ITT) remission according to SCCAI\\<3 at week 6\n\n\\*The Simple Clinical Colitis Activity Index (SCCAI). score ranges from 0 to 19. clinical remission will be defined according to SCCAI\\<3', 'timeFrame': 'week 6'}, {'measure': 'Sustained steroid free remission', 'description': 'according to SCCAI\\<3 at week 24 score ranges from 0 to 19. clinical remission will be defined according to SCCAI\\<3', 'timeFrame': 'week 24'}, {'measure': 'Endoscopic remission', 'description': 'Defined as Mayo score 0 or 1. Mayo score 0 or 1 means endoscopic remission.\n\n\\*The Mayo Score for ulcerative colitis disease activity provides an assessement of disease severity and can be used to monitor patients during therapy.', 'timeFrame': 'week 12'}, {'measure': 'Change in medical therapy', 'description': 'Need for additional or change in medical therapy according to the physician decision.', 'timeFrame': 'by week 12'}, {'measure': 'Fecal calprotectin', 'description': 'Fecal calprotectin will be analyzed locally, and will be defined as median/mean change in calprotectin from baseline.', 'timeFrame': 'week 12'}]",7,17 Years,65 Years,ALL,False,Wolfson Medical Center,OTHER_GOV,0,90.0,ESTIMATED,2025-09-01T16:18:17.177235,v2_robust,True,True,False,False,False,
NCT01225887,Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer,A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma,Nintedanib,"['BIBF 1120', 'Multitargeted Tyrosine Kinase Inhibitor BIBF 1120', 'tyrosine kinase inhibitor BIBF 1120', 'Vargatef', 'Intedanib', 'BIBF-1120', 'Nintedanib']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Endometrial Adenocarcinoma,"['Endometrial Adenocarcinoma', 'Endometrial Clear Cell Adenocarcinoma', 'Endometrial Mucinous Adenocarcinoma', 'Endometrial Serous Adenocarcinoma', 'Endometrial Squamous Cell Carcinoma', 'Endometrial Transitional Cell Carcinoma', 'Endometrial Undifferentiated Carcinoma', 'Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm', 'Recurrent Uterine Corpus Carcinoma']",[],COMPLETED,,2011-10,2016-01,"[{'measure': 'Number of Participants With Adverse Events', 'description': 'The incidence of adverse events (grade 3 or higher) as assessed by the National Cancer Institute CTCAE version 4.0', 'timeFrame': 'Up to 5 years'}, {'measure': 'Objective Tumor Response', 'description': 'Complete and Partial Tumor Response by RECIST 1.1', 'timeFrame': 'For disease that can be evaluated by physical exam,response was assessed prior to each cycle CT scan or MRI if used to follow lesion for measurable disease every other cycle up to 5 years.'}, {'measure': 'Progression-free Survival > 6 Months', 'description': 'Whether or not the patient survived progression-free for at least 6 months.', 'timeFrame': 'for disease that can be evaluated by physical exam, progression was assessed prior to each cycle. CT scan or MRI if used to follow lesion for measurable disease every other cycle up to 5 years.'}]","[{'measure': 'Overall Survival', 'description': 'The observed length of life from entry into the study to death or the date of last contact.', 'timeFrame': 'From study entry to death or last contact, up to 5 years'}, {'measure': 'Progression Free Survival', 'description': 'the period of progression free survival for patients with persistent or recurrent endometrial cancer treated with study drug.', 'timeFrame': 'The duration of time from study entry to time of progression or death, whichever occurs first, assessed up to 5 years'}]",5,18 Years,,FEMALE,False,Gynecologic Oncology Group,NETWORK,1,37.0,ACTUAL,2025-09-01T16:18:17.177311,v2_robust,True,True,True,False,True,
NCT00114387,VEAPS: Vitamin E Atherosclerosis Prevention Study,VEAPS: Vitamin E Atherosclerosis Prevention Study,DL-alpha-tocopherol,['DL-alpha-tocopherol'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Atherosclerosis,['Atherosclerosis'],['vitamin E'],COMPLETED,,1996-07,2000-09,[{'measure': 'Rate of change of the distal common carotid artery (CCA) far wall intima-media thickness (IMT)'}],[],1,40 Years,,ALL,True,National Institute on Aging (NIA),NIH,1,353.0,,2025-09-01T16:18:17.177390,v2_robust,True,True,True,False,False,
NCT00003487,Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus,Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Adenocarcinoma of the Esophagus,Antineoplaston therapy (Atengenal + Astugenal),"['Antineoplaston therapy (Atengenal + Astugenal)', 'A10 (Atengenal); AS2-1 (Astugenal)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Adenocarcinoma of the Esophagus,['Adenocarcinoma of the Esophagus'],"['esophageal cancer', 'recurrent esophageal cancer', 'stage IV esophageal cancer']",TERMINATED,Slow accrual,1996-05-30,2001-04-27,"[{'measure': 'Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable', 'description': 'Objective response rate per The International Working Group response criteria (1999): Complete Response (CR), disappearance of all disease sustained for at least four weeks; Partial Response (PR), \\>=50% decrease in the sum of the products of of the greatest perpendicular diameters of all measurable lesions, sustained for at least four weeks. Stable Disease (SD), \\< 50% change in the sum of the products of of the greatest perpendicular diameters of all measurable lesions, sustained for at least twelve weeks.', 'timeFrame': '59 months'}]",[],1,18 Years,99 Years,ALL,False,Burzynski Research Institute,OTHER,0,8.0,ACTUAL,2025-09-01T16:18:17.177401,v2_robust,True,True,False,True,False,Slow accrual
NCT05212493,The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder,The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder,Cannabis oil,['Cannabis oil'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Autism Spectrum Disorder,['Autism Spectrum Disorder'],"['Autism', 'Cannabis', 'co-morbid symptoms', 'ASD', 'Cannabidiol']",COMPLETED,,2019-11-14,2023-12-31,"[{'measure': 'Cannabinoids levels change', 'description': 'To compare CBD, THC their and metabolites blood levels before and after intervention', 'timeFrame': '3 months'}, {'measure': 'Changes in attention span', 'description': 'To characterize the effect of medical cannabis treatment on the attention span using Conners teacher questionnaires. Significant change is defined as a change of 10% in questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Changes in cognitive level', 'description': 'To examine the effect of cannabis treatment on cognitive level using part of Wechsler test. Significant change is defined as a change of 10% in questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Comparison of efficacy between two different cannabis oil products', 'description': 'To compare efficacy of medical cannabis products with the same CBD: THC ratio in terms of communication skills using ADOS test. Significant change is defined as a change of 10% in raw questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Changes in adaptive behavior', 'description': 'To examine the effect of cannabis treatment on adaptive behavior as per ADOS test. Significant change is defined as a change of 10% in raw questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Changes in violent behavior', 'description': 'To examine the effect of cannabis treatment on violent behavior as per specific trial-designed questionnaire. Significant change is defined as a change of 10% in questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}]","[{'measure': 'Side effects', 'description': 'To identify side effects as per parents report in a specific trial-designed questionnaire. Significant change is defined as a change of 10% in new side effects as examined by questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Therapeutic failure', 'description': 'To identify therapeutic failure reasons as per Professional expert opinion. Significant reason is defined as reason that will effect at least 20% of therapeutic failure cases.', 'timeFrame': '6 months'}, {'measure': 'Changes in sleep problems', 'description': 'To examine whether high concentration CBD cannabis oil is effective in improving sleep as per Sleep questionnaire. Significant change is defined as a change of 10% in raw questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Changes in eating problems', 'description': 'To examine whether high concentration CBD cannabis oil is effective in improving eating as per eating questionnaire. Significant change is defined as a change of 10% in raw questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Changes in hormonal profile', 'description': 'To compare hormonal profile measured as per by Hospital Lab SOP before and during treatment. measured hormones are: TSH, FT4, 17OH-testosterone, LH, prolactine. Significant change is defined as a clinically significant diversion from lab defined normal ranges, according to age and sex, between baseline and 3 months.', 'timeFrame': '3 months'}, {'measure': 'Changes in biochemical parameters', 'description': 'To compare liver enzymes measured as per by Hospital Lab SOP before and during treatment. Measured enzymes are: ALT, AST, GGT, Bilirubin. Significant change is defined as a clinicaly significant diversion (more than twice the Upper Limit of Noraml for each enzyme) from lab defined normal ranges, between baseline and 3 months.', 'timeFrame': '3 months'}]",12,5 Years,25 Years,ALL,False,Assaf-Harofeh Medical Center,OTHER_GOV,2,128.0,ACTUAL,2025-09-01T16:18:17.177430,v2_robust,True,True,True,False,False,
NCT00966693,"Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma","Phase I/II Study of Lenalidomide (Revlimid), Thalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma",Dexamethasone,"['N-(2,6-Dioxo-3-piperidyl)phthalimide', 'Alin', 'Dexinoral', 'Hexadrol', 'Dexalocal', 'Auxiloson', 'Methylfluorprednisolone', 'Dexapos', 'Kevadon', 'Gammacorten', 'Auricularum', 'Dexone', 'Thalomid', 'Alin Oftalmico', 'Decadrol', 'Decasone R.p.', 'Spersadex', '2, 6-Dioxo-3-phthalimidopiperidine', 'Softenon', 'Contergan', 'Deltafluorene', 'Dexa-sine', 'Deronil', 'Dexa-Rhinosan', 'Dinormon', 'Dexacortin', 'Mymethasone', 'Cortidexason', 'Thalidomide', 'Talimol', 'Millicorten', 'N-Phthalylglutamic Acid Imide', 'Desamethasone', 'Alin Depot', 'Distaval', 'Baycuten N', '(+)-Thalidomide', 'Dexafarma', 'Dexamecortin', 'Visumetazone', 'Sedoval K-17', 'Dexa-Mamallet', 'Fortecortin', 'CC-5013', 'Pantosediv', 'Amplidermis', 'Dectancyl', 'Dekacort', 'Adexone', 'CDC 501', 'Desameton', 'Fluorodelta', 'Neurosedyn', 'Dexafluorene', 'Lenalidomide', '.alpha.-Phthalimidoglutarimide', 'Decadron', 'Anemul mono', 'Cortisumman', 'Aacidexam', 'Dexamethasone', 'Alba-Dex', 'Loverine', 'Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-', 'Dexamethasonum', 'Decameth', 'CC5013', 'Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-', 'Dexameth', 'Synovir', 'Lokalison-F', 'Aknichthol Dexa', 'Hexadecadrol', 'N-Phthaloylglutamimide', 'Orgadrone', 'Decacort', 'Dexa-Scheroson', 'Decalix', 'Alpha-Phthalimidoglutarimide', 'Sedalis', '(-)-Thalidomide', 'Revlimid', 'Baycuten', 'Dexacortal', 'Dexamonozon']",85,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Recurrent Plasma Cell Myeloma,"['Recurrent Plasma Cell Myeloma', 'Refractory Plasma Cell Myeloma']",[],COMPLETED,,2009-08-25,2018-07-20,"[{'measure': 'Number of Participants With Dose Limitations Toxicities of the Combination of Lenalidomide and Thalidomide and Dexamethasone (LTD) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)', 'description': 'To determine the dose limitations toxicities of the combination of lenalidomide and thalidomide and dexamethasone (LTD) in patients with relapsed/refractory multiple myeloma (RRMM).', 'timeFrame': 'After one 28-day cycle'}, {'measure': 'Complete Response(CR) and Very Good Partial Response(VGPR)', 'description': 'To determine the best overall response (CR+VGPR+PR) of the lenalidomide, thalidomide, dexamethasone combination based on IMWG criteria at nadir.', 'timeFrame': 'Evaluated each 28-day cycle and nadir of criteria is considered best overall response (median time to best response for this study was 2 cycles (range for best overall response was 1-21 cycles).'}]","[{'measure': 'Time to Progression', 'description': 'Time to Progression was estimated using Kaplan Meier analysis.', 'timeFrame': 'Up to 9 years'}, {'measure': 'Progression Free Survival', 'description': 'Estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups was made using the log-rank test. Cox proportional hazard regression will be employed for multivariate analysis on time-to-event outcomes.', 'timeFrame': 'Up to 9 years'}, {'measure': 'Time to Best Response', 'description': 'Estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups was made using the log-rank test. Cox proportional hazard regression will be employed for multivariate analysis on time-to-event outcomes.', 'timeFrame': 'Up to 9 years'}, {'measure': 'Incidence of Adverse Events', 'description': 'Linear regression was utilized to assess the effect of patient prognostic factors on the toxicity rate.', 'timeFrame': 'Up to 9 years'}, {'measure': 'Time to Next Therapy', 'description': 'Estimated using the method of Kaplan and Meier.', 'timeFrame': 'Up to 4.5 years'}]",7,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,77.0,ACTUAL,2025-09-01T16:18:17.177487,v2_robust,True,True,True,False,True,
NCT00910793,Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Asthmatic Patients,"Open-Label, Prospective Study to Assess the Effects of Formoterol and Beclometasone Dipropionate Combination Therapy on Central and Peripheral Airway Dimensions in Asthmatic Patients",Inuvair,['Inuvair'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Asthma,['Asthma'],"['Asthma', 'Formoterol', 'Beclomethasone Dipropionate', 'Computational Fluid Dynamics', 'Functional Imaging', 'Central and Peripheral Airways']",COMPLETED,,2008-08,2010-08,"[{'measure': 'Differences in airway dimension', 'description': 'The primary objective of this study is to evaluate the effect of the combination therapy on central and peripheral airway dimensions with CFD. The following primary outcome parameters will be determined:\n\n* Total airway resistance for the segmented airways\n* Peripheral airway resistance(from 4th bifurcation on) for the segmented airways\n* Total airway volume for the segmented airways\n* Peripheral airway volume (from the 4th bifurcation on) for the segmented airways\n* Relative compliance for each lobe\n* Density of the lung parenchyma given per predefined lung zone', 'timeFrame': 'airway dimension will be measured at visit 2 and visit 7'}]","[{'measure': 'Lung function tests: dynamic lung volumes, static lung volumes and airway resistances', 'description': 'The secondary outcome parameters that will be obtained with the lung function tests are:\n\n* Dynamic lung volumes: Forced Expiratory Volume in 1 sec (FEV1), Forced Vital Capacity (FVC), Peak Expiratory Flow (PEF),Maximum expiratory flow when 50% of the FVC remain to be exhaled (MEF50) , Maximum expiratory flow when 25% of the FVC remain to be exhaled (MEF25)\n* Static lung volumes: Vital Capacity (VC),Inspiratory Vital Capacity (IVC), Functional Residual Capacity (FCR), Total Lung Capacity (TLC)\n* Airway resistances: Airway Resistance (Raw), Specific Airway Conductance(SGaw) (based on body plethysmography)', 'timeFrame': 'lung function tests will be perfomed at te following visits: screening, visit 1 (2 weeks after screening), visit 3 (6 weeks after screening), visit 5 (14 weeks after screening) and visit 7 (26 weeks after screening)'}, {'measure': 'Subjective asthma control score', 'description': 'Asthma control scores will be obtained with the Dutch Asthma Control Test.', 'timeFrame': 'Asthma Control Test (ACT) will be performed on visit 1, 2, 3, 5 and 7'}, {'measure': 'Exhaled Nitric Oxide (NO)', 'timeFrame': 'Exhaled NO will be measured on visit 2, 3, 5 and 7'}, {'measure': 'Adverse events as a measure of safety', 'timeFrame': 'Follow up of adverse events will be done during the entire study duration'}]",5,18 Years,,ALL,False,Wilfried De Backer,OTHER,1,29.0,ACTUAL,2025-09-01T16:18:17.177509,v2_robust,True,True,True,False,True,
NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)",Asparaginase,"['Cortril', 'Hexadrol', 'Mega-Star', 'Laspar', 'Baycadron', 'Heb-Cort', 'Delta-Dome', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate', 'Promifen', 'Metysolon', 'Cytosar', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', 'Dexapos', 'Lantarel', 'Cyclostin', 'Dalisol', 'Prednilonga', 'Auricularum', 'Citrec', 'Medrol Veriderm', 'Oncaspar', 'Cort-Dome', 'Cytosine-beta-arabinoside', 'Mercaptopurinum', 'Rayos', 'Alin Oftalmico', 'Depo-Nisolone', 'Asparaginase-E.Coli', 'Barseb HC', 'Folinoral', 'Spersadex', 'Prednicort', 'Deltafluorene', 'Methylprednisolone', 'TaperDex', 'Dexa-Rhinosan', 'Dexacortin', '1-.beta.-D-Arabinofuranosylcytosine', 'Prednisone', 'Folaxin', '6-Mercaptopurine', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', 'Folinic Acid Calcium Salt Pentahydrate', 'Vepesid', 'WR138719', 'Cyclostine', 'Barseb-HC', 'Dexafarma', 'MTX', '3H-Purine-6-thiol', 'Fortecortin', 'Mercaptina', 'Aracytin', 'Metex', 'Panasol-S', 'Brimexate', 'Cytarabine', 'Paronal', 'Cortifan', 'Amethopterin', 'Dectancyl', 'Decadron DP', 'Novatrex', 'Rescufolin', 'Dexamethasone Intensol', 'Perrigo Prednisone', 'CHX-3311', 'Imo', 'leucovorin', '6H-Purine-6-thione, 1,7-dihydro- (9CI)', 'Predni-M-Tablinen', 'Udicil', 'Methotrexate LPF', 'Aracytidine', 'Ondena', 'Cytosine-.beta.-arabinoside', 'Factor, Citrovorum', 'Folaren', 'WR-19039', 'Methotrexate Methylaminopterin', 'Mercaleukim', 'Alti-Mercaptopurine', 'Deltadehydrocortisone', 'Sieropresol', 'Lederfolat', 'PEGLA', 'Prednidib', 'Asta B 518', 'Aknichthol Dexa', 'Dexa-Scheroson', 'Cicloxal', 'WR 138719', 'Ledoxina', '6-Purinethiol', 'Firmacort', 'Ara-C', 'Cytarabinum', 'U-19920', 'Dacortin', 'Asparaginase II', 'Arabinofuranosylcytosine', 'Cromatonbic Folinico', 'Adlone', 'Daunoblastina', 'Puri-Nethol', 'Leucosar', 'Foliplus', 'Cortispray', 'B518', 'Medlone 21', 'Vincristine, sulfate', 'U 19920', 'Re-82-TAD-15', 'ZoDex', '7-Mercapto-1,3,4,6-tetrazaindene', 'Dexalocal', 'Metotrexato', 'Cytoxan', 'FI-6339', '6-Thiopurine', 'Metilbetasone Solubile', 'Emthexat', 'Ciclofosfamide', '(-)-Cyclophosphamide', 'ASP-1', 'Rectoid', 'Meprosona-F', 'Cerubidine', 'Starasid', 'Metrotex', 'Kyocristine', 'Decadrol', 'Decortisyl', 'Decasone R.p.', '1-Beta-D-arabinofuranosylcytosine', 'Vincrex', 'Calcium Folinate', 'Texate', 'Emmetipi', 'Deronil', 'Tremetex', 'Hydrocortone', 'PEG-L-Asparaginase (Enzon - Kyowa Hakko)', 'Hautosone', 'VP 16213', 'Medrate', 'Depo Moderin', 'Proctocort', 'Desamethasone', 'Mercapurin', 'Solpredone', 'Ledertrexate', 'Medsatrexate', 'Visumetazone', 'Calfolex', 'CTX', 'Orasone', 'Dexa-Mamallet', 'Etoposide', 'Syklofosfamid', 'Amplidermis', 'Hytone', 'Cyclophosphanum', 'Divical', 'Cyclophosphamid monohydrate', 'Domolene', 'Calcium (6S)-Folinate', 'Lestaurtinib', 'Disintox', 'B-518', 'Wellcovorin', 'L-Asparaginase', '6 MP', 'Prednicen-M', 'Cehafolin', 'Purine-6-thiol, monohydrate', 'Metrocort', '.delta.1-Cortisone', 'Ismipur', 'Folix', 'Decadron', 'Methotrexate', 'Vincristine Sulfate', 'Mercaptopurine', 'Dermacort', 'Pegaspargase', 'B 518', 'Lcf-ASP', 'Aacidexam', 'Dexamethasone', 'Arabinosylcytosine', 'Purinethiol', 'Fosfaseron', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', 'Claphene', 'Dexameth', 'Ecofol', 'Folinac', 'Deltra', 'Neosar', 'Oncaspar-IV', 'Decacort', 'Farmitrexat', 'Vincasar', '6-Thioxopurine', 'Servisone', 'folinic acid', 'Lederfolin', 'Eldecort', 'Cyclophosphane', 'Cortef', 'LenaDex', 'VP-16', 'CL-14377', 'Azathiopurine', 'Folinvit', 'Cortenema', 'Folex', 'CYCLO-cell', 'CL 14377', 'Alin', 'CEP701', 'Dexinoral', 'VP-16213', 'Cyclophosphan', 'Lastet', 'Methylfluorprednisolone', 'Cytarbel', 'L-Asnase', 'Rubilem', 'Cycloblastine', 'Cloridrato de Daunorubicina', 'Gammacorten', 'Decorton', 'Dexone', 'Leucogen', 'Dxevo', 'Leunase', 'Purine-6-thiol (8CI)', 'Asparaginase', 'Toposar', 'Daunomycin, hydrochloride', 'Mexate-AQ', 'Fauldexato', '6-MP', 'Citofolin', 'SPM-924', 'RP-13057', 'Esametone', 'Mymethasone', '.beta.-Cytosine arabinoside', 'WR-28453', 'Millicorten', 'Nutracort', 'Genuxal', 'Alin Depot', 'Econosone', 'CEP-701', 'Vincosid', 'Leukerin', 'Dexamecortin', 'Radilem', 'Rubidomycin Hydrochloride', 'Predicorten', 'Clafen', 'Genoxal', 'Colaspase', 'VP-16-213', 'Serasa', 'Dekacort', 'Mercaleukin', 'SK-Prednisone', 'Metacortandracin', 'Adexone', 'Alexan', 'Fluorodelta', 'Emovis', 'ARA-cell', 'Dexafluorene', 'Delta 1-Cortisone', 'Cerubidin', 'Prednitone', 'Adasone', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', 'Emtexate', 'Daunorubicin Hydrochloride', 'Folidar', 'Kidrolase', 'Methoblastin', 'Anemul mono', 'Cortisumman', '1.beta.-D-Arabinofuranosylcytosine', 'Alba-Dex', 'Emthexate', 'Deltacortene', 'Oncovin', 'EPEG', 'Mitoxan', 'PEG-L-Asparaginase', '6 Thiopurine', 'Leupurin', 'Deltasone', 'U-4748', 'Polyethylene Glycol-L-Asparaginase', 'Erpalfa', 'Rheumatrex', 'Mern', 'Revimmune', 'Cetacort', 'Meprolone', 'L-ASP', 'Mexate', 'Panafcort', 'WR-138719', 'DeCortin', 'Foliben', 'Bw 57-323H', 'Folidan', 'Prednisonum', 'Dexamonozon', 'VP16213', 'Folinate Calcium', 'Komed-HC', 'Carloxan', 'Daunomycin Hydrochloride', 'Tonofolin', 'WR- 138719', 'Auxiloson', 'Purinethol', '1, 2-Dehydrocortisone', 'Cycloblastin', 'Cyclophosphamide', 'Purimethol', 'Cytosine Arabinoside', 'Aeroseb-HC', 'KT-5555', 'Beta-Cytosine Arabinoside', 'Leurocristine, sulfate', 'Lumexon', 'NCI-C04886', 'Cytophosphane', 'Leucovorin Calcium', 'Ciclofosfamida', 'VP 16-213', 'DepMedalone', 'Rescuvolin', 'Lisacort', 'Dexa-sine', 'Dinormon', 'PEG-Asparaginase', 'Cortidexason', 'Methotrexatum', 'Veriderm Medrol', 'Citrovorum Factor', 'WR-2785', 'Duralone', 'L-Asparaginase with Polyethylene Glycol', 'Baycuten N', 'Cyclophosphamidum', 'Deltacortisone', 'Cyclophospham', 'CEP 701', 'Predicor', 'CP monohydrate', 'PRED', 'Leurocristine Sulfate', 'Calinat', 'Daunoblastin', 'Hemady', 'Folex PFS', 'Abitrexate', 'Prednisone Intensol', 'Trexeron', 'Urbason', 'Caberdelta M', 'Desameton', 'Paracort', '6 Thiohypoxanthine', 'Hydrocortisone', 'Deltison', 'Cyclophosphamide Monohydrate', 'Maxtrex', 'Purine, 6-mercapto-', 'Alpha-Methopterin', 'Cortisol', 'Cytophosphan', 'Medrol', 'Therapeutic Hydrocortisone', 'Prednilen', 'Loverine', 'Dexamethasonum', 'VP 16', 'Elspar', 'VP16', 'Decameth', 'Aracytine', 'Trixilem', 'Flynoken A', 'Summicort', 'Ofisolona', 'Daunorubicin.HCl', 'Methylprednisolonum', 'Lokalison-F', 'L-Asparagine Amidohydrolase', 'Hexadecadrol', 'Orgadrone', '6-Mercaptopurine Monohydrate', 'Spectrila', 'Decalix', 'Polyethylene Glycol L-Asparaginase', 'Wyacort', 'FOLI-cell', 'Baycuten', 'Meticorten', 'Calcifolin', 'Metypresol', 'Daunoblastine', 'MK-965', 'Daunorubicini Hydrochloridum', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', 'Predniment', 'Flocofil', 'Adinepar', 'Cortancyl', 'Medrone', 'Tarabine PFS', 'Dexacortal', 'Calcium Leucovorin', 'Arabine']",429,INTERVENTIONAL,['PHASE3'],PHASE3,,Acute Lymphoblastic Leukemia,"['Acute Lymphoblastic Leukemia', 'Acute Undifferentiated Leukemia', 'Childhood T Acute Lymphoblastic Leukemia']",[],COMPLETED,,2008-01-15,2024-06-30,"[{'measure': 'Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)', 'description': 'EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.', 'timeFrame': 'From start of post-induction therapy for up to 10 years'}]","[{'measure': 'Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2', 'description': 'Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. EFS will be compared between patients on treatment Arm C at DL2 to those on Arm B.', 'timeFrame': 'From start of post-induction therapy for up to 10 years.'}, {'measure': 'Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)', 'description': 'Lestaurtinib-related dose-limiting toxicity proportions, as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, will by summarized by dose level for Safety phase patients.', 'timeFrame': 'Up to 12 weeks from start of induction'}, {'measure': 'Pharmacokinetic AGP Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy', 'description': 'Pharmacokinetic AGP levels in infants given lestaurtinib at DL2 in combination with chemotherapy will be described with mean and standard deviation for those with available data.', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Pharmacokinetic Albumin in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy', 'description': 'Pharmacokinetic albumin in infants given lestaurtinib at DL2 in combination with chemotherapy will be described with mean and standard deviation for those with available data.', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy', 'description': 'Summarized with mean and standard deviation for those with available data in Arm C', 'timeFrame': 'Sampled between weeks 6-12 from start of induction'}, {'measure': 'Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts', 'description': 'Described via mean and standard deviation by group.', 'timeFrame': 'Sampled at the start of induction'}, {'measure': 'Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts', 'description': 'Described via means and standard deviations in available Arm C relapse samples', 'timeFrame': 'At relapse (up to 3 years)'}, {'measure': 'Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts', 'description': 'Described via means and standard deviations in samples which have primary resistance to lestaurtinib', 'timeFrame': 'Sampled at the start of induction'}, {'measure': 'Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts', 'description': 'Described via means and standard deviations in samples which have acquired resistance to lestaurtinib', 'timeFrame': 'At relapse (up to 3 years)'}, {'measure': 'Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm', 'description': 'Three-year EFS estimates and 90% CI will be reported by treatment arm and end-induction MRD status.', 'timeFrame': '3 Years from end of Induction)'}, {'measure': 'Identification of Gene Expression Patterns in Diagnostic Infant Leukemia Samples That Correlate With Survival Outcomes', 'description': 'EFS outcomes will be reported by genotype.', 'timeFrame': 'At 3 years'}, {'measure': 'Identification of Gene Expression Patterns in Diagnostic Infant Leukemia Samples That Correlate With PIA Values', 'description': 'Means and standard deviations of Plasma Inhibitory Activity (PIA) will be given by genotype', 'timeFrame': 'At 3 years'}, {'measure': 'Percent Probability for Event-free Survival (EFS) for Patients on Arm A', 'description': 'EFS time is defined as time from treatment assignment to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.', 'timeFrame': 'From start of post-induction therapy for up to 10 years'}]",14,,1 Year,ALL,False,Children's Oncology Group,NETWORK,1,218.0,ACTUAL,2025-09-01T16:18:17.177600,v2_robust,True,True,True,False,True,
NCT00574093,Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD,12 Months Case Series Open Study to Assess the Safety and Efficacy of Intravitreal Injection of Lucentis (Ranibizumab 0.5 mg)Used in Combination With Visudyne (Verteporfin PDT) in Naive Subjects With Subfoveal CNV Secondary to AMD,Ranibizumab; Verteporfin,['Ranibizumab; Verteporfin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Neovascular Age Related Macular Degeneration,['Neovascular Age Related Macular Degeneration'],"['combination therapy', 'Lucentis', 'Visudyne']",COMPLETED,,2008-01,2009-10,"[{'measure': 'the mean change from baseline in BCVA letters with ETDRS at Month 3,6,12. -the number of retreatments, the treatment-free interval and the % of retreated patients at month 3, 6, 12. -the mean retinal thickness change from baseline at month 3, 6 and 12.', 'timeFrame': '12 months'}]","[{'measure': '% of patients that gain ≥5, ≥10, ≥15 letters BCVA; % of patients that lose <15 letters; Mean BCVA change and mean change of the total area of the lesion from baseline; Change of FA leakage; Mean retinal sensitivity change at month 3, 6 and 12', 'timeFrame': '12 months'}]",2,50 Years,95 Years,ALL,False,"Fondazione G.B. Bietti, IRCCS",OTHER,0,15.0,ESTIMATED,2025-09-01T16:18:17.177731,v2_robust,True,True,True,False,False,
NCT03980821,A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies,"A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4635 in Japanese Patients With Advanced Solid Malignancies.",AZD4635,['AZD4635'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Malignancies,['Advanced Solid Malignancies'],[],COMPLETED,,2019-07-04,2020-09-07,"[{'measure': 'The incidence of Adverse event and SAE', 'description': 'Investigate the safety and tolerability of AZD4635', 'timeFrame': 'From the informed consent to 30 days post last dose'}, {'measure': 'The incidence of Dose-limiting toxicity (DLTs)', 'description': 'Investigate the safety and tolerability of AZD4635', 'timeFrame': '25 days (Cycle0 and Cycle1)'}]","[{'measure': 'Objective response rate (ORR)', 'description': 'Summarize based on RECIST 1.1 by cohort and overall.', 'timeFrame': 'Tumor assessment is Cycle 4 Day 1 and then on Day 1 of each even numbered cycle (+/-5 days) until disease progression. Expected to be for up to 6 months.'}, {'measure': 'Maximum plasma concentration (Cmax)', 'description': 'Characterize the single-dose and multiple-dose plasma of AZD4635', 'timeFrame': 'Samples will be collected at pre-specified time points in the single-dose and multiple-dose portion of the study beginning with Cycle 1 Day 1 until last dose. Expected to be for up to 6 months.'}, {'measure': 'Disease control rate (DCR)', 'description': 'Summarize based on RECIST 1.1 by cohort and overall.', 'timeFrame': 'Tumor assessment is Cycle 4 Day 1 and then on Day 1 of each even numbered cycle (+/-5 days) until disease progression. Expected to be for up to 6 months.'}, {'measure': 'Area under the plasma concentration-time curve (AUC)', 'description': 'Characterize the single-dose and multiple-dose plasma of AZD4635', 'timeFrame': 'Samples will be collected at pre-specified time points in the single-dose and multiple-dose portion of the study beginning with Cycle 1 Day 1 until last dose. Expected to be for up to 6 months.'}]",6,20 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,0,10.0,ACTUAL,2025-09-01T16:18:17.177832,v2_robust,True,True,True,False,True,
NCT03692221,Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease,Percutaneous Image Guided Delivery of Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Symptomatic Degenerated Intervertebral Disc Disease,MSC Treatment group 1 (low dose),"['MSC Treatment group 1 (low dose)', 'MSC Treatment group 2 (high dose)']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Disc Degeneration,['Disc Degeneration'],['Back pain'],WITHDRAWN,Stalled due to Covid,2019-06,2022-09-30,"[{'measure': 'Rate of treatment related adverse events', 'description': ""assessing for worsening of patients' baseline symptoms or functions (will be considered an AE); (also general AE events), particularly AE events related to the procedures/treatment. All AEs will be assessed by common terminology criteria for adverse events. ."", 'timeFrame': 'From baseline/randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year.'}]","[{'measure': 'Changes in Pain -Visual Analogue Scale (VAS) for back pain', 'description': 'Temporal evaluation of pain before and after the procedure will be analyzed through documentation of Visual Analogue Scale of back pain (VAS).\n\nThe VAS is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. It is a unidimensional measure of pain intensity The instrument is presented by a straight horizontal line of fixed length, usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (symptom, pain, health) orientated from the left (worst) to the right (best). Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the ""no pain"" anchor and the patient\'s mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. No pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm) (11).', 'timeFrame': 'Baseline, 1 month, 6 months and 1 year'}, {'measure': 'Changes in Pain - Oswestry Disability Index (ODI) scores over time', 'description': 'Temporal evaluation of pain before and after the procedure will be analyzed through documentation of Oswestry Disability Index (ODI) scores over time. Scoring - For each section the total possible score is 5: if the first statement is marked the section score = 0; if the last statement is marked, it = 5. If all 10 sections are completed the score is calculated. Interpretation scores go from minimal 0% disability to 100% disability.', 'timeFrame': 'Baseline, 1 month, 6 months and 1 year'}, {'measure': 'changes in Quality of life - Short form Health Survey 36 (SF-36)', 'description': 'Temporal evaluation of quality of life before and after the procedure will be analyzed through documentation of SF36 quality of life questionnaire scores. Although this study is not cancer related, this questionnaire is a validated instrument for the evaluation of treatment related impact on quality of life - a critical outcome measure. Scoring - consisting of eight scaled scores which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.', 'timeFrame': 'Baseline, 1 month, 6 months and 1 year'}, {'measure': 'changes in MRI monitoring of transplant site', 'description': 'Magnetic resonance T2 mapping will be performed on all discs undergoing treatment for evaluation of potential quantitative, reproducible imaging change following treatment.', 'timeFrame': 'Baseline and 1 year, if a subject were to withdraw prior to completion of the study and received MSC an MRI with be obtained.'}]",5,18 Years,80 Years,ALL,True,University Hospitals Cleveland Medical Center,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:17.178057,v2_robust,True,True,False,True,True,Stalled due to Covid
NCT04979221,Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19,Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19,Cyproheptadine,['Cyproheptadine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,COVID-19 Pneumonia,['COVID-19 Pneumonia'],[],UNKNOWN,,2021-07-26,2022-02-28,"[{'measure': 'Ventilatory support', 'description': 'Number of days free from ventiltory support during the first 28 days', 'timeFrame': 'Day 28'}]","[{'measure': 'Mechanical ventilation', 'description': 'Duration of mechanical ventilation', 'timeFrame': 'Through study completion, an average of 6 months'}, {'measure': 'Mortality during 28 days', 'timeFrame': 'Day 28'}, {'measure': 'ICU Mortality', 'timeFrame': 'Through study completion, an average of 6 months'}, {'measure': 'Hospital Mortality', 'timeFrame': 'Through study completion, an average of 6 months'}, {'measure': 'Length of stay in the intensive care unit', 'timeFrame': 'Through study completion, an average of 6 months'}, {'measure': 'Length of stay in the hospital', 'timeFrame': 'Through study completion, an average of 6 months'}, {'measure': 'Renal replacement therapy', 'timeFrame': 'Day 28'}]",8,18 Years,,ALL,False,Hospital de Clinicas de Porto Alegre,OTHER,0,274.0,ESTIMATED,2025-09-01T16:18:17.178104,v2_robust,True,True,False,False,False,
NCT03096821,Extended Analysis for Leukemia/Lymphoma Treatment,A Prospective Investigator-initiated Translational Study Evaluating Individualized Treatment Regiments Based on Respective Biomarker Analyses for Refractory Leukemia and Lymphoma Patients,ngFDS selected treatment,"['ngFDS selected treatment', 'Treatment based on ngFDS']",2,OBSERVATIONAL,[],,,Relapsed Hematologic Malignancy,['Relapsed Hematologic Malignancy'],[],COMPLETED,,2015-09,2020-01-30,"[{'measure': 'progression-free survival', 'description': 'To compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has progressed on. The treatment concept is deemed for clinical benefit for the individual patient who has a PSF ratio (PSF on molecular profiling-based therapy/PSF on prior therapy) of ≥ 1.3. For this purpose we will reject the null hypothesis, which is defined as follows: ≤ 15% of patients would have a PFS ratio of ≥ 1.3. Thus, the individual patient is his own control. For tumor types with high numbers of patients per cohort, the overall response rate (ORR) will be evaluated.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months'}]","[{'measure': 'overall response rate', 'description': ""overall response rate (ORR: achieving either CR or PR). For lymphoma patients' responses were classified as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) according to the criteria proposed by the International Workshop for malignant lymphoma. For leukemia patients, responses were assessed following the response criteria defined by the recommendations of the European Leukemia net."", 'timeFrame': '4 months'}]",2,18 Years,,ALL,False,Medical University of Vienna,OTHER,0,143.0,ACTUAL,2025-09-01T16:18:17.178167,v2_robust,False,True,True,False,False,
NCT06643221,Exercise as an Immune Adjuvant for Allogeneic Cell Therapies,Exercise-induced Adrenergic Receptor Signaling as an Immune Adjuvant for Allogeneic Cell Therapies,Isoproterenol,"['Isoproterenol', 'Bisoprolol Fumarate Tablet 10 mg', 'Roflumilast 500 Mcg Oral Tablet', 'Nadolol (1 x 80 mg) Tablets (Invamed, Inc)', 'Placebo', 'Carvedilol 50 mg']",6,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Leukemia,"['Leukemia', 'Hematopoetic Stem Cell Transplantation', 'Donor Lymphocyte Infusion', 'CAR T-Cell Therapy', 'Lymphoma', 'Cell Therapy']","['exercise', 'cell therapy', 'beta-blockers', 'immune function', 'phosphodiesterase inhibitor', 'CAR T-cells', 'NK-cells', 'cytokine-induced killer cells', 'cytokine-induced memory-like NK-cells', 'monoclonal antibodies', 'leukemia', 'lymphoma', 'donor lymphocyte infusion', 'gamma-delta T-cells']",RECRUITING,,2018-01-24,2028-12-30,"[{'measure': 'Immune Cell Enumeration and Phenotyping', 'description': 'Whole blood samples will be analyzed for complete blood counts and to quantify lymphocyte and monocyte subtypes using flow cytometry and a comprehensive immunophenotyping panel. This panel is designed to identify major immune cell populations, as well as markers related to differentiation, exhaustion, migration, activation, and inhibition. Specific cell types expressing a surface protein, or combinations of surface proteins, will be reported as the percentage of cells positive for expression and/or by mean fluorescent intensity (MFI). For descriptive purposes, the cell counts of all major lymphocyte and monocyte subtypes will be expressed as cells per microliter (cells/µL) of whole blood. Additionally, isolated peripheral blood mononuclear cells (PBMCs) and expanded cell products will be quantified and phenotyped in a similar manner.', 'timeFrame': 'immediately after the intervention'}, {'measure': 'Cytolysis in vitro', 'description': 'We will assess whether lymphocytes collected during or after exercise, as well as cell products manufactured from these lymphocytes, are more effective at killing hematologic cancer target cells. Using in vitro assays, such as flow cytometry and bioluminescence-based assays, we will compare the cytolytic activity of both the collected lymphocytes and the manufactured cell products to those obtained under resting conditions. Results will be measured as the time required to achieve 10%, 20%, 30%, 40%, and 50% cytolysis, or as the percentage of target cells killed at specific time points (e.g., 4, 8, 24, and 48 hours). We will also evaluate the impact of combination therapies, such as monoclonal antibodies targeting the tumor model, as appropriate.', 'timeFrame': 'immediately after the intervention'}, {'measure': 'Tumor Burden and Tumor Free Survival', 'description': 'Tumor burden will be evaluated in immunocompromised mice engrafted with human tumors by measuring the size, number, and progression of tumors using imaging techniques such as bioluminescence, MRI, or CT scans, along with physical measurements where applicable. Overall tumor burden will be assessed through metrics like peak tumor size and photon intensity in bioluminescence imaging. Tumor-free survival will be defined as the time from treatment until either the recurrence of detectable tumors or the last follow-up without tumor recurrence. Data will be reported as overall tumor reduction (e.g., percentage decrease in tumor size or number), peak tumor burden, and photon intensity, as well as the duration of tumor-free survival in days. Additional analyses will explore the effects of treatment on delaying tumor progression and improving overall survival.', 'timeFrame': 'up to 120-days'}, {'measure': 'Clinical xGvHD Score', 'description': 'The development of xGvHD (xenogeneic graft-versus-host disease) will be assessed using a clinical scoring system with a possible aggregate score ranging from 0 to 10. Animals will be monitored regularly, and a total score of 5 or higher on two consecutive assessment days will indicate the presence of moderate xGvHD. This scoring system allows for the systematic evaluation of disease severity and progression in response to treatment.', 'timeFrame': 'up to 120-days'}, {'measure': 'Survival', 'description': 'Survival will be monitored as a critical endpoint in this study. Death will be recorded when any of the following criteria are met: (1) the animal experiences greater than 20% weight loss compared to its baseline weight at two consecutive weigh-ins, indicating significant deterioration in health; or (2) the animal exhibits signs of severe morbidity, characterized by an xGvHD score exceeding 7. These criteria ensure that any adverse effects related to treatment or disease progression are accurately captured, allowing for a comprehensive assessment of the survival outcomes in the context of xGvHD.', 'timeFrame': 'up to 120 days'}]","[{'measure': 'Single-Cell Secretome', 'description': 'We will assess the functional phenotype of purified cell types, including CD4+ and CD8+ T cells as well as natural killer (NK) cells, isolated from blood lymphocytes or expanded cell products. This will be accomplished using the Isoplexis single-cell platform and a multiplexed analysis of over 32 cytokines. Polyfunctionality will be evaluated by quantifying the number of distinct cytokines secreted by individual cells (ranging from 0 to 32) after a culture period of 4 to 18 hours. Each assay will include controls: unstimulated cells as a negative control, tumor cells to represent a target, and phorbol myristate acetate (PMA) as a positive control.', 'timeFrame': 'immediately after the intervention'}, {'measure': 'CITE-Seq Analysis of Immune Cell Populations', 'description': 'We will use CITE-Seq to analyze transcriptional and surface protein differences in key human immune cell populations in response to exercise, with and without in vitro tumor challenge. Cell clusters will be annotated using the Azimuth package based on reference human PBMCs. Additionally, we will conduct differential gene expression (DE) analysis and perform Gene Set Enrichment Analysis (GSEA) using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) terms, applying fold-change and difference metrics for all major immune cell clusters defined by the Azimuth multimodal atlas. We will also sequence various chains of the T-cell receptor (alpha, beta, gamma and delta) to determine T-cell clonal characteristics and antigen specificity using public databases (e.g. VDJdb).', 'timeFrame': 'immediately after the intervention'}, {'measure': 'Human Cell Engraftment and Immune Reconstitution:', 'description': 'In xenogeneic mice, peripheral blood counts and flow cytometry will be performed on days +7, +14, +21, +28, and +35 following tail bleeding into heparinized capillary tubes. This will assess human CD45+ cell engraftment (% of total human and mouse CD45+ cells) and differences in human immune cell reconstitution using a limited panel of lineage markers due to the restricted blood volumes in mice. If necessary, selected experiments will involve euthanizing mice to evaluate differences in human CD45+ cell and lymphocyte subsets in the bone marrow and spleen.', 'timeFrame': 'up to 120-days'}, {'measure': 'Pathology and Immunohistochemistry', 'description': 'In additional experiments, tissues-including the large and small intestine, liver, lung, and skin-from xenogeneic mice will be harvested for pathological evaluation of xenogeneic graft-versus-host disease (xGvHD). Immunohistochemistry will be performed to assess the types of infiltrating human cells present in the mouse tissues. The quantification of immune cells will be conducted using image analysis software to count the number of positive-staining cells per field of view, allowing for a comparison of immune cell infiltration across different tissues and experimental conditions.', 'timeFrame': 'up to 120-days'}]",9,21 Years,55 Years,ALL,True,University of Arizona,OTHER,1,100.0,ESTIMATED,2025-09-01T16:18:17.178198,v2_robust,True,True,False,False,True,
NCT00119314,"Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin","Carcinoma Unknown Primary: Treatment With Gemcitabine, Docetaxel and Capecitabine (GTX) an Evaluation and Treatment Study of The Cancer Institute of New Jersey Oncology Group",capecitabine,"['gemcitabine hydrochloride', 'capecitabine', 'docetaxel']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Carcinoma of Unknown Primary,['Carcinoma of Unknown Primary'],"['newly diagnosed carcinoma of unknown primary', 'recurrent carcinoma of unknown primary']",WITHDRAWN,slow accrual,2004-07,2005-07,[],[],0,18 Years,,ALL,False,University of Medicine and Dentistry of New Jersey,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:17.178323,v2_robust,True,True,False,True,False,slow accrual
NCT02510014,Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder,"An Open-Label, Long-Term Safety and Tolerability Study of Depot Buprenorphine (RBP-6000) in Treatment-Seeking Subjects With Opioid Use Disorder",SUBOXONE sublingual film,"['SUBOXONE sublingual film', 'RBP-6000', 'SUBOXONE', 'Atrigel buprenorphine', 'buprenorphine']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Opioid Use Disorder,"['Opioid Use Disorder', 'Opioid-related Disorders']",[],COMPLETED,,2015-07-27,2017-01-31,"[{'measure': 'Participants With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period', 'description': 'TEAE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= a marked limitation in activity. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent one of the outcomes listed in this definition.', 'timeFrame': 'Day 1 to Week 49 (De novo arm); Day 1 to Week 25 (Roll-over arm)'}, {'measure': 'Percentage Change From Baseline to End of Study (Weeks 25 and 49) in Vital Signs', 'description': 'Vital signs include\n\n* systolic blood pressure (mmHg)\n* diastolic blood pressure (mmHg)\n* respiratory rate (breaths/minute)\n* weight (kg)\n* body mass index (kg/m\\^2)\n* waist-to-hip ratio\n\nBaseline is defined as the last non-missing value prior to subcutaneous injection of RBP-6000 on Day 1.', 'timeFrame': 'Baseline (Day 1 predose) End of Study: Week 49 (De novo arm); Week 25 (Roll-over arm)'}, {'measure': 'Shifts in Suicidality Using the Columbia Suicide Severity Rating Scale (C-SSRS) From Baseline to Most Severe Assessment During the Treatment Period', 'description': ""The C-SSRS asks questions of study participants regarding whether they had suicidal ideation and/or suicidal behavior since the last visit using the electronic version of the scale. Only the most severe assessment is reported in this summary. Participants who experienced suicidal ideation and suicidal behavior are only summarized in the suicidal behavior since behavior is more severe than ideation.\n\nC-SSRS baseline version was completed during the screening visit. C-SSRS 'since-last-visit' version was completed weekly for the first month and at least every month until the end of the study.\n\nShift table category titles are structured as: baseline category/treatment category. The category 'No Suicidal Ideation or Behaviour' has been abbreviated as 'No Suicidal I or B'."", 'timeFrame': 'Baseline (Screening visit, days -21 to -15), End of Study: Week 49 (De novo arm); Week 25 (Roll-over arm)'}, {'measure': 'Worst Local Injection Site Pain From Injections as Measured by Participant-Reported Visual Analog Scale (VAS)', 'description': ""Injection site pain as measured by participant-reported VAS. The participant-reported VAS for injection site pain was measured on a 100 mm scale with 'no pain' at 0 mm and 'strongest pain ever' at 100 mm (total scale of 0-100). Participants marked where along the scale reflected their localized injection pain.\n\nThe injection site pain VAS scores were obtained (after the completion of the injection) within 1 minute and at 5, 10, 15, 30 and 60 minutes (+- 5 minutes). The timing of the injection site pain VAS should have been measured from the end of the injection.\n\nData represents the worst pain recorded for each participant across all injections and all VAS records. The mean value is presented.\n\nDe Novo subjects were given injections on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281 and 309.\n\nRoll-over subjects were given injections on Days 1, 29, 57, 85, 113, 141."", 'timeFrame': 'De Novo Subjects: Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281 and 309 Roll-over Subjects: Days 1, 29, 57, 85, 113, 141'}]","[{'measure': 'Change From Baseline in the Clinical Opiate Withdrawal Scale (COWS) at End of Study (Weeks 25 and 49)', 'description': 'COWS is an 11-item instrument used to assess signs and symptoms of opioid withdrawal. The score is the sum of the responses for a total range of 0-48. The COWS is commonly used by clinicians treating patients with buprenorphine to monitor the severity of withdrawal. COWS scores below 5 are considered not indicative of withdrawal. Scores from 5 to 12 are considered mild withdrawal; from 13 to 24 moderate withdrawal; 25 to 36 moderately severe withdrawal, and 37-48 severe withdrawal. Negative change from baseline values indicate a lessening of withdrawal symptoms.\n\nBaseline was defined as the last non-missing value prior to subcutaneous injection on Day 1. Baseline value is reported as an observed actual value. Weeks 25 and 49 represent change from baseline values.', 'timeFrame': 'Baseline (Day 1 predose), End of Study: Week 49 (De novo arm); Week 25 (Roll-over arm)'}, {'measure': 'Change From Baseline in the Subjective Opiate Withdrawal Scale (SOWS) at End of Study (Weeks 25 and 49)', 'description': 'The Subjective Opiate Withdrawal Scale (SOWS) contains 16 symptoms whose intensity the participant rates on a scale of 0 (not at all) to 4 (extremely) for a full scale of 0 (no withdrawal symptoms) to 64 (extreme withdrawal symptoms). Negative change from baseline values indicate a lessening of withdrawal symptoms.\n\nBaseline was defined as the last non-missing value prior to subcutaneous injection on Day 1. Baseline value is reported as an observed actual value. Weeks 25 and 49 represent change from baseline values.', 'timeFrame': 'Baseline (Day 1 predose), End of Study: Week 49 (De novo arm); Week 25 (Roll-over arm)'}, {'measure': 'Change From Baseline in the Opioid Craving Visual Analog Scale (VAS) at End of Study (Weeks 25 and 49)', 'description': ""The opioid craving scale was a 100 mm scale with 'no craving' indicated by 0 mm and 'strongest craving ever' indicated by 100 mm. Participants marked where along the scale reflected their craving for opioids.\n\nBaseline was defined as the last non-missing value prior to subcutaneous injection on Day 1. Baseline value is reported as an observed actual value. Weeks 25 and 49 represent change from baseline values."", 'timeFrame': 'Baseline (Day 1 predose), End of Study: Week 49 (De novo arm); Week 25 (Roll-over arm)'}, {'measure': 'Cumulative Distribution Function (CDF) of the Percentage Abstinence Collected From Week 1 Through End of Study (Weeks 25 and 49)', 'description': ""Participants' self-reported illicit opioid drug use from the timeline followback (TLFB) interview and results from the urine drug screens (UDS) for opioids were combined into a single endpoint. Opioids assessed included codeine, hydrocodone, hydromorphone, methadone, morphine, opiates, oxycodone, and oxymorphone (by UDS) and amphetamine/methadone, buprenorphine, methadone, and opioids in the TLFB.\n\nData represent the count of participants at various percentage abstinence levels. Abstinence was defined as urine samples being negative for opioids AND negative self-reports (obtained from Timeline Followback (TLFB) interviews) for illicit opioid use. The endpoint was based on visits in which paired urine samples and self-reports were expected for each subject as specified in the schedule of events. All missing reports for opioids were considered nonnegative."", 'timeFrame': 'Weekly during Month 1, Every other week from Month 2-6, Monthly from Month 7-12. De novo arm stopped at Week 49. Roll-over arm stopped at Week 25'}]",8,18 Years,65 Years,ALL,False,Indivior Inc.,INDUSTRY,0,775.0,ACTUAL,2025-09-01T16:18:17.178340,v2_robust,True,True,True,False,True,
NCT02591914,"An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration",,Fovista™,"['Avastin®', 'Lucentis®', 'Fovista™', 'Eylea®']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Neovascular Age-Related Macular Degeneration,['Neovascular Age-Related Macular Degeneration'],[],COMPLETED,,2014-02,2016-05-24,"[{'measure': 'Safety endpoints include adverse events, vital signs, ophthalmic variables [ophthalmic examination, intraocular pressure (IOP), fluorescein angiogram (FA), optical coherence tomography (OCT)], ECG, and laboratory variables.', 'timeFrame': 'Month 24'}]","[{'measure': 'Mean change in amount of fibrosis as assessed by fundus photography and OCT evaluation.', 'timeFrame': 'Month 24'}]",2,50 Years,,ALL,False,Retinal Consultants of Arizona,OTHER,1,30.0,ACTUAL,2025-09-01T16:18:17.178355,v2_robust,True,True,True,False,True,
NCT06332014,Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China,A Phase 4 Single Arm Open Label Study for the Efficacy and Safety of Prolia in Treatment of Male Subjects With Osteoporosis in Mainland China,Prolia,"['Denosumab', 'Prolia']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Osteoporosis,['Osteoporosis'],"['Prolia', 'Denosumab', 'AMG 162', 'Osteoporosis']",RECRUITING,,2024-08-06,2026-08-04,"[{'measure': 'Percent change from baseline in bone mineral density (BMD) of lumbar spine at month 12', 'timeFrame': 'Baseline and Month 12'}]","[{'measure': 'Percent change from baseline in serum C-terminal telopeptide (CTx) at month 3, 6, 9, and 12', 'timeFrame': 'Baseline and Months 3, 6, 9, and 12'}, {'measure': 'Percent change from baseline in serum procollagen Type 1 N-Telopeptide (P1NP) at month 3, 6, 9, and 12', 'timeFrame': 'Baseline and Months 3, 6, 9, and 12'}, {'measure': 'Percent change from baseline in total hip and femoral neck BMD at month 6 and 12', 'timeFrame': 'Baseline and Months 6 and 12'}, {'measure': 'Percent change from baseline in lumbar spine BMD at month 6', 'timeFrame': 'Baseline and Month 6'}, {'measure': 'Number of participants with adverse events (AE)', 'timeFrame': 'Up to 12 Months'}]",6,30 Years,90 Years,MALE,False,Amgen,INDUSTRY,0,100.0,ESTIMATED,2025-09-01T16:18:17.178362,v2_robust,True,True,False,False,True,
NCT01345214,A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia,"An Open-label, Multiple-Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia",ONO-7746,['ONO-7746'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Chemotherapy-Induced Thrombocytopenia,['Chemotherapy-Induced Thrombocytopenia'],"['ONO-7746', 'Chemotherapy Induced Thrombocytopenia', 'Thrombocytopenia']",TERMINATED,The study was terminated due to slow accrual of subjects.,2011-05,,"[{'measure': 'Safety and tolerability of ONO-7746 across ascending multiple doses using vital signs, physical examinations, ECGs, ECOG performance status, CT/MRI, laboratory tests', 'timeFrame': 'up to four 21-day cycles (up to 84 days)'}]","[{'measure': 'Characterization of PK profiles on ONO-7746 and exploration of the PD effect of ONO-7746, including changes in platelet counts and any potential effects on ECGs', 'timeFrame': 'up to four 21-day cycles (up to 84 days)'}]",2,18 Years,,ALL,False,Ono Pharma USA Inc,INDUSTRY,0,17.0,ACTUAL,2025-09-01T16:18:17.178377,v2_robust,True,True,False,True,True,The study was terminated due to slow accrual of subjects.
NCT00490516,ACP-104 in Acutely Psychotic Subjects With Schizophrenia,"A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 in Acutely Psychotic Subjects With Schizophrenia",ACP-104,"['Placebo', 'ACP-104']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Schizophrenia,['Schizophrenia'],"['Schizophrenia, psychotic disorders']",COMPLETED,,2007-06,2008-02,"[{'measure': 'PANSS', 'timeFrame': '6 weeks'}]",[],1,18 Years,60 Years,ALL,False,ACADIA Pharmaceuticals Inc.,INDUSTRY,0,247.0,ACTUAL,2025-09-01T16:18:17.178529,v2_robust,True,True,True,False,False,
NCT06204016,Estradiol and Stress Reactivity in Women,Associations of Estradiol and Stress Reactivity in Pre- and Postmenopausal Women,Estradiol Valerate,"['P-Tabletten', 'Progynova21', 'Estradiol Valerate', 'Placebo']",4,OBSERVATIONAL,[],,,Stress vs. Control,"['Stress vs. Control', 'Estradiol vs. Placebo']","['stress reactivity', 'mood homeostasis', 'neuroimaging (fMRI)', 'menopause', 'menstrual cycle', 'sex hormones', ""women's mental health"", 'estradiol']",RECRUITING,,2024-03-07,2025-12,"[{'measure': 'Associations between elevated E2 concentration and acute stress effects on subjective experience', 'description': 'Ratings of positive and negative affect as well as stress, before and after stress induction. Comparing E2 against placebo in pre- and postmenopausal women.', 'timeFrame': 'Measured twice two-three months apart; each time: approx. 45 minutes before stress onset, just before stress onset, immediately after stress, approx. 40 minutes, 60 minutes and 120 minutes after stress onset'}, {'measure': 'Associations of E2 and acute stress effects on Hypothalamic-Pituitary-Adrenal-axis (HPA) response', 'description': 'Cortisol saliva samples before and after the stress task as indicator of stress/HPA-axis activation. Comparing E2 against placebo in pre- and postmenopausal women.', 'timeFrame': 'Measured twice two-three months apart; each time: approx. 45 minutes before stress onset, just before stress onset, immediately after stress, approx. 40 minutes, 60 minutes and 120 minutes after stress onset'}, {'measure': 'Association between E2 concentration and acute stress induced effects on neural level.', 'description': 'Variability in activity of the brains stress network will be quantified using fMRI to assess differences between stress vs. control conditions during the stress task. Changes in activity will be assessed within regions associated with stress reactivity and regulation (amygdala, hippocampus, prefrontal cortex, anterior cingulate cortex (ACC), middle frontal gyrus (MFG), right superior temporal gyrus (STG), insula, striatum and praecuneus). Comparing E2 against placebo in pre- and postmenopausal women.', 'timeFrame': 'Measured twice three months apart; each time: approx. 5 minutes during neuroimaging'}, {'measure': 'Association between E2 concentration and brain volume changes', 'description': 'Via structural MRI scans changes in brain volume following E2 administration compared to placebo will be assessed, especially for the following brain regions: amygdala, hippocampus, prefrontal cortex (including orbito frontal cortex), anterior cingulate cortex (ACC), insula, middle frontal gyrus (MFG), right superior temporal gyrus (STG), fusiform gyrus, thalamus, cerebellum and inferior parietal lobule (IPL). Comparing E2 against placebo in pre- and postmenopausal women.', 'timeFrame': 'Measured twice two- three months apart; each time: approx. 10 minutes during neuroimaging'}, {'measure': 'Association between E2 concentration and connectivity (resting state) changes', 'description': 'Via a resting state scan, effects of estradiol concentration compared to placebo administration on connectivity changes will be assessed by applying whole brain network (especially Default Mode, Dorsal Attention, Frontoparietal, and Limbic networks) and region of interest analysis (especially of the amygdala, middle temporal gyrus (MTG), inferior frontal gyrus (IFG), postcentral gyrus, striatum, insula and ventrolateral, dorsolateral and medial prefrontal cortex (PFC), fusiform gyrus and anterior cingulate gyrus (ACC)). Comparing E2 against placebo in pre- and postmenopausal women.', 'timeFrame': 'Measured twice two-three months apart; each time: approx. 10 minutes during neuroimaging'}, {'measure': 'Changes in hormonal levels induced by increased E2 concentration.', 'description': 'Changes in E2 levels (pmol/L) will be assessed from blood samples before and after pill intake (placebo or estradiol valerate) and stress induction. Comparing E2 against placebo in pre- and postmenopausal women.', 'timeFrame': 'Measured twice two-three months apart; pill intake a day before and on the day of neuroimaging'}, {'measure': 'Changes in hormonal levels induced by increased E2 concentration.', 'description': 'Changes in progesterone, testosterone, and allopregnanolone levels (nmol/L) will be assessed from blood samples before and after pill intake (placebo or estradiol valerate) and stress induction. Comparing E2 against placebo in pre- and postmenopausal women.', 'timeFrame': 'Measured twice two-three months apart; pill intake a day before and on the day of neuroimaging'}]","[{'measure': 'Associations between E2 concentration and acute stress effects on physiological responses.', 'description': 'Measurements of heart rate and skin conductance as indicators of stress during fMRI. Comparing E2 against placebo in pre- and postmenopausal women. Comparing placebo against estradiol as well as pre- and postmenopausal women.', 'timeFrame': 'Measured twice two-three months apart; each time: 20 minutes during the fMRI stress task'}, {'measure': 'Association between E2 concentration and chronic stress', 'description': 'Associations of chronic stress, assessed via hair cortisol measures and chronic stress questionnaire (Trier Inventar of Chronic Stress - TICS; value range = \\[0 228\\]; higher outcome relates to a higher chronic stress rating), with estradiol and stress reactivity. Comparing E2 against placebo in pre- and postmenopausal women.', 'timeFrame': 'Measured twice two-three months apart'}, {'measure': 'Association between E2 concentration and effects on aftermath of stress.', 'description': 'To assess the subjective experience during the period following stress induction,an ecological momentary assessement EMA (7 days) will be obtained. Comparing E2 against placebo in pre- and postmenopausal women.', 'timeFrame': 'Measured twice two-three months apart; each time for 7days'}, {'measure': 'Associations between elevated E2 concentration and acute stress effects on subjective experience', 'description': 'Ratings of self-esteem before and after stress induction. Comparing E2 against placebo in pre- and postmenopausal women.', 'timeFrame': 'Measured twice two-three months apart; each time: approx. 45 minutes before stress onset and120 minutes after stress onset'}, {'measure': 'Associations between elevated E2 concentration and acute stress effects on subjective experience', 'description': 'Ratings of state anxiety before and after stress induction. Comparing E2 against placebo in pre- and postmenopausal women.', 'timeFrame': 'Measured twice two-three months apart; each time: approx. 45 minutes before stress onset and120 minutes after stress onset'}]",12,18 Years,60 Years,FEMALE,True,International Research Training Group 2804,OTHER,3,74.0,ESTIMATED,2025-09-01T16:18:17.178548,v2_robust,False,True,False,False,False,
NCT00302016,Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia,"An Open-label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.",AMN107,['AMN107'],1,EXPANDED_ACCESS,[],,,Chronic Myeloid Leukemia,['Chronic Myeloid Leukemia'],"['Chronic myeloid leukemia', 'AMN 107', 'Imatinib resistant or intolerant', 'nilotinib', 'enact']",NO_LONGER_AVAILABLE,,2006-01,,[],[],0,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,,,2025-09-01T16:18:17.178617,v2_robust,False,True,False,False,False,
NCT00005006,Parathyroid Hormone (PTH) With Alendronate for Osteoporosis,Cyclical vs Daily Continuous PTH in Combination With Alendronate vs Alendronate Alone,Parathyroid Hormone,"['Forteo', 'Fosamax', 'Parathyroid Hormone', 'Alendronate', 'Teriparatide']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Osteoporosis,['Osteoporosis'],"['Anabolic agent', 'hPTH', 'PTH', 'Parathyroid hormone', 'Bone mass', 'Bone turnover', 'Bone formation', 'Alendronate', 'Osteoporosis', 'Cyclical therapy']",COMPLETED,,1987-09,2006-12,[],[],0,50 Years,,FEMALE,False,Helen Hayes Hospital,OTHER,1,140.0,ACTUAL,2025-09-01T16:18:17.178658,v2_robust,True,True,True,False,False,
NCT00817206,Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily,"Ph3, Open Label, Multi-Ctr, Pros, Rand Study -Efficacy and Safety, Conversion Prograf® Capsules BID to LCPTacro Tablets QD, for Prevent of Acute Allograft Rejection in Stable Kidney Transplant pt.",LCP-Tacro,"['LCP-Tacro', 'Prograf', 'tacrolimus', 'tacrolimus modified release']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Renal Failure,['Renal Failure'],"['kidney transplantation', 'renal transplantation', 'maintenance immunosuppression', 'tacrolimus', 'Prevention of acute allograft rejection']",COMPLETED,,2008-12,2011-02,"[{'measure': 'Composite Endpoint for Efficacy Failure Within 12 Months of Randomization: Death, Graft Failure, Biopsy-proven Acute Rejection or Loss to Follow-up.', 'timeFrame': '12 months'}]",[],1,18 Years,,ALL,False,Veloxis Pharmaceuticals,INDUSTRY,1,326.0,ACTUAL,2025-09-01T16:18:17.178666,v2_robust,True,True,True,False,False,
NCT02799706,Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer,Phase IIIb Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer. A Joint Study of the EORTC ROG and GUCG,Degarelix,"['Degarelix', 'approved GnRH agonist']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Prostate Cancer,['Prostate Cancer'],"['Prostate cancer', 'GnRH antagonist', 'GnRH agonist', 'radiation therapy', 'very high risk localized prostate cancer', 'locally advanced prostate cancer']",ACTIVE_NOT_RECRUITING,,2017-09-25,2026-06-30,"[{'measure': 'Progression free survival', 'description': 'The primary endpoint is progression-free survival defined as the time in days from randomization to death, clinical or biochemical progression, whichever comes first.\n\nWhere\n\n* PSA progression based on Phoenix definition, i.e. a rise by 2 ng/mL or more above the nadir PSA (Ref. 17) confirmed by a second value measured minimum 3 months later\n* Clinical progression is defined as onset of obstructive symptoms requiring local treatment and demonstrated to be caused by cancer progression or evidence of metastases detected by clinical symptoms and confirmed by imaging\n* Start of another line of systemic therapy in absence of progression\n* Death due to any cause', 'timeFrame': 'through study completion, an average of 1 year'}]","[{'measure': 'Clinical progression-free survival', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Time to next systemic anticancer therapy (including secondary hormonal manipulation)', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': '♦ Proportion of patients switching from GnRH antagonists to GnRH agonists', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': '♦ Overall survival', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Incidence of clinical cardiovascular events', 'description': '♦ the incidence of clinical cardiovascular events - CCE (i.e. arterial embolic or thrombotic events, hemorrhagic or ischemic cerebrovascular conditions, myocardial infarction, and other ischemic heart disease) in patients who had cardiovascular events before entering the trial and in those without such events.', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': '♦ Incidence of urinary tract infection', 'timeFrame': 'through study completion, an average of 1 year'}]",7,18 Years,80 Years,MALE,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,885.0,ESTIMATED,2025-09-01T16:18:17.178674,v2_robust,True,True,False,False,False,
NCT05432206,MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva,Randomized Double-blind Cross-over Placebo-controlled Trial to Study the Impact on Behavioral and Psychological Symptoms of Dementia of Medical Cannabinoids (CBD/THC) in Patients with Severe Dementia in Long-term Care Facilities in Geneva,Cannabis Sativa Oil,"['Cannabis Sativa Oil', 'Placebo']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Dementia with Behavioral Disturbance,['Dementia with Behavioral Disturbance'],"['Dementia', 'Medical cannabis', 'Cannabinoids', 'Behavioral symptoms']",COMPLETED,,2023-09-29,2024-11-29,"[{'measure': 'Cohen-Mansfield Agitation Inventory Scale (CMAI)', 'description': 'Change from baseline in the Cohen-Mansfield Agitation Inventory score. Scores range from 29 to 203 - higher scores mean a worse outcome ( A total score \\>45 is usually regarded as clinically significant agitation).', 'timeFrame': '4 and 8 weeks - after 1 week washout'}]","[{'measure': 'Neuropsychiatric Inventory (NPI)', 'description': 'Change from baseline in the Neuropsychiatric Inventory score. Scores range from 0 to 144 - higher scores mean a worse outcome.', 'timeFrame': '4 and 8 weeks - after 1 week wash-out'}, {'measure': 'Unified Parkinson disease rigidity scale (UPDRS)', 'description': 'Change from baseline in the Unified Parkinson disease rating scale (UPDRS - item 22) rigidity score. Scores range from 0 to 4 - higher scores mean a worse outcome.', 'timeFrame': '4 and 8 weeks - after 1 week wash-out'}, {'measure': 'Pain (Doloplus)', 'description': 'Change from baseline in the Doloplus score. Scores range from 0 to 30 - higher scores mean a worse outcome.', 'timeFrame': '4 and 8 weeks - after 1 week wash-out'}, {'measure': 'Daily activity', 'description': 'Change from baseline in the score evaluating the most incapacitating daily activity. Scores range 0 to 10 - higher scores mean a greater difficulty for patients.', 'timeFrame': '4 and 8 weeks - after 1 week wash-out'}, {'measure': 'Behavioral Trouble', 'description': 'Change from baseline in the score evaluating the most incapacitating behavioral trouble. Scores range 0 to 10 - higher scores mean a greater trouble.', 'timeFrame': '4 and 8 weeks - after 1 week wash-out'}, {'measure': 'Team', 'description': ""Score evaluating the team's impression of change. Scores range 1 to 7. Higher scores mean greater deterioration."", 'timeFrame': '4 and 8 weeks - after 1 week wash-out'}, {'measure': 'Family', 'description': ""Score evaluating the family's impression of change. Scores range 1 to 7. Higher scores mean greater deterioration."", 'timeFrame': '4 and 8 weeks - after 1 week wash-out'}, {'measure': 'Evolution of dosages for each patient', 'description': 'Dosage adjustments of medical cannabis and psychotropic drugs.', 'timeFrame': '4 and 8 weeks'}, {'measure': 'Change in enzymatic activity', 'description': 'Change in cytochromes P450 (1A2, 2B6, 2C9, 2C19,2D6 and 3A4/5 ) enzymatic activities using Geneva cocktail approach.', 'timeFrame': '8 weeks'}, {'measure': 'Therapeutic Drug Monitoring', 'description': 'Therapeutic drug monitoring of plasma concentrations of Tetrahydrocannabinol, 11-Hydroxy-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, Cannabidiol.', 'timeFrame': '8 weeks'}, {'measure': 'Endocannabinoids', 'description': 'Evaluation of plasma levels of endocannabinoids - anandamide and 2-arachidonylglycerol.', 'timeFrame': '8 weeks'}]",12,55 Years,,ALL,False,Fondation pour l'accueil et l'hébérement des personnes âgées,OTHER,1,27.0,ACTUAL,2025-09-01T16:18:17.178728,v2_robust,True,True,True,False,False,
NCT05732506,Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria,Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria,Edoxaban,"['Edoxaban', 'Lixiana']",2,OBSERVATIONAL,[],,,Auricular Fibrillation,['Auricular Fibrillation'],[],COMPLETED,,2023-02-01,2025-04-09,"[{'measure': 'Major bleeding.', 'description': 'Proportion of patients who had a major bleeding during the 12 months of follow-up.', 'timeFrame': '12 months'}]","[{'measure': 'Stroke or systemic embolism.', 'description': 'Proportion of patients who suffered stroke or systemic embolism during the 12 months of follow-up.', 'timeFrame': '12 months'}]",2,75 Years,,ALL,False,Galaxia Empírica,NETWORK,0,411.0,ACTUAL,2025-09-01T16:18:17.178799,v2_robust,False,True,True,False,False,
NCT02638506,RCT Evaluating Intranasal Fentanyl in the Pain Management of Children With Headaches,Randomized Controlled Trial Evaluating the Additive Value of Intranasal Fentanyl on Ibuprofen in the Pain Management of Children With Moderate to Severe Headaches,Fentanyl,"['Fentanyl', 'Fentanyl citrate']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Headaches,['Headaches'],"['Headaches, Migraines, Fentanyl']",TERMINATED,Covid restrictions,2016-01,2020-08-18,"[{'measure': ""The primary outcome measure will be the difference of the subjects' self-reported pain scores as assessed by the VAS at the fifteenth minute after administration of the initial drug therapy, which correspond to its peak analgesic effect."", 'timeFrame': '15 minutes'}]",[],1,8 Years,18 Years,ALL,True,St. Justine's Hospital,OTHER,0,62.0,ACTUAL,2025-09-01T16:18:17.178832,v2_robust,True,True,False,True,False,Covid restrictions
NCT00415506,Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation,"A PhaseI/II Prospective, Randomized, Dose-Ranging Pilot Study of Rituximab in the Treatment of Refractory Scleritis and Non-Infectious Orbital Inflammation",Rituximab,['Rituximab'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Scleritis,"['Scleritis', 'Orbital Disease']",[],COMPLETED,,2007-01,2011-03,"[{'measure': 'Reduction of Medications', 'description': 'Reduction (decrease in dosage) of systemic corticosteroids or immunosuppressive therapy by at least 50% by 24 weeks.', 'timeFrame': '24 Weeks'}, {'measure': 'Improved Control of Inflammation', 'description': 'For patients with scleritis, disease activity as measured by a modified grading system first described by McCluskey et al. (McCluskey and Wakefield 1987; McCluskey and Wakefield 1991). Improvement in scleritis activity will be defined as a reduction in this grading score of 2 or more, or an overall score of 4 or less by 24 weeks.\n\nFor patients with orbital inflammation, disease activity as measured by a modified grading system first devised by Werner (Werner 1977). Improvement in orbital inflammation will be defined as a reduction in this grading score of 2 or more, or an overall score of 3 or less.', 'timeFrame': '24 weeks'}]",[],2,18 Years,,ALL,False,Oregon Health and Science University,OTHER,1,20.0,ACTUAL,2025-09-01T16:18:17.178904,v2_robust,True,True,True,False,False,
NCT04281706,Impact of Etomidate vs. Propofol on Infectious Complications Post Cardiac Surgery,Impact of Etomidate vs. Propofol on Development of Sepsis and Infectious Complications Post Cardiac Surgery,Etomidate vs Propofol as induction agent,['Etomidate vs Propofol as induction agent'],1,OBSERVATIONAL,[],,,Postoperative Complications,['Postoperative Complications'],[],COMPLETED,,2019-10-15,2021-01-01,"[{'measure': 'Sepsis', 'description': 'Incidence of sepsis according to diagnosis-related group coding between surgical intervention and hospital discharge (according to SEPSIS II)', 'timeFrame': 'surgical intervention to hospital discharge, average 30 days'}]","[{'measure': 'Pneumonia', 'description': 'Incidence of pneumonia within between surgical intervention and hospital discharge', 'timeFrame': 'surgical intervention to hospital discharge, average 30 days'}, {'measure': 'Mediastinitis', 'description': 'Incidence of mediastinitis within between surgical intervention and hospital discharge', 'timeFrame': 'surgical intervention to hospital discharge, average 30 days'}, {'measure': 'Surgical Site Infections', 'description': 'Incidence of surgical site infections between surgical intervention and hospital discharge', 'timeFrame': 'surgical intervention to hospital discharge, average 30 days'}, {'measure': 'ICU Mortality', 'description': 'Proportion of patients that died before ICU discharge', 'timeFrame': 'surgical intervention to ICU discharge, average 30 days'}, {'measure': 'Hospital mortality', 'description': 'Proportion of patients that died before hospital discharge', 'timeFrame': 'surgical intervention to hospital discharge, average 30 days'}, {'measure': 'Intensive Care Unit length of stay', 'description': 'Time patients spend on the ICU', 'timeFrame': 'ICU admission to ICU discharge, average 30 days'}, {'measure': 'Hospital length of stay', 'description': 'Time patients spend admitted to the hospital', 'timeFrame': 'hospital admission to hospital discharge, average 30 days'}]",8,18 Years,100 Years,ALL,,"Charite University, Berlin, Germany",OTHER,0,1495.0,ACTUAL,2025-09-01T16:18:17.178927,v2_robust,False,True,True,False,False,
NCT01618006,Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery,Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery,Aspirin,['Aspirin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Postoperative; Dysfunction Following Cardiac Surgery,['Postoperative; Dysfunction Following Cardiac Surgery'],[],COMPLETED,,2012-01,2013-08,"[{'measure': 'Serum Thromboxane: Define an inadequate aspirin response as a value >0.69 ng/ml, which is 2 SD above the mean of aspirin-treated patients', 'timeFrame': 'Postoperative Day 4'}]","[{'measure': 'Arachidonic Acid Induced Light Transmission Aggregometry (LTA): Aggregation will be expressed as the maximum percent change in light transmittance from baseline, with platelet-poor plasma used as a reference.', 'timeFrame': 'Postoperative Day 4'}, {'measure': 'Arachidonic Acid Induced Multiple Electrode Platelet Aggregometry (MEA):Aggregation was recorded for 6 minutes and will be reported as the area under the curve (aggregation units x min).', 'timeFrame': 'Postoperative Day 4'}, {'measure': 'DNA genetic analyses for single nucleotide polymorphisms', 'timeFrame': 'A single preoperative blood sample was drawn (on average of 1 week prior to surgery)'}]",4,18 Years,,ALL,False,Hamilton Health Sciences Corporation,OTHER,0,120.0,ACTUAL,2025-09-01T16:18:17.178948,v2_robust,True,True,True,False,False,
NCT02210806,"Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation","Efficacy, Dose-ranging and Safety Evaluation (A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Single Dose, Five-arm, Crossover, and Dose-ranging Study of A006 in Adult Asthma Patients)",A006 DPI,"['Albuterol DPI', 'A006 DPI', 'Albuterol', 'Proventil® MDI', 'Proventil®']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Asthma,['Asthma'],"['Asthma', 'Mild-to-moderate persistent asthma', 'Mild asthma', 'Moderate asthma', 'Persistent asthma']",COMPLETED,,2014-07,2014-10,"[{'measure': 'Area Under the Curve (AUC[0-6h]) of Post-Dose FEV1 Percentage Change (∆%FEV1) from the Same-Day Pre-Dose Baseline', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. Area under the curve (AUC), from baseline to 6 hours post-dose, for the treatment period is calculated using the trapezoidal rule. Statistical analysis is performed using a one-sided t-test.', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}]","[{'measure': 'Area Under the Curve (AUC[0-6h]) of Placebo Adjusted Post-Dose FEV1 Percentage Change (∆∆%FEV1) from the Same-Day Pre-Dose Baseline', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. ∆∆FEV1% for the study visit is calculated by subtracting the mean ∆%FEV1 for subjects in a randomized treatment arm from their ∆%FEV1. Area under the curve (AUC), from baseline to 6 hours post-dose, for the study visit is calculated using the trapezoidal rule.', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}, {'measure': 'Area Under the Curve (AUC[0-6h]) of Post-Dose FEV1 Volume Changes (∆FEV1) from the Same-Day Pre-Dose Baseline', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. Area under the curve (AUC), from baseline to 6 hours post-dose, for the treatment period is calculated using the trapezoidal rule.', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}, {'measure': 'Time to Onset of Bronchodilator Effect (t[onset])', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. t\\[onset\\] is the point where post-dose ∆%FEV1 first reaches ≥ 12% over the pre-dose baseline. Determined by linear interpolation.', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}, {'measure': 'Peak Bronchodilator Response (F[max])', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. F\\[max\\] is the maximum post-dose ∆%FEV1.', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}, {'measure': 'Time to Peak ∆FEV1 Effect (t[max])', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. The time to peak ∆FEV1 effect, t\\[max\\], is defined as the time of F\\[max\\].', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}, {'measure': 'Area Under the Curve (AUC[0-6h]) of Post-Dose FEV1 in Volume from the Same-Day Pre-Dose Baseline', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. Area under the curve (AUC), from baseline to 6 hours post-dose, for the treatment period is calculated using the trapezoidal rule.', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}, {'measure': 'F[max] of Post-Dose FEV1 in Volume', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. F\\[max\\] of post-dose FEV1 in volume is the maximum post-dose FEV1.', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}, {'measure': 'Efficacy Duration-1', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. Efficacy Duration-1 is total duration of bronchodilator effects when ∆%FEV1 is ≥ 12% above the baseline.', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}, {'measure': 'Efficacy Duration-2', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. Efficacy Duration-2 is total duration of bronchodilator effects when ∆FEV1 is ≥ 200 mL above the baseline.', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}, {'measure': 'Efficacy Duration-3', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. Efficacy Duration-3 is total duration of bronchodilator effects when ∆FEV1 is ≥ 100 mL above the baseline.', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}, {'measure': 'Bronchodilator Response', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. Subjects that demonstrate a ≥ 12% increase for ∆%FEV1 will be classified as having a bronchodilator response.', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}, {'measure': 'Dose Response Curve', 'description': 'The forced expiratory volume in the 1st second (FEV1) is measured with a clinically accepted model of spirometer. Subjects perform a pre-dose baseline FEV1 prior to dosing and perform subsequent FEV1 tests at 5, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing during each treatment period. The dose response curve is the AUC\\[0-6h\\] of ∆%FEV1 versus study drug dosage.', 'timeFrame': 'Within 30 minutes prior to dosing (baseline) to 6 hours post-dose'}]",13,18 Years,55 Years,ALL,False,"Amphastar Pharmaceuticals, Inc.",INDUSTRY,0,22.0,ACTUAL,2025-09-01T16:18:17.179016,v2_robust,True,True,True,False,False,
NCT06867406,A Trial to Evaluate KPC000154 Tablets in Healthy Subjects,"A Phase I, Single-Center, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KPC000154 Tablets in Healthy Adult Volunteers",KPC000154 10mg Tablet Intervention,"['KPC000154 60mg Tablet Intervention', 'KPC000154 120mg Tablet Intervention', 'KPC000154 10mg Tablet Intervention', 'KPC000154 300mg Tablet Intervention', 'Placebo-controlled（MAD）', 'KPC000154 200mg Tablet Intervention', 'KPC000154 120mg multiple-dose Tablet Intervention（To Be Determined）', 'KPC000154 400mg Tablet Intervention', 'KPC000154 30mg Tablet Intervention', 'Placebo-controlled（SAD）', 'KPC000154 80mg multiple-dose Tablet Intervention（To Be Determined）', 'KPC000154 40mg multiple-dose Tablet Intervention（To Be Determined）']",12,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Subjects、Lipid Metabolism,['Healthy Subjects、Lipid Metabolism'],[],NOT_YET_RECRUITING,,2025-03-07,2026-01-31,"[{'measure': 'Pharmacokinetic profile of KPC000154 after single and multiple oral administration (Cmax)', 'description': 'Maximum plasma concentration (Cmax) of KPC000154', 'timeFrame': '12.8 month'}, {'measure': 'Pharmacokinetic profile of KPC000154 after single and multiple oral administration (AUC0-t)', 'description': 'Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of KPC000154', 'timeFrame': '12.8 month'}, {'measure': 'Pharmacokinetic profile of KPC000154 after single and multiple oral administration (Tmax)', 'description': 'Time to reach maximum plasma concentration (Tmax) of KPC000154', 'timeFrame': '12.8 month'}]","[{'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v5.0', 'description': 'safety measures', 'timeFrame': '12.8 month'}]",4,18 Years,55 Years,ALL,True,"Kunming Pharmaceuticals, Inc.",INDUSTRY,0,92.0,ESTIMATED,2025-09-01T16:18:17.179181,v2_robust,True,True,False,False,True,
NCT02487706,Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal Disease,Removal of Dolutegravir by Hemodialysis in HIV-infected Patients With End-stage Renal Disease,Dolutegravir,['Dolutegravir'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,HIV,['HIV'],"['Hemodialysis', 'HIV-infection']",COMPLETED,,2015-06,2015-07,"[{'measure': 'hemodialysis extraction ratio of dolutegravir', 'timeFrame': 'Day 5'}, {'measure': 'hemodialysis clearance of dolutegravir', 'timeFrame': 'Day 5'}]","[{'measure': 'percentage of patients presenting adverse events related to dolutegravir', 'timeFrame': 'From Baseline to day 5'}]",3,18 Years,99 Years,ALL,False,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",OTHER,0,5.0,ACTUAL,2025-09-01T16:18:17.179194,v2_robust,True,True,True,False,True,
NCT01155206,Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon,Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon,glucagon,"['glucagon 0.65ng/kg/min', 'glucagon']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetes,['Diabetes'],"['glucagon,', 'high physiological dose and basal dose of glucagon', 'hepatic lipoprotein production,', 'free fatty acid', 'intestinal lipoprotein production', 'particle', 'glucagon affects production of fat in intestine and liver.']",COMPLETED,,2009-06,2010-01,"[{'measure': 'Triglyceride-rich lipoprotein production rate', 'timeFrame': '0-10 hours'}]",[],1,18 Years,40 Years,ALL,True,"University Health Network, Toronto",OTHER,0,9.0,ACTUAL,2025-09-01T16:18:17.179203,v2_robust,True,True,True,False,False,
NCT01462006,Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF),Double-blind Placebo-controlled Pilot Study of Sirolimus in IPF,sirolimus,['sirolimus'],1,INTERVENTIONAL,['NA'],,,Idiopathic Pulmonary Fibrosis,"['Idiopathic Pulmonary Fibrosis', 'Diffuse Parenchymal Lung Disease', 'Interstitial Lung Disease']",[],COMPLETED,,2011-10,2016-03,"[{'measure': 'fibrocytes', 'description': 'change in peripheral blood concentration of CXCR4+ fibrocytes', 'timeFrame': 'up to 22 weeks'}, {'measure': 'number of subjects with drug side-effects', 'timeFrame': 'up to 22 weeks'}]",[],2,21 Years,85 Years,ALL,False,University of Virginia,OTHER,1,32.0,ACTUAL,2025-09-01T16:18:17.179267,v2_robust,True,True,True,False,False,
NCT00956306,A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function,A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function,Udenafil,"['DA-8159; Zydena', 'Udenafil']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Hepatic Impairment,['Hepatic Impairment'],"['Udenafil,DA-8159,hepatic impairment,healthy volunteers']",COMPLETED,,2007-11,2012-09,"[{'measure': 'Pharmacokinetics (AUC and Cmax), Safety', 'timeFrame': 'up to 72 hours'}]",[],1,20 Years,64 Years,MALE,True,"Dong-A Pharmaceutical Co., Ltd.",INDUSTRY,0,18.0,ACTUAL,2025-09-01T16:18:17.179276,v2_robust,True,True,True,False,True,
NCT00065806,Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Test the Safety and Efficacy of Lipitor (Atorvastatin) in Reducing the Progression of Carotid IMT in Early Childhood SLE",Atorvastatin,"['Atorvastatin', 'Placebo atorvastatin', 'Atorvastatin Calcium', 'Lipitor']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,"Lupus Erythematosus, Systemic","['Lupus Erythematosus, Systemic']","['Pediatric lupus', 'Atherosclerosis', 'SLE', 'HMG CoA reductase inhibitor']",COMPLETED,,2003-09,2009-12,"[{'measure': 'Change in Mean-Mean Common Carotid IMT (CIMT)', 'description': 'For the common carotid arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right common near wall mean, right common far wall mean, left common near wall mean and left common far wall mean). These summary variables were then averaged to estimate a single mean-mean common CIMT for each participant visit.', 'timeFrame': 'Change from baseline to 36 months'}]","[{'measure': 'Change in Mean-Max CIMT', 'description': 'For each side, segment and wall, the maximum CIMT over the 4 angles of interrogation was selected to produce 12 summary variables (right common near wall max, right common far wall max, right bifurcation near wall max, right bifurcation far wall max, right internal near wall max, right internal far wall max, left common near wall max, left common far wall max, left bifurcation near wall max, left bifurcation far wall max, left internal near wall max and left internal far wall max). These 12 summary variables were then averaged to estimate a single mean-max CIMT for each participant visit.', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Mean-Mean CIMT', 'description': 'For each side, segment and wall, mean CIMT values were averaged over the 4 angles of interrogation to produce 12 summary variables (right common near wall mean, right common far wall mean, right bifurcation near wall mean, right bifurcation far wall mean, right internal near wall mean, right internal far wall mean, left common near wall mean, left common far wall mean, left bifurcation near wall mean, left bifurcation far wall mean, left internal near wall mean and left internal far wall mean). These 12 summary variables were then averaged to estimate a single mean-mean CIMT for each participant visit.', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Mean-Max Common CIMT', 'description': 'For each side and wall of the common carotid arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right common near wall max, right common far wall max, left common near wall max and left common far wall max). These summary variables were then averaged to estimate a single mean-max common CIMT for each participant visit.', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Mean-Max Internal CIMT', 'description': 'For each side and wall of the internal carotid arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right internal near wall max, right internal far wall max, left internal near wall max and left internal far wall max). These summary variables were then averaged to estimate a single mean-max internal CIMT for each participant visit.', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Mean-Mean Internal CIMT', 'description': 'For the internal carotid arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right internal near wall mean, right internal far wall mean, left internal near wall mean and left internal far wall mean). These summary variables were then averaged to estimate a single mean-mean internal CIMT for each participant visit.', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Mean-Max Bifurcation CIMT', 'description': 'For each side and wall of the bifurcation arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right bifurcation near wall max, right bifurcation far wall max, left bifurcation near wall max and left bifurcation far wall max). These summary variables were then averaged to estimate a single mean-max bifurcation CIMT for each participant visit.', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Mean-Mean Bifurcation CIMT', 'description': 'For the bifurcation arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right bifurcation near wall mean, right bifurcation far wall mean, left bifurcation near wall mean and left bifurcation far wall mean). These summary variables were then averaged to estimate a single mean-mean bifurcation CIMT for each participant visit.', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Mean-Max Far Wall CIMT', 'description': 'For the far wall measurements for each side and segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 6 summary variables (right common far wall max, right bifurcation far wall max, right internal far wall max, left common far wall max, left bifurcation far wall max, and left internal far wall max). These 6 summary variables were then averaged to estimate a single mean-max far wall CIMT for each participant visit.', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Mean-Mean Far Wall CIMT', 'description': 'For the far wall measurements for each side and segment, mean CIMT values were averaged over the 4 angles of interrogation to produce 6 summary variables (right common far wall mean, right bifurcation far wall mean, right internal far wall mean, left common far wall mean, left bifurcation far wall mean and left internal far wall mean). These 6 summary variables were then averaged to estimate a single mean-mean far wall CIMT for each participant visit.', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Mean-Max Near Wall CIMT', 'description': 'For the near wall measurements for each side and segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 6 summary variables (right common near wall max, right bifurcation near wall max, right internal near wall max, left common near wall max, left bifurcation near wall max, and left internal near wall max). These 6 summary variables were then averaged to estimate a single mean-max near wall CIMT for each participant visit.', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Mean-Mean Near Wall CIMT', 'description': 'For the near wall measurements for each side and segment, mean CIMT values were averaged over the 4 angles of interrogation to produce 6 summary variables (right common near wall mean, right bifurcation near wall mean, right internal near wall mean, left common near wall mean, left bifurcation wall mean and left internal far wall mean). These 6 summary variables were then averaged to estimate a single mean-mean far wall CIMT for each participant visit.', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Natural Log of mg/L for hsCRP', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Total Cholesterol', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in HDL Cholesterol', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in LDL Cholesterol', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Triglycerides', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Lipoprotein A', 'timeFrame': 'Change from baseline to 36 months'}, {'measure': 'Change in Homocysteine', 'timeFrame': 'Change from baseline to 36 months'}]",19,10 Years,21 Years,ALL,False,Laura Schanberg,OTHER,0,221.0,ACTUAL,2025-09-01T16:18:17.179304,v2_robust,True,True,True,False,False,
NCT00119704,Treatment of Tennis Elbow With Botulinum Toxin,Treatment of Lateral Epicondylitis With Botulinum Toxin: A Randomized Controlled Trial,Botulinum toxin A injection or normal saline,['Botulinum toxin A injection or normal saline'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,"Epicondylitis, Lateral Humeral","['Epicondylitis, Lateral Humeral']",[],COMPLETED,,2002-09,2005-03,[{'measure': '100 mm visual analog scale (VAS)'}],[{'measure': 'Grip strength measured with a Jamar Hydraulic Hand Dynamometer with the elbow fully extended and the hand in middle position.'}],2,18 Years,,ALL,False,Chinese University of Hong Kong,OTHER,1,60.0,,2025-09-01T16:18:17.179365,v2_robust,True,True,True,False,False,
NCT06530004,Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children,Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children,Rituximab,['Rituximab'],1,OBSERVATIONAL,[],,,Nephrotic Syndrome,"['Nephrotic Syndrome', 'Rituximab', 'Children', 'Efficacy']",[],RECRUITING,,2020-03-01,2028-03-01,"[{'measure': 'The median relapse-free survival', 'description': 'The median relapse-free survival of nephrotic syndrome before and after RTX treatment was compared.', 'timeFrame': '1 year'}, {'measure': 'Different sequential group curative effect evaluation', 'description': 'After comparing the preventive RTX and recurrence RTX maintain annual recurrent treatment。', 'timeFrame': '1 year'}]","[{'measure': 'Risk factors for renal disease recurrence after RTX treatment.', 'description': 'Multivariate cox analysis was used to analyze the risk factors of relapse after rituximab treatment in children with nephrotic syndrome by including gender, age of onset of nephrotic syndrome, course of disease before rituximab, history of immunosuppressive therapy, age of rituximab treatment, and maintenance immunosuppressive therapy after rituximab.', 'timeFrame': '1 year'}]",3,1 Year,18 Years,ALL,False,The First Affiliated Hospital of Xiamen University,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:17.179470,v2_robust,False,True,False,False,False,
NCT04505904,Oxytocin and Approach-avoid in Grief,A Pull to be Close: the Differentiating Effects of Oxytocin and Grief Stimulus Type on Approach Behavior in Complicated Grief,Syntocinon,"['Syntocinon', 'Placebo']",2,INTERVENTIONAL,['NA'],,,Prolonged Grief Disorder,"['Prolonged Grief Disorder', 'Bereavement']","['Oxytocin', 'Approach/Avoid', 'Older adults', 'Complicated Grief']",COMPLETED,,2015-03-20,2017-05-12,"[{'measure': 'Reaction Time (ms) of a Push or Pull of a Joystick in a Standard Interactive Approach/Avoid Task.', 'description': 'Participants completed the approach avoid task twice per session, with reversed instructions on the second run (i.e., ""pull for yellow"" became ""push for yellow""). Each seven-minute run of the task consisted of 144 2500ms trials (288 trials per visit, 576 trials total across runs/sessions; 500ms inter-trial-interval). Order of instructions (i.e., ""push yellow"" vs. ""pull yellow"") was randomized and counterbalanced across participants and sessions, to address potential for order effects/habituation. Stimuli were presented via Inquisit 4 (2014), in a pseudorandomized order determined by genetic algorithm (Wager \\& Nichols, 2003).\n\nRelative approach/avoidance bias was computed by subtracting median response time (RT; latency to joystick full extension) on PULL/approach trials in each stimulus category from PUSH/avoid trials in the same category (Rinck \\& Becker, 2007). Positive response bias values indicate relative approach bias; negative values indicate relative avoidance bias.', 'timeFrame': '120 minutes'}]",[],1,55 Years,80 Years,ALL,False,University of Arizona,OTHER,0,44.0,ACTUAL,2025-09-01T16:18:17.179487,v2_robust,True,True,True,False,False,
NCT07053904,Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors,"A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Sequential Treatment With P1101 and P1801 in Patients With Advanced Solid Tumors",Sequential use of P1101 and P1801,['Sequential use of P1101 and P1801'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],[],ENROLLING_BY_INVITATION,,2025-04-21,2029-12-31,"[{'measure': 'Incidence of Dose-Limiting Toxicities (DLTs)', 'description': 'Incidence of Dose-Limiting Toxicities (DLTs) of P1801', 'timeFrame': 'P1801 treatment cycle is comprised of 2 doses of P1801 administered on Day 1 (CnD1) and Day 15 (CnD15) at each cycle. Eligible patients will be monitored for the occurrence of DLTs during a 28-day period (Cycle 1) after the first administration of P1801.'}, {'measure': 'MTD of P1801', 'description': 'The MTD is defined as the highest dose level at which no more than 1 out of 6 patients experiences a DLT during the 28-day observation period.', 'timeFrame': 'highest dose level at which no more than 1 out of 6 patients experiences a DLT during the 28-day observation period.'}]",[],2,18 Years,,ALL,False,PharmaEssentia,INDUSTRY,1,54.0,ESTIMATED,2025-09-01T16:18:17.179506,v2_robust,True,True,False,False,False,
NCT03658304,Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma,A Single Arm Phase II Trial of the Intraoperative Intravesical Instillation of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract,Mitomycin c,['Mitomycin c'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Urothelial Carcinoma,['Urothelial Carcinoma'],[],COMPLETED,,2018-12-05,2023-10-17,"[{'measure': 'Bladder Tumor Recurrence Rate', 'description': 'The bladder tumor recurrence rate will be measured by the percentage of subjects who are confirmed by bladder biopsy to have a recurrence of urothelial carcinoma in the bladder following nephroureterectomy', 'timeFrame': '1 year'}]","[{'measure': 'Time to Bladder Tumor Recurrence', 'description': 'Determine the median time to bladder tumor recurrence. A subject is considered to have had a bladder tumor recurrence when they have been confirmed by bladder biopsy to have a recurrence of urothelial carcinoma in the bladder following nephroureterectomy.', 'timeFrame': '3 years'}, {'measure': 'Percentage of Subjects Who Had a Bladder Tumor Recurrence 3 Years Post-operatively', 'description': 'Determine the percentage of subjects who are confirmed by bladder biopsy to have a recurrence of urothelial carcinoma in the bladder following nephroureterectomy 3 years post-operatively.', 'timeFrame': '3 years'}]",3,18 Years,99 Years,ALL,False,University of Florida,OTHER,0,29.0,ACTUAL,2025-09-01T16:18:17.179528,v2_robust,True,True,True,False,False,
NCT00585104,Myocardial Hemodynamic Effects of Levosimendan,Myocardial Hemodynamic Effects of Levosimendan,levosimendan,"['Simdax', 'levosimendan']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Heart Failure,['Heart Failure'],[],COMPLETED,,2006-09,2008-12,"[{'measure': 'Change in Left Ventricular End-diastolic Pressure (LVEDP) Using Pressure-volume Catheter.', 'description': 'Left ventricular end-diastolic pressure (LVEDP) recorded from CD Leycom ConductNT software analysis.', 'timeFrame': 'From baseline to 30-minutes after levosimendan started.'}]",[],1,18 Years,,ALL,False,University of Utah,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:17.179568,v2_robust,True,True,True,False,False,
NCT02277704,Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions,"A Phase 2, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken at Bedtime in Subjects With Military-Related PTSD and Related Conditions (Protocol No. TNX-CY-P201) -""AtEase STUDY""",TNX-102 SL,"['TNX-102 SL', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,PTSD,['PTSD'],"['PTSD', 'Military-related PTSD and other related conditions']",COMPLETED,,2014-10,2016-05,"[{'measure': 'The Mean Change From Baseline (Visit 2) in the Total CAPS-5 Score After 12 Weeks of Treatment Evaluated at Visit 9 (Week 12).', 'description': 'The mean change from baseline (Visit 2) in the Total CAPS-5 score after 12 weeks of treatment evaluated at Visit 9 (Week 12). The primary efficacy comparison will be the change from baseline in total CAPS-5 score for the 2.8 mg treatment arm compared to placebo. CAPS-5 score ranges from 0-80 with lower scores indicating less severe PTSD symptoms.', 'timeFrame': 'Day 1, Week 12'}]","[{'measure': ""Change From Baseline in Patients' Quality of Sleep Using the PROMIS Sleep Disturbance Scale After 12 Weeks of Treatment"", 'description': ""Change from baseline in patients' quality of sleep using the PROMIS (Patient -Reported Outcome Measurement Information System) Sleep Disturbance scale after 12 weeks of treatment comparing the 2.8 mg treatment arm to placebo. Raw scores are converted to T-scores using published conversion tables. Sleep Disturbance T-score ranges from 28.9 to 76.5. Lower scores indicate less sleep disturbance"", 'timeFrame': 'Day 1, Week 12'}, {'measure': 'Clinician Global Impression - Improvement Scale Responder Rate at Week 12', 'description': 'Responder rates in CGI-I (Clinician Global Impression - Improvement Scale) after 12 weeks of treatment comparing the 2.8 mg treatment arm to placebo. Responder rate is defined as the number of patients scored as either a 1 or 2 on CGI-I at Week 12. The score ranges from 1 to 7 with the following anchors for each score:1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse', 'timeFrame': 'Week 12'}, {'measure': 'Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score', 'description': 'Mean Change from Baseline in SDS Total Score at Week 12. Score ranges from 0 to 30. A score of 0 means the patient is unimpaired, and a score of 30 means the patient is highly impaired.', 'timeFrame': 'Day 1, Week 12'}]",4,18 Years,65 Years,ALL,False,"Tonix Pharmaceuticals, Inc.",INDUSTRY,0,245.0,ACTUAL,2025-09-01T16:18:17.179577,v2_robust,True,True,True,False,False,
NCT01194804,E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients,Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 Protocol,Eculizumab,"['Soliris', 'Eculizumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Paroxysmal Nocturnal Hemoglobinuria,['Paroxysmal Nocturnal Hemoglobinuria'],"['Hemolytic Paroxysmal Nocturnal Hemoglobinuria', 'Eculizumab', 'PNH']",COMPLETED,,2008-04,2011-03,"[{'measure': 'Change From Baseline in Lactate Dehydrogenase', 'timeFrame': '52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)'}]","[{'measure': 'Change From Baseline in FACIT-Fatigue Scale Total Score', 'description': 'The FACIT-Fatigue scale, Version 4.0, is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.', 'timeFrame': '52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)'}, {'measure': 'Change From Baseline in PNH Red Blood Cell (RBC) Count', 'timeFrame': '52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)'}, {'measure': 'Change From Baseline in Number of Units of Packed RBCs Transfused', 'description': 'Baseline is defined as the number of units transfused in 3 months prior to baseline', 'timeFrame': '52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)'}, {'measure': 'Change From Baseline in Plasma Free Hemoglobin', 'timeFrame': '52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)'}]",5,12 Years,,ALL,False,"Alexion Pharmaceuticals, Inc.",INDUSTRY,1,27.0,ACTUAL,2025-09-01T16:18:17.179661,v2_robust,True,True,True,False,False,
NCT05635604,Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.,Molecular Stratification of Signaling Pathways Underlying Migraine Pathophysiology.,Eptinezumab,"['Eptinezumab', 'PACAP-38']",2,INTERVENTIONAL,['NA'],,,Migraine,['Migraine'],"['Headache', 'Vascular effect']",COMPLETED,,2023-03-01,2023-08-04,"[{'measure': 'A subjective report of a migraine attack', 'description': 'The participants report whether they feel a migraine attack (Yes or no).', 'timeFrame': 'Time of reporting migraine attack is from the baseline to 24 hours after eptinezumab/placebo administration.'}]","[{'measure': 'Headache', 'description': 'Headache intensity will be recorded by numerical rating scale (NRS) from 0 to 10 (0, no headache; 1, a feeling of pressure; 10, worst imaginable headache).', 'timeFrame': 'Time of headache measurements is from from the baseline to 24 hours eptinezumab/placebo administration.'}, {'measure': 'Changes in the superficial temporal artery (STA).', 'description': 'Diameter of the frontal branch of the superficial temporal artery (STA).\n\nRepeated measurements covering the diameter of STA before and after eptinezumab/placebo administration and PACAP-38 infusion measured by millimeters (mm).', 'timeFrame': 'Time of headache measurements is from from the baseline to 24 hours eptinezumab/placebo administration.'}]",3,18 Years,60 Years,ALL,False,Danish Headache Center,OTHER,0,38.0,ACTUAL,2025-09-01T16:18:17.179681,v2_robust,True,True,True,False,False,
NCT00408304,Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.,Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.,omega-3 fatty acid,['omega-3 fatty acid'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Hepatitis C,['Chronic Hepatitis C'],"['interferon alpha', 'depression', 'omega 3']",UNKNOWN,,2006-12,2007-12,"[{'measure': 'The effect of omega three fatty acids would be estimated through two questionnaires which filled by the patients monthly'}, {'measure': 'with the BDI questionnaire which estimates the level of depression of the patient and'}, {'measure': ""the SF36 questionnaire which provides information about the overall influence of a disease upon a patient's daily life and mental status.""}]","[{'measure': 'Secondary outcome measures include monthly results of biochemical and hematologic blood tests, including levels of:'}, {'measure': 'albumin'}, {'measure': 'bilirubin'}, {'measure': 'ALT'}, {'measure': 'CRP'}, {'measure': 'hemoglobin'}, {'measure': 'WBC'}, {'measure': 'platelets'}]",11,,,ALL,False,Bnai Zion Medical Center,OTHER_GOV,0,60.0,,2025-09-01T16:18:17.179812,v2_robust,True,True,False,False,False,
NCT01785004,Vitamin D and Omega-3 Adiposity Trial (VITAL Adiposity),"Interrelationship of Vitamin D Supplementation, Adiposity and CVD Risk Factors in a Randomized Clinical Trial",omega-3 fatty acids (fish oil),"['Omacor, 1 capsule a day.', 'Each capsure of Omacor contains 840 milligrams of marine omega-3 fatty acid', '(465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).', 'omega-3 fatty acids (fish oil)']",4,INTERVENTIONAL,['NA'],,,Adiposity,['Adiposity'],"['Adiposity', 'Body composition', 'Vitamin D', 'Adipokines', 'Omega-3 fatty acid']",UNKNOWN,,2012-07,2022-07,"[{'measure': 'Body Composition', 'description': 'We will measure by DXA, changes in body composition (i) total body fat and lean mass, (ii) regional and standardized body fat and lean mass (trunkal, androidal (abdominal), appendicular (limb) and derived ratios (trunk/limb; android/gynoid)) among those randomized to vitamin D supplementation vs. those randomized to placebo.', 'timeFrame': '2 years'}]","[{'measure': 'Anthropometric Measurements', 'description': 'We will perform and compare changes in anthropometric measurements, including BMI, waist circumference and waist-hip ratio.', 'timeFrame': '2 years'}, {'measure': 'Mediation of CVD risk factors by body composition', 'description': 'We will compare 2 year changes in CVD risk factors: (lipids \\[triglycerides, HDL, LDL\\]), glucose homeostasis (hemoglobin A1c, glucose, insulin, HOMA-IR) and blood pressure between treatment groups, and assess whether changes in body composition mediate any treatment effects.', 'timeFrame': '2 years'}, {'measure': 'Adipokines', 'description': 'Among 200 participants, we will assess effect of vitamin D supplementation on adipokines to assess for 2-year changes among those randomized to supplementation vs. placebo.', 'timeFrame': '2 years'}, {'measure': 'Achieved 25(OH)D level', 'description': 'We will assess whether achieved 25(OH)D levels with supplementation are affected by baseline and change in body composition and BMI.', 'timeFrame': '2 years'}]",5,50 Years,,ALL,True,Brigham and Women's Hospital,OTHER,1,600.0,ESTIMATED,2025-09-01T16:18:17.179830,v2_robust,True,True,False,False,False,
NCT04658004,NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia,Clinical Trial for the Safety and Efficacy of NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia,NKG2D CAR T-cells,"['NKG2D CAR T-cells', 'NKG2D CAR-T cells injection']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],"['Acute Myeloid Leukemia', 'CAR T-cell therapy', 'NKG2D']",NOT_YET_RECRUITING,,2021-01-15,2027-01-15,"[{'measure': 'Dose-limiting toxicity (DLT)', 'description': 'Adverse events assessed according to NCI-CTCAE v5.0 criteria', 'timeFrame': 'Baseline up to 28 days after NKG2D targeted CAR T-cells infusion'}, {'measure': 'Incidence of treatment-emergent adverse events (TEAEs)', 'description': 'Incidence of treatment-emergent adverse events \\[Safety and Tolerability\\]', 'timeFrame': 'Up to 2 years after NKG2D targeted CAR T-cells infusion'}]","[{'measure': 'Acute Myeloid Leukemia (AML), Overall response rate (ORR)', 'description': 'Assessment of ORR (ORR = CR + CRi) at Month 1, 3, 6, 12, 18 and 24', 'timeFrame': 'At Month 1, 3, 6, 12, 18 and 24'}, {'measure': 'AML, Overall survival (OS)', 'description': '. AML, Overall survival (OS) From the first infusion of NKG2D CAR-T cells to death or the last visit', 'timeFrame': 'Up to 2 years after NKG2D CAR-T cells infusion'}, {'measure': 'AML, Event-free survival (EFS)', 'description': 'From the first infusion of NKG2D CAR-T cells to the occurrence of any event, including death, relapse or gene relapse disease progression (any one occurs first), and the last visit', 'timeFrame': 'Up to 2 years after NKG2D CAR-T cells infusion'}, {'measure': 'Quality of life', 'description': 'Assessment using European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scale \\[For item1-28: max score: 112, min score: 28, higher scores mean a better outcome; for item 28-29: max score: 14, min score: 2, higher scores mean a worse outcome\\] to measure Quality of life at Baseline, Month 1, 3, 6, 9 and 12', 'timeFrame': ':At Baseline, Month 1, 3, 6, 9 and 12'}, {'measure': 'Activities of Daily Living (ADL) score', 'description': 'Assessment using Activities of Daily Living (ADL) scale (Barthel Index) \\[max score: 100, min score: 0, higher scores mean a better outcome\\] at Baseline, Month 1, 3, 6, 9 and 12', 'timeFrame': 'At Baseline, Month 1, 3, 6, 9 and 12'}, {'measure': 'Instrumental Activities of Daily Living (IADL) score', 'description': 'Assessment of Instrumental Activities of Daily Living (IADL) scale \\[max score: 56, min score: 14, higher scores mean a worse outcome\\] at Baseline, Month 1, 3, 6, 9 and 12', 'timeFrame': 'At Baseline, Month 1, 3, 6, 9 and 12'}, {'measure': 'Hospital Anxiety and Depression Scale (HADS) score', 'description': 'Assessment using Hospital Anxiety and Depression Scale (HADS) \\[max score: 42, min score: 0, higher scores mean a worse outcome\\] at Baseline, Month 1, 3, 6, 9 and 12', 'timeFrame': 'At Baseline, Month 1, 3, 6, 9 and 12'}]",9,3 Years,70 Years,ALL,False,Zhejiang University,OTHER,1,36.0,ESTIMATED,2025-09-01T16:18:17.179849,v2_robust,True,True,False,False,True,
NCT06750484,Trial of Trastuzumab Deruxtecan in Previously Treated HER2,Open-label Single-arm Phase 2 Trial of Trastuzumab Deruxtecan in Previously Treated HER2-Immunohistochemistry (IHC) 0 Advanced Breast Cancer,Trastuzumab Deruxtecan,['Trastuzumab Deruxtecan'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer Metastatic,['Breast Cancer Metastatic'],[],RECRUITING,,2025-06-20,2028-12-31,"[{'measure': 'Objective Response Rate', 'description': 'The confirmed Objective Response Rate to Trastuzumab Deruxtecan by RECIST (Response Evaluation Criteria In Solid Tumors) defined as the sum of complete response (CR) rate and partial response (PR) rate based on BICR and Investigator assessment.', 'timeFrame': 'After cycle 3, approximately 63 days'}]","[{'measure': 'High-sensitivity quantitative HER2 protein assay (HS-HER2) assay', 'description': 'HS-HER2 assay to evaluate the distribution of quantitative HER2 signal across IHC 0 tumors (attomole/mm2)', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Correlation between HER2 protein expression', 'description': 'The secondary endpoint is measured by the HS-HER2 assay in the CLIA lab setting with objective response and clinical benefit from Trastuzumab Deruxtecan.', 'timeFrame': 'Last follow up visit (40 days [+7] from last dose)'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'Progression Free Survival based on investigator assessment, in all subjects', 'timeFrame': 'From the date of enrolment to the earliest date of the first objective documentation of radiographic disease progression according to mRECIST version 1.1 or death due to any cause. up to 3 years'}, {'measure': 'Overall Survival (OS)', 'description': 'Overall Survival in all subjects', 'timeFrame': '(every 3 months +/-14 days) for up to 3 years'}]",5,18 Years,,ALL,False,Yale University,OTHER,2,50.0,ESTIMATED,2025-09-01T16:18:17.179892,v2_robust,True,True,False,False,False,
NCT03132584,Cyclophosphamide and Alemtuzumab In Lymphoma,"Ph1 Cyclophosphamide & Alemtuzumab in CD52+ R/R Double-Hit, Diffuse Lg B-cell or High Gr B-cell Lymphomas, NOS With MYC & BCL2 Over-expression, MYC-Positive Transformed Follicular Lymphoma, & CD52+ Mature T-cell Lymphoproliferative Disorder",Cyclophosphamide,"['Endoxan', 'Revimmune', 'Alemtuzumab', 'Campath', 'Cycloblastin', 'Cyclophosphamide', 'Lyophilized Cytoxan', 'Neosar', 'Cytoxan', 'Procytox']",10,INTERVENTIONAL,['PHASE1'],PHASE1,,Non Hodgkin Lymphoma,"['Non Hodgkin Lymphoma', 'High-grade B-cell Lymphoma', 'Diffuse Large B Cell Lymphoma']",['Non Hodgkin Lymphoma'],TERMINATED,slow accrual,2017-07-30,2018-01-30,"[{'measure': 'MTD of Cyclophosphamide and Alemtuzumab', 'description': 'maximum tolerated dose of the combination of cyclophosphamide and alemtuzumab', 'timeFrame': '28 days'}]","[{'measure': 'Overall Response Rate', 'description': 'Non-Hodgkin Lymphoma Response Criteria, which will be reported descriptively', 'timeFrame': '12 Months'}, {'measure': 'Complete Response Rate', 'description': 'Non-Hodgkin Lymphoma Response Criteria, which will be reported descriptively', 'timeFrame': '12 Months'}, {'measure': 'Progression Free Survival', 'description': 'Progression-free will be estimated using the method of Kaplan and Meier.', 'timeFrame': 'up to 5 years'}, {'measure': 'Overall Survival', 'description': 'Overall survival will be estimated using the method of Kaplan and Meier.', 'timeFrame': 'up to 5 years'}, {'measure': 'Response Rate', 'description': 'Assess response by PET/CT and in the bone marrow after one cycle of therapy', 'timeFrame': '28 Days'}]",6,18 Years,75 Years,ALL,False,Dana-Farber Cancer Institute,OTHER,2,3.0,ACTUAL,2025-09-01T16:18:17.179913,v2_robust,True,True,False,True,False,slow accrual
NCT05272384,Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma,A Phase 1 Study of Nivolumab in Combination With ASTX727 in B-cell Lymphoma (NHL or HL) With an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL),Decitabine and Cedazuridine,"['Cedazuridine/Decitabine Combination Agent ASTX727', 'DEC-C', 'Inqovi', 'Cedazuridine/Decitabine Tablet', 'C-DEC', 'CDA Inhibitor E7727/Decitabine Combination Agent ASTX727', 'Decitabine and Cedazuridine', 'ASTX 727', 'ASTX727', 'ASTX-727', 'Inaqovi']",11,INTERVENTIONAL,['PHASE1'],PHASE1,,Recurrent B-Cell Non-Hodgkin Lymphoma,"['Recurrent B-Cell Non-Hodgkin Lymphoma', 'Recurrent Diffuse Large B-Cell Lymphoma', 'Recurrent Hodgkin Lymphoma', 'Refractory B-Cell Non-Hodgkin Lymphoma', 'Refractory Diffuse Large B-Cell Lymphoma', 'Refractory Hodgkin Lymphoma']",[],RECRUITING,,2022-11-03,2027-06-28,"[{'measure': 'Incidence of adverse events', 'description': 'Frequency of subjects experiencing toxicities will be tabulated. Toxicities will be assessed and graded according to Common Terminology Criteria for Adverse Events version 5.0 terminology. Exact 95% confidence intervals around the toxicity proportions will be calculated.', 'timeFrame': 'Up to 2 years'}]","[{'measure': 'Complete response rate', 'description': 'Will be reported along with the 95% confidence intervals.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Partial response rate', 'description': 'Will be reported along with the 95% confidence intervals.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall response rate', 'description': 'Will be reported along with the 95% confidence intervals.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Duration of response', 'description': ""Will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates."", 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival', 'description': ""Will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates."", 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression survival', 'description': ""Will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates."", 'timeFrame': 'Up to 2 years'}]",7,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,32.0,ESTIMATED,2025-09-01T16:18:17.180027,v2_robust,True,True,False,False,True,
NCT01692184,Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292,"A Phase 1, Two-part Study to Investigate the Safety and Pharmacokinetics of AVL-292 Following Multiple Oral Doses and to Evaluate the Effect of Food on the Pharmacokinetics of AVL-292 Following a Single Oral Dose in Healthy Adult Subjects",50 mg AVL-292,"['AVL-292', '200 mg AVL-292', '50 mg AVL-292', '350 mg AVL-292', 'Placebo capsules', '100 mg AVL-292']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['AVL-292', 'Safety', 'Pharmacokinetics', 'Pharmacodynamics', 'Pharmacology, Clinical']",COMPLETED,,2012-08-01,2012-10-08,"[{'measure': 'Adverse Events', 'description': 'Number of participants with adverse events', 'timeFrame': 'Up to 28 days after last AVL-292 dose'}, {'measure': 'PK-(Cmax)', 'description': 'Maximum observed concentration in plasma', 'timeFrame': '24 hours after the last AVL-292 dose on days 1 and 7'}, {'measure': 'PK-(AUC)', 'description': 'Area under the plasma concentration-time curve', 'timeFrame': '24 hours after the last AVL-292 dose days 1 and 7'}]","[{'measure': 'Pharmacodynamic response measured in percentage of target occupancy by AVL-292 in peripheral blood mononuclear cells', 'description': 'Pharmacodynamic response measured in percentage of target occupancy by AVL-292 in peripheral blood mononuclear cells', 'timeFrame': '24 hours after the last AVL-292 dose days 1 and 7'}]",4,18 Years,65 Years,ALL,True,Celgene,INDUSTRY,0,54.0,ESTIMATED,2025-09-01T16:18:17.180038,v2_robust,True,True,True,False,True,
NCT03318484,Sonodynamic Therapy on Patients With Femoropopliteal PAD and Claudication,Sonodynamic Therapy Manipulate Atherosclerosis Regression Trial Among Patients With Femoropopliteal PAD and Claudication,Optimal Medical Care,['Optimal Medical Care'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Peripheral Arterial Disease,"['Peripheral Arterial Disease', 'Atherosclerosis', 'Cardiovascular Diseases']",[],WITHDRAWN,Re-registered,2017-11,2019-11,"[{'measure': 'PWT change, mins', 'description': 'Change from baseline peak walking time (PWT) at 6 months is assessed by graded treadmill test (Gardner protocol). The patient continues the test until walking can no longer be tolerated because of claudication symptoms.', 'timeFrame': 'Measured at baseline, 1, 3 and 6 months.'}, {'measure': 'MDS TBR change, (%)', 'description': 'Change from baseline most disease segments (MDS) at 3 months is assessed by 18FDG-PET imaging. Uptake of FDG by the common and superficial femoral artery is expressed as the target, vessel wall to background, lumen ratio (TBR). The mean max MDS TBR is defined as the arterial segment centered on the slice of artery demonstrating the highest FDG uptake at baseline within the index vessel, and calculated as a mean of maximum TBR values derived from three contiguous axial segments.', 'timeFrame': 'Measured at baseline, 1 and 3 months.'}]","[{'measure': 'COT change, mins', 'description': 'Change from baseline claudication onset time (COT) at 6 months is assessed by graded treadmill test (Gardner protocol). The patient continues the test until calf muscle discomfort is first noticed.', 'timeFrame': 'Measured at baseline, 1, 3, and 6 months.'}, {'measure': 'AS TBR change, (%)', 'description': 'Change from baseline active slice (AS) at 3 months is assessed by 18FDG-PET imaging. Uptake of FDG by the common and superficial femoral artery is expressed as the target, vessel wall to background, lumen ratio (TBR). The mean max AS TBR is defined as average mean maximal TBR of only slices with TBR \\>1.6 from index vessel at baseline.', 'timeFrame': 'Measured at baseline, 1 and 3 months.'}, {'measure': 'WV TBR change, (%)', 'description': 'Change from baseline whole vessel (WV) TBR at 3 months is assessed by 18FDG-PET imaging. Uptake of FDG by the common and superficial femoral artery is expressed as the target, vessel wall to background, lumen ratio (TBR). The mean max WV TBR is defined as a single whole vessel average mean maximal TBR of all the slices that compose the index vessel.', 'timeFrame': 'Measured at baseline, 1 and 3 months.'}, {'measure': 'Serum inflammation cytokine level', 'description': 'Including Interleukin-6, Interleukin-1β, and high-sensitivity C-reactive protein (hs-CRP) level in serum', 'timeFrame': 'Measured at baseline, 1, 3, and 6 months.'}, {'measure': 'Pre-exercise ABI', 'description': 'Ankle-Brachial Index (ABI) is the ratio of the blood pressure at the ankle to the blood pressure of the upper arm. Pre-exercise ABI is collected routinely with the patient supine immediately prior to a treadmill test.', 'timeFrame': 'Measured at baseline, 1, 3, and 6 months.'}, {'measure': 'Post-exercise ABI', 'description': 'Ankle-Brachial Index (ABI) is the ratio of the blood pressure at the ankle to the blood pressure of the upper arm. Post-exercise ABI is collected routinely with the patient supine immediately following a treadmill test.', 'timeFrame': 'Measured at baseline, 1, 3, and 6 months.'}, {'measure': 'Intimal-medial thickness, (mm)', 'description': 'Estimation of the intimal-medial thickness for common femoral artery by doppler ultrasound.', 'timeFrame': 'Measured at baseline, 1, 3, and 6 months.'}, {'measure': 'Peak flow velocity, (cm/s)', 'description': 'Estimation of the systolic and diastolic peak flow velocity of the affected segments by doppler ultrasound.', 'timeFrame': 'Measured at baseline, 1, 3, and 6 months.'}, {'measure': ""Vessels' diameter, (mm)"", 'description': ""Estimation of the vessels' diameter for common femoral artery by doppler ultrasound."", 'timeFrame': 'Measured at baseline, 1, 3, and 6 months.'}, {'measure': 'Diameter stenosis, (%)', 'description': 'Estimation of the maximum diameter stenosis of the affected segments by doppler ultrasound.', 'timeFrame': 'Measured at baseline, 1, 3, and 6 months.'}, {'measure': 'WIQ score', 'description': 'The Walking Impairment Questionnaire (WIQ) assesses the severity of the subjective walking impairment on distance, speed, and stair climbing scales. It is administered as a self report. Range: Minimum score is 0.2, maximum 100.', 'timeFrame': 'Measured at baseline, 1, 3, and 6 months.'}, {'measure': 'SF-36 score', 'description': 'The patient reported SF-36 data assesses subjective physical limitations, leg symptoms, social function, treatment satisfaction, and quality of life. It is administered as a self report. Higher scores are indicative of better outcome. The summary scores is compiled by taking the mean of five subscales generated from the original questions. Range: Minimum score is 11.1, maximum 85.', 'timeFrame': 'Measured at baseline, 1, 3, and 6 months'}]",14,40 Years,,ALL,False,First Affiliated Hospital of Harbin Medical University,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:17.180163,v2_robust,True,True,False,True,False,Re-registered
NCT04420884,A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors,"An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors",Dazostinag,"['Pembrolizumab', 'Platinum', 'Dazostinag', '5-fluorouracil', 'TAK-676']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Solid Neoplasms,['Solid Neoplasms'],['Drug Therapy'],ACTIVE_NOT_RECRUITING,,2020-07-22,2026-03-31,"[{'measure': 'Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity', 'description': 'A severity grade is defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Grade 1 scales as Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 scales as Moderate (minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living \\[ADL\\]); Grade 3 scales as Severe (severe or medically significant but not immediately life threatening hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 scales as Life-threatening consequences, urgent intervention indicated, and Grade 5 scales as Death related to Adverse Event (AE).', 'timeFrame': 'Up to approximately 68 months'}, {'measure': 'Number of Participants with Dose-Limiting Toxicities (DLTs)', 'description': 'A DLT will be defined as any of the TEAEs, but not limited to, those that occur during Cycle 1 and are considered by the investigator to be at least possibly related to dazostinag as a SA or in combination with pembrolizumab. TEAEs meeting DLT definitions occurring in Cycle 2 or later will be considered in the determination of the RDE of dazostinag, both in the dazostinag SA and the combination with pembrolizumab arms. Toxicity will be evaluated according to NCI CTCAE version 5.0.', 'timeFrame': 'Up to approximately 68 months'}, {'measure': 'Number of Participants Reporting One or More Treatment Emergent Serious Adverse Event (SAEs)', 'timeFrame': 'Up to approximately 68 months'}, {'measure': 'Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations', 'timeFrame': 'Up to approximately 68 months'}]","[{'measure': 'Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Overall Response Rate (ORR)', 'description': 'ORR is defined as the percentage of participants who achieve confirmed complete response (cCR) + confirmed partial response (cPR) during the study in response-evaluable population. ORR will be assessed based on Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1.', 'timeFrame': 'Up to approximately 68 months'}, {'measure': 'Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Disease Control Rate (DCR)', 'description': 'DCR is defined as the percentage of participants who achieve cCR + cPR + stable disease (SD) greater than (\\>) 6 weeks during the study in response-evaluable population. The DCR will be assessed based on RECIST version 1.1.', 'timeFrame': 'Up to approximately 68 months'}, {'measure': 'Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Duration of Response (DOR)', 'description': 'DOR is the time from the date of first documentation of a cPR or better to the date of first documentation of progressive disease for responders (cPR or better). Responders without documentation of progressive disease will be censored at the date of last response assessment that is SD or better. DOR will be assessed based on RECIST version 1.1.', 'timeFrame': 'Up to approximately 68 months'}, {'measure': 'Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Time to Response (TTR)', 'description': 'TTR is defined as the time from the date of first dose administration to the date of first documented cPR or better by the investigator. TTR will be assessed based on RECIST version 1.1.', 'timeFrame': 'Up to approximately 68 months'}, {'measure': 'Expansion Phase Only: Progression-Free Survival (PFS)', 'description': 'PFS is defined as the time from the date of first dose administration to the date of first documented disease progression or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to approximately 29 months'}, {'measure': 'Expansion Phase Only: Overall Survival (OS)', 'description': 'OS is defined as the time from the date of first dose administration to the date of death.', 'timeFrame': 'Up to approximately 29 months'}, {'measure': 'Expansion Phase Only: OS Rate at 12 Months', 'description': '12-month OS rate is defined as the percentage of participants who are still alive at 12 months from their first dose administration.', 'timeFrame': 'Up to 29 months'}, {'measure': 'Expansion Phase Only: OS Rate at 6 Months', 'description': '6-month OS rate is defined as the percentage of participants who are still alive at 6 months from their first dose administration.', 'timeFrame': 'Up to 29 months'}]",12,18 Years,,ALL,False,Takeda,INDUSTRY,0,248.0,ACTUAL,2025-09-01T16:18:17.180215,v2_robust,True,True,False,False,True,
NCT06520384,Radiofrequency Applications and Alcoholic Neurolysis of Genicular Nerve for the Treatment of Knee Osteoarthritic Pain,Comparison of Radiofrequency Applications and Alcoholic Neurolysis of Genicular Nerve for the Treatment of Knee Osteoarthritic Pain: A Randomized Trial,Alcohol 30%,"['Alcohol 50%', 'Alcohol 70%', 'Alcohol 30%']",3,INTERVENTIONAL,['NA'],,,Radiofrequency,"['Radiofrequency', 'Alcohol', 'Genicular Nerve', 'Knee Osteoarthritis', 'Pain']",[],COMPLETED,,2024-07-25,2025-01-05,"[{'measure': 'Degree of knee pain', 'description': 'The degree of knee pain will be assessed using the visual analog scale (VAS). Each patient will obtain a score between 0 and 10 (Zero means no pain, and 10 means the worst pain). VAS will be assessed preoperative and postoperative 1, and 6 months', 'timeFrame': '6 months postoperative'}]","[{'measure': 'Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores', 'description': 'Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): range from 0 to 96 (0 represents the best health status and 96 the worst possible status). The higher the score, the poorer the function. It will be assessed preoperative and postoperative 1, and 6 months.', 'timeFrame': '6 months postoperative'}, {'measure': 'Patient satisfaction', 'description': 'Degree of patient satisfaction will be assessed on a 5-point Likert scale Patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied ; 5, extremely satisfied).', 'timeFrame': '6 months postoperative'}, {'measure': 'Incidence of adverse events', 'description': 'Incidence of adverse events such as bleeding, neurological damage, infection, abnormal proprioception, numbness, paresthesia, and motor weakness will be recorded.', 'timeFrame': '6 months postoperative'}]",4,18 Years,,ALL,False,Tanta University,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:17.180239,v2_robust,True,True,True,False,True,
NCT00505284,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy",Placebo,"['E2007 (8 mg)', 'Perampanel', 'E2007 (2 mg)', 'E2007 (4 mg)', 'Placebo', 'E2007 (6 mg)']",6,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Diabetic Neuropathy,['Diabetic Neuropathy'],['Diabetic neuropathy'],COMPLETED,,2007-06,2008-07,"[{'measure': 'Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT)', 'description': 'Average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified baseline observation carried forward (BOCF).', 'timeFrame': 'Baseline to Week 15/EOT'}, {'measure': 'Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 30% Reduction in Pain Score', 'description': 'Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified BOCF.', 'timeFrame': 'Baseline to Week 15/EOT'}, {'measure': 'Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 50% Reduction in Pain Score', 'description': 'Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified BOCF.', 'timeFrame': 'Baseline to Week 15/EOT'}, {'measure': 'Mean Change in Average Pain Scores From Baseline at Each Study Week', 'description': 'Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). Last on-treatment value refers to last 7 days of available diary data while subject was on double-blind study drug.', 'timeFrame': 'Baseline, Week 1 to Week 17'}]","[{'measure': 'Change in Average Sleep Interference Scores From Baseline to Week 15/EOT', 'description': 'Average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for sleep interference (0=pain did not interfere with sleep, to 10=pain completely interfered with sleep \\[unable to sleep\\]). Based on modified BOCF.', 'timeFrame': 'Baseline to Week 15/EOT'}, {'measure': 'Change in Short Form - McGill Pain Questionnaire (SF-MPQ) From Baseline to Week 15/EOT', 'description': 'SF-MPQ sensory score = sum of intensity scores for descriptors 1-11 (throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, splitting). Each descriptor scored as 0=none, 1=mild, 2=moderate, or 3=severe. Range of possible sensory scores, 0 to 33, with a score of 33 being the most severe intensity.', 'timeFrame': 'Baseline and Week 15/EOT'}, {'measure': 'Analysis of Patient Global Impression of Change (PGIC) at Week 15/EOT', 'description': 'At the EOT (Visit 7) or Early Withdrawal Visit (as appropriate), the subject assessed his/her status compared to how they felt before entering the study. This assessment included an evaluation of pain frequency and intensity, the occurrence of AEs, and overall functional status using a 7-point scale where 1=very much improved and 7=very much worse. Using Modified BOCF.', 'timeFrame': 'Week 15/EOT'}, {'measure': 'Change From Baseline to Week 15/EOT in SF-36 Physical and Mental Component Scores', 'description': 'Short Form 36 Health Survey Questionnaire (SF-36) measuring limitations in Physical Components including physical activities, usual role activities (due to physical problems), measuring bodily pain, general health perceptions, and Mental Components including social activities, usual role activities (due to emotional problems), vitality (energy and fatigue. Each of the 8 domains are described by a score ranging from 0 to 100, for a range of total possible scores of 0-400 for physical and 0-400 for mental. Higher scores reflect better subject status.', 'timeFrame': 'Baseline and Week 15/EOT'}, {'measure': 'Change From Baseline to Week 15/EOT in Hospital Anxiety and Depression Scale (HADS) Anxiety and Depression Subscale Scores', 'description': 'HADS anxiety subscale score=sum of scores for 7 anxiety items, each scored on a 4-pt scale (0, 1, 2, or 3), where a higher score indicates worse anxiety. Range of possible HADS anxiety subscale scores, 0 to 21. HADS depression subscale score=sum of scores for 7 depression items, each scored on a 4-pt scale (0, 1, 2, or 3), where a higher score indicates worse depression. Range of possible HADS depression subscale scores, 0 to 21.', 'timeFrame': 'Baseline and Week 15/EOT'}, {'measure': 'Withdrawal Due to Treatment Failure During Double-Blind Dosing Period', 'description': ""Based on data reported on the End of Study case report form (CRF): If a subject terminated the study early during the Double-blind Dosing Period due to 'lack of therapeutic efficacy,' the subject was counted as a withdrawal due to treatment failure."", 'timeFrame': 'Baseline and Week 15'}, {'measure': 'Presence or Absence of Allodynia at Week 15/EOT', 'description': ""Investigators rated subjects' allodynia as mild, moderate, severe, or not present. The presence of allodynia (yes/no) at Week 15/EOT was analyzed."", 'timeFrame': 'Week 15/EOT'}, {'measure': 'Analysis of Rescue Analgesic Medication Use (Acetaminophen) During Double-Blind Dosing Period', 'description': 'If acetaminophen was not reported on the Pain Therapy CRF or on the Concomitant Medication CRF, it was assumed that the subject did not use rescue analgesic medication.', 'timeFrame': 'Baseline to Week 15'}]",12,18 Years,,ALL,False,Eisai Inc.,INDUSTRY,1,352.0,ACTUAL,2025-09-01T16:18:17.180309,v2_robust,True,True,True,False,False,
NCT00510484,Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis,"A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 24,000 Unit Capsules in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis",Pancrelipase Delayed Release,"['Pancrelipase Delayed Release', 'Placebo Comparator']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Cystic Fibrosis,['Cystic Fibrosis'],"['Pancreatic exocrine insufficiency', 'Cystic Fibrosis']",COMPLETED,,2007-11,2008-03,"[{'measure': 'Coefficient of Fat Absorption (%)', 'description': 'This coefficient is calculated from fat intake and fat excretion : 100\\*\\[fat intake-fat excretion\\]/fat intake. Stools were collected on 3 days during the 5 days treatment period. Higher values indicate a better response.', 'timeFrame': '5 days'}]","[{'measure': 'Coefficient of Nitrogen Absorption (%)', 'description': 'This coefficient is calculated from nitrogen intake and nitrogen excretion : 100\\*\\[nitrogen intake-nitrogen excretion\\]/nitrogen intake. Stools were collected on 3 days during the 5 days treatment period. Higher values indicate a better response.', 'timeFrame': '5 days'}, {'measure': 'Total Fat Excretion (Grams)', 'description': 'Total amount of fat excreted during the stool collection period. Stools were collected on 3 days during the 5 days treatment period. Lower values indicate a better response.', 'timeFrame': '5 days'}, {'measure': 'Total Stool Weight (Grams)', 'description': 'Total weight of the stools collected during the stool collection period. Stools were collected on 3 days during the 5 days treatment period. Lower values indicate a better response.', 'timeFrame': '5 days'}, {'measure': 'Stool Frequency', 'description': 'Stool frequency is the average of the daily number of stools recorded during the treatment period. Lower values indicate a better response.', 'timeFrame': '5 days'}, {'measure': 'Percentage of Days With no Flatulence.', 'description': 'The percentage of days with no flatulence is calculated from the diary during the treatment period: 100\\*(number of days with no flatulence/number of days recorded in diary). Higher values indicate a better response.', 'timeFrame': '5 days'}, {'measure': 'Percentage of Days With no Abdominal Pain.', 'description': 'The percentage of days with no abdominal pain is calculated from the diary during the treatment period: 100\\*(number of days with no abdominal pain / number of days recorded in diary). Higher values indicate a better response.', 'timeFrame': '5 days'}]",7,12 Years,,ALL,False,Solvay Pharmaceuticals,INDUSTRY,0,35.0,ACTUAL,2025-09-01T16:18:17.180361,v2_robust,True,True,True,False,False,
NCT05260684,Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US,Comparative Effectiveness of Different Targeted Therapies for BRAF-mutated Unresectable/Metastatic Melanoma in the United States,Encorafenib,"['Binimetinib', 'Vemurafenib', 'Trametinib', 'Encorafenib', 'Cobimetinib', 'Dabrafenib', 'Administration route: Oral']",7,OBSERVATIONAL,[],,,Melanoma,['Melanoma'],"['BRAF-mutant', 'Metastatic melanoma']",COMPLETED,,2022-01-17,2023-12-31,"[{'measure': 'Overall Survival (OS)', 'description': 'As per COLUMBUS trial, OS was defined as the time from the date of randomization to the date of death due to any cause; if death was not observed, participants were censored at the date of last contact or the data analysis cut-off date, whichever occurred first. As per Flatiron EHR, OS was defined as the time from the index date to the date of death; participants without a date of death were censored at their last known activity date or the end of the follow-up period, whichever occurred first. Index date in each treatment group was defined as the date of treatment initiation. Kaplan-Meier analyses was used for analysis.', 'timeFrame': 'COLUMBUS: From date of randomization until death or censoring (approx 80.5 months); Flatiron: From index date until death due or censoring or end of follow-up period (92.7 months)'}]",[],1,18 Years,,ALL,False,Pfizer,INDUSTRY,0,716.0,ACTUAL,2025-09-01T16:18:17.180556,v2_robust,False,True,True,False,False,
NCT03978884,Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes,"An Open Label, Single Arm Prospective Study to Evaluate Efficacy and Safety of Losartan Based Therapy Reslio® (Losartan) and Resilo-h® (Losartan+Hydrochlorthiazide) in Diabetic and Uncontrolled Hypertensive Patients",Losartan 50Mg Tab,"['Losartan 50Mg Tab', 'Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET', 'Amlodipine 5mg', 'Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetes Mellitus,"['Diabetes Mellitus', 'Hypertension']",[],WITHDRAWN,Unable to effective arrange trial logistics,2019-06-01,2020-12-31,"[{'measure': 'Proportion of Subjects achieving Target Blood Pressure', 'timeFrame': '12 weeks'}]",[],1,18 Years,80 Years,ALL,False,The University of The West Indies,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:17.180571,v2_robust,True,True,False,True,False,Unable to effective arrange trial logistics
NCT02076633,Intratumoral Administration of L19IL2/L19TNF,A Phase II Study of Intratumoral Application of L19IL2/L19TNF in Melanoma Patients in Clinical Stage III or Stage IV M1a With Presence of Injectable Cutaneous and/or Subcutaneous Lesions,L19IL2+L19TNF,['L19IL2+L19TNF'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Malignant Melanoma, Skin","['Malignant Melanoma, Skin']","['L19', 'monoclonal', 'antibody', 'IL-2', 'TNFα', 'Interleukin', 'Phase II', 'metastatic melanoma', 'clinical stage III', 'Clinical stage IV M1a']",COMPLETED,,2012-12,2015-05,"[{'measure': 'Rate of patients with complete response (CR) of L19IL2 treated Index/Non-Index lesions at week 12.', 'timeFrame': 'Week 12'}]","[{'measure': 'Efficacy of L19IL2/L19TNF treated Index/non treated lesions', 'description': '* Rate of patients with CR, PR and SD of all metastases at week 12, 24 and 36 (objective response rate according to RECIST v 1.1)\n* Duration of objective response and disease control of all metastases\n* Median overall survival (mOS)', 'timeFrame': 'week 12, 24 and 36'}, {'measure': 'Overall survival (OS)', 'timeFrame': '1 year'}, {'measure': 'Safety of the combination treatment with L19IL2 and L19TNF', 'description': 'Evaluation of the type and the number of adverse events eventually present', 'timeFrame': '1 year'}]",4,18 Years,,ALL,False,Philogen S.p.A.,INDUSTRY,0,21.0,ACTUAL,2025-09-01T16:18:17.180631,v2_robust,True,True,True,False,True,
NCT06215833,Recovery of TIVA vs Inhalation in Pediatric Anesthesia,Comparison of Emergence and Recovery Profile After Total Intravenous Anesthesia ( TIVA ) Vs Inhalational Anesthesia in Opioid Free Pediatric Tonsillectomy,Propofol,"['Propofol', 'Cetal suppository', 'Sevoflurane']",3,OBSERVATIONAL,[],,,Best Technique for Pediatric Anesthesia,['Best Technique for Pediatric Anesthesia'],[],NOT_YET_RECRUITING,,2024-01-30,2025-12-30,"[{'measure': 'level of consciousness score', 'description': '* Awake =2\n* Arousal with minimal stimulation =1\n* Responsive only to tactile stimulation =0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}, {'measure': 'physical activity score', 'description': '* Able to move on command =2\n* Some weakness in movement = 1\n* Unable to voluntarily move = 0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}, {'measure': 'hemodynamic stability score', 'description': '* Blood pressure \\< 15% of baseline MAP value =2\n* Blood pressure 15%-30% of baseline MAP value =1\n* Blood pressure \\< 30% below baseline MAP value =0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}, {'measure': 'respiratory stability score', 'description': '* Able to breathe deeply = 2\n* Tachypnea with good coughs =1\n* Dyspneic with weak cough = 0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}, {'measure': 'Oxygen saturation score', 'description': '* Maintain value \\> 90% on room air = 2\n* Requires supplemental O2 to maintain value \\> 90% = 1\n* So2 \\< 90% with supplemental O2 = 0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}, {'measure': 'post operative pain score', 'description': '* None or mild = 2\n* Moderate to severe pain controlled =1\n* Persistent severe pain = 0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}, {'measure': 'post operative emetic score', 'description': '* None or mild nausea with no active vomiting = 2\n* Transient vomiting =1\n* Persistent moderate to severe nausea and vomiting=0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}]",[],7,4 Years,10 Years,ALL,False,Assiut University,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:17.180695,v2_robust,False,True,False,False,False,
NCT01212133,A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India,A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India,liraglutide,['liraglutide'],1,OBSERVATIONAL,[],,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],COMPLETED,,2010-11,2012-04,"[{'measure': 'The number of serious adverse drug reactions (SADRs) during the study period', 'timeFrame': 'during 26 weeks of treatment'}]","[{'measure': 'The number of adverse drug reactions (ADR) during the study period', 'timeFrame': 'during 26 weeks of treatment'}, {'measure': 'The number of serious adverse events (SAE) during the study period', 'timeFrame': 'during 26 weeks of treatment'}, {'measure': 'Frequency of hypoglycaemic episodes', 'timeFrame': 'during 26 weeks of treatment'}]",4,,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,1386.0,ACTUAL,2025-09-01T16:18:17.180725,v2_robust,False,True,True,False,True,
NCT00117533,Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta,A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta,pegylated IFN alfa-2b plus ribavirin,['pegylated IFN alfa-2b plus ribavirin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Hepatitis B,"['Chronic Hepatitis B', 'Chronic Hepatitis D']","['chronic hepatitis B;', 'chronic hepatitis delta;', 'treatment;', 'pegylated interferon alfa-2b;', 'ribavirin']",UNKNOWN,,2005-09,2007-06,[{'measure': 'the efficacy of 24-week pegylated IFN alfa-2b plus RBV for SVR of HDV in patients with dual chronic hepatitis D and B'}],"[{'measure': 'the efficacy of pegylated IFN alfa-2b plus RBV in patients with dual chronic hepatitis D and B on: The biochemical response rate'}, {'measure': 'The degree of histologic change'}]",3,18 Years,,ALL,False,National Taiwan University Hospital,OTHER,2,20.0,,2025-09-01T16:18:17.180742,v2_robust,True,True,False,False,False,
NCT03167333,The Role of Synovitis in Osteoarthritis,Does Synovitis Affect Treatment Efficacy in Intra-articular Injection Therapy to Osteoarthritis,platelet rich plasma,"['Hyaluronic acid', 'platelet rich plasma']",2,INTERVENTIONAL,['NA'],,,Synovitis of Knee,"['Synovitis of Knee', 'Osteoarthritis, Knee']",[],UNKNOWN,,2020-03-01,2020-03-01,"[{'measure': 'visual analog scale(VAS)', 'timeFrame': 'before injection at baseline'}, {'measure': 'visual analog scale(VAS)', 'timeFrame': '4 weeks(first evaluation)'}, {'measure': 'visual analog scale(VAS)', 'timeFrame': '12 weeks(secondary evaluation)'}, {'measure': 'The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index)', 'timeFrame': 'before injection at baseline'}, {'measure': 'The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index)', 'timeFrame': '4 weeks(first evaluation)'}, {'measure': 'The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index)', 'timeFrame': '12 weeks(secondary evaluation)'}]","[{'measure': 'Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed simultaneously.', 'timeFrame': 'before injection at baseline'}, {'measure': 'Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed', 'timeFrame': '4 weeks(first evaluation)'}, {'measure': 'Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed', 'timeFrame': '12 weeks(secondary evaluation)'}]",9,45 Years,75 Years,ALL,False,"Taipei Veterans General Hospital, Taiwan",OTHER_GOV,0,100.0,ESTIMATED,2025-09-01T16:18:17.180752,v2_robust,True,True,False,False,False,
NCT06499233,Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease,Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia (PJP) in Patients With Autoimmune Inflammatory Rheumatic Disease (AIIRD),Trimethoprim/Sulfamethoxazole,"['TMP/SMX', 'Trimethoprim/Sulfamethoxazole']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pneumonia, Pneumocystis","['Pneumonia, Pneumocystis', 'Autoimmune Inflammatory Rheumatic Disease', 'Autoimmune Diseases', 'Connective Tissue Disease', 'Prevention']",[],RECRUITING,,2024-07-20,2026-12-31,"[{'measure': 'Number of participants with PJP infection', 'description': 'Defined as documentation/diagnosis of Pneumocystis from a properly obtained specimen (induced sputum, bronchoalveolar lavage, or biopsy) in a patient with clinical manifestations compatible with PJP.', 'timeFrame': '6 months, 12 months'}]","[{'measure': 'TMP/SMZ related adverse drug reactions', 'description': 'Symptoms and signs that may be related to adverse drug reactions during treatment (such as nausea, vomiting, anorexia, jaundice, rashes and hives, and shock); incidence, duration and severity of adverse events', 'timeFrame': '6 months, 12 months'}, {'measure': 'PJP-related mortality', 'description': 'PJP-related mortality at the end of month 6.', 'timeFrame': '6 months, 12 months'}, {'measure': 'All cause mortality', 'description': 'All cause mortality', 'timeFrame': '6 months, 12 months'}]",4,18 Years,,ALL,False,Tongji Hospital,OTHER,0,800.0,ESTIMATED,2025-09-01T16:18:17.180838,v2_robust,True,True,False,False,True,
NCT01742533,Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure,A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Hormone Replacement Therapy in Patients With Premature Ovarian Failure,Hormone Replacement Therapy,['Hormone Replacement Therapy'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Premature Ovarian Failure，,['Premature Ovarian Failure，'],"['Hormone Replacement Therapy，', 'Premature Ovarian Failure，', 'Stem Cell Therapy']",UNKNOWN,,2012-03,2014-03,"[{'measure': 'Serum Level of follicle-stimulating hormone', 'timeFrame': '48 weeks after treatment'}]","[{'measure': 'Uterine and Ovary characteristics of B ultrasound， including Uterine/Ovarian size and Blood Flow', 'timeFrame': '48 weeks after treatment'}, {'measure': 'Modified Kupperman Score', 'timeFrame': '48 weeks after treatment'}, {'measure': 'Incidence of Adverse Events and Serious Adverse Events', 'timeFrame': '48 weeks after treatment'}]",4,18 Years,39 Years,FEMALE,False,"Shenzhen Beike Bio-Technology Co., Ltd.",INDUSTRY,0,40.0,ESTIMATED,2025-09-01T16:18:17.180882,v2_robust,True,True,False,False,True,
NCT05200052,Effect of Colchicine On Left Ventricle Function After Anterior Myocardial Infarction Assessed By Speckle Tracking,Effect of Colchicine Use On Left Ventricle Systolic Function Using Speckle Tracking Echocardiography in Patients With Anterior S-T Segment Elevation Myocardial Infarction,Colchicine 0.5 mg Oral Tablet,"['Colchicine 0.5 mg Oral Tablet', 'Standard anti ischemic treatment']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Anterior MI,"['Anterior MI', 'Colchicine']",[],COMPLETED,,2022-02-01,2022-08-01,"[{'measure': 'Average of global longitudinal strain pattern', 'description': 'Assessment of left ventricular longitudinal strain by speckle tracking echocardiography after beforr and after colchicine', 'timeFrame': '6 months'}]","[{'measure': 'Number of mortality during study', 'description': 'Death from any cause', 'timeFrame': '6 months'}]",2,,,ALL,True,Ain Shams University,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:17.180924,v2_robust,True,True,True,False,False,
NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)",SOC,['SOC'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Clostridium Difficile Infection,['Clostridium Difficile Infection'],"['Clostridium difficile', 'recurrent Clostridium difficile', 'vancomycin', 'metronidazole', 'monoclonal antibody', 'Clostridium difficile infection (CDI)']",COMPLETED,,2011-10-10,2014-12-09,"[{'measure': 'Percentage of Participants With Clostridium Difficile Infection (CDI) Recurrence', 'description': 'CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic Clostridium (C.) difficile following clinical cure of the initial CDI episode', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Percentage of Participants With One or More Adverse Events (AEs) During 4 Weeks Following Infusion', 'description': ""An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE."", 'timeFrame': 'Up to 28 days'}, {'measure': 'Percentage of Participants With Any Drug-related AE During 4 Weeks Following Infusion', 'description': ""An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE was an AE determined by the investigator to be related to the drug."", 'timeFrame': 'Up to 28 days'}, {'measure': 'Percentage of Participants With Any Serious Adverse Events (SAEs) During 4 Weeks Following Infusion', 'description': ""A SAE is any AE occurring at any dose or during any use of Sponsor's product that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer, or is associated with an overdose (whether accidental or intentional); or is other important medical events."", 'timeFrame': 'Up to 28 days'}, {'measure': 'Percentage of Participants With Any Serious Drug-related Adverse Events During 4 Weeks Following Infusion', 'description': ""A SAE is any AE occurring at any dose or during any use of Sponsor's product that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer, or is associated with an overdose (whether accidental or intentional); or is other important medical events. A serious drug-related AE was a SAE determined by the investigator to be related to the drug."", 'timeFrame': 'Up to 28 days'}, {'measure': 'Percentage of Participants Who Discontinued Study Medication Due to an AE During 4 Weeks Following Infusion', 'description': ""An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol-specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE."", 'timeFrame': 'Up to 28 days'}, {'measure': 'Percentage of Participants With Infusion-specific AEs', 'description': 'Infusion-specific AEs included local infusion site AEs; and systemic AEs which include nausea, vomiting, chills, fatigue, feeling hot, infusion site conditions (bruising, coldness, erythema, extravasation, pain, phlebitis, pruritus), pyrexia, arthralgia, musculoskeletal pain, myalgia, dizziness, headache, dysphonia, nasal congestion, pruritus, rash, pruritic rash, urticaria, flushing, hot flush, hypertension, and hypotension.', 'timeFrame': 'Up to 24 hours'}]","[{'measure': 'Percentage of Participants With Global Cure', 'description': 'Global Cure is defined as the clinical cure of the initial CDI episode and no CDI recurrence through Week 12. Clinical cure is defined as participants who received ≤ 14 day regimen of SOC therapy and have no diarrhea (≤2 loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the initial CDI episode.', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Percentage of Participants With CDI Recurrence in Those With Clinical Cure of the Initial CDI Episode', 'description': 'CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Clinical cure is defined as participants who received ≤ 14 day regimen of SOC therapy and have no diarrhea (≤2 loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the baseline CDI episode.', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Percentage of Participants ≥ 65 Years of Age at Study Entry With CDI Recurrence', 'description': 'CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Percentage of Participants With a History of CDI in the 6 Months Prior to Enrollment With CDI Recurrence', 'description': 'CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Percentage of Participants With Clinically Severe CDI at Study Entry With CDI Recurrence', 'description': 'CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Clinically severe CDI is defined as a Zar Score ≥ 2 based on the presence of 1 or more of the following: 1) age \\>60 years old (1 point); 2)body temperature \\>38.3°C (\\>100°F) (1 point); 3) albumin level ˂2.5 mg/dL (1 point); 4) peripheral white blood cell count \\>15,000 cells/mm\\^3 within 48 hours (1 point); 5) endoscopic evidence of pseudomembranous colitis (2 points); and 6) treatment in Intensive Care Unit (2 points).', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Percentage of Participants With the B1/NAP1/027 Strain of C. Difficile at Study Entry With CDI Recurrence', 'description': 'CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Percentage of Participants With an Epidemic Strain of C. Difficile (Ribotypes 027, 014, 002, 001, 106, and 020) at Study Entry With CDI Recurrence', 'description': 'CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Percentage of Participants With Compromised Immunity at Study Entry With CDI Recurrence', 'description': 'CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Compromised immunity is defined as follows: an active hematological malignancy (including leukemia, lymphoma, multiple myeloma), an active malignancy requiring recent cytotoxic chemotherapy, receipt of a prior hematopoietic stem cell transplant, receipt of a prior solid organ transplant, asplenia, or neutropenia/pancytopenia due to other conditions.', 'timeFrame': 'Up to 12 weeks'}]",15,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,1452.0,ACTUAL,2025-09-01T16:18:17.180973,v2_robust,True,True,True,False,True,
NCT05340452,"Bioequivalence Study of Klaribact 125mg/5ml, Suspension","An Open Label, Randomized, Two Way Cross Over, Two Period, Two Treatment, Two Sequence Bioequivalence Study of Klaribact (Clarithromycin) 125mg/5ml Suspension Compared With Klaricid (Clarithromycin) 125mg/5ml Suspension in 24 Healthy Adult Subjects Under Fasting Condition.",Klaribact 125mg/5ml Suspension,"['Klaribact 125mg/5ml Suspension', 'Klaricid 125mg/5ml Suspension']",2,INTERVENTIONAL,['NA'],,,Healthy,['Healthy'],"['Bioequivalence Study', 'macrolide antibiotic', 'Bioavailability comparison']",COMPLETED,,2013-06-29,2013-10-25,"[{'measure': 'maximum plasma concentration', 'description': 'maximum drug concentration in plasma after dose', 'timeFrame': 'up to 24 hours post dose'}, {'measure': 'Time to reach maximum plasma concentration', 'description': 'Time required for the drug to reach maximum plasma concentration', 'timeFrame': '0 to 24 hours post dose'}, {'measure': 'AUC', 'description': 'Area under the time versus plasma drug concentration curve', 'timeFrame': '0 to 24hours post dose'}]",[],3,18 Years,50 Years,ALL,True,University of Karachi,OTHER,2,24.0,ACTUAL,2025-09-01T16:18:17.180992,v2_robust,True,True,True,False,False,
NCT02301052,Evaluation of Allium Ampeloprasum Spp.Iranicum Cream Effect for the Management of Hemorrhoids Symptoms,Double Blind Randomized Placebo-control Trial of Allium Ampeloprasum Spp.Iranicum Cream Effect for the Management of Hemorrhoids Symptoms,Leek topical cream,"['Allium Ampeloprasum Spp.Iranicum topical cream', 'Anti-hemorrhoid topical cream', 'placebo topical cream', 'Leek topical cream']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Hemorrhoids,['Hemorrhoids'],"['hemorrhoids', 'Allium Ampeloprasum', 'herbal medicine', 'traditional persian medicine']",UNKNOWN,,2014-09,2014-12,"[{'measure': 'pain (visual analogue scale(0-10))', 'description': 'method of measurement: visual analogue scale(0-10)', 'timeFrame': '3 weeks'}, {'measure': 'bleeding ( questionnaire)', 'description': 'method of measurement questionnaire:grade (0-4) that was defined as follow: 0=no symptom, 1= mild, 2=moderate, 3= severe, 4=very severe.', 'timeFrame': '3 weeks'}, {'measure': 'itching ( questionnaire)', 'description': 'method of measurement questionnaire: grade (0-4) that was defined as follow: 0=no symptom, 1= mild, 2=moderate, 3= severe, 4=very severe.', 'timeFrame': '3 weeks'}, {'measure': 'defecate discomfort (visual analogue scale(0-10)', 'description': 'method of measurement: visual analogue scale(0-10)', 'timeFrame': '3 weeks'}, {'measure': 'total improvement (visual analogue scale(0-10)', 'description': 'method of measurement:visual analogue scale(0-10)', 'timeFrame': '3 weeks'}]","[{'measure': 'constipation (questionnaire)', 'description': 'method of measurement: questionnaire', 'timeFrame': '3 weeks'}]",6,18 Years,65 Years,ALL,True,Shiraz University of Medical Sciences,OTHER,0,75.0,ESTIMATED,2025-09-01T16:18:17.181016,v2_robust,True,True,False,False,False,
NCT00989352,Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma,Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy,Methotrexate,"['Lomustine', 'Procarbazine', 'Methotrexate', 'Rituximab']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Primary Non Hodgkin Lymphoma of the Central Nervous System,['Primary Non Hodgkin Lymphoma of the Central Nervous System'],"['PCNSL', 'Lymphoma', 'Methotrexate', 'Lomustine', 'Procarbazine', 'Rituximab', 'Elderly', 'Chemotherapy']",UNKNOWN,,2009-09,2011-09,"[{'measure': 'Complete remission rate', 'timeFrame': '30 days after end of immuno-chemotherapy'}]","[{'measure': 'Duration of response', 'timeFrame': 'within 5 years'}, {'measure': 'Overall survival time', 'timeFrame': 'within 5 years'}, {'measure': 'Neuropsychological state (according to Mini-Mental State and IPCG testing)', 'timeFrame': 'within 5 years'}, {'measure': '(Serious) adverse events ([S]AEs)', 'timeFrame': 'within 30 days after treatment'}]",5,65 Years,,ALL,False,University Hospital Freiburg,OTHER,4,56.0,ESTIMATED,2025-09-01T16:18:17.181032,v2_robust,True,True,False,False,True,
NCT06016452,A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma,A Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma,Chlorophyllin,"['Stratum A (Symptomatic)', 'Stratum A (Asymptomatic)', 'Chlorophyllin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Diffuse Glioma,"['Diffuse Glioma', 'Radionecrosis of Brain', 'High Grade Glioma', 'Glioblastoma Multiforme']",[],RECRUITING,,2023-11-13,2025-11,"[{'measure': 'Response rates', 'description': 'Clinical-radiological', 'timeFrame': '1 month post treatment with chlorophyllin'}]","[{'measure': 'Survival Analysis', 'description': 'Progression-Free Survival and Overall Survival using Kaplan-Meier survival plot.', 'timeFrame': '3 months'}, {'measure': 'Health Questionnaire', 'description': 'EORTC QOL C -30 and (Brain module) BN-20 questionnaire. The global score and scores of subdomains will be calculated and compared with baseline.', 'timeFrame': '3 months'}, {'measure': 'Response rates', 'description': 'Radiological response rates at 3 months using Response Assessment in Neuro-Oncology (RANO) criteria.', 'timeFrame': '3 months'}]",4,18 Years,70 Years,ALL,False,Tata Memorial Centre,OTHER,1,118.0,ESTIMATED,2025-09-01T16:18:17.181150,v2_robust,True,True,False,False,False,
NCT04017052,Application of a TBE-Vaccine in Obese Persons,Application of a TBE-Vaccine in Obese Persons,FSME-IMMUN Vaccine,['FSME-IMMUN Vaccine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Tick Borne Encephalitis,['Tick Borne Encephalitis'],[],UNKNOWN,,2015-04-15,2020-12-30,"[{'measure': 'Humoral immunity (TBE NT)', 'description': 'Humoral immunity tested with TBE Neutralisation test- Neutralizing antibody titer against TBE', 'timeFrame': '1 month +/- 7 days after booster (v3)'}]","[{'measure': 'TBE-NT titer course', 'description': 'TBE-NT titer course evaluation', 'timeFrame': 'before booster at day 0 at all visits until 3 years after booster vaccination at V5 (36 months+/-1 month)'}, {'measure': 'Cellular immune response with flow cytometry', 'description': 'Cellular immune response:\n\nCharacterisation of lymphocyte sub-population with flow cytometry: detection of CD surface markers of lymphocytes with antibody panels - CD19, CD3, IgD, IgM, IgG, IgA, CD10, CD27, CD127, CCR4, CD8, CD4, CD28, CD31, CD38, CCR7, CD45RA, CD25, CD24, CD38 und FOXP3', 'timeFrame': 'evaluated before (V1 day 0) and 1 week after booster vaccination (V2 day 7+3d)'}, {'measure': 'Measurement of Cytokines with Luminex platform/ELISA', 'description': 'Measurement of cytokines IL-2, IFNgamma, IL-10, TNF-alpha und IL-6 in supernatants of PBMC cultures re-stimulated with TBE antigen; duration of stimulation: 48h.\n\nMeasurement with Luminex Platform/ELISA', 'timeFrame': 'evaluated before (V1 day 0) and 1 week after booster vaccination (V2 day 7+3d)'}]",4,18 Years,60 Years,ALL,True,Medical University of Vienna,OTHER,0,73.0,ACTUAL,2025-09-01T16:18:17.181169,v2_robust,True,True,False,False,False,
NCT03959852,Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain,A Combination Study With Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain in the Emergency Department,Fentanyl,"['Ketamine Hydrochloride', 'Ketamine', 'Fentanyl Citrate', 'Fentanyl']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pain, Acute","['Pain, Acute']","['Moderate', 'Severe', 'Pain']",TERMINATED,Residency completed.,2019-11-18,2020-06-05,"[{'measure': 'Analgesia of combination fentanyl and SDK as assessed using the pain scale 1-10', 'description': 'Analgesia of combination fentanyl and SDK as assessed using the pain scale 1-10', 'timeFrame': 'ED encounter (less than 24 hours)'}, {'measure': 'Analgesia of fentanyl as assessed using the pain scale 1-10', 'description': 'Analgesia of fentanyl as assessed using the pain scale 1-10', 'timeFrame': 'ED encounter (less than 24 hours)'}, {'measure': 'Analgesia of ketamine as assessed using the pain scale 1-10', 'description': 'Analgesia of katamine as assessed using the pain scale 1-10', 'timeFrame': 'ED encounter (less than 24 hours)'}]","[{'measure': 'OARRS report', 'description': 'A retrospective review of OARRS report will be performed with each patient.', 'timeFrame': 'ED encounter (less than 24 hours)'}, {'measure': 'Opioid sparing response as assessed by number of times additional rescue doses of fentanyl were required', 'description': 'Opioid sparing response as assessed by number of times additional rescue doses of fentanyl were required', 'timeFrame': 'ED encounter (less than 24 hours)'}]",5,18 Years,65 Years,ALL,True,Mercy Health Ohio,OTHER,0,6.0,ACTUAL,2025-09-01T16:18:17.181266,v2_robust,True,True,False,True,False,Residency completed.
NCT05076552,"A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer","A Phase 1a/1b Open-label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Patients With Advanced or Metastatic Solid Tumors",TACH101,['TACH101'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Cancer,"['Advanced Cancer', 'Metastatic Solid Tumor', 'Solid Tumor']","['Cancer', 'Solid Tumors', 'Advanced Cancer', 'TACH101', 'Metastatic Solid Tumor']",ACTIVE_NOT_RECRUITING,,2023-02-17,2025-07,"[{'measure': 'Phase 1a Dose Escalation: MTD of TACH101', 'timeFrame': 'Day 1 to End of Treatment (up to approximately 201 days)'}, {'measure': 'Phase 1a Dose Escalation: RP2D of TACH101', 'timeFrame': 'Day 1 to End of Treatment (up to approximately 201 days)'}, {'measure': 'Phase 1b Dose Expansion: ORR', 'timeFrame': 'Day 1 to End of Treatment (up to approximately 201 days)'}]","[{'measure': 'Phase 1a Dose Escalation: Number of Participants Who Experience Dose-limiting Toxicities (DLTs)', 'timeFrame': 'Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length = 28 days)'}, {'measure': 'Phase 1a Dose Escalation: Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'description': 'A TEAE is defined as any untoward medical occurrence in participants that happened after study drug administration. Any clinically significant abnormalities in vital signs, clinical laboratory tests, or electrocardiograms (ECGs) will be recorded as adverse events (AEs).', 'timeFrame': 'Lead-in Day 1 to End of Treatment (up to approximately 204 days)'}, {'measure': 'Phase 1a Dose Escalation: Area Under the Plasma Concentration-Time Curve (AUC) for TACH101', 'timeFrame': 'Lead-in Day 1 to Cycle 8 Day 1 (cycle = 28 days)'}, {'measure': 'Phase 1a Dose Escalation: Maximum Concentration (Cmax) of TACH101', 'timeFrame': 'Lead-in Day 1 to Cycle 8 Day 1 (cycle = 28 days)'}, {'measure': 'Phase 1a Dose Escalation: Observed Predose Plasma Concentration During Multiple Dosing (Ctrough) of TACH101', 'timeFrame': 'Lead-in Day 1 to Cycle 8 Day 1 (cycle = 28 days)'}, {'measure': 'Phase 1a Dose Escalation: Time to Reach Maximum Concentration (tmax) for TACH101', 'timeFrame': 'Lead-in Day 1 to Cycle 8 Day 1 (cycle = 28 days)'}, {'measure': 'Phase 1a Dose Escalation: Apparent Terminal Elimination Half-life (t1/2) of TACH101', 'timeFrame': 'Lead-in Day 1 to Cycle 8 Day 1 (cycle = 28 days)'}, {'measure': 'Phase 1a Dose Escalation: Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) of TACH101', 'timeFrame': 'Lead-in Day 1 to Cycle 8 Day 1 (cycle = 28 days)'}, {'measure': 'Phase 1a Dose Escalation: Apparent Clearance After Extravascular Administration (CL/F) of TACH101', 'timeFrame': 'Lead-in Day 1 to Cycle 8 Day 1 (cycle = 28 days)'}, {'measure': 'Phase 1a Dose Escalation: ORR', 'timeFrame': 'Day 1 to End of Treatment (up to approximately 201 days)'}, {'measure': 'Phase 1a Dose Escalation: Duration of Response (DOR)', 'timeFrame': 'Day 1 to End of Treatment (up to approximately 201 days)'}, {'measure': 'Phase 1a Dose Escalation: Clinical Benefit Rate (CBR)', 'timeFrame': 'Day 1 to End of Treatment (up to approximately 201 days)'}, {'measure': 'Phase 1b Dose Expansion: Number of Participants With TEAEs', 'description': 'A TEAE is defined as any untoward medical occurrence in participants that happened after study drug administration. Any clinically significant abnormalities in vital signs, clinical laboratory tests, or ECGs will be recorded as AEs.', 'timeFrame': 'Lead-in Day 1 to End of Treatment (up to approximately 203 days)'}, {'measure': 'Phase 1b Dose Expansion: Concentration at 2 Hours Postdose (C2h) of TACH101', 'timeFrame': 'Cycle 1 Day 1 to Cycle 10 Day 1 (cycle = 28 days)'}, {'measure': 'Phase 1b Dose Expansion: Cmax of TACH101', 'timeFrame': 'Cycle 1 Day 1 to Cycle 10 Day 1 (cycle = 28 days)'}, {'measure': 'Phase 1b Dose Expansion: Ctrough of TACH101', 'timeFrame': 'Cycle 1 Day 1 to Cycle 10 Day 1 (cycle = 28 days)'}, {'measure': 'Phase 1b Dose Expansion: DOR', 'timeFrame': 'Day 1 to End of Treatment (up to approximately 201 days)'}, {'measure': 'Phase 1b Dose Expansion: CBR', 'timeFrame': 'Day 1 to End of Treatment (up to approximately 201 days)'}]",21,18 Years,,ALL,False,"Tachyon Therapeutics, Inc.",INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:17.181317,v2_robust,True,True,False,False,True,
NCT02657252,Polidocanol Versus Glucose Treatment of Telangiectasia Trial,"Polidocanol Versus Glucose For Sclerotherapy Treatment Of Telangiectasia Of The Lower Limbs: Protocol For A Randomized, Controlled Clinical Trial",Glucose,"['Varithena', 'Glucose', 'Hypertonic dextrose', 'Asclera', 'Polidocanol with Glucose']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Varicose Veins,"['Varicose Veins', 'Telangiectasis']","['telangiectasis', 'varicose veins', 'veins', 'glucose', 'sclerotherapy']",COMPLETED,,2015-01,2016-11,"[{'measure': 'Change From Baseline in Extent of Telangiectasias', 'description': 'Efficiency in promoting the disappearance of the treated telangiectasias, making the comparison between the initial measurements in centimeters and after two months, then comparing the treatment between the two treatments', 'timeFrame': '2 months'}]","[{'measure': 'Skin Hyperpigmentation', 'description': 'Observed after two months of treatment the occurrence of hyperpigmentation stains in the treated areas. Measuring in centimeters those stains and compare the two treatments together.', 'timeFrame': '2 months'}, {'measure': 'Number of Participants With Deep Venous Thrombosis (DVT)', 'description': 'Observe after one week of treatment occurred if clinical signs and symptoms of deep vein thrombosis (DVT) and perform duplex ultrasound for confirmation. Compare the results between the two groups to establish a security policy.', 'timeFrame': '1 week'}]",3,18 Years,65 Years,FEMALE,False,UPECLIN HC FM Botucatu Unesp,OTHER,1,115.0,ACTUAL,2025-09-01T16:18:17.181432,v2_robust,True,True,True,False,False,
NCT00547352,Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection,Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference,tadalafil,"['tadalafil', 'LY450190', 'sildenafil', 'IC351', 'Cialis']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Impotence,['Impotence'],[],COMPLETED,,2004-06,2005-06,"[{'measure': 'Patient choice of drug at visit 5', 'timeFrame': '14-15 weeks'}]","[{'measure': 'PAIRS self-administered scale scores', 'timeFrame': '14-15 weeks'}]",2,18 Years,,MALE,False,Eli Lilly and Company,INDUSTRY,1,160.0,ACTUAL,2025-09-01T16:18:17.181479,v2_robust,True,True,True,False,False,
NCT05371652,A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants,"A Multicenter, Open Label, Long-term Safety Study of BHV3000 for the Acute Treatment of Migraine in Chinese Subjects",Rimegepant 75mg Orally Disintegrating Tablets (ODT),['Rimegepant 75mg Orally Disintegrating Tablets (ODT)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Acute Migraine,['Acute Migraine'],['Migraine'],COMPLETED,,2022-05-19,2024-02-06,"[{'measure': 'Treatment Safety Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'description': 'An adverse event was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily have a causal relationship with the investigational product. TEAEs were events that started after the first dose of trial drug and did not occur or worsen relative to the first dose.', 'timeFrame': 'From Day 1 of study treatment up to Week 52 of the treatment safety period'}, {'measure': 'Follow-up Safety Period: Number of Participants With TEAEs', 'description': 'An adverse event was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily have a causal relationship with the investigational product. TEAEs were events that started after the first dose of trial drug and did not occur or worsen relative to the first dose.', 'timeFrame': 'From Week 52 to Week 54 of the follow-up safety period'}, {'measure': 'Treatment Safety Period: Number of Participants With Serious Adverse Events (SAEs)', 'description': 'An adverse event was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily have a causal relationship with the investigational product. SAE referred to any untoward medical occurrence that met any of the following criteria at any dose for a participant that received the investigational product: death, life-threatening, permanent or severe disability or incapacity, hospitalization or prolongation of hospitalization required or congenital anomaly or birth defect.', 'timeFrame': 'From Day 1 of study treatment up to Week 52 of the treatment safety period'}, {'measure': 'Follow-up Safety Period: Number of Participants With SAEs', 'description': 'An adverse event was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily have a causal relationship with the investigational product. SAE referred to any untoward medical occurrence that met any of the following criteria at any dose for a participant that received the investigational product: death, life-threatening, permanent or severe disability or incapacity, hospitalization or prolongation of hospitalization required or congenital anomaly or birth defect.', 'timeFrame': 'From Week 52 to Week 54 of the follow-up safety period'}, {'measure': 'Treatment Safety Period: Number of Participants With AEs Leading to Study Drug Discontinuation', 'description': 'An AE was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily had a causal relationship with the investigational product. AEs that led to study drug discontinuation were reported in this outcome measure.', 'timeFrame': 'From Day 1 of study treatment up to Week 52 of the treatment safety period'}, {'measure': 'Follow-up Safety Period: Number of Participants With AEs Leading to Study Drug Discontinuation', 'description': 'An AE was any untoward medical occurrence in a clinical trial participant administered an investigational product that may present with symptoms/signs, disease, or laboratory abnormalities and which did not necessarily had a causal relationship with the investigational product. AEs that led to study drug discontinuation were reported in this outcome measure.', 'timeFrame': 'From Week 52 to Week 54 of the follow-up safety period'}, {'measure': 'Treatment Safety Period: Number of Participants With Electrocardiogram (ECG) Abnormalities', 'description': ""ECG abnormalities criteria included: QT Interval Corrected Using Fridericia's Formula (QTcF) millisecond (msec): less than or equal to (\\<=)450, 450 - \\<=480, 480- \\<=500, greater than (\\>)500."", 'timeFrame': 'From Day 1 of study treatment up to Week 52 of the treatment safety period'}, {'measure': 'Follow-up Safety Period: Number of Participants With ECG Abnormalities', 'description': 'ECG abnormalities criteria included: QTcF msec: \\<=450, 450 - \\<=480, 480- \\<=500, \\>500.', 'timeFrame': 'From Week 52 to Week 54 of the follow-up safety period'}, {'measure': 'Treatment Safety Period: Number of Participants With Vital Signs Abnormalities', 'description': 'Vital signs abnormalities included blood pressure (BP) millimeters of mercury (mmHg): systolic BP \\<90 and \\>140; diastolic BP \\<50 and \\>90 and pulse rate (beats per minute) :\\<40 and \\>120.', 'timeFrame': 'From Day 1 of study treatment up to Week 52 of the treatment safety period'}, {'measure': 'Follow-up Safety Period: Number of Participants With Vital Signs Abnormalities.', 'description': 'Vital signs abnormalities included BP mmHg: systolic BP \\<90 and \\>140; diastolic BP \\<50 and \\>90 and pulse rate (beats per minute) :\\<40 and \\>120.', 'timeFrame': 'From Week 52 to Week 54 of the follow-up safety period'}, {'measure': 'Treatment Safety Period: Number of Participants With Hematology Test Abnormalities', 'description': 'Hematology parameters included: hemoglobin increased, anemia, leukocytosis, white blood cell decreased, platelet count decreased, neutrophil count decreased, lymphocyte count increased, lymphocyte count decreased. As per National Cancer Institute of Common Terminology Criteria for Adverse Events (NCI CTCAE) version(v)5.0-Grade(G) 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: moderate; minimal, local or non-invasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL), Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE. Grade 3 and 4 abnormalities were reported in this outcome measure.', 'timeFrame': 'From Day 1 of study treatment up to Week 52 of the treatment safety period'}, {'measure': 'Follow-up Safety Period: Number of Participants With Hematology Test Abnormalities', 'description': 'Hematology parameters included: hemoglobin increased, anemia, leukocytosis, white blood cell decreased, platelet count decreased, neutrophil count decreased, lymphocyte count increased, lymphocyte count decreased. As per NCI CTCAE v5.0-Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental ADL, Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE. Grade 3 and 4 abnormalities were reported in this outcome measure.', 'timeFrame': 'From Week 52 to Week 54 of the follow-up safety period'}, {'measure': 'Treatment Safety Period: Number of Participants With Chemistry Test Abnormalities', 'description': 'Chemistry Test Abnormalities included: hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypoglycemia, creatinine increased, blood lactate dehydrogenase increased, hypoalbuminemia, creatine phosphokinase (CPK) increased, aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased, alkaline phosphatase increased, chronic kidney disease, cholesterol high, hypertriglyceridemia. As per NCI CTCAE v5.0-G1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, G2: moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental ADL, G3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. G4: life-threatening consequences; urgent intervention indicated. G5: death related to AE. G3 and 4 abnormalities were reported in this outcome measure.', 'timeFrame': 'From Day 1 of study treatment up to Week 52 of the treatment safety period'}, {'measure': 'Follow-up Safety Period: Number of Participants With Chemistry Test Abnormalities', 'description': 'Chemistry Test Abnormalities included: hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypoglycemia, creatinine increased, blood lactate dehydrogenase increased, hypoalbuminemia, CPK increased, aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased, alkaline phosphatase increased, chronic kidney disease, cholesterol high, hypertriglyceridemia. As per NCI CTCAE v5.0-G1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, G2: moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental ADL, G3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. G4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE. G3 and 4 abnormalities were reported in this outcome measure.', 'timeFrame': 'From Week 52 to Week 54 of the follow-up safety period'}]","[{'measure': 'Change From Observation Period in the Number of Migraine Days by Pain Intensity at Every 4 Week Interval and Overall Period', 'description': 'The number of migraine days and severity of migraine attacks was analyzed for every 4-week interval and overall period during long-term treatment with rimegepant in participants was compared to the observation period. Pain intensity of migraine was graded into mild, moderate, or severe and severity was judged by investigator.', 'timeFrame': 'Baseline (observation period); Week 1 to 4, 5 to 8, 9 to 12, 13 to 16, 17 to 20, 21 to 24, 25 to 28, 29 to 32, 33 to 36, 37 to 40, 41 to 44, 45 to 48, 49 to 52 and Overall (Week 1 to 52)'}]",15,18 Years,,ALL,False,Pfizer,INDUSTRY,0,241.0,ACTUAL,2025-09-01T16:18:17.181491,v2_robust,True,True,True,False,True,
NCT06288152,Evaluation of Thiosulfate Enhanced Organ Preservation Solution in Kidney Transplantation,Evaluation of Thiosulfate Enhanced Organ Preservation Solution in Kidney Transplantation,Sodium Thiosulfate,"['Seacalphyx', 'Sodium Thiosulfate']",2,INTERVENTIONAL,['NA'],,,Renal Transplant,"['Renal Transplant', 'Kidney Transplant']","['Thiosulfate', 'Transplant', 'Renal', 'Kidney']",NOT_YET_RECRUITING,,2024-03-01,2027-03-01,"[{'measure': 'Effects of STS will be measured by: Delayed graft function', 'description': 'Number of participants requiring dialysis use post-transplant', 'timeFrame': '1 year'}]",[],1,18 Years,,ALL,False,Alp Sener,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:17.181571,v2_robust,True,True,False,False,False,
NCT01657552,Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects,"A Phase I, Open-label, Three-Period, Single Sequence, Crossover Study Evaluating the Drug-Drug Interaction Between Eltrombopag and Boceprevir and Between Eltrombopag and Telaprevir in Healthy Adult Subjects",Eltrombopag,"['Eltrombopag', 'Telaprevir', 'Boceprevir']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Thrombocytopaenia,['Thrombocytopaenia'],"['Drug interaction', 'INCIVEK (telaprevir),', 'SB-497115 (eltrombopag)', 'Pharmacokinetics', 'Thrombocytopenia', 'VICTRELIS (boceprevir)']",COMPLETED,,2012-08-01,2012-10-26,"[{'measure': 'Composite pharmacokinetic (PK) parameters of eltrombopag following administration of boceprevir for 10 days with a single dose of eltrombopag', 'description': 'Plasma eltrombopag PK Parameters: area under the concentration time-curves from time zero to infinity AUC(0-infinity) and maximum concentration (Cmax).', 'timeFrame': 'For 17 days'}, {'measure': 'Composite PK parameters of boceprevir following administration of boceprevir for 10 days with a single dose of eltrombopag', 'description': 'Plasma boceprevir PK Parameters: AUC from time zero to the dosing interval AUC(0-τ), Cmax, and Concentraction at end of the dosing interval (Cτ)', 'timeFrame': 'For 17 days'}, {'measure': 'Composite PK parameters of eltrombopag following administration of telaprevir for 10 days with a single dose of eltrombopag', 'description': 'Plasma eltrombopag PK Parameters: AUC(0-infinity) and Cmax', 'timeFrame': 'For 17 days'}, {'measure': 'Composite PK parameters of telaprevir following administration of telaprevir for 10 days with a single dose of eltrombopag', 'description': 'Plasma telaprevir PK Parameters: AUC(0-τ), Cmax, and Cτ.', 'timeFrame': 'For 17 days'}]","[{'measure': 'Composite PK parameters of eltrombopag following administration of boceprevir for 10 days with a single dose of eltrombopag', 'description': 'Plasma eltrombopag PK Parameters: AUC from time zero to the last measurable concentration (AUC(0-t)), AUC obtained by extrapolation (%) (%AUCex), time from administration to first quantifiable concentration (tlag), time from administration to Cmax (tmax), elimination half life (t1/2), and apparent clearance (CL/F).', 'timeFrame': 'For 17 days'}, {'measure': 'Composite PK parameters of boceprevir following administration of boceprevir for 10 days with a single dose of eltrombopag', 'description': 'Plasma boceprevir PK Parameter: tmax.', 'timeFrame': 'For 17 days'}, {'measure': 'Composite PK parameters of eltrombopag following administration of telaprevir for 10 days with a single dose of eltrombopag', 'description': 'Plasma eltrombopag PK Parameters: AUC(0-t), %AUCex, tlag, tmax, t1/2, and CL/F.', 'timeFrame': 'For 17 days'}, {'measure': 'Composite PK parameters of telaprevir following administration of telaprevir for 10 days with a single dose of eltrombopag', 'description': 'Plasma telaprevir PK Parameter: tmax.', 'timeFrame': 'For 17 days'}, {'measure': 'Safety and tolerability as assessed by the collection of adverse events', 'timeFrame': 'For 28 days'}, {'measure': 'Safety and tolerability as assessed by change from baseline in clinical laboratory tests', 'description': 'Clinical laboratory tests include hematology, clinical chemistry, urinalysis tests.', 'timeFrame': 'For 28 days'}, {'measure': 'Safety and tolerability as assessed by change from baseline in vital sign', 'description': 'Vital sign measurements will include systolic and diastolic blood pressure and pulse rate.', 'timeFrame': 'For 28 days'}]",11,18 Years,64 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,56.0,ACTUAL,2025-09-01T16:18:17.181597,v2_robust,True,True,True,False,True,
NCT05198752,A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors,"A Phase 1 Clinical Study to Evaluate the Tolerability, Safety,Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients With Advanced Malignant Solid Tumours",Neoantigen mRNA Personalised Cancer SW1115C3,['Neoantigen mRNA Personalised Cancer SW1115C3'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumor,['Solid Tumor'],[],UNKNOWN,,2022-03-18,2024-06-12,"[{'measure': '，Dose-limiting toxicity incidence (participants who experience DLT)', 'timeFrame': '21 day'}]","[{'measure': 'Objective response rate(ORR) assessment per RECIST Version 1.1', 'timeFrame': '1 year'}]",2,18 Years,80 Years,ALL,False,Stemirna Therapeutics,INDUSTRY,0,30.0,ESTIMATED,2025-09-01T16:18:17.181647,v2_robust,True,True,False,False,False,
NCT00997347,The Extended Gestational Age Medical Abortion Study,The Extended Gestational Age Medical Abortion Study: The Effectiveness of Medical Abortion With Mifepristone and Misoprostol at 57-63 Days Versus 64-70 Days Gestation,Mifepristone and misoprostol,['Mifepristone and misoprostol'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Medical Abortion,['Medical Abortion'],[],COMPLETED,,2009-07,2012-02,"[{'measure': 'Efficacy: Proportion of women who successfully complete abortion without surgical intervention to resolve viable pregnancy or incomplete abortion', 'timeFrame': '7-36 days'}]","[{'measure': 'Proportion of individual side effects experienced by participants', 'timeFrame': '7-14 days'}, {'measure': 'Proportion of women who determined method acceptable (i.e., overall acceptability of method, time to abortion completion, bleeding, side effects, and pain)', 'timeFrame': '7-14 days'}, {'measure': 'Bleeding patterns, i.e. proportion of women who experienced heavy, moderate, or light bleeding according by day since abortion began', 'timeFrame': '7-14 days'}, {'measure': 'Average number of missed days of work or school due to the abortion procedure', 'timeFrame': '7-14 days'}]",5,18 Years,,FEMALE,True,Gynuity Health Projects,OTHER,0,1400.0,ACTUAL,2025-09-01T16:18:17.181682,v2_robust,True,True,True,False,False,
NCT00801047,Intravenous Remifentanil Patient-controlled Analgesia (PCA) and Epidural Patient Controlled Epidural Analgesia (PCEA) for Labor Analgesia,Comparison of the Efficacy Intravenous Remifentanil PCA and Epidural PCEA for Labor Analgesia,Bupivacaine epidural,"['Remifentanil', 'Bupivacaine epidural']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Labor,"['Labor', 'Pain']","['Epidural', 'Labor', 'Remifentanil']",COMPLETED,,2010-02,2012-07,"[{'measure': 'Primary analgesia end-point: VAS pain Score', 'timeFrame': '1-6 hours'}]",[],1,18 Years,40 Years,FEMALE,False,Hadassah Medical Organization,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:17.181715,v2_robust,True,True,True,False,False,
NCT06657547,Urinary Concentration After Salmeterol,Urinary Concentration After Salmeterol in Well-trained Men and Females,Salmeterol inhalation and urine samples,['Salmeterol inhalation and urine samples'],1,INTERVENTIONAL,['NA'],,,Healthy,['Healthy'],"['Urinary concentration', 'Beta2-adrenergic stimulation']",RECRUITING,,2024-10-31,2026-12-31,"[{'measure': 'Urine concentration', 'description': 'Difference in urine concentration with salmeterol administered before performance tests in different conditions', 'timeFrame': 'Through study completion, an average on 1 week'}]",[],1,18 Years,40 Years,ALL,False,University of Copenhagen,OTHER,0,24.0,ESTIMATED,2025-09-01T16:18:17.181743,v2_robust,True,True,False,False,False,
NCT02998047,A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma,A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma,Lintuzumab AC 225,"['HuM195-Ac225', 'Lintuzumab AC 225']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Refractory Multiple Myeloma,['Refractory Multiple Myeloma'],[],TERMINATED,Poor recruitment,2016-12,2020-05,"[{'measure': 'Maximum Tolerated dose of Lintuzumab-AC225', 'description': 'establish the maximum tolerated dose as monotherapy', 'timeFrame': 'Through study completion, an average of 2.5 year'}, {'measure': 'Adverse events- Treatment Emergent', 'description': 'safety of lintuzumab-Ac225', 'timeFrame': 'Through study completion, an average of 2.5 year'}]","[{'measure': 'Response rates (objective response rate, complete response rate, stringent complete response rate, very good partial response rate and partial response rate)', 'description': 'response rate, including ORR, CR, sCR, VGPR, and PR, PFS, and OS. Efficacy assessments will include serum and urine analyses for paraprotein levels and bone marrow analyses.', 'timeFrame': 'Through study completion, an average of 2.5 year'}, {'measure': 'Progression free survival', 'description': 'Progression free survival', 'timeFrame': 'Through study completion, an average of 2.5 year'}, {'measure': 'Overall survival', 'description': 'Overall survival', 'timeFrame': 'Through study completion, an average of 2.5 year'}]",5,18 Years,,ALL,True,Actinium Pharmaceuticals,INDUSTRY,0,2.0,ACTUAL,2025-09-01T16:18:17.181792,v2_robust,True,True,False,True,True,Poor recruitment
NCT03934047,Visual Field Infiltration of Tranexamic Acid Reduced the Blood Loss in Total Knee Arthroplasty,Visual Field Infiltration of Tranexamic Acid Reduced the Blood Loss in Total Knee Arthroplasty,Tranexamic Acid 100 MG/ML,['Tranexamic Acid 100 MG/ML'],1,INTERVENTIONAL,['NA'],,,Total Knee Arthroplasty,['Total Knee Arthroplasty'],[],UNKNOWN,,2019-04-26,2020-06-01,"[{'measure': 'Blood loss', 'description': 'Blood loss calculated by hemoglobin level', 'timeFrame': '1 week after operation'}]",[],1,18 Years,99 Years,ALL,False,"Second Affiliated Hospital, School of Medicine, Zhejiang University",OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:17.181815,v2_robust,True,True,False,False,False,
NCT01513447,Intracutaneous Sterile Water Injections,Intracutaneous Sterile Water Injection as an Adjunct to Neuraxial Labor Analgesia: A Randomized Controlled Trial,Intracutaneous injections,['Intracutaneous injections'],1,INTERVENTIONAL,['NA'],,,Labor Pain,['Labor Pain'],"['sterile water injections', 'back labor']",TERMINATED,low qualified candidate enrollment,2011-12,2013-12,"[{'measure': 'Number of Participants With Breakthrough Back Labor Pain', 'description': 'It is anticipated that intracutaneous sterile water injections will provide additional pain relief as part of a multimodal analgesic regimen in women, especially in women with back labor.', 'timeFrame': 'within 24 hours'}]","[{'measure': 'Total Local Anesthetic Consumption', 'description': 'It is anticipated that intracutaneous sterile water injections will decrease the amount of local anesthetic consumption.', 'timeFrame': '24 hours'}]",2,18 Years,60 Years,FEMALE,True,Northwestern University,OTHER,0,8.0,ACTUAL,2025-09-01T16:18:17.181829,v2_robust,True,True,False,True,False,low qualified candidate enrollment
NCT05494047,"Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile","A Phase III, Randomized, Double-blind and Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Influenza Vaccine, Inactivated, Quadrivalent Developed by Sinovac Biotech Co., Ltd. Compared to a Licensed Quadrivalent Influenza Vaccine, VaxigripTetra™, in Individuals Aged 3 Years and Older in Chile",Tetravalent influenza vaccine developed by Sinovac Biotech Co.,"['Tetravalent influenza vaccine developed by Sinovac Biotech Co.', 'Sinovac vaccine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Influenza,"['Influenza', 'Vaccines']","['influenza', 'vaccine', 'immunogenicity', 'clinical-trial']",UNKNOWN,,2022-07-14,2023-07-31,"[{'measure': 'Seroconversion for influenza', 'description': 'Seroconversion rates and geometric mean titers of human influenza antibody for each of the four antigens.', 'timeFrame': '28 days after the last dose of vaccination'}]","[{'measure': 'Antibody titer 1:40 or more', 'description': 'Proportion of subjects with antibody titer ≥1:40', 'timeFrame': '28 days after the last dose of vaccination'}, {'measure': 'Cellular immunity-ELISPOT', 'description': 'Quantification by ELISPOT of specific Spot Forming Cells for cytokines, molecules and immunoglobulins induced by both vaccines', 'timeFrame': '28 days after the last dose'}, {'measure': 'Cellular immunity-Cytometry', 'description': 'Quantification by flow cytometry of CD3+CD4+ and CD3+CD8+ cells positive for Activation Induced Markers, induced by both vaccines.', 'timeFrame': '28 days after the last dose'}, {'measure': 'Cellular immunity-Luminex (TM)', 'description': '• Quantification by Luminex® of cytokines secreted by specific CD3+CD4+ and CD3+CD8+ cells induced by each vaccine', 'timeFrame': '28 days after the last dose'}]",5,3 Years,,ALL,True,Pontificia Universidad Catolica de Chile,OTHER,2,1600.0,ESTIMATED,2025-09-01T16:18:17.181840,v2_robust,True,True,False,False,False,
NCT02124447,"Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy",Comparison of Efficacy and Patient Tolerability of Four Commercially Available Bowel Purgatives for Screening and Surveillance Colonoscopy: A Single Tertiary Medical Center Experience.,PEG+E,"['Golytely', 'Prepopik', 'PEG+E', 'P+MC', 'Suprep', 'sulfate', 'MoviPrep', 'PEG+Asc']",8,INTERVENTIONAL,['NA'],,,Patients Undergoing Screening or Surveillance Colonoscopy,['Patients Undergoing Screening or Surveillance Colonoscopy'],[],WITHDRAWN,Protocol issues. Modifications potentially will be undertaken and resubmitted to IRB,2014-06,2015-06,"[{'measure': 'Efficacy of bowel cleansing according to the Boston Bowel Preparation Score (BPPS)', 'timeFrame': 'Patient outcome will be assessed at the time of the colonoscopy by the performing physician and ducomentation of this outcome will occur within 24 hours of the procedure'}]","[{'measure': 'Patient tolerability and satisfaction', 'description': 'Will be assessed using a previously studied satisfaction questionnaire (7 items)', 'timeFrame': 'Outcome of satisfaction will be assessed on a single survey that the patient will provide the day of their colonoscopy and will be recorded by study personnel up to 30 days thereafter'}]",2,18 Years,90 Years,ALL,False,Medical College of Wisconsin,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:17.181909,v2_robust,True,True,False,True,False,Protocol issues. Modifications potentially will be undertaken and resubmitted to IRB
NCT00520247,Effect of Enalapril Plus Folic Acid on Blood Pressure and Glycometabolism,Efficacy of Antihypertensive and Plasma Total Homocysteine Lowering Combined Therapy With Enalapril and Folic Acid in Hypertensive Patients:A Multicenter Double Blind Randomized Clinical Trial,enalapril plus folic acid,['enalapril plus folic acid'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Plasma Total Homocysteine Level,"['Plasma Total Homocysteine Level', 'Blood Pressure']","['enalapril', 'folic acid', 'hyperglycemia', 'hypertension', 'fasting plasma glucose']",COMPLETED,,2005-09,2006-02,"[{'measure': ""Blood pressure of study participants was measured at baseline, 2th week, 4th week, 6th week and at the end of trial Subjects' plasma total homocysteine concentration were measured at baseline, 4th week and at 8th week."", 'timeFrame': '8 weeks'}]","[{'measure': ""Participants' living habit and life style were collected at baseline with the original questionnaires. A follow up questionnaire was sent out at 2th week, 4th week, 6th week and at the end of the trial."", 'timeFrame': '8 weeks'}]",2,28 Years,75 Years,ALL,False,Anhui Medical University,OTHER,6,443.0,ACTUAL,2025-09-01T16:18:17.181935,v2_robust,True,True,True,False,False,
NCT02129647,Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas,Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas,Axitinib,"['Inlyta', 'Axitinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Neurofibromatosis Type 2,"['Neurofibromatosis Type 2', 'Vestibular Schwannomas']","['Neurofibromatosis Type 2', 'Vestibular Schwannomas', 'Axitinib']",COMPLETED,,2014-04,2019-02-05,"[{'measure': 'Expression Levels of p-S6 Based Immunohistochemistry (Histoscore)', 'description': 'The histoscore is given as the sum of the percentage of staining multiplied by an ordinal value corresponding to the intensity level (0 = none, 1 = weak, 2 = moderate, 3 = strong). With 4 intensity levels, the resulting score ranged from 0 (no staining in the tumor) to 300 (diffuse intense staining of the tumor).', 'timeFrame': '10 days'}, {'measure': 'Expression Levels of p-ERK Based Immunohistochemistry (Histoscore)', 'description': 'The histoscore is given as the sum of the percentage of staining multiplied by an ordinal value corresponding to the intensity level (0 = none, 1 = weak, 2 = moderate, 3 = strong). With 4 intensity levels, the resulting score ranged from 0 (no staining in the tumor) to 300 (diffuse intense staining of the tumor).', 'timeFrame': '10 days'}, {'measure': 'Expression Levels of p-AKT Based Immunohistochemistry (Histoscore)', 'description': 'The histoscore is given as the sum of the percentage of staining multiplied by an ordinal value corresponding to the intensity level (0 = none, 1 = weak, 2 = moderate, 3 = strong). With 4 intensity levels, the resulting score ranged from 0 (no staining in the tumor) to 300 (diffuse intense staining of the tumor).', 'timeFrame': '10 days'}, {'measure': 'Pre-Operative Everolimus Blood Levels', 'timeFrame': 'Baseline'}, {'measure': 'Post-Operative Everolimus Blood Levels', 'timeFrame': '10 days'}]",[],5,18 Years,,ALL,False,NYU Langone Health,OTHER,0,13.0,ACTUAL,2025-09-01T16:18:17.181947,v2_robust,True,True,True,False,False,
NCT04569747,"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)",ADJUVANT ENDOCRINE THERAPY,"['Tamoxifen', 'Exemestane', 'Anastrozole', 'ADJUVANT ENDOCRINE THERAPY', 'Leuprolide, or other LHRH agonist (per investigator discretion)', 'Letrozole']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,HER2-positive Breast Cancer,"['HER2-positive Breast Cancer', 'Invasive Carcinoma of the Breast', 'Breast Cancer', 'Node Negative Breast Cancer', 'Micrometastasis Breast Cancer', 'Hormone Receptor Positive Breast Cancer']","['HER2-positive Breast Cancer', 'Invasive Carcinoma of the Breast', 'Breast Cancer', 'Node Negative Breast Cancer', 'Micrometastasis Breast Cancer', 'Hormone Receptor Positive Breast Cancer']",RECRUITING,,2021-01-11,2030-09-01,"[{'measure': 'Invasive Disease Free Survival at 3 Years', 'description': 'Kaplan-Meier estimates of iDFS will be estimated and plotted with the corresponding 95% confidence intervals.\n\nfrom the time of randomization until the occurrence of the first of the following events: invasive local/regional recurrence, Contralateral invasive breast cancer, Distant recurrence, Death from any cause', 'timeFrame': '3 Years'}]","[{'measure': 'Invasive Disease Free Survival at 7 Years', 'description': 'Kaplan-Meier estimates of iDFS will be estimated and plotted with the corresponding 95% confidence intervals.\n\nfrom the time of randomization until the occurrence of the first of the following events: invasive local/regional recurrence, Contralateral invasive breast cancer, Distant recurrence, Death from any cause', 'timeFrame': '7 years'}, {'measure': 'Invasive Disease Free Survival at 10 Years', 'description': 'Kaplan-Meier estimates of iDFS will be estimated and plotted with the corresponding 95% confidence intervals.\n\nfrom the time of randomization until the occurrence of the first of the following events: invasive local/regional recurrence, Contralateral invasive breast cancer, Distant recurrence, Death from any cause', 'timeFrame': '10 years'}, {'measure': 'Recurrence-free interval (RFI) at 3 Years', 'description': 'RFI will be estimated and plotted with the corresponding 95% confidence intervals, using Kaplan-Meier estimates for the study as a whole and for subgroups of patients determined by intrinsic subtype (HER2-enriched, luminal, basal Time of randomization until the occurrence of the first of the following events:Invasive local/regional recurrence, Distant recurrence, Death from breast cancer', 'timeFrame': '3 Years'}, {'measure': 'Recurrence-free interval (RFI) at 7 Years', 'description': 'RFI will be estimated and plotted with the corresponding 95% confidence intervals, using Kaplan-Meier estimates for the study as a whole and for subgroups of patients determined by intrinsic subtype (HER2-enriched, luminal, basal Time of randomization until the occurrence of the first of the following events:Invasive local/regional recurrence, Distant recurrence, Death from breast cancer', 'timeFrame': '7 Years'}, {'measure': 'Recurrence-free interval (RFI) at 10 Years', 'description': 'RFI will be estimated and plotted with the corresponding 95% confidence intervals, using Kaplan-Meier estimates for the study as a whole and for subgroups of patients determined by intrinsic subtype (HER2-enriched, luminal, basal Time of randomization until the occurrence of the first of the following events:Invasive local/regional recurrence, Distant recurrence, Death from breast cancer', 'timeFrame': '10 Years'}, {'measure': 'Breast cancer-specific survival (BCSS) at 3 Years', 'description': 'defined as the time period between randomization and death due to breast cancer.', 'timeFrame': '3 Years'}, {'measure': 'Breast cancer-specific survival (BCSS) at 7 Years', 'description': 'defined as the time period between randomization and death due to breast cancer.', 'timeFrame': '7 Years'}, {'measure': 'Breast cancer-specific survival (BCSS) at 10 Years', 'description': 'defined as the time period between randomization and death due to breast cancer.', 'timeFrame': '10 Years'}, {'measure': 'Overall survival', 'description': 'OS will be estimated and plotted with the corresponding 95% confidence intervals, using Kaplan-Meier estimates for the study as a whole and for subgroups of patients determined by intrinsic subtype (HER2-enriched, luminal, basal).', 'timeFrame': 'randomization and death. Surviving patients classified as lost-to-follow-up or having withdrawn consent to be followed will be censored at their date of last contact or withdrawal of consent to be followed, whichever occurs first up to 10 years'}, {'measure': 'Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0', 'description': 'NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for AE reporting', 'timeFrame': 'baseline to 5 Years'}, {'measure': 'Total patient chair time of drug administration', 'description': 'Mean difference will be estimated between HP FDC SC and IV admin of HP in sub-study', 'timeFrame': 'baseline to 18 Months'}]",12,18 Years,,ALL,False,Dana-Farber Cancer Institute,OTHER,1,375.0,ESTIMATED,2025-09-01T16:18:17.182051,v2_robust,True,True,False,False,True,
NCT05409547,A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF,"A Multi-center, Open, Randomized, Controlled Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for Pegylated Recombinant Human Granulocyte Colony Stimulating Factor",PEG-rhG-CSF,"['rhG-CSF', 'PEG-rhG-CSF']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Granulocyte Colony-stimulating Factor,"['Granulocyte Colony-stimulating Factor', 'Stem Cell Mobilization']","['Hematopoietic stem cell mobilization', 'Hematopoietic stem cell transplantation', 'pegylated granulocyte colony-stimulating factor']",UNKNOWN,,2022-06-30,2025-04-30,"[{'measure': 'Efficiency of stem cell mobilization', 'description': 'Count of collected CD34+ cells (CD34+ \\> 2×10\\^6 /kg will be considered as successful mobilization).', 'timeFrame': '3years'}]","[{'measure': 'Time of hematopoietic reconstitution', 'description': '1. The time period(days) between reinfusion of hematopoietic stem cells and neutrophils exceed 0.5×10\\^9/L for 3 consecutive days.\n2. The time period(days) between reinfusion of hematopoietic stem cells and platelet count is greater than 20×10\\^9/L for 3 consecutive times.', 'timeFrame': '3years'}]",2,18 Years,60 Years,ALL,False,Ning Huang,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:17.182218,v2_robust,True,True,False,False,False,
NCT02935647,Burst Suppression Anesthesia for Treatment of Severe Depression,Burst Suppression Anesthesia for Treatment of Severe Depression,Diprivan,"['Diprivan', 'Propofol']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Major Depressive Disorder,['Major Depressive Disorder'],[],COMPLETED,,2016-10-01,2018-09,"[{'measure': 'Hamilton Rating Scale for Depression', 'timeFrame': '3 weeks'}]","[{'measure': 'Quick Inventory of Depressive Symptoms', 'timeFrame': '3 weeks'}]",2,18 Years,55 Years,ALL,False,University of Utah,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:17.182237,v2_robust,True,True,True,False,False,
NCT01876849,An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus,An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus,exenatide,"['Byetta', 'exenatide']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],"['diabetes', 'exenatide', 'Byetta', 'Amylin', 'Lilly']",COMPLETED,,2003-12,2008-07,"[{'measure': 'Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events.', 'description': 'Visits for this study occur at 6-mo (±2 wk) intervals until exenatide is approved for marketing.', 'timeFrame': '128 weeks (average treatment period)'}]",[],1,30 Years,75 Years,ALL,False,AstraZeneca,INDUSTRY,1,275.0,ACTUAL,2025-09-01T16:18:17.182314,v2_robust,True,True,True,False,True,
NCT05264649,Effect of Acupuncture vs Chinese Medicine vs Combined Therapy on Aromatase Inhibitor-related Arthralgia Among Women With Early-Stage Breast Cancer,Effect of Acupuncture vs Chinese Medicine vs Combined Therapy on Aromatase Inhibitor-related Arthralgia Among Women With Early-Stage Breast Cancer,Guizhi-Shaoyao-Zhimu decoction,['Guizhi-Shaoyao-Zhimu decoction'],1,INTERVENTIONAL,['NA'],,,Arthralgia,['Arthralgia'],"['aromatase inhibitors-associated arthralgia', 'aromatase inhibitors', 'breast cancer', 'musculoskeletal disorders', 'hormonal anti-estrogen therapy', 'endocrine therapy']",UNKNOWN,,2022-05-05,2023-03-03,"[{'measure': 'Brief Pain Inventory-Worst Pain Item (BFI-WP)', 'description': 'a 0- to 10-point scale (0 \\[no pain\\] to 10 \\[pain as bad as you can imagine)', 'timeFrame': 'Change from baseline at 6 weeks'}]","[{'measure': 'Brief Pain Inventory - Short Form (BPI-SF)', 'description': 'The Brief Pain Inventory-Short Form (BPI-SF) was used to evaluate the worst pain, pain severity, and pain- related interference scores. (0 \\[no pain\\] to 10 \\[pain as bad as you can imagine)', 'timeFrame': 'Change from baseline at 6 weeks'}, {'measure': 'Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)', 'description': 'The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was used in the evaluation of pain (score range, 0-20), stiffness (score range, 0-8), physical function of lower limb (score range, 0-68).', 'timeFrame': 'Change from baseline at 6 weeks'}, {'measure': 'Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (M-SACRAH)', 'description': 'Affections of the Hands (M-SACRAH) was used in the evaluation of pain, stiffness, physical function of upper limb.', 'timeFrame': 'Change from baseline at 6 weeks'}, {'measure': 'Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES)', 'description': 'The Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) measured physical and functional well- being and endocrine symptoms (score range, 0-128)', 'timeFrame': 'Change from baseline at 6 weeks'}]",5,20 Years,90 Years,FEMALE,False,Show Chwan Memorial Hospital,OTHER,0,72.0,ESTIMATED,2025-09-01T16:18:17.182341,v2_robust,True,True,False,False,False,
NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)","A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)",CK-2017357,"['tirasemtiv', 'Rilutek', 'Riluzole', 'CK-2017357']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Amyotrophic Lateral Sclerosis,['Amyotrophic Lateral Sclerosis'],[],COMPLETED,,2012-10,2014-03,"[{'measure': 'The Change From Baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) Total Score to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment', 'description': ""The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: gross motor tasks, fine motor tasks, bulbar functions, and respiratory function. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The total score ranges from 0 to 48, with higher scores reflecting more normal function and lower scores reflecting more impaired function."", 'timeFrame': 'Baseline, 8 weeks, 12 weeks'}]","[{'measure': 'Change From Baseline in Maximum Voluntary Ventilation (MVV) to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment', 'description': 'MVV was measured as the volume (in liters) of air that could be exhaled during 12 seconds of rapid deep breathing; for analysis purposes, the measured volume was extrapolated to 1 minute (to give units of L/min).', 'timeFrame': 'Baseline, 8 weeks, 12 weeks'}, {'measure': 'Change From Baseline in Sniff Nasal Inspiratory Pressure (SNIP) to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment', 'description': 'SNIP was measured at functional residual capacity, the bottom of the tidal breathing cycle, through 1 plugged nostril while the other remained open. Inspiratory pressure is a negative number where a larger negative number represents . . . A forceful, maximal inspiratory sniff was performed and a peak pressure value reported. The best result (ie, the highest number) from 5 tests was recorded as the SNIP.', 'timeFrame': 'Baseline, 8 weeks, 12 weeks'}, {'measure': 'Change From Baseline in Slow Vital Capacity (SVC) to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment', 'description': 'SVC was measured using a spirometer (in units of liters). Following 3 to 5 breaths at rest, the patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs). Values obtained were converted to % predicted values (ie, the test result as a percent of predicted values for the patients of similar demographic and baseline characteristics \\[eg, height, age, sex\\]).', 'timeFrame': 'Baseline, 8 weeks, 12 weeks'}, {'measure': 'Change From Baseline in Maximum Handgrip Strength in the Weaker Hand to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment', 'description': 'Maximum handgrip strength was measured using an electronic hand dynamometer; patients were asked to squeeze the device with the maximum possible force.', 'timeFrame': 'Baseline, 8 weeks, 12 weeks'}, {'measure': 'Change From Baseline in Handgrip Fatigability (at 60% of Target in the Weaker Hand) to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment', 'description': 'Handgrip fatigability was measured immediately following determination of maximum handgrip strength (via an electronic hand dynamometer). Once maximum handgrip strength was achieved, the force of the grip was timed for 2 minutes or until the grip strength had dropped to 60% of the maximum, whichever came first.', 'timeFrame': 'Baseline, 8 weeks, 12 weeks'}, {'measure': 'Change From Baseline in Muscle Strength Mega-Score Based on Percent Change in Muscle Strength Measurements to the Average at the End of Weeks 8 and 12 of Double-blind Treatment', 'description': 'A hand-held dynamometer (HHD), with a scale of 0 to 300 pounds, was used to measure muscle strength and handgrip strength (bilateral); the muscle groups tested were: elbow flexion (bilateral), wrist extension (bilateral), knee extension (bilateral), and ankle dorsiflexion (bilateral). For each assessment time point, the percent change from baseline was calculated for each muscle group and handgrip strength. The muscle strength mega-score was calculated as the average of the changes (ie, percent change from baseline) observed for each muscle groups as well as handgrip strength. For this endpoint, negative values indicate a decline in muscle strength.', 'timeFrame': 'Baseline, 8 weeks, 12 weeks'}]",7,18 Years,,ALL,False,Cytokinetics,INDUSTRY,0,711.0,ACTUAL,2025-09-01T16:18:17.182479,v2_robust,True,True,True,False,False,
NCT01546649,A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer,,TAP-144-SR(6M),"['TAP-144-SR(6M)', 'TAP-144-SR(3M)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Premenopausal Breast Cancer,['Premenopausal Breast Cancer'],[],COMPLETED,,2012-04,2014-12,"[{'measure': 'Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=<30 pg/mL) From Week 4 Through Week 48', 'description': 'Comparison of both the treatment groups was done by assessing the suppressive effect on serum E2 concentration maintained at menopausal level (=\\<30pg/mL). Suppression rate was calculated as proportion of participants maintained at menopausal level.', 'timeFrame': 'Week 4 up to Week 48'}]","[{'measure': 'Concentration of Serum E2', 'description': 'The measure indicates serum E2 concentration at baseline and post-baseline time points.', 'timeFrame': 'Baseline, Hour (hr) 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673'}, {'measure': 'Concentration of Serum Luteinizing Hormone (LH)', 'description': 'This measure indicates serum LH concentration at baseline and post-baseline time points. It was measured in milli-international units per milliliter (mIU/mL).', 'timeFrame': 'Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673'}, {'measure': 'Concentration of Follicle Stimulating Hormone (FSH)', 'description': 'This measure indicates serum FSH concentration at baseline and post-baseline time points.', 'timeFrame': 'Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673'}, {'measure': 'Disease Free Survival (DFS) Rate at Week 96', 'description': 'DFS is defined as time from randomization to earliest day of onset the events, recurrence \\[including recurrence in the ipsilateral breast\\], secondary cancer \\[including breast cancer in the contralateral breast\\] and death. DFS at Week 96 was defined as the percentage, calculated with Kaplan-Meier method, of participants did not experience any events at Week 96 since the randomization.', 'timeFrame': 'Week 96'}, {'measure': 'Distant Disease Free Survival (DDFS) Rate at Week 96', 'description': 'DDFS is defined as time from randomization to earliest day of onset the events, distant recurrence, secondary cancer \\[including breast cancer in the contralateral breast\\] and death. DDFS at week 96 was defined as the percentage calculated with Kaplan-Meier method, of participants did not experience any events at week 96 since the randomization.', 'timeFrame': 'Week 96'}, {'measure': 'Serum Unchanged TAP-144 Level', 'description': 'This measure indicates the unchanged TAP-144 level in serum.', 'timeFrame': 'Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309 and 337'}, {'measure': 'QT Interval Measured by 12-lead Electrocardiogram (ECG)', 'description': '12-lead electrocardiography measurement was performed in supine position after 5 minutes at rest. Each measurement was recorded continuously for 10 seconds at the recording speed of 25 millimeter/second (mm/second).', 'timeFrame': 'Baseline, Hour 1, 3, 6 on Day 1, Day 29, 85, 169 and 337'}]",8,20 Years,,FEMALE,False,Takeda,INDUSTRY,0,167.0,ACTUAL,2025-09-01T16:18:17.182599,v2_robust,True,True,True,False,False,
NCT04955938,"A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms","A Phase Ib Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms",Ivosidenib,"['IDHIFA', 'Ivosidenib', 'Enasidenib', 'Fedratinib', 'Tibsovo', 'INREBIC']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,IDH Mutation,"['IDH Mutation', 'IDH1 Mutation', 'IDH2 Gene Mutation', 'Blood Cancer', 'Myeloproliferative Neoplasm']","['Leukemia', 'myeloid', 'blood cancer', 'Myeloproliferative Neoplasm']",WITHDRAWN,unable to accrue,2021-10-29,2023-06-07,"[{'measure': 'Maximum Tolerated Dose of Fedratinib Combined with Ivosidenib in Participants Who Have IDH1 Mutations', 'description': 'The maximum tolerated dose of fedratinib in combination with ivosidenib in participants who have IDH1-mutated blood cancer. This will be assessed by the number of reported dose-limiting toxicities and adverse events among participants according to the Common Terminology Criteria for Adverse Events version 5.', 'timeFrame': '24 months'}, {'measure': 'Maximum Tolerated Dose of Fedratinib Combined with Enasidenib in Participants Who Have IDH2 Mutations', 'description': 'The maximum tolerated dose of fedratinib in combination with ivosidenib in participants who have IDH1-mutated blood cancer. This will be assessed by the number of reported dose-limiting toxicities and adverse events among participants according to the Common Terminology Criteria for Adverse Events version 5.', 'timeFrame': '24 months'}]","[{'measure': '1-Year Overall Survival', 'description': 'The number of patients who are living 1 year after the beginning of treatment on study as assessed by data from clinical records.', 'timeFrame': '12 months'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'Overall response rate as assessed by the number of participants who achieve a complete molecular response (CMR), cytogenetic complete response (CCR), acute leukemia response-complete (ALR-C), or acute leukemia response-partial (ALR-P).', 'timeFrame': '24 months'}, {'measure': 'Time to Response', 'description': 'Time to response will be defined as time from treatment administration to first documented complete molecular response (CMR), cytogenetic complete response (CCR), acute leukemia response-complete (ALR-C), or acute leukemia response-partial (ALR-P). DCR will be defined as the portion of subjects achieving a complete molecular response,cytogenetic complete response (CCR), acute leukemia response-complete (ALR-C), or acute leukemia response-partial (ALR-P) or stabilized disease for ≥ 3 months.', 'timeFrame': '24 months'}]",5,18 Years,,ALL,False,University of Chicago,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:17.182656,v2_robust,True,True,False,True,True,unable to accrue
NCT00399438,A Study of BMS-562086 in Patients With Irritable Bowel Syndrome,A Dose-Ranging Study of the Pharmacodynamic Effects of BMS-562086 on Gastrointestinal Transit in Women With Diarrhea-Predominant Irritable Bowel Syndrome,Placebo,"['BMS-562086', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Irritable Bowel Syndrome,['Irritable Bowel Syndrome'],['Diarrhea-predominant irritable bowel syndrome'],COMPLETED,,2006-12,2008-01,"[{'measure': 'Radioscintigraphy will be used to determine the effects of BMS-562086 on gastrointestinal transit', 'timeFrame': 'taken at baseline on nominal study days 3,4, and 5 and post dose on nominal study days 14,15, 16'}]","[{'measure': 'Daily diary will be used to record the effects of BMS-562086 on bowel patterns and visceral symptoms.', 'timeFrame': 'throughout the study'}, {'measure': 'Safety', 'timeFrame': 'Safety labs at screening, nominal study days -3, 8, 15, 42, and 70 (discharge). ECGs will be taken at screening, nominal days 5 or 6, 14, and discharge. Vital signs will be taken at screening, on nominal days 3, 4, 5, 7, 8, 10, 11, 42 and discharge'}, {'measure': 'Blood pharmacokinetics', 'timeFrame': 'PK samples will be taken on nominal days 8, 14 (serial: predose 0.5, 1, 2, 4, 6, 9 hours post dose), 15 (pre dose and 9 hours post dose), 16, 42 and discharge'}]",4,18 Years,65 Years,FEMALE,False,Bristol-Myers Squibb,INDUSTRY,0,39.0,ESTIMATED,2025-09-01T16:18:17.182783,v2_robust,True,True,True,False,True,
NCT05834738,"Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy","A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)",Atrasentan,"['Atrasentan Hydrochloride', 'Placebo', 'CHK-01', 'ABT-627', 'Atrasentan']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,IgA Nephropathy,"['IgA Nephropathy', 'Immunoglobulin A Nephropathy']","['Kidney Diseases', 'Kidney Disease, Chronic', 'Urologic Diseases', 'Glomerulonephritis', 'Glomerular Disease', 'Glomerulonephritis, IGA', 'Glomerulopathy', 'Immunoglobulin Disease']",ACTIVE_NOT_RECRUITING,,2023-07-20,2026-08-19,"[{'measure': 'Change From Baseline in Proteinuria at Week 12 in Both Treatment Periods 1 and 2', 'description': 'The change in urine protein: creatinine ratio (UPCR) from baseline to Week 12', 'timeFrame': 'Baseline and 12 weeks or approximately 3 months'}]","[{'measure': 'Change From Baseline in Proteinuria at Week 24 in Treatment Periods 2', 'description': 'The change in UPCR from baseline to Week 24', 'timeFrame': 'Baseline and 24 weeks or approximately 6 months'}, {'measure': 'Number of Subjects With Adverse Events (AEs)', 'description': 'Type, incidence, severity, seriousness, and relatedness of AEs will be collected.', 'timeFrame': 'From informed consent until end of study, approximately 60 weeks'}, {'measure': 'Plasma Concentration of Atrasentan', 'description': 'Blood samples will be collected for the measurement of plasma concentrations of atrasentan.', 'timeFrame': 'Treatment Period 1: Pre-dose on Weeks 2, 6 and 12; Treatment Period 2: Pre-dose on Weeks 2, 6, 12 and 24'}]",4,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,54.0,ACTUAL,2025-09-01T16:18:17.182859,v2_robust,True,True,False,False,True,
NCT00777738,Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia,A Phase IIA Trial Testing the Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia,BORTEZOMIB,['BORTEZOMIB'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Waldenstrom Macroglobulinemia,['Waldenstrom Macroglobulinemia'],"[""Advanced Waldenström's macroglobulinemia"", 'Bortezomib', 'Dexamethasone', 'Safety', 'Efficacy']",COMPLETED,,2008-10,2012-08,"[{'measure': ""Complete and partial remission, defined by the 2nd Workshop on Waldenstrom's macroglobulinemia"", 'timeFrame': '3 months and 6 months'}]","[{'measure': 'Duration of the response', 'timeFrame': 'during the study'}, {'measure': 'Overall survival', 'timeFrame': 'during the study'}, {'measure': 'Quality of life', 'timeFrame': 'months 0, 3, 12, 24'}]",4,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,34.0,ACTUAL,2025-09-01T16:18:17.182881,v2_robust,True,True,True,False,False,
NCT01947738,Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1),"A Two-Part, Double-Blind, Randomized, Placebo-Controlled, Sequential, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-891 in Healthy Subjects",VBY-891,"['VBY-891', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Healthy', 'Subjects', 'Safety', 'Tolerability', 'VBY891', 'Maximum', 'Pharmacodynamic', 'Pharmacokinetic']",COMPLETED,,2013-03,2013-05,"[{'measure': 'Safety and Tolerability of VBY-891', 'description': 'Compare number of adverse events experienced by male versus female subjects', 'timeFrame': 'For 7 days (single dose) or 17 days (multiple dose)'}]","[{'measure': 'VBY-891 Blood Levels', 'description': 'Assessment of VBY-891 levels in blood after single or multiple doses', 'timeFrame': '3 days (single dose) or 10 days (multiple dose)'}]",2,18 Years,60 Years,ALL,True,Virobay Inc.,INDUSTRY,1,89.0,ACTUAL,2025-09-01T16:18:17.182924,v2_robust,True,True,True,False,True,
NCT02066038,Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation,"A Multi-center, Open-labeled Phase 2 Study of First Line Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in ⅢB/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation",Erlotinib,"['Tarceva', 'Erlotinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Lung, Carcinoma","['Lung, Carcinoma']","['chemotherapy', 'maintenance therapy', 'erlotinib']",UNKNOWN,,2014-01,2016-03,"[{'measure': 'Response Evaluation Criteria in Solid Tumors(RECIST) 1.1', 'description': 'Patients were imaged with computed tomography (CT) scan', 'timeFrame': 'eight weeks'}]",[],1,18 Years,75 Years,ALL,False,Sun Yat-sen University,OTHER,2,60.0,ESTIMATED,2025-09-01T16:18:17.182934,v2_robust,True,True,False,False,False,
NCT02420938,"Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients","Urelumab (CD137 mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",Rituximab,"['Rituxan', 'Rituximab', 'Urelumab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Leukemia,['Leukemia'],"['Leukemia', 'Chronic Lymphocytic Leukemia', 'CLL', 'Small Lymphocytic Lymphoma', 'SLL', 'Refractory/relapsed', 'High-risk molecular features', 'Rituximab', 'Rituxan', 'Urelumab']",WITHDRAWN,,2015-07,,"[{'measure': 'Overall Response (OR) of Urelumab and Rituximab in Participants with High-Risk Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL).', 'description': 'Response assessed by investigator, based on physical examinations, CT scans, laboratory results, and bone marrow examinations, based on modified 2008 IWCLL criteria for response for chronic lymphocytic leukemia (CLL). Overall response (OR) includes complete remission (CR), CR with incomplete marrow recovery (CRi) or partial remission (PR). Minimal residual disease (MRD) assessed in bone marrow by multi-color flow cytometry.', 'timeFrame': '12 weeks'}]",[],1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:17.182997,v2_robust,True,True,False,True,False,
NCT02146638,Post Operative Pain Control: Morphine vs Fentanyl,Post Operative Pain Control: Continuous Infusion of Morphine vs Fentanyl. Clinical Outcomes,Morphine,"['Fentanest', 'Fentanyl', 'Morphine']",3,INTERVENTIONAL,['NA'],,,Post Operative Analgesia,['Post Operative Analgesia'],"['post operative analgesia, morphine, fentanyl']",COMPLETED,,2012-04,2012-09,"[{'measure': 'pain scores', 'description': 'data were recorded at 1,6,18 and 24 hours after surgery', 'timeFrame': 'data were recorded during the 24 post operative hours'}]","[{'measure': 'analgesic requirements', 'description': 'if VAS value was equal or higher than 6 patients received ketorolac 30 mg iv', 'timeFrame': 'during the 24 hours after surgery'}]",2,35 Years,59 Years,FEMALE,False,Catholic University of the Sacred Heart,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:17.183069,v2_robust,True,True,True,False,False,
NCT02877238,Remote Preconditioning and Myocardial Protection,Protection by Remote Ischemic Preconditioning During Congenital Cardiac Defects Repair Surgery With Sevoflurane But Not Propofol -A Clinical Trial,Sevoflurane plus remote ischemic preconditioning,"['Total intravenous anesthesia plus remote ischemic preconditioning', 'Group B', 'Group A', 'Sevoflurane plus remote ischemic preconditioning']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Congenital Heart Disease,['Congenital Heart Disease'],"['remote ischemic preconditioning', 'sevoflurane', 'total intravenous anesthetic']",COMPLETED,,2016-08,2017-05,"[{'measure': 'Troponin I levels', 'description': 'The investigators will obtain blood samples for troponin I level pre-Cardiopulmonary bypass, 6, 12 and 24 hours after the surgery. Troponin I levels, as a marker of myocardial ischemia, have been used in previous adult and pediatric studies on preconditioning.', 'timeFrame': 'within first 24 hours after cardiac surgery'}]","[{'measure': 'Highest inotropic score during the first 24 hours after cardiac surgery', 'description': 'Inotrope score is a useful predictor of morbidity and mortality in children who undergo heart surgery.\n\nThe inotropic score is calculated as follows: 1 point is assigned for each mcg/kg/min of dopamine and dobutamine, and 10 points is assigned for each 0.1 mcg/kg/min of epinephrine, norepinephrine, and phenylephrine. Inotrope score is a useful predictor of morbidity and mortality in children who undergo heart surgery', 'timeFrame': 'within first 24 hours after cardiac surgery'}, {'measure': 'Mortality at 30 days', 'description': 'Proportion of patients who dies within 30 days of their surgical repair', 'timeFrame': '30 days'}, {'measure': 'Cardiac function', 'description': 'Cardiac rhythm on return if it will be sinus rhythm or return with ventricular fibrillation', 'timeFrame': 'within first 24 hours of cardiac surgery'}]",4,6 Months,12 Years,ALL,False,Assiut University,OTHER,0,91.0,ACTUAL,2025-09-01T16:18:17.183159,v2_robust,True,True,True,False,False,
NCT05122338,Effect of Transversus Abdominis Plane Block With Compound Lidocaine and Esketamine on Pain After Surgery,Effect of Ultrasound-guided Transversus Abdominis Plane Block With Compound Lidocaine and Esketamine on Postoperative Pain in Patients Undergoing Colorectal Cancer Surgery: a Randomized Double-blind Controlled Trial,Normal saline,"['Ropivacaine', 'Ropivacaine Hydrochloride Injection', 'Esketamine', 'Esketamine injection', 'Normal saline', 'Compound lidocaine', 'Compound Lidocaine Hydrochloride Injection', '0. 9% Sodium Chloride Injection']",8,INTERVENTIONAL,['NA'],,,Postoperative Pain,['Postoperative Pain'],"['Compound lidocaine', 'Ropivacaine', 'Transversus abdominis plane block', 'opioid consumption']",UNKNOWN,,2021-12-01,2022-06-15,"[{'measure': 'Postoperative opioid consumption', 'description': 'Each patient was administered analgesics using a PCA (Patient-controlled analgesia) pump containing opioid in normal saline after leaving PACU (Postanesthesia care unit). Opioid cumulative consumption is recorded for 48 hours postoperatively.', 'timeFrame': '48 hours after surgery'}]","[{'measure': 'Pain Score (NRS)', 'description': 'The pain score at rest or after movement was evaluated by pain 11-point numerical rating scale (NRS): 0 = no pain, 10 = greatest imaginable pain.', 'timeFrame': '48 hours after surgery'}, {'measure': 'Time of First Postoperative Analgesic Requirement', 'description': 'First postoperative pain (NRS≥5) is initially controlled by titration of opioid.', 'timeFrame': '1 hour after surgery'}, {'measure': 'Total Dose of First Postoperative Analgesic Requirement', 'description': 'First postoperative pain (NRS≥5) is initially controlled by titration of opioid.', 'timeFrame': '1 hour after surgery'}, {'measure': 'The incidence of Side Effects', 'description': 'The number of patients with side effects including nausea, vomiting, dizziness, headache, shivering, and pruritus is recorded for 48 hours postoperatively.', 'timeFrame': '48 hours after surgery'}, {'measure': 'Apfel score', 'description': 'The Apfel score was recorded for evaluating risk for developing postoperative nausea and vomiting (PONV).', 'timeFrame': 'The 1 day before the surgery'}, {'measure': 'Mean time until passage of flatus', 'description': 'Gastrointestinal motility was evaluated by recording mean time until passage of flatus', 'timeFrame': '96 hours after surgery'}, {'measure': 'Diffusion area of local anesthetics after transversus abdominis plane block', 'description': 'Diffusion area of local anesthetics after transversus abdominis plane block was calculated under ultrasound assistance.', 'timeFrame': '30 minutes after transversus abdominis plane block'}, {'measure': 'Normalized Area of Hyperalgesia Around the Incision', 'description': ""The skin around the incision is stimulated in steps of 5 mm at intervals of 1 s starting outside of the hyperalgesic area in the direction of the incision. The distance from the incision to the first point where a 'painful', 'sore' or 'sharper'feeling occurred is measured and noted. This measurement is repeated at predefined radial lines around the incision. To eliminate the variable length of incision, this length is subtracted from the longer diameter leaving four radial distances from the end and from the middle of the incision. The normalized area of hyperalgesia is calculated by summing up the areas of the remaining four triangles measured by and Von Frey filament."", 'timeFrame': '48 hours after surgery'}, {'measure': 'The level of cytokines in blood By ELISA kits', 'description': 'Blood is collected to measure the level of cytokines (such as IL-18, IL-17, IL-23 ) using ELISA kits.', 'timeFrame': '48 hours after surgery'}, {'measure': 'The level of chemokines in blood By ELISA kits', 'description': 'Blood is collected to measure the level of chemokines (such as CXCL1, CCL7, CCL2) using ELISA kits.', 'timeFrame': '48 hours after surgery'}]",11,20 Years,65 Years,ALL,False,Tianjin Medical University General Hospital,OTHER,0,160.0,ESTIMATED,2025-09-01T16:18:17.183180,v2_robust,True,True,False,False,False,
NCT03228238,ANti-Oxidant in Variant Angina (ANOVA) Trial,Effects of Long-term Vitamin C+E and Statin Therapy on Vasospasm Improvement and Regression of Atheroma in Patients With Variant Angina,Vitamin C and Vitamin E,"['Statin', 'Ascorbic acid and Tocopherol', 'Standard medication for variant angina', 'Atorvastatin', 'Calcium Channel blocker or NG', 'Vitamin C and Vitamin E']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Variant Angina,['Variant Angina'],[],UNKNOWN,,2014-09-01,2021-02-28,"[{'measure': 'Vasospasm at 6months', 'description': 'Severity of vasospasm in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to control subgroup.', 'timeFrame': 'at 6 months'}, {'measure': 'Vasospasm at 2 years', 'description': 'Severity of vasospasm in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to control subgroup.', 'timeFrame': 'at 2 years'}, {'measure': 'Vasospasm at 4 years', 'description': 'Severity of vasospasm in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to control subgroup.', 'timeFrame': 'at 4 years'}, {'measure': 'Vasospasm at 6 years', 'description': 'Severity of vasospasm in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to control subgroup.', 'timeFrame': 'at 6 years'}]","[{'measure': 'Changes from baseline in Vasospasm', 'description': 'Changes of Vasospasm in Control subgroup, Vitamin subgroup, Statin subgroup, and Dual subgroup compared to baseline vasospasm assessed by provocation test.', 'timeFrame': 'at 6 months, and at 2, 4, and 6 years follow up period'}, {'measure': 'Composed improvement of Vascular endothelial function(Brachial arterial expansion capability)', 'description': 'in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to control subgroup', 'timeFrame': 'at 6 months, and at 2, 4, and 6 years follow up period'}, {'measure': 'Improvement of Vascular endothelial function(Brachial arterial expansion capability)', 'description': 'in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to baseline endothelial function test results', 'timeFrame': 'at 6 months, and at 2, 4, and 6 years follow up period'}, {'measure': 'Comparative analysis of improvement of Vascular endothelial function(Brachial arterial expansion capability)', 'description': 'in Vitamin subgroup, Statin subgroup, and Dual subgroup', 'timeFrame': 'at 6 months, and at 2, 4, and 6 years follow up period'}, {'measure': 'Composed improvement of Arterial stiffness(Pulse wave velocity(PWV))', 'description': 'in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to control subgroup', 'timeFrame': 'at 6 months, and at 2, 4, and 6 years follow up period'}, {'measure': 'Improvement of Arterial stiffness(Pulse wave velocity(PWV))', 'description': 'in Vitamin subgroup, Statin subgroup, and Dual subgroup compared to baseline endothelial function test results', 'timeFrame': 'at 6 months, and at 2, 4, and 6 years follow up period'}, {'measure': 'Comparative analysis of improvement of Arterial stiffness(Pulse wave velocity(PWV))', 'description': 'in Vitamin subgroup, Statin subgroup, and Dual subgroup', 'timeFrame': 'at 6 months, and at 2, 4, and 6 years follow up period'}]",11,30 Years,,ALL,False,Seoul National University Hospital,OTHER,0,300.0,ESTIMATED,2025-09-01T16:18:17.183266,v2_robust,True,True,False,False,False,
NCT04604938,The Effects of Losartan on Reward Reinforcement Learning,The Role of the Renin-angiotensin System in Reward Reinforcement Learning,Losartan,"['Placebo oral tablet', 'Cozaar Oral Tablet', 'Losartan']",3,INTERVENTIONAL,['NA'],,,Healthy,['Healthy'],"['Losartan', 'Reward reinforcement learning']",UNKNOWN,,2020-10-10,2022-03-31,"[{'measure': 'BOLD-level activity as assessed by fMRI during the learning phase', 'description': 'During the paradigm subjects will learn the reward properties of stimuli via the presentation of trial-wise feedback. The neural activation during the prediction of positive and negative outcome feedback will be assessed by functional magnetic resonance imaging (fMRI), particularly in prefrontal and subcortical regions. The effects of treatment will be determined by comparing the losartan- and placebo-treated groups.', 'timeFrame': '90 minutes to 110 minutes after treatment'}, {'measure': 'BOLD-level activity as assessed by fMRI during the learning transfer phase', 'description': 'Following the initial learning phase subjects learning transfer will be examined by asking subjects to choose between stimuli with high versus low reward probabilities. The neural activation during correct responses will be assessed by functional magnetic resonance imaging (fMRI), particularly in prefrontal and subcortical regions. The effects of treatment will be determined by comparing the losartan- and placebo-treated groups.', 'timeFrame': '111 minutes to 120 minutes after treatment'}]","[{'measure': 'Choice accuracy for the stimulus with the high reward probability during the learning phase', 'description': 'During the learning phase accuracies (in percent) for choosing the stimulus with the highest reward probability will be computed. Effects of treatment on choice accuracy in the probabilistic learning task will be examined by comparing accuracies (percent) between the losartan- and placebo-treated group.', 'timeFrame': '90 minutes to 110 minutes after treatment'}, {'measure': 'Learning rate for positive and negative outcomes', 'description': 'The learning rate will be determined by performing computational modelling. The learning rate index for positive and negative outcomes during the learning phase will be compared between the losartan- and placebo-treated group.', 'timeFrame': '90 minutes to 110 minutes after treatment'}, {'measure': 'Choice accuracy during the learning transfer phase', 'description': 'Following the initial learning phase subjects learning transfer will be examined by asking subjects to choose between stimuli with high versus low reward probabilities. For the transfer phase the choice accuracy for selecting stimuli with the highest reward probability and avoiding stimuli with the lowest reward probability will be computed. The effects of treatment will be determined by comparing the accuracy between the losartan- and placebo-treated groups.', 'timeFrame': '111 minutes to 120 minutes after treatment'}]",5,18 Years,30 Years,MALE,True,University of Electronic Science and Technology of China,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:17.183292,v2_robust,True,True,False,False,False,
NCT00370838,Comparison of Keppra and Clonidine in the Treatment of Tics,Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome,Levetiracetam,"['Levetiracetam', 'Clonidine', 'Levetiracetam (Keppra)', 'Catapres']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Tic Disorders,"['Tic Disorders', 'Tourette Syndrome']","['Tics', 'Tourette syndrome', 'levetiracetam', 'clonidine']",COMPLETED,,2007-02,2009-06,"[{'measure': 'Yale Global Tic Severity Scale (YGTSS):', 'description': 'The YGTSS is a semi-structured clinical interview designed to measure current tic severity \\[Leckman et al., 1989\\], and consists of separate rating of motor (0-25) and vocal (0-25) tics. Ratings are made along 5 discriminant dimensions, scaled 0-5 for each including number, frequency, intensity, complexity, and interference. Total of these scores (0-50) is a Total Tic Score (TTS). The YGTSS contains an impairment ranking, 0-50 points, based on the impact of the tic disorder on areas such as self esteem, family life, social acceptance, and school. 0=no tics present; 100=most severe tics.', 'timeFrame': 'Baseline (Day 8 or Day 64), Final (6 weeks later: Day 50 or Day 106)'}, {'measure': 'Total Tic Score', 'description': 'The TTS is a portion of the YGTSS \\[Leckman et al., 1989\\], and consists of separate rating of motor (0-25) and vocal (0-25) tics. Ratings are made along 5 discriminant dimensions, scaled 0-5 for each including number, frequency, intensity, complexity, and interference. Total of these scores (0-50) is a Total Tic Score (TTS). A score of 0 represent no tics present, a score of 50 represents the most severe tics in each category listed.', 'timeFrame': 'Baseline (Day 8 or Day 64), Final (6 weeks later: Day 50 or Day 106)'}]","[{'measure': 'Clinical Global Impression-Improvement (CGI-I):', 'description': 'Clinical Global Impression-Improvement (CGI-I): The CGI-I is used to compare current severity to baseline. A score of 1 corresponds to ""very much improved; 2 equals ""much improved;"" 3 denotes minimal change; and 4 represents ""no change."" Scores above 4 are used to indicate deterioration, i.e., 5 equals ""minimally worse;"" 6 is ""much worse;"" and 7 is ""very much worse.""', 'timeFrame': 'Baseline (Day 8 or Day 64), Final (6 weeks later: Day 50 or Day 106)'}, {'measure': 'Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS):', 'description': 'The severity of obsessive-compulsive disorder (OCD) is evaluated using the CY-BOCS \\[Scahill et al 1997\\]. Obsessions and compulsions are rated on 5 separate scales yielding three summary scores: Obsessions (0-20), Compulsions (0-20) and Total score (0-40). The CY-BOCS is the most widely used instrument to assess the severity of OCD symptoms in research studies. It includes checklist of specific obsessions and compulsions followed by examiner ratings of time spent, interference, distress, resistance and control over the obsessions and compulsions.0=no obsessions or compulsions; 40=most severe OC', 'timeFrame': 'Baseline (Day 8 or Day 64), Final (6 weeks later: Day 50 or Day 106)'}, {'measure': 'DuPaul Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale:', 'description': 'The presence of Attention Deficit Hyperactivity Disorder (ADHD) symptoms are assessed using the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) version of the DuPaul ADHD rating scale, which incorporates the symptom items for ADHD from the DSM into a rating scale format that quantifies symptom severity. Each item is rated as not at all, just a little, pretty much, and very much (0, 1, 2, and 3). There are 18 items in total are summed, with a minimum score of 0 (meaning no inattention or hyperactivity) with a maximum score of 54 (severe inattention and hyperactivity).', 'timeFrame': 'Baseline (Day 8 or Day 64), Final (6 weeks later: Day 50 or Day 106)'}, {'measure': 'Multidimensional Anxiety Scale for Children (MASC):', 'description': 'The child\'s anxiety will be followed using the multidimensional Anxiety Scale for Children (MASC) (Stallings and March, 1995) and is now considered the preferred instrument for rating childhood anxiety. It is a 39-item questionnaire, ranking each item as ""Never"", ""Rarely"", ""Sometimes"", or ""Often"" (0, 1, 2, 3). The sum of all responses yeilds a score (maximum MASC score is 117). A score of 0 represents no anxiety, and a score of 117 represents severe anxiety.', 'timeFrame': 'Baseline (Day 8 or Day 64), Final (6 weeks later: Day 50 or Day 106)'}, {'measure': 'Modified Pittsburgh Side Effect Scale', 'description': 'Side effects will be assessed by an expanded (modified) Pittsburgh Side Effect Scale modified to include side effects of levetiracetam and clonidine. Significant adverse events will be reported to the UCB, JCCI, and FDA within 24 hours. Positive responses are tallied as ""number of side effects"" for the responding period.', 'timeFrame': 'Baseline (Day 8 or Day 64), Final (6 weeks later: Day 50 or Day 106)'}]",7,7 Years,19 Years,ALL,False,Harvey S. Singer,OTHER,1,12.0,ACTUAL,2025-09-01T16:18:17.183319,v2_robust,True,True,True,False,True,
NCT00858338,Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer,Phase-II Study of Adjuvant Intraperitoneal FUDR Treatment Added to Chemoradiation (5-fluorouracil/Leucovorin Plus Total Dose 4500 cGy of External Beam Radiotherapy) in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma (R0 Resection and at Least D1 Lymph-node Dissection),Floxuridine (IP),"['Floxuridine (IP)', 'FUDR']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastric Cancer,"['Gastric Cancer', 'Stomach Cancer']","['stomach cancer', 'gastroesophageal junction cancer', 'GEJ cancer', 'intraperitoneal', 'adjuvant chemoradiation therapy', 'resection of advanced stomach cancer', 'locally advanced stomach cancer']",COMPLETED,,2002-12,2012-02,"[{'measure': 'toxicity of IP FUDR after surgery prior to chemoradiation', 'timeFrame': '6 months'}]","[{'measure': 'overall survival', 'description': 'every 4 months the first year after treatment; every 6 months 2nd and 3rd year; yearly thereafter up to a total 10 years', 'timeFrame': 'up to 10 years'}, {'measure': 'Time to relapse, disease specific survival', 'description': 'every 4 months the first year after treatment; every 6 months 2nd and 3rd year; yearly thereafter up to a total 10 years', 'timeFrame': 'up to 10 years'}]",3,18 Years,,ALL,False,NYU Langone Health,OTHER,1,28.0,ACTUAL,2025-09-01T16:18:17.183368,v2_robust,True,True,True,False,False,
NCT06300138,Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis,A Randomized Controlled Clinical Trial of Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis,Itraconazole,['Itraconazole'],1,INTERVENTIONAL,['NA'],,,Sporotrichosis,['Sporotrichosis'],"['Sporotrichosis', 'local hyperthermia']",RECRUITING,,2024-03-15,2026-12,"[{'measure': 'the overall clinical clearance rate of skin lesions', 'description': 'Three months after treatment, the overall clinical clearance rate of skin lesions in the three groups.', 'timeFrame': 'Three months'}]","[{'measure': 'Overall clinical clearance rate and recurrence rate', 'description': 'Overall clinical clearance rate and recurrence rate of skin lesions in three groups', 'timeFrame': 'Six months'}, {'measure': 'adverse reactions and incidence', 'description': 'adverse reactions and incidence in three groups', 'timeFrame': 'Six months'}, {'measure': 'the clearance rate of target skin lesions', 'description': 'Three months after treatment, the clearance rate of target skin lesions in hyperthermia treatment group and hyperthermia combined with antifungal therapy group.', 'timeFrame': 'Three months'}, {'measure': 'overall lesion clearance rate', 'description': 'In patients with multiple lesions, the overall lesion clearance rate was 3 months after treatment.', 'timeFrame': 'Three months'}]",5,,,ALL,False,First Hospital of China Medical University,OTHER,0,150.0,ESTIMATED,2025-09-01T16:18:17.183380,v2_robust,True,True,False,False,True,
NCT00738738,6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD),"A Phase 3, 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder",PD-0332334,"['PD-0332334', 'imagabalin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Generalized Anxiety Disorder,['Generalized Anxiety Disorder'],['Generalized Anxiety Disorder Elderly'],WITHDRAWN,Please see Detailed Description for termination reason.,2009-01,2009-02,"[{'measure': 'Discontinuations due to adverse events or adverse events occurring during and after the discontinuation of trial medication', 'timeFrame': 'Weekly'}, {'measure': 'The nature, incidence, duration, and severity of adverse events.', 'timeFrame': 'Weekly'}, {'measure': 'Suicide related adverse events will be further assessed using the Columbia Suicide Severity Rating Scale as needed', 'timeFrame': 'As needed'}, {'measure': 'The primary outcome is safety which will be assessed throughout the 6-months by physical exams, monitoring of vital signs, body weight changes, and clinical safety laboratory', 'timeFrame': 'Screening, Baseline, Wk 4, Wk 14, Wk 26/EOT, & at FU; Vital signs at every vist'}, {'measure': 'Electrocardiograms will be performed to assess any changes in cardiac functioning related to the compound', 'timeFrame': 'Screening, Baseline, Wk 4, Wk 15 & Wk 26/EOT'}]","[{'measure': 'Symptom severity of generalized Anxiety Disorder (GAD) will be measured by the Hamilton Rating Scale for Anxiety (HAM-A).', 'timeFrame': 'Screening, Baseline, Wk 1-2, Wk 4, Wk 14, Wk 26/EOT & Wk 27 (FU)'}, {'measure': 'Overall Health Care utilization will be assessed with the Health Care Utilization (HCU) questionnaire.', 'timeFrame': 'Twice at Wk 13 and Wk 26/EOT'}, {'measure': 'Also, the Daily Diary (including the Daily assessment of Symptoms DAS-A and Global Anxiety - Visual Analog Scale (GA-VAS) and the Clinical Global Impression of Severity (CGI-S) will be used to assess symptoms of GAD.', 'timeFrame': 'Screening, Baseline, Wk 1-2, Wk 4, Wk 14, Wk 26/EOT'}, {'measure': 'Plasma concentrations will be collected to evaluate the population pharmacokinetics and the dose/exposure relationships for safety and efficacy .', 'timeFrame': '1 time'}]",9,65 Years,,ALL,False,Pfizer,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:17.183459,v2_robust,True,True,False,True,True,Please see Detailed Description for termination reason.
NCT00268138,Elmex Gel Efficacy in Preventing White Spot Lesions,Phase 4 Study Prevention of Incipient Carious Lesions (White Spot Lesions) in Patients With Fixed Orthodontic Appliances Following the Application of Elmex Gel,elmex gel,"['fluoride', 'elmex gel']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Dental Caries,['Dental Caries'],"['amine fluoride', 'white spot lesions', 'qlf']",UNKNOWN,,2006-04,2010-12,"[{'measure': 'time and frequency of visually detected WSL (white spot lesions)', 'timeFrame': '3 month'}]","[{'measure': 'mineral loss according to QLF readings', 'timeFrame': '3 month'}, {'measure': 'Frequency and chronoloy of WSL', 'timeFrame': '3 month'}]",3,10 Years,60 Years,ALL,True,Hadassah Medical Organization,OTHER,1,314.0,ESTIMATED,2025-09-01T16:18:17.183491,v2_robust,True,True,False,False,False,
NCT02779738,A Study of Merestinib (LY2801653) in Healthy Participants,The Effect of Food on the Bioavailability of Merestinib in Healthy Subjects,Merestinib,"['Merestinib', 'LY2801653']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2016-05,2016-08,"[{'measure': 'Pharmacokinetics (PK): Maximum Concentration (Cmax) for Merestinib for High-Fat Meal and Fasted State', 'timeFrame': 'Predose through 120 hours after administration of study drug'}, {'measure': 'Pharmacokinetics: Maximum Concentration (Cmax) for Merestinib for Standard Meal and Fasted State', 'timeFrame': 'Predose through 120 hours after administration of study drug'}, {'measure': 'Pharmacokinetics: Area Under The Concentration Curve AUC(0-∞) for Merestinib for High-Fat Meal and Fasted State', 'timeFrame': 'Predose through 120 hours after administration of study drug'}, {'measure': 'Pharmacokinetics: Area Under The Concentration Curve AUC(0-∞) for Merestinib for Standard Meal and Fasted State', 'timeFrame': 'Predose through 120 hours after administration of study drug'}]","[{'measure': 'Pharmacokinetics: Maximum Concentration (Cmax) for Metabolites (M1 and M2) for High-Fat Meal and Fasted State', 'timeFrame': 'Predose through 120 hours after administration of study drug'}, {'measure': 'Pharmacokinetics: Maximum Concentration (Cmax) for Metabolites (M1 and M2) for Standard Meal and Fasted State', 'timeFrame': 'Predose through 120 hours after administration of study drug'}, {'measure': 'Pharmacokinetics: Area Under the Concentration Curve AUC(0-∞) for Metabolites (M1 and M2) for High-Fat Meal and Fasted State', 'timeFrame': 'Predose through 120 hours after administration of study drug'}, {'measure': 'Pharmacokinetics: Area Under the Concentration Curve AUC(0-∞) for Metabolites (M1 and M2) for Standard Meal and Fasted State', 'timeFrame': 'Predose through 120 hours after administration of study drug'}]",8,18 Years,65 Years,ALL,True,Eli Lilly and Company,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:17.183501,v2_robust,True,True,True,False,False,
NCT02179138,Paper Applicator Acceptability Study,"EVALUATION OF A USER-FILLED, PAPER APPLICATOR FOR DELIVERY OF TENOFOVIR 1% GEL AMONG WOMEN IN RURAL KWAZULU-NATAL, SOUTH AFRICA",TFV 1% gel,['TFV 1% gel'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,HIV Prevention,['HIV Prevention'],[],WITHDRAWN,Study no longer relevant based on change in regulatory pathway for TFV 1% gel,,,"[{'measure': 'Overall acceptability', 'description': 'Overall acceptability of user-filled, paper applicator compared to prefilled, plastic applicator', 'timeFrame': 'over 3 months of use'}, {'measure': 'context of use', 'description': 'Description of context of use of user-filled, paper applicator', 'timeFrame': 'over three months'}, {'measure': 'challenges encountered', 'description': 'Challenges encountered during use of user-filled, paper applicator and recommendations to address challenges', 'timeFrame': 'over three months'}, {'measure': 'Applicator Preference', 'description': 'Applicator preferences between the user-filled, paper applicator and prefilled, plastic applicator', 'timeFrame': 'Over three months'}]",[],4,18 Years,,FEMALE,True,CONRAD,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:17.183531,v2_robust,True,True,False,True,False,Study no longer relevant based on change in regulatory pathway for TFV 1% gel
NCT05210738,Single-incision Sling vs Urethral Bulking During Prolapse Surgery for Occult Stress Incontinence,A Cohort Observational Study Comparing the Outcomes of Single-incision Sling vs Urethral Bulking During Prolapse Surgery for Occult Stress Incontinence,Bulkamid bulking agent,['Bulkamid bulking agent'],1,OBSERVATIONAL,[],,,"Stress Incontinence, Female","['Stress Incontinence, Female']",[],COMPLETED,,2019-01-01,2021-06-01,"[{'measure': 'Urinary Distress Inventory, Short Form (UDI-6)', 'timeFrame': 'one year after surgery'}, {'measure': 'Incontinence Impact Questionnaire, Short Form (IIQ-7)', 'timeFrame': 'one year after surgery'}, {'measure': 'Voiding diary', 'timeFrame': 'one year after surgery'}]","[{'measure': 'The rate of complications in both groups which includes adverse events, rate of urine retention with prolonged catheterization, and UTI.', 'timeFrame': 'one year after surgery'}]",4,18 Years,85 Years,FEMALE,True,The Christ Hospital,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:17.183566,v2_robust,False,True,True,False,True,
NCT06469138,A Study to Investigate 14C-bemcentinib in Healthy Male Subjects,"A Phase 1, Open-label, Nonrandomized Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects",Bemcentinib,"['Bemcentinib', 'BGB324']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Non-Small Cell Lung Cancer,"['Non-Small Cell Lung Cancer', 'Metastatic Melanoma', 'Acute Myeloid Leukemia', 'Myelodysplastic Syndromes', 'Metastatic Pancreatic Cancer', 'Glioblastoma', 'Malignant Mesothelioma', 'COVID-19']",[],COMPLETED,,2022-08-02,2022-09-23,"[{'measure': 'Total Radioactivity - Plasma Maximum Observed Concentration (Cmax)', 'description': 'This endpoint will report the relevant data for the parameters assessed in order to measure total radioactivity in plasma (based upon plasma samples collected at set timepoints during the study). Analysis was derived from obtaining plasma samples from participants at set timepoints described and deriving PK parameters through the use of noncompartmental procedures in validated software (WinNonlin Version 8.3.5).', 'timeFrame': 'Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose'}, {'measure': 'Total Radioactivity - Whole Blood Maximum Observed Concentration (Cmax)', 'description': 'This endpoint will report the relevant data for the parameters assessed in order to measure total radioactivity in whole blood (based upon whole blood samples collected at set timepoints during the study). Analysis was derived from obtaining whole blood samples from participants at set timepoints described and deriving PK parameters through the use of noncompartmental procedures in validated software (WinNonlin Version 8.3.5).', 'timeFrame': 'Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose'}, {'measure': 'Plasma Pharmacokinetic Parameters Bemcentinib - Maximum Observed Concentration (Cmax)', 'description': 'Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for 14C-bemcentinib. This endpoint will report the summary of derived pharmacokinetic parameters for the maximum observed concentration (Cmax) of 14C-bemcentinib in plasma. Analysis was derived from obtaining plasma samples from participants at set timepoints described and deriving PK parameters through the use of noncompartmental procedures in validated software (WinNonlin Version 8.3.5).', 'timeFrame': 'Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose'}, {'measure': 'Plasma Pharmacokinetic Parameters Bemcentinib - Time to Maximum Observed Concentration (Tmax)', 'description': 'Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for 14C-bemcentinib. This endpoint will report the summary of derived pharmacokinetic parameters for the time to maximum observed concentration (Tmax) of 14C-bemcentinib in plasma. Analysis was derived from obtaining plasma samples from participants at set timepoints described and deriving PK parameters through the use of noncompartmental procedures in validated software (WinNonlin Version 8.3.5).', 'timeFrame': 'Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose'}, {'measure': 'Plasma Pharmacokinetic Parameters Bemcentinib - Terminal Elimination Half-life (t1/2)', 'description': 'Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for 14C-bemcentinib. This endpoint will report the summary of derived pharmacokinetic parameters for the terminal elimination half-life (t1/2) of 14C-bemcentinib in plasma. Analysis was derived from obtaining plasma samples from participants at set timepoints described and deriving PK parameters through the use of noncompartmental procedures in validated software (WinNonlin Version 8.3.5).', 'timeFrame': 'Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose'}, {'measure': 'Plasma Pharmacokinetic Parameters Bemcentinib - Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞)', 'description': 'Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for 14C-bemcentinib. This endpoint will report the summary of derived pharmacokinetic parameters for the area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-∞) of 14C-bemcentinib in plasma. Analysis was derived from obtaining plasma samples from participants at set timepoints described and deriving PK parameters through the use of noncompartmental procedures in validated software (WinNonlin Version 8.3.5).', 'timeFrame': 'Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose'}, {'measure': 'Plasma Pharmacokinetic Parameters Bemcentinib - Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast)', 'description': 'Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for 14C-bemcentinib. This endpoint will report the summary of derived pharmacokinetic parameters for the area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-tlast) of 14C-bemcentinib in plasma. Analysis was derived from obtaining plasma samples from participants at set timepoints described and deriving PK parameters through the use of noncompartmental procedures in validated software (WinNonlin Version 8.3.5).', 'timeFrame': 'Samples collected over a 2-week period: Days 1-8: Predose, 15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose, Days 8-15: 192, 216, 240, 264, 288, 312, and 336 hours post-dose'}]","[{'measure': 'Number of Participants With Adverse Events', 'description': 'This secondary endpoint relates to the number of participants who report an adverse event (AE) during the study.', 'timeFrame': 'Collection of AEs occurs through ad hoc reporting from the participants from the point of signature of informed consent through to study completion (up to 5 weeks).'}, {'measure': 'Number of Participants Who Report a Change From Normal Range Values for Laboratory Safety Parameters (Serum Biochemistry, Serum Haematology or Urinalysis) From First Dose on Day 1 to Study Completion.', 'description': 'This secondary endpoint will report the number of participants who record a value which is deemed as outside of the normal range (clinically significant values only) for any of the serum biochemistry, serum haematology or urinalysis parameters as defined in the study protocol following first dose administration on Day 1 up to completion of the study.', 'timeFrame': 'From Day 1 to study completion (up to 5 weeks)'}, {'measure': 'Number of Participants Who Report a Change From Normal Range Values for Any of the Associated 12-Lead ECG Parameters From First Dose on Day 1 to Study Completion.', 'description': 'This secondary endpoint will report the number of participants who record a value which is deemed as outside of the normal range (clinically significant values only) for any of the 12-Lead ECG parameters as defined in the study protocol following first dose administration on Day 1 up to completion of the study.', 'timeFrame': 'From Day 1 to study completion (up to 5 weeks)'}, {'measure': 'Number of Participants Who Report a Change From Normal Range Values for Any of the Vital Signs Parameters From First Dose on Day 1 to Study Completion.', 'description': 'This secondary endpoint will report the number of participants who record a value which is deemed as outside of the normal range (clinically significant values only) for any of the vital signs parameters as defined in the study protocol following first dose administration on Day 1 up to completion of the study.', 'timeFrame': 'From Day 1 to study completion (up to 5 weeks)'}, {'measure': 'Number of Participants Who Report a Change From Normal With Respect to Physical Examination Parameters From First Dose on Day 1 to Study Completion.', 'description': 'This secondary endpoint will report the number of participants who record a change which is deemed as outside of normal range (clinically significant changes only) for any of the physical examination parameters as defined in the study protocol following first dose administration on Day 1 up to completion of the study.', 'timeFrame': 'From Day 1 to study completion (up to 5 weeks)'}]",12,35 Years,55 Years,MALE,True,BerGenBio ASA,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:17.183577,v2_robust,True,True,True,False,True,
NCT01564758,Post Marketing Surveillance Study on Linezolid,"Post Marketing Surveillance on the Efficacy, Safety and Tolerability of Linezolid (Zyvox) in the Treatment of Gram Positive Infections",Linezolid,['Linezolid'],1,OBSERVATIONAL,[],,,Gram-Positive Bacterial Infections,['Gram-Positive Bacterial Infections'],"['non-interventional', 'non-comparative', 'open-label study', 'safety', 'Linezolid', 'gram positive infections', 'Filipino']",COMPLETED,,2004-02,2005-03,"[{'measure': 'Number of Participants With Adverse Events (AEs)', 'description': 'Any untoward medical occurrence in a participant who received study treatment was considered an AE without regard to possibility of causal relationship.', 'timeFrame': 'Baseline up to End of Treatment (EOT) (Day 10 up to 28)'}]","[{'measure': 'Number of Participants With Clinical Response', 'description': 'Clinical response assessed by Investigator at EOT visit as Cure: complete resolution of signs or symptoms of infection and no need to start another antibiotic. Improvement: incomplete resolution of signs or symptoms of infection but no need to start another antibiotic. Failure: death, or need to start another antibiotic. For participants previously assessed as failures, the outcome was failure at subsequent time points.', 'timeFrame': 'EOT (Day 10 up to 28)'}]",2,18 Years,,ALL,False,Pfizer,INDUSTRY,0,99.0,ACTUAL,2025-09-01T16:18:17.183708,v2_robust,False,True,True,False,True,
NCT06361758,Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC,"Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC: A Single Arm, Multicenter, Phase II Trial. (SCALE)",Cadonilimab+Lenvatinib,['Cadonilimab+Lenvatinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],['cadonilimab (anti PD-1/CTLA-4 bispecific antibody)'],WITHDRAWN,"The PI has initiated a global multicenter Phase II clinical trial in the same direction, conducted by Akesobio.",2024-05-31,2027-05-31,"[{'measure': 'Objective Response Rate (ORR) per RECIST v1.1', 'description': 'Defined as the proportion of patients who achieved complete response (CR) and partial response (PR) according to RECIST v1.1.', 'timeFrame': 'Up to two years'}]","[{'measure': 'Objective Response Rate (ORR) per mRECIST', 'description': 'Defined as the proportion of patients who achieved complete response (CR) and partial response (PR) according to mRECIST.', 'timeFrame': 'Up to two years'}, {'measure': 'Disease control Rate (DCR)', 'description': 'Defined as the proportion of patients who achieved complete response (CR), partial response (PR), and stable disease (SD) according to RECIST v1.1 and mRECIST respectively.', 'timeFrame': 'Up to two years'}, {'measure': 'Duration of response (DoR)', 'description': 'Defined as the time from the first dose to disease progression or death in patients who achieve complete or partial response.', 'timeFrame': 'Up to two years'}, {'measure': 'Progression-Free-Survival (PFS)', 'description': 'Defined as the time between signing the informed consent form to the disease progression (according to RECIST v1.1 criteria) or death due to any cause.', 'timeFrame': 'Up to two years'}, {'measure': 'Overall survival Overall survival (OS)', 'description': 'Defined as the time between the first dose to death due to any causes.', 'timeFrame': 'Up to three years'}, {'measure': 'Incidence of Adverse Events', 'description': 'Adverse events (AEs) ; serious adverse events (SAEs); Treatment related Adverse events (TRAEs); Use NCI-CTCAE version 5.0 for classification and grading.', 'timeFrame': 'Up to two years'}]",7,18 Years,75 Years,ALL,False,Shanghai Zhongshan Hospital,OTHER,2,0.0,ACTUAL,2025-09-01T16:18:17.183716,v2_robust,True,True,False,True,True,"The PI has initiated a global multicenter Phase II clinical trial in the same direction, conducted by Akesobio."
NCT04229758,Restarting Anticoagulation After Traumatic Intracranial Hemorrhage,"Restarting Anticoagulation After Traumatic Intracranial Hemorrhage (Restart tICrH): a Prospective Randomized Open Label Blinded Endpoint (PROBE) Pragmatic Time-dose, Response Adaptive Clinical Trial",Anticoagulants,['Anticoagulants'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Hemorrhage,"['Hemorrhage', 'Intracranial Hemorrhages', 'Bleeding', 'Trauma']","['Anticoagulation', 'Anticoagulant', 'Anticoagulants', 'Restart', 'Delay', 'Hemorrhage', 'ICH', 'SAH', 'SDH', 'DOAC', 'NOAC', 'apixaban', 'rivaroxaban', 'edoxaban']",NOT_YET_RECRUITING,,2021-10,2027-02,"[{'measure': '60 Day Composite of Thrombotic and Bleeding Events', 'description': 'Composite of Thrombotic events, defined as DVT, PE, MI, Ischemic Strokes, and systemic emboli, cardiovascular death along with bleeding events defined as non-CNS major bleeding, worsening index tICrH, or new intracranial hemorrhage.', 'timeFrame': '60 days following index bleeding event'}]","[{'measure': '60 Day Disability Rating Scale (1-29 with 29 being worse)', 'description': 'DRS is a scale to measure disability after an injury', 'timeFrame': '60 days following index bleeding event'}, {'measure': '60 Day Modified Rankin Scale (1-6 with 6 being worse)', 'description': 'The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.', 'timeFrame': '60 days following index bleeding event'}, {'measure': 'Standard Gamble Patient Reported utilities for endpoints', 'description': 'Performed prior to randomization and immediately after each endpoint', 'timeFrame': 'pre-randomization and after endpoints'}]",4,18 Years,,ALL,False,University of Texas at Austin,OTHER,0,1100.0,ESTIMATED,2025-09-01T16:18:17.183736,v2_robust,True,True,False,False,False,
NCT03815058,A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.,"A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced Melanoma",Pembrolizumab,"['Pembrolizumab', 'Keytruda']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Melanoma,['Advanced Melanoma'],[],COMPLETED,,2019-01-08,2025-01-21,"[{'measure': 'Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECISTv.1.1) After Randomization', 'timeFrame': 'The time from randomization to disease progression/death (up to approximately 24 months)'}]","[{'measure': 'Objective Response Rate (ORR) According to RECISTv.1.1 After Randomization', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Overall Survival (OS) After Randomization', 'timeFrame': 'The time from randomization to death from any cause (up to approximately 24 months).'}, {'measure': 'Duration of Response (DOR) According to RECISTv.1.1 After Randomization', 'timeFrame': 'The time from randomization up to approximately 24 months.'}, {'measure': 'Mean Change in Global Health Status (GHS)/Health-related Quality of Life (HRQoL) Score After Randomization', 'description': 'The 2-item GHS/HRQoL questionnaire of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ C30) uses a 7-point scale from 1=very poor to 7= excellent. Score range for GHS/HRQoL is 2-14. A negative change from baseline indicates deterioration in GHS.', 'timeFrame': 'From randomization up to approximately 24 months.'}, {'measure': 'Objective Response Rate (ORR) According to RECISTv.1.1 After Cross Over', 'timeFrame': 'Up to 12 months from the time of cross-over'}, {'measure': 'Percentage of Participants With Adverse Events (AEs)', 'timeFrame': 'Baseline up to 90 days after the final dose of study drug (up to approximately 27 months)'}]",7,18 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,1,131.0,ACTUAL,2025-09-01T16:18:17.183771,v2_robust,True,True,True,False,True,
NCT01543958,Sevelamer for Reducing Endotoxemia and Immune Activation,Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study,Sevelamer carbonate,"['Sevelamer carbonate', 'Renvela']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV-1 Infection,['HIV-1 Infection'],[],COMPLETED,,2011-11,2012-11,"[{'measure': 'Change in Endotoxin', 'description': 'Change in LPS from baseline to week 8, where baseline value is the average of pre-entry and entry values.', 'timeFrame': 'baseline and Week 8'}, {'measure': 'Change in Soluble CD14 (sCD14)', 'description': 'Change in soluble CD14 (sCD14) from baseline to week 8, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}]","[{'measure': 'Change in Endotoxin', 'description': 'Change in endotoxin from baseline to week 4, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 4'}, {'measure': 'Change in Endotoxin', 'description': 'Change in endotoxin from week 8 to week 16', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in sCD14', 'description': 'Change in sCD14 from baseline to week 4, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 4'}, {'measure': 'Change in sCD14', 'description': 'Change in sCD14 from week 8 to week 16', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in CD4+ T-cell Activation', 'description': 'Change from baseline to week 8 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in CD4+ T-cell Activation', 'description': 'Change from baseline to week 4 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 4'}, {'measure': 'Change in CD4+ T-cell Activation', 'description': 'Change from week 8 to week 16 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in CD8+ T-cell Activation', 'description': 'Change from baseline to week 4 in CD8+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 4'}, {'measure': 'Change in CD8+ T-cell Activation', 'description': 'Change in CD8+ T-cell activation defined as the %CD38+/HLA-DR+ from baseline to week 8, where baseline is the average of pre-entry and entry', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Change in CD8+ T-cell Activation', 'description': 'Change in CD8+ T-cell activation defined as the %CD38+/HLA-DR+ from week 8 to week 16', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in Proportion of Cycling CD8+', 'description': 'Change from baseline to week 4 in cycling CD8+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 4'}, {'measure': 'Change in Proportion of Cycling CD8+', 'description': 'Change from baseline to week 8 in cycling CD8+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in Proportion of Cycling CD8+', 'description': 'Change from week 8 to week 16 in cycling CD8+ , defined as the %Ki67+', 'timeFrame': 'from week 8 to week 16'}, {'measure': 'Change in Proportion of Cycling CD4+', 'description': 'Change from baseline to week 4 in cycling CD4+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 4'}, {'measure': 'Change in Proportion of Cycling CD4+', 'description': 'Change from baseline to week 8 in cycling CD4+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in Proportion of Cycling CD4+', 'description': 'Change from week 8 to week 16 in cycling CD4+ , defined as the %Ki67+', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in Blood Phosphate Levels', 'description': 'Change in blood phosphate levels from baseline to week 4, where baseline value is the average of pre-entry and entry', 'timeFrame': 'from baseline to week 4'}, {'measure': 'Change in Blood Phosphate Levels', 'description': 'Change in blood phosphate levels from baseline to week 8', 'timeFrame': 'Baseline to Week 8'}, {'measure': 'Change in Blood Phosphate Levels', 'description': 'Change in blood phosphate levels from week 8 to week 16', 'timeFrame': 'from week 8 to week 16'}, {'measure': 'Change in log10 HIV RNA Levels', 'description': 'Change in log10 HIV RNA levels from baseline to week 4, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 4'}, {'measure': 'Change in log10 HIV RNA Levels', 'description': 'Change in log10 HIV RNA levels from baseline to week 8, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in log10 HIV RNA Levels', 'description': 'Change in log10 HIV RNA levels from week 8 to week 16', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in CD4+ T-cell Counts', 'description': 'Change in CD4+ T-cell counts from baseline to week 4, where baseline is the average of pre-entry and entry', 'timeFrame': 'baseline and week 4'}, {'measure': 'Change in CD4+ T-cell Counts', 'description': 'Change in CD4+ T-cell counts from baseline to week 8, where baseline is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in CD4+ T-cell Counts', 'description': 'Change in CD4+ T-cell counts from week 8 to week 16', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in IL-6', 'description': 'Changes in levels of systemic inflammation marker IL-6 from baseline to week 4, where baseline is the average of pre-entry and entry', 'timeFrame': 'baseline and week 4'}, {'measure': 'Change in IL-6', 'description': 'Changes in levels of systemic inflammation marker IL-6 from baseline to week 8, where baseline is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in IL-6', 'description': 'Changes in levels of systemic inflammation marker IL-6 from week 8 to week 16', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in C-reactive Protein (CRP)', 'description': 'Changes in levels of systemic inflammation marker CRP from baseline to week 4, where baseline is the average of pre-entry and entry', 'timeFrame': 'baseline and week 4'}, {'measure': 'Change in CRP', 'description': 'Changes in levels of systemic inflammation marker CRP from baseline to week 8, where baseline is the average of pre-entry and entry', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Change in CRP', 'description': 'Changes in levels of systemic inflammation marker CRP from week 8 to week 16, where baseline is the average of pre-entry and entry', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in D-dimer', 'description': 'Change in levels of coagulation biomarker d-dimer from baseline to week 4, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 4'}, {'measure': 'Change in D-dimer', 'description': 'Change in levels of coagulation biomarker d-dimer from baseline to week 8, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in D-dimer', 'description': 'Change in levels of coagulation biomarker d-dimer from week 8 to week 16', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in Tissue Factor', 'description': 'Change in levels of coagulation biomarker tissue factor from baseline to week 4, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 4'}, {'measure': 'Change in Tissue Factor', 'description': 'Change in levels of coagulation biomarker tissue factor from baseline to week 8, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in Tissue Factor', 'description': 'Change in levels of coagulation biomarker tissue factor from week 8 to week 16', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in Total Cholesterol', 'description': 'Change in total cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in Total Cholesterol', 'description': 'Change in total cholesterol from week 8 to week 16', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in LDL Cholesterol', 'description': 'Change in fasting LDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in LDL Cholesterol', 'description': 'Change in fasting LDL cholesterol from week 8 to week 16', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in HDL Cholesterol', 'description': 'Change in fasting HDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in HDL Cholesterol', 'description': 'Change in fasting HDL cholesterol from week 8 to week 16', 'timeFrame': 'from week 8 to week 16'}, {'measure': 'Change in Non-HDL Cholesterol', 'description': 'Change in non-HDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in Non-HDL Cholesterol', 'description': 'Change in non-HDL cholesterol from week 8 to week 16', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Change in Fasting Glucose', 'description': 'Change in fasting glucose from baseline to week 8, where baseline value is the average of pre-entry and entry', 'timeFrame': 'baseline and week 8'}, {'measure': 'Change in Fasting Glucose', 'description': 'Change in fasting glucose from week 8 to week 16', 'timeFrame': 'week 8 and week 16'}, {'measure': 'Primary Adverse Events', 'description': 'Number of subjects experiencing primary adverse events, defined as all reported Grade ≥ 2 signs and symptoms, Grade ≥ 2 laboratory abnormalities and other serious adverse events (SAEs)', 'timeFrame': 'baseline and week 16'}]",50,18 Years,,ALL,False,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,NETWORK,1,40.0,ACTUAL,2025-09-01T16:18:17.183807,v2_robust,True,True,True,False,True,
NCT02778958,Comparisons of iv Ibuprofen and iv Paracetamol During Bariatric Surgery,Comparisons of iv Ibuprofen and iv Paracetamol for Postoperative Pain Levels and Opioid Consumption During Bariatric Surgery,paracetamol,"['ibuprofen', 'paracetamol', 'Acetaminophen', 'İntrafen']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Bariatric Surgery Candidate,"['Bariatric Surgery Candidate', 'Obesity, Morbid']","['bariatric surgery', 'morbid obesity', 'nonopioid analgesics']",COMPLETED,,2016-01,2017-03,"[{'measure': 'Opioid (morphine) consumption', 'description': 'iv morphine patient controlled analgesia for multimodal analgesia', 'timeFrame': 'First 24 hours during postoperative period'}]","[{'measure': 'Postoperative pain level', 'description': 'Visual analog scale for evaluation of postoperative pain levels', 'timeFrame': 'First 24 hours during postoperative period'}]",2,18 Years,65 Years,ALL,False,Inonu University,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:17.183900,v2_robust,True,True,True,False,False,
NCT04955158,Dexmedetpmidine Versus Ketamine for Postoperative Sore Throat in Sinus Surgery,Impact of Dexmedetomidine Versus Ketamine Soaked Pharyngeal Packing on Postoperative Sore Throat in Functional Endoscopic Sinus Surgery: a Randomized Double Blind Trial,Dexmedetomidine,"['Ketamine', 'ketalar', 'Precedex', 'Dexmedetomidine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Sore Throat,['Sore Throat'],[],COMPLETED,,2021-08-19,2023-02-15,"[{'measure': 'Incidence of postoperative sore throat (POST)', 'description': 'On arrival in the post anesthesia care unit, the patient was immediately evaluated for the presence of sore throat (time 0 hour) using a standardized scale. The severity of POST was graded on a 4-point scale ranging from 0 to 3; 0 being no sore throat, 1 being mild discomfort (complains only with questioning), 2 being moderate sore throat (complains on their own), and 3 being severe sore throat (change in voice, hoarseness, and throat pain). Evaluations occurred at 0, 1, 2, 4, 6, 12 and 24 hours postoperatively.', 'timeFrame': '24 hour after surgery'}]","[{'measure': 'Postoperative nausea and vomiting (PONV) score', 'description': 'PONV score was assessed and documented using a Verbal Descriptive Scale, which correlates to visual analog nausea scores, with an objective measure of severity: 0 = no PONV: patient reports no nausea and has had no emesis episodes; 1 = mild PONV: patient reports nausea but declines antiemetic treatment; 2 = moderate PONV: patient reports nausea and accepts antiemetic treatment; and 3 = severe PONV: nausea with any emesis episode (retching or vomiting). The score was obtained at 0, 30, 60, 90, and 120 minutes after PACU arrival; 4 mg IV ondansetron for occurred nausea \\& vomiting.', 'timeFrame': '2 hours postoperative'}]",2,18 Years,65 Years,ALL,False,Assiut University,OTHER,0,143.0,ACTUAL,2025-09-01T16:18:17.183910,v2_robust,True,True,True,False,False,
NCT03646058,Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode,Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode,Buprenorphine,"['Temgesic', 'Buprenorphine', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Suicidal Ideation,"['Suicidal Ideation', 'Major Depressive Episode']","['Treatment', 'Suicidal ideas', 'Depression', 'Buprenorphine', 'Opioid agonist', 'Mental pain']",RECRUITING,,2021-10-10,2027-01,"[{'measure': 'Changes in Beck Scale for Suicidal Ideation (SSI) scores from Day 0 to 7', 'description': 'Clinician-based questionnaire measuring level of suicidal ideas over the last 7 days; 21 items scored 0 to 2; total score ranges from 0 to 38 (last 2 items not counted), higher scores mean more intense suicidal ideas.', 'timeFrame': '7 days'}]","[{'measure': 'Changes in Beck Scale for Suicidal Ideation (SSI) scores', 'description': 'Clinician-based questionnaire measuring level of suicidal ideas over the last 7 days; 21 items scored 0 to 2; total score ranges from 0 to 38 (last 2 items not counted); higher scores mean more intense suicidal ideas.', 'timeFrame': 'Day 8 to day 28'}, {'measure': 'Changes in Beck Depression Inventory II (BDI-II) scores from Day 0 to 28', 'description': 'Self questionnaire measuring depression level over the last 7 days; 13 items scored 0 to 3, with the total score ranging from 0 to 39; higher scores mean higher level of depression.', 'timeFrame': '28 days'}, {'measure': 'Changes in Montgomery-Asberg Depression Rating Scale (MADRS) from Day 0 to 28', 'description': 'Clinician-based questionnaire measuring the level of depression of the last 7 days; 10 items score 0 to 6, with the total scores ranging fron 0 to 60; Higher scores mean higher level of depression.', 'timeFrame': '28 days'}, {'measure': 'Changes in Physical and Psychological Pain - Visual Analog Scale (PPP-VAS) scores from Day 0 to 28', 'description': 'Visual Analog Scale measuring physical then psychological pain over 3 periods each (current, worst over the last 7 days, mean over the last 7 days); 6 dimensions in total; each dimension is scored from 0 (no pain) to 10 (maximal pain).', 'timeFrame': '28 days'}, {'measure': 'Reasons for discontinuing treatment over the first 28 days', 'description': ""Patient's self-report; measurement will be the overall (over 28 days) incidence for each event reported."", 'timeFrame': '28 days'}, {'measure': 'Side effects over the first 28 days', 'description': ""Patient's self-report; measurement will be the overall (over 28 days) incidence for each event reported."", 'timeFrame': '28 days'}, {'measure': 'Withdrawal symptoms', 'description': ""Patient's self-report; measurement will be the incidence of any withdrawal symptom during the withdrawal phase."", 'timeFrame': 'Day 22 to day 28'}, {'measure': 'Occurence of a suicide attempt during the whole study', 'description': 'Interview based; measurement will be the incidence of any suicide attempt between Day 0 and 28, between Day 29 and 90, and between Day 90 and 180.', 'timeFrame': '180 days'}, {'measure': 'Changes in Iowa Gambling Task (IGT) scores between Day 0 and 28', 'description': 'Computerized test measuring decision-making; scores are the difference between advantageous and disadvantageous choices; scores range from -100 to + 100, higher scores means better performance', 'timeFrame': '28 days'}, {'measure': 'Changes in modified Stroop test scores between Day 0 and 28', 'description': 'Classical Stroop test modified with suicide-related words to measure specific attention bias; scores are the number of errors and total reaction time; higher scores mean worse performance', 'timeFrame': '28 days'}, {'measure': 'Changes in verbal fluency test scores between Day 0 and 28', 'description': 'Classical test measuring verbal fluency skills for semantic and phonological categories; Patients are instructed to give as many words as possible for a given category then for words starting with a given letter, within a 1 minute time frame; Scores are the number of correct words; higher scores mean higher performance', 'timeFrame': '28 days'}, {'measure': 'Changes in N-Back test scores between Day 0 and 28', 'description': 'Classical test of working memory using letters; scores are the number of words correctly identified for each level of recall (0 to 2 back); higher scores mean better performance; also, the number of omission and commission errors.', 'timeFrame': '28 days'}, {'measure': 'Changes in Go/No-Go test between Day 0 and 28', 'description': 'Classical test of cognitive inhibition, letter version; scores are the number of omission and commission errors (higher scores mean worse performance) and reaction times (higher scores mean better performance)', 'timeFrame': '28 days'}, {'measure': 'Changes in Trail Making Test (TMT) scores between Day 0 and 28', 'description': 'Classical test of planning abilities; scores are the difference between the time to complete parts B and A of the test; Higher scores mean worse performance.', 'timeFrame': '28 days'}, {'measure': 'Changes in Implicit Association Test (IAT) scores between Day 0 and 28', 'description': 'IAT version adapted for suicide/death; scores are the measure of reaction times in the association between suicide/death words and me/myself words; lower scores mean higher association.', 'timeFrame': '28 days'}, {'measure': 'Changes in Magnetic Resonance Imaging (MRI) T1 measures between Day 0 and 28', 'description': 'Brain structural MRI-T1 sequence measured at Day 0 and Day 28 (5 minutes)', 'timeFrame': '28 days'}, {'measure': 'Changes in Magnetic Resonance Imaging (MRI) T2 measures between Day 0 and 28', 'description': 'Brain structural MRI-T2 sequence measured at Day 0 and Day 28 (5 minutes)', 'timeFrame': '28 days'}, {'measure': 'Changes in Magnetic Resonance Imaging (MRI) Diffusion Tensor Imaging (DTI) measures between Day 0 and 28', 'description': 'Brain Diffusion Tensor Imaging (DTI) sequence measured at Day 0 and Day 28 (20 minutes)', 'timeFrame': '28 days'}, {'measure': 'Changes in Magnetic Resonance Imaging (MRI) Resting State (RS) measures between Day 0 and 28', 'description': 'Brain functional Resting State (RS) sequence measured at Day 0 and Day 28 (15 minutes)', 'timeFrame': '28 days'}]",20,18 Years,65 Years,ALL,False,Centre Hospitalier Universitaire de Nīmes,OTHER,0,180.0,ESTIMATED,2025-09-01T16:18:17.183929,v2_robust,True,True,False,False,False,
NCT03955458,EXPAREL Facia Iliaca Compartment Block for Intertrochanteric Hip Fracture,"A Phase-4, Multicenter, Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of EXPAREL When Administered Via Fascia Iliaca Compartment Block Versus Fascia Iliaca Compartment Block With Continuous Infusion of Ropivacaine Per Standard of Care Through a Catheter in Intertrochanteric Hip Fracture Patients",EXPAREL,"['EXPAREL', 'Bupivacaine Hydrochloride', 'Ropivacaine']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Hip Fractures,"['Hip Fractures', 'Intertrochanteric Fractures']","['EXPAREL', 'FICB', 'Fascia Iliaca Compartment Block', 'Ropivacaine']",WITHDRAWN,Recruitment difficulties,2019-08-26,2020-05,"[{'measure': 'Primary objective (total opioid consumption in morphine equivalents)', 'description': 'to compare total opioid consumption in morphine equivalents following FICB with EXPAREL +bupivacaine HCl to that following continuous infusion of ropivacaine via catheter, from end of FICB placement through 72 hours post-FICB, in subjects undergoing repair of intertrochanteric hip fracture To be measured as date, time, and dosage of all medication administered from the time ICF is signed to 72-hours post-surgery.', 'timeFrame': 'Through 72 hours post-FICB'}]",[],1,65 Years,85 Years,ALL,False,"Pacira Pharmaceuticals, Inc",INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:17.184018,v2_robust,True,True,False,True,False,Recruitment difficulties
NCT04312048,the Effect of Isosorbide Mononitrate in Reducing Pain During Cooper Intrauterine Device Insertion,the Effect of Vaginal Isosorbide Mononitrate Administration in Reducing Pain During Cooper Intrauterine Device Insertion in Nulliparous Women : a Randomized Controlled Trial,Isosorbide mononitrate,"['Isosorbide mononitrate', 'placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,IUD Insertion Pain,['IUD Insertion Pain'],[],COMPLETED,,2020-04-15,2020-11-30,"[{'measure': 'pain during IUD insertion', 'description': ""intensity of patient-perceived pain at time of IUD insertion, using a visual analog scale. The VAS scale is graded from 0 to 100 on a 100 mm horizontal straight line, where 'zero' corresponds to no pain at all, and '100' to the worst possible pain imaginable."", 'timeFrame': '5 minutes'}]","[{'measure': 'duration of IUD insertion', 'description': 'duration of IUD insertion from speculum in to speculum out', 'timeFrame': '5 minutes'}]",2,,,FEMALE,False,Cairo University,OTHER,0,110.0,ACTUAL,2025-09-01T16:18:17.184156,v2_robust,True,True,True,False,False,
NCT05643248,"To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects","A Single Ascending Dose Pilot Study to Assess the Safety, Tolerability and Pharmacokinetics of NEX-20A Given as a Subcutaneous Prolonged-release Injection to Healthy Male Subjects",NEX-20A,['NEX-20A'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Multiple Myeloma,['Multiple Myeloma'],[],COMPLETED,,2022-11-28,2023-09-26,"[{'measure': 'Number of subjects with a clinical significant change from baseline in the systolic blood pressure at 36 days', 'description': 'Measured in mmHg after 10 minutes supine rest. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the diastolic blood pressure at 36 days', 'description': 'Measured in mmHg after 10 minutes supine rest. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the ECG parameter PQ/PR at 36 days', 'description': 'Measured in ms in supine position after 10 minutes of rest using an ECG machine. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the ECG parameter QRS at 36 days', 'description': 'Measured in ms in supine position after 10 minutes of rest using an ECG machine. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the ECG parameter QT at 36 days', 'description': 'Measured in ms in supine position after 10 minutes of rest using an ECG machine. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the ECG parameter QTcF at 36 days', 'description': 'Measured in ms in supine position after 10 minutes of rest using an ECG machine. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the haematology blood parameters measurements at 36 days', 'description': 'Blood samples for the analysis of haematology will be collected through venepuncture or an indwelling venous catheter. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the clinical chemistry blood laboratory measurements at 36 days', 'description': 'Blood samples for the analysis of clinical chemistry parameters will be collected through venepuncture or an indwelling venous catheter. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the coagulation parameters blood laboratory measurements at 36 days', 'description': 'Blood samples for the analysis of clinical coagulation parameters will be collected through venpuncture or an indwelling venous catheter. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the physical examination of the head at 36 days', 'description': 'Physical examination including assessment of the head. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the physical examination of eyes at 36 days', 'description': 'Physical examination including assessment of the eyes. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the physical examination of the ears at 36 days', 'description': 'Physical examination including assessment of the ears.Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the physical examination of the nose at 36 days', 'description': 'Physical examination including assessment of the nose.Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the physical examination of the throat at 36 days', 'description': 'Physical examination including assessment of the throat. .Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the physical examination of the skin at 36 days', 'description': 'Physical examination including assessment of the skin. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the physical examination of the thyroid at 36 days', 'description': 'Physical examination including assessment of the thyroid. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the physical examination of neurological status at 36 days', 'description': 'Physical examination including neurological status. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the physical examination of the lungs at 36 days', 'description': 'Physical examination of the lungs including percussion, inspection, palpation, and auscultation.Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the cardiovascular status of at 36 days', 'description': 'Physical examination including inspection, palpation, and auscultation of the heart. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the physical examination of the abdomen at 36 days', 'description': 'Physical examination including assessments of the abdomen (liver and spleen). Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the physical examination of lymph nodes at 36 days', 'description': 'Physical examination including assessments of the lymph nodes. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in the physical examination of extremitets at 36 days', 'description': 'Physical examination including assessments of the extremitets. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with treatment-related adverse events a assessed by frequency', 'description': 'Number of events.Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with treatment-related adverse events a assessed by seriousness', 'description': 'Seriousness of adverse events.Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with treatment-related adverse events a assessed by intensity', 'description': 'Intensity of adverse events.Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in local tolerability i.e skin reactions assessed by visual inspection.', 'description': 'Visual inspection. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}, {'measure': 'Number of subjects with a clinical significant change from baseline in local tolerability i.e skin reactions assessed by photography.', 'description': 'Photography of injection site. Descriptive individual data.', 'timeFrame': 'From first dose until day 36'}]","[{'measure': 'Maximum observed plasma concentration (Cmax)', 'description': 'Measurement of lenalidomid', 'timeFrame': 'pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours'}, {'measure': 'Time of occurrence of Cmax (Tmax)', 'description': 'Measurement of lenalidomid', 'timeFrame': 'pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours'}, {'measure': 'Area under the plasma concentration vs. time curve (AUC) from time 0 to 8 hours', 'description': 'Measurement of lenalidomid', 'timeFrame': 'pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours'}, {'measure': 'AUC from time 0 to 12 hours', 'description': 'Measurement of lenalidomid', 'timeFrame': 'pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours'}, {'measure': 'AUC from time 0 to 7 days', 'description': 'Measurement of lenalidomid', 'timeFrame': 'pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours'}, {'measure': 'AUC from time 0 to infinity', 'description': 'Measurement of lenalidomid', 'timeFrame': 'pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours'}, {'measure': 'Terminal elimination half-life', 'description': 'Measurement of lenalidomid', 'timeFrame': 'pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours'}]",34,18 Years,65 Years,MALE,True,Nanexa AB,INDUSTRY,1,9.0,ACTUAL,2025-09-01T16:18:17.184167,v2_robust,True,True,True,False,True,
NCT00157248,"Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048","Long-term, Open-label Follow-up Treatment of Patients With Atrial Fibrillation Who Have Been Previously Treated With BIBR 1048 in the PETRO Trial (Trial 1160.20 - NCT01227629). (PETRO Extension Trial: PETRO-Ex)",dabigatran etexilate,['dabigatran etexilate'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Atrial Fibrillation,"['Atrial Fibrillation', 'Stroke']",[],TERMINATED,,2003-12,,"[{'measure': 'Yearly Event Rate for Composite Endpoint of Stroke, Transient Ischaemic Attacks, System Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and Mortality.', 'description': 'Time to first occurrence of stroke, transient ischaemic attacks, system thromboembolism, myocardial infarction, other major adverse cardiac events and mortality. Yearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Yearly Event Rate for Major Bleeding', 'description': 'Time to first occurrence of fatal or life-threatening, retroperitoneal, intracranial, intraocular, or intraspinal bleeding, which required surgical treatment, led to a transfusion of a minimum of 2 units of packed cells or whole blood, or led to a fall in hemoglobin of 20g/L or less.\n\nYearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Yearly Event Rate for Major + Minor/Relevant Bleeding', 'description': 'Time to first occurrence of either major or minor/relevant bleeding. Yearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Yearly Event Rate for Any Bleeding', 'description': 'Time to first occurrence of any bleeding event. Yearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Yearly Event Rate for Minor Bleeding', 'description': 'Time to first occurrence of minor bleeding. A minor bleeding event is any bleed that does not qualify as a major bleed. All minor bleeding events not fulfilling one of the criteria for clinically relevant were classified as nuisance bleeds.\n\nClinically-relevant was defined as spontaneous skin hematoma ≥25 cm², spontaneous nose bleed \\>5 min, macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention, spontaneous rectal bleeding, gingival bleeding \\>5 min, leading to hospitalization, leading to a transfusion of \\<2 units of packed cells or whole blood and any other bleeding event considered clinically relevant by the investigator.\n\nYearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}]","[{'measure': 'Yearly Event Rate for Stroke', 'description': 'Time to first occurrence of any fatal or non-fatal stroke. Yearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Yearly Event Rate of Ischaemic Stroke', 'description': 'Time to first occurrence of any ischaemic stroke. Yearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Yearly Event Rate of Haemorrhagic Stroke', 'description': 'Time to first occurrence of any haemorrhagic stroke. Yearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Yearly Event Rate for Transient Ischaemic Attacks', 'description': 'Time to first occurrence of any transient ischaemic attacks. Yearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Yearly Event Rate for Systemic Thromboembolism', 'description': 'Time to first occurrence of any non-central nervous system systemic thromboembolism.\n\nYearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Yearly Event Rate of Myocardial Infarction', 'description': 'Time to first occurrence of any myocardial infarction. Yearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Yearly Event Rate of Other Major Adverse Cardiac Events', 'description': 'Time to first occurrence of any other major adverse cardiac events. Yearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Yearly Event Rate of Death', 'description': 'Time to death of any cause. Yearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Yearly Event Rate for Composite Secondary Endpoint of Ischaemic Stroke, Transient Ischaemic Attacks, Non-central Nervous System Systemic Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and All-cause Mortality', 'description': 'Time to first occurrence of ischaemic stroke, transient ischaemic attacks, non-central nervous system systemic thromboembolism, myocardial infarction, other major adverse cardiac events and all-cause mortality.\n\nYearly event rate (%) = number of subjects with event / subject-years \\* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25', 'timeFrame': '5 years'}, {'measure': 'Severe Adverse Event', 'description': 'Frequency of patients with severe adverse events.', 'timeFrame': '5 years'}, {'measure': 'Laboratory Analyses', 'description': 'Frequency of patients with possible clinically significant abnormalities, i.e. with values out of normal range.\n\nNormal ranges are defined as:\n\n* Alanine aminotransferase (ALT): 5-45 \\[U/L\\]\n* Aspartate aminotransferase (AST): 10-40 \\[U/L\\]\n* Bilirubin, total: 0.2-1.0 \\[mg/dL\\]', 'timeFrame': '5 years'}]",16,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,361.0,ACTUAL,2025-09-01T16:18:17.184217,v2_robust,True,True,False,True,True,
NCT01684748,Angiotensin II Blockade and Inflammation in Obesity,Angiotensin II Blockade and Adipose Tissue Inflammation in Obesity,Olmesartan medoxomil,"['Olmesartan medoxomil', 'Benicar']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Overweight,"['Overweight', 'Obese', 'Prehypertension', 'Hypertension']","['angiotensin II', 'obesity', 'diabetes']",COMPLETED,,2009-02,2011-08,"[{'measure': 'Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time)', 'description': ""Data collected from the intravenous glucose tolerance tests included blood concentrations of glucose and insulin. Glucose was measured immediately on a YSI glucose analyzer and insulin was measured via ELISA colormetric kits once all study samples were collected. To analyze changes in insulin sensitivity, the MINMOD software was used. The MINMOD software uses Bergman's minimal model to determine insulin sensitivity during an intravenous glucose tolerance test. Both glucose and insulin values were inserted at each timepoint collected (33 in total over the 3-hour protocol) and the software was run to generate the insulin sensitivity value at baseline and post-test. This information was then used to calculate the change of insulin sensitivity from baseline to post-testing after each 8-week intervention."", 'timeFrame': 'Baseline testing to post-testing after 8-week intervention'}]",[],1,18 Years,75 Years,ALL,False,Virginia Polytechnic Institute and State University,OTHER,1,20.0,ACTUAL,2025-09-01T16:18:17.184306,v2_robust,True,True,True,False,False,
NCT00005848,"R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","Phase II Trial of R115777 (NSC 702818) an Inhibitor of Farnesyl Protein Transferase, in Patients With Hormone Refractory Prostate Cancer",chemotherapy,"['chemotherapy', 'tipifarnib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],"['adenocarcinoma of the prostate', 'stage IV prostate cancer', 'recurrent prostate cancer']",COMPLETED,,2000-04,2007-05,[],[],0,18 Years,,MALE,False,Fox Chase Cancer Center,OTHER,1,7.0,ACTUAL,2025-09-01T16:18:17.184322,v2_robust,True,True,True,False,False,
NCT02013648,Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™),Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML),Dasatinib,"['Cytarabine', 'ARA-cell', 'Daunorubicin', 'Daunoblastin', 'Idarubicin', 'Sprycel', 'Dasatinib']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Acute Myeloid Leukemia (AML),['Acute Myeloid Leukemia (AML)'],"['AML', 'Dasatinib', 'Core Binding Factor (CBF)']",COMPLETED,,2014-07,2024-02,"[{'measure': 'Event-free Survival', 'description': 'To assess event-free survival (EFS) after intensive induction (daunorubicin and cytarabine) and consolidation (high-dose cytarabine) chemotherapy with or without dasatinib in patients with CBF-AML', 'timeFrame': '4 years'}]","[{'measure': 'Cumulative incidence of relapse (CIR)', 'timeFrame': '4 years'}, {'measure': 'Cumulative incidence of death (CID)', 'timeFrame': '4 years'}, {'measure': 'overall survival', 'timeFrame': '4 years'}, {'measure': 'relapse-free survival', 'timeFrame': '4 years'}, {'measure': 'PIA analysis', 'description': 'Pharmacodynamic inhibition of KIT as assessed by the KIT plasma inhibitory assay (PIA)', 'timeFrame': '4 years'}, {'measure': 'toxicity', 'description': 'Type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events \\[NCI CTCAE\\] version 4.03), timing and relatedness of non-hematologic toxicity observed during different treatment cycles.', 'timeFrame': '7 months (standard arm) / 19 months (investigational arm)'}]",7,18 Years,,ALL,False,University of Ulm,OTHER,0,204.0,ACTUAL,2025-09-01T16:18:17.184476,v2_robust,True,True,True,False,True,
NCT02260648,A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia,A Double-Blind Efficacy and Safety Study of Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia,Evacetrapib,"['Atorvastatin', 'Evacetrapib', 'Placebo', 'Ezetimibe', 'LY2484595']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypercholesterolemia,['Hypercholesterolemia'],[],TERMINATED,Study termination due to insufficient efficacy.,2015-01,2015-11,"[{'measure': 'Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) Measured by Beta Quantification', 'description': 'The mixed-effects model for repeated measures (MMRM) was used for the Least Squares Mean (LS Mean) estimates at Week 12 for LDL-C adjusting for baseline as response variables, baseline measurement as a covariate, treatment, Visit (4,5,6, or 7), and treatment-by-visit interaction as fixed effects, and participant as a random effect.', 'timeFrame': 'Baseline, Week 12'}]","[{'measure': 'Percent Change From Baseline to Week 12 in High-Density Lipoprotein Cholesterol (HDL-C)', 'description': 'The MMRM was used for the LS Mean estimates at Week 12 for HDL-C adjusting for baseline as response variables, baseline measurement as a covariate, treatment, visit, and treatment-by-visit interaction as fixed effects, and participant as a random effect, and treatment-by-visit interaction as fixed effects, and participant as a random effect.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percent Change From Baseline to Week 12 in LDL-C (Direct)', 'description': 'The MMRM was used for the LS Mean estimates at Week 12 for LDL-C (direct) adjusting for baseline as response variables, baseline measurement as a covariate, treatment, visit, and treatment-by-visit interaction as fixed effects, and participant as a random effect.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percent Change From Baseline to Week 12 in Non HDL-C', 'description': 'The MMRM was used for the LS Mean estimates at Week 12 for Non HDL-C adjusting for baseline as response variables, baseline measurement as a covariate, treatment, visit, and treatment-by-visit interaction as fixed effects, and participant as a random effect.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percent Change From Baseline to Week 12 in Lipoprotein-a', 'description': 'The analysis of covariance (ANCOVA) model using last observation carried forward (LOCF) was applied to analyze percent changes from baseline.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percent Change From Baseline to Week 12 in Apolipoprotein A-I', 'description': 'The ANCOVA model using last observation carried forward (LOCF) was applied to analyze percent changes from baseline.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percent Change From Baseline to Week 12 in Apolipoprotein B', 'description': 'The ANCOVA model using last observation carried forward (LOCF) was applied to analyze percent changes from baseline.', 'timeFrame': 'Baseline, Week 12'}]",7,20 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,149.0,ACTUAL,2025-09-01T16:18:17.184495,v2_robust,True,True,False,True,False,Study termination due to insufficient efficacy.
NCT01760148,Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2),Study of Parameters of Early Hepatitis C Virus Dynamics for Predicting the Outcome of Standard Interferon Therapy With Chinese Cohort (Second Phase),interferon alpha 2b,"['FDA Approval number:S20030032,H10940157', 'interferon alpha 2b', 'Generic: Recombinant Human Interferon alpha-2b,Ribavirin', 'Brand: Kaiyinyisheng,Weilake', 'Other Names:IFN+Ribavirin']",5,OBSERVATIONAL,[],,,"Hepatitis C, Chronic","['Hepatitis C, Chronic', 'Liver Diseases', 'Interferon Deficiency']","['Hepatitis C Virus', 'HCV', 'Interferon', 'Prediction', 'SVR', 'Sustained Virus Response']",UNKNOWN,,2012-07,2014-03,"[{'measure': 'Absolute Blood HCV RNA Copies at designed time points', 'description': 'Blood HCV RNA copies were assayed with Roche - COBAS® AmpliPrep/COBAS® TaqMan® HCV Test.', 'timeFrame': '0hr,24hr,1wk,2wk,4wk,6wk,12wk,24wk,48wk,72wk'}]","[{'measure': 'IL-28B polymorphism', 'description': 'IL28 gene polymorphism,rs8099917,rs12979860,etc', 'timeFrame': 'Baseline'}, {'measure': 'HCV genotype', 'description': 'HCV NS5A is cloned into T vector and sequenced for evolutionary analysis.', 'timeFrame': 'Baseline'}, {'measure': 'Alanine Aminotransferase (ALT) and Aspartate transaminase (AST)', 'description': 'ALT AST are assayed to detect the hepatic function.', 'timeFrame': 'Baseline,4wk,12wk,24wk,48wk'}, {'measure': 'Fibrosis stage', 'description': 'Fibrosis is analyzed with Fibroscan.', 'timeFrame': 'Baseline,4wk,12wk,24wk,48wk'}, {'measure': 'Regular blood test', 'description': 'The distribution and absolute count of the different types of blood cells are assayed.', 'timeFrame': 'Baseline,4wk,12wk,24wk,48wk'}, {'measure': 'Electrocardiography', 'description': 'Electrocardiography is taken to avoid severe side effects.', 'timeFrame': 'Baseline,4wk,12wk,24wk,48wk'}, {'measure': 'Alcohol ,smoking condition', 'description': 'Patients are asked whether they take alcohol or smoke cigarettes during the therapy period.', 'timeFrame': 'Baseline,4wk,12wk,24wk,48wk'}, {'measure': 'Drug abuse history', 'description': 'Patients will be asked about their drug usage history.', 'timeFrame': 'Baseline'}]",9,,,ALL,False,Junqi Niu,OTHER,1,300.0,ESTIMATED,2025-09-01T16:18:17.184528,v2_robust,False,True,False,False,False,
NCT02766855,Efficacy of Topical Cysteamine in Nephropathic Cyctinosis,,Cysteamine,['Cysteamine'],1,INTERVENTIONAL,['NA'],,,Nephropathic Cyctinosis,"['Nephropathic Cyctinosis', 'Corneal Cystine Crystals']","['cysteamine', 'nephropathic cystinosis', 'cystine crystals']",COMPLETED,,2004-01,2016-03,"[{'measure': 'Number of participants with improvement of photophobia, corneal cystine crystals and visual acuity following treatment with topical cysteamine 0.55% eye drops in patients with nephropathic cystinosis.', 'description': 'Patients had a baseline ophthalmic examination before initiation of topical cysteamine 0.55% eye drops and subsequent monthly follow up exams. The following parameters were recorded pretreatment, on each monthly visit and post treatment at last follow up visit: photophobia, slit lamp assessment of corneal cystine crystals and visual acuity. Photophobia was classified as grade 0 (none) for no photophobia, grade 1 (mild) for photophobia in bright light, grade 2 (moderate) for photophobia in room light and grade 3 (severe) for photophobia in dim light. Corneal cystine crystals were graded as Grade 0 = None, Grade 1 = 1-10 crystals/mm, Grade 2 = 11- 50 crystals/mm, Grade 3 = more than 50 crystals/mm. The level of cystine in the corneal layers was recorded and the location whether peripheral or central was also identified. Visual acuity was measured by Snellen chart at 20 feet with best distance correction.', 'timeFrame': 'Photophobia, slit lamp assessment of corneal cystine crystals and visual acuity are recorded pretreatment, on each monthly visit up to 48 months.'}]",[],1,8 Months,19 Years,ALL,False,The Eye Center and The Eye Foundation for Research in Ophthalmology,OTHER,0,26.0,ACTUAL,2025-09-01T16:18:17.184632,v2_robust,True,True,True,False,False,
NCT05583955,A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus),"A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Ten-week Prospective Study to Evaluate the Efficacy and Safety of NOE-105 in Adult Male Patients With Childhood Onset Fluency Disorder (Orpheus)",NOE-105,"['Placebo to match', 'NOE-105', 'Escalating dose levels of NOE-105', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Childhood-Onset Fluency Disorder,['Childhood-Onset Fluency Disorder'],[],COMPLETED,,2022-07-25,2023-11-24,"[{'measure': 'Change from baseline to end point in severity subset of the MLGSSS', 'description': 'MLGSSS refers to Maguire-Leal-Garibaldi Self-rated Stuttering Scale', 'timeFrame': 'Up to 71 days'}, {'measure': 'Number of participants with adverse events', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment', 'timeFrame': 'Up to 71 days'}, {'measure': 'Severity of the adverse events', 'description': 'Adverse events will be categorized as mild, moderate or severe by the investigator', 'timeFrame': 'Up to 71 days'}, {'measure': 'Change in the hematological parameters', 'description': 'Platelet count, RBC count, Hemoglobin, hematocrit and differential WBC count will be assessed', 'timeFrame': 'Up to 71 days'}, {'measure': 'Change in clinical chemistry', 'description': 'Urea, creatinine, potassium, SGOT, SGPT, glucose, sodium chloride, magnesium, phosphates, calcium, total and conjugated bilirubin, GGT, total protein albumin, phosphokinase, and plasma prolactin will be assessed', 'timeFrame': 'Up to 71 days'}, {'measure': 'Change in the vital signs', 'description': 'Temperature, weight, height, pulse rate and blood pressure will be assessed.', 'timeFrame': 'Up to 71 days'}]","[{'measure': 'Change from baseline to end point in SDS', 'description': 'SDS refers to Sheehan disability scale', 'timeFrame': 'Up to 71 days'}, {'measure': 'PGI-S rating at end point', 'description': 'PGI-S refers to patient global impression of severity', 'timeFrame': 'Up to 71 days'}, {'measure': 'CGI-C rating at end point', 'description': 'Clinician global impression of change', 'timeFrame': 'Up to 71 days'}, {'measure': 'Rating of the medication satisfaction questionnaire at end point', 'description': ""To evaluate the patient's satisfaction in treatment with NOE-105"", 'timeFrame': 'Up to 71 days'}, {'measure': 'Change from baseline to end point in clinician-rated stuttering severity instrument-4', 'description': 'To evaluate the effect of NOE-105 on the change in stuttering severity', 'timeFrame': 'Up to 71 days'}, {'measure': 'PGI-C rating at end point', 'description': 'PGI-C refers to patient global impression of change', 'timeFrame': 'Up to 71 days'}, {'measure': 'Change in mood as rated by the patient through change from baseline to end point in Quick inventory of depressive symptomology (QIDS-16)', 'timeFrame': 'Up to 71 days'}]",13,18 Years,55 Years,MALE,False,Noema Pharma AG,INDUSTRY,0,75.0,ACTUAL,2025-09-01T16:18:17.184657,v2_robust,True,True,True,False,True,
NCT00030355,Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia,A Phase I/II Open-Label Study Of The Intravenous Administration Of Homoharringtonine (CGX-635) Salvage Therapy For The Treatment Of Refractory Acute Promyelocytic Leukemia,homoharringtonine,['homoharringtonine'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Leukemia,['Leukemia'],"['recurrent childhood acute myeloid leukemia', 'recurrent adult acute myeloid leukemia', 'adult acute promyelocytic leukemia (M3)', 'childhood acute promyelocytic leukemia (M3)', 'adult acute myeloid leukemia with t(15;17)(q22;q12)']",WITHDRAWN,,,,"[{'measure': 'Safety by physical examinations, vital signs, laboratory studies (routine hematology, clinical chemistry, pharmacokinetics, urinalysis, chest x-ray, and EKG), and solicited and unsolicited adverse events'}, {'measure': 'Efficacy by response to treatment'}]","[{'measure': 'Pharmacokinetics'}, {'measure': 'Duration of treatment response'}, {'measure': 'Survival'}, {'measure': 'Induction mortality'}, {'measure': 'Hospitalizations'}]",7,12 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,0.0,ACTUAL,2025-09-01T16:18:17.184676,v2_robust,True,True,False,True,True,
NCT02681055,Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects,"An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia",MN-001,"['tipelukast', 'MN-001']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-alcoholic Steatohepatitis,"['Non-alcoholic Steatohepatitis', 'Hypertriglyceridemia', 'Non-alcoholic Fatty Liver Disease', 'Hypercholesterolemia']","['NASH', 'NAFLD']",COMPLETED,,2016-03,2019-10-01,"[{'measure': 'Mean Change From Baseline at 12 Weeks of MN-001 Treatment on Cholesterol Efflux Capacity', 'description': 'Change from baseline to 12 weeks of MN-001 on Cholesterol Efflux Capacity (CEC) in NAFLD subjects with hypertriglyceridemia. CEC, a key step in reverse cholesterol transport, was inversely associated with the incidence of cardiovascular events and is considered to be a new biomarker to assess cardiovascular risk. Cholesterol efflux was calculated as the percent of cholesterol removed from the cells and appearing in the culture medium normalized to a reference serum pool. The ability of serum HDL to remove cholesterol from cultured cells was assessed as an in vitro method to evaluate functional changes in HDL mediated by changes due to MN-001 treatment.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Mean Change From Baseline to Week 8 on Triglyceride Levels After 8 Weeks MN-001 Treatment', 'description': 'Change from baseline to 8 weeks of MN-001 on serum triglyceride levels in NASH subjects with hypertriglyceridemia', 'timeFrame': '8 weeks'}]","[{'measure': 'Number of Treatment-emergent Adverse Events', 'description': 'Safety and tolerability of MN-001 by assessing the number of subjects who experienced treatment-emergent adverse events. A treatment-emergent adverse event is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the trial intervention.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12 and 13'}, {'measure': 'Mean Plasma Concentration of MN-001 and MN-002 (Metabolite) After a Single Dose of MN-001 in Six Subjects', 'description': 'Mean plasma concentration of of MN-001 and its metabolite, MN-002, after a single 250 mg oral dose of MN-001 in nonalcoholic steatohepatitis and nonalcoholic fatty liver disease patients.', 'timeFrame': '24 hours'}, {'measure': 'Mean Serum Lipids From Baseline to Week 8', 'description': 'Mean change from baseline to week 8 on total cholesterol, high-density lipoproteins, low-density lipoproteins', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Mean Change in Liver Enzymes From Baseline to Week 8', 'description': 'Measure the effect of MN-001/002 on alanine aminotransferase (ALT) and aspartate aminotransferase (AST) mean change from Baseline to Week 8', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Measure the Effect of MN-001/002 on Percentage of Fat in the Liver', 'description': 'To measure the effect of MN-001/002 on percentage of fat in the liver by MRI mean change from baseline to Week 12', 'timeFrame': 'Baseline and Week 12'}]",7,18 Years,,ALL,False,MediciNova,INDUSTRY,0,19.0,ACTUAL,2025-09-01T16:18:17.184683,v2_robust,True,True,True,False,True,
NCT04663555,Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19,"Effect of Dexamethasone in Patients With ARDS and COVID-19 - Prospective, Multi-centre, Open-label, Parallel-group, Randomized Controlled Trial (REMED Trial)",Dexamethasone,['Dexamethasone'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Covid19,"['Covid19', 'ARDS']","['Covid19', 'ARDS', 'dexamethasone']",COMPLETED,,2021-02-02,2023-02-23,"[{'measure': 'Number of ventilator-free days (VFDs) at 28 days after randomization', 'description': 'Number of ventilator-free days (VFDs) at 28 days after randomisation, defined as being alive and free from mechanical ventilation (more than 48 hours)', 'timeFrame': '28 days'}]","[{'measure': 'Mortality from any cause at 60 days after randomization', 'timeFrame': '60 days'}, {'measure': 'WHO clinical progression scale at day 14', 'description': 'WHO clinical progression scale (range, 0-10, where 0 = no illness, 1-9 = increasing level of care, and 10 = death) (WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection, 2020) assessed at day 14', 'timeFrame': '14 days'}, {'measure': 'Dynamics of inflammatory marker', 'description': 'Dynamics of inflammatory marker (CRP) change from Day 1 to Day 14', 'timeFrame': '14 days'}, {'measure': 'Adverse events related to corticosteroids', 'description': 'new infections, new thrombotic complications', 'timeFrame': '28 days'}, {'measure': 'Functional independence', 'description': 'Independence at 90 days after randomization assessed by Barthel Index', 'timeFrame': '90 days'}]",6,18 Years,,ALL,False,Brno University Hospital,OTHER,10,235.0,ACTUAL,2025-09-01T16:18:17.184700,v2_robust,True,True,True,False,True,
NCT04351555,A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer,"A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer",Osimertinib,"['AZD9291; TAGRISSO', 'Osimertinib', 'Carboplatin', 'Cisplatin', 'Placebo', 'Pemetrexed']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-Small Cell Lung Cancer,['Non-Small Cell Lung Cancer'],['Resectable; NSCLC; Osimertinib; EGFRm Positive; Neoadjuvant; Adjuvant'],ACTIVE_NOT_RECRUITING,,2020-12-16,2029-06-13,"[{'measure': 'Major Pathological Response (MPR)', 'description': 'Defined as ≤10% residual cancer cells in the main tumour, as assessed per central pathology laboratory post-surgery', 'timeFrame': 'From date of randomization to an average of 12 weeks after the first dose'}]","[{'measure': 'Pathological complete response (pCR)', 'description': 'Defined as absence of any viable cancer cells in the dissected tumour samples, including the main tumour, lymph nodes, and margins as assessed per central pathology laboratory post-surgery', 'timeFrame': 'From date of randomization to an average of 12 weeks after the first dose'}, {'measure': 'Event-free survival (EFS)', 'description': 'An event is defined as documented disease progression that precludes surgery or prevents completion of definitive surgery; recurrence or a new lesion, local or distant (a new primary malignancy, confirmed by pathology if clinically feasible, is not considered to be an EFS event); death due to any cause', 'timeFrame': 'From date of randomization up to approximately 5.5 years after the last patient is randomized'}, {'measure': 'Overall Survival (OS)', 'description': 'OS will be defined as the time from the date of randomisation until death due to any cause', 'timeFrame': 'From date of randomization up to approximately 5.5 years after the last patient is randomized'}, {'measure': 'Disease free survival (DFS)', 'description': 'DFS is defined as the time from the date of surgery until the first date of disease recurrence (local or distant) or date of death due to any cause, whichever occurs first.', 'timeFrame': 'From date of randomization up to approximately 5.5 years after the last patient is randomized'}, {'measure': 'Downstaging', 'description': 'Measured using pathologic mediastinal lymph node evaluation', 'timeFrame': 'From date of randomization to an average of 12 weeks after the first dose'}, {'measure': 'Difference between treatment arms in change from baseline in EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 items)', 'description': 'Assess disease-related symptoms, functioning, and global health status/quality-of-life in patients', 'timeFrame': 'From date of randomization up to approximately 5.5 years after the last patient is randomized'}, {'measure': 'Concordance of EGFRm status between tumour tissue DNA and patient-matched plasma-derived ctDNA', 'timeFrame': 'Baseline'}, {'measure': 'Corcordance of EGFR mutation status between the local and central cobas EGFR mutation test results from baseline tumour samples', 'timeFrame': 'Baseline'}, {'measure': 'PK plasma concentrations of osimertinib', 'timeFrame': 'From the pre-dose of Cycle 2 to post-dose of Cycle 3 (each cycle is 21 days)'}, {'measure': 'Difference between treatment arms in change from baseline in EORTC QLQ-LC13 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 items)', 'description': 'Assess lung cancer-associated symptoms and side effects from conventional chemotherapy and radiotherapy', 'timeFrame': 'From date of randomization up to approximately 5.5 years after the last patient is randomized'}]",11,18 Years,100 Years,ALL,False,AstraZeneca,INDUSTRY,0,358.0,ACTUAL,2025-09-01T16:18:17.184763,v2_robust,True,True,False,False,False,
NCT04893655,Effect of Dobutamine on Hepatic Blood Flow During Goal-directed Hemodynamic Therapy,Effect of Dobutamine on Hepatic Blood Flow During Goal-directed Hemodynamic Therapy,Dobutamine Hydrochloride,['Dobutamine Hydrochloride'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,General Anesthesia,['General Anesthesia'],"['hepatic blood flow', 'dobutamine', 'hepatic vascular pressure']",COMPLETED,,2021-09-14,2023-07-25,"[{'measure': 'change in portal and arterial hepatic blood flow during goal-directed hemodynamic therapy with dobutamine', 'description': 'flow measurements with echo probe', 'timeFrame': 'from start anesthesia until end of anesthesia, up to a maximum of 11 hours'}, {'measure': 'Changes in portal vein and caval vein pressures before and after dobutamine infusion', 'description': 'pressure measurements with 25gauge needle', 'timeFrame': 'from start anesthesia until end of anesthesia, up to a maximum of 11 hours'}]","[{'measure': 'change in systemic hemodynamic measurements :cardiac index, during goal-directed hemodynamic therapy with dobutamine', 'description': 'change in cardiac index (measurements with PiCCO catheter)', 'timeFrame': 'from start anesthesia until end of anesthesia, up to a maximum of 11 hours'}, {'measure': 'change in systemic vascular resistance (SVR), during goal-directed hemodynamic therapy with dobutamine', 'description': 'change in systemic vascular resistance (SVR)', 'timeFrame': 'from start anesthesia until end of anesthesia, up to a maximum of 11 hours'}, {'measure': 'change in portal venous resistance (PVR), during goal-directed hemodynamic therapy with dobutamine', 'description': 'change in portal venous resistance (PVR)', 'timeFrame': 'from start anesthesia until end of anesthesia, up to a maximum of 11 hours'}, {'measure': 'change in systemic hemodynamic measurements :heart rate, during goal-directed hemodynamic therapy with dobutamine', 'description': 'change in heart rate (measurements with PiCCO catheter)', 'timeFrame': 'from start anesthesia until end of anesthesia, up to a maximum of 11 hours'}, {'measure': 'change in systemic hemodynamic measurements :blood pressure, during goal-directed hemodynamic therapy with dobutamine', 'description': 'change in blood pressure (measurements with PiCCO catheter)', 'timeFrame': 'from start anesthesia until end of anesthesia, up to a maximum of 11 hours'}, {'measure': 'change in systemic hemodynamic measurements :central venous pressure, during goal-directed hemodynamic therapy with dobutamine', 'description': 'change in cardiac index (measurements with central line)', 'timeFrame': 'from start anesthesia until end of anesthesia, up to a maximum of 11 hours'}, {'measure': 'change in systemic hemodynamic measurements :pulse pressure variation, during goal-directed hemodynamic therapy with dobutamine', 'description': 'change in pulse pressure variation (measurements with PiCCO catheter)', 'timeFrame': 'from start anesthesia until end of anesthesia, up to a maximum of 11 hours'}, {'measure': 'change in systemic hemodynamic measurements :stroke volume variation, during goal-directed hemodynamic therapy with dobutamine', 'description': 'change in stroke volume variation (measurements with PiCCO catheter)', 'timeFrame': 'from start anesthesia until end of anesthesia, up to a maximum of 11 hours'}, {'measure': 'change in systemic hemodynamic measurements : Systemic Vascular Resistance Index (SVRI), during goal-directed hemodynamic therapy with dobutamine', 'description': 'change in Systemic Vascular Resistance Index (SVRI) (measurements with PiCCO catheter)', 'timeFrame': 'from start anesthesia until end of anesthesia, up to a maximum of 11 hours'}, {'measure': 'change in systemic hemodynamic measurements : Left Ventricular contractility (dPmx), during goal-directed hemodynamic therapy with dobutamine', 'description': 'change in Left Ventricular contractility (dPmx) (measurements with PiCCO catheter)', 'timeFrame': 'from start anesthesia until end of anesthesia, up to a maximum of 11 hours'}]",12,18 Years,80 Years,ALL,False,"University Hospital, Ghent",OTHER,0,58.0,ACTUAL,2025-09-01T16:18:17.184803,v2_robust,True,True,True,False,False,
NCT04543955,Telotristat With Lutathera in Neuroendocrine Tumors,Study of Telotristat (Xermelo) in Combination With Luetetium Lu177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors,Telotristat (Low-Dose),"['Telotristat (Low-Dose)', 'Xermelo', 'Telotristat (High-Dose)']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Neuroendocrine Tumors,['Neuroendocrine Tumors'],['NET'],TERMINATED,Sponsor cancelled research,2021-09-13,2022-06-03,"[{'measure': 'Progression-Free Survival (PFS)', 'description': 'Progression-free survival at 20 months.', 'timeFrame': '20 months'}]","[{'measure': 'Overall Response Rate (ORR)', 'description': 'Overall response rate using RECIST v1.1 at 6 and 12 months after therapy', 'timeFrame': '6 and 12 months'}, {'measure': 'Median Progression-Free Survival (PFS)', 'description': 'Median progression-free survival.', 'timeFrame': '36 month'}, {'measure': 'Urinary 5-HIAA', 'description': 'Levels of urinary 5-Hydroxyindoleacetic acid (5-HIAA) will be measured at baseline and 12 months.', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Quality of Life (QLQ-C30)', 'description': 'The Quality of Life Questionnaire C30 (QLQ-C30) was developed by the European Organization for Research and Treatment of Cancer (EORTC) to assess quality of life in cancer patients.It includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality-of-life and financial impact. Subjects respond on a four-point scale from ""not at all"" to ""very much"" for most items.Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden.', 'timeFrame': '20 month'}, {'measure': 'Quality of Life (QLQ-GI.NET21)', 'description': 'The Quality of Life GI Neuroendocrine Tumor survey (QLQ-GINET21) contains a total of 21 items: four single-item assessments relating to muscle and/or bone pain (MBP), body image (BI), information (INF) and sexual functioning (SX), together with 17 items organised into five proposed scales: endocrine symptoms (ED; three items), GI symptoms (GI; five items), treatment-related symptoms (TR; three items), social functioning (SF) and disease-related worries (DRW; three items). The response format of the questionnaire is a four-point Likert scale. Responses are linearly transformed to a 0-100 scale using EORTC guidelines, with higher scores reflecting more severe symptoms.', 'timeFrame': '20 month'}]",6,18 Years,100 Years,ALL,False,"Lowell Anthony, MD",OTHER,1,1.0,ACTUAL,2025-09-01T16:18:17.184877,v2_robust,True,True,False,True,False,Sponsor cancelled research
NCT00002926,Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia,Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Secondary (SAML) to MDS of More Acute Than 6 Months Duration,cytarabine,"['cytarabine', 'etoposide', 'idarubicin']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Leukemia,"['Leukemia', 'Myelodysplastic Syndromes']","['secondary acute myeloid leukemia', 'refractory anemia', 'refractory anemia with ringed sideroblasts', 'refractory anemia with excess blasts', 'refractory anemia with excess blasts in transformation', 'chronic myelomonocytic leukemia', 'de novo myelodysplastic syndromes', 'previously treated myelodysplastic syndromes', 'secondary myelodysplastic syndromes', 'refractory cytopenia with multilineage dysplasia', 'childhood myelodysplastic syndromes']",UNKNOWN,,1996-12,,[],[],0,16 Years,60 Years,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,80.0,ESTIMATED,2025-09-01T16:18:17.184949,v2_robust,True,True,False,False,False,
NCT05968326,A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC,"A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma",Autogene cevumeran,"['Tecentriq', 'Atezolizumab', 'Autogene cevumeran', 'mFOLFIRINOX']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Adenocarcinoma, Pancreatic Ductal","['Adenocarcinoma, Pancreatic Ductal']",[],RECRUITING,,2023-10-18,2029-12-27,"[{'measure': 'Disease Free Survival (DFS)', 'timeFrame': 'From randomization to first recurrence of PDAC or first occurrence of new cancer, as determined by the investigator, or death from any cause (whichever occurs first), up to approximately 6 years'}]","[{'measure': 'DFS Rates at 12, 24, and 36 Months', 'timeFrame': 'Months 12, 24, 36'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'From randomization to death from any cause (up to approximately 6 years)'}, {'measure': 'OS Rates at 3 and 5 Years', 'timeFrame': 'Years 3 and 5'}, {'measure': 'Percentage of Participants With Adverse Events (AEs)', 'timeFrame': 'Up to approximately 6 years'}]",5,18 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,1,260.0,ESTIMATED,2025-09-01T16:18:17.185012,v2_robust,True,True,False,False,True,
NCT04399226,Dexmedetomidine-Propofol and Ketamine-Propofol During Upper Gastrointestinal System Sedation,Efficacy and Safety of Deksmedetomidine-propofol or Ketamine-propofol,Dexmedetomidine,"['ketamine', 'propofol', 'Dexmedetomidine']",3,OBSERVATIONAL,[],,,Anesthesia; Reaction,['Anesthesia; Reaction'],"['Dexmedetomidine, Ketamine, Propofol, Sedation']",COMPLETED,,2019-10-18,2020-03-13,"[{'measure': 'Demographic data', 'description': 'no difference', 'timeFrame': '2 minutes'}]","[{'measure': 'adverse events', 'description': 'Nausea, vomiting and allergic reaction, cough', 'timeFrame': '2 minutes'}]",2,18 Years,60 Years,ALL,True,Yuzuncu Yıl University,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:17.185081,v2_robust,False,True,True,False,True,
NCT06423326,"Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer","A Single-Arm Phase II Clinical Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma",Cisplatin,"[""Peyrone's Chloride"", 'DDP', 'Paclitaxel Albumin', 'Cisplatyl', 'Metaplatin', 'Neoplatin', 'Placis', 'Platinol', 'Platinum Diamminodichloride', 'Gemcitabine', 'Citoplatino', 'Albumin-bound Paclitaxel', 'Platinoxan', 'Platistin', 'Cis-diamminedichloridoplatinum', 'ABI 007', 'Nanoparticle Paclitaxel', 'Difluorodeoxycytidine', 'Cysplatyna', 'Cis-platinous Diamine Dichloride', 'Platinum', 'Platinex', ""Peyrone's Salt"", 'Blastolem', 'ABI-007', 'Cis-platinum II', 'Cisplatinum', 'Platinol-AQ', 'Plastistil', 'Lederplatin', 'Platiran', 'Paclitaxel Nanoparticle Albumin-bound', 'Nanoparticle Albumin-bound Paclitaxel', 'dFdCyd', 'Abiplatin', 'Cis-diamminedichloro Platinum (II)', 'Cisplatin', 'paclitaxel albumin-stabilized nanoparticle formulation', 'Cis-diammine-dichloroplatinum', 'Paclitaxel Protein-Bound', 'Platamine', 'Briplatin', 'Cis-diamminedichloroplatinum', 'Abraxane', 'Albumin-Stabilized Nanoparticle Paclitaxel', 'Platiblastin-S', 'CDDP', 'Platinol- AQ', 'Platinol-AQ VHA Plus', 'Protein-bound Paclitaxel', 'Platiblastin', 'Cis-platinum', 'Citosin', 'Cisplatina', 'Platosin', 'Nab-paclitaxel', 'Cis-dichloroammine Platinum (II)', 'dFdC', 'Cismaplat', 'Cis-platinum II Diamine Dichloride']",60,INTERVENTIONAL,['PHASE2'],PHASE2,,Borderline Resectable Pancreatic Ductal Adenocarcinoma,"['Borderline Resectable Pancreatic Ductal Adenocarcinoma', 'Resectable Pancreatic Adenocarcinoma', 'Stage I Pancreatic Cancer AJCC v8', 'Stage II Pancreatic Cancer AJCC v8', 'Stage III Pancreatic Cancer AJCC v8']",[],RECRUITING,,2024-08-06,2026-12-31,"[{'measure': 'Clinical Response Rate to Neoadjuvant Chemotherapy', 'description': 'Clinical response is defined as biochemical, radiological, pathological response or stable disease. • Biochemical response (or CA 19-9 response) is defined as \\>50% decrease from baseline with tumor response. Radiologic response is defined as complete response (CR), partial response (PR) or stable disease (SD) after the neoadjuvant therapy per RECIST 1.1. Pathologic response is defined by CAP scoring system as 0 (complete response), 1 (moderate response), 2 (minimal response) and 3 (poor or no response). Stable disease is defined as the absence of biochemical response (\\>50% CA 19-9 reduction), radiological response (per RECIST 1.1), or major pathological response (CAP Score 0-1), without metastasis / unresectability, and patient undergoes surgical resection. Clinical response rate (including clinical, biochemical, radiological, pathological response or stable disease) will be reported as a proportion, with an exact 90% confidence interval estimated using the Clopper-Pearson method.', 'timeFrame': 'Up to 24 months'}]","[{'measure': 'Treatment Completion', 'description': 'Feasibility will be defined as completion of all preoperative and operative therapy. Treatment completion will reported as a proportion, with an exact 95% confidence interval estimated using the Clopper-Pearson method.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Incidence of Adverse Events (AEs)', 'description': 'AEs, with severity will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Descriptive statistics will be reported, using frequencies and percentages for each toxicity.', 'timeFrame': 'Up to 28 days after last dose of study treatment'}, {'measure': 'Radiologic Response Rate', 'description': 'Radiological response rate will be defined as complete response, partial response or stable disease after study treatment evaluated using Response Evaluation Criteria in Solid Tumors version 1.1. Radiologic response rate will be reported as a proportion, with an exact 95% confidence interval estimated using the Clopper-Pearson method.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Pathological Response Rate', 'description': 'To assess the major pathological response rate (CAP 0-1) in the surgical resection specimen', 'timeFrame': 'Up to 24 months'}, {'measure': 'Neoadjuvant Systemic Chemotherapy Rate', 'description': 'To assess the rate of neoadjuvant systemic chemotherapy completion (Duration 4 months) without dose reduction', 'timeFrame': 'Up to 4 months'}, {'measure': 'R0 Resection Rate', 'description': 'R0 resection indicates a microscopically margin-negative resection. R0 resection rate will reported as a proportion, with an exact 95% confidence interval estimated using the Clopper-Pearson method.', 'timeFrame': 'At time of surgery'}, {'measure': 'Nodal Status', 'description': 'N0, N1, and N2 will be reported using frequencies and percentages.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Recurrence-Free Survival (RFS)', 'description': 'RFS will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median RFS will be estimated using the Brookmeyer-Crowley approach.', 'timeFrame': 'From surgery to recurrence or death, assessed up to 24 months'}, {'measure': 'Overall Survival (OS) Rate', 'description': 'OS will be estimated using the Kaplan-Meier method, and median survival will be calculated. A 95% confidence interval will be estimated using the Brookmeyer-Crowley approach.', 'timeFrame': 'From study treatment start to date of death, assessed up to 24 months'}, {'measure': 'Carbohydrate Antigen (CA)19-9 response', 'description': 'CA19-9 response will be defined as \\> 50% decrease from baseline will be correlated with tumor response. CA19-9 will be reported as a proportion, with an exact 95% confidence interval estimated using the Clopper-Pearson method. CA19-9 will be correlated with RFS and OS using log-rank tests and Cox proportional hazards regression. Model assumptions will be checked and verified.', 'timeFrame': 'Up to 24 months'}]",11,18 Years,,ALL,False,Emory University,OTHER,2,36.0,ESTIMATED,2025-09-01T16:18:17.185108,v2_robust,True,True,False,False,True,
NCT01366378,Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX,"A Phase 1, Open-Label, Study of the Effect of Cimetidine, a Known Inhibitor of Active Renal Secretion, on the Single-Dose Pharmacokinetics of Intravenously-Administered Methylnaltrexone in Healthy Adults",methylnaltrexone,['methylnaltrexone'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Adult Subjects,['Healthy Adult Subjects'],[],COMPLETED,,2007-01,2007-02,"[{'measure': 'Peak plasma concentration (Cmax) of MNTX prior to and following multi-dose cimetidine regimen', 'description': 'To assess the potential effects of cimetidine on the pharmacokinetics of MNTX', 'timeFrame': '7 days'}]","[{'measure': 'Area under the plasma concentration (AUC) of MNTX prior to and following a multi-dose cimetidine regimen', 'description': 'To assess the potential effects of cimetidine on the pharmacokinetics of MNTX', 'timeFrame': '7 days'}, {'measure': 'Half-life of MNTX prior to and following a multi-dose cimetidine regimen', 'description': 'To assess the potential effects of cimetidine on the pharmacokinetics of MNTX', 'timeFrame': '7 days'}, {'measure': 'Clearance (both total and renal)of MNTX prior to and following a multi-dose cimetidine regimen', 'description': 'To assess the potential effects of cimetidine on the pharmacokinetics of MNTX', 'timeFrame': '7 days'}, {'measure': 'Volume of distribution of MNTX prior to and following a multi-dose cimetidine regimen', 'description': 'To assess the potential effects of cimetidine on the pharmacokinetics of MNTX', 'timeFrame': '7 days'}, {'measure': 'Number of subject with adverse events as measured before, during, and after administration of cimetidine', 'description': 'To assess the potential effects of cimetidine on safety, and tolerability of MNTX', 'timeFrame': '7 days'}]",6,18 Years,45 Years,ALL,True,"Bausch Health Americas, Inc.",INDUSTRY,0,18.0,ACTUAL,2025-09-01T16:18:17.185308,v2_robust,True,True,True,False,True,
NCT02130778,Natriuretic Effect of GLP-1in Healthy Non Obese Subjects,"Natriuretic Effect of GLP-1 in Healthy Non Obese Subjects Followed by Oral Sodium Load: A Randomized, Placebo-controlled, Cross-over Study",Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline,['Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Sodium Excretion by Urination,['Sodium Excretion by Urination'],[],COMPLETED,,2014-04,2015-10,"[{'measure': 'Evidence of the positive effect on natriuresis (level of sodium in urin sample) following the of GLP1 infusion', 'timeFrame': 'Within the 10 minutes after the infusion synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline'}]",[],1,18 Years,70 Years,ALL,True,Clinical Hospital Centre Zagreb,OTHER,1,15.0,ACTUAL,2025-09-01T16:18:17.185367,v2_robust,True,True,True,False,False,
NCT02490878,Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases,Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases,bevacizumab,"['bevacizumab', 'corticosteroids']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Radionecrosis,"['Radionecrosis', 'Brain Metastases']",[],TERMINATED,Slow accrual,2016-04,2022-12-15,"[{'measure': 'Change in M. D. Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score', 'description': 'The MD Anderson Symptom Inventory for brain tumor (MDASI-BT) is a 28-item multi-symptom patient-reported outcome measure assessing the severity of symptoms experienced by cancer patients and the interference with daily living caused by these symptoms, with 9 items specific to brain tumors. Each item ranges from 0 (best condition) to 10 (worst condition). A subscale score (Symptom Severity) is the average of the subscale items with 0 being ""not present"" and 10 being ""as bad as you can imagine."", given that a specified minimum numbers of items were completed. A negative change in score from baseline to given time point indicates a worsening score.', 'timeFrame': 'Baseline, 2, 4, 6 and 8 weeks'}]","[{'measure': 'Toxicity (CTCAE Version 4.0)', 'description': 'Toxicity associated with bevacizumab and corticosteroids in patients with radionecrosis using CTCAE Version 4.0. The number of patients reporting a grade 3 or higher, 4 or higher, or 5 at least possibly related to treatment are included in this table.', 'timeFrame': 'Up to 1.5 years post-treatment'}, {'measure': 'Quality of Life Measure Using the Single Item Linear Analogue Scale (LASA)', 'description': 'The Linear Analogue Scale used is a 5-question survey. Patients are asked to score the following questions on a 1(as bad as it can be) -10 (as good as it can be) scale: 1) your overall quality of life, 2) your overall (intellectual) well being, 3) your overall physical well being, 4) your overall emotional well being, and 5) your overall spiritual well being. The change in score was computed from baseline to 1.5 years post-treatment. A negative difference is thought of as a worsening score from baseline.', 'timeFrame': 'Up to 1.5 years post-treatment'}, {'measure': 'Quality of Life Measure Using the Dexamethasone Symptoms Questionnaire - Chronic (DSQ-C)', 'description': 'The DSQ-C was developed for use in the brain tumor patient population. It consists of 18 questions rated on a 4-point scale (1 to 4, with 4 indicating a worse symptom) to indicate the presence and severity of symptoms. For each patient, the sum across all 18 questions were computed(18-72, with 18 being a score of 1 for each of the 18 questions and 72 being a score of 4 for each of the questions, refering to the previous sentence, a score of 18(a score of 1, 18 times) indicates the best possible score. A score of 72(a score of 4, 18 times) indicates the worst possible. The mean for total score across each week (weeks 2, 4, 6, 8) is reported.', 'timeFrame': 'Baseline and weeks 2, 4, 6, 8 of treatment'}, {'measure': 'Quality of Life Measure Using the The M. D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) Score.', 'description': 'The MDASI-BT was developed and validated for use in the brain tumor patient population, including those with brain metastases and typically requires less than 4 minutes to complete. It consists of 23 symptoms rated on a 0 to 10 numerical rating scale (NRS) to indicate the presence and severity of the symptom, with 0 being ""not present"" and 10 being ""as bad as you can imagine."" MDASI-BT Symptom Scoring: A global symptom score for the MDASI symptom severity scale is obtained by taking the average of the 23 items together. This puts the score on a 0-10 scalenumerical rating scale (NRS) to indicate the presence and severity of the symptom, with 0 being ""not present"" and 10 being ""as bad as you can imagine."" The mean global symptom at baseline and at weeks 2, 4, 6, 8 were used in this analysis.', 'timeFrame': 'Up to 1.5 years post-treatment'}, {'measure': 'Progression Free Survival', 'description': 'Progression free survival is defined as the time from start of treatment to the earliest of the date patient stops placebo or bevacizumab for either alternative therapy or crossover to bevacizumab (if initially on placebo). Result will be summarized by Kaplan-Meier method.', 'timeFrame': 'Up to 16 weeks'}, {'measure': 'Time to Maximum Radiographic Response', 'description': 'Time from start of treatment to maximum radiographic response', 'timeFrame': 'Up to 16 weeks'}, {'measure': 'Time to Stopping Corticosteroids', 'description': 'Time to stopping corticosteroids is defined as the time from start of protocol treatment to the last day corticosteroids were given. Time to stopping corticosteroid will be summarized by Kaplan-Meier curve with log-rank tests conducted to investigate differences between treatment arms.', 'timeFrame': 'Up to 16 weeks'}]",8,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,2,19.0,ACTUAL,2025-09-01T16:18:17.185404,v2_robust,True,True,False,True,False,Slow accrual
NCT02372578,Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy,"A Phase 2a Randomized, Double-Blind, Multicenter, Placebo and Active Controlled Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy",ASP3662,"['ASP3662', 'pregabalin placebo', 'pregabalin', 'ASP3662 placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Painful Diabetic Peripheral Neuropathy (PDPN),['Painful Diabetic Peripheral Neuropathy (PDPN)'],"['Painful diabetic peripheral neuropathy (PDPN)', 'ASP3662']",TERMINATED,The study was terminated due to futility analysis.,2015-05-27,2016-05-20,"[{'measure': 'Change from Baseline in mean 24-hour average pain intensity as reported on the NPRS', 'description': 'Numerical Pain Rating Scale (NPRS)', 'timeFrame': 'Baseline to Week 6/ End of Treatment (EOT)'}]","[{'measure': 'Percentage of Responders in mean 24-hour average pain intensity score', 'timeFrame': 'Baseline to Week 6/ EOT'}, {'measure': 'Change from Baseline in mean of 24-hour average pain intensity score', 'timeFrame': 'Baseline to Weeks 1, 2, 3, 4, 5 and 6'}, {'measure': 'Change from Baseline in mean daily worst pain score', 'timeFrame': 'Baseline to Week 6/ EOT'}, {'measure': 'Change from Baseline in mean daily average pain score', 'timeFrame': 'Baseline to Week 6/ EOT'}, {'measure': 'Patient Global Impression Change (PGIC)', 'timeFrame': 'Week 6/ EOT'}, {'measure': 'Clinical Global Impression of Change (CGIC)', 'timeFrame': 'Week 6/ EOT'}]",7,18 Years,75 Years,ALL,False,"Astellas Pharma Global Development, Inc.",INDUSTRY,0,115.0,ACTUAL,2025-09-01T16:18:17.185463,v2_robust,True,True,False,True,False,The study was terminated due to futility analysis.
NCT01469078,Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D),Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D) (PK-CKD-05),Monofer®,['Monofer®'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Kidney Disease,['Chronic Kidney Disease'],"['Chronic Kidney Disease', 'CKD stage 5', 'Iron deficiency']",COMPLETED,,2011-10,2012-11,"[{'measure': 'Determination of changes in Iron pharmacokinetic parameters from plasma/serum concentration profile', 'description': 'The follwoing parameter will be determined: AUC0-t, AUC, Cmax, Tmax, Ke, and T1/2', 'timeFrame': 'From exposure to 7 days post-exposure'}]","[{'measure': 'Changes in pharmacodynamic parametres', 'description': 'Changes in the following parametres will be determined: Hemoglobin (Hb), Reticulocyte Count, Reticuloycyte Hemoglobin Content (CHr), Ferritin, Total Iron Binding Capacity (TIBC) and Transferrin Saturation (TfS)', 'timeFrame': 'From 0 hours to 4, 8, 24, 48, 72 hours post-exposure and end of study visit'}, {'measure': 'Safety evaluation', 'description': 'The following parameters will be evaluated: Laboratory safety variable, physical examination, vital signs and Electrocardiogram (ECG)', 'timeFrame': 'From screening to 7 days post-exposure'}]",3,18 Years,,ALL,False,Pharmacosmos A/S,INDUSTRY,1,18.0,ACTUAL,2025-09-01T16:18:17.185529,v2_robust,True,True,True,False,True,
NCT06892678,DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma,DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma,DFMO,"['DFMO', 'Difluoromethylornithine', 'iWilfin']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Osteosarcoma Recurrent,"['Osteosarcoma Recurrent', ""Ewing's Tumor Recurrent""]",[],RECRUITING,,2025-04-07,2030-04,"[{'measure': 'Feasibility of Administering DFMO', 'description': 'Feasibility will be defined as the ability to successfully administer DFMO to at least 80% of subjects who initiate therapy until either disease recurrence or completion of the maximally allowed duration of therapy. Results will be summarized using basic descriptive statistics.', 'timeFrame': 'Up to 2 years'}]","[{'measure': 'Event Free Survival', 'description': 'The number/percentage of participants with event-free survival (EFS) will be determined. Event-free survival will be defined as the time from diagnosis until drug discontinuation, disease progression, recurrence at any site, secondary malignancy, death from any cause, or last follow-up, whichever is observed first.', 'timeFrame': 'Up to 2 years'}]",2,,39 Years,ALL,False,Montefiore Medical Center,OTHER,1,15.0,ESTIMATED,2025-09-01T16:18:17.185542,v2_robust,True,True,False,False,False,
NCT00325078,Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease,"Tumor Necrosis Factor Alpha Inhibitor (Lnfliximab, Adalimumab) Treatment for Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease: A Phase I/II Study Assessing Clinical and Immune Responses to Treatment and Genetic Influences",Infliximab,['Infliximab'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Chronic Granulomatous Disease,"['Chronic Granulomatous Disease', ""Crohn'S-like IBD"", 'Inflammatory Bowel Disease (IBD)']","['Remicade', ""Crohn's Disease"", 'IBD', 'CGD Infection', 'Infliximab', 'Chorionic Granulomatous Disease', 'CGD', 'Inflammatory Bowel Disease']",TERMINATED,Insufficient patient participation,2006-05,2012-06,"[{'measure': 'Safety of Study Drug', 'description': 'Number of Infections from Baseline to 1 year', 'timeFrame': 'Baseline to 1 year'}, {'measure': 'Efficacy of Treatment With Study Drug', 'description': ""Measured participant Crohn's disease Activity Index (CDAI) values. The CDAI is a tool comprised of clinical and laboratory factors such as stool frequency, consistency, abdominal pain, general well being, weight and blood profile as an objective measure of disease activity. A higher score corresponds to greater severity of inflammatory bowel disease; severe disease conventionally defined as \\>450, a remission as \\<150, and a response to treatment as a fall of CDAI of \\>70 points. Infections and IBD are not expected in healthy control subjects. The greater the score, the more severe the disease, and a score of less than 5 represents clinical remission."", 'timeFrame': 'Baseline, 1 year'}]",[],2,10 Years,,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,40.0,ACTUAL,2025-09-01T16:18:17.185627,v2_robust,True,True,False,True,True,Insufficient patient participation
NCT06281678,A Study of IBI363 in Subjects with Advanced Solid Malignancies,"A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies",IBI363,['IBI363'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Melanoma,"['Melanoma', 'Non-small Cell Lung Cancer', 'Colorectal Cancer', 'Renal Cell Cancer']",[],RECRUITING,,2024-04-08,2026-12-31,"[{'measure': 'Objective response rate (ORR)', 'timeFrame': 'up to 2 years'}]","[{'measure': 'Adverse Event （AE）', 'timeFrame': 'Up to 90 days post last dose'}, {'measure': 'Dose-limiting Toxicity （DLT）', 'timeFrame': 'The DLT observation period is 35 days starting from the first day of cycle 1 (C1D1) for subjects assigned to 1000 μg/kg Q2W, while 28 days starting from the C1D1 for subjects assigned to 2000/3000/4000 μg/kg Q3W.'}]",3,18 Years,,ALL,False,Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,0,178.0,ESTIMATED,2025-09-01T16:18:17.185666,v2_robust,True,True,False,False,True,
NCT02423278,The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer,"The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer: a Multicenter, Open-label, Randomized Trial",S-1+Oxaliplatin,"['S-1+Oxaliplatin', 'SOX chemo Regimen']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Gastric Cancer,"['Gastric Cancer', 'Surgery', 'Effects of Chemotherapy']","['gastrectomy', 'lymphadenectomy', 'gastric cancer', 'adjuvant chemotherapy', 'overall survival']",UNKNOWN,,2010-01,2020-12,"[{'measure': 'Overall Survival', 'timeFrame': 'five years after surgery'}, {'measure': 'Relapse-free Survival', 'timeFrame': 'five years after surgery'}]","[{'measure': 'Early complications', 'description': 'Rate of early postoperative events, such as anastomotic leak, intra-abdominal hemorrhage, adhesive intestinal obstruction and surgical site infection, in each arm.', 'timeFrame': 'within the first 30 days after surgery'}, {'measure': 'Perioperative mortality', 'timeFrame': 'within the first 30 days after surgery'}, {'measure': 'Life quality measured by HRQOL score', 'description': 'a questionnaire form would be sent to each enrolled patients after surgery.', 'timeFrame': 'five years after surgery'}, {'measure': 'Length of Hospital stay', 'description': 'The duration between admission and final discharge from hospital. An average of 4 weeks is expected.', 'timeFrame': 'an expected average of 4 weeks after admission'}]",6,18 Years,65 Years,ALL,False,"First Affiliated Hospital, Sun Yat-Sen University",OTHER,3,200.0,ESTIMATED,2025-09-01T16:18:17.185721,v2_robust,True,True,False,False,False,
NCT03525678,A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody,"A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)",Belantamab mafodotin frozen liquid,"['Belantamab mafodotin lyophilized powder', 'Belantamab mafodotin frozen liquid']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,['Multiple Myeloma'],"['Relapsed Refractory multiple myeloma', 'Antibody-drug conjugate', 'Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events', 'Quality of Life Questionnaire 20-item Multiple Myeloma module', 'Multiple Myeloma', 'Quality of Life Questionnaire 30-item Core module']",COMPLETED,,2018-06-18,2024-09-12,"[{'measure': 'Overall Response Rate (ORR) by Independent Review Committee (IRC) (Full Analysis Population)', 'description': 'ORR was determined according to the 2016 international myeloma working group (IMWG) response criteria by IRC. ORR was calculated as the percentage of participants with a confirmed partial response (PR) or better (that is \\[i.e.\\], PR, very good partial response \\[VGPR\\], complete response \\[CR\\] and stringent complete response \\[sCR\\]). Confidence intervals were based on the exact method.', 'timeFrame': 'Up to 48 weeks'}, {'measure': 'Overall Response Rate by Independent Review Committee (Efficacy Population)', 'description': 'ORR was determined according to the 2016 IMWG response criteria by IRC. ORR was calculated as the percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Efficacy Population comprised of first 130 intent-to-treat participants whether or not randomized treatment (frozen solution) was administered. Intent-to-treat Population comprised of all randomized participants whether or not randomized treatment was administered.', 'timeFrame': 'Up to 48 weeks'}]","[{'measure': 'Overall Response Rate by Investigator Assessment (IA) (Full Analysis Population)', 'description': 'ORR was determined by the investigator according to the 2016 IMWG response criteria. ORR was calculated as the percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Overall Response Rate by Investigator Assessment (Efficacy Population)', 'description': 'ORR was determined by the investigator according to the 2016 IMWG response criteria. ORR was calculated as the percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Clinical Benefit Rate (CBR) by Investigator Assessment (Full Analysis Population)', 'description': 'CBR was determined by the investigator according to the 2016 IMWG response criteria. CBR was calculated as the percentage of participants with a confirmed minimal response (MR) or better (i.e., MR, PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Clinical Benefit Rate by Investigator Assessment (Efficacy Population)', 'description': 'CBR was determined by the investigator according to the 2016 IMWG response criteria. CBR was calculated as the percentage of participants with a confirmed MR or better (i.e., MR, PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Clinical Benefit Rate by Independent Review Committee (Full Analysis Population)', 'description': 'CBR was determined according to the 2016 IMWG response criteria by IRC. CBR was calculated as the percentage of participants with a confirmed MR or better (i.e., MR, PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Clinical Benefit Rate by Independent Review Committee (Efficacy Population)', 'description': 'CBR was determined according to the 2016 IMWG response criteria by IRC. CBR was calculated as the percentage of participants with a confirmed MR or better (i.e., MR, PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Duration of Response (DoR) by Investigator Assessment (Full Analysis Population)', 'description': 'DoR is defined as the time from first documented evidence of PR or better until the earliest date of documented disease progression (PD) per IMWG response criteria; or death due to PD among participants who achieved an overall response, i.e., confirmed PR or better. DOR based on responses assessed by investigator is presented. Median and inter-quartile range (first quartile and third quartile) of DOR are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Duration of Response by Investigator Assessment (Efficacy Population)', 'description': 'DoR is defined as the time from first documented evidence of PR or better until the earliest date of documented PD per IMWG response criteria; or death due to PD among participants who achieved an overall response, i.e., confirmed PR or better. DOR based on responses assessed by investigator is presented. Median and inter-quartile range (first quartile and third quartile) of DOR are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Duration of Response by Independent Review Committee (Full Analysis Population)', 'description': 'DoR is defined as the time from first documented evidence of PR or better until the earliest date of documented PD per IMWG response criteria; or death due to PD among participants who achieved an overall response, i.e., confirmed PR or better. DOR based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of DOR are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Duration of Response by Independent Review Committee (Efficacy Population)', 'description': 'DoR is defined as the time from first documented evidence of PR or better until the earliest date of documented PD per IMWG response criteria; or death due to PD among participants who achieved an overall response, i.e., confirmed PR or better. DOR based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of DOR are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Time to Response by Investigator Assessment (Full Analysis Population)', 'description': 'Time to response is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better). Time to response based on responses assessed by investigator is presented. Median and inter-quartile range (first quartile and third quartile) of time to response are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Time to Response by Investigator Assessment (Efficacy Population)', 'description': 'Time to response is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better). Time to response based on responses assessed by investigator is presented. Median and inter-quartile range (first quartile and third quartile) of time to response are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Time to Response by Independent Review Committee (Full Analysis Population)', 'description': 'Time to response is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better). Time to response based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of time to response are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Time to Response by Independent Review Committee (Efficacy Population)', 'description': 'Time to response is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better). Time to response based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of time to response are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Progression Free Survival by Investigator Assessment', 'description': 'Progression free survival is defined as the time from randomization until the earliest date of documented PD per IMWG, or death due to any cause. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Progression free survival based on responses assessed by investigator is presented. Median and inter-quartile range (first quartile and third quartile) of progression free survival are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Progression Free Survival by Independent Review Committee', 'description': 'Progression free survival is defined as the time from randomization until the earliest date of documented PD per IMWG, or death due to any cause. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Progression free survival based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of progression free survival are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Time to Progression by Investigator Assessment', 'description': 'Time to progression is defined as the time from randomization until the earliest date of documented PD per IMWG, or death due to PD. Time to Progression based on responses assessed by investigator is presented. Median and inter-quartile range (first quartile and third quartile) of time to progression are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Time to Progression by Independent Review Committee', 'description': 'Time to progression is defined as the time from randomization until the earliest date of documented PD per IMWG, or death due to PD. Time to Progression based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of time to progression are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Overall Survival', 'description': 'Overall survival is defined as the time from randomization until death due to any cause. Overall survival was analyzed using the Kaplan-Meier method by dose level. Median and inter-quartile range (first quartile and third quartile) of overall survival are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Number of Participants With Change From Baseline in Hematology Parameters With Respect to the Normal Range', 'description': 'Following parameters were assessed:basophils,eosinophils,hematocrit,mean corpuscular hemoglobin (MCH),MCH concentration,MC volume,monocyte,erythrocytes, reticulocytes.Baseline is latest pre-dose assessment(Day1)with a non-missing value, including unscheduled visits.Data was categorized as decrease to low(value below lower limit of normal range\\[LNR\\]),increase to high(value above upper LNR),change to normal/no change(NC).If values were unchanged(eg.high to high) or whose value became normal,were recorded in change to normal/NC category.Participants were counted twice if participant had both decreased to low/increased to high during post-Baseline(PB).Data for worst case PB is presented.Full Safety Population(FSP) comprised of all participants who received at least 1dose of study drug(frozen liquid or lyophilized powder). 3 out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Grade Change From Baseline in Hematology Parameters', 'description': 'Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), lymphocyte count (Lymph), neutrophil count (Neutro), platelet count (PC), and leukocyte count (leuko). The laboratory parameters were graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with increase to grade 3 and increase to grade 4 have been presented.', 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Change From Baseline in Clinical Chemistry Parameters With Respect to the Normal Range', 'description': 'Blood samples were collected for analysis of clinical chemistry parameters: bicarbonate, direct bilirubin(D.Bil), calcium, chloride, lactate dehydrogenase(LDH), total protein,Urea enzymatic colorimetry.Baseline is latest pre-dose assessment(Day 1) with a non-missing value, including unscheduled visits. Number of participants with worst case clinical chemistry change from Baseline with respect to normal range are presented. Data was categorized as decrease to low (value below the lower LNR), increase to high (value above the upper LNR) and change to normal or NC. If values were unchanged (example: high to high), or whose value became normal, were recorded in the change to normal or NC category. Participants were counted twice if the participant had both decreased to low and increased to high during post Baseline. 3 out of 221participants did not receive any study treatment, were excluded from FSP.', 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters', 'description': 'Blood samples were collected for analysis of:glucose(Gl), albumin, alkaline phosphatase (ALP), alanine aminotransferase(ALT), aspartate aminotransferase(AST), total bilirubin(T.Bil),creatinine kinase (CK),creatinine, gamma glutamyl transferase (GGT),potassium (Pot), magnesium (Mg),sodium (Sod), phosphate (Ph) urate \\& estimated glomerular filtration rate (eGFR). Values (Hyper and hypo) for Gl, Pot, Mg and Sod is presented. Grading was according to NCI-CTCAE version 4.03. Grade1: mild; Grade2: moderate; Grade3: severe or medically significant; Grade4: life-threatening consequences.Baseline is latest pre-dose assessment(Day 1) with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case PB is presented.Only those participants with increase to grade3 and increase to grade4 have been presented. 3 out of 221participants did not receive any study treatment, were excluded from FSP.', 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Abnormal Findings During Physical Examination', 'description': 'Physical examination included assessment of the head, eyes, ears, nose, throat, skin, thyroid, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes, and extremities. This analysis was planned, but data was not collected and captured in the database.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Number of Participants With Change From Baseline in Pulse Rate', 'description': ""Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Number of participants with worst case change from Baseline in pulse rate is presented. Data is categorized as: pulse rate 'decrease to \\<60 beats per minute \\[bpm\\]', 'increase to \\>100 bpm' and 'change to normal or no change'. If values were unchanged (example: increase to \\>100 bpm to increase to \\>100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to \\<60 bpm' and 'increased to \\>100 bpm' during post Baseline. Data for worst-case post Baseline is presented."", 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Change From Baseline in Body Temperature', 'description': ""Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Number of participants with worst case change from Baseline in body temperature are presented. Data is categorized as: body temperature 'decrease to \\<=35 degrees celsius', 'increase to \\>=38 degrees celsius' and 'change to normal or no change'. If values were unchanged (example: increase to \\>=38 to increase to \\>=38 degrees celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to \\<=35' and 'increased to \\>=38 degrees celsius' during post Baseline. Data for worst-case post Baseline is presented."", 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Grade Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)', 'description': 'SBP and DBP were graded using NCI CTCAE version 4.03. For SBP: Grade 0: \\<120 millimeter mercury (mmHg); Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: \\>=160 mmHg. For DBP: Grade 0: \\<80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: \\>=100 mmHg. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with increase to grade 2 and increase to grade 3 have been presented.', 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Serious Adverse Events (SAEs), Common (>=5%) Non-serious Adverse Events and Adverse Events of Special Interest (AESI)', 'description': 'An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Adverse events which were not Serious were considered as non-serious adverse events. Number of participants who had SAEs and common (\\>=5%) non-SAEs are presented. Number of participants with AESI (keratopathy, dry eye events, blurred vision, thrombocytopenia, infusion-related reactions, corneal events and neutropenia) are also presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Number of Participants With Change From Baseline in Best Corrected Visual Acuity (BCVA) Test Scores', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. BCVA score was assessed individually for each eye. BCVA test scores were categorized as no change/improved vision, possible worsened vision and definite worsened vision. No change/improved vision was defined as a change from Baseline \\<0.12 Logarithm of the Minimum Angle of Resolution (logMAR) score; a possible worsened vision was defined as a change from Baseline \\>=0.12 to \\<0.3 logMAR score; a definite worsened vision was defined as a change from Baseline \\>=0.3 logMAR score. Data for worst-case change from Baseline is presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Intraocular Pressure (IOP) >=22 mmHg Anytime Post-Baseline', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. IOP was assessed individually for each eye. Number of participants with IOP \\>=22 mmHg anytime post-Baseline are presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Number of Participants With Shift in Pupillary Examination Findings From Normal (Baseline) to Abnormal (Worst Post-Baseline)', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Number of participants with shift in pupillary examination findings from normal (Baseline) to abnormal (worst post-Baseline) are presented.', 'timeFrame': 'Baseline and Up to 186 weeks'}, {'measure': 'Number of Participants With Shift in Extraocular Muscle Movement From Yes (Baseline) to no (Worst Post-Baseline)', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Extraocular muscle movement was assessed individually for each eye. Number of participants with shift in extraocular muscle movement from yes (Baseline) to no (worst post-Baseline) are presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Baseline and Up to 186 weeks'}, {'measure': 'Number of Participants With Shift in Corneal Epithelium Findings From Normal (Baseline) to Abnormal (Worst Post-Baseline) for Corneal Epithelium (CE) and Corneal Stroma (CS)', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Corneal epithelium findings for CE and CS were assessed individually for each eye. Number of participants with shift in corneal epithelium findings from normal (Baseline) to abnormal (worst post-Baseline) for CE and CS are presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Baseline and Up to 186 weeks'}, {'measure': 'Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline)', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Corneal epithelium findings like active edema, active opacity, corneal neovascularization (CN), corneal ulcer, epithelial microcystic edema (EME) and subepithelial were performed using a slit lamp. Number of participants with shift in corneal epithelium findings from no (Baseline) to yes (worst post-Baseline) are presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Baseline and Up to 186 weeks'}, {'measure': 'Number of Participants With Shift in Tear Break-up Time From >10 Seconds (Baseline) to <=5 Seconds (Worst Post-Baseline)', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Number of participants with shift in tear break-up time from \\>10 seconds (Baseline) to \\<=5 seconds (worst post-Baseline) are presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Baseline and Up to 186 weeks'}, {'measure': 'Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. Pharmacokinetic (PK) parameters of GSK2857916 were calculated using non-compartmental methods. Full Pharmacokinetic (PK) Population comprised of all participants in the Full Safety Population who had atleast 1 non-missing PK assessment.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, end of infusion (EOI), 2 hours and 24 hours post start of infusion (SOI) on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Area Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Maximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Time to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Terminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'AUC(0-infinity) of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'AUC(0-tau) of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'AUC(0-tlast) of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Cmax of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Tmax of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 't1/2 of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'AUC(0-infinity) of Cysteine-maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'AUC(0-tau) of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'AUC(0-tlast) of Cysteine-maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 't1/2 of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody (ADA) Result', 'description': ""Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated electrochemiluminescent (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Confirmed positive ADA samples were further characterized in the titration assay to quasi-quantitate the amount of ADA in the sample. Additionally, confirmed positive ADA samples were also tested in a validated neutralizing antibody assay to determine the potential neutralizing activity of the ADA."", 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Titers of Anti-drug Antibodies Against GSK2857916', 'description': 'Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. Titers of anti-drug antibodies against GSK2857916 is presented. No participant was found with positive results for ADA test in arm GSK2857916 3.4 mg/kg (Lyophilized). Hence, titer values was not presented for the arm.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)', 'description': 'The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. It included symptomatic toxicities drawn from the CTCAE like blurred vision, chills, constipation, decreased appetite, fatigue, general pain, heart palpitations, mouth/throat sores, nausea, nosebleed, shortness of breath, vomiting and watery eyes. Items were scored individually on a 0 to 4 scale for severity, frequency and interference. Number of participants with symptomatic AEs (those who had a maximum post-Baseline rating greater than 0, example; 1, 2, 3, or 4) measured by PRO-CTCAE are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Worst Change From Baseline in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Score', 'description': 'The NEI-VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question to assess the impact of ocular toxicity on visual function. Items were coded to a 0 to 100 scale and averaged to calculate domains. Domain scores ranged from 0 to 100; higher scores are better. Therefore, increase in score means improvement. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for worst-case post Baseline is presented.', 'timeFrame': 'Baseline (Day 1) and up to Week 186'}, {'measure': 'Worst Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score', 'description': 'The OSDI is a 12-item questionnaire designed to assess both the frequency of dry eye symptoms and their impact on vision-related functioning. The total OSDI score was calculated as (sum of scores for all questions answered\\*100) divided by (total number of questions answered\\*4). Domain scores ranged from 0 to 100; lower scores are better. Therefore, decrease in score from Baseline means improvement. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for worst-case post Baseline is presented.', 'timeFrame': 'Baseline (Day 1) and up to Week 186'}, {'measure': 'Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score', 'description': 'The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \\[PF\\], role functioning \\[RF\\], cognitive functioning \\[CF\\], emotional functioning \\[EF\\] and social functioning \\[SF\\]), three symptom scales (fatigue, pain and nausea/vomiting \\[N/V\\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \\[AL\\] and financial difficulties \\[FD\\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.', 'timeFrame': 'Baseline (Day 1) and Week 07, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 61, Week 79, Week 97, Week 115, Week 133, Week 151, Week 169, and Week 186'}, {'measure': 'Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score', 'description': 'The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The module comprised of 20 questions that addressed four myeloma-specific HRQoL domains: disease symptoms (DS), side effects of treatment (SET), future perspective (FP) and body image (BI). Responses are 1 to 4. Scores were averaged and scales were transformed to 0 to 100 scale. A high score for disease symptoms and side effects of treatment represented a high level of symptomatology or problems, whereas a high score for future perspective and body image represented better outcomes. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.', 'timeFrame': 'Baseline (Day 1) and Week 07, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 61, Week 79, Week 97, Week 115, Week 133, Week 151, Week 169, and Week 186'}]",62,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,221.0,ACTUAL,2025-09-01T16:18:17.185756,v2_robust,True,True,True,False,True,
NCT06497985,A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients,"A Randomised, Open-label, Multicenter Phase III Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients Who Failed at Least Second-line Standard Therapies",Tucidinostat,"['Fruquintinib', 'Chidamide', 'Sintilimab', 'Tucidinostat', 'Bevacizumab']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Colorectal Cancer,['Colorectal Cancer'],[],RECRUITING,,2024-11-27,2028-09-30,"[{'measure': 'Overall Survival (OS)', 'description': 'From randomization to the date of death from any cause.', 'timeFrame': 'Up to approximately 2 years'}]","[{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS assessed by investigator per RECIST v1.1, measured from the date of randomization until progression or death, whichever occurs first.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Overall response rate (ORR)', 'description': 'Proportion of participants who achieved complete response (CR) or partial response (PR) assessed by investigator according to RECIST v1.1.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Duration of response (DOR)', 'description': 'From the first occurrence of PR or CR until the date of first documented progression according to RECIST 1.1, or death, whichever occurs first.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Disease control rate (DCR)', 'description': 'Proportion of participants who achieved CR or PR, or stable disease (SD) assessed by investigator according to RECIST v1.1.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score', 'description': 'EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire, contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and global health status/QOL scale.Change from baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life Scale scores will be presented.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores', 'description': 'The EQ-5D-5L is a self-reported health status questionnaire that consisted of 2 components: health state profile and optional VAS. EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problem, slight problem, moderate problem, severe problem, and extreme problem. Change from baseline in health utility index scores will be presented.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS) Score', 'description': ""EQ-5D-5L consisted of 2 components: health state profile and optional VAS. The VAS records the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. Change from baseline in EQ-5D-5L VAS scores will be presented."", 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Safety and Tolerability', 'description': 'Number of Participants Who Experience an Adverse Event (AE) assessed by CTCAE v5.0.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Plasma concentrations of tucidinostat', 'description': 'Plasma samples were collected from the participants at the defined time points. Plasma concentrations were measured using a validated, specific, and sensitive method.', 'timeFrame': 'Up to approximately 6 months'}]",10,18 Years,75 Years,ALL,False,"Chipscreen Biosciences, Ltd.",INDUSTRY,0,430.0,ESTIMATED,2025-09-01T16:18:17.185841,v2_robust,True,True,False,False,True,
NCT03520985,Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma,"Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial",Pomalidomide,"['Pomalidomide', 'Dexamethasone', 'Imnovid®']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Refractory Multiple Myeloma,['Refractory Multiple Myeloma'],"['refractory Multiple Myeloma', 'Phase II', 'Pomalidomide', 'OptiPOM']",TERMINATED,Feasibility (low patient accrual and financial reasons),2018-10-01,2021-02-03,"[{'measure': 'Overall Response Rate (ORR)', 'description': 'OR is defined as minimal response or better, assessed according to the IMWG criteria.', 'timeFrame': 'From date of registration until 28 days after last dose of trial medication with longest treatment time of approximately 36 months'}]","[{'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from registration until death from any cause. Patients not having an event at the time of analysis will be censored at the date they were last known to be alive.', 'timeFrame': 'From date of registration until 28 days after last dose of trial medication with longest treatment time of approximately 36 months'}, {'measure': 'Overall Survival (OS) at 12 months', 'description': 'OS, as defined above, will be evaluated at 12 months.', 'timeFrame': 'at 12 months'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS is defined as the time from registration until progression according the IMWG criteria or death from any cause, whichever occurs first. Patients not having an event at the time of analysis as well as patients starting a new anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting a new treatment, if any.', 'timeFrame': 'From date of registration until 28 days after last dose of trial medication with longest treatment time of approximately 36 months'}]",4,18 Years,,ALL,False,Swiss Cancer Institute,OTHER,0,34.0,ACTUAL,2025-09-01T16:18:17.185897,v2_robust,True,True,False,True,False,Feasibility (low patient accrual and financial reasons)
NCT00376285,"Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033","A Phase 1, Randomized, Investigator and Subject Blind, Sponsor Open Study to Determine the Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033 When Co-Administered in Otherwise Healthy Obese Adult Subjects","CP-742,033","['CP-742,033', 'Fenofibrate']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Obesity,['Obesity'],[],WITHDRAWN,,2006-11,,[{'measure': 'Toleration and safety'}],"[{'measure': 'Efficacy biomarkers, serum lipids'}]",2,18 Years,65 Years,ALL,True,Pfizer,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:17.185982,v2_robust,True,True,False,True,True,
NCT02662985,Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA),"A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis",AIN457 (secukinumab),"['AIN457 (secukinumab)', 'Secukinumab', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Psoriatic Arthritis,['Psoriatic Arthritis'],"['Power Doppler Ultrasonography', 'Psoriatic Arthritis', 'Enthesitis', 'Synovitis', 'Outcome Measures in Rheumatology', 'Spondyloarthritis Research Consortium of Canada', 'active psoriatic arthritis', 'secukinumab', 'Arthritis', 'GLOESS', 'monoclonal antibody', 'PsA']",COMPLETED,,2016-08-22,2020-11-10,"[{'measure': 'Difference Between Secukinumab and Placebo in Terms of Joint Synovitis as Measured by the Power Doppler Ultrasonography (PDUS) Global OMERACT-EULAR Synovitis Score (GLOESS)', 'description': 'Mixed model repeated measures (MMRM) analysis of change in Global OMERACT-EULAR Synovitis Score (GLOESS) score at Week 12 (observed data) to compare treatments\n\nThe range for the GLOESS score is 0 to 144. GLOESS is the ultrasound scoring system measured for 24 pairs of joints. The scoring is from 0 to 3 for each joint; so the minimum score can be 0 and maximum can be 144.', 'timeFrame': '12 weeks'}]","[{'measure': 'Proportion of Participants With American College of Rheumatology (ACR)-20 Response', 'description': ""ACR 20 responder has ≥ 20% improvement in TJC and SJC and \\>20% improvement in 3 of the following 5 domains: patient's assessment of disease activity, physician's assessment of disease activity, patient's"", 'timeFrame': 'Week 12'}, {'measure': 'Proportion of Participants With American College of Rheumatology (ACR)-50 Response', 'description': ""ACR 50 responder has ≥ 50% improvement in TJC and SJC and \\>25% improvement in 3 of the following 5 domains: patient's assessment of disease activity, physician's assessment of disease activity, patient's assessment of PsA pain, HAQ-DI, or hsCRP."", 'timeFrame': 'Week 12'}, {'measure': 'Spondyloarthritis Research Consortium of Canada (SPARCC)', 'description': 'Repeated measures mixed effect (MMRM) analysis of SPARCC total score change from baseline to Week 12 between the 2 treatment groups.\n\nSPARCC index ranges from 0 to 16.', 'timeFrame': 'Baseline to Week 12'}]",4,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,166.0,ACTUAL,2025-09-01T16:18:17.186094,v2_robust,True,True,True,False,False,
NCT06624085,A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,"A Phase Ib Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",Glofitamab,"['Oxaliplatin', 'Gemcitabine', 'Tocilizumab', 'Glofitamab', 'Obinutuzumab']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Lymphoma,['Lymphoma'],[],RECRUITING,,2025-04-28,2030-03-31,"[{'measure': 'Incidence of Adverse Events (AEs)', 'timeFrame': 'Up to 3 years'}, {'measure': 'Complete response (CR) rate', 'timeFrame': 'Up to 3 years'}]","[{'measure': 'Objective response rate (ORR)', 'timeFrame': 'Up to 3 years'}, {'measure': 'Duration of response (DOR)', 'timeFrame': 'From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 3 years)'}, {'measure': 'Duration of CR', 'timeFrame': 'From the first occurrence of a documented CR to disease progression or death from any cause, whichever occurs first (up to 3 years)'}, {'measure': 'Progression-free survival (PFS)', 'timeFrame': 'From enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 3 years)'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'From enrollment to date of death from any cause (up to 3 years)'}, {'measure': 'Serum concentration of glofitamab', 'timeFrame': 'Up to 3 years'}, {'measure': 'Incidence of anti-drug antibodies to glofitamab', 'timeFrame': 'Baseline up to 3 years'}]",9,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,50.0,ESTIMATED,2025-09-01T16:18:17.186156,v2_robust,True,True,False,False,True,
NCT04763343,Ketamine Treatment of Youth Suicide Attempters,Ketamine Treatment of Youth Suicide Attempters for Fast Reduction of Severe Suicide Risk and Facilitation of Long-term Collaborative Clinical Engagement: A Double Blind Randomized Placebo Controlled Trial,Ketamine Hydrochloride,"['Saline', 'Ketamine Hydrochloride']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Suicide, Attempted","['Suicide, Attempted']",[],RECRUITING,,2022-06-27,2026-09,"[{'measure': 'Rate of remission of suicidal symptoms at the end of treatment.', 'description': 'Remission of suicide symptoms will be defined by a 50% or greater reduction in the clinician-rated baseline Beck Scale for Suicidal Ideation (SSI) score, and SSI score less than the score of 4. SSI scores can range from 0 to 38, and a higher score indicates increased severity of suicidal ideation. The primary outcome of the remission rate will be compared between the two groups.', 'timeFrame': 'Up to 3 months post-discharge'}]","[{'measure': 'Number of CAMS sessions needed to achieve enduring mental state', 'description': 'Number of CAMS sessions needed to achieve enduring mental state', 'timeFrame': 'Up to 3 months post-discharge'}, {'measure': 'Change of Beck Scale for Suicide Ideation score will be analyzed', 'description': 'Change of Beck Scale for Suicide Ideation (SSI) score will be analyzed. SSI scores can range from 0 to 38, and a higher score indicates increased severity of suicidal ideation.', 'timeFrame': 'Up to 3 months post-discharge'}]",3,14 Years,30 Years,ALL,False,"Tatiana Falcone, MD",OTHER,3,62.0,ESTIMATED,2025-09-01T16:18:17.186170,v2_robust,True,True,False,False,False,
NCT02054143,The Effect of Sevoflurane on Cerebral CO2 Sensitivity and Systemic Arteries,The Effect of Sevoflurane on Cerebral Vasoreactivity Ans Systemic Arteries,Sevoflurane,"['Sevorane', 'Sevoflurane']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Sevoflurane Anesthesia,['Sevoflurane Anesthesia'],"['sevoflurane', 'cerebral vasoreactivity', 'arterial stiffness', 'Transcranial Doppler', 'SphygmoCor']",COMPLETED,,2012-11,2013-04,"[{'measure': 'Blood flow velocity in the middle cerebral artery', 'description': 'Systolic, diastolic and mean blood flow velocities are measured with transcranial doppler device.', 'timeFrame': 'Changes from baseline in blood flow velocity at the 15th, 20th and 25th minutes of the operation'}]","[{'measure': 'Arterial wall stiffness of the radial artery', 'description': 'The stiffness of the radial artery is assessed. Stiffness rate is concluded from the augmentation pressure and augmentation index, from which both values are provided by the tonometry device.', 'timeFrame': 'Changes from baseline in arterial stiffness at the 15th, 20th and 25th minutes of the operation'}, {'measure': 'Changes in the central systolic and diastolic blood pressure', 'description': 'CEntral blood pressure values are measured by means of tonometry device on the radial artery.', 'timeFrame': 'Changes from baseline in central blood pressure at the 15th, 20th and 25th minutes of the operation'}]",3,18 Years,60 Years,ALL,False,University of Debrecen,OTHER,0,24.0,ACTUAL,2025-09-01T16:18:17.186186,v2_robust,True,True,True,False,False,
NCT04277143,A Pharmacokinetics Study of Daptomycin in Critically Ill Patients and Effects of Daptomycin on Kidney,The Influence Factors of Pharmacokinetics/Pharmacodynamics of Daptomycin in Severe Patients and the the Effect of Different Blood Concentration of Daptomycin on the Outcomes of Renal Function,Daptomycin,['Daptomycin'],1,OBSERVATIONAL,[],,,"Outcome, Fatal","['Outcome, Fatal', 'Infection']","['daptomycin', 'pharmacokinetics', 'pharmacodynamics', 'critical ill patients', 'outcome']",UNKNOWN,,2020-12-01,2022-12-31,"[{'measure': 'Apparent volume of distribution', 'description': ""Apparent volume of distribution of daptomycin in the patient's blood"", 'timeFrame': '1 week'}, {'measure': 'Peak plasma concentration', 'description': 'Peak plasma concentration of daptomycin', 'timeFrame': '1 week'}, {'measure': 'Plasma trough concentration', 'description': 'Plasma trough concentration of daptomycin', 'timeFrame': '1 week'}, {'measure': 'Area under the plasma concentration versus time curve (AUC)', 'description': 'Area under the plasma concentration versus time curve (AUC) of daptomycin', 'timeFrame': '1 week'}, {'measure': 'Clearance of daptomycin', 'description': 'Daptomycin is metabolized mainly by the kidneys', 'timeFrame': '1 week'}, {'measure': 'Half-life', 'description': 'Half-life of plasma daptomycin', 'timeFrame': '1 week'}, {'measure': 'Protein binding rate', 'description': 'Reversible binding of daptomycin to plasma proteins (mainly serum albumin)', 'timeFrame': '1 week'}, {'measure': 'Serum creatinine', 'description': 'Serum creatinine can reflect kidney function', 'timeFrame': '1 week'}, {'measure': 'Urine output', 'description': 'Urine volume can reflect kidney function', 'timeFrame': '1 week'}, {'measure': 'Blood Urea Nitrogen', 'description': 'It can reflect kidney function', 'timeFrame': '1 week'}, {'measure': 'Urine protein', 'description': 'Reflect kidney function', 'timeFrame': '1 week'}, {'measure': 'Cystatin C', 'description': 'Reflect kidney function', 'timeFrame': '1 week'}, {'measure': 'β2-microglobulin(β2-MG)', 'description': 'Reflect kidney function', 'timeFrame': '1 week'}, {'measure': 'Major Adverse kidney Event（MAKE）', 'description': 'Major Adverse kidney Event（MAKE）Refers to death, need for renal replacement therapy, and creatinine levels that are twice or more the baseline value；It can reflects the outcome of renal function.', 'timeFrame': '28days'}, {'measure': 'ICU mortality', 'description': 'Reflect patient prognosis', 'timeFrame': '28days'}, {'measure': 'In-hospital mortality', 'description': 'Reflect patient prognosis', 'timeFrame': '28days'}, {'measure': 'ICU hospital stay length', 'description': 'Reflect patient prognosis', 'timeFrame': '28 days'}, {'measure': 'Total hospital stay length', 'description': 'Reflect patient prognosis', 'timeFrame': '28 days'}]","[{'measure': 'White blood cell count', 'description': ""Reflect the severity of the patient's infection"", 'timeFrame': '1 week'}, {'measure': 'Neutrophil ratio', 'description': ""Reflect the severity of the patient's infection"", 'timeFrame': '1 week'}, {'measure': 'C-Reactive Protein', 'description': ""Reflect the severity of the patient's infection"", 'timeFrame': '1 week'}, {'measure': 'Procalcitonin', 'description': ""Reflect the severity of the patient's infection"", 'timeFrame': '1 week'}, {'measure': 'Interleukin-6', 'description': ""Reflect the severity of the patient's infection"", 'timeFrame': '1 week'}, {'measure': 'Bacterial culture results', 'description': ""Reflect the severity of the patient's infection"", 'timeFrame': '1 week'}, {'measure': 'Body temperature', 'description': ""Reflect the severity of the patient's infection"", 'timeFrame': '1 week'}, {'measure': 'Vascular drug use days', 'description': ""Assess patients' systemic circulation"", 'timeFrame': '1 week'}]",26,18 Years,65 Years,ALL,,Zhongnan Hospital,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:17.186301,v2_robust,False,True,False,False,True,
NCT01222143,"Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia","A Phase I/II Study Evaluating the Safety and Efficacy of Nilotinib Combined With Mitoxantrone, Etoposide, and High-Dose Cytarabine (NOVE-HiDAC) Induction Chemotherapy Followed by Consolidation Therapy for Poor-Risk Patients With C-kit Positive Acute Myeloid Leukemia (AML) up to Age 65",NOVE-HiDAC,"['Nilotinib', 'NOVE-HiDAC']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],"['AML', 'NOVE-HiDAC', 'Nilotinib']",TERMINATED,,2010-10,2015-04,"[{'measure': 'To determine the maximum tolerated dose (MTD) of nilotinib when combined with the NOVE-HiDAC regimen (mitoxantrone, etoposide, and modified high-dose cytarabine).', 'description': 'To determine the maximum tolerated dose (MTD) of nilotinib combined with mitoxantrone, etoposide, and modified high-dose cytarabine (NOVE-HiDAC) induction chemotherapy followed by consolidation chemotherapy for patients with poor risk c-kit positive AML.', 'timeFrame': '2 years'}, {'measure': 'To evaluate the toxicity of the treatment regimen.', 'timeFrame': '2 years'}, {'measure': 'To determine the complete response (CR) rate of this combination at the maximum tolerate dose (MTD) of nilotinib.', 'timeFrame': '2 years'}]","[{'measure': 'To determine the disease-free survival of this combination.', 'timeFrame': '2 years'}, {'measure': 'To evaluate the pharmacodynamic effects of nilotinib on pERK and pAKT (phosphorylated ERK and AKT) in AML cells in vivo.', 'timeFrame': '2 years'}, {'measure': 'To correlate clinical responses with the degree of pAKT and pERK inhibition achieved in vivo.', 'timeFrame': '2 years'}, {'measure': 'To correlate the degree of pAKT and pERK inhibition with nilotinib pharmacokinetics.', 'timeFrame': '2 years'}, {'measure': 'To correlate pAKT and pERK inhibition with c-kit mutations.', 'timeFrame': '2 years'}]",8,18 Years,65 Years,ALL,False,"University Health Network, Toronto",OTHER,1,12.0,ACTUAL,2025-09-01T16:18:17.186341,v2_robust,True,True,False,True,False,
NCT04515043,EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754),AN EXPLORATORY FOLLOW-UP STUDY OF LONG TERM ANTI-TELOMERASE IMMUNE RESPONSE AFTER INVAC-1 VACCINATION IN PATIENTS WITH LONG TERM SURVIVAL. Addendum to INVAC1-CT-101 PROTOCOL - EUDRACT NUMBER : 2013-004369-15,INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.,"['blood sampling', 'INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Solid Tumor, Adult","['Solid Tumor, Adult']",[],COMPLETED,,2020-10-16,2020-12-19,"[{'measure': 'long term anti telomerase specific memory responses', 'description': 'will be measured by ELISPOT on blood of patients who were treated by INVAC-1 in the phase I NCT02301754 study and are still alive at the present time', 'timeFrame': '1 day visit'}]",[],1,18 Years,,ALL,False,Invectys,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:17.186368,v2_robust,True,True,True,False,False,
NCT03763643,PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant,PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant,Rituximab,['Rituximab'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Focal Segmental Glomerulosclerosis,['Focal Segmental Glomerulosclerosis'],[],RECRUITING,,2019-07-01,2026-12-31,"[{'measure': 'Feasibility assessment', 'description': 'quantifying the number and proportion of patients who can undergo the steps of recruitment, informed consent, enrollment, randomization, and follow-ups within the time frame of interest.', 'timeFrame': 'through study completion, an average of 1 year'}]","[{'measure': 'Patient and graft survival at 1 year post-transplant', 'description': 'Outcome is reported as the number of participants who survive with a functional graft one year post-transplant.', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Graft function at 1 year post-transplant', 'description': 'Graft function will be assessed using the glomerular filtration rate (GFR) and Schwartz equation (for age ≤17 years) or the CKD-EPI (for age ≥18 years).', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Proportion with acute rejection at 1 year post-transplant', 'description': 'Outcome is reported as the percentage of participants who experience an acute graft rejection at one ear post-transplant.', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Proportion with CD19+ <1%', 'description': 'Outcome is reported as the percentage with participants with a reconstitution of CD19+ B cells at one year post-transplant.', 'timeFrame': '1 month, 6 months, and 12 months'}, {'measure': 'Recurrent FSGS free survival', 'description': 'To determine the difference in rate of recurrent FSGS after 1 year post-transplant in patients receiving plasmapheresis and rituximab prior to or at the time of kidney transplantation compared to those receiving plasmapheresis alone.', 'timeFrame': 'after 1 year post-transplant'}]",6,1 Year,65 Years,ALL,False,University of Minnesota,OTHER,1,60.0,ESTIMATED,2025-09-01T16:18:17.186376,v2_robust,True,True,False,False,False,
NCT03456843,Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer,SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer,Antiandrogen Therapy,"['Anti-androgen Treatment', 'Androgen Deprivation Therapy', 'Anti-androgen Therapy', 'Taxotere', 'Docecad', 'ADT', 'RP56976', 'Antiandrogen Therapy', 'Hormone-Deprivation Therapy', 'Taxotere Injection Concentrate', 'Docetaxel', 'Hormone Deprivation Therapy', 'Antiandrogen Treatment']",13,INTERVENTIONAL,['PHASE2'],PHASE2,,Stage IV Prostate Adenocarcinoma AJCC v7,['Stage IV Prostate Adenocarcinoma AJCC v7'],[],RECRUITING,,2018-03-20,2027-03,"[{'measure': 'Failure-free survival (FFS)', 'description': 'Failure is defined as any one of the following events: PSA progression, clinical progression, radiographic progression, or death from prostate cancer. The % of men who fail within 2 years of randomization will be compare between the two groups using a one-sided log-rank test.', 'timeFrame': 'At 2 years'}]","[{'measure': 'Cancer-specific survival', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall complication rate', 'timeFrame': 'Up to 2 years'}, {'measure': 'Time to biochemical progression', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival', 'timeFrame': 'Through study completion, a minimum of 4 years'}]",5,18 Years,,MALE,False,Yale University,OTHER,1,190.0,ESTIMATED,2025-09-01T16:18:17.186428,v2_robust,True,True,False,False,False,
NCT00707915,Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons,Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons: a Pilot Study,Drug: Benzodiazepine (listed out below),['Drug: Benzodiazepine (listed out below)'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Adverse Effects,['Adverse Effects'],"['aged', 'benzodiazepines', 'hypnotics', 'cognition', 'posture']",COMPLETED,,2008-01,2010-07,"[{'measure': 'Completion Rate', 'description': 'The number of subjects who have successfully completed dose-reduction and all the assessments scheduled until week 8 divided by the total number of enrolled subjects', 'timeFrame': '8 weeks'}]","[{'measure': 'A Change in a Total Scale Score in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Japanese Version, From Baseline to Week 8.', 'description': 'This brief test is to assess areas of cognitive functioning and profile impairment across domains with 12 subtests, including: List Learning, Story Memory, Figure Copy, Line Orientation, Digit Span, Coding, Picture Naming, Semantic Fluency, List Recall, List Recognition, Story Recall, and Figure Recall. This assessment is repeatable and not subject to practice effects. A total scale score ranges between 40 and 160; a higher score indicates better cognitive function. A change in the score between the baseline and week 8 is defined as a secondary outcome measure.', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Clinical Stabilometric Platform (CSP)', 'description': 'CSP (ANIMA® GS-7, Tokyo) measures a total length of the trunk motion by varying the resistance applied to the platform for 30 seconds with eyes closed with feet together. Change in the total length of the trunk motion from baseline to week 8 will be recorded.', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Critical Flicker Fusion Test (CFF)', 'description': 'The CFF threshold has been regarded as a functional measure of psychomotor function. Sub-threshold intermittent light is perceived as a flicker. If the frequency is gradually increased, the flicker becomes gradually less distinct until it is finally perceived as a continuous light (fusion threshold). The device (T.K.K.501c) provides luminance with a mean intensity of 500Lux±10% and a range of frequency of 20-60Hz. A change in the critical fusion frequency from baseline to week 8 will be recorded.', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Leeds Sleep Evaluation Questionnaire (LSEQ)', 'description': 'The LSEQ comprises 10 self-rating 100-mm-line analogue questions regarding changes in the quality of sleep and early morning behavior, following any given intervention. Scores range between 0 and 100. Scores beneath 50 indicate better sleep. This will be performed at week 8.', 'timeFrame': 'Week 8'}, {'measure': 'Clinical Global Impression (CGI)', 'description': ""The CGI rating scales are commonly used measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders (Guy, W., 1976). The CGI - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. This will be performed at week 8."", 'timeFrame': 'Week 8'}]",6,50 Years,,ALL,False,Minamihanno Hospital,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:17.186538,v2_robust,True,True,True,False,False,
NCT04481815,Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,"Efficacy and Safety Study of Lenalidomide Plus Rituximab and Methotrexate Chemotherapy（R2-MTX） Versus Rituximab and Methotrexate Chemotherapy（R-MTX） in Newly Diagnosed Primary Central Nervous System Lymphoma: a Multicenter, Open-Label, Randomised Phase 2 Study",Rituximab,"['Lenalidomide', 'Methotrexate', 'Rituximab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,PCNSL,['PCNSL'],"['PCNSL', 'Lenalidomide']",RECRUITING,,2020-10-01,2025-12-30,"[{'measure': '2-year progression free survival', 'description': 'From date of patients sign informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years', 'timeFrame': '2 years'}]","[{'measure': 'Objective response rate', 'description': 'At the end of Cycle 6 (each cycle is 21 days) the ratio of numbers of patients with complete response and partial response to all the participants receiving treatment', 'timeFrame': 'At the end of Cycle 6 chemotheray'}, {'measure': 'Overall survival', 'description': 'From date of patients sign informed consent until the date of death or the date of last follow-up time, whichever came first, assessed up to 3 years', 'timeFrame': '3 years'}, {'measure': 'Progression free survival', 'description': 'From date of patients sign informed consent until the date of progression or death or the date of last follow-up time, whichever came first, assessed up to 3 years', 'timeFrame': '3 years'}, {'measure': 'Treatment-related adverse events', 'description': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': '1 year'}]",5,18 Years,75 Years,ALL,False,"Second Affiliated Hospital, School of Medicine, Zhejiang University",OTHER,0,240.0,ESTIMATED,2025-09-01T16:18:17.186605,v2_robust,True,True,False,False,True,
NCT05507515,A Phase 1 Study of ONO-2020 in Healthy Participants,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Five-part Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of ONO-2020 in Healthy Participants",ONO-2020,"['ONO-2020', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2022-07-29,2023-12-24,"[{'measure': 'Incidence, severity, and type of treatment emergent adverse events (TEAEs)', 'description': 'Incidence of TEAEs will be summarized overall, and by study part and dose group using frequency and percentage.', 'timeFrame': 'Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21'}, {'measure': 'Vital signs (blood pressure)', 'description': 'Observed values and change from baseline results will be summarized by analysis time point, and summaries of clinically significant and non-clinically significant abnormalities will be provided by each time point.', 'timeFrame': 'Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21'}, {'measure': 'Vital signs (pulse rate)', 'description': 'Observed values and change from baseline results will be summarized by analysis time point, and summaries of clinically significant and non-clinically significant abnormalities will be provided by each time point.', 'timeFrame': 'Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21'}, {'measure': 'Vital signs (body temperature)', 'description': 'Observed values and change from baseline results will be summarized by analysis time point, and summaries of clinically significant and non-clinically significant abnormalities will be provided by each time point.', 'timeFrame': 'Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21'}, {'measure': 'Vital signs (respiratory rate)', 'description': 'Observed values and change from baseline results will be summarized by analysis time point, and summaries of clinically significant and non-clinically significant abnormalities will be provided by each time point.', 'timeFrame': 'Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21'}, {'measure': '12-lead electrocardiograms (ECGs) parameters, such as but not limited to heart rate, RR, PR, QRS, QT, and corrected QT intervals (QTcF)', 'description': 'The number and percentage of subjects with normal, abnormal not clinically significant and abnormal clinically significant of ECG results will be tabulated at each time point.', 'timeFrame': 'Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21'}, {'measure': 'Clinically significant abnormal telemetry electrocardiograms (ECGs)', 'description': 'The number and percentage of subjects with normal, abnormal not clinically significant and abnormal clinically significant of telemetry ECGs results will be tabulated at each time point.', 'timeFrame': 'Part A and D: Day 1'}, {'measure': 'Clinically significant abnormal physical examination findings', 'description': 'The number and percentage of subjects with normal, abnormal not clinically significant and abnormal clinically significant of physical examination results will be tabulated at each time point.', 'timeFrame': 'Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21'}, {'measure': 'Clinical laboratory abnormalities (hematology, clinical chemistry, coagulation, and urinalysis)', 'description': 'The number and percentage of subjects with abnormal laboratory results at any time during the study will be tabulated.', 'timeFrame': 'Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21'}, {'measure': 'Ophthalmologic examination findings (pupil size and pupillary light reflex)', 'description': 'The number and percentage of subjects with miosis will be summarized by laterality at each time point.', 'timeFrame': 'Part A, C and D: From Day 1 up to Day 7, Part B and E: From Day 1 up to Day 21'}, {'measure': 'Clinically abnormal findings in Mini-International Neuropsychiatric Interview Screen (M.I.N.I.-Screen)', 'description': 'Responses to the M.I.N.I.-Screen will be listed.', 'timeFrame': 'Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21'}, {'measure': 'Clinically abnormal findings in Columbia Suicide Severity Rating Scale (C-SSRS)', 'description': 'Responses to the suicidality assessment scale (C-SSRS) will be listed.', 'timeFrame': 'Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21'}]","[{'measure': 'Pharmacokinetics (Cmax in plasma)', 'timeFrame': 'Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19'}, {'measure': 'Pharmacokinetics (Tmax in plasma)', 'timeFrame': 'Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19'}, {'measure': 'Pharmacokinetics (AUClast in plasma)', 'timeFrame': 'Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19'}, {'measure': 'Pharmacokinetics (AUCinf in plasma)', 'timeFrame': 'Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19'}, {'measure': 'Pharmacokinetics (T1/2 in plasma)', 'timeFrame': 'Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19'}, {'measure': 'Pharmacokinetics (CL/F in plasma)', 'timeFrame': 'Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19'}, {'measure': 'Pharmacokinetics (Aet in urine)', 'timeFrame': 'Part A and D: Day 1 through Day 4'}, {'measure': 'Pharmacokinetics (fe/F in urine)', 'timeFrame': 'Part A and D: Day 1 through Day 4'}, {'measure': 'Pharmacokinetics (CLR in urine)', 'timeFrame': 'Part A and D: Day 1 through Day 4'}, {'measure': 'Pharmacokinetics (Ctrough in plasma)', 'timeFrame': 'Part B and E: Day 2 through Day 13'}, {'measure': 'Pharmacokinetics (ONO-2020 concentration in CSF)', 'timeFrame': 'Part C: Day 2'}]",23,18 Years,,ALL,True,Ono Pharmaceutical Co. Ltd,INDUSTRY,0,132.0,ACTUAL,2025-09-01T16:18:17.186622,v2_robust,True,True,True,False,True,
NCT00167115,Metabolic Effects of Alcohol,Metabolic Effects of Alcohol in the Form of Wine in Persons With Type 2 Diabetes Mellitus,Alcohol,['Alcohol'],1,INTERVENTIONAL,['NA'],,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],"['Alcohol', 'Type 2 diabetes mellitus', 'Plama glucose', 'HDL cholesterol']",COMPLETED,,2004-12,2005-09,"[{'measure': 'Fasing plasma glucose'}, {'measure': 'Fasting plasma HDL cholesterol'}]",[{'measure': 'Episodes of hypoglycemia'}],3,40 Years,,ALL,False,"Bantle, John P., MD",INDIV,0,20.0,,2025-09-01T16:18:17.186687,v2_robust,True,True,True,False,False,
NCT02605915,Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer,"A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Patients With HER2-Positive Breast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer",Atezolizumab,"['RO0452317', 'Trastuzumab emtansine', 'Tecentriq, RO5541267', 'RO4368451', 'Carboplatin', 'RO5304020', 'Doxorubicin', 'Cyclophosphamide', 'Trastuzumab', 'Atezolizumab', 'Docetaxel', 'Pertuzumab']",12,INTERVENTIONAL,['PHASE1'],PHASE1,,HER2-Positive Metastatic Breast Cancer,"['HER2-Positive Metastatic Breast Cancer', 'HER2-Negative Metastatic Breast Cancer', 'Locally Advanced or Early Breast Cancer']",[],COMPLETED,,2015-12-31,2019-11-13,"[{'measure': 'Percentage of Participants With Dose Limiting Toxicities (DLT) - Cohort 1A, 1B, 1C, 1D, 1F', 'timeFrame': 'Baseline up to Day 21'}, {'measure': 'Percentage of Participants With DLT - Cohort 1E', 'timeFrame': 'Baseline up to Day 28'}, {'measure': 'Percentage of Participants With Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for AEs, Version 4.0 (NCI CTCAE V4.0)', 'timeFrame': 'Baseline up to approximately 3 years'}]","[{'measure': 'Maximum Serum Concentration (Cmax) of Atezolizumab', 'description': 'Cohorts 1A, 1B, 1C, 1D, E1, 1F, 2A, 2B, 2C, 2D: 30 minutes after end of infusion on Day 1 Cycle 1 (cycle length=21 days); pre-infusion (Hour 0) on Day 1 of Cycle 1, 2, 3 (except cohort 1E), 4, 8, on Day 1 of every 8 cycles until study treatment/early discontinuation, 120 days after treatment completion/discontinuation (up to approximately 3 years)', 'timeFrame': 'Cohorts 1A, 1B, 1C, 1D, E1, 1F, 2A, 2B, 2C, 2D: pre-infusion (Hour 0), 30 minutes after end of atezolimumab infusion on Day 1 Cycle 1 (cycle length=21 days) up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Minimum Serum Concentration (Cmin) of Atezolizumab', 'timeFrame': 'pre-infusion (Hour 0) on Day 1 of Cycle 1, 2, 3 (except cohort 1E), 4, 8 (cycle length=21 days), on Day 1 of every 8 cycles until study treatment/early discontinuation, 120 days after treatment completion/discontinuation (up to approximately 3 years)'}, {'measure': 'Cmin of Trastuzumab', 'timeFrame': 'Cohorts 1A, 1F, 2A, 2D: pre-infusion (Hour 0) on Day 1 of Cycle 1, 3 (cycle length=21 days), at study treatment/early discontinuation, 120 days after treatment completion or discontinuation (up to approximately 3 years)'}, {'measure': 'Cmin of Trastuzumab Emtansine', 'timeFrame': 'Cohorts 1B, 1C, 1D, 2B, 2C: pre-infusion (Hour 0) on Day 1 of Cycle 1, 3 (cycle length=21 days), at study treatment/early discontinuation, 120 days after treatment completion or discontinuation (up to approximately 3 years)'}, {'measure': 'Cmin of Pertuzumab', 'timeFrame': 'Cohorts 1A, 1F, 2A, 2D: pre-infusion (Hour 0) on Day 1 of Cycle 1, 3 (cycle length=21 days), at study treatment/early discontinuation, 120 days after treatment completion or discontinuation (up to approximately 3 years)'}, {'measure': 'Cmin of Doxorubicin', 'timeFrame': 'Cohort 1E: at the end of doxorubicin infusion, 4 and 8 hours after doxorubicin infusion on Day 1 of Cycle 1 and 4 (cycle length=21 days)'}, {'measure': 'Cmin of Cyclophosphamide', 'timeFrame': 'Cohort 1E: at the end of cyclophosphamide infusion on Day 1 of Cycle 1 and 4 (cycle length=21 days), 4 and 8 hours after cyclophosphamide infusion on Day 1 of Cycle 1'}, {'measure': 'Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Atezolimumab', 'timeFrame': 'pre-infusion (Hour 0) on Day 1 of Cycle 1, 2, 3 (except cohort 1E), 4, 8 (cycle length=21 days), on Day 1 of every 8 cycles until study treatment/early discontinuation, 120 days after treatment completion/discontinuation (up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Trastuzumab', 'timeFrame': 'Cohorts 1A, 1F, 2A, 2D: pre-infusion (Hour 0) on Day 1 of Cycle 1, 3 (cycle length=21 days), at study treatment/early discontinuation, 120 days after treatment completion or discontinuation (up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Trastuzumab Emtansine', 'timeFrame': 'Cohorts 1B, 1C, 1D, 2B, 2C: pre-infusion (Hour 0) on Day 1 of Cycle 1, 3 (cycle length=21 days), at study treatment/early discontinuation, 120 days after treatment completion or discontinuation (up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Pertuzumab', 'timeFrame': 'Cohorts 1A, 1F, 2A, 2D: pre-infusion (Hour 0) on Day 1 of Cycle 1, 3 (cycle length=21 days), at study treatment/early discontinuation, 120 days after treatment completion or discontinuation (up to approximately 3 years)'}, {'measure': 'Number of Treatment Cycles Received', 'timeFrame': 'Baseline up to approximately 3 years'}, {'measure': 'Percentage of Participants With Various Dose Intensity', 'timeFrame': 'Baseline up to approximately 3 year'}, {'measure': 'Plasma Concentration of Doxorubicin', 'timeFrame': 'Cohort 1E: at the end of doxorubicin infusion, 4 and 8 hours after doxorubicin infusion on Day 1 Cycle 1 and 4 (cycle length=21 days)'}, {'measure': 'Plasma Concentration of Cyclophosphamide', 'timeFrame': 'Cohort 1E: at the end of cyclophosphamide infusion on Day 1 of Cycle 1 and 4 (cycle length=21 days), 4 and 8 hours after cyclophosphamide infusion on Day of Cycle 1'}, {'measure': 'Plasma Concentration of 4-Hydroxycyclophosphamide', 'timeFrame': 'Cohort 1E: at the end of cyclophosphamide infusion on Day 1 of Cycle 1 and 4 (cycle length=21 days), 4 and 8 hours after cyclophosphamide infusion on Day of Cycle 1'}, {'measure': 'Plasma Concentration of Docetaxel', 'timeFrame': 'Cohort 1F: at the end of docetaxel infusion, 4 and 8 hours after docetaxel infusion on Day 1 Cycle 1 and 3 (cycle length=21 days)'}]",20,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,98.0,ESTIMATED,2025-09-01T16:18:17.186740,v2_robust,True,True,True,False,True,
NCT01880515,Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib),"Phase II, Open-label, Single Blind, Randomised Clinical Trial With Tetracycline as a Prophylaxis for Rash and Dermatological Recommendations Versus Dermatological Recommendations in Patients With NSCLC Receiving Treatment With BIBW 2992",Tetracycline,"['Tetracycline', 'Tetrex®', 'Tetracycline hydrocloride']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Skin Rash,"['Skin Rash', 'Lung Cancer']","['Lung cancer', 'BIBW 2992', 'Skin Rash', 'Tetracycline', 'Afatinib']",COMPLETED,,2010-12,2014-11,"[{'measure': 'Frequency of Participants Who Experienced Any Grade of Rash As Characterized By The Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0', 'description': 'Sum of participants who experienced any grade rash according to the Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0, from the initiation of BIBW2992 compared to week 8.', 'timeFrame': 'Percentage of adverse events at week 8'}]","[{'measure': 'Quality of Life (QoL)', 'description': 'A QoL questionnaire from European Organization for Research and Treatment of Cancer (EORTC) organization (Spanish version) will be performed at initiation of BIBW 2992 and then every month of follow-up until progression', 'timeFrame': 'from baseline to 6 months'}, {'measure': 'Progression Free-survival', 'description': 'The measure will be from the start of consumption to the first documented evidence of progression according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, or if patients still survive the measure will be made after 24 weeks', 'timeFrame': '24 weeks from baseline'}, {'measure': 'Progression Free Survival', 'description': 'From the start of consumption of BIBW 2992 to the date progression or last follow up', 'timeFrame': 'Participants will be followed for the duration of the treatment, an average of 8 weeks.'}]",4,18 Years,,ALL,False,Instituto Nacional de Cancerologia de Mexico,OTHER,0,107.0,ACTUAL,2025-09-01T16:18:17.186769,v2_robust,True,True,True,False,True,
NCT06192615,Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II),Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II),Intravenous Dexmedetomidine,"['Intravenous Precedex', 'Sublingual Placebo', 'Intravenous Dexmedetomidine', 'Placebo', 'Intravenous Placebo', 'Sublingual Dexmedetomidine', 'Sublingual Precedex']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Delirium,['Delirium'],[],RECRUITING,,2025-01-06,2029-03-31,"[{'measure': 'Delirium', 'description': 'The primary outcome will be delirium occurring on postoperative day one. Delirium will be assessed using the Confusion Assessment Method (CAM) twice daily. Delirium will be defined as present if either the morning or afternoon assessment are positive for delirium.', 'timeFrame': 'Postoperative day 1'}]","[{'measure': 'Delirium', 'description': 'Postoperative delirium will also be assessed as a secondary outcome assessed within the first three days after surgery, and separately within the first seven days following surgery. Delirium will be assessed using the CAM in the same fashion as the primary outcome. In the event the patient is reintubated the CAM-ICU may also be used to assess for postoperative delirium as a secondary outcome.', 'timeFrame': 'Postoperative Day 1 to Day 7'}, {'measure': 'Delirium Severity', 'description': 'Delirium severity will be assessed using the CAM-Severity (CAM-S) within the first three days following surgery, and separately within the first seven days following surgery. The CAM-S ranges from 0 (no delirium features) to 19, with higher scores indicating worsening delirium severity.', 'timeFrame': 'Postoperative day 1 to day 7'}, {'measure': 'Telephonic Montreal Cognitive Assessment', 'description': 'Global cognitive function will be assessed with the T-MoCA in-hospital and at three time points after hospital discharge. Different versions of the T-MOCA will be administered at each time point to minimize learning effects. The T-MoCA ranges from 0 (worst) to 22 (best) points, does not require visual cues or writing, and importantly, can be administered over the phone.', 'timeFrame': '30, 180 and 365 days'}, {'measure': 'Global Health', 'description': 'Global health will be assessed at 30, 180 and 365 days using the Patient Reported Outcome Measurement Information System (PROMIS) 29 Profile version 2.1. This assessment results in several subscale scores, each reported as a t-score.', 'timeFrame': '30, 180 and 365 days'}, {'measure': 'Pain at Rest and Upon Exertion', 'description': 'Pain will be assessed within the first seven days following surgery, using a trajectory of pain scores at rest and upon exertion/deep breathing. Pain scores will be elicited from patients daily using the Pain Numeric Rating Scale.', 'timeFrame': 'Postoperative day 1 to day 7'}, {'measure': 'Opioid and Analgesic Administration', 'description': 'Outcomes for opioid administration will evaluate the (a) frequency and (b) total consumption, defined as morphine equivalents, in the first 24 and 48 hours postoperatively. These will be captured based off medical record review.', 'timeFrame': '48 hours postoperatively'}, {'measure': 'Hospital Length of Stay', 'description': 'Hospital length of stay will be defined as the number of days after surgery until the time of discharge from the hospital.', 'timeFrame': 'Postoperatively until discharge, an average of six days'}, {'measure': 'Intensive Care Unit Length of Stay', 'description': 'Intensive Care Unit (ICU) length of stay will be calculated as the time from discharge from the initial index ICU stay minus the time of admission into the cardiovascular ICU and will be reported in hours.', 'timeFrame': 'Postoperatively until discharge, an average of 24 hours'}, {'measure': 'Readmission', 'description': 'Hospital readmission will be evaluated within the first 30 days postoperatively using the Society for Thoracic Surgery database or via patient report during follow up phone calls.', 'timeFrame': '30 days postoperatively'}, {'measure': 'Inpatient Morbidity', 'description': 'Major cardiac events will be evaluated within 30 days postoperatively and include stroke, atrial fibrillation and renal failure. These outcomes will be assessed using the Society for Thoracic Surgery database and medical record review.', 'timeFrame': '30 days postoperatively'}, {'measure': 'Mortality', 'description': 'All-cause mortality will be assessed in-hospital and at 30, 180 and 365 days postoperatively. Mortality will be assessed using a combination of electronic medical record review, Society for Thoracic Surgery database, and family report during the follow up phone calls.', 'timeFrame': 'Postoperatively until discharge, an average of six days, and at 30, 180 and 365 days postoperatively'}]",12,60 Years,,ALL,False,Massachusetts General Hospital,OTHER,0,1800.0,ESTIMATED,2025-09-01T16:18:17.186941,v2_robust,True,True,False,False,False,
NCT04131335,Use of Prophylactic Lubricating Drops After Cataract Surgery,"Patient Satisfaction and Dry Symptoms in NHS Patients Undergoing Routine Uncomplicated Cataract Surgery Treated With Prophylactic Phosphate-free, Preservative-free Lubricant Eye Drops. A Randomised Controlled Prospective Study.",AEONTM Repair,['AEONTM Repair'],1,INTERVENTIONAL,['NA'],,,Dry Eye,"['Dry Eye', 'Cataract Surgery', 'Patient Related Outcome Measures', 'Patient Satisfaction']",[],UNKNOWN,,2019-10-14,2020-06,"[{'measure': 'Patient Satisfaction (CatPROM 5)', 'description': 'Validated patient satisfaction questionnaire are used. Specially designed and validated conversion tables are used to convert raw scores from questionnaires to Rasch calibrated measures.', 'timeFrame': '6 weeks'}, {'measure': 'Self-reported Health Outcome', 'description': ""A validated self-reported health questionnaire is used where a descriptive and vertical Visual Analogue Scale (VAS) are used. The descriptive scale assesses 5 domains at three levels of difficulty (no / some / extreme problems). The VAS is used to to record patients' self-reported health on a scale from 0-100 (100/100 being excellent health, 0/100 being very poor health."", 'timeFrame': '6 weeks'}, {'measure': 'Patient Reported Symptoms (Speed II questinnaire)', 'description': 'A validated questionnaire is used with a grading system to grade severity of dry eye . symptoms. Score out of 28. Higher the score, the more significant the dry eye symptoms.', 'timeFrame': '6 weeks'}]","[{'measure': 'Visual Acuity', 'timeFrame': '6 weeks'}, {'measure': 'Cornea and Conjunctival Staining Scores', 'description': 'The Oxford Scale is used to grade staining of the conjunctiva and cornea. 0-5 (0 no staining, 5 significant staining).', 'timeFrame': '6 weeks'}, {'measure': 'Schirmer 1 test', 'description': 'Evaluation of aqueous tear production. Score of more than 10mm is normal. Less than 10mm indicates aqueous tear deficiency .', 'timeFrame': '6 weeks'}, {'measure': 'Tear Break up Time', 'description': 'Score of more than 10 seconds is normal. Less than 10 seconds indicates tear evaporative eye disease', 'timeFrame': '6 weeks'}, {'measure': 'Cataract incision site and size', 'description': 'Assess cataract incision size in relation to other tests and symptoms.', 'timeFrame': '6 weeks'}]",8,18 Years,100 Years,ALL,True,Guy's and St Thomas' NHS Foundation Trust,OTHER,2,168.0,ESTIMATED,2025-09-01T16:18:17.186982,v2_robust,True,True,False,False,False,
NCT06654635,Ultrasound Guided Rhomboid Intercostal Plane Block Versus Thoracic Erector Spinae Plane Block in Upper Abdominal Surgery,Comparison Between Ultrasound Guided Rhomboid Intercostal Plane Block and Thoracic Erector Spinae Plane Block in Patients Undergoing Upper Abdominal Surgery: A Randomized Controlled Trial,Rhomboid intercostal plane block,['Rhomboid intercostal plane block'],1,INTERVENTIONAL,['NA'],,,Ultrasound,"['Ultrasound', 'Rhomboid Intercostal Plane Block', 'Thoracic Erector Spinae Plane Block', 'Upper Abdominal Surgery']",[],RECRUITING,,2024-01-01,2025-05-01,"[{'measure': 'Total morphine consumption', 'description': 'Rescue analgesia will be provided in the form of IV morphine 3 mg boluses if the patient indicates The visual analogue scale (VAS). ≥ 4 with maximum dose 20 mg for 24 hours. The total amount of morphine (mg) given will be recorded for the 3 groups.', 'timeFrame': '24 hours postoperatively'}]","[{'measure': 'Degree of pain', 'description': 'Postoperative pain will be assessed by visual analogue scale (VAS) 30 min from admission to PACU, 2, 4, 6, 12, 18 and 24 h postoperative (0= no pain, 10= sever pain).', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Time to 1st request of rescue analgesia', 'description': 'Time to 1st request for the rescue of analgesia (time from the end of surgery till first dose of morphine administrated ) will be recorded.', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Heart rate', 'description': 'Heart rate will be measured preoperative, after induction, after receiving block and every 15 min till the end of surgery', 'timeFrame': 'Every 15 min till the end of surgery'}, {'measure': 'Mean arterial blood pressure', 'description': 'Mean arterial blood pressure will be measured preoperative, after induction, after receiving block and every 15 min till the end of surgery', 'timeFrame': 'Every 15 min till the end of surgery'}, {'measure': 'Incidence of side effects', 'description': 'Any undesirable adverse events will be treated and recorded (e.g., bradycardia, hypotension, pneumothorax, hematoma, nerve injury and nausea, vomiting, local anesthetic systemic toxicity (LAST), respiratory depression or any other complication).', 'timeFrame': '24 hours Postoperatively'}]",6,21 Years,65 Years,ALL,False,Tanta University,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:17.187032,v2_robust,True,True,False,False,True,
NCT00415935,PRINTO (the Paediatric Rheumatology International Trials Organisation),,methotrexate,['methotrexate'],1,OBSERVATIONAL,[],,,Juvenile Idiopathic Arthritis,['Juvenile Idiopathic Arthritis'],[],UNKNOWN,,,2006-12,[],[],0,,16 Years,ALL,False,Institute of Child Health,OTHER,0,,,2025-09-01T16:18:17.187097,v2_robust,False,True,False,False,False,
NCT01511835,Efficacy of Myo-inositol in Preventing Gestational Diabetes in High-risk Pregnant Women,,Folic Acid,['Folic Acid'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Gestational Diabetes,['Gestational Diabetes'],"['diabetes', 'pregnancy', 'myo-inositol']",UNKNOWN,,,,"[{'measure': 'OGTT', 'description': 'The diagnostic 75g oral glucose tolerance test (OGTT) is performed between 24 and 28 weeks of gestation.'}]","[{'measure': 'Number of pregnant women with gestational diabetes'}, {'measure': 'Number of pregnant women requiring insulin treatment'}, {'measure': 'Weight gain at the end of pregnancy'}, {'measure': 'Number of newborn infants whose weight is more than 4000 g'}, {'measure': 'Number of newborn infants requiring Neonatal Intensive Care (NIC)'}]",6,20 Years,45 Years,FEMALE,,AGUNCO Obstetrics and Gynecology Centre,OTHER,0,,,2025-09-01T16:18:17.187109,v2_robust,True,True,False,False,False,
NCT00154635,Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease,"A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease",DCB-AD1,['DCB-AD1'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Dementia, Alzheimer Type","['Dementia, Alzheimer Type']","[""Alzheimer's disease"", 'Fo-ti', 'Chinese herbs']",UNKNOWN,,2005-09,,[{'measure': 'ADAS-Cog'}],"[{'measure': 'CIBIC-PLUS'}, {'measure': 'IADL'}, {'measure': 'Behav-AD'}, {'measure': 'MMSE'}, {'measure': 'CDR'}]",6,50 Years,,ALL,False,National Taiwan University Hospital,OTHER,3,80.0,,2025-09-01T16:18:17.187211,v2_robust,True,True,False,False,False,
NCT01383135,Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2,Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2,F18-FPPRGD2,['F18-FPPRGD2'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Breast Cancer,"['Breast Cancer', 'Non-Small-Cell Lung Cancer', 'Glioblastoma', 'Other Cancers']",['Healthy volunteers'],COMPLETED,,2010-10,2013-12,"[{'measure': 'Tracer Dosimetry by Organ', 'description': 'Normal radiopharmaceutical biodistribution was analyzed visually to obtain dosimetry data in healthy volunteers. Organs with the highest radiation absorbed dose (dosimetry) are provided below. Dosimetry was calculated by drawing regions-of-interest around organs with visually appreciable radiopharmaceutical uptake greater than background and using organ-level internal dose assessment software from Vanderbuilt University (2003).\n\nResults are reported in mSv/MBq (milli-Sieverts per mega-Bequerel) which is a measurement of the mean absorbed radiation dose within an organ.', 'timeFrame': '5 hours'}, {'measure': 'F18-FPPRGD2 Time-activity at Specified Timepoints', 'description': 'Radiopharmaceutical pharmacokinetics describe the change in radiopharmaceutical distribution in the body (from the blood to organs, tissues, cells) over time. Radiopharmaceutical pharmacokinetics are used to determine optimal imaging time, ie, when target activity (organ or cell of interest) is greater than background activity (blood). Optimal imaging time must also be balanced with tracer bio-metabolism and radioactive decay. F18-FPPRGD2 pharmacokinetics was measured in healthy volunteers to estimate optimal imaging time. Scans were used to visually identify regions of interest (organs of F18-FPPRGD2 accumulation), and detected radiation was plotted as a measurement over time.', 'timeFrame': '30, 60, and 90 minutes post-injection'}, {'measure': 'Sensitivity of F18-FPPRGD2 PET/CT in Breast Cancer', 'description': 'Sensitivity is the ability of a test to correctly identify patients with the disease being investigated. In this instance, how well F18-FPPRGD2 PET/CT detects true-positive patients. Sensitivity is defined as \\[TP/ (TP+FN)\\], where TP= true positive, and FN = false negative. The outcome is reported as a percentage without dispersion. A higher percentage indicates a greater probability that a lesion identified based on scan results is cancerous, and a lower percentage indicates reduced confidence in that result.', 'timeFrame': '3 hours'}, {'measure': 'Specificity of F18 FPPRGD2 PET/CT in Breast Cancer', 'description': 'Specificity is the ability of a test to correctly identify patients who do not have the disease being investigated. In this instance, how well F18 FPPRGD2 PET/CT detects true-negative patients. Specificity is:\n\n\\[TN/ (TN+FP)\\], where TN= true negative, and FP = false positive.', 'timeFrame': 'an estimated average of 3 hours'}, {'measure': 'Glioblastoma Primary Tumor Response Assessed by PET Scan', 'description': 'Primary tumor response was assessed after 6 weeks of treatment as the change in tumor metabolism based on the maximum standardized uptake value (SUVmax) as determined by positron emission tomography (PET) scans. Decreased SUVmax correlates to a reduction of tumor metabolism, and is considered an indicator of primary tumor response. Reduction of SUVmax was determined as the change from baseline in uptake of F-18FPPRGD2. The outcome is reported as the baseline and week 6 values, with standard deviation.', 'timeFrame': 'Baseline and Week 6'}]","[{'measure': 'Glioblastoma Primary Tumor Response Assessed by CT Scan', 'description': 'Primary tumor response was assessed after 6 weeks of treatment as the change in tumor metabolism based on the maximum standardized uptake value (SUVmax) as determined by computed tomography (CT) scans. Decreased SUVmax correlates to a reduction of tumor metabolism, and is considered an indicator of primary tumor response. Reduction of SUVmax was determined as the change from baseline in uptake of F-18FPPRGD2. The outcome is reported as the mean difference from baseline to week 6, with standard deviation.', 'timeFrame': 'Baseline and Week 6'}]",6,18 Years,,ALL,True,Stanford University,OTHER,0,27.0,ACTUAL,2025-09-01T16:18:17.187227,v2_robust,True,True,True,False,False,
NCT05038735,"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","EPIK-B5: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With HR-positive, HER2-negative Advanced Breast Cancer With a PIK3CA Mutation, Who Progressed on or After Aromatase Inhibitor and a CDK4/6 Inhibitor",Alpelisib,"['Alpelisib-matching placebo', 'Alpelisib', 'Fulvestrant']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],"['Alpelisib', 'Fulvestrant', 'Advanced breast cancer', 'Phase III', 'HR-positive', 'HER-2 negative', 'CDK4/6 inhibitor', 'PIK3CA mutation', 'Progression free survival', 'aromatase inhibitor']",ACTIVE_NOT_RECRUITING,,2021-12-17,2028-01-26,"[{'measure': 'Progression-free survival (PFS) based on BIRC assessments and using RECIST v1.1 criteria', 'description': 'To determine whether treatment with alpelisib plus fulvestrant prolongs progression-free survival (PFS) compared to treatment with placebo plus fulvestrant. PFS is the defined as the time from randomization to date of randomization to the date of the first documented progression as per BIRC criteria using RECIST v1.1 or death due to any cause, whichever comes first.', 'timeFrame': 'From randomization to date of the first documented progression or death due to any cause, assessed up to a maximum duration of 60 months.'}]","[{'measure': 'Overall survival (OS)', 'description': 'To determine whether treatment with alpelisib plus fulvestrant prolongs overall survival (OS) compared to treatment with placebo plus fulvestrant. OS is defined as the time from randomization to the date of death due to any cause', 'timeFrame': 'From the date of randomization to the date of death up to a maximum duration of 60 months'}, {'measure': 'Overall response rate (ORR) with confirmed response based on BIRC assessments and using RECIST v1.1 criteria', 'description': 'To evaluate alpelisib plus fulvestrant compared to placebo plus fulvestrant, with regards to objective response by RECIST 1.1 criteria. Overall response rate (ORR) with confirmed response is defined as the proportion of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), as per BIRC and according to RECIST 1.1', 'timeFrame': 'From the date of randomization up to a maximum duration of 60 months'}, {'measure': 'Clinical benefit rate (CBR) with confirmed response based on BIRC assessments and using RECIST v1.1 criteria', 'description': 'To evaluate alpelisib plus fulvestrant compared to placebo plus fulvestrant, with regards to objective response by RECIST 1.1 criteria. CBR with confirmed response is defined as the proportion of participants with a best overall response of confirmed CR or PR, or SD lasting for a duration of at least 24 weeks. CR, PR and SD are defined as per BIRC review according to RECIST 1.1', 'timeFrame': 'From the date of randomization up to a maximum duration of 60 months'}, {'measure': 'Duration of response (DOR) with confirmed response based on BIRC assessments and using RECIST v1.1 criteria', 'description': 'To evaluate alpelisib plus fulvestrant compared to placebo plus fulvestrant, with regards to objective response by RECIST 1.1 criteria. Duration of response (DOR) with confirmed response only applies to participants whose best overall response is confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 based on tumor response data per BIRC review. The start date is the date of first documented response of CR or PR and the end date is defined as the date of the first documented progression or death due to underlying cancer.', 'timeFrame': 'From first documented response to the date of first progression or deaths, up to a maximum duration of 60 months'}, {'measure': 'Time to response (TTR) based on BIRC assessments and using RECIST v1.1 criteria', 'description': 'To evaluate alpelisib plus fulvestrant compared to placebo plus fulvestrant, with regards to objective response by RECIST 1.1 criteria. Time to response (TTR) is defined as the time from the date of randomization to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed. CR and PR are based on tumor response data as per BIRC review and according to RECIST 1.1', 'timeFrame': 'From the date of randomization to the first documented response up to a maximum duration of 60 months'}, {'measure': 'PFS based on BIRC assessment and using RECIST v1.1 criteria for participants by PIK3CA mutation status', 'description': 'To evaluate the association between PIK3CA mutation status with PFS upon treatment with alpelisib. PFS is the defined as the time from randomization to date of randomization to the date of the first documented progression as per BIRC criteria using RECIST v1.1 or death due to any cause, whichever comes first. Results will be presented by PIK3CA mutation status measured in circulating tumor deoxyribonucleic acid (ctDNA) collected at baseline.', 'timeFrame': 'From the date of randomization up to a maximum duration of 60 months'}, {'measure': 'Time to definitive deterioration of Eastern Cooperative Oncology Group (ECOG) performance status (PS) from baseline', 'description': 'To evaluate treatment with alpelisib plus fulvestrant compared to placebo plus fulvestrant, with respect to time to deterioration of ECOG performance status. Time to definitive deterioration in ECOG PS is defined as the time from the date of randomization to the date when ECOG PS has definitively deteriorated by at least one category compared with baseline. Deterioration is considered definitive if there is no subsequent improvement in ECOG PS back to the baseline category or above.', 'timeFrame': 'From the date of randomization up to maximum duration of 60 months'}, {'measure': 'Time to definitive (10%) deterioration in the global health status/Quality of Life (QoL) and symptom scale scores of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)', 'description': ""To evaluate patient-reported outcomes of alpelisib plus fulvestrant compared to placebo and fulvestrant. Time from date of randomization to date of event, defined as at least a 10% worsening from baseline with no later improvement above this threshold observed during the course of the treatment or until death due to any cause, in the global health status/QOL and symptom scale scores of EORTC QLQ-C30, a questionnaire to assess the quality of life of cancer patients. The questionnaire contains 30 items and is composed of both multi-item scales and single-item measures based on the patient's experience over the past week. This includes 5 functional scales, 3 symptom scales, 6 single items and a global health status/QoL scale. The scales and single-item measures range in score from 0 - 100. A high scale score represents a higher response level."", 'timeFrame': 'From the date of randomization up to maximum duration of 60 months'}, {'measure': 'Change from baseline in global health status/QoL and symptom scale scores of the EORTC QLQ-C30', 'description': ""To evaluate patient-reported outcomes of alpelisib plus fulvestrant compared to placebo and fulvestrant. Change from baseline in the domain scores, health states, overall health status, and index values at the time of each assessment. EORTC QLQ-C30 is a questionnaire to assess the quality of life of cancer patients. The questionnaire contains 30 items and is composed of both multi-item scales and single-item measures based on the patient's experience over the past week. This includes 5 functional scales, 3 symptom scales, 6 single items and a global health status/QoL scale. The scales and single-item measures range in score from 0 - 100. A high scale score represents a higher response level."", 'timeFrame': 'From the date of randomization up to maximum duration of 60 months'}, {'measure': 'Time from randomization to objective tumour progression on next line treatment or death from any cause (PFS2)', 'description': 'To explore the long-term benefit intermediate to PFS and OS. PFS2 is defined as time from date of randomization to the first documented progression on nextline therapy or death from any cause, whichever occurs first. Disease progression will be determined based on investigator assessment of progression on next-line therapy.', 'timeFrame': 'From the date of randomization up to maximum duration of 60 months'}]",11,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,211.0,ACTUAL,2025-09-01T16:18:17.187327,v2_robust,True,True,False,False,False,
NCT04146935,Examining the Effect of Burosumab on Muscle Function,Examining the Effect of Burosumab on Muscle Function Using MR Spectroscopy,Burosumab Injection [Crysvita],"['Crysvita', 'Burosumab Injection [Crysvita]']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,X-linked Hypophosphatemia,['X-linked Hypophosphatemia'],"['Crysvita', 'Burosumab']",COMPLETED,,2019-11-13,2022-08-25,"[{'measure': 'Skeletal Muscle Adenosine Triphosphate (ATP) Synthesis Rate', 'description': 'Rates of mitochondrial phosphorylation activity were assessed in the soleus/gastrocnemius muscle complex of the right calf by 31P magnetic resonance spectroscopy saturation transfer technique (micro-mol/g/min)', 'timeFrame': '2.5 months'}]","[{'measure': 'Serum Phosphate', 'description': 'measured in mg/dl', 'timeFrame': '2.5 months'}, {'measure': 'Intracellular Phosphate Concentration in Umol/g Muscle', 'description': 'Intracellular phosphorus concentration in skeletal muscle (umol/g muscle)', 'timeFrame': '2.5 months'}]",3,18 Years,65 Years,ALL,False,Yale University,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:17.187404,v2_robust,True,True,True,False,False,
NCT00000808,A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers,A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers,Nevirapine,['Nevirapine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,HIV Infections,"['HIV Infections', 'Pregnancy']","['Pregnancy', 'Pregnancy Complications, Infectious', 'Acquired Immunodeficiency Syndrome', 'AIDS-Related Complex', 'Nevirapine']",COMPLETED,,,1998-09,[],[],0,13 Years,60 Years,FEMALE,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,49.0,,2025-09-01T16:18:17.187428,v2_robust,True,True,True,False,False,
NCT00632008,Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers,"A Randomised, Double-blind, Placebo-controlled Study to Determine the Efficacy of Soluble Beta-1,3/1,6-glucan in Chronic Foot Ulcers in Diabetes",Soluble beta-glucan (SBG),"['Placebo comparator', 'Soluble beta-glucan (SBG)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Diabetic Foot Ulcers,['Chronic Diabetic Foot Ulcers'],[],COMPLETED,,2007-03,2009-10,[],[],0,18 Years,,ALL,False,Biotec Pharmacon ASA,INDUSTRY,0,122.0,ACTUAL,2025-09-01T16:18:17.187433,v2_robust,True,True,True,False,False,
NCT00908908,A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors,"An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors",eribulin,"['E7389', 'eribulin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],"['Advanced Solid Tumors', 'Failure of Multiple Prior Chemotherapy Regimens']",COMPLETED,,2009-03,2011-05,"[{'measure': 'Excretion Balance of Radio-labeled 14C-eribulin: Total Recovery of Radioactive Dose in Urine and Feces.', 'timeFrame': '312 hours postdose'}, {'measure': 'Pharmacokinetics: AUC (0-t) for Total Radioactivity in Plasma', 'description': 'Area under the plasma concentration-time curve from time zero to last quantifiable plasma concentration measuring total radioactivity exposure.', 'timeFrame': 'Between Days 1 and 8 of Cycle 1'}, {'measure': 'Pharmacokinetics AUC (0-t) for Eribulin in Plasma', 'description': 'Area under the plasma concentration-time curve from time zero to last quantifiable plasma concentration measuring exposure to eribulin.', 'timeFrame': 'Between Days 1 and 8 of Cycle 1'}]",[],3,18 Years,,ALL,False,Eisai Inc.,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:17.187519,v2_robust,True,True,True,False,False,
NCT00804908,A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma",temozolomide,"['ABT-888', 'Temodal', 'veliparib', 'temozolomide', 'Temodar']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Melanoma,"['Melanoma', 'Metastatic Melanoma', 'Skin Cancer']","['Temozolomide', 'Skin cancer', 'Melanoma', 'Metastatic Melanoma', 'ABT-888', 'MM']",COMPLETED,,2009-02,2016-01,"[{'measure': 'Progression-Free Survival (PFS): Time to Event', 'description': 'PFS: the number of days from the date that the participant was randomized to the date the participant experienced a confirmed event of disease progression (radiological, as determined by the central imaging center; or clinical, as determined by the investigator), or to the date of death (all causes of mortality) if disease progression was not reached. All events were included whether the participant was still taking or had discontinued study drug. Events of death were included for participants who had not experienced a confirmed event of disease progression, provided the death occurred within 8 weeks of the last available disease progression assessment. The distribution of PFS, as determined by the central imaging center (radiological)/ investigator (clinical), was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% confidence intervals (95% CIs) for the quartiles for the PFS distribution are provided.', 'timeFrame': 'Every Cycle (28 Days) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.'}]","[{'measure': 'Overall Survival (OS): Time to Event', 'description': 'OS was defined as the number of days from the date the participant was randomized to the date of death. All deaths were included, whether the participant was still taking or had discontinued study drug. If a participant had not died and was lost to follow-up, then data were censored at the last study visit or contact date, or date the participant was last known to be alive, whichever was later; if the participant was not lost to follow-up, then data were censored at the last study visit or contact date, whichever was later. The distribution of OS was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the OS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ groups were statistically significantly better than the Placebo + TMZ group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints.', 'timeFrame': 'Per protocol, survival follow-up information was to be obtained every 3 months for up to 18 months after the final visit for the subject. The maximum observed follow-up at the overall survival analysis time was 21.0 months.'}, {'measure': '12-Month Overall Survival (OS) Rate', 'description': 'The 12-month overall survival rate was defined as the percentage of participants surviving at 12 months. The distribution of 12-month OS rate was estimated using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the PFS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values.', 'timeFrame': 'Per protocol, survival was to be assessed every 4 weeks or as needed after participant is registered as off-study for up to 18 months. The maximum observed follow-up at the overall survival analysis time was 21.0 months.'}, {'measure': '6-month Progression-Free Survival Rate', 'description': 'The 6-month progression-free survival rate was defined as the percentage of participants without disease progression at 6 months.The distribution of 6-month progression-free survival rate, as determined by the central imaging center (radiological)/ investigator (clinical), was estimated using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the PFS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values.', 'timeFrame': 'Every Cycle (28 Days) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.'}, {'measure': 'Objective Response Rate', 'description': 'The objective response rate was defined as the percentage of participants with a confirmed CR or PR per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by computed tomography (CT) scan: complete response (CR), disappearance of all target lesions; partial response (PR), ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values.', 'timeFrame': 'Every 2 cycles (8 weeks) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.'}, {'measure': 'Time to Disease Progression', 'description': 'The distribution of time to disease progression, as determined by the central imaging center (radiological)/ investigator (clinical), was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the PFS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values.', 'timeFrame': 'Every Cycle (28 Days), until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.'}, {'measure': 'Disease Control Rate', 'description': 'The disease control rate was defined as the percentage of participants who had at least stable disease (complete response, partial response, or stable disease) through the end of Week 8. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values.', 'timeFrame': 'Week 8'}, {'measure': 'Time to Neurological/Brain Metastases Progression', 'description': 'Time to neurological/brain metastases progression, defined as the number of days from the date of randomization to the date the participant experienced an event of neurological/brain metastases progression, was estimated using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the distribution are provided. All events of progression were included, regardless of whether the event occurred while the participant was still taking study drug. If a participant did not experience an event, data were censored at the date of the last available brain CT scan. For participants with no postbaseline brain CT scans, data were censored at randomization. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ groups were statistically significantly better than the Placebo + TMZ group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values.', 'timeFrame': 'Every 2 cycles (8 weeks) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.'}]",8,18 Years,,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,0,346.0,ACTUAL,2025-09-01T16:18:17.187533,v2_robust,True,True,True,False,False,
NCT06762808,Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC,Phase II Trial of Atezolizumab and Tiragolumab for Patients With Detectable Circulating Tumor DNA After Definitive Treatment for HPV-positive Squamous Cell Carcinoma,Atezolizumab,"['Atezolizumab', 'Talazoparib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Squamous Cell Carcinoma,['Squamous Cell Carcinoma'],[],WITHDRAWN,0 participants,2025-05-01,2025-08-08,"[{'measure': 'Safety and Adverse Events (AEs)', 'description': 'Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0', 'timeFrame': 'Through study completion; an average of 1 year.'}]",[],1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,2,0.0,ACTUAL,2025-09-01T16:18:17.187614,v2_robust,True,True,False,True,True,0 participants
NCT03503708,Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease,Antioxidant for Improvement of Hepatic Function in Patients With Alcohol Liver Disease Without Cirrhosis: Non-randomized Interventional Cohort Study,Livitol-70,['Livitol-70'],1,INTERVENTIONAL,['NA'],,,Alcoholic Liver Disease,['Alcoholic Liver Disease'],[],NOT_YET_RECRUITING,,2018-05-30,2028-11-30,"[{'measure': 'Change from baseline in AST(Aspartate Aminotransferase)', 'description': 'The above mentioned test will be measured with panel of Liver function test at central laboratory.', 'timeFrame': '3 months'}, {'measure': 'Change from baseline in ALT(Alanine Aminotransferase)', 'description': 'The above mentioned test will be measured with panel of Liver function test at central laboratory.', 'timeFrame': '3 months'}, {'measure': 'Change from baseline in ALP(Alkaline Phosphatase)', 'description': 'The above mentioned test will be measured with panel of Liver function test at central laboratory.', 'timeFrame': '3 months'}, {'measure': 'Change from baseline in GGT(Gamma Glutamyl Transferase)', 'description': 'The above mentioned test will be measured with panel of Liver function test at central laboratory.', 'timeFrame': '3 months'}, {'measure': 'Change from baseline in serum total bilirubin', 'description': 'The above mentioned test will be measured with panel of Liver function test at central laboratory.', 'timeFrame': '3 months'}, {'measure': 'Number of Subject with adverse events', 'description': 'Adverse events is defined as any untoward medical occurrence that may not necessarily have a causal relationship with the treatment, but resulted in a dose reduction or discontinuation of treatment.', 'timeFrame': '3 months'}]","[{'measure': 'Change in radiological response', 'description': 'The degree of fatty infiltration will be assessed by ultrasound.', 'timeFrame': '3 months'}, {'measure': 'Change in maddrey discriminant function(DF)', 'timeFrame': '3 months'}]",8,18 Years,,ALL,False,Composite Interceptive Med Science,INDUSTRY,0,40.0,ESTIMATED,2025-09-01T16:18:17.187621,v2_robust,True,True,False,False,True,
NCT03516708,Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer,Phase I/II Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer,Epacadostat,"['INCB024360', 'Epacadostat', 'FOLFOX chemotherapy', 'CAPOX chemotherapy']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Rectal Cancer,['Rectal Cancer'],"['Immunotherapy', 'Kynurenine', 'Colon', 'Indoleamine 2,3 dioxygenase', 'IDO1']",RECRUITING,,2020-01-06,2030-08-12,"[{'measure': 'Phase I only: Recommended phase II dose (RP2D) of epacadostat with standard of care radiation and chemotherapy in preoperative treatment of locally advanced rectal cancer', 'description': 'The recommended phase 2 dose (RP2D) is defined as the dose level immediately below the maximally administered dose at which 0 or 1 of a cohort of 3 to 6 patients experienced a dose-limiting toxicity (DLT) during first 2 cycles.', 'timeFrame': 'Completion of the first 2 cycles of treatment for all patients (estimated to be 86 months)'}, {'measure': 'Phase II Treatment Cohort only: Neoadjuvant Rectal (NAR) Score', 'description': 'Neoadjuvant Rectal Score (NAR Score) is calculated by following formula: NAR = (\\[5pN\n\n\\- 3(cT - pT) + 12\\]2)/9.61 (with higher scores representing poorer prognosis), where cT=clinical tumor stage, pT=pathologic tumor stage, and pN=pathologic nodal stage.', 'timeFrame': 'At the time of surgery (approximately week 28)'}]","[{'measure': 'Phase I and Phase II Treatment Cohort only: Safety and toxicity profile of the combination as measured by adverse events experienced', 'description': 'The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting.', 'timeFrame': 'Through 4 weeks after completion of treatment (approximately 28 weeks)'}, {'measure': 'Phase I only: Neoadjuvant Rectal (NAR) Score', 'description': 'Neoadjuvant Rectal Score (NAR Score) is calculated by following formula: NAR = (\\[5pN\n\n\\- 3(cT - pT) + 12\\]2)/9.61 (with higher scores representing poorer prognosis), where cT=clinical tumor stage, pT=pathologic tumor stage, and pN=pathologic nodal stage.', 'timeFrame': 'At the time of surgery (approximately week 28)'}, {'measure': 'Phase I and Phase II Treatment Cohort only: Pathological complete response rate (pCR)', 'description': 'Pathologic complete response (pCR) is defined as no histology evidence of invasive tumor cells in the surgical specimen.', 'timeFrame': 'At the time of surgery (approximately week 25)'}, {'measure': 'Phase I and Phase II Treatment Cohort only: Progression-free survival (PFS)', 'description': 'Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. For those who are alive and do not experience progression, they are censored at the time of loss to follow-up.', 'timeFrame': 'Through completion of follow-up (estimated to be 3 years and 32 weeks)'}, {'measure': 'Phase I and Phase II Treatment Cohort only: Complete clinical response rate (cCR)', 'description': 'Clinical complete response (cCR) is defined as no clinical evidence of tumor as assessed by radiographic, endoscopic, and physical examinations after completion of planned protocol therapy.', 'timeFrame': 'At the time of preoperative assessment (approximately week 28)'}]",7,18 Years,,ALL,False,Washington University School of Medicine,OTHER,2,49.0,ESTIMATED,2025-09-01T16:18:17.187737,v2_robust,True,True,False,False,True,
NCT04701008,Efficacy of Ketamine in Post Anesthesia Recovery Room,Observational Study of the Efficacy of Ketamine for Rescue Analgesia in the Post Anesthesia Recovery Room,Ketamine,['Ketamine'],1,OBSERVATIONAL,[],,,"Pain, Postoperative","['Pain, Postoperative', 'Ketamine Adverse Reaction', 'Pain, Refractory', 'Pain, Intractable', 'Pain, Acute']","['pain score reduction', 'reduction in pain scores', 'post-operative pain', 'ketamine use in recovery room', 'recovery room', 'ketamine recovery', 'ketamine rescue']",COMPLETED,,2020-09-01,2021-05-28,"[{'measure': 'Reduction in pain score after ketamine use in PACU', 'description': 'The Numeric Rating Scale (NRS-11) is an 11-point scale for patient self-reporting of pain. It is what is used most often in our recovery room for pain assessment. A score of 0/10 means no pain, and 10/10 means worst pain.', 'timeFrame': 'in the immediate post-operative period in recovery room'}]","[{'measure': 'Incidence of side effects after ketamine use', 'timeFrame': 'in the immediate post-operative period in recovery room'}]",2,18 Years,,ALL,True,University of Alberta,OTHER,0,143.0,ACTUAL,2025-09-01T16:18:17.187772,v2_robust,False,True,True,False,False,
NCT00355108,ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome,ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome. Beneficial or Iatrogenic Effects.,tranexamic acid,['tranexamic acid'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,"Telangiectasia, Hereditary Hemorrhagic","['Telangiectasia, Hereditary Hemorrhagic', 'Osler-Rendu Disease']","['Rendu Osler syndrome', 'Epistaxis', 'Tranexamic acid', 'clinical trial']",COMPLETED,,2006-09,2010-05,"[{'measure': 'The primary efficacy criterion is the average monthly duration of epistaxis.', 'timeFrame': 'after first 3 month period treatment or placebo and after second 3 month period treatment or placebo'}]","[{'measure': 'the average monthly number of epistaxis,', 'timeFrame': 'after first 3 month period treatment or placebo and after second 3 month period treatment or placebo'}, {'measure': 'the average duration of one episode of epistaxis measured over a month,', 'timeFrame': 'after first 3 month period treatment or placebo and after second 3 month period treatment or placebo'}, {'measure': 'the Haemoglobin level', 'timeFrame': 'after first 3 month period treatment or placebo and after second 3 month period treatment or placebo'}, {'measure': 'estimation of Quality of life.', 'timeFrame': 'over first 3 month period treatment or placebo and over second 3 month period treatment or placebo'}, {'measure': 'Outcome of following Adverse Event: arterial or veinous thrombosis, allergic accident', 'timeFrame': 'during first 3 month period treatment or placebo and over second 3 month period treatment or placebo'}]",6,18 Years,90 Years,ALL,False,Hospices Civils de Lyon,OTHER,0,170.0,ACTUAL,2025-09-01T16:18:17.187782,v2_robust,True,True,True,False,True,
NCT00664625,A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects,"Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-791325 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1",BMS-791325,"['BMS-791325', 'Placebo']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Chronic Hepatitis C,['Chronic Hepatitis C'],[],COMPLETED,,2008-05,2009-06,"[{'measure': 'Safety Outcome Measures', 'timeFrame': 'Safety and tolerability assessments will be performed for a period of 7 days after administration of a single dose'}]","[{'measure': 'Pharmacokinetic Measures', 'timeFrame': 'Pharmacokinetic assessments will be done for a period of 72 hours following administration of a single oral dose'}, {'measure': 'Pharmacodynamic Measures', 'timeFrame': 'Antiviral activity will be assessed by the magnitude and rate of change in plasma HCV RNA levels for a period of 7 days after dosing'}]",3,18 Years,60 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:17.187919,v2_robust,True,True,True,False,True,
NCT07046325,Comparison Between Dexametidomedine\Bupivacaine and Plain Bupivacaine in Superior Trunk Block for Arthroscopic Shoulder Surgeries,Comparison Between Dexametidomedine\Bupivacaine and Plain Bupivacaine in Superior Trunk Block for Arthroscopic Shoulder Surgeries,dexametedomidine,"['dexametedomidine', 'Bupivacain']",2,INTERVENTIONAL,['NA'],,,"Post Operative Pain, Acute","['Post Operative Pain, Acute', 'Arthroscopic Shoulder Surgery']",[],COMPLETED,,2025-01-20,2025-05-01,"[{'measure': 'Duration of analgesia of Superior trunck block.', 'description': 'The DOA will be defined as the time interval between STB and the first need for the rescue analgesics.', 'timeFrame': '24 hours'}]",[],1,20 Years,50 Years,ALL,False,Ain Shams University,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:17.188222,v2_robust,True,True,True,False,False,
NCT06805825,A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit,A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit,NN3201,['NN3201'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Gastrointestinal Stromal Tumors,"['Gastrointestinal Stromal Tumors', 'Small-cell Lung Cancer', 'Adenoid Cystic Carcinoma', 'Uveal Melanoma', 'Neuroendocrine Tumors', 'Chromophobe Renal Cell Carcinoma', 'Clear Cell Renal Cell Carcinoma']","['GIST', 'SCLC', 'ACC', 'NET', 'ChRCC', 'ccRCC', 'Novelty Nobility', 'cKit', 'c-kit', 'Gastrointestinal Stromal Tumors', 'Small-cell Lung Cancer', 'Adenoid Cystic Carcinoma', 'Uveal Melanoma', 'Neuroendicrine Tumors', 'Chromophobe Renal Cell Carcinoma', 'Clear Cell Renal Cell Carcinoma', 'advanced GIST', 'advanced SCLC', 'advanced ACC', 'advanced NET', 'advanced ChRCC', 'advanced ccRCC']",RECRUITING,,2025-02-03,2027-12-31,"[{'measure': 'Number of subjects with Dose-limiting Toxicities:', 'description': 'A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0 and is considered by the investigator to be clinically relevant and attributed to the study treatment during the first 21 days after the first dose of study treatment.', 'timeFrame': '3 weeks'}, {'measure': 'Incidence of Adverse Events:', 'description': 'Number of subjects with adverse events (AEs) according to severity, seriousness, and relationship to study drug', 'timeFrame': '1 year'}]","[{'measure': 'Choose which dose(s) will be used in the expansion cohorts', 'description': 'Assessing which dose(s) have anti-tumor benefit and an acceptable incidence of adverse events that allow for continued enrollment', 'timeFrame': '1 year'}, {'measure': 'Pharmacokinetics (PK) of NN3201', 'description': 'Pharmacokinetics (PK) of NGM120 by measuring serum concentration of NGM120 at specified timepoints', 'timeFrame': '3 years'}, {'measure': 'Assessment of anti-tumor activity', 'description': 'Assessment of anti-tumor activity by RECIST 1.1', 'timeFrame': '3 years'}, {'measure': 'Choose which dose(s) may be used in a future study', 'description': 'Assessing which dose(s) have anti-tumor benefit and an acceptable incidence of adverse events that may be used in a future study.', 'timeFrame': '3 years'}]",6,18 Years,,ALL,False,"Novelty Nobility, Inc.",INDUSTRY,0,67.0,ESTIMATED,2025-09-01T16:18:17.188282,v2_robust,True,True,False,False,True,
NCT02413125,Comparison of Nasal Saline Irrigation Bottle Contamination Between Two Solutions,Comparison of Nasal Saline Irrigation Bottle Contamination Between Two Solutions,Normal saline,['Normal saline'],1,INTERVENTIONAL,['NA'],,,Sinusitis,['Sinusitis'],[],UNKNOWN,,2015-02,2015-06,"[{'measure': 'Bacterial contamination of nasal saline irrigation bottle following normal saline solution assessed by performing a bacterial culture', 'description': 'Patients will be provided an irrigation bottle and instructed to use normal saline for 1 month. Following this period, the saline irrigation bottle will be collected and a bacterial culture of the irrigation bottle will be performed to determine the bacterial contamination present following use.', 'timeFrame': '1 month'}, {'measure': 'Bacterial contamination of nasal saline irrigation bottle following ChitoRhino irrigation solution assessed by performing a bacterial culture', 'description': 'Patients will be provided an irrigation bottle and instructed to use the ChitoRhino irrigation solution for 1 month. Following this period, the saline irrigation bottle will be collected and a bacterial culture of the irrigation bottle will be performed to determine the bacterial contamination present following use.', 'timeFrame': '1 month'}]",[],2,18 Years,,ALL,True,University of Virginia,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:17.188293,v2_robust,True,True,False,False,False,
NCT01404325,Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients,"A 2-arm, Prospective, Randomized, Controlled, Open-label, 12 Month Phase III Trial to Evaluate the Efficacy Regarding Renal Function of Everolimus in Combination With a Centre Specific Standard Immunosuppressive Regimen Consisting of CNI, Purinantagonists and Steroids Versus a Standard Triple Immunosuppressive Regimen in Lung Transplant Recipients.",standard therapy,"['Everolimus', 'RAD001', 'standard therapy']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Lung Transplantation,['Lung Transplantation'],"['Lung transplantation', 'everolimus', 'kidney function', 'renal function']",COMPLETED,,2012-02-01,2017-01-05,"[{'measure': 'Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 Months', 'description': 'Calculated Glomerular Filtration Rate (cGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 months The CKD-EPI equation, expressed as a single equation, is GFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)\\^-1.209 × 0.993Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1', 'timeFrame': 'Month 12'}]","[{'measure': 'Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at Month 1, 3, 6, 9, 12', 'description': 'Calculated Glomerular Filtration Rate (cGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at Month 1, 3, 6, 9 and 12. The CKD-EPI equation, expressed as a single equation, is GFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)\\^-1.209 × 0.993Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1', 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': ""Calculated Glomerular Filtration Rate (cGFR) According to Cystatin C-based Hoek's Formula at Month 1, 3, 6, 9, 12"", 'description': ""Calculated Glomerular Filtration Rate (cGFR) according to Cystatin C-based Hoek's formula at Month 1, 3, 6, 9, 12"", 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': 'Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 1, 3, 6, 9, 12', 'description': 'Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 1, 3, 6, 9, 12 cGFR (in mL/min/1.73 m2) = 186.3\\*(C-1.154)\\*(A-0.203)\\*G\\*R where C = the serum concentration of creatinine (mg/dL), A = age (years), G = 0.742 when gender is female, otherwise G = 1, R = 1.21 when race is black, otherwise R = 1.', 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': 'Calculated Glomerular Filtration Rate (cGFR) According to Cockcroft-Gault at Month 1, 3, 6, 9, 12', 'description': 'Calculated Glomerular Filtration Rate (cGFR) according to Cockcroft-Gault at Month 1, 3, 6, 9, 12 For men: GFR=(140-Age) x Body weight (kg) / 72 x Serum Creatinine (mg/dl) For women: GFR=0.85 (140 -Age) x Body weight(kg)/ 72 x Serum Creatinine (mg/dl)', 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': 'Incidence of Patients Experiencing a Decline in GFR of < 10, 10-15, 15-20, 20-25 and > 25 mL/Min From Baseline to Month 6 and 12.', 'description': 'Incidence of patients experiencing a decline in GFR of \\< 10, 10-15, 15-20, 20-25 and \\> 25 mL/min from Baseline to Month 6 and 12calculated by the CKD-EPI method. Participants are counted in each decline level observed for that participant; this means participants may be counted in more than 1 decline level.', 'timeFrame': 'Baseline, Month 6, Month 12'}, {'measure': 'Incidence of Renal Replacement Therapy at Month 6 and Month 12', 'description': 'Incidence of renal replacement therapy at Month 6 and Month 12: There were no incidences in either group where renal replacement therapy was required', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Time to Renal Replacement Therapy at Month 6 and Month 12', 'description': 'Time to renal replacement therapy at Month 6 and Month 12: There were no incidences in either group where renal replacement therapy was required', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Incidence of Acute Rejection Episodes at Month 6 and Month 12', 'description': 'Incidence of acute rejection episodes at Month 6 and Month 12. This table counts multiple occurrences of rejection in the same patient as different incidents. Every incident is associated with both an A and a B classification.\n\nClassification A: Acute Rejection Grade 0 - none, Grade 1-minimal, Grade 2- mild, Grade 3-moderate, Grade 4-Severe; Classification B: Airway Inflammation-Grade 0-none, Grade 1R-low grade, Grade 2R-high grade, Grade X-ungradeable', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Incidence of Graft Loss/Re-transplantation at Month 6 and Month 12', 'description': 'Incidence of graft loss/re-transplantation at Month 6 and Month 12', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Incidence of Bronchiolitis Obliterans Syndrome (BOS) at Month 6 and Month 12', 'description': 'Incidence of Bronchiolitis obliterans syndrome (BOS) at Month 6 and Month 12 BOS 0 is FEV1 \\> 90% of baseline and FEF25-75% \\> 75% of baseline; BOS 0-p is FEV1 81-90% of baseline and/or FEF25-75% ≤ 75% of baseline; BOS 1 is FEV1 66-80% of baseline; BOS 2 is FEV1 51-65% of baseline; BOS 3 is FEV1 ≤ 50% of baseline', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Incidence of Death at Month 6 and Month 12', 'description': 'Incidence of death at Month 6 and Month 12', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Quality of Life (QoL, SF36) at Month 6 and Month 12', 'description': 'Quality of Life (QoL, SF36) at Month 6 and Month 12 Scores can range from a minimum of 0 (maximum disability) to a maximum of 100 (no disability).', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Exercise Capacity 6-Minute Walk Test(6MWT) at Month 6 and Month 12', 'description': 'Exercise capacity (6MWT) at Month 6 and Month 12 Measured by the Borg Scale. THE BORG SCALE 0 is Nothing at all, 0.5 is Very, very slight (just noticeable); 1 is Very slight, 2 is Slight (light); 3 is Moderate; 4 is Somewhat severe; 5 is Severe (heavy), 7 is Very severe, 10 is Very, very severe (maximal)The higher the Borg score implies increased shortness of breath and/or increased fatigue.', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Incidence of Treated Arterial Hypertension up to Month 12', 'description': 'Incidence of treated of arterial hypertension up to Month 12', 'timeFrame': 'up to Month 12'}, {'measure': 'Incidence of Diabetes Mellitus up to Month 12', 'description': 'Incidence of Diabetes Mellitus up to Month 12', 'timeFrame': 'up to Month 12'}, {'measure': 'Trough Levels of Everolimus at Month 1, 3, 6, 9, 12', 'description': 'Trough levels of everolimus at Month 1, 3, 6, 9, 12', 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': 'Adherence to Target Ranges of Everolimus at Month 1, 3, 6, 9, 12', 'description': 'Adherence to target ranges of everolimus at Month 1, 3, 6, 9, 12', 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': 'Trough Levels of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12', 'description': 'Trough levels of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12', 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': 'Adherence to Target Ranges of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12', 'description': 'Adherence to target ranges of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12', 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': 'Trough Levels of Tacrolimus at Month 1, 3, 6, 9, 12', 'description': 'Trough levels of Tacrolimus at Month 1, 3, 6, 9, 12', 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': 'Adherence to Target Ranges of Tacrolimus at Month 1, 3, 6, 9, 12', 'description': 'Adherence to target ranges of Tacrolimus at Month 1, 3, 6, 9, 12', 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': 'Incidence of Bacterial, Viral, and Fungal Infections at Month 12', 'description': 'Incidence of bacterial, viral, and fungal infections at Month 12', 'timeFrame': 'Month 12'}, {'measure': 'Triglyceride Levels at Month 1, 3, 6, 9, 12', 'description': 'Triglyceride levels at Month 1, 3, 6, 9, 12', 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': 'Total Cholesterol Levels at Month 1, 3, 6, 9, 12', 'description': 'Total Cholesterol levels at Month 1, 3, 6, 9, 12', 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': 'Low-Density Lipoprotein (LDL)Cholesterol Levels at Month 1, 3, 6, 9, 12', 'description': 'LDL Cholesterol levels at Month 1, 3, 6, 9, 12', 'timeFrame': 'Month 1, 3, 6, 9, 12'}, {'measure': 'High-Density Lipoprotein (HDL)Cholesterol Levels at Month 1, 3, 6, 9, 12', 'description': 'HDL Cholesterol levels at Month 1, 3, 6, 9, 12', 'timeFrame': 'Month 1, 3, 6, 9, 12'}]",27,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,130.0,ACTUAL,2025-09-01T16:18:17.188306,v2_robust,True,True,True,False,False,
NCT02637076,Xyrem and Brain Dopamine in Narcolepsy,Does Xyrem Influence Brain Dopamine in Patients With Narcolepsy? A PET Imaging Investigation,Xyrem,"['gamma-hydroxybutyrate', 'Sodium Oxybate', 'Xyrem']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Narcolepsy With Cataplexy,"['Narcolepsy With Cataplexy', 'Healthy Controls']","['Xyrem', 'narcolepsy with cataplexy', 'positron emission tomography', 'dopamine']",COMPLETED,,2016-01,2020-01-23,"[{'measure': '[C-11]Raclopride BPND at 1 Hour Post Xyrem', 'description': 'BPND (Binding Potential) of \\[C-11\\]raclopride measures 1 hour after taking a single 3g dose of Xyrem.', 'timeFrame': '1 hour post Xyrem'}, {'measure': '% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem', 'description': ""\\[C-11\\] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy.\n\n% change was calculated as follows: (1 hour BPND - baseline BPND)/baseline BPND \\*100; Mean % change represents the mean of each participant's individual % change within the group."", 'timeFrame': '1 hour post Xyrem'}, {'measure': '[C-11]Raclopride BPND at 7 Hours Post Xyrem', 'description': 'BPND (Binding Potential) of \\[C-11\\]raclopride measures 7 hours after taking a single 3g dose of Xyrem.', 'timeFrame': '7 hours post Xyrem'}, {'measure': '% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem', 'description': ""\\[C-11\\] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy.\n\n% change was calculated as follows: (7 hours BPND - baseline BPND)/baseline BPND \\*100; Mean % change represents the mean of each participant's individual % change within the group."", 'timeFrame': '7 hours post Xyrem'}]","[{'measure': '[C-11]DTBZ BPND at 5 Hours Post Xyrem', 'description': 'Measurement of \\[C-11\\]DTBZ 5 hours after taking a single dose of 3g Xyrem', 'timeFrame': '5 hours post single Xyrem dose'}, {'measure': '% Change in PET [C-11] Dihydrotetrabenazine (DTBZ) Binding From Baseline to Five Hours Post Xyrem', 'description': ""\\[C-11\\] DTBZ is a radioligand that binds to the vesicular monoamine transporter and which is sensitive to dopamine occupancy.\n\n% change was calculated as follows: (5 hour BPND - baseline BPND)/baseline BPND \\*100; Mean % change represents the mean of each participant's individual % change within the group."", 'timeFrame': '5 hours post single Xyrem dose'}, {'measure': 'Blood Gamma-hydroxybutyrate (GHB) Concentration (AUC)', 'description': 'The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem, as measured by Area Under the Curve.', 'timeFrame': 'multiple time points from 0 to 7 hours post-Xyrem'}, {'measure': 'Blood Gamma-hydroxybutyrate (GHB) Cmax', 'description': 'The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem as measured by Cmax.', 'timeFrame': 'multiple time points from 0 to 7 hours post-Xyrem'}, {'measure': 'Duration of Drowsiness', 'description': 'Period of time when the participant was experiencing the sedative action of Xyrem. Data derived from self-report as well as anesthesiologist observation.', 'timeFrame': 'observed after receiving single dose of Xyrem, up to 9 hours'}]",9,19 Years,,ALL,True,Centre for Addiction and Mental Health,OTHER,0,17.0,ACTUAL,2025-09-01T16:18:17.188526,v2_robust,True,True,True,False,False,
NCT05281276,Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC),A Phase Ib Study of Chidamide in Combination With Celecoxib in Patients With Metastatic Colorectal Cancer Who Had Progression or Were Intolerant of at Least Two Lines of Systemic Therapies (CCmCC),chidamide,"['HBI-8000', 'Celebrex', 'chidamide', 'tucidinostat', 'celecoxib']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Metastatic Colorectal Cancer,['Metastatic Colorectal Cancer'],['Metastatic Colorectal Cancer'],TERMINATED,The overall profile does not support development for metastatic colorectal cancer,2022-09-20,2024-03-26,"[{'measure': 'Maximum Feasible Dose (MFD)', 'description': 'Maximum Feasible Dose (MFD): is defined as the highest dose for which ≤1 of 6 evaluable subjects experiencing DLT during the first treatment cycle (28 days) of the combination therapy. If the dose of Cohort 1 is not tolerable by ≥2 evaluable subjects, the MFD will be considered as not determined.', 'timeFrame': 'defined as the highest dose for which ≤1 of 6 evaluable subjects experiencing DLT during the first treatment cycle (28 days) of the combination therapy, assessed up to 24 months'}, {'measure': 'Pharmacokinetics profiles-(AUC0-t)', 'description': 'Area under the plasma concentration-time curve from time zero to time t(AUC0-t)', 'timeFrame': 'Run-in period, on day1, blood sample will be 0, 1, 2, 6, 12, and 24 hours; on day3, blood sample will be 0, 1, 2, 6, 12, 24, 48, and 72 hours.Combination therapy period, on day1 & day25, blood sample will be 0, 1, 2, 6, 12, 24, 48 and 72 hours.'}, {'measure': 'Pharmacokinetics profiles-(AUC0-∞)', 'description': 'Area under the plasma concentration-time curve from time zero to infinity(AUC0-∞)', 'timeFrame': 'Run-in period, on day1, blood sample will be 0, 1, 2, 6, 12, and 24 hours; on day3, blood sample will be 0, 1, 2, 6, 12, 24, 48, and 72 hours.Combination therapy period, on day1 & day25, blood sample will be 0, 1, 2, 6, 12, 24, 48 and 72 hours.'}, {'measure': 'Pharmacokinetics profiles-(Cmax)', 'description': 'Maximum plasma concentration(Cmax)', 'timeFrame': 'Run-in period, on day1, blood sample will be 0, 1, 2, 6, 12, and 24 hours; on day3, blood sample will be 0, 1, 2, 6, 12, 24, 48, and 72 hours.Combination therapy period, on day1 & day25, blood sample will be 0, 1, 2, 6, 12, 24, 48 and 72 hours.'}, {'measure': 'Pharmacokinetics profiles-(Tmax)', 'description': 'Time to maximum plasma concentration(Tmax)', 'timeFrame': 'Run-in period, on day1, blood sample will be 0, 1, 2, 6, 12, and 24 hours; on day3, blood sample will be 0, 1, 2, 6, 12, 24, 48, and 72 hours.Combination therapy period, on day1 & day25, blood sample will be 0, 1, 2, 6, 12, 24, 48 and 72 hours.'}, {'measure': 'Pharmacokinetics profiles-(T1/2)', 'description': 'Half-life(T1/2)', 'timeFrame': 'Run-in period, on day1, blood sample will be 0, 1, 2, 6, 12, and 24 hours; on day3, blood sample will be 0, 1, 2, 6, 12, 24, 48, and 72 hours.Combination therapy period, on day1 & day25, blood sample will be 0, 1, 2, 6, 12, 24, 48 and 72 hours.'}, {'measure': 'Pharmacokinetics profiles-(Kel)', 'description': 'Elimination rate constant(Kel)', 'timeFrame': 'Run-in period, on day1, blood sample will be 0, 1, 2, 6, 12, and 24 hours; on day3, blood sample will be 0, 1, 2, 6, 12, 24, 48, and 72 hours.Combination therapy period, on day1 & day25, blood sample will be 0, 1, 2, 6, 12, 24, 48 and 72 hours.'}, {'measure': 'Pharmacokinetics profiles-(AUC0-τ,ss)', 'description': 'Area under the plasma concentration-time curve from time zero to time τ (dosing interval) at steady state(AUC0-τ,ss)', 'timeFrame': 'Run-in period, on day1, blood sample will be 0, 1, 2, 6, 12, and 24 hours; on day3, blood sample will be 0, 1, 2, 6, 12, 24, 48, and 72 hours.Combination therapy period, on day1 & day25, blood sample will be 0, 1, 2, 6, 12, 24, 48 and 72 hours.'}, {'measure': 'Pharmacokinetics profiles-(Cave,ss)', 'description': 'Average plasma concentration at steady state(Cave,ss)', 'timeFrame': 'Run-in period, on day1, blood sample will be 0, 1, 2, 6, 12, and 24 hours; on day3, blood sample will be 0, 1, 2, 6, 12, 24, 48, and 72 hours.Combination therapy period, on day1 & day25, blood sample will be 0, 1, 2, 6, 12, 24, 48 and 72 hours.'}, {'measure': 'Pharmacokinetics profiles-(Cmin,ss)', 'description': 'Minimum (trough) plasma concentration at steady state(Cmin,ss)', 'timeFrame': 'Run-in period, on day1, blood sample will be 0, 1, 2, 6, 12, and 24 hours; on day3, blood sample will be 0, 1, 2, 6, 12, 24, 48, and 72 hours.Combination therapy period, on day1 & day25, blood sample will be 0, 1, 2, 6, 12, 24, 48 and 72 hours.'}, {'measure': 'Pharmacokinetics profiles-(Cmax,ss)', 'description': 'Maximum (peak) plasma concentration at steady state(Cmax,ss)', 'timeFrame': 'Run-in period, on day1, blood sample will be 0, 1, 2, 6, 12, and 24 hours; on day3, blood sample will be 0, 1, 2, 6, 12, 24, 48, and 72 hours.Combination therapy period, on day1 & day25, blood sample will be 0, 1, 2, 6, 12, 24, 48 and 72 hours.'}, {'measure': 'Pharmacokinetics profiles-(Tmax,ss)', 'description': 'Time to maximum plasma concentration at steady state(Tmax,ss)', 'timeFrame': 'Run-in period, on day1, blood sample will be 0, 1, 2, 6, 12, and 24 hours; on day3, blood sample will be 0, 1, 2, 6, 12, 24, 48, and 72 hours.Combination therapy period, on day1 & day25, blood sample will be 0, 1, 2, 6, 12, 24, 48 and 72 hours.'}, {'measure': 'Pharmacokinetics profiles-(DF)', 'description': 'Degree of fluctuation(DF)', 'timeFrame': 'Run-in period, on day1, blood sample will be 0, 1, 2, 6, 12, and 24 hours; on day3, blood sample will be 0, 1, 2, 6, 12, 24, 48, and 72 hours.Combination therapy period, on day1 & day25, blood sample will be 0, 1, 2, 6, 12, 24, 48 and 72 hours.'}]","[{'measure': 'Progression-free survival', 'description': 'defined as the time from first day of dosing until the date of first objective disease progression or death. Patients who have not progressed or died at the time of analysis will be censored at the time of the latest date of tumor assessment', 'timeFrame': 'from the time of first day of dosing (Run-in period Day1) until the date of first objective disease progression or death, assessed up to 24 months'}, {'measure': 'Objective response', 'description': 'ORR, defined as the percentage of patients with CR and PR of total number of analysis set', 'timeFrame': 'From enrollment until disease progression or unacceptable toxicity, assessed up to 24 months'}]",15,20 Years,,ALL,False,Taipei Medical University Shuang Ho Hospital,OTHER,0,9.0,ACTUAL,2025-09-01T16:18:17.188622,v2_robust,True,True,False,True,False,The overall profile does not support development for metastatic colorectal cancer
NCT02860676,Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961,A Phase 1 Extension Study to Determine the Safety of UC-961 (Cirmtuzumab) at the Recommended Phase 2 Dose for Retreatment of Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961,cirmtuzumab,"['cirmtuzumab', 'UC-961']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Lymphocytic Leukemia,['Chronic Lymphocytic Leukemia'],"['CLL', 'cancer', 'UC-961', 'cirmtuzumab']",COMPLETED,,2016-11-03,2018-05-22,"[{'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'Adverse events assessed by CTCAE v4.0 during treatment and 3 month follow-up', 'timeFrame': '1 year'}]","[{'measure': 'Overall response rate', 'timeFrame': '1 year'}, {'measure': 'Progression free survival', 'timeFrame': '1 year'}, {'measure': 'Stable Disease Rate (SD)', 'timeFrame': '1 year'}, {'measure': 'Partial Response Rate (PR)', 'timeFrame': '1 year'}, {'measure': 'Minimal Residual Disease Rate (MRD)', 'timeFrame': '1 year'}]",6,18 Years,,ALL,False,"University of California, San Diego",OTHER,0,3.0,ACTUAL,2025-09-01T16:18:17.188788,v2_robust,True,True,True,False,True,
NCT00143117,"Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation","A Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men With Premature Ejaculation","UK-390,957","['UK-390,957']",1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Ejaculation,['Ejaculation'],[],COMPLETED,,2004-08,2005-06,[{'measure': 'Assessment of efficacy and safety'}],[{'measure': 'Assessment of Quality of Sexual Life'}],2,18 Years,,MALE,False,Pfizer,INDUSTRY,0,460.0,,2025-09-01T16:18:17.188961,v2_robust,True,True,True,False,True,
NCT00884117,Influenza Resistance Information Study,Influenza Resistance Information Study (IRIS),Oseltamivir,"['Oseltamivir', 'Tamiflu']",2,OBSERVATIONAL,[],,,Influenza,['Influenza'],[],COMPLETED,,2009-01,2015-11,"[{'measure': 'Number of Participants With Genotypic Resistance', 'description': 'Samples were analyzed using reverse transcriptase-polymerase chain reaction (RT-PCR). Pre-defined mutations in viral ribonucleic acid (RNA) were noted, the presence of which was defined as genotypic resistance. The number of participants with genotypic resistance at Baseline was reported. The number of participants with genotypic resistance post-Baseline was determined by a collective count of all participants who had a resistance mutation at least once on Days 3, 6, and/or 10. (Hereafter, ""H"" stands for hemagglutinin and ""N"" stands for neuraminidase in abbreviations of viral subtype such as H1N1, H1N1pdm09, and H3N2.)', 'timeFrame': 'Baseline (Day 1) and post-Baseline (Days 3, 6, 10)'}, {'measure': 'Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections', 'description': 'Pre-defined mutations in viral RNA were noted, the presence of which was defined as genotypic resistance. Treatment-emergent resistance was defined as the presence of genotypic or phenotypic resistance from a post-Baseline sample in the setting of a previously non-resistant Baseline sample. The percentage of participants with treatment-emergent resistance was reported by study year for participants with H3N2 or H1N1pdm09 infections. Only data with evaluable participants were reported.', 'timeFrame': 'From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10) during Study Years 1, 2, 3, 4, 5, 6, 7'}]","[{'measure': 'Number of Participants With Viral RNA Detected by RT-PCR on Day 1 Among Adults Treated With Oseltamivir', 'timeFrame': 'Baseline (Day 1)'}, {'measure': 'Number of Participants With Viral RNA Detected by RT-PCR on Day 3 Among Adults Treated With Oseltamivir', 'timeFrame': 'Day 3'}, {'measure': 'Number of Participants With Viral RNA Detected by RT-PCR on Day 6 Among Adults Treated With Oseltamivir', 'timeFrame': 'Day 6'}, {'measure': 'Number of Participants With Viral RNA Detected by RT-PCR on Day 10 Among Adults Treated With Oseltamivir', 'timeFrame': 'Day 10'}, {'measure': 'Number of Participants With Viral RNA Detected by RT-PCR on Day 1 Among Children Treated With Oseltamivir', 'timeFrame': 'Baseline (Day 1)'}, {'measure': 'Number of Participants With Viral RNA Detected by RT-PCR on Day 3 Among Children Treated With Oseltamivir', 'timeFrame': 'Day 3'}, {'measure': 'Number of Participants With Viral RNA Detected by RT-PCR on Day 6 Among Children Treated With Oseltamivir', 'timeFrame': 'Day 6'}, {'measure': 'Number of Participants With Viral RNA Detected by RT-PCR on Day 10 Among Children Treated With Oseltamivir', 'timeFrame': 'Day 10'}, {'measure': 'Time to Non-Detection of Viral RNA', 'description': 'Time to non-detection/viral clearance was the time between symptom onset and the day on which viral RNA was no longer detected, or the last visit date if the participant was not RNA-negative at that visit. Time to non-detection/viral clearance was estimated using Kaplan-Meier analysis and expressed in days.', 'timeFrame': 'From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10)'}, {'measure': 'Time to Non-Detection of Viral RNA Among Participants With H3N2 Infections', 'description': 'Time to non-detection/viral clearance was the time between symptom onset and the day on which viral RNA was no longer detected, or the last visit date if the participant was not RNA-negative at that visit. Time to non-detection/viral clearance was estimated using Kaplan-Meier analysis and expressed in days.', 'timeFrame': 'From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10)'}, {'measure': 'Time to Non-Detection of Viral RNA Among Participants With H1N1pdm09 Infections', 'description': 'Time to non-detection/viral clearance was the time between symptom onset and the day on which viral RNA was no longer detected, or the last visit date if the participant was not RNA-negative at that visit. Time to non-detection/viral clearance was estimated using Kaplan-Meier analysis and expressed in days.', 'timeFrame': 'From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10)'}, {'measure': 'Time to Non-Detection of Viral RNA Among Participants With Influenza B Infections', 'description': 'Time to non-detection/viral clearance was the time between symptom onset and the day on which viral RNA was no longer detected, or the last visit date if the participant was not RNA-negative at that visit. Time to non-detection/viral clearance was estimated using Kaplan-Meier analysis and expressed in days.', 'timeFrame': 'From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10)'}, {'measure': 'Viral Load Among Adults Treated With Oseltamivir', 'description': 'Viral load was determined for those with detectable virus above the lower limit of quantification (LLQ) of 1.82 for influenza A viruses and 1.99 for influenza B viruses. The viral load from each sample was averaged among all participants and expressed in log10 of the number of viral particles per milliliter (log10 vp/mL).', 'timeFrame': 'Days 1, 3, 6, 10'}, {'measure': 'Viral Load Among Children Treated With Oseltamivir', 'description': 'Viral load was determined for those with detectable virus above the LLQ of 1.82 for influenza A viruses and 1.99 for influenza B viruses. The viral load from each sample was averaged among all participants and expressed in log10 vp/mL.', 'timeFrame': 'Days 1, 3, 6, 10'}, {'measure': 'Percentage of Participants With Symptom Resolution on Day 6 Comparing Resistant and Susceptible Viruses', 'description': 'Pre-defined mutations in viral RNA were noted, the presence of which was defined as genotypic resistance. Phenotypic resistance was defined as 50% inhibitory concentration (IC50) more than 10-fold higher than the median value for all viruses of the same subtype. Treatment-emergent resistance was defined as the presence of genotypic or phenotypic resistance from a post-Baseline sample in the setting of a previously non-resistant Baseline sample. Susceptible viruses were those that did not exhibit treatment-emergent resistance. The percentage of participants with mild or absent symptoms on Day 6 was reported and stratified by resistant and susceptible viruses.', 'timeFrame': 'Day 6'}, {'measure': 'Percentage of Participants by Day of Viral RNA First Not Detected Comparing Resistant and Susceptible Viruses', 'description': 'Pre-defined mutations in viral RNA were noted, the presence of which was defined as genotypic resistance. Phenotypic resistance was defined as IC50 more than 10-fold higher than the median value for all viruses of the same subtype. Treatment-emergent resistance was defined as the presence of genotypic or phenotypic resistance from a post-Baseline sample in the setting of a previously non-resistant Baseline sample. Susceptible viruses were those that did not exhibit treatment-emergent resistance. The percentage of participants by earliest post-Baseline test day on which viral RNA was not detected was reported and stratified by resistant and susceptible viruses.', 'timeFrame': 'Days 3, 6, 10'}, {'measure': 'Percentage of Participants With Resistant Versus Susceptible Viruses by Baseline Viral Load', 'description': 'Pre-defined mutations in viral RNA were noted, the presence of which was defined as genotypic resistance. Phenotypic resistance was defined as IC50 more than 10-fold higher than the median value for all viruses of the same subtype. Treatment-emergent resistance was defined as the presence of genotypic or phenotypic resistance from a post-Baseline sample in the setting of a previously non-resistant Baseline sample. Susceptible viruses were those that did not exhibit treatment-emergent resistance. The mean viral load from each sample was expressed in log10 vp/mL and stratified by resistant and susceptible viruses.', 'timeFrame': 'Baseline (Day 1)'}, {'measure': 'Total Daily Symptom Score According to Global Assessment by the Investigator Among Adults Treated With Oseltamivir', 'description': 'Symptoms were assessed on Days 1, 6, and 10. The Investigator rated seven symptoms of fever, sore throat, nasal congestion, cough, aches/pains, headache, and fatigue on a scale of 0 (absent/no problem) to 3 (severe/major problem). The global score was calculated as a sum of all individual symptom scores. Global scores may range from 0 to 21, with higher scores indicating worse or more pronounced symptoms.', 'timeFrame': 'Days 1, 6, 10'}, {'measure': 'Total Daily Symptom Score According to Global Assessment by the Investigator Among Children Treated With Oseltamivir', 'description': 'Symptoms were assessed on Days 1, 6, and 10. The Investigator rated seven symptoms of fever, sore throat, nasal congestion, cough, aches/pains, headache, and energy/tiredness on a scale of 0 (absent/no problem) to 3 (severe/major problem). The global score was calculated as a sum of all individual symptom scores. Global scores may range from 0 to 21, with higher scores indicating worse or more pronounced symptoms.', 'timeFrame': 'Days 1, 6, 10'}, {'measure': 'Body Temperature Among Adults Treated With Oseltamivir', 'description': 'Body temperature was measured by the Investigator using an oral or tympanic thermometer at Baseline and Day 10. Body temperature at each visit was averaged among all participants and expressed in degrees Celsius.', 'timeFrame': 'Days 1, 10'}, {'measure': 'Change From Baseline in Body Temperature Among Adults Treated With Oseltamivir', 'description': 'Body temperature was measured by the Investigator using an oral or tympanic thermometer at Baseline and Day 10. The change in body temperature between visits was averaged among all participants and expressed in degrees Celsius.', 'timeFrame': 'Baseline (Day 1) to Day 10'}, {'measure': 'Body Temperature Among Children Treated With Oseltamivir', 'description': 'Body temperature was measured by the Investigator using an oral or tympanic thermometer at Baseline and Day 10. Body temperature at each visit was averaged among all participants and expressed in degrees Celsius.', 'timeFrame': 'Days 1, 10'}, {'measure': 'Change From Baseline in Body Temperature Among Children Treated With Oseltamivir', 'description': 'Body temperature was measured by the Investigator using an oral or tympanic thermometer at Baseline and Day 10. The change in body temperature between visits was averaged among all participants and expressed in degrees Celsius.', 'timeFrame': 'Baseline (Day 1) to Day 10'}]",25,,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,4561.0,ACTUAL,2025-09-01T16:18:17.189000,v2_robust,False,True,True,False,False,
NCT06082817,An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD,An Open-Label Pilot Study of the Pharmacokinetics and Safety of 50 Mg Oral Testosterone Undecanoate (Kyzatrex) in Menopausal Women with Low Testosterone and Hypoactive Sexual Desire Disorder,Oral Testosterone Undecanoate,"['Kyzatrex', 'Oral Testosterone Undecanoate']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hypoactive Sexual Desire Disorder,['Hypoactive Sexual Desire Disorder'],[],NOT_YET_RECRUITING,,2025-01-01,2025-12-31,"[{'measure': 'Testosterone', 'description': 'serum concentration of total testosterone to assess safety (adverse events) and pharmacokinetics', 'timeFrame': 'days 0, 7, 28, 56'}]","[{'measure': 'Female Sexual Function Index', 'description': 'Female Sexual Function Index to assess changes in each domain and total, total range 2-36, lower the score the more dysfunction therefore worse function', 'timeFrame': 'Days 0, 28, 56, 84'}]",2,21 Years,75 Years,FEMALE,True,San Diego Sexual Medicine,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:17.189445,v2_robust,True,True,False,False,True,
NCT05160740,Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer,Multicenter Randomized Controlled Clinical Trial of Indocyanine Green Molecular Fluorescence Imaging in the Diagnosis and Treatment of Primary Liver Cancer,Indocyanine green for injection,"['ICG', 'Indocyanine green for injection']",2,INTERVENTIONAL,['NA'],,,Liver Cancer,['Liver Cancer'],"['indocyanine green', 'local resection']",RECRUITING,,2021-09-23,2025-12-31,"[{'measure': '3-year disease free survival rate', 'description': 'No tumor recurrence within 3 years after surgery divided by total number of patients', 'timeFrame': '36 months'}]","[{'measure': 'Positive margin rate', 'description': 'Compare positive margin rate in both groups', 'timeFrame': '14 days'}, {'measure': 'Negative margin rate', 'description': 'Compare negative margin rate in both groups', 'timeFrame': '14 days'}, {'measure': 'Length of the shortest cutting edge', 'description': 'The shortest distance between tumor and resection margin was compared between the two groups by pathological diagnosis', 'timeFrame': '14 days'}, {'measure': 'Operation time', 'description': 'Compare operation time in both groups', 'timeFrame': '1 day'}, {'measure': 'Intraoperative blood loss', 'description': 'Compare intraoperative blood loss in both groups', 'timeFrame': '1 day'}, {'measure': 'Intraoperative blood transfusion volume', 'description': 'Compare intraoperative blood transfusion volume in both groups', 'timeFrame': '1 day'}, {'measure': 'The number of small lesions of HCC', 'description': 'Small lesions detected by ICG fluorescence and confirmed by pathology in the intervention group', 'timeFrame': '14 days'}, {'measure': 'Residual tumor at the margin of liver cross-section', 'description': 'The number of residual tumors confirmed by ICG fluorescence detection at the liver margin of the intervention group', 'timeFrame': '14 days'}, {'measure': 'Intraoperative biliary fistula detection rate', 'description': 'The number of cases of successful intraoperative detection of biliary fistula by fluorescence in the intervention group divided by the total number of cases in the intervention group.', 'timeFrame': '1 day'}, {'measure': 'Extrahepatic metastases of primary hepatocellular carcinoma', 'description': 'The number of extrahepatic metastases of primary liver cancer detected by ICG and confirmed by pathology in the intervention group', 'timeFrame': '14 days'}, {'measure': 'Postoperative hospital stay', 'description': 'Compare Postoperative hospital stay in both groups. Eg: Postoperative hospital stay is the number of days from the day of surgery to the day of discharge.', 'timeFrame': '30 days'}, {'measure': 'Postoperative liver function index 1', 'description': 'Compare the levels of Alanine aminotransferase on postoperative days 1, 3, and 5 in both groups', 'timeFrame': '5 days'}, {'measure': 'Postoperative liver function index 2', 'description': 'Compare the levels of Aspartate aminotransferase on postoperative days 1, 3, and 5 in both groups', 'timeFrame': '5 days'}, {'measure': 'Postoperative liver function index 3', 'description': 'Compare the levels of serum albumin on postoperative days 1, 3, and 5 in both groups', 'timeFrame': '5 days'}, {'measure': 'Postoperative liver function index 4', 'description': 'Compare the levels of total bilirubin on postoperative days 1, 3, and 5 in both groups', 'timeFrame': '5 days'}, {'measure': 'Postoperative hemoglobin', 'description': 'Compare hemoglobin on postoperative days 1, 3, and 5 in both groups', 'timeFrame': '5 days'}, {'measure': 'Postoperative platelets', 'description': 'Compare platelets on postoperative days 1, 3, and 5 in both groups', 'timeFrame': '5 days'}, {'measure': 'Prothrombin time', 'description': 'Compare prothrombin time on postoperative days 1, 3, and 5 in both groups', 'timeFrame': '5 days'}, {'measure': 'Mortality rates', 'description': 'Perioperative death was defined as death occurring within 90 days after surgery', 'timeFrame': '3 months'}]",20,18 Years,66 Years,ALL,False,Zhujiang Hospital,OTHER,0,348.0,ESTIMATED,2025-09-01T16:18:17.189605,v2_robust,True,True,False,False,False,
NCT00258440,Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer,A Pilot Trial of Extended Interval Dosing of Epoetin Alfa (Procrit®) for the Treatment of Anemia in Oncology Patients,Weekly procrit dosing,"['Interval Dosing', 'Weekly procrit dosing']",2,INTERVENTIONAL,['NA'],,,Anemia,"['Anemia', 'Fatigue', 'Unspecified Adult Solid Tumor, Protocol Specific']","['fatigue', 'anemia', 'unspecified adult solid tumor, protocol specific']",TERMINATED,Sponsor discontinued funding of the study,2003-05,2008-09,"[{'measure': 'Number of Subjects That Maintained Target Hemoglobin Level (11-12 g/dL) Maintenance Weekly for 12 Weeks', 'timeFrame': '12 weeks'}]","[{'measure': 'Pharmacokinetics (PK) and Pharmacodynamics Assays That Measure Concentration of Erythropoietin in Serum.', 'timeFrame': 'every other week'}, {'measure': 'Quality of Life at Baseline and Weeks 4, 8, 16, 24, and 28', 'timeFrame': 'weeks 4,8,16,24 and 28'}, {'measure': 'Number of Adverse Events (AEs) Experienced as Measure of Safety and Tolerability.', 'timeFrame': 'On study, averaging 3 to 6 months.'}]",4,18 Years,,ALL,False,OHSU Knight Cancer Institute,OTHER,1,7.0,ACTUAL,2025-09-01T16:18:17.189645,v2_robust,True,True,False,True,True,Sponsor discontinued funding of the study
NCT01453140,In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus,Phase I- II Study of in Vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for the Treatment of Steroid-refractory Acute Graft-versus-host Disease,Cyclophosphamide and Sirolimus,"['Other names:', 'Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus', 'Interleukin-2', 'Other names: Cytoxan', 'Low dose IL-2 with Cytoxan + Sirolimus', 'Azactidine', 'Cyclophosphamide and Sirolimus', 'Low dose IL-2, Vidaza, Cytoxan & Sirolimus', 'Cytoxan']",9,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Graft Versus Host Disease,['Graft Versus Host Disease'],[],TERMINATED,Dose Limiting Toxicities,2011-08,2012-07,"[{'measure': 'Response Rate of Patients With Steroid-refractory Graft-versus-host Disease (GVHD) Using Cyclophospahmide and Sirolimus Combined With 3 Variations of Low-dose IL 2 and Low-dose Vidaza.', 'description': 'The primary objective of this study is to determine the response rate of patients treated steroid-refractory graft-versus-host disease (GVHD) using cyclophospahmide and sirolimus combined with 3 variations of low-dose IL 2 and low-dose Vidaza with an outcome goal of promoting CD4+CD25+FoxP3+ Tregs.', 'timeFrame': '28 days to 100 days post transplant'}]",[],1,18 Years,70 Years,ALL,False,Hackensack Meridian Health,OTHER,0,3.0,ACTUAL,2025-09-01T16:18:17.189711,v2_robust,True,True,False,True,False,Dose Limiting Toxicities
NCT01043640,Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders,Allogeneic Hematopoietic Stem Cell Transplantation for Standard Risk Inherited Metabolic Disorders,Campath-1H,"['Cytoxan(R)', 'Mycophenolate Mofetil', 'Campath-1H', 'Alemtuzumab', 'MMF', 'Busulfan', 'Cyclosporine A', 'Cyclophosphamide', 'CsA', 'Busulfex(R)']",10,INTERVENTIONAL,['PHASE2'],PHASE2,,Mucopolysaccharidosis,"['Mucopolysaccharidosis', 'Hurler Syndrome', 'Hunter Syndrome', 'Maroteaux-Lamy Syndrome', 'Sly Syndrome', 'Alpha Mannosidosis', 'Fucosidosis', 'Aspartylglucosaminuria', 'Adrenoleukodystrophy (ALD)', 'Krabbe Disease', 'Metachromatic Leukodystrophy (MLD)', 'Sphingolipidoses', 'Peroxisomal Disorders']",['inherited metabolic disorders'],COMPLETED,,2009-12,2017-06,"[{'measure': 'Number of Patients With Donor Derived Engraftment', 'description': ""Donor derived engraftment is defined as 80 percent or greater donor cells in the recipient's bone marrow and blood cells."", 'timeFrame': 'Day 100 Post Transplant'}]","[{'measure': 'Number of Patients With Grade 0 Graft-Versus-Host Disease (GVHD)', 'description': 'GVHD grading is performed using modified Glucksberg criteria and is as follows:\n\ngrade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4', 'timeFrame': 'Day 100 Post Transplant'}, {'measure': 'Number of Patients With Grade 1 Graft-Versus-Host Disease (GVHD)', 'description': 'GVHD grading is performed using modified Glucksberg criteria and is as follows:\n\ngrade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4', 'timeFrame': 'Day 100 Post Transplant'}, {'measure': 'Number of Patients With Grade 2 Graft-Versus-Host Disease (GVHD)', 'description': 'GVHD grading is performed using modified Glucksberg criteria and is as follows:\n\ngrade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4', 'timeFrame': 'Day 100 Post Transplant'}, {'measure': 'Number of Patients With Grade 3 Graft-Versus-Host Disease (GVHD)', 'description': 'GVHD grading is performed using modified Glucksberg criteria and is as follows:\n\ngrade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4', 'timeFrame': 'Day 100 Post Transplant'}, {'measure': 'Number of Patients With Grade 4 Graft-Versus-Host Disease (GVHD)', 'description': 'GVHD grading is performed using modified Glucksberg criteria and is as follows:\n\ngrade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4', 'timeFrame': 'Day 100 Post Transplant'}, {'measure': 'Number of Patients Who Died Peri-Transplant', 'description': 'Peri-transplant is defined as within 100 days of transplant.', 'timeFrame': 'By Day 100 Post Transplant'}, {'measure': 'Donor Cell Chimerism Following Transplant', 'description': 'Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin.', 'timeFrame': 'Day 28'}, {'measure': 'Donor Cell Chimerism Following Transplant', 'description': 'Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin.', 'timeFrame': 'Day 42'}, {'measure': 'Donor Cell Chimerism Following Transplant', 'description': 'Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin.', 'timeFrame': 'Day 100'}, {'measure': 'Donor Cell Chimerism Following Transplant', 'description': 'Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin.', 'timeFrame': '6 months'}, {'measure': 'Donor Cell Chimerism Following Transplant', 'description': 'Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin.', 'timeFrame': 'One year'}]",12,,21 Years,ALL,False,"Masonic Cancer Center, University of Minnesota",OTHER,0,46.0,ACTUAL,2025-09-01T16:18:17.189736,v2_robust,True,True,True,False,False,
NCT04158440,Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Clinical Study on Toripalimab Combined With Platinum-Based Doublet Drug Chemotherapy for Resectable, Stage II-III, Non-Small Cell Lung Cancer",4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab,"['Carboplatin;', '4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )', 'Paclitaxel;', '4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab', 'Pemetrexed;', 'Docetaxel', 'Cisplatin;']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Stage II-III Non-small Cell Lung Cancer,['Stage II-III Non-small Cell Lung Cancer'],[],ACTIVE_NOT_RECRUITING,,2020-04-07,2025-12-31,"[{'measure': 'MPR rate in stage III population evaluated by BIPR', 'description': 'Major Pathological Response (MPR) Rate.MPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes in neoadjuvant therapy.', 'timeFrame': 'up to 7 weeks after neoadjuvant'}, {'measure': 'EFS in stage III population evaluated by investigators', 'description': 'Event Free Survival (EFS):EFS is defined as the time from randomization until radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause.', 'timeFrame': 'up to 3 years'}, {'measure': 'MPR rate in stage II-III population evaluated by BIPR', 'description': 'Major Pathological Response (MPR) Rate.MPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes in neoadjuvant therapy.', 'timeFrame': 'up to 7 weeks after neoadjuvant'}, {'measure': 'EFS in stage II-III population evaluated by investigators', 'description': 'Event Free Survival (EFS):EFS is defined as the time from randomization until radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause.', 'timeFrame': 'EFS: up to 3 years'}]","[{'measure': 'pCR rate in stage III population evaluated by BIPR and investigators', 'description': 'Pathological Complete Response (pCR) Rate :pCR rate is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes following completion of neoadjuvant therapy.', 'timeFrame': 'pCR:up to 7 weeks after neoadjuvant;'}, {'measure': 'EFS in stage III population evaluated by IRC', 'description': 'EFS is defined as the time from randomization until radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause. EFS determined either by biopsy assessed by blinded central pathologist or by imaging using RECIST 1.1 assessed by investigator.', 'timeFrame': 'EFS by IRC:up to 3 years'}, {'measure': 'Disease-free survival (DFS) in stage III evaluated by IRC and investigators', 'description': 'DFS is defined as the time from postoperation until radiographic disease progression, local or distant recurrence, or death due to any cause.', 'timeFrame': 'DFS:up to 3 years'}, {'measure': 'pCR rate in stage II-III population evaluated by BIPR and investigators', 'description': 'Pathological Complete Response (pCR) Rate :pCR rate is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes following completion of neoadjuvant therapy.', 'timeFrame': 'pCR:up to 7 weeks after neoadjuvant'}, {'measure': 'EFS in stage II-III population evaluated by IRC', 'description': 'EFS is defined as the time from randomization until radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause. EFS determined either by biopsy assessed by blinded central pathologist or by imaging using RECIST 1.1 assessed by investigator.', 'timeFrame': 'EFS by IRC:up to 3 years'}, {'measure': 'Disease-free survival (DFS) in stage II-III population evaluated by IRC and investigators', 'description': 'DFS is defined as the time from postoperation until radiographic disease progression, , local or distant recurrence, or death due to any cause.', 'timeFrame': 'DFS:up to 3 years'}, {'measure': 'Overall survival (OS) rate in stage III and II-III population', 'description': 'OS is defined as the time from randomization until death from any cause.', 'timeFrame': 'OS up to 5 years'}, {'measure': '2-3 years overall survival (OS) rate in stage III and II-III population', 'description': 'OS rate is defined as survival probability n stage III and II-III population at a given time point（2y，3y）', 'timeFrame': 'OS up to 5 years'}]",12,18 Years,70 Years,ALL,False,"Shanghai Junshi Bioscience Co., Ltd.",OTHER,0,501.0,ACTUAL,2025-09-01T16:18:17.189779,v2_robust,True,True,False,False,False,
NCT01980589,"A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects","A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects",Carfilzomib,"['PR-171', 'Dexamethasone', 'PR171', 'Cyclophosphamide', 'Carfilzomib', 'Kyprolis® (carfilzomib) for Injection']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Multiple Myeloma,['Multiple Myeloma'],['multiple myeloma'],COMPLETED,,2013-08,2016-03,"[{'measure': 'Number of Participants With Dose-limiting Toxicities (DLTs)', 'description': 'The MTD is defined as the highest carfilzomib dose at which fewer than 33% of participants experience a treatment-related dose-limiting toxicity (DLT) during the first 28-day cycle. The number of participants who experienced a DLT is reported.\n\nDose-limiting toxicities are defined as any of the following carfilzomib-related adverse events:\n\nNonhematologic:\n\n* ≥ Grade 3 non-hematological toxicity\n* ≥ Grade 3 acute kidney injury (creatinine \\> 3 × baseline or \\> 4.0 mg/dL) lasting \\> 72 hours\n\nHematologic:\n\n* Grade 4 neutropenia (absolute neutrophil count \\[ANC\\] \\< 0.5 × 10\\^9/L) lasting for \\> 7 days\n* Febrile neutropenia (ANC \\< 1.0 × 10\\^9/L with a fever ≥ 38.3ºC) of any duration\n* Grade 4 thrombocytopenia (\\< 25 × 10\\^9/L) that persists for \\> 14 days, despite holding treatment\n* Grade 3 or 4 thrombocytopenia associated with \\> Grade 1 bleeding', 'timeFrame': 'First cycle treatment over 28-days'}]","[{'measure': 'Overall Response Rate (ORR)', 'description': 'Participants were evaluated for disease response and progression by the investigator according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). Disease response and progression assessments included serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), serum immunofixation, serum free light chain (SFLC), bone marrow sample (including fluorescent in situ hybridization \\[FISH\\]), plasmacytoma evaluation, and skeletal survey. Overall response rate is defined as the percentage of participants with a best response of stringent complete response, complete response, very good partial response (VGPR), or partial response.', 'timeFrame': 'Disease response was assessed at the end of each cycle and 30 days after the last treatment; maximum treatment duration was 32 weeks.'}, {'measure': 'Time To Response (TTR)', 'description': 'Time to response is defined as months from treatment start to first documentation of response of partial response or better. Summary of time to response includes confirmed responders of PR or better only.', 'timeFrame': 'Disease response was assessed at the end of each cycle and 30 days after the last treatment; maximum treatment duration was 32 weeks.'}, {'measure': 'Number of Participants With Adverse Events', 'description': 'Adverse events (AEs) were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 and using the following scale:\n\nGrade 1 = Mild, Grade 3 = Moderate; Grade 3 = Severe, Grade 4 = Life-threatening; Grade 5 = Fatal.', 'timeFrame': 'From first dose of study drug until 30 days after last dose; median duration of treatment was 31 weeks.'}]",4,18 Years,,ALL,False,Amgen,INDUSTRY,0,22.0,ACTUAL,2025-09-01T16:18:17.189945,v2_robust,True,True,True,False,True,
NCT00953589,480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV),"480 STUDY: Phase 2b Open-label, Randomized Study in Treatment Naïve Subjects With HCV G1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron™ Plus Ribavirin Given Bi-Weekly to PEG-Intron™ Plus Ribavirin Given Weekly",ribavirin,"['ribavirin', 'Ribasphere']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Hepatitis C, Chronic","['Hepatitis C, Chronic']",['treatment naive'],COMPLETED,,2009-07,2011-01,"[{'measure': 'Primary efficacy endpoint: EVR: the proportion of subjects in each arm that have at least a 2 log drop in HCV RNA from Baseline', 'timeFrame': 'Week 12'}]","[{'measure': 'the proportion of subjects in each arm demonstrating HCV RNA undetectable (< 10 IU/mL) after 12 weeks of randomized treatment', 'timeFrame': 'Week 12'}]",2,18 Years,69 Years,ALL,False,"Biolex Therapeutics, Inc.",INDUSTRY,0,74.0,ACTUAL,2025-09-01T16:18:17.189976,v2_robust,True,True,True,False,False,
NCT01118689,Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia,"A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia",MLN0128,['MLN0128'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Relapsed Multiple Myeloma,"['Relapsed Multiple Myeloma', 'Refractory Multiple Myeloma', 'Waldenstrom Macroglobulinemia']",[],COMPLETED,,2010-11,2013-07,"[{'measure': 'determine the dose limiting toxicities', 'timeFrame': '28-days'}]",[],1,18 Years,,ALL,False,"Millennium Pharmaceuticals, Inc.",INDUSTRY,0,39.0,ACTUAL,2025-09-01T16:18:17.189997,v2_robust,True,True,True,False,False,
NCT01992289,Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002,Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002,EDI200,"['EDI200', 'APO200']",2,OBSERVATIONAL,[],,,X-linked Hypohidrotic Ectodermal Dysplasia,['X-linked Hypohidrotic Ectodermal Dysplasia'],"['XLHED', 'HED', 'Hypohidrotic ectodermal dysplasia', 'Christ-Siemens-Touraine Syndrome']",UNKNOWN,,2014-03,2025-03,"[{'measure': 'Growth and development', 'description': 'Growth and development as compared with age-matched standards', 'timeFrame': 'Annually up to age 10 years'}, {'measure': 'Dentition', 'description': 'Dentition assessed by dental examinations and radiographs at ages 2 yrs, 5 yrs, and 10 yrs', 'timeFrame': 'Change from baseline dentition at 2, 5 and 10 years'}]","[{'measure': 'Mortality', 'description': 'At each annual visit the subject and his family will be questioned regarding mortality, hospitalization, infections, unexplained fevers and heat intolerance occurring since the last annual visit.', 'timeFrame': 'Annually up to age 10 years'}, {'measure': 'Hospitalizations', 'description': 'At each annual visit the subject and his family will be questioned regarding mortality, hospitalization, infections, unexplained fevers and heat intolerance occurring since the last annual visit.', 'timeFrame': 'Annually up to age 10 years'}, {'measure': 'Infections', 'description': 'At each annual visit the subject and his family will be questioned regarding mortality, hospitalization, infections, unexplained fevers and heat intolerance occurring since the last annual visit.', 'timeFrame': 'Annually up to age 10 years'}, {'measure': 'Unexplained fevers', 'description': 'At each annual visit the subject and his family will be questioned regarding mortality, hospitalization, infections, unexplained fevers and heat intolerance occurring since the last annual visit.', 'timeFrame': 'Annually up to age 10 years'}, {'measure': 'Heat intolerance', 'description': 'At each annual visit the subject and his family will be questioned regarding mortality, hospitalization, infections, unexplained fevers and heat intolerance occurring since the last annual visit.', 'timeFrame': 'Annually up to age 10 years'}, {'measure': 'Sweat gland density', 'description': ""Sweat duct density (number/cm2) from at least two different sites on the soles of the feet or the palms of the hands will be determined through analysis of images collected annually if positive findings were observed at the end of protocol ECP-002 and will continue until negative results are observed on two consecutive evaluations. This will be accomplished by direct visualization with an FDA 510(k) device, the Lucid VivaScope 1500 (www.lucid-tech.com). This technology has been tested in controls and XLHED-affected males from the newborn period to adulthood without complication. An adhesive ring will be placed on the subject's palm to which the VivaScope will be attached via a magnetic lock. A series of photographs will be taken of an area approximately 6mm X 6mm. An individual trained in the use of this device will be involved in the acquisition of all images."", 'timeFrame': 'Annually up to age 10 years'}, {'measure': 'Sweat function', 'description': 'Maximal sweating on the volar lower arm surface of each subject will be induced by pilocarpine iontophoresis followed by sweat collection using the Macroduct Sweat Collection System developed primarily for sweat collection and analysis in the diagnosis of Cystic Fibrosis from the newborn period on (www.wescor.com).\n\nFollowing completion of the pilocarpine iontophoresis the Webster Sweat Inducer electrodes and discs are removed from the subject, the application site is wiped once with alcohol, and a Macroduct Sweat Collector is placed over the site of one electrode. The Macroduct Sweat Collector is held in place for approximately 30 minutes using a Velcro Macroduct Strap. Sweat volume is determined from microliter markings on a collection coil diagram. Sweat rate will be determined annually if positive findings were observed at the end of protocol ECP-002 and will continue until negative results are observed on two consecutive evaluations.', 'timeFrame': 'Annually up to age 10 years'}, {'measure': 'Skin health', 'description': 'Skin examination and history of skin disorders will be evaluated at each annual visit by detailed physical exam and medical history.', 'timeFrame': 'Annually up to age 10 years'}, {'measure': 'Hair growth', 'description': 'At the year 5 and 10 visits the total and anagen hair counts and follicular unit counts in the scalp will be determined from color macrophotographs of clipped hair in a 1 cm2 circular target area centered by a cosmetic ink dot. Hair in the target area will first be clipped to approximately a 1 mm length for determination of total hair count and hairs per follicular unit, and then clipped further to about 0.35 mm to monitor hair growth over the 2-3 day period between phototrichograms. The sponsor will provide all of the equipment necessary for photography and to cut the hair to the exact lengths specified. A second photogram will be taken approximately 2-3 days later for the determination of anagen and telogen hair counts, based on the number of hairs that have lengthened over the intervening time period, as well as hair properties including growth rate and hair width.', 'timeFrame': 'Change from baseline hair growth at 5 and 10 years'}, {'measure': 'Respiratory health', 'description': 'Annual medical history and physical exam related to asthma, sinusitis, nosebleeds and nasal congestion will be evaluated annually. Pulmonary function testing (FVC and FEV1) will be performed on all subjects starting at age 5 years at a laboratory experienced with pediatric subjects. Additionally, levels of exhaled nitric oxide (eNO) as an indicator of pulmonary inflammation will be quantified non-invasively with an age-group appropriate device in all subjects age 5 years and older.', 'timeFrame': 'Annually up to age 10 years'}, {'measure': 'Ocular health', 'description': 'The eye examination will be performed by an ophthalmologist experienced in assessments of tear film and ocular surface in infants as well as children and adults. The examination will document the presence/absence of signs of infection, inflammation and corneal irritation, as well as a tear film break-up time. For children 5 years or older the assessment will also include the Shirmer test for rate of tear production and the OCULAR SURFACE DISEASE INDEX© questionnaire.', 'timeFrame': 'Annually up to age 10 years'}, {'measure': 'Number of participants with adverse events', 'description': 'The annual safety evaluations will consist of safety laboratory sampling, assessment of adverse events and concomitant medications, and a physical examination with vital signs.', 'timeFrame': 'Annually up to age 10 years'}]",14,6 Months,1 Year,MALE,False,Edimer Pharmaceuticals,INDUSTRY,0,10.0,ACTUAL,2025-09-01T16:18:17.190004,v2_robust,False,True,False,False,True,
NCT05129189,Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression,Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide,ASC22 group,['ASC22 group'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV Infections,['HIV Infections'],['Functional cure of HIV， ASC22，PD-1'],UNKNOWN,,2022-06-29,2023-07-31,"[{'measure': 'HIV-1 DNA levels', 'description': 'Change in HIV-1 DNA levels from baseline at each cycle of treatment', 'timeFrame': '52 weeks'}]","[{'measure': 'CD4+ T-cell count, CD4+ T-cell percentage, CD8+ T-cell count, CD4+/CD8+ ratio', 'description': 'Changes in CD4+ T-cell count, CD4+ T-cell percentage, CD8+ T-cell count, CD4+/CD8+ ratio, and change from baseline at each cycle of treatment', 'timeFrame': '52 weeks'}, {'measure': 'HIV gag-specific CD8+ T ratio', 'description': 'Change from baseline in HIV gag-specific CD8+ T ratio at each cycle of treatment', 'timeFrame': '52 weeks'}, {'measure': 'HIV-1 RNA', 'description': 'Change in HIV-1 RNA from baseline at each cycle of treatment', 'timeFrame': '52 weeks'}]",4,18 Years,,ALL,False,Shanghai Public Health Clinical Center,OTHER_GOV,0,15.0,ESTIMATED,2025-09-01T16:18:17.190101,v2_robust,True,True,False,False,False,
NCT00143689,NRTI-Sparing Pilot Study,"A Pilot Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor Sparing Regimen in Antiretroviral-Naïve, HIV-infected Patients",lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine,['lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,HIV,"['HIV', 'Mitochondrial Toxicity']",[],COMPLETED,,2002-04,2008-02,"[{'measure': 'Changes in mitochondrial DNA/Nuclear DNA (mtDNA/nDNA) ratio at 48 weeks, as a marker of mitochondrial toxicity.', 'timeFrame': '48 weeks'}]","[{'measure': 'Changes in mitochondrial DNA/Nuclear DNA (mtDNA/nDNA) ratio at 96 weeks', 'timeFrame': '96 weeks'}, {'measure': 'Proportions of patients with viral load below 50 and below 400 copies/mL'}, {'measure': 'Viral load changes from baseline'}, {'measure': 'Rates and extent of immune reconstitution (CD4 count increase)'}, {'measure': 'Rates and severity of dyslipidemia and insuline resistance/diabetes'}]",6,18 Years,,ALL,False,University of British Columbia,OTHER,3,13.0,ACTUAL,2025-09-01T16:18:17.190150,v2_robust,True,True,True,False,False,
NCT00437489,A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.,"A 16 Week Open-Label Outpatient, Randomized, Parallel Study Assessing The Impact Of Two Different Initial Dose Prescriptions For Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents.",Inhaled Human Insulin (Exubera),['Inhaled Human Insulin (Exubera)'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],TERMINATED,"This protocol was terminated not for safety reasons, but because Pfizer decided to return the worldwide rights for Exubera to Nektar, on 18 October 2007.",2007-06,2007-12,"[{'measure': 'Change in HbA1c From Baseline', 'description': 'Mean change of hemoglobin A1c (HbA1c %) from baseline to week 16', 'timeFrame': 'From baseline to week 16'}]","[{'measure': 'Fasting Plasma Glucose, and Overall Absolute, Pre-meal, and Post-meal Blood Glucose Change From Baseline to Week 16 (LOCF)', 'description': 'Mean change of fasting plasma glucose, and overall absolute (based on the mean of 7-point home blood glucose monitoring (HGM) values), pre- and post-meal blood glucose (based on the mean of pre- or post-meal HGM values). Change from pre- to post-meal blood glucose based on the mean of difference of pre-meal HGM values from post-meal HGM values.', 'timeFrame': 'From baseline to week 16'}, {'measure': 'Number of Subjects Who Experienced Hypoglycemia and Nocturnal Hypoglycemia', 'description': 'Cumulative Number Subjects Who Experienced Hypoglycemia \\& Nocturnal Hypoglycemia. Hypoglycemia:1)Clinical picture includes prompt resolution with food intake, subcutaneous glucagon, or intravenous glucose, 2)blood glucose check showing glucose \\<3.27 mmol/L (59 mg/dl), 3)glucose measurement of 2.7 mmol/L (49 mg/dl) or less, with or without symptoms.', 'timeFrame': 'week 16'}, {'measure': 'Hypoglycemia Event Rate Per Month', 'description': 'Monthly event rate was calculated as the daily event rate multiplied by 30, and the daily event rate was calculated as the total number of events divided by the days in study up to the specified timepoint (ie, Week 4 or Week 16).', 'timeFrame': 'up to week 4 or 16'}]",4,18 Years,,ALL,False,Pfizer,INDUSTRY,0,49.0,ACTUAL,2025-09-01T16:18:17.190226,v2_robust,True,True,False,True,False,"This protocol was terminated not for safety reasons, but because Pfizer decided to return the worldwide rights for Exubera to Nektar, on 18 October 2007."
NCT04840589,Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors,"Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors",BET Bromodomain Inhibitor ZEN-3694,"['BETi ZEN-3694', 'ZEN003694', 'ZEN-3694', 'BET Bromodomain Inhibitor ZEN-3694', 'ZEN 3694']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Metastatic Malignant Solid Neoplasm,"['Metastatic Malignant Solid Neoplasm', 'Recurrent Malignant Solid Neoplasm', 'Recurrent Platinum-Resistant Ovarian Carcinoma', 'Refractory Ovarian Carcinoma']",[],RECRUITING,,2022-02-02,2026-01-01,"[{'measure': 'Safety and tolerability', 'description': 'Will calculate maximum tolerated dose and dose limiting toxicity with dose escalation using standard 3+3 design.', 'timeFrame': 'Up to 1 cycle of treatment for doublet group (4 weeks) and up to 2 cycles for triplet group (6 weeks)'}, {'measure': 'Phase 2 recommended dose for the combined regimens', 'timeFrame': 'Up to 1 cycle of treatment for doublet group (4 weeks) and up to 2 cycles for triplet group (6 weeks)'}]","[{'measure': 'Objective response rate (ORR)', 'description': 'Defined as partial or complete response to the combined regimens in the entire cohort and in the expansion cohort. Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1) only. All treatment decisions should be made by RECIST v1.1 only.', 'timeFrame': 'Up to 1 year post-treatment'}, {'measure': 'Progression-free survival', 'timeFrame': 'Up to 1 year post-treatment'}, {'measure': 'Overall survival', 'timeFrame': 'Up to 1 year post-treatment'}, {'measure': 'Incidence of adverse events', 'description': 'Will include grade 3 and 4 immune and non-immune events assessed by Common Terminology Criteria for Adverse Events version 5.0.', 'timeFrame': 'Up to 1 year post-treatment'}, {'measure': 'Clinical benefit', 'description': 'Defined as ORR and stable disease.', 'timeFrame': 'Up to 1 year post-treatment'}, {'measure': 'Whole exome sequencing', 'description': 'Will assess: a) CCNE1, MYC, BRD4 status b) MSI status and tumor mutational burden c) B2M mutation/deficiency and alteration in antigen processing/presentation machinery (MHC1) d) Alteration in other molecular pathways such as HRD/BRCA, PI3K.', 'timeFrame': 'Up to 1 year post-treatment'}, {'measure': 'Next generation sequencing ribonucleic acid sequencing', 'description': 'Will assess: a) Functional CCNE1, MYC, BRD4 gene expression status at baseline and at 4 weeks b) Alteration in tumor immune microenvironment and immune markers/signature like interferon-gamma signature.', 'timeFrame': 'Up to 1 year post-treatment'}, {'measure': 'PD-L1 expression in tumor cells and tumor-associated immune cells', 'timeFrame': 'Up to 1 year post-treatment'}, {'measure': 'Multiplex analysis of tumor infiltrating immune cells', 'description': 'Will assess immune cell subpopulations and their activation status.', 'timeFrame': 'Up to 1 year post-treatment'}, {'measure': 'Pharmacokinetic (PK) parameters', 'description': 'Individual PK parameters will be estimated, specifically maximum concentration, area under the concentration-time curve, half-life, apparent clearance, and apparent volume of distribution using non-compartmental methods. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) calculated for each dose level. PK parameters will be reported descriptively for exploratory comparison with historical data.', 'timeFrame': 'Pre dose, and then 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 h after dose on cycle 1, day 1; and pre dose and 1-3 hours post-dose on cycle 2, day 1'}, {'measure': 'Phenotypic characteristics of peripheral blood mononuclear cells over treatment', 'description': 'Will compare these phenotypic characteristics to baseline to assess different immune cells subset and their activation status peripherally.', 'timeFrame': 'At 4 weeks (cycle 2 day 1 of treatment)'}, {'measure': 'Circulating tumor deoxyribonucleic acid', 'description': 'Assessed in plasma using TSO500 panel. Will assess: a) CCNE1, MYC, and BRD4 (if BRD4 became available) status at baseline and during treatment to assess if blood-based status is concordant with tissue based status and if the status changes during therapy b) Blood based molecular residual disease and tumor mutational burden.', 'timeFrame': 'Up to 1 year post-treatment'}, {'measure': 'Pro-inflammatory and anti-inflammatory cytokines analyses', 'description': 'Assessed in plasma.', 'timeFrame': 'Up to 1 year post-treatment'}]",15,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,66.0,ESTIMATED,2025-09-01T16:18:17.190260,v2_robust,True,True,False,False,True,
NCT06087289,"A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","KANDOVA - A Two-Part Phase Ib/IIa Study to Evaluate the Safety and Tolerability of KAND567, in Combination With Carboplatin Therapy, and to Determine the Recommended Phase II Dose (RPIID) of KAND567: An Open-Label, Multicenter Dose Escalation Study With an Expansion Cohort in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",KAND567,"['Carboplatin', 'Fractalkine', 'KAND567']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Epithelial Ovarian Cancer,"['Epithelial Ovarian Cancer', 'Fallopian Tube Cancer', 'Peritoneal Cancer']","['Fractalkine', 'Ovarian cancer']",COMPLETED,,2023-04-26,2025-04-03,"[{'measure': 'Evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as measured by the occurence of adverse events (AEs)', 'description': 'Measured by occurence of AEs and serious adverse events (SAEs)', 'timeFrame': 'From the first IMP administration to the subject (Day 1) until the end of study visit (Week 20)'}, {'measure': 'Evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as measured by the occurrence of dose limiting toxicities (DLTs)', 'description': 'Measured by the occurrence of DLTs', 'timeFrame': 'From the first IMP administration to the subject (Day 1) until the end of study visit (Week 20)'}, {'measure': 'Evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as measured by vital signs', 'description': 'Measured by the occurrence of clinically abnormal vital signs', 'timeFrame': 'From the first IMP administration to the subject (Day 1) until the end of study visit (Week 20)'}, {'measure': 'Evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as measured by ECG', 'description': 'Measured by the occurrence of clinically abnormal electrocardiography (ECG)', 'timeFrame': 'From the first IMP administration to the subject (Day 1) until the end of study visit (Week 20)'}, {'measure': 'Evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as measured by lab safety tests', 'description': 'Measured by the occurrence of clinically abnormal lab test results (routine clinical chemistry, haematology, and urinalysis)', 'timeFrame': 'From the first IMP administration to the subject (Day 1) until the end of study visit (Week 20)'}, {'measure': 'Determine the Recommended Phase II Dose (RPIID) of KAND567 in combination with carboplatin therapy in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer', 'description': 'In Part 1/Phase Ib, RPIID of KAND567 in combination with carboplatin therapy will be determined based on safety and tolerability (DLTs).', 'timeFrame': 'From the first KAND567 IMP administration to the subject (Day 2) until the end of study visit (Week 20).'}]","[{'measure': 'Overall Response Rate (ORR)', 'description': 'Evaluate ORR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Gynecologic Cancer Intergroup (GCIG) definitions, i.e., best overall response in subjects with measurable disease, or without measurable disease who are evaluable by CA 125.', 'timeFrame': 'Week 12 and 18'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'Evaluate PFS according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Gynecologic Cancer Intergroup (GCIG) definitions, i.e., the time from start of treatment to disease progression or death.', 'timeFrame': 'From the first IMP administration to the subject (Day 1) to Week 12 and 18'}, {'measure': 'Overall survival (OS)', 'description': 'Evaluate OS according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Gynecologic Cancer Intergroup (GCIG) definitions, i.e., the time from the start of treatment to death due to any cause.', 'timeFrame': 'From the first IMP administration to the subject (Day 1) until the end of study visit (Week 20)'}, {'measure': 'Disease control rate (DCR)', 'description': 'Evaluate DCR, i.e., Complete response (CR) + Partial response (PR) + Stable disease (SD), according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Gynecologic Cancer Intergroup (GCIG) definitions, where: CR=Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameter; and SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.', 'timeFrame': 'Week 12 and 18'}, {'measure': 'Duration of response', 'description': 'Evaluate duration of response according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Gynecologic Cancer Intergroup (GCIG) definitions, i.e., time from documentation of tumor response to disease progression.', 'timeFrame': 'From the first IMP administration to the subject (Day 1) until the end of study visit (Week 20)'}, {'measure': 'Change in pain score', 'description': 'Change in pain score (patient reported outcome), as measured by the Numeric Rating Scale (NRS). The NRS is a scale rating pain from ""no pain"" to ""worst pain possible"" from 0 to 10, where a higher value indicates greater pain intensity.', 'timeFrame': 'From baseline (Week 1) to Weeks 4, 7, 10, 13, 16 and 20.'}, {'measure': 'Determine the plasma exposure of KAND567', 'description': 'Blood samples will be collected for the determination of concentrations of KAND567 in plasma. The determination of the total concentration of KAND567 in plasma will be carried out using Liquid Chromatography - Tandem Mass Spectrometry (LC-MS/MS). KAND567 PK drug concentration data will be graphically visualized together with normalized PK drug concentration data from the previous KAN0001 study (i.e., no formal PK analysis will be performed).', 'timeFrame': 'For each 21-day treatment cycle, on Day 7 (0, 1, 2, and 4 hours after KAND567 morning dose) and Day 14 (0, 2 and 4 hours after KAND567 morning dose). Each subject receives up to 6 treatment cycles (or until unacceptable toxicity or disease progression)'}]",13,18 Years,,FEMALE,False,Kancera AB,INDUSTRY,1,18.0,ACTUAL,2025-09-01T16:18:17.190333,v2_robust,True,True,True,False,True,
NCT02839668,The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC),The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer,Lidocaine,"['TIVA-TCI', 'Diprivan', 'Atropine', 'lidocaine 1%, lignocaine', 'Neostigmine', 'paracetamol', 'Sevoflurane', 'Acetaminophen', 'Lidocaine', 'Tramadol', 'atropine sulfate', 'Tramal', 'Prostigmin, vagostigmin']",13,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],"['breast cancer', 'angiogenesis', 'VEGF']",COMPLETED,,2016-08,2019-09,"[{'measure': 'serum concentration of vascular endothelial growth factor A (VEGF-A)', 'timeFrame': '1 year'}]","[{'measure': 'pain score', 'description': 'assesed using visual-analogue scale', 'timeFrame': '1 year'}, {'measure': 'survival of patients', 'timeFrame': 'up to 5 years'}, {'measure': 'Vascular endothelial growth factor receptor 1 and 2 (VEGFR1 and VEGFR2) density', 'timeFrame': 'at the end of the study'}]",4,18 Years,80 Years,FEMALE,False,Iuliu Hatieganu University of Medicine and Pharmacy,OTHER,1,120.0,ACTUAL,2025-09-01T16:18:17.190394,v2_robust,True,True,True,False,False,
NCT04768868,The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors,"A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of the WEE1 Inhibitor IMP7068 Monotherapy in Patients With Advanced Solid Tumors",IMP7068,['IMP7068'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],"['Breast Cancer', 'Ovarian Cancer', 'Prostate Cancer', 'Pancreatic Cancers']",UNKNOWN,,2021-02-25,2023-08-30,"[{'measure': 'Part 1 Dose Escalation: Incidence of treatment emergent adverse events (TEAEs)', 'timeFrame': 'Day 1 through to 30 days after last dose (approximately 4 cycles (84 days plus 30 day follow-up )); Each cycle is 21 days'}, {'measure': 'Part 1 Dose Escalation: Severity of treatment emergent adverse events (TEAEs), according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0', 'timeFrame': 'Day 1 through to 30 days after last dose (approximately 4 cycles (84 days plus 30 day follow-up )); Each cycle is 21 days'}, {'measure': 'Part 1 Dose Escalation: Recommended Phase 2 Dose (RP2D) of IMP7068 monotherapy', 'description': 'Recommended Phase 2 Dose (RP2D) of IMP7068 monotherapy (selected by the safety monitoring committee (SMC) based on pharmacokinetics, target saturation at steady state, pharmacodynamics, safety, tolerability and preliminary anti-tumor effects of the dose range studied)', 'timeFrame': 'Day 1 through to start of dose expansion phase (approximately 1 year)'}, {'measure': 'Part 2 Dose Expansion: Overall Response Rate (ORR)', 'description': 'Overall Response Rate (ORR) for all cohorts (percentage of patients who had a best response rating of complete response (CR) and partial response (PR), according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, which was maintained ≥4 weeks)', 'timeFrame': 'Day 1 through 30 days after last dose, estimated to be 5 months'}]","[{'measure': 'Plasma Concentration of IMP7068', 'timeFrame': 'Day -7 to repeat dose Day 1; postdose at multiple time points from Day 1 to Day 21 in Cycle 1 (Cycle 1 = 21 days), Day 1 on Cycle 2 (Cycle 2 onwards = 21 day-cycles) and subsequent cycles (Up to 26 months)'}, {'measure': 'Part 1 Dose Escalation: Objective response rate (ORR): percentage of patients who had a best response', 'timeFrame': 'Within the first year: every 6 weeks, thereafter every 12 weeks to end of treatment (EOT) visit (approximately 84 days), documented disease progression, withdrawal of consent, loss to follow-up, death or termination of the study (whichever occurs first)'}, {'measure': 'Part 1 Dose Escalation: Progression-free survival (PFS): duration of time from date of first dose to date of disease progression (according to RECIST v1.1) or death due to any cause, whichever comes first)', 'timeFrame': 'Within the first year: every 6 weeks (±7 days); thereafter: every 12 weeks (±7 days); or when clinically indicated (Approximately 1 year )'}, {'measure': 'Part 1 Dose Escalation: Overall survival (OS): time from date of first dose to death due to any cause', 'timeFrame': 'Every 12 weeks±14 days after the last dose, until up to 2 years, withdrawal of consent, loss to follow-up, death, or termination of the study, whichever occurs first'}, {'measure': 'Part 1 Dose Escalation: Duration of response (DOR): duration of time a patient is evaluated as either complete response (CR) or partial response (PR) as best response until the first date that the criteria for progression are met, or death.', 'timeFrame': 'Day 1 through 30 days after last dose, estimated to be 5 months'}, {'measure': 'Part 1 Dose Escalation: Disease control rate (DCR): proportion of patients who had a best response rating of complete response (CR) or partial response (PR), or stable disease (SD), which was maintained ≥6 weeks from Day 1 of Cycle 1', 'timeFrame': 'Day 1 through 30 days after last dose, estimated to be 5 months'}, {'measure': 'Part 2 Dose Expansion: Progression-free survival (PFS) duration of time from date of first dose to date of disease progression (according to RECIST v1.1) or death due to any cause, whichever comes first)', 'timeFrame': 'Day 1 through 30 days after last dose, estimated to be 5 months'}, {'measure': 'Part 2 Dose Expansion: Duration of response (DOR) duration of time a patient is evaluated as either CR or PR as best response until the first date that the criteria for progression are met, or death', 'timeFrame': 'Day 1 through 30 days after last dose, estimated to be 5 months'}, {'measure': 'Part 2 Dose Expansion: Incidence of Treatment emergent adverse events (TEAE)', 'timeFrame': 'Day 1 through 30 days after last dose, estimated to be 5 months'}, {'measure': 'Part 2 Dose Expansion: Severity of Treatment emergent adverse events (TEAE) according to the NCI-CTCAE, version 5.0', 'timeFrame': 'Day 1 through 30 days after last dose, estimated to be 5 months'}]",14,18 Years,,ALL,False,"Impact Therapeutics, Inc.",INDUSTRY,1,350.0,ESTIMATED,2025-09-01T16:18:18.414167,v2_robust,True,True,False,False,True,
NCT02227368,Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR,"A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients With Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR",Ticagrelor,"['Aspirin', 'Brilinta', 'Comparator', 'Ticagrelor']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Peripheral Artery Disease (PAD),['Peripheral Artery Disease (PAD)'],"['Myocardial Infarction', 'Peripheral Arterial disease', 'Mycardial Ischemia', 'Heart Diseases', 'Cardiovascular Diseases', 'Vascular Diseases', 'Altherosclerosis', 'Arteriosclerosis', 'Arterial Occlusive Diseases', 'Peripheral Vascular Diseases', 'Ticagrelor', 'Ticlopidine', 'Platelet Aggregation inhibitors', 'Hematologic Agents', 'Therapeutic Uses', 'Pharmacologic Actions', 'Purinegic P2Y Receptor Antagonists', 'Purinegic P2 Receptor Antagonists', 'Purinergic Antagonists', 'Purinergic Agents', 'Neurotransmitter Agents', 'Molecular Mechanisms of Pharmacological Actions', 'Physiological Effects of Drugs', 'Fibrinolytic Agents', 'Crardiovascular Agents']",TERMINATED,,2014-10-20,2016-05-23,"[{'measure': 'Change From Baseline in Log Transformed Peak Walking Time (PWT) at Week 26 or Early Termination (ET)', 'timeFrame': '26 Weeks'}]","[{'measure': 'Change From Baseline in Log Transformed Claudication Onset Time (COT) at Week 26 or Early Termination (ET)', 'timeFrame': '26 Weeks'}]",2,50 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,1,40.0,ACTUAL,2025-09-01T16:18:18.414183,v2_robust,True,True,False,True,False,
NCT01663168,EARNEST Rifabutin Pharmacokinetics (PK) Substudy,Toxicity and Pharmacokinetics of Different Rifabutin Doses in HIV-infected Adults and Adolescents Taking Lopinavir / Ritonavir as Second-line Anti-retroviral Therapy (ART) (EARNEST Rifabutin PK Substudy),Rifabutin,"['Rifabutin', 'Mycobutin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV,"['HIV', 'Tuberculosis']","['HIV', 'Tuberculosis', 'Rifabutin', 'HIV Protease Inhibitors', 'EARNEST trial', 'Randomized Controlled Trial', 'Pilot Projects', 'Second-line ART', 'Drug Toxicity', 'Pharmacokinetics', 'Drug Interactions']",UNKNOWN,,2011-12,2014-01,"[{'measure': 'Grade 3/4 adverse events', 'description': 'The primary analysis will be the difference in proportions ever experiencing one or more grade 3 or 4 adverse events (AEs) after substudy randomisation, with non-inferiority demonstrated if the upper limit of the 90% confidence interval around the risk difference(Group 2 - Group 1) lies below +20%.', 'timeFrame': 'Minimum 24 weeks, maximum 100 weeks'}]","[{'measure': 'Rifabutin and its 25-o-desacetyl metabolite pharmacokinetic parameters (from a population PK model)', 'description': 'Population PK models being developed at the University of Capetown for daily and thrice weekly rifabutin dosing will be used to estimate rifabutin PK parameters (time-concentration curve (AUC), trough (Cmin), and apparent oral clearance (CL/F)), which will be compared between groups using geometric means (ttest for the log-transformed values).', 'timeFrame': '28 weeks'}, {'measure': 'Lopinavir/ritonavir pharmacokinetic parameters (from a population PK model)', 'description': 'Population PK models being developed at the University of Capetown for daily and thrice weekly rifabutin dosing will be used to estimate lopinavir and ritonavir PK parameters (time-concentration curve (AUC), trough (Cmin), and apparent oral clearance (CL/F)), which will be compared between groups using geometric means (ttest for the log-transformed values).', 'timeFrame': '28 weeks'}, {'measure': 'Raltegravir pharmacokinetic parameters (from a population PK model)', 'description': 'Population PK models as above. Parameters include time-concentration curve (AUC), trough (Cmin), and apparent oral clearance (CL/F)', 'timeFrame': '28 weeks'}, {'measure': 'Response to TB therapy', 'description': 'Culture positive at 24 weeks or subsequent relapse/recurrence', 'timeFrame': '24 weeks or at relapse/recurrence (up to maximum 100 weeks)'}, {'measure': 'Rifamycin resistance', 'timeFrame': '24 weeks or at relapse/recurrence (up to maximum 100 weeks)'}]",6,12 Years,,ALL,False,Justine Boles,OTHER_GOV,1,140.0,ESTIMATED,2025-09-01T16:18:18.414195,v2_robust,True,True,False,False,True,
NCT06769568,Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia,The Safety and Efficacy of Reduced-dose Conditioning Regimen Containing TBI in Hematopoietic Stem Cell Transplantation Treating Elderly Patients With Aplastic Anemia,reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia,['reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Aplastic Anaemia,"['Aplastic Anaemia', 'HSCT', 'TBI', 'Old Age']","['aplastic anemia', 'HSCT', 'old age', 'conditioning regimen']",NOT_YET_RECRUITING,,2025-01-31,2028-09-30,"[{'measure': 'overall survival', 'description': '2-year overall survival', 'timeFrame': '2 year after HSCT'}]",[],1,50 Years,,ALL,False,"Institute of Hematology & Blood Diseases Hospital, China",OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:18.414217,v2_robust,True,True,False,False,False,
NCT01018368,Study of VX-770 and Rifampin in Healthy Male Subjects,An Open-Label Phase 1 Study to Examine the Effect of Multiple Doses of Rifampin on the Single-Dose Pharmacokinetics of VX 770 in Healthy Subjects,VX-770,"['VX-770', 'Rifampin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Cystic Fibrosis,['Cystic Fibrosis'],[],COMPLETED,,2009-11,2010-03,"[{'measure': 'VX 770 pharmacokinetic (PK) parameters', 'timeFrame': '17 days'}]","[{'measure': 'VX 770 metabolite PK parameters in plasma', 'timeFrame': '17 days'}, {'measure': 'Rifampin concentration at time zero (C0) and AUC at steady state (AUCtau) following the administration of multiple doses of rifampin', 'timeFrame': '17 days'}, {'measure': 'Safety as measured by adverse events, physical examinations, vital signs, electrocardiograms (ECGs), and clinically significant laboratory assessments', 'timeFrame': '17 days'}]",4,18 Years,55 Years,MALE,True,Vertex Pharmaceuticals Incorporated,INDUSTRY,0,24.0,ESTIMATED,2025-09-01T16:18:18.414277,v2_robust,True,True,True,False,True,
NCT02083250,"Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia,Busulfan,"['Busulfanum', 'GT 41', 'BUS', '1, 4-Bis[methanesulfonoxy]butane', 'Tetramethylene bis[methanesulfonate]', 'Mylecytan', 'Fludara', 'Zolinza', 'Busulphan', 'Suberoylanilide Hydroxamic Acid', 'Bussulfam', 'Myelosan', 'Methanesulfonic acid, tetramethylene ester', 'Vorinostat', 'SH T 586', 'Busulfan', 'Myleran', 'Clofarex', 'Misulban', 'Tetramethylene Bis(methanesulfonate)', 'Suberanilohydroxamic Acid', '2-F-ara-AMP', 'SAHA', 'CB-2041', 'Clofarabine', 'Beneflur', 'Myeloleukon', 'GT-41', 'MSK-390', 'Misulfan', 'Glyzophrol', 'Sulfabutin', 'Joacamine', 'Methanesulfonic Acid Tetramethylene Ester', 'L-001079038', 'Clolar', 'Mielucin', 'Fludarabine Phosphate', 'Busulfex', 'CB 2041', '9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-', 'WR-19508', 'Mitosan', 'Myeleukon']",44,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Lymphoblastic Leukemia in Remission,"['Acute Lymphoblastic Leukemia in Remission', 'Acute Myeloid Leukemia in Remission', 'Allogeneic Hematopoietic Stem Cell Transplantation Recipient', 'Myelodysplastic Syndrome', 'Previously Treated Myelodysplastic Syndrome', 'Recurrent Acute Lymphoblastic Leukemia', 'Recurrent Acute Myeloid Leukemia']",[],COMPLETED,,2014-03-06,2021-11-12,"[{'measure': 'Maximum tolerated dose of vorinostat when given in combination with fludarabine phosphate, clofarabine, and busulfan before stem cell transplant assessed using Common Terminology Criteria for Adverse Events version 4', 'description': 'The 2-stage time-to-event continual reassessment method will be used. Toxicity will be tabulated by dose, type, and grade. The probability of toxicity over 30 days as a function of dose will be estimated by fitting a Bayesian binary outcome regression model.', 'timeFrame': '30 days'}]","[{'measure': 'Recurrence-free survival', 'description': 'Will be estimated by the Kaplan and Meier method.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Overall survival', 'description': 'Will be estimated by the Kaplan and Meier method.', 'timeFrame': 'Up to 5 years'}]",3,,60 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,1,70.0,ACTUAL,2025-09-01T16:18:18.414510,v2_robust,True,True,True,False,True,
NCT02053350,Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection,"Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection: A Randomized, Double-blind, Placebo-controlled Trial",Alanyl-glutamine,"['alagln', 'Alanyl-glutamine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Clostridium Difficile Infection,['Clostridium Difficile Infection'],"['Clostridium difficile', 'glutamine', 'diarrhea', 'alanyl-glutamine']",TERMINATED,Funding ended,2015-04,2017-04-05,"[{'measure': 'Number of Participants With Recurrent C. Difficile Infection', 'description': 'Day 40 clinical failure - clinical failure includes death or CDI recurrence assessed 40 days post randomization or lack of clinical cure', 'timeFrame': 'At day forty'}, {'measure': 'Mortality', 'description': 'Death from any cause at days 40, 70 and 190', 'timeFrame': 'Up to 6 months after end of treatment'}]",[],2,18 Years,,ALL,False,University of Virginia,OTHER,0,7.0,ACTUAL,2025-09-01T16:18:18.414522,v2_robust,True,True,False,True,False,Funding ended
NCT06810050,Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis,"Safety and Effectiveness of CGB-500 Topical Ointment with 0.5% and 1% Tofacitinib for the Treatment of Atopic Dermatitis: a Randomized, Dose-Ranging, Vehicle-Controlled, Double-Blind Trial",CGB-500 with 0.5% tofacitinib,"['Vehicle (placebo)', 'CGB-500 Ointment with 1% tofacitinib', 'CGB-500 with 0.5% tofacitinib']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Atopic Dermatitis (AD),['Atopic Dermatitis (AD)'],"['Phase 2b study, study the safety and effectiveness of CGB-500 topical ointment with 0.5% and 1% tofacitinib,']",RECRUITING,,2024-12-18,2025-10-30,"[{'measure': 'Safety and tolerability', 'description': '• Overall Incidence of safety events tabulated using the current version of the medical dictionary for regulatory activities (MedDRA).', 'timeFrame': 'From enrollment to end of study at 8 weeks'}, {'measure': 'evaluate effectiveness', 'description': 'Primary Efficacy Endpoint\n\n• Proportion of participants achieving Investigator\'s Global Assessment (IGA) response of ""Clear"" (Score 0) or ""Almost Clear"" (Score 1) with ≥ 2 grade of improvement at Week 8.', 'timeFrame': 'From enrollment to end of study at 8 weeks'}]",[],2,12 Years,,ALL,False,CAGE Bio Inc.,INDUSTRY,0,180.0,ESTIMATED,2025-09-01T16:18:18.414640,v2_robust,True,True,False,False,True,
NCT04342650,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,"Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial",Chloroquine Diphosphate,"['Placebo oral tablet', 'Chloroquine Diphosphate', 'chloroquine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,COVID-19,"['COVID-19', 'SARS-CoV Infection', 'Severe Acute Respiratory Syndrome (SARS) Pneumonia', 'Clinical Trial']",[],COMPLETED,,2020-04-08,2020-06-08,"[{'measure': 'Proportion of patients with onset of severe acute respiratory syndrome (SARS)', 'description': 'Evaluate if CQ diphosphate prevents the onset of SARS in patients on intervention group through standardized questionnaires.', 'timeFrame': '7 days after randomization'}]","[{'measure': 'Mortality rate', 'description': 'Mortality rate between intervention and placebo group on days 7, 14, and 28 after randomization', 'timeFrame': 'after randomization, up to 28 days'}, {'measure': 'Number of participants in need of intensive care support', 'description': 'Proportion of participants in need and duration of intensive care support after randomization', 'timeFrame': 'during and after intervention, up to 28 days'}, {'measure': 'Viral concentration', 'description': 'Viral load change in blood and oropharyngeal swab samples', 'timeFrame': 'After randomization, up to 7 days'}, {'measure': 'Cumulative incidence of serious adverse events', 'description': 'Incidence of serious adverse events during and after treatment', 'timeFrame': 'During and after intervention, up to 28 days'}, {'measure': 'Cumulative incidence of grade 3 and 4 adverse events', 'description': 'Incidence of grade 3 and 4 adverse events during and after treatment', 'timeFrame': 'During and after intervention, up to 28 days'}, {'measure': 'Proportion of patients with discontinued treatment', 'description': 'proportion of discontinuation or temporary suspension of treatment (for any reason)', 'timeFrame': 'after randomization, up to 28 days'}, {'measure': 'Incidence of cardiac lesions', 'description': 'proportion of patients with increased levels of troponin I', 'timeFrame': 'after randomization, up to 120 days'}, {'measure': 'Incidence of cardiac disfunctions', 'description': 'proportion and magnitude of QTcF interval increases higher than 500ms', 'timeFrame': 'after randomization, up to 120 days'}, {'measure': 'Change in respiratory capacity', 'description': 'Changes measured on day 120 will be compared to baseline, through spirometry.', 'timeFrame': 'Day 120 after randomization'}]",10,18 Years,,ALL,False,Fundação de Medicina Tropical Dr. Heitor Vieira Dourado,OTHER,0,152.0,ACTUAL,2025-09-01T16:18:18.414652,v2_robust,True,True,True,False,True,
NCT02499250,Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients,Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients and the Mechanism,Optimal medical treatment,"['Optimal medical treatment', 'OMT']",2,INTERVENTIONAL,['NA'],,,Refractory Angina Pectoris,['Refractory Angina Pectoris'],"['refractory angina pectoris', 'remote ischemic conditioning', 'life quality', 'anxiety', 'depression', 'inflammation']",UNKNOWN,,2015-01,2017-01,"[{'measure': 'Frequencies of angina pectoris onset', 'description': 'The total times of angina pectoris onset over one week', 'timeFrame': '30 days'}, {'measure': 'Canadian Cardiovascular Society Angina Class', 'description': 'Ranging from class 1 to class 4 according to its definition', 'timeFrame': '30 days'}]","[{'measure': 'Flow mediated vasodilation in percentage increase', 'description': 'Reported as percent increase of brachial artery diameter induced by release of the forearm after ligation, accessed by experienced ultrasound professional.', 'timeFrame': '30 days'}, {'measure': 'Flow mediated vasodilation in absolute increase', 'description': 'Reported as absolute increase (cm) of brachial artery diameter induced by release of the forearm after ligation, accessed by experienced ultrasound professional.', 'timeFrame': '30 days'}, {'measure': 'Self-Rating Anxiety Scale', 'description': 'Reported as the Self-Rating Anxiety score', 'timeFrame': '30 days'}, {'measure': 'Self-Rating Depression Scale', 'description': 'Reported as the Self-Rating Depression score', 'timeFrame': '30 days'}, {'measure': 'Inflammatory cytokines expression', 'description': 'Reported as the serum levels of inflammatory cytokines measured by ELISA kits, including tumor necrosis factor(TNF-α)，Interleukine(IL)-6，and IL-10; The expression of signaling proteins in separated blood mononuclear cells,including hypoxia inducible factor(HIF) 1α.', 'timeFrame': '30 days'}, {'measure': 'Grip strength', 'description': 'Measured by a simple Grip strength meter (CAMRY) and reported as kilograms of strength.', 'timeFrame': '30 days'}, {'measure': 'Skin and muscle abnormalities', 'description': 'Whether or not the skin of the arm has bruises, and whether or not the arm has sore or pain feeling.', 'timeFrame': '1,7 and 30 days'}, {'measure': 'Circulating CD34+ progenitor cells', 'description': 'The percent of circulating cluster of differentiation(CD)34+ progenitor cells in separated mononuclear cells measured by flow cytometry.', 'timeFrame': '30 days'}]",10,18 Years,,ALL,False,"Navy General Hospital, Beijing",OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:18.414698,v2_robust,True,True,False,False,False,
NCT01067950,Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study,"International, Multicenter, Prospective, Randomized, Parallel Group, Open Label Protocol to Evaluate Safety and Efficacy of Isolated Pancreas Transplantation Compared to Intensive Insulin Therapy in Type 1 Diabetic Patients With Overt Diabetic Nephropathy and Mildly Reduced Renal Function",Intensive Insulin Therapy,['Intensive Insulin Therapy'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Type 1 Diabetes,['Type 1 Diabetes'],"['isolated pancreas transplant', 'intensive insulin therapy']",UNKNOWN,,2010-03,,"[{'measure': 'The primary end-point is the 5-year evaluation of efficacy/failure rate, a composite end-point including: (i) patient mortality and (ii) renal function impairment', 'timeFrame': '5 years'}]","[{'measure': 'Secondary objectives are to evaluate and to compare the safety and the efficacy of the two treatments (IPT versus IIT).', 'timeFrame': '5 years'}]",2,25 Years,55 Years,ALL,False,Nantes University Hospital,OTHER,0,180.0,ESTIMATED,2025-09-01T16:18:18.414763,v2_robust,True,True,False,False,True,
NCT01139450,Study of 0417 Ointment in the Treatment of Atopic Dermatitis,"Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0417 Ointment",0417,"['Vehicle of 0417 test product', 'Tacrolimus Ointment 0.03%', '0417']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Atopic Dermatitis,['Atopic Dermatitis'],['Atopic Dermatitis'],COMPLETED,,2008-01,2009-08,"[{'measure': ""Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment"", 'timeFrame': '4 weeks'}]","[{'measure': 'The Mean Change From Baseline in the Total Individual Clinical Signs and Symptoms Per Body Region', 'timeFrame': 'Baseline, 4 weeks'}, {'measure': 'The Mean Change From Baseline in Pruritus', 'timeFrame': 'Baseline, 4 weeks'}, {'measure': 'The Mean Change From Baseline in the Percentage Total Body Surface Affected (%BSA)', 'timeFrame': 'Baseline, 4 weeks'}]",4,8 Years,,ALL,False,Fougera Pharmaceuticals Inc.,INDUSTRY,0,899.0,ACTUAL,2025-09-01T16:18:18.414773,v2_robust,True,True,True,False,False,
NCT07034950,Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation,Study on the Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation Under Hilar Nerve Blockade,Intravenous esketamine using Dixon's up-and-down sequential method,"['Intravenous the dose of esketamine ED95', 'Local anaesthesia using 10 ml of 1% lidocaine', 'Intravenous fentanyl 1 μg∙kg-1', 'Ultrasound-guided hepatic hilar nerve block (HHNB)', 'Standardized premedication (midazolam 0.03 mg∙kg-1)', ""Intravenous esketamine using Dixon's up-and-down sequential method""]",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Hepatic Neoplasm,"['Hepatic Neoplasm', 'Hepatic Cancer']","['hepatic hilar nerve block', 'Ultrasound-guided', 'Thermal Ablation', 'Esketamine', 'Pain']",ACTIVE_NOT_RECRUITING,,2025-06-29,2028-06-30,"[{'measure': 'thermal ablation-induced somatic responses to pain', 'description': 'Positive: Body movement or complaint of pain. Negative: No body movement or no reported pain. This scale will be administered during the surgery at the first stage of the research.', 'timeFrame': 'Day 1 (During the surgery at the first stage of the research)'}, {'measure': 'Incidence of respiratory depression', 'description': 'By comparing with the control group, evaluate the safety of ED95 of esketamine by the incidence of respiratory depression at T2-T5 of the second stage of the research.\n\nThe primary outcome is the incidence of respiratory depression, which is defined as SpO2 \\<90% or EtCO2 \\>55 mmHg.\n\nT2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; and T5: In the PACU.', 'timeFrame': 'Day 1 (T2-T5 of the second stage of the research)'}]","[{'measure': 'HR', 'description': 'HR: heart rate. T1: Prior to anesthesia (10 minutes after positioning); T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; and T5: In the PACU.', 'timeFrame': 'Day 1 (T1-T5 of the first and second stages of the research)'}, {'measure': 'MAP', 'description': 'MAP: Mean Arterial Pressure. T1: Prior to anesthesia (10 minutes after positioning); T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; and T5: In the PACU.', 'timeFrame': 'Day 1 (T1-T5 of the first and second stages of the research)'}, {'measure': 'RR', 'description': 'RR: respiratory rate. T1: Prior to anesthesia (10 minutes after positioning); T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; and T5: In the PACU.', 'timeFrame': 'Day 1 (T1-T5 of the first and second stages of the research)'}, {'measure': 'SPO2', 'description': 'SPO2: peripheral oxygen saturation. T1: Prior to anesthesia (10 minutes after positioning); T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; and T5: In the PACU.', 'timeFrame': 'Day 1 (T1-T5 of the first and second stages of the research)'}, {'measure': 'EtCO2', 'description': 'EtCO2: End-expiratory carbon dioxide. T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; and T5: In the PACU.', 'timeFrame': 'Day 1 (T2-T5 of the first and second stages of the research)'}, {'measure': 'Adverse events', 'description': 'Adverse events will encompass a range of systems, including the cardiovascular system (eg. high/low blood pressure and sinus tachycardia/bradycardia), as well as symptoms such as nausea, vomiting, dizziness, and mental symptoms.\n\nT2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; T5: In the PACU.\n\nT6 to T8: 2, 6, and 24 hours after the procedure.', 'timeFrame': 'Day 1 (T2-T8 of the first and second stages of the research)'}, {'measure': 'NRS', 'description': 'The Numeric Rating Scale (NRS) will be utilized to assess postoperative pain, with a range of 0 representing no pain and 10 representing severe pain. This scale will be administered at 2, 6, and 24 hours following the procedure.\n\nT6 to T8: 2, 6, and 24 hours after the procedure.', 'timeFrame': 'Day 1 (T6-T8 of the first and second stages of the research)'}, {'measure': 'The need for remedial analgesia', 'description': 'The consumption of remedial analgesia will be the total consumption of acetaminophen documented at 2, 6, and 24 hours after the procedure.\n\nT6 to T8: 2, 6, and 24 hours after the procedure.', 'timeFrame': 'Day 1 (T6-T8 of the first and second stages of the research)'}, {'measure': 'Success rate of anesthesia', 'description': 'Anesthesia success will be defined as inadequate analgesia requiring ≤3 rescue doses of remifentanil within 10 min throughout the procedure. The success rate of anesthesia will be calculated by dividing the number of successful anesthesia cases by the total number of cases.\n\nT2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors', 'timeFrame': 'Day 1 (T2-T4 of the second stage of the research)'}, {'measure': 'Induction duration', 'description': 'Induction duration is defined as the period from the start of anaesthetic drug injection to the commencement of the surgical procedure at the second stage of the research.', 'timeFrame': 'Day 1 of the second stage of the research'}, {'measure': 'Duration of awakening', 'description': 'Duration of awakening is defined as the period from the conclusion of the surgical procedure to the moment of eye-opening.', 'timeFrame': 'Day 1 of the second stage of the research'}, {'measure': 'Duration of stay in the hospital', 'description': 'Duration of stay in the hospital is measured from the moment the patient enters the operating room until the moment they are discharged.', 'timeFrame': 'Day 1 and Day 2 of the second stage of the research'}, {'measure': 'The satisfaction of the sonographer', 'description': 'The satisfaction score of the sonographer will be collected postoperatively on Day 1, using a scale ranging from 0 to 10, with 0 representing dissatisfaction and 10 representing very satisfied.', 'timeFrame': 'Day 1 of the second stage of the research'}, {'measure': 'The satisfaction of patients', 'description': 'The satisfaction of patients will be collected postoperatively on Day 2, using a scale ranging from 0 to 10, with 0 representing dissatisfaction and 10 representing very satisfied.', 'timeFrame': 'Day 2 of the second stage of the research'}, {'measure': 'Tumor prognosis', 'description': 'The prognosis of the tumor will be evaluated according to ultrasound examination at 1, 3, and 6 months after the operation.\n\nT9-T11: 1, 3, and 6 months after the operation.', 'timeFrame': 'T9-T11 of the second stage of the research (up to 6 months)'}]",17,18 Years,80 Years,ALL,False,The First Affiliated Hospital of Xiamen University,OTHER,0,79.0,ESTIMATED,2025-09-01T16:18:18.414794,v2_robust,True,True,False,False,True,
NCT06799650,Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV,Clinical Study to Evaluate the Efficacy and Safety of Gammora® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral Treatment-Naïve Participants,Gammora®,"['Ritonavir', 'Gammora®', 'Darunavir', 'Tenofovir', '3TC']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV Seropositivity,['HIV Seropositivity'],"['HIV cure', 'integrase peptide', 'proviral HIV DNA', 'apoptosis', 'antiretroviral therapy']",RECRUITING,,2025-01-01,2025-11-01,"[{'measure': 'Total Proviral HIV DNA quantitation', 'description': 'Total HIV DNA measured by qPCR', 'timeFrame': 'Weekly from time of randomization for 27 consecutive weeks'}, {'measure': 'Episomal Proviral HIV DNA quantitation', 'description': 'Episomal HIV DNA measured by qPCR', 'timeFrame': 'Weekly from time of randomization for 27 consecutive weeks'}, {'measure': 'Apoptosis markers', 'description': 'Evaluated by flow cytometry exclusively in the CD4+ T cell gates, using the PE Annexin V Apoptosis Detection kit (BD Biosciences)', 'timeFrame': 'Three times per week during from randomization to week 3 and weekly from that point through week 27'}]","[{'measure': 'HIV Viral load', 'description': 'Viral RNA in copies per mL of plasma', 'timeFrame': 'Weekly from time of randomization for 27 consecutive weeks'}, {'measure': 'CD4 T cell counts', 'description': 'CD4+ T cell count per mL', 'timeFrame': 'Weekly from time of randomization for 27 consecutive weeks'}, {'measure': 'CD8 T cell counts', 'description': 'CD8+ T cell count per mL', 'timeFrame': 'Weekly from time of randomization for 27 consecutive weeks'}, {'measure': 'Levels of Lymphocyte T Cell activation markers (CD38 and HLA-DR in CD4 and CD8+ T cells) for each participant', 'description': 'CD38 and HLA-DR in CD4 and CD8+ T cell lymphocytes by flow cytometry', 'timeFrame': 'Weekly for 12 weeks and every 4 weeks after that'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'A list of adverse events, separated by treatment-related or not treatment-related as assessed by CTCAE v4.0 per participant.', 'timeFrame': 'Weekly for 12 weeks and every 4 weeks after that'}]",8,18 Years,50 Years,MALE,False,Federal University of São Paulo,OTHER,1,40.0,ESTIMATED,2025-09-01T16:18:18.414807,v2_robust,True,True,False,False,True,
NCT01183650,A Study of Tadalafil in Benign Prostatic Hyperplasia,A Study to Evaluate the Pharmacokinetics of Tadalafil Administered Once Daily in Japanese and Non-Japanese Subjects With Benign Prostatic Hyperplasia,Tadalafil,"['Adcirca', 'Tadalafil', 'Cialis', 'LY450190']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Benign Prostatic Hyperplasia,['Benign Prostatic Hyperplasia'],[],COMPLETED,,2010-07,2011-04,"[{'measure': 'Pharmacokinetics: Area Under the Concentration Curve (AUC) for Tadalafil and Metabolite IC710', 'description': 'AUC for Day 1 is reported as AUC(tau \\[t\\], day 1), which is AUC from time zero to 24 hours (t) postdose on Day 1. AUC for Day 10 is reported as AUC(t,steady state \\[ss\\]), which is AUC during one 24-hour dosing interval at steady-state.', 'timeFrame': '1 day and 10 days'}, {'measure': 'Pharmacokinetics: Concentration Maximum (Cmax) of Tadalafil and Metabolite IC710', 'timeFrame': '1 day and 10 days'}, {'measure': 'Pharmacokinetics: Time to Concentration Maximum (Tmax) of Tadalafil and Metabolite IC710', 'timeFrame': '1 day and 10 days'}]",[],3,45 Years,,MALE,False,Eli Lilly and Company,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:18.414886,v2_robust,True,True,True,False,False,
NCT00003891,Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors,"A Phase I Study of NX211 Given as an IV Infusion Days 1, 2 and 3 Every 3 Weeks in Patients With Solid Tumors",lurtotecan liposome,['lurtotecan liposome'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Unspecified Adult Solid Tumor, Protocol Specific","['Unspecified Adult Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific']",COMPLETED,,1999-02-25,2008-09-22,[],[],0,18 Years,120 Years,ALL,False,NCIC Clinical Trials Group,NETWORK,1,37.0,ACTUAL,2025-09-01T16:18:18.414945,v2_robust,True,True,True,False,False,
NCT05610891,Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG,"A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults With Inoperable Relapsed or Refractory High-Grade Glioma",CLR 131,"['iopofosine I 131', 'CLR 131']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,High-Grade Glioma,['High-Grade Glioma'],[],ACTIVE_NOT_RECRUITING,,2023-10-01,2026-09,"[{'measure': 'Safety Evaluation of CLR 131', 'description': 'Will be assessed by physical examination, performance status, vital signs, laboratory changes over time, and adverse events. Evaluations will use a nonparametric Wilcoxon Signed Rank test and a linear mixed effects modeling will be conducted to evaluate longitudinal changes.', 'timeFrame': 'Assessed throughout the study to 1-year post-infusion follow-up period'}, {'measure': 'Efficacy Evaluation for Progression Free Survival', 'description': 'To determine the therapeutic activity defined as Progression Free Survival (PFS) using Kaplan Meier estimator. PFS is defined as the time from arm assignment until disease progression or death.', 'timeFrame': 'Day 84 post-infusion follow-up period through 3 years following completion of treatment.'}]","[{'measure': 'Treatment Response of CLR 131', 'description': 'Determine antitumor activity (treatment response) defined as the reduction in tumor volume, measured by MRI scans acquired as FLAIR images and based on the RAPNO criteria for responses.', 'timeFrame': 'From date of arm assignment until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months.'}, {'measure': 'Dose Determination for CLR 131', 'description': 'Identify the recommended Phase 2/3 dose of CLR 131 in relapsed pHGG patients based on both safety and efficacy assessments as defined by the primary endpoints concluded from this study.', 'timeFrame': 'From date of arm assignment until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months.'}, {'measure': 'Dosimetry Evaluation for Total Body and Organ', 'description': 'To determine total body and organ dosimetry, together, of CLR 131 in relapsed pHGG patients, measured by conjugate planar whole-body imaging and/or blood collection drawn for radiologic dosimetry analysis for a subset of patients. Organ time/activity integrals will be entered into OLINDA/EXM software to produce total body and organ dosimetry values for CLR 131.', 'timeFrame': '4 hours post-infusion and concluding 4 weeks post-initial imaging'}, {'measure': 'Tumor Response to CLR 131', 'description': 'Determine the tumor uptake of CLR 131 and utility of SPECT/CT as a potential diagnostic for response. Images will be reconstructed using quantitative SPECT reconstruction methods with compensation for attenuation, scatter and the full collimator-detector response including septal penetration and scatter. A registered CT image will be used as the attenuation map for the SPECT images. Image data will be converted to activity per cubic centimeters using a sensitivity measurement made using a point source in air.', 'timeFrame': '4 hours post-infusion and concluding 4 weeks post-initial imaging'}]",6,10 Years,25 Years,ALL,False,"Cellectar Biosciences, Inc.",INDUSTRY,1,50.0,ESTIMATED,2025-09-01T16:18:18.414957,v2_robust,True,True,False,False,True,
NCT04335591,Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6),A Double-blind Randomized Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-associated Pain,75 mg linzagolix tablet,"['Placebo tablet to match 75 mg linzagolix tablet', '200 mg linzagolix tablet', '75 mg linzagolix tablet', 'Placebo capsule to match Add-back capsule', 'Add-back capsule (E2 1 mg / NETA 0.5 mg)', 'Placebo tablet to match 200 mg linzagolix tablet']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Endometriosis,['Endometriosis'],"['Dysmenorrhea', 'Dyspareunia', 'Dyschezia', 'Non-menstrual pelvic pain']",COMPLETED,,2020-03-05,2022-12-15,"[{'measure': 'Dysmenorrhea', 'description': 'Proportion of subjects with reduction of DYS (Month 3 MCT) and stable or decreased use of analgesics for EAP at Month 12', 'timeFrame': '6-month extension study treatment period (from Month 6 to Month 12)'}, {'measure': 'Non-menstrual Pelvic Pain', 'description': 'Proportion of subjects with reduction of NMPP (Month 3 MCT) and stable or decreased use of analgesics for EAP at Month 12', 'timeFrame': '6-month extension study treatment period (from Month 6 to Month 12)'}]",[],2,18 Years,50 Years,FEMALE,False,"Kissei Pharmaceutical Co., Ltd.",INDUSTRY,0,356.0,ACTUAL,2025-09-01T16:18:18.415270,v2_robust,True,True,True,False,False,
NCT06233474,Study of Intra-articular Allocetra in Knee Osteoarthritis,"A Phase 1/2a Randomized, Double-Blind Placebo-controlled Study of Intra-articular Allocetra in Knee Osteoarthritis",Allocetra,['Allocetra'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Osteoarthritis, Knee","['Osteoarthritis, Knee']",[],ACTIVE_NOT_RECRUITING,,2024-01-26,2026-02-01,"[{'measure': 'Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injection', 'description': 'Number and severity of adverse events (AEs), serious adverse events (SAEs) and treatment disruptions/ discontinuations throughout the study from Day 0 and up to 6 months following the last injection', 'timeFrame': '7 months following Day 0'}]","[{'measure': 'Weekly average of knee pain.', 'description': 'Evaluation of change from baseline in weekly average of knee pain as measured using NRS (Numeric Rating Scale ) assessed at 3 months and 6 months from last study treatment.\n\nScores range from 0-10 points, with higher scores indicating greater pain intensity', 'timeFrame': '4 months and 7 months following Day 0.'}, {'measure': 'Change from baseline in WOMAC total score.', 'description': 'Change from baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) total score at 3 months, 6 months, and 12 months from last study treatment administration.\n\nHigher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.', 'timeFrame': '4 months, 7 months and 13 months following Day 0.'}, {'measure': 'Change in quality of life- Euro Quality of Life-5-dimension (EQ-5D) questionnaire', 'description': 'Change from baseline in QoL as measured by Euro Quality of Life-5-dimension (EQ-5D) questionnaire at 6 months and at 12 months from last study treatment administration.', 'timeFrame': '4 months, 7 months and 13 months following Day 0.'}]",4,45 Years,80 Years,ALL,False,Enlivex Therapeutics Ltd.,INDUSTRY,1,160.0,ESTIMATED,2025-09-01T16:18:18.415429,v2_robust,True,True,False,False,True,
NCT01864174,Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes,"A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adults Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise",Metformin XR,"['Placebo matching with Metformin IR', 'Metformin IR', 'Placebo matching with Metformin XR', 'Metformin XR', 'Glucophage XR', 'Glucophage']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],[],COMPLETED,,2013-06-20,2016-06-01,"[{'measure': 'Adjusted Mean Change From Baseline in HbA1c', 'description': 'Mean change in glycated hemoglobin (HbA1c) from baseline to Week 24 in the double-blind treatment period.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Number of Participants With Death, Serious Adverse Events (SAEs), SAEs Related to Study Therapy, SAEs Leading to Discontinuation, Adverse Events (AEs) Related to Study Therapy, and AEs Leading to Discontinuation', 'description': 'SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Treatment-related=having certain, probable, possible, or missing relationship to study drug. All listed events are treatment emergent, which is defined as nonserious and serious AEs with an onset from Day 1 of the double-blind treatment up to and including 4 days and 30 days respectively, after the last dose date of double-blind study. randomized.', 'timeFrame': 'Date of first dose (Day 1) up to 30 post last dose of study drug (approx. 28 weeks)'}]","[{'measure': 'Mean Change in Fasting Plasma Glucose (FPG)', 'description': 'The mean change in fasting plasma glucose (FPG) from baseline to Week 24 in the double-blind treatment period was assessed. The lack of glycemic control criteria for initiation of rescue medication during Week 12 to Week 24 was having a FPG \\> 200 mg/dL (11.1 mmol/L). mg/dL = milligrams per deciliter; mmol/L = millimole per Liter', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Mean Change in Mean Daily Glucose (MDG)', 'description': 'The mean change in Mean Daily Glucose (MDG) from baseline to Week 24 in the double-blind treatment period was assessed. Prior to the Day 1 visit (between Week -1 and Day 1) and in the week before the Week 24/Study Termination and Rescue or Early Treatment Termination visit, participants performed 7-point finger stick blood glucose monitoring (before and 2 hours after 3 meals per day, and at bedtime) for 3 consecutive days in order to determine their MDG.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percent of Participants With HbA1c < 7%', 'description': 'Percent of participants achieving a therapeutic glycemic response (defined as HbA1c \\< 7.0%) at Week 24 in the double-blind treatment period.', 'timeFrame': 'Week 24'}]",5,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,1736.0,ACTUAL,2025-09-01T16:18:18.415439,v2_robust,True,True,True,False,True,
NCT05355974,Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure,Vasopressor Utilization to Support Mean Arterial Pressure During Rapid Sequence Intubation: A Clinical Trial (Rapid-Press Trial),Norepinephrine,"['Plasma-lyte', 'Plasma-Lyte 148', ""Ringer's Injection"", 'normal saline', 'NS', 'Lactated Ringers, Intravenous', '0.9 percent Sodium Chloride', 'LR', ""Hartmann's Solution"", 'Norepinephrine Bitartrate', 'Plasmalyte', 'Norepinephrine', 'Levophed', 'Norepinephrine-Dextrose']",14,INTERVENTIONAL,['PHASE3'],PHASE3,,Respiratory Failure,"['Respiratory Failure', 'Hypotension and Shock', 'Hypotension on Induction', 'Intubation Complication', 'Anesthesia Intubation Complication']","['mean arterial pressure', 'Rapid Sequence Intubation', 'vasopressor', 'Norepinephrine', 'Hypotension from Intubation']",COMPLETED,,2022-08-09,2024-07-10,"[{'measure': 'Systolic Blood Pressure', 'description': 'Change in systolic blood pressure during rapid sequence intubation in mmHg.', 'timeFrame': '1 hour after Rapid Sequence Intubation'}]","[{'measure': 'Change in serum creatinine (Acute Kidney Injury)', 'description': 'Change in serum creatinine (in mL) after rapid sequence intubation and development of Acute Kidney Injury as defined by ≥0.3 mg/dL (≥26.5 micromol/L) within 48 hours', 'timeFrame': '24 hours after Rapid Sequence Intubation'}, {'measure': 'Acute Kidney Injury', 'description': 'Change in urine output (in mL) after rapid sequence intubation and development of Acute Kidney Injury as defined by Urine volume \\<0.5 mL/kg/hour for six hours', 'timeFrame': '24 hours after Rapid Sequence Intubation'}]",3,18 Years,,ALL,False,Wright State University,OTHER,0,42.0,ACTUAL,2025-09-01T16:18:18.415498,v2_robust,True,True,True,False,False,
NCT02558374,Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension,"A Double-masked, Randomized, Multi-center, Active-controlled, Parallel Group, 6-month Study With a 3-month Interim Analysis Assessing the Ocular Hypotensive Efficacy and Safety of AR-13324 Ophthalmic Solution, 0.02% QD Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure",AR-13324 Ophthalmic Solution 0.02%,"['AR-13324 Ophthalmic Solution 0.02%', 'Timolol Maleate Ophthalmic Solution 0.5% BID', 'Netarsudil']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Open-angle Glaucoma,"['Open-angle Glaucoma', 'Ocular Hypertension']",[],COMPLETED,,2015-09,2016-12,"[{'measure': 'IOP (Intraocular Pressure)', 'description': 'The primary efficacy outcome is mean IOP', 'timeFrame': '3 months'}]","[{'measure': 'Extent of Exposure', 'description': 'Exposure to study medication in days for all treatment groups', 'timeFrame': '6 months'}]",2,18 Years,,ALL,False,Aerie Pharmaceuticals,INDUSTRY,0,708.0,ACTUAL,2025-09-01T16:18:18.415516,v2_robust,True,True,True,False,False,
NCT02957474,"A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects","A Phase 1, Open Label, Single Center, Randomized, Six-Sequence, Crossover Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects",GED-0301,"['Mongersen', 'GED-0301', 'Omeprazole']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['Healthy Volunteers', 'Pharmacokinetics', 'Food Effect', 'Proton Pump', 'GED-0301', 'Mongersen']",COMPLETED,,2016-11,2016-12,"[{'measure': 'Pharmacokinetics - Cmax', 'description': 'Maximum observed concentration in plasma', 'timeFrame': 'Up to Day 17'}, {'measure': 'Pharmacokinetics -AUC0-∞', 'description': 'Estimation of AUC from time zero extrapolated to infinity', 'timeFrame': 'Up to Day 17'}]","[{'measure': 'Adverse Event (AE)', 'description': 'Number of participants with adverse events', 'timeFrame': 'Up to Day 22'}]",3,18 Years,65 Years,ALL,True,Celgene,INDUSTRY,0,18.0,ACTUAL,2025-09-01T16:18:18.415525,v2_robust,True,True,True,False,True,
NCT00508274,Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China,An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or Metastatic Breast Cancer,lapatinib,"['LAP016, GW572016', 'lapatinib', 'capecitabine']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Neoplasms, Breast","['Neoplasms, Breast']","['Advanced Metastatic Breast Cancer', 'HER2 positive', 'HER2+', 'breast cancer', 'lapatinib', 'TYVERB', 'TYKERB', 'Capecitabine']",TERMINATED,Primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportable due to local regulations in China.,2007-07-18,2020-07-01,"[{'measure': 'Clinical Benefit Rate (CBR)', 'description': 'CBR is defined by the percentage of participants achieving either a confirmed tumor response of complete response (CR) or partial response (PR) or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A ""partial response"" requires a decrease of 30% or more, ""complete response"" requires all target lesions disappear, ""Progression"" requires an increase of at least 20%, and ""Stable disease"" falls in between these two. All responses have a repeat assessment to confirm the response.', 'timeFrame': 'Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 90 months'}]","[{'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS is defined as the time from first dose date until the date of disease progression or death due to any reason, whichever occurs first.', 'timeFrame': 'Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90.38 months.'}, {'measure': 'Six Months Progression-Free Survival', 'description': 'Six Months Progression-Free Survival is defined as the percentage of surviving participants who are progression-free longer than six months (greather than 180 days) after the first start date of study treatment.', 'timeFrame': 'at Baseline and every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed up to 90.38 months, with 6 months PFS reported.'}, {'measure': 'Time to Response (TTR)', 'description': 'Time to response is defined as the time from first dose date until first documentation of disease response. TTR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for time to response.', 'timeFrame': 'Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 14.78 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'Duration of response (complete response, partial response or stable disease) is defined as the time of first documentation of disease response until the date of disease progression or death due to breast cancer, whichever occurs first. DOR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for duration of response.', 'timeFrame': 'Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 88.80 months.'}, {'measure': 'Number of Participants With Central Nervous System (CNS) as First Site of Relapse', 'description': 'Number of participants who had Central Nervous System metastasis as the first site of relapse. CT, Magnetic Resonance Imaging, etc. were used for the assessment.', 'timeFrame': 'Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90 months'}]",6,18 Years,,FEMALE,False,Novartis Pharmaceuticals,INDUSTRY,0,52.0,ACTUAL,2025-09-01T16:18:18.415556,v2_robust,True,True,False,True,False,Primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportable due to local regulations in China.
NCT05576974,"A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)","A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)",Pegsitacianine,['Pegsitacianine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Head and Neck Cancer,"['Head and Neck Cancer', 'Unknown Primary Cancer', 'Head and Neck Squamous Cell Carcinoma']",[],RECRUITING,,2024-04-17,2027-12-31,"[{'measure': 'Diagnostics performance and safety of 1 mg/kg Pegsitacianine in patients with HNSCC', 'description': ""Pegsitacianine fluorescence from in vivo and excised tissues will be imaged using intraoperative and post-operative NIR cameras and will be correlated with the histopathological confirmation of tumor and normal tissues to determine Pegsitacianine's diagnostic performance. Patient safety will be assessed for 10 days (±48 hours) post dose. All patients will be monitored for vital signs and physical examination pretreatment and at various time points up to Day 6 (±24 hours). All patients will be monitored for comprehensive metabolic panel (CMP) and complete blood count (CBC) with differentials pretreatment and at various time points up to Day 10 (±48 hours). All patients will be monitored for TEAEs, and concomitant medication use from the start of dosing up to Day 10 (±48 hours). TEAEs will be followed closely during the study to identify any potential DLTs"", 'timeFrame': '5 years'}, {'measure': 'Diagnostics performance and safety of 1 mg/kg Pegsitacianine in patients with UPC', 'description': ""Pegsitacianine fluorescence from in vivo and excised tissues will be imaged using intraoperative and post-operative NIR cameras and will be correlated with the histopathological confirmation of tumor and normal tissues to determine Pegsitacianine's diagnostic performance. Patient safety will be assessed for 10 days (±48 hours). All patients will be monitored for vital signs and physical examination pretreatment and at various time points up to Day 6 (±48 hours). All patients will be monitored for comprehensive metabolic panel (CMP) and complete blood count (CBC) with differentials pretreatment and at various time points up to Day 10 (±48 hours). All patients will be monitored for TEAEs, and concomitant medication use from the start of dosing up to Day 10 (±48 hours). TEAEs will be followed closely during the study to identify any potential DLTs"", 'timeFrame': '5 years'}]","[{'measure': 'Pegsitacianine fluorescence imaging in HNSCC, UPC primary cancers that are HPV positive and HPV negative', 'description': ""Pegsitacianine fluorescence from in vivo and excised tissues will be imaged using intraoperative and post-operative NIR cameras and will be correlated with the histopathological confirmation of tumor and normal tissues to determine Pegsitacianine's diagnostic performance. Assessment of use of Pegsitacianine for intra-operative imaging of HNSCC, UPC and metastatic lymph nodes will include quantification of intraoperative and postoperative fluorescence signals from histology confirmed tumor and normal tissues, calculation of TBR and diagnostic performance. Feasibility determination will be based on a combined assessment of intraoperative in vivo and ex vivo fluorescent signals together with ex vivo examinations (histological examination, NIR flatbed scanning)."", 'timeFrame': '5 years'}]",3,18 Years,99 Years,ALL,False,University of Texas Southwestern Medical Center,OTHER,1,120.0,ESTIMATED,2025-09-01T16:18:18.415654,v2_robust,True,True,False,False,True,
NCT06090474,"Multiple Dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability of NDC-002 in Healthy Volunteers","An Open-label, One-sequence, Three-period, Multiple-dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability Between NDC-002A/NDC-002B and NDC-002C in Healthy Volunteers",NDC-002,['NDC-002'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Stroke Sequelae,"['Stroke Sequelae', 'Stroke']",[],COMPLETED,,2023-01-12,2023-03-15,"[{'measure': 'Safety Evaluation: Adverse events', 'description': 'Subjective/objective symptoms', 'timeFrame': 'Up to 10 days post final dose'}, {'measure': 'Pharmacokinetic Evaluation: AUCss,τ of NDC-002B/C', 'description': 'after single and concomitant administration of NDC-002B/C', 'timeFrame': 'Day 1, Day 7, Day15, Day 29, Day 36'}, {'measure': 'Pharmacokinetic Evaluation: Css,max of NDC-002B/C', 'description': 'after single and concomitant administration of NDC-002B/C', 'timeFrame': 'Day 1, Day 7, Day15, Day 29, Day 36'}]","[{'measure': 'Pharmacokinetic Evaluation: AUCss,inf of NDC-002B/C', 'description': 'after single and concomitant administration of NDC-002B/C', 'timeFrame': 'Day 1, Day 7, Day15, Day 29, Day 36'}, {'measure': 'Pharmacokinetic Evaluation: Tss,max of NDC-002B/C', 'description': 'after single and concomitant administration of NDC-002B/C', 'timeFrame': 'Day 1, Day 7, Day15, Day 29, Day 36'}, {'measure': 'Pharmacokinetic Evaluation: Tss,1/2 of NDC-002B/C', 'description': 'after single and concomitant administration of NDC-002B/C', 'timeFrame': 'Day 1, Day 7, Day15, Day 29, Day 36'}]",6,19 Years,55 Years,ALL,True,Dr. Noah Biotech Inc.,INDUSTRY,0,33.0,ACTUAL,2025-09-01T16:18:18.415669,v2_robust,True,True,True,False,True,
NCT02803918,"A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)","Randomized, Double-blind, Placebo-controlled, Dose Escalation, Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin and/or Basal Insulin",Lixisenatide (AVE0010),"['Lixisenatide (AVE0010)', 'Metformin', 'Basal Insulin', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],[],COMPLETED,,2017-05-17,2020-01-27,"[{'measure': 'Number of patients with adverse events (AEs)', 'timeFrame': 'Up to 10 weeks'}, {'measure': 'Number of patients with treatment-emergent adverse events (TEAEs)', 'timeFrame': 'Up to 10 weeks'}, {'measure': 'Number of patients with anti-lixisenatide antibodies', 'timeFrame': 'Up to 10 weeks'}]","[{'measure': 'Assessment of pharmacokinetic (PK) parameters: lixisenatide plasma concentration', 'timeFrame': 'Day 14, Day 28 and Day 42'}, {'measure': 'Assessment of PK parameters: maximum concentration (Cmax)', 'timeFrame': 'Day 42'}, {'measure': 'Assessment of PK parameters: time to reach Cmax (Tmax)', 'timeFrame': 'Day 42'}, {'measure': 'Assessment of PK parameters: area under up to last concentration (AUClast)', 'timeFrame': 'Day 42'}, {'measure': 'Assessment of PK parameters: area under curve (AUC)', 'timeFrame': 'Day 42'}, {'measure': 'Assessment of pharmacodynamic parameter: plasma glucose AUC-0-4.5 hours', 'timeFrame': 'Day 14, Day 28 and Day 42'}]",9,10 Years,17 Years,ALL,False,Sanofi,INDUSTRY,0,23.0,ACTUAL,2025-09-01T16:18:18.415676,v2_robust,True,True,True,False,True,
NCT06066918,Prophylactic Pregabalin Treatment Following Spinal Cord Injury,The Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among Spinal Cord Injury Patients Who Have Yet to Develop Central Pain,Pregabalin 75mg,"['Lyrica', 'Pregabalin 75mg']",2,INTERVENTIONAL,['NA'],,,Spinal Cord Injuries,"['Spinal Cord Injuries', 'Spinal Cord Diseases']",[],RECRUITING,,2021-07-13,2026-02-05,"[{'measure': 'Central pain', 'description': 'development of central pain by interview (yes /no )', 'timeFrame': '1 year'}, {'measure': 'McGill Pain Questionnaire', 'description': 'Range 0 -78. higher scores mean worse outcome.', 'timeFrame': '3 months'}]",[],2,18 Years,,ALL,False,Loewenstein Hospital,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:18.415737,v2_robust,True,True,False,False,False,
NCT01093118,A Study to Evaluate TMI-358 in the Treatment of Distal Subungual Onychomycosis,"A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TMI-358 in the Treatment of Distal Subungual Onychomycosis of the Toenail",TMI-358,"['MMI-467', 'TMI-358']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Distal Subungual Onychomycosis,['Distal Subungual Onychomycosis'],['Distal subungual onychomycosis'],TERMINATED,Business decision,2009-09,,"[{'measure': 'Cure rates', 'description': 'Based on clinical evaluations (nail measurements, KOH, and mycological culture for dermatophytes), cure categories will be defined as either mycological cure, clinical cure, complete cure, or effective treatment.', 'timeFrame': '48 weeks'}]",[],1,18 Years,75 Years,ALL,False,"Talima Therapeutics, Inc.",INDUSTRY,0,120.0,ESTIMATED,2025-09-01T16:18:18.415772,v2_robust,True,True,False,True,False,Business decision
NCT04967118,Neonatal Pain Management and Pain Monitoring Using New Methods,Neonatal Pain Management and Pain Monitoring Using New Methods: A Randomized Controlled Trial With Crossover Design,30% oral glucose,"['30% oral glucose', 'Sweet taste']",2,INTERVENTIONAL,['NA'],,,"Pain, Acute","['Pain, Acute', 'Procedural Pain', 'Infant']",[],RECRUITING,,2023-05-02,2024-12-31,"[{'measure': 'Change in scores of Premature Infant Pain profile-Revised (PIPP-R) scale', 'description': 'Pain intensity will be assessed using pain assessment tool, the Premature Infant Pain Profile Revised (PIPP-R). PIPP-R is an internationally widely used multidimensional pain assessment scale consisting of three behavioral indicators, two physiological indicators, and two contextual indicators.', 'timeFrame': 'Baseline 1, measured pre-intervention'}, {'measure': 'Change in scores of Premature Infant Pain profile-Revised (PIPP-R) scale', 'description': 'Pain intensity will be assessed using pain assessment tool, the Premature Infant Pain Profile Revised (PIPP-R). PIPP-R is an internationally widely used multidimensional pain assessment scale consisting of three behavioral indicators, two physiological indicators, and two contextual indicators.', 'timeFrame': 'Baseline 2, measured pre-procedure'}, {'measure': 'Change in scores of Premature Infant Pain profile-Revised (PIPP-R) scale', 'description': 'Pain intensity will be assessed using pain assessment tool, the Premature Infant Pain Profile Revised (PIPP-R). PIPP-R is an internationally widely used multidimensional pain assessment scale consisting of three behavioral indicators, two physiological indicators, and two contextual indicators.', 'timeFrame': 'Measured during painful procedure'}, {'measure': 'Change in scores of Premature Infant Pain profile-Revised (PIPP-R) scale', 'description': 'Pain intensity will be assessed using pain assessment tool, the Premature Infant Pain Profile Revised (PIPP-R). PIPP-R is an internationally widely used multidimensional pain assessment scale consisting of three behavioral indicators, two physiological indicators, and two contextual indicators.', 'timeFrame': 'Measured immediately after painful procedure'}, {'measure': 'Change in scores of Neonatal Infant Acute Pain Assessment Scale (NIAPAS)', 'description': 'Pain intensity will be assessed using pain assessment tool, the Neonatal Infant Acute Pain Assessment Scale (NIAPAS). NIAPAS is multidimensional pain assessment scale used in Finland. It consist of five behavioral indicators, three physiological indicators, and one contextual indicator.', 'timeFrame': 'Baseline 1, measured pre-intervention'}, {'measure': 'Change in scores of Neonatal Infant Acute Pain Assessment Scale (NIAPAS)', 'description': 'Pain intensity will be assessed using pain assessment tool, the Neonatal Infant Acute Pain Assessment Scale (NIAPAS). NIAPAS is multidimensional pain assessment scale used in Finland. It consist of five behavioral indicators, three physiological indicators, and one contextual indicator.', 'timeFrame': 'Baseline 2, measured pre-procedure'}, {'measure': 'Change in scores of Neonatal Infant Acute Pain Assessment Scale (NIAPAS)', 'description': 'Pain intensity will be assessed using pain assessment tool, the Neonatal Infant Acute Pain Assessment Scale (NIAPAS). NIAPAS is multidimensional pain assessment scale used in Finland. It consist of five behavioral indicators, three physiological indicators, and one contextual indicator.', 'timeFrame': 'Measured during painful procedure'}, {'measure': 'Change in scores of Neonatal Infant Acute Pain Assessment Scale (NIAPAS)', 'description': 'Pain intensity will be assessed using pain assessment tool, the Neonatal Infant Acute Pain Assessment Scale (NIAPAS). NIAPAS is multidimensional pain assessment scale used in Finland. It consist of five behavioral indicators, three physiological indicators, and one contextual indicator.', 'timeFrame': 'Measured immediately after painful procedure'}, {'measure': 'Change in the activation in the somatosensory cortical areas following the noxious stimulation (baseline)', 'description': 'In this study pain will be assessed measuring changes cortical hemodynamics by near-infrared spectroscopy (NIRS). A 2-channel NIRS will be used. The emitted probe provides near-infrared light through on optical fiber will be is placed slightly posterior to Cz position with reference to the international EEG 10-20 system. The receive probes will be fastened over somatosensory and occipital area. In the area of the somatosensory cortex, receive probes will be placed 2 to 4 cm from the emitted probe so that they are placed slightly behind C3 or C4 point. The occipital region receive probe will be attached 2 to 4 cm from the emitted probe.', 'timeFrame': 'Baseline 1, measured pre-intervention'}, {'measure': 'Change in the activation in the somatosensory cortical areas following the noxious stimulation', 'description': 'In this study pain will be assessed measuring changes cortical hemodynamics by near-infrared spectroscopy (NIRS). A 2-channel NIRS will be used. The emitted probe provides near-infrared light through on optical fiber will be is placed slightly posterior to Cz position with reference to the international EEG 10-20 system. The receive probes will be fastened over somatosensory and occipital area. In the area of the somatosensory cortex, receive probes will be placed 2 to 4 cm from the emitted probe so that they are placed slightly behind C3 or C4 point. The occipital region receive probe will be attached 2 to 4 cm from the emitted probe.', 'timeFrame': 'Baseline 2, measured pre-procedure'}, {'measure': 'Change of the activation in the somatosensory cortical areas following the noxious stimulation', 'description': 'In this study pain will be assessed measuring changes cortical hemodynamics by near-infrared spectroscopy (NIRS). A 2-channel NIRS will be used. The emitted probe provides near-infrared light through on optical fiber will be is placed slightly posterior to Cz position with reference to the international EEG 10-20 system. The receive probes will be fastened over somatosensory and occipital area. In the area of the somatosensory cortex, receive probes will be placed 2 to 4 cm from the emitted probe so that they are placed slightly behind C3 or C4 point. The occipital region receive probe will be attached 2 to 4 cm from the emitted probe.', 'timeFrame': 'Measured during painful procedure'}, {'measure': 'Change of the activation in the somatosensory cortical areas following the noxious stimulation', 'description': 'In this study pain will be assessed measuring changes cortical hemodynamics by near-infrared spectroscopy (NIRS). A 2-channel NIRS will be used. The emitted probe provides near-infrared light through on optical fiber will be is placed slightly posterior to Cz position with reference to the international EEG 10-20 system. The receive probes will be fastened over somatosensory and occipital area. In the area of the somatosensory cortex, receive probes will be placed 2 to 4 cm from the emitted probe so that they are placed slightly behind C3 or C4 point. The occipital region receive probe will be attached 2 to 4 cm from the emitted probe.', 'timeFrame': 'Measured immediately after painful procedure'}, {'measure': 'Change in heart rate (HR)', 'description': ""Neonates' physiological reactions to procedural pain during heel lance will be monitored continuously and measured by recording changes in heart rate using bedside patient monitor."", 'timeFrame': 'Baseline 1, measured pre-intervention'}, {'measure': 'Change in heart rate (HR)', 'description': ""Neonates' physiological reactions to procedural pain during heel lance will be monitored continuously and measured by recording changes in heart rate using bedside patient monitor."", 'timeFrame': 'Baseline 2, measured pre-procedure'}, {'measure': 'Change in heart rate (HR)', 'description': ""Neonates' physiological reactions to procedural pain during heel lance will be monitored continuously and measured by recording changes in heart rate using bedside patient monitor."", 'timeFrame': 'Measured during painful procedure'}, {'measure': 'Change in heart rate (HR)', 'description': ""Neonates' physiological reactions to procedural pain during heel lance will be monitored continuously and measured by recording changes in heart rate using bedside patient monitor."", 'timeFrame': 'Measured immediately after procedure'}, {'measure': 'Change in oxygen saturation', 'description': ""Neonates' physiological reactions to procedural pain during heel lance will be monitored continuously and measured by recording changes in oxygen saturation using bedside patient monitor."", 'timeFrame': 'Baseline 1, measured pre-intervention'}, {'measure': 'Change in oxygen saturation', 'description': ""Neonates' physiological reactions to procedural pain during heel lance will be monitored continuously and measured by recording changes in oxygen saturation using bedside patient monitor."", 'timeFrame': 'Baseline 2, measured pre-procedure'}, {'measure': 'Change in oxygen saturation', 'description': ""Neonates' physiological reactions to procedural pain during heel lance will be monitored continuously and measured by recording changes in oxygen saturation using bedside patient monitor."", 'timeFrame': 'Measured during painful procedure'}, {'measure': 'Change in oxygen saturation', 'description': ""Neonates' physiological reactions to procedural pain during heel lance will be monitored continuously and measured by recording changes in oxygen saturation using bedside patient monitor."", 'timeFrame': 'Measured immediately after painful procedure'}, {'measure': 'Change in respiratory rate', 'description': ""Neonates' physiological reactions to procedural pain during heel lance will be monitored continuously and measured by recording changes in respiratory rate using bedside patient monitor."", 'timeFrame': 'Baseline 1, measured pre-intervention'}, {'measure': 'Change in respiratory rate', 'description': ""Neonates' physiological reactions to procedural pain during heel lance will be monitored continuously and measured by recording changes in respiratory rate using bedside patient monitor."", 'timeFrame': 'Baseline 2, measured pre-procedure'}, {'measure': 'Change in respiratory rate', 'description': ""Neonates' physiological reactions to procedural pain during heel lance will be monitored continuously and measured by recording changes in respiratory rate using bedside patient monitor."", 'timeFrame': 'Measured during procedure'}, {'measure': 'Change in respiratory rate', 'description': ""Neonates' physiological reactions to procedural pain during heel lance will be monitored continuously and measured by recording changes in respiratory rate using bedside patient monitor."", 'timeFrame': 'Measured immediately after procedure'}]","[{'measure': 'Recovery measured by change in scores of the Premature Infant Pain profile-Revised (PIPP-R)', 'description': ""Time to recovery from painful stimulus will be considered the amount of time in minutes that pass until the neonates' PIPP-R scores returns to baseline values."", 'timeFrame': '3 minutes after painful procedure'}, {'measure': 'Recovery measured by change in scores of the Premature Infant Pain profile-Revised (PIPP-R)', 'description': ""Time to recovery from painful stimulus will be considered the amount of time in minutes that pass until the neonates' PIPP-R scores returns to baseline values."", 'timeFrame': '5 minutes after painful procedure'}, {'measure': 'Recovery measured by change in scores of the Premature Infant Pain profile-Revised (PIPP-R)', 'description': ""Time to recovery from painful stimulus will be considered the amount of time in minutes that pass until the neonates' PIPP-R scores returns to baseline values."", 'timeFrame': '10 minutes after painful procedure'}, {'measure': 'Recovery measured by change in scores of the Neonatal Infant Acute Pain Assessment Scale (NIAPAS)', 'description': ""Time to recovery from painful stimulus will be considered the amount of time in minutes that pass until the neonates' NIAPAS scores returns to baseline values."", 'timeFrame': '3 minutes after painful procedure'}, {'measure': 'Recovery measured by change in scores of the Neonatal Infant Acute Pain Assessment Scale (NIAPAS)', 'description': ""Time to recovery from painful stimulus will be considered the amount of time in minutes that pass until the neonates' NIAPAS scores returns to baseline values."", 'timeFrame': '5 minutes after painful procedure'}, {'measure': 'Recovery measured by change in scores of the Neonatal Infant Acute Pain Assessment Scale (NIAPAS)', 'description': ""Time to recovery from painful stimulus will be considered the amount of time in minutes that pass until the neonates' NIAPAS scores returns to baseline values."", 'timeFrame': '10 minutes after painful procedure'}, {'measure': 'Recovery as measured by changes in somatosensory cortex activation', 'description': 'Time to recovery from painful stimulus will be considered the amount of time in minutes that pass until the activation in the somatosensory cortical area measured by NIRS returns to baseline values.', 'timeFrame': '3 minutes after painful procedure'}, {'measure': 'Recovery as measured by changes in somatosensory cortex activation', 'description': 'Time to recovery from painful stimulus will be considered the amount of time in minutes that pass until the activation in the somatosensory cortical area measured by NIRS returns to baseline values.', 'timeFrame': '5 minutes after painful procedure'}, {'measure': 'Recovery as measured by changes in somatosensory cortex activation', 'description': 'Time to recovery from painful stimulus will be considered the amount of time in minutes that pass until the activation in the somatosensory cortical area measured by NIRS returns to baseline values', 'timeFrame': '10 minutes after painful procedure'}, {'measure': 'Recovery as measured by changes in heart rate (HR)', 'description': 'The physiological responses of neonates to recovery from the pain of the procedure are continuously monitored and measured by recording changes in respiratory rate using a patient monitor.', 'timeFrame': '3 minutes after painful procedure'}, {'measure': 'Recovery as measured by changes in heart rate (HR)', 'description': 'The physiological responses of neonates to recovery from the pain of the procedure are continuously monitored and measured by recording changes in respiratory rate using a patient monitor.', 'timeFrame': '5 minutes after painful procedure'}, {'measure': 'Recovery as measured by changes in heart rate (HR)', 'description': 'The physiological responses of neonates to recovery from the pain of the procedure are continuously monitored and measured by recording changes in respiratory rate using a patient monitor.', 'timeFrame': '10 minutes after painful procedure'}, {'measure': 'Recovery as measured by changes in oxygen saturation', 'description': 'The physiological responses of neonates to recovery from the pain of the procedure are continuously monitored and measured by recording changes in oxygen saturation using a patient monitor.', 'timeFrame': '3 minutes after painful procedure'}, {'measure': 'Recovery as measured by changes in oxygen saturation', 'description': 'The physiological responses of neonates to recovery from the pain of the procedure are continuously monitored and measured by recording changes in oxygen saturation using a patient monitor.', 'timeFrame': '5 minutes after painful procedure'}, {'measure': 'Recovery as measured by changes in oxygen saturation', 'description': 'The physiological responses of neonates to recovery from the pain of the procedure are continuously monitored and measured by recording changes in oxygen saturation using a patient monitor.', 'timeFrame': '10 minutes after painful procedure'}, {'measure': 'Recovery as measured by changes in respiratory rate', 'description': 'The physiological responses of neonates to recovery from the pain of the procedure are continuously monitored and measured by recording changes in respiratory rate using a patient monitor.', 'timeFrame': '3 minutes after painful procedure'}, {'measure': 'Recovery as measured by changes in respiratory rate', 'description': 'The physiological responses of neonates to recovery from the pain of the procedure are continuously monitored and measured by recording changes in respiratory rate using a patient monitor.', 'timeFrame': '5 minutes after painful procedure'}, {'measure': 'Recovery as measured by changes in respiratory rate', 'description': 'The physiological responses of neonates to recovery from the pain of the procedure are continuously monitored and measured by recording changes in respiratory rate using a patient monitor.', 'timeFrame': '10 minutes after painful procedure'}]",42,32 Weeks,42 Weeks,ALL,False,University of Oulu,OTHER,0,36.0,ESTIMATED,2025-09-01T16:18:18.415812,v2_robust,True,True,False,False,False,
NCT06137118,AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia,A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia,AZD0486,['AZD0486'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,B-cell Acute Lymphoblastic Leukemia (B-ALL),['B-cell Acute Lymphoblastic Leukemia (B-ALL)'],"['B-cell acute lymphoblastic leukemia', 'Leukemia', 'B-lymphocytes', 'AZD0486']",RECRUITING,,2023-12-29,2027-06-29,"[{'measure': 'Part A: Frequency of DLTs', 'description': 'DLTs are dose-limiting toxicities as defined in the study protocol', 'timeFrame': 'Up to 28 days'}, {'measure': 'Parts A & B: Safety Evaluation of AZD0486', 'description': 'Frequency, severity, and relationship to study drug of AEs and SAEs; dose modifications; changes in laboratory evaluations; QTc, and vital signs changes.', 'timeFrame': 'From signing of informed consent through data cutoff, up to 42 months'}, {'measure': 'Parts B & C: Rate of CR within 3 cycles', 'description': 'To evaluate the efficacy of AZD0486 based on NCCN response criteria (in Part B and C).', 'timeFrame': 'Up to three cycles of 28 days each'}]","[{'measure': 'Part A: Rate of CR within 3 cycles', 'description': 'the percentage of participants with a best response of CR within 3 cycles based on NCCN response criteria by investigators', 'timeFrame': 'Up to 3 cycles of 28 days each'}, {'measure': 'Part A,B,C: Rate of CR/CRh and CR/CRh/CRi within 3 cycles', 'description': 'proportion of participants achieving CR/CRh/CRi within 3 cycles based on NCCN response criteria by investigators (Part A) based on the response evaluable population, and by central review confirmation (Parts B and C) based on the FAS.', 'timeFrame': 'Up to 3 cycles of 28 days each'}, {'measure': 'Parts A, B, C: Rate of CR, CR/CRh and CR/CRh/CRi at any time during the study', 'description': 'Rate of CR, CR/CRh and CR/CRh/CRi at any time during study (Best CR, best CR/CRh and best CR/CRh/CRi)', 'timeFrame': 'From first dose to end of treatment or data cutoff, whichever comes first, assessed up to 42 months'}, {'measure': 'Parts A, B, C: Duration of CR, CR/CRh and CR/CRh/CRi', 'description': 'the time from the date of first documented CR, CR/CRh, or CR/CRh/CRi response, respectively, until the date of documented relapse or death due to any cause in the absence of disease progression or relapse, whichever occurs earlier.', 'timeFrame': 'From first dose to last progression or data cutoff, whichever comes first, assessed up to 42 months'}, {'measure': 'Parts A, B, C: Event-free survival (EFS)', 'description': 'Event-free survival is defined as the time from the date of the first dose until the date of a relapse after achieving a CR/CRh/CRi, or death due to any cause, whichever occurs first.', 'timeFrame': 'From First dose to last progression or data cutoff, whichever comes first, assessed up to 42 months'}, {'measure': 'Parts A, B, C: Overall Survival (OS)', 'description': 'The OS is defined as the time from date of first dose until death due to any cause regardless of whether the participant withdraws from treatment or receives a TTNT.', 'timeFrame': 'From First dose to data cutoff, up to 42 months'}, {'measure': 'Parts B &C: Subsequent alloSCT or donor lymphocyte infusion if used as an alloSCT substitute', 'description': 'Percentage of participants who received a subsequent alloSCT, or DLI if used as an alloSCT substitute, post AZD0486 treatment', 'timeFrame': 'From first dose to EOT, up to 42 Months'}, {'measure': 'Part A, B, C:MRD-negative rate of CR', 'description': 'To evaluate the impact of AZD0486 on MRD-negative rate of CR, CR/CRh and CR/CRi', 'timeFrame': 'From First dose to data cutoff, up to 42 months'}, {'measure': 'Parts A, B, & C: PK characterization of AZD0486', 'description': 'Derived PK parameter: AUC', 'timeFrame': 'From first dose to data cutoff, up to 42 months'}, {'measure': 'Parts A, B & C: PK Characterization of AZD0486', 'description': 'Derived PK parameter: Cmax', 'timeFrame': 'From first dose to data cutoff, up to 42 months'}, {'measure': 'Parts A, B, C: PK Characterization of AZD0486', 'description': 'Derived PK Parameter: tmax', 'timeFrame': 'From first dose to data cutoff, up to 42 months'}, {'measure': 'Parts A, B, C: PK Characterization of AZD0486', 'description': 'Derived PK parameter: Ctrough', 'timeFrame': 'From first dose to data cutoff, up to 42 months'}, {'measure': 'Parts A, B, C: PK Characterization of AZD0486', 'description': 'Derived PK Parameter: t1/2', 'timeFrame': 'From first dose to data cutoff, up to 42 months'}, {'measure': 'Parts A, B, C: PK Characterization of AZD0486', 'description': 'Derived PK Parameter: CL of AZD0486', 'timeFrame': 'From first dose to data cutoff, up to 42 months'}, {'measure': 'Parts A, B, C: ADA characterization of AZD0486', 'description': 'Summary of pre-existing and treatment-induced ADAs for AZD0486 (positive or negative, titres)', 'timeFrame': 'From First dose to EOT, up to 42 months'}, {'measure': 'Part C: Safety Evaluation of AZD0486', 'description': 'Frequency, severity, and relationship to study drug of AEs and SAEs; dose modifications; changes in laboratory evaluations; QTc, and vital signs changes.', 'timeFrame': 'From signing of informed consent through completion of study treatment, an average of 6 months'}]",19,12 Years,,ALL,False,AstraZeneca,INDUSTRY,0,142.0,ESTIMATED,2025-09-01T16:18:18.415921,v2_robust,True,True,False,False,True,
NCT04366518,"Toward a Computationally-Informed, Personalized Treatment for Hallucinations","Toward a Computationally-Informed, Personalized Treatment for Hallucinations",Rivastigmine Transdermal System,"['Scopolamine', 'Placebo Patch', 'Rivastigmine Transdermal System']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,"Hallucinations, Auditory","['Hallucinations, Auditory', 'Psychosis']",[],RECRUITING,,2021-07-15,2032-08,"[{'measure': 'Number of conditioned hallucinations exhibited during saline vs placebo administration', 'description': 'Participants will perform the Conditioned Hallucinations task while in the scanner; the authors hypothesize that number of conditioned hallucinations exhibited during the task will be higher under placebo than physostigmine, but only in those who have high prior weighting on baseline assessment.', 'timeFrame': 'During fMRI scans / task completion which will take approximately 90 minutes'}]","[{'measure': 'Prior-Weighting Parameter of the Hierarchical Gaussian Filter', 'description': 'Behavioral responses will be used to fit a parameter of the Hierarchical Gaussian Filter model corresponding to the ratio of precision of priors to precision of incoming sensory evidence.', 'timeFrame': 'During fMRI scans / task completion which will take approximately 90 minutes'}, {'measure': 'Functional correlation with model belief trajectories', 'description': 'Behavioral responses will be used to fit belief trajectories across the course of the experiment, and whole-brain analyses will measure correlation of brain activity with these computed trajectories.', 'timeFrame': 'During fMRI scans / task completion which will take approximately 90 minutes'}]",3,18 Years,65 Years,ALL,False,Yale University,OTHER,1,35.0,ESTIMATED,2025-09-01T16:18:18.415931,v2_robust,True,True,False,False,False,
NCT00014118,Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer,A Phase II Trial OF Chemoradiation For Organ Preservation In Resectable Stage III or IV Squamous Cell Carcinomas Of The Larynx Or Oropharynx,carboplatin,"['paclitaxel', 'carboplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Head and Neck Cancer,['Head and Neck Cancer'],"['stage III squamous cell carcinoma of the oropharynx', 'stage IV squamous cell carcinoma of the oropharynx', 'stage III squamous cell carcinoma of the larynx', 'stage IV squamous cell carcinoma of the larynx']",COMPLETED,,2001-06-06,2009-05,"[{'measure': 'Organ preservation rate'}, {'measure': 'Feasibility and toxicity'}, {'measure': 'Utility of pre- and post-treatment organ function instruments'}, {'measure': 'Disease-free survival and patterns of failure'}, {'measure': 'Objective tumor response rate (complete and partial response)'}, {'measure': 'Changes in quality of life'}, {'measure': 'Correlation of the presence of human papilloma virus infection and p-glycoprotein with outcome'}]",[],7,18 Years,120 Years,ALL,False,Eastern Cooperative Oncology Group,NETWORK,1,,,2025-09-01T16:18:18.415947,v2_robust,True,True,True,False,False,
NCT00652418,Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography,Evaluation of a Single Intravenous Injection of Magnevist (SH L 451 A) at 0.1 mmol/kg and 0.2 mmol/kg in Contrast-enhanced 3D-Magnetic Resonance Angiography in Patients With Arterial Disease in the Abdominal to Leg Regions in the Ability of Detecting of Vessel Abnormalities,"Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)","['Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Magnetic Resonance Angiography,"['Magnetic Resonance Angiography', 'Peripheral Vascular Diseases', 'Peripheral Arterial Diseases']","['Magnevist', 'Magnetic Resonance Angiography', 'Meglumine gadopentetate', 'Determination of effective dose in MRA']",COMPLETED,,2004-07,2004-10,"[{'measure': 'Diagnostic ability', 'timeFrame': 'MRI image in blinded read'}]","[{'measure': 'Visibility', 'timeFrame': 'MRI image in blinded read'}, {'measure': 'Diagnostic confidence', 'timeFrame': 'MRI image in blinded read'}]",3,20 Years,,ALL,False,Bayer,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:18.415989,v2_robust,True,True,True,False,False,
NCT01471418,The Use of PET/CT to Evaluate Synovitis in the Temporomandibular Joint (TMJ),Investigation of the Use of Positron Emission Tomography With 18F-FDG PET/CT for the Diagnosis of Synovitis in the Temporomandibular Joint,PET/CT with 18-FDG,['PET/CT with 18-FDG'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Temporomandibular Joint,"['Temporomandibular Joint', 'Conservative Treatment Therapy']","['TMJ', 'orofacial pain', 'synovitis', 'arthroscopy']",WITHDRAWN,29-Apr-14 UPENN IRB granted approval to close study due to lack of funding,2011-12,2012-10,"[{'measure': 'The primary outcome variable will be the presence or absence of 18F-FDG uptake on positron emission tomography combined with computed tomography (CT) of the temporomandibular joint.', 'timeFrame': '1 year'}]",[],1,18 Years,70 Years,ALL,True,University of Pennsylvania,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:18.415998,v2_robust,True,True,False,True,False,29-Apr-14 UPENN IRB granted approval to close study due to lack of funding
NCT04535518,Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease,"Efficacy of Primary Treatment With Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease: a Multicenter, Open-label, Blinded-end Randomized Controlled Study.",IVIG,"['Aspirin', 'IVIG', 'Intravenous Immunoglobulins, Human', 'Acetylsalicylic acid', 'Remicade', 'Infliximab']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Kawasaki Disease,['Kawasaki Disease'],"['Kawasaki disease', 'infliximab', 'coronary artery lesion']",WITHDRAWN,lack of funding,2020-10,2022-09,"[{'measure': 'Percentage of the regression of coronary artery lesion (CAL) at one month of illness', 'description': 'The regression of CAL is defined as z \\< 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.Two-dimensional echocardiography will be performed to evaluate CAL at 1 month of illness. The measurement of each patient included the diameter of the left main coronary artery (LMCA), the left anterior descending artery (LAD), the left circumflex coronary artery (LCX), and the proximal and middle segments of the right coronary artery (RCA). Z score of each coronary artery will be calculated (Journal of the American Society of Echocardiography, 2011, 24(1):60-74).', 'timeFrame': 'at one month of illness'}]","[{'measure': 'Percentage of the need for additional treatment', 'description': ""Participants who have recurrent or persistent fever (axillary temperature ≥37.5°C or rectal temperature ≥38°C) after 36 hours of completion of initial IVIG infusion will be given additional treatment, including a second dose of IVIG (2 g/kg), or a high dose of methylprednisolone (10 to 30 mg/kg per day), or other immunosuppressive agents such as ciclosporin and cyclophosphamide, or a combination with two or more drugs, or even more aggressive treatment such as plasmapheresis, depending on patients'condition and physicians' experience. Axillary temperature (or rectal temperature) will be measured every 6 hours a day during hospitalization."", 'timeFrame': 'from admission to discharge (about 2 weeks of illness)'}, {'measure': 'z scores of LMCA throughout the study period', 'description': 'This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of LMCA will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness.', 'timeFrame': 'from admission to 12 months of illness'}, {'measure': 'z scores of LAD throughout the study period', 'description': 'This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of LAD will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness.', 'timeFrame': 'from admission to 12 months of illness'}, {'measure': 'z scores of LCX throughout the study period', 'description': 'This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of LCX will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness.', 'timeFrame': 'from admission to 12 months of illness'}, {'measure': 'z scores of the proximal segment of RCA throughout the study period', 'description': 'This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of the proximal segment of RCA will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness.', 'timeFrame': 'from admission to 12 months of illness'}, {'measure': 'z scores of the middle segment of RCA throughout the study period', 'description': 'This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of the middle segment of RCA will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness.', 'timeFrame': 'from admission to 12 months of illness'}, {'measure': 'Duration of fever (hours) after initiation of initial IVIG infusion', 'description': 'Participants with an axillary temperature \\<37.5℃ (or rectal temperature \\<38℃) for more than 24 hours are considered afebrile. Axillary temperature (or rectal temperature) will be measured every 6 hours a day during hospitalization. Record the time of the initiation of IVIG infusion and the time of the body temperature first becoming normal.', 'timeFrame': 'from initiation of initial IVIG infusion to the first record of being afebrile (defined as an axillary temperature <37.5 for more than 24 hours)'}, {'measure': 'Change in serum C-reactive protein (CRP) concentration', 'description': 'CRP level is measured before initial IVIG infusion and 72 hours after completion of initial IVIG infusion.Change would be described by difference.', 'timeFrame': 'from admission to 72 hours after completion of initial IVIG infusion'}, {'measure': 'Number of patients with serious adverse events', 'description': 'This is a composite outcome, including death, hypertension (defined as the blood pressure (BP) ≥90th percentile for age and height or ≥ 120/80 mmHg in the children younger than 13, and ≥ 120/80 mmHg in children ≥ 13 years), severe infection (such as septicopyemia, pulmonary infection and urinary system infection), allergic reactions, heart failure, thrombosis, etc.', 'timeFrame': 'from admission to 12 months of illness'}, {'measure': 'Percentage of the regression of coronary artery lesion (CAL) at 3 months of illness', 'description': 'The regression of CAL is defined as the z \\< 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.', 'timeFrame': 'at 3 months of illness'}, {'measure': 'Percentage of the regression of coronary artery lesion (CAL) at 6 months of illness', 'description': 'The regression of CAL is defined as the z \\< 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.', 'timeFrame': 'at 6 months of illness'}, {'measure': 'Percentage of the regression of coronary artery lesion (CAL) at 9 months of illness', 'description': 'The regression of CAL is defined as the z \\< 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.', 'timeFrame': 'at 9 months of illness'}, {'measure': 'Percentage of the regression of coronary artery lesion (CAL) at 12 months of illness', 'description': 'The regression of CAL is defined as the z \\< 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.', 'timeFrame': 'at 12 months of illness'}]",14,1 Month,14 Years,ALL,False,Children's Hospital of Fudan University,OTHER,4,0.0,ACTUAL,2025-09-01T16:18:18.416007,v2_robust,True,True,False,True,True,lack of funding
NCT06657690,Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC,"The Efficacy and Safety of Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic Nasopharyngeal Carcinoma: a Prospective, Single-arm Phase 2 Study",Irinotecan liposome,"['S-1', 'Irinotecan liposome']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Recurrent or Metastatic Nasopharyngeal Carcinoma,['Recurrent or Metastatic Nasopharyngeal Carcinoma'],[],RECRUITING,,2024-11-01,2027-10-31,"[{'measure': 'Objective response rate (ORR)', 'description': 'Objective response rate (ORR) is defined as the proportion of patients with a complete response or partial response to treatment', 'timeFrame': 'Through study completion, an average of 1 year'}]","[{'measure': 'Progression-free survival (PFS)', 'description': 'Progression-Free Survival PFS is defined as the duration from the date of treatment to progression or death', 'timeFrame': 'Through study completion, an average of 1 year'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS) is defined as the duration from the date of treatment to death or last follow-up, with no restriction on the cause of death.', 'timeFrame': 'Through study completion, an average of 1 year'}, {'measure': 'Incidence of adverse events', 'description': 'NCI-CTCAE 5.0 standard is adopted.', 'timeFrame': '1 year'}]",4,18 Years,70 Years,ALL,False,Sun Yat-sen University,OTHER,0,56.0,ESTIMATED,2025-09-01T16:18:18.416187,v2_robust,True,True,False,False,True,
NCT05768490,Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases,"A Prospective, Multicenter, Randomized, Controlled Clinical Study of Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases",Almonertinib,['Almonertinib'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Brain Metastases,"['Brain Metastases', 'Radiotherapy', 'EGFR Activating Mutation']",[],RECRUITING,,2023-03-15,2029-12-31,"[{'measure': 'overall survival', 'description': 'The time from randomization to death from any cause.', 'timeFrame': '3 years'}]","[{'measure': 'intracranial progression free survival', 'description': 'patients were randomized from the time of observation of intracranial disease progression or death from any cause', 'timeFrame': '2 years'}, {'measure': 'progression free survival', 'description': 'patients were randomized from the time of observation of systemic disease progression or death from any cause', 'timeFrame': '2 years'}, {'measure': 'intracranial objective response rate', 'description': 'proportion of patients with complete or partial response of intracranial lesions', 'timeFrame': '6 months'}]",4,18 Years,75 Years,ALL,False,Sun Yat-sen University,OTHER,0,232.0,ESTIMATED,2025-09-01T16:18:18.416262,v2_robust,True,True,False,False,False,
NCT03046290,Pudendal Block Versus Penian Block For Circumcision In Children,Pudendal Block Versus Penian Block For Circumcision In Children: A Double Blind Randomised Controlled Trial,Lidocaine,"['Ropivacaine', 'Lidocaine']",2,INTERVENTIONAL,['NA'],,,Regional Anesthesia,"['Regional Anesthesia', 'Postoperative Pain', 'Circumcision']",[],UNKNOWN,,2017-01,2017-04,"[{'measure': 'postoperative pain score', 'description': 'using the FLACC (Face Leg Activity Cry Consolability) Scale', 'timeFrame': 'pain score at 0 hours postoperatively'}]","[{'measure': 'Degree of satisfaction of the patient or his/her parents and the surgeon assessed by telephone interview', 'description': 'telephone interview', 'timeFrame': 'Day 5 after the procedure'}]",2,1 Year,5 Years,MALE,False,Université Libre de Bruxelles,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:18.416344,v2_robust,True,True,False,False,False,
NCT00348790,Vatalanib in Treating Patients With Recurrent or Progressive Meningioma,A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas,vatalanib,"['PTK787', 'vatalanib', 'ZK 222584']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Brain and Central Nervous System Tumors,"['Brain and Central Nervous System Tumors', 'Sarcoma']","['adult grade I meningioma', 'adult grade II meningioma', 'adult grade III meningioma', 'adult malignant hemangiopericytoma', 'adult anaplastic meningioma', 'adult papillary meningioma', 'adult melanocytic lesion', 'recurrent adult brain tumor']",COMPLETED,,2006-05,2013-07,"[{'measure': 'Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment.', 'description': 'Patients were assessed with imaging techniques (MRI) during screening/baseline and then every 2 months after starting treatment. Survival status and disease status were recorded. The number of patients who did not experience an event (defined as either death for any reason or progression of their disease) by 6 months after starting treatment were counted.', 'timeFrame': 'From the date the first patient began treatment until the date the last patient has disease progression, becomes deceased, or completes 6 months of treatment'}]","[{'measure': 'Determine Efficacy (Radiographic and Clinical Improvement)', 'description': 'Efficacy will be assessed by MRI scan and neurological exam upon study entry, every 2 weeks for 2 months, then every 8 weeks while on treatment', 'timeFrame': 'At baseline, every 2 weeks for 2 months, then every 8 weeks while on treatment'}, {'measure': 'Best Overall Response Rate (ORR)', 'description': 'Overall Response Rate (ORR) will be as assessed by MRI scan every 2 months while on study treatment and follow-up for up to 1 year after discontinuation of study treatment. The RR is the best response recorded from the start of the treatment until disease progression (PD) where the following definitions apply.\n\nComplete Response (CR): Complete disappearance of all measurable and evaluable disease. No new lesions.\n\nPartial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions.\n\nStable/No Response: Does not qualify for CR, PR, or PD Progressive disease (PD):25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) worsening of evaluable disease, new lesions, clinical worsening OR failure to return for evaluation due to death/deteriorating condition', 'timeFrame': 'Every 2 months for up to 1 year after study treatment.'}, {'measure': 'To Correlate the Response Rates With Expression of Certain Types of Genes', 'description': 'Correlation of response rates with the expression of certain types of genes will be assessed by examining tissue samples taken from previous surgery and testing for certain genes', 'timeFrame': 'At the end of study treatment'}, {'measure': 'Safety of Vatalanib in Patients With Recurrent of Progressive Meningiomas', 'description': 'Safety of vatalanib will be assessed using National Cancer Institute Common Terminology Criteria of Adverse Events (NCI CTCAE) 3.0 and graded using the following:\n\nGrade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Fatal', 'timeFrame': 'Every week while on study treatment until 30 days after last treatment.'}, {'measure': 'Number of Months Patients Survive After Being Treatment on the Study.', 'timeFrame': 'From the date the first patient began treatment until the date the last patient became deceased.'}, {'measure': 'Overall Survival (OS)', 'description': 'Overall Survival will be measured from the first treatment on study until death of any cause.', 'timeFrame': 'Every 2 months for up to 1 year after study treatment.'}]",7,18 Years,,ALL,False,Northwestern University,OTHER,1,25.0,ACTUAL,2025-09-01T16:18:18.416354,v2_robust,True,True,True,False,True,
NCT05388890,Treatment of Atrophic Gastritis After HP Eradication With Modified Liujunzi Decoction Based on Syndrome Differentiation,Clinical Study on the Efficacy of Modified Liujunzi Prescription on the Treatment of Atrophic Gastritis After HP Eradication,MLD,"['WFC', 'MLD']",2,OBSERVATIONAL,[],,,Chronic Atrophic Gastritis,['Chronic Atrophic Gastritis'],"['Chronic Atrophic Gastritis', 'Modified Liujunzi Decoction', 'Treatment Based on Syndrome Differentiation', 'Clinical Study', 'Efficacy', 'Cohort Study']",RECRUITING,,2022-08-02,2025-12-31,"[{'measure': 'Therapeutic effectiveness of gastric mucosal lesions', 'description': 'Referring to the CAG of the ""Guidelines for Clinical Research on New Chinese Medicines (2002)"", the effective treatment of gastric mucosal lesions is defined as ""the pathological score decreased by 1 point compared with the previous point"". The effective rate of gastric mucosal lesions treatment = the number of cases with a decrease of ≥ 1 point by the previous score / the total number of cases × 100%. The effective rate of gastric mucosal lesions from different category will be calculated: respectively for atrophy, chronic inflammation, activity, intestinal metaplasia, and intraepithelial neoplasia .', 'timeFrame': 'Half a year,a year'}]","[{'measure': 'The efficacy of OLGA,OLGIM', 'description': 'The efficacy of OLGA staging: OLGA staging decreased by ≥1 stage compared with the baseline is considered as effecacy.The effective rate = the number of cases with ≥1 stage decreased compared with the previous stage/the total number of cases × 100%.\n\nThe efficacy of OLGIM staging:The OLGIM staging decreased by ≥1 stage from the baseline is considered effective for patients with intestinal metaplasia. The effective rate = the number of cases staging decreased by ≥ 1 stage compared with the previous stage /the total number of cases × 100%', 'timeFrame': 'Half a year,a year'}, {'measure': 'Changes in clinical symptom scores', 'description': 'Evaluate referring to the symptom grading and quantification standard of ""Guidelines for Clinical Research on Chronic Atrophic Gastritis"" from ""Guidelines for Clinical Research on New Chinese Medicines (2002)"".According to the clinical symptom severity assign different points. No, mild, moderate and severe symptoms are recorded as 0, 1, 2, and 3 point respectively. Record the changes of the symptom score at 6 months and 12 months compared with the baseline and evaluate . The calculation formula is "" the total score after treatment-the score in baseline "".', 'timeFrame': 'The third month,half a year ,the ninth month,a year.'}, {'measure': 'The recurrence of HP', 'description': '13C-UBT was performed to determine HP, and the DOB value more than 4 is defined as the recurrence of HP.', 'timeFrame': 'Half a year,a year'}]",4,18 Years,70 Years,ALL,False,Peking University First Hospital,OTHER,0,286.0,ESTIMATED,2025-09-01T16:18:18.416386,v2_robust,False,True,False,False,False,
NCT04445090,A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1569912 in Healthy Male Subjects (Single-blind, Partially Randomized Within Dose Groups, Placebo-controlled, Parallel-group Design) With an Additional Relative Bioavailability/ Food Effect Part (Open-label, Randomized, Three-way Crossover Design)",BI 1569912,"['BI 1569912', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],TERMINATED,Identification of potential mutagenic metabolite in human plasma,2020-07-21,2021-09-10,"[{'measure': 'SRD-part: % of subjects with drug-related adverse events', 'timeFrame': 'up to 14 days'}, {'measure': 'BA/FE-part: AUC0-tz (area under the concentration-time curve of BI 1569912 in plasma over the time interval from 0 to the last quantifiable data point)', 'timeFrame': 'up to 4 days'}, {'measure': 'BA/FE-part: Cmax (maximum measured concentration of BI 1569912 in plasma)', 'timeFrame': 'up to 4 days'}]","[{'measure': 'SRD-Part: AUC0-∞ (area under the concentration-time curve of BI 1569912 in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': 'up to 4 days'}, {'measure': 'SRD-Part: Cmax (maximum measured concentration of BI 1569912 in plasma)', 'timeFrame': 'up to 4 days'}, {'measure': 'BA/FE-Part: AUC0-∞ (area under the concentration-time curve of BI 1569912 in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': 'up to 4 days'}]",6,18 Years,45 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,68.0,ACTUAL,2025-09-01T16:18:18.416426,v2_robust,True,True,False,True,True,Identification of potential mutagenic metabolite in human plasma
NCT07047690,A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis,"A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nemolizumab in Adult Patients With Systemic Sclerosis",Nemolizumab,"['CD14152', 'Nemolizumab', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Systemic Sclerosis,['Systemic Sclerosis'],"['Limited Cutaneous Systemic Sclerosis', 'Diffuse Cutaneous Systemic Sclerosis', 'Interstitial Lung Disease']",NOT_YET_RECRUITING,,2025-08-29,2027-10-29,"[{'measure': 'Change From Baseline (BL) in Modified Rodnan Skin Score (mRSS) at Week 52', 'description': 'mRSS is the assessment of skin involvement includes semiquantitative estimation of skin thickness, pliability (hardness), and fixation to underlying structures (tethering).Cutaneous thickness is assessed in 17 body surface areas using a 0-3 scale, where mRSS of score 0=""normal"" with fine wrinkles but no skin thickness; score 1=""mild"" skin thickness; score 2= ""moderate"" skin thickness with difficulty in making skin folds and no wrinkles; and score 3=""severe"" skin thickness with inability to make skin folds between 2 examining fingers. Where higher score indicating more severe disease.', 'timeFrame': 'Baseline, at Week 52'}]","[{'measure': 'Change From Baseline in Forced Vital Capacity (FVC) at Week 52', 'description': 'FVC will be assessed with the Flow screen spirometer.', 'timeFrame': 'Baseline, at Week 52'}, {'measure': 'Proportion of Responders to the Treatment Based on the Revised Composite Response Index in Systemic Sclerosis (rCRISS) at Week 52', 'description': ""Responders are defined as participants who meet all the following criteria: Improvement in 2 out of the 5 rCRISS components \\>=5% absolute increase from BL in ppFVC (percent predicted forced vital capacity), \\>=25% relative decrease from BL in mRSS, Health Assessment Questionnaire Disability Index (HAQ-DI), PGA (Patient's Global Assessment), CGA(Clinician/Physician's Global Assessment) score. Worsening in no more than 1 rCRISS component \\>=5% absolute decrease from BL in ppFVC, \\>=25% relative increase from BL in mRSS, HAQ-DI, PGA, CGA score. No significant SSc-related event."", 'timeFrame': 'At Week 52'}, {'measure': 'Change From Baseline in mRSS at Weeks 8, 12, 24, 28, 36, 44, 52', 'description': 'mRSS is the assessment of skin involvement includes semiquantitative estimation of skin thickness, pliability (hardness), and fixation to underlying structures (tethering).Cutaneous thickness is assessed in 17 body surface areas using a 0-3 scale, where mRSS of score 0=""normal"" with fine wrinkles but no skin thickness; score 1=""mild"" skin thickness; score 2= ""moderate"" skin thickness with difficulty in making skin folds and no wrinkles; and score 3=""severe"" skin thickness with inability to make skin folds between 2 examining fingers. Where higher score indicating more severe disease.', 'timeFrame': 'Baseline, at Week 8, 12, 24, 28, 36, 44, 52'}, {'measure': 'Percent change from Baseline in mRSS at Week 52', 'description': 'mRSS is the assessment of skin involvement includes semiquantitative estimation of skin thickness, pliability (hardness), and fixation to underlying structures (tethering).Cutaneous thickness is assessed in 17 body surface areas using a 0-3 scale, where mRSS of score 0=""normal"" with fine wrinkles but no skin thickness; score 1=""mild"" skin thickness; score 2= ""moderate"" skin thickness with difficulty in making skin folds and no wrinkles; and score 3=""severe"" skin thickness with inability to make skin folds between 2 examining fingers. Where higher score indicating more severe disease.', 'timeFrame': 'Baseline, at Week 52'}, {'measure': 'Change from Baseline in Percent Predicted FVC (ppFVC) at Week 52', 'description': 'FVC will be assessed with the Flow screen spirometer.', 'timeFrame': 'Baseline, at Week 52'}, {'measure': 'Percent Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52', 'description': 'HAQ-DI is a participant-reported questionnaire and sensitive to change in disease activity (cutaneous and visceral involvement and with changes in physiological parameters over time).Each question is rated on a 0 to 3 scale (0 = without difficulty; 3 = unable to do), and additional points can be added if aids or devices (i.e., cane, walker) are needed for specific activities. An increased score indicated worse functionality.', 'timeFrame': 'Baseline, at Week 52'}, {'measure': ""Percent Change From Baseline in Patient's Global Assessment (PGA) Score at Week 52"", 'description': ""The participant's global impression of health Numeric Rating Scale 0-10 (NRS) will be self-administered by the participant. 0 represents excellent and 10 represents extremely poor."", 'timeFrame': 'Baseline, at Week 52'}, {'measure': ""Percent Change From Baseline in Clinician's Global Assessment (CGA) Score at Week 52"", 'description': ""The clinician global impression of health Numeric Rating Scale 0-10 (NRS) will be filled out by the participant's clinician after all other study procedures have been completed. 0 represents excellent and 10 represents extremely poor."", 'timeFrame': 'Baseline, at Week 52'}, {'measure': 'Incidence and Severity of TEAEs, Treatment-Emergent SAEs, Treatment-Emergent AEs of Special Interest (AESIs), Significant SSc-Related TEAEs, TEAEs Leading to Investigational Product Discontinuation and Study Discontinuation.', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A Serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: Results in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, Other serious (important medical events).', 'timeFrame': 'From baseline of study intervention to 12 weeks after last dose (52 weeks)'}, {'measure': 'Incidence of Abnormal Vital Signs', 'description': 'Change from BL in pulse rate, blood pressure, respiration rate, and body temperature will be assessed by visit and treatment group including participants with treatment emergent changes.', 'timeFrame': 'From baseline of study intervention to 12 weeks after last dose (52 weeks)'}, {'measure': 'Incidence of Abnormal Laboratory Parameters', 'description': 'Change from BL in hematology, clinical chemistry, and lipid variables will be assessed by visit and treatment group including participants with treatment-emergent changes.', 'timeFrame': 'From baseline of study intervention to 12 weeks after last dose (52 weeks)'}, {'measure': 'Incidence of Abnormal Electrocardiogram (ECG) Findings', 'description': 'Observed values of heart rate, QRS duration, PR interval, RR interval and QT interval will be summarized by visit and treatment group including participants with clinically significant abnormal results.', 'timeFrame': 'From baseline of study intervention to 12 weeks after last dose (52 weeks)'}, {'measure': 'Incidence of Abnormal Weight Change', 'description': 'Change from BL in weight (kilograms) will be assessed by visit and treatment and medically significant changes will be recorded as adverse events.', 'timeFrame': 'From baseline of study intervention to 12 weeks after last dose (52 weeks)'}]",14,18 Years,,ALL,False,Galderma R&D,INDUSTRY,0,162.0,ESTIMATED,2025-09-01T16:18:18.416440,v2_robust,True,True,False,False,True,
NCT05234190,Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients,"A Single-arm, Open-label, Multi-center, Phase I/II Study Evaluating the Safety and Clinical Activity of QEL-001, an Autologous CAR T Regulatory Cell Treatment Targeting HLA-A2, in HLA-A2/ A28neg Patients That Have Received an HLA-A2pos Liver Transplant.",QEL-001,"['HLA-A2 CAR-Treg', 'QEL-001']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Rejection; Transplant, Liver","['Rejection; Transplant, Liver', 'Liver Failure', 'Liver Diseases']","['Regulatory T cells', 'Chimeric Antigen Receptor', 'Autologous', 'Genetically modified cells']",RECRUITING,,2022-01-21,2040-03,"[{'measure': 'Safety and Tolerability', 'description': 'Incidence of protocol defined Dose Limiting Toxicities (DLTs).', 'timeFrame': '28 Days post infusion'}, {'measure': 'Long-term safety', 'description': 'Incidence and grade of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) according to CTCAE V5.0.', 'timeFrame': 'Day of infusion through to Week 82 and up to 15 years post infusion'}]","[{'measure': 'Immunosuppression related outcome', 'description': 'Ability to withdraw immunosuppression (IS) as measured by the percentage of subjects who have stable Liver Function Tests and are IS free at two months and at one year following IS withdrawal.', 'timeFrame': '2 months and 1 year post withdrawal of immune suppression'}, {'measure': 'Tolerance related outcome', 'description': 'Ability to achieve operational tolerance as measured by the proportion of subjects meeting the clinical, biochemical and histological operational tolerance criteria at one year following IS withdrawal.', 'timeFrame': '1 year following immune suppression withdrawal'}, {'measure': 'Composite efficacy failure outcome', 'description': 'Proportion of subjects with composite event: acute rejection (AR), biopsy proven acute rejection (BPAR), reintroduction of IS or graft loss.', 'timeFrame': '1 year following immune suppression withdrawal'}]",5,18 Years,75 Years,ALL,False,Quell Therapeutics Limited,INDUSTRY,0,33.0,ESTIMATED,2025-09-01T16:18:18.416492,v2_robust,True,True,False,False,True,
NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,"A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors",levofloxacin,['levofloxacin'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Brain and Central Nervous System Tumors,"['Brain and Central Nervous System Tumors', 'Breast Cancer', 'Extragonadal Germ Cell Tumor', 'Infection', 'Lung Cancer', 'Lymphoma', 'Ovarian Cancer', 'Small Intestine Cancer', 'Testicular Germ Cell Tumor', 'Unspecified Adult Solid Tumor, Protocol Specific']","['stage I adult Hodgkin lymphoma', 'stage II adult Hodgkin lymphoma', 'stage III adult Hodgkin lymphoma', 'stage IV adult Hodgkin lymphoma', 'recurrent breast cancer', 'recurrent adult Hodgkin lymphoma', 'stage I cutaneous T-cell non-Hodgkin lymphoma', 'stage II cutaneous T-cell non-Hodgkin lymphoma', 'stage III cutaneous T-cell non-Hodgkin lymphoma', 'stage IV cutaneous T-cell non-Hodgkin lymphoma', 'recurrent cutaneous T-cell non-Hodgkin lymphoma', 'limited stage small cell lung cancer', 'extensive stage small cell lung cancer', 'recurrent small cell lung cancer', 'small intestine lymphoma', 'stage II malignant testicular germ cell tumor', 'stage III malignant testicular germ cell tumor', 'unspecified adult solid tumor, protocol specific', 'stage I grade 2 follicular lymphoma', 'stage I grade 3 follicular lymphoma', 'stage I adult diffuse small cleaved cell lymphoma', 'stage I adult diffuse mixed cell lymphoma', 'stage I adult diffuse large cell lymphoma', 'stage I adult immunoblastic large cell lymphoma', 'stage I adult lymphoblastic lymphoma', 'stage I adult Burkitt lymphoma', 'stage II ovarian germ cell tumor', 'stage III ovarian germ cell tumor', 'stage IV ovarian germ cell tumor', 'stage III grade 1 follicular lymphoma', 'stage III grade 2 follicular lymphoma', 'stage III grade 3 follicular lymphoma', 'stage III adult diffuse small cleaved cell lymphoma', 'stage III adult diffuse mixed cell lymphoma', 'stage III adult diffuse large cell lymphoma', 'stage III adult immunoblastic large cell lymphoma', 'stage III adult lymphoblastic lymphoma', 'stage III adult Burkitt lymphoma', 'stage IV grade 1 follicular lymphoma', 'stage IV grade 2 follicular lymphoma', 'stage IV grade 3 follicular lymphoma', 'stage IV adult diffuse small cleaved cell lymphoma', 'stage IV adult diffuse mixed cell lymphoma', 'stage IV adult diffuse large cell lymphoma', 'stage IV adult immunoblastic large cell lymphoma', 'stage IV adult lymphoblastic lymphoma', 'stage IV adult Burkitt lymphoma', 'recurrent grade 1 follicular lymphoma', 'recurrent grade 2 follicular lymphoma', 'recurrent grade 3 follicular lymphoma', 'recurrent adult diffuse small cleaved cell lymphoma', 'recurrent adult diffuse mixed cell lymphoma', 'recurrent adult diffuse large cell lymphoma', 'recurrent adult immunoblastic large cell lymphoma', 'recurrent adult lymphoblastic lymphoma', 'recurrent adult Burkitt lymphoma', 'stage I adult T-cell leukemia/lymphoma', 'stage II adult T-cell leukemia/lymphoma', 'stage III adult T-cell leukemia/lymphoma', 'stage IV adult T-cell leukemia/lymphoma', 'recurrent adult T-cell leukemia/lymphoma', 'extragonadal germ cell tumor', 'adult central nervous system germ cell tumor', 'primary central nervous system non-Hodgkin lymphoma', 'infection', 'intraocular lymphoma', 'stage I mantle cell lymphoma', 'contiguous stage II grade 1 follicular lymphoma', 'contiguous stage II grade 2 follicular lymphoma', 'contiguous stage II grade 3 follicular lymphoma', 'contiguous stage II adult diffuse small cleaved cell lymphoma', 'contiguous stage II mantle cell lymphoma', 'contiguous stage II adult diffuse mixed cell lymphoma', 'contiguous stage II adult immunoblastic large cell lymphoma', 'contiguous stage II adult diffuse large cell lymphoma', 'contiguous stage II adult Burkitt lymphoma', 'contiguous stage II adult lymphoblastic lymphoma', 'noncontiguous stage II grade 1 follicular lymphoma', 'noncontiguous stage II grade 2 follicular lymphoma', 'noncontiguous stage II grade 3 follicular lymphoma', 'noncontiguous stage II adult diffuse small cleaved cell lymphoma', 'noncontiguous stage II mantle cell lymphoma', 'noncontiguous stage II adult diffuse mixed cell lymphoma', 'noncontiguous stage II adult immunoblastic large cell lymphoma', 'noncontiguous stage II adult diffuse large cell lymphoma', 'noncontiguous stage II adult Burkitt lymphoma', 'noncontiguous stage II adult lymphoblastic lymphoma', 'stage III mantle cell lymphoma', 'stage IV mantle cell lymphoma', 'recurrent mantle cell lymphoma', 'angioimmunoblastic T-cell lymphoma', 'anaplastic large cell lymphoma', 'stage I mycosis fungoides/Sezary syndrome', 'stage II mycosis fungoides/Sezary syndrome', 'stage III mycosis fungoides/Sezary syndrome', 'stage IV mycosis fungoides/Sezary syndrome', 'recurrent mycosis fungoides/Sezary syndrome', 'contiguous stage II marginal zone lymphoma', 'contiguous stage II small lymphocytic lymphoma', 'noncontiguous stage II small lymphocytic lymphoma', 'noncontiguous stage II marginal zone lymphoma', 'recurrent marginal zone lymphoma', 'recurrent small lymphocytic lymphoma', 'stage I marginal zone lymphoma', 'stage I small lymphocytic lymphoma', 'stage II small lymphocytic lymphoma', 'stage II marginal zone lymphoma', 'stage III small lymphocytic lymphoma', 'stage III marginal zone lymphoma', 'stage IV small lymphocytic lymphoma', 'stage IV marginal zone lymphoma', 'extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue', 'nodal marginal zone B-cell lymphoma', 'splenic marginal zone lymphoma']",COMPLETED,,1999-08,2005-09,[],[],0,16 Years,,ALL,False,Cancer Research Campaign Clinical Trials Centre,OTHER,0,,,2025-09-01T16:18:18.416545,v2_robust,True,True,True,False,False,
NCT05622890,"A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer","A Single-arm, Phase III Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Advanced High-grade Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer With High Expression of Folate Receptor-α",Mirvetuximab Soravtansine,"['MIRV', 'Mirvetuximab Soravtansine', 'IMGN853']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Epithelial Ovarian Cancer,"['Epithelial Ovarian Cancer', 'Peritoneal Cancer', 'Fallopian Tube Cancer']","['Platinum resistant', 'Folate-receptor alpha expression', 'Phase 3', 'Antibody-drug conjugate', 'mirvetuximab soravtansine', 'IMGN853', 'Epithelial Ovarian Cancer', 'Peritoneal Cancer', 'Fallopian Tube Cancer', 'MIRV', 'FRα']",UNKNOWN,,2022-08-18,2023-12-31,"[{'measure': 'Objective Response Rate (ORR)', 'description': 'Objective response rate (ORR), which includes best response of complete response (CR) or partial response (PR) as assessed by the BIRC.', 'timeFrame': 'Up to 2 years'}]","[{'measure': 'Duration of response (DOR)', 'description': 'The time interval from initial response (CR or PR) assessed by the investigator and the BIRC to progressive disease (PD) assessed by the BIRC', 'timeFrame': 'Up to 2 years'}, {'measure': 'ORR assessed by the investigator', 'description': 'The best response of CR or PR assessed by the investigator.', 'timeFrame': 'Up to 2 years'}, {'measure': 'DOR assessed by the investigator', 'description': 'The time interval from initial response (CR or PR) assessed by the investigator to PD assessed by the investigator', 'timeFrame': 'Up to 2 years'}, {'measure': 'Treatment-emergent adverse events (TEAEs) and Laboratory results,physical examinations, or vital signs', 'description': ""Adverse Events (AE's) will be evaluated according to the NCI CTCAE v5.0. AE's will be coded using the latest Medical Dictionary for Regulatory Activities (MedDRA) version and summarized per system organ class (SOC) and preferred term (PT)."", 'timeFrame': 'Up to 2 years'}, {'measure': 'Determination of CA-125 response with GCIG criteria', 'description': 'GCIG CA-125 response rate will be calculated using the CA-125 Response-Evaluable population and its exact 95% CI will be estimated using the Clopper-Pearson method.', 'timeFrame': 'Up to 2 years'}, {'measure': 'PFS assessed by the BIRC', 'description': 'The time interval from the first dose of IMGN853 to radiographic PD or death assessed by the BIRC, whichever occurs first.', 'timeFrame': 'Up to 2 years'}, {'measure': 'PFS assessed by the investigator', 'description': 'The time interval from the first dose of IMGN853 to radiographic PD or death assessed by the investigator, whichever occurs first.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival (OS)', 'description': 'The time interval from the first dose of IMGN853 to death', 'timeFrame': 'Up to 2 years'}, {'measure': 'Summary statistics of intact ADC, total Ab (TAb), DM4 and S-methyl DM4 concentration data over time', 'description': 'To assess the PK properties of IMGN853 and its key metabolites', 'timeFrame': 'Up to 2 years'}, {'measure': 'Incidence of seroconversion of ADA caused by IMGN853 and its relationship to safety and efficacy', 'description': 'Subjects will be evaluated for anti-drug antibody (ADA) levels. Confirmatory experiments will be conducted for positive samples. ADA titers and neutralizing antibodies (Nabs) will be further determined as appropriate after the confirmation of positivity.', 'timeFrame': 'Up to 2 years'}]",11,18 Years,,FEMALE,False,"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",INDUSTRY,0,35.0,ESTIMATED,2025-09-01T16:18:18.416590,v2_robust,True,True,False,False,True,
NCT06713590,A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants,"A Phase 1, Open-Label, Randomized Study of Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants",Axatilimab,['Axatilimab'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Participants,['Healthy Participants'],"['INCA34176', 'Axatilimab']",COMPLETED,,2025-01-14,2025-06-10,"[{'measure': 'Pharmacokinetics Parameter: Cmax of axatilimab', 'description': 'Maximum Observed Plasma Concentration of axatilimab.', 'timeFrame': 'Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60'}, {'measure': 'Pharmacokinetics Parameter: AUC(0-t) of axatilimab', 'description': 'Area Under the concentration- time curve up to the last measurable concentration of axatilimab.', 'timeFrame': 'Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60'}, {'measure': 'Pharmacokinetics Parameter: AUC 0-∞ of axatilimab', 'description': 'Area Under the Concentration-time Curve From 0 to Infinity of axatilimab.', 'timeFrame': 'Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60'}, {'measure': ""Number of participants with Treatment Emergent Advers Events (TEAE's)"", 'description': 'Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.', 'timeFrame': 'Up to 3 months'}]","[{'measure': 'ADA', 'description': 'Percent of patients with anti-drug antibody (ADA).', 'timeFrame': 'Pre dose on Day 1, Post dose Days 8, 15, 22, 28 and 60'}, {'measure': 'Pharmacokinetics Parameter: Tmax of axatilimab', 'description': 'Time to reach maximum plasma concentration of axatilimab.', 'timeFrame': 'Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60'}, {'measure': 'Pharmacokinetics Parameter: t1/2 of axatilima', 'description': 'Apparent terminal phase disposition half-life of axatilimab.', 'timeFrame': 'Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60'}, {'measure': 'Pharmacokinetics Parameter: CL (or CL/F) of axatilimab', 'description': 'Dose clearance of axatilimab.', 'timeFrame': 'Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60'}, {'measure': 'Pharmacokinetics Parameter: Vz (or Vz/F) of axatilimab', 'description': 'Volume of distribution of axatilimab.', 'timeFrame': 'Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60'}]",9,18 Years,55 Years,ALL,True,Incyte Corporation,INDUSTRY,0,72.0,ACTUAL,2025-09-01T16:18:18.416718,v2_robust,True,True,True,False,True,
NCT03384290,Study of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects,"A Dose Escalating Single Blind Study to Assess the Safety, Tolerability and Pharmacokinetics of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects",PRS-060,"['PRS-060', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Subjects,['Healthy Subjects'],"['Asthma', 'Anticalin', 'PRS-060', 'Healthy Volunteers', 'Pieris', 'IL-4 receptor alpha', 'IL-13', 'IL-4']",COMPLETED,,2017-12-08,2018-10-11,"[{'measure': 'Number of participants with Adverse Events (AEs) after a single inhaled or IV infusion dose of PRS-060.', 'description': 'The number of participants with treatment related AEs as assessed by CTCAE v4.0. Subjects will be monitored for AEs during study participation (beginning at the time study drug is first administered) until 30 days after dosing.', 'timeFrame': 'From time of dose until 30 days after dosing.'}, {'measure': 'Change in blood pressure.', 'description': 'To assess blood pressure (systolic and diastolic) as a criterion of safety and tolerability variables.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in heart rate.', 'description': 'To assess changes in beats per minute (BPM) as a criterion of safety and tolerability variables.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in body temperature.', 'description': 'To assess changes in body temperature as a criterion of safety and tolerability variables as measure in degrees Celsius.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in electrocardiograms (ECGs).', 'description': 'To assess changes in cardiovascular system function (change in QTC parameters) as a criterion of safety and tolerability variables.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in FEV1 (Forced expiratory volume 1-second)', 'description': 'To assess changes in FEV1 (Forced expiratory volume 1-second) as measured in L.', 'timeFrame': 'Pre-dose and post-dose at 5,10, 20 minutes,1 and 4 hours'}, {'measure': 'Change in FEV6 (Forced expiratory volume 6-seconds)', 'description': 'To assess changes in FEV6 (Forced expiratory volume 6-seconds) as measured in L.', 'timeFrame': 'Pre-dose and post-dose at 5, 10, 20 minutes,1 and 4 hours'}, {'measure': 'Change in peak expiratory flow rate (PEFR)', 'description': 'To assess changes in PEFR (Peak expiratory flow rate) as measured in L/s.', 'timeFrame': 'Pre-dose and post-dose at 5, 10, 20 minutes,1 and 4 hours'}, {'measure': 'Change in forced vital capacity (FVC)', 'description': 'To assess changes in FVC (Forced vital capacity) as measured by a percentage (%) predicted.', 'timeFrame': 'Pre-dose and post-dose at 5, 10, 20 minutes,1 and 4 hours'}, {'measure': 'Change in sodium levels as part of standard serum chemistry panel.', 'description': 'To assess changes in sodium levels as measured in mmol/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in potassium levels as part of standard serum chemistry panel.', 'description': 'To assess changes in potassium levels as measured in mmol/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in chloride levels as part of standard serum chemistry panel.', 'description': 'To assess changes in chloride levels as measured in mmol/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in bicarbonate levels as part of standard serum chemistry panel.', 'description': 'To assess changes in bicarbonate levels as measured in mmol/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in blood urea nitrogen (BUN) / Urea levels as part of standard serum chemistry panel.', 'description': 'To assess changes in BUN/Urea levels as measured in mmol/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in creatinine levels as part of standard serum chemistry panel.', 'description': 'To assess changes in creatinine levels as measured in umol/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total protein levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total protein levels as measured in g/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Changes in total albumin levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total albumin levels as measured in g/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total ALP levels as part of standard serum chemistry panel.', 'description': 'To assess changes in ALP levels as measured in U/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total ALT levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total ALT levels as measured in U/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total AST levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total AST levels as measured in U/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total bilirubin levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total bilirubin levels as measured in umol/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total indirect bilirubin levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total indirect bilirubin levels as measured in umol/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total amylase levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total amylase levels as measured in U/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total lipase levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total lipase levels as measured in U/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total uric acid levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total uric acid levels as measured in mmol/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total creatine kinase (CK) levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total CK levels as measured in U/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total calcium levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total calcium levels as measured in mmol/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total magnesium levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total magnesium levels as measured in mmol/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total lactate dehydrogenase (LDH) levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total LDH levels as measured in U/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total immunoglobulin (IgG) levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total IgG levels as measured in g/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total immunoglobulin (IgA) levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total IgA levels as measured in g/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Changes in total immunoglobulin (IgE) levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total IgE levels as measured in g/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in total immunoglobulin (IgM) levels as part of standard serum chemistry panel.', 'description': 'To assess changes in total IgM levels as measured in g/L.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in hematocrit as part of standard hematology panel.', 'description': 'To assess changes in total hematocrit levels as measured by %.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in red blood cell (RBC) counts as part of standard hematology panel.', 'description': 'To assess changes in total red blood cell (RBC) counts as measured by 10\\^6/uL.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in platelet (PLT) counts as part of standard hematology panel.', 'description': 'To assess changes in platelet counts as measured by 10\\^9/uL.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in white blood cell (WBC) counts as part of standard hematology panel.', 'description': 'To assess changes in white blood cell (WBC) counts as measured by 10\\^3/uL.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in neutrophil percentage as part of standard hematology panel.', 'description': 'To assess changes in neutrophil percentage as measured by %.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in lymphocyte percentage as part of standard hematology panel.', 'description': 'To assess changes in lymphocyte percentage as measured by %.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in eosinophil percentage as part of standard hematology panel.', 'description': 'To assess changes in eosinophil percentage as measured by %.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in basophil percentage as part of standard hematology panel.', 'description': 'To assess changes in basophil percentage as measured by %.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in monocyte percentage as part of standard hematology panel.', 'description': 'To assess changes in monocyte percentage as measured by %.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in clarity as part of a standard urinalysis panel.', 'description': 'To assess changes in clarity of the urine sample.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in specific gravity as part of a standard urinalysis panel.', 'description': 'To assess changes in specific gravity of the urine sample.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in pH as part of a standard urinalysis panel.', 'description': 'To assess changes in pH of the urine sample.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in protein levels as part of a standard urinalysis panel.', 'description': 'To assess changes in protein levels of the urine sample.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in glucose levels as part of a standard urinalysis panel.', 'description': 'To assess changes in glucose levels of the urine sample as measured by a positive or negative result.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in ketone levels as part of a standard urinalysis panel.', 'description': 'To assess changes in ketone levels of the urine sample as measured by a positive or negative result.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in blood levels as part of a standard urinalysis panel.', 'description': 'To assess changes in blood levels of the urine sample as measured by a positive or negative result.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in nitrite levels as part of a standard urinalysis panel.', 'description': 'To assess changes in nitrite levels of the urine sample.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}, {'measure': 'Change in leukocyte esterase levels as part of a standard urinalysis panel.', 'description': 'To assess changes in leukocyte esterase levels of the urine sample.', 'timeFrame': 'Screening, day 1, day 2, day 3 and 30 days after dosing.'}]","[{'measure': 'PK assessment: Cmax (observed maximum serum concentration taken directly from the individual concentration-time curve)', 'description': 'Evaluation of the PK of a single inhaled or IV infusion dose of PRS-060', 'timeFrame': 'Pre-dose and post-dose at 5, 10, 20 minutes,1 and 4 hours'}, {'measure': 'PK assessment Tmax (Time to reach maximum serum concentration, taken directly from the individual concentration-time curve)', 'description': 'Evaluation of the PK of a single inhaled or IV infusion dose of PRS-060', 'timeFrame': 'Pre-dose and post-dose at 5, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 8,12,15,18, 36 and 48 hours and at 30 days)'}, {'measure': 'PK assessment: t1/2 (Terminal half-life)', 'description': 'Evaluation of the PK of a single inhaled or IV infusion dose of PRS-060', 'timeFrame': 'Pre-dose and post-dose at 5, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 8,12,15,18, 36 and 48 hours and at 30 days'}, {'measure': 'PK assessment: AUC(0-last) (Area under the serum concentration-curve from time zero to the time of last quantifiable analyte concentration)', 'description': 'Evaluation of the PK of a single inhaled or IV infusion dose of PRS-060', 'timeFrame': 'Pre-dose and post-dose at 5, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 8,12,15,18, 36 and 48 hours and at 30 days'}, {'measure': 'PK assessment: AUC (Area under the concentration-time curve in the serum zero (pre-dose) extrapolated to infinite time)', 'description': 'Evaluation of the PK of a single inhaled or IV infusion dose of PRS-060', 'timeFrame': 'Pre-dose and post-dose at 5, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 8,12,15,18, 36 and 48 hours and at 30 days'}, {'measure': 'PK assessment: AUC(0-24) (Area under the plasma concentration-curve)', 'description': 'Evaluation of the PK of a single inhaled or IV infusion dose of PRS-060', 'timeFrame': 'Pre-dose and post-dose at 5, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 8,12,15,18, 36 and 48 hours and at 30 days'}, {'measure': 'PK assessment: Vz/F (Apparent volume of distribution during terminal phase)', 'description': 'Evaluation of the PK of a single inhaled or IV infusion dose of PRS-060', 'timeFrame': 'Pre-dose and post-dose at 5, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 8,12,15,18, 36 and 48 hours and at 30 days'}, {'measure': 'PK assessment: CL/F (Apparent oral clearance estimated as dose divided by AUC)', 'description': 'Evaluation of the PK of a single inhaled or IV infusion dose of PRS-060', 'timeFrame': 'Pre-dose and post-dose at 5, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 8,12,15,18, 36 and 48 hours and at 30 days'}, {'measure': 'PK assessment of urine', 'description': 'Evaluation of PRS-060 levels in the urine after a single inhaled or IV infusion dose of PRS-060', 'timeFrame': 'Pre-dose and continuously during the following time-intervals: 0-4, 4-8, 8-12, 12-18, 18-24, 24-30, 30-36, 36-42 and 42-48 hours'}]",60,18 Years,55 Years,ALL,True,Pieris Australia Pty Ltd,INDUSTRY,0,72.0,ACTUAL,2025-09-01T16:18:18.416739,v2_robust,True,True,True,False,True,
NCT00806897,Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®,"Prospective, Multicentre, Open Label, Non-controlled, 24-week Observation in Type 2 Diabetics Using Once Daily Levemir® (Insulin Detemir) as Part of Their ITT Regimen",insulin detemir,"['insulin detemir', 'NN304', 'Levemir®']",3,OBSERVATIONAL,[],,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],COMPLETED,,2009-01,2009-12,"[{'measure': 'Change in HbA1c from baseline', 'timeFrame': 'at 24 weeks'}]","[{'measure': 'Change in body weight', 'timeFrame': 'at 12 weeks/24weeks'}]",2,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,74.0,ACTUAL,2025-09-01T16:18:18.416750,v2_robust,False,True,True,False,False,
NCT01527097,Influence of Atorvastatin on Psoriasis Severity and Endothelial Function,"Atorvastatin to Reduce Psoriasis Severity and Improve Endothelial Function in Patients With Severe Psoriasis and Non-Elevated LDL Levels: A Randomized, Double Blind, Placebo-Controlled Study.",Atorvastatin,"['Atorvastatin', 'Atorvastatin placebo', 'Lipitor']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Psoriasis,['Psoriasis'],"['Cardiovascular Diseases', 'Pharmacologic Actions', 'Endothelial Function', 'Dermatology', 'Inflammatory Disease', 'Skin Disease']",WITHDRAWN,We strongly feel that the ability to recruit the required number of patients is very low and thus decided to stop the study.,2012-08,2015-04,"[{'measure': 'The primary efficacy outcome variable of the study is defined as the composite endpoint of improving of psoriatic severity and endothelial function (assessed by FMD changes).', 'description': 'Patient invited to clinic visits at 3,6 and 12 month follow up.At this visits in addition primary outcome will be measured.', 'timeFrame': '3,6 and 12 months after randomization.'}]",[],1,20 Years,,ALL,False,shmuel fuchs,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:18.416781,v2_robust,True,True,False,True,False,We strongly feel that the ability to recruit the required number of patients is very low and thus decided to stop the study.
NCT05514197,The Impact of Intravenous Vitamin C Combined With Nerve Blocks on Postoperative Pain and Recovery After Total Knee Arthroplasty,The Impact of Intravenous Vitamin C Combined With Nerve Blocks on Postoperative Pain and Recovery After Total Knee Arthroplasty.,Ascorbic acid 5000mg,"['Ascorbic acid 5000mg', 'Control Rx']",2,INTERVENTIONAL,['NA'],,,Ascorbic Acid,"['Ascorbic Acid', 'Postoperative Pain']","['Ascorbic Acid', 'Total knee arthroplasty', 'Regional analgesia']",COMPLETED,,2022-06-01,2023-12-07,"[{'measure': 'Visual analogue scale for pain', 'description': 'Marking on a continuous 10 centimeter line from 0 to 10, representing no pain to worst pain', 'timeFrame': '15 minutes postoperatively'}, {'measure': 'Visual analogue scale for pain', 'description': 'Marking on a continuous 10 centimeter line from 0 to 10, representing no pain to worst pain', 'timeFrame': 'first hour postoperatively'}, {'measure': 'Visual analogue scale for pain', 'description': 'Marking on a continuous 10 centimeter line from 0 to 10, representing no pain to worst pain', 'timeFrame': '6th hour postoperatively'}, {'measure': 'Visual analogue scale for pain', 'description': 'Marking on a continuous 10 centimeter line from 0 to 10, representing no pain to worst pain', 'timeFrame': '24th hour postoperatively'}, {'measure': 'Visual analogue scale for pain', 'description': 'Marking on a continuous 10 centimeter line from 0 to 10, representing no pain to worst pain', 'timeFrame': '48th hour postoperatively'}]","[{'measure': 'Visual analogue scale for sngcetion', 'description': 'Marking on a continuous 10 centimeter line from 0 to 10, representing no sore to worst sore', 'timeFrame': '48 hours postoperatively'}, {'measure': 'Morphine consumption', 'description': 'Amount of IM morphine consumption in the first 24 hours postoperatively', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Time to first rescue morphine requirement at post-anesthetic care unit', 'description': 'Duration from arriving post-anesthetic care unit to requiring first morphine injection', 'timeFrame': 'up to 2 hours'}, {'measure': 'Severity of postoperative nausea/ vomiting and dizziness', 'description': 'From 0 to 5, 0: non, 1: mild, 2: moderate, 3: severe, 4: unbearable', 'timeFrame': '48 hours postoperatively'}]",9,50 Years,80 Years,ALL,False,Chimei Medical Center,OTHER,0,73.0,ACTUAL,2025-09-01T16:18:18.416790,v2_robust,True,True,True,False,False,
NCT01313897,"UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma","UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma",Bortezomib,"['Bortezomib', 'Velcade']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,['Multiple Myeloma'],['Multiple Myeloma'],COMPLETED,,2011-01,2016-10,"[{'measure': 'Therapeutic Efficacy', 'description': 'Number of participants with an objective response of Partial Response (PR) or better according to European Society for Blood and Marrow Transplantation (EBMT) criteria within 180 days post Expanded Natural Killer Cell Infusion. The minimum criteria to meet the EBMT definition of PR or better included: \\>= 50% reduction in size of soft tissue plasmacytomas (if assessed); AND \\>= 50% reduction in plasma cells in bone marrow biopsy (if biopsy was performed and if \\>= 30% plasma cells at baseline); AND \\>=50% reduction in serum M protein and reduction in urine M protein \\>= 90% or to 200 mg/24hr OR \\>= 50% decrease in the difference between involved and uninvolved serum free light chain levels (if serum M protein \\< 1 g/dL, urine \\< 200 mg/24 hrs, and an involved serum free light chain level \\>= 10 mg/dL at baseline).', 'timeFrame': '180 days'}]",[],1,18 Years,75 Years,ALL,True,University of Arkansas,OTHER,1,10.0,ACTUAL,2025-09-01T16:18:18.416887,v2_robust,True,True,True,False,False,
NCT04267497,Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study),"Phase I, Prospective, Randomised, Controlled Study on the Safety and Efficacy of Nebulised Liposomal Amphotericin as an Adjuvant Treatment for Invasive Pulmonary Aspergillosis",Amphotericin B Liposomal 50 MG,"['Amphotericin B Liposomal 50 MG', 'Ambisome']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Invasive Pulmonary Aspergillosis,['Invasive Pulmonary Aspergillosis'],[],COMPLETED,,2019-10-18,2022-11-10,"[{'measure': 'Reduction of >20% of FVC postnebulization compared to values before amphotericin nebulization', 'description': 'FVC will be measured with the Micro Spirometer (Micro Medical Ltd; Rochester UK) 3 times before and after nebulization and the higher value will be recorded.', 'timeFrame': 'During amphotericin treatment: week 1 to week 6'}, {'measure': 'Reduction of >20% of FEV1 postnebulization compared to values before amphotericin nebulization', 'description': 'FEV1 will be measured with the Micro Spirometer (Micro Medical Ltd; Rochester UK) 3 times before and after nebulization and the higher value will be recorded.', 'timeFrame': 'During amphotericin treatment: week 1 to week 6'}]","[{'measure': 'Fr Resp/min (Breathing rate per minute)', 'description': 'Change in Fr Resp/min values postnebulization compared to values before nebulization', 'timeFrame': 'During amphotericin treatment: week 1 to week 6'}, {'measure': 'Sat 02 (%) (Percentage of oxygen saturation)', 'description': 'Change in Sat 02 (%) values postnebulization compared to values before nebulization', 'timeFrame': 'During amphotericin treatment: week 1 to week 6'}, {'measure': 'Fr Card/min (Heart rate per minute)', 'description': 'Change in Card/min values postnebulization compared to values before nebulization', 'timeFrame': 'During amphotericin treatment: week 1 to week 6'}, {'measure': 'Number of events observed at pulmonary level.', 'description': 'Symptomatic cough, bronchospasm (auscultation), dyspnea or shortness of breath, need for bronchodilator treatment.', 'timeFrame': 'During amphotericin treatment: week 1 to week 6'}, {'measure': 'Pharmacokinetics. Concentrations of amphotericin', 'description': 'Amphotericin concentrations in bronchoalveolar lavage and in plasma.', 'timeFrame': 'Week 6'}, {'measure': 'Radiological response', 'description': 'Evaluated by PET-TC', 'timeFrame': 'Week 6'}, {'measure': 'Microbiological response.', 'description': 'Evaluated in bronchoalveolar lavage (BAL)', 'timeFrame': 'Week 6'}]",9,18 Years,,ALL,False,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,OTHER,0,13.0,ACTUAL,2025-09-01T16:18:18.416976,v2_robust,True,True,True,False,False,
NCT05438797,The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer,Clinical Study on the Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer,Adoptive TIL-TCM transfer therapy,"['TIL-TCM', 'Adoptive TIL-TCM transfer therapy']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Advanced Pancreatic Cancer,['Advanced Pancreatic Cancer'],[],UNKNOWN,,2021-04-02,2024-04,"[{'measure': 'Dose-limiting toxicity (DLT)', 'description': 'To evaluate the Safety and Effectiveness of specific TIL-TCM cells in the Treatment of patients with advanced relapse-refractory or metastatic pancreatic cancer', 'timeFrame': 'Baseline up to 28 days after TIL-TCM cells infusion'}, {'measure': 'Maximum Tolerated Dose（MTD）', 'description': 'To evaluate the Safety and Effectiveness of specific TIL-TCM cells in the Treatment of patients with advanced relapse-refractory or metastatic pancreatic cancer', 'timeFrame': 'Baseline up to 28 days after TIL-TCM cells infusion'}, {'measure': 'incidence of adverse events( AE )and Serious adverse events(SAE)', 'description': 'Adverse events assessed according to NCI-CTCAE v5.0 criteria.', 'timeFrame': 'up to 72 weeks after TIL-TCM cells infusion'}]","[{'measure': 'Overall response rate (ORR)', 'description': 'ORR is defined as the percentage of patients who have a clinical response (objective tumor regression).ORR is computed by: the sum of the number of patients with Complete Response (CR) and number of patients with Partial Response (PR) / total number of patients. The total number of patients is the sum of the number of patients with CR, PR, stable disease (SD) or progressive disease (PD). The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) is used as the criteria to determine whether a tumor disappears (CR), shrinks (PR), stays the same (SD) or gets bigger (PD).', 'timeFrame': '18 months'}, {'measure': 'Duration of response (DOR)', 'description': 'DOR is the time between the initial response to treatment per RECIST v1.1 and subsequent disease progression among patients achieving Complete Response (CR) or Partial Response (PR). RECIST v1.1 is used as the criteria to determine whether a tumor disappears (CR) or shrinks (PR).', 'timeFrame': '18 months'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS is the length of time from the date patient enrolled in to the date on which tumor progresses or the patient dies for any cause.', 'timeFrame': '18 months'}]",6,18 Years,70 Years,ALL,False,Sizhen Wang,OTHER,1,3.0,ESTIMATED,2025-09-01T16:18:18.417015,v2_robust,True,True,False,False,True,
NCT01949610,"A Study to Evaluate Absorption, Metabolism, and Excretion of 14C-JNJ26489112 in Healthy Male Participants","Absorption, Metabolism, and Excretion of 14C-JNJ26489112 After a Single Oral Dose in Healthy Male Subjects",14C-JNJ26489112,['14C-JNJ26489112'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Participants,['Healthy Participants'],"['Healthy Participants', 'JNJ26489112', '14C-JNJ26489112', 'Absorption', 'Metabolism', 'Excretion']",COMPLETED,,2010-01,2010-03,"[{'measure': 'Pharmacokinetics of 14C-JNJ-26489112 in plasma', 'timeFrame': '240 hours'}, {'measure': 'Mass balance after an oral dose of 14C-JNJ-26489112 as generated from recovery of total radioactivity excreted in urine and feces', 'timeFrame': '240 hours'}, {'measure': 'Routes of 14C-JNJ-26489112 elimination measured through total radioactivity concentrations in urine and feces', 'timeFrame': '240 hours'}, {'measure': 'Whole blood and plasma partitioning of total radioactivity through measurement of total radioactivity levels in blood', 'timeFrame': '240 hours'}, {'measure': 'Identification of major metabolites in plasma, urine, and feces', 'timeFrame': '240 hours'}]","[{'measure': 'Number of participants with adverse events as a measure of safety and tolerability', 'timeFrame': 'Up to Day 15'}, {'measure': 'Number of participants with a suicide-related outcome', 'description': 'Suicide related outcome measures will be assessed by using Columbia-Suicide Severity Rating Scale (C-SSRS). By using the C-SSRS, potential suicide-related events will be categorized using the codes defined by the Columbia Classification Algorithm of Suicide Assessment from Code 0: no event that can be assessed based on the C-SSRS to Code 9: not enough information, nonfatal. The 4 suicide-related outcomes of interest are the following: suicidal ideation (Code 4), suicidal behavior (Codes 1 to 3), suicidal behavior or ideation (Codes 1 to 4), and possible suicidal behavior or ideation (Codes 1 to 6 and 9).', 'timeFrame': 'Screening (Days -21 to -1), Day 2 and end-of-study (Day 15)'}]",7,18 Years,55 Years,MALE,True,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,10.0,ACTUAL,2025-09-01T16:18:18.417057,v2_robust,True,True,True,False,True,
NCT02959710,"Evaluation of PK of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production","A Phase 1, Pilot, Single-Dose, 3-Way Crossover Study to Compare the Pharmacokinetics of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production",AC-1204 mixed in water,"['AC-1202 mixed in Ensure®', 'AC-1202 mixed in water', 'AC-1204 mixed in water']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Healthy volunteers', 'AC-1202', 'AC-1204', 'Pharmacokinetic', 'ketone body']",COMPLETED,,2016-11,2017-04,"[{'measure': 'total ketones AUC0-t', 'description': 'The area under the concentration-time curve, from time 0 to the last observed non-zero concentration, as calculated by the linear trapezoidal method.', 'timeFrame': '0-24 hours'}, {'measure': 'total ketones AUC0-inf', 'description': 'The area under the concentration-time curve from time 0 extrapolated to infinity. AUC0-inf is calculated as the sum of AUC0-t plus the ratio of the last measurable serum concentration to the elimination rate constant.', 'timeFrame': '0-24 hours'}, {'measure': 'total ketones AUC%extap', 'description': 'Percent of AUC0-inf extrapolated, represented as (1 - AUC0-t/AUC0-inf)\\*100', 'timeFrame': '0-24 hours'}, {'measure': 'total ketones Cmax', 'description': 'Maximum observed concentration', 'timeFrame': '0-24 hours'}, {'measure': 'total ketones Kel', 'description': 'Apparent first-order terminal elimination rate constant calculated from a semi-log plot of the serum concentration versus time curve. The parameter will be calculated by linear least-squares regression analysis using the maximum number of points in the terminal log-linear phase (e.g., there or more non-zero serum concentrations)', 'timeFrame': '0-24 hours'}, {'measure': 'total ketones T 1/2', 'description': 'Apparent first-order terminal elimination half-life will be calculated as 0.693/Kel', 'timeFrame': '0-24 hours'}, {'measure': 'total ketones Tmax', 'description': 'Time to reach Cmax. If the value occurs at more than one time points, Tmax is defined as the first time point with this value', 'timeFrame': '0-24 hours'}, {'measure': 'β hydroxybutyrate AUC0-t', 'description': 'The area under the concentration-time curve, from time 0 to the last observed non-zero concentration, as calculated by the linear trapezoidal method.', 'timeFrame': '0-24 hours'}, {'measure': 'β hydroxybutyrate AUC0-inf', 'description': 'The area under the concentration time curve from time 0 extrapolated to infinity. AUC0inf is calculated as the sum of AUC0t plus the ratio of the last measurable serum concentration to the elimination rate constant.', 'timeFrame': '0-24 hours'}, {'measure': 'β hydroxybutyrate AUC%extap', 'description': 'Percent of AUC0-inf extrapolated, represented as (1 AUC0t/ AUC0inf)\\* 100', 'timeFrame': '0-24 hours'}, {'measure': 'β hydroxybutyrate Cmax', 'description': 'Maximum observed concentration', 'timeFrame': '0-24 hours'}, {'measure': 'β hydroxybutyrate Kel', 'description': 'Apparent first-order terminal elimination rate constant calculated from a semi-log plot of the serum concentration versus time curve. The parameter will be calculated by linear least-squares regression analysis using the maximum number of points in the terminal log-linear phase (e.g., three or more nonzero serum concentrations)', 'timeFrame': '0-24 hours'}, {'measure': 'β hydroxybutyrate T 1/2', 'description': 'Apparent first-order terminal elimination half-life will be calculated as 0.693/Kel', 'timeFrame': '0-24 hours'}, {'measure': 'β hydroxybutyrate Tmax', 'description': 'Time to reach Cmax. If the value occurs at more than one time point, Tmax is defined as the first time point with this value', 'timeFrame': '0-24 hours'}, {'measure': 'estimate of acetoacetate AUC0-t', 'description': 'The area under the concentration-time curve, from time 0 to the last observed non-zero concentration, as calculated by the linear trapezoidal method.', 'timeFrame': '0-24 hours'}, {'measure': 'estimate of acetoacetate AUC0-inf', 'description': 'The area under the concentration-time curve from time 0 extrapolated to infinity. AUC0-inf is calculated as the sum of AUC0-t plus the ratio of the last measurable serum concentration to the elimination rate constant.', 'timeFrame': '0-24 hours'}, {'measure': 'estimate of acetoacetate AUC%extap', 'description': 'Percent of AUC0-inf extrapolated, represented as (1 - AUC0-t/AUC0-inf)\\* 100', 'timeFrame': '0-24 hours'}, {'measure': 'estimate of acetoacetate Cmax', 'description': 'Maximum observed concentration', 'timeFrame': '0-24 hours'}, {'measure': 'estimate of acetoacetate Kel', 'description': 'Apparent first-order terminal elimination rate constant calculated from a semi-log plot of the serum concentration versus time curve. The parameter will be calculated by linear least-square regression analysis using the maximum number of points in the terminal log-linear phase (e.g., three or more non-zero concentrations)', 'timeFrame': '0-24 hours'}, {'measure': 'estimate of acetoacetate T 1/2', 'description': 'Apparent first-order terminal elimination half-life will be calculated as 0.693/Kel', 'timeFrame': '0-24 hours'}, {'measure': 'estimate of acetoacetate Tmax', 'description': 'Time to reach Cmax. If the value occurs at more than one time point, Tmax is defined as the first time point with this value', 'timeFrame': '0-24 hours'}]",[],21,18 Years,55 Years,MALE,True,Cerecin,INDUSTRY,1,16.0,ESTIMATED,2025-09-01T16:18:18.417216,v2_robust,True,True,True,False,False,
NCT00531310,Reduced Intensity AlloSCT in(CML) With Persistent Disease,A Pilot Study of Reduced Intensity Allogeneic Stem Cell Transplantation in Patients With Chronic Myeloid Leukemia (CML) and Adoptive Cellular Immunotherapy Only in Patients With Persistent Disease and Matched Family Donors,"Reduced Intensity Conditioning, Busulfan and Fludarabine","['Reduced Intensity Conditioning, Busulfan and Fludarabine', 'RIC']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Myeloid Leukemia,['Chronic Myeloid Leukemia'],"['CML', 'allogeneic SCT', 'matched family donor', 'unrelated donor', 'cord blood donor', 'persistent disease']",TERMINATED,Poor accrual,2003-01,2010-06,"[{'measure': 'To determine the toxicity associated with reduced intensity therapy and allogeneic SCT in selected patients with CML.', 'timeFrame': 'Until Study End'}]",[],1,,30 Years,ALL,False,Columbia University,OTHER,0,5.0,ACTUAL,2025-09-01T16:18:18.417290,v2_robust,True,True,False,True,False,Poor accrual
NCT01763710,Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer,Neurotoxicity Characterization Phase II Randomized Study of Nab-paclitaxel Versus Conventional Paclitaxel as First-line Therapy of Metastatic HER2-negative Breast Cancer.,Paclitaxel 80 mg/m2,"['Paclitaxel 80 mg/m2', 'Nab-paclitaxel 150 mg/m2 days 1 and 15', 'Nab-paclitaxel 100 mg/m2 days 1, 8 and 15', 'Nab-paclitaxel 150 mg/m2 days 1, 8 and 15']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],"['Breast cancer', 'Neurotoxicity']",COMPLETED,,2012-12,2015-12,"[{'measure': 'TNS - Total Neuropathy Score', 'timeFrame': 'Every 3 months up to 6 months'}]","[{'measure': 'Evaluate the incidence of neuropathy induced by study treatment (conventional paclitaxel vs nab-paclitaxel)', 'timeFrame': 'Every 3 weeks up to 24 weeks'}, {'measure': 'Evaluate the electromyographic abnormalities and the correlation of these alterations with the assessment of the TNS scale and NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) v4.0', 'timeFrame': 'Every 12 weeks up to 24 weeks'}, {'measure': 'Determine the predictive value of genetic variants (SNPs) for the development of neuropathy', 'timeFrame': 'In the two weeks before start treatment'}, {'measure': 'Determine the clinical activity of both treatments (response rate, time to progression)', 'timeFrame': 'Every 8-12 weeks up to 24 weeks'}, {'measure': 'Determine toxicity profile and safety of study treatments (NCI-CTCAE v4.0)', 'timeFrame': 'Every 2 weeks up to 24 weeks'}, {'measure': 'Determine time to neurotoxicity onset', 'timeFrame': 'Every 2 weeks up to 24 weeks'}, {'measure': 'Determine time to recovery from neurotoxicity', 'timeFrame': 'Every 2 weeks up to 24 weeks'}, {'measure': 'Determine time to progression', 'timeFrame': 'Every 8-12 weeks up to 24 weeks'}, {'measure': 'Assess quality of live (EORTC QLQ-C30 and EORTC QLQ-CIPN20)', 'timeFrame': 'Every 4 weeks up to 24 weeks'}]",10,18 Years,,FEMALE,False,Fundacion Oncosur,NETWORK,0,60.0,ACTUAL,2025-09-01T16:18:18.417335,v2_robust,True,True,True,False,True,
NCT00344513,Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF),Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients,Beta-blockers including Carvedilol,"['ACE inhibitors', 'Beta-blockers including Carvedilol']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Heart Failure, Congestive","['Heart Failure, Congestive']","['registry', 'OPTIMIZE', 'Heart failure', 'OPTIMIZE-HF']",COMPLETED,,2002-12-16,2005-06-30,[{'measure': 'Evaluate the number and percentage of eligible patients who are discharged on optimal therapy. Evaluate all HF indicators recommended by JCAHO and CMS.'}],[{'measure': 'Mortality Recurrent hospitalization Number of patients receiving beta-blockers therapy within 60 to 90 days of initiation and mean beta-blocker dose 60-90 days following discharge.'}],2,,,ALL,False,GlaxoSmithKline,INDUSTRY,0,50000.0,,2025-09-01T16:18:18.417377,v2_robust,True,True,True,False,False,
NCT00794313,Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease,Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease,Amantadine 300 mg,"['Sugar Pill', 'Topamax', 'Amantadine 300 mg', 'Topiramate']",4,INTERVENTIONAL,['NA'],,,Parkinson's Disease,"[""Parkinson's Disease""]","['Parkinsons disease', 'dyskinesia', 'amantadine', 'efficacy']",TERMINATED,Funding Ended,2009-09,2010-06,"[{'measure': 'Forceplate AUC', 'description': 'Area under the curve for the root mean squared velocity in the anterior-posterior direction as measured by a forceplate.', 'timeFrame': 'Every 1/2 hour for 8 hour levodopa cycle'}]","[{'measure': 'Modified Abnormal Involuntary Movement Scale Area Under the Curve', 'description': 'Area under the curve computed for whole body (total) mAIMS (Modified Abnormal Involuntary Movement Scale) scores at each time measurement. This is a commonly utilized scale that is completed by an observer who judges the severity of levodopa induced dyskinesia (LID) in 7 body parts (face, neck, trunk, both legs, and both arms). All body parts are rated separately on this 0 (none) to 4 (severe - markedly impairs activities) scale. Thus, the total score can range from 0 - 28 with 28 indicating the most severe LID. mAIMS ratings occur as the subject performs the cognitive task while standing on the force plate. mAIMS ratings are made every half hour during the levodopa (LD) dose cycle.', 'timeFrame': 'Measured every 1/2 hour for a levodopa dose cycle (starting 1 hour prior to infusion and ending 4 hours post 2-hour infusion)'}]",2,21 Years,,ALL,False,Oregon Health and Science University,OTHER,0,3.0,ACTUAL,2025-09-01T16:18:18.417431,v2_robust,True,True,False,True,False,Funding Ended
NCT03104413,A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment",placebo for risankizumab IV,"['risankizumab SC', 'placebo for risankizumab IV', 'SKYRIZI', 'ABBV-066 BI 655066', 'risankizumab IV']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Crohn's Disease,"[""Crohn's Disease""]","['ABBV-066', 'BI 655066']",COMPLETED,,2017-12-18,2021-05-19,"[{'measure': ""US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission"", 'description': ""The CDAI consists of 8 components; 7 are based on participant diary entries, participant interviews, physical examinations, measurement of body weight and height and 1 is based on laboratory analysis. CDAI clinical remission of Crohn's disease is defined as CDAI \\< 150."", 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Endoscopic Response', 'description': 'The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \\> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).', 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With Clinical Remission', 'description': 'Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.', 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With Endoscopic Response', 'description': 'The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \\> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).', 'timeFrame': 'Week 12'}]","[{'measure': 'US Specific: Percentage of Participants With Clinical Remission', 'description': 'Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.', 'timeFrame': 'Week 12'}, {'measure': ""US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response"", 'description': ""Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline."", 'timeFrame': 'Week 4'}, {'measure': ""US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response"", 'description': ""Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline."", 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue', 'description': ""The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement."", 'timeFrame': 'Week 12'}, {'measure': ""US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission"", 'description': ""Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical remission of Crohn's disease is defined as CDAI \\< 150."", 'timeFrame': 'Week 4'}, {'measure': 'US Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response', 'description': ""Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.\n\nEndoscopic response was a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \\> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline)."", 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Stool Frequency (SF) Remission', 'description': 'Stool Frequency (SF) remission is defined as an average daily SF \\<= 2.8 and not worse than baseline.', 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Abdominal Pain (AP) Remission', 'description': 'The Abdominal Pain rating is an assessment that is graded from 0 to 3: 0= None, 1= Mild, 2= Moderate and 3= Severe. AP remission is defined as average daily AP score \\<= 1 and not worse than baseline.', 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Endoscopic Remission', 'description': 'Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable', 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Enhanced Clinical Response', 'description': 'Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission', 'timeFrame': 'Week 4'}, {'measure': 'US Specific: Percentage of Participants With Ulcer-Free Endoscopy', 'description': 'Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline', 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Enhanced Clinical Response', 'description': 'Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission', 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Baseline', 'description': ""Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver."", 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With CD-Related Hospitalization', 'description': ""Participants with at least one admission to the hospital due to Crohn's Disease."", 'timeFrame': 'Up to Week 12'}, {'measure': 'US Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline', 'description': 'Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.', 'timeFrame': 'Week 12'}, {'measure': ""Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission"", 'description': ""The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. CDAI clinical remission of Crohn's disease is defined as CDAI \\< 150."", 'timeFrame': 'Week 12'}, {'measure': ""Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response"", 'description': ""Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline."", 'timeFrame': 'Week 4'}, {'measure': 'Global Outside of US: Percentage of Participants With Clinical Remission', 'description': 'Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.', 'timeFrame': 'Week 4'}, {'measure': ""Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response"", 'description': ""Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline."", 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue', 'description': ""The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement."", 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score', 'description': 'The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.', 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response', 'description': ""Enhanced clinical response was defined as ≥ 60% decrease in average daily Stool Frequency and/or ≥ 35% decrease in average daily Abdominal Pain score and both not worse than baseline, and/or clinical remission. Endoscopic Response was defined as a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \\> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline)."", 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US:: Percentage of Participants With Endoscopic Remission', 'description': 'Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable', 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With Enhanced Clinical Response', 'description': 'Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission', 'timeFrame': 'Week 4'}, {'measure': 'Global Outside of US: Percentage of Participants With Ulcer-Free Endoscopy', 'description': 'Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline', 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With Enhanced Clinical Response', 'description': 'Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission', 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Baseline', 'description': ""Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver."", 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With CD-Related Hospitalization', 'description': ""Participants with at least one admission to the hospital due to Crohn's Disease."", 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline', 'description': 'Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.', 'timeFrame': 'Week 12'}, {'measure': ""Global Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment"", 'description': ""WPAI: CD is a questionnaire used to evaluate lost productivity due to CD ; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Total work productivity impairment takes into account both hours missed due to CD symptoms and the patient's assessment of the degree to which CD affected their productivity while working (overall work impairment \\[OWI\\]). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity."", 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score', 'description': ""The Short Form-36 Health Survey determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement."", 'timeFrame': 'Week 12'}]",35,16 Years,80 Years,ALL,False,AbbVie,INDUSTRY,0,618.0,ACTUAL,2025-09-01T16:18:18.417636,v2_robust,True,True,True,False,False,
NCT02264613,ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas,A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone or in Combination in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein,ALRN-6924,['ALRN-6924'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Solid Tumor,"['Solid Tumor', 'Lymphoma', 'Peripheral T-Cell Lymphoma']",[],COMPLETED,,2014-10,2020-04,"[{'measure': 'Evaluate the safety and tolerability of ALRN-6924 in adult patients with advanced solid tumors or lymphomas with wild-type (WT) TP53 who are refractory to or intolerant of standard therapy, or for whom no standard therapy exists - Phase 1', 'description': 'Number of participants with treatment-related adverse events as assessed by CTCAE v.4.0', 'timeFrame': 'From Day 1 of treatment until 30 days after the last cycle of treatment (each cycle is 28 days)'}, {'measure': 'Evaluate the safety and tolerability of ALRN-6924 in adult patients with advanced solid tumors or lymphomas with wild-type (WT) TP53 who are refractory to or intolerant of standard therapy, or for whom no standard therapy exists - Phase 2', 'description': 'Number of participants with treatment-related adverse events as assessed by CTCAE v.4.0', 'timeFrame': 'From Day 1 of treatment until 30 days after the last cycle of treatment (each cycle is 28 days)'}, {'measure': 'Determine the maximum tolerated dose (MTD) - Phase 1', 'description': 'Determine the dose limiting toxicities (DLT) and the maximum tolerated dose (MTD) or the optimal biological dose (OBD) of ALRN-6924 in adult patients with advanced solid tumors or lymphomas', 'timeFrame': 'From the first dose until the end of the first cycle (each cycle is 28 days)'}, {'measure': 'Determine Overall Response Rate - Phase 2', 'description': 'The proportion of efficacy-evaluable patients who achieve complete response (CR) or partial response (PR), per investigator assessment, in accordance with RECIST 1.1 or iRECIST (for solid tumor patients) or Response Assessment in Neuro-Oncology (RANO) criteria (for glioblastoma patients).', 'timeFrame': 'From the first dose until the first documented date of progression or date of death from any cause, whichever comes first, assessed up to 100 months'}]","[{'measure': 'Determine Pharmacokinetic parameters of ALRN-6924 when administered to patients with advanced solid tumors or lymphomas', 'description': 'Peak Plasma Concentration (Cmax)', 'timeFrame': '8 weeks'}, {'measure': 'Determine Pharmacokinetic parameters of ALRN-6924 when administered to patients with advanced solid tumors or lymphomas', 'description': 'Area under the plasma concentration versus time curve (AUC)', 'timeFrame': '8 weeks'}, {'measure': 'Determine Pharmacokinetic parameters of ALRN-6924 when administered to patients with advanced solid tumors or lymphomas', 'description': 'Time of Peak Plasma Concentration (Tmax)', 'timeFrame': '8 weeks'}, {'measure': 'Assess additional measures of anti-tumor activity, including duration of response, progression free survival, overall survival and time to response', 'description': 'The proportion of efficacy-evaluable patients who achieve complete response (CR) or partial response (PR), per investigator assessment, in accordance with RECIST 1.1 or iRECIST (for solid tumor patients) or Response Assessment in Neuro-Oncology (RANO) criteria (for glioblastoma patients).', 'timeFrame': 'From the first dose until the first documented date of progression or date of death from any cause, whichever comes first, assessed up to 100 months'}, {'measure': 'Assess additional pharmacologic properties, including biomarkers and immunogenicity', 'description': 'The correlation of response with MDM2, MDMX, and/or CDK4 gene copy number and other genetic and protein biomarkers', 'timeFrame': 'Up to 24 weeks'}]",9,18 Years,,ALL,False,"Aileron Therapeutics, Inc.",INDUSTRY,0,149.0,ACTUAL,2025-09-01T16:18:18.417899,v2_robust,True,True,True,False,True,
NCT07111013,A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease,"A 12-Month, Multicenter, Open-Label Extension (OLE) Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease",Lifitegrast/perfluorohexyloctane (PFHO),['Lifitegrast/perfluorohexyloctane (PFHO)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Dry Eye Disease,['Dry Eye Disease'],[],NOT_YET_RECRUITING,,2025-12,2027-04,"[{'measure': 'Incidence of Treatment Emergent Adverse Events', 'timeFrame': 'Assessed for 12 months'}]",[],1,18 Years,,ALL,False,Bausch & Lomb Incorporated,INDUSTRY,0,150.0,ESTIMATED,2025-09-01T16:18:18.417933,v2_robust,True,True,False,False,True,
NCT05470413,Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata,"A Randomized, Double-Blinded, and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata",SHR0302,"['SHR0302', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Alopecia Areata,['Alopecia Areata'],[],ACTIVE_NOT_RECRUITING,,2022-04-18,2024-02-15,"[{'measure': 'Percentage of subjects achieving a SALT score ≤ 20 at week 24', 'description': 'Percentage of subjects achieving a SALT score ≤ 20 at week 24', 'timeFrame': '24 weeks'}]","[{'measure': 'Percentage of subjects achieving a 50% improvement in SALT score (SALT50) at Week 24.', 'description': 'Percentage of subjects achieving a 50% improvement in SALT score (SALT50) at Week 24.', 'timeFrame': '24 weeks'}, {'measure': 'Percentage of subjects with a SALT score ≤ 20 at Weeks 4, 8, 12, 16, 28, 36, 44, and 52.', 'description': 'Percentage of subjects with a SALT score ≤ 20 at Weeks 4, 8, 12, 16, 28, 36, 44, and 52.', 'timeFrame': 'Weeks 4, 8, 12, 16, 28, 36, 44, and 52'}, {'measure': 'Percentage of subjects achieving a 50% improvement in SALT score (SALT50) at Weeks 4, 8, 12, 16, 28, 36, 44, and 52.', 'description': 'Percentage of subjects achieving a 50% improvement in SALT score (SALT50) at Weeks 4, 8, 12, 16, 28, 36, 44, and 52.', 'timeFrame': 'Weeks 4, 8, 12, 16, 28, 36, 44, and 52.'}, {'measure': 'Percentage of subjects achieving a 75% improvement in SALT score (SALT75) at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.', 'description': 'Percentage of subjects achieving a 75% improvement in SALT score (SALT75) at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.', 'timeFrame': 'Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.'}, {'measure': 'Percentage of subjects achieving a 90% improvement in SALT score (SALT90) at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.', 'description': 'Percentage of subjects achieving a 90% improvement in SALT score (SALT90) at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.', 'timeFrame': 'Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.'}, {'measure': 'Absolute change from baseline in SALT score at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.', 'description': 'Absolute change from baseline in SALT score at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.', 'timeFrame': 'Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.'}, {'measure': 'Percentage change from baseline in SALT score at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.', 'description': 'Percentage change from baseline in SALT score at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.', 'timeFrame': 'Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.'}, {'measure': 'Percentage of subjects with an absolute SALT score ≤ 10 at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.', 'description': 'Percentage of subjects with an absolute SALT score ≤ 10 at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.', 'timeFrame': 'Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.'}, {'measure': 'Percentage of subjects achieving ""Satisfied"" in Subject\'s Global Assessment (SGA) at Weeks 24, 36, and 52.', 'description': 'Percentage of subjects achieving ""Satisfied"" in Subject\'s Global Assessment (SGA) at Weeks 24, 36, and 52.', 'timeFrame': 'Weeks 24, 36, and 52.'}]",10,18 Years,65 Years,ALL,False,Reistone Biopharma Company Limited,INDUSTRY,0,330.0,ACTUAL,2025-09-01T16:18:18.417942,v2_robust,True,True,False,False,False,
NCT02734160,A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer,"A Phase 1b Dose-Escalation and Cohort-Expansion Study of the Safety, Tolerability, and Efficacy of a Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With the Anti-PD-L1 Antibody Durvalumab (MEDI4736) in Recurrent or Refractory Metastatic Pancreatic Cancer",Galunisertib,"['MEDI4736', 'Galunisertib', 'LY2157299', 'Durvalumab']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Metastatic Pancreatic Cancer,['Metastatic Pancreatic Cancer'],"['immunotherapy', 'check point inhibitors', 'transforming growth factor (TGF)-beta R1 kinase inhibitor']",COMPLETED,,2016-06-15,2019-04-17,"[{'measure': 'Number of Participants with Galunisertib in Combination with Durvalumab Dose-Limiting Toxicities (DLTs)', 'timeFrame': 'Cycle 1 (28 Days)'}]","[{'measure': 'Pharmacokinetics (PK): Maximum Concentration (Cmax) of Galunisertib', 'timeFrame': 'Predose Day 1 Cycle 1 through Predose Day 1 Cycle 7 (28 Day Cycles)'}, {'measure': 'PK: Area Under the Curve (AUC) at Steady State of Galunisertib', 'timeFrame': 'Predose Day 1 Cycle 1 through Predose Day 1 Cycle 7 (28 Day Cycles)'}, {'measure': 'PK: Minimum Concentration (Cmin) of Durvalumab', 'timeFrame': 'Predose Day 1 Cycle 1 through Predose Day 1 Cycle 7 (28 Day Cycles)'}, {'measure': 'Number of Participants with Anti-Durvalumab Antibodies', 'timeFrame': 'Predose Day 1 Cycle 2 through Predose Day 1 Cycle 4 (28 Day Cycles)'}, {'measure': 'Progression-free Survival (PFS)', 'timeFrame': 'Baseline to Objective Progressive Disease or Death (Estimated up to 18 Months)'}, {'measure': 'Objective Response Rate (ORR): Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR)', 'timeFrame': 'Baseline to Objective Progressive Disease (Estimated up to 18 Months)'}, {'measure': 'Duration of Response (DoR)', 'timeFrame': 'Date of CR or PR to Date of Objective Progressive Disease or Death Due to Any Cause (Estimated up to 18 Months)'}, {'measure': 'Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and Stable Disease (SD)', 'timeFrame': 'Baseline to Objective Progressive Disease or Start of New Anti-Cancer Therapy (Estimated up to 18 Months)'}, {'measure': 'Time to Response', 'timeFrame': 'Baseline to Date of CR or PR (Estimated up to 4 Months)'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'Baseline to Date of Death from Any Cause (Estimated up to 30 Months)'}]",11,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,1,37.0,ACTUAL,2025-09-01T16:18:18.418014,v2_robust,True,True,True,False,False,
NCT03463460,Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer,"A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma",Sunitinib Malate,"['Sutent', 'SU011248', 'SU11248', 'Sunitinib Malate', 'sunitinib']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Thymic Carcinoma,['Thymic Carcinoma'],[],RECRUITING,,2018-06-19,2027-04-30,"[{'measure': 'Response defined by a complete response (CR) or partial response (PR) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1', 'description': 'Response will be defined for patients with measurable disease and who receive at least one dose of combination treatment. Exact binomial 95% confidence intervals for the true PR + CR response rate will be calculated.', 'timeFrame': 'Up to 24 months'}]","[{'measure': 'Incidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0', 'description': 'Frequency and severity of adverse events and tolerability of the regimen in each of the treatment arms will be collected and summarized using descriptive statistics. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. Events will be summarized based on frequency and proportion of total subjects, by system organ class and preferred term. Separate summaries with descriptive statistics (counts, percentage, mean, standard deviation, etc.) will be given for all AEs, treatment-related AEs, AEs by toxicity grade, serious adverse events and AEs leading to discontinuation of study treatment and dose modification. The incidence of deaths and the primary cause of death will be summarized.', 'timeFrame': 'Up to 30 days after the last dose of treatment'}, {'measure': 'Overall survival (OS)', 'description': 'OS is defined as the duration from study registration to death due to any cause, whichever comes first. Patients last known to be alive will be censored at the date of last contact.', 'timeFrame': 'From study registration up to 24 months'}, {'measure': 'Progression free survival (PFS)', 'description': 'PFS is defined as the duration from study registration to progression, symptomatic deterioration, or death due to any cause, whichever comes first. Patients last known to be alive and progression-free will be censored at the date of \\[last contact or disease assessment\\]. PFS will be defined on patients with both measurable and non-measurable disease.', 'timeFrame': 'From study registration up to 24 months'}]",4,18 Years,,ALL,False,Dwight Owen,OTHER,1,30.0,ESTIMATED,2025-09-01T16:18:18.418040,v2_robust,True,True,False,False,True,
NCT05616260,Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health,Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health,Acetazolamide,"['Diamox', 'Acetazolamide', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Obstructive Sleep Apnea,['Obstructive Sleep Apnea'],"['obstructive sleep apnea', 'OSA', 'CPAP', 'Acetazolamide']",RECRUITING,,2022-12-02,2025-04-30,"[{'measure': 'Apnea Hypopnea Index', 'description': 'The AHI is a measure of sleep apnea severity and is defined as the number of apneas (no breathing for 10+ seconds) and hypopneas (reduced breathing for 10+ seconds associated with a \\>=3% desaturation or cortical arousal) per hour of sleep.', 'timeFrame': '14 days'}, {'measure': '24-hour Mean Blood Pressure', 'description': 'Based on 24h blood pressure measurements', 'timeFrame': '14 days'}]","[{'measure': 'Hypoxic Burden', 'description': 'Respiratory event-associated area under the desaturation curve from pre-event baseline', 'timeFrame': '14 days'}, {'measure': 'Reactive Hyperemia Index', 'description': 'Based on a device called EndoPAT, which measures non-invasively bloodflow before, during, and after 5-minutes of occlusion to one arm.', 'timeFrame': '14 days'}, {'measure': 'Response Speed', 'description': 'Based on 10-minute Psychomotor vigilance task (PVT)', 'timeFrame': '14 days'}, {'measure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (SDA) instrument', 'description': 'Based on response pattern scoring, the PROMIS 8-item SDA score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep disturbance.', 'timeFrame': '14 days'}, {'measure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment (SRI) instrument', 'description': 'Based on response pattern scoring, the PROMIS 8-item SRI score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep-related impairment.', 'timeFrame': '14 days'}, {'measure': 'Epworth Sleepiness Scale (ESS)', 'description': 'The ESS is an 8-item instrument assessing the likelihood of dozing off in 8 different situations with points for each item ranging from 0 to 3 (0 = would never doze off; 3 = high chance of dozing off). The points for each item are summed up, thus the total score ranges from 0 to 24, with higher ESS scores indicating greater sleepiness.', 'timeFrame': '14 days'}, {'measure': '24-hour Mean Systolic Blood Pressure', 'description': 'Based on 24h blood pressure measurements', 'timeFrame': '14 days'}, {'measure': '24-hour Mean Diastolic Blood Pressure', 'description': 'Based on 24h blood pressure measurements', 'timeFrame': '14 days'}]",10,18 Years,50 Years,ALL,False,"University of California, San Diego",OTHER,0,46.0,ESTIMATED,2025-09-01T16:18:18.418096,v2_robust,True,True,False,False,False,
NCT01224860,Telmisartan Versus Losartan in Kidney Transplantation,"A Prospective, Randomized, Open Label Blinded End Point (Probe), Crossover Study to Compare the Effects of Telmisartan and Losartan on Metabolic Profile of Renal Transplant Patients",Telmisartan,"['Telmisartan', 'Losartan']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Renal Transplant,['Renal Transplant'],"['Telmisartan', 'Losartan', 'Renal transplant']",COMPLETED,,2009-01,2014-01,"[{'measure': 'Insulin sensitivity.', 'description': 'Glucose disposal rate as assessed by an euglycemic hyperinsulinemic clamp.', 'timeFrame': 'At baseline and then every four months.'}, {'measure': 'Insulin sensitivity.', 'description': 'Glucose disposal rate as assessed by an euglycemic hyperinsulinemic clamp.', 'timeFrame': 'At 9 month.'}]","[{'measure': 'Systemic variables.', 'description': 'Sitting systolic/diastolic blood pressure, 24-h blood pressure profile.', 'timeFrame': 'At baseline and then every four months.'}, {'measure': 'Systemic variables.', 'description': 'Sitting systolic/diastolic blood pressure, 24-h blood pressure profile.', 'timeFrame': 'At 9 month.'}, {'measure': 'Metabolic variables.', 'description': 'Morning fasting blood glucose, Glucose tolerance test, Glicated hemoglobin, Morning fasting insulin, HOMA index, Lipid profile (total cholesterol, triglycerides, HDL, LDL, apolipoprotein A, B.', 'timeFrame': 'At baseline and then every four months.'}, {'measure': 'Metabolic variables.', 'description': 'Morning fasting blood glucose, Glucose tolerance test, Glicated hemoglobin, Morning fasting insulin, HOMA index, Lipid profile (total cholesterol, triglycerides, HDL, LDL, apolipoprotein A, B.', 'timeFrame': 'At 9 month.'}, {'measure': 'Renal variables.', 'description': 'UAE (as assessed by nephelometry in three consecutive overnight urine collections), GFR/RPF (as assessed by Iohexol and PAH plasma clearance, respectively), Albumin fractional clearance.', 'timeFrame': 'At baseline and then every four months.'}, {'measure': 'Renal variables.', 'description': 'UAE (as assessed by nephelometry in three consecutive overnight urine collections), GFR/RPF (as assessed by Iohexol and PAH plasma clearance, respectively), Albumin fractional clearance.', 'timeFrame': 'At 9 month.'}]",8,18 Years,80 Years,ALL,False,Mario Negri Institute for Pharmacological Research,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:18.418177,v2_robust,True,True,True,False,False,
NCT03771560,Folinic Acid in Autism,An Examination of Changes in Urinary Metabolites With Use of Folinic Acid in Children With Autism Spectrum Disorder (ASD),folinic acid,"['leucovorin calcium', 'folinic acid']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Autism Spectrum Disorder,['Autism Spectrum Disorder'],[],COMPLETED,,2018-02-15,2018-06-30,"[{'measure': 'Aberrant Behavior Checklist (ABC) - Parent Reported Change', 'description': 'The Aberrant Behavior Checklist - parent reported version measures aberrant behavior in children and young adults. There are 58 questions.The scoring of one question can range from 0 (not a problem) to 3 (severe) points on a Likert scale. The total possible score range for the ABC is 0 - 174. Analysis will be performed for mean of total score change over time.\n\nScoring from 0-3\n\nNot a problem = 0, Slightly = 1, Moderately Serious =2, Severe =3\n\nLower score indicates better performance.', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Aberrant Behavior Checklist (ABC) - Teacher Reported Change', 'description': 'The Aberrant Behavior Checklist - teacher reported version measures aberrant behavior in children and young adults. There are 58 questions. The scoring of ABC questions can range from 0 (not a problem) to 3 (severe) points on a likert scale. The total possible score range for the ABC is 0 - 174. Analysis will be performed for mean of total score change over time.\n\nScoring from 0-3\n\nNot a problem = 0, Slightly = 1, Moderately Serious =2, Severe =3\n\nLower score indicates better performance.', 'timeFrame': 'Baseline to Week 12'}]","[{'measure': 'Social Responsiveness Scale (SRS) - Parent Reported Change', 'description': 'The Social Responsiveness Scale - parent reported version measures social ability in children and young adults. There are 65 questions. The questions on the scale with anchors 1 (Not True) - 4 (Almost Always True). The scoring of SRS questions can range from 0-3 (with possible reverse scoring) based on scoring instructions for data analysis. The total possible score range for the SRS is 0 - 195. Analysis will be performed for mean of total score change over time.\n\nAnchors Not True = 1 Sometimes True = 2 Often True = 3 Almost Always True = 4\n\nLower score indicates better performance.', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Social Responsiveness Scale (SRS) - Teacher Reported Change', 'description': 'The Social Responsiveness Scale - teacher reported version measures social ability in children and young adults. There are 65 questions. The questions on the scale with anchors 1 (Not True) - 4 (Almost Always True). The scoring of SRS questions can range from 0-3 (with possible reverse scoring) based on scoring instructions for data analysis. The total possible score range for the SRS is 0 - 195. Analysis will be performed for mean of total score change over time.\n\nAnchors Not True = 1 Sometimes True = 2 Often True = 3 Almost Always True = 4\n\nLower score indicates better performance.', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Pediatric Quality of Life (PedsQL) - Parent Reported Change', 'description': ""Pediatric Quality of Life is reported by parent only and it assesses improvement of the child's overall quality of life through questions about physical, emotional, social and school functioning. There are 23 questions. The scoring of PedsQL questions can range from 0 (Never) to 4 (Almost Always) points on a Likert scale. Questions are reversed scored and linearly transformed to a 0 - 100 scale for data analysis as follows: 0=100, 1=75, 2=50, 3=23, 4=0. The total score = sum of all the questions over the number of items answered on. The total possible score range for the PedsQL is 0 - 100. Analysis will be performed for mean of total score change over time.\n\nScoring from 0 to 4\n\nNever = 0, Almost Never = 1, Sometimes = 2, Often = 3, Almost Always =4\n\nHigher score indicates better performance."", 'timeFrame': 'Baseline to Week 12'}]",5,5 Years,25 Years,ALL,False,"University of California, San Francisco",OTHER,0,18.0,ACTUAL,2025-09-01T16:18:18.418199,v2_robust,True,True,True,False,False,
NCT01709760,A Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With RA,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis",Methotrexate,"['Methotrexate', 'TuNEX', 'ENIA11', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],"['ENIA11', 'MTX', 'RA', 'TNF']",UNKNOWN,,2012-11,2019-12,"[{'measure': 'ACR20 responder at last treatment visit', 'description': 'The primary efficacy endpoint is defined as ACR20 responder at last treatment visit (Week 24).', 'timeFrame': 'Week 24'}]",[],1,20 Years,,ALL,False,Mycenax Biotech Inc.,INDUSTRY,0,91.0,ACTUAL,2025-09-01T16:18:18.418334,v2_robust,True,True,False,False,False,
NCT01412060,A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Cariprazine (RGH-188) in the Prevention of Relapse in Patients With Schizophrenia",Placebo,"['RGH-188', 'Cariprazine', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Schizophrenia,['Schizophrenia'],"['Schizophrenia', 'Schizophrenic disorder']",COMPLETED,,2011-09-27,2014-09-03,"[{'measure': 'Time From Baseline to the First Symptom Relapse During the Double-blind Phase', 'description': ""Relapse was defined as meeting ≥1 of the following criteria:1-Hospitalization due to worsening of condition;2-increase in Positive and Negative Syndrome Scale(PANSS) total score by ≥30% for participants,scored ≥50 or a ≥10-point increase for participants,scored \\<50 at randomization;3-increase in Clinical Global Impressions-Severity(CGI-S) score by ≥2 points at Week 20;4-deliberate self-injury or aggressive behaviour;5-suicidal/homicidal ideation judged clinically significant by Investigator;6-score of \\>4 on 1 or more of following PANSS items:P1,P2,P3,P6,P7,G8 or G14. Second assessment not performed based on Investigator discretion.\n\nPANSS is 30-item rating scale. Each item scored on 7-point scale. Total score ranges from 30 to 210. Lower score indicates fewer schizophrenic symptoms. CGI-S is 7-point scale,measures severity of participant's illness in comparison with others with same diagnosis. Lower score indicates less severe illness. 25th percentile for time to relapse was reported."", 'timeFrame': 'Up to 34 Weeks and Bi-Weekly thereafter until Week 92'}]",[],1,18 Years,60 Years,ALL,False,Forest Laboratories,INDUSTRY,1,765.0,ACTUAL,2025-09-01T16:18:18.418364,v2_robust,True,True,True,False,False,
NCT00868660,Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose,"A Phase I, Double Blind, Placebo-Controlled Study of ZP1848 Administered as Subcutaneous Bolus Injections in Healthy Subjects Followed by Multiple Doses in Patients With Crohn's Disease in Remission",ZP1848,['ZP1848'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Inflammatory Bowel Disease,['Inflammatory Bowel Disease'],[],COMPLETED,,2009-01,2010-02,"[{'measure': 'safety and tolerability', 'timeFrame': 'January2009-January2010'}]","[{'measure': 'Pharmacokinetics', 'timeFrame': 'Jan 2009 - Jan 2010'}]",2,18 Years,60 Years,ALL,False,Zealand Pharma,INDUSTRY,0,66.0,ACTUAL,2025-09-01T16:18:18.418397,v2_robust,True,True,True,False,True,
NCT01789320,Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis,"Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis",triamcinolone acetonide (Triesence®),"['TA', 'triamcinolone acetonide', 'triamcinolone acetonide (Triesence®)', 'Triesence', 'corticosteroid']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Uveitis,"['Uveitis', 'Intermediate Uveitis', 'Posterior Uveitis', 'Panuveitis', 'Noninfectious Uveitis']","['uveitis', 'intermediate uveitis', 'posterior uveitis', 'panuveitis', 'noninfectious uveitis', 'microneedle', 'suprachoroidal space', 'SCS', 'inflammation', 'ocular inflammatory conditions', 'triamcinolone acetonide', 'TA', 'Triesence', 'injection', 'IVT', 'intravitreal', 'corticosteroid', 'sympathetic ophthalmia', 'temporal arteritis', 'vitreous haze']",COMPLETED,,2013-02,2015-03,"[{'measure': 'Change in Intraocular Pressure (IOP)', 'description': 'Intraocular pressure is the fluid pressure inside the eye. Intraocular pressure change from baseline at week 8 was measured by Goldmann applanation tonometry. Tonometry is the method eye care professionals use to determine this pressure. Intraocular pressure is typically measured in millimeters of mercury. A higher pressure inside the eye can be a risk factor for developing glaucoma or glaucoma progression leading to optic nerve damage. A negative change indicates a reduction in intraocular pressure.', 'timeFrame': 'Change from baseline in IOP at 8 weeks'}, {'measure': 'Best Corrected Visual Acuity', 'description': ""Visual acuity (VA) rates a person's ability to recognize small details with precision. Best corrected VA refers to this measurement when the best vision has be achieved following refraction. Visual acuity change from baseline at 8 and 26 weeks was measured following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol using standardized lighting and lanes and an ETDRS eye chart. This eye chart comprises rows of letters, with 5 letters per row, and with the letter size from line to line varying logarithmically and is used to estimate visual acuity. Visual acuity is scored with reference to the logarithm of the minimum angle of resolution or logMAR. Zero logMAR indicates standard vision, positive values indicate poor vision and negative values indicate good vision. A negative changes indicates an improvement in visual acuity."", 'timeFrame': 'Change from baseline at 8 weeks and 26 weeks.'}]","[{'measure': 'Central Subfield Thickness Using Optical Coherence Tomography (OCT)', 'description': 'Central subfield thickness (CST) is a measure of the thickness of the retina in the 1 mm diameter circle centered on the fovea or center of the macular where eyesight is the sharpest. CST change from baseline at 8 and 26 weeks was measured using optical coherence tomography (OCT). OCT is a diagnostic imaging technique used to capture 2 and 3 dimensional images within biological tissue, e.g., for determining the amount of edema contained in the retina. CST is typically measured in microns. A negative change represents a reduction in retinal thickness and an improvement in cases of retinal edema.', 'timeFrame': 'Change from baseline at 8 weeks and 26 weeks.'}, {'measure': 'Vitreous Haze Grade', 'description': 'Vitreous haze scale (Nussenblatt 1985 as modified in Lowder 2011). Scores include value 0 (no inflammation), +0.5 (trace inflammation), +1 (mild blurring of the retinal vessels and optic nerve), +1.5 (optic nerve head and posterior retina view obscuration greater than +1 but less than +2), +2 (moderate blurring of the optic nerve head), +3 (marked blurring of the optic nerve head), and +4 (optic nerve head not visible) A higher score indicates a worse outcome.', 'timeFrame': 'Change from baseline at 8 weeks and 26 weeks'}]",4,18 Years,,ALL,False,"Clearside Biomedical, Inc.",INDUSTRY,0,11.0,ACTUAL,2025-09-01T16:18:18.418449,v2_robust,True,True,True,False,False,
NCT04642820,Drugs Brain and Behavior (DDP),Drugs Brain and Behavior,Methamphetamine,"['Methamphetamine', 'placebo oral tablet']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Stimulant Use,['Stimulant Use'],[],COMPLETED,,2020-11-01,2024-06-01,"[{'measure': 'Change in SUbjective Effects as Assessed by Score on ""Feel Drug"", ""Feel High"", ""Like Drug"", and ""Want More"" Sub-scales of Drug Effects Questionnaire (DEQ).', 'description': 'Participants will complete The Drug Effects Questionnaire during the initial baseline session to determine their subjective stimulant profile. The Dug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: ""Feel Drug"", ""Feel High"", ""Like Drug"", and ""Want More"". All sub-scales are scored on a visual analogue scale (Scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.', 'timeFrame': 'Time Frame: Day 1(baseline), 3'}]",[],1,18 Years,35 Years,ALL,True,University of Chicago,OTHER,1,138.0,ACTUAL,2025-09-01T16:18:18.418483,v2_robust,True,True,True,False,False,
NCT00005820,Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy,A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer,nitrocamptothecin,['nitrocamptothecin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],"['adenocarcinoma of the prostate', 'stage IV prostate cancer', 'recurrent prostate cancer']",COMPLETED,,2000-05,2006-09,"[{'measure': 'median time to disease and PSA progression', 'timeFrame': 'Up to 2 years'}]","[{'measure': 'overall survival', 'timeFrame': 'Up to 2 years'}]",2,,,MALE,False,Alliance for Clinical Trials in Oncology,OTHER,1,35.0,ACTUAL,2025-09-01T16:18:18.418496,v2_robust,True,True,True,False,False,
NCT00774020,Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB),"A 6 Months, Open-Label Phase IV Study to Confirm the Safety and Efficacy of Single Intravenous Dose of 5 mg Zoledronic Acid for the Patients of Paget's Disease of Bone (PDB) in China",Zoledronic acid,['Zoledronic acid'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Paget's Disease of Bone,"[""Paget's Disease of Bone""]","[""Paget's Disease of Bone"", 'Serum Alkaline Phosphatase']",COMPLETED,,2008-10-30,2011-01-14,"[{'measure': 'The proportion of patients who achieve therapeutic response (a reduction of at least 75% from baseline in total Serum Alkaline Phosphatase (SAP) excess or normalization of SAP.', 'timeFrame': 'at the end of 3 months and 6 months'}]","[{'measure': 'The percent change from baseline in total Serum Alkaline Phosphatase (SAP).', 'timeFrame': 'at the end of 3 months and 6 months'}, {'measure': 'The percent change from baseline in serum cross-linked C-telopeptide of type I collagen (CTX).', 'timeFrame': 'at the end of 3 months and 6 months'}]",3,30 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,9.0,ACTUAL,2025-09-01T16:18:18.418534,v2_robust,True,True,True,False,False,
NCT00826020,Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis,Prospective Evaluation of a Parenteral Omega-3 Fatty Acid Preparation (Omegaven™) in Therapy of Patients With TPN-Induced Cholestasis,Omegaven™,"['Omega-3 fat emulsion', 'Omegaven™']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Parenteral Nutrition Associated Liver Disease PNALD,"['Parenteral Nutrition Associated Liver Disease PNALD', 'Cholestasis']","['PN', 'parenteral nutrition', 'fat emulsions', 'omega-6 fatty acid', 'liver disease', 'fatty acid deficiency']",COMPLETED,,2009-05-01,2017-10-06,"[{'measure': 'Number of Patients With Progression to Small Bowel Transplantation.', 'description': 'Whether or not the subject had an intestine-containing transplant or not', 'timeFrame': 'Bi-weekly x4, then monthly until the completion of the study, for an overall average of 5.5 years follow-up for the cohort'}]","[{'measure': 'Number of Subjects With Reversal of Biochemical Cholestasis', 'description': 'Of patients starting with elevated total serum bilirubin, the number that progress to normalization of serum total bilirubin in routine bloodwork', 'timeFrame': 'weekly x 4, then bi-weekly x4, then monthly until the completion of the study, with an average follow-up of 5.5 years for the study cohort'}]",2,19 Years,,ALL,False,University of Nebraska,OTHER,0,72.0,ACTUAL,2025-09-01T16:18:18.418545,v2_robust,True,True,True,False,False,
NCT02250820,A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE),A Qualitative Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography,Dexmedetomidine,"['Pentobarbital', 'Dexmedetomidine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Heart Disease,['Heart Disease'],"['Pediatric', 'Sedation', 'Transthoracic echocardiography', 'TTE', 'Dexmedetomidine', 'Pentobarbital']",COMPLETED,,2014-11,2017-12,"[{'measure': 'Sedation Quality', 'description': 'The primary outcome variable will be the sedation quality for the first 60 minutes after sedation drug is administered. It will be assessed if child is sedated within 30 minutes of administration of sedative drug, and if sedation is maintained for at least 30 minutes to allow a detailed transthoracic echocardiographic study. Sedation is defined as achieving Ramsay sedation level \\>3.', 'timeFrame': '60 minutes'}]","[{'measure': 'Time to sedation', 'description': 'Time from first dose of sedative medication to sedation. Sedation is defined as achieving Ramsay sedation level \\>3.', 'timeFrame': 'Participants will be followed for the time it takes to reach a sedated state, an expected average of 30 minutes'}, {'measure': 'Delirium prior to sedation', 'description': 'The incidence of delirium prior to achieving sedation.', 'timeFrame': 'Participants will be followed for the time it takes to reach a sedated state, an expected average of 30 minutes'}, {'measure': 'Duration of sedation level >3', 'timeFrame': 'Participants will be followed for the duration of the procedure, an expected average of 1 hour'}, {'measure': 'Sonographer Pauses', 'description': 'The number of sonographer pauses over 2 minutes due to patient movement or medical intervention will be counted.', 'timeFrame': 'Participants will be followed for the duration of the procedure, an expected average of 1 hour'}, {'measure': 'Need for rescue nasal Dexmedetomidine', 'description': 'The incidence of need for rescue nasal dexmedetomidine, due to patient arousal or movement prior to completion of TTE.', 'timeFrame': 'Participants will be followed for the duration of the procedure, an expected average of 1 hour'}, {'measure': 'Incidence-severity of respiratory complications', 'description': 'We will document the incidence and severity of respiratory complications (including supplemental oxygen).', 'timeFrame': 'Participants will be followed for the duration of their outpatient hospital stay, an expected average of 2 hours'}, {'measure': 'Vital sign deviations of more than 30% from baseline', 'description': 'We will document the incidence of blood pressure or heart rate deviations of more than 30% from baseline. Baseline will be measured prior to sedative administration.', 'timeFrame': 'Participants will be followed for the duration of their outpatient hospital stay, an expected average of 2 hours'}, {'measure': 'Post anesthesia drowsiness or agitation', 'description': 'We will document the incidence-severity of post anesthesia drowsiness or agitation.', 'timeFrame': 'Participants will be followed for the duration of their post procedure stay, an expected average of 1 hour'}, {'measure': 'Duration of Post Anesthesia Care Unit (PACU) Phase', 'description': 'We will document the duration of stay in Post Anesthesia Care Unit (PACU) phase in minutes.', 'timeFrame': 'Participants will be followed for the duration of their post procedure stay, an expected average of 1 hour'}, {'measure': 'Time to oral fluid intake', 'description': 'We will document the time (in minutes) to oral fluid intake during the PACU phase', 'timeFrame': 'Participants will be followed for the duration of their post procedure stay, an expected average of 1 hour'}, {'measure': 'Time to discharge', 'description': 'We will document the time it takes a patient to be discharged from the hospital after the completion of the TTE.', 'timeFrame': 'Participants will be followed for the duration of their post procedure stay, an expected average of 1 hour'}, {'measure': 'Satisfaction of the Parents', 'description': 'The satisfaction of the sedation technique will be completed by the parents by asking a series of questions during a follow-up phone call the next business day after the TTE.', 'timeFrame': 'up to 3 days'}]",13,3 Months,24 Months,ALL,False,"Children's Hospital Medical Center, Cincinnati",OTHER,0,280.0,ACTUAL,2025-09-01T16:18:18.418559,v2_robust,True,True,True,False,False,
NCT04451720,Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis,"A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult Japanese Subjects With Moderate to Severe Palmoplantar Pustulosis",Risankizumab,"['SKYRIZI', 'Placebo', 'ABBV-066', 'Risankizumab']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Palmoplantar Pustulosis (PPP),['Palmoplantar Pustulosis (PPP)'],"['Palmoplantar Pustulosis (PPP)', 'Risankizumab', 'SKYRIZI']",COMPLETED,,2020-07-20,2022-11-21,"[{'measure': 'Change From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score', 'description': 'The Palmoplantar Pustulosis Area and Severity Index (PPPASI) assesses the severity of palmoplantar pustulosis lesions and their response to therapy. In the PPPASI system, the palms and soles are divided into 4 regions: the right palm, left palm, right sole, left sole which account for 20%, 20%, 30%, and 30%, respectively, of the total surface area of the palms and soles. Each of these areas are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPPASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.', 'timeFrame': 'Baseline (Week 0) through Week 16'}]","[{'measure': 'Percentage of Participants Achieving at least 50% Improvement in PPPASI (PPPASI-50)', 'description': 'The Palmoplantar Pustulosis Area and Severity Index (PPPASI) assesses the severity of palmoplantar pustulosis lesions and their response to therapy. In the PPPASI system, the palms and soles are divided into 4 regions: the right palm, left palm, right sole, left sole which account for 20%, 20%, 30%, and 30%, respectively, of the total surface area of the palms and soles. Each of these areas are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPPASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.', 'timeFrame': 'Baseline (Week 0) through Week 16'}, {'measure': 'Percentage of Participants Achieving at least 75% Improvement in PPPASI (PPPASI-75)', 'description': 'The Palmoplantar Pustulosis Area and Severity Index (PPPASI) assesses the severity of palmoplantar pustulosis lesions and their response to therapy. In the PPPASI system, the palms and soles are divided into 4 regions: the right palm, left palm, right sole, left sole which account for 20%, 20%, 30%, and 30%, respectively, of the total surface area of the palms and soles. Each of these areas are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPPASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.', 'timeFrame': 'Baseline (Week 0) through Week 16'}]",3,18 Years,,ALL,False,AbbVie,INDUSTRY,0,119.0,ACTUAL,2025-09-01T16:18:18.418625,v2_robust,True,True,True,False,False,
NCT00001720,Treatment of Childhood Osteoporosis With Alendronate (Fosamax),Alendronate Versus Placebo for Idiopathic Juvenile Osteoporosis,Alendronate,['Alendronate'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Osteoporosis,['Osteoporosis'],"['Glucocorticoids', 'Bone Mineral Density', 'Bisphosphonates', 'Vertebral Fracture', 'Childhood Osteoporosis']",COMPLETED,,1998-03,2003-06,[],[],0,,,ALL,False,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,0,50.0,,2025-09-01T16:18:18.418741,v2_robust,True,True,True,False,False,
NCT04316182,Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION),A Phase II triAl of Cabozantinib for hepaTocellular carcInoma Patients intOlerant to Sorafenib Treatment or First Line Treatment Different to sorafeNib. (ACTION Trial),Cabozantinib,"['Cabozantinib', 'Cabometix']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],"['Hepatocellular Carcinoma', 'Cabozantinib']",COMPLETED,,2020-07-31,2023-02-22,"[{'measure': 'Rate of Adverse Events (AE) ≥ Grade 3 (CTCAE 5.0) Excluding Palmar-plantar Erythrodysesthesia', 'description': 'Percentage of patients with Grade 3 AEs in relation with total number of treated patients', 'timeFrame': 'Up to 18 months'}, {'measure': 'Rate of Adverse Events', 'description': 'Percentage of patients with AEs in relation with total number of treated patients', 'timeFrame': 'Up to 18 months'}, {'measure': 'Rate of Related-AEs', 'description': 'Percentage of patients with related AEs in relation with total number of treated patients', 'timeFrame': 'Up to 18 months'}, {'measure': 'Rate of Death Due to Adverse Events', 'description': 'Percentage of patients who die during treatment due to adverse events in relation with total number of treated patients', 'timeFrame': 'Up to 18 months'}, {'measure': 'Rate of AEs Leading to Treatment Discontinuation', 'description': 'Percentage of patients with AEs leading to treatment discontinuation in relation with total number of treated patients', 'timeFrame': 'Up to 18 months'}]","[{'measure': 'Time to Progression (TTP)', 'description': 'Time from the date of start of treatment until the date of objective disease progression or death', 'timeFrame': 'Up to 18 months'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'ORR is defined as the number of subjects with a best overall response of a complete response (CR) or partial response (PR) divided by the number of included patients', 'timeFrame': 'Up to 18 months'}, {'measure': 'Pattern of Progression', 'description': 'Type of progression divided by number of patients', 'timeFrame': 'Up to 18 months'}, {'measure': 'Overall Survival (OS)', 'description': 'Time from the date of start of treatment until the date of death', 'timeFrame': 'Up to 18 months'}, {'measure': 'Post-progression Survival (PPS)', 'description': 'Time from the date of disease progression until the date of death', 'timeFrame': 'Up to 18 months'}, {'measure': 'Rate of Patients Who Develop New Extra-hepatic Spread', 'description': 'Number of subjects who develop new extra-hepatic spread divided by number of included patients', 'timeFrame': 'Up to 18 months'}]",11,18 Years,,ALL,False,Fundacion Clinic per a la Recerca Biomédica,OTHER,1,24.0,ACTUAL,2025-09-01T16:18:18.418916,v2_robust,True,True,True,False,True,
NCT06007482,A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors,"An Open-Label, Multicenter, First-in-Human, Phase 1 Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors",ES009,['ES009'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumor,['Advanced Solid Tumor'],['Leukocyte immunoglobulin-like receptor B2 (LILRB2)'],COMPLETED,,2023-09-26,2025-02-18,"[{'measure': 'The frequency and severity of adverse events of ES009', 'description': 'Adverse events will be assessed and assigned by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.', 'timeFrame': '1-3 years'}, {'measure': 'Maximum tolerated dose (MTD) of ES009', 'description': 'The MTD of ES009 will be determined.', 'timeFrame': '1-3 years'}, {'measure': 'Optimal biological dose (OBD) of ES009', 'description': 'The OBD of ES009 will be determined.', 'timeFrame': '1-3 years'}, {'measure': 'Recommended phase 2 dose (RP2D) of ES009', 'description': 'The RP2D of ES009 will be determined.', 'timeFrame': '1-3 years'}, {'measure': 'Maximum administered dose (MAD) of ES009', 'description': 'The MAD of ES009 will be determined.', 'timeFrame': '1-3 years'}]","[{'measure': 'Maximum observed serum concentration (Cmax) of ES009', 'description': 'Maximum observed serum concentration (Cmax) of ES009 will be measured.', 'timeFrame': '1-3 years'}, {'measure': 'Trough observed serum concentration (Ctrough) of ES009', 'description': 'Trough observed serum concentration (Ctrough)of ES009 will be measured.', 'timeFrame': '1-3 years'}, {'measure': 'Area under the serum concentration time curve (AUC) of ES009', 'description': 'Area under the serum concentration time curve (AUC) of ES009 will be measured.', 'timeFrame': '1-3 years'}, {'measure': 'Time to Cmax (Tmax) of ES009', 'description': 'Time to Cmax (Tmax) of ES009 will be measured.', 'timeFrame': '1-3 years'}, {'measure': 'The terminal elimination half life of ES009', 'description': 'The terminal elimination half-life (t 1/2) of ES009 will be measured.', 'timeFrame': '1-3 years'}, {'measure': 'Immunogenicity of ES009', 'description': 'Frequency of anti-drug antibodies (ADA) against ES009 will be determined.', 'timeFrame': '1-3 years'}, {'measure': 'Preliminary antitumor activity of ES009', 'description': 'Tumor response will be measured by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1) by Investigator assessment.', 'timeFrame': '1-3 years'}]",12,18 Years,,ALL,False,Elpiscience Biopharma Australia Pty. Ltd.,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:18.418929,v2_robust,True,True,True,False,True,
NCT03034382,Morphine and/or Nalbuphine as Adjuvants in Ultrasound Guided Interscalene Block: for Shoulder Surgeries,Adjuvants to Ultrasonic Guided Interscalene Block In Arthroscopic Rotator Cuff Repair; Morphine and/or Nalbuphine,Morphine,"['Nalbuphine', 'Lidocaine Hydrochloride 1% and epinephrine 1:400,000', 'Morphine', 'lidocaine HCL and Adrenaline', 'morphine sulphate', 'nubain', 'Marcaine HCL', 'Bupivacaine 0.5%']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Rotator Cuff Tear,['Rotator Cuff Tear'],"['morphine', 'nalbuphine', 'arthroscopic rotator cuff repair', 'ultrasound guided interscalene block']",UNKNOWN,,2016-01,2017-06,"[{'measure': 'the total number of analgesic requests', 'description': 'the combination of opioid agonist and mixed agonist-antagonist peripherally prevents the development of early tolerance of the opioid agonist; thus the agonist would maintain the same efficacy and this will be obvious clinically by a reduction in the requests for supplementary analgesia.', 'timeFrame': '72 hours postoperative followup'}]","[{'measure': 'duration of analgesia', 'description': 'duration of analgesia when morphine or nalbuphine or both used in interscalene block using VAS.', 'timeFrame': '72 hours followup'}, {'measure': 'patient satisfaction', 'description': '\\- The patient satisfaction score. Patients were also asked to rate their satisfaction with the analgesia on a scale of 0-10 (0 for total dissatisfaction to 10 for total satisfaction).', 'timeFrame': '72 hours followup'}, {'measure': 'The first time to ask for analgesics', 'timeFrame': '72 hours followup'}, {'measure': 'sedation score', 'description': 'recorded every 4 hours; ranging from alert, drowsy, sleeping but responsive to verbal commands up to unarousable (we consider sedation score 3 or more as clinically significant sedation that mandate close patient observation every hour).', 'timeFrame': '72 hours followup'}, {'measure': 'number of vomiting attacks', 'description': 'recorded every 4 hours. A vomiting attack was defined by events of vomiting that occurred in a rapid sequence (\\<1 minute between events). If vomiting was separated by more than 1 minute; they will be considered to be separate attacks. Retching (the same as vomiting but without expulsion of gastric contents) was considered as vomiting. If the patient experienced vomiting; ondansetron 4 mg IV was given.', 'timeFrame': '72 hours followup'}, {'measure': 'itching', 'description': 'Itching is assessed using an ordinal scale (0 = no itch, 1 = mild, 2 = moderate, 3 = severe).', 'timeFrame': '72 hours followup'}]",7,18 Years,65 Years,ALL,False,Assiut University,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:18.418989,v2_robust,True,True,False,False,False,
NCT02227082,Olaparib and Radiotherapy in Inoperable Breast Cancer,Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast Andregional Lymph Nodes in Patients With Breast Cancer,olaparib,"['KU-0059436', 'olaparib', 'AZD2281']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Locally Advanced Malignant Neoplasm,"['Locally Advanced Malignant Neoplasm', 'Inflammatory Breast Carcinoma', 'Triple-Negative Invasive Breast Carcinoma']","['radiotherapy', 'olaparib', 'breast cancer', 'locally advanced breast cancer']",COMPLETED,,2013-10-21,2020-08,"[{'measure': 'The incidence of dose limiting toxicities.', 'timeFrame': '1 year'}]","[{'measure': 'Acute toxicity', 'description': 'severity, duration and relation with treatment of all adverse events according to CTCAE version 4.03 occurring from start of treatment until 3 months after end of treatment', 'timeFrame': '3 months after treatment'}, {'measure': 'Late toxicity', 'description': 'severity, duration and relation with treatment of all adverse events that are possibly, probably or definitely related to the combination treatment according to CTCAE version 4.03', 'timeFrame': '3 months until 2 years after end of treatment'}]",3,18 Years,,FEMALE,False,The Netherlands Cancer Institute,OTHER,0,7.0,ACTUAL,2025-09-01T16:18:18.419014,v2_robust,True,True,True,False,True,
NCT06956482,PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis,PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis,N-Acetylcysteine (NAC) Treatment,"['Placebo of Prednisolone', 'Prednisolone', 'N-Acetylcysteine (NAC) Treatment', 'Placebo of N-acetylcysteine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Alcoholic Hepatitis,['Alcoholic Hepatitis'],"['Alcoholic hepatitis', 'survival, prednisolone', 'N-acetylcysteine', 'liver insufficiency']",NOT_YET_RECRUITING,,2025-10,2026-10,"[{'measure': 'Rate of patients alive with compensated liver disease', 'description': 'Rate of patients alive with compensated liver disease defined as a MELD score \\<17 at 90 days.\n\nMELD score will be calculated according to the formula given in Dunn et al. Hepatology 2005:\n\nMELD = 9.57 x ln (creatinine in mg/dL) + 3.78 x ln (bilirubin in mg/dL) + 11.2 x ln (INR) + 6.43', 'timeFrame': '90 days'}]",[],1,18 Years,75 Years,ALL,False,"University Hospital, Lille",OTHER,0,477.0,ESTIMATED,2025-09-01T16:18:18.419094,v2_robust,True,True,False,False,False,
NCT02743182,HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients,HBsAg Loss Adding Pegylated Interferon Alfa-2a in HBeAg-negative Patients Treated With Nucleos(t)Ide Analogues.,Pegylated interferon alfa-2a,['Pegylated interferon alfa-2a'],1,INTERVENTIONAL,['NA'],,,Chronic Hepatitis B (HBeAg-negative),['Chronic Hepatitis B (HBeAg-negative)'],[],COMPLETED,,2015-01,2018-11,"[{'measure': 'Number of patients with HBsAg loss', 'description': 'HBsAg will be evaluated one year after treatment completion (96 weeks). Efficacy will be calculated as a proportion (rate of patients with HBsAg loss/treated patients)', 'timeFrame': '1 year after treatment completion'}]",[],1,18 Years,,ALL,False,José Antonio Carrion,OTHER,1,119.0,ACTUAL,2025-09-01T16:18:18.419104,v2_robust,True,True,True,False,False,
NCT05072782,"Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)","Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)",Infliximab CT-P13,"['Remsima', 'Infliximab CT-P13', 'Immunosuppressors (Thiopurines or Methotrexate)']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Crohn Disease,['Crohn Disease'],"[""Crohn's Disease"", 'Rutgeerts score i2', 'Infliximab CT-P13', 'Postoperative reccurrence', 'Ileocolonic resection']",UNKNOWN,,2021-12-21,2024-06-15,"[{'measure': 'Number of patients with an i0-i1 modified Rutgeerts score at 12 months.', 'description': 'Number of patients with an i0-i1 modified Rutgeerts score at 12 months.', 'timeFrame': 'Month12'}]","[{'measure': 'Number of patients with an i3-i4 modified Rutgeerts score at 12 months', 'description': 'Number of patients with an i3-i4 modified Rutgeerts score at 12 months', 'timeFrame': 'Month 12'}, {'measure': 'Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months', 'description': 'Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months', 'timeFrame': 'Month 12'}, {'measure': 'Proportion of patients with an i0 modified Rutgeerts score at 12 months', 'description': 'Proportion of patients with an i0 modified Rutgeerts score at 12 months', 'timeFrame': 'Month 12'}, {'measure': 'Patient Reporting Outcome score at 12 months.', 'description': 'Patient Reporting Outcome score at 12 months will be assessed for the evaluation of disease activity (clinical remission).', 'timeFrame': 'Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12'}, {'measure': 'Clinical postoperative recurrence', 'description': 'Clinical postoperative recurrence within 12 months defined by : Average daily Stool Frequency ≥ 3.5 and average daily Abdominal Pain score ≥ 1.5, AND\n\n* increased CRP compared to inclusion, at least + 10 mg/l\n* OR increased fecal calprotectin compared to inclusion, at least + 250 μg/g\n\nAverage daily Stool frequency, average daily Abdominal Pain score, CRP and Calprotectin feacal will be combined to report the clinical postoperative recurrence (this outcome is is expressed without units)', 'timeFrame': 'Baseline, Month 4, Month 8, Month 12'}, {'measure': 'Surgical recurrence within 12 months', 'description': 'Surgical recurrence within 12 months defined by need for a new ileocolonic resection. Proportion of surgical recurrence within 12 months', 'timeFrame': 'Baseline, Month 4, Month 8, Month 12'}, {'measure': 'Endoscopic dilatation within 12 months', 'description': 'Endoscopic dilatation within 12 months defined by a need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS \\> 4) before endoscopy Proportion of endoscopic dilatation within 12 months', 'timeFrame': 'Baseline, Month 4, Month 8, Month 12'}, {'measure': 'Time to clinical postoperative recurrence will be assessed', 'description': 'Time to clinical postoperative recurrence will be assessed', 'timeFrame': 'Baseline, Month 4, Month 8, Month 12'}, {'measure': 'Serious adverse events', 'description': 'Occurence of Serious Adverse Events', 'timeFrame': 'Screening, Baseline, Month 4, Month 8, Month 12'}, {'measure': 'Quality of life: EQ5D-5L questionnaires', 'description': 'Quality of life will be assessed with the EQ5D-5L questionnaire', 'timeFrame': 'Baseline, week 2, week 6, Month 4, Month 8, Month 12'}, {'measure': 'Work productivity and activity impairement questionnaires', 'description': 'Work productivity and activity impairement will be assessed with work productivity and activity impairement questionnaires', 'timeFrame': 'Baseline, week 2, week 6, Month 4, Month 8, Month 12'}]",12,18 Years,75 Years,ALL,False,Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives,OTHER,1,360.0,ESTIMATED,2025-09-01T16:18:18.419126,v2_robust,True,True,False,False,True,
NCT02948582,"Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Randomized, Placebo-Controlled, Double-Blind, Dose Ranging, Single-Dose, 6-Way Crossover Study to Assess Safety, Efficacy and Pharmacokinetics of EP-101 Using eFlow Nebuliser in Patients With COPD",Glycopyrrolate Inhalation Solution12.5μg,"['Placebo 0.5mL', 'Glycopyrrolate Inhalation Solution 400μg', 'Glycopyrrolate Inhalation Solution 200μg', 'Glycopyrrolate Inhalation Solution 50μg', 'GIS', 'Placebo', 'Glycopyrrolate Inhalation Solution12.5μg', 'Glycopyrrolate Inhalation Solution 100μg']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Obstructive Pulmonary Disease,['Chronic Obstructive Pulmonary Disease'],"['Chronic Obstructive Pulmonary Disease', 'COPD', 'Emphysema', 'Chronic bronchitis']",COMPLETED,,2010-07,2010-11,"[{'measure': 'Trough FEV1 (Change From Baseline)', 'description': 'Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.\n\nTrough FEV1 was defined as the mean of FEV1 values obtained at 23 hours 30 minutes and 24 hours post-dose of each Treatment Visit.', 'timeFrame': '24hr post dose'}, {'measure': 'Standardized FEV1AUC0-12 Area Under the FEV1 Curve From 0 to 12 Hours Post-dose ( Actual and Change From Baseline).', 'description': 'Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.. The standardized actual FEV1 AUC(0-12) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-12) was also calculated similarly, using the change from pre-dose FEV1.', 'timeFrame': '0-12h post dose'}, {'measure': 'Standardized FEV1AUC12-24 Area Under the FEV1 Curve From 12 to 24 Hours Post- Dose (Actual and Change From Baseline).', 'description': 'Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized actual FEV1 AUC(12-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(12-24) was also calculated similarly, using the change from pre-dose FEV1.', 'timeFrame': '12-24h post dose'}, {'measure': 'Standardized FEV1 AUC0-24 Area Under the FEV1 Curve From 0 to 24 Hours Post-dose (Actual and Change Baseline)', 'description': 'Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The standardized actual FEV1 AUC(0-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-24) was also calculated similarly, using the change from pre-dose FEV1.', 'timeFrame': '0 to 24h'}, {'measure': 'Peak FEV1 (Change From Baseline and Percent Change)', 'description': 'spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The peak FEV1 was defined as the highest post-dose FEV1 value within 4 hrs after the dose. Percent change from baseline was calculated as 100 times the difference of peak FEV1 minus baseline FEV1 divided by baseline FEV1.', 'timeFrame': '0-4h post dose'}]","[{'measure': 'Cmax; Maximum Observed Plasma Concentration', 'description': 'Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr', 'timeFrame': '0 to 12 hour'}, {'measure': 'Tmax; Time to Maximum Observed Plasma Concentration', 'description': 'Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr', 'timeFrame': '0 to 12 hours'}, {'measure': 't1/2; Plasma Half-life', 'description': 'Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr', 'timeFrame': '0 to 12 hour'}, {'measure': 'AUC0-t; Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Drug Concentration.', 'description': 'Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr', 'timeFrame': '0 to 12 hour'}, {'measure': 'AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity', 'description': 'Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr', 'timeFrame': '0 to 12 hour'}, {'measure': 'Number of Subjects Who Died, Number of Subjects With Treatment Emergent SAEs, Number of Subjects Who Discontinued Due to AE', 'description': ""AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment"", 'timeFrame': 'Day 69 (includes dosing Day 1, washout Day 12, safety follow up Day 69)'}, {'measure': 'Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study', 'description': 'Vital signs were measured at screening and at each Treatment Visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.', 'timeFrame': '0-24 h'}, {'measure': 'Number of Clinically Significant Abnormal Laboratory Results Reported During the Study', 'description': 'Clinical safety lab parameters were collected at screening and at the post study assessment. Any laboratory values that were out of range of normal reference values were evaluated by the Investigators.', 'timeFrame': 'Day -14, Day 69'}, {'measure': 'Number of Subjects With Clinically Significant ECG Parameters Reported During the Study', 'description': 'ECGs were recorded at screening and at each study treatment visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.', 'timeFrame': '0 to 24h'}, {'measure': 'Percentage of Subjects With Treatment Emergent AEs', 'description': ""AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment"", 'timeFrame': 'Day 69 (includes dosing Day 1, washout Day 12, safety follow up Day 69)'}]",15,40 Years,75 Years,,False,Sunovion Respiratory Development Inc.,INDUSTRY,0,42.0,ACTUAL,2025-09-01T16:18:18.419243,v2_robust,True,True,True,False,True,
NCT01016782,Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea,"Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0444 Gel",0444,['0444'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Inflammatory Rosacea,['Inflammatory Rosacea'],"['Inflammatory Rosacea', 'Rosacea']",COMPLETED,,2008-01,2009-07,"[{'measure': 'Reduction in the number of papules and pustules from Baseline to End of Treatment', 'timeFrame': '70 Days'}]","[{'measure': ""Reduction in the Investigator's Global Evaluation, Clear or Almost Clear"", 'timeFrame': '70 Days'}]",2,18 Years,,ALL,False,Fougera Pharmaceuticals Inc.,INDUSTRY,0,867.0,ACTUAL,2025-09-01T16:18:18.419281,v2_robust,True,True,True,False,False,
NCT05372224,Effect of Vitamin D and Denosumab on Bone Remodelling in Women With Postmenopausal Osteoporosis,Vitamin D Improves Osteoporosis in Postmenopausal Women With Denosumab Failure,Cholecalciferol,"['Histofil®', 'Cholecalciferol']",2,INTERVENTIONAL,['NA'],,,Hypovitaminosis D,"['Hypovitaminosis D', 'Osteoporosis, Postmenopausal', 'Menopause']","['Vitamin D', 'Postmenopausal Osteoporosis', 'Denosumab', 'Hypovitaminosis D', 'Osteoporosis', 'Osteopenia']",COMPLETED,,2020-06-22,2021-06-22,"[{'measure': 'Number of participants with hip T-score improvement at 12 months', 'description': 'It refers to the number of participants who improved their hip T-score at three months after treatment.', 'timeFrame': '12 months'}, {'measure': 'Number of participants with lumbar spine T-score improvement at 12 months', 'description': 'It refers to the number of participants who improved their lumbar spine T-score at three months after treatment.', 'timeFrame': '12 months'}, {'measure': 'Number of participants with osteoporosis of the hip at 12 months', 'description': 'It refers to the number of participants that present a hip T-score above -2.5 three months after treatment.', 'timeFrame': '12 months'}, {'measure': 'Number of participants with osteoporosis of the lumbar spine at 12 months', 'description': 'It refers to the number of participants that present a lumbar spine T-score greater than -2.5 three months after treatment.', 'timeFrame': '12 months'}, {'measure': 'Number of participants with osteopenia on the hip at 12 months', 'description': 'It refers to the number of participants that present a hip T-score from -1 to -2.4 three months after treatment.', 'timeFrame': '12 months'}, {'measure': 'Number of participants with osteopenia of the lumbar spine at 12 months', 'description': 'It refers to the number of participants that present a lumbar spine T-score from -1 to -2.4 three months after treatment.', 'timeFrame': '12 months'}, {'measure': 'Number of participants with normal hip T-score at 12 months', 'description': 'It refers to the number of participants that present a hip T-score below -1 three months after treatment.', 'timeFrame': '12 months'}, {'measure': 'Number of participants with normal lumbar spine T-score at 12 months', 'description': 'It refers to the number of participants that present a lumbar spine T-score below -1 three months after treatment.', 'timeFrame': '12 months'}, {'measure': 'Number of participants with improvement in serum levels of vitamin D at 12 months', 'description': 'Improvement in serum levels of 25-hydroxy vitamin D \\[25(OH)D\\] was considered when serum vitamin D levels increased concerning baseline levels.', 'timeFrame': '12 months'}, {'measure': 'Number of participants with clinical remission of hypovitaminosis D at 12 months', 'description': 'Remission of hypovitaminosis D was considered when serum levels of 25-hydroxy vitamin D \\[25(OH)D\\] were above 29 pg/ml.', 'timeFrame': '12 months'}]","[{'measure': 'Number of participants with vitamin D sufficiency at 12 months', 'description': 'It refers to the number of participants who reached serum levels of vitamin D above 29 pg/ml after three months of treatment.', 'timeFrame': '12 months'}, {'measure': 'Number of participants with vitamin D insufficiency at 12 months', 'description': 'It refers to the number of participants who reached serum levels of vitamin D of 21 to 29 pg/ml after three months of treatment.', 'timeFrame': '12 months'}, {'measure': 'Number of participants with vitamin D deficiency at 12 months', 'description': 'It refers to the number of participants who reached serum levels of vitamin D less than 20 pg/ml after three months of treatment.', 'timeFrame': '12 months'}]",13,45 Years,89 Years,FEMALE,False,Hospital Regional 1o de Octubre,OTHER,2,55.0,ACTUAL,2025-09-01T16:18:18.419306,v2_robust,True,True,True,False,False,
NCT00970424,Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus on Background Treatment With Pioglitazone",Placebo,"['Dutogliptin', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Diabetes Mellitus, Type II","['Diabetes Mellitus, Type II']",[],TERMINATED,,2009-08,,"[{'measure': 'Hemoglobin A1c Level (HbA1c)', 'timeFrame': 'HbA1c is drawn at Visit 1 (Week -16 to -4), Visit 3 (Week -2), Visit 4 (Week 0), Visit 5 (Week 4), Visit 6 (Week 10), Visit 7 (Week 18) and Week 8 (Week 26)'}]","[{'measure': 'Fasting Plasma Glucose Level (FPG)', 'timeFrame': 'FPG is drawn at Visit 1 (Week -16 to -4), Visit 2 (Week -4), Visit 3 (Week -2), Visit 4 (Week 0), Visit 5 (Week 4), Visit 6 (Week 10), Visit 7 (Week 18) and Visit 8 (Week 26).'}]",2,18 Years,85 Years,ALL,False,Forest Laboratories,INDUSTRY,1,252.0,ACTUAL,2025-09-01T16:18:18.419354,v2_robust,True,True,False,True,False,
NCT04458324,Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury,Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury,Buspirone Hydrochloride,"['Buspirone Hydrochloride', 'Buspirone placebo', 'Buspar']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Spinal Cord Injuries,['Spinal Cord Injuries'],['Function Electrical Stimulation (FES)-Rowing'],RECRUITING,,2020-12-22,2026-07-31,"[{'measure': 'Change in baseline aerobic exercise capacity', 'description': 'Participants perform incremental FES rowing exercise test to determine maximum oxygen consumption (VO2 peak)', 'timeFrame': 'Baseline, 3 months, 6 months'}, {'measure': 'Change in baseline ventilation during exercise', 'description': 'Participants perform incremental FES rowing exercise test to determine ventilation during exercise (VE peak).', 'timeFrame': 'Baseline, 3 months, 6 months'}]","[{'measure': 'Change from baseline in glucoregulatory status', 'description': 'Blood will be taken via standard venipuncture to measure the homeostasis model assessment (HOMA) of insulin resistance.', 'timeFrame': 'Baseline, 3 months, 6 months'}, {'measure': 'Change from baseline in glucoregulatory status', 'description': 'Blood will be taken via standard venipuncture to measure the quantitative insulin check index (QUICKI).', 'timeFrame': 'Baseline, 3 months, 6 months'}, {'measure': 'Change from baseline in glucoregulatory status', 'description': 'Blood will be taken via standard venipuncture to measure hemoglobin A1c.', 'timeFrame': 'Baseline, 3 months, 6 months'}, {'measure': 'Change from baseline in serum lipids', 'description': 'Blood will be taken via standard venipuncture to measure plasma total cholesterol.', 'timeFrame': 'Baseline, 3 months, 6 months'}, {'measure': 'Change from baseline in serum lipids', 'description': 'Blood will be taken via standard venipuncture to measure low-density lipoprotein cholesterol.', 'timeFrame': 'Baseline, 3 months, 6 months'}, {'measure': 'Change from baseline in serum lipids', 'description': 'Blood will be taken via standard venipuncture to measure high density apolipoprotein cholesterol.', 'timeFrame': 'Baseline, 3 months, 6 months'}, {'measure': 'Change from baseline in serum lipids', 'description': 'Blood will be taken via standard venipuncture to measure triglycerides.', 'timeFrame': 'Baseline, 3 months, 6 months'}, {'measure': 'Change from baseline in visceral adiposity', 'description': 'The investigators will use a 5th generation General Electric Healthcare dual x-ray absorptiometry (DXA) scanner for regional fat measurements, the DXA software can be used to define standard regions that will allow comparability of measurements throughout the study.', 'timeFrame': 'Baseline, 3 months, 6 months'}, {'measure': 'Change in baseline forced vital capacity', 'description': 'Spirometry will be used to measure lung function, specifically forced vital capacity (FVC).', 'timeFrame': 'Baseline, 3 months, 6 months'}, {'measure': 'Change in baseline maximal voluntary ventilation', 'description': 'Spirometry will be used to measure lung function, specifically maximal voluntary ventilation (MVV).', 'timeFrame': 'Baseline, 3 months, 6 months'}, {'measure': 'Change in baseline forced expiratory capacity in the first second', 'description': 'Spirometry will be used to measure lung function, specifically forced expiratory capacity in the first second (FEV1).', 'timeFrame': 'Baseline, 3 months, 6 months'}]",13,18 Years,40 Years,ALL,False,Spaulding Rehabilitation Hospital,OTHER,0,70.0,ESTIMATED,2025-09-01T16:18:18.419376,v2_robust,True,True,False,False,False,
NCT01004224,A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies,"A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies",BGJ398,['BGJ398'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3","['Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3', 'Squamous Lung Cancer With FGFR1 Amplification', 'Bladder Cancer With FGFR3 Mutation or Fusion', 'Advanced Solid Tumors With FGFR1 Amplication', 'Advanced Solid Tumors With FGFR2 Amplication', 'Advanced Solid Tumors With FGFR3 Mutation']","['advanced solid tumors', 'lung cancer', 'bladder cancer', 'BGJ398', 'FGFR', 'kinase inhibitor', 'advanced solid malignancies']",COMPLETED,,2009-12-11,2018-10-08,"[{'measure': 'Incidence rate and category of dose-limiting toxicities will be tabulated for patients included in the dose escalation portion of the study, to establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPTD)', 'description': 'Incidence rate and category of dose-limiting toxicities will be tabulated for patients included in the dose escalation portion of the study, to establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPTD). This will be calculated using an established statistical model, based on incidence of adverse events and serious adverse events, physical examinations, vital signs, electrocardiograms, and laboratory parameters', 'timeFrame': '23 months'}]","[{'measure': 'To assess preliminary anti-tumor activity of BGJ398 for patients in expansion Arm 4 (previously treated patients with advanced/metastatic UCC with FGFR3 gene alterations)', 'description': 'overall response rate (ORR), as assessed by investigator per RECIST v 1.0; overall survival (OS), duration of response (DOR) and disease control rate (DCR) will be assessed', 'timeFrame': '23 months'}, {'measure': 'To determine the pharmacokinetic (PK) profiles of oral BGJ398', 'description': 'Time vs. concentration profiles, PK parameters of BGJ398 and known active metabolite(s).', 'timeFrame': '23 months'}, {'measure': 'To evaluate the pharmacodynamic effect of the drug.', 'description': 'Pre- vs. post treatment serial changes in FGF23 plasma levels (not done for patients enrolled to expansion Arm 4)', 'timeFrame': '23 months'}, {'measure': 'Assess preliminary anti-tumor activity for patients not in Arm 4.', 'description': 'Overall tumor response rate (ORR) and PFS assessed by investigator per RECIST', 'timeFrame': '23 months'}]",5,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,208.0,ACTUAL,2025-09-01T16:18:18.419425,v2_robust,True,True,True,False,True,
NCT00255424,Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients,A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients Not on Dialysis,ferumoxytol or oral iron,['ferumoxytol or oral iron'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Anemia,['Anemia'],[],COMPLETED,,2004-05,2006-08,[{'measure': 'The mean change in hemoglobin from baseline.'}],[{'measure': 'Change in iron indices.'}],2,18 Years,,ALL,False,"AMAG Pharmaceuticals, Inc.",INDUSTRY,0,304.0,,2025-09-01T16:18:18.419437,v2_robust,True,True,True,False,False,
NCT00265824,Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM),Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2,bevacizumab,"['bevacizumab', 'bevacizumab, erlotinib']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Colorectal Cancer,['Colorectal Cancer'],"['stage IV colon cancer', 'stage IV rectal cancer', 'adenocarcinoma of the colon', 'adenocarcinoma of the rectum', 'chemotherapy']",COMPLETED,,2005-05,,"[{'measure': 'Progression-free survival during maintenance therapy', 'timeFrame': 'Tumor evaluation every 2 months'}]",[],1,18 Years,80 Years,ALL,False,GERCOR - Multidisciplinary Oncology Cooperative Group,OTHER,0,700.0,ACTUAL,2025-09-01T16:18:18.419534,v2_robust,True,True,True,False,False,
NCT04425824,Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma,"Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma: An Exploratory Small Sample, Phase II, Single-center Clinical Trail",Toripalimab combine with Rituximab,"['JS001 combine with rituxan', 'Toripalimab combine with Rituximab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Diffuse Large B-cell Lymphoma,"['Diffuse Large B-cell Lymphoma', 'Rituximab', 'Toripalimab']","['DLBCL', 'CD20', 'Toripalimab', 'Rituximab']",UNKNOWN,,2020-06-15,2022-12-31,"[{'measure': 'Objective Response Rate(ORR)', 'description': 'From the beginning of treatment, adopt Lugano 2014 evaluation standard, imaging examinations are performed every 2 cycles to assess changes in disease until progression or death', 'timeFrame': 'up to 24 months'}, {'measure': 'Progression Free Survival(PFS)', 'description': 'From the date into this study to disease progression or death', 'timeFrame': 'up to 24 months'}]","[{'measure': 'To assessment of the safety events', 'description': 'Number of subjects experiencing different-grade toxicity', 'timeFrame': 'up to 24 months'}, {'measure': 'Assessment of the correlation between tumor cell PD-L1 expression intensity and efficacy', 'description': 'Subjects will be according to the Lugano 2014 criteria assessed with computed tomograph(CT) at screening,after completion of treantment therapy and during the post-treatment follow-up period.Baseline biopsies for immunologic analyses will be obtained from patients. Secondary histologic outcome include percent PD-L1 positive tumor cells by immunohistochemistry.', 'timeFrame': 'up to 24 months'}]",4,18 Years,80 Years,ALL,False,Chinese Academy of Medical Sciences,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:18.419599,v2_robust,True,True,False,False,True,
NCT00371124,"Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children","A Randomised, Double-Masked Study to Compare The Safety and Efficacy of Bilateral 0.5%, 0.1% & 0.01% Atropine Treatment In Controlling Progression of Myopia In Children",Atropine Eye drops,['Atropine Eye drops'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Myopia,['Myopia'],"['Myopia treatment', 'Atropine']",UNKNOWN,,2006-03,,[{'measure': 'Spherical equivalent refraction determined by cycloplegic autorefraction'}],"[{'measure': 'Axial length determined by non-contact partial coherence interferometry'}, {'measure': 'Ocular symptoms'}, {'measure': 'Induced cycloplegia assessed by near acuity and amplitude of accommodation tests'}, {'measure': 'Pupil reactivity and diameter assessment'}, {'measure': 'Ocular surface and anterior segment changes assessed by slit-lamp and intraocular pressure assessed by non-contact tonometry'}, {'measure': 'Posterior segment changes assessed by fundus photography and ophthalmoscopy'}, {'measure': 'Retinal function assessed by distance acuity test and electroretinography'}]",8,6 Years,12 Years,ALL,False,Singapore National Eye Centre,OTHER_GOV,0,400.0,ESTIMATED,2025-09-01T16:18:18.419698,v2_robust,True,True,False,False,False,
NCT05667324,Septorhinoplasty Post-operative Pain Control With SPG Nerve Block,Post-operative Pain Control With Sphenopalantine Ganglion Nerve Block in Septorhinoplasty Patients,Ropivacaine,"['Ropivacaine', 'Placebo', 'Dexamethasone']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Deviated Nasal Septum,['Deviated Nasal Septum'],"['Post-op pain', 'septorhinoplasty', 'deviated septum']",COMPLETED,,2023-04-12,2025-02-28,"[{'measure': 'Decrease the opioid requirement post-operatively as assessed by providers.', 'description': 'post operative period', 'timeFrame': '7 days +/- 2 days'}]","[{'measure': 'Decrease in post-anesthesia care unit observation time.', 'description': 'PACU duration times', 'timeFrame': '60-180 minutes'}, {'measure': 'Efficiency of SMS based survey for post-operative data collection.', 'timeFrame': '5 days post-operatively +/- 1 day'}]",3,18 Years,80 Years,ALL,False,University of Florida,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:18.419713,v2_robust,True,True,True,False,False,
NCT00759824,"A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide","A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide","Adriamycin, cyclophosphamide, vindesine, valproic acid","['Adriamycin, cyclophosphamide, vindesine, valproic acid']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Small Cell Lung Carcinoma,['Small Cell Lung Carcinoma'],"['Small cell lung carcinoma', 'Valproic acid', 'Adriamycin', 'Cyclophosphamide', 'Vindesine', 'Second-line chemotherapy']",COMPLETED,,2008-09,2014-06,"[{'measure': 'Six-months progression-free survival', 'timeFrame': 'The period between the day of registration and the date of first progression'}]","[{'measure': 'Survival', 'timeFrame': 'Survival will be dated from the date of registration'}, {'measure': 'Response rate', 'timeFrame': 'Every three cycles of chemotherapy'}, {'measure': 'Toxicity', 'timeFrame': 'After each course of chemotherapy and at the end of treatment'}]",4,18 Years,,ALL,False,European Lung Cancer Working Party,OTHER,0,64.0,ACTUAL,2025-09-01T16:18:18.419789,v2_robust,True,True,True,False,False,
NCT03812224,A Controlled Trial of Erenumab in Migraine Prevention,"A Phase 3 Japanese Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention",Erenumab,"['Aimovig®', 'AMG 334', 'Erenumab', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Migraine,['Migraine'],[],COMPLETED,,2019-04-12,2020-11-25,"[{'measure': 'Change From Baseline in Mean Monthly Migraine Days (MMD) Over Months 4, 5, and 6 of the Double-blind Treatment Period', 'description': 'A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined either as a migraine with or without aura, lasting for ≥ 4 hours, and meeting at least 1 of the following criteria:\n\n1. ≥ 2 of the following pain features:\n\n   * unilateral\n   * throbbing\n   * moderate to severe\n   * exacerbated with exercise/physical activity\n2. ≥ 1 of the following associated symptoms:\n\n   * nausea\n   * vomiting\n   * photophobia and phonophobia\n\nThe change from baseline in monthly migraine days was calculated as the average number of migraine days per month during the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment period minus the number of migraine days during the 4-week baseline period.', 'timeFrame': '4-week baseline period and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment period'}]","[{'measure': 'Percentage of Participants With at Least a 50% Reduction From Baseline in Mean Monthly Migraine Days Over Months 4, 5, and 6 of the DBTP', 'description': 'A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined either as a migraine with or without aura, lasting for ≥ 4 hours, and meeting at least 1 of the following criteria:\n\n1. ≥ 2 of the following pain features:\n\n   * unilateral\n   * throbbing\n   * moderate to severe\n   * exacerbated with exercise/physical activity\n2. ≥ 1 of the following associated symptoms:\n\n   * nausea\n   * vomiting\n   * photophobia and phonophobia', 'timeFrame': '4-week baseline period and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment period'}, {'measure': 'Change From Baseline in Mean Monthly Acute Migraine-specific Medication Treatment Days Over Months 4, 5, and 6 of the DBTP', 'description': 'An acute migraine-specific medication treatment day is any calendar day during which a participant took a migraine-specific medication (e.g., triptan or ergotamine).\n\nThe change from baseline in monthly acute migraine-specific treatment days was calculated as the average number of migraine-specific treatment days per month during the last 3 months of the 24-week double-blind treatment period minus the number of migraine-specific treatment days during the 4-week baseline period.', 'timeFrame': '4-week baseline period and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment period'}]",3,20 Years,65 Years,ALL,False,Amgen,INDUSTRY,0,261.0,ACTUAL,2025-09-01T16:18:18.419814,v2_robust,True,True,True,False,False,
NCT02730923,Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA),"A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma",AZD2014,"['Arimidex', 'Anastrozole', 'AZD2014']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Endometrial Carcinoma,"['Endometrial Carcinoma', 'Metastatic Carcinoma', 'Hormone Receptor Positive Tumor']","['Clinical Trials, Randomized', 'Clinical Trial, Phase I', 'Clinical Trial, Phase II', 'Multicenter Trials', 'Aromatase Inhibitors', 'mTOR kinase inhibitor']",ACTIVE_NOT_RECRUITING,,2016-04,2024-12,"[{'measure': 'Number of patients with severe toxicities occurring during the first 8 weeks of follow-up assessed using National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) V4', 'description': 'Severe toxicities defined as\n\n* Any grade ≥ 4 treatment related toxicity\n* Any grade≥ 3 treatment related toxicity lasting more than 7 days', 'timeFrame': 'during the first 8 weeks of follow up'}, {'measure': 'The 8-week non progression rate using RECIST v1.1 to assess tumor response to treatment', 'timeFrame': '8 weeks after start of treatment'}]","[{'measure': 'Number of patients with AE graded using CTCAE V4', 'timeFrame': 'For each participant, up to 30 days after the last dose of treatment (up to 3 years)'}, {'measure': 'Progression-free survival (PFS) defined as the duration of time from start of treatment to time of progression or death, whichever occurs first', 'timeFrame': 'up to 3 years'}, {'measure': 'Overall survival (OS) defined as the duration of time from start of treatment to time of death.', 'timeFrame': '3 years'}, {'measure': 'Best response rate defined as (percentage of patients with complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) according to RECIST V1.1)', 'timeFrame': 'Up to 3 years'}, {'measure': 'Duration of objective response as per RECIST v1.1', 'timeFrame': 'Up to 3 years'}, {'measure': 'Area under the curve (AUC) of AZD2014', 'timeFrame': 'Week 1 Day 1: pre-dose, 2h and 6-8 hours later and Week 2 Day 1: pre-dose, 2h and 6-8 hours later.'}, {'measure': 'Apparent clearance of AZD2014', 'timeFrame': 'Week 1 Day 1: pre-dose, 2h and 6-8 hours later and Week 2 Day 1: pre-dose, 2h and 6-8 hours later'}, {'measure': 'The accumulation of the 47S precursor ribosomal ribonucleic acid (rRNA), which reflects RNA polymerase I activity analysed by fluorescence in situ hybridization (FISH)', 'timeFrame': 'Baseline and 8 weeks after treatment'}, {'measure': 'The expression of components of rRNA methylation complex analysed by real time quantitative PCR (RTqPCR)', 'timeFrame': 'Baseline and 8 weeks after treatment'}, {'measure': 'The levels of circulating anti-fibrillarin (anti-FBL) autoantibody on serum samples by Elisa assays', 'timeFrame': 'Baseline and 8 weeks after treatment'}, {'measure': 'Levels of expression of fibrillarin assessed by immunohistochemistry (IHC)', 'timeFrame': 'Baseline and 8 weeks after treatment'}, {'measure': 'Levels of expression of nucleolin assessed by IHC', 'timeFrame': 'Baseline and 8 weeks after treatment'}, {'measure': 'Levels of expression of protein B23 assessed by IHC', 'timeFrame': 'Baseline and 8 weeks after treatment'}, {'measure': 'Levels of expression of upstream binding factor (UBF) assessed by IHC', 'timeFrame': 'Baseline and 8 weeks after treatment'}, {'measure': 'Levels of expression of phosphorylated UBF assessed by IHC', 'timeFrame': 'Baseline and 8 weeks after treatment'}]",17,18 Years,,FEMALE,False,Centre Leon Berard,OTHER,0,72.0,ESTIMATED,2025-09-01T16:18:18.419876,v2_robust,True,True,False,False,True,
NCT06854523,Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI),Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction,PCSK9 inhibitor,"['Statin+ezetimibe', 'PCSK9 inhibitor']",2,INTERVENTIONAL,['NA'],,,Acute Myocardial Infarction,['Acute Myocardial Infarction'],"['Acute Myocardial Infarction', 'Pericoronary artery fat attenuation index', 'Index of Plaque Attenuation', 'PCSK9 Inhibitor']",NOT_YET_RECRUITING,,2025-04-15,2026-12-31,"[{'measure': 'Changes in Index of Plaque Attenuation (IPA) measured by OCT for non-culprit lesions at baseline and 12 months of follow-up.', 'description': 'IPA is a quantitative analysis tool based on OCT technology to evaluate plaque stability.', 'timeFrame': '12 months'}, {'measure': 'Changes in pericoronary artery fat attenuation index (FAI) measured by CCTA for non-culprit lesions at baseline and 12 months of follow-up', 'description': 'FAI is a quantitative indicator of inflammation in perivascular adipose tissue measured by CCTA.', 'timeFrame': '12 months'}]","[{'measure': 'Progress of target lesion plaques', 'description': 'To assess plaque progression, OCT evaluation will include fiber cap thickness, lipid core amplitude, minimum lumen area, and minimum lumen diameter. CCTA evaluation will include CAD-RADS grade , plaque volume, plaque properties, calcification score, epicardial fat volume and plaque attenuation.\n\nNotes: CAD-RADS indicates Coronary Artery Disease-Reporting and Data System, which range from 0 to 5. The higher CAD-RADS grade, the more severe of the coronary stenosis.', 'timeFrame': '12 months'}, {'measure': 'The overall incidence of the first major adverse cardiovascular events (MACEs) within 12 months in different treatment groups', 'description': 'MACEs was defined as the composite of myocardial infarction, ischemic stroke, cardiovascular death and coronary revascularization', 'timeFrame': '12 months'}, {'measure': 'The proportion of LDLC at each visit node that meets the recommended guidelines and the changes compared to baseline', 'timeFrame': '1week；1months；3 months； 6 months; 9 months; 12 months'}, {'measure': 'Changes in inflammatory factors (interleukin 6, C reaction protein) at each visit node compared to baseline', 'timeFrame': '1week；1months；3 months； 6 months; 9 months; 12 months'}]",6,18 Years,,ALL,False,Yun Dai Chen,OTHER,0,300.0,ESTIMATED,2025-09-01T16:18:18.420026,v2_robust,True,True,False,False,True,
NCT02594423,Strategies for Management of Corneal Neovascularisation,Management of Active and Established Corneal Neovascularisation to Prevent Visual Impairment,Bevacizumab,"['Avastin(BEVACIZUMAB)', 'Bevacizumab']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Corneal Neovascularisation,['Corneal Neovascularisation'],[],UNKNOWN,,2015-12,2018-08,"[{'measure': 'Decreased corneal neovascularisation', 'description': 'A comparison of total vascularisation of the corneal area as measured by our grading system (Faraj LA et al, 2015) before and after treatment.', 'timeFrame': '6 months'}]","[{'measure': ""Improved/maintained Snellen's visual acuity"", 'description': 'Visual acuity is assessed using Snellen chart and vision is expressed in LOGMAR units', 'timeFrame': '10 months'}, {'measure': 'Decreased corneal opacity related to lipid deposition', 'description': 'The response to treatment will be judged clinically by biomicroscopy examination and quantitatively by comparison with pre-treatment slit lamp photographs. The comparison of the pre and post treatment slit lamp images will be done by two independent blind reviewers.', 'timeFrame': '10 months'}, {'measure': 'Reduced episodes of graft rejection(in corneal graft patients)', 'description': 'Number of rejection episodes will be recorded', 'timeFrame': '10 months'}]",4,18 Years,,ALL,False,University of Nottingham,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:18.420107,v2_robust,True,True,False,False,False,
NCT00001723,Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases,"Safety and Efficacy of Orlistat (Xenical, Hoffmann LaRoche) in African American and Caucasian Children and Adolescents With Obesity-Related Comorbid Conditions",Orlistat,"['Xenical (orlistat)capsules', 'Placebo capsule', 'Orlistat', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Diabetes Mellitus,"['Diabetes Mellitus', 'Hypertension', 'Metabolic Disease', 'Obesity', 'Sleep Apnea Syndrome']","['Dyslipidemia', 'Race', 'Body Fat', 'Visceral Fat', 'Sleep Apnea', 'Fat-Soluble Vitamins', 'Type 2 Diabetes', 'Obesity', 'Childhood Obesity']",COMPLETED,,1998-05,2011-10,"[{'measure': 'Change in BMI Standard Deviation Score', 'description': 'Body Mass index standard deviation score calculated for age and sex according to Centers for Disease Control standards. See: Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002; (246): 1-190.', 'timeFrame': 'baseline to 6 months'}]","[{'measure': 'Change in Body Weight', 'description': 'Weight in kg', 'timeFrame': 'baseline to 6 months'}, {'measure': 'Change in Body Mass Index', 'description': 'BMI is calculated in kg/m2. Change from baseline to 6 months of treatment', 'timeFrame': 'baseline to 6 months'}, {'measure': 'Change in Body Fat (kg)', 'description': 'body fat distribution measures obtained from Dual-energy X-ray Absorptiometry (DEXA)', 'timeFrame': 'baseline to 6 months'}, {'measure': 'Effect of Race on Change in Weight (kg)', 'description': 'Difference in change of weight in kg according to race (Non-Hispanic White versus Non-Hispanic Black)', 'timeFrame': 'baseline to 6 months'}]",5,12 Years,17 Years,ALL,False,Jack Yanovski,NIH,2,200.0,ACTUAL,2025-09-01T16:18:18.420245,v2_robust,True,True,True,False,False,
NCT00146523,An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression,"An International, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of CORLUX™ (Mifepristone) vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Psychotic Major Depression (PMD)",Mifepristone,"['Mifepristone', 'placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Major Depressive Disorder,['Major Depressive Disorder'],"['Psychotic Major Depression', 'PMD', 'Depression', 'Major Depression', 'Psychosis']",COMPLETED,,2005-05,2006-07,"[{'measure': 'The change in a measure of psychosis', 'timeFrame': 'screening and on Days 0, 7, 14, 28, 42, and 56'}]","[{'measure': 'The change in a measure of depression', 'timeFrame': 'screening and on Days 0, 7, 14, 28, 42, and 56'}]",2,18 Years,75 Years,ALL,False,Corcept Therapeutics,INDUSTRY,0,247.0,ACTUAL,2025-09-01T16:18:18.420328,v2_robust,True,True,True,False,False,
NCT01696123,Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine,,MLC601,"['NeuroAid', 'MLC601']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Alzheimer Disease,['Alzheimer Disease'],"['Alzheimer disease', 'Cholinesterase inhibitors', 'MLC601', 'NeuroAiD', 'neuroprotection', 'neuroregeneration']",COMPLETED,,2011-01,2012-08,"[{'measure': 'changes in the Mini-Mental State Examination (MMSE) relative to baseline measurements', 'description': 'change in the Mini-Mental State Examination (MMSE) relative to baseline measurements will be evaluated every 4 weeks up to 18 months.', 'timeFrame': 'every 4 weeks up to 18 months'}, {'measure': 'changes in the cognitive subscale of the AD Assessment Scale (ADAS-cog) relative to baseline measurements', 'description': 'change in the cognitive subscale of the AD Assessment Scale (ADAS-cog) relative to baseline measurements will be evaluated every 4 weeks up to 18 months.', 'timeFrame': 'every 4 weeks up to 18 months'}]","[{'measure': 'to measure included adverse events (AEs)', 'description': 'Safety and tolerability evaluations included physical examinations, electrocardiography, vital sign monitoring and laboratory testing weekly for the first 8 weeks and every 4 weeks thereafter. AEs were defined as any sign, symptom, syndrome or disease that occurred for the first time or worsened after baseline, whether they were considered treatment related.', 'timeFrame': 'every 4 weeks'}, {'measure': 'measuring withdrawal rate', 'description': 'measuring any withdrawal rate among intervention group', 'timeFrame': 'every 4 weeks'}]",4,50 Years,,ALL,False,Shahid Beheshti University of Medical Sciences,OTHER,0,125.0,ACTUAL,2025-09-01T16:18:18.420378,v2_robust,True,True,True,False,True,
NCT05659823,Postoperative Pain After Caesarian Section,"Impact of Guideline Recommendations for Post-caesarean Analgesia on Pain, Nausea and Pruritus",Bupivacaine-fentanyl-morphine elective group,"['Bupivacaine-fentanyl elective group', 'Bupivacaine-fentanyl-morphine elective group', 'Bupivacaine-fentanyl emergency group']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pain, Postoperative","['Pain, Postoperative', 'Pruritus', 'Nausea and Vomiting Following Administration of Anaesthetic Agent', 'Consumption']",[],COMPLETED,,2020-11-02,2021-11-05,"[{'measure': 'Postoperative pain at postoperative care unit arrival', 'description': 'Postoperative pain during rest and movement measured by numeric rating scale (NRS).', 'timeFrame': 'Immediately upon arrival at postoperative care unit'}, {'measure': 'Postoperative pain at 30 minutes', 'description': 'Postoperative pain during rest and movement measured by numeric rating scale (NRS).', 'timeFrame': 'At postoperative care unit 30 minutes after arrival'}, {'measure': 'Postoperative pain at 60 minutes', 'description': 'Postoperative pain during rest and movement measured by numeric rating scale (NRS).', 'timeFrame': 'At postoperative care unit 60 minutes after arrival'}, {'measure': 'Postoperative pain at 90 minutes', 'description': 'Postoperative pain during rest and movement measured by numeric rating scale (NRS).', 'timeFrame': 'At postoperative care unit 90 minutes after arrival'}, {'measure': 'Postoperative pain at 120 minutes', 'description': 'Postoperative pain during rest and movement measured by numeric rating scale (NRS).', 'timeFrame': 'At postoperative care unit 120 minutes after arrival'}, {'measure': 'Postoperative pain at maternity ward arrival', 'description': 'Postoperative pain during rest and movement measured by numeric rating scale (NRS).', 'timeFrame': 'Immediately upon arrival at maternity ward'}, {'measure': 'Postoperative pain at maternity ward 4 hours after arrival', 'description': 'Postoperative pain during rest and movement measured by numeric rating scale (NRS).', 'timeFrame': 'At maternity ward 4 hours after arrival'}, {'measure': 'Postoperative pain at maternity ward 8 hours after arrival', 'description': 'Postoperative pain during rest and movement measured by numeric rating scale (NRS).', 'timeFrame': 'At maternity ward 8 hours after arrival'}, {'measure': 'Postoperative pain at maternity ward 12 hours after arrival', 'description': 'Postoperative pain during rest and movement measured by numeric rating scale (NRS).', 'timeFrame': 'At maternity ward 12 hours after arrival'}, {'measure': 'Postoperative pain at maternity ward 16 hours after arrival', 'description': 'Postoperative pain during rest and movement measured by numeric rating scale (NRS).', 'timeFrame': 'At maternity ward 16 hours after arrival'}, {'measure': 'Postoperative pain at maternity ward 20 hours after arrival', 'description': 'Postoperative pain during rest and movement measured by numeric rating scale (NRS).', 'timeFrame': 'At maternity ward 20 hours after arrival'}]","[{'measure': 'Postoperative nausea and vomiting at postoperative care unit', 'description': 'Present (yes/no) during stay at the postoperative care unit', 'timeFrame': 'During stay at postoperative care unit, estimated average 2 hours'}, {'measure': 'Postoperative nausea and vomiting at maternity ward', 'description': 'Present (yes/no) during stay at the maternity ward', 'timeFrame': 'During stay at maternity ward, estimated average 22 hours'}, {'measure': 'Postoperative pruritus at postoperative care unit', 'description': 'Present (yes/no) during stay at the postoperative care unit', 'timeFrame': 'During stay at postoperative care unit, estimated average 2 hours'}, {'measure': 'Postoperative pruritus at maternity ward', 'description': 'Present (yes/no) during stay at the maternity ward', 'timeFrame': 'During stay at maternity ward, estimated average 22 hours'}, {'measure': 'Postoperative additional oxycodone consumption at postoperative care unit', 'description': 'Number of mg of oxycodone administered as additional analgetics', 'timeFrame': 'During stay at postoperative care unit, estimated average 2 hours'}, {'measure': 'Postoperative additional oxycodone consumption at maternity ward', 'description': 'Number of mg of oxycodone administered as additional analgetics', 'timeFrame': 'During stay at maternity ward, estimated average 22 hours'}]",17,18 Years,60 Years,FEMALE,False,Conrad Arnfinn Bjørshol,OTHER_GOV,0,108.0,ACTUAL,2025-09-01T16:18:18.420463,v2_robust,True,True,True,False,False,
NCT01355159,High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention,Effect of Folic Acid Supplementation in Pregnancy on Preeclampsia-Folic Acid Clinical Trial (FACT),Folic Acid 4 mg,"['Folate', 'Folic Acid 4 mg', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Pregnancy Complications,"['Pregnancy Complications', 'Preeclampsia']","['Pregnancy', 'Folic Acid supplementation', 'Preeclampsia']",COMPLETED,,2011-04,2016-09,"[{'measure': 'Preeclampsia', 'description': ""PE is defined as diastolic blood pressure ≥90 mmHg on two occasions ≥4 hours apart and proteinuria developed in women greater than 20+0 weeks of gestation. Proteinuria is defined as: urinary protein ≥300mg in 24 hour urine collection OR in the absence of 24 hour collection, ≥2+ dipstick proteinuria, OR random protein-creatinine ratio ≥30mg protein/mmol.\n\nOR HELLP (Haemolysis, Elevated, Liver Enzymes, Low Platelets) syndrome defined as: Haemolysis (characteristic peripheral blood smear), Serum LDH ≥ 600U/L, Serum AST ≥ 70U/L, and Platelet count \\<100 x109/L\n\nOR Superimposed pre-eclampsia, defined as history of pre-existing hypertension (diagnosed pre-pregnancy or before 20+0 weeks' gestation) with new proteinuria."", 'timeFrame': 'Participants will be followed from 20+0 weeks of gestational age until 42 days postpartum (after delivery)'}]","[{'measure': 'Maternal Death', 'description': 'According to the World Health Organization, ""A maternal death is defined as the death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes.', 'timeFrame': 'Time Frame: Participants will be followed from 20+0 weeks of gestation until 42 days postpartum (after delivery)'}, {'measure': 'Spontaneous Abortion', 'description': 'Spontaneous abortion or miscarriage defined as death of a fetus \\<500g or \\<20 weeks of gestation', 'timeFrame': 'Participants will be followed from randomization until 20+0 weeks of gestation'}, {'measure': 'Placenta Abruption', 'description': 'Placental abruption (abruptio placentae) is the premature detachment of a normally positioned placenta from the wall of the uterus.', 'timeFrame': 'Participants will be followed from 20+0 weeks of gestation until delivery'}, {'measure': 'Premature Rupture of Membranes', 'description': 'Rupture of the membranes (rupture of the amniotic sac) before the onset of labor.', 'timeFrame': ""Participants will be followed from randomization (8-16 weeks' completed gestation) until the onset of labor""}, {'measure': 'Preterm Birth', 'description': 'Birth that occur earlier than 37+0 weeks of gestational age.', 'timeFrame': 'Participants will be followed from 20+0 weeks to 36+6 weeks of gestation'}, {'measure': 'HELLP (Hemolysis, Elevated Liver Enzyme Levels & Low Platelet Count)', 'description': 'Haemolysis (characteristic peripheral blood smear), Serum LDH \\>=600U/L, Serum AST \\>=70U/L, Platelet count \\<100 x109/L', 'timeFrame': 'Participants will be followed from 20+0 weeks of gestation until delivery'}, {'measure': 'Severe Preeclampsia', 'description': 'Severe PE: Defined as PE with convulsion or HELLP or delivery \\<34 weeks.', 'timeFrame': 'Participants will be followed from 20+0 weeks of gestation until delivery.'}, {'measure': 'Antenatal Inpatient Length of Stay', 'description': 'Length of inpatient stay before admission for delivery in days', 'timeFrame': ""Participants will be followed from date of randomization (8-16 weeks' completed gestation) until admission for delivery""}, {'measure': 'Stillbirth', 'description': 'Fetal death defined as death of fetus of at least 500 grams birth weight or, if birth weight is unavailable, a gestational age of at least 20+0 weeks of gestation.', 'timeFrame': 'Participants will be followed from 20+0 weeks of gestation up to delivery.'}, {'measure': 'Intrauterine Growth Restriction (<3rd Percentile)', 'description': 'Intrauterine growth restriction is defined as a birth weight less than the 3rd percentile of the population, adjusted for sex and gestational age, based on the current population-based Canadian reference standard.', 'timeFrame': 'Participants will be followed from 20+0 weeks of gestation until delivery'}, {'measure': 'Intrauterine Growth Restriction (<10th Percentile)', 'description': 'Intrauterine growth restriction is defined as a birth weight less than the 10th percentile of the population, adjusted for sex and gestational age, based on the current population-based Canadian reference standard.', 'timeFrame': 'Participants will be followed from 20+0 weeks of gestation until delivery'}, {'measure': 'Neonatal Death', 'description': 'Neonatal death defined as death of a baby that occurred during first 28 days of life.', 'timeFrame': 'Participants will be followed from birth until 28 days of life'}, {'measure': 'Perinatal Mortality', 'description': 'The perinatal mortality is defined as the number of deaths (fetal deaths and neonatal deaths) of babies ≥ 500 grams birth weight or, if birth weight is unavailable, a gestational age ≥ 20+0 weeks, up to 28 completed days after birth.', 'timeFrame': 'Participants will be followed from 20+0 weeks of gestation until 28 days of life.'}, {'measure': 'Retinopathy of Prematurity', 'description': 'Retinopathy of prematurity a retinopathy typically occurring in premature infants treated with high concentrations of oxygen, characterized by vascular dilatation, proliferation, tortuosity, edema, retinal detachment, and fibrous tissue behind the lens confirmed by retinal examination according to an International Committee for the Classification of Retinopathy of Prematurity.', 'timeFrame': 'Infants born to the participant will be followed for the duration of hospital stay, or up to 6 weeks'}, {'measure': 'Early Onset Sepsis', 'description': 'Within first 48hr of life, confirmed by positive blood or cerebrospinal fluid cultures', 'timeFrame': 'Infants born to the participants will be followed first 48 hours of life.'}, {'measure': 'Necrotising Enterocolitis', 'description': ""Necrotizing enterocolitis (NEC) according to modified Bell's criteria stage 2 or higher (grossly bloody stool, plus absent bowel sounds with or without abdominal tenderness and radiographic findings such as intestinal dilation, ileus, pneumatosis intestinalis), excluding isolated spontaneous intestinal perforations."", 'timeFrame': 'Infants borm to the participants will be followed for the duration of hospital stay, or up to 6 weeks.'}, {'measure': 'Intraventricular Hemorrhage (IVH)', 'description': '* IVH Grade 1(Blood in germinal matrix)\n* IVH Grade 2 (Blood in germinal matrix and extending into the ventricles)\n* IVH Grade 3 (Ventricular enlargement)\n* IVH Grade 4 (Intraparenchymal lesion)', 'timeFrame': 'Time Frame: Infants born to the participants will be followed for the duration of hospital stay, or up to 6 weeks'}, {'measure': 'Ventilation', 'description': 'Ventilatory support after initial resuscitation, with/without intubation.', 'timeFrame': 'Infants born to the participants will be followed for the duration of hospital stay, or up to 6 weeks.'}, {'measure': 'Need for Oxygen at 28 Days', 'timeFrame': 'Infants to the participants will be followed for 28 days after birth.'}, {'measure': 'Composite Severe Adverse Fetal/Neonatal Outcome', 'description': 'Composite outcome included any of retinopathy of prematurity, periventricular leukomacia, early onset sepsis, necrotizing enterocolitis, intraventricular haemorrhage, ventilation. Need for O2at 28 days, NICU admission', 'timeFrame': 'Outcomes included in the composite outcome were measured for each of their respective time frames, up to 6-weeks after birth'}, {'measure': ""Length of Stay in 'High Level' Neonatal Care Unit"", 'timeFrame': 'Infants to the participants will be followed for the duration of hospital stay, or up to 6 weeks.'}, {'measure': 'Neonatal Death', 'description': 'Neonatal death defined as death of the infant occurred before 28 days of life', 'timeFrame': 'Infants to the participants will be followed for 28 days after birth.'}, {'measure': 'Periventricular Leukomalacia', 'description': 'One of the two outcomes used to measure neonatal morbidity.', 'timeFrame': 'Infants to the participants were followed for 28 days after birth.'}, {'measure': 'Neonatal Intensive Care Unit (NICU) Admission', 'description': 'This outcome measured whether or not the infant was admitted into the NICU.', 'timeFrame': 'Infants to the participants will be followed for the duration of hospital stay, or up to 6 weeks.'}]",25,18 Years,,FEMALE,False,Ottawa Hospital Research Institute,OTHER,1,2464.0,ACTUAL,2025-09-01T16:18:18.420539,v2_robust,True,True,True,False,True,
NCT00456859,Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease,Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease (CAP-KD),Kremezin,['Kremezin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,"Kidney Failure, Chronic","['Kidney Failure, Chronic']","['chronic kidney disease', 'oral carbonaceous adsorbent', 'randomized clinical trial', 'composite endpoint']",COMPLETED,,2004-04,2007-09,"[{'measure': 'The composite primary endpoint comprises the following events:'}, {'measure': 'Doubling of serum Creatinine'}, {'measure': 'Increase in serum Creatinine to 6.0 mg/dl or more'}, {'measure': 'Endstage renal disease (ESRD; defined as that requiring dialysis or renal transplantation)'}, {'measure': 'Death'}]","[{'measure': 'Variation in urinary protein'}, {'measure': 'Changes in Creatinine Clearance'}, {'measure': 'Changes in health-related quality of life (HRQOL)'}, {'measure': 'Occurrence of adverse events'}]",9,20 Years,,ALL,False,Institute for Health Outcomes and Process Evaluation Reseach,OTHER,0,450.0,,2025-09-01T16:18:18.420647,v2_robust,True,True,True,False,True,
NCT04391959,Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD),"A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)",AZR-MD-001 Active,"['AZR-MD-001 Vehicle', 'AZR-MD-001 Vehicle is an ophthalmic ointment', 'AZR-MD-001 Active', 'AZR-MD-001 is an ophthalmic ointment']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Meibomian Gland Dysfunction,['Meibomian Gland Dysfunction'],[],COMPLETED,,2020-07-17,2021-01-06,"[{'measure': 'Meibum Gland Secretion Score (MGS)', 'description': 'Change from Baseline in MGS. The MGS can range from 0 (highly abnormal) to 45 (Normal). Meibomian gland assessment was completed using a handheld instrument, Meibomian Gland Evaluator, along the eyelid margin to ensure measurement consistency. A total of 15 glands will be evaluated along the lower eyelid margin, consisting of 5 glands located in each of the temporal, central and nasal regions, as shown below. For each of the 15 glands, expressed secretion characteristics will be graded on a 0-3 scale. For more detail see: Lane SS, DuBiner HB, Epstein RJ, et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction (MGD). Cornea. 2012; 31(4): 396-404.', 'timeFrame': 'Month 3'}]","[{'measure': 'Total OSDI', 'description': 'Change from Baseline in Total Ocular Surface Disease Index (OSDI). The Total OSDI can range from 0 (normal) to 100 (abnormal). The OSDI questionnaire consists of 12 questions regarding ocular symptoms, environmental triggers, and vision-related functioning. The patient was asked to rate each symptom using a 5-point scale (0 to 4), where 0 = none of the time; 1 = some of the time; 2 = half of the time; 3 = most of the time; and 4 = all of the time. Seven questions related to visual functioning allow a response of ""N/A"" (not applicable). The total OSDI was calculated from the raw scores of each of the 12 questions based on the formula: (\\[sum of scores for all questions answereda\\] X 100)/(\\[total number of questions answered\\] X 4).\n\nQuestions answered with N/A were excluded in the calculation of total OSDI.', 'timeFrame': 'Day 14 to Month 3'}]",2,18 Years,,ALL,False,Azura Ophthalmics,INDUSTRY,1,31.0,ACTUAL,2025-09-01T16:18:18.420663,v2_robust,True,True,True,False,False,
NCT00001259,A Treatment Study for Premenstrual Syndrome (PMS),"The Treatment of Menstrually-Related Mood Disorders With the Gonadotropin Releasing Hormone (GnRH) Agonist, Depot Leuprolide Acetate (Lupron)",Leuprolide,"['Estradiol Patches', 'Placebo injection', 'Placebo patch', 'Placebo suppository', 'Leuprolide', 'Progesterone']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Premenstrual Syndrome,"['Premenstrual Syndrome', 'Menstruation Disturbances']","['Depression', 'Menstrual Cycle', 'Gonadal Steroids', 'Estradiol', 'Progesterone', 'Mood Disorders']",COMPLETED,,1992-08-11,2020-02-06,"[{'measure': 'Mean Beck Depression Inventory Score', 'description': 'The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures the severity of symptoms accompanying depression. Each item has a minimum score of 0 and a maximum score of 3, with higher numbers consistent with more severe symptoms. The score of each item is summed to amount the overall BDI score, with a minimum score of 0 and a maximum score of 63. Higher BDI scores are consistent with more severe depression. Score of 16 or greater is consistent with clinical depression.\n\nEach participant completed the BDI every 2 weeks during each of the study phases throughout the 6-month study. Outcome measures reported consist of the average of two BDI scores from each phase of the study: the last 4 weeks of the GnRH agonist alone; weeks 6 and 8 of placebo alone; during the 4-week long estradiol phase (weeks 2 and 4 of estradiol) and the 4-week long progesterone phase (weeks 2 and 4 of progesterone).', 'timeFrame': 'Placebo: Weeks 6 and 8 of Placebo; Lupron only: Weeks 6 and 8 or 10 and 12; Estradiol or progesterone: Weeks 2 and 4'}]",[],1,18 Years,45 Years,FEMALE,False,National Institute of Mental Health (NIMH),NIH,0,60.0,ACTUAL,2025-09-01T16:18:18.420686,v2_robust,True,True,True,False,False,
NCT00907959,A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer,A Phase 2 Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer,BZL101,['BZL101'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Breast Cancer,['Metastatic Breast Cancer'],[],UNKNOWN,,2012-01,2015-07,"[{'measure': 'The primary outcomes of the Phase 2 trial will be safety and toxicity as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and tumor response rate defined by new RECIST criteria 1.1.', 'timeFrame': 'Monthly'}]",[],1,18 Years,,FEMALE,False,Bionovo,INDUSTRY,0,80.0,ESTIMATED,2025-09-01T16:18:18.420704,v2_robust,True,True,False,False,True,
NCT00550459,Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients,"A Pilot, Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Effects of Titrated Oral Tolvaptan 15, 30, or 60 mg QD on Cognitive and Neurological Function in Elderly Hyponatremic Patients",Tolvaptan,"['OPC-41061', 'Placebo', 'Tolvaptan']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Hyponatremia,['Hyponatremia'],"['Hyponatremia', 'Cognitive', 'Neurological Function', 'Elderly']",COMPLETED,,2007-08,2009-03,"[{'measure': 'Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)', 'description': 'Change from baseline to Day 22 in sum of all speed domain Z-scores:Reaction Time (Simple=recognize ""yes"" 50 times;Choice=recognize ""yes"" or ""no"" 50 times;Digit Vigilance=match 45 digits);Psychomotor Speed (Morse Tapping=tap button for 30 seconds with right \\& left hands);Processing Speed (Rapid Visual Information Processing=detect consecutive sequences of 3 odd or 3 even digits;Numeric Working Memory=recognize numbers from series of 5 digits among 30;Word Recognition=remember 15 prior learned words from 30 total;results age-matched to healthy controls from Cognitive Drug Research normative data', 'timeFrame': 'baseline and Day 22'}]","[{'measure': 'Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests', 'description': 'Change from baseline in the individual neurocognitive domains Z-score for Reaction Time in Computer Tests (simple reaction time test, choice reaction time test, digit vigilance test); ITT population', 'timeFrame': 'baseline and Day 22'}, {'measure': 'Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test', 'description': 'Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Psychomotor Speed (mean tap rate of Morse tapping test); ITT population', 'timeFrame': 'baseline and Day 22'}, {'measure': 'Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test', 'description': 'Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test; ITT population', 'timeFrame': 'baseline and Day 22'}, {'measure': 'Change From Baseline in Overall Neurocognitive Composite Score', 'description': 'Change from Baseline to Day 22 in the overall Neurocognitive Composite Score (NCS)comprising the sum of 7 neurocognitive domain Z-scores (Reaction Time, Psychomotor Speed, Processing Speed, Continuity of Attention, Working Memory/Executive Functions, Quality of Episodic Verbal Memory, and Postural Stability); ITT population', 'timeFrame': 'baseline and Day 22'}, {'measure': 'Change From Baseline in Gait Test (Timed Get-Up-and-Go Test)', 'description': 'Change from baseline to Day 22 in Gait Test (Timed Get-Up-and-Go Test=time it takes for a seated subject to rise from a chair, walk 3 meters, walk around an object and return to sit in chair. Values: under 10 sec (no difficulties), 10 to 20 sec (starting to have balance difficulty), over 30 sec (at high risk for falls and dependent in most activities of daily living and mobility); test assesses risk to elderly subjects of falling and higher scores in seconds indicate higher risk of falling; ITT population', 'timeFrame': 'baseline and Day 22'}, {'measure': 'Change From Baseline in Postural Stability Test', 'description': 'Change from baseline to Day 22 in Postural Stability Test Z-score (This test measures gross motor control. The ability to stand upright without moving is assessed using the SWAY meter that is modeled on the Wright Ataxiameter. A cord from the meter is attached to the subject who is required to stand as still as possible with feet apart and eyes closed for 1 minute. The test is then repeated with eyes open for 1 minute. The outcomes of these tests are combined and measured as a movement Z-score. Higher result=better postural stability); ITT population', 'timeFrame': 'baseline and Day 22'}, {'measure': 'Change From Baseline in Serum Sodium; ITT Population', 'description': 'Change from Baseline to Day 22 in Serum Sodium; ITT population', 'timeFrame': 'Baseline and Day 22'}, {'measure': 'Number of Patients With Vital Sign Abnormalities: Blood Pressure', 'description': 'Incidence of abnormal systolic \\& diastolic blood pressure values post-baseline (abnormal systolic values: \\>=180 mmHg + increase of \\>=20 mmHg, \\<= 90 mmHg + decrease \\>=20 mmHg; abnormal diastolic values: \\>=105 mmHg+increase of \\>=15 mmHg, \\<=50 mmHg + decrease of \\>= 15 mmHg)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Vital Sign Abnormalities: Pulse Rate', 'description': 'Incidence of abnormal pulse rate post-baseline \\[abnormal values: \\>=120 beats per minute (bpm) + increase of \\>=15 bpm; \\<=50 bpm + decrease of \\>=15 bpm\\]', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Vital Sign Abnormalities: Body Weight', 'description': 'Incidence of clinically significant body weight change post-baseline (defined as change upward or downward of \\>=7%)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Vital Sign Abnormalities: Body Temperature', 'description': 'Incidence of potentially clinically significant changes in body temperature post-baseline (defined as an increase of \\>=1.1 to \\>=38.3 degrees Celsius)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin', 'description': 'Incidence of clinically significant hemoglobin abnormalities post-baseline (normal range=11.8-16.8 g/dL)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT)', 'description': 'Incidence of potentially clinically significant Activated Partial Thromboplastin Time (aPTT) levels post-baseline (normal range=22-34 seconds)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes', 'description': 'Incidence of potentially clinically significant lymphocyte count post-baseline (normal range = 16-46%)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Hematology Laboratory Abnormalities: Neutrophils', 'description': 'Incidence of potentially clinically significant neutrophil count post-baseline (normal range=1.8-8 thousands/microliter)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)', 'description': 'Incidence of potentially clinically significant BUN levels post-baseline (normal range=7-30 mg/dL)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid', 'description': 'Incidence of potentially clinically significant uric acid levels post-baseline (normal range=4-8.5 mg/dL)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol', 'description': 'Incidence of potentially clinically significant cholesterol levels post-baseline (normal range=0-199 mg/dL)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose', 'description': 'Incidence of potentially clinically significant glucose levels post-baseline (normal range=70-125 mg/dL)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium', 'description': 'Incidence of potentially clinically significant magnesium levels post-baseline (normal range=1.2-2 mEq/L)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QT >500 Milliseconds (Msec)', 'description': 'Incidence of potentially clinically significant ECG abnormalities (QT\\>500 msec) post-baseline', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval', 'description': 'Incidence of potentially clinically significant ECG abnormalities involving QRS interval (change \\> 100 msec)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec', 'description': 'Incidence of potentially clinically significant ECG abnormalities (QTcB increase 30-60 msec)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec', 'description': 'Incidence of potentially clinically significant ECG abnormalities (QTcF increase 30-60 msec post-baseline)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment', 'description': 'Incidence of potentially clinically significant ECG abnormalities: ST Segment', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave', 'description': 'Incidence of potentially clinically significant ECG abnormalities: T wave', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI)', 'description': 'Incidence of potentially clinically significant ECG abnormalities: Right bundle branch block (RBBB), Left bundle branch block (LBBB), myocardial infarction (MI)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia', 'description': 'Incidence of potentially clinically significant ECG abnormalities: arrhythmia', 'timeFrame': '28 days'}]",29,50 Years,,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,1,57.0,ACTUAL,2025-09-01T16:18:18.420712,v2_robust,True,True,True,False,False,
NCT03917459,COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure,"A Randomized, Double-blind, Active-controlled Study to Assess the Effect of Sacubitril/Valsartan Compared With Enalapril to Improve Erectile Function in Patients With Heart Failure With Reduced Ejection Fraction and Erectile Dysfunction",LCZ696,"['LCZ696 matching placebo', 'LCZ696', 'Enalapril', 'Enalapril matching placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Heart Failure,"['Heart Failure', 'Heart Failure, Systolic', 'Erectile Dysfunction']","['heart failure', 'systolic heart failure', 'heart failure with reduced ejection fraction', 'erectile dysfunction', 'Enalapril', 'Enalaprilat', 'LCZ696', 'Sacubitril/valsartan']",COMPLETED,,2019-04-16,2021-05-25,"[{'measure': 'Erectile Function Score Using Index of Erectile Function (IIEF-15)', 'description': ""The International Index of Erectile Function (IIEF-15) was used to assess erectile function in male patients with chronic heart failure. The IIEF-15 is a patient self-reported assessment of erectile dysfunction (ED) and consists of 15 questions assessing different aspects associated with ED. The domain evaluating erectile function consists of items 1, 2, 3, 4, 5 \\& 15 and its total score was used here. Total score range =1-30. Items 1-5 is 6-point Likert-type scale from '0' (= No sexual activity), '1' (=Almost never or never) to '5' (= Almost always or always). Items 15 is 5-point Likert-type scale from '1' (= very low) to '5 '(= very high). Higher score indicates better outcome"", 'timeFrame': 'Week 12 (3 months)'}]","[{'measure': 'Summary of Change From Baseline in Self-reported Frequency of Sexual Activity Per Week', 'description': ""Assessment of early-onset effect and end of study effect, regarding improvement in sexual activity, using patient's self-reported frequency of sexual activity per week. Patient was asked to complete a diary assessing sexual activity on a weekly basis"", 'timeFrame': 'Baseline, Week 4, Week 12'}, {'measure': 'Summary of Change From Baseline in NT-proBNP Levels', 'description': 'Change in n-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels compared to baseline assessed at Week 4 and Week 12', 'timeFrame': 'Baseline, Week 4, Week 12'}]",3,18 Years,75 Years,MALE,False,Novartis Pharmaceuticals,INDUSTRY,0,27.0,ACTUAL,2025-09-01T16:18:18.420925,v2_robust,True,True,True,False,False,
NCT00641680,Rhinocort Aqua Versus Placebo and Fluticasone Propionate,"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-group, Phase IIIb Study to Assess the Efficacy, Safety & Product Attributes of Rhinocort Aqua(Budesonide) Versus Placebo and FluticasonePropionate as an Active Comparator in Patients 12yrs Age &Older With SeasonalAllergicRhinitis",Budesonide,"['Fluticasone propionate', 'Flonase®', 'Placebo', 'Budesonide', 'Rhinocort AQUA']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Seasonal Allergic Rhinitis,['Seasonal Allergic Rhinitis'],"['Seasonal allergic rhinitis', 'Nasal symptoms', 'Congestion', 'Rhinorrhea', 'Sneeze', 'budesonide', 'Rhinocort AQUA', 'Fluticasone propionate', 'Flonase']",COMPLETED,,2003-04,2003-07,"[{'measure': 'To compare once daily treatment with Rhinocort against placebo and at reliving the nasal symptoms of seasonal allergic rhinitis.', 'timeFrame': '2 weeks'}]","[{'measure': 'To compare once daily treatment with Rhinocort against Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.', 'timeFrame': '2 weeks'}, {'measure': 'To compare once daily treatment with placebo against Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.', 'timeFrame': '2 weeks'}, {'measure': 'Safety assessment via adverse events and clinical measurements.', 'timeFrame': '2 & 4 weeks'}]",4,12 Years,,ALL,False,AstraZeneca,INDUSTRY,0,750.0,ESTIMATED,2025-09-01T16:18:18.421019,v2_robust,True,True,True,False,True,
NCT00000580,Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin,,"immunoglobulins, intravenous","['immunoglobulins, intravenous']",1,INTERVENTIONAL,['PHASE3'],PHASE3,,Hepatitis B,"['Hepatitis B', 'Hepatitis, Viral, Human', 'Liver Diseases']",[],COMPLETED,,1975-11,1986-06,[],[],0,,3 Years,ALL,False,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,0,,,2025-09-01T16:18:18.421071,v2_robust,True,True,True,False,False,
NCT02436980,Premedication for ERCP With Midazolam or Tramadol,Effects of Midazolam or Tramadol Premedication on Early Cognitive Function in ERCP: a Randomized Controlled Double-Blind Study,Tramadol,"['Midazolam', 'CONTRAMAL', 'Tramadol', 'DORMICUM']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Disease,['Chronic Disease'],"['premedication', 'ERCP', 'midazolam', 'tramadol', 'cognitive']",COMPLETED,,2009-01,2009-12,"[{'measure': 'The early cognitive functions after ERCP', 'description': 'The early cognitive functions after ERCP assessed by mini-mental test (MMT)', 'timeFrame': 'Postprocedure in the first 60 minutes'}]","[{'measure': 'Number of Participants with Adverse Events', 'description': 'With any side effects', 'timeFrame': 'Postprocedure in first 60 minutes'}]",2,18 Years,70 Years,ALL,False,Karadeniz Technical University,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:18.421086,v2_robust,True,True,True,False,True,
NCT00618280,"Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail","Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail",nicotine nasal spray,"['nicorette nasal spray', 'nicotine nasal spray']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Tobacco Use Disorder,"['Tobacco Use Disorder', 'Schizophrenia']",[],COMPLETED,,2008-01,2010-08,"[{'measure': 'Effect of nicotine or placebo in healthy subjects and schizophrenic patients on attentional network activity in brain with functional magnetic resonance imaging and EEG', 'timeFrame': 'after last subject out'}]","[{'measure': '-Effect of nicotine on a4b2 nAch receptor genotype -Gene Expression of a4b2 nAch -effect of 24 h nicotine withdrawal on modulation special hormones -effect of nicotine on neurophysiological correlates of social stress', 'timeFrame': 'after last subject out'}]",2,18 Years,55 Years,ALL,True,"Heinrich-Heine University, Duesseldorf",OTHER,1,101.0,ACTUAL,2025-09-01T16:18:18.421101,v2_robust,True,True,True,False,False,
NCT00821080,Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma,A Phase I Study of Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma,Sirolimus,"['Sirolimus', 'Vandetanib']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Glioblastoma,['Glioblastoma'],"['vandetanib', 'sirolimus', 'recurrent glioblastoma']",COMPLETED,,2008-10,2015-02,"[{'measure': 'To determine the optimal, safe dose of vandetanib in combination with sirolimus. MTD and dose-limiting toxicity (DLT) of this combination therapy will also be established', 'timeFrame': '3 years'}]",[],1,18 Years,,ALL,False,Massachusetts General Hospital,OTHER,3,33.0,ACTUAL,2025-09-01T16:18:18.421230,v2_robust,True,True,True,False,False,
NCT04653480,"Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC",Surufatinib and Toripalimab Combined With Chemotherapy for Second-line Treatment of Advanced RAS/BRAF Mutant and Microsatellite Stable Colorectal Cancer,Surufatinib,"['chemotherapy', 'Surufatinib', 'Toripalimab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Colorectal Cancer,['Colorectal Cancer'],[],UNKNOWN,,2021-02-01,2025-06,"[{'measure': 'Overall Response Rate', 'description': 'the proportion of patients in a trial whose tumor is destroyed or significantly reduced by a drug. ORR is generally defined as the sum of complete responses (CRs) - patients with no detectable evidence of a tumor over a specified time period - and partial responses (PRs) - patients with a decrease in tumor size over a specified time period.', 'timeFrame': '2 months'}]","[{'measure': 'Overall Survival', 'description': 'Refers to the time of death from enrollment to any cause', 'timeFrame': '2 years'}, {'measure': 'Progression Free Survival', 'description': 'the time elapsed between treatment initiation and tumor progression', 'timeFrame': '6 months'}]",3,18 Years,75 Years,ALL,False,Zhejiang University,OTHER,0,61.0,ESTIMATED,2025-09-01T16:18:18.421341,v2_robust,True,True,False,False,False,
NCT02534480,Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose),"A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Young Volunteers",NGP 555,"['NGP 555', 'NGP555']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Alzheimer's Disease,"[""Alzheimer's Disease""]",['Amyloid'],COMPLETED,,2015-03,2015-11,"[{'measure': 'Number of subjects with adverse events as a measure of safety and tolerability', 'timeFrame': '0-96 hours post-dose'}]",[],1,18 Years,55 Years,ALL,True,NeuroGenetic Pharmaceuticals Inc,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:18.421355,v2_robust,True,True,True,False,True,
NCT01452880,Remifentanil in Extracorporeal Shock Wave Lithotripsy,Total Intravenous Anaesthesia Using Remifentanil In Extracorporeal Shock Wave Lithotripsy (ESWL). Comparison of Two Dosages.,Remifentanil,['Remifentanil'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Kidney Calculi,['Kidney Calculi'],"['Remifentanil', 'Lithotripsy', 'Conscious Sedation']",COMPLETED,,2010-01,2010-07,"[{'measure': 'VAS score', 'description': 'Before the beginning of ESWL and at the end of the treatment patient were asked to point out the intensity of pain they were feeling on an 11-points visual analog scale (VAS), ranged from 0 ""no pain"" to 10 ""worst pain"".', 'timeFrame': 'Vas score was monitored up to the end of surgery, for about forty minutes'}]",[],1,18 Years,70 Years,ALL,False,University of Roma La Sapienza,OTHER,0,228.0,ACTUAL,2025-09-01T16:18:18.421368,v2_robust,True,True,True,False,False,
NCT02152280,A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke,A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke,Danhong Injection,"['Danhong Injection', 'Normal Saline']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Stroke,['Stroke'],[],UNKNOWN,,2014-03,2015-12,"[{'measure': 'Percentage comparisons of two groups of patients on the modified Rankin Scale 0-2 grades on the 90th day.', 'description': 'Percentage comparisons of two groups of patients on the modified Rankin Scale 0-2 grades on the 90th day.', 'timeFrame': '0-90 day'}]",[],1,18 Years,,ALL,False,"Beijing Bozhiyin T&S Co., Ltd.",INDUSTRY,0,320.0,ESTIMATED,2025-09-01T16:18:18.421378,v2_robust,True,True,False,False,False,
NCT02079480,"Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects","Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986090 in Healthy Subjects",BMS-986090,"['Keyhole limpet hemocyanin', 'KLH', 'Placebo matching with BMS-986090', 'BMS-986090']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Adult Volunteers,['Healthy Adult Volunteers'],[],TERMINATED,,2014-05,2016-04,"[{'measure': 'Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests', 'description': 'AE = Adverse event\n\nECG = Electrocardiogram', 'timeFrame': 'Up to Day 85 after single dose of BMS-986090'}, {'measure': 'Safety and tolerability of multiple dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests', 'timeFrame': 'Up to Day 106 after multiple dose of BMS-986090'}]","[{'measure': 'Maximum observed serum concentration (Cmax) of BMS-986090 single dose subcutaneous (SC) and intravenous (IV)', 'timeFrame': 'Days 1 -85'}, {'measure': 'Time of maximum observed serum concentration (Tmax) of single dose BMS-986090 SC and IV', 'timeFrame': 'Days 1 -85'}, {'measure': 'Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of single dose BMS-986090 SC and IV', 'timeFrame': 'Days 1 -85'}, {'measure': 'Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of single dose BMS-986090 SC and IV', 'timeFrame': 'Days 1 -85'}, {'measure': 'Terminal serum half-life (T-HALF) of single dose BMS-986090 SC and IV', 'timeFrame': 'Days 1 -85'}, {'measure': 'Total body clearance (CLT) of single dose BMS-986090 IV', 'timeFrame': 'Days 1 -85'}, {'measure': 'Apparent total body clearance (CLT/F) of single dose BMS-986090 SC', 'timeFrame': 'Days 1 -85'}, {'measure': 'Volume of distribution at terminal phase (Vz) of single dose BMS-986090 IV', 'timeFrame': 'Days 1 -85'}, {'measure': 'Volume of distribution during steady state (Vss) of single dose BMS-986090 IV', 'timeFrame': 'Days 1 -85'}, {'measure': 'Apparent volume of distribution at terminal phase (Vz/F) of single dose BMS-986090 SC', 'timeFrame': 'Days 1 -85'}, {'measure': 'Absolute bioavailability (F) of single dose BMS-986090 SC', 'timeFrame': 'Days 1 -85'}, {'measure': 'Maximum observed serum concentration (Cmax) of multiple dose BMS-986090 SC', 'timeFrame': 'Days 1 -106'}, {'measure': 'Time of maximum observed serum concentration (Tmax) of multiple dose BMS-986090 SC', 'timeFrame': 'Days 1 -106'}, {'measure': 'Terminal serum half-life (T-HALF) of multiple dose BMS-986090 SC', 'timeFrame': 'Days 1 -106'}, {'measure': 'Area under the serum concentration-time curve in one dosing Interval [AUC(TAU)] of multiple dose BMS-986090 SC', 'timeFrame': 'Days 1 -106'}, {'measure': 'Trough observed plasma concentration (Ctrough) of multiple dose BMS-986090 SC', 'timeFrame': 'Days 1 -106'}, {'measure': 'Average concentration over a dosing interval (Css-avg) of multiple dose BMS-986090 SC', 'timeFrame': 'Days 1 -106'}, {'measure': 'Degree of Fluctuation (DF) of multiple dose BMS-986090 SC', 'timeFrame': 'Days 1 -106'}, {'measure': 'AUC accumulation index (AI_AUC); ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose of BMS-986090 SC (multiple dose)', 'timeFrame': 'Days 1 -106'}, {'measure': 'Cmax accumulation index (AI_Cmax); ratio of Cmax at steady state to Cmax after the first dose of BMS-986090 SC (multiple dose)', 'timeFrame': 'Days 1 -106'}, {'measure': 'Apparent total body clearance (CLT/F) of multiple dose BMS-986090 SC', 'timeFrame': 'Days 1 -106'}, {'measure': 'Anti-KLH immunoglobulin G (IgG) and IgM antibody levels of single dose BMS-986090 SC', 'timeFrame': 'Days 1 -85'}, {'measure': 'Immunogenicity of BMS-986090 following single SC / IV infusion measured by frequency of subjects with positive anti-drug-antibody (ADA) assessment and frequency of subjects who develop positive ADA following a negative baseline', 'timeFrame': 'Days 1 -85'}, {'measure': 'Receptor occupancy (RO) of BMS-986090 following single SC or IV infusion', 'timeFrame': 'Days 1 -85'}]",26,18 Years,45 Years,ALL,True,Bristol-Myers Squibb,INDUSTRY,0,130.0,ACTUAL,2025-09-01T16:18:18.421400,v2_robust,True,True,False,True,True,
NCT01516580,Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients,Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial,"Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C","['Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C', 'Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,B-cell Non Hodgkin Lymphoma,"['B-cell Non Hodgkin Lymphoma', 'Mature B-cell Leukemia Burkitt-type']",[],UNKNOWN,,2011-12,2021-12,"[{'measure': 'Event free survival', 'description': 'Minimum time to death from any cause, presence of viable cells in residue after \\[2nd (Rituximab-)CYVE\\], relapse, progressive disease, or second malignancy measured from randomization.', 'timeFrame': '24 months'}]","[{'measure': 'Survival', 'description': 'Overall survival', 'timeFrame': '5 years'}, {'measure': 'Acute toxicity', 'description': 'Acute toxicity during treatment according to NCI-CTC V4', 'timeFrame': '6 months'}, {'measure': 'Long term toxicity', 'description': 'Long term toxicity, especially immune reconstitution, cardiac toxicity', 'timeFrame': '5 years'}]",4,6 Months,17 Years,ALL,False,"Gustave Roussy, Cancer Campus, Grand Paris",OTHER,1,482.0,ACTUAL,2025-09-01T16:18:18.421427,v2_robust,True,True,False,False,False,
NCT00203580,Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study),A Randomized Trial of the Effect of Low-Molecular-Weight Heparin Versus Warfarin Sodium on the Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (Main LITE Study),Tinzaparin sodium,['Tinzaparin sodium'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Thrombosis,"['Thrombosis', 'Thromboembolism', 'Venous Thrombosis']","['venous thromboembolism', 'low-molecular-weight heparin']",COMPLETED,,1994-12,2002-03,"[{'measure': 'objectively documented recurrent venous thromboembolism during initial treatment or during the 12 week follow-up period'}, {'measure': 'death during initial treatment or during the 12 week follow-up period'}, {'measure': 'safety endpoint for assessing harm was the occurrence of bleeding (all, major or minor) during the 12 week treatment interval'}]","[{'measure': 'recurrent venous thromboembolism at 12 months'}, {'measure': 'death at 12 months'}]",5,18 Years,,ALL,False,University of Calgary,OTHER,3,910.0,,2025-09-01T16:18:18.421440,v2_robust,True,True,True,False,True,
NCT05740280,"iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects","iCP-NI - A Phase 1, Double Blind, Placebo Controlled, Single and Multiple Intravenous Infusion, Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects",iCP-NI,"['iCP-NI', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['COVID-19', 'Pneumonia', 'Virus Diseases', 'Infections']",SUSPENDED,The Sponsor has put the study on hold and will recommence in due time.,2023-01-19,2023-08-17,"[{'measure': 'Part A: Incidence and severity of adverse events (AEs)', 'timeFrame': 'Screening to Follow Up (Day 28+2 days)'}, {'measure': 'Part B: Incidence and severity of adverse events (AEs)', 'timeFrame': 'Screening to Follow Up (Day 28+2 days)'}, {'measure': 'Part A: Incidence of laboratory abnormalities, based on hematology, clinical chemistry, and urinalysis test results', 'timeFrame': 'Screening to Follow Up (Day 7)'}, {'measure': 'Part B: Incidence of laboratory abnormalities, based on hematology, clinical chemistry, and urinalysis test results', 'timeFrame': 'Screening to Follow Up (Day 28+2 days)'}, {'measure': 'Part A: Number of participants with abnormal 12-lead ECG parameters', 'timeFrame': 'Screening to Follow Up (Day 7)'}, {'measure': 'Part B: Number of participants with abnormal 12-lead ECG parameters', 'timeFrame': 'Screening to Follow Up (Day 28+2 days)'}, {'measure': 'Part A: Number of participants with abnormal vital signs measurements', 'timeFrame': 'Screening to Follow Up (Day 7)'}, {'measure': 'Part B: Number of participants with abnormal vital signs measurements', 'timeFrame': 'Screening to Follow Up (Day 28+2 days)'}, {'measure': 'Part A: Number of participants with abnormal physical examinations', 'timeFrame': 'Screening to Follow Up (Day 7)'}, {'measure': 'Part B: Number of participants with abnormal physical examinations', 'timeFrame': 'Screening to Follow Up (Day 28+2 days)'}]","[{'measure': 'Part A: Pharmacokinetics (PK): Area under the concentration time curve from time 0 extrapolated to infinity (AUC0-∞) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Area under the concentration time curve from time 0 extrapolated to infinity (AUC0-∞) of iCP-NI', 'timeFrame': 'Day 1 (Pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Pharmacokinetics (PK): Area under the concentration time curve from time 0 to the time of the last quantifiable concentration (AUC0-tlast) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Area under the concentration time curve from time 0 to the time of the last quantifiable concentration (AUC0-tlast) of iCP-NI', 'timeFrame': 'Day 1 (Pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Pharmacokinetics (PK): Area under the concentration-time curve over a dosing interval (τ) (AUC0-τ) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Area under the concentration-time curve over a dosing interval (τ) (AUC0-τ) of iCP-NI', 'timeFrame': 'Day 1 (Pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Pharmacokinetics (PK): Maximum observed concentration (Cmax) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Maximum observed concentration (Cmax) of iCP-NI', 'timeFrame': 'Day 1 (Pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Pharmacokinetics (PK): Time of the maximum observed concentration (tmax) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Time of the maximum observed concentration (tmax) of iCP-NI', 'timeFrame': 'Day 1 (pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Pharmacokinetics (PK): Apparent terminal elimination half life (t1/2) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Apparent terminal elimination half life (t1/2) of iCP-NI', 'timeFrame': 'Day 1 (Pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Pharmacokinetics (PK): Accumulation ratio based on AUC0-τ (ARAUC) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Accumulation ratio based on AUC0-τ (ARAUC) of iCP-NI', 'timeFrame': 'Day 1 (Pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Serum concentrations of anti-iCP-NI antibodies', 'description': 'Serum concentrations of anti-iCP-NI antibodies will be determined using a validated analytical procedure.', 'timeFrame': 'Day -1, Follow up (Day 7) and Immunogenicity Visit (Day 28 + 2 days)'}, {'measure': 'Part B: Serum concentrations of anti-iCP-NI antibodies', 'description': 'Serum concentrations of anti-iCP-NI antibodies will be determined using a validated analytical procedure.', 'timeFrame': 'Day -1, Day 7 (pre-am dose) and Follow up (Day 28 + 2 days)'}, {'measure': 'Part A: Serum concentrations of neutralizing antibodies', 'description': 'Serum concentrations of neutralizing antibodies will be determined using a validated analytical procedure.', 'timeFrame': 'Day -1, Follow up (Day 7) and Immunogenicity Visit (Day 28 + 2 days)'}, {'measure': 'Part B: Serum concentrations of neutralizing antibodies', 'description': 'Serum concentrations of neutralizing antibodies will be determined using a validated analytical procedure.', 'timeFrame': 'Day -1, Day 7 (pre-am dose) and Follow up (Day 28 + 2 days)'}]",28,18 Years,55 Years,ALL,True,"Cellivery Therapeutics, Inc.",INDUSTRY,1,64.0,ESTIMATED,2025-09-01T16:18:18.421450,v2_robust,True,True,False,True,True,The Sponsor has put the study on hold and will recommence in due time.
NCT00349180,Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium),"Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium（RP54563）20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement",Enoxaparin sodium,['Enoxaparin sodium'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,"Arthroplasty, Replacement, Hip","['Arthroplasty, Replacement, Hip']","['Total Hip Replacement', 'Enoxaparin']",COMPLETED,,2006-06,,[{'measure': 'Incidence of VTE'}],[{'measure': 'Incidence of bleeding'}],2,20 Years,,ALL,False,Sanofi,INDUSTRY,0,156.0,,2025-09-01T16:18:18.421488,v2_robust,True,True,True,False,False,
NCT05546580,Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+),"An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+): The FRIDA Study",Iadademstat,"['Iadademstat', 'XOSPATA®', 'Gilteritinib Oral Tablet', 'ORY-1001, RO7051790']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,"Acute Myeloid Leukemia, in Relapse","['Acute Myeloid Leukemia, in Relapse', 'Acute Myeloid Leukemia Refractory']","['Acute Myeloid Leukemia, FLT3 mut']",RECRUITING,,2022-11-14,2025-11-30,"[{'measure': 'Adverse Events (AE)', 'description': 'Number of participants with Adverse Events (AE) after treatment with iadademstat in combination with gilteritinib in patients with FLT3-mutated R/R AML.', 'timeFrame': 'Up to 18 months'}, {'measure': 'Laboratory value abnormalities and/or adverse events (AE)', 'description': 'Number of participants with laboratory value abnormalities and/or Adverse Events (AE) after treatment with iadademstat in combination with gilteritinib in patients with FLT3-mutated R/R AML.', 'timeFrame': 'Up to 18 months'}, {'measure': 'Vital sign abnormalities and/or adverse events (AEs)', 'description': 'Number of participants with vital signs abnormalities and/or Adverse Events (AE) after treatment with iadademstat in combination with gilteritinib in patients with FLT3-mutated R/R AML.', 'timeFrame': 'Up to 18 months'}, {'measure': 'Routine 12-lead electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)', 'description': 'Number of participants with Routine 12-lead electrocardiogram (ECG )abnormalities and/or Adverse Events (AE) after treatment with iadademstat in combination with gilteritinib in patients with FLT3-mutated R/R AML.', 'timeFrame': 'Up to 18 months'}, {'measure': 'Recommend Phase 2 dose (RP2D)', 'description': 'Determine the recommended Phase 2 dose (RP2D) of iadademstat in combination with gilteritinib in patients with FLT3-mutated R/R', 'timeFrame': 'Up to 18 months'}, {'measure': 'iadademstat tmax', 'description': 'Measurement of the time it takes for iadademstat to reach the maximum concentration (Cmax) in blood.', 'timeFrame': 'Up to 26 days'}, {'measure': 'Iadademstat Cmax', 'description': 'Measurement of the highest concentration of iadademstat in the blood after a dose is given.', 'timeFrame': 'Up to 26 days'}, {'measure': 'iadademstat Cmin', 'description': 'Measurement of the lowest concentration of iadademstat in the blood, after a dose is given.', 'timeFrame': 'Up to 26 days'}, {'measure': 'iadademstat AUC', 'description': ""Measurement of how much iadadmestat reaches a person's bloodstream in a given period of time after a dose is given."", 'timeFrame': 'Up to 26 days'}, {'measure': 'iadademstat Target Engagement (TE)', 'description': 'Percent of drug covalently bound to LSD1 molecule', 'timeFrame': 'Up to 26 days'}, {'measure': 'OR rate', 'description': 'Proportion of patients achieving complete remission (CR), CR with incomplete hematologic recovery (CRi), and partial remission (PR).', 'timeFrame': 'Up to 18 months'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Time from start of treatment to the time of death from any cause.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Event-Free-Survival (EFS)', 'description': 'Time from start of treatment to the date of failure to achieve CR or CRi, relapse from CR/CRi, or death from any cause, whichever occurs first.', 'timeFrame': 'Up to 18 months'}, {'measure': 'Overall response rate', 'description': 'Percentage of patients with complete remission (CR), CR with incomplete blood count recovery (CRi), or PR.', 'timeFrame': 'Up to 6 months'}, {'measure': 'Time to Response (TTR)', 'description': 'Time from the date of initial dosing at RP2D/expansion dose to first documentation of either a type of CR or Partial Response (PR).', 'timeFrame': 'Up to 6 months'}, {'measure': 'Duration of Remission (DoR)', 'description': 'Time from the date of first documentation of any type of remission to the date of first documentation of progression of remission for remitters', 'timeFrame': 'Up to 18 months'}, {'measure': 'Transfusion independence rate', 'description': 'A patient is defined as red blood cell (RBC) and/or platelet-transfusion independent if he/she receives no RBC and/or platelet transfusions for a period of at least 8 weeks. Rate of transfusion independence is the percentage of patients who become RBC and/or platelet transfusion independent (from the number of patients transfusion dependent at baseline).', 'timeFrame': 'Up to 18 months'}, {'measure': 'Transplantation Rate Time Frame', 'description': 'Percentage of patients undergoing Hematopoietic Stem Cell Transplantation (HSCT) during the study period.', 'timeFrame': 'Up to 18 months'}]",18,18 Years,,ALL,False,Oryzon Genomics S.A.,INDUSTRY,0,50.0,ESTIMATED,2025-09-01T16:18:18.421556,v2_robust,True,True,False,False,True,
NCT04979780,Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort,Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort,"Rivaroxaban (Xarelto, BAY59-7939)","['Rivaroxaban (Xarelto, BAY59-7939)', 'Low molecular weight heparin (LMWH)', 'Direct Oral Anticoagulants (DOAC)']",3,OBSERVATIONAL,[],,,Treatment of Venous Thromboembolism in Cancer Patients,"['Treatment of Venous Thromboembolism in Cancer Patients', 'Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients']",[],COMPLETED,,2021-07-20,2022-03-31,"[{'measure': 'Risk of recurrent VTE', 'timeFrame': 'at 3 month after treatment'}, {'measure': 'Any clinically-relevant bleeding-related hospitalization', 'description': 'Cunningham algorithm for identification of bleeding-associated hospitalizations', 'timeFrame': 'at 3 month after treatment'}, {'measure': 'All-cause mortality', 'timeFrame': 'at 3 month after treatment'}]","[{'measure': 'Recurrent VTE at 6- and 12-months post-index VTE', 'timeFrame': 'at 6 and 12 months post-index VTE'}, {'measure': 'Composite of any major or clinically-relevant nonmajor bleeding-related hospitalization at 6- and 12-months post-index VTE', 'description': 'including:\n\n* Intracranial hemorrhage (ICH)\n* Critical organ bleeding (e.g., intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, or pericardial bleeding or intramuscular with compartment syndrome)\n* Extracranial bleeding-related hospitalizations', 'timeFrame': 'at 6 and 12 months post-index VTE'}, {'measure': 'Any clinically-relevant bleeding-related hospitalization', 'description': 'per the Cunningham algorithm for identification of bleeding-associated hospitalizations', 'timeFrame': 'at 6 and 12 months'}, {'measure': 'Intracranial hemorrhage (ICH)', 'timeFrame': 'at 3, 6 and 12 months'}, {'measure': 'Critical organ bleeding', 'timeFrame': 'at 3, 6 and 12 months'}, {'measure': 'Extracranial bleeding-related hospitalizations', 'timeFrame': 'at 3, 6 and 12 months'}, {'measure': 'All-cause mortality at 6- and 12-months.', 'timeFrame': 'at 6 and 12 months'}, {'measure': 'Incidence rates of recurrent VTE', 'description': 'Incidence rates of recurrent VTE in DOAC and LMWH patients experiencing CAT regardless of the bleeding risk associated with cancer type.', 'timeFrame': 'at 3, 6 and 12 months'}, {'measure': 'Incidence rates any clinically-relevant bleeding-related to recurrent VTE', 'description': 'Incidence rates of any clinically-relevant bleeding-related in DOAC and LMWH patients experiencing CAT regardless of the bleeding risk associated with cancer type.', 'timeFrame': 'at 3, 6 and 12 months'}, {'measure': 'All cause-mortality', 'description': 'Incidence rates of all cause-mortality in DOAC and LMWH patients experiencing CAT regardless of the bleeding risk associated with cancer type.', 'timeFrame': 'at 3, 6 and 12 months'}, {'measure': 'Duration of anticoagulation treatment', 'timeFrame': 'at 3, 6 and 12 months'}, {'measure': 'DOAC discontinuation rates at 3-, 6- and 12-months follow-up', 'timeFrame': 'at 3, 6 and 12 months'}, {'measure': 'LMWH discontinuation rates at 3-, 6- and 12-months follow-up', 'timeFrame': 'at 3, 6 and 12 months'}]",16,18 Years,,ALL,,Bayer,INDUSTRY,0,3708.0,ACTUAL,2025-09-01T16:18:18.421569,v2_robust,False,True,True,False,False,
NCT02867280,Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection,A Prospective Multicenter Non-randomized Controlled Study of Sorafenib (Nexavar) Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection,Sorafenib,"['Sorafenib', 'Nexavar']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Hepatocellular Carcinoma,"['Hepatocellular Carcinoma', 'Recurrence']","['Sorafenib', 'Microvascular invasion', 'adjuvant therapy', 'hepatocellular carcinoma']",TERMINATED,Midterm analysis showed negative results.,2016-06-01,2020-01-31,"[{'measure': 'Recurrence free survival', 'description': 'To determine the recurrence free survival rate at 2 years after hepatectomy', 'timeFrame': '2 years'}]","[{'measure': 'Time To Recurrence', 'description': 'To determine the median postoperative time to recurrence', 'timeFrame': 'From date of liver resection until the date of first documented relapse, assessed up to 5 years'}, {'measure': 'Recurrence rate', 'description': 'To determine the recurrence rate within 2 years after hepatectomy', 'timeFrame': '2 years'}, {'measure': 'Recurrence free survival', 'description': 'To determine the recurrence free survival at postoperative 1-year, 3-year, and 5-year', 'timeFrame': '1year, 3years, 5 years'}, {'measure': 'Overall survival', 'description': 'To determine the overall survival at postoperative 3-year and 5-year', 'timeFrame': '3 years, 5 years'}, {'measure': 'Incidence of Treatment-related Adverse Events measures using CTCAE v4.0', 'description': 'measures using CTCAE v4.0', 'timeFrame': '2 years'}, {'measure': 'Incidence of dose modification of sorafenib due to adverse events.', 'description': 'The actual total dose of sorafenib for every patients will be collected as well.', 'timeFrame': '2 years'}]",7,18 Years,75 Years,ALL,False,Sun Yat-sen University,OTHER,0,154.0,ACTUAL,2025-09-01T16:18:18.421600,v2_robust,True,True,False,True,True,Midterm analysis showed negative results.
NCT02460380,The Effects of Vitamin D on Angiogenic Factors in Women With Polycystic Ovary Syndrome,The Effects of Vitamin D Supplementation on Transforming Growth Factor-beta1 and Vascular Endothelial Growth Factor in Vitamin D-Deficient Women With Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Trial,Vitamin D3,['Vitamin D3'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Polycystic Ovary Syndrome,"['Polycystic Ovary Syndrome', 'Vitamin D Deficiency']",[],COMPLETED,,2013-10,2015-03,"[{'measure': 'Effect of Vitamin D on Angiogenic Factors', 'description': 'Serum TGF-β1/sENG ratio as a measure of TGF-β1 bioavailability', 'timeFrame': 'Baseline (pre-treatment) and 8 weeks later (post-treatment)'}, {'measure': 'Effect of Vitamin D on Angiogenic Factors', 'description': 'Serum VEGF level', 'timeFrame': 'Baseline (pre-treatment) and 8 weeks later (post-treatment)'}]","[{'measure': 'The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS', 'description': 'Interval between periods as a measure ovulatory dysfunction', 'timeFrame': 'Baseline (pre-treatment) and 4 months later (two months after the completion of treatment)'}, {'measure': 'The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS', 'description': 'Blood pressure', 'timeFrame': 'Baseline (pre-treatment) and 4 months later (two months after the completion of treatment)'}, {'measure': 'The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS', 'description': 'The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance. Insulin resistance is a condition in which cells fail to respond to the normal actions of the hormone insulin. The HOMA index was calculated as the product of fasting plasma blood glucose and insulin divided by 22.5.', 'timeFrame': 'Baseline (pre-treatment) and 8 weeks later (post-treatment)'}, {'measure': 'The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS', 'description': 'Free testosterone', 'timeFrame': 'Baseline (pre-treatment) and 8 weeks later (post-treatment)'}, {'measure': 'The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS', 'description': 'Lipid profile', 'timeFrame': 'Baseline (pre-treatment) and 8 weeks later (post-treatment)'}, {'measure': 'The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS', 'description': 'Ferriman-Gallwey score is a method used to assess and quantify hirsutism in women. A total score \\< 8 is considered normal whereas a score of 8 to 15 indicates mild hirsutism. A score \\>15 indicates moderate or severe hirsutism.', 'timeFrame': 'Baseline (pre-treatment) and 4 months later (two months after the completion of treatment)'}]",8,18 Years,38 Years,FEMALE,False,Maimonides Medical Center,OTHER,0,93.0,ACTUAL,2025-09-01T16:18:18.421623,v2_robust,True,True,True,False,False,
NCT05680480,A Study of Telitacicept in Lupus Nephritis,"A Phase Ⅱ, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Telitacicept in Lupus Nephritis",Placebo,['Placebo'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Lupus Nephritis,['Lupus Nephritis'],"['lupus', 'nephritis', 'Telitacicept', 'RC 18']",RECRUITING,,2023-04-17,2026-01,"[{'measure': 'Percentage of Participants with Complete Renal Response (CRR)', 'description': 'CRR is defined as estimated glomerular filtration rate (GFR) is no more than 20% below the baseline value or ≥ 60 mL/min/1.73m\\^2 and 24-hour urinary protein: creatinine ratio ≤ 0.5 mg/mg and did not receive prohibited or rescue therapy resulting in treatment failure.', 'timeFrame': 'Week 48'}]","[{'measure': 'Percentage of participants with Partial Renal Response (PRR)', 'description': 'PRR is defined as 24-hour urinary protein: creatinine ratio reduced by 50% compared to baseline value.', 'timeFrame': 'Week 24 and Week 48'}, {'measure': 'Incidence of AE, SAE', 'description': 'An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A SAE is any untoward medical occurrence that at any dose resulting in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant and which the investigator regards as serious based on appropriate medical judgment.', 'timeFrame': 'Up to Week 48'}]",3,18 Years,75 Years,ALL,False,"RemeGen Co., Ltd.",INDUSTRY,0,120.0,ESTIMATED,2025-09-01T16:18:18.421657,v2_robust,True,True,False,False,False,
NCT00086879,Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme,Randomized Phase II of TARCEVA™ (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme,carmustine,"['carmustine', 'temozolomide', 'erlotinib hydrochloride']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Brain and Central Nervous System Tumors,['Brain and Central Nervous System Tumors'],"['adult glioblastoma', 'recurrent adult brain tumor', 'adult giant cell glioblastoma', 'adult gliosarcoma']",COMPLETED,,2004-05,2011-03,[{'measure': 'Progression-free survival at 6 months'}],"[{'measure': ""Response (complete [CR] or partial response [PR]) measured by McDonald's criteria at least 4 weeks after first documented response and every 8 weeks until disease progression or until start of another treatment""}, {'measure': 'Severe toxic events assessed by CTCAE v3.0 at the end of each course'}, {'measure': 'Progression-free survival at 1 year'}, {'measure': 'Overall survival at 6 months and 1 year'}]",5,18 Years,120 Years,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,110.0,ACTUAL,2025-09-01T16:18:18.421806,v2_robust,True,True,True,False,False,
NCT02450279,Scintigraphic Comparison of Lung Deposition With Two Nebulizers During Invasive Mechanical Ventilation,,technetium-99m - Diethylenetriaminepentaacetic acid,['technetium-99m - Diethylenetriaminepentaacetic acid'],1,INTERVENTIONAL,['NA'],,,Post-operative Neurosurgery,['Post-operative Neurosurgery'],"['Aerosol delivery', 'Invasive mechanical ventilation', 'Jet Nebulizer', 'Vibrating-Mesh nebulizer']",TERMINATED,Never started,2016-03,,"[{'measure': 'Pulmonary deposition', 'timeFrame': 'Immediately after nebulization by imaging assessment, an expected average of 30 minutes'}]","[{'measure': 'Penetration index', 'timeFrame': 'Immediately after nebulization by imaging assessment, an expected average of 30 minutes'}, {'measure': 'Mechanical ventilation settings', 'timeFrame': 'During nebulisation time, an expected average of 15 minutes'}, {'measure': 'Lung function', 'timeFrame': 'Preoperative assessment, the day before inclusion'}]",4,18 Years,90 Years,ALL,False,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:18.421818,v2_robust,True,True,False,True,False,Never started
NCT06231979,Adding Dexmedetomidine to Bupivacaine for Bilateral Erector Spinae Block,Effects of Adding Dexmedetomidine to Bupivacaine for Bilateral Erector Spinae Block in Lumbar Fusion Surgeries,Dexmedetomidine,"['Normal saline sodium chloride 0.9%', 'DEX', 'Bupivacain', 'Normal saline', 'Dexmedetomidine', 'Bup']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Erector Spinae Block,"['Erector Spinae Block', 'Lumbar Fusion Surgeries', 'Dexmedetomidine']",[],NOT_YET_RECRUITING,,2024-02-25,2025-10-01,"[{'measure': 'the cummulative opioid consumption during first 48 h postoperatively.', 'timeFrame': '48 hours postoperatively.'}]","[{'measure': 'Change in stress marker Super Oxide Dismutase (SOD) .', 'description': 'Change in stress marker Super Oxide Dismutase (SOD) level in serum after centrifugation between preoperative at time of cannulation and 24h. Postoperative.', 'timeFrame': '24 hours postoperative.'}, {'measure': 'Postoperative pain score using Visual Analogue Scale (VAS).', 'timeFrame': 'immediately postoperative'}]",3,18 Years,65 Years,ALL,True,Assiut University,OTHER,0,48.0,ESTIMATED,2025-09-01T16:18:18.421844,v2_robust,True,True,False,False,False,
NCT06879379,KPD Consolidation After ASCT in NDMM Patients,"A Randomized, Multicenter Study Comparing Post-Transplant KPD Regimen Consolidation With No Consolidation in Newly Diagnosed Multiple Myeloma (NDMM) Transplant-eligible Patients","KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation","['KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation']",1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,"Multiple Myeloma, Newly Diagnosed","['Multiple Myeloma, Newly Diagnosed']",['consolidation'],RECRUITING,,2025-03,2029-03,"[{'measure': 'Minimal residual disease (MRD) negativity rate prior to maintenance therapy', 'description': 'The primary endpoint of this study is to compare the minimal residual disease (MRD) negativity rate prior to maintenance therapy in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients who receive KPD consolidation therapy versus those who do not receive consolidation therapy after triplet or quadraplet induction therapy and autologous stem cell transplantation (ASCT).', 'timeFrame': '36 months'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'Compare the overall response rate (ORR) including the rates of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR), prior to maintenance therapy according to the IMWG (International Myeloma Working Group) assessment criteria, between the two treatment groups。', 'timeFrame': '36 months'}]","[{'measure': 'Progression-free survival (PFS)', 'description': 'Time interval from ASCT to disease progression or death.', 'timeFrame': '36 months'}, {'measure': 'Overall Survival (OS)', 'description': 'Time interval from ASCT to death', 'timeFrame': '36 months'}]",4,18 Years,,ALL,False,Peking University People's Hospital,OTHER,0,202.0,ESTIMATED,2025-09-01T16:18:18.421878,v2_robust,True,True,False,False,False,
NCT04162379,Oral Prednisolone Effect on Cancer WHO Stepladder Analgesia Protocol,Effect of Salutatory Oral Prednisolone Dosing on Cancer Pain WHO Stepladder Analgesic Drug Protocol,Oral tablet,"['oral adjuvant analgesia', 'Oral tablet']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Steroid Anlgesia in Cancer Pain,['Steroid Anlgesia in Cancer Pain'],"['Steroid, analgesia, Prednisolone, Cancer, cancer Pain, pain WHO stepladder.']",COMPLETED,,2019-11-15,2020-03-01,"[{'measure': 'Pain intensity: visual analogue scale', 'description': 'global Pain intensity, assessed by a visual analogue scale (VAS) 0-10.', 'timeFrame': 'from day one to day 28'}]",[],1,18 Years,75 Years,ALL,False,Mansoura University,OTHER,0,39.0,ACTUAL,2025-09-01T16:18:18.421898,v2_robust,True,True,True,False,False,
NCT01085279,Fractional Laser as Treatment Option for Various Pigment Disorders (Fractional-3),"Non-ablative 1,550 nm Fractional Laser Therapy Versus Triple Topical Therapy for the Treatment of Melasma: a Randomized Controlled Split-face Study",Modified Kligman's formula (Triple topical therapy),"['modified Kligman formula', ""Modified Kligman's formula (Triple topical therapy)""]",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Pigmentation Disorder,['Pigmentation Disorder'],"['fractional laser', 'melasma', 'topical bleaching']",COMPLETED,,2009-03,2010-02,"[{'measure': ""Physician's global assessment"", 'description': 'Improvement of hyperpigmentation was assessed by an independent blinded dermatologist. The results were scored on a scale from zero to six (0: total clearance (100% improvement), 1: almost total clearance (90-99% improvement), 2: distinct clearance (75-89% improvement) 3: moderate clearance (50-74% improvement) 4: mild clearance (25-49% improvement) 5: no change, 6: worsening of hyperpigmentation).', 'timeFrame': 'T0, 3 weeks, and 3 and 6 months follow-up'}]","[{'measure': 'L-value', 'description': 'Improvement of hyperpigmentation was assessed by color measurement through reflectance spectroscopy (Microflash 200 d, Datacolor International, Lawrenceville, GA). This instrument, with an aperture of 4 mm, determines color by measuring the intensity of reflected light of particular wavelengths. In this study, the obtained L value, indicating the lightness of the measured area of skin, was used.', 'timeFrame': 'T0, 3 weeks and 3 and 6 months follow-up'}, {'measure': 'Melanin index', 'description': 'Melanin index was measured using a spectrometer (Derma-Spectrometer, Cortex Technology ApS, Hadsund, Denmark) in order to assess changes in the amount of dermal and epidermal melanin.', 'timeFrame': 'T0, 3 weeks and 3, and 6 months follow-up'}, {'measure': ""Patient's global assessment"", 'description': ""Patients were asked to score the improvement of hyperpigmentation on a visual analogue scale (VAS) from 0 to 10 (Patient's Global Assessment, PGA) at all follow-up moments."", 'timeFrame': '3 weeks, 3 and 6 months follow-up'}, {'measure': ""Patient's satisfaction"", 'description': ""Patient's satisfaction was scored on a visual analogue scale (VAS) from 0 to 10."", 'timeFrame': '3 weeks, 3 and 6 months follow-up'}]",5,18 Years,,ALL,False,Netherlands Institute for Pigment Disorders,OTHER,0,29.0,ACTUAL,2025-09-01T16:18:18.421906,v2_robust,True,True,True,False,False,
NCT02534896,To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis,To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis,Treatment I,"['Treatment III', 'Treatment II', 'Treatment I']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Active Rheumatoid Arthritis,['Active Rheumatoid Arthritis'],[],TERMINATED,,2015-11,2018-06,"[{'measure': 'Good/Moderate European League Against Rheumatism Responders', 'timeFrame': 'week 1'}]","[{'measure': 'Good European League Against Rheumatism -Responders', 'timeFrame': 'Day 8'}, {'measure': 'Good/Moderate European League Against Rheumatism Responders', 'timeFrame': 'Day 15'}, {'measure': 'Good European League Against Rheumatism Responders', 'timeFrame': 'Day 15'}]",4,18 Years,90 Years,ALL,False,Sun Pharmaceutical Industries Limited,INDUSTRY,0,150.0,ACTUAL,2025-09-01T16:18:18.422010,v2_robust,True,True,False,True,False,
NCT00644696,Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma,A Phase One Study of Intravenous Irinotecan and Bortezomib in Children With Recurrent/Refractory High-Risk Neuroblastoma,Irinotecan and Bortezomib,"['Cefpodoxime', 'Velcade', 'Irinotecan and Bortezomib', 'Cefixime']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Neuroblastoma,['Neuroblastoma'],"['Neuroblastoma', 'Irinotecan', 'Bortezomib']",COMPLETED,,2008-04,2012-07,"[{'measure': 'Determine highest dose of IV irinotecan administered in conjunction with bortezomib without causing severe side effects.', 'timeFrame': '3 years'}]","[{'measure': 'Measure the neuroblastoma tumors after treatment with irinotecan and bortezomib to determine whether there was a change in size.', 'timeFrame': '24 months'}]",2,1 Year,25 Years,ALL,False,University of Michigan Rogel Cancer Center,OTHER,1,18.0,ACTUAL,2025-09-01T16:18:18.422107,v2_robust,True,True,True,False,False,
NCT01303796,A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia,A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia,Sapacitabine,"['Decitabine intravenous', 'CYC682', 'Sapacitabine', 'Decitabine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],['AML'],COMPLETED,,2011-10-01,2017-07-31,"[{'measure': 'Overall Survival', 'description': 'The distribution of overall survival was estimated by the method of Kaplan and Meier. A log-rank analysis stratified by randomization stratification factors was used to compare overall survival between Arm A (decitabine/sapacitabine) versus Arm C (decitabine). Cox proportional hazards models were used to identify predictive factors for overall survival.', 'timeFrame': 'up to 43 months'}]","[{'measure': 'Complete Remission (CR)', 'description': 'Normalization of peripheral neutrophils to \\>=1000 /microliter, platelet to \\>=100,000/microliter within 2 weeks of bone marrow biopsy/aspirate, and bone marrow to \\<=5 % blasts; independent of transfusions\\*; and no extramedullary leukemia.\n\n\\* independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response', 'timeFrame': 'up to 43 months'}, {'measure': 'Complete Remission With Incomplete Platelet Count Recovery (CRp)', 'description': 'Normalization of bone marrow to \\<=5% blasts; peripheral neutrophils \\>=1000 /microliter, platelet \\<=100,000 /microliter within 2 weeks of bone marrow biopsy/aspirate; independent of transfusions\\*; and no extramedullary leukemia.\n\n\\*independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response', 'timeFrame': 'up to 43 months'}, {'measure': 'Partial Remission (PR)', 'description': 'Normalization of peripheral neutrophils to \\>=1000 /microliter, platelet to \\>=100,000/microliter within 2 weeks of bone marrow biopsy/aspirate, \\>=50% decrease in bone marrow blasts over pre-treatment but still \\>5%; independent of transfusions\\*\n\n\\*independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response', 'timeFrame': 'up to 43 months'}, {'measure': 'Hematological Improvement', 'description': 'HI with duration (HI)\n\n1. Erythroid response (HI-E) for patients with pre-treatment hemoglobin \\< 11 g/dL; Major response: \\>2 g/dL increase in hemoglobin; for RBC, transfusion independence\\* Minor response: 1 to 2 g/dL increase in hemoglobin; for RBC, a 50% decrease in transfusion requirements\n2. Platelet response (HI-P) for pre-treatment platelet count \\<100,000/mm3; Major response: an absolute increase of platelet count by \\>=30,000/mm3; stabilization of platelet counts and platelet transfusion independence\\* Minor response: \\>=50% increase in platelet count with a net increase \\> 10,000/mm3 but \\<30,000/mm3\n3. Neutrophil response (HI-N) for absolute neutrophil count (ANC) \\< 1,500/mm3 before therapy; Major response: \\>=100% increase, or an absolute increase of \\>500/mm3, whichever is greater Minor response: \\>=100% increase, but absolute increase \\< 500/mm3\n\n   * independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response', 'timeFrame': 'up to 43 months'}, {'measure': 'Stable Disease (SD)', 'description': 'Failure to achieve at least hematologic improvement (HI), but no evidence of clinically significant progression for \\> 16 weeks.', 'timeFrame': 'up to 43 months'}, {'measure': 'Blood Products Transfused', 'description': 'Number of units of packed red blood cells (PRBC) and/or platelet transfusions administered per 8-week period prior to the first dose of study drug and through the date of treatment discontinuation.', 'timeFrame': 'up to 43 months'}, {'measure': 'Hospitalized Days', 'description': 'In-patient days in hospital.', 'timeFrame': 'up to 12 months'}, {'measure': '1-year Survival', 'description': 'One-year survival is the percentage of patients who are alive at 1-year measured from the date of randomization.', 'timeFrame': 'Percentage of patients alive at 1 year after randomization (participants were assessed up to 43 months for overall survival curve estimation but this measure presents the 1 year survival rate percentage).'}, {'measure': 'Duration of Complete Remission (dCR)', 'description': 'Durations of normalization of peripheral neutrophils to \\>=1000 /microliter, platelet to \\>=100,000/microliter within 2 weeks of bone marrow biopsy/aspirate, and bone marrow to \\<=5 % blasts; independent of transfusions\\*; and no extramedullary leukemia.\n\n\\* independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response', 'timeFrame': 'up to 43 months'}, {'measure': 'Duration of Complete Remission With Incomplete Platelet Count Recovery (dCRp)', 'description': 'Duration of normalization of bone marrow to \\<=5% blasts; peripheral neutrophils \\>=1000 /microliter, platelet \\<=100,000 /microliter within 2 weeks of bone marrow biopsy/aspirate; independent of transfusions\\*; and no extramedullary leukemia.\n\n\\*independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response', 'timeFrame': 'up to 43 months'}, {'measure': 'Duration of Partial Remission (dPR)', 'description': 'Duration of normalization of peripheral neutrophils to \\>=1000 /microliter, platelet to \\>=100,000/microliter within 2 weeks of bone marrow biopsy/aspirate, \\>=50% decrease in bone marrow blasts over pre-treatment but still \\>5%; independent of transfusions\\*\n\n\\*independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response', 'timeFrame': 'up to 43 months'}, {'measure': 'Duration of Hematological Improvement (dHI)', 'description': 'Duration of HI\n\n1. Erythroid response (HI-E) for patients with pre-treatment hemoglobin \\< 11 g/dL; Major response: \\>2 g/dL increase in hemoglobin; for RBC, transfusion independence\\* Minor response: 1 to 2 g/dL increase in hemoglobin; for RBC, a 50% decrease in transfusion requirements\n2. Platelet response (HI-P) for pre-treatment platelet count \\<100,000/mm3; Major response: an absolute increase of platelet count by \\>=30,000/mm3; stabilization of platelet counts and platelet transfusion independence\\* Minor response: \\>=50% increase in platelet count with a net increase \\> 10,000/mm3 but \\<30,000/mm3\n3. Neutrophil response (HI-N) for absolute neutrophil count (ANC) \\< 1,500/mm3 before therapy; Major response: \\>=100% increase, or an absolute increase of \\>500/mm3, whichever is greater Minor response: \\>=100% increase, but absolute increase \\< 500/mm3\n\n   * independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response', 'timeFrame': 'up to 43 months'}, {'measure': 'Duration of Stable Disease (dSD)', 'description': 'Failure to achieve at least hematologic improvement (HI), but no evidence of clinically significant progression for \\> 16 weeks.', 'timeFrame': 'up to 43 months'}]",14,70 Years,,ALL,False,"Cyclacel Pharmaceuticals, Inc.",INDUSTRY,0,482.0,ACTUAL,2025-09-01T16:18:18.422117,v2_robust,True,True,True,False,False,
NCT00418496,Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma,A Phase I Study of Bolus High Dose Interleukin-2 With Sorafenib (BAY 43-9006) in Patients With Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma,Aldesleukin,"['Nexavar', 'Sorafenib', 'Proleukin', 'Aldesleukin']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Renal Cancer,"['Renal Cancer', 'Melanoma']","['Unresectable', 'Metastatic']",COMPLETED,,2006-11-08,2013-10,"[{'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'Determine the MTD for high dose (HD) aldesleukin and sorafenib in patients with metastatic or unresectable clear cell renal cell carcinoma and metastatic melanoma', 'timeFrame': 'up to 1 year'}]","[{'measure': 'Determine the progression free survival.', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Evaluate in a preliminary manner the response rate.', 'timeFrame': 'Up to 12 weeks'}]",3,18 Years,,ALL,False,Ohio State University Comprehensive Cancer Center,OTHER,2,17.0,ACTUAL,2025-09-01T16:18:18.422223,v2_robust,True,True,True,False,False,
NCT04153396,Preemptive Infiltration With Betamethasone and Ropivacaine for Postoperative Pain in Laminoplasty or Laminectomy,Preemptive Infiltration With Betamethasone and Ropivacaine for Postoperative Pain in Laminoplasty or Laminectomy (PRE-EASE),The Treatment group,"['The Control group', 'The Treatment group']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pain, Postoperative","['Pain, Postoperative', 'Neurosurgery']","['Pain, Postoperative', 'Betamethasone;', 'Ropivacaine;', 'Wound Infiltration', 'Laminoplasty or Laminectomy']",COMPLETED,,2021-09-01,2022-06-03,"[{'measure': 'The cumulative butorphanol dose during the 48 hours after surgery via the PCA device.', 'description': 'All participates will receive an electronic intravenous patient-controlled analgesia (PCA) device. Participates will be advised to push the analgesic demand button if they feel pain.', 'timeFrame': 'Within 48 hours after the operation'}]","[{'measure': 'The Visual Analogue Scale (VAS) during movement (VASm)', 'description': 'The pain will be assessed by the visual analogue scale (VAS) scores: an 11-point VAS score during movement (VASm) will be recorded (0 indicates no pain, 10 indicates the most severe pain imaginable, a higher score means worse pain)', 'timeFrame': 'At 2 hours, 4 hours, 8 hours, 24 hours, 48 hours and 72 hours, and 1 week, 2 weeks, 4 weeks, 6 weeks and 3 months and 6 months after surgery.'}, {'measure': 'The Visual Analogue Scale (VAS) at rest (VASr)', 'description': 'The pain will be assessed by the visual analogue scale (VAS) scores: an 11-point VAS score at rest (VASr) will be recorded (0 indicates no pain, 10 indicates the most severe pain imaginable, a higher score means worse pain)', 'timeFrame': 'At 2 hours, 4 hours, 8 hours, 24 hours, 48 hours and 72 hours, and 1 week, 2 weeks, 4 weeks, 6 weeks and 3 months and 6 months after surgery.'}, {'measure': 'The total times that participants press patient-controlled analgesia button', 'description': 'The total times that participants press patient-controlled analgesia button including effective presses and ineffective presses.', 'timeFrame': 'Within 48 hours after the operation'}, {'measure': 'The first analgesia demand on the PCA device', 'description': 'The time from the end of the surgery to the first administration of analgesia via the PCA device', 'timeFrame': 'Within 48 hours postoperatively'}, {'measure': 'Patient Satisfaction Score (PSS)', 'description': 'The Patient Satisfaction Score (PSS): 0 for unsatisfactory, and 10 for very satisfied', 'timeFrame': 'At 2 hours, 4 hours, 8 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 4 weeks, 6 weeks, 3 months and 6 months after surgery'}, {'measure': 'The Postoperative Nausea and Vomiting (PONV)', 'description': 'The Postoperative Nausea and Vomiting (PONV) will be measured using an ordinal scale, with 0 indicating no nausea; 1, mild nausea not requiring treatment; 2, nausea requiring treatment; 3, vomiting.', 'timeFrame': 'At 2 hours, 4 hours, 8 hours, 24 hours, 48 hours after surgery'}, {'measure': 'Ramsay Sedation Scale (RSS)', 'description': 'The Ramsay Sedation Scale (RSS): A 6-point scale will be used to assess sedation levels, with 1 indicating agitated, anxious; 2, cooperative; 3, only responds to commands; 4, strong response to glabellar tapping or noisy stimulants; 5, weak response to glabellar tapping or noisy stimulants; 6, no response.', 'timeFrame': 'At 2 hours, 4 hours, 8 hours, 24 hours, 48 hours after surgery'}, {'measure': 'The World Health Organization Quality of Life-BREF (WHOQOL-BREF) scores', 'description': 'The World Health Organization Quality of Life-BREF (WHOQOL-BREF) scores will be used to obtain scores for four domains related to quality of life: physical health (7 items), psychological (6 items), social relationships (3items) and environment (8items). It will also include two stand-alone questions on overall quality of life and satisfaction with health. Each question will be rated on a scale of 1-5 with higher scores signifying better quality of life.', 'timeFrame': 'At 6 months postoperatively'}, {'measure': 'The Oswestry Disability Index (ODI)', 'description': 'Functional disability will be assessed by the Oswestry Disability Index. It includes 10 questions about pain and activities of daily living. Each item has five response categories from no pain related disability (0), to the worst possible pain disability (100). The ODI has been reported to be the most widely used and validated outcome measure in spinal surgery.', 'timeFrame': 'Preoperatively and at 4 weeks, 6 weeks and 3 months, 6 months after surgery.'}, {'measure': 'Patient Scar Assessment and the Observer Scar Assessment Scale (POSAS)', 'description': 'The Patient and Observer Scar Assessment Scale includes subjective symptoms of pain and pruritus and consists of 2 numerical scales: The Patient Scar Assessment Scale and the Observer Scar Assessment Scale. It assesses vascularity, pigmentation, thickness, relief, pliability, surface area and overall opinion for a scar on a score of 1 (normal skin) to 10 (worst scar imaginable). and it incorporates patient assessments of pain, itching, color, stiffness, thickness, relief and overall opinion. Participants were asked to rate the severity of their scar compared to normal skin. The overall opinion scale score ranged from 1 (normal skin) to 10 (very different from normal skin)', 'timeFrame': 'At 6 months postoperatively'}]",11,18 Years,64 Years,ALL,False,Beijing Tiantan Hospital,OTHER,0,116.0,ACTUAL,2025-09-01T16:18:18.422321,v2_robust,True,True,True,False,False,
NCT02231762,Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET,"Phase II, Multicentre, Open Label Study to Evaluate the Efficacy of the Combination of Lanreotide Autogel 120mg and Temozolomide in Patients With Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) G1/G2 - A Pilot-Study",Lanreotide Autogel 120 mg,"['Lanreotide Autogel 120 mg', 'Temozolomide (TMZ)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastroenteropancreatic Neuroendocrine Tumors,['Gastroenteropancreatic Neuroendocrine Tumors'],[],COMPLETED,,2014-10,2017-06,"[{'measure': 'Disease Control Rate (DCR) After 6 Months', 'description': 'All tumour assessments were performed using the Response Evaluation Criteria In Solid Tumours (RECIST) criteria (1.1). Computer Tomography (CT-scan) or Magnetic Resonance Imaging (MRI) could be used for as method of tumour measurement and the same method of tumour measurement was used throughout the study for each subject. CT scans/MRI were performed at screening or baseline visit then at weeks 12, 24 and at early withdrawal or at anytime during the study in the case of any clinical or biological signs of tumour progression.\n\nThe DCR was defined as the proportion of subjects with a response of CR, PR or SD after 6 months of combination treatment and was described in the ITT population along with its 95% Confidence Interval (CI) and was compared to 45% with an exact binomial proportion test. The Last Observation Carried Forward (LOCF) method was used to replace missing assessments at the end of the combination phase.', 'timeFrame': '6 months'}]","[{'measure': 'DCR After 12 Months', 'description': 'All tumour assessments were performed using the RECIST criteria (1.1). CT-scan or MRI could be used for as method of tumour measurement and the same method of tumour measurement was used throughout the study for each subject. CT scans/MRI were performed at screening or baseline visit then at baseline, weeks 12, 24, 36, 48 (end of study) and at study withdrawal or at anytime during the study in the case of any clinical or biological signs of tumour progression.\n\nThe DCR was defined as the proportion of subjects with a response of CR, PR or SD after 6 months combination treatment followed by either 6 months of lanreotide ATG 120 mg maintenance treatment or no treatment. The DCR was described in the ITT population along with its 95% CI and was compared to 45% with an exact binomial proportion test. The LOCF method was used to replace missing assessments at the end of the maintenance phase.', 'timeFrame': '12 months'}, {'measure': 'Progression-Free Survival (PFS) Within 12 Months', 'description': 'PFS was defined as the time from the date of treatment start to the date of the first documented disease progression or death due to any cause within the first 12 months of treatment. If a subject had not progressed or died after 12 months of treatment or when any further anti-neoplastic therapy was received, PFS was censored at the time of the last tumour assessment before the analysis cut-off date or the anti-neoplastic therapy date.\n\nA Kaplan-Meier estimate of the PFS was calculated to determine the number of subjects at risk. Median PFS time (50% of subjects who would not progress or die) of the ITT population is presented along with 95 % CI.', 'timeFrame': '12 months'}, {'measure': 'Time To Response (TtR) Within 12 Months', 'description': 'TtR was defined as the time from the date of treatment start to the date of the first documented objective response (CR or PR) within the first 12 months of treatment (combination and maintenance phases). A Kaplan Meier estimate of the TtR survival function was constructed.\n\nThe Kaplan-Meier method was used to estimate the median TtR and its 95% CI for subjects in the ITT population (50% of subjects were expected to have a CR or PR at this time).', 'timeFrame': '12 months'}, {'measure': 'Duration of Response (DoR) Within 12 Months', 'description': 'The DoR is an estimation of the time from first documented objective response (CR or PR) to the first date of progressive disease (PD) or death due to disease progression for subjects who experienced an objective response within the first 12 months of treatment (combination and maintenance phases).\n\nThe Kaplan-Meier method was used to estimate the median DoR and its 95% CI for subjects in the ITT population who had an objective response.', 'timeFrame': '12 months'}, {'measure': 'The Number of Subjects With a Biochemical Response Using Chromogranin-A (CgA) Levels After 6 Months', 'description': 'Blood samples for CgA blood tumour marker analysis were taken at baseline, weeks 12, 24 and at early withdrawal. The biochemical response after 6 months combination treatment was estimated for subjects with abnormal CgA levels at baseline. Abnormal CgA levels were defined as above the upper limit of normal range (≥100 micrograms/litre \\[mcg/L\\]).\n\nBiochemical response based on CgA levels was categorised as: PR (decrease of CgA ≥ 50%, compared to the baseline CgA), SD (decrease \\< 50 % or an increase ≤25%, compared to the baseline CgA) or PD (defined as an increase ≥25 %, compared to the baseline CgA).\n\nThe number of subjects in each response category at each time point in the combination phase is presented. Analysis was only carried out on subjects in the ITT population who had abnormal CgA at baseline.', 'timeFrame': '6 months'}, {'measure': 'The Number of Subjects With a Biochemical Response Using CgA Levels After 12 Months', 'description': 'Blood samples for CgA blood tumour marker analysis were taken at baseline, weeks 12, 24, 36, 48 (end of study) and at early withdrawal. The biochemical response after 12 months combination and maintenance treatment was estimated for subjects with abnormal CgA levels at baseline. Abnormal CgA levels were defined as above the upper limit of normal range (≥100 mcg/L).\n\nBiochemical response based on CgA levels was categorised as: PR (decrease of CgA ≥50 % compared to the baseline CgA), SD (decrease \\< 50% or an increase ≤ 25% compared to the baseline CgA) or PD (defined as an increase ≥ 25%, compared to the baseline CgA).\n\nThe number of subjects in each response category at each time point in the maintenance phase is presented. Analysis was only carried out on subjects in the ITT population who had abnormal CgA at baseline.', 'timeFrame': '12 months'}, {'measure': 'The Number of Subjects With a Biochemical Response Using 5-Hydroxy-Indol-Amino-Acid (HIAA) Levels After 6 Months', 'description': 'Urine samples for 5-HIAA urinary tumour marker analysis were taken at at baseline, weeks 12, 24and early withdrawal.\n\nBiochemical response based on 5-HIAA levels was categorised as: Response (5-HIAA reduction compared to baseline) or Progression (5-HIAA increase compared to baseline).\n\nThe number of subjects in each response category at each time point in the combination phase is presented. Analysis was only carried out on subjects in the ITT population with functioning NET.', 'timeFrame': '6 months'}, {'measure': 'The Number of Subjects With a Biochemical Response Using 5-HIAA Levels After 12 Months', 'description': 'Urine samples for 5-HIAA urinary tumour marker analysis were taken at baseline, weeks 12, 24, 36, 48 (end of study) and early withdrawal.\n\nBiochemical response based on 5-HIAA levels was categorised as: Response (5-HIAA reduction compared to baseline) or Progression (5-HIAA increase compared to baseline).\n\nThe number of subjects in each response category at each time point in the maintenance phase is presented. Analysis was only carried out on subjects in the ITT population with functioning NET.', 'timeFrame': '12 months'}, {'measure': 'The Number of Subjects With a Symptomatic Response After 6 Months', 'description': 'Symptomatic response was evaluated as absolute change from baseline in the number of episodes of the lead symptoms (i.e. diarrhoea and flushing) using the mean of the last 3 days before the visit, at each visit, as compared to baseline.\n\nSymptomatic responses were categorised as: Reduction, Increase or Stability of occurrences of diarrhoea / Reduction, Increase or Stability of occurrences of flushing.\n\nThe number of subjects in each response category at week 24 (end of the combination phase) is presented. Analysis was only carried out on subjects in the ITT population with functioning NET.', 'timeFrame': '6 months'}, {'measure': 'The Number of Subjects With a Symptomatic Response After 12 Months - Maintenance Phase', 'description': 'Symptomatic response was evaluated as absolute change from baseline in the number of episodes of the lead symptoms (i.e. diarrhoea and flushing) using the mean of the last 3 days before the visit, at each visit, as compared to baseline.\n\nSymptomatic responses were categorised as: Reduction, Increase or Stability of occurrences of diarrhoea / Reduction, Increase or Stability of occurrences of flushing.\n\nThe number of subjects in each response category at week 48 (end of study) is presented. Analysis was only carried out on subjects in the ITT population with functioning NET.', 'timeFrame': '12 months'}, {'measure': 'European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Core 30 Questionnaire (QLQ-C30): Mean Change From Baseline at 6 Months', 'description': ""Subjects were instructed to complete the QLQ-C30 questionnaire at baseline, weeks 12, 24 or at early withdrawal. The first 28 questions used a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) \\& 6 other single items. The last 2 questions represented subject's assessment of overall health \\& quality of life, coded on a 7-point scale (1=very poor to 7=excellent). The mean change from baseline at week 24 (end of the combination phase) is presented for global health status (scoring of questions 29 \\& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Each individual subscore was transformed to range from 0 to 100. A higher score represents a higher level response. Thus, a better QoL/a better level of functioning/a worse level of symptoms."", 'timeFrame': '6 months'}, {'measure': 'EORTC QoL Questionnaire QLQ-C30: Mean Change From Baseline at 12 Months', 'description': ""Subjects were instructed to complete QLQ-C30 questionnaire at baseline, weeks 12, 24, 36, 48 (end of study) or at early withdrawal. The first 28 questions used a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) \\& 6 other single items. The last 2 questions represented subject's assessment of overall health \\& quality of life, coded on a 7-point scale (1=very poor to 7=excellent). The mean change from baseline at week 48 (end of study) is presented for global health status (scoring of questions 29 \\& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Each individual subscore was transformed to range from 0 to 100. A higher score represents a higher level response. Thus, a better QoL/a better level of functioning/a worse level of symptoms."", 'timeFrame': '12 months'}, {'measure': 'Quality of Life Gastrointestinal Neuroendocrine Tumour 21 Questionnaire (QLQ-GI.NET21): Mean Change From Baseline at 6 Months', 'description': 'Subjects were instructed to complete the QLQ-GI.NET21 questionnaire at baseline, weeks 12, 24 or at early withdrawal. It contained 21 questions that used a 4-point scale (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much) to evaluate 3 defined multi-item symptom scales (endocrine, gastrointestinal and treatment related side effects), 2 single item symptoms (bone/muscle pain and concern about weight loss), 2 psychosocial scales (social function and disease-related worries) and 2 other single items (sexuality and communication). Each individual subscore was transformed to range from 0 to 100. The mean change from baseline at week 24 (end of combination phase) is presented with a higher score representing a higher level response. Thus, a better level of functioning/a worse level of symptoms.', 'timeFrame': '6 months'}, {'measure': 'QoL Questionnaire QLQ-GI.NET21: Mean Change From Baseline at 12 Months', 'description': 'Subjects were instructed to complete the QLQ-GI.NET21 questionnaire at baseline, weeks 12, 24, 36, 48 (end of study) or at early withdrawal. It contained 21 questions that used a 4-point scale (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much) to evaluate 3 defined multi-item symptom scales (endocrine, gastrointestinal and treatment related side effects), 2 single item symptoms (bone/muscle pain and concern about weight loss), 2 psychosocial scales (social function and disease-related worries) and 2 other single items (sexuality and communication). Answers were converted into grading scale, with values between 0 and 100. Each individual subscore was transformed to range from 0 to 100. The mean change from baseline at week 48 (end of study) is presented with a higher score representing a higher level response. Thus, a better level of functioning/a worse level of symptoms.', 'timeFrame': '12 months'}, {'measure': 'DCR by O6-methylguanine-DNA Methyl-transferase (MGMT) Expression and Methylation and Somatostatin Receptor (SSTR) Expression After 6 Months', 'description': 'In all subjects whose tumour tissue was available, MGMT expression/methylation and SSTR expression was analysed. After 6 months, the DCR (SD+PR+CR) by MGMT methylation and expression and by SSTR 2a and SSTR 5 expression was evaluated.\n\nDCR in response to MGMT methylation and expression results are presented. SSTR 2a and SSTR 5 expression is categorised as: No Receptors, Cytoplasmatic Expression (CE), Focal Expression (FE), Complete Circumferent Membrane Expression (CCME).\n\nThe DCR was defined as the proportion of subjects with a response of CR, PR or SD after 6 months of combination treatment within each methylation/expression category. The DCR was described in the ITT population along with its 95% CI and was compared to 45% with an exact binomial proportion test.', 'timeFrame': '6 months'}, {'measure': 'Pharmacokinetic (PK) Results: Lanreotide ATG 120 mg Serum Concentrations Within 12 Months', 'description': 'Lanreotide ATG levels were measured in a subset of subjects to evaluate if temozolomide co-treatment had an impact on lanreotide serum concentration over a 12 month period.\n\nBlood samples were collected for the determination of lanreotide ATG in serum at baseline, weeks 4, 12, 24 and 48 (end of study).\n\nThe concentrations of lanreotide ATG in serum were determined by a validated radioimmunoassay analysis method with a lower limit of quantitation of 0.08 nanograms \\[ng\\]/mL).\n\nSerum concentrations of lanreotide ATG at each of the time points in the combination and maintenance phase are presented. Only subjects with data available for analysis are presented.', 'timeFrame': 'Baseline (week 1) and weeks 4, 12, 24 and 48'}]",17,18 Years,,ALL,False,Ipsen,INDUSTRY,0,57.0,ACTUAL,2025-09-01T16:18:18.422448,v2_robust,True,True,True,False,False,
NCT03605862,Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection,"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection",Nitazoxanide,"['Nitazoxanide', 'NT-300', 'NTZ (nitazoxanide)', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Enterovirus,"['Enterovirus', 'Rhinovirus']","['Enterovirus', 'Rhinovirus']",COMPLETED,,2018-09-11,2019-02-04,"[{'measure': 'Time From First Dose to Symptom Response Over 21 Days of Follow up Based Upon the FLU-PRO Instrument (Novel Endpoint)', 'description': 'Subjects used the FLU-PRO questionnaire once daily in the evening to score the severity of 32 FLU-PRO symptoms. Symptom response was deemed achieved when the rating for each of the 32 FLU-PRO symptoms was ≤ its assigned threshold for 2 consecutive daily diary periods without use of symptom relief medication. The symptom response thresholds were developed by applying an algorithm to blinded symptoms data to select the set of 32 symptom thresholds most closely associated with patient-reported usual health.', 'timeFrame': 'Up to 21 days'}]","[{'measure': 'Time From First Dose to Ability to Perform All Normal Activities', 'description': 'Subjects completed a diary including rating ability to perform normal activities on a scale from 0 (able to perform no normal activities) to 10 (able to perform all normal activities) daily in the evening. The time from first dose to ability to perform all normal activities is the time in hours between the first dose of study medication and that time when the subject first reported a score of ""10"" (able to perform all normal activities) for two consecutive daily diary periods without use of symptom relief medication.', 'timeFrame': 'Up to 21 days'}, {'measure': 'Proportions Experiencing Complications of EV/RV Infection', 'description': 'Complications of colds due to EV/RV infection include pneumonia, otitis media, bronchitis, sinusitis, exacerbations of asthma or COPD, worsening of pre-existing health conditions, secondary infections requiring systemic antibiotic use, hospitalization due to cold or complications of the cold, and death due to cold or complications of the cold. Proportions experiencing complications of EV/RV infection were compared across treatment groups.', 'timeFrame': '28 days'}]",3,12 Years,,ALL,False,Romark Laboratories L.C.,INDUSTRY,0,1756.0,ACTUAL,2025-09-01T16:18:18.422604,v2_robust,True,True,True,False,False,
NCT01315262,On Demand Versus Daily Sildenafil for Patients Undergoing Radical Prostatectomy,"On Demand Versus Daily Sildenafil for Patients Undergoing Bilateral Nerve Sparing Radical Prostatectomy: a Randomized, Open Label, Parallel Group Trial",Sildenafil,['Sildenafil'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Erectile Dysfunction,['Erectile Dysfunction'],"['Sildenafil 100', 'restoring erectile function after radical prostatectomy']",UNKNOWN,,2011-01,2012-12,"[{'measure': 'Proportion of patients with an Erectile Function domain score of International Index of Erectile Function ( IIEF) => 22 at the end of the wash-out period (44 wks after surgery)', 'timeFrame': '44 wks after surgery'}]","[{'measure': 'Proportion of patients with an Erectile Function domain score of IIEF => 22 at the end of the study (52 wks after surgery)', 'timeFrame': '52 wks after surgery'}, {'measure': 'IIEF - Domain Scores for: Erection Hardness Score (1-4) Intercourse success rates defined by the Sexual Encounter Profile (SEP) questionnaire (questions 2 and 3) Safety Endpoints: Adverse event summarized Global assessment questions', 'description': 'Responses to IIEF - Domain Scores for:\n\n* Erectile Function\n* Orgasmic Function\n* Sexual Desire\n* Intercourse Satisfaction\n* Overall Satisfaction c. Erection Hardness Score\n* Intercourse success rates defined by the SEP questionnaire (questions 2 and 3)\n* Safety Endpoints: Adverse event data will be summarized\n* Global assessment questions:', 'timeFrame': '3-6-9-12 months'}]",3,18 Years,65 Years,MALE,False,Università Vita-Salute San Raffaele,OTHER,0,200.0,ESTIMATED,2025-09-01T16:18:18.422633,v2_robust,True,True,False,False,True,
NCT00216762,Safety Study of Rituximab (Rituxan®) in Chronic Urticaria,"Phase I/II Open Label Evaluation of the Safety and Efficacy of Rituximab in Patients With Chronic Urticaria (The Rituximab Urticaria Study - ""RUSTY"")",Rituximab,"['Rituxan ®', 'Rituximab']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Urticaria,['Urticaria'],"['Urticaria', 'Hives']",TERMINATED,Full Clinical Hold,2006-01,2007-05,"[{'measure': 'Safety of Rituximab infusions in this patient population', 'timeFrame': '1 year or time until reconstitution of B cells'}]",[],1,18 Years,70 Years,ALL,False,Johns Hopkins University,OTHER,1,15.0,ESTIMATED,2025-09-01T16:18:18.422783,v2_robust,True,True,False,True,True,Full Clinical Hold
NCT02239562,sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF) in Autoimmune Hepatitis",sPIF,"['synthetic PreImplantation Factor', ""Ringer's lactated solution"", 'sPIF', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Autoimmune Hepatitis,['Autoimmune Hepatitis'],"['sPIF', 'synthetic PreImplantation Factor', 'Autoimmune', 'Liver', 'Hepatitis']",COMPLETED,,2014-11-14,2016-12-29,"[{'measure': 'Safety/Tolerability Measured by Clinical Laboratory Tests, Metabolics, Cytokines, Anti-PIF Antibody, Periodic Physical Examination, Including Vital Signs Measurements and 12-lead ECG', 'description': 'Single Ascending Dose (SAD):\n\nAdverse events, concomitant medications: Days 1, 2, 3, 5, 8 Vital signs, Physical exams: Days 1, 2, 8 Complete blood counts (CBC), Serum chemistry, Liver function tests, Pharmacokinetics: Days 1, 2, 8 Lipids, Coagulation, Urinalysis, Pregnancy test: Days 1, 8 EKG, chest x-ray (CXR): Days 1 and 8\n\nMultiple Ascending Dose (MAD):\n\nAdverse events, concomitant medications: Days 1, 2, 3, 4, 5, 8, 15, 29 Vital signs, Physical exams: Days 1, 2, 3, 4, 5, 8, 15, 29 CBC, Serum chemistry, Liver function tests, Pharmacokinetics: Days 1, 3, 5, 8, 15, 29 Lipids, Coagulation, Urinalysis, Pregnancy test, EKG: Days 1, 5, 29 CXR: Days 1, 29', 'timeFrame': '29 Day'}]","[{'measure': 'Number of Participants With Anti-sPIF Antibodies and Drug Interactions', 'description': 'Following sPIF administration, using a validated assay, serum samples were tested for anti-sPIF antibodies', 'timeFrame': '29 Day'}]",2,18 Years,70 Years,FEMALE,False,"Christopher O'Brien, MD",OTHER,1,36.0,ACTUAL,2025-09-01T16:18:18.422791,v2_robust,True,True,True,False,True,
NCT03656562,Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients,"A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythematosus (SLE)",VAY736,"['CFZ533', 'CFZ533 Placebo', 'Iscalimab/Placebo', 'VAY736 Placebo', 'Ianalumab', 'VAY736', 'Ianalumab/Placebo', 'Iscalimab']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Systemic Lupus Erythematosus (SLE),['Systemic Lupus Erythematosus (SLE)'],"['Systemic Lupus Erythematosus', 'SLE', 'Anti-CD40', 'anti-BAFF-receptor', 'B-cell depletion', 'BAFF-receptor blockade', 'ianalumab', 'VAY736', 'iscalimab', 'CFZ533']",ACTIVE_NOT_RECRUITING,,2018-12-19,2026-04-24,"[{'measure': 'Percentage of Participants With SLE Responder Index (SRI)-4 Response Status at Week 29 With Reduced Steroid Dose Maintained Between Weeks 17 and 29', 'description': ""The primary endpoint is a composite of SRI-4 response at Week 29 with sustained reduction in oral corticosteroid from Week 17 through Week 29. Patients taking other rescue medication or prohibited medication or drop out before Week 29 were considered non-responders.\n\nSRI-4 response is defined as below:\n\n* having \\>= 4 points reduction from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score (score is 0 to 105; a higher score indicating more severe disease) AND\n* no new British Isles Lupus Activity Group (BILAG)-2004 A organ domain score and no more than one new BILAG-2004 B organ domain scores compared with baseline AND\n* \\<10 mm point increase from baseline with scale 0 to 100 mm in the physician's global assessment from baseline\n\nSustained reduction in oral corticosteroid is defined as below:\n\n* =\\< 5 mg/day or less than or equal to baseline dose, whichever was lower at Week 17 AND\n* no increase of that dose from Week 17 through Week 29"", 'timeFrame': 'Baseline, Week 17 to Week 29'}]","[{'measure': ""Changes Between Baseline and Week 29 in the Physicians' Global Assessment (PhGA) Visual Analog Scale (VAS) Assessing Patient's Overall Disease Activity"", 'description': 'The Physician\'s global assessment (PhGA-VAS) of disease activity was performed using 100 mm VAS ranging from ""no disease activity"" (score 0) to ""maximal disease activity"" (score 100), after the question on how well the patient was doing with the disease considering all aspects affected by the disease. The investigator was then measuring the distance in mm from the left edge of the scale and entering the value.', 'timeFrame': 'Baseline, Week 5, Week 9, Week 13, Week 17, Week 21, Week 25, Week 29'}, {'measure': ""Changes Between Baseline and Week 29 in the Patient's Global Assessment (PGA) Visual Analog Scale (VAS) Assessing Patient's Global Disease Activity"", 'description': 'The patient\'s global assessment of disease activity was performed using a Visual Analogue Scale (VAS) of 100 mm ranging from ""no disease activity"" (score 0) to ""severe disease activity"" (score 100), after the question on how well the patient was doing with the disease considering all aspects affected by the disease. The investigator was then measuring the distance in mm from the left edge of the scale and entering the value.', 'timeFrame': 'Baseline, Week 5, Week 9, Week 13, Week 17, Week 21, Week 25, Week 29'}, {'measure': 'Flare Rate and Time to First Flare', 'description': ""Flare rate and time to first flare, with flare defined as one new 'A' score or two or more 'B' score using BILAG -2004"", 'timeFrame': '18 months'}, {'measure': 'Time to First Flare', 'description': ""Time to first flare, with flare defined as one new 'A' score or two or more 'B' score using BILAG -2004"", 'timeFrame': '18 months'}, {'measure': 'PK Cohort 1 - Cmax,ss', 'description': 'PK Cohort 1 (VAY736): free VAY736 serum concentration (Cmax at steady state)', 'timeFrame': '18+ months'}, {'measure': 'PK Cohort 1 - Ctrough,ss', 'description': 'PK Cohort 1 (VAY736): free VAY736 serum concentration (Ctrough at steady state)', 'timeFrame': '18+ months'}, {'measure': 'PK Cohort 2 - Cmax,ss', 'description': 'PK Cohort 2 (CFZ533): free CFZ533 concentration in plasma (Cmax at steady state).', 'timeFrame': '18 months'}, {'measure': 'PK Cohort 2 - Ctrough,ss', 'description': 'PK Cohort 2 (CFZ533): free CFZ533 concentration in plasma (Ctrough at steady state).', 'timeFrame': '18 months'}, {'measure': 'PD Cohort 2 (CFZ533): Total Soluble CD40', 'description': 'PD Cohort 2 (CFZ533): total soluble CD40 in plasma.', 'timeFrame': '18 months'}]",10,18 Years,75 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,107.0,ACTUAL,2025-09-01T16:18:18.422825,v2_robust,True,True,False,False,False,
NCT06719362,"A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies","A First-in-human, Open-label, Dose Escalation, Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies in Patients With Advanced Solid Tumors",M3T01,"['Pembrolizumab', 'KEYTRUDA', 'FOLFOX regimen', 'Oxaliplatin, Leucovorin, Fluorouracil', 'M3T01']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],[],RECRUITING,,2025-06-17,2030-02,"[{'measure': 'Treatment-emergent adverse events', 'description': 'Safety parameters including clinical assessments, vital signs, laboratory testing, and electrocardiograms (ECG) will be used to assess treatment-emergent adverse events (TEAE). Adverse events will be graded using the NCI-CTCAE v5.0. Investigators will determine relatedness of all treatment emergent adverse events (TEAE) to the investigational agent(s).', 'timeFrame': '4 years'}, {'measure': 'Dose-limiting toxicities', 'description': 'The DLT evaluation period will be defined as the first 21 days after infusion of M3T01 as monotherapy or in combination with other systemic therapies (including pembrolizumab, temozolomide, and FOLFOX). Site investigators will grade toxicities using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.', 'timeFrame': '21 days after C1D1'}, {'measure': 'Serious adverse events', 'description': 'Clinical assessments, vital signs, laboratory testing, and electrocardiograms (ECG) will be used to assess serious adverse events (SAE) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.', 'timeFrame': '4 years'}, {'measure': 'Immune-related adverse events', 'description': 'Clinical assessments, vital signs, laboratory testing, and electrocardiograms (ECG) will be used to assess immune-related adverse events (irAE) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.', 'timeFrame': '4 years'}]","[{'measure': 'PK Profile of M3T01', 'description': 'Serum PK parameters including the area under the curve (AUC), maximum concentration (Cmax), minimum concentration (Cmin), time to maximum concentration (Tmax), half-life (t1/2), and other serum concentration vs time parameters.', 'timeFrame': '4 years'}, {'measure': 'Immunogenicity of M3T01', 'description': '• Incidence of anti-drug antibodies (ADA) and neutralizing antibodies (nAbs) against M3T01 and correlation with M3T01 PK parameters, toxicity, and clinical efficacy.', 'timeFrame': '4 years'}, {'measure': 'Antitumor Activity of M3T01', 'description': 'Tumor response (for all solid tumors other than glioblastoma) will be evaluated by site investigators per RECIST v1.1 to assess the objective response rate (ORR), best overall response (BOR), disease control rate (DCR), duration of response (DOR), progression free survival (PFS), and overall survival (OS). Tumor assessment CT or MRI scans will be performed every 8 weeks for the first 6 months and then every 12 weeks thereafter. Tumor assessments for subjects with glioblastoma will be performed with contrast-enhanced MRI per the Response Assessment in Neuro-Oncology (RANO 2.0) criteria.', 'timeFrame': '4 years'}]",7,18 Years,,ALL,False,Providence Health & Services,OTHER,0,110.0,ESTIMATED,2025-09-01T16:18:18.422924,v2_robust,True,True,False,False,True,
NCT04987762,Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children,"An Open-Label, Multicenter, Multiple-Dose, Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children 4 to 12 Years of Age",Adhansia XR,['Adhansia XR'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Attention Deficit/Hyperactivity Disorder,['Attention Deficit/Hyperactivity Disorder'],"['ADHD', 'methylphenidate', 'Adhansia XR', 'Pediatric']",TERMINATED,due to administrative reasons not related to efficacy or safety.,2021-08-03,2022-04-27,"[{'measure': 'The Number of Participants With Adverse Events as a Measure of Safety', 'description': ""Adverse events (AEs) were documented and reported from the time the subject/parent(s)/legal guardian provided informed consent/assent up to 7 days after the last study drug administration. AEs that were ongoing at the subject's last study visit were followed until resolution or for 30 days after study drug administration."", 'timeFrame': 'Up to 9 months'}]",[],1,4 Years,12 Years,ALL,False,Purdue Pharma LP,INDUSTRY,0,103.0,ACTUAL,2025-09-01T16:18:18.423070,v2_robust,True,True,False,True,True,due to administrative reasons not related to efficacy or safety.
NCT00987246,Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis,Study on the Efficacy of LAS41005 Compared to Placebo and to LAS106521 in the Treatment of Actinic Keratosis Grade I to II,Placebo Gel,"['Placebo Gel', 'LAS106521', 'LAS41005']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Actinic Keratosis,['Actinic Keratosis'],"['Actinic Keratosis', 'AK', 'NMSC', 'Combination']",COMPLETED,,2008-06,2009-06,"[{'measure': 'Histological status of AK target lesion', 'timeFrame': 'Day 140'}]",[],1,18 Years,85 Years,ALL,False,"Almirall, S.A.",INDUSTRY,0,470.0,ACTUAL,2025-09-01T16:18:18.423079,v2_robust,True,True,True,False,False,
NCT00090246,2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091),"A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of 2 Doses of Aprepitant for the Prevention of Postoperative Nausea and Vomiting","MK0869, aprepitant","['MK0869, aprepitant', 'Comparator: ondansetron IV']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Postoperative Nausea and Vomiting,['Postoperative Nausea and Vomiting'],[],COMPLETED,,2004-05-13,2005-04-20,"[{'measure': 'Prevention of PONV in the 24 hours following end of surgery; Tolerability', 'timeFrame': '24 hours'}]",[],1,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,922.0,ACTUAL,2025-09-01T16:18:18.423111,v2_robust,True,True,True,False,False,
NCT00006246,Busulfan in Treating Children and Adolescents With Refractory CNS Cancer,Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis,busulfan,['busulfan'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Brain and Central Nervous System Tumors,"['Brain and Central Nervous System Tumors', 'Childhood Germ Cell Tumor', 'Leukemia', 'Lymphoma', 'Metastatic Cancer', 'Retinoblastoma', 'Sarcoma']","['recurrent childhood acute lymphoblastic leukemia', 'childhood infratentorial ependymoma', 'recurrent childhood rhabdomyosarcoma', 'recurrent childhood brain tumor', 'recurrent retinoblastoma', 'recurrent childhood lymphoblastic lymphoma', 'childhood central nervous system germ cell tumor', 'recurrent childhood acute myeloid leukemia', 'recurrent/refractory childhood Hodgkin lymphoma', 'leptomeningeal metastases', 'childhood high-grade cerebral astrocytoma', 'childhood oligodendroglioma', 'childhood choroid plexus tumor', 'childhood grade I meningioma', 'childhood grade II meningioma', 'childhood grade III meningioma', 'recurrent childhood large cell lymphoma', 'recurrent childhood brain stem glioma', 'recurrent childhood supratentorial primitive neuroectodermal tumor', 'recurrent childhood cerebellar astrocytoma', 'recurrent childhood cerebral astrocytoma', 'recurrent childhood medulloblastoma', 'recurrent childhood visual pathway and hypothalamic glioma', 'recurrent childhood ependymoma', 'recurrent childhood malignant germ cell tumor']",COMPLETED,,2000-11,,"[{'measure': 'Toxicities of IT administered busulfan in children and adolescents with refractory CNS malignancies'}, {'measure': 'Maximum tolerated dose of IT administered busulfan'}, {'measure': 'Serum and CSF pharmacokinetics of IT administered busulfan'}]",[],3,3 Years,21 Years,ALL,False,Pediatric Brain Tumor Consortium,NETWORK,1,28.0,ACTUAL,2025-09-01T16:18:18.423118,v2_robust,True,True,True,False,False,
NCT02122146,A Study Of PF-06664178 In Patients With Advanced Solid Tumors,"A Phase 1, Dose Escalation Study Of Pf-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors",PF-06664178,['PF-06664178'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Neoplasms,['Neoplasms'],"['ADC', 'PF-06664178', 'solid tumors', 'tumors', 'neoplasm metastasis', 'NSCLC', 'non small cell lung cancer', 'OVCA', 'ovarian cancer', 'Phase 1', 'breast cancer']",TERMINATED,The study was prematurely discontinued due to a business-related decision on 09-FEB-2016. The decision to terminate the trial was based on the overall results.,2014-08,2016-06,"[{'measure': 'First Cycle Dose Limiting Toxicities (DLTs) In Order to Determine the Maximum Tolerated Dose(MTD)', 'description': 'Number of participants that experienced dose limiting toxicities(DLTs) at given dose level.', 'timeFrame': 'Day 1 up to Day 21'}, {'measure': 'Number of Patients With All-Causality Treatment-Emergent Adverse Events(TEAEs) [Part 2 & 3]', 'description': 'An adverse event (AE) was any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. TEAEs were those AEs with initial onset or increasing in severity after the first dose of study drug.', 'timeFrame': 'Day 1 up to Day 21'}, {'measure': 'Number of Participants With Laboratory Abnormalities [Part 2 & 3]', 'description': 'Number of participants with a laboratory abnormality meeting specified criteria. The laboratory test included: hematology( hemoglobin, platelets, white blood cell count, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils), chemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen or urea, creatinine, uric acid, glucose, albumin, phosphorous or phosphate), coagulation (prothrombin time or International normalized ratio, partial thromboplastin time), Urinalysis (urine protein, urine blood) and pregnancy test.', 'timeFrame': 'On Day1, Day4, Day8, Day15 of the first cycle; on Day1, Day8, Day15 of the second cycle; on Day 1 of the subsequent cycles; end of treatment visit(no longer than 1 week after the patient has been discontinued)'}]","[{'measure': 'Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs ) [Part 1]', 'description': 'An adverse event (AE) was any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. TEAEs were those AEs with initial onset or increasing in severity after the first dose of study drug.', 'timeFrame': 'From screening up to 28 days after the last treatment administration in each cycle, and follow-up visits(At least 28 days and no more than 35 days after discontinuation of treatment)'}, {'measure': 'Number of Participants With Laboratory Abnormalities[Part 1]', 'description': 'Number of participants with a laboratory abnormality meeting specified criteria. The laboratory test included: hematology( hemoglobin, platelets, white blood cell count, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils), chemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen or urea, creatinine, uric acid, glucose, albumin, phosphorous or phosphate), coagulation (prothrombin time or International normalized ratio, partial thromboplastin time), Urinalysis (urine protein, urine blood) and pregnancy test.', 'timeFrame': 'Screening; on Day1, Day4, Day8, Day15 of the first cycle; on Day1, Day8, Day15 of the second cycle; on Day 1 of the subsequent cycles; end of treatment visit(no longer than 1 week after the patient has been discontinued)'}, {'measure': 'Overall Incidence of Anti-PF-06664178-Antibodies[Part 1]', 'description': 'Number of participants with the presence of anti-PF-06664178 antibodies', 'timeFrame': 'Day 1, 15, 21, and every 21 days thereafter up to 24 months, and end of treatment'}, {'measure': 'Overall Incidence of Anti-PF-06664178-Antibodies [Part 2 & 3]', 'description': 'Number of participants with the presence of anti-PF-06664178 antibodies', 'timeFrame': 'Day 1, 15, 21, and every 21 days thereafter up to 24 months, and end of treatment'}, {'measure': 'Overall Number of Participants With Objective Tumor Response[Part 1]', 'description': 'Objective tumor response, was assessed using the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 by calculating the Overall Response Rate, and Prolonged Stable Disease. The criterion is defined as: Objective Progression(PD):20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5mm; Stable (SD): All target lesions must be assessed. Stable can follow PR only in the rare case that the sum increases by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer holds; symptomatic deterioration(Sym):Participants with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time; Indeterminate (In):Progression has not been determined and one, or more non-target sites were not assessed, or assessment methods were inconsistent with those used at baseline.', 'timeFrame': 'Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months'}, {'measure': 'Overall Number of Participants With Objective Tumor Response [Part 2 & 3]', 'description': 'Objective tumor response, as assessed using the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 by calculating the Overall Response Rate (ORR), and Prolonged Stable Disease (SD).No Progression Free Survival (PFS) was completed. The criterion is as follow: Objective Progression(PD), Stable (SD), symptomatic deterioration(Sym), and Indeterminate (In)', 'timeFrame': 'Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) for PF-06664178 [Part 1 ,2 & 3]', 'description': 'Cmax of PF-06664178 was observed directly from data', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) for Total Antibody (PF-06479118) [Part 1 ,2 & 3]', 'description': 'Cmax of total antibody PF-06479118 was observed directly from data', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) for Unconjugated Payload (PF-06380101) [Part 1 ,2 & 3]', 'description': 'Cmax of unconjugated payload PF-06380101 was observed directly from data', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Area Under the Concentration-Time Curve Over the Dosing Interval(AUCtau) of PF-06664178 [Part 1 ,2 & 3]', 'description': 'AUCtau refers to area under the concentration-time profile from time zero to the time tau, the dosing interval', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Area Under the Concentration-Time Curve Over the Dosing Interval(AUCtau) of Total Antibody(PF-06479118) [Part 1 ,2 & 3]', 'description': 'AUCtau refers to area under the concentration-time profile from time zero to the time tau, the dosing interval.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Area Under the Concentration-Time Curve Over the Dosing Interval(AUCtau) of Unconjugated Payload(PF-06380101) [Part 1 ,2 & 3]', 'description': 'AUCtau refers to area under the concentration-time profile from time zero to the time tau, the dosing interval.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Systemic Clearance (CL) of PF-06664178 [Part 1 ,2 & 3]', 'description': 'CL is a quantitative measure of the rate at which a drug substance is removed from the body.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Systemic Clearance (CL) of Total Antibody (PF-06479118) [Part 1 ,2 & 3]', 'description': 'CL is a quantitative measure of the rate at which a drug substance is removed from the body.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Systemic Clearance (CL) of Unconjugated Payload (PF-06380101) [Part 1 ,2 & 3]', 'description': 'CL is a quantitative measure of the rate at which a drug substance is removed from the body.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Volume of Distribution (Vss) of PF-06664178 [Part 1 ,2 & 3]', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Volume of Distribution (Vss) of Total Antibody (PF-06479118) [Part 1 ,2 & 3]', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Volume of Distribution (Vss) of Unconjugated Payload (PF-06380101) [Part 1 ,2 & 3]', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Terminal Elimination Half-Life (t1/2) of PF-06664178 [Part 1 ,2 & 3]', 'description': 'Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Terminal Elimination Half-Life (t1/2) of Total Antibody (PF-06479118)[Part 1 ,2 & 3]', 'description': 'Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Terminal Elimination Half-Life (t1/2) of Unconjugated Payload (PF-06380101) [Part 1 ,2 & 3]', 'description': 'Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Trop-2 Expression Levels on Archived Tissue [Part 2 & 3]', 'description': 'Number of participents meeting the following criterion for Trop-2 expression assessment : low expression, medium expression and high expression', 'timeFrame': 'Day 1'}, {'measure': 'Accumulation Ratio (Rac) of PF-06664178 [Part 1 ,2 & 3]', 'description': 'Accumulation ratio refers to AUCtau for cycle 4/AUCtau for cycle 1, where AUCtau is defined as area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to the time tau, the dosing interval.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Accumulation Ratio (Rac) of Total Antibody (PF-06479118) [Part 1 ,2 & 3]', 'description': 'Accumulation ratio refers to AUCtau for cycle 4/AUCtau for cycle 1, where AUCtau is defined as area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to the time tau, the dosing interval.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Accumulation Ratio (Rac) of Unconjugated Payload (PF-06380101) [Part 1 ,2 & 3]', 'description': 'Accumulation ratio refers to AUCtau for cycle 4/AUCtau for cycle 1, where AUCtau is defined as area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to the time tau, the dosing interval.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}]",28,18 Years,,ALL,False,Pfizer,INDUSTRY,0,31.0,ACTUAL,2025-09-01T16:18:18.423148,v2_robust,True,True,False,True,True,The study was prematurely discontinued due to a business-related decision on 09-FEB-2016. The decision to terminate the trial was based on the overall results.
NCT04215146,A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study,A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study,Paclitaxel,"['Paclitaxel', 'Avelumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer Metastatic,['Breast Cancer Metastatic'],"['Breast', 'Breast Cancer', 'Breast Cancer Metastatic', 'Locally Advanced Breast Cancer', 'Pelareorep', 'Avelumab', 'Paclitaxel', 'Reovirus', 'Oncolytic virus', 'HR+ breast cancer', 'HER2- breast cancer', 'Breast malignancy']",ACTIVE_NOT_RECRUITING,,2020-06-10,2025-06,"[{'measure': 'Overall Response Rate', 'description': 'Overall response rate at week 16 according to RECIST V1.1', 'timeFrame': 'at week 16'}]",[],1,18 Years,,FEMALE,False,Oncolytics Biotech,INDUSTRY,1,48.0,ACTUAL,2025-09-01T16:18:18.423161,v2_robust,True,True,False,False,False,
NCT07071246,Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis,Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis,Rituximab Injection,"['Rituximab Injection', 'RTX']",2,INTERVENTIONAL,['NA'],,,Treatment,['Treatment'],"['myasthenia gravis', 'rituximab', 'efficacy', 'safety']",ACTIVE_NOT_RECRUITING,,2022-08-01,2027-07-31,"[{'measure': '70% enrolled patients reached the minimum state (MM) or better state of MGFA - post intervention state (PIs) at 1 year after administration of study drug', 'description': 'No functional impairment and some muscle weakness may be detected by a specialist neurologist', 'timeFrame': '12 months'}, {'measure': '80% enrolled patients reached the clinical complete remission (CSR) of MGFA - post intervention status (PIs) at 2 years after administration of study drug', 'description': 'No signs and symptoms of muscle weakness for at least 1 year, no medical treatment for MG during this period, no evidence of muscle weakness after examination by a professional neurologist, mild eyelid closure weakness is allowed', 'timeFrame': '24 months'}, {'measure': 'Safety: The incidence of treatment-related adverse reactions and withdrawal because of serious adverse reaction', 'description': 'Any adverse reaction, like fever, rash, dizziness and so on.', 'timeFrame': 'through study completion'}]","[{'measure': 'The proportion of patients with ocular myasthenia gravis (OMG) progressed to generalized myasthenia gravis (GMG).', 'description': 'OMG progressed to the GMG at 2 years after treatment of study drug.', 'timeFrame': 'After 2 years of follow-up'}]",4,18 Years,,ALL,False,Tang-Du Hospital,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:18.423178,v2_robust,True,True,False,False,True,
NCT00231946,ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301),A Double-Blind Placebo-Controlled Study of VP4896 For the Treatment of Mild-to-Moderate Alzheimer's Disease,VP4896,['VP4896'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Alzheimer's Disease,"[""Alzheimer's Disease""]","['gonadotropins', 'hormone therapy', 'HRT', 'Antigonadotropin', 'Leuprolide']",COMPLETED,,2005-09,,"[{'measure': ""Cognitive assessment and Caregiver's impression of change at baseline and at weeks 8, 24, 34, and 50.""}]","[{'measure': 'Ability to perform Activities of Daily Living (ADL) at baseline and weeks 8, 24, 34, and 50. Impression of disease severity assessment at week 50.'}]",2,60 Years,,ALL,False,Voyager Pharmaceutical Corporation,INDUSTRY,0,555.0,,2025-09-01T16:18:18.423199,v2_robust,True,True,True,False,False,
NCT06319846,Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）,"A Multicenter, Double-blind, Double-dummy, Randomized Clinical Trial Comparing the Efficacy and Safety of Tirofiban Versus Placebo in Preventing Recurrence of Stroke for Patients With Intracranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）",Tirofiban,"['Tirofiban', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Ischemic Stroke, Acute","['Ischemic Stroke, Acute', 'TIA', 'Symptomatic Intracranial Artery Stenosis']",[],RECRUITING,,2024-07-11,2026-12,"[{'measure': 'Any new ischemic stroke at 3-month', 'description': 'Incidence of any new ischemic stroke at 3-month', 'timeFrame': 'at 3-month'}, {'measure': 'Type 3 or 5 bleeding events according to the BARC criteria at 3-month', 'description': 'Incidence of type 3 or 5 bleeding events according to the BARC criteria at 3-month', 'timeFrame': 'at 3-month'}]","[{'measure': 'Any new ischemic stroke within 1 year', 'description': 'Incidence of any new ischemic stroke within 1 year', 'timeFrame': 'within 1 year'}, {'measure': 'New clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ myocardial infarction/vascular death) within 3 months and 1 year; Each new vascular event will be independently evaluated.', 'description': 'Incidence of new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ myocardial infarction/vascular death) within 3 months and 1 year; Each new vascular event will be independently evaluated.', 'timeFrame': 'Within 3 months after randomization and 1 year'}, {'measure': 'Disabling stroke (Modified Rankin Scale score, mRS>1) at 3 months and 1 year', 'description': 'Proportion of patients with disabling stroke (Modified Rankin Scale score, mRS\\>1) at 3 months and 1 year. Scores on the modified Rankin scale range from 0 (no neurologic deficit) to 6 (death).', 'timeFrame': 'at 3 months and 1 year'}, {'measure': 'Incidence and severity of recurrent stroke and TIA', 'description': 'Incidence and severity of recurrent stroke and TIA during follow-up to 3 months and 1-year (Severity is measured using a six-level ordered categorical scale that incorporates the mRS: fatal stroke/severe non-fatal stroke \\[mRS 4 or 5\\]/moderate stroke \\[mRS 2 or 3\\]/mild stroke \\[mRS 0 or 1\\]/TIA/no stroke-TIA)', 'timeFrame': 'Within 3 months after randomization and 1 year'}, {'measure': 'Neurological impairment at 3 months (NIHSS increased≥4 from baseline ).', 'description': 'Proportion of patients with neurological impairment at 3 months ( National Institutes of Health Stroke Scale \\[NIHSS\\] score increased≥4 from baseline).', 'timeFrame': 'at 3 months'}]",7,40 Years,,ALL,False,Beijing Tiantan Hospital,OTHER,0,4674.0,ESTIMATED,2025-09-01T16:18:18.423229,v2_robust,True,True,False,False,False,
NCT05303688,Does Preventive Dexketoprofen Reduce Pain After Orthognathic Surgery,"Does Preventive Single Dose of Intravenous Dexketoprofen Reduce Pain and Swelling After Orthognathic Surgery? A Prospective, Randomized, Double Blind Clinical Trial","iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey)","['iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey)', 'Steril Salin (control)']",2,INTERVENTIONAL,['NA'],,,"Pain, Postoperative","['Pain, Postoperative']","['Preventive analgesia', 'Pain', 'Swelling', 'Orthognathic surgery', 'Dexketoprofen', '3dMD']",COMPLETED,,2018-03-01,2019-02-01,"[{'measure': 'Postoperative 1st hours Pain Score on the Visual Analog Scale', 'description': 'The postoperative pain was assessed using a 10-cm visual analogue scale (VAS) at postoperative 1st hours. ""0"" represents least pain, ""50"" represents moderate pain, and 100 represents maximum pain.', 'timeFrame': 'postoperative 1st hours'}, {'measure': 'Postoperative 3rd hours Pain Score on the Visual Analog Scale', 'description': 'The postoperative pain was assessed using a 10-cm visual analogue scale (VAS) at postoperative 3rd hours. ""0"" represents least pain, ""50"" represents moderate pain, and 100 represents maximum pain.', 'timeFrame': 'postoperative 3rd hours.'}, {'measure': 'Postoperative 6th hours Pain Score on the Visual Analog Scale', 'description': 'The postoperative pain was assessed using a 10-cm visual analogue scale (VAS) at postoperative 6th hours.""0"" represents least pain, ""50"" represents moderate pain, and 100 represents maximum pain.', 'timeFrame': 'postoperative 6th hours.'}, {'measure': 'Postoperative 9th hours Pain Score on the Visual Analog Scale', 'description': 'The postoperative pain was assessed using a 10-cm visual analogue scale (VAS) at postoperative 9th hours.""0"" represents least pain, ""50"" represents moderate pain, and 100 represents maximum pain.', 'timeFrame': 'postoperative 9th hours.'}, {'measure': 'Postoperative 12th hoursPain Score on the Visual Analog Scale', 'description': 'The postoperative pain was assessed using a 10-cm visual analogue scale (VAS) at postoperative 12th hours. ""0"" represents least pain, ""50"" represents moderate pain, and 100 represents maximum pain.', 'timeFrame': 'postoperative 12th hours.'}, {'measure': 'Postoperative 24th hours Pain Score on the Visual Analog Scale', 'description': 'The postoperative pain was assessed using a 10-cm visual analogue scale (VAS) at postoperative 24th hours. ""0"" represents least pain, ""50"" represents moderate pain, and 100 represents maximum pain.', 'timeFrame': 'postoperative 24th hours.'}, {'measure': '3D measure of postoperative swelling', 'description': '3dMD Face System (3dMD, ATLANTA, GA, USA) was used for 3D imaging of postoperative swelling. The same clinician took the 3D images from patients in natural head position, maximum intercuspation and eyes open. The 3dMD Vultus Software (3dMD, Atlanta, GA) was used to analyse the images. The 3-month postoperative 3D image (t90) was selected as the reference image to compare with other images. After cutting and customizing the images by anatomical structures, scans t0-t30 were matched to the reference scan t90. The forehead, nasion, tragus, medial and lateral canthus were used for surface matching. After surface matching, the volume difference between the masks was calculated', 'timeFrame': '3D images were taken one (T0) day before surgery.'}, {'measure': '3D measure of postoperative swelling', 'description': '3dMD Face System (3dMD, ATLANTA, GA, USA) was used for 3D imaging of postoperative swelling. The same clinician took the 3D images from patients in natural head position, maximum intercuspation and eyes open. The 3dMD Vultus Software (3dMD, Atlanta, GA) was used to analyse the images. The 3-month postoperative 3D image (t90) was selected as the reference image to compare with other images. After cutting and customizing the images by anatomical structures, scans t0-t30 were matched to the reference scan t90. The forehead, nasion, tragus, medial and lateral canthus were used for surface matching. After surface matching, the volume difference between the masks was calculated', 'timeFrame': '3D images were taken 1 (T1) day after surgery.'}, {'measure': '3D measure of postoperative swelling', 'description': '3dMD Face System (3dMD, ATLANTA, GA, USA) was used for 3D imaging of postoperative swelling. The same clinician took the 3D images from patients in natural head position, maximum intercuspation and eyes open. The 3dMD Vultus Software (3dMD, Atlanta, GA) was used to analyse the images. The 3-month postoperative 3D image (t90) was selected as the reference image to compare with other images. After cutting and customizing the images by anatomical structures, scans t0-t30 were matched to the reference scan t90. The forehead, nasion, tragus, medial and lateral canthus were used for surface matching. After surface matching, the volume difference between the masks was calculated', 'timeFrame': '3D images were taken3 (T3) day after surgery.'}, {'measure': '3D measure of postoperative swelling', 'description': '3dMD Face System (3dMD, ATLANTA, GA, USA) was used for 3D imaging of postoperative swelling. The same clinician took the 3D images from patients in natural head position, maximum intercuspation and eyes open. The 3dMD Vultus Software (3dMD, Atlanta, GA) was used to analyse the images. The 3-month postoperative 3D image (t90) was selected as the reference image to compare with other images. After cutting and customizing the images by anatomical structures, scans t0-t30 were matched to the reference scan t90. The forehead, nasion, tragus, medial and lateral canthus were used for surface matching. After surface matching, the volume difference between the masks was calculated', 'timeFrame': '3D images were taken 7 (T7) day after surgery.'}, {'measure': '3D measure of postoperative swelling', 'description': '3dMD Face System (3dMD, ATLANTA, GA, USA) was used for 3D imaging of postoperative swelling. The same clinician took the 3D images from patients in natural head position, maximum intercuspation and eyes open. The 3dMD Vultus Software (3dMD, Atlanta, GA) was used to analyse the images. The 3-month postoperative 3D image (t90) was selected as the reference image to compare with other images. After cutting and customizing the images by anatomical structures, scans t0-t30 were matched to the reference scan t90. The forehead, nasion, tragus, medial and lateral canthus were used for surface matching. After surface matching, the volume difference between the masks was calculated', 'timeFrame': '3D images were taken 14 (T14) day after surgery.'}, {'measure': '3D measure of postoperative swelling', 'description': '3dMD Face System (3dMD, ATLANTA, GA, USA) was used for 3D imaging of postoperative swelling. The same clinician took the 3D images from patients in natural head position, maximum intercuspation and eyes open. The 3dMD Vultus Software (3dMD, Atlanta, GA) was used to analyse the images. The 3-month postoperative 3D image (t90) was selected as the reference image to compare with other images. After cutting and customizing the images by anatomical structures, scans t0-t30 were matched to the reference scan t90. The forehead, nasion, tragus, medial and lateral canthus were used for surface matching. After surface matching, the volume difference between the masks was calculated', 'timeFrame': '3D images were taken 21 (T21) day after surgery.'}, {'measure': '3D measure of postoperative swelling', 'description': '3dMD Face System (3dMD, ATLANTA, GA, USA) was used for 3D imaging of postoperative swelling. The same clinician took the 3D images from patients in natural head position, maximum intercuspation and eyes open. The 3dMD Vultus Software (3dMD, Atlanta, GA) was used to analyse the images. The 3-month postoperative 3D image (t90) was selected as the reference image to compare with other images. After cutting and customizing the images by anatomical structures, scans t0-t30 were matched to the reference scan t90. The forehead, nasion, tragus, medial and lateral canthus were used for surface matching. After surface matching, the volume difference between the masks was calculated', 'timeFrame': '3D images were taken 30 (T30) day after surgery.'}, {'measure': '3D measure of postoperative swelling', 'description': '3dMD Face System (3dMD, ATLANTA, GA, USA) was used for 3D imaging of postoperative swelling. The same clinician took the 3D images from patients in natural head position, maximum intercuspation and eyes open. The 3dMD Vultus Software (3dMD, Atlanta, GA) was used to analyse the images. The 3-month postoperative 3D image (t90) was selected as the reference image to compare with other images. After cutting and customizing the images by anatomical structures, scans t0-t30 were matched to the reference scan t90. The forehead, nasion, tragus, medial and lateral canthus were used for surface matching. After surface matching, the volume difference between the masks was calculated', 'timeFrame': '3D images were taken 90 (T90) day after surgery.'}]",[],14,18 Years,45 Years,ALL,True,TC Erciyes University,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:18.423411,v2_robust,True,True,True,False,False,
NCT01980888,Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia",Idelalisib,"['GS-1101', 'Zydelig®', 'Idelalisib', 'Rituximab', 'Placebo', 'CAL-101', 'Bendamustine']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Lymphocytic Leukemia,['Chronic Lymphocytic Leukemia'],[],TERMINATED,,2014-02-05,2016-06-16,"[{'measure': 'Progression-Free Survival', 'description': 'Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an independent review committee (IRC).', 'timeFrame': 'Up to 22 months'}]","[{'measure': 'Overall Response Rate', 'description': 'Overall response rate (ORR) is defined as the proportion of participants who achieve a confirmed complete or partial response. ORR was to be assessed by an IRC.', 'timeFrame': 'Up to 22 months'}, {'measure': 'Nodal Response Rate', 'description': 'Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.', 'timeFrame': 'Up to 22 months'}, {'measure': 'Complete Response Rate', 'description': 'Complete response rate is defined as the proportion of participants who achieve a confirmed complete response. Complete response rate was to be assessed by an IRC.', 'timeFrame': 'Up to 22 months'}, {'measure': 'Overall Survival', 'description': 'Overall survival is defined as the interval from randomization to death from any cause. Overall survival was to be assessed by an IRC.', 'timeFrame': 'Up to 22 months'}, {'measure': 'Minimal Residual Disease Negativity Rate at Week 36', 'description': 'Minimal residual disease (MRD) negativity rate is defined as the proportion of participants with MRD \\< 10\\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab or bendamustine (whichever is later) for participants receiving the final dose of rituximab after the original scheduled date. MRD negativity rate was to be assessed by an IRC.', 'timeFrame': 'Up to 22 months'}]",6,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,0,311.0,ACTUAL,2025-09-01T16:18:18.423464,v2_robust,True,True,False,True,False,
NCT03864588,Comparing Ropivacaine Adductor Canal Blockade by Surgeon Versus Anesthesiologist,A Randomized Controlled Trial Comparing Intraoperative Surgeon-Performed Versus Anesthesiologist-Performed Adductor Canal Blockade After Primary Total Knee Arthroplasty,Ropivacaine,['Ropivacaine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pain, Postoperative","['Pain, Postoperative', 'Satisfaction']",[],UNKNOWN,,2018-10-01,2019-09,"[{'measure': 'Change in visual analog scale pain score', 'description': ""The primary end point is the patients' reported visual analogue pain score (VAS). 0-100mm scale"", 'timeFrame': 'Up to 6 weeks post-surgery'}]","[{'measure': 'Change in range of motion', 'description': 'Range of motion', 'timeFrame': 'up to 6 weeks post-surgery'}, {'measure': 'Change in timed up and go', 'description': 'Timed up and go', 'timeFrame': 'up to 6 weeks post-surgery'}, {'measure': 'Change in daily opioid consumption', 'description': 'daily opioid consumption', 'timeFrame': 'up to 6 weeks post-surgery'}]",4,18 Years,80 Years,ALL,False,Rothman Institute Orthopaedics,OTHER,1,164.0,ESTIMATED,2025-09-01T16:18:18.423513,v2_robust,True,True,False,False,False,
NCT01437488,Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy,A Phase II Study of Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy,Cabazitaxel,"['XRP-6258', 'Jevtana', 'Pegfilgrastim', 'Cabazitaxel', 'Neulasta']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Urothelial Carcinoma,['Urothelial Carcinoma'],"['Urothelial carcinoma', 'Urothelial cancer']",COMPLETED,,2012-02-16,2017-03-30,"[{'measure': 'Overall Response Rate', 'description': 'To determine the overall response rate of patients who have disease response while on treatment with Cabazitaxel. CT scan will be used to measure tumor pre-treatment and then every 3 cycles (every 63 days)', 'timeFrame': 'Every 3 cycles or 63 days'}]","[{'measure': 'Overall Survival', 'description': 'To determine the percentage of patients alive at 12 months from trial entry. Overall survival will be measured from date of randomization to date of death due to any cause.', 'timeFrame': 'At 12 months'}, {'measure': 'Progression Free Survival', 'description': 'To determine the progression free survival (PFS) of patients with advanced or recurrent urothelial carcinoma who have previously been treated with a platinum based regimen while on treatment with cabazitaxel. Defined as a 20% increase in the largest diameter of the largest lesion by CT scan.', 'timeFrame': 'Every 3 cycles or 63 days'}, {'measure': 'Number of Participants Who Tolerated Cabazitaxel', 'timeFrame': 'Up to 30 days after completion of study treatment'}]",4,18 Years,,ALL,False,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER,1,14.0,ACTUAL,2025-09-01T16:18:18.423598,v2_robust,True,True,True,False,False,
NCT05108688,Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache,Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache Following Obstetric Surgery Under Spinal Anesthesia: A Randomized Controlled Trial,Mirtazapine,"['Mirtazapine', 'Sumatriptan']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Headache,['Headache'],[],COMPLETED,,2021-11-15,2023-12-20,"[{'measure': 'Incidence of refractory headache ((number of patients)(n),% of patients) (refractory: failed intervention and conservative treatment) after 72 hours', 'description': 'Incidence of refractory headache ((number of patients)(n),% of patients) (refractory: failed intervention and conservative treatment) after 72 hours after intervention (Day 0)', 'timeFrame': '72 hours after intervention (Day 0)'}]",[],1,18 Years,40 Years,FEMALE,False,Ain Shams University,OTHER,0,210.0,ACTUAL,2025-09-01T16:18:18.423615,v2_robust,True,True,True,False,False,
NCT01789788,"A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus","A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6811135 in Patients With Type 2 Diabetes Mellitus.",Placebo,"['RO6811135', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Diabetes Mellitus Type 2,['Diabetes Mellitus Type 2'],[],COMPLETED,,2013-03,2013-09,"[{'measure': 'Safety: Incidence of adverse events', 'timeFrame': 'approximately 5 months'}]","[{'measure': 'Pharmacokinetics: Area under the concentration-time curve (AUC)', 'timeFrame': 'Day 1 and Day 14'}, {'measure': 'Pharmacodynamics of RO681135: Blood analysis', 'timeFrame': '14 days'}]",3,18 Years,65 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,56.0,ACTUAL,2025-09-01T16:18:18.423625,v2_robust,True,True,True,False,True,
NCT07098988,Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC,"A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)",Matching placebo for visugromab,"['Matching placebo for visugromab', 'Carboplatin AUC 5', 'Pemetrexed 500 mg/m^2']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Non-Squamous Non-Small Cell Lung Cancer,"['Metastatic Non-Squamous Non-Small Cell Lung Cancer', 'Adult Solid Tumor']","['CTL-002', 'Visugromab', 'GDF-15']",NOT_YET_RECRUITING,,2025-07-30,2031-03-31,"[{'measure': 'Objective Response Rate', 'description': 'Percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the Investigator at any time during the core trial period', 'timeFrame': 'up to 24 months'}]","[{'measure': 'Adverse Events', 'description': 'Incidence, type and severity of adverse events, treatment emergent adverse events, treatment-related adverse events and serious adverse events', 'timeFrame': 'up to 27 months'}, {'measure': 'CR rate', 'description': 'Complete response rate', 'timeFrame': 'up to 24 months'}, {'measure': 'PR rate', 'description': 'Partial response rate', 'timeFrame': 'up to 24 months'}, {'measure': 'DOR', 'description': 'Duration of response', 'timeFrame': 'up to 24 months'}, {'measure': 'ORR', 'description': 'Objective response rate', 'timeFrame': 'up to 24 months'}, {'measure': 'TTR', 'description': 'Time-to-response rate', 'timeFrame': 'up to 24 months'}, {'measure': 'PFS', 'description': 'Progression-free survival', 'timeFrame': 'up to 48 months'}, {'measure': 'OS', 'description': 'Overall survival', 'timeFrame': 'up to 48 months'}, {'measure': 'Participant weight course over time', 'timeFrame': 'up to 48 months'}, {'measure': 'Maximum Concentration (Cmax) of visugromab', 'description': 'Cmax is the maximum observed serum concentration of visugromab', 'timeFrame': 'At designated time points (up to 24 months)'}, {'measure': 'Minimum Concentration (Cmin) of visugromab', 'description': 'Cmin is the minimum observed serum concentration of visugromab', 'timeFrame': 'At designated time points (up to 24 months)'}, {'measure': ""Participants' subjective well-being as assessed by Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)"", 'description': 'NSCLC-SAQ is a participant reported outcome with seven (7) items assessing five (5) symptom domains of NSCLC: cough, fatigue, pain, dyspnea, and appetite. Each item is scored individually from 0 (""None/Never"") to 4 (""Severe/Always""). The total score is calculated by summing domain scores, which are derived as follows: single-item domains (cough, dyspnea, appetite) use the item score; fatigue uses the mean of two items (or one if only one is answered); pain uses the highest score of two items (or one if only one is answered). The total score ranges from 0-20, with higher scores indicating more severe symptoms. If any domain score is missing, a total score is not computed.', 'timeFrame': 'up to 27 months'}, {'measure': ""Participants' quality of life as assessed by 5-day Functional Living Index-Emesis (5-day FLIE)"", 'description': 'FLIE consists of 18 items, with 9 items on nausea and 9 items on vomiting. The impact of nausea and vomiting is assessed through their effects on physical and social activities, and emotional well-being. Each item is rated using a visual analog scale (VAS) from 1 to 7 (In some questions, ""1"" means that nausea or vomiting does not affect the daily life at all, while in other questions, ""1"" means it affects the daily life a lot). Scoring is calculated per the FLIE Scoring and Administration Manual. Higher scores indicate less impact of nausea and vomiting on daily life. At least 12 of 18 items must be completed to compute the total score.', 'timeFrame': 'At designated time points (up to 3 months)'}]",14,18 Years,,ALL,False,CatalYm GmbH,INDUSTRY,0,107.0,ESTIMATED,2025-09-01T16:18:18.423642,v2_robust,True,True,False,False,True,
NCT05778188,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia","A Phase 2, Two-Stage, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia With Long-Term Follow-Up",RLS-0071,"['RLS-0071', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hypoxic-Ischemic Encephalopathy,['Hypoxic-Ischemic Encephalopathy'],"['Birth Asphyxia', 'Anoxic brain injury']",RECRUITING,,2023-07-27,2026-04,"[{'measure': 'Frequency and severity of adverse events (AEs) and serious adverse events (SAEs) by treatment group at Day 14', 'description': 'Number of participants with AEs and SAEs graded between Grade 1 (mild in severity) and Grade 5 (death related to AE).', 'timeFrame': 'Day 1 to Day 14'}, {'measure': 'Frequency and severity of events of special interest and SAEs by treatment group at 24 months', 'description': 'Number of participants with events of special interest and SAEs graded between Grade 1 (mild in severity) and Grade 5 (death related to AE).\n\nEvents of special interest are: autoimmune disorder, persistent hypotension, persistent pulmonary hypertension, acute kidney injury, major venous thrombosis, severe intracranial hemorrhage, pulmonary hemorrhage, culture proven sepsis, necrotizing enterocolitis, severe thrombocytopenia, hepatic dysfunction, hyperbilirubinemia, coagulopathy, hypocalcemia, cerebral palsy, developmental or speech delay, learning disability, and visual or hearing impairment.', 'timeFrame': 'Day 1 to 24 months'}, {'measure': 'Frequency of premature discontinuation by treatment group due to AEs at Day 14', 'description': 'Number of participants who prematurely discontinue from the study due to AEs', 'timeFrame': 'Day 1 to Day 14'}, {'measure': 'Acute brain injury at Day 4, assessed through magnetic resonance imaging (MRI), using a standardized scoring system', 'description': 'Brain injury MRI score includes scoring extent of injury across 4 domains (Grey matter, White matter/cortex, Cerebellum, and Additional). A score of 0 indicates a normal brain MRI, whereas the maximum score of 57 indicates extensive bilateral injury.', 'timeFrame': 'Day 4'}, {'measure': 'Acute brain injury at Day 12, assessed through magnetic resonance imaging (MRI), using a standardized scoring system', 'description': 'Brain injury MRI score includes scoring extent of injury across 4 domains (Grey matter, White matter/cortex, Cerebellum, and Additional). A score of 0 indicates a normal brain MRI, whereas the maximum score of 57 indicates extensive bilateral injury.', 'timeFrame': 'Day 12'}]","[{'measure': 'Composite of mortality and neurodevelopmental impairment (NDI) at 24 months', 'timeFrame': 'Day 1 to 24 months'}, {'measure': 'Mortality at 3, 6, 12, 18, and 24 months', 'description': 'Number of participants alive at each timepoint', 'timeFrame': 'Day 1 to 3, 6, 12, 18, and 24 months'}, {'measure': 'Number of participants with clinically significant laboratory abnormalities, events of special interest, and SAEs at 3, 6, 12, and 18 months', 'timeFrame': 'Day 1 to 3, 6, 12, and 18 months'}, {'measure': 'Neurocognitive developmental outcome assessed by Bayley-4 at 24 months of age', 'description': 'The Bayley Scales of Infant and Toddler Development (4th Edition) consists of 5 subdomains: the Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior scales. Cognitive, Language, and Motor domains include a total of 264 items, each ranked between 0-2 (where 0 is not present and 2 is mastery); the Social-Emotional and Adaptive Behavior domains are assessed through caregiver questionnaires.', 'timeFrame': '24 months'}, {'measure': 'Neurodevelopmental growth impact: Diagnosis of cerebral palsy at 24 months of age', 'description': 'Number of participants diagnosed with cerebral palsy', 'timeFrame': '24 months'}, {'measure': 'Neurodevelopmental growth impact: Grading of cerebral palsy by using the Gross Motor Function Classification System-Expanded and Revised (GMFCS-E&R) at 24 months of age', 'description': 'The GMFCS is a 5-level classification system for children and young people with cerebral palsy, where Level 1 indicates ability to walk without limitations and Level 5 indicates reliance on a manual wheelchair.', 'timeFrame': '24 months'}, {'measure': 'Number of participants diagnosed with mild, moderate, or severe visual impairment and hearing impairment', 'timeFrame': 'Day 1 to 24 months'}, {'measure': 'Number of days of supplemental nutritional support required', 'timeFrame': 'Day 1 to 24 months'}, {'measure': 'Seizure occurrence', 'description': 'Discrete number of seizures recorded', 'timeFrame': 'Day 1 to Day 14'}, {'measure': 'Total seizure burden (total number of minutes seizing as measured by continuous electroencephalogram [EEG]) during hospitalization', 'timeFrame': 'Day 1 to Day 14'}, {'measure': 'Electrical activity abnormality scoring as measured by EEG', 'timeFrame': 'Day 1 to Day 14'}, {'measure': 'Impact on infant and family wellness, assessed by the Mother-to-Infant Bonding Scale (MIBS)', 'description': 'The MIBS is a 9-item questionnaire, with total scores ranging from 0 to 27. A high score indicates weaker mother-to-infant bonding.', 'timeFrame': '3 and 12 months'}, {'measure': 'Impact on infant and family wellness, assessed by the Parenting Stress Index, 4th Edition Short Form (PSI-4-SF)', 'description': 'The PSI-4 is a 36-item questionnaire focusing on three domains: Parental Distress, Parent-Child Dysfunctional Interaction, and Difficult Child, which combine to form a Total Stress scale. Scores are assessed following conversion into percentile ranks. Scores falling in the 90th or higher percentile indicate clinically significant parenting stress.', 'timeFrame': '3, 12, and 24 months'}, {'measure': 'Quality of life assessment over the first 24 months of life', 'description': 'A quality of life questionnaire will be used to collect information regarding the care of the aging child over the first 24 months of life.', 'timeFrame': 'Day 4 to 24 months'}]",19,,10 Hours,ALL,False,"ReAlta Life Sciences, Inc.",INDUSTRY,1,42.0,ESTIMATED,2025-09-01T16:18:18.423663,v2_robust,True,True,False,False,True,
NCT02362503,Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients,"A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)",BMS-663068,['BMS-663068'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,HIV Infections,['HIV Infections'],[],ACTIVE_NOT_RECRUITING,,2015-02-23,2026-09-30,"[{'measure': 'Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort', 'description': 'Plasma samples were collected for analysis of HIV-1 RNA. Mean change in log10 HIV-1 RNA from Day 1 was estimated using analysis of covariance (ANCOVA) with log10 HIV-1 RNA change from Day 1 at Day 8 as dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 log10 HIV-1 RNA as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. The analysis was performed on Intent-to-Treat Exposed (ITT-E) Population which comprised of all randomized participants who received at least one dose of study treatment. Missing HIV-1 RNA values at Day 8 were imputed using (a) Day 1 Observation Carried Forward (D1OCF) for participants without a value during blinded treatment (i.e, imputing a zero change from Day 1) or (b) Last Observation Carried Forward (LOCF) for participants with an early value during blinded treatment before the Day 8 analysis visit window.', 'timeFrame': 'Day 1 and Day 8'}]","[{'measure': 'Percentage of Participants With HIV-1 RNA Decreases From Day 1 That Exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8-Randomized Cohort', 'description': 'The percentage of participants in the Randomized Cohort with HIV-1 RNA decreases from Day 1 that exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8 was determined by comparing HIV-1 RNA Day 1 measurement of each participant to their Day 8 measurement. This was an ITT analysis that classified participants without HIV-1 RNA at Day 1 or Day 8 as failures. The percentage of responders along with 95% confidence interval based on Wilson score is presented.', 'timeFrame': 'Day 1 and Day 8'}, {'measure': 'Percentage of Participants With HIV-1 RNA <40 c/mL at Weeks 24, 48 and 96-Randomized Cohort', 'description': 'The durability of response (that is, the number of participants achieving HIV-1 RNA \\<40 c/mL) at Weeks 24, 48 and 96 of open-label fostemsavir plus OBT in the Randomized Cohort was assessed using the Food and Drug Administration (FDA) snapshot algorithm in which participants without HIV-1 RNA at Weeks 24, 48 and 96 or those who changed OBT due to lack of efficacy through Weeks 24, 48 and 96 were counted as failures. The percentage of participants in the Randomized Cohort who achieved virologic success (HIV-1 RNA \\<40 c/mL) at Weeks 24, 48 and 96 is presented along with 95% Wilson confidence interval. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.', 'timeFrame': 'At Weeks 24, 48 and 96'}, {'measure': 'Number of Participants With On-treatment Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation (AELD)-Randomized Cohort', 'description': 'An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; an important medical event that may jeopardize the participant or require intervention. Number of participants with on-treatment SAEs and AEs leading to withdrawal of study treatment is presented. SAEs and AELDs were collected in Safety Population which comprised of all participants who received at least one dose of study treatment. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.', 'timeFrame': 'Up to Week 96 analysis cut-off date'}, {'measure': 'Number of Participants With Toxicity Grade Increase in Clinical Chemistry Results to Grade 3-4 Relative to Baseline-Randomized Cohort', 'description': 'Laboratory toxicities were graded for severity according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with clinical chemistry toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.', 'timeFrame': 'Baseline and up to Week 96 analysis cut-off date'}, {'measure': 'Number of Participants With Toxicity Grade Increase in Hematology Results to Grade 3-4 Relative to Baseline-Randomized Cohort', 'description': 'Laboratory toxicities were graded for severity according to the DAIDS grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with hematology toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.', 'timeFrame': 'Baseline and up to Week 96 analysis cut-off date'}, {'measure': 'Number of Participants With Centers for Disease Control (CDC) Class C Events-Randomized Cohort', 'description': 'Disease progression during open label fostemsavir plus OBT was assessed based on the occurrence of new AIDS defining events (CDC Class C events) or death. The number of participants with on-treatment CDC Class C AIDS events is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.', 'timeFrame': 'Up to Week 96 analysis cut-off date'}, {'measure': 'Change From Day 1 in Cluster of Differentiation (CD) 4+ T-cell Count at Day 8-Randomized Cohort', 'description': 'CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell counts from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an in-dependent variable, and Day 1 CD4+ cell count as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (i.e., imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.', 'timeFrame': 'Day 1 and Day 8'}, {'measure': 'Change in CD4+ T- Cell Count Percentage From Day 1 at Day 8-Randomized Cohort', 'description': 'CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count percentage from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell count percentage from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 CD4+ cell count percentage as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (ie, imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.', 'timeFrame': 'Day 1 and Day 8'}, {'measure': 'Change From Baseline in log10 HIV-1 RNA for Fostemsavir When Given With OBT Through Week 96-Randomized Cohort', 'description': 'Blood samples were collected for the analysis of HIV-1 RNA. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.', 'timeFrame': 'Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96'}, {'measure': 'Change From Baseline in CD4+ T- Cell Count Through Week 96-Randomized Cohort', 'description': 'CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline.', 'timeFrame': 'Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96'}, {'measure': 'Change From Baseline in CD4+ T- Cell Count Percentage Through Week 96', 'description': 'Percentage CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline.', 'timeFrame': 'Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96'}, {'measure': 'Number of Participants With Treatment-emergent Viral Genotypic Substitution of Interest in the GP160 Domain as a Measure of Genotypic Resistance-Randomized Cohort', 'description': 'Plasma samples were collected for emergent drug resistance testing. The number of participants with emergent viral genotypic substitutions of interest in the GP160 domain was identified by the next-generation sequencing (NGS) assay. Protocol defined virologic failure (PDVF) through Week 96 Population comprised of all participants with available phenotypic and genotypic resistance data meeting at the time protocol defined virologic failure (PDVF) was met. The criteria for PDVF was a) Confirmed, or last available prior to discontinuation, HIV-1 RNA \\>=400 c/mL at any time after prior confirmed suppression to \\<400 c/mL prior to Week 24 or Confirmed, or last available prior to discontinuation, \\> 1 log10 c/mL increase in HIV-1 RNA at any time above nadir level where nadir is \\>=40 c/mL prior to Week 24. b) Confirmed, or last available prior to discontinuation, HIV-1 RNA \\>=400 c/mL at or after Week 24.', 'timeFrame': 'Week 96'}, {'measure': 'Number of Participants With Indicated Fold Change Ratio (FCR) Using the Monogram PhenoSense Entry Assay-Randomized Cohort', 'description': 'The phenotypic resistance to a drug is defined in terms of a fold change (FC) in IC50s, i.e., the ratio of the 50% inhibitory concentration (IC50) of the clinical isolate to the IC50 of a reference strain (wild type control). FCR was calculated as FC at PDVF divided by Baseline FC. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. FCR\\<1 indicates that FC is smaller on-treatment than at Baseline. FCR \\>3 indicates that on-treatment FC is 3 times greater than it was at Baseline.', 'timeFrame': 'Week 96'}]",14,18 Years,,ALL,False,ViiV Healthcare,INDUSTRY,0,371.0,ACTUAL,2025-09-01T16:18:18.423740,v2_robust,True,True,False,False,True,
NCT05327803,Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease,"A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients With Treatment-refractory Mycobacterium Avium Complex Lung Disease",Epetraborole,"['Epetraborole', 'Placebo', 'AN2-501971']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,MAC Lung Disease,"['MAC Lung Disease', 'Treatment Refractory MAC Lung Disease']","['NTM', 'Respiratory Infection', 'antimycobacterial activity', 'antimycobacterial agent', 'antimycobacterial therapy', 'MAC infections', 'MAC lung disease', 'MAC lung infection', 'MAC pulmonary infection', 'Mycobacteria', 'mycobacterial disease', 'mycobacterium', 'Mycobacterium Avium Complex', 'Mycobacterium Avium Complex Infections', 'Mycobacterium avium complex lung disease', 'Mycobacterium Infections', 'Nontuberculous', 'Nontuberculous mycobacteria / mycobacterial / mycobacterium', 'Non-tuberculous mycobacteria disease', 'Non-tuberculous mycobacterial (NTM) infections', 'Nontuberculous mycobacterial lung disease', 'Non-tuberculous mycobacterial lung disease', 'Nontuberculous mycobacterial pulmonary disease', 'NTM infection', 'NTM lung disease', 'NTM Pulmonary Disease', 'NTM lung infection', 'Pulmonary MAC disease', 'Pulmonary MAC lung disease', 'Pulmonary Mycobacterium Avium Complex disease', 'Treatment refractory MAC lung disease', 'Treatment refractory mycobacterial lung disease', 'Treatment refractory NTM lung disease', 'Treatment refractory NTM lung infection', 'Treatment refractory NTM pulmonary disease']",TERMINATED,EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study.,2022-05-20,2024-12-18,"[{'measure': 'Phase 2: Assessment of novel Patient Reported Outcome instrument psychometric properties', 'description': 'Assessment of novel Patient Report outcomes', 'timeFrame': 'Screening (Day -14 to Day -7) to Month 6 + 1 week'}, {'measure': 'Phase 2: Percentage of Participants Achieving Clinical Response', 'description': 'Detection of within-patient changes in symptoms reported in a novel Patient-Reported Outcome (PRO) instrument at Month 3 and Month 6.', 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole', 'description': 'Percentage of Participants reporting treatment emergent adverse events', 'timeFrame': 'Baseline to Month 16'}, {'measure': 'Phase 3: Percentage of Participants Achieving Clinical Response', 'description': 'Detection of within-patient changes in symptoms reported in a novel Patient-Reported Outcome (PRO) instrument at Month 6', 'timeFrame': 'Baseline to Month 6'}]","[{'measure': 'Phase 2: Percentage of Participants Achieving Culture Conversion', 'description': 'Sputum conversion will be assessed using culture conversion based on 3 consecutive monthly negative sputum cultures for MAC by Month 6.', 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 2: Percentage of Participants Achieving Microbiological Improvement', 'description': 'Microbiological improvement will be assessed at Month 3 and Month 6 using decrease in MAC colony counts of ≥1 category.', 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 2: Change from Baseline in QOL-B Respiratory Domain PRO', 'description': 'Mean change from baseline in Quality of Life - Bronchiectasis (QOL-B) respiratory domain score measured monthly through Month 6.', 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 2: Change from Baseline in NTM Symptoms Module PRO', 'description': 'Mean change from baseline in NTM Symptoms Module score measured monthly through Month 6.', 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 2: Change from Baseline in SGRQ-C PRO', 'description': ""Mean change from baseline in total Saint George's Respiratory Questionnaire for COPD Patients (SGRQ-C) score measured monthly through Month 6"", 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 2: Concordance Analysis of PRO-based Clinical Response and Microbiological Response', 'description': 'Concordance between clinical response in a novel Patient-Reported Outcome (PRO) instrument and microbiological response will be assessed at Months 3 and 6. Microbiological response will be assessed using both sputum culture conversion and microbiological improvement.', 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 2: Percentage of Participants with Reinfection', 'description': 'By-subject reinfection will be assessed at Month 6, End of Therapy, and Late Follow-up. Reinfection is defined as a new pulmonary MAC infection caused by pathogen\\[s\\] different from the baseline MAC isolate.', 'timeFrame': 'Baseline to Month 16'}, {'measure': 'Phase 2: Percentage of Participants with Relapse', 'description': 'By-subject relapse will be assessed at Month 6, End of Therapy, and Late Follow-up. Relapse is defined as a pulmonary MAC infection caused by the same baseline MAC isolate after initial culture conversion.', 'timeFrame': 'Baseline to Month 16'}, {'measure': 'Phase 2: Maximum plasma concentration (Cmax) of epetraborole', 'description': 'Cmax is the maximum plasma concentration of epetraborole estimated by population PK model.', 'timeFrame': 'Day 1 and Day 29'}, {'measure': '14. Phase 2: Area Under the Plasma Concentration-Time Curve from Time Point 0 Hours Until 24 hours [AUC(0-24)] post dose', 'description': 'AUC(0-24) is defined as area under the plasma concentration-time curve of epetraborole from timepoint 0 hours until 24 hours post dose estimated by population PK model.', 'timeFrame': 'Day 29'}, {'measure': 'Phase 2: Volume of distribution (Vd) of epetraborole', 'description': 'Vd is the apparent volume of distribution of epetraborole estimated by population PK model.', 'timeFrame': 'Day 29'}, {'measure': 'Phase 3: Percentage of Participants Achieving Culture Conversion', 'description': 'Sputum conversion will be assessed using culture conversion based on 3 consecutive monthly negative sputum cultures for MAC by Month 6.', 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 3: Percentage of Participants Achieving Microbiological Improvement', 'description': 'Microbiological improvement will be assessed at Month 3 and Month 6 using decrease in MAC colony counts of ≥1 category.', 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 3: Change from Baseline in QOL-B Respiratory Domain PRO', 'description': 'Mean change from baseline in Quality of Life - Bronchiectasis (QOL-B) respiratory domain score measured monthly through Month 6.', 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 3: Change from Baseline in NTM Symptoms Module PRO', 'description': 'Mean change from baseline in NTM Symptoms Module score measured monthly through Month 6.', 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 3: Change from Baseline in SGRQ-C PRO', 'description': ""Mean change from baseline in total Saint George's Respiratory Questionnaire for COPD Patients (SGRQ-C) score measured monthly through Month 6."", 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 3: Concordance Analysis of PRO-based Clinical Response and Microbiological Response', 'description': 'Concordance between clinical response in a novel Patient-Reported Outcome (PRO) instrument and microbiological response will be assessed at Months 3 and 6. Microbiological response will be assessed using both sputum culture conversion and microbiological improvement', 'timeFrame': 'Baseline to Month 6'}, {'measure': 'Phase 3: Percentage of Participants with Reinfection', 'description': 'By-subject reinfection will be assessed at Month 6, End of Therapy, and Late Follow-up. Reinfection is defined as a new pulmonary MAC infection caused by pathogen\\[s\\] different from the baseline MAC isolate.', 'timeFrame': 'Baseline to Month 16'}, {'measure': 'Phase 3: Percentage of Participants with Relapse', 'description': 'By-subject relapse will be assessed at Month 6, End of Therapy, and Late Follow-up. Relapse is defined as a pulmonary MAC infection caused by the same baseline MAC isolate after initial culture conversion.', 'timeFrame': 'Month 6, End of Therapy and Late Follow-up'}, {'measure': 'Phase 3: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole', 'description': 'Percentage of Participants reporting treatment emergent adverse events.', 'timeFrame': 'Baseline to Month 16'}, {'measure': 'Phase 3: Maximum plasma concentration (Cmax) of epetraborole', 'description': 'Cmax is the maximum plasma concentration of epetraborole estimated by population PK model.', 'timeFrame': 'Day 1 and Day 29'}, {'measure': 'Phase 3: Area Under the Plasma Concentration-Time Curve from Time Point 0 Hours Until 24 hours [AUC(0-24)] post dose', 'description': 'AUC(0-24) is defined as area under the plasma concentration-time curve of epetraborole from timepoint 0 hours until 24 hours post dose estimated by population PK model.', 'timeFrame': 'Day 29'}, {'measure': 'Phase 3: Volume of distribution (Vd) of epetraborole', 'description': 'Vd is the apparent volume of distribution of epetraborole estimated by population PK model.', 'timeFrame': 'Day 29'}]",27,18 Years,,ALL,False,"AN2 Therapeutics, Inc",INDUSTRY,0,177.0,ACTUAL,2025-09-01T16:18:18.423776,v2_robust,True,True,False,True,True,EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study.
NCT03654703,Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML,Improved Post-Transplant Cyclophosphamide Regimens for Unmanipulated Haploidentical Transplant in Pediatric Patients With Refractory Acute Myeloid Leukemia,Cyclophosphamide,"['Cyclophosphamide', 'Cy']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hematopoietic System--Cancer,['Hematopoietic System--Cancer'],"['HSCT, AML， R-AML']",UNKNOWN,,2015-03-01,2020-03-01,"[{'measure': 'Disease status', 'description': 'Disease status can be measured by test the of (minimal residual disease) MRD via flow cytometry one time each month until one year after HSCT. MRD\\<0.0001 （complete remission), if not, relapse.', 'timeFrame': '1 year'}]",[],1,3 Years,18 Years,ALL,False,Capital Research Institute of Pediatrics,OTHER_GOV,0,100.0,ESTIMATED,2025-09-01T16:18:18.423789,v2_robust,True,True,False,False,False,
NCT06419803,Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2),Strict Versus Permissive Threshold for Initiation of Pharmacotherapy in Gestational Diabetes Mellitus (GDM) With Continuous Glucose Monitoring Use - A Randomized Control Trial (START 2 Trial),Insulin,"['Lantus', 'Lispro', 'Levemir', 'Insulin', 'Humalog', 'NPH']",6,INTERVENTIONAL,['NA'],,,Gestational Diabetes,"['Gestational Diabetes', 'Pregnancy Related']","['gestational diabetes', 'pregnancy', 'insulin', 'Initiation of medication']",RECRUITING,,2024-09-01,2026-05,"[{'measure': 'Neonatal Composite Outcome', 'description': 'Neonatal composite including the following measures: large for gestational age (LGA) of neonate defined as birth weight \\>90th percentile for gestational age using the Fenton growth chart, hypoglycemia o defined as glucose \\<40 mg/dL \\<48 hours after birth or glucose, hyperbilirubinemia, stillbirth or neonatal death, birth trauma', 'timeFrame': 'First 28 days of birth'}]","[{'measure': 'Neonatal Outcome: Gestational Age of Birth', 'description': 'Gestational age at delivery in weeks and days', 'timeFrame': 'Delivery Time'}, {'measure': 'Neonatal Outcome: APGAR Score', 'description': 'Scoring system provided a standardized assessment for infants after delivery from 0-10', 'timeFrame': 'At 1 minute of life and at 5 min of life'}, {'measure': 'Neonatal Outcome: Birthweight', 'description': 'Birthweight in grams, Macrosomia (birthweight \\>4000g, Small for gestational age (\\<10th percentile based on Fenton Growth Charts)', 'timeFrame': 'Delivery Time'}, {'measure': 'Neonatal Outcome: Respiratory distress', 'description': 'Breathing difficulties after birth requiring supplemental oxygen, mask, intubation, and/or surfactant', 'timeFrame': 'Within first 24 hours after delivery'}, {'measure': 'Neonatal Outcome: Admission to Neonatal intensive Care Unit', 'description': 'Admission to neonatal intensive care unit (NICU)', 'timeFrame': 'From delivery to discharge from NICU'}, {'measure': 'Maternal Outcomes: Maternal hypoglycemia', 'description': 'Maternal episode of hypoglycemia \\< 60 mg/dL throughout the pregnancy', 'timeFrame': 'Initiation of insulin to delivery'}, {'measure': 'Maternal Outcomes: Shoulder Dystocia', 'description': ""An obstetric emergency where the anterior fetal shoulder becomes stuck on the maternal pubic symphysis, delaying the birth of the baby's body"", 'timeFrame': 'At Delivery'}, {'measure': 'Maternal Outcomes: Obstetric anal sphincter injury (OASIS)', 'description': '3rd degree and 4th degree perineal injuries', 'timeFrame': 'At Delivery'}, {'measure': 'Maternal Outcomes: Operative Delivery', 'description': 'Vacuum-assisted and Forcep-assisted vaginal Delivery', 'timeFrame': 'At Delivery'}, {'measure': 'Maternal Outcomes: Cesarean Delivery', 'description': 'Cesarean birth', 'timeFrame': 'At Delivery'}, {'measure': 'Maternal Outcomes: Postpartum hemorrhage', 'description': 'Defined as cumulative blood loss ≥1000 mL, or bleeding associated with signs/symptoms of hypovolemia within 24 hours of the birth process', 'timeFrame': 'Within 24 hours of delivery'}, {'measure': 'Maternal Outcomes: Hypertensive Disorders of Pregnancy', 'description': 'Hypertensive disorders of pregnancy: gestational hypertension, Preeclampsia without severe features, Pre-eclampsia with severe features, severe range blood pressures defined as (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥110 mmHg), symptoms of central nervous dysfunction, thrombocytopenia with Platelet count \\<100,000 platelets/microL, hepatic abnormalities, kidney impairment, and or pulmonary edema', 'timeFrame': 'From gestational age of 20 weeks during pregnancy to 6 weeks postpartum'}]",13,18 Years,,FEMALE,True,Thomas Jefferson University,OTHER,1,430.0,ESTIMATED,2025-09-01T16:18:18.423933,v2_robust,True,True,False,False,False,
NCT02501603,"Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer","An Open-label, Multicenter Phase II Study of Afatinib Plus Weekly Taxol as Second Line Treatment for Advanced/Recurrent Gastric and Gastroesophageal Junction Cancer",afatinib,"['paclitaxel', 'afatinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastric Cancer,"['Gastric Cancer', 'Gastroesophageal Junction Cancer']",[],COMPLETED,,2016-07,2022-12-20,"[{'measure': 'compare progression free survival as measured by RECIST 1.1', 'description': 'To identify antitumor activity of afatinib plus weekly taxol(paclitaxel) and explore predictive biomarker', 'timeFrame': 'Every 6 weeks until progression, an expected average of 10 months'}]","[{'measure': 'antitumor efficacy as measured by RECIST 1.1', 'timeFrame': 'every 6 weeks until progression, an expected average of 10 months'}, {'measure': 'safety as measured by CTCAE', 'timeFrame': 'every 3 weeks until progression, an expected average of 10 months'}]",3,19 Years,,ALL,False,Yonsei University,OTHER,0,72.0,ESTIMATED,2025-09-01T16:18:18.424034,v2_robust,True,True,True,False,True,
NCT03722303,Lipografting Versus Steroid Injections for Treatment of Carpal Tunnel Syndrome,Lipografting Versus Steroid Injections for Treatment of Primary Mild to Moderate Carpal Tunnel Syndrome,Steroid Injection,"['Steroid Injection', 'Cortisone Injection']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Carpal Tunnel Syndrome,['Carpal Tunnel Syndrome'],"['carpal', 'tunnel', 'injection', 'steroid', 'lipografting', 'numbness', 'tingling', 'median nerve']",SUSPENDED,lack of funding,2016-12-19,2025-12,"[{'measure': 'Functional Outcome Score', 'description': 'This score will be determined by Quick-Disabilities of the Arm, Shoulder and Hand (QuickDASH), which is a validated tool/survey for measuring upper extremity disability. The QuickDASH is scored in two components: the disability/symptom section (11 items, scored 1-5) and the optional high performance sport/music or work modules (4 items, scored 1-5). These raw scores are used to calculate a score out of 100, with a higher score indicating greater disability.', 'timeFrame': 'Up to 1 year post-treatment'}]","[{'measure': 'Score on the Michigan Hand Questionnaire (MHQ)', 'description': 'The MHQ is hand-specific outcomes instrument that measures outcomes of patients with conditions of, or injury to, the hand or wrist. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.', 'timeFrame': 'Up to 1 year post-treatment'}, {'measure': ""Score on the Brigham Women's Carpal Tunnel Questionnaire"", 'description': ""Brigham Women's Carpal Tunnel Questionnaire is a validated tool for measuring severity of symptoms for carpal tunnel syndrome. The questionnaire is self-administered, with each item scored from 1 to 5 (where 1 indicates no symptoms or no functional difficulty, and 5 indicates maximum symptoms or an inability to perform the functional task)."", 'timeFrame': 'Up to 1 year post-treatment'}]",3,18 Years,,ALL,True,Columbia University,OTHER,1,100.0,ESTIMATED,2025-09-01T16:18:18.424141,v2_robust,True,True,False,True,False,lack of funding
NCT04018703,The Study of Different Sedative Medications in Monitored Anesthesia Care During Eye Surgery With Local Anesthesia,Effective Dose of Dexmedetomidine or Midazolam in Monitored Anesthesia Care for Patients Undergoing Ophthalmologic Surgery With Retrobulbar Nerve Block,Dexmedetomidine,"['Midazolam', 'Dexmedetomidine']",2,INTERVENTIONAL,['NA'],,,Balanced Anesthesia,"['Balanced Anesthesia', 'Adjuvants,Anesthesia']","['Monitored anesthesia care', 'Ophthalmic surgery', 'Dexmedetomidine', 'Midazolam']",UNKNOWN,,2019-11-01,2021-12-31,"[{'measure': ""Perioperative change of Observer's Assessment of Alertness/Sedation scale (OAA/S)"", 'description': 'Conventional subjective sedation scales with 1 to 5. Successful sedation was defined as an OAA/S scale score between 1 and 3, while failure was defined as an OAA/S score of more than 3.', 'timeFrame': 'OAA/S score will be recorded from patient arrival in the operating room to about 30 minutes after surgery at following time points: before sedative administration, before skin incision, every 5 minutes intraoperatively and every 10 minutes in PACU.'}, {'measure': 'Numerical rating scale (NRS)', 'description': 'The surgeons rated anesthesia management on a numerical rating scale (NRS), ranging from 0 to 10, with 10 defined as the best condition and 0 as the worst.', 'timeFrame': 'Immediately after surgery, the surgeons report NRS only once'}]","[{'measure': 'Intraocular pressure', 'description': 'Measured with Tono-Pen tonometer', 'timeFrame': 'Intraocular pressure will be measured at two time points: before sedative medication administration and before skin incision.'}, {'measure': 'Bispectral index (BIS)', 'description': 'Anesthesia depth index', 'timeFrame': 'Bis will be continuously recorded with BIS monitor from arrival in the operating room to discharge to ward (about 30 minutes after surgery).'}, {'measure': 'Visual analogue scale (VAS)', 'description': 'Patient self-report pain score ranging from 0 to 10, with 0 defined as no pain at all and 10 as the intolerable pain.', 'timeFrame': 'VAS will be recorded at the following time points until 1h postoperatively: before sedative medication administration, before skin incision, every 10 minutes intraoperatively and 1h postoperatively'}]",5,18 Years,80 Years,ALL,False,Eye & ENT Hospital of Fudan University,OTHER,0,150.0,ESTIMATED,2025-09-01T16:18:18.424160,v2_robust,True,True,False,False,False,
NCT05247203,Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus,"A Phase I, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Telitacicept in Chinese Subjects With Systemic Lupus Erythematosus (SLE)",standard therapy,['standard therapy'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Systemic Lupus Erythematosus,['Systemic Lupus Erythematosus'],"['Systemic Lupus Erythematosus', 'Telitacicept', 'Pharmacokinetics', 'Lupus Erythematosus, Systemic', 'Connective Tissue Diseases', 'Autoimmune Diseases']",COMPLETED,,2022-05-11,2023-11-13,"[{'measure': 'Peak plasma concentration (Cmax) of Telitacicept', 'description': 'Cmax is defined as peak plasma concentration of Telitacicept', 'timeFrame': 'up to 42 days following the last dose of Telitacicept'}, {'measure': 'Time to reach Cmax (tmax) of Telitacicept', 'description': 'tmax is defined as time to reach Cmax of Telitacicept', 'timeFrame': 'up to 42 days following the last dose of Telitacicept'}, {'measure': 'Observed plasma concentration of Telitacicept just prior to the beginning of a dosing interval (Ctrough)', 'description': 'Ctrough is defined as observed plasma concentration of Telitacicept just prior to the beginning of a dosing interval', 'timeFrame': 'up to 42 days following the last dose of Telitacicept'}, {'measure': 'Average concentration (Cav) of Telitacicept', 'description': 'Average concentration of Telitacicept', 'timeFrame': 'up to 42 days following the last dose of Telitacicept'}, {'measure': 'Area under the curve from time zero to last quantifiable concentration (AUC 0-t) of Telitacicept', 'description': 'AUC 0-t is defined as area under the curve from time zero to last quantifiable concentration of Telitacicept', 'timeFrame': 'up to 42 days following the last dose of Telitacicept'}, {'measure': 'Area under the curve from time zero to tau (AUC 0-tau) of Telitacicept', 'description': 'AUC 0-tau is defined as area under the curve from time zero to tau of Telitacicept', 'timeFrame': 'up to 42 days following the last dose of Telitacicept'}, {'measure': 'Terminal elimination rate constant (λz) of Telitacicept', 'description': 'λz is defined as terminal elimination rate constant', 'timeFrame': 'up to 42 days following the last dose of Telitacicept'}, {'measure': 'Terminal elimination half-life (t1/2z) of Telitacicept', 'description': 't1/2z is defined as terminal elimination half-life of Telitacicept', 'timeFrame': 'up to 42 days following the last dose of Telitacicept'}, {'measure': 'Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of Telitacicept', 'description': 'Vz/F is defined as apparent volume of distribution during the terminal phase after extravascular administration of Telitacicept', 'timeFrame': 'up to 42 days following the last dose of Telitacicept'}, {'measure': 'Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of Telitacicept', 'description': 'CL/F is defined as apparent total body clearance of drug from plasma after extravascular administration of Telitacicept', 'timeFrame': 'up to 42 days following the last dose of Telitacicept'}]","[{'measure': 'Percentage of participants achieving a SLE Responder Index (SRI)', 'description': 'Percentage of subjects with a ≥ 4 point reduction from baseline in SELENA-SLEDAI score, and no worsening (increase of \\< 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.', 'timeFrame': 'Week 4, 8, 12, 16, 20, and 24'}, {'measure': 'Percentage of participants achieving a SELENA-SLEDAI improvement of ≥4 points', 'description': 'SELENA-SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105.', 'timeFrame': 'Week 4, 8, 12, 16, 20, and 24'}, {'measure': 'Change From Baseline to W24 in patient global assessment (PGA)', 'description': 'PGA is a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe).', 'timeFrame': 'Week 4, 8, 12, 16, 20, and 24'}, {'measure': 'Change From Baseline to W24 in IgG', 'description': 'Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.', 'timeFrame': 'Week 4, 8, 12, 16, 20, and 24'}, {'measure': 'Change From Baseline to W24 in IgA', 'description': 'Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.', 'timeFrame': 'Week 4, 8, 12, 16, 20, and 24'}, {'measure': 'Change From Baseline to W24 in IgM', 'description': 'Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.', 'timeFrame': 'Week 4, 8, 12, 16, 20, and 24'}, {'measure': 'Change From Baseline to W24 in C3', 'description': 'Complement (C3/C4) are proteins that are part of the immune system.', 'timeFrame': 'Week 4, 8, 12, 16, 20, and 24'}, {'measure': 'Change From Baseline to W24 in C4', 'description': 'Complement (C3/C4) are proteins that are part of the immune system.', 'timeFrame': 'Week 4, 8, 12, 16, 20, and 24'}, {'measure': 'Number of Participants Experiencing Adverse Events (AEs)', 'description': 'Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.', 'timeFrame': 'up to 28 days following the last dose of Telitacicept'}]",19,18 Years,65 Years,ALL,False,"RemeGen Co., Ltd.",INDUSTRY,0,92.0,ACTUAL,2025-09-01T16:18:18.424322,v2_robust,True,True,True,False,True,
NCT01302327,GLP Analogs for Diabetes in Wolfram Syndrome Patients,,Exenatide,['Exenatide'],1,INTERVENTIONAL,['NA'],,,Diabetes Mellitus Associated With Genetic Syndrome,"['Diabetes Mellitus Associated With Genetic Syndrome', 'Wolfram Syndrome']","['Wolfram syndrome', 'Diabetes mellitus', 'Exenatide', 'GLP-1 analog', 'beta cell function']",WITHDRAWN,"Very rare disease, we were unable to recruit patients",2011-03-01,2013-03-01,"[{'measure': 'beta cell function', 'description': 'IVGTT test and meal test will be performed before starting treatment with Exenetide and after 3 months of treatment.', 'timeFrame': '3 months'}]",[],1,18 Years,,ALL,False,Hadassah Medical Organization,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:18.424399,v2_robust,True,True,False,True,False,"Very rare disease, we were unable to recruit patients"
NCT00344227,Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study),Prospective Optical Coherence Tomography (OCT) Imaging of Patients With Neovascular Age-Related Macular Degeneration (AMD) Treated With Intra-Ocular Lucentis™ (Ranibizumab): PrONTO Study,Lucentis (Ranibizumab),['Lucentis (Ranibizumab)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Neovascular Age-Related Macular Degeneration,['Neovascular Age-Related Macular Degeneration'],"['neovascularization', 'age-related macular degeneration', 'vascular endothelial growth factor (VEGF)', 'antigen-binding fragment (Fab)', 'antiangiogenesis', 'optical coherence tomography (OCT)']",COMPLETED,,2004-08,2007-04,"[{'measure': 'Mean Visual Acuity'}, {'measure': 'Total number of treatments'}]","[{'measure': 'Time to decrease of OCT central retinal thickness'}, {'measure': 'Time to improved visual acuity'}, {'measure': 'Proportion gaining 3 lines of vision'}, {'measure': 'Proportion stable or improved'}, {'measure': 'Frequency of Retreatment'}]",7,50 Years,,ALL,False,University of Miami,OTHER,1,40.0,,2025-09-01T16:18:18.424557,v2_robust,True,True,True,False,False,
NCT06904027,A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders,"A Single-arm, Prospective, Multi-center Post-market Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders",Glycerol phenylbutyrate Oral Liquid,"['Glyceryl tri-(4-phenylbutyrate)', 'HPN-100', 'Glycerol phenylbutyrate Oral Liquid', 'RAVICTI', 'GT4P']",5,OBSERVATIONAL,[],,,Urea Cycle Disorders,['Urea Cycle Disorders'],"['Chinese', 'Pediatric patients', 'Urea cycle disorders', 'Glycerol phenylbutyrate']",NOT_YET_RECRUITING,,2025-07,2031-07,"[{'measure': 'Mean blood ammonia levels at month 3 after enrollment.', 'description': 'The average of blood ammonia levels at months 3 after enrollment.', 'timeFrame': 'months 3'}]","[{'measure': 'Mean blood ammonia levels', 'description': 'The average of blood ammonia levels at period of baseline, month 1, month 6, and every 6 months thereafter (1-5 years)', 'timeFrame': 'Baseline, Month 1, Month 6, and every 6 months thereafter (1-5 years)'}, {'measure': 'Maximum blood ammonia levels', 'description': 'The maximum blood ammonia levels at period of baseline, month 1, month 3, month 6, and every 6 months thereafter (1-5 years)', 'timeFrame': 'Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)'}, {'measure': 'Frequency of hyperammonaemic crisis', 'description': 'The frequency of hyperammonaemic crisis at period of baseline, month 1, month 3, month 6, and every 6 months thereafter (1-5 years)', 'timeFrame': 'Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)'}, {'measure': 'Height', 'description': ""The change of height to the baseline in children aged 0-18 years old, and the proportion of weight in the upper, upper-middle, middle, lower-middle, and lower categories for each age group, according to the growth standards for children under 7 years old (WS/T 423-2022) and standard for height level classification among children and adolescents aged 7\\~18 years (WS/T 612-2018）issued by the National Health Commission of the People's Republic of China."", 'timeFrame': 'Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years).'}, {'measure': 'Weight', 'description': ""The change of weight to the baseline in children aged 0-7 years old, and the proportion of weight in the upper, upper-middle, middle, lower-middle, and lower categories for each age group, according to the growth standards for children under 7 years old issued by the National Health Commission of the People's Republic of China (WS/T 423-2022)."", 'timeFrame': 'Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)'}, {'measure': 'Head circumference', 'description': ""The change of head circumference to the baseline in children aged 0-3 years old, and the proportion of head circumference in the upper, upper-middle, middle, lower-middle, and lower categories for each age group, according to the growth standards for children under 7 years old issued by the National Health Commission of the People's Republic of China (WS/T 423-2022)."", 'timeFrame': 'Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)'}, {'measure': 'Dose adjustment changes', 'description': 'The changes of dose adjustment in glycerol phenylbutyrate throughout the study', 'timeFrame': 'Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)'}, {'measure': 'Mean Neonatal Behavioral Neurological Assessment Scores: Behavioral ability, passive muscle tone, active muscle tone, primitive reflexes, and general assessment', 'description': 'The neonatal behavioral neurological assessment (NBNA) scale was used for newborn participants who were at least 2 months of age, consisting of 20 items, with a maximum score of 40 points. The total scores of the NBNA are derived from the cumulative sum of the scores obtained in behavioral ability (6 items), passive muscle tone (4 items), active muscle tone (4 items), primitive reflexes (3 items), and general assessment (3 items), which are collected according to the scales have been actually completed by the subjects in the clinical practice. The total scores greater than 37 is considered normal, while a score less than or equal to 37 is considered abnormal.', 'timeFrame': 'Month 6, every year thereafter (1-5 years)'}, {'measure': 'Mean Bayley Scale of Infant Development Scores: mental scale, motor scale', 'description': 'The Bayley Scale of Infant Development was used for infant participants whose ages range from 2 months to 30 months, consisting of 244 behavioral items, including 163 items on the mental scale and 81 items on the motor scale. The scores of each infant on the mental and motor scales are converted into standard scores with a mean of 100 and a standard deviation of 16 according to age groups, thereby calculating the Mental Development Index (MDI) and the Psychomotor Development Index (PDI). A total score of MDI and PDI, which are collected according to the scales have been actually completed by the subjects in the clinical practice, are less than 70 indicates developmental delay, 70-79 indicates a borderline state, 80-89 indicates low average, 90-109 indicates average, 110-119 indicates high average, 120-129 indicates superior, and a score of 130 or above indicates very superior.', 'timeFrame': 'Month 6, every year thereafter (1-5 years)'}, {'measure': 'Mean Gesell Developmental Diagnosis Scale Scores', 'description': 'The assessment for Gesell Developmental Diagnosis Scale Scores was used for participants whose ages range from 30 months to 6 years, including five areas: gross motor skills, fine motor skills, adaptive behavior, language, and personal-social behavior. The observed behavioral patterns are identified based on the standard of normal behavioral patterns and are expressed in terms of age. This age is then compared with the actual age to calculate the Developmental Quotient (DQ), which is DQ = Developmental Age / Actual Age × 100, and the values of DQ are collected according to the scales have been actually completed by the subjects in the clinical practice. A DQ of 85 or above is considered normal for the nervous system, a DQ between 75 and 85 (inclusive of 75 but exclusive of 85) indicates a borderline level of nervous system impairment, and a DQ below 75 indicates nervous system damage.', 'timeFrame': 'Month 6, every year thereafter (1-5 years)'}, {'measure': 'Mean Wechsler Preschool and Primary Scale of Intelligence Scores: The Verbal Intelligence Quotient, the Performance Intelligence Quotient', 'description': 'The Chinese - Wechsler Preschool and Primary Scale of Intelligence (C - WYCSI) was used for children participants whose ages range from 4 to 6 years. The Verbal Intelligence Quotient (VIQ) test includes five subtests: Information, Picture Vocabulary, Arithmetic, Picture Comprehension, and Comprehension. The Performance Intelligence Quotient (PIQ) test includes five subtests: Animal Hatching, Picture Completion, Mazes, Geometric Shapes, and Block Design. The intelligence quotient (IQ) score obtained from the 10 subtests of VIQ and PIQ is the Full Intelligence Quotient (FIQ). The values for VIQ, PIQ and FIQ are collected according to the scales have been actually completed by the subjects in the clinical practice. FIQ is divided into five levels: ≥130 is superior, 116 - 129 is above average, 85 - 115 is average, 70 - 84 is below average, and \\< 70 is intellectual disability.', 'timeFrame': 'Month 6, every year thereafter (1-5 years)'}, {'measure': 'Mean Wechsler Intelligence Scale for Children Scores: The Verbal Intelligence Quotient, the Performance Intelligence Quotient', 'description': 'The Chinese-Wechsler intelligence scale of children (C-WISC）was used for participants whose ages range from 7 to 18 years. This scale consists of 11 subtests. The Verbal Intelligence Quotient (VIQ) test includes Information, Comprehension, Similarities, Arithmetic, Digit Span, and Vocabulary. The Performance Intelligence Quotient (PIQ) test includes Picture Completion, Picture Arrangement, Block Design, Object Assembly, and Coding. First, the raw score is calculated based on the test results of the examinee. Then, the corresponding age-specific scale score coefficient is checked and converted into a scale score. The sum of the VIQ and PIQ scale scores is the full intelligence quotient (FIQ) score, which are collected according to the scales have been actually completed by the subjects in the clinical practice. A FIQ of ≥120 is classified as high intelligence, 90-119 is classified as normal intelligence, and a score \\< 90 is classified as low intelligence.', 'timeFrame': 'Month 6, every year thereafter (1-5 years)'}]",13,0 Years,18 Years,ALL,False,Tongji Hospital,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:18.424570,v2_robust,False,True,False,False,False,
NCT02958527,Drug Use Investigation Of Effexor (SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL PRACTICE),DRUG USE INVESTIGATION OF EFFEXOR(REGISTERED) SR CAPSULES,venlafaxine,"['venlafaxine', 'Effexor']",2,OBSERVATIONAL,[],,,Depression/Depressed State,['Depression/Depressed State'],"['Effexor', 'Depression', 'Depressed state']",COMPLETED,,2016-10-03,2020-05-11,"[{'measure': 'Number of Participants With Adverse Drug Reactions', 'description': 'An adverse drug reaction (ADR) was any untoward medical occurrence attributed to Effexor in a participant who received Effexor. A serious ADR was a ADR resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Relatedness to Effexor was assessed by the physician.', 'timeFrame': '12 weeks from the start date (up until 52 weeks)'}]","[{'measure': 'Change From Baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D17) Total Scores at Pre-specified Evaluation Points', 'description': 'HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with depression (symptoms such as depressed mood, work and activities, sleep, suicide, psychomotor agitation/retardation, appetite, sexual interest, anxiety, and somatic symptoms). The items of the HAM-D17 are rated on a scale of 0 to 2 (8 items) or from 0 to 4 (9 items), and the total score ranges from 0 to 52, higher scores indicating more severity. Change from baseline: mean score at observation minus mean score at baseline. Evaluation was performed at Week 4, 8, 12, 16, 24, 36, and 52.', 'timeFrame': '12 weeks from the start date ( up until 52 weeks)'}, {'measure': 'Change From Baseline in the Montgomery - Asberg Depression Rating Scale (MADRS) Total Scores at Pre-specified Evaluation Points', 'description': 'MADRS is a clinician-administered rating scale that assesses the overall severity of depressive symptoms. The MADRS had a 10-item checklist (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). Items are scored from 0 to 6, and the total score ranges from 0 to 60, higher scores indicating more severity. Change from baseline: mean score at observation minus mean score at baseline. Evaluation was performed at Week 4, 8, 12, 16, 24, 36, and 52.', 'timeFrame': '12 weeks from the start date ( up until 52 weeks)'}, {'measure': 'Clinical Global Impressions-Severity', 'description': 'CGI-S is a 7-point clinician-administered rating scale that assesses overall severity of the current illness state. The score ranges from 1 to 7, higher scores indicating more affected: ""1: normal, not at all ill,"" ""2: borderline mentally ill,"" ""3: mildly ill,"" ""4: moderately ill,"" ""5: markedly ill,"" ""6: severely ill,"" or ""7: among the most extremely ill patients."" Evaluation was performed at Week 4, 8, 12, 16, 24, 36, and 52.', 'timeFrame': '12 weeks from the start date (up until 52 weeks)'}, {'measure': 'Changes in the Clinical Global Impressions-Improvement', 'description': 'CGI-I is a 7-point clinician-administered rating scale that assesses overall improvement of the disease/condition. The score ranges from 1 to 7, higher scores indicating more affected: was assessed as ""1: markedly improved,"" ""2: moderately improved,"" ""3: mildly improved,"" ""4: no change,"" ""5: slightly worsened,"" ""6: worsened,"" or ""7: severely worsened."" Evaluation was performed at Week 4, 8, 12, 16, 24, 36, and 52.', 'timeFrame': '12 weeks from the start date (up until 52 weeks)'}]",5,18 Years,,ALL,False,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,0,1408.0,ACTUAL,2025-09-01T16:18:18.424703,v2_robust,False,True,True,False,True,
NCT05419427,Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis,"A Randomized,Double Blind,Active Controlled Parallel Arm Multicenter Study Comparing Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Denosumab of Intas Pharmaceutical Limited (60 mg/mL) With Prolia® in Postmenopausal Women With Osteoporosis",Denosumab,"['INTP23', 'Denosumab', 'Denosumab-Ref', 'Prolia']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,"Osteoporosis, Postmenopausal","['Osteoporosis, Postmenopausal']",[],RECRUITING,,2021-11-11,2024-11-24,"[{'measure': 'Maximum measured concentration after first dose of denosumab and denosumab-ref., ,', 'timeFrame': 'Day 1 to Day 181'}, {'measure': 'Area under the concentration versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method between denosumab and denosumab-ref postmenopausal women with osteoporosis', 'timeFrame': 'Day 1 to Day 181'}, {'measure': 'Area under the concentration versus time curve from time zero to infinity. Where AUC 0-∞= AUC0-t + Ct2, Ct is the last measurable concentration and t2 is the terminal rate constant', 'timeFrame': 'Day 1 to Day 181'}]","[{'measure': 'Maximum percent reduction from baseline Emax percent reduction from baseline serum C-terminal telopeptide (CTX) after first dose of denosumab and denosumab-ref*', 'timeFrame': 'Day 1 to Day 181'}, {'measure': 'Area under the percent reduction from baseline versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method', 'timeFrame': 'Day 1 to Day 181'}]",5,55 Years,90 Years,FEMALE,False,Lambda Therapeutic Research Ltd.,INDUSTRY,1,552.0,ESTIMATED,2025-09-01T16:18:18.424721,v2_robust,True,True,False,False,False,
NCT00327327,Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma,"A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Gemcitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma",imexon,"['imexon', 'gemcitabine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Pancreatic Adenocarcinoma,['Pancreatic Adenocarcinoma'],[],COMPLETED,,2004-02,2009-10,"[{'measure': 'Determine maximally tolerated dose (MTD)', 'timeFrame': 'until MTD reached'}, {'measure': 'determine dose limiting toxicities.', 'timeFrame': 'until MTD reached'}]","[{'measure': 'Changes in plasma thiol levels', 'timeFrame': 'until MTD reached'}, {'measure': 'pharmacokinetics', 'timeFrame': 'until MTD reached'}, {'measure': 'objective tumor responses.', 'timeFrame': 'until MTD reached'}]",5,18 Years,,ALL,False,AmpliMed Corporation,INDUSTRY,0,105.0,ACTUAL,2025-09-01T16:18:18.424774,v2_robust,True,True,True,False,False,
NCT05510427,Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification,Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification,Infigratinib,"['Infigratinib', 'Atezolizumab', 'Bevacizumab']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Cholangiocarcinoma,"['Cholangiocarcinoma', 'Liver Cancer']",[],WITHDRAWN,Per PI's request,2023-08-07,2023-08-07,"[{'measure': 'Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0', 'timeFrame': 'through study completion; an average of 1 year.'}]",[],1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:18.424786,v2_robust,True,True,False,True,True,Per PI's request
NCT06043427,Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma,A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma,Paclitaxel,"['Paclitaxel', 'Ramucirumab', 'Zanidatamab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastroesophageal Adenocarcinoma,['Gastroesophageal Adenocarcinoma'],[],RECRUITING,,2024-04-16,2026-06-30,"[{'measure': 'Progression-free survival', 'timeFrame': '36 months'}]","[{'measure': 'Overall survival', 'timeFrame': '36 months'}, {'measure': 'Objective response rate', 'timeFrame': '36 months'}, {'measure': 'Number and severity of adverse events', 'timeFrame': '36 months'}, {'measure': 'Quality of Life utilizing the EORTC QLQ C30', 'timeFrame': '36 months'}, {'measure': 'Quality of Life utilizing the EORTC QLQ-OES18', 'timeFrame': '36 months'}]",6,18 Years,,ALL,False,Canadian Cancer Trials Group,NETWORK,1,168.0,ESTIMATED,2025-09-01T16:18:18.424931,v2_robust,True,True,False,False,True,
NCT01419327,Fosrenol Post-marketing Surveillance for Hemodialysis in Japan,Special Drug Use Investigation of Fosrenol (Long-term Investigation for Patients With Hemodialysis),"Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet","['Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet']",1,OBSERVATIONAL,[],,,Hyperphosphatemia,['Hyperphosphatemia'],"['Fosrenol', 'Hyperphosphatemia', 'Hemodialysis']",COMPLETED,,2009-03-23,2019-05-28,"[{'measure': 'Incidence of adverse drug reactions in subjects who received Fosrenol', 'timeFrame': 'After Fosrenol administration, up to 8 years'}]","[{'measure': 'Timing of onset of common ADRs related to the priority survey items', 'description': 'The items are\n\n* Gastrointestinal symptoms\n* Secondary hyperparathyroidism\n* Hypocalcaemia and decreased blood calcium', 'timeFrame': 'After Fosrenol administration, up to 8 years'}, {'measure': 'Effect on bones: Alkaline phosphatase over time', 'timeFrame': 'After Fosrenol administration, up to 8 years'}, {'measure': 'Effect on bones: Change in bone density', 'timeFrame': 'After Fosrenol administration, up to 8 years'}, {'measure': 'Cardiothoracic ratio over time', 'timeFrame': 'After Fosrenol administration, up to 8 years'}, {'measure': 'PWV and ABI over time', 'timeFrame': 'After Fosrenol administration, up to 8 years'}, {'measure': 'Serum P, albumin-corrected serum Ca and serum intact PTH, and Ca-P product over time', 'timeFrame': 'After Fosrenol administration, up to 8 years'}, {'measure': 'Percentage of patients achieving the serum P control goal', 'timeFrame': 'After Fosrenol administration, up to 8 years'}]",8,,,ALL,False,Bayer,INDUSTRY,0,3267.0,ACTUAL,2025-09-01T16:18:18.425044,v2_robust,False,True,True,False,True,
NCT02234427,Pharmacogenomics of Antiplatelet Response,Pharmacogenomics of Antiplatelet Response,Aspirin,['Aspirin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Atherosclerosis,['Atherosclerosis'],"['aspirin, atherosclerosis']",COMPLETED,,2014-06,2015-05,"[{'measure': 'Differential Gene Expression', 'description': 'Differences in platelet transcriptome before and after 2-week aspirin therapy The expression levels of genes before aspirin therapy was compared with the expression level of the genes after aspirin therapy. The expression levels were measured using the FPKM unit (Fragments Per Kilobase of transcript per Million mapped reads). The gene with the highest difference (pre vs. post) in FPKM is being reported with name in the units area and the actual difference in the number area', 'timeFrame': '2-weeks'}]",[],1,45 Years,75 Years,ALL,False,Johns Hopkins University,OTHER,0,34.0,ACTUAL,2025-09-01T16:18:18.425052,v2_robust,True,True,True,False,False,
NCT01458327,Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial,"An Open-Label Proof-of-Principle Study Testing the Use of an Additional MDMA-Assisted Therapy Session in People Who Relapsed After Participating in a Phase 2 Clinical Trial of MDMA-Assisted Therapy to Treat Chronic, Treatment-Resistant Posttraumatic Stress Disorder",Midomafetamine,"['Midomafetamine', 'MDMA', '3,4-methylenedioxymethamphetamine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Posttraumatic Stress Disorder,['Posttraumatic Stress Disorder'],"['MDMA', 'PTSD', 'therapy']",COMPLETED,,2010-12-15,2014-06-27,"[{'measure': 'Baseline Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV)', 'description': ""The CAPS-IV is a structured clinical interview designed to assess the symptoms and severity of PTSD. The CAPS-IV provides a means to evaluate the frequency and intensity dimensions of each symptom, the impact of symptoms on the patient's social and occupational functioning, the overall severity of the symptom complex, global improvement since baseline, and the validity of the ratings obtained. Total severity scores range from 0 to 136, with higher scores indicating greater severity of PTSD symptoms."", 'timeFrame': 'Less than 4 weeks before first experimental session'}, {'measure': 'Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 2-month Follow-up', 'description': ""The CAPS-IV is a structured clinical interview designed to assess the symptoms and severity of PTSD. The CAPS-IV provides a means to evaluate the frequency and intensity dimensions of each symptom, the impact of symptoms on the patient's social and occupational functioning, the overall severity of the symptom complex, global improvement since baseline, and the validity of the ratings obtained. Total severity scores range from 0 to 136, with higher scores indicating greater severity of PTSD symptoms."", 'timeFrame': '2 months post experimental session'}, {'measure': 'Clinician-Administered PTSD Scale (CAPS-IV)) at 12-month Follow-up', 'description': 'The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.', 'timeFrame': '12 months post experimental session'}, {'measure': 'Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up', 'description': 'The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.', 'timeFrame': 'Baseline to 2 months post experimental session'}, {'measure': 'Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 12-month Follow-up', 'description': 'The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.', 'timeFrame': 'Baseline to 12 months post experimental session'}]",[],5,18 Years,,ALL,False,Lykos Therapeutics,INDUSTRY,0,3.0,ACTUAL,2025-09-01T16:18:18.425206,v2_robust,True,True,True,False,False,
NCT05333861,"An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA","An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA",hetrombopag,['hetrombopag'],1,OBSERVATIONAL,[],,,Primary Immune Thrombocytopenia,"['Primary Immune Thrombocytopenia', 'Aplastic Anemia']",['Hetrombopag'],NOT_YET_RECRUITING,,2022-05-01,2026-05-01,"[{'measure': 'Adverse events', 'description': ""Information will be collected via reports from the Investigators based on the patient's medical records and classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0"", 'timeFrame': 'Data will be collected for all routine visits completed during the study period no more than 24 months.'}]","[{'measure': 'Number and proportion of patients achieving hematologic response after 3/6/12/24 months treatment', 'description': ""Laboratory measures of CBC will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts and other hematologic assessments will be based on local laboratory results."", 'timeFrame': 'Data will be collected for all routine visits completed during the study period which is no more than 24 months.'}, {'measure': 'The maximum continuous duration and total duration of response', 'description': 'Hematologic assessments will be based on local laboratory results', 'timeFrame': 'Data will be collected for all routine visits completed during the study period which is no more than 24 months.'}, {'measure': 'Number and proportion of patients requiring rescue medication.', 'description': ""Information will be collected via the patient's medical records."", 'timeFrame': 'Data will be collected for all routine visits completed during the study period which is no more than 24 months.'}, {'measure': 'Change from enrollment in the 36-Item Short Form Survey (SF-36)', 'description': 'SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting.', 'timeFrame': 'Data will be collected for all routine visits completed during the study period which is no more than 24 months.'}, {'measure': 'Change from enrollment in the use of concomitant ITP/AA medications throughout the study', 'description': ""Information will be collected via the patient's medical records."", 'timeFrame': 'Data will be collected for all routine visits completed during the study period which is no more than 24 months.'}, {'measure': 'Number and proportion of patients achieving a sustained remission off-treatment (SROT) after discontinuation of hetrombopag', 'description': 'The proportion of responders that were able to taper and discontinue hetrombopag maintaining the response during a period of observation of at least six months.', 'timeFrame': 'Data will be collected for all routine visits completed during the study period which is no more than 24 months.'}]",7,,,ALL,False,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",OTHER,1,1150.0,ESTIMATED,2025-09-01T16:18:18.425235,v2_robust,False,True,False,False,True,
NCT06299761,Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications,"An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-825 and BBI-825 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Resistance Gene Amplifications",BBI-825,"['BBI-825', 'ribonucleotide reductase inhibitor']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumor,['Solid Tumor'],"['Amplification', 'Oncogene Amplification', 'ribonucleotide reductase inhibitor', 'RNR inhibitor']",COMPLETED,,2024-03-28,2025-06-25,"[{'measure': 'Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-825', 'description': 'TEAEs will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.', 'timeFrame': 'Start of Cycle 1 until 30 days following last dose (each cycle is 28 days)'}, {'measure': 'Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of BBI-825', 'description': 'The MTD and/or RP2D of BBI-825 will be determined.', 'timeFrame': 'Start of Cycle 1 until 30 days following last dose (each cycle is 28 days)'}]","[{'measure': 'Maximum observed plasma concentration (Cmax) of BBI-825', 'description': 'Maximum observed plasma concentration (Cmax) of BBI-825 will be determined.', 'timeFrame': 'Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)'}, {'measure': 'Trough observed plasma concentration (Ctrough) of BBI-825', 'description': 'Trough observed plasma concentration (Ctrough) of BBI-825 will be determined.', 'timeFrame': 'Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)'}, {'measure': 'Time to Cmax (Tmax) of BBI-825', 'description': 'Time to Cmax (Tmax) of BBI-825 will be determined.', 'timeFrame': 'Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)'}, {'measure': 'Area under the concentration time curve (AUC) of BBI-825', 'description': 'Area under the concentration time curve (AUC) of BBI-825 will be determined.', 'timeFrame': 'Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)'}, {'measure': 'Anti-tumor activity of BBI-825 as determined by RECISTv1.1', 'description': 'Number of participants achieving a best response of progressive disease, stable disease, partial response, or complete response.', 'timeFrame': 'Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)'}]",7,18 Years,99 Years,ALL,False,Boundless Bio,INDUSTRY,0,19.0,ACTUAL,2025-09-01T16:18:18.425397,v2_robust,True,True,True,False,True,
NCT01891461,Study to Compare the Addition of Floseal to Our Standard of Care to Control Post Operative Bleeding in TKR,"A Prospective, Randomized Study to Compare the Addition of Granules of Gelatine + Thrombin to Our Standard of Care (SOC) to Control Post Operative Bleeding in Total Knee Replacement",Floseal,"['Floseal', 'Hemostatic Matrix']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Intraoperative Bleeding,"['Intraoperative Bleeding', 'Post-operative Bleeding']","['total knee arthroplasty', 'post-operative bleeding', 'floseal']",COMPLETED,,2012-01,2017-01,"[{'measure': 'Need of transfusion post-op (yes/no, how many)', 'timeFrame': 'post op day 1 to 7'}]",[],1,18 Years,,ALL,True,Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal,OTHER,1,132.0,ACTUAL,2025-09-01T16:18:18.425414,v2_robust,True,True,True,False,False,
NCT04820361,Effect of Cannabinoids on Pain in Fabry Disease Patients,"Effect of Cannabinoids on Pain in Fabry Disease Patients; a Prospective, Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Study","Cannabis sativa L., folium cum flore","['Cannabis sativa L., folium cum flore', 'Placebo', 'Spasmolytic']",3,INTERVENTIONAL,['NA'],,,"Pain, Neuropathic","['Pain, Neuropathic']",[],UNKNOWN,,2022-07-07,2023-12-29,"[{'measure': 'NRS', 'description': 'NRS is a straightforward commonly used method to illustrate pain.', 'timeFrame': 'Daily NRS score after 28 days will be compared to baseline NRS score, evaluated before titration phase starts'}]","[{'measure': 'QST', 'description': 'Pain thresholds using the quantitative sensory testing.', 'timeFrame': 'At baseline and after 28 days of treatment with study drug and placebo, respectively.'}, {'measure': 'WHO-Quality of life score (WHOQOL-BREF)', 'description': 'Improvement of quality of life.', 'timeFrame': 'Between baseline and treatment after 28 days.'}, {'measure': 'Patient global impression of change (PGIC)', 'description': 'Improvement of quality of life.', 'timeFrame': 'For the average pain of treatment week 4.'}, {'measure': 'Short form McGrill Paint Questionnaire (SF-MPQ)', 'description': 'Improvement of neuropathic pain.', 'timeFrame': 'Compared between baseline and average pain of treatment after 28 days.'}, {'measure': 'Douleur Neuropathic en 4 questions (DN4-Questionnaire)', 'description': 'Improvement of neuropathic pain.', 'timeFrame': 'Compared between baseline and treatment week 4.'}, {'measure': 'Profile of Mood States (POMS questionnaire)', 'description': 'Change in Profile of Mood States.', 'timeFrame': 'Between baseline and treatment week 4.'}, {'measure': 'Insomnia severity Index', 'description': 'Change in Insomnia severity score.', 'timeFrame': 'Between baseline and treatment after 28 days.'}]",8,18 Years,70 Years,ALL,False,"Albina Nowak, MD",OTHER,1,22.0,ESTIMATED,2025-09-01T16:18:18.425514,v2_robust,True,True,False,False,False,
NCT03155061,Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors,Phase 1 Dose Escalating and Expansion Study of ONO-4578 Given as Monotherapy and Combinations of ONO-4578 and ONO-4538 in Subjects With Advanced or Metastatic Solid Tumors,ONO-4578,"['ONO-4538', 'ONO-4578']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced or Metastatic Solid Tumors,['Advanced or Metastatic Solid Tumors'],[],ACTIVE_NOT_RECRUITING,,2017-04-19,2027-03,"[{'measure': 'Evaluation of the safety (adverse event, clinical laboratory test, 12-lead electrocardiography, chest X-ray, ECOG performance status)', 'timeFrame': 'Through study completion, an average of 1 year'}]","[{'measure': 'Maximum observed serum concentration(Cmax)', 'timeFrame': 'Up to Cycle 1 (each cycle is 28 days)'}, {'measure': 'Area Under the blood concentration-time Curve(AUC)', 'timeFrame': 'Up to Cycle 1 (each cycle is 28 days)'}, {'measure': 'Half-life(T1/2) of ONO-4578 both alone and in combination with ONO-4538', 'timeFrame': 'Up to Cycle 1 (each cycle is 28 days)'}]",4,20 Years,,ALL,False,Ono Pharmaceutical Co. Ltd,INDUSTRY,0,183.0,ESTIMATED,2025-09-01T16:18:18.425536,v2_robust,True,True,False,False,True,
NCT02105961,Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD),Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level,Mepolizumab,"['Mepolizumab', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Pulmonary Disease, Chronic Obstructive","['Pulmonary Disease, Chronic Obstructive']","['Chronic Obstructive Pulmonary Disease', 'exacerbations', 'SB240563', 'mepolizumab', 'eosinophils']",COMPLETED,,2014-04-24,2017-01-16,"[{'measure': 'Rate of Moderate or Severe Exacerbations', 'description': 'Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (\\>=24 hours) or result in death. Moderate and severe exacerbations occurring from the start of investigational product (IP) up to the Week 52 visit, including exacerbations reported after early discontinuation from IP by participants who remained in the study, were included in the analysis. The analysis was performed on the modified intent-to-treat (mITT) Population (all randomized participants who received at least one dose of study treatment).', 'timeFrame': 'From randomization to Week 52'}]","[{'measure': 'Time to First Moderate/Severe Exacerbation', 'description': 'Kaplan Meier estimates of the probability of a moderate or severe exacerbation are expressed as the percentage of participants with an exacerbation over time (by Week 8, 16, 24, 32, 40, 48, 52). Analysis of time to first moderate/severe exacerbation was performed on the mITT population and included exacerbations reported on-treatment and those reported after early discontinuation from IP by participants who remained in the study.', 'timeFrame': 'From randomization to Week 52'}, {'measure': 'Rate of COPD Exacerbations Requiring Emergency Department (ED) Visits and/or Hospitalizations (Hosp)', 'description': 'COPD exacerbations requiring an ED visit and/or hosp occurring from the start of IP up to the Week 52 visit, including exacerbations reported after early discontinuation from IP by participants who remained in the study, were included in the analysis. This analysis was performed on the mITT population.', 'timeFrame': 'From randomization to Week 52'}, {'measure': ""Change From Baseline in Mean Total St. George's Respiratory Questionnaire (SGRQ) Score"", 'description': 'The SGRQ for COPD is a 40-item questionnaire derived from the original SGRQ , designed to measure health impairment by addressing the frequency of respiratory symptoms and current state of the participant. SGRQ Total Scores range from 0 to 100 with higher scores indicating worse health-related quality of life and reductions indicating improvement. The Baseline value will be the last measurement collected prior to the first dose of investigational product.Change from Baseline is calculated as the post-dose visit value minus the Baseline value. Mean change from Baseline in SGRQ score at Week 52 has been presented.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Change From Baseline in Mean COPD Assessment Test (CAT) Score', 'description': 'The CAT is an 8-item questionnaire developed for use in routine clinical practice to measure the health status of participants with COPD. Each question is assessed on a 6-point scale ranging from 0 (no impairment) to 5 (maximum impairment) with the CAT score ranging from 0-40. Higher scores indicate greater disease impact with reductions indicating improvement. The Baseline value will be the last measurement collected prior to the first dose of investigational product. Change from Baseline is calculated as the post-dose visit value minus the Baseline value. Mean change from Baseline in CAT score at Week 52 has been presented.', 'timeFrame': 'Baseline and Week 52'}]",5,40 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,674.0,ACTUAL,2025-09-01T16:18:18.425550,v2_robust,True,True,True,False,False,
NCT01455142,A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes,A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes,insulin degludec/insulin aspart,"['insulin degludec/insulin aspart', 'IDegAsp']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 1']",[],COMPLETED,,2011-10,2012-01,"[{'measure': 'Area under the serum insulin degludec concentration-time curve', 'timeFrame': 'From 0 to 120 hours after single-dose (SD)'}, {'measure': 'Maximum observed serum insulin degludec concentration', 'timeFrame': 'After single-dose (within 0 to 120 hours after dosing)'}, {'measure': 'Area under the serum insulin aspart concentration-time curve', 'timeFrame': 'From 0 to 12 hours after single-dose'}, {'measure': 'Maximum observed serum insulin aspart concentration', 'timeFrame': 'After single-dose (within 0 to 12 hours after dosing)'}]","[{'measure': 'Area under the glucose infusion rate curve', 'timeFrame': 'From 0 to 26 hours after single-dose'}, {'measure': 'Maximum glucose infusion rate', 'timeFrame': 'After single-dose (within 0 to 120 hours after dosing)'}]",6,18 Years,64 Years,ALL,False,Novo Nordisk A/S,INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:18.425583,v2_robust,True,True,True,False,False,
NCT06891742,Phase I Study of OriC902 in Treatment of Advanced HCC,"A Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, and Initial Efficacy of a GPC3-targeted Chimeric Antigen Receptor Autologous T Cell Injection (OriC902) in GPC3-positive Advanced Hepatocellular Carcinoma (HCC) Subjects",OriC902,['OriC902'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,HCC,['HCC'],"['GPC3', 'HCC', 'CART']",RECRUITING,,2025-02-24,2028-03-31,"[{'measure': 'MTD or biologically effective dose', 'description': 'SRC will select MTD or biologically effective dose', 'timeFrame': '1year'}, {'measure': 'RP2D', 'description': 'SRC will select RP2D based on safety, initial efficacy (if any) and PK data', 'timeFrame': '1year'}, {'measure': 'Incidence and severity of AE and SAE,', 'description': 'To evaluate the incidence and severity of AE and SAE', 'timeFrame': '2year'}]","[{'measure': 'PK of OriC902', 'description': 'Blood was collected according to the collection point of the protocol to analyze PK parameters', 'timeFrame': '2year'}, {'measure': 'Peripheral blood concentration of two antibodies(PD-L1&VEGF)', 'description': 'Peripheral blood samples were collected from each subject for analysis of serum CAR-T-activated and inflammatory cytokines, including peripheral blood anti-PD-L1 and anti-VEGFA antibodies', 'timeFrame': '2year'}, {'measure': 'Evaluate initial efficacy of OriC902', 'description': 'Assessment according to RECIST 1.1', 'timeFrame': '3year'}]",6,18 Years,75 Years,ALL,False,Peking University,OTHER,1,44.0,ESTIMATED,2025-09-01T16:18:18.425597,v2_robust,True,True,False,False,True,
NCT00614042,Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma,A Phase 1/1b Study of TRU-016 in Patients With Previously Treated Chronic Lymphocytic Leukemia or Select Subtypes of Non-Hodgkin's Lymphoma,TRU-016 (anti-CD37 protein therapeutic),['TRU-016 (anti-CD37 protein therapeutic)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Lymphocytic Leukemia (CLL),"['Chronic Lymphocytic Leukemia (CLL)', ""Non-Hodgkin's Lymphoma (NHL)""]","['CLL', 'NHL', 'TRU-016', 'chronic lymphocytic leukemia', ""non-Hodgkin's lymphoma""]",COMPLETED,,2008-01,2012-03,"[{'measure': 'Safety and tolerability of TRU-016 administered IV in patients with CLL or NHL', 'timeFrame': '4 weeks after treatment'}]","[{'measure': 'Preliminary indication of response as defined by NCI 1996 criteria', 'timeFrame': '3 months after treatment'}]",2,18 Years,,ALL,False,Aptevo Therapeutics,INDUSTRY,0,96.0,ACTUAL,2025-09-01T16:18:18.425695,v2_robust,True,True,True,False,True,
NCT00876642,Trial Comparing Best Supportive Care to Aloe Vera Gel,Phase III Trial Comparing Best Supportive Care to Aloe Vera Gel as a Prophylactic Agent for Radiation Induced Skin Toxicity,Aloe vera gel,['Aloe vera gel'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Radiation Dermatitis,['Radiation Dermatitis'],"['Radiation dermatitis', 'best supportive care', 'Aloe vera gel', 'phase III study was to assess the effectiveness of aloe vera and vitamin E.']",COMPLETED,,2007-03,2008-12,[{'measure': 'Acute radiation-induced dermatitis of grade 2 or higher during postoperative radiotherapy for breast cancer.'}],"[{'measure': 'quality of life,interruptions of treatment and pain.'}]",2,18 Years,85 Years,ALL,False,Marilia Medicine School,OTHER,0,137.0,ACTUAL,2025-09-01T16:18:18.425876,v2_robust,True,True,True,False,False,
NCT00766142,Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer,Clinical Phase II Study Evaluating Systemic Chemotherapy in Combination With Cetuximab as Adjuvant Treatment in Patients With Completely Surgically Resected Peritoneal Carcinomatosis of Colorectal Origin,fluorouracil,"['fluorouracil', 'leucovorin calcium', 'oxaliplatin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Colorectal Cancer,"['Colorectal Cancer', 'Primary Peritoneal Cavity Cancer']","['adenocarcinoma of the colon', 'recurrent colon cancer', 'stage IV colon cancer', 'adenocarcinoma of the rectum', 'recurrent rectal cancer', 'stage IV rectal cancer', 'peritoneal carcinomatosis']",TERMINATED,"In 2008, new data highlighted that Cetuximab had no efficacy in case of KRAS mutation. As such, eligibility criteria were revised and limited to KRAS wild-type. Inclusions were thus slown down considerably, and the trial was stopped.",2007-05-01,2013-09-17,"[{'measure': 'Median Progression-free Survival (PFS) Time', 'description': 'Progression-free survival time is defined as the time from the date of surgery to the date of progression (as per RECIST v1.1) or death of any cause, whichever occurs first.\n\nProgression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.', 'timeFrame': 'Since surgery, up to 5 years'}]","[{'measure': '30-day Mortality Rate', 'description': 'Rate of deaths observed within 30 days of surgery', 'timeFrame': 'from the date of surgery up to 30 days'}, {'measure': 'Mean Number of Adverse Events Per Patient, Within 30 Days of Surgery', 'timeFrame': 'from the date of surgery up to 30 days'}, {'measure': 'Overall Survival (OS) Time', 'description': 'OS is the delay between surgery and death', 'timeFrame': 'from surgery, up to five years.'}]",4,18 Years,120 Years,ALL,False,Institut Bergonié,OTHER,6,18.0,ACTUAL,2025-09-01T16:18:18.425899,v2_robust,True,True,False,True,True,"In 2008, new data highlighted that Cetuximab had no efficacy in case of KRAS mutation. As such, eligibility criteria were revised and limited to KRAS wild-type. Inclusions were thus slown down considerably, and the trial was stopped."
NCT00650442,Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System,Evaluation of the Adhesion Quality and Primary Dermal Irritation Potential of an Alternate Second Generation Estradiol Transdermal Systems in Normal Healthy Female Volunteers,Estradiol Transdermal System Placebo - Alternate Adhesive,"['Estradiol Transdermal System Placebo - Current Adhesive', 'Estradiol Transdermal System Placebo - Alternate Adhesive']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2003-01,2003-02,"[{'measure': 'Transdermal Adhesion', 'timeFrame': 'within 30 days'}]",[],1,40 Years,66 Years,FEMALE,True,Mylan Pharmaceuticals Inc,INDUSTRY,0,39.0,ACTUAL,2025-09-01T16:18:18.425954,v2_robust,True,True,True,False,False,
NCT02466386,"Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder","A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder",SPD489,"['SPD489', 'Lisdexamfetamine dimesylate']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Attention Deficit Hyperactivity Disorder (ADHD),['Attention Deficit Hyperactivity Disorder (ADHD)'],[],COMPLETED,,2015-08-21,2020-01-03,"[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs)', 'description': 'An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs was defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of investigational product.', 'timeFrame': 'From start of study drug administration up to follow-up (Week 53)'}, {'measure': ""Change From Baseline in Sleep Patterns Assessed by Children's Sleep Habits Questionnaire (CSHQ) at Week 52/ Early Termination (ET)"", 'description': ""Sleep patterns included sleep diary data and children's sleep habits questionnaire (CSHQ), which was parent report questionnaire designed to screen for the most common sleep problems in children, and consisted of 33 items for scoring and several extra items intended to provide administrators with other potentially useful information about respondents. The instrument evaluates the child's sleep based on behavior within 8 different sub scales: bedtime resistance, sleep-onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep-disordered breathing, and daytime sleepiness. Each item receives a score from 1 (problem occurs rarely) to 3 (problem usually occurs); therefore, a higher score is the worse outcome. Scale ranges are as follows: bedtime resistance: 6 to 18, sleep onset delay: 1 to 3, sleep duration: 3 to 9, sleep anxiety: 4 to 12, night walkings: 3 to 9, parasomnias: 7 to 21, sleep-disordered breathing: 3 to 9, and daytime sleepiness: 8 to 24."", 'timeFrame': 'Week 52/ET'}, {'measure': 'Number of Participants With Potentially Clinically Significant Changes in Electrocardiogram (ECG) Parameters at Week 52/ Early Termination (ET)', 'description': '12-lead ECG was evaluated and recorded. ECG variables included heart rate, PR interval, QRS interval, QT interval, and corrected QT interval (QTc). The QTc was calculated using both Bazett (QTcB=QT/\\[RR\\]1/2) and Fridericia (QTcF=QT/\\[RR\\]1/3) corrections. Here, \\> = represents ""greater than or equal to"", \\< represents ""lesser than"" and \\> represents ""greater than"".', 'timeFrame': 'Week 52/ET'}, {'measure': 'Number of Participants With a Positive Response Using Columbia Suicide Severity Rating Scale (C-SSRS) at Week 52/ Early Termination (ET)', 'description': 'C-SSRS was semi-structured interview that captured the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview included definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. The C-SSRS contained 2 required items pertaining to suicidal ideation, 4 required items pertaining to suicidal behavior, and 1 required item pertaining to non-suicidal but self-injurious behavior. In situations where there was a positive response to the screening questions, there were 8 additional suicidal ideation items and 4 additional suicidal behavior items which were completed. Thus, there was a maximum of 19 items to be completed. Here number of participants responded as yes to suicidal ideation or behaviour were reported.', 'timeFrame': 'Week 52/ET'}, {'measure': 'Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Values at Week 52/ Early Termination (ET)', 'description': 'Clinical laboratory evaluations included biochemistry and endocrinology, hematology, and urinalysis. Number of participants with potentially clinically significant changes in clinical laboratory values were reported.', 'timeFrame': 'Week 52/ET'}, {'measure': 'Number of Participants With Potentially Clinically Significant Changes in Vital Signs at Week 52/ Early Termination (ET)', 'description': 'Vital sign assessments included blood pressure, pulse and respiratory rate. Number of participants with potentially clinically significant changes in vital signs were reported.', 'timeFrame': 'Week 52/ET'}, {'measure': 'Number of Participants With Shift From Baseline in Body Mass Index (BMI) Percentiles at Week 52/Early Termination (ET)', 'description': 'BMI was derived from height and weight. BMI was normalized by sex and age using the CDC growth charts. BMI percentiles were categorized as: Underweight (BMI \\< 5th percentile); Healthy weight (BMI 5th percentile up to \\< 85th percentile); Overweight (BMI 85th percentile \\< 95th percentile); Obese (BMI \\>= 95th percentile). Number of participants with shift from baseline in BMI percentile categories at Week 52/ET was reported.', 'timeFrame': 'Week 52/ET'}]","[{'measure': 'Clinical Global Impressions Global Improvement (CGI-I) at Week 52/ Early Termination (ET)', 'description': ""CGI-I was an overall assessment of global symptom improvement by evaluation of the participant's condition severity and improvement over time. Scoring was done based on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), where higher score reported worse condition. The scoring was elaborated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse."", 'timeFrame': 'Week 52/ET'}, {'measure': 'Change From Baseline in Clinician-Administered Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Preschool Version Total Score at Week 52/ Early Termination (ET)', 'description': 'ADHD-RS-IV Preschool Version was adapted from the ADHD Rating Scale-IV and provided examples appropriate for the developmental level of preschool children. The ADHD-RS-IV Preschool Version was an 18-item questionnaire that required the respondent to rate the frequency of occurrence of ADHD symptoms as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) criteria. Each item was scored on a 4-point scale ranging from 0 (never or rarely) to 3 (very often) with total scores ranging from 0-54. The 18 items were grouped into 2 subscales: hyperactivity/impulsivity (even numbered items 2-18) and inattentiveness (odd numbered items 1-17).', 'timeFrame': 'Week 52/ET'}]",9,4 Years,5 Years,ALL,False,Shire,INDUSTRY,0,113.0,ACTUAL,2025-09-01T16:18:18.426015,v2_robust,True,True,True,False,True,
NCT01928186,"FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer","Imaging Early Response of ER+, HER2- Breast Cancer to Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET",Fluorothymidine F-18,"['18F-FLT', ""3'-deoxy-3'-[18F]fluorothymidine"", 'Run-in (short pre-surgery course) of endocrine-targeted therapy', 'Fluorothymidine F-18']",4,INTERVENTIONAL,['NA'],,,Estrogen Receptor Positive,"['Estrogen Receptor Positive', 'HER2/Neu Negative', 'Male Breast Carcinoma', 'Stage IA Breast Cancer', 'Stage IB Breast Cancer', 'Stage IIA Breast Cancer', 'Stage IIB Breast Cancer', 'Stage IIIA Breast Cancer', 'Stage IIIB Breast Cancer', 'Stage IIIC Breast Cancer']",[],COMPLETED,,2011-09,2015-07-20,"[{'measure': 'Percent Change in Net Influx Constant (Ki) by FLT PET', 'description': ""Percent change between pre-treatment (baseline) and post-therapy PET measurements in breast tumors will be computed.\n\nAssociation between Ki-67 and Ki by FLT (KFLT) decline will be analyzed using the mid-P adjustment to Fisher's exact test to evaluate the potential clinical utility of change in FLT as a biomarker for early response, using Ki-67 as the standard for early response."", 'timeFrame': 'Baseline to up to 6 weeks'}, {'measure': 'Percent Change in SUV by FLT PET', 'description': 'Percent change between pre-treatment (baseline) and post-therapy measurements of FLT standardized uptake value (SUV) in breast tumors will be computed.', 'timeFrame': 'Baseline to up to 6 weeks'}, {'measure': 'Percentage of Ki-67 Positive Tumor Cells in Surgical (Post-therapy) Sample', 'description': 'Surgically removed breast tumor tissue is stained using immuno-histochemistry techniques to visualize dividing cells expressing the Ki-67 protein, which is a cellular marker for proliferation.', 'timeFrame': '1 to 6 weeks post-therapy start'}, {'measure': 'Percentage Change in Ki-67 Positive Cells Between Pre-therapy and Post-therapy Tumor Specimens', 'description': 'Tumor tissue samples from pre-treatment (baseline) biopsy and post-treatment surgery are stained using immuno-histochemistry techniques to visualize dividing cells expressing the Ki-67 protein, which is a cellular marker for proliferation.\n\nThe % values of positive cells from the baseline and post-treatment samples are then compared for each individual patient.\n\nAssociation between Ki-67 and KFLT decline will be analyzed to evaluate the potential clinical utility of change in FLT as a biomarker for early response, using Ki-67 as the standard for early response.', 'timeFrame': 'Baseline to up to 6 weeks'}]","[{'measure': 'Percentage Change in K1 (Blood Flow Parameter) by FLT PET', 'description': 'Percent change between pre-treatment (baseline) and post-therapy PET measurements in breast tumors will be computed.', 'timeFrame': 'Baseline to up to 6 weeks'}, {'measure': 'Baseline Ki (Flux Constant) Values by FLT PET', 'description': 'Ki (flux constant) in breast tumor tissue as determined by the pre-therapy (baseline) FLT PET scan', 'timeFrame': 'Baseline'}, {'measure': 'Baseline FLT Transport (K1) Values by FLT PET', 'description': 'K1 (blood flow measure) in breast tumor tissue as determined by the pre-therapy (baseline) FLT PET', 'timeFrame': 'Baseline'}, {'measure': 'Baseline Standardized Uptake Values (SUV) by FLT PET', 'description': 'FLT SUV in breast tumor tissue as determined by the pre-therapy (baseline) FLT PET', 'timeFrame': 'Baseline'}, {'measure': 'Post-therapy Ki (Flux Constant) Values by FLT PET', 'description': 'Ki (flux constant) in breast tumor tissue as determined by the post-therapy FLT PET', 'timeFrame': '1 to 6 weeks post-therapy start'}, {'measure': 'Post-treatment FLT Transport (K1) Values by FLT PET', 'description': 'K1 (blood flow measure) in breast tumor tissue as determined by the post-therapy FLT PET', 'timeFrame': '1 to 6 weeks post-therapy start'}, {'measure': 'Post-treatment Standardized Uptake Values (SUV) by FLT PET', 'description': 'FLT SUV in breast tumor tissue as determined by the post-treatment FLT PET', 'timeFrame': '1 to 6 weeks post-therapy start'}]",11,18 Years,,ALL,False,University of Washington,OTHER,1,28.0,ACTUAL,2025-09-01T16:18:18.426028,v2_robust,True,True,True,False,False,
NCT02095886,Relative Bioavailability Study With BMS-955176,Assessment of BMS-955176 Bioavailability From a Micronized Crystalline Tablet Relative to a Spray-Dried Dispersion Suspension and Assessment of Additional Experimental Formulations Relative to the Micronized Crystalline Tablet in Healthy Subjects,BMS-955176,['BMS-955176'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Infection, Human Immunodeficiency Virus","['Infection, Human Immunodeficiency Virus']",[],COMPLETED,,2014-03-25,2014-07-07,"[{'measure': 'Maximum observed plasma concentration (Cmax) of BMS-955176', 'timeFrame': 'Days 1-4 of Periods 1, 2, 3 and 4'}, {'measure': 'Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-955176', 'timeFrame': 'Days 1-4 of Periods 1, 2, 3 and 4'}, {'measure': 'Area under the plasma concentration-time curve from time zero to 72 hours post-dose [AUC(0-72)] of BMS-955176', 'timeFrame': 'Days 1-4 of Periods 1, 2, 3 and 4'}]","[{'measure': 'Time of maximum observed plasma concentration (Tmax) of BMS-955176', 'timeFrame': 'Days 1-4 of Periods 1, 2, 3 and 4'}, {'measure': 'Terminal plasma half-life (T-HALF) of BMS-955176', 'timeFrame': 'Days 1-4 of Periods 1, 2, 3 and 4'}, {'measure': 'Apparent total body clearance (CLT/F) of BMS-955176', 'timeFrame': 'Days 1-4 of Periods 1, 2, 3 and 4'}, {'measure': 'Safety and tolerability based on incidence of adverse events (AEs), serious AEs, AEs leading to discontinuation and deaths, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs and physical examinations', 'timeFrame': 'Up to Period 4/Day 4 (discharge)'}]",7,18 Years,50 Years,ALL,True,ViiV Healthcare,INDUSTRY,1,47.0,ACTUAL,2025-09-01T16:18:18.426077,v2_robust,True,True,True,False,True,
NCT06047886,UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy,Feasibility Study of CD34 Selection for GVHD Prophylaxis Using the Automated CliniMACS,Infusion of CD34 selected hematopoietic stem cells,['Infusion of CD34 selected hematopoietic stem cells'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,AML,"['AML', 'ALL', 'Lymphoid Malignancies', 'Myelodysplastic Syndromes', 'CML', 'Primary Myelofibrosis']","['hematologic malignancies', 'graft failure']",RECRUITING,,2025-04-22,2029-12,"[{'measure': 'Severe acute GVHD', 'description': 'Incidence of severe (grade III-IV) acute GVHD \\<=25% at 100 days', 'timeFrame': '6 years'}, {'measure': 'extensive chronic GVHD', 'description': 'Incidence of extensive chronic GVHD \\<=10% at one year.', 'timeFrame': '6 years'}, {'measure': 'donor chimerism', 'description': 'Improvement of donor chimerism by \\>=15%', 'timeFrame': '6 years'}, {'measure': 'Clinical improvement', 'description': 'Clinical improvement, defined as an increase of blood counts with transfusion independence if anemia or thrombocytopenia or freedom for infections if reduced leukocytes', 'timeFrame': '6 years'}]","[{'measure': 'Non-relapse mortality', 'description': 'Rate of one-year non-relapse mortality (NRM).', 'timeFrame': '6 years'}, {'measure': 'Disease relapse', 'description': 'Rate of one-year relapse', 'timeFrame': '6 years'}, {'measure': 'overall survival', 'description': 'Rate of one-year overall survival (OS).', 'timeFrame': '6 years'}, {'measure': 'Absolute neutrophil count', 'description': 'ANC engraftment or increase', 'timeFrame': '6 years'}]",8,4 Weeks,75 Years,ALL,False,University of Alabama at Birmingham,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:18.426140,v2_robust,True,True,False,False,False,
NCT01480986,IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC,a Prospective Study on the Efficacy and Safety Using Sequential Therapy of Irinotecan Combined With Cisplatin (IP)and Octretide Lar in the First Line Treatment of Metastatic or Inoperable Gastrointestinal Poorly Differentiated Neuroendocrine Carcinoma: the IPO-NEC Trial,"Irinotecan combined with cisplatin, octreotide lar","['Irinotecan combined with cisplatin, octreotide lar']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Progression Free Survival of the Treatment,['Progression Free Survival of the Treatment'],[],COMPLETED,,2011-09,2013-12,"[{'measure': 'Progression Free Survival for Irinotecan plus cisplatin and octreotide', 'description': 'The primary objective is to investigate the overall progression free suvival for irinotecan plus cisplatin and octretide. The respective PFS of the two treatment steps will also be investigated. The result will be compared with the history treatment outcomes for patients of poorly differentiated neuroendocrine carcinoma.', 'timeFrame': '2 years'}]","[{'measure': 'Disease control rate', 'description': 'The second objective includes the disease control rate of irinotecan plus cisplatin and octretide theray.', 'timeFrame': '2 years'}, {'measure': 'Overall survival', 'description': 'The secondary objective includes the investigation of the overall survival for the patients receiving the sequential treatment of irinotecan plus cisplatin and octretide.', 'timeFrame': '3 years'}, {'measure': 'Safety', 'description': 'The secondary objective also includes the investigation on the safety profiles of the two interventions, irinotecan plus cisplatin treatment and octretide. The safety profile will be described using incidence of AEs and SAEs, using CTCAE criteria', 'timeFrame': '3 years'}]",4,18 Years,,ALL,False,Peking University,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:18.426175,v2_robust,True,True,True,False,True,
NCT01019486,Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D),Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D),Regadenoson myocardial perfusion imaging,"['Regadenoson (Lexiscan)', 'Regadenoson MRI myocardial blood flow', 'Regadenoson myocardial perfusion imaging', 'Cardiolite (sestamibi)', 'Prohance (Gadoteridol)']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Coronary Artery Disease,"['Coronary Artery Disease', 'Type 1 Diabetes Mellitus']","['Myocardial blood flow', 'Cardiac magnetic resonance imaging', 'Myocardial perfusion imaging', 'Coronary artery flow reserve', 'Regadenoson']",COMPLETED,,2009-11,2011-12,"[{'measure': 'Coronary Blood Flow Assessment With Regadenoson Stress by Cardiac MRI Between Non-diabetic and Type 1 Diabetic Subjects.', 'description': 'Measurement of Myocardial blood flow measurements (MBF) and myocardial perfusion index obtained from 6 regions within the mid ventricular LV short axis slice.', 'timeFrame': '1 month'}]","[{'measure': 'Measured Coronary Blood Flow is Directly Correlated With Coronary Flow Reserve Measured Invasively in the Cardiac Catheterization Laboratory After Regadenoson Pharmacologic Stress.', 'description': 'Regional coronary blood flow reserve (CFR) in a target artery (defined on MPI study) compared to flow in a less diseased atherosclerotic vessel following vasodilator response to intravenously administered regadenoson.', 'timeFrame': 'within 6 months'}, {'measure': 'Myocardial Perfusion Index', 'description': 'Myocardial perfusion indices radionuclide stress and rest images and were obtained from 6 regions within the mid ventricular LV short axis slice. Each was corrected for decay and standardized to a 30 mCi administered dose for each part of a two day study.', 'timeFrame': '1 month'}]",3,25 Years,65 Years,ALL,False,"University of Colorado, Denver",OTHER,0,26.0,ACTUAL,2025-09-01T16:18:18.426193,v2_robust,True,True,True,False,False,
NCT01550770,Exploratory Study of Propofol and Fentanyl Pharmacodynamics,"An Open Label, Exploratory Study of Propofol and Fentanyl Pharmacodynamics",propofol,['propofol'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,General Anesthesia,['General Anesthesia'],[],COMPLETED,,2012-02,2012-07,"[{'measure': 'Difference between Modified Observers Assessment of Alertness (MOAAS) and transdermal electrical stimulation (TES)', 'description': 'MOAAS and TES assessment of increasing level(s) of sedation', 'timeFrame': '1 day'}]",[],1,18 Years,55 Years,ALL,True,Ethicon Endo-Surgery,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:18.426278,v2_robust,True,True,True,False,False,
NCT01792570,DRV/r + RPV QD: Efficacy and Toxicity Reduction,Strategic Study of Dual-therapy With Darunavir/Ritonavir and Rilpivirine QD Versus Triple-therapy in Patients With Suppressed Viral Load: Virological Efficacy and Evaluation of Non-HIV Related Morbidity.,RPV + DRV/r,"['the drugs will depend on the successful regimen.', 'RVP: rilpivirine; brand name: EdurantTM.', 'RPV + DRV/r', 'DRV: darunavir; brand name: PrezistaTM.', 'continue the PI/r-containing HAART.']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Human Immunodeficiency Virus,['Human Immunodeficiency Virus'],"['HIV-1', 'darunavir', 'rilpivirine', 'strategic study']",COMPLETED,,2014-09-30,2018-12-31,"[{'measure': 'HIV-RNA < 50 cp/mL', 'description': 'Responders: HIV+ subjects with HIV-RNA \\< 50 cp/mL at week 48 according to the intention-to-treat (ITT-TLOVR) approach.', 'timeFrame': 'Week 48'}]","[{'measure': 'ACTG grade III and IV events.', 'description': 'Safety will be assessed through the number of ACTG grade III and IV in the specified safety parameters.', 'timeFrame': 'over 96 weeks.'}]",2,18 Years,,ALL,False,ASST Fatebenefratelli Sacco,OTHER,3,37.0,ACTUAL,2025-09-01T16:18:18.426309,v2_robust,True,True,True,False,True,
NCT04596670,68Ga-ICAM-1pep PET/CT in Cancer Patients,68Ga-ICAM-1pep PET/CT Imaging of Tumor Responses to Radiotherapy in Cancer Patients,68Ga-ICAM-1pep,"['68Ga-ICAM-1pep', '68Ga-CD54pep']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Cancer,['Cancer'],"['PET/CT', 'Radiotherapy', 'ICAM-1', '68Ga labeling']",RECRUITING,,2024-09-20,2025-12-31,"[{'measure': 'Quantitate the standardized uptake values (SUVs) of 68Ga-ICAM-1pep at baseline.', 'description': 'Perform PET/CT imaging using 68Ga-ICAM-1pep before radiotherapy.The semiquantitative analysis will be performed by the same nuclear medicine physician for all cases, and the standardized uptake values (SUVs) of 68Ga-ICAM-1pep in the tumor lesions will be measured.', 'timeFrame': 'At baseline'}, {'measure': 'Characterize changes in the standardized uptake values (SUVs) of 68Ga-ICAM-1pep during radiotherapy.', 'description': 'Perform PET/CT imaging using 68Ga-ICAM-1pep after radiotherapy. The semiquantitative analysis will be performed by the same nuclear medicine physician for all cases, and the standardized uptake values (SUVs) of 68Ga-ICAM-1pep in the tumor lesions will be measured. The SUVs of 68Ga-ICAM-1pep in the tumor lesions after radiotherapy will be compared with that at the baseline.', 'timeFrame': '3 to 4 weeks after beginning of radiotherapy'}]",[],2,18 Years,80 Years,ALL,False,Peking University Cancer Hospital & Institute,OTHER,1,20.0,ESTIMATED,2025-09-01T16:18:18.426381,v2_robust,True,True,False,False,False,
NCT01753570,"Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)","A Phase 3 Study of MP-424 in Combination With IFN Beta and RBV, in Subjects With Genotype 1/2 Hepatitis C, Who Are Treatment-Naïve or Have Received Interferon Based Therapy",MP-424,"['RBV(48 weeks)', 'IFN beta(24 weeks)', 'IFN beta(48 weeks)', 'MP-424', 'RBV(24 weeks)']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Hepatitis C(CHC),['Chronic Hepatitis C(CHC)'],['Feron'],COMPLETED,,2012-12,2015-10,"[{'measure': 'Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)', 'timeFrame': '72 weeks(RBV+IFN beta), 48 weeks(MP-424+RBV+IFN beta)'}]","[{'measure': 'Undetectable HCV RNA at 4 Weeks After Beginning of Drug Administration (RVR, Rapid Viral Response)', 'timeFrame': '4 weeks'}, {'measure': 'Undetectable HCV RNA at Completion of Drug Administration (ETR, End-of-treatment Response)', 'timeFrame': '48 weeks(RBV+IFN beta), 24 weeks(MP-424+RBV+IFN beta)'}, {'measure': 'Undetectable HCV RNA at 12 Weeks After Completion of Drug Administration', 'timeFrame': '60 weeks(RBV+IFN beta), 36 weeks(MP-424+RBV+IFN beta)'}, {'measure': 'Transition of Serum HCV RNA Levels', 'timeFrame': 'Baseline，Day2，Day3，1Week，2Weeks，3Weeks，4Weeks，12Weeks，End of treatment，Follow-up 12weeks，Follow-up 24weeks'}, {'measure': 'Number of Participants With the Emergence of Resistance-associated Variants After MP-424 Administration at the Non-structural 3 Protease Region of HCV.', 'description': 'To examine the emergence of resistance-associated variants after MP-424 administration.', 'timeFrame': 'From baseline to 24 weeks after completion of drug administration'}]",6,20 Years,70 Years,ALL,False,Mitsubishi Tanabe Pharma Corporation,INDUSTRY,1,74.0,ACTUAL,2025-09-01T16:18:18.426395,v2_robust,True,True,True,False,False,
NCT05654870,"Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia",Valbenazine,"['Placebo', 'NBI-98854', 'Valbenazine']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Schizophrenia,['Schizophrenia'],"['schizophrenia', 'valbenazine', 'antipsychotic', 'VMAT2', 'NBI-98854', 'dopamine', 'PANSS', 'Adjunctive']",TERMINATED,Study ATS3020 was closed due to business reasons. Neurocrine Biosciences will continue to conduct study ATS3019 (NCT05110157). There were no unexpected safety findings for this compound that motivated the decision.,2023-01-05,2023-11-08,"[{'measure': 'Change in Positive and Negative Syndrome Scale (PANSS) Total Score from Baseline to Week 10', 'timeFrame': 'Baseline, Week 10'}]","[{'measure': 'Change in Clinical Global Impression of Severity (CGI-S) Score from Baseline to Week 10', 'timeFrame': 'Baseline, Week 10'}, {'measure': 'Change in Personal and Social Performance (PSP) Score from Baseline to Week 10', 'timeFrame': 'Baseline, Week 10'}]",3,13 Years,,ALL,False,Neurocrine Biosciences,INDUSTRY,0,8.0,ACTUAL,2025-09-01T16:18:18.426601,v2_robust,True,True,False,True,False,Study ATS3020 was closed due to business reasons. Neurocrine Biosciences will continue to conduct study ATS3019 (NCT05110157). There were no unexpected safety findings for this compound that motivated the decision.
NCT02790073,Phase 2 Study With SNF472 in Calciphylaxis Patients,Phase 2 Open Label Single Arm Repeat Dose Study to Assess the Effect of SNF472 on Wound Healing in Uraemic Calciphylaxis Patients,SNF472,['SNF472'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Calciphylaxis,"['Calciphylaxis', 'Calcific Uremic Arteriolopathy']","['Calciphylaxis', 'Calcific Uremic Arteriolopathy', 'Dialysis', 'End Stage Renal Disease', 'Rare disease (ORPHA280062)', 'Calcification', 'Calcium Metabolism Disorders', 'Calcinosis', 'Metabolic Diseases']",COMPLETED,,2016-05,2017-11-15,"[{'measure': 'Wound Healing', 'description': 'Absolute change in Bates-Jensen Wound Assessment (BWAT) total score between baseline (Week 1) and Week 12 for the primary lesion (the largest one).\n\nThe Bates-Jensen Wound Assessment (BWAT) is a standardized tool for quantitative assessment of wound healing that includes the 13 items listed below.\n\n* Size\n* Depth\n* Edges\n* Undermining or pockets\n* Necrotic tissue type\n* Necrotic tissue amount\n* Exudate type\n* Exudate amount\n* Surrounding skin color\n* Peripheral tissue edema\n* Peripheral tissue induration\n* Granulation tissue\n* Epithelialization\n\nEach item was rated on a scale of 1 (best) to 5 (worst). The Bates-Jensen Wound Assessment (BWAT) total score is the sum of the individual items with a possible range of 13 (best) to 65 (worst).', 'timeFrame': '12 weeks'}]","[{'measure': 'Wound Pain', 'description': 'Absolute change from baseline (Week 1) and Week 12 in the Pain Visual Analogue Scale (VAS) Score.\n\nThe Pain Visual Analogue Scale (VAS) Score is a horizontal line, 100 mm in length, anchored by word descriptors at each end. The subject marked the point on the line that represented his/her perception of his/her current pain status. The Pain Visual Analogue Scale (VAS) Score was determined by measuring in millimeters from the left hand end of the line (no pain) to the point that the subject marked. The Pain Visual Analogue Scale (VAS) Score range 0 (best) to 100 (Worst).', 'timeFrame': '12 weeks'}, {'measure': 'Wound-QoL Global Score', 'description': 'Absolute change from baseline (Week 1) and Week 12 in the Wound-QoL global score.\n\nThe Wound-QoL questionnaire measures the disease-specific, health related QoL of patients with chronic wounds. It consists of 17 items on impairments that are assessed in retrospect to the preceding 7 days and rated on a 0 (best) to 4 (worse) scale with possible responses from ""not at all"" to ""very much"". The total score is the average of the 17 responses.', 'timeFrame': '12 weeks'}]",3,18 Years,,ALL,False,Sanifit Therapeutics S. A.,OTHER,0,14.0,ACTUAL,2025-09-01T16:18:18.426709,v2_robust,True,True,True,False,False,
NCT00535873,Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older,A Phase II Study of Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia Age 65 or Older.,Lenalidomide,"['Lenalidomide', 'Revlimid', 'CC-5013']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Leukemia,"['Leukemia', 'CLL', 'Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma']","['Leukemia', 'CLL', 'chronic lymphocytic leukemia', 'SLL', 'small lymphocytic lymphoma', 'Untreated CLL', 'Lenalidomide', 'CC-5013', 'Revlimid', 'Oral']",COMPLETED,,2007-10,2013-02,"[{'measure': 'Overall Response Rate (ORR)', 'description': 'ORR defined as number of participants with best response of Complete Response (CR) or Partial Response (PR) out of total number of participants. CR is defined as absence of lymphadenopathy, hepatomegaly or splenomegaly on physical exam. Normal Complete Blood Count (CBC) with polymorphonuclear leukocytes \\>1500/µL, platelets \\>100,000/µL, hemoglobin \\>11.0 g/dL (untransfused); lymphocyte count \\<5,000/µL; Bone marrow aspirate and biopsy must be normocellular for age with \\<30% of nucleated cells being lymphocytes. Lymphoid nodules must be absent. PR requires a 50% decrease in peripheral lymphocyte count from , 50% reduction in lymphadenopathy, and/or 50% reduction in splenomegaly/hepatomegaly for a period of at least two months from completion of therapy. These patients must have one of the following: Polymorphonuclear leukocytes 1,500/µL or 50% improvement ; Platelets \\>100,000/µL or 50% improvement ; Hemoglobin \\>11.0 g/dL (untransfused) or 50% improvement from pre-treatment value.', 'timeFrame': 'From 3 cycles (90 days) up to 6 cycles (approximately 180 days)'}]",[],1,65 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,61.0,ACTUAL,2025-09-01T16:18:18.426751,v2_robust,True,True,True,False,False,
NCT01469273,Prophylaxis of Gastrointestinal Infections With EcN,Prophylaxis of Gastrointestinal Infections in Newborn and Infants With a Suspension Containing the Probiotic Escherichia Coli Strain Nissle,Mutaflor® Suspension,"['Mutaflor® Suspension', 'Prophylaxis', 'Nissle', 'Newborn', 'Mutaflor', 'EcN']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Infantile Diarrhea,['Infantile Diarrhea'],"['Diarrhea', 'EcN', 'E. coli strain Nissle 1917', 'Gastrointestinal infection', 'Infant', 'Newborn', 'Probiotic drug', 'Prevention', 'Prophylaxis']",UNKNOWN,,2011-11,2013-12,"[{'measure': 'Number of diarrhea episodes', 'description': 'To show superiority of a prophylaxis with a probiotic suspension containing E. coli strain Nissle against gastrointestinal infections associated with diarrhea, compared to an untreated control group', 'timeFrame': '12 months / first year of life'}]","[{'measure': 'Number of days with diarrhea', 'description': 'To show prophylaxis with a probiotic suspension containing E. coli strain Nissle against gastrointestinal infections associated with diarrhea within the first 12 months of life compared to an untreated control group.', 'timeFrame': '12 months / first year of life'}]",2,3 Hours,12 Months,ALL,True,Hospital San Bartolome,OTHER,1,198.0,ESTIMATED,2025-09-01T16:18:18.426843,v2_robust,True,True,False,False,False,
NCT04958473,A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer,"A Single-center, Non-randomized Controlled, Single-arm, Phase II Clinical Trial of Sintilimab in Combination With Axitinib in the Treatment of Advanced Renal Cell Carcinoma",Sintilimab,"['Axitinib', 'Inlyta', 'Tyvyt', 'IBI 308', 'Sintilimab']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Renal Cell Carcinoma,"['Renal Cell Carcinoma', 'Clear Cell Renal Cell Carcinoma']",[],UNKNOWN,,2021-08-01,2025-08-01,"[{'measure': 'Overall response rate (ORR)', 'description': 'To be assessed by RECIST 1.1', 'timeFrame': 'Up to 12 months'}]","[{'measure': 'Progression free survival (PFS)', 'description': 'Progression Free Survival (PFS) is the time from randomization to date of first documentation of objective progression of disease assessed by BICR (by RECIST version 1.1) or death due to any cause.', 'timeFrame': 'From randomization up to 3 years.'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is the time from date of randomization to date of death due to any cause.', 'timeFrame': 'Every 3 months up to 3 years.'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'DC is defined as complete response (CR), partial response (PR), or stable disease (SD) according to the RECIST v.1.1 recorded from randomization until disease progression assessed by BICR or death due to any cause.', 'timeFrame': 'Every 6 weeks up to 18 months from patient enrollment in the study, then every 12 weeks up to 3 years from randomization'}, {'measure': 'Incidence of treatment-related adverse events', 'description': 'To be assessed by CTCAE v4.03.', 'timeFrame': 'Up to 3 years.'}]",5,18 Years,,ALL,False,Tianjin Medical University Second Hospital,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:18.426857,v2_robust,True,True,False,False,True,
NCT01863173,Effect of Metoprolol on Thalassemia Cardiomyopathy,The Effect of Metoprolol Succinate on the Cardiac Function of Patients With Thalassemia Cardiomyopathy a Double Blind Randomized Study,metoprolol,"['metoprolol', 'placebo']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,B Thalassemia,['B Thalassemia'],"['Thalassemia cardiomyopathy', 'metoprolol succinate', 'echocardiography', 'six minute walk test']",COMPLETED,,2012-01,2012-12,"[{'measure': 'ejection fraction', 'description': 'LV contractility', 'timeFrame': '6 months'}, {'measure': '6 minutes walk test', 'description': 'functional capacity', 'timeFrame': '6 months'}, {'measure': 'endsystolic volume', 'description': 'functional capacity', 'timeFrame': '6 months'}]","[{'measure': 'patient compliance', 'description': 'drug complication,', 'timeFrame': '6 months'}]",4,13 Years,25 Years,ALL,False,Shiraz University of Medical Sciences,OTHER,0,45.0,ACTUAL,2025-09-01T16:18:18.427000,v2_robust,True,True,True,False,False,
NCT00502073,Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005),,cyclosporine,['cyclosporine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Dry Eye Syndromes,['Dry Eye Syndromes'],[],COMPLETED,,,,[],[],0,18 Years,,ALL,,"Sirion Therapeutics, Inc.",INDUSTRY,0,,,2025-09-01T16:18:18.427012,v2_robust,True,True,True,False,False,
NCT03778073,Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma,A Phase 1 Study of Cosibelimab (TG-1501) in Subjects With Relapsed or Refractory Lymphoma,Cosibelimab,"['Cosibelimab + Ublituximab + Bendamustine combination', 'Cosibelimab']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,B-cell Non Hodgkin Lymphoma,"['B-cell Non Hodgkin Lymphoma', ""Richter's Transformation""]",['relapsed or refractory'],TERMINATED,Strategic/Business Decision,2019-04-17,2022-08-01,"[{'measure': 'Adverse Events That Are Related to Treatment', 'description': 'Number of Participants With Treatment-Related Adverse Events, any potential abnormal laboratory results and any dose-limiting toxicities', 'timeFrame': '6 months of therapy'}]","[{'measure': 'Overall Response Rate', 'description': 'Objective response in subjects treated with interventions', 'timeFrame': 'Up to 12 months'}]",2,18 Years,,ALL,False,"TG Therapeutics, Inc.",INDUSTRY,0,18.0,ACTUAL,2025-09-01T16:18:18.427019,v2_robust,True,True,False,True,True,Strategic/Business Decision
NCT01478373,Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib,DOVIGIST: Phase II Trial to Evaluate the Efficacy and Safety of Dovitinib (TKI258) in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib,Dovitinib (TKI258),['Dovitinib (TKI258)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastrointestinal Stromal Tumors,['Gastrointestinal Stromal Tumors'],"['GIST', 'Dovitinib']",COMPLETED,,2012-01,2014-07,"[{'measure': 'Antitumor Activity of Dovitinib in Terms of Disease Control Rate (DCR): Complete Response+Partial Response +Stable Disease', 'description': 'DCR is defined as the proportion of patients with a best overall response of Complete Responses (CR), Partial Response (PR) and Stable Disease (SD) at 12 weeks according to RECIST (version 1.1). Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm 1;Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.', 'timeFrame': '12 Weeks'}]","[{'measure': 'Progression-free Survival (PFS) of Patients Treated With Dovitinib', 'description': 'The PFS duration: time from entry into the study to the date of the first documented progression (assessed using conventional RECIST (version 1.1) or death due to any cause. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.', 'timeFrame': '9 months'}, {'measure': 'Time to Treatment Failure (TTF)of Patients Treated With Dovitinib', 'description': ""TTF: the date of entry into the study to the earliest date of the first objective tumor progression, date of death due to any cause, or date of discontinuation due to reasons other than 'Protocol deviation' or 'Administrative problems'."", 'timeFrame': '9 months'}, {'measure': 'Duration of Response or Stable Disease (SD)', 'description': 'Duration of response or SD: time from date of entry into study to earliest date of first objective tumor progression or death. DCR is defined as proportion of patients with best overall response of CR, PR and SD at 12 weeks according to RECIST (version 1.1). CR: Disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm 1; PR: At least a 30% decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters. PD: At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.', 'timeFrame': '9 months'}, {'measure': 'Time to Tumor Progression (TTP)of Patients Treated With Dovitinib', 'description': 'TTP: time from the date of entry into the study to first documentation of tumor progression or death due to the underlying cancer. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.', 'timeFrame': '9 months'}, {'measure': 'Overall Response Rate (ORR) of Patients Treated With Dovitinib', 'description': 'Outcome Measure Description: ORR: proportion of patients whose best overall response is either complete response (CR) or partial response (PR) according to RECIST (version 1.1). Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm 1;Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Overall Survival (OS) of Patients Treated With Dovitinib', 'description': 'Outcome Measure Description: OS: time from the date of entry into the study to the date of death due to any cause. A patient who has not died by the date of the analysis cut-off would have the OS censored at the time of the last contact before the cut-off date.', 'timeFrame': '21 months (9 months of estimated treatment plus 12 months of survival follow up)'}, {'measure': 'DCR (CR+PR+SD) at the End of Treatment', 'description': 'DCR is defined as the proportion of patients with a best overall response of CR, PR and SD at the end of dovitinib treatment according to RECIST (version 1.1). Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm 1;Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.', 'timeFrame': 'Up to 9 months of estimated treatment'}]",8,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,39.0,ACTUAL,2025-09-01T16:18:18.427027,v2_robust,True,True,True,False,False,
NCT05852873,PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway,PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway,Nirmatrelvir/ritonavir,"['Nirmatrelvir/ritonavir', 'Placebo tablets', 'Paxlovid tablets', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,"Post COVID-19 Condition, Unspecified","['Post COVID-19 Condition, Unspecified', 'SARS-CoV2 Infection', 'COVID-19']","['Nirmatrelvir ritonavir', 'Prevention']",RECRUITING,,2023-05-12,2026-04,"[{'measure': 'Symptoms of long-COVID', 'description': 'a dichotomous variable for presence of any of the three most important long-COVID symptoms: (i) fatigue, (ii) dyspnea and (iii) cognitive symptoms (defined as memory and/or concentration problems).', 'timeFrame': 'Change in symptoms from baseline to 3, 6 and 12 months follow-up'}]","[{'measure': 'Symptoms individually and grouped by organ system', 'description': 'All individual symptoms separately, and grouped by systems (systemic symptoms, chest-symptoms, cognitive, other neuropsychiatric symptoms).', 'timeFrame': 'Change in symptoms from baseline to 3, 6, 12 and 24 months follow-up'}, {'measure': 'Graded responses for symptoms and symptom constellations', 'description': 'Graded responses for separate symptoms and symptom constellations, including an ordinal variable graded 0-3 for the presence of the 3 symptoms in the primary outcome.', 'timeFrame': 'Change in symptoms from baseline to 3, 6, 12 and 24 months follow-up'}, {'measure': 'Risk factors for long-COVID', 'description': 'Analysis of patient characteristics and other factors that may affect the occurrence of long-COVID', 'timeFrame': 'Up to 24 months'}, {'measure': 'Severity of acute disease', 'description': 'Severity of acute disease using an 8-step scale (1 - no limitation of activities, 2 - limitations of activities, not hospitalised, 3 - hospitalised not requiring specific treatment, 4 - hospitalised, requiring medical treatment, but not supplemental oxygen, 5 - need of supplemental oxygen, 6 - need of non-invasive ventilatory support (CPAP, BiPAP), 7 - need ov invasive ventilation, 8 - death', 'timeFrame': '28 days'}, {'measure': 'Hospitalisation', 'description': 'Hospitalisation - binary outcome', 'timeFrame': '28 days'}, {'measure': 'Severe adverse events', 'description': 'Severe adverse events', 'timeFrame': 'Up to 24 months'}, {'measure': 'Absence from work', 'description': 'Absence from work, full or partial sick leave', 'timeFrame': 'Up to 24 months'}, {'measure': 'Societal costs', 'description': 'Societal cost / economic analysis, including estimated cost of absence from work/school, hospitalizations, deaths, QALYs lost according to EQ-5D-5L, and more', 'timeFrame': 'Up to 24 months'}, {'measure': 'Symptoms of long-COVID', 'description': 'a dichotomous variable for presence of any of the three most important long-COVID symptoms: (i) fatigue, (ii) dyspnea and (iii) cognitive symptoms (defined as memory and/or concentration problems).', 'timeFrame': 'Change in symptoms from baseline to 3, 6 and 12 months follow-up'}]",10,18 Years,64 Years,ALL,False,Haukeland University Hospital,OTHER,5,2000.0,ESTIMATED,2025-09-01T16:18:18.427145,v2_robust,True,True,False,False,True,
NCT04162873,Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer,"RESILIENCE: Effect of Comprehensive Celecoxib Through Treatment for Advanced-Stage Head and Neck Cancer: A Randomized, Double-Blinded, Placebo-Controlled Trial",Celecoxib,"['Celebrex', 'Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-', 'Celecoxib', 'YM 177', 'SC-58635']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,"['Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8', 'Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8', 'Nasal Cavity and Paranasal Sinus Carcinoma', 'Oral Cavity Carcinoma', 'Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8', 'Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8', 'Recurrent Hypopharyngeal Carcinoma', 'Recurrent Laryngeal Carcinoma', 'Recurrent Nasal Cavity and Paranasal Sinus Carcinoma', 'Recurrent Oral Cavity Carcinoma', 'Recurrent Oropharyngeal Carcinoma', 'Stage III Hypopharyngeal Carcinoma AJCC v8', 'Stage III Laryngeal Cancer AJCC v8', 'Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8', 'Stage IV Hypopharyngeal Carcinoma AJCC v8', 'Stage IV Laryngeal Cancer AJCC v8', 'Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8', 'Stage IVA Hypopharyngeal Carcinoma AJCC v8', 'Stage IVA Laryngeal Cancer AJCC v8', 'Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8', 'Stage IVB Hypopharyngeal Carcinoma AJCC v8', 'Stage IVB Laryngeal Cancer AJCC v8', 'Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8', 'Stage IVC Hypopharyngeal Carcinoma AJCC v8', 'Stage IVC Laryngeal Cancer AJCC v8', 'Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8']",[],TERMINATED,Insufficient funding,2019-11-27,2023-04-26,"[{'measure': 'The Number of Days From Surgery to the Initiation of Radiation and Adjuvant Therapy', 'description': 'The day of surgery will be considered day 0 and the number of days will be counted until the first dose of adjuvant radiation. This outcome measure will report the mean number of days from surgery to the initiation of radiation and adjuvant therapy for the Celecoxib and Placebo Arms.', 'timeFrame': 'up to 3 months'}]","[{'measure': 'Assessment of Overall Pain Control and Management for Patients on Celecoxib Compared to Placebo - Visual Analog Scale.', 'description': 'Assessment of subjective pain scores on the visual analog scale of pain intensity averaged over a week at rest, with a swallow, and with a cough. The subjects rated their pain from 0-10 on the pain intensity scale. Scores are reported as means of the pain score with standard deviation.\n\nThis outcome is reported scores collected at the post-surgery visit; 9 to 29 days after the start of study treatment.', 'timeFrame': 'Up to 29 days from the start of study treatment'}, {'measure': 'Assessment of Overall Pain Control and Management for Patients on Celecoxib Compared to Placebo - Pain Control Questionnaire.', 'description': 'Patient satisfaction was assessed with a pain control questionnaire. The participants were asked questions about their pain satisfaction over the last seven days. The pain control questionnaire was scored from 0-100, with smaller values indicating poor pain control satisfaction and larger values indicating excellent pain control satisfaction.\n\nThis outcome was assessed at post-surgery and end of treatment for up to 5 months', 'timeFrame': 'post-surgery (up to 29 days from surgery) and end of treatment (up to 5 months from surgery)'}, {'measure': 'Assessment of Overall Pain Control and Management for Patients on Celecoxib Compared to Placebo.', 'description': 'Narcotic consumption was assessed in daily total morphine equivalents averaged over a week. This outcome was assessed at 7 days after surgery and 35 days after surgery.\n\nMorphine equivalent dose (MED) is the amount of opioid prescription drugs a patient is taking per day. MED is the sum of the total morphine milligram equivalents (MMEs), a common unit for assessing milligrams of morphine, dose per day.\n\nThe Post-Surgery (1-7 days) time point is MED from 1 to 7 days after surgery. The Post-Surgery (1-14 days) time point is MED from 1 to 14 days after surgery. The Post-Surgery (1-26 days) time point is MED from 1 to 26 days after surgery. The Post-Surgery (1-35 days) time point is MED from 1 to 35 days after surgery. The End of Treatment time point is MED from 1 to 146 days after surgery.', 'timeFrame': 'Post-Surgery (1-7 days) up to 7 days, Post-Surgery (1-14 days) up to 14 days, Post-Surgery (1-26 days) up to 26 days, Post-Surgery (1-35 days) up to 35 days, and End of Treatment up to 146 days.'}, {'measure': 'Assessment of Functional Outcomes for Patients on Celecoxib Compared to Placebo', 'description': ""Assessment of current activity level was assessed utilizing Karnofsky Performance Status (KPS) at the following time points: pre-operation, day 14 of adjuvant therapy, and end of treatment (or last assessment). The KPS is a scale used to measure a subject's ability to perform daily tasks from 100 Normal no complaints no evidence of disease, 50 Requires considerable assistance and frequent medical care, and 0 Dead.\n\nThis assessment was measured at Post-Operation (up to 29 days after surgery), Mid Radiation (up to 112 days after surgery), and End of Treatment (up to 146 days after surgery)."", 'timeFrame': 'Post-Operation (up to 29 days after surgery), Mid Radiation (up to 112 days after surgery), and End of Treatment (up to 146 days after surgery)'}, {'measure': 'Assessment of Functional Outcomes for Patients on Celecoxib Compared to Placebo', 'description': 'Assessment of current activity level was assessed utilizing Functional Oral Intake Scale (FOIS) at the following time points: pre-operation, day 14 of adjuvant therapy, and end of treatment (or last assessment).\n\nFOIS is a standardized scale assessed by the treating investigator to assess the functional level of oral intake in patients with dysphagia. The FOIS measures from 1 (Aspirates saliva, Nothing by mouth),2 (Tube dependent, Nothing by mouth/minimal trials), 3 (Tube dependent, Full trials by mouth), 4 (Total Oral Single, texture trials), 5 (Total Oral, Multiple texture trials), 6 (Total Oral, By mouth/ restrictions Minimal), and 7 (Regular diet, By mouth/ no restrictions). This assessment was measured for up to 5 months.\n\nThis assessment was measured at Post-Operation (up to 29 days after surgery), Mid Radiation (up to 112 days after surgery), and End of Treatment (up to 146 days after surgery).', 'timeFrame': 'Post-Operation (up to 29 days after surgery), Mid Radiation (up to 112 days after surgery), and End of Treatment (up to 146 days after surgery)'}, {'measure': 'Assessment of Functional Outcomes for Patients on Celecoxib Compared to Placebo', 'description': 'Assessment of swallowing capabilities was assessed by determining gastrostomy tube (G-tube) utilization at the following time points: pre-operation, day 14 of adjuvant therapy, and end of treatment (or last assessment). A G-tube is a tube inserted surgically through the abdomen and into the stomach to deliver liquids, medications, and nutrients directly into the stomach.\n\nThe responses in this outcome measure are Yes (G-tube is being utilized), No (G-tube is not being utilized), and Not Assessed (G-tube utilized was not assessed).\n\nThis assessment was measured at Post-Operation (up to 29 days after surgery), Mid Radiation (up to 112 days after surgery), and End of Treatment (up to 146 days after surgery).', 'timeFrame': 'Post-Operation (up to 29 days after surgery), Mid Radiation (up to 112 days after surgery), and End of Treatment (up to 146 days after surgery)'}, {'measure': 'To Assess the Effect of Celecoxib Therapy on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC QLQ-HN43) Compared to Placebo.', 'description': 'The EORTC QLQ-HN43 is a 43-question assessment for determining the health-related quality of life of head and neck cancer patients participating in clinical trials. Patients indicate which symptoms/problems they have experienced during the past week, from ""1 Not at All"" to ""4 Very Much"".\n\nThe assessment was scored according to the ""EORTC QLQ-C30 Scoring Manual"", reporting data as 19 subscales with scores from 0-100. A high scale score represents a higher response level.\n\nA high functional scale score (FS) represent a high/healthy level of function and includes body image, social contact, \\& sexuality A high symptom scale score (SS) represent a high level of symptomatology/problems and includes anxiety, cough, head and neck pain, swallowing, neurologic problems, senses, speech, social eating, weight loss, problems w/ skin, shoulder, wound healing, dry mouth, opening mouth, neck swelling, \\& teeth.\n\nThis outcome will report the mean score of each subscale.', 'timeFrame': 'Up to 29 days after surgery (up to 32 days after initiation of study treatment)'}, {'measure': 'To Assess the Effect of Celecoxib Therapy on the MDASI-HN Questionnaire Compared to Placebo.', 'description': 'This outcome will report the quality of life questionnaire, the M. D. Anderson symptom inventory head neck (MDASI-HN) at the Post-Operation Visit. This was assessed up to 29 days after surgery (up to 32 days after initiation of study treatment).\n\nMDASI-HN is a 28-question, 2-part questionnaire for patients with head and neck cancer that assesses the severity of symptoms and impact on daily life. In Part I, subjects indicated how severe their symptoms were from ""0 Not present"" to ""10 As Bad as You can Imagine"". In Part II, subjects indicated how symptoms have interfered with their live from ""0 Did not Interfere"" to ""10 Interfered Completely"".\n\nThis assessment was scored according to the The M. D. Anderson Symptom Inventory User Guide.', 'timeFrame': 'Up to 29 days after surgery (up to 32 days after initiation of study treatment)'}, {'measure': 'Assessment of the Average Number of Treatment Days Missed During Adjuvant Radiation for Patients on Celecoxib Compared to Placebo.', 'description': 'This outcome will report the number of participants who missed treatment days during adjuvant radiation, who did not miss any treatment days during adjuvant radiation, and the number of participants who did not start adjuvant radiation therapy.', 'timeFrame': 'up to 140 days'}]",10,18 Years,,ALL,False,University of Utah,OTHER,1,13.0,ACTUAL,2025-09-01T16:18:18.427251,v2_robust,True,True,False,True,False,Insufficient funding
NCT06006169,"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1 Monotherapy, SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors",BL-B01D1,"['izalontamab brengitecan', 'iza-bren', 'BL-B01D1', 'SI-B003', 'BMS-986507']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Head and Neck Squamous Cell Carcinoma,['Head and Neck Squamous Cell Carcinoma'],[],RECRUITING,,2023-10-20,2025-10,"[{'measure': 'Objective response rate (ORR)', 'description': 'ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Recommended Phase II Dose (RP2D)', 'description': 'The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study.', 'timeFrame': 'Up to approximately 24 months'}]","[{'measure': 'Progression-free survival (PFS)', 'description': 'The PFS is defined as the time from the first dose of medication to disease progression or death, whichever occurred first.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Disease control rate (DCR)', 'description': 'The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \\[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\\]).', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Duration of response (DOR)', 'description': ""The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first."", 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Treatment-Emergent Adverse Event (TEAE)', 'description': 'TEAE is defined as any adverse and unexpected change in body structure, function, or chemistry or any exacerbation of an existing condition (i.e., any clinically significant adverse change in frequency and/or intensity) during treatment. The type, frequency, and severity of TEAE will be assessed during treatment.', 'timeFrame': 'Up to approximately 24 months'}]",6,18 Years,75 Years,ALL,False,"Sichuan Baili Pharmaceutical Co., Ltd.",INDUSTRY,0,186.0,ESTIMATED,2025-09-01T16:18:18.427376,v2_robust,True,True,False,False,True,
NCT02301169,A Study to Investigate the Effects of a New Treatment in Patients With Chronic Pain,A Study to Investigate the Effects of T4P1001 Treatment in Patients With Peripheral Neuropathic Pain,Administration of T4P1001 capsules,"['Administration of T4P1001 capsules', 'Administration of placebo capsules']",2,INTERVENTIONAL,['NA'],,,Peripheral Neuropathies,['Peripheral Neuropathies'],['Pain'],COMPLETED,,2014-03,2014-11,"[{'measure': ""Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Average Pain Scores (APS) During 4 Weeks of Treatment"", 'description': '11-point Numeric Rating Scale (NRS). Scale from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine. Lower values represent a better outcome. Unit: arithmetic average of 7 days of a 11-point NRS', 'timeFrame': 'Time zero equals baseline (Day 1) up to Day 42'}]","[{'measure': ""Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Worst Pain Scores (WPS)"", 'description': '11-point Numeric Rating Scale (NRS) Scale from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine. Lower values represent a better outcome. Unit: arithmetic average of 7 days of a 11-point NRS', 'timeFrame': 'Time zero equals baseline (Day 1) up to Day 42'}, {'measure': ""Patient's Change From Baseline of Investigator Global Assessment of Change (IGAC)"", 'description': 'IGAC is an investigator subjective evaluation of patient condition using a NRS from 0 to 10 with 0 meaning best and 10 worst Lower values represent a better outcome.', 'timeFrame': 'Time zero equals baseline (Day 1) up to Day 28'}, {'measure': ""Patient's Change of Pain Intensity After Heat Pain Stimuli From Baseline to End of Treatment Period"", 'description': '11-point Numeric Rating Scale (NRS) from 0 to 10; 0 meaning no pain, 10 pain as bad as you can imagine Lower values represent a better outcome Unit: arithmetic average on 6 reported scores per Visit.', 'timeFrame': 'Time zero equals baseline (Day 1) up to Day 28'}, {'measure': ""Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Brief Pain Inventory (BPI)."", 'description': 'Arithmetic average of 3 questions on an 11-point Numeric Rating Scale (NRS) from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine.\n\nLower values represent a better outcome', 'timeFrame': 'Time zero equals baseline (Day 1) up to Day 28'}]",5,18 Years,,ALL,False,Tools4Patient,OTHER,0,42.0,ACTUAL,2025-09-01T16:18:18.427617,v2_robust,True,True,True,False,False,
NCT02727283,"A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers","A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Ascending Dose Escalating, 4 Period Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of Single Doses of GSK3179106, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers",GSK3179106,"['GSK3179106', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Irritable Bowel Syndrome,['Irritable Bowel Syndrome'],"['Healthy volunteer', 'Safety', 'Pharmacokinetics', 'Dose escalation', 'GSK3179106', 'Rearranged during Transfection', 'Irritable Bowel Syndrome', 'Adults']",COMPLETED,,2015-11-26,2016-03-18,"[{'measure': 'Number of subjects with adverse events (AE) and clinical observations as a measure of safety', 'description': 'An AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.', 'timeFrame': 'Up to 10 weeks in each cohort'}, {'measure': 'Assessment of physical examination findings as a measure of safety', 'description': 'Physical examination will include the assessment of the cardiovascular, respiratory, gastrointestinal and neurological systems. A brief physical examination will be conducted at follow-up visit which include, at a minimum assessments of the lungs, cardiovascular system, and abdomen (liver and spleen). Height and weight will also be measured and recorded (height will only be recorded at screening assessment).', 'timeFrame': 'Screening, Day-1 and at follow-up (up to 10 weeks) in each cohort'}, {'measure': 'Safety as assessed by 12-lead electrocardiogram (ECG)', 'description': 'Triplicate 12-lead ECGs will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT interval (QTc).', 'timeFrame': 'Up to 10 weeks in each cohort'}, {'measure': 'Safety as assessed by systolic and diastolic blood pressure measurements', 'description': 'Three readings of systolic and diastolic pressure will be taken at each time point and the average will be calculated electronically', 'timeFrame': 'Up to 10 weeks in each cohort'}, {'measure': 'Safety as assessed by temperature measurements', 'description': 'Temperature measurements will be taken at Screening, Day-1 and pre-dose in each treatment period. For all other vital sign time points if clinically indicated', 'timeFrame': 'Up to 10 weeks in each cohort'}, {'measure': 'Safety as assessed by pulse rate measurements', 'description': 'Three readings of systolic and diastolic pressure will be taken at each time point and the average will be calculated electronically', 'timeFrame': 'Up to 10 weeks in each cohort'}, {'measure': 'Composite of clinical laboratory assessments as a measure of safety includes hematology, clinical chemistry and urinalysis', 'description': 'Clinical safety laboratory assessments include hematology, clinical chemistry, urinalysis and additional parameters', 'timeFrame': 'Up to 10 weeks in each cohort'}, {'measure': 'Bristol Stool Form Scale', 'description': 'The Bristol Stool Form Scale describes 7 types of stool and will be used by the subject to monitor the changes in defecation pattern during the study', 'timeFrame': 'Up to Day 4 in each cohort'}]","[{'measure': 'Area under the plasma concentration-time curve (AUC) from zero to time t (AUC [0-t]) of GSK3179106 administered under fasting condition', 'description': 'PK parameters under fasting conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h postdose in each treatment period of cohort 1'}, {'measure': 'AUC from zero to infinity (AUC [0-infinity]) of GSK3179106 administered under fasting condition', 'description': 'PK parameters under fasting conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 1'}, {'measure': 'AUC from zero to 24 h (AUC [0-24 h]) of GSK3179106 administered under fasting condition', 'description': 'PK parameters under fasting conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 1'}, {'measure': 'Maximum observed plasma concentration (Cmax) of escalating single oral doses of GSK3179106 administered under fasting conditions', 'description': 'PK parameters under fasting conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 1'}, {'measure': 'Time to maximum observed plasma concentration (tmax) of GSK3179106 administered under fasting condition', 'description': 'PK parameters under fasting conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 1'}, {'measure': 'Apparent terminal phase half-life (t1/2) of GSK3179106 administered under fasting condition', 'description': 'PK parameters under fasting conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 1'}, {'measure': 'Clearance (CL/F) of GSK3179106 administered under fasting condition', 'description': 'PK parameters under fasting conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 1'}, {'measure': 'Volume of distribution (V/F) of GSK3179106 administered under fasting condition', 'description': 'PK parameters under fasting conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 1'}, {'measure': 'Absorption rate constant (Ka) of GSK3179106 administered under fasting condition', 'description': 'PK parameters under fasting conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 1'}, {'measure': 'Area under the plasma concentration-time curve (AUC) from zero to time t (AUC [0-t]) of GSK3179106 administered under fasting and fed condition', 'description': 'PK parameters under fasting and fed conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 2'}, {'measure': 'AUC from zero to infinity (AUC [0-infinity]) of GSK3179106 administered under fasting condition fasting and fed condition', 'description': 'PK parameters under fasting and fed conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 2'}, {'measure': 'AUC from zero to 24 h (AUC [0-24 h]) of GSK3179106 administered under fasting condition fasting and fed condition', 'description': 'PK parameters under fasting and fed conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 2'}, {'measure': 'Maximum observed plasma concentration (Cmax) of escalating single oral doses of GSK3179106 administered under fasting and fed condition', 'description': 'PK parameters under fasting and fed conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 2'}, {'measure': 'Time to maximum observed plasma concentration (tmax) of GSK3179106 administered under fasting and fed condition', 'description': 'PK parameters under fasting and fed conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 2'}, {'measure': 'Apparent terminal phase half-life (t1/2) of GSK3179106 administered under fasting and fed condition', 'description': 'PK parameters under fasting and fed conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 2'}, {'measure': 'Clearance (CL/F) of GSK3179106 administered under fasting and fed condition', 'description': 'PK parameters under fasting and fed conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 2'}, {'measure': 'Volume of distribution (V/F) of GSK3179106 administered under fasting and fed condition', 'description': 'PK parameters under fasting and fed conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 2'}, {'measure': 'Absorption rate constant (Ka) of GSK3179106 administered under fasting and fed condition', 'description': 'PK parameters under fasting and fed conditions', 'timeFrame': 'Day 1 Pre-dose and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, 24 h, 36 h, 48 h, 60 h and 72 h post-dose in each treatment period of cohort 2'}]",26,18 Years,55 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:18.427706,v2_robust,True,True,True,False,True,
NCT07130383,A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors,An Open-label Phase II Clinical Study of MHB036C for Injection Combined With MHB039A for Injection in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors,MHB036C for Injection,"['MHB039A for Injection', 'MHB036C for Injection']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Breast Cancer,"['Advanced Breast Cancer', 'Advanced Malignant Solid Tumor']",[],NOT_YET_RECRUITING,,2025-09,2031-08,"[{'measure': '(Dose-Expansion Stage): Objective tumor response (ORR) determined by investigators according to RECIST v1.1', 'description': 'Objective tumor response for target lesions will be assessed by imaging/measurement compared with the overall tumor burden at baseline (Day -28 to -1). ORR is evaluated by the number of participants with best overall response of CR and PR (Confirmed CR/PR assessment require at least 1 repeat).', 'timeFrame': 'Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years'}]","[{'measure': 'Duration of response (DOR) determined by investigators according to RECIST v1.1', 'description': 'DoR was defined as the period from the first occurrence of CR or PR to PD or death from any cause. If no PD or death after CR/PR, the cut-off date of progression-free survival (PFS) would be used \\[Confirmed CR/PR assessment require at least one repeat (≥4 weeks)\\].', 'timeFrame': 'Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years'}, {'measure': 'Disease control rate (DCR) determined by investigators according to RECIST v1.1', 'description': 'Objective tumor response for target lesions will be assessed by imaging/measurement compared with the overall tumor burden at baseline (Day -28 to -1). DCR was evaluated by the number of participants with best overall response of CR, PR and stable disease (SD) \\[Confirmed CR/PR assessment require at least one repeat (≥4 weeks); SD shall be assessed at least 5 weeks after the first dose\\].', 'timeFrame': 'Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years'}, {'measure': 'Progression-free survival (PFS) determined by investigators according to RECIST v1.1', 'description': 'Objective tumor response for target lesions will be assessed by imaging/measurement compared with the overall tumor burden at baseline (Day -28 to -1). PFS was defined as the time from random assignment (dose expansion stage) or first dose (dose escalation stage) to PD or death from any cause.', 'timeFrame': 'Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years'}, {'measure': 'Overall survival (OS)', 'description': 'OS was defined as the time from random assignment or first dose to death from any cause.', 'timeFrame': 'Baseline up until death up to approximately 5 years'}, {'measure': 'Incidence and severity of adverse events (AEs)', 'description': ""AE assessed by investigator exclusively related to subject's underlying disease or medical condition \\[graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0\\]."", 'timeFrame': 'Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years.'}, {'measure': 'Pharmacokinetic (PK) parameters of total antibody, ADC, and free toxin at various time points', 'description': 'The PK parameters at different time points include:Area Under the Concentration-Time Curve (AUC).', 'timeFrame': 'From pre-dose to 22 days after the first dose'}, {'measure': 'Pharmacokinetic (PK) parameters of total antibody, ADC, and free toxin at various time points', 'description': 'The PK parameters at different time points include:Maximum Plasma Concentration (Cmax).', 'timeFrame': 'From pre-dose to 22 days after the first dose'}]",8,18 Years,75 Years,ALL,False,Minghui Pharmaceutical (Hangzhou) Ltd,INDUSTRY,0,210.0,ESTIMATED,2025-09-01T16:18:18.427714,v2_robust,True,True,False,False,True,
NCT05000983,A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries,"A Between Patient, Pilot Randomized Controlled Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries",PluroGel,"['PluroGel', 'Standard dressing']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Burns,['Burns'],"['burn', 'wound', 'debridement']",RECRUITING,,2021-10-20,2027-12-31,"[{'measure': 'Primary outcome', 'description': 'Days to over 80% area of burn injury healed', 'timeFrame': '1-14 days'}]","[{'measure': 'Patient and caregiver satisfaction and perception of pain', 'description': 'Measure satisfaction and perception of pain using a survey', 'timeFrame': 'At each dressing change'}, {'measure': 'Proportion requiring surgery', 'description': 'Proportion of burn injuries that require skin grafting in each group', 'timeFrame': '1-14 days'}, {'measure': 'Relative surface area skin grafted', 'description': 'Calculate area of burn needing grafting and area of burn that does not need graft', 'timeFrame': '1-14 days'}]",4,18 Years,,ALL,False,University of Manitoba,OTHER,1,25.0,ESTIMATED,2025-09-01T16:18:18.427763,v2_robust,True,True,False,False,False,
NCT03271983,Pharmacokinetics of Metronidazole Dermal Products,Evaluation of the Bioavailability of Metronidazole Dermal Products,Metronidazole gel 1,"['Metronidazole cream', 'Metronidazole gel 1', 'metronidazole', 'Metronidazole gel 2']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Bioequivalence,['Bioequivalence'],[],COMPLETED,,2019-04-09,2019-11-03,"[{'measure': 'PK Parameters', 'description': 'Area under the concentration-time curve from 0 to 25 h', 'timeFrame': '3 study sessions/subject; each session was 25 h; blood samples obtained at the following time points: -60 min, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 23, 24, 25 h; at least one week washout period between each study session'}]",[],1,18 Years,45 Years,ALL,True,"University of Maryland, Baltimore",OTHER,1,7.0,ACTUAL,2025-09-01T16:18:18.427829,v2_robust,True,True,True,False,False,
NCT04276883,Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder,"A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine Efficacy and Safety of BXCL501 In Agitation Associated With Bipolar Disorder",Sublingual film containing Dexmedetomidine (BXCL501),"['Placebo Film', 'Dexmedetomidine', 'Sublingual film containing Dexmedetomidine (BXCL501)', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Agitation Associated With Bipolar Disorder,"['Agitation Associated With Bipolar Disorder', 'Agitation,Psychomotor', 'Bipolar Disorder']",[],COMPLETED,,2020-02-24,2020-05-21,"[{'measure': 'Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score', 'description': 'The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).', 'timeFrame': 'Baseline and 120 minutes'}]","[{'measure': 'Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score Over Time', 'description': 'Effect on agitation onset was measured by change from baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) total score. The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items -poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).', 'timeFrame': 'Baseline and 20, 30, 45, 60, 90, 120 minutes post-dose'}]",2,18 Years,75 Years,ALL,False,BioXcel Therapeutics Inc,INDUSTRY,1,380.0,ACTUAL,2025-09-01T16:18:18.427872,v2_robust,True,True,True,False,False,
NCT04994483,Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease",Simufilam,"['Placebo', 'PTI-125', 'Simufilam']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Alzheimer Disease,['Alzheimer Disease'],[],COMPLETED,,2021-11-03,2024-10-02,"[{'measure': ""Change From Baseline in the 12-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12)"", 'description': 'The change from baseline to Week 52 in the ADAS-Cog12, a psychometrician-administered battery comprised of several cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Scores range from 0 (best) to 80 (worst).', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}, {'measure': ""Change From Baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)"", 'description': 'The change from baseline to Week 52 in the ADCS-ADL, a 23-item study partner questionnaire that covers both basic activities of daily living (ADL) and more complex ADL or instrumental ADL. Scores range from 0 to 78, with a lower score indicating greater severity of functional loss.', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}]","[{'measure': ""Change From Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS)"", 'description': 'The change from baseline to Week 52 in the iADRS, where scores range from 0 to 146 with lower scores indicating worse performance.', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}, {'measure': 'Change From Baseline in the Neuropsychiatric Inventory (NPI)', 'description': 'The change from baseline to Week 52 in the NPI, a 12-item study partner interview, which records the frequency and severity of common neuropsychiatric symptoms in dementia, as well as the level of study partner distress due to each of the neuropsychiatric problems. Scores range from 0 to 144, with higher scores indicating more frequent and severe symptoms, and greater levels of partner distress.', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}, {'measure': 'Change From Baseline in the Mini-Mental State Exam (MMSE)', 'description': 'The change from baseline to Week 52 in the MMSE, a set of standardized questions covering several target areas: orientation, registration, attention and calculation, short-term verbal recall, naming, repetition, 3-step command, reading, writing, and visuospatial cognitive assessment. Scores range from 0 to 30, lower scores indicate more severe impairment.', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}, {'measure': 'Change From Baseline in the Clinical Dementia Rating Sum of Boxes (CDR-SB)', 'description': 'The change from baseline to Week 52 in the CDR-SB, which characterizes 6 domains of cognitive and functional performance applicable to AD and related dementias: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Scores for each domain have a minimum of 0 and a maximum of 3, and the 6 domain scores are summed to give the CDR-SB, which has a minimum score of 0 and a maximum score of 18. Higher scores indicate more severe impairment.', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}, {'measure': 'Change From Baseline in the Zarit Burden Interview (ZBI)', 'description': 'The change from baseline to Week 52 in the ZBI, a 22-item study partner questionnaire designed to assess the stress or burden experienced by caregivers of people with dementia. Scores range from 0 to 88, with a higher score indicating greater stress or burden.', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}]",7,50 Years,87 Years,ALL,False,"Cassava Sciences, Inc.",INDUSTRY,1,804.0,ACTUAL,2025-09-01T16:18:18.427888,v2_robust,True,True,True,False,False,
NCT04777383,The Effects of Iontophoresed Vasoactive Drugs on Cutaneus Blood Flow,A Non-randomized Experimental Study of Optically Registered Pharmacodynamic Responses During Iontophoresis of Vasoactive Substances to the Skin of Healthy Volunteers,Acetylcholine,"['Phenylephrine, 10 mg/ml, Unimedic', 'Atropine', 'Miochol-E, 10mg/ml, Bausch and Lomb', 'Neostigmine', 'Sterile water', 'Norepinephrine, 1 mg/ml, Pfizer', 'Acetylcholine', 'Sterile water, 100 ml, Braun', 'Atropine, 10 mg/ml, Bausch & Lomb', 'Neostigmine, 2.5 mg/ml, Unimedic Pharma', 'Phenylephrine', 'Norepinephrine']",12,INTERVENTIONAL,['NA'],,,Cardiovascular Diseases,"['Cardiovascular Diseases', 'Vascular Diseases']","['iontophoresis', 'pharmacology', 'tissue viability imaging', 'multi-exposure laser speckle contrast imaging']",UNKNOWN,,2019-04-01,2021-12-31,"[{'measure': 'Locally induced changes in red blood cell concentration and movement due to iontophoresis of vasoactive substances.', 'description': 'Optically derived arbitrary values that correlate to the concentration and movement of red blood cells in the vessels.', 'timeFrame': 'Measured prior the onset of iontophoresis (baseline), then continuously for the duration of the iontophoretic pulse (10 minutes) and for the 30 minute wash-out period following each iontophoretic pulse.'}]",[],1,18 Years,45 Years,ALL,True,"University Hospital, Linkoeping",OTHER,0,90.0,ESTIMATED,2025-09-01T16:18:18.428091,v2_robust,True,True,False,False,False,
NCT02153983,Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome,Pilot Study of the Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome,Colchicine 0.6Mg Cap,"['RCT Placebo', 'RCT Colchicine', 'Colchicine 0.6Mg Tab', 'Placebo capsules given', 'Colchicine 0.6Mg Cap', 'Open-Label Colchicine 0.6 mg given twice daily']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Obesity,"['Obesity', 'Metabolic Disease']","['Obesity', 'Colchicine', 'Inflammation', 'Metabolic Syndrome', 'Dyslipidemia']",COMPLETED,,2014-05-31,2018-08-15,"[{'measure': 'Change in Insulin Sensitivity From FSIVGTT', 'description': ""Change (3 month minus minus baseline) in insulin sensitivity value, calculated from frequently-sampled intravenous glucose tolerance tests by Bergman's Minimal Model using intent-to-treat. Higher values represent a better outcome. There are no data from the evaluation-only participants, since they were not followed longitudinally."", 'timeFrame': 'Baseline to 3 months'}]","[{'measure': 'Change in HOMA-IR Index', 'description': 'Change (3 month minus minus baseline) in calculated homeostasis model of insulin sensitivity, calculated from derived from fasting glucose and insulin values = fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5) using intent-to-treat. Higher values represent a worse outcome. There are no data from the evaluation-only participants, since they were not followed longitudinally.', 'timeFrame': 'Baseline to 3 months'}, {'measure': 'Changes in C-reactive Protein', 'description': 'Change (3 month minus minus baseline) in High-Sensitivity C-reactive protein concentrations using intent-to-treat. Higher values represent a worse outcome. There are no data from the evaluation-only participants, since they were not followed longitudinally.', 'timeFrame': 'Baseline to 3 months'}]",3,18 Years,100 Years,ALL,True,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,2,77.0,ACTUAL,2025-09-01T16:18:18.428104,v2_robust,True,True,True,False,False,
NCT02534883,Cervical Ripening in Postmenopausal Women,"Cervical Ripening in Postmenopausal Women: A Randomized, Double Blind, Placebo Controlled Trial",Misoprostol,"['non active drug', 'Misoprostol', 'Placebo', 'Cytotec']",4,INTERVENTIONAL,['NA'],,,Stenosis of Cervix,['Stenosis of Cervix'],[],TERMINATED,not able to meet enrollment,2015-08,2016-12,"[{'measure': 'Efficacy (Cervical Ripening)', 'description': 'To evaluate the efficacy of two doses of 200ug of misoprostol (for a total of 400ug), administered vaginally, on cervical ripening before diagnostic and operative hysteroscopic procedures in postmenopausal women (amenorrhea greater than 1 year). Efficacy is represented by time to dilation.', 'timeFrame': 'At time of surgery/cervical dilation'}]","[{'measure': 'Number of Recorded Side Effects.', 'description': 'Secondary aim: to evaluate if cervical ripening with misoprostol reduces side effects', 'timeFrame': 'At time of surgery/cervical dilation'}, {'measure': 'Dilation Time in Minutes', 'description': 'Time from beginning of cervical dilation to completion of cervical dilation.', 'timeFrame': 'At time of procedure.'}, {'measure': 'Maximum Dilator Size', 'description': 'The largest cervical dilator that could be passed through the internal cervical os.', 'timeFrame': 'At time of procedure.'}, {'measure': 'Number of Complications', 'description': 'Count of complications at time of surgery.', 'timeFrame': 'At time of procedure.'}, {'measure': 'Resistance Score', 'description': 'Ease of Dilation Per Surgeon on a numeric scale of 1(easier than normal) to 5 (more difficult than normal) with 3 being ""normal.""', 'timeFrame': 'At time of procedure.'}]",6,45 Years,85 Years,FEMALE,False,St. Louis University,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:18.428122,v2_robust,True,True,False,True,False,not able to meet enrollment
NCT04006483,Meta-analysis of Stannous Fluoride and the Effects on Dental Plaque,A Review of Meta-Analyses on Bioavailable Stannous Fluoride Dentifrices: Effects on Dental Plaque,Stannous fluoride dentifrice,"['Stannous fluoride dentifrice', 'Positive control dentifrice', 'Negative control dentifrice']",3,OBSERVATIONAL,[],,,Dental Plaque,['Dental Plaque'],[],COMPLETED,,2018-01-08,2018-11-30,"[{'measure': 'Dental Plaque Scores', 'description': 'Change from baseline as measured by mean plaque score reduction from baseline (via Quigley-Hein, Turesky Modification Index or Rustogi Modification of the Navy Plaque index).', 'timeFrame': 'Up to 12 weeks'}]",[],1,18 Years,,ALL,,Procter and Gamble,INDUSTRY,0,2359.0,ACTUAL,2025-09-01T16:18:18.428164,v2_robust,False,True,True,False,False,
NCT01591083,The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers,The Studies of the Pathophysiologic Mechanisms of Poor Ulcer Healing & Clinical Improvement to the High Ulcer Rebleeding Rate for Patients With Comorbid Illnesses,"esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)","['esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)', 'Nexium']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Peptic Ulcer Bleeding,['Peptic Ulcer Bleeding'],"['Peptic ulcer rebleeding, double dose of esomeprazole']",COMPLETED,,2011-08,2014-07,"[{'measure': 'recurrent bleeding', 'timeFrame': 'within 28 days after the first bleeding event'}]","[{'measure': 'the length of hospitalization', 'timeFrame': 'within 28 days after the first bleeidng event'}, {'measure': 'the amount of blood transfusion', 'timeFrame': 'within 28 days after the first bleeding event'}, {'measure': 'major events such as surgery or transarterial embolization', 'timeFrame': 'within 28 days after the first bleeding event'}, {'measure': 'the fading rate of major stigmata of recent hemorrhage', 'description': 'At the primary gastroscopy, the adherent clot is vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.\n\nSecond-look endoscopy is scheduled 48-72 hours after successful primary endoscopic hemostasis and intravenous high-dose proton pump inhibitor infusion. For each patient with either suspected or active recurrent bleeding, emergent endoscopy is conducted earlier before the schedule to confirm and treat peptic ulcer recurrent bleeding.\n\nMultiple logistic regression analysis is applied to assess the independent risk factors related to residual major stigmata or early recurrent bleeding of peptic ulcers.', 'timeFrame': 'within 3 days after the first bleeding event'}, {'measure': 'mortality', 'timeFrame': 'within 28 days and 120 days after the first bleeding event'}]",6,18 Years,95 Years,ALL,False,National Cheng-Kung University Hospital,OTHER,1,474.0,ACTUAL,2025-09-01T16:18:18.428179,v2_robust,True,True,True,False,False,
NCT01415583,Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy,Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy,Dexamethasone,"['Dexamethasone', 'Decadron']",2,INTERVENTIONAL,['NA'],,,Post-operative Hemorrhage,['Post-operative Hemorrhage'],[],COMPLETED,,2010-07,2011-11,"[{'measure': 'Number of Participants With Post-tonsillectomy Bleeding', 'timeFrame': '2 weeks after surgery'}]",[],1,3 Years,18 Years,ALL,False,Massachusetts Eye and Ear Infirmary,OTHER,0,314.0,ACTUAL,2025-09-01T16:18:18.428213,v2_robust,True,True,True,False,False,
NCT01829841,A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer,"A Randomized, Positive-controlled, Double-blind, Multicenter, Phase II Study of Famitinib as First/Second Line Treatment in Patients With Advanced Metastatic Renal Cell Cancer",Famitinib,"['Famitinib', 'Sunitinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Renal Cell Cancer,"['Renal Cell Cancer', 'Metastatic Renal Cell Cancer']","['MRCC', 'Metastatic Renal Cell Cancer', 'Famitinib', 'Sunitinib']",COMPLETED,,2011-05,2016-05,"[{'measure': 'Objective Response Rate', 'timeFrame': '18 weeks'}]","[{'measure': 'Progress free survival (PFS)', 'timeFrame': '3 years'}, {'measure': 'Disease Control Rate (DCR)', 'timeFrame': '3 years'}, {'measure': 'Overall Survival (OS)', 'timeFrame': '3 years'}, {'measure': 'Quality of Life', 'timeFrame': '42-day cycle visit until disease progress'}, {'measure': 'Number of Participants with Adverse Events as a Measure of Safety', 'timeFrame': '3 years'}]",6,18 Years,75 Years,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,1,150.0,ACTUAL,2025-09-01T16:18:18.428220,v2_robust,True,True,True,False,True,
NCT02183441,Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers,"Relative Bioavailability of a Single Oral Dose of BI 1356 (5 mg) After Co-administration With Multiple Oral Doses of Ritonavir (200 mg Bid for 3 Days) Compared to the Bioavailability of a Single Oral Dose of BI 1356 (5 mg) Alone in Healthy Male Volunteers (an Open-label, Randomized, Two-way Crossover, Clinical Phase I Study)",BI 1356,"['Norvir®', 'Ritonavir', 'BI 1356']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2008-04,,"[{'measure': 'AUC0-24 (Area under the concentration-time curve of BI 1356 in plasma over the time interval from 0 to 24 hours)', 'timeFrame': 'up to 24 hours after start of treatment'}, {'measure': 'Cmax (Maximum measured concentration of BI 1356 in plasma)', 'timeFrame': 'up to 96 hours after start of treatment'}]","[{'measure': 'AUC (Area under the concentration time curve of the analytes in plasma at different time points)', 'timeFrame': 'up to 96 hours after start of treatment'}, {'measure': '%AUCtz-∞ (Percentage of the extrapolated part of the area under the concentration time curve of the analytes in plasma from 0 to infinity)', 'timeFrame': 'up to 96 hours after start of treatment'}, {'measure': 'tmax (Time from dosing to the maximum concentration of the analytes in plasma)', 'timeFrame': 'up to 96 hours after start of treatment'}, {'measure': 't1/2 (Terminal half-life of the analytes in plasma)', 'timeFrame': 'up to 96 hours after start of treatment'}, {'measure': 'λz (Terminal rate constant of the analytes in plasma)', 'timeFrame': 'up to 96 hours after start of treatment'}, {'measure': 'MRTpo (Mean residence time in the body after po administration of the analytes in plasma)', 'timeFrame': 'up to 96 hours after start of treatment'}, {'measure': 'CL/F (Apparent clearance of BI 1356 in plasma after extravascular administration )', 'timeFrame': 'up to 96 hours after start of treatment'}, {'measure': 'Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) of BI 1356', 'timeFrame': 'up to 96 hours after start of treatment'}, {'measure': 'Aet1-t2 (Amount of the analytes that is eliminated in urine from the time interval t1 to t2)', 'timeFrame': 'up to 24 hours after start of treatment'}, {'measure': 'fet1-t2 (Fraction of BI 1356 excreted unchanged in urine from time point t1 to t2)', 'timeFrame': 'up to 24 hours after start of treatment'}, {'measure': 'CLR,t1-t2 (Renal clearance of the analytes in plasma)', 'timeFrame': 'up to 24 hours after start of treatment'}, {'measure': 'Cmax (Maximum measured concentration of CD 1750 in Plasma)', 'timeFrame': 'up to 96 hours after start of treatment'}, {'measure': 'Number of patients with adverse events', 'timeFrame': 'up to 53 days'}]",15,18 Years,50 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:18.428270,v2_robust,True,True,True,False,True,
NCT00408941,EEG and Auditory Evoked Potentials During Local Anesthesia,EEG and Auditory Evoked Potentials During Local Anesthesia,Propofol,"['Prilocaine', 'Propofol']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Healthy,['Healthy'],"['EEG', 'AEP', 'Artefacts', 'Propofol', 'Local Anaesthesia']",UNKNOWN,,2006-12,2006-12,[{'measure': 'differences of AEP during sedation with and without local anaesthesia'}],"[{'measure': 'fraction of high frequency artefacts'}, {'measure': 'time to LOC'}, {'measure': 'differences AEP awake with and without local anaesthesia'}]",4,18 Years,35 Years,MALE,True,Technical University of Munich,OTHER,0,15.0,,2025-09-01T16:18:18.428313,v2_robust,True,True,False,False,False,
NCT06138041,Intravenous Lidocaine Infusion Reduce Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy,"Effect of Intravenous Lidocaine Infusion on Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy: a Double-center, Double-blind, Randomized Controlled Trial",intravenous lidocaine infusion,"['Saline', 'intravenous lidocaine infusion']",2,INTERVENTIONAL,['NA'],,,Postoperative Pneumonia,"['Postoperative Pneumonia', 'Postoperative Pulmonary Atelectasis', 'Postoperative Pulmonary Edema']",[],NOT_YET_RECRUITING,,2025-02-01,2025-08-30,"[{'measure': 'Incidence of PPCs', 'description': 'Pulmonary complications is defined as one or more of the following complications: respiratory infection; respiratory failure; pneumothorax;atelectasis; pleural effusion; bronchospasm; aspiration pneumonitis; anastomotic fistula', 'timeFrame': '1, 2, 3, 4, 5, 6, 7 days after surgery'}]","[{'measure': 'respiratory infection', 'timeFrame': '1, 2, 3, 4, 5, 6, 7 days after surgery'}, {'measure': 'respiratory failure', 'timeFrame': '1, 2, 3, 4, 5, 6, 7 days after surgery'}, {'measure': 'pneumothorax;atelectasis', 'timeFrame': '1, 2, 3, 4, 5, 6, 7 days after surgery'}, {'measure': 'pleural effusion', 'timeFrame': '1, 2, 3, 4, 5, 6, 7 days after surgery'}, {'measure': 'bronchospasm', 'timeFrame': '1, 2, 3, 4, 5, 6, 7 days after surgery'}, {'measure': 'aspiration pneumonitis', 'timeFrame': '1, 2, 3, 4, 5, 6, 7 days after surgery'}, {'measure': 'anastomotic fistula', 'timeFrame': '1, 2, 3, 4, 5, 6, 7 days after surgery'}, {'measure': 'moderate to severe pain within 24 and 48 hours at rest and when coughing', 'timeFrame': '24 and 48 hours after surgery'}, {'measure': 'moderate to severe pain within 24 and 48 hours at coughing', 'timeFrame': '24 and 48 hours after surgery'}, {'measure': 'additional rescue analgesics use', 'timeFrame': '24 and 48 hours after surgery'}]",11,18 Years,85 Years,ALL,False,Sichuan Cancer Hospital and Research Institute,OTHER,0,770.0,ESTIMATED,2025-09-01T16:18:18.428367,v2_robust,True,True,False,False,False,
NCT05662241,A Phase 3 Study of Obexelimab in Patients with IgG4-Related Disease,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with IgG4-Related Disease (INDIGO)",Obexelimab,['Obexelimab'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,IgG4 Related Disease,['IgG4 Related Disease'],"['IgG4', 'IgG4-RD']",ACTIVE_NOT_RECRUITING,,2022-09-30,2027-12-31,"[{'measure': 'Primary outcome measure', 'description': 'Time to first IgG4-RD flare, defined as the reappearance of previous signs/symptoms or appearance of new signs/symptoms of IgG4-RD that requires initiation of rescue therapy in the opinion of the investigator and the Adjudication Committee (AC), from randomization to Week 52.', 'timeFrame': 'Randomization to Week 52'}]",[],1,18 Years,,ALL,False,"Zenas BioPharma (USA), LLC",INDUSTRY,0,194.0,ACTUAL,2025-09-01T16:18:18.428386,v2_robust,True,True,False,False,False,
NCT01118741,Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA),A Multi-institutional Translational Clinical Trial of Disulfiram in Men With Recurrent Prostate Cancer as Evident by a Rising PSA,Disulfiram,"['Antabuse', 'Disulfiram']",2,INTERVENTIONAL,['NA'],,,Prostate Cancer,['Prostate Cancer'],"['Rising PSA', 'Recurrent Non Metastatic Prostate Cancer']",COMPLETED,,2010-05,2012-06,"[{'measure': 'Proportion of Subjects With a Demethylation Response at Each Dose Level', 'description': 'For both of the doses explored (i.e. disulfiram 250 mg PO daily and 500 mg PO daily) the proportion of subjects with a demethylation response was computed. A demethylation response was defined as a \\>=10% decrease from baseline in global 5-methyl cytosine content as assessed from peripheral blood mononuclear cells.', 'timeFrame': '24 months'}]","[{'measure': 'Clinical Response', 'description': 'To assess the clinical response measured by prostate specific antigen (PSA) progression at 6 months after treatment with the defined dose of disulfiram in prostate cancer (PCa) patients with evidence of biochemical relapse after local therapy. Reported as number of participants with PSA progression by 6 months.\n\nCriteria used to assess: A rise in PSA noted at 6 months, greater than 50% over PSA value at baseline and \\> 2 ng/ml, above the nadir. The rise was confirmed by a second PSA value obtained at least 1 week from that reference value.', 'timeFrame': 'Up to 6 months'}]",2,18 Years,,MALE,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,0,19.0,ACTUAL,2025-09-01T16:18:18.428395,v2_robust,True,True,True,False,False,
NCT00193141,Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer,"Paclitaxel, Carboplatin, Infusional 5-Fluorouracil, and Radiation Therapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer",Paclitaxel,"['5-Fluorouracil', 'Paclitaxel', 'Carboplatin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Esophagus Cancer,['Esophagus Cancer'],[],COMPLETED,,1999-10,2007-07,"[{'measure': 'To compare the efficacy of full dose radiation therapy versus preoperative radiation therapy plus surgical resection, when used in combination with neo-adjuvant chemotherapy, in the treatment of localized esophageal cancer'}]","[{'measure': 'To compare the toxicity of these two treatment approaches in localized esophageal cancer'}, {'measure': 'To evaluate the utility of clinical restaging in guiding local therapy (surgical resection vs definitive radiation therapy) following neo-adjuvant treatment'}, {'measure': 'To evaluate the toxicity of additional chemotherapy and radiation therapy following completion of neo-adjuvant treatment.'}]",4,18 Years,,ALL,False,"SCRI Development Innovations, LLC",OTHER,1,200.0,,2025-09-01T16:18:18.428540,v2_robust,True,True,True,False,False,
NCT04988841,Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma,Prospective randomIzed Clinical Trial Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma Treated With CTLA-4 and PD1 Inhibitors,MaaT013,"['Ipilimumab', 'Nivolumab', 'Placebo of Maat013', 'Normacol', 'fecal microbiotherapy placebo', 'MaaT013', 'Osmotic laxative solution', 'hypertonic enema solution', 'MoviPrep', 'fecal microbiotherapy']",10,INTERVENTIONAL,['PHASE2'],PHASE2,,Melanoma,['Melanoma'],"['Fecal microbiome transfer', 'Microbiome restoration biotherapeutic', 'Full-ecosystem intestinal microbiome', 'Response to anti- CTLA-4 and anti PD1', 'the tumor microenvironment', 'Peripheral blood T cell subpopulations', 'Efficacy and safety of MaaT013']",COMPLETED,,2022-01-20,2025-04-22,"[{'measure': 'To assess whether the safety of a 23-week treatment with MaaT013, combined with ipilimumab+nivolumab, is different from that of ipilimumab+nivolumab+placebo in patients with melanoma naïve to Ipilimumab and anti-PD1', 'description': 'Safety will be measured by the occurrence of treatment-related adverse events of Grade 3, grade 4 and grade 5, as graded by the CTCAE v 5.0, during the 27 weeks of the trial', 'timeFrame': 'During the 27 weeks of the trial.'}]","[{'measure': 'To assess whether a 23-week treatment with MaaT013, combined with Ipilimumab and Nivolumab, is more efficient than Ipilimumab and Nivolumab + placebo in patients with melanoma naïve to Ipilimumab and anti PD1.', 'description': 'Efficacy will be assessed by the best overall response rate, between baseline and week 27, without confirmation of partial or complete response rated by Response Evaluation Criteria in Solid Tumors (RECIST v1.1.; 19) in the experimental and control arms.', 'timeFrame': 'During the 27 weeks of the trial.'}, {'measure': 'To assess changes in the tumor microenvironment in patients who have received MaaT013 and placebo ;', 'description': 'Changes in the tumor micro environment (TME) pre and post MaaT013 or placebo', 'timeFrame': 'During the 27 weeks of the trial.'}, {'measure': 'Changes in plasma levels of proteins or metabolites that play a role in immune activity against cancer and/or are associated with gut microbiome composition, pre and post MaaT013 or placebo', 'description': 'Changes in plasma levels of proteins or metabolites that play a role in immune activity against cancer and/or are associated with gut microbiome composition, pre and post MaaT013 or placebo : IL-6, IL-8, MCP1, IL-1β, TNF α, sCD25, sCTLA-4, sPD-L1, short chain fatty acids (SCFA), all in micromol/L', 'timeFrame': 'During the 27 weeks of the trial.'}, {'measure': 'Changes in signatures of peripheral blood T or immune cells cell. T cell or other immune cells will be sorted and transcriptomic analysis will be performed to determine changes induce by MaaT013 or placebo treatment.', 'description': 'Changes in peripheral blood immune cell subpopulations pre and post MaaT013 or placebo', 'timeFrame': 'During the 27 weeks of the trial.'}, {'measure': 'To assess the evolution of gut microbial members and metabolites;', 'description': 'Changes in gut microbiome and metabolites pre and post MaaT013 or placebo and in patients who met the inclusion criteria, received Ipilimumab+Nivolumab, agreed to have stool microbiome analyses at baseline and week 9, but did not receive MaaT013 or placebo.', 'timeFrame': 'During the baseline and 9 weeks of the trial.'}, {'measure': 'To assess, on an open basis, the efficacy and safety of MaaT013 combined with Nivolumab in a subset of patients who failed to respond to placebo', 'description': 'Best response rate, either complete or partial, rated by RECIST and iRECIST in patients with disease progression who received placebo and subsequently, MaaT013, in an open-label basis', 'timeFrame': 'During the 51 weeks of the trial.'}, {'measure': 'To assess progression-free survival at week 15, 27, 51', 'description': 'Progression-free survival rated by RECIST and iRECIST at week 15, 27 and 51', 'timeFrame': 'During the 15, 27 and 51 weeks of the trial.'}, {'measure': 'To assess response (either partial or complete), stable disease and progression at week 15, 27, 51', 'timeFrame': 'During the 15, 27 and 51 weeks of the trial.'}, {'measure': 'To assess overall survival at week 15, 27, 51.', 'description': 'Time point assessment of response (either partial or complete), stable disease and progression at week 15, 27 and 51', 'timeFrame': 'During the 15, 27 and 51 weeks of the trial.'}, {'measure': 'To assess best overall response rate, either complete or partial, with or without confirmation of response, rated by iRECIST v1.1 and PET scan at weeks 15, 27 and 51, using EORTC criteria', 'description': 'Best overall response rate, either complete or partial, with or without confirmation of response, rated by iRECIST v1.1. (20) and PET scan at weeks 15, 27 and 51, using EORTC criteria', 'timeFrame': 'During the 15, 27 and 51 weeks of the trial.'}, {'measure': 'Best overall response rate, with confirmation of response, rated by RECIST (19)', 'description': 'Best overall response rate, without confirmation of response between baseline and week 27, rated by RECIST (19)', 'timeFrame': 'During the 27 weeks of the trial.'}, {'measure': 'To assess disease control rate (complete or partial response or stable disease)', 'description': 'Disease control rate (complete or partial response or stable disease) rated by RECIST and iRECIST', 'timeFrame': 'During the 15, 27 and 51 weeks of the trial.'}, {'measure': 'To assess pseudo progression rate', 'description': 'Pseudo progression rate evaluated by iRECIST', 'timeFrame': 'During the 15, 27 and 51 weeks of the trial.'}, {'measure': 'The description of favorable gut microbiome will be based upon analyses performed in patients of the placebo arm,', 'description': 'This is why patients who met the inclusion criteria, received Ipilimumab+Nivolumab, who consented to have gut microbiome analyses at baseline and week 9, but were not included in the randomized trial, will be followed until week 27.', 'timeFrame': 'During the 27 weeks of the trial.'}]",15,18 Years,80 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,70.0,ACTUAL,2025-09-01T16:18:18.428554,v2_robust,True,True,True,False,True,
NCT00930241,Twice Daily Versus Once Daily Administration of the Tacrolimus in Lung Transplantation,Prospective Randomized Trial to Compare a Twice Daily to a Once Daily Administration of the Tacrolimus in Lung Transplanted Patients,Advagraf®,"['Advagraf®', 'Prograf®']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Lung Transplantation,['Lung Transplantation'],"['Lung Transplantation', 'Tacrolimus', 'Deterioration of graft function']",TERMINATED,"logistic reasons (insufficient funding, technical problems with MEMS)",2009-07,2012-07,"[{'measure': 'Improvement of adherence as measured by Tacrolimus trough level below the target level and dispensing of less than 50% of the prescribed doses in the last three days measured electronically before this subtherapeutic drug monitoring', 'timeFrame': '6 months'}]","[{'measure': 'Deterioration of graft function (FEV1) before and at month 12 after conversion', 'timeFrame': '6 months'}, {'measure': 'Number of drug holidays (intake of less than 50% of prescribed doses in 24 hours) measured electronically', 'timeFrame': '6 months'}]",3,18 Years,70 Years,ALL,False,Hannover Medical School,OTHER,0,25.0,ACTUAL,2025-09-01T16:18:18.428573,v2_robust,True,True,False,True,False,"logistic reasons (insufficient funding, technical problems with MEMS)"
NCT06414941,The Effect of Dexmedetomidine and Esketamine Combined Infusion Quality of Sleep Undergoing Modified Radical Mastectomy,Dexmedetomidine Combined With Esketamine Effects the Quality of Sleep,Dexmedetomidine administration,"['Dexmedetomidine plus low-dose esketamine administration', 'Dexmedetomidine plus high-dose esketamine administration', 'Dexmedetomidine administration']",3,INTERVENTIONAL,['NA'],,,Dexmedetomidine Plus Esketamine Affect Postoperative Sleep Quality,['Dexmedetomidine Plus Esketamine Affect Postoperative Sleep Quality'],"['Esketamine', 'Sleep quality', 'Dexmedetomidine']",RECRUITING,,2024-05-15,2024-10-20,"[{'measure': 'Pittsburgh sleep quality index (PSQI)', 'description': 'Our primary outcome was Pittsburgh sleep quality index (PSQI) at the day after surgery', 'timeFrame': 'the day after surgery'}]","[{'measure': 'Pittsburgh sleep quality index (PSQI)', 'description': 'Our primary outcome was Pittsburgh sleep quality index (PSQI) on 1 day after surgery', 'timeFrame': '1 day after surgery'}, {'measure': 'pain visual analogue scale scores', 'description': 'Our primary outcome was pain visual analogue scale scores', 'timeFrame': 'The first 48 hours after operation'}]",3,25 Years,65 Years,FEMALE,True,Anqing Municipal Hospital,OTHER,0,105.0,ESTIMATED,2025-09-01T16:18:18.428589,v2_robust,True,True,False,False,False,
NCT01536041,A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients,"A Double-blind, Placebo-controlled, Four-way Crossover Study to Compare the Safety and Efficacy of ONO-6950 20 mg and 200 mg QD Versus Placebo and Montelukast (Singulair) in Asthmatic Patients Who Experience Exercise-induced Bronchoconstriction",ONO-6950,"['ONO-6950', 'Montelukast', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Asthma,['Asthma'],"['asthma', 'Adult']",COMPLETED,,2012-03,,"[{'measure': 'Inhibition of maximum fall in Forced Expiratory Volume in One Second (FEV1) after exercise', 'timeFrame': '60 minutes following the exercise challenge'}]","[{'measure': 'AUC (0-30 min)', 'description': 'area under the concentration time curve integrating fall in FEV1 following exercise over the 30 minute interval immediately following exercise', 'timeFrame': '30 minutes following the exercise challenge'}, {'measure': 'AUC (0-60 min)', 'description': 'area under the concentration time curve integrating fall in FEV1 following exercise over the 60 minute interval immediately following exercise', 'timeFrame': '60 minutes following the exercise challenge'}, {'measure': 'Time to recovery of FEV1 to within 5% of the pre-exercise baseline', 'timeFrame': '90 minutes following the exercise challenge'}, {'measure': 'Proportion of patients using a short acting beta agonist (rescue medication)', 'timeFrame': '90 minutes following the exercise challenge'}, {'measure': 'Ratio of responder/non-responder in FEV1', 'timeFrame': '60 minutes following the exercise challenge'}]",6,18 Years,60 Years,ALL,False,Ono Pharma USA Inc,INDUSTRY,1,59.0,ACTUAL,2025-09-01T16:18:18.428601,v2_robust,True,True,True,False,False,
NCT06658054,Erector Spinae Plan Block (ESPB) with Dexmedetomidine and Dexamethasone in Lumbar Spine Fusion,Analgesic Efficacy of Erector Spinae Plane Block with Dexmedetomidine and Dexamethasone As Adjuvants in Single to Three-Level Lumbar Spine Fusion,Adjuvant analgesia,"['Adjuvant analgesia', 'Control (Standard treatment)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Lumbar Degenerative Disease,['Lumbar Degenerative Disease'],"['analgesia', 'ESPB', 'erector spinae plane block', 'dexmedetomidine', 'dexamethasone', 'bupivacaine', 'randomized', 'blinded', 'postoperative', 'opioid', 'PONV', 'nausea', 'vomitting', 'fusion']",NOT_YET_RECRUITING,,2024-11,2026-11,"[{'measure': 'Postoperative opioid consumption', 'description': 'measured in morphine milligram equivalents (MME)', 'timeFrame': '24 hours postoperatively'}]",[],1,18 Years,,ALL,False,University of Southern California,OTHER,0,46.0,ESTIMATED,2025-09-01T16:18:18.428616,v2_robust,True,True,False,False,False,
NCT04697654,"The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers","A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers",TLC19,"['TLC19 Vehicle (same formulation as TLC19 but without the active ingredient)', 'TLC19 (Hydroxychloroquine Liposome Inhalation Suspension)', 'TLC19 Vehicle', 'TLC19']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,COVID-19,['COVID-19'],"['hydroxychloroquine', 'Inhalation']",COMPLETED,,2020-10-08,2021-06-18,"[{'measure': 'Incidence of AEs', 'description': 'To evaluate the severity, seriousness, outcome, and action taken of AE', 'timeFrame': '0-28 Days'}]","[{'measure': 'Maximum blood concentration', 'description': 'Cmax', 'timeFrame': '0-168 hours'}, {'measure': 'Time to reach maximum blood concentration', 'description': 'Tmax', 'timeFrame': '0-168 hours'}, {'measure': 'Area under the blood concentration-time curve', 'description': 'AUC0-last', 'timeFrame': '0-168 hours'}]",4,18 Years,65 Years,ALL,True,Taiwan Liposome Company,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:18.428659,v2_robust,True,True,True,False,False,
NCT02469454,Effect of t of the Etonogestrel Releasing Implant on Infant Growth and Development,Effect of the Immediately Postpartum Insertion of the Etonogestrel Releasing Implant on Infant Growth and Development,early insertion,"['early insertion', 'conventional insertion']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Contraception,"['Contraception', 'Newborn', 'Child Development', 'Growth']","['etonogestrel-implant', 'newborn', 'growth', 'Child Development']",COMPLETED,,2015-06,2016-09,"[{'measure': 'neonatal growth', 'timeFrame': '12 months'}]","[{'measure': 'child development', 'description': 'Child development will be evaluated by Bayley III Scale', 'timeFrame': '12 months'}]",2,18 Years,40 Years,FEMALE,True,University of Sao Paulo,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:18.428713,v2_robust,True,True,True,False,False,
NCT00130754,Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation,"A Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Thymoglobuline in Non-myeloablative Allogeneic Hemapoietic Stem-cell Transplantation (NST)",Thymoglobuline,['Thymoglobuline'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Stem Cell Transplantation,"['Stem Cell Transplantation', 'Graft Vs Host Disease']",[],COMPLETED,,2005-02,2007-11,"[{'measure': 'Acute GVHD occurrence', 'timeFrame': '100d'}, {'measure': 'Acute GVHD grading', 'timeFrame': '100d'}]","[{'measure': 'Time to acute GVHD', 'timeFrame': '100d'}, {'measure': 'Chronic GVHD occurrence', 'timeFrame': '1y'}, {'measure': 'Chronic GVHD grading', 'timeFrame': '1y'}, {'measure': 'Engraftment/graft rejection', 'timeFrame': '21d'}, {'measure': 'Overall survival', 'timeFrame': '1y'}, {'measure': 'Disease free survival', 'timeFrame': '1y'}, {'measure': 'Infections', 'timeFrame': '1y'}, {'measure': 'Transplant-related mortality (TRM)', 'timeFrame': '1y'}, {'measure': 'Transplant-related toxicity (TRT)', 'timeFrame': '1y'}]",11,18 Years,75 Years,ALL,False,Hadassah Medical Organization,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:18.428721,v2_robust,True,True,True,False,False,
NCT01350154,"Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients","Does Modulation of the nNOS System in Patients With Muscular Dystrophy and Defect nNOS Signalling Affect Cardiac, Muscular or Cognitive Function?",Sildenafil,"['Sildenafil', 'Sildenafil (Revatio)', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Becker Muscular Dystrophy,['Becker Muscular Dystrophy'],"['clinical trial', 'sildenafil', 'revatio', 'muscular dystrophy', 'adult', 'nNOS']",COMPLETED,,2011-11,2013-04,"[{'measure': 'Difference in change from baseline to 4 week placebo/sildenafil treatment in handgrip test with concomitant ultrasound measurement of flow in the brachial artery', 'description': 'Primary outcome for substudy 1', 'timeFrame': 'Baseline and 4 weeks treatment'}, {'measure': 'Difference in changes from baseline to 4 week placebo/sildenafil treatment in resting cardiac end-diastolic volume measured by MRI', 'description': 'Primary outcome for substudy 2', 'timeFrame': 'Baseline and 4 week treatment'}, {'measure': 'Difference in changes from baseline to 4 week placebo/sildenafil treatment in cerebrovascular reactivity to CO2 inhalation and finger stimulation measured by BOLD fMRI', 'description': 'Primary outcome for substudy 3', 'timeFrame': 'Baseline and 4 weeks treatment'}, {'measure': 'Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in Cognitive function measured by Cambridge Neuropsychological Test Automated Battery (CANTAB)', 'description': 'Primay outcome for substudy 3', 'timeFrame': 'Baseline and 4 weeks treatment'}]","[{'measure': 'Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in 6 minutes walk test', 'description': 'Substudy 1', 'timeFrame': 'Baseline and 4 weeks treatment'}, {'measure': 'Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in max test, measured by O2 uptake during maximal exercise on bike', 'description': 'Substudy 1', 'timeFrame': 'Baseline and 4 weeks treatment'}, {'measure': 'Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in Quality of life by SF36', 'description': 'Substudy 1', 'timeFrame': 'Baseline and 4 weeks treatment'}, {'measure': 'Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in resting cardiac function measured by cardiac MRI', 'description': 'Substudy 2. Evaluation of resting cardiac ejection fraction and end-systolic volume.', 'timeFrame': 'Baseline and 4 weeks treatment'}, {'measure': 'Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in cardiac function during hand grip exercise measured by cardiac MRI', 'description': 'Substudy 2. Cardiac volumes and ejection fraction during 1 minute repeated maximal force hand exercise will be measured.', 'timeFrame': 'Baseline and 4 weeks treatment'}, {'measure': 'Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in cerebrovascular reactivity and blood flow', 'description': 'Substudy 3. fMRI BOLD evaluation of visual stimulation, MRI angiography for arterial diameter, arterial spin labeling for evaluation of cerebral blood flow and blood volumen.', 'timeFrame': 'Baseline and 4 weeks treatment'}, {'measure': 'Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in basic activity and metabolites of the brain', 'description': 'Substudy 3.Resting state network by fMRI and metabolites in brain regions by MRI spectroskopy.', 'timeFrame': 'Baseline and 4 weeks treatment'}, {'measure': 'Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in cognitive function measured by paper and pen test battery', 'description': ""Substudy 3. A paper and pen cognitive test battery will be applied, including Trail making A and B, Addenbrooke's Cognitive Examination, Symbol DIgital MOdality tests"", 'timeFrame': 'Baseline and 4 weeks treatment'}, {'measure': 'Difference in changes from baseline to 4 weeks treatment placebo/sildenafil in plasma levels of signalling molecules', 'description': 'Substudy 3. From blood samples taken at baseline, 4 and 10 weeks, analysis of several signalling molecules relevant for cardiac and cerebrovascular function will be performed.', 'timeFrame': 'Baseline and 4 weeks treatment'}]",13,18 Years,80 Years,MALE,False,"Rigshospitalet, Denmark",OTHER,1,17.0,ACTUAL,2025-09-01T16:18:18.428743,v2_robust,True,True,True,False,False,
NCT03493854,"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer","A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer",Cyclophosphamide,"['RO0452317', 'RG6264', 'Paclitaxel', 'FDC of Pertuzumab and Trastuzumab SC', 'RO4368451', 'Trastuzumab IV', 'Hormone Therapy', 'Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf', 'Perjeta', 'Doxorubicin', 'Trastuzumab SC', 'Pertuzumab IV', 'Cyclophosphamide', 'RO7198574', 'Herceptin', 'Docetaxel']",16,INTERVENTIONAL,['PHASE3'],PHASE3,,Early Breast Cancer,['Early Breast Cancer'],[],COMPLETED,,2018-06-14,2023-06-02,"[{'measure': 'Trough Serum Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8)', 'description': 'The observed pertuzumab trough serum concentration (Ctrough) at Cycle 7 was assessed following 3 cycles of pertuzumab IV and trastuzumab IV or the fixed-dose combination (FDC) of pertuzumab and trastuzumab SC. The Per Protocol Pharmacokinetics (PK) analysis population includes all enrolled participants who adhered to the protocol. Exclusions from the Per Protocol PK analysis population were made for the following reasons: participants were missing the Ctrough pre-dose Cycle 8 PK sample, participants with a Ctrough sample collected with at least 2 days deviation from the planned date on Day 21 (i.e., before Day 19 or after Day 23), participants given a dose amount that deviated from the planned dose by \\>20% within 3 cycles (from Cycle 5), participants with a dose delay of more than 7 days, a subcutaneous injection site other than thigh was used, if the Cycle 8 pre-dose and post-dose samples were switched, and an assay error impacting Ctrough measurement.', 'timeFrame': 'Pre-dose on Cycle 8, Day 1 (up to 21 weeks)'}]","[{'measure': 'Ctrough of Trastuzumab During Cycle 7 (Pre-Dose Cycle 8)', 'description': 'The observed trastuzumab trough serum concentration (Ctrough) at Cycle 7 was assessed following 3 cycles of pertuzumab IV and trastuzumab IV or the fixed-dose combination (FDC) of pertuzumab and trastuzumab SC. The Per Protocol Pharmacokinetics (PK) analysis population includes all enrolled participants who adhered to the protocol. Exclusions from the Per Protocol PK analysis population were made for the following reasons: participants were missing the Ctrough pre-dose Cycle 8 PK sample, participants with a Ctrough sample collected with at least 2 days deviation from the planned date on Day 21 (i.e., before Day 19 or after Day 23), participants given a dose amount that deviated from the planned dose by \\>20% within 3 cycles (from Cycle 5), participants with a dose delay of more than 7 days, a subcutaneous injection site other than thigh was used, if the Cycle 8 pre-dose and post-dose samples were switched, and an assay error impacting Ctrough measurement.', 'timeFrame': 'Pre-dose on Cycle 8, Day 1 (up to 21 weeks)'}, {'measure': 'Percentage of Participants With Total Pathological Complete Response (tpCR), According to Local Pathologist Assessment', 'description': ""Total pCR (tpCR) was defined as eradication of invasive disease in the breast and axilla; that is, ypT0/is ypN0, according to the local pathologists' assessment. Pathologic response to therapy was determined at the time of surgery. The tpCR rate is the percentage of participants in the ITT population who achieved a tpCR. Participants with missing data for tpCR (i.e., do not undergo surgery or have an invalid pCR assessment) were included in the analysis and classified as non-responders. Rates of tpCR were calculated in each treatment arm and were assessed using the difference between the Arm B: Pertuzumab and Trastuzumab FDC SC and the Arm A: Pertuzumab IV and Trastuzumab IV tpCR rates and corresponding 95% Clopper-Pearson confidence intervals (CIs). The difference between the tpCR rates along with corresponding 95% Hauck-Anderson CIs were calculated. The lower bound of the CI will reliably reflect the largest tpCR difference that can be considered unlikely."", 'timeFrame': 'Following completion of surgery (up to 33 weeks)'}, {'measure': 'Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Invasive Disease-Free Survival (iDFS; Excluding Second Primary Non-Breast Cancer [SPNBC]) Criteria', 'description': 'iDFS (excluding SPNBC) is defined as the time from the first date of no disease (i.e., the date of primary surgery) to the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence; ipsilateral local-regional invasive breast cancer reccurrence; distant recurrence; contralateral invasive breast cancer; or death attributable to any cause. Ipsilateral or contralateral in situ disease and SPNBC (including in situ carcinomas and non-melanoma skin cancers) will not be counted as progressive disease or relapse.', 'timeFrame': 'At 1, 2, 3, and 4 years'}, {'measure': 'Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to iDFS (Including SPNBC) Criteria', 'description': 'Invasive disease-free survival (iDFS) including second primary non-breast cancer (SPNBC) is defined as the time from the first date of no disease (i.e., the date of primary surgery) to the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence; ipsilateral local-regional invasive breast cancer reccurrence; distant recurrence; contralateral invasive breast cancer; or death attributable to any cause. It also includes SPNBC as an event (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).', 'timeFrame': 'At 1, 2, 3, and 4 years'}, {'measure': 'Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Event-Free Survival (EFS; Excluding SPNBC) Criteria', 'description': 'Event-free survival (EFS) excluding second primary non-breast cancer (SPNBC) is defined as the time from enrollment to the first occurrence of one of the following events: breast cancer progression; breast cancer recurrence; or death from any cause. Ipsilateral or contralateral in situ disease and SPNBC (including in situ carcinomas and non-melanoma skin cancers) will not be counted as progressive disease or relapse.', 'timeFrame': 'At 1, 2, 3, and 4 years'}, {'measure': 'Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to EFS (Including SPNBC) Criteria', 'description': 'Event-free survival (EFS) including second primary non-breast cancer (SPNBC) is defined as the time from enrollment to the first occurrence of one of the following events: breast cancer progression; breast cancer recurrence; or death from any cause. It also includes SPNBC as an event (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).', 'timeFrame': 'At 1, 2, 3, and 4 years'}, {'measure': 'Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Distant Recurrence-Free Interval (DRFI) Criteria', 'description': 'The distant recurrence-free interval (DRFI) is defined as the time between randomization and the date of distant breast cancer recurrence.', 'timeFrame': 'At 1, 2, 3, and 4 years'}, {'measure': 'Kaplan-Meier Estimate of the Percentage of Participants in Overall Survival', 'description': 'Overall survival is defined as the time from randomization to death from any cause.', 'timeFrame': 'At 1, 2, 3, and 4 years'}, {'measure': 'Summary of the Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0), Over the Course of the Entire Study', 'description': 'The adverse event (AE) severity grading scale for the NCI CTCAE v4.0 was used for assessing AE severity. Any AEs that were not specifically listed in the NCI CTCAE, v4.0 were graded per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to AE. The terms ""severe"" and ""serious"" are not synonymous and are independently assessed for each AE. Multiple occurrences of AEs were counted only once per participant at the highest (worst) grade.', 'timeFrame': 'From first dose of study treatment until 28 days after last dose of study treatment (up to 1 year, 6 months)'}, {'measure': 'Number of Participants With a Primary Cardiac Event During the Neoadjuvant Phase', 'description': 'A primary cardiac event is defined as the occurrence of either of the following events: - Incidence of a symptomatic ejection fraction decrease (heart failure) of New York Heart Association (NYHA) Class III or IV and a drop in left ventricular ejection fraction (LVEF) of at least 10-percentage points from baseline and to below 50%; or - Cardiac death, defined as: Definite cardiac death (due to heart failure, myocardial infarction, or documented primary arrhythmia); or, Probable cardiac death (sudden unexpected death within 24 hours of a definite or probable cardiac event \\[e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia\\] without documented etiology).', 'timeFrame': 'From first dose of study treatment until the completion of neoadjuvant therapy (24 weeks)'}, {'measure': 'Number of Participants With a Secondary Cardiac Event During the Neoadjuvant Phase', 'description': 'A secondary cardiac event is defined as asymptomatic or mildly symptomatic Left Ventricular Systolic Dysfunction (LVSD) of NYHA Class II, defined as a left ventricular ejection fraction (LVEF) decrease of at least 10-percentage points below the baseline measurement to an absolute LVEF value of \\<50% confirmed by a second assessment within approximately 3 weeks.', 'timeFrame': 'From first dose of study treatment until the completion of neoadjuvant therapy (24 weeks)'}, {'measure': 'Number of Participants With a Primary Cardiac Event During the Adjuvant Phase', 'description': 'A primary cardiac event is defined as the occurrence of either of the following events: - Incidence of a symptomatic ejection fraction decrease (heart failure) of New York Heart Association (NYHA) Class III or IV and a drop in left ventricular ejection fraction (LVEF) of at least 10-percentage points from baseline and to below 50%; or - Cardiac death, defined as: Definite cardiac death (due to heart failure, myocardial infarction, or documented primary arrhythmia); or, Probable cardiac death (sudden unexpected death within 24 hours of a definite or probable cardiac event \\[e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia\\] without documented etiology).', 'timeFrame': 'From surgery until 28 days after the last dose of adjuvant treatment (42 weeks)'}, {'measure': 'Number of Participants With a Secondary Cardiac Event During the Adjuvant Phase', 'description': 'A secondary cardiac event is defined as asymptomatic or mildly symptomatic Left Ventricular Systolic Dysfunction (LVSD) of NYHA Class II, defined as a left ventricular ejection fraction (LVEF) decrease of at least 10-percentage points below the baseline measurement to an absolute LVEF value of \\<50% confirmed by a second assessment within approximately 3 weeks.', 'timeFrame': 'From surgery until 28 days after the last dose of adjuvant treatment (42 weeks)'}, {'measure': 'Number of Participants With Laboratory Test Abnormalities at the Highest NCI CTCAE v4 Grade Post-Baseline Over the Course of the Entire Study', 'description': ""Clinical laboratory tests were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest (worst) severity grade (according to NCI-CTCAE v4.0) post-baseline. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a medical intervention or a change in concomitant therapy. For a participant with multiple post-baseline abnormalities, only the highest (worst) grade for a given laboratory test is reported. 'Any Grade' indicates the total number of participants with a post-baseline abnormality of any grade for the specified test."", 'timeFrame': 'From first dose of study treatment until 28 days after last dose of study treatment (up to 1 year, 6 months)'}]",15,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,500.0,ACTUAL,2025-09-01T16:18:18.428781,v2_robust,True,True,True,False,True,
NCT02796105,Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors,Evaluation of Efficacy and Safety of Medroxiprogesterone Acetate (Progevera 10 mg®) Versus GnRh Antagonist (Orgalutran®) in Ovarian Stimulation Cycles of Oocyte Donors,Progevera,"['Progevera', 'Orgalutran']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Infertility,['Infertility'],[],COMPLETED,,2016-06,2017-07-10,"[{'measure': 'donor ovarian response', 'timeFrame': '1 month'}]",[],1,18 Years,35 Years,FEMALE,False,Fundació Privada Eugin,OTHER,0,232.0,ACTUAL,2025-09-01T16:18:18.428865,v2_robust,True,True,True,False,False,
NCT00388505,Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis,"A Randomized, Open-label Multicentre Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to Tobramycin Solution for Inhalation in Cystic Fibrosis Subjects",Tobramycin Inhalation Powder,"['Tobramycin Inhalation Powder', 'Tobramycin Solution for Inhalation']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Cystic Fibrosis,['Cystic Fibrosis'],['tobramycin'],COMPLETED,,2006-02,2009-03,"[{'measure': 'Number of Participants With Treatment-emergent Adverse Events', 'description': 'An adverse event (AE) is any untoward medical occurrence, including any unfavorable and unintended sign, symptom or disease temporally associated with the use of the study medication that does not necessarily have a causal relationship with study medication. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs inpatient hospitalization, results in persistent or significant disability, is a congenital anomaly or defect, or is a significant medical event that may jeopardize the patient or require intervention to prevent one of the outcomes listed above.', 'timeFrame': '25 weeks'}]","[{'measure': 'Serum Tobramycin Concentrations', 'description': 'Serum tobramycin concentrations were measured in a subset of participants at Week 1 (start of cycle 1), Week 5 (End of Cycle 1), Week 17 (start of cycle 3) and Week 21 (end of cycle 3). Serum samples were collected at pre-dose and post-dose at specified intervals; one specimen between 0 to 2 hours; two additional specimens between 2 and 5 hours (sample times must have been a minimum of 2 hours apart).', 'timeFrame': 'Weeks 1, 5, 17 and 21'}, {'measure': 'Percentage of Participants With a Decrease From Baseline in Auditory Acuity', 'description': 'Audiology testing was performed only at selected centers. Auditory acuity was measured from 250 to 8000 Hertz using a standard dual-channel audiometer.', 'timeFrame': 'Baseline and Day 28 of Cycles 1, 2 and 3 (Weeks 5, 13 and 21)'}, {'measure': 'Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%FEV1)', 'description': 'Forced expiratory volume in one second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 is then converted to a percentage of normal (percent predicted) based on height, weight, and race. FEV1 was measured at Baseline (prior to beginning study treatment) and predose on Day 28 of Cycles 1, 2 and 3 and at the follow-up visit.\n\nRelative change = 100 \\* ((Day 28 of Cycle 3 value - Baseline value)/ Baseline value).', 'timeFrame': 'Baseline and Day 28 of Cycles 1, 2 and 3 (Weeks 5, 13 and 21) and Final Visit (Week 25)'}, {'measure': 'Patient Satisfaction Assessed Using the Treatment Satisfaction Questionnaire for Medication', 'description': ""Patient's self-reported treatment satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM, a validated instrument) which was modified by adding four study-specific questions; the standard fourteen questions of the TSQM were not altered. Responses to nearly all items are rated on a five-point or seven-point rating scale and the items are factored into 4 domains. The TSQM domain scores range from 0 to 100 with higher scores representing higher satisfaction for that domain."", 'timeFrame': 'Day 28 of Cycles 1, 2 and 3 (Weeks 5, 13 and 21).'}, {'measure': 'Change From Baseline in Pseudomonas Aeruginosa Sputum Density', 'description': ""Three Pseudomonas aeruginosa biotypes were assessed in patient's sputum; mucoid, dry and small colony variant. Overall density is defined as the sum of all bio-types in Pseudomonas aeruginosa density."", 'timeFrame': 'Baseline and Day 28 of Cycles 1, 2 and 3 (Weeks 5, 13 and 21) and Final Visit (Week 25).'}, {'measure': 'Change From Baseline in Tobramycin Minimum Inhibitory Concentration', 'description': 'The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation. The MIC of tobramycin against total Pseudomonas aeruginosa colonization was assessed over the course of the study.', 'timeFrame': 'Baseline and Day 28 of Cycles 1, 2 and 3 (Weeks 5, 13 and 21) and Final Visit (Week 25)'}, {'measure': 'Antipseudomonal Antibiotic Usage During the Study', 'description': 'The average number of days patients required antipseudomonal antibiotics during the course of the study.', 'timeFrame': '25 Weeks'}, {'measure': 'Hospitalization Due to Respiratory Events During the Study', 'description': 'The average number of days patients were hospitalized due to respiratory events during the course of the study.', 'timeFrame': '25 Weeks'}]",9,6 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,517.0,ACTUAL,2025-09-01T16:18:18.428910,v2_robust,True,True,True,False,True,
NCT00443105,Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study,,Tacrolimus 0.03% ointment (Protopic),['Tacrolimus 0.03% ointment (Protopic)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Allergic Conjunctivitis,['Allergic Conjunctivitis'],[],UNKNOWN,,,,[],[],0,5 Years,,ALL,,Assaf-Harofeh Medical Center,OTHER_GOV,0,,,2025-09-01T16:18:18.428980,v2_robust,True,True,False,False,False,
NCT02070705,DCE MRI in Patients With Pancreatic Cancer,The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer,Ferumoxytol,"['Feraheme', 'Ferumoxytol', 'Ferumoxytol Non-Stoichiometric Magnetite']",3,INTERVENTIONAL,['NA'],,,Familial Pancreatic Cancer,"['Familial Pancreatic Cancer', 'Pancreatic Adenocarcinoma', 'Pancreatic Intraductal Papillary-Mucinous Neoplasm']",[],TERMINATED,Loss of funding,2014-01-31,2024-08-07,"[{'measure': 'Presence of pancreatic cancer (yes or no) for patients that are either at high risk for hereditary pancreatic cancer (Group I)', 'description': 'Descriptive statistical analysis will be conducted for primary endpoints.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Presence of pancreatic cancer (yes or no) for patients with cystic lesions of the pancreas (Group II)', 'description': 'Descriptive statistical analysis will be conducted for primary endpoints.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Change in tumor margins in patients who have undergone chemotherapy for pancreatic cancer (Group III)', 'description': 'The change of dynamic contrast enhanced magnetic resonance imaging (DCE MRI) parameters from baseline will be correlated with the tumor margins determined by pathological specimen following surgical resection through linear regression model.', 'timeFrame': 'Baseline to up to 2 years'}]","[{'measure': 'Disease free survival (Group I)', 'description': 'Kaplan-Meier method will be used to estimate the survival distribution for disease free survival. The estimated median and 95% confidence interval will be computed.', 'timeFrame': 'Time of enrollment to time of diagnosis, assessed up to 5 years'}, {'measure': 'Disease free survival (Group II)', 'description': 'Kaplan-Meier method will be used to estimate the survival distribution for disease free survival. The estimated median and 95% confidence interval will be computed.', 'timeFrame': 'Time of surgical resection to time of disease recurrence, if applicable, assessed up to 5 years'}, {'measure': 'Disease free survival (Group III)', 'description': 'Kaplan-Meier method will be used to estimate the survival distribution for disease free survival. The estimated median and 95% confidence interval will be computed.', 'timeFrame': 'Time of surgical resection to time of recurrence, assessed up to 5 years'}, {'measure': 'Overall survival (Group I)', 'description': 'Kaplan-Meier method will be used to estimate the survival distribution for overall survival. The estimated median and 95% confidence interval will be computed.', 'timeFrame': 'Time of surgical resection to time of death, assessed up to 5 years'}, {'measure': 'Overall survival (Group II)', 'description': 'Kaplan-Meier method will be used to estimate the survival distribution for overall survival. The estimated median and 95% confidence interval will be computed.', 'timeFrame': 'Time of surgical resection to time of death, assessed up to 5 years'}, {'measure': 'Overall survival (Group III)', 'description': 'Kaplan-Meier method will be used to estimate the survival distribution for overall survival. The estimated median and 95% confidence interval will be computed.', 'timeFrame': 'Time of surgical resection to time of death, assessed up to 5 years'}, {'measure': 'Surgical pathological diagnosis and T & N stage according to the American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) staging system (Group II)', 'description': 'Will be assessed as potential confounders or effect modifiers in the model. Will report c-statistics for each model.', 'timeFrame': 'At time of surgery'}, {'measure': 'Surgical pathological diagnosis and T & N stage according to the AJCC TNM staging system (Group III)', 'description': 'Will be assessed as potential confounders or effect modifiers in the model. Will report c-statistics for each model.', 'timeFrame': 'At time of surgery'}, {'measure': 'Resection margin status (R0, R1 or R2) (Group III)', 'description': 'Will be assessed as potential confounders or effect modifiers in the model. Will report c-statistics for each model.', 'timeFrame': 'At time of surgery'}, {'measure': 'DCE- MRI imaging parameters (Group I)', 'description': 'The DCE- MRI parameters will be obtained from the pancreases in the control group and will be descriptively analyzed for use as a comparison in other groups.', 'timeFrame': 'Up to 5 years'}, {'measure': 'DCE- MRI imaging parameters (Group II)', 'description': 'The DCE- MRI parameters will be obtained from the pancreases in the control group and will be descriptively analyzed for use as a comparison in other groups.', 'timeFrame': 'Once prior to surgery'}, {'measure': 'DCE- MRI imaging parameters (Group III)', 'description': 'The DCE- MRI parameters will be obtained from the pancreases in the control group and will be descriptively analyzed for use as a comparison in other groups.', 'timeFrame': 'Up to 5 years'}, {'measure': 'DCE- MRI imaging parameters and descriptional analysis of normal pancreas DCE- MRI images (Group IV)', 'description': 'The DCE- MRI parameters will be obtained from the pancreases in the control group and will be descriptively analyzed for use as a comparison in other groups.', 'timeFrame': 'Once at time of enrollment'}]",16,18 Years,85 Years,ALL,True,OHSU Knight Cancer Institute,OTHER,4,77.0,ACTUAL,2025-09-01T16:18:18.428999,v2_robust,True,True,False,True,False,Loss of funding
NCT03105505,"The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis","The Efficacy Of Lyclear (Permethrin 5%) Vs Fusidic Acid1% and Synthomycine 5% for Demodex -Blepharitis Treatment, Prospective-Randomized Trial.",Permethrin 5%,"['Permethrin 5%', 'Synthomycine 5%', 'Fusidic Acid 1% M/R Eye Drops']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Inflammation of the Eyelids,['Inflammation of the Eyelids'],[],UNKNOWN,,2017-04-28,2018-09,"[{'measure': 'Decrease in demodex infestation in group A (permethrin 5%).', 'description': 'significant decrease in demodex infestation in comparison to group B and C.', 'timeFrame': '2 months'}, {'measure': 'Improvement in symptoms and complaints in group A.', 'description': 'OSDI Questionnaires that describe the severity of the ocular surface disease condition are filled in each visit.', 'timeFrame': '2 months'}]",[],2,18 Years,,ALL,False,Barzilai Medical Center,OTHER,0,75.0,ESTIMATED,2025-09-01T16:18:18.429177,v2_robust,True,True,False,False,False,
NCT03752905,A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB),"A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)",PTR-01,"['Recombinant human collagen 7 (rC7)', 'PTR-01', 'Normal saline']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Recessive Dystrophic Epidermolysis Bullosa,['Recessive Dystrophic Epidermolysis Bullosa'],['RDEB'],COMPLETED,,2019-01-09,2020-11-30,"[{'measure': 'Incidence of treatment-emergent adverse events', 'description': 'The primary endpoint of this study is safety and tolerability, as assessed by treatment-emergent adverse events, infusion-associated reactions (IAR) and immunogenicity', 'timeFrame': 'Up to Day 127'}]","[{'measure': 'To measure the peak serum concentration (Cmax) of PTR-01', 'description': 'Pharmacokinetic parameter estimates of Cmax', 'timeFrame': 'Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose'}, {'measure': 'To measure the time to peak concentration (Tmax) of PTR-01', 'description': 'Pharmacokinetic parameter estimates of Tmax', 'timeFrame': 'Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose'}, {'measure': 'To measure the area under the curve (AUC) of PTR-01', 'description': 'Pharmacokinetic parameter estimates of AUC', 'timeFrame': 'Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose'}, {'measure': 'To measure the clearance of PTR-01', 'description': 'Pharmacokinetic parameter estimates of clearance', 'timeFrame': 'Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose'}, {'measure': 'To measure the half-life (t1/2) of PTR-01', 'description': 'Pharmacokinetic parameter estimates of t1/2', 'timeFrame': 'Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose'}, {'measure': 'Change from Baseline in rC7', 'description': 'Change in rC7 on skin biopsy by immunofluorescence (IF)', 'timeFrame': 'Screening and Day 127'}, {'measure': 'Change from Baseline in anchoring fibrils', 'description': 'Change in anchoring fibrils on skin biopsy by electron microscopy (EM)', 'timeFrame': 'Screening and Day 127'}, {'measure': 'Duration of rC7 residence in tissue', 'description': 'Duration of rC7 residence in tissue by skin biopsy', 'timeFrame': 'Screening and Day 127'}]",9,16 Years,,ALL,False,"Phoenix Tissue Repair, Inc.",INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:18.429205,v2_robust,True,True,True,False,True,
NCT04720105,Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis,"Investigator-Initiated, Open Label Trial of a Combination of Halobetasol Propionate 0.01% Andtazarotene 0.045% Lotion (Duobrii®) for Plaque Type Psoriasis of the Hands and/or Feet",Duobrii®,"['Duobrii®', 'HP/TAZ', 'Halobetasol propionate 0.01%/tazarotene 0.045% lotion']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Palmoplantar Psoriasis,"['Palmoplantar Psoriasis', 'Plaque Psoriasis']","['Palmoplantar', 'Psoriasis', 'Plaque']",COMPLETED,,2020-11-19,2022-03-29,"[{'measure': 'Palmoplantar Physician Global Assessment (ppPGA)', 'description': 'Number of participants achieving Palmoplantar Physician Global Assessment (ppPGA) of 0 (clear) or 1 (almost clear/minimal) after 24 weeks of treatment. The ppPGA is based on the Investigators Global Assessment (IGA) modified version 11, specifically applied to the hands and/or feet: 0 (clear), 1 (almost clear/minimal), 2 (mild), 3 (moderate), 4 (marked/moderate-to-severe), 5 (severe)', 'timeFrame': 'Baseline and Week 24'}]","[{'measure': 'Dermatology Quality of Life Index (DLQI)', 'description': 'Patient-reported outcomes evaluated by Dermatology Quality of Life Index (DLQI). DLQi is a 10-item questionnaire, each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). Higher score indicates poorer health outcome.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Numerical Rating Scale (NRS)', 'description': 'Treatment satisfaction evaluated by a Numerical Rating Scale (NRS). Full scale from 0 to 10, higher score indicates poorer health outcome.', 'timeFrame': 'Baseline and Week 24'}]",3,18 Years,,ALL,False,Icahn School of Medicine at Mount Sinai,OTHER,1,22.0,ACTUAL,2025-09-01T16:18:18.429232,v2_robust,True,True,True,False,False,
NCT02687594,"Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)","Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis or Peritoneal Dialysis",sucroferric oxyhydroxide,"['PA21 (Velphoro)', 'sucroferric oxyhydroxide']",2,OBSERVATIONAL,[],,,Hyperphosphatemia,['Hyperphosphatemia'],[],COMPLETED,,2016-04-06,2019-04-06,"[{'measure': 'Incidence of Adverse Drug Reactions (ADRs)', 'timeFrame': 'through study completion, up to 42 months'}, {'measure': 'Proportion of Adverse Drug Reactions (ADRs)', 'timeFrame': 'through study completion, up to 42 months'}]","[{'measure': 'Patient Reported Outcome questionnaire - Adherence to Velphoro based on the standard Morisky questionnaire', 'description': 'Patient reported outcomes will be evaluated by descriptive statistics', 'timeFrame': 'through study completion, up to 42 months'}, {'measure': 'Patient Reported Outcome questionnaire - Perceived Pill based on the ACTG questionnaire', 'description': 'Patient reported outcomes will be evaluated by descriptive statistics', 'timeFrame': 'through study completion, up to 42 months'}, {'measure': 'Patient Reported Outcome questionnaire - Treatment satisfaction based on the 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9)', 'description': 'Patient reported outcomes will be evaluated by descriptive statistics', 'timeFrame': 'through study completion, up to 42 months'}]",5,18 Years,,ALL,False,Vifor Fresenius Medical Care Renal Pharma,INDUSTRY,0,1400.0,ACTUAL,2025-09-01T16:18:18.429254,v2_robust,False,True,True,False,True,
NCT05479994,Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,"A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",BGB-11417,"['BGB-11417', 'sonrotoclax']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Leukemia,"['Leukemia', 'Lymphoma', 'Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'Small Lymphocytic Lymphoma', 'Relapsed Chronic Lymphocytic Leukemia']","['Refractory Chronic Lymphocytic Leukemia', 'Leukemia', 'Lymphoma', 'Small Lymphocytic Lymphoma']",ACTIVE_NOT_RECRUITING,,2022-10-24,2027-08-25,"[{'measure': 'Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)', 'description': 'Defined as the proportion of participants who achieved a complete response (CR), complete remission with incomplete marrow recovery (CRi), nodular partial response (nPR), or partial response (PR) per the 2018 iwCLL guidelines for participants with chronic lymphocytic leukemia (CLL) or Defined as the proportion of participants who achieved PR or better per the Lugano Classification for partiticpants with small lymphocytic lymphoma (SLL)', 'timeFrame': 'Up to 2 Years'}]","[{'measure': 'Overall Response Rate (ORR) as assessed by the investigator', 'description': 'Defined as the proportion of participants who achieved a complete response (CR), complete remission with incomplete marrow recovery (CRi), nodular partial response (nPR), or partial response (PR) per the 2018 iwCLL guidelines for participants with chronic lymphocytic leukemia (CLL) or Defined as the proportion of participants who achieved PR or better per the Lugano Classification for participants with small lymphocytic lymphoma (SLL)', 'timeFrame': 'Up to 2 Years'}, {'measure': 'Duration of response (DoR) as determined by the IRC and the investigator', 'description': 'DoR is defined as the time from first determination of response until first documentation of progression or death, whichever occurs first', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Progression Free Survival (PFS) as determined by the IRC and the investigator', 'description': 'PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Time to Response (TTR) as assessed by investigator and IRC', 'description': 'TTR is defined as the time from treatment initiation to the first documented response.', 'timeFrame': 'Up to 2 Years'}, {'measure': 'Overall Survival (OS)', 'description': 'defined as time from the start of treatment to the date of death due to any cause', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Participants Reported Outcome as measured by EQ-5D-5L questionnaires', 'description': 'The EQ-5D-5L descriptive system assesses health in five dimensions (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY / DEPRESSION), each of which has five levels of response (no problems, slight problems, moderate problems, severe problems, extreme problems/unable to).', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Participant Reported Outcomes as measured by NFLymSI-18', 'description': ""The National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index-18 (NFLymSI-18) questionnaire contains 18 items, each of which utilizes a Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and is divided into a total score."", 'timeFrame': 'Up to 5 Years'}, {'measure': 'Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'description': 'with adverse events leading to discontinuation, and AEs graded according NCI-CTCAE Version 5 and the Grading Scale for Hematologic Toxicity in CLL Studies', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Number of participants with clinically significant changes from baseline in vital signs', 'description': 'Vital signs include systolic and diastolic blood pressure, heart rate, and body temperature', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Number of participants with clinically significant changes from baseline in clinical laboratory values', 'description': 'Laboratory values include hematology, clinical chemistry, coagulation, and urinalysis', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Number of Participants With Clinically Significant Physical Examination Findings', 'description': 'A full physical examination includes head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal and musculoskeletal systems', 'timeFrame': 'Up to 5 Years'}]",12,18 Years,,ALL,False,BeiGene,INDUSTRY,0,100.0,ACTUAL,2025-09-01T16:18:18.429261,v2_robust,True,True,False,False,True,
NCT02915094,Kineret in the Treatment of Rheumatoid Arthritis,Kineret in the Treatment of Rheumatoid Arthritis,Anakinra,"['Anakinra', 'Kineret']",2,OBSERVATIONAL,[],,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],[],COMPLETED,,2012-10,2016-01,"[{'measure': 'Disease Activity Score 28 (DAS28)', 'description': 'The DAS28 measures the progress and improvement of Rheumatoid Arthritis. DAS28 values range from 2.0 to 10.0 while higher values mean a higher disease activity. A DAS 28 below the value of 2.6 is interpreted as Remission. Both the number of joints with tenderness upon touching and swelling are counted. In addition, the erythrocyte sedimentation rate is measured. Also, the patient makes a subjective assessment of disease activity during the preceding 7 days on a scale between 0 and 100, where 0 is ""no activity"" and 100 is ""highest activity possible"".', 'timeFrame': '0-52 weeks'}, {'measure': 'ACR response', 'description': 'The ACR (American College of Rheumatology) Criteria measures the effectiveness of treatments for Rheumatoid Arthritis. The ACR is reported as % improvement, comparing disease activity at two discrete time points.', 'timeFrame': '0-52 weeks'}, {'measure': 'Health Assessment Questionnaire', 'description': 'The patients will at each visit complete a questionnaire about their health status and the impairment in usual activities due to the rheumatoid disorder.', 'timeFrame': '0-52 weeks'}]",[],3,18 Years,,ALL,False,Swedish Orphan Biovitrum,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:18.429359,v2_robust,False,True,True,False,False,
NCT03786094,"Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer","An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer",Eribulin,"['Eribulin Injection [Halaven]', 'Balixafortide', 'POL6326', 'Eribulin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Metastatic Breast Cancer,"['Metastatic Breast Cancer', 'Locally Recurrent Breast Cancer']",[],TERMINATED,The study was halted early due to failure to meet the primary endpoint.,2019-05-30,2021-10-19,"[{'measure': 'Progression Free Survival (2nd Line+ Population)', 'description': 'To evaluate the efficacy of balixafortide + eribulin versus eribulin monotherapy on the primary endpoint of progression free survival (PFS). PFS, as assessed by the Independent Review Committee, defined as the time from the date of randomization to the earliest evidence of documented progressive disease or death from any cause. Patients who were alive without postbaseline assessments or without documented progressive disease, lost to follow-up, withdrew consent, started an anticancer therapy prior to observing a progressive disease or with an event documented after 2 or more missing tumor assessments were censored.\n\nPFS was evaluated according to RECIST v1.1 guidelines for complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).', 'timeFrame': 'Patients received treatment until PD by RECIST v1.1 criteria was met or until one of the treatment discontinuation or study withdrawal criteria was met.'}, {'measure': 'Progression Free Survival (3rd Line+ Population)', 'description': 'To evaluate the efficacy of balixafortide + eribulin versus eribulin monotherapy on the primary endpoint of progression free survival (PFS). PFS, as assessed by the Independent Review Committee, defined as the time from the date of randomization to the earliest evidence of documented progressive disease or death from any cause. Patients who were alive without postbaseline assessments or without documented progressive disease, lost to follow-up, withdrew consent, started an anticancer therapy prior to observing a progressive disease or with an event documented after 2 or more missing tumor assessments were censored.\n\nPFS was evaluated according to RECIST v1.1 guidelines for complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).', 'timeFrame': 'Patients received treatment until PD by RECIST v1.1 criteria was met or until one of the treatment discontinuation or study withdrawal criteria was met.'}]","[{'measure': 'Overall Survival (3rd Line+ Population)', 'description': 'To compare the overall survival (OS) between patients in the balixafortide + eribulin treatment arm versus eribulin monotherapy treatment arm. OS is defined as the time from date of randomization to date of death due to any cause. Patients who are lost to follow-up or are not known to have died at the time of data-cut-off for analysis or who do not have any follow up since randomization were censored.', 'timeFrame': 'The Investigator monitored the patient for OS status every 6 months (or more frequently) until: death, the patient withdrew consent to follow-up for survival, or until the patient was lost to follow-up (whichever occurred first).'}]",3,18 Years,,ALL,False,Spexis AG,INDUSTRY,0,432.0,ACTUAL,2025-09-01T16:18:18.429376,v2_robust,True,True,False,True,False,The study was halted early due to failure to meet the primary endpoint.
NCT03294694,Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,A Phase 1 Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer,Ribociclib,"['ICI 182,780', 'Ribociclib', 'LEE011', 'Kisqali', 'Fulvestrant', 'PDR001', 'ZD9238', 'Faslodex', 'LEE-011']",9,INTERVENTIONAL,['PHASE1'],PHASE1,,Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer,"['Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer', 'HER2-Negative Breast Cancer', 'Metastatic Epithelial Ovarian Cancer']","['Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer', 'HER2-Negative Breast Cancer', 'Metastatic Epithelial Ovarian Cancer']",TERMINATED,Safety Implications,2017-11-08,2020-10-14,"[{'measure': 'Cohort A: MTD/RP2D of the Combination of Ribociclib + PDR001', 'description': 'Toxicity will be graded according to NCI CTCAE, Version 4.0.', 'timeFrame': '4 weeks'}, {'measure': 'Cohort B: MTD/RP2D of the Combination of Ribociclib + PDR001 + Fulvestrant', 'description': 'Toxicity will be graded according to NCI CTCAE, Version 4.0.', 'timeFrame': '4 weeks'}]","[{'measure': 'Number of Participants with Adverse Events', 'description': 'Toxicity will be graded according to NCI CTCAE, Version 4.0.', 'timeFrame': 'All participants will be evaluable for toxicity from the time of their first treatment with any study agent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months'}, {'measure': 'Objective Response Rate', 'description': 'ORR is defined as the proportion of patients with complete response or partial response by RECIST 1.1 and immune-related RECIST (irRECIST)', 'timeFrame': '2 Years'}]",4,18 Years,,ALL,False,Dana-Farber Cancer Institute,OTHER,1,33.0,ACTUAL,2025-09-01T16:18:18.429415,v2_robust,True,True,False,True,True,Safety Implications
NCT02401594,PROphylaxis in NOn Major Orthopaedic Surgery,"A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery",Rivaroxaban,"['Rivaroxaban', 'Group 2:', 'Enoxaparin', 'Group 1:']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-major Orthopaedic Surgery,['Non-major Orthopaedic Surgery'],"['Non-major orthopaedic surgery', 'deep vein thrombosis']",TERMINATED,Remaining outdated treatments and additional costs too high for new manufacturing,2015-12-08,2018-04-16,"[{'measure': 'Major VTE', 'description': 'composite of proximal DVT (asymptomatic and symptomatic) assessed by ultrasonography, symptomatic events (distal and proximal DVT, PE) and VTE related deaths.\n\nThe treatment period ranges from 15 days to 3 months depending on the type of surgery', 'timeFrame': 'From date of randomization until the date of the end of the treatment period (up to 3 months maximum).'}]","[{'measure': 'Major bleeding', 'description': 'bleeding event that meets at least one of the following criteria \\[5\\]:\n\n* fatal bleeding;\n* critical bleeding (intracranial, intraocular, intraspinal, pericardial, retroperitoneal);\n* clinically overt bleeding (at surgical or extrasurgical site) associated with a decrease in the haemoglobin level of more than 2 g/dL (20 g/l; 1.24 mmol/L) compared with the pre-randomization level;\n* clinically overt bleeding (at surgical or extrasurgical site) leading to transfusion of two or more units of whole blood or packed cells;\n* bleeding located at the surgical site and leading to re-operation or to any unusual medical intervention or procedure for relief (e.g. draining or puncture of an haematoma at the surgical site, transfer to an ICU or emergency room) The treatment period ranges from 15 days to 3 months depending on the type of surgery', 'timeFrame': 'From date of randomization until the date of the end of the treatment period (up to 3 months maximum).'}, {'measure': 'Clinically relevant non-major bleeding', 'description': ""overt bleeding not meeting the criteria for major bleeding and corresponds to any bleeding necessitating medical intervention or a specific, unscheduled consultation or treatment discontinuation, or resulting in a deterioration of the subject's quality of life. Some examples of clinically significant bleeding are given below:\n\n* Epistaxis that lasts more than five minutes or recurrent or necessitates packing,\n* Spontaneous macroscopic haematuria or haematuria lasting more than 24 hours after instrumentation,\n* Gastrointestinal haemorrhage (melena or rectorrhagia),\n* Haemoptysis,\n* Subcutaneous haematoma \\> 100 cm². The treatment period ranges from 15 days to 3 months depending on the type of surgery"", 'timeFrame': 'From date of randomization until the date of the end of the treatment period (up to 3 months maximum)..'}, {'measure': 'Overt thrombocytopenia', 'description': 'platelet count \\<100 giga/L or fall ≥ 50% of the platelet count as compared with the first post-operative count which will be done as local lab for all centres The treatment period ranges from 15 days to 3 months depending on the type of surgery', 'timeFrame': 'From date of randomization until the date of the end of the treatment period (up to 3 months maximum)..'}, {'measure': 'Mortality', 'description': 'All cause mortality The treatment period ranges from 15 days to 3 months depending on the type of surgery', 'timeFrame': 'From date of randomization until the date of the end of the treatment period (up to 3 months maximum)..'}]",5,18 Years,,ALL,False,Centre Hospitalier Universitaire de Saint Etienne,OTHER,1,3608.0,ACTUAL,2025-09-01T16:18:18.429440,v2_robust,True,True,False,True,False,Remaining outdated treatments and additional costs too high for new manufacturing
NCT00058994,An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD,An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-related Macular Degeneration,anecortave acetate,['anecortave acetate'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Macular Degeneration,"['Macular Degeneration', 'Maculopathy, Age-Related']","['AMD', 'anecortave acetate', 'wet AMD', 'age-related macular degeneration', 'Macular Degeneration', 'Maculopathy, Age-Related', 'Age-Related Maculopathies', 'Age-Related Maculopathy', 'Maculopathies, Age-Related']",COMPLETED,,2003-03,2006-11,[],[],0,50 Years,,ALL,False,Alcon Research,INDUSTRY,0,,,2025-09-01T16:18:18.429491,v2_robust,True,True,True,False,False,
NCT06204094,Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer,"Total Neoadjuvant CAPOX and PD-1 Inhibitor（Sintilimab） Combined with Node-sparing Short-course Radiotherapy for MSS Locally Advanced of Middle and Low Rectal Cancer(CASINOs): an Open Label, Single-arm, Prospective Clinical Trial",Sintilimab,"['Sintilimab', 'IBI308', 'Capecitabine', 'Oxaliplatin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Locally Advanced Rectal Cancer,['Locally Advanced Rectal Cancer'],"['rectal cancer', 'microsatellite stability', 'node-sparing', 'CAPOX', 'radiotherapy', 'sintilimab', 'immunotherapy', 'neoadjuvant']",RECRUITING,,2024-02-05,2028-09-01,"[{'measure': 'Complete response', 'description': 'Pathological complete response (pCR) ：absence of residual tumour on resected specimen. Clinical complete response（cCR）: no residual tumour visible on imaging or colonoscopy and biopsy.', 'timeFrame': 'within 10 days after TNT therapy or surgery'}]","[{'measure': 'Tumor regression grade', 'description': 'TRG is evaluated according to the AJCC system. TRG0-1 is defined as good response, TRG2 as moderate response, and TRG3 as poor response.', 'timeFrame': 'within 10 days after surgery'}, {'measure': 'Local recurrence rate(LRR)', 'description': 'Presence of adenocarcinoma within the rectal wall or within the mesorectum confirmed by pathology.', 'timeFrame': '3 years after sugery'}, {'measure': 'Disease free survival(DFS)', 'description': 'the time from randomization to recurrence of tumor or death', 'timeFrame': '3 years after treatment'}, {'measure': 'Overall survival(OS)', 'description': 'the time from randomization to death', 'timeFrame': '3 years after enrollment'}, {'measure': 'Adverse effects rate', 'description': 'Rate of radiotherapy, chemotherapy and immunotherapy related adverse events', 'timeFrame': 'From date of initiation of treatment until the date of death from any cause, assessed up to 5 years'}, {'measure': 'Rectal specific quality of life assessment via QLQ-CR29', 'description': 'Rectal specific quality of life according to European Organization for Research and Treatment of Cancer ( EORTC) Quality of life questionnaire QLQ-CR29. scale from 0 to 100, A higher scale represents better function and a higher quality of life.', 'timeFrame': 'Baseline and months 3, 6, 12, 24, 36, 60 after the TNT treatment or surgery'}, {'measure': 'Quality of life assessment via QLQ-C30', 'description': 'Quality of life according to EORTC Quality of life Questionnaire QLQ-C30 version 3.0. Score range from 0 to 100 points. A higher score represents better function and a higher quality of life.', 'timeFrame': 'Baseline and months 3, 6, 12, 24, 36, 60 after the TNT treatment or surgery'}, {'measure': 'Validation of the Wexner score', 'description': 'The change of severity of fecal incontinence assessment according to Wexner score. a score from 0-20, where 0 is perfect continence and 20 is complete incontinence.', 'timeFrame': 'Months 3, 6, 12, 24, 36, 60 after the TNT treatment or surgery'}]",9,18 Years,75 Years,ALL,False,Jinhua Central Hospital,OTHER,0,37.0,ESTIMATED,2025-09-01T16:18:18.429526,v2_robust,True,True,False,False,True,
NCT02426294,Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin,"A Phase IV, Multicenter, Randomized, Active Comparator Controlled Study of the Addition of Pioglitazone Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Alogliptin",Pioglitazone,"['Actos', 'Glimepiride', 'Pioglitazone', 'Amaryl']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],[],UNKNOWN,,2015-02,2016-05,"[{'measure': 'Evidence of efficacy of glycemic control indicated by the mean changes of HbA1c (%) at week 26 from baseline', 'timeFrame': '26 weeks'}]","[{'measure': 'Evidence of changes of insulin resistance and secretion at week 26 from baseline', 'description': 'Homeostatic model assessment model', 'timeFrame': '26 weeks'}, {'measure': 'Evidence of changes of Lipid profile at week 26 from baseline', 'description': 'LDL (Low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol and triglyceride', 'timeFrame': '26 weeks'}, {'measure': 'Evidence of efficacy of glycemic control indicated by the mean changes of HbA1c (%) at week 12 from baseline', 'timeFrame': '12 weeks'}]",4,19 Years,80 Years,ALL,False,Pusan National University Hospital,OTHER,0,154.0,ESTIMATED,2025-09-01T16:18:18.429558,v2_robust,True,True,False,False,False,
NCT00112294,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,A Randomized Multicenter Phase III Study of Taxane/Carboplatin/Cetuximab Versus Taxane/Carboplatin as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,Paclitaxel (Taxane),"['Erbitux', 'Docetaxel (Taxane)', 'Carboplatin', 'Cetuximab', 'Paclitaxel (Taxane)']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-Small-Cell Lung Carcinoma,['Non-Small-Cell Lung Carcinoma'],['Non-Small Cell Lung Cancer'],COMPLETED,,2004-12,2008-08,"[{'measure': 'Median Number of Months of Progression-free Survival (PFS)', 'description': 'Interval between randomization date \\& earliest date of disease progression/death due to any cause, assessed by the Independent Radiology Review Committee (IRRC) using modified World Health Organization (WHO) criteria to define progressive disease (PD): \\>=25% increase in sum of products of diameters (SOPD) of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion. If no progression/death, date of last tumor assessment used. For participants who had no on-study tumor assessments \\& were still alive, date of randomization used.', 'timeFrame': 'From randomization to evidence of disease progression/death or date of last tumor assessment (up to 26 months).'}]","[{'measure': 'Number of Participants With Complete Response (CR) or Partial Response (PR)', 'description': 'Tumor response was defined as the number of participants whose best response was CR or PR, per the IRRC assessment, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR: \\>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression. To qualify as CR or PR, no new lesions could be present.', 'timeFrame': 'From randomization to end of study drug therapy (up to 174 weeks).'}, {'measure': 'Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD)', 'description': 'Disease control was defined as the number of participants whose best response was CR, PR, or SD, per the IRRC assessment, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR:\\>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression (to qualify as CR or PR, no new lesions could be present); SD: participants who did not meet the criteria for CR, PR, or PD (PD:\\>=25% increase in SOPD of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion).', 'timeFrame': 'From randomization to end of study drug therapy (up to 174 weeks).'}, {'measure': 'Median Number of Months of Response', 'description': 'Median number of months of response (time from first occurrence of CR/PR to date of PD/death, \\[per IRRC assessment,using modified WHO criteria\\]) calculated for participants whose best response=CR/PR.For participants who did not progress/die, date of last tumor assessment used.CR:disappearance of all index/non-index lesions;PR:\\>= 50% reduction in SOPD of index lesions compared with baseline, no evidence of progression.No new lesions present.PD:\\>=25% increase in SOPD of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion.', 'timeFrame': 'Time from first occurrence of CR or PR (whichever was recorded first) to the date of PD, death or date of last tumor assessment (up to 19 months).'}, {'measure': 'Median Number of Months to Response', 'description': 'The median number of months to response was calculated for participants whose best response was CR or PR. It was defined as the time from the first dose of study therapy to the first date that criteria for PR or CR (whichever occurred first)were met. Response was assessed by the IRRC, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR: \\>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression. To qualify as CR or PR, no new lesions could be present.', 'timeFrame': 'Time from first dose of study therapy to the date of PR or CR, whichever occurred first (up to 13 months).'}, {'measure': 'Median Number of Months of Survival', 'description': 'The median number of months of survival was defined as the time from randomization to the date of death. For participants who did not die, the date of last contact was used.', 'timeFrame': 'From randomization to death or date of last contact (up to 41 months).'}, {'measure': 'Number of Participants With Improvement of Symptoms', 'description': 'Symptoms were assessed using the Functional Assessment of Cancer Therapy - Lung Cancer Subscale (FACT-LCS) questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic in all symptoms assessed) to 28 (symptom-free on all symptoms assessed). Symptom response (improvement) was defined as \\>= 2-point increase from baseline in score (maintained for 2 consecutive assessments, at least 3 weeks apart). Participants with a baseline score of \\>= 27 were not evaluable, as it would not have been possible to show an improvement. Participants with no baseline data were also not evaluable.', 'timeFrame': 'From randomization to evidence of disease progression/death or date of last symptom assessment (up to 33 weeks).'}, {'measure': 'Median Number of Months Until Symptomatic Progression (Worsening of Symptoms)', 'description': 'Symptoms were assessed using the FACT-LCS questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic) to 28 (symptom-free). Symptomatic progression was defined as \\>= 2-point decrease from baseline in score (maintained for 2 consecutive assessments at least 3 weeks apart). Time to symptomatic progression was defined as the time from randomization to date of symptoms worsening. For participants with no symptom progression, the date of the last symptom assessment was used. See also Outcome Measure 15.', 'timeFrame': 'From randomization to evidence of disease progression/death or date of last symptom assessment (up to 33 weeks).'}, {'measure': 'Number of Participants Who Died, or Experienced Other Serious Adverse Events (SAEs) and Adverse Events (AEs)', 'description': 'An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). An SAE was defined as an AE that resulted in death, was life-threatening, required hospitalization (or prolongation of existing hospitalization), or was an important medical event.', 'timeFrame': 'From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).'}, {'measure': 'Number of Participants Experiencing AEs Leading to Study Drug Discontinuation', 'description': 'An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). The results presented are stratified according to which drug was discontinued.', 'timeFrame': 'From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).'}, {'measure': 'Number of Participants Experiencing Other Significant AEs: Acneform Rash', 'description': 'An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term ""acneform rash"" were of particular importance. These AEs were: rash, rash pustular, rash erythematous, dermatitis acneiform, dermatitis exfoliative, rash papular, rash pruritic, rash generalised, rash macular, rash maculo-papular, acne, acne pustular, skin desquamation and dry skin.', 'timeFrame': 'From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).'}, {'measure': 'Number of Participants Experiencing Other Significant AEs: Infusion Reaction', 'description': 'AE=any new untoward medical occurrence or worsening of pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term ""infusion reaction"" were of particular importance. These AEs were: infusion-related reaction, hypersensitivity, anaphylactic reaction, anaphylactic shock, and anaphylactoid reaction regardless of when they occurred. The terms dyspnea, pyrexia and chills were also grouped under infusion reaction, provided the onset date of these toxicities occurred on the first day of study treatment.', 'timeFrame': 'From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).'}, {'measure': 'Number of Participants Experiencing Other Significant AEs: Cardiac AEs', 'description': 'An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term ""cardiac AE"" were of particular importance. These AEs, coded as preferred or other level Medical Dictionary for Regulatory Activities \\[MedDRA\\] terms were: coronary artery disorders, cardiac arrhythmias, heart failures not elsewhere classified, left ventricular failures, sudden cardiac death, cardiac death and sudden death.', 'timeFrame': 'From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).'}, {'measure': 'Number of Participants Who Exprienced the Most Frequent Grade 3-4 Hematology Abnormalities Occurring in >=5% Participants', 'description': 'Abnormalities were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), version 3.0. The scale is graded from 1 (least severe) to 4 (life threatening). Grade 3 and 4 criteria are defined as follows: Neutropenia: Grade 3, neutrophils \\<1.0 - 0.5 x 10\\^9/L; Grade 4, \\<0.5 x 10\\^9/L. Leukopenia: Grade 3, leukocytes \\<2.0 - 1.0 x 10\\^9/L; Grade 4, \\<1.0 x 10\\^9/L. Thrombocytopenia: Grade 3, platelets \\<50.0 - 25.0 x 10\\^9/L; Grade 4, \\<25.0 x 10\\^9/L. Anemia: Grade 3, hemoglobin \\<4.9 - 4.0 millimoles (mmol)/L, Grade 4, \\<4.0 mmol/L.', 'timeFrame': 'From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).'}, {'measure': 'Number of Participants Who Experienced the Most Frequent Grade 3-4 Serum Chemistry Abnormalities Occurring in >=5% Participants', 'description': 'Abnormalities were graded according to the NCI CTC, version 3.0. The scale is graded from 1 (least severe) to 4 (life threatening). Grade 3 and 4 criteria are defined as follows: Hyperglycemia (non-fasting): Grade 3, serum glucose \\>13.9 - 27.8 mmol/L; Grade 4 \\>27.8 mmol/L or acidosis. Hypomagnesemia: Grade 3, serum magnesium \\>1.23 - 3.30 mmol/L; Grade 4 \\>3.30 mmol/L. Hyponatremia: Grade 3, serum sodium \\<130 - 120 mmol/L; Grade 4 \\<120 mmol/L. Low albumin: Grade 3, serum albumin \\<20 g/L; Grade 4 not applicable.', 'timeFrame': 'From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).'}, {'measure': 'Number of Participants Who Had Unscheduled Visits to Physicians, Clinics, Hospitals and Other Unscheduled Major Medicinal Procedures', 'description': 'Participants were to complete log to collect information on unscheduled visits to physicians,clinics,hospitals \\& other unscheduled major procedures.If asked, participants were to complete and return log to site upon routinely scheduled visits.The purpose of this exploratory analysis was to understand the economical implications as a secondary objective.This was not a pivotal study \\& therefore not needed to support any arguments with regulatory authorities concerning cost-benefit,hence,it was not necessary to conduct this analysis. There is no intent on conducting this analysis in the future.', 'timeFrame': 'Day 1 of each cycle of treatment, at the end of study therapy evaluation and at the first follow-up visit (6 weeks after the end of study therapy evaluation).'}]",16,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,755.0,ACTUAL,2025-09-01T16:18:18.429631,v2_robust,True,True,True,False,True,
NCT05014594,Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT,Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT,Dapagliflozin (10Mg Tab) along with standard medical therapy,"['Placebo of dapaglifozin along with standard medical therapy', 'Dapagliflozin (10Mg Tab) along with standard medical therapy']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cirrhosis,"['Cirrhosis', 'Ascites Hepatic']",[],UNKNOWN,,2021-09-03,2022-05-19,"[{'measure': 'control of ascites at 6-months', 'description': 'Control of ascites will be defined as follows-\n\n* Complete response will be total absence of ascites.\n* Partial response as presence of ascites not requiring paracentesis\n* Non response will be defined as persistence of severe ascites requiring paracentesis.', 'timeFrame': '6 months'}]","[{'measure': 'Change in eGFR measured by MDRD-6 at 3 months and 6 months', 'description': 'eGFR will be measured by MDRD-6 formula', 'timeFrame': '6 months'}, {'measure': 'Change in urine output at 2-weeks, 3-months and 6-months', 'description': 'Change in 24-hour urine output (ml) at 6-months', 'timeFrame': '6-months'}, {'measure': 'Change in serum sodium (mEq/l) at 2-weeks, 3-months and 6 months', 'description': 'Change in serum sodium (mEq/l)', 'timeFrame': '6 months'}, {'measure': 'Change in 24-hours urinary sodium (mEq) at 2 weeks, 3 months and 6 months', 'description': 'Change in 24-hours urinary sodium (mEq)', 'timeFrame': '6 months'}, {'measure': 'Change in HbA1c at 3 and 6 months', 'description': 'Change in HbA1c', 'timeFrame': '6 months'}, {'measure': 'Change in Child-Turcotte-Pugh (CTP) score at 3 months and 6 months', 'description': 'Change in CTP score. The CTP score incorporates the variables of serum bilirubin, albumin, prothrombin time-INR, grade of ascites and hepatic encephalopathy. The score ranges from 5-15 and a higher score portends a worse prognosis', 'timeFrame': '6 months'}, {'measure': 'Change in model for end stage liver disease (MELD) score at 3 months and 6 months', 'description': 'Change in MELD score. The MELD score incorporates the variables of serum bilirubin, creatinine and Internation Normalised Ratio (INR). Higher MELD score indicates worse prognosis', 'timeFrame': '6 months'}, {'measure': 'Incidence of spontaneous bacterial peritonitis (SBP), urinary tract infection (UTI) and other infections', 'description': 'The diagnosis of SBP will be based on neutrophil count in ascitic ﬂuid of \\>250/mm3 as determined by microscopy and positive ascitic fluid culture or \\>250 /mm3 with negative culture called as culture negative neutrocytic ascites.Other infections will be diagnosed as per CDC criteria.', 'timeFrame': '6 months'}, {'measure': 'Incidence of overt hepatic encephalopathy over 6-months', 'description': 'Over hepatic encephalopathy (HE) will be defined as grade II or higher HE as per the West haven classification', 'timeFrame': '6 months'}, {'measure': 'Incidence of acute kidney injury over 6-months', 'description': 'Acute kidney injury will be defined as per the International Club of Ascites criteria', 'timeFrame': '6 months'}, {'measure': 'Incidence of Hyponatremia (serum sodium <130 meq/L), hypokalemia (Serum potassium < 3.5 meq/L), hyperkalemia (Serum potassium >6meq/L) over 6-months.', 'description': 'Hyponatremia: serum sodium \\<130 meq/L hypokalemia: serum potassium \\< 3.5 meq/L hyperkalemia: serum potassium \\>6meq/L)', 'timeFrame': '6 months'}, {'measure': 'Incidence of skeletal fractures over 6-months', 'description': 'Incidence of skeletal fractures over 6-months', 'timeFrame': '6 months'}, {'measure': 'Change in bone densitometry as assessed by DEXA at 6-months', 'description': 'Bone densitometry will be assessed by DEXA', 'timeFrame': '6 months'}, {'measure': 'Incidence of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic coma over 6-months', 'description': 'Incidence of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic coma over 6-months', 'timeFrame': '6 months'}, {'measure': 'Incidence of hepatocellular carcinoma over 6-months', 'description': 'Hepatocellular carcinoma will be diagnosed based on imaging findings and AFP', 'timeFrame': '6 months'}, {'measure': 'Changes in plasma renin activity and aldosterone levels at 6- months', 'description': 'Changes in plasma renin activity (ng/ml/hr) and aldosterone (ng/dL) levels at 6- months', 'timeFrame': '6 months'}, {'measure': 'Frequency and volume of LVP over 6-months.', 'description': 'Frequency and volume of ascitic fluid removed (in litres) over 6-months.', 'timeFrame': '6 months'}, {'measure': 'Survival at 6-months', 'description': 'Survival at 6-months after start of therapy', 'timeFrame': 'Survival at 6-months'}, {'measure': 'Safety of dapaglifozin as assessed by adverse effects', 'description': 'Safety of dapaglifozin as assessed by adverse effects', 'timeFrame': '6 months'}, {'measure': 'Renal resistive index at 6 months', 'description': 'Renal resistive index will be measured using ultrasound doppler interrogation of intrarenal arteries using formula (peak systolic velocity - end-diastolic velocity) / peak systolic velocity', 'timeFrame': '6 months'}]",21,18 Years,70 Years,ALL,False,"Post Graduate Institute of Medical Education and Research, Chandigarh",OTHER,0,44.0,ESTIMATED,2025-09-01T16:18:18.429833,v2_robust,True,True,False,False,True,
NCT06243094,Antibiotic Therapy Practices for Ventilator-Associated Pneumonia (PETUNIA),Survey on Antibiotic Therapy Practices for Ventilator-Associated Pneumonia in ICU Patients,Antibiotic,"['Antibiotic', 'antimicrobial therapy']",2,OBSERVATIONAL,[],,,Ventilator Associated Pneumonia,['Ventilator Associated Pneumonia'],"['antibiotic', 'intensive care', 'guidelines', 'outcome']",RECRUITING,,2024-03-12,2025-03-12,"[{'measure': 'Characteristics of Initial Antibiotic Treatment', 'description': 'Empirical / guided / directly targeted Monotherapy or combination therapy Monotherapy or combination therapy against resistant GNB Addition of an antibiotic active against Methicillin-Resistant Staphylococcus aureus Molecule(s) and class(es) of antibiotics Time from the onset of suspected VAP to initiation of initial antibiotic treatment Total dose in the first 24 hours for each molecule Administration modalities in the first 24 hours for each molecule Conducting plasma level measurements Appropriate treatment (in patients with microbiologically confirmed VAP) Time from the onset of suspected VAP to initiation of appropriate antibiotic treatment (in patients with microbiologically confirmed VAP)\n\nNote for the reviewer: our study is descriptive, and multiple characteristics of initial antibiotic treatment have been validated by the institutional review board and methodologist, as a descriptive outcome.', 'timeFrame': '3 days'}, {'measure': 'Characteristics of Definitive Antibiotic Treatment (for patients alive at Day 3 only)', 'description': 'Monotherapy or combination therapy Molecule(s) and class(es) of antibiotics Broadening of antibiotic spectrum Discontinuation of all antibiotics (prescribed for VAP treatment) at Day 3 and Day 5 Antibiotic de-escalation at Day 3 and Day 5 by reducing the spectrum of an initial antibiotic or by discontinuing a component of an initial combination of antibiotics\n\nNote for the reviewer: our study is descriptive, and multiple characteristics of definite antibiotic treatment have been validated by the institutional review board and methodologist, as a descriptive outcome.', 'timeFrame': '7 days'}, {'measure': 'Total Duration of Appropriate Treatment', 'description': 'Total Duration of Appropriate Treatment for the episode of VAP', 'timeFrame': 'ICU stay (up to 28 days)'}]",[],3,18 Years,,ALL,False,French Society for Intensive Care,OTHER,0,1060.0,ESTIMATED,2025-09-01T16:18:18.430062,v2_robust,False,True,False,False,False,
NCT06999694,Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC,Proton Radiotherapy Combined With Tremelimumab and Durvalumab for BCLC Stage B and C Hepatocellular Carcinoma,Tremelimumab,"['Tremelimumab', 'Durvalumab', 'Imjudo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,HCC - Hepatocellular Carcinoma,"['HCC - Hepatocellular Carcinoma', 'Durvalumab', 'Tremelimumab', 'Proton Radiotherapy']",[],NOT_YET_RECRUITING,,2025-05-20,2033-05-31,"[{'measure': 'Progression free survival', 'description': 'Progression free survival is defined as the time from signing the informed consent to the first occurrence of disease progression or death from any cause (whichever occurs first) according to RECIST1.1', 'timeFrame': '12 months'}]","[{'measure': 'Local control', 'description': 'Local control is defined as the time from signing the informed consent to the first occurrence of disease progression in the irradiated field according to RECIST1.1', 'timeFrame': '12 months'}, {'measure': 'Time to progression', 'description': 'Time to progression is defined as the time from signing the informed consent to the first occurrence of disease progression according to RECIST1.1', 'timeFrame': '12 months'}, {'measure': 'Overall Response Rate', 'description': 'Overall Response Rate is defined as a complete or partial response according to RECIST1.1', 'timeFrame': '12 months'}, {'measure': 'Overall survival', 'description': 'Overall survival is defined as the time from signing the informed consent to death from any cause.', 'timeFrame': '12 months'}, {'measure': 'Incidence and severity of adverse events', 'description': 'Adverse events will be graded using CTCAE v5', 'timeFrame': '12 months'}]",6,18 Years,,ALL,False,Chang Gung Memorial Hospital,OTHER,0,45.0,ESTIMATED,2025-09-01T16:18:18.430105,v2_robust,True,True,False,False,True,
NCT01492166,"Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice","A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Mixtard® 30 NovoLet® as Monotherapy, or in Combination With Oral Hypoglycaemic Agent ( OHA ), in Treatment of Subjects With Type 2 Diabetes in Routine Clinical Practice",biphasic human insulin 30,['biphasic human insulin 30'],1,OBSERVATIONAL,[],,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],COMPLETED,,2006-11,2007-06,"[{'measure': 'Change in fasting blood glucose (FBG)'}, {'measure': 'Change in 2-hour post prandial blood glucose'}, {'measure': 'Change in HbA1c (glycosylated haemoglobin)'}, {'measure': 'Change in prandial glucose increment (PGI)'}]","[{'measure': 'Frequency of minor and major hypoglycaemia'}, {'measure': 'Occurrence of Adverse Drug Reactions (ADR)'}]",6,,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,1935.0,ACTUAL,2025-09-01T16:18:18.430244,v2_robust,False,True,True,False,True,
NCT02365766,Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects,Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188,Pembrolizumab,"['Pembrolizumab', 'Gemzar', 'MK-3475', 'Cisplatin', 'Platinol', 'Gemcitabine']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Urothelial Carcinoma,"['Urothelial Carcinoma', 'Bladder Cancer']","['MK-3475', 'Gemcitabine', 'Cisplatin', 'Pembrolizumab', 'Neoadjuvant Bladder Cancer']",COMPLETED,,2015-05-27,2024-02-23,"[{'measure': 'Phase Ib: Safety of Pembrolizumab in Combination With Gemcitabine-Cisplatin', 'description': 'Number of patients with experienced Dose-Limiting Toxicities (DLTs) will be monitored as a safety and tolerability of pembrolizumab in combination with gemcitabine and cisplatin . The Pembrolizumab DLT is defined as a drug-related adverse events (AEs) per Common Terminology Criteria for Adverse Events (CTCAE) V4 criteria that occurs in the first 4 weeks of treatment of pembrolizumab (C1D8 - C2D14) and meets the DLT definition per protocol.', 'timeFrame': 'Up to 4 weeks'}, {'measure': 'Rate of Pathologic Muscle Invasive Response (PaIR)', 'description': 'Pathologic muscle invasion response (PaIR), or ≤ypT1N0M0, rate is assessed from the consolidative surgery (radical cystectomy (RC) / nephroureterectomy (NU) - lymph node dissection (LND)) specimen.', 'timeFrame': 'Within 2-7 weeks post last dose of pembrolizumab (up to 6 months)'}]","[{'measure': 'Relapse-Free Survival (RFS) at 18 Months', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \\>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD.\n\nRelapse-Free Survival is defined by the date of randomization until the criteria for disease progression is met as defined by RECIST 1.1 or death occurs.', 'timeFrame': '18 months'}, {'measure': 'Overall Survival (OS) at 5 Years', 'description': 'Determine the Overall survival at 5 years. OS is defined by the date of randomization to date of death from any cause.', 'timeFrame': '5 years'}, {'measure': 'Radical Cystectomy (RC) Rate', 'description': 'To compare the radical cystectomy (RC) rates in subjects who are cisplatin-eligible with those who are cisplatin-ineligible.', 'timeFrame': 'Within 2-7 weeks post last dose of pembrolizumab (up to 6 months)'}]",5,18 Years,,ALL,False,Jason R. Brown,OTHER,2,83.0,ACTUAL,2025-09-01T16:18:18.430280,v2_robust,True,True,True,False,True,
NCT01668966,"A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)","A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis",Tocilizumab,"['Tocilizumab', 'RoActemra, Actemra']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],[],COMPLETED,,2013-12-09,2016-05-11,"[{'measure': 'Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'description': 'An adverse event (AE) is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started. An SAE can be a) fatal, b) life-threatening, c) requires/prolongs hospitalization, d) results in persistent/significant incapacity/disability, e) results in congenital anomaly/birth defect or f) is considered as a significant medical event by the investigator.', 'timeFrame': 'Baseline up to approximately 104 weeks'}, {'measure': 'Percentage of Participants With TEAEs of Special Interest', 'description': 'An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started. Nine categories of AE of special interest are identified for tocilizumab which includes a) serious/medically significant infections, b) myocardial infarction/acute coronary syndrome, c) gastrointestinal perforations, d) malignancies, e) anaphylaxis/hypersensitivity reactions, f) demyelinating disorders, g) stroke, h) serious and/or medically significant bleeding events, and i) serious/medically significant hepatic events. Data reported is an average of the nine categories.', 'timeFrame': 'Baseline up to approximately 104 weeks'}, {'measure': 'Percentage of Participants With TEAEs Leading to Change in Dose or Study Drug Discontinuation', 'description': 'An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started.', 'timeFrame': 'Baseline up to approximately 104 weeks'}]","[{'measure': 'Change From Baseline (CFB) in Disease Activity Score 28 Using Erythrocyte Sedimentation Rate (DAS28-ESR) at Specified Time Points', 'description': 'The DAS28-ESR is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and general health (GH) (patient global assessment of disease activity \\[PGA\\] using visual analog scale \\[VAS\\], range 1-100 millimeters \\[mm\\]) (higher scores indicate higher disease activity). DAS28-ESR is calculated according to the following formula: DAS28-ESR equals (=) \\[0.56 multiplied by (\\*) the square root (√) of TJC\\] plus (+) \\[0.28 \\* √ of SJC\\] + (0.70 \\* the natural logarithm \\[ln\\] ESR in mm/h) + (0.014\\*GH in mm VAS). DAS28-ESR scale is transformed and ranges from 0 to 10. A negative CFB indicated improvement.', 'timeFrame': 'Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)'}, {'measure': 'CFB in Simplified Disease Activity Index (SDAI) Score at Specified Time Points', 'description': 'The SDAI is a combined index for measuring disease activity. SDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), physician global assessment (PhGA) and PGA of disease activity, both scored 0 to 10 centimeters (cm) as assessed by VAS, and C-reactive protein level (CRP) in milligrams per deciliter (mg/dL) where normal is less than (\\<) 1 mg/dL. SDAI is calculated according to the following formula: SDAI = TJC + SJC + PhGA + PGA + CRP. SDAI ranges from 0 to 86. A negative CFB indicated improvement.', 'timeFrame': 'Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)'}, {'measure': 'CFB in Swollen Joint Count (SJC) at Specified Time Points', 'description': 'For SJC, a total of 66 joints are assessed. The presence of a swollen joint is scored as 1 and absence as 0. Total score is calculated by adding the scores, which ranges from 0 (best possible score or no swollen joint) to 66 (worse possible score or all swollen joints). Lower scores indicated no swollen joint and higher scores indicated worsening swollen joints.', 'timeFrame': 'Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)'}, {'measure': 'CFB in Tender Joint Count (TJC) at Specified Time Points', 'description': 'The number of tender joints is recorded on the joint assessment form, no tenderness = 0, tenderness = 1, for 68 joints and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68.', 'timeFrame': 'Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)'}, {'measure': 'Percentage of Participants Reaching Clinical Remission (DAS28-ESR Score Less Than [<] 2.6 and/or SDAI Score Less Than or Equal to [</=] 3.3) Among Participants for Whom Tocilizumab Treatment Was Discontinued', 'description': 'Remission: DAS28-ESR score \\<2.6 and SDAI score \\</=3.3. DAS28-ESR index included SJC and TJC, both scored 0-28, as well as APR determined as ESR in mm/hr, and GH (ranges 1-100 mm; higher scores=higher disease activity). DAS28=(0.56\\*√TJC)+(0.28\\*√SJC) +(0.70\\*ln ESR) +(0.014\\*GH). DAS28-ESR scale is transformed and ranges from 0 to 10. Negative CFB indicated improvement. DAS28 \\>2.6 (clinical remission); DAS28 2.6 to 3.2 (low disease activity); DAS28 \\>3.2 to 5.1 = moderate to high disease activity. SDAI is sum of TJC and SJC (both scored 0-28), PhGA and PGA of disease activity (both scored 0 to 10 cm as assessed by VAS, higher scores=higher disease activity), and CRP in mg/dL where normal is \\<1 mg/dL. SDAI=TJC + SJC + PhGA + PGA + CRP. SDAI ranged from 0 to 86. A negative CFB indicated improvement. SDAI \\<=3.3 (clinical remission), \\>3.4 to 11 (low disease activity) \\>11 to 26 (moderate disease activity), and \\>26 = (high/severe disease activity).', 'timeFrame': 'Baseline up to approximately 104 weeks'}, {'measure': 'Time to RA Crisis Among Participants Who Discontinued After Clinical Remission', 'description': 'RA crisis is any worsening of participant disease acitivity that, in the opinion of the investigator, required intensified treatment other than supportive therapy, and may have included restart of the treatment with the study drug. Time to RA crisis is defined as the period of remission without drug until the RA crisis documentation.', 'timeFrame': 'Baseline up to approximately 104 weeks'}, {'measure': 'CFB in PGA of Disease Activity Using VAS Score at Specified Time Points', 'description': 'PGA of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as ""no disease activity"" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as ""maximum disease activity"" (maximum arthritis disease activity). A negative CFB indicated improvement.', 'timeFrame': 'Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)'}, {'measure': 'CFB in PGA of Pain Using VAS Score at Specified Time Points', 'description': 'PGA of pain is assessed on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as ""no pain"" and the right-hand extreme equals 100 mm, and is described as ""unbearable pain"". A negative change indicated improvement.', 'timeFrame': 'Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)'}, {'measure': 'CFB in PhGA of Disease Activity Using VAS Score at Specified Time Points', 'description': 'PhGA of disease activity is assessed on a 0 to 100 mm horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as ""no disease activity"" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as ""maximum disease activity"" (maximum arthritis disease activity).', 'timeFrame': 'Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)'}, {'measure': 'CFB in Health Assessment Questionnaire-Disease Index (HAQ-DI) Score at Specified Time Points', 'description': 'HAQ-DI is a self-reported participant questionnaire specific for RA. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Total score for HAQ-DI is the sum of all questions and ranges from 0 = without any difficulty to 60 = unable to do. A negative CFB indicates improvement.', 'timeFrame': 'Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)'}]",13,18 Months,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,23.0,ACTUAL,2025-09-01T16:18:18.430397,v2_robust,True,True,True,False,True,
NCT06519266,PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases,A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination With Ipilimumab and Nivolumab Compared to Ipilimumab and Nivolumab Only in Patients With Uveal Melanoma Liver Metastases,IPI1/NIVO3,"['Nivolumab 1 mg/kg', 'IPI3/NIVO1', 'Nivolumab 3 mg/kg', 'Ipilimumab 1 mg/kg', 'Ipilimumab 3 mg/kg', 'IPI1/NIVO3']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Uveal Melanoma,"['Uveal Melanoma', 'Liver Metastases']","['Percutaneous Hepatic Perfusion', 'Immunotherapy', 'Uveal Melanoma', 'Liver metastases', 'SCANDIUM III trial']",RECRUITING,,2024-06-10,2030-12-31,"[{'measure': 'Progression-free survival (PFS)', 'description': 'The primary objective is to evaluate progression-free survival in patients with uveal melanoma hepatic dominant metastases randomized to either percutaneous hepatic perfusion (PHP) in combination with IPI1/NIVO3 or the combination of IPI3/NIVO1 only', 'timeFrame': '24 month'}]","[{'measure': 'Adverse events', 'description': 'Frequency and severity of AEs and SAEs graded according to the NCI CTCAE v5.0.', 'timeFrame': '24 month'}, {'measure': 'Overall response rate', 'description': 'Evaluation of objective response rate (ORR), defined as the percentage of patients achieving a confirmed complete or partial response, as defined by RECIST version 1.1 criteria', 'timeFrame': '24 month'}, {'measure': 'Clinical benefit rate', 'description': 'Evaluation of clinical benefit rate (CBR), defined as the percentage of patients achieving confirmed SD or any confirmed CR or PR. As defined by RECIST version 1.1 criteria', 'timeFrame': '24 month'}, {'measure': 'Hepatic progression-free survival', 'description': 'Evaluation of hepatic PFS (hPFS), defined as the time-to-event defined by the first documented disease progression in the liver or death due to any cause, whichever occurs first, from randomization. hPFS will be determined based on tumor assessment using RECIST version 1.1 criteria.', 'timeFrame': '24 month'}, {'measure': 'Overall survival', 'description': 'Evaluation of overall survival (OS), defined as the time from randomization to death from any cause.', 'timeFrame': '24 month'}, {'measure': 'Melanoma-specific survival', 'description': 'Evaluation of melanoma-specific survival (MSS), defined as the time from randomization to death from uveal melanoma', 'timeFrame': '24 month'}, {'measure': 'Duration of response', 'description': 'Evaluation of duration of response (DOR), defined as the time to first documented progression or death due to underlying cancer from the first document CR or PR', 'timeFrame': '24 month'}, {'measure': 'Quality of Life as assessed by FACT-G', 'description': 'Evaluation of QoL using The Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire, where overall scores for FACT-G and the sub scales physical (PWB), social (SWB), emotional (EWB), and functional well-being (FWB) will be reported.', 'timeFrame': '24 month'}, {'measure': 'Quality of Life as assessed by EQ-5D-5L', 'description': 'Evaluation of QoL using EQ-5D-5L where EQ-VAS (0-100) will be reported', 'timeFrame': '24 month'}]",10,18 Years,,ALL,False,Vastra Gotaland Region,OTHER_GOV,0,40.0,ESTIMATED,2025-09-01T16:18:18.430435,v2_robust,True,True,False,False,True,
NCT01080456,Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fasting Condition,"A Randomized, Single Dose, Open Label, Bioequivalence Study of Tacrolimus Capsules 1 mg in Normal Healthy Male Subjects Under Fasting Condition",Tacrolimus 1 mg capsule,"['Tacrolimus Capsule', 'Tacrolimus 1 mg capsule']",2,INTERVENTIONAL,['NA'],,,Healthy Volunteers,['Healthy Volunteers'],['Bioequivalence study in healthy volunteers'],COMPLETED,,2007-09,2007-10,"[{'measure': 'To demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 1 mg manufactured by Panacea Biotec Limited, India and the corresponding Reference Product (B): Prograf (Tacrolimus) Capsules 1 mg manufactured by Astellas Pharma, Inc., USA', 'timeFrame': 'up to 3 days'}]",[],1,18 Years,55 Years,MALE,True,Panacea Biotec Ltd,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:18.430532,v2_robust,True,True,True,False,False,
NCT06247956,Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer,"A Randomized, Open, Multicenter Phase II Clinical Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the First-line Treatment of Advanced Gastric and Esophageal Cancer",SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection,"['Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection', 'SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma,['Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma'],[],RECRUITING,,2024-03-11,2025-12-30,"[{'measure': 'ORR based on RECIST v1.1 assessment.', 'timeFrame': 'All enrolled subjects were evaluated every 6 or 9 weeks starting with the first dose, up to 1 years'}]","[{'measure': 'DCR based on RECIST v1.1 assessment', 'timeFrame': 'All enrolled subjects were evaluated every 6 or 9 weeks starting with the first dose, up to 1 years'}]",2,18 Years,75 Years,ALL,False,"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",INDUSTRY,0,240.0,ESTIMATED,2025-09-01T16:18:18.430540,v2_robust,True,True,False,False,False,
NCT06903156,Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG),"Prospective Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Comparative Trial of the Efficacy and Safety of Different Dosages in Sequential Therapy With Mexidol® in Patients With Primary Open-angle Glaucoma",Mexidol,"['Ethylmethylhydroxypyridine Succinate', 'Mexidol']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Primary Open-Angle Glaucoma (POAG),['Primary Open-Angle Glaucoma (POAG)'],"['Glaucoma', 'Primary Open-Angle Glaucoma (POAG)', 'Glaucomatous Optic Neuropathy (GON)', 'Mitochondrial Dysfunction', 'Neuroprotection', 'Retiniprotection', 'Mexidol', 'Ethylmethylhydroxypyridine Succinate']",COMPLETED,,2021-11-15,2023-09-07,"[{'measure': 'Mean change in mean deviation (MD) in static automated perimetry (SAP) at the end of the course of therapy vs. baseline', 'timeFrame': 'Day 104'}]","[{'measure': 'Mean change in the mean deviation (MD) of static automated perimetry (SAP) 14, 45 and 75 days from the start of therapy vs. baseline', 'timeFrame': '14, 45 and 75 days'}, {'measure': 'Mean change in pattern standard deviation (PSD) at static automated perimetry (SAP) 14, 45, 75 and 104 days from the start of therapy vs. baseline', 'timeFrame': '14, 45, 75 and 104 days'}, {'measure': 'Change in the number of relative scotomas (first and second order), number of absolute scotomas after 14, 45, 75 and 104 days from the start of therapy vs. baseline', 'timeFrame': '14, 45, 75 and 104 days'}, {'measure': 'Mean change in visual acuity according to visometry without correction after 14, 45, 75 and 104 days from the start of therapy vs. baseline', 'timeFrame': '14, 45, 75 and 104 days'}, {'measure': 'Mean change in visual acuity according to visometry with correction after 14, 45, 75 and 104 days from the start of therapy vs. baseline', 'timeFrame': '14, 45, 75 and 104 days'}, {'measure': 'Mean change in the value of the threshold of electrical sensitivity of the optic nerve after 14, 45, 75 and 104 days from the beginning of therapy vs. baseline', 'timeFrame': '14, 45, 75 and 104 days'}, {'measure': 'Mean change in the value of the electrical lability of the optic nerve after 14, 45, 75 and 104 days from the start of therapy vs. baseline level', 'timeFrame': '14, 45, 75 and 104 days'}, {'measure': 'Dynamics of changes severity according to optical coherence tomography data after 14, 45, 75 and 104 days from the beginning of therapy in comparison with the initial level', 'timeFrame': '14, 45, 75 and 104 days'}, {'measure': 'Dynamics of the severity of changes according to Heidelberg retinal tomography data after 14, 45, 75 and 104 days from the start of therapy vs. baseline', 'timeFrame': '14, 45, 75 and 104 days'}]",10,35 Years,75 Years,ALL,False,Pharmasoft,INDUSTRY,0,102.0,ACTUAL,2025-09-01T16:18:18.430549,v2_robust,True,True,True,False,False,
NCT07034456,Sensory and Vascular Effects of Kinesio and Magnetic Tape in Healthy Subjects,Possible Mechanisms of Action of Magnetic Tape Through Its Application on the Epidermis,Topical Anesthetic Cream,['Topical Anesthetic Cream'],1,INTERVENTIONAL,['NA'],,,Healthy Volunteers,['Healthy Volunteers'],"['Magnetic Tape', 'Cutaneous Stimulation', 'Somatosensory System', 'Blood Flow']",NOT_YET_RECRUITING,,2025-07,2026-01,"[{'measure': 'Mechanical pain sensitivity (300g Von Frey monofilament)', 'description': 'Pain intensity will be assessed using a 300g Von Frey filament applied to the skin. Participants will report pain on an 11-point verbal Numeric Rating Scale (vNRS) from 0 (no pain) to 10 (worst imaginable pain). This measurement is performed in three regions (lumbar area, posterior thigh, and forearm) before and after each intervention. Higher NRS scores indicate greater mechanical pain sensitivity.\n\nAdditionally, it will be applied on intervention location site to assess the cream effect and confirm the anesthetic effects', 'timeFrame': 'Baseline (pre-intervention), Post-cream (immediately after cream removal), Mid-intervention (with tape on), and Immediate Post-intervention (immediately after tape removal) at each weekly visit (Visits 1-4)'}]","[{'measure': 'Mechanical Detection Threshold (Von Frey Filaments)', 'description': 'A set of von Frey filaments of increasing thickness (0.008-300 g) will be applied until the participant detects the stimulus in 3 out of 5 attempts. The smallest filament force (in grams) perceived is recorded as the threshold. Measurements are taken in the lumbar region, posterior thigh, and forearm. Higher thresholds indicate reduced tactile sensitivity.\n\nAdditionally, it will be applied on intervention location site to assess the cream effect and confirm the anesthetic effects', 'timeFrame': 'Baseline (pre-intervention), Post-cream (immediately after cream removal), Mid-intervention (with tape on), and Immediate Post-intervention (immediately after tape removal) at each weekly visit (Visits 1-4)'}, {'measure': 'Pressure Pain Threshold (Algometer)', 'description': 'A digital algometer with a 1-cm² probe will be pressed gradually (1 kg/s) against the skin until participants report the first painful sensation. The force (kg/cm²) at which pain is first perceived is the PPT. Measurements are taken twice at each site (lumbar, thigh, forearm), and the average is used for analysis. Higher PPT values indicate lower pain sensitivity', 'timeFrame': 'Baseline (pre-intervention), Mid-intervention (with tape on) and Immediate Post-intervention (immediately after tape removal) at each weekly visit (Visits 1-4)'}, {'measure': 'Painful pressure sensitivity (algometer)', 'description': 'A standard pressure of 5 kg is applied with an algometer on the lumbar region, thigh and forearm. Participants rate their pain on a 0-10 verbal Numeric Rating Scale (vNRS). This is done twice and averaged. Higher scores indicate greater evoked pain under a fixed force', 'timeFrame': 'Baseline (pre-intervention), Mid-intervention (with tape on) and Immediate Post-intervention (immediately after tape removal) at each weekly visit (Visits 1-4)'}, {'measure': 'Blood Flow Assessed by Color Doppler Ultrasound', 'description': 'Blood flow in the paravertebral lumbar region, thigh and forearm will be assessed using power Doppler ultrasound. Perfusion parameters (e.g., number of color signals, fractional moving blood volume) are recorded over 20-30 seconds at rest, before and after the intervention. Higher perfusion values may indicate increased blood flow', 'timeFrame': 'Baseline (pre-intervention), Mid-intervention (5 min with tape on) and Immediate Post-intervention (5 min after tape removal) at each weekly visit (Visits 1-4)'}, {'measure': 'Assessment of participant blinding post-intervention', 'description': 'After each session, participants complete a brief questionnaire indicating whether they believe they received magnetic or placebo tape, and anesthetic or moisturizing cream. The proportion of correct guesses is used to evaluate blinding effectiveness', 'timeFrame': 'Immediately Post-intervention after each of the four intervention visits (Visits 1-4)'}]",6,18 Years,35 Years,ALL,True,Patricia Beltra Lopez,OTHER,3,30.0,ESTIMATED,2025-09-01T16:18:18.430598,v2_robust,True,True,False,False,False,
NCT04198922,Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease,Acalabrutinib for Chronic Graft-Versus-Host Disease,Acalabrutinib,"['ACP-196', 'Bruton Tyrosine Kinase Inhibitor ACP-196', '1420477-60-6', 'Acalabrutinib', 'Benzamide']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Recurrent Moderate-Severe Chronic Graft Versus Host Disease,"['Recurrent Moderate-Severe Chronic Graft Versus Host Disease', 'Hematopoietic and Lymphoid Cell Neoplasm']",[],ACTIVE_NOT_RECRUITING,,2020-12-11,2027-04-30,"[{'measure': 'Best response (complete and partial response [CR + PR])', 'description': 'The composite outcome of CR and PR, calculated according to the proposed response definitions of the 2014 National Institutes of Health Consensus Conference. Exact 95% confidence intervals (CI) will be calculated for the objective response rate using the Clopper and Pearson method. Will also compare the observed best ORR with the published efficacy of ibrutinib (67%) and provide the 95% CI for the difference.', 'timeFrame': 'Within the first 6 months of treatment when the best response rate is known for each patient'}]","[{'measure': 'Incidence of adverse events (AEs)', 'description': 'Defined as grade 3 and above according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 and all serious AEs (SAEs) described for the population receiving at least one dose of acalabrutinib at least from the time of consent through the safety follow-up period. Any AE/SAE at least possibly related to acalabrutinib therapy will be reported for the duration of the study.', 'timeFrame': 'Up to 30 days following the last dose of acalabrutinib'}, {'measure': 'Duration of response (DOR)', 'description': 'Will be described for the group achieving at least a PR, defined as the number of weeks the subject maintains a PR or CR. Will be estimated using the Kaplan-Meier method. Approximate 95% CIs for median DOR will be computed using the formula proposed by Brookmeyer and Crowley.', 'timeFrame': 'From the date the PR is documented until loss of the response or start of another systemic immunosuppressive treatment for chronic graft versus host disease (GVHD), whichever occurs first, assessed up to 3 years'}, {'measure': 'Change in patient-reported outcomes: Lee Chronic GVHD Symptom Scale score', 'description': 'Will be assessed by the Lee Chronic GVHD Symptom Scale score. Scores will be calculated based on published algorithms with absolute changes and clinically meaningful changes described for the population as a whole and based on CR + PR versus stable disease (SD) + mixed response (MR) + progressive disease (PD).', 'timeFrame': 'Baseline up to 3 years'}, {'measure': 'Change in patient-reported outcomes: Patient-Reported Outcomes Measurement Information System-29', 'description': 'Will be assessed by the Patient-Reported Outcomes Measurement Information System-29. Scores will be calculated based on published algorithms with absolute changes and clinically meaningful changes described for the population as a whole and based on CR + PR versus stable disease (SD) + mixed response (MR) + progressive disease (PD).', 'timeFrame': 'Baseline up to 3 years'}, {'measure': 'Failure-free survival', 'description': 'Will be defined as the duration of relapse-free survival without adding any other systemic treatment for chronic GVHD. Will be estimated with the composite event of death from any cause, relapse and addition of secondary immune suppressive agents using the Kaplan-Meier method. Systemic immune-suppressive agents include orally or intravenously administered systemically active immune-suppressive drugs, as well as procedures including extra-corporeal photopheresis.', 'timeFrame': 'At 6 months and 1 year'}, {'measure': 'Organ-specific response rates', 'description': 'Response rates by organ will also be calculated and reported as ORR (CR+PR) versus all other categories (SD, PD, MR).', 'timeFrame': 'Up to 3 years'}]",7,18 Years,,ALL,False,Fred Hutchinson Cancer Center,OTHER,1,51.0,ACTUAL,2025-09-01T16:18:18.430750,v2_robust,True,True,False,False,True,
NCT05049122,Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52),"A Single-arm, 52 Weeks, Phase 4 Study to Assess the Efficacy and Safety of Dupilumab in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) Who Are Not Adequately Controlled With Existing Therapies",Dupilumab SAR231893,"['REGN668', 'Dupilumab SAR231893']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Rhinosinusitis With Nasal Polyps,['Chronic Rhinosinusitis With Nasal Polyps'],[],COMPLETED,,2021-10-22,2023-07-05,"[{'measure': 'Percentage of Participants With NPS Improvement From Baseline >=1 at Week 24', 'description': 'The NPS was the sum of right and left nostril scores as assessed by central video recordings of nasal endoscopy (NE). For each nostril, NPS was graded based on polyp size: Grade 0:No polyps; Grade 1:Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate; Grade 2:Polyps reaching below the lower border of the middle turbinate; Grade 3:Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate; Grade 4:Large polyps causing complete obstruction of the inferior nasal cavity. Score ranged from 0-8; higher scores indicated more severity. The baseline value was defined as the last available value before first study treatment administration.', 'timeFrame': 'Baseline (Day 1) and Week 24'}]","[{'measure': 'Change From Baseline in Bilateral NPS at Week 24', 'description': 'The NPS was the sum of right and left nostril scores as assessed by central video recordings of NE. For each nostril, NPS was graded based on polyp size: Grade 0:No polyps; Grade 1:Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate; Grade 2:Polyps reaching below the lower border of the middle turbinate; Grade 3:Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate; Grade 4:Large polyps causing complete obstruction of the inferior nasal cavity. Score ranged from 0-8; higher scores indicated more severity. For participants who discontinued for other reasons, missing data are imputed using multiple imputation techniques assuming missing at random, and non-missing data collected after treatment discontinuation were used in the analysis. The baseline value was defined as the last available value before first study treatment administration.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Nasal Congestion/Obstruction (NC) Symptom Severity Score Using the CRSwNP Nasal Symptom Diary at Week 24', 'description': 'The NC was assessed by the participant using a diary on a daily basis from Visit 1 and throughout the study on a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). It was scored as a reflective score (evaluation of symptom severity over the past 24 hours) by the participants. The score ranged from 0-3; higher scores indicated more severity. The baseline value was defined as the last available value before first study treatment administration. For participants who discontinued for other reasons, missing data are imputed using multiple imputation techniques assuming missing at random, and non-missing data collected after treatment discontinuation were used in the analysis. The baseline value was defined as the last available value before first study treatment administration.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Opacification of Sinuses Assessed by Computerized Tomography (CT) Scan Using the Lund Mackay (LMK) Score at Week 24', 'description': 'The LMK system is based on localization with points given for degree of opacification: 0 = normal, 1 = partial opacification, 2 = total opacification. These points were applied to the maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal sinus on each side. The osteomeatal complex (OC) was graded as 0 = not occluded or 2 = occluded. The total score was the sum of scores from each side and ranged from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. For participants who discontinued for other reasons, missing data are imputed using multiple imputation techniques assuming missing at random, and non-missing data collected after treatment discontinuation were used in the analysis. The baseline value was defined as the last available value before first study treatment administration.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Total Symptom Score (TSS) at Week 24', 'description': 'The TSS was the sum of participant-assessed nasal symptom scores for nasal congestion and/or obstruction, decreased/loss of sense of smell and rhinorrhea (average of the non-missing anterior/posterior nasal discharge). On a daily basis from Visit 1 and throughout the study, participants used a diary to respond to the morning individual rhinosinusitis symptom questions using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. For participants who discontinued for other reasons, missing data are imputed using multiple imputation techniques assuming missing at random, and non-missing data collected after treatment discontinuation were used in the analysis. The baseline value was defined as the last available value before first study treatment administration.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Loss of Smell Symptom Severity Score Using the Nasal Symptom Diary at Week 24', 'description': 'The severity of loss of smell was reported by the participants using the nasal symptom diary with a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. For participants who discontinued for other reasons, missing data are imputed using multiple imputation techniques assuming missing at random, and non-missing data collected after treatment discontinuation were used in the analysis. The baseline value was defined as the last available value before first study treatment administration.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Visual Analogue Scale (VAS) for Rhinosinusitis at Week 24', 'description': 'The VAS for rhinosinusitis was used to evaluate the total disease severity. Rhinosinusitis was divided into mild, moderate and severe based on total severity VAS score (0 to 10 centimeters \\[cm\\] where mild: VAS 0 to 3; moderate: VAS \\>3 to 7 and severe: VAS \\>7 to 10). The participants were asked to indicate on a VAS the answer to the question: ""How troublesome are your symptoms of your rhinosinusitis?"" The range of the VAS was from 0 (not troublesome) to 10 (worst thinkable troublesome), where higher score indicated worse disease. For participants who discontinued for other reasons, missing data were imputed using multiple imputation techniques assuming missing at random, and non-missing data collected after treatment discontinuation were used in the analysis. The baseline value was defined as the last available value before first study treatment administration.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation at the End of 24-Week Treatment Period', 'description': 'An Adverse Event (AE) was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were defined as AEs that developed or worsened in grade or became serious during TE period which was defined as the period from the time of first dose of study treatment until the last visit in the study. Serious adverse events (SAE) were defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. Data reported is till the end of 24-week treatment period.', 'timeFrame': 'From Baseline (Day 1) up to Week 24'}]",8,18 Years,,ALL,False,Sanofi,INDUSTRY,1,25.0,ACTUAL,2025-09-01T16:18:18.430773,v2_robust,True,True,True,False,True,
NCT05108922,A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4),"A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease",Donanemab,"['LY3002813', 'Aducanumab', 'Donanemab']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Mild Cognitive Impairment (MCI),"['Mild Cognitive Impairment (MCI)', 'Alzheimer Disease']","[""Alzheimer's Disease with MCI or Mild Dementia""]",COMPLETED,,2021-11-16,2023-09-19,"[{'measure': 'Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab', 'description': ""Amyloid deposition in the brain is one of the defining neuropathologic findings of Alzheimer's disease (AD). Amyloid PET scan assesses cerebral amyloid load using florbetapir tracer which is standardized into Centiloids for evaluation of AD. Florbetapir exhibits high affinity specific binding to amyloid plaques. Centiloid values on Centiloid scale is based on mean composite Standardized Uptake Value Ratio (SUVR) in cingulate, frontal, parietal and temporal cortexes using whole cerebellum as reference region. SUVR is ratio of tracer uptake in each of cingulate, frontal, parietal and temporal cortexes relative to cerebellum. Complete brain amyloid plaque clearance is a binary outcome and is defined as a Centiloid value \\<24.1 from the florbetapir F18 PET scan."", 'timeFrame': '6 Months'}, {'measure': 'Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Low/Medium (Intermediate) Subpopulation (Superiority) on Donanemab Versus Aducanumab', 'description': 'Complete brain amyloid plaque clearance is a binary outcome and is defined as a Centiloid value \\<24.1 from the florbetapir F18 PET scan.', 'timeFrame': '6 Months'}]","[{'measure': 'Mean Absolute Change From Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on Donanemab Versus Aducanumab', 'description': 'Florbetapir PET imaging was used as a quantitative amyloid biomarker. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a Centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. A negative change indicates an improvement from baseline.', 'timeFrame': 'Baseline, 6 Months'}, {'measure': 'Mean Percent Change From Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) Donanemab Versus Aducanumab', 'description': 'Florbetapir PET imaging was used as a quantitative amyloid biomarker. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a Centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. A negative change indicates an improvement from baseline.', 'timeFrame': 'Baseline, 6 Months'}, {'measure': 'Change From Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan in the Low/Medium (Intermediate) Tau Subpopulation (Superiority) on Donanemab Versus Aducanumab', 'description': 'Florbetapir PET imaging was used as a quantitative amyloid biomarker. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a Centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. A negative change indicates an improvement from baseline.', 'timeFrame': 'Baseline, 6 Months'}, {'measure': 'Mean Absolute Change From Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on Donanemab Versus Aducanumab', 'description': 'Florbetapir PET imaging was used as a quantitative amyloid biomarker. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a Centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. A negative change indicates an improvement from baseline.', 'timeFrame': 'Baseline, 12 Months'}, {'measure': 'Mean Percent Change From Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) Donanemab Versus Aducanumab', 'description': 'Florbetapir PET imaging was used as a quantitative amyloid biomarker. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a Centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. A negative change indicates an improvement from baseline.', 'timeFrame': 'Baseline, 12 Months'}, {'measure': 'Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab', 'description': ""Amyloid deposition in the brain is one of the defining neuropathologic findings of Alzheimer's disease (AD). Amyloid PET scan assesses cerebral amyloid load using florbetapir tracer which is standardized into Centiloids for evaluation of AD. Florbetapir exhibits high affinity specific binding to amyloid plaques. Centiloid values on Centiloid scale is based on mean composite Standardized Uptake Value Ratio (SUVR) in cingulate, frontal, parietal and temporal cortexes using whole cerebellum as reference region. SUVR is ratio of tracer uptake in each of cingulate, frontal, parietal and temporal cortexes relative to cerebellum. Complete brain amyloid plaque clearance is a binary outcome and is defined as a Centiloid value \\<24.1 from the florbetapir F18 PET scan."", 'timeFrame': '12 Months'}, {'measure': 'Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Low/Medium (Intermediate) Subpopulation (Superiority) on Donanemab Versus Aducanumab', 'description': ""Amyloid deposition in the brain is one of the defining neuropathologic findings of Alzheimer's disease (AD). Amyloid PET scan assesses cerebral amyloid load using florbetapir tracer which is standardized into Centiloids for evaluation of AD. Florbetapir exhibits high affinity specific binding to amyloid plaques. Centiloid values on Centiloid scale is based on mean composite Standardized Uptake Value Ratio (SUVR) in cingulate, frontal, parietal and temporal cortexes using whole cerebellum as reference region. SUVR is ratio of tracer uptake in each of cingulate, frontal, parietal and temporal cortexes relative to cerebellum. Complete brain amyloid plaque clearance is a binary outcome and is defined as a Centiloid value \\<24.1 from the florbetapir F18 PET scan."", 'timeFrame': '12 Months'}, {'measure': 'Mean Absolute Change From Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan in the Low/Medium (Intermediate) Tau Subpopulation (Superiority) on Donanemab Versus Aducanumab', 'description': 'Florbetapir PET imaging was used as a quantitative amyloid biomarker. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a Centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. A negative change indicates an improvement from baseline.', 'timeFrame': 'Baseline, 12 Months'}, {'measure': 'Mean Absolute Change From Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on Donanemab 6 Months Versus Aducanumab 12 Months', 'description': 'Florbetapir PET imaging was used as a quantitative amyloid biomarker. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a Centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. A negative change indicates an improvement from baseline.', 'timeFrame': 'Baseline, 6 Months and 12 Months'}, {'measure': 'Mean Absolute Change From Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Non-inferiority) on Donanemab 6 Months Versus Aducanumab 12 Months', 'description': 'Florbetapir PET imaging was used as a quantitative amyloid biomarker. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a Centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. A negative change indicates an improvement from baseline.', 'timeFrame': 'Baseline, 6 Months and 12 Months'}, {'measure': 'Mean Absolute Change From Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on Donanemab Versus Aducanumab', 'description': 'Florbetapir PET imaging was used as a quantitative amyloid biomarker. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a Centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. A negative change indicates an improvement from baseline.', 'timeFrame': 'Baseline, 18 Months'}, {'measure': 'Time to Reach Complete Amyloid Plaque Clearance on Donanemab Versus Aducanumab', 'description': 'Time to reach complete amyloid plaque clearance at 18 months was evaluated.', 'timeFrame': '18 Months'}, {'measure': 'Mean Percent Change From Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) Donanemab Versus Aducanumab', 'description': 'Florbetapir PET imaging was used as a quantitative amyloid biomarker. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a Centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. A negative change indicates an improvement from baseline.', 'timeFrame': 'Baseline, 18 Months'}, {'measure': 'Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab', 'description': ""Amyloid deposition in the brain is one of the defining neuropathologic findings of Alzheimer's disease (AD). Amyloid PET scan assesses cerebral amyloid load using florbetapir tracer which is standardized into Centiloids for evaluation of AD. Florbetapir exhibits high affinity specific binding to amyloid plaques. Centiloid values on Centiloid scale is based on mean composite Standardized Uptake Value Ratio (SUVR) in cingulate, frontal, parietal and temporal cortexes using whole cerebellum as reference region. SUVR is ratio of tracer uptake in each of cingulate, frontal, parietal and temporal cortexes relative to cerebellum. Complete brain amyloid plaque clearance is a binary outcome and is defined as a Centiloid value \\<24.1 from the florbetapir F18 PET scan."", 'timeFrame': '18 Months'}, {'measure': 'Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Low/Medium (Intermediate) Subpopulation (Superiority) on Donanemab Versus Aducanumab', 'description': 'Complete brain amyloid plaque clearance is a binary outcome and is defined as a Centiloid value \\<24.1 from the florbetapir F18 PET scan.', 'timeFrame': '18 Months'}, {'measure': 'Mean Absolute Change From Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan in the Low/Medium (Intermediate) Tau Subpopulation (Superiority) on Donanemab Versus Aducanumab', 'description': 'Florbetapir PET imaging was used as a quantitative amyloid biomarker. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a Centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. A negative change indicates an improvement from baseline.', 'timeFrame': 'Baseline, 18 Months'}, {'measure': 'Mean Absolute Change From Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Non-inferiority) on Donanemab 6 Months Versus Aducanumab 18 Months', 'description': 'Florbetapir PET imaging was used as a quantitative amyloid biomarker. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a Centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. A negative change indicates an improvement from baseline.', 'timeFrame': 'Baseline, 6 Months and 18 Months'}]",19,50 Years,85 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,148.0,ACTUAL,2025-09-01T16:18:18.430928,v2_robust,True,True,True,False,False,
NCT04193722,The Effect of Hyperbaric OxygeN Therapy on brEast Cancer Patients With Late Radiation toxicitY - UMBRELLA HONEY Trial,The Effect of Hyperbaric Oxygen Therapy on Breast Cancer Patients With Late Radiation Toxicity,Hyperbaric oxygen therapy,"['Oxygen', 'Hyperbaric oxygen therapy']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,"['Breast Cancer', 'Radiation Toxicity']","['Breast cancer', 'Radiotherapy', 'Hyperbaric oxygen therapy', 'Late toxicity', 'Trials within cohorts', 'Patient reported outcomes']",COMPLETED,,2019-08-28,2023-05-08,"[{'measure': 'Change in breast/chest wall pain: EORTC QLQ-BR23 questionnaire', 'description': 'The primary endpoint of this study is the difference in proportion of patient-reported breast/chest wall pain grade 3-4 between control and intervention group. Pain is assessed by means of the EORTC QLQ-BR23 questionnaire on a 4-point Likert scale. At baseline all patients have a pain score of 3 or 4 (see inclusion criteria). The proportion of patients with 3-4 at 6 months will be compared between intervention and control group. A higher score indicates more pain.', 'timeFrame': 'Baseline and 6 months after baseline (i.e. 3 months after HBOT)'}]","[{'measure': 'Change in patient-reported quality of life: (EORTC QLQ) C30', 'description': 'Quality of life (QoL) measured by European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30. QoL will be scored on a scale of 0-100. A higher score indicates a better outcome. Change in score between baseline and 6 months will be compared between intervention and control group.', 'timeFrame': 'Baseline and 6 months after baseline (i.e. 3 months after HBOT)'}, {'measure': 'Change in patient-reported late radiation toxicity', 'description': 'Late radiation toxicity is assessed by means of a late radiation toxicity questionnaire (ability to move the arm, (breast) edema, fibrosis) in both control group and intervention group. Change in patient reported late radiation toxicity will be compared between intervention and control group. Late radiation toxicity will be assessed on a 4-point Likert scale. A higher score indicates worse outcomes.', 'timeFrame': 'Baseline and 6 months after baseline (i.e. 3 months after HBOT)'}, {'measure': 'Physician-reported late radiation toxicity', 'description': 'Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 only in intervention group. CTCAE criteria are assessed on a scale of 0-3.', 'timeFrame': 'Baseline (prior to HBOT), 3 months after baseline (i.e. after HBOT) and 6 months after baseline (i.e. 3 months after the last HBO session)'}, {'measure': 'Patient-reported cosmetic outcome', 'description': 'Assessed by means of the breast cancer questionnaire (BREAST-Q) in both control group and intervention group. BREAST-Q scores will be assessed using the BREAST-Q scoring tables.', 'timeFrame': 'Baseline and 6 months after baseline (i.e. 3 months after HBOT)'}, {'measure': 'Physician-reported cosmetic outcome', 'description': 'Reported by means of medical photograph (cosmetic outcome judged by group of experts and ""Breast Cancer Conservative Treatment - cosmetic results"" (BCCT.core) program) and with physical examination using the Patient and Observer Scar Assessment Scale (POSAS) score v2.0. Physician reported cosmetic outcome will only be assessed in the intervention group.', 'timeFrame': 'Baseline and 6 months after baseline (i.e. 3 months after HBOT)'}, {'measure': 'Number of participants with side effects of treatment with hyperbaric oxygen therapy', 'description': 'Side effects of HBOT will be monitored using the MacFie classification only in the intervention group.', 'timeFrame': 'During hyperbaric oxygen treatment sessions and at 3 months after last HBO session'}, {'measure': 'Oxygenation of the skin', 'description': 'Skin oxygenation will be measured prior to HBOT and after last treatment session using transcutaneous oxygen measurement. The contralateral breast will be used as a reference. Only assessed in the intervention group.', 'timeFrame': 'Baseline and prior to last hyperbaric oxygen session (i.e. 3 months after baseline).'}]",8,18 Years,,FEMALE,False,UMC Utrecht,OTHER,0,189.0,ACTUAL,2025-09-01T16:18:18.431023,v2_robust,True,True,True,False,True,
NCT00704522,Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED),Evaluation of Adherence Rate in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program.,Ribavirin (SCH 18908),"['Rebetol', 'Ribavirin (SCH 18908)']",2,OBSERVATIONAL,[],,,"Hepatitis C, Chronic","['Hepatitis C, Chronic', 'Hepacivirus']",[],COMPLETED,,2005-03,2009-04,"[{'measure': 'Number of Participants Who Complete Treatment With PegIntron Pen/Rebetol Therapy for Hepatitis C When Administered With a Patient Assistance Program', 'timeFrame': '24 or 48 weeks (depending on genotype) and 24 weeks of follow up'}, {'measure': 'Average Length of Treatment With PegIntron/Rebetol', 'timeFrame': 'After start of treatment'}]",[],2,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,601.0,ACTUAL,2025-09-01T16:18:18.431045,v2_robust,False,True,True,False,False,
NCT03928522,Antibiotic Elution in Total Knee Arthroplasty,Prospective Randomized Study Investigating the Characterization of Antibiotics From Antibiotic Impregnated Cement After Total Knee Arthroplasty,hand mixed vancomycin,"['Vancomycin', 'hand mixed tobramycin', 'Tobramycin', 'hand mixed vancomycin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Total Knee Replacement,['Total Knee Replacement'],[],COMPLETED,,2019-01-28,2019-09-30,"[{'measure': 'Amount of Vancomycin and Tobramycin Eluted From Hand Mixed Cement With Both Antibiotics After Total Knee Arthroplasty', 'description': 'We wanted to measure the effect of elution level of vancomycin and tobramycin together', 'timeFrame': '24 hours'}]",[],1,18 Years,,ALL,False,Washington University School of Medicine,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:18.431134,v2_robust,True,True,True,False,False,
NCT00516022,"Mistletoe as Complementary Treatment in Patients With Advanced Non-small-cell Lung Cancer (NSCLC), Treated With Carboplatin/Gemcitabine Chemotherapy Combination.","Mistletoe as Complementary Treatment in Patients With Advanced Non-small-cell Lung Cancer (NSCLC), Treated With Carboplatin/Gemcitabine Chemotherapy Combination: Randomized Phase II Study",Mistletoe extract,"['Mistletoe extract', ""There's no drug to be administered in the control group.""]",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Non Small Cell Lung Cancer,['Non Small Cell Lung Cancer'],[],COMPLETED,,2007-04,2011-05,"[{'measure': 'Quality Of Life', 'description': 'To check the effect of the treatment(or lack of it) on the quality of life of the patients enrolled to the trial.', 'timeFrame': 'During the trial'}, {'measure': 'Improvement in QOL. Improvement in the toxicity profile of the chemotherapy treatment', 'description': 'To check on the difference in QoL of all patients.', 'timeFrame': 'During all the trial'}]","[{'measure': 'Objective Response', 'description': 'The patients are asked to answer questions and the doctor will check blood works resolts.', 'timeFrame': 'During all the duration of the trial'}, {'measure': 'Improvement in time to tumor progression (TTP) and survival Safety profile of mistletoe extract with combination of chemotherapy treatment', 'description': 'Looking out for difference in toxicity profile of all patients', 'timeFrame': 'During duration of all the trial'}]",4,18 Years,,ALL,False,Rambam Health Care Campus,OTHER,1,79.0,ACTUAL,2025-09-01T16:18:18.431230,v2_robust,True,True,True,False,True,
NCT05176951,A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease,"A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease",Treprostinil Palmitil,"['INS1009', 'Treprostinil Palmitil', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Pulmonary Hypertension,['Pulmonary Hypertension'],"['Pulmonary Hypertension', 'Interstitial Lung Disease', 'Treprostinil Palmitil']",COMPLETED,,2022-12-22,2024-03-14,"[{'measure': 'Number of Participants Who Experience Any Number of Treatment Emergent Adverse Events (TEAEs)', 'timeFrame': 'Up to Day 140'}, {'measure': 'Number of Participants Who Experience Any Number of Serious Adverse Events (SAEs)', 'timeFrame': 'Up to Day 140'}, {'measure': 'Change from Baseline in Saturation of Peripheral Capillary Oxygenation (SpO2) Levels', 'timeFrame': 'Pre-, during, and post- 6-minute walk test (6MWT) at Baseline, Week 5, Week 10, and Week 16'}]","[{'measure': 'Maximum Plasma Concentration (Cmax) of Treprostinil Palmitil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'Cmax of Treprostinil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'Time to Maximum Plasma Concentration (Tmax) of Treprostinil Palmitil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'Tmax of Treprostinil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'Area Under Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUCtau) of Treprostinil Palmitil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'AUCtau of Treprostinil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'Area Under Concentration-time Curve From 0 to Infinity (AUC∞) of Treprostinil Palmitil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'AUC∞ of Treprostinil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'Area Under Concentration-time Curve From Time 0 to Last Measurable Concentration (AUClast) of Treprostinil Palmitil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'AUClast of Treprostinil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'Apparent Total Clearance (CL/F) of Treprostinil Palmitil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'CL/F of Treprostinil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'Elimination Half-life (t1/2) of Treprostinil Palmitil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 't1/2 of Treprostinil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'Apparent Volume of Distribution After Terminal Phase (Vd/F) of Treprostinil Palmitil', 'timeFrame': 'Day 1 to Week 16'}, {'measure': 'Vd/F of Treprostinil', 'timeFrame': 'Day 1 to Week 16'}]",19,18 Years,80 Years,ALL,False,Insmed Incorporated,INDUSTRY,0,39.0,ACTUAL,2025-09-01T16:18:18.431272,v2_robust,True,True,True,False,True,
NCT02060851,Effects of Early Short-term Intravenous Iron Supplements Combined EPO in Preterm Infants,Effects of Early Parenteral Iron Combined Erythropoietin in Preterm Infants,Vifor,"['Vifor', 'iron-supplemented combined EPO group', 'an iron-supplemented group', 'Vifor and EPO']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Malnutrition,['Malnutrition'],"['EPO', 'Intravenous iron', 'iron storage', 'preterm anemia']",COMPLETED,,2014-02,2014-06,"[{'measure': 'Number of participants with Hematological evaluation', 'description': 'Hematological evaluation including RBC, Hb, MCV, MCH, MCHC, RET, CRP were measured before and after the intervention. The three groups were all peripheral blood.', 'timeFrame': 'up to 2 weeks'}]","[{'measure': 'Iron storage', 'description': 'Iron storage evaluation including ferritin, serum iron, TIBC on the days were measured before and after the intervention.', 'timeFrame': 'up to 2 weeks'}]",2,,24 Hours,ALL,False,Kunshan First People's Hospital Affiliated to Jiangsu University,INDUSTRY,0,96.0,ACTUAL,2025-09-01T16:18:18.431280,v2_robust,True,True,True,False,False,
NCT00143351,Mozart Relapse Study,"Open Extension Study Evaluating the Long-term Efficacy, Safety, and Tolerability of Oral Ziprasidone in the Treatment of Resistant/Intolerant Schizophrenic Patients Who Have Acutely Responded to Ziprasidone in the Mozart Study",Ziprasidone,['Ziprasidone'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Schizophrenia,['Schizophrenia'],[],COMPLETED,,2003-06,2005-09,[{'measure': 'long-term efficacy of oral Ziprasidone in the maintenance treatment'}],[{'measure': 'To assess the efficacy of ziprasidone in the relapse prevention of schizophrenia To collect long-term data on safety and tolerability of oral Ziprasidone'}],2,18 Years,,ALL,False,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,0,75.0,,2025-09-01T16:18:18.431291,v2_robust,True,True,True,False,True,
NCT00498251,Prevention of Lung Edema After Thoracic Surgery,Does Inhaled Salbutamol Prevent Lung Edema After Thoracic Surgery? A Randomized Controlled Study,inhalation of salbutamol (5 mg),"['inhalation of salbutamol (5 mg)', 'ipratropium']",2,INTERVENTIONAL,['NA'],,,"Lung Injury, Acute","['Lung Injury, Acute', 'Thoracotomy', 'Anesthesia', 'Intensive Care, Surgical', 'Extravascular Lung Water']","['lung injury, acute', 'thoracic surgical procedures', 'lung cancer', 'salbutamol']",COMPLETED,,2004-09,2007-06,"[{'measure': 'reduction in extravascular lung water', 'timeFrame': 'within the first 24 hours after lung surgery'}]","[{'measure': 'changes in oxygenation indices, hemodynamics and radiological lung injury score', 'timeFrame': 'within the first 48 hours'}]",2,,,ALL,False,"University Hospital, Geneva",OTHER,0,30.0,ACTUAL,2025-09-01T16:18:18.431376,v2_robust,True,True,True,False,False,
NCT03255551,Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure,"Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients With Hypertension: Prospective, Multicenter, Observational Study",Amosartan,['Amosartan'],1,OBSERVATIONAL,[],,,Hypertension,['Hypertension'],[],COMPLETED,,2014-01-01,2015-12-31,"[{'measure': 'Patients with essential hypertension evaluated the mean blood pressure after taking amosartan.', 'description': 'Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients with Hypertension', 'timeFrame': '6 month'}]",[],1,18 Years,,ALL,False,Seoul National University Bundang Hospital,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:18.431385,v2_robust,False,True,True,False,False,
NCT01162551,Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma,Phase 2 Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma,Sirolimus and Methotrexate,"['Trexall®', 'Rapamune®', 'MTX', 'SIROLIMUS', 'METHOTREXATE', 'amethopterin', 'Sirolimus and Methotrexate', 'AY-22989', 'rapamycin']",9,INTERVENTIONAL,['PHASE2'],PHASE2,,Cancer,"['Cancer', 'Leukemia', 'Lymphoma']","['Leukemia', ""Non-Hodgkin's Lymphoma""]",COMPLETED,,2010-05,2017-02,"[{'measure': 'Response Rate', 'description': 'Number of participants who achieve a Complete Response (CR), Complete Response with in the absence of total platelet recovery (CRp), or Partial Response (PR). Per response criteria in this protocol: Complete Response (CR) - M1 bone marrow (\\<5% blasts) with no evidence of circulating blasts or extramedullary disease and recovery of peripheral blood counts (absolute neutrophil count (ANC)\\> 500/μL and platelets \\> 50,000/ μL); Complete Response in the absence of total platelet recovery (CRp) - M1 bone marrow (\\<5% blasts) with no evidence of circulating blasts or extramedullary disease with recovery of peripheral blood counts except for platelets (ANC\\> 500/μL, platelets \\< 50,000uL); and Partial Response (PR) - M2 bone marrow (5% but \\<25% blasts), with no evidence of circulating blasts or extramedullary disease and normalization of peripheral blood counts (ANC \\> 500/μL and platelets \\>50,000/μL).', 'timeFrame': 'Day 28'}]","[{'measure': 'Number of Dose Adjustments To Maintain Trough Levels', 'description': 'One goal of this study is to maintain trough levels of sirolimus within a certain range. The outcome measure counts the number of dose adjustments up or down that were needed to meet goal level based on weekly tough level measurements.', 'timeFrame': 'Day 28'}]",2,,25 Years,ALL,False,Children's Hospital of Philadelphia,OTHER,1,5.0,ACTUAL,2025-09-01T16:18:18.431421,v2_robust,True,True,True,False,False,
NCT03957551,Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma,Cabozantinib and Pembrolizumab as a Front-line Therapy for Advanced Metastatic Melanoma,Cabozantinib,"['Pembrolizumab', 'Keytruda', 'XL184', 'Cabometyx®', 'Cabozantinib', 'COMETRIQ™']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced Metastatic Melanoma,['Advanced Metastatic Melanoma'],[],TERMINATED,Study was terminated early due to changes in the treatment of melanoma,2019-08-27,2024-09-12,"[{'measure': 'Phase I: Number of Participants With a Dose Limiting Toxicity (DLT) Using CTCAE, Version 4.03', 'description': 'All adverse events (AEs) will be considered in DLT assessment unless an event is clearly unrelated to trial treatment. The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 will be used.', 'timeFrame': 'Up to 21 days'}, {'measure': 'Phase II: Overall Response Rate', 'description': 'The overall response rate (ORR) is the percentage of patients with a complete response (CR) or partial response (PR) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1). A complete response (CR) is the disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \\<10 mm, and partial response (PR) is a \\>=30% decrease in the sum of the longest diameter of target lesions.', 'timeFrame': 'Initiation of treatment up to 2 years'}]","[{'measure': 'Disease Control Rate', 'description': 'The disease control rate (DCR) is the percentage of patients with a complete response (CR), partial response (PR) or stable disease (SD) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1). A complete response (CR) is the disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \\<10 mm, partial response (PR) is a \\>=30% decrease in the sum of the longest diameter of target lesions, and stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.', 'timeFrame': 'Initiation of treatment up to 2 years'}, {'measure': 'Progression-Free Survival', 'description': 'Progression-free survival (PFS) is defined as the time from study treatment initiation to the date of first documentation of disease progression or death due to any cause. Otherwise, patients were censored at date of last radiographic assessment.', 'timeFrame': 'Initiation of treatment up to 2 years'}, {'measure': 'Overall Survival at 2 Years', 'description': 'Overall survival (OS) is defined as the time from study treatment initiation to death due to any cause. Patients still alive were censored at the last date known to be alive. Cumulative OS was descriptively summarized over time with the Kaplan-Meier method. The landmark estimate at 2 years and associated 95% confidence interval is reported.', 'timeFrame': 'Initiation of treatment up to 2 years'}]",5,18 Years,,ALL,False,John Rieth,OTHER,2,28.0,ACTUAL,2025-09-01T16:18:18.431486,v2_robust,True,True,False,True,True,Study was terminated early due to changes in the treatment of melanoma
NCT05677451,"24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up","A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy, Pharmacokinetics and Safety of Remibrutinib (LOU064) for 24 Weeks in Adolescents From 12 to Less Than 18 Years of Age With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Followed by an Optional Open-label Extension for up to Another 3 Years and an Optional Safety Long-term Treatment-free Follow-up Period for up to an Additional 3 Years",LOU064 (blinded),"['LOU064 (blinded)', 'remibrutinib', 'placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Spontaneous Urticaria,['Chronic Spontaneous Urticaria'],"['BTK inhibitor', 'Chronic spontaneous urticaria', 'Urticaria activity score', 'Hives severity score', 'Itch severity score']",RECRUITING,,2023-07-11,2032-03-30,"[{'measure': 'Change from baseline in UAS7', 'description': 'The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. Complete UAS7 response is UAS7 = 0.\n\nNegative change from baseline indicates improvement.', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Change fron baseline in ISS7', 'description': 'Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate).\n\nNegative change from baseline indicates improvement.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change from baseline in HSS7', 'description': 'Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (\\>12 hives/12 hours).\n\nNegative change from baseline indicates improvement.', 'timeFrame': 'Baseline, Week 12'}]","[{'measure': 'Cmax of remibrutinib', 'description': 'The maximum (peak) observed blood drug concentration after single dose administration', 'timeFrame': 'At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake'}, {'measure': 'Tmax of remibrutinib', 'description': 'The time to reach maximum (peak) blood drug concentration after single dose administration', 'timeFrame': 'At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake'}, {'measure': 'AUClast of remibrutinib', 'description': 'The Area Under the Curve (AUC) from pre-dose to the last measurable concentration sampling time', 'timeFrame': 'At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake'}, {'measure': 'Absolute change from baseline in ISS7', 'description': 'Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate).\n\nNegative change from baseline indicates improvement.', 'timeFrame': 'Baseline - Week 12'}, {'measure': 'Absolute change from baseline in HSS7', 'description': 'Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (\\>12 hives/12 hours).\n\nNegative change from baseline indicates improvement.', 'timeFrame': 'Baseline - Week 12'}, {'measure': 'Achievement of UAS7 ≤ 6 (yes/no)', 'description': 'Disease activity control is defined as UAS7 ≤ 6. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42.', 'timeFrame': 'Week 12 and over time'}, {'measure': 'Achievement of UAS7 = 0 (yes/no)', 'description': 'Complete absence of hives and itch is defined as UAS7 = 0. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42.', 'timeFrame': 'Week 12 and over time'}, {'measure': 'Absolute change from baseline in CDLQI score', 'description': 'The Children Dermatology life Quality Index (CDLQI) score range is 0 to 30, with 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).', 'timeFrame': 'Week 12'}, {'measure': 'Number of weeks without angioedema, assessed by the cumulative number of weeks with an AAS7 = 0 response', 'description': 'Angioedema Activity Score (AAS7) is a measure of the frequency and intensity of angioedema episodes. The total possible range of scores over 7 days is 0-105 where higher scores indicate increased angioedema activity.', 'timeFrame': 'baseline - Week 12'}, {'measure': 'Occurrence of treatment-emergent adverse events (AE) and serious adverse events (SAE) during the core period', 'description': 'To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the core period of the study.', 'timeFrame': '28 weeks'}, {'measure': 'Occurrence of treatment emergent AEs, and SAEs during the Open Label Extension (OLE) period', 'description': 'To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the OLE period of the study.', 'timeFrame': '3 years'}]",14,12 Years,17 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,100.0,ESTIMATED,2025-09-01T16:18:18.431506,v2_robust,True,True,False,False,True,
NCT02933229,"The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study",,H. pylori eradication,['H. pylori eradication'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Helicobacter Pylori,"['Helicobacter Pylori', 'the Operative Link on Gastric Intestinal Metaplasia', 'Operative Link on Gastric Intestinal Assessment']",[],NOT_YET_RECRUITING,,2016-10,2031-10,"[{'measure': 'The proportion of more severe inflammation in the gastric mucosa for 15 years after H. pylori eradication at five points of the stomach compared with original status', 'timeFrame': '15 years'}, {'measure': 'The proportion of more severe atrophy in the gastric mucosa for 15 years after H. pylori eradication at five points of the stomach compared with original status', 'timeFrame': '15 years'}, {'measure': 'The proportion of more severe IM in the gastric mucosa for 15 years after H. pylori eradication at five points of the stomach compared with original status', 'timeFrame': '15 years'}]","[{'measure': 'The proportion of more advanced stages for 15 years after H. pylori eradication by using operative link on gastritis assessment (OLGA) system compared with original status.', 'timeFrame': '15 years'}, {'measure': 'The proportion of more advanced stages for 15 years after H. pylori eradication by using operative link for gastritis intestinal metaplasia (OLGIM) system compared with original status.', 'timeFrame': '15 years'}]",5,18 Years,60 Years,ALL,False,Shandong University,OTHER,0,300.0,ESTIMATED,2025-09-01T16:18:18.431569,v2_robust,True,True,False,False,False,
NCT01890629,"Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)","A Multicenter, Randomized, Active-controlled, Parallel Group, Open-label, Exploratory Study to Evaluate the Efficacy on Glucose Variability(MAGE, Glucose SD) and Safety of Initial Combination Therapy of Gemigliptin 50mg q.d., Versus Sitagliptin 100mg q.d., or Glimepiride 2mg q.d. With Metformin 500-1,000mg q.d. in Patients With Type 2 Diabetes",Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin,['Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],['diabetes mellitus'],COMPLETED,,2013-05,2014-08,"[{'measure': 'Mean Amplitude Glycemic Excursion', 'timeFrame': 'Change of MAGE at Week 12 from baseline'}]","[{'measure': 'Glucagon', 'timeFrame': 'Change of Glucagon at Week 12 from baseline'}, {'measure': 'Active GLP-1', 'timeFrame': 'Change of Active GLP-1 at Week 12 from baseline'}, {'measure': 'CRP', 'timeFrame': 'Change of CRP at Week 12 from baseline'}, {'measure': 'Nitrotyrosine', 'timeFrame': 'Change of nitrotyrosine at Week 12 from baseline'}, {'measure': 'Glycated albumin', 'timeFrame': 'Change of glycated albumin at Week 4 from baseline'}, {'measure': 'Fructosamine', 'timeFrame': 'Change of fructosamine at Week 4 from baseline'}, {'measure': 'Glucose Standard Deviation in CGMS data', 'timeFrame': 'Change of Glucose SD at Week 12 from baseline'}]",8,20 Years,70 Years,ALL,False,LG Life Sciences,INDUSTRY,0,69.0,ACTUAL,2025-09-01T16:18:18.431607,v2_robust,True,True,True,False,False,
NCT00805129,Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium,Phase II Study of Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium,Everolimus,['Everolimus'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Bladder Cancer,"['Bladder Cancer', 'Metastatic Transitional Cell Carcinoma']","['URETER', 'URINARY BLADDER', 'RAD001', 'Everolimus', 'Urothelium', '08-123']",COMPLETED,,2008-12-05,2021-12-15,"[{'measure': 'Number of Participants Who Were Progression Free at 2 Months', 'description': 'To measure the two-month PFS rate of Everolimus (RAD001) as determined by RECIST. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions', 'timeFrame': '2 months'}, {'measure': 'Number of Participants Evaluated for Toxicity', 'description': 'To determine the safety and toxicity of Everolimus (RAD001) in this patient population with toxicities being evaluated by CTCAE v3.0', 'timeFrame': 'through study completion, up to 25 months'}]","[{'measure': 'Response Rate', 'description': 'To determine the response rate of Everolimus in patients with progressive urothelial cancer who have received prior cytotoxic chemotherapy using the Response Evaluation Criteria in Solid Tumors (version 1.0). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', 'timeFrame': 'through study completion, up to 25 months'}, {'measure': 'Proportion of Pretreatment Primary Tumor Samples With mTOR Pathway Markers', 'description': 'To assess markers for activated mTOR pathway (including phospho-S6 and phospho-4E BP1) in all pre-treatment tissue specimens and correlate with response to treatment and PFS.', 'timeFrame': '25 months'}]",4,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,46.0,ACTUAL,2025-09-01T16:18:18.431657,v2_robust,True,True,True,False,True,
NCT02957929,"Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally","A Phase 1, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001, to Investigate the Effect of Food on APX001 and to Investigate the Drug-Drug Interaction Potential of APX001",APX001 single IV dose,"['APX001 single oral dose 3', 'APX001 single IV dose', 'APX001 multiple oral doses 2', 'Matching placebo control', 'APX001 single oral dose 1', 'APX001 multiple oral doses 1', 'Cytochrome P450 substrates', 'APX001 single oral dose 2', 'APX001 multiple oral doses 3', 'APX001 single oral dose fasted', 'APX001 single oral dose fed']",11,INTERVENTIONAL,['PHASE1'],PHASE1,,Fungal Infection,['Fungal Infection'],[],COMPLETED,,2016-10-31,2017-04-20,"[{'measure': 'Safety and tolerability of single and multiple oral doses of APX001 as measured by adverse events (AEs), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG).', 'timeFrame': '21 days'}]","[{'measure': 'Pharmacokinetics of single and multiple doses of APX001 as measured by maximum observed concentration (Cmax).', 'timeFrame': '21 days'}, {'measure': 'Pharmacokinetics of single and multiple dose of APX001 as measured by area under the curve (AUC).', 'timeFrame': '21 days'}, {'measure': 'Pharmacokinetics of single and multiple doses of APX001 as measured by terminal half life (t1/2).', 'timeFrame': '21 days'}, {'measure': 'Pharmacokinetics of single and multiple doses of APX001 as measured by volume of distribution (Vd).', 'timeFrame': '21 days'}, {'measure': 'Pharmacokinetics of single and multiple doses of APX001 as measured by elimination rate constant (Kel).', 'timeFrame': '21 days'}, {'measure': 'Pharmacokinetics of single and multiple doses of APX001 as measured by accumulation ratio.', 'timeFrame': '21 days'}]",7,18 Years,55 Years,ALL,True,Basilea Pharmaceutica,INDUSTRY,0,46.0,ACTUAL,2025-09-01T16:18:18.431672,v2_robust,True,True,True,False,True,
NCT02220829,Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy,Prophylactic Versus Therapeutic Alpha-Blockers in Prostate Cancer Patients Undergoing Radical Course Radiation Therapy ± HDR Boost. a GROUQ Phase III Randomized Clinical Trial (PCS-VII).,Preventive administration of Rapaflo,"['Rapaflo', 'Standard Care', 'Preventive administration of Rapaflo', 'Silodosin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Urinary Problems,"['Urinary Problems', 'Prostate Cancer']","['alpha-blocker', 'symptomatic urinary problems', 'radiation therapy', 'prostate cancer']",COMPLETED,,2016-06,2023-08,"[{'measure': 'To determine the rate of increase and the mean difference from the baseline IPSS score in the alpha-blocker (Rapaflo) group compared to the standard arm.', 'timeFrame': 'IPSS will be assessed before radiation therapy (RT), 4 weeks into RT, the last day of RT, and monthly for first 6 months and also at 9 and 12 months from the start of RT.'}]","[{'measure': 'To determine the rate of IPSS return to baseline, in the alpha-blocker (Rapaflo) group compared to the standard after the end of radiation treatment.', 'timeFrame': 'IPSS score will be assessed at before radiation therapy (RT), at 4 and 12 weeks after the end of RT.'}, {'measure': 'To determine the rate of therapy dependence in both groups.', 'timeFrame': 'At 3 and 6 months from start of radiation therapy.'}]",3,18 Years,,MALE,False,Sir Mortimer B. Davis - Jewish General Hospital,OTHER,0,148.0,ACTUAL,2025-09-01T16:18:18.431695,v2_robust,True,True,True,False,False,
NCT05370729,Impact of N-acetylcysteine Infusion and Intralipid Infusion on Myocardial Injury in Aluminum Phosphide Toxicity,Impact of Combining N-acetylcysteine Intravenous Infusion and Intralipid Emulsion Infusion Versus Intralipid Infusion Alone on Myocardial Injury in Aluminum Phosphide Toxicity,N-acetyl cysteine,"['NAC', 'N-acetyl cysteine']",2,INTERVENTIONAL,['NA'],,,Myocardial Injury,['Myocardial Injury'],"['Aluminum phosphide poisonings', 'Intralipid emulsion', 'N-acetylcystiene', 'Myocardial injury', 'Echocardiography']",UNKNOWN,,2022-05,2025-05,"[{'measure': 'Echocardiography', 'description': 'Follow up cardiac function by echocardiography focusing on LV EF', 'timeFrame': '24 hours'}]","[{'measure': 'Renal function test', 'description': 'Effect on renal function by measuring serum creatinine and serum BUN', 'timeFrame': '24 hours'}, {'measure': 'Total days of ICU stay', 'description': 'ICU stay', 'timeFrame': 'Up to two weeks'}]",3,18 Years,70 Years,ALL,False,Assiut University,OTHER,0,58.0,ESTIMATED,2025-09-01T16:18:18.431855,v2_robust,True,True,False,False,False,
NCT03516331,A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects,"A Phase 1, Open Label, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects",FDL176 & FDL169 coadministration,['FDL176 & FDL169 coadministration'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Cystic Fibrosis,['Cystic Fibrosis'],['Cystic Fibrosis'],COMPLETED,,2018-03-07,2018-08-22,"[{'measure': 'Pharmacokinetic parameters, Cmax', 'description': 'The pharmacokinetic parameters of FDL176 when co-administered with FDL169, compared to the pharmacokinetics of FDL176 alone; maximal plasma concentration (Cmax)', 'timeFrame': '72 days'}]","[{'measure': 'Incidence of Treatment-Emergent Adverse Events', 'description': 'Safety and tolerability of FDL176 when co-administered with FDL169, compared to FDL176 alone. as determined by the incidence of adverse events (Aes) and serious adverse events (SAE)s.', 'timeFrame': '72 days'}]",2,18 Years,55 Years,ALL,True,Flatley Discovery Lab LLC,OTHER,0,16.0,ACTUAL,2025-09-01T16:18:18.431895,v2_robust,True,True,True,False,True,
NCT01087931,Pain Relief at Iliac Crest Bone Harvest Sites in Spine Surgery Using Bupivacaine,Local Anesthetic Use at Iliac Crest Bone Graft Site in Spinal Reconstructive Surgery,Bupivacaine,"['Marcaine.', 'Bupivacaine']",2,INTERVENTIONAL,['NA'],,,Pain,['Pain'],"['Local anesthetic', 'Iliac crest bone harvest', 'Patients undergoing spine surgery that require use of iliac crest bone autograft']",COMPLETED,,2010-04,2011-10,"[{'measure': 'Pain, Cumulative Visual Analog Score, 1st Follow Up', 'description': 'Cumulative Visual Analog Score pain score scores were calculated using the sum of scores (at rest and with movement, pain on average at rest and with movement, and maximum pain at rest and with movement) Range = 0-60 for cumulative visual analog pain score with 0=no pain and 60=worst pain ever.', 'timeFrame': 'about 4 to 5 weeks after surgery'}, {'measure': 'Pain, Cumulative Visual Analog Score, Final Follow up', 'description': 'Cumulative Visual Analog Score pain score scores were calculated using the sum of scores (at rest and with movement, pain on average at rest and with movement, and maximum pain at rest and with movement) Range = 0-60 for cumulative visual analog pain score with 0=no pain and 60=worst pain ever.', 'timeFrame': 'about 18 to 20 weeks after surgery'}]","[{'measure': 'Narcotic Use, 1st Follow up', 'description': 'Number of participants using narcotics for pain', 'timeFrame': 'about 4 to 5 weeks after surgery'}, {'measure': 'Narcotic Use, Final Follow up', 'description': 'Number of participants using narcotics for pain', 'timeFrame': 'about 18 to 20 weeks after surgery'}]",4,18 Years,,ALL,False,Vanderbilt University,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:18.431904,v2_robust,True,True,True,False,False,
NCT00159731,Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy,An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy,Pregabalin,['Pregabalin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetic Peripheral Neuropathy,['Diabetic Peripheral Neuropathy'],[],COMPLETED,,2005-01,2006-05,[{'measure': 'Adverse events'}],[],1,18 Years,,ALL,False,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,0,160.0,,2025-09-01T16:18:18.431934,v2_robust,True,True,True,False,True,
NCT00801931,Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders,Double Umbilical Cord Blood Transplantation for Patients With Malignant and Non-Malignant Disorders,Alemtuzumab,"['Lemtrada', 'Thymoglobulin', 'ATG[horse]', 'Neosar', 'Rabbit Antithymocyte Globulin', 'Cytoxan', 'Fludara', 'Atgam', 'Alemtuzumab', 'Tepadina', 'Busulfan', 'Myleran', 'Dilantin', 'Cyclophosphamide', 'Fludarabine', 'Thiotepa', 'Melphalan', 'Phenytoin', 'Alkeran', 'Fosphenytoin', 'Campath', 'Horse Antithymocyte Globulin', 'Busulfex']",23,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Leukemia,"['Leukemia', 'Lymphoma', 'Neuroblastoma', 'Immunodeficiencies', 'Anemia']","['Cord Blood Transplant', 'Allogeneic Stem Cell Transplant']",TERMINATED,Poor accrual,2007-09-06,2009-05-05,"[{'measure': 'Graft Failure Rate', 'description': 'Number of patients to experience graft failure.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Response Rate (Complete and Partial Response)', 'description': 'Response rate to each regimen will be measured.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS will be summarized using the Kaplan and Meier curves.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Disease Free Survival (DFS)', 'description': 'DFS will be summarized using the Kaplan and Meier curves.', 'timeFrame': 'Up to 2 years'}]",[],4,,30 Years,ALL,False,Columbia University,OTHER,0,1.0,ACTUAL,2025-09-01T16:18:18.431947,v2_robust,True,True,False,True,False,Poor accrual
NCT00003231,Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer,"Preoperative Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2)",cisplatin,"['cisplatin', 'docetaxel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Cancer,['Lung Cancer'],"['squamous cell lung cancer', 'large cell lung cancer', 'stage IIIA non-small cell lung cancer', 'adenocarcinoma of the lung']",COMPLETED,,1997-04,2000-09,[],[],0,18 Years,75 Years,ALL,False,Swiss Cancer Institute,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:18.431960,v2_robust,True,True,True,False,False,
NCT03217331,CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices,CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices,CRD-102,['CRD-102'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Right Heart Failure,"['Right Heart Failure', 'Left Ventricular Assist Device']",[],COMPLETED,,2018-03-06,2019-05-30,"[{'measure': 'Safety: Subject incidence of adverse events', 'description': 'Number of adverse events as a measure of safety and tolerability.', 'timeFrame': '40 days'}]",[],1,18 Years,85 Years,ALL,False,Cardiora Pty. Ltd.,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:18.431973,v2_robust,True,True,True,False,True,
NCT05151731,A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema,"A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients With Diabetic Macular Edema",Vamikibart,"['RO7200220', 'Lucentis', 'Vamikibart', 'Ranibizumab']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Diabetic Macular Edema,['Diabetic Macular Edema'],[],COMPLETED,,2021-12-31,2025-04-21,"[{'measure': 'Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants', 'timeFrame': 'Baseline, Week 44 and Week 48'}]","[{'measure': 'Number of Participants With Systemic and Ocular Adverse Events (AEs)', 'timeFrame': 'Up to Week 72'}, {'measure': 'Number of Participants With Abnormal Laboratory Findings, Abnormal Vital Signs Values, or Abnormal Electrocardiogram (ECG) Parameters', 'timeFrame': 'Up to Week 72'}, {'measure': 'Number of Participants With Abnormalities in Standard Ophthalmological Assessments', 'timeFrame': 'Up to Week 72'}, {'measure': 'Mean Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Previously Treated Participants', 'timeFrame': 'Baseline, Week 44 and Week 48'}, {'measure': 'Mean Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Overall Enrolled Population', 'timeFrame': 'Baseline, Week 44 and Week 48'}, {'measure': 'Mean Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Treatment-naïve Participants', 'timeFrame': 'Baseline, Week 20 and Week 24'}, {'measure': 'Mean Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Previously Treated Participants', 'timeFrame': 'Baseline, Week 20 and Week 24'}, {'measure': 'Mean Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall Enrolled Population', 'timeFrame': 'Baseline, Week 20 and Week 24'}, {'measure': 'Mean Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants', 'timeFrame': 'Baseline, Week 32 and Week 36'}, {'measure': 'Mean Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants', 'timeFrame': 'Baseline, Week 32 and Week 36'}, {'measure': 'Mean Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall Enrolled Population', 'timeFrame': 'Baseline, Week 32 and Week 36'}, {'measure': 'Change From Baseline in BCVA Over Time', 'timeFrame': 'From baseline up to end of study (up to Week 72)'}, {'measure': 'Percentage of Participants Gaining Greater Than or Equal to (≥) 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time', 'timeFrame': 'From baseline up to end of study (up to Week 72)'}, {'measure': 'Percentage of Participants Avoiding a Loss of ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time', 'timeFrame': 'From baseline up to end of study (up to Week 72)'}, {'measure': 'Percentage of Participants With BCVA ≥ 69 Letters (20/40 Snellen Equivalent), or ≥ 84 Letters (20/20 Snellen Equivalent) Over Time', 'timeFrame': 'From baseline up to end of study (up to Week 72)'}, {'measure': 'Percentage of Participants With BCVA of Less Than or Equal to (≤) 38 Letters (Snellen Equivalent 20/200) Over Time', 'timeFrame': 'From baseline up to end of study (up to Week 72)'}, {'measure': 'Change From Baseline in Central Subfield Thickness (CST) at Week 48', 'timeFrame': 'Baseline, Week 48'}, {'measure': 'Change From Baseline in CST at Week 36', 'timeFrame': 'Baseline, Week 36'}, {'measure': 'Change From Baseline in CST at Week 24', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change From Baseline in CST Over Time', 'timeFrame': 'From baseline up to end of study (up to Week 72)'}, {'measure': 'Percentage of Participants With Absence of Diabetic Macular Edema (DME) Over Time', 'timeFrame': 'From baseline up to end of study (up to Week 72)'}, {'measure': 'Percentage of Participants With Absence of Intraretinal Fluid and/or Subretinal Fluid Over Time', 'timeFrame': 'From baseline up to end of study (up to Week 72)'}]",23,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,394.0,ACTUAL,2025-09-01T16:18:18.431980,v2_robust,True,True,True,False,True,
NCT04448431,Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression,"A Randomised, Double-blind, Parallel-group, Active Controlled Study Evaluating the Efficacy of Vortioxetine Versus Desvenlafaxine in Adult Patients Suffering From Major Depressive Disorder With Partial Response to SSRI Treatment",Vortioxetine,"['Desvenlafaxine', 'Vortioxetine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Major Depressive Disorder,['Major Depressive Disorder'],[],COMPLETED,,2020-06-18,2022-02-04,"[{'measure': 'Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score', 'description': 'The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.', 'timeFrame': 'From baseline to Week 8'}]","[{'measure': 'Remission (defined as a MADRS total score =<10)', 'description': 'The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.', 'timeFrame': 'At Week 8'}, {'measure': 'Response (defined as a => 50% decrease from baseline in MADRS total score)', 'description': 'The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.', 'timeFrame': 'At Week 8'}, {'measure': 'Change in MADRS anhedonia factor score', 'description': '(based on items 1(apparent sadness),2 (reported sadness),6 (concentration difficulties),7 (lassitude),8 (inability to feel))', 'timeFrame': 'From baseline to Week 8'}, {'measure': 'Change in Digital Symbol Substitution Test (DSST) total score', 'description': 'DSST assesses psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-s period. Each correct symbol is counted, and the total score ranges from 0 (\\< normal functioning) to 133 (\\> normal functioning).', 'timeFrame': 'From baseline to Week 8'}, {'measure': 'The proportion number of Hard Choice/number of High Reward trials and number of Low choice/number of Low Reward trials when performing the Effort- Expenditure for Rewards Task (EEfRT)', 'description': ""The EEfRT is a computerized task which measures reward motivation in which participants are presented with a series of repeated trials during which they choose between performing a ''hard-task'' or an ''easy-task'' in order to earn varying amounts of monetary rewards."", 'timeFrame': 'From baseline to Week 8'}, {'measure': 'Change in Clinical Global Impression - Severity of Illness (CGI-S) score', 'description': 'The CGI-S scale measures the severity of psychiatric symptoms on a 7-point scale from 1-7. The scores indicated the following: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. The score ranged from 1-7, where 1 indicated absence of symptoms and higher score indicated greater severity of symptoms.', 'timeFrame': 'from baseline to Week 8'}, {'measure': 'Clinical Global Impression Scale- Global Improvement (CGI-I) score', 'description': ""The Clinical Global Impression - global improvement CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse)"", 'timeFrame': 'at Day 7,28,56'}, {'measure': 'Change in Functioning Assessment Short Test (FAST) total score', 'description': 'The FAST is a valid and reliable instrument, easy to apply which requires a short period of time to administer. Evaluates functioning taking into account the last 15 days. It was developed for the clinical evaluation of the main difficulties presented by psychiatric patients, and has been validated in several languages for patients with bipolar disorder. The FAST scale consists of 24 items which allow the assessment of six specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships and leisure time', 'timeFrame': 'From baseline to Week 8'}, {'measure': 'Change in FAST sub-domain scores', 'description': 'The FAST is a clinician-rated scale designed to assess difficulty in functioning. The FAST consists of 24 items in 6 specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, leisure time. Each item is rated on a 4-point scale from 0 (no difficulty) to 3 (severe difficulty). The items are summed to yield a total score ranging from 0 to 72 with higher scores reflecting more serious difficulties.', 'timeFrame': 'From baseline to Week 8'}, {'measure': 'Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) total score', 'description': 'The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)', 'timeFrame': 'From baseline to Week 8'}, {'measure': 'Change in Q-LES-Q work subscale', 'description': 'The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)', 'timeFrame': 'From baseline to Week 8'}, {'measure': 'Change in Q-LES-Q household duties subscale', 'description': 'The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)', 'timeFrame': 'From baseline to Week 8'}, {'measure': 'Change in Q-LES-Q school/course subscale', 'description': 'The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)', 'timeFrame': 'From baseline to Week 8'}, {'measure': 'Change in Q-LES-Q leisure time activities subscale', 'description': 'The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)', 'timeFrame': 'From baseline to Week 8'}, {'measure': 'Change in Q-LES-Q social relations subscale', 'description': 'The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good)', 'timeFrame': 'From baseline to Week 8'}]",16,18 Years,65 Years,ALL,False,H. Lundbeck A/S,INDUSTRY,0,605.0,ACTUAL,2025-09-01T16:18:18.431992,v2_robust,True,True,True,False,False,
NCT02833831,Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants,"A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive Controlled Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Subjects",ALS-008176,"['Moxifloxacin', 'Placebo', 'ALS-008176']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2016-06-02,2017-02-24,"[{'measure': 'Change from baseline in Corrected QT intervals (QTc)', 'description': 'Change from baseline in QTc intervals with Fredericia correction will be analyzed.', 'timeFrame': 'Baseline up to Day 2'}]","[{'measure': 'Number of participants with adverse events as a measure of safety and tolerability', 'timeFrame': '10 to 14 days after last study drug intake'}, {'measure': 'Change from baseline in ECG parameters: RR interval, PR interval and QRS interval', 'description': 'Change from baseline in other ECG parameters (RR interval, PR interval and QRS interval) will be analyzed.', 'timeFrame': 'Baseline up to Day 2'}, {'measure': 'ALS-008112 and ALS 008144 plasma concentration-effect relationship for changes in QT/QTc (Panels 1 and 2)', 'timeFrame': 'up to Day 15 in Panel 1; up to Day 2 in Panel 2'}, {'measure': 'Change from Baseline in QT/QTc interval in healthy subjects (Panel 2)', 'timeFrame': 'up to Day 2'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'timeFrame': 'up to Day 15 in Panel 1; up to Day 2 in Panel 2'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'timeFrame': 'up to Day 15 in Panel 1; up to Day 2 in Panel 2'}, {'measure': 'Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0- last])', 'timeFrame': 'up to Day 15 in Panel 1'}, {'measure': 'Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0- infinity])', 'timeFrame': 'up to Day 15 in Panel 1'}, {'measure': 'Elimination Half-Life (t1/2)', 'timeFrame': 'up to Day 15 in Panel 1'}, {'measure': 'Elimination Rate Constant (Lambda[z])', 'timeFrame': 'up to Day 15 in Panel 1'}, {'measure': 'Plasma Concentration at 24 hours post dosing', 'timeFrame': 'up to Day 15 in Panel 1'}, {'measure': 'Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24])', 'timeFrame': 'up to Day 15 in Panel 1; up to Day 2 in Panel 2'}, {'measure': 'Change from baseline in Heart Rate', 'description': 'Change from baseline in heart rate will be analyzed.', 'timeFrame': 'Baseline up to Day 2'}, {'measure': 'Change from baseline in T wave morphology', 'description': 'Change from baseline in T wave morphology will be analyzed.', 'timeFrame': 'Baseline up to Day 2'}, {'measure': 'Frequency of T wave morphology changes', 'description': 'T-wave morphology changes will be analyzed.', 'timeFrame': 'up to Day 2'}]",16,18 Years,50 Years,ALL,True,"Janssen Research & Development, LLC",INDUSTRY,0,103.0,ACTUAL,2025-09-01T16:18:18.432151,v2_robust,True,True,True,False,True,
NCT02607631,A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor,A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy,Pembrolizumab,['Pembrolizumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Thymic Epithelial Tumors,['Thymic Epithelial Tumors'],"['Thymic epithelial tumors', 'Pembrolizumab']",COMPLETED,,2015-11,2018-08,"[{'measure': 'Response rate by RECIST 1.1', 'description': 'complete response plus partial response as determined by RECIST 1.1', 'timeFrame': '24 months'}]","[{'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'include safety profiles', 'timeFrame': '24 months'}, {'measure': 'Progression free survival', 'description': 'time from the on-study date to date of disease progression', 'timeFrame': '24 months'}, {'measure': 'Overall survival', 'description': 'time from the on-study date to death as a result of any cause', 'timeFrame': '24 months'}]",4,18 Years,,ALL,False,Samsung Medical Center,OTHER,0,33.0,ACTUAL,2025-09-01T16:18:18.432162,v2_robust,True,True,True,False,True,
NCT05978531,Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice,"A Prospective, Observational Study of Bafiertam Evaluating Persistence on Treatment, Safety, Tolerability, and Effectiveness in Routine Clinical Practice.",Monomethyl Fumarate,"['Monomethyl Fumarate', 'BLS-11', 'Bafiertam']",3,OBSERVATIONAL,[],,,Relapsing Remitting Multiple Sclerosis,['Relapsing Remitting Multiple Sclerosis'],[],TERMINATED,Business decision,2023-08-17,2025-02-24,"[{'measure': 'Percentage of participants on treatment with Bafiertam at 1 Year.', 'description': 'Percentage of participants on treatment with Bafiertam at 1 Year.', 'timeFrame': '12 months'}]","[{'measure': 'Percentage of Participants on Treatment with Bafiertam at 6 months', 'description': 'Percentage of Participants on Treatment with Bafiertam at 6 months', 'timeFrame': '6 months'}, {'measure': 'Treatment Satisfaction Questionnaire for Medication (TSQM-9)', 'description': 'Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score (range 0 - 100) at Month 6 and 12 months.TSQM Version 9 is comprised of 9 questions that provide scores on four scales: effectiveness (3 items), convenience (3 items), and global satisfaction (3 items). The scale scores are transformed and range from 0 to 100. Higher scores indicate greater satisfaction.', 'timeFrame': '12 months'}, {'measure': 'Number of Participants with Adverse Events (AEs) Leading to Treatment Discontinuation.', 'description': 'Number of Participants with AEs Leading to Treatment Discontinuation.', 'timeFrame': '12 months'}]",4,18 Years,,ALL,False,Banner Life Sciences LLC,INDUSTRY,0,25.0,ACTUAL,2025-09-01T16:18:18.432171,v2_robust,False,True,False,True,True,Business decision
NCT01523431,Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients,Influence of Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype on Clinical Outcomes and Pharmacokinetics in Chinese Patients With Metastatic Colorectal Cancer,Irinotecan Injection [Camptosar],"['CPT-11', 'Irinotecan Injection [Camptosar]', 'Leucovorin', 'LV', '5-fluorouracil', '5-FU', 'FOLFIRI regimen']",7,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Metastatic Colorectal Cancer,['Metastatic Colorectal Cancer'],"['Colorectal cancer', 'Irinotecan', 'UGT1A1 genotype', 'Neutropenia', 'diarrhea', 'response', 'pharmacokinetic']",COMPLETED,,2012-03-08,2016-04-27,"[{'measure': 'Incidence of toxicity, especially neutropenia and diarrhea', 'description': 'Association between UGT1A1 polymorphism, CPT-11 dosage and incidence of toxicity, especially neutropenia and diarrhea.', 'timeFrame': 'From the beginning of treatment to the whole treatment period, an expected average of 6-8 months.'}]","[{'measure': 'Response rate', 'description': 'Association between UGT1A1 polymorphism, CPT-11 dosage and tumor response.', 'timeFrame': 'Every 6 weeks, an expected average of 6-8 months.'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Association between UGT1A1 polymorphism, CPT-11 dosage and PFS. PFS is defined as the length of time from randomise to disease progression or to death from any cause other than progression.', 'timeFrame': 'An expected average of 6-8 months.'}, {'measure': 'Pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38G.', 'description': 'Association between UGT1A1 polymorphism, CPT-11 dosage and pharmacokinetics of irinotecan. Plasma concentration of irinotecan and its metabolites, SN-38 and SN-38G are determined using high-performance liquid chromatography-tandem mass spectrometry method (HPLC-MS/MS).', 'timeFrame': 'The first treatment cycle.'}]",4,18 Years,,ALL,False,The Affiliated Hospital of the Chinese Academy of Military Medical Sciences,OTHER,0,583.0,ACTUAL,2025-09-01T16:18:18.432324,v2_robust,True,True,True,False,False,
NCT01921231,Selective Subarachnoid Anesthesia. Comparison of Hyperbaric Bupivacaine and Hyperbaric Prilocaine,Selective Subarachnoid Anesthesia. Comparison of Hyperbaric Bupivacaine and Hyperbaric Prilocaine in Knee Arthroscopy and Inguinal Hernia Repair in Ambulatory Surgery,Hyperbaric Prilocaine 1%,"['Hyperbaric bupivacaine 0.5%', 'Hyperbaric Prilocaine 1%']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Knee Arthroscopy (for Diagnostic or Therapy),"['Knee Arthroscopy (for Diagnostic or Therapy)', 'Inguinal Hernia Repair (Not Urgent)']",[],COMPLETED,,2007-05,2007-12,"[{'measure': 'Length of stay in post-operative care unit (in minutes)', 'description': 'Time in minutes from closing the surgical incision until to having criteria for discharge to home.', 'timeFrame': 'Participants will be followed an average of 6 hours from surgical incision closure to accomplish discharge criteria to go home'}]","[{'measure': 'Level of motor blocking', 'description': 'Assessed by Bromage score who ranges from Complete block (unable to move feet or knees, score 1) to Able to perform partial knee bend (score 6 who means nil block).', 'timeFrame': 'At surgical incision and at 60 minutes after anesthesia'}, {'measure': 'Fast-track (by-pass recovery area)', 'description': ""Number (and percentage) of patients in each arm that can be transferred directly from the operating room to postsurgical ward. A minimal score of 12 (on modified Aldrete's scoring system with no score \\<1 in any individual category) would be required for a patient to be fast-tracked."", 'timeFrame': 'Participants will be assessed when surgical incision is closed with surgical staples'}, {'measure': 'Peak sensory block level', 'description': 'The sensory block level was determined pricking dermatomes with a pin from down to up.', 'timeFrame': 'One minute before surgical incision'}, {'measure': 'Transient neurological symptoms', 'description': 'Researchers surveyed if appears pain originated in gluteal region and radiating to both lower extremities following patients by phone.', 'timeFrame': 'At hospital discharge (an average of 8 hours after admission), and at home at 24, 48 and 72 hours after surgery'}]",5,18 Years,,ALL,False,Dr. Pere Roura-Poch,OTHER,0,119.0,ACTUAL,2025-09-01T16:18:18.432339,v2_robust,True,True,True,False,False,
NCT03530631,Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance,Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance,Adderall,"['Adderall', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Expectancy Versus Pharmacotherapy Effect of Adderall,['Expectancy Versus Pharmacotherapy Effect of Adderall'],[],COMPLETED,,2018-11-10,2018-12-18,"[{'measure': 'Number of Participants Consistently Attending and Completing Four Neuroimaging Sessions', 'description': 'Using a balanced placebo design, participants were either administered mixed amphetamine salts or placebo. Their cognitive performance was assessed in the MRI scanner. The main outcome measure was the feasibility of participants attending four neuroimaging sessions.', 'timeFrame': 'A total of 4 imagining sessions, an average of 60 minutes each'}]",[],1,18 Years,24 Years,ALL,True,University of Alabama at Birmingham,OTHER,0,4.0,ACTUAL,2025-09-01T16:18:18.432439,v2_robust,True,True,True,False,False,
NCT05124002,Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma,"Recombinant Human Adenovirus Type 5 Combined With Hepatic Artery Infusion Chemotherapy of FOLFOX in Patients With Intrahepatic Mass-forming Cholangiocarcinoma: a Single-site, Single-arm, Prospective Study",Recombinant Human Adenovirus Type 5,"['Recombinant Human Adenovirus Type 5', 'FOLFOX', 'HAIC of FOLFOX', 'H101']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,"Cholangiocarcinoma, Intrahepatic","['Cholangiocarcinoma, Intrahepatic']","['oncolytic virus', 'intrahepatic mass-forming cholangiocarcinoma']",RECRUITING,,2022-08-01,2026-04-01,"[{'measure': 'Progression-free survival (PFS)', 'description': 'The median amount of time from registration until disease progression or death, whichever occurs first. Disease progression was assessed via RECIST 1.1 criteria.', 'timeFrame': 'up to 1 month'}]","[{'measure': '1 year survival rate', 'description': 'The percentage of participants who are alive one year after the start of the treatment.', 'timeFrame': '1 year'}, {'measure': 'Objective response rate (ORR)', 'description': 'The percentage of participants who have achieved either a complete or partial response, as assessed by Response Criteria in Solid Tumors (RECIST 1.1).', 'timeFrame': 'up to 1month'}, {'measure': 'Disease control rate (DCR)', 'description': 'The percentage of participants who have achieved complete response, partial response and stable disease, as assessed by Response Criteria in Solid Tumors (RECIST 1.1).', 'timeFrame': 'up to 1 month'}]",4,18 Years,,ALL,False,Beijing Tsinghua Chang Gung Hospital,OTHER,0,66.0,ESTIMATED,2025-09-01T16:18:18.432462,v2_robust,True,True,False,False,False,
NCT00346502,Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia),Phase I/II Evaluation of Topical Application of 20% Betulinic Acid Ointment in the Treatment of Dysplastic Nevi With Moderate to Severe Dysplasia,20% betulinic acid ointment,"['BA', '20% betulinic acid ointment', 'Betulinic Acid']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Dysplastic Nevus Syndrome,['Dysplastic Nevus Syndrome'],[],WITHDRAWN,No subjects enrolled,2006-01,2015-12,"[{'measure': 'Safety', 'description': 'The development of any systemic toxicity (Grade 1 or greater) or Grade 3 local toxicity in 3 of 7 patients at any given dose level will result in the termination of all applications at that level; furthermore, no higher frequency of cohorts will be entered in the Study. This dose level is defined as a dose-limiting toxicity, with the maximum tolerated dose (MTD) being one dose level below.', 'timeFrame': 'Weekly'}, {'measure': 'Efficacy', 'description': 'The response to the topical application of 20% betulinic acid ointment will be assessed histologically. Both the untreated control lesion and the betulinic acid treated lesion will be totally excised after four weeks (30 days) of treatment. Surgery to remove the lesions will take place between day 31 and day 37. The lesions will be processed for microscopic examination and will be examined by the Pathology Department of UIC/UIH. At the completion of the Study, all slides will be reviewed by a consultant dermato-pathologist.\n\nEvidence of regression, fibrosis, depigmentation, nuclear atypia, and apoptosis of melanocytes will be recorded for both untreated control and betulinic acid treated lesions. If the treated lesions demonstrate a significant difference in the points mentioned above, then the data will be quantitatively tabulated and interpreted.', 'timeFrame': '4-5 Weeks'}]",[],2,18 Years,,ALL,True,University of Illinois at Chicago,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:18.432494,v2_robust,True,True,False,True,True,No subjects enrolled
NCT04480502,ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma,"ENVASARC: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy",Ipilimumab,"['Ipilimumab', 'Yervoy']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Undifferentiated Pleomorphic Sarcoma,"['Undifferentiated Pleomorphic Sarcoma', 'Myxofibrosarcoma']",['sarcoma'],ACTIVE_NOT_RECRUITING,,2020-12-09,2024-10,"[{'measure': 'Objective response rate (ORR) by RECIST 1.1 assessed by blinded independent central review', 'timeFrame': '40 months'}]","[{'measure': 'Duration of response (DR) assessed by blinded independent central review', 'timeFrame': '40 months'}, {'measure': 'Disease control rate (DCR) assessed by blinded independent central review', 'timeFrame': '40 months'}, {'measure': 'Progression free survival (PFS) assessed by blinded independent central review', 'timeFrame': '40 months'}, {'measure': 'Overall survival (OS)', 'timeFrame': '40 months'}, {'measure': 'Characterize envafolimab pharmacokinetics (PK) in patients receiving envafolimab as a single agent and in combination with ipilimumab', 'timeFrame': '40 months'}, {'measure': 'Characterize ipilimumab PK in patients given ipilimumab with envafolimab', 'timeFrame': '40 months'}, {'measure': 'Objective response rate (ORR) by investigator assessment', 'timeFrame': '40 months'}, {'measure': 'Progression free survival (PFS) by investigator assessment', 'timeFrame': '40 months'}, {'measure': 'Characterize the immunogenicity of envafolimab and ipilimumab', 'timeFrame': '40 months'}]",10,12 Years,,ALL,False,Tracon Pharmaceuticals Inc.,INDUSTRY,0,207.0,ACTUAL,2025-09-01T16:18:18.432646,v2_robust,True,True,False,False,False,
NCT06534502,"Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures","A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Zonisamide Oral Suspension (100 mg/5 ml) to Determine a Dosing Regimen in Children 1 Month to 17 Years of Age With Partial-onset Seizures",Zonisamide Oral Product,"['Zonisamide oral suspension', 'Zonisamide Oral Product', 'ZONISADE']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Seizures,"['Seizures', 'Seizures, Focal', 'Seizure, Partial Onset', 'Seizure Disorder, Partial', 'Seizure, Partial', 'Epilepsies, Partial', 'Epilepsy']","['Partial-onset (focal) seizures', 'Pediatrics', 'ZONISADE', 'Zonisamide']",NOT_YET_RECRUITING,,2025-07,2026-09,"[{'measure': 'Concentration of serum zonisamide', 'description': 'The concentration in serum of zonisamide following administration of zonisamide oral suspension, 100 mg/5 ml', 'timeFrame': 'Up to 15 weeks'}]","[{'measure': 'Incidence of treatment-emergent adverse events (TEAEs)', 'description': 'Incidence of treatment-emergent adverse events (TEAEs), serious and non-serious, reported throughout the study.', 'timeFrame': 'Up to 15 weeks'}, {'measure': 'Number and/or percentage of participants who discontinued the study because of adverse events', 'description': 'Number and/or percentage of participants who discontinued the study because of adverse events', 'timeFrame': 'Up to 15 weeks'}, {'measure': 'Number and/or percentage of participants who required zonisamide dose reduction because of TEAEs.', 'description': 'Number and/or percentage of participants who required zonisamide dose reduction because of TEAEs.', 'timeFrame': 'Up to 15 weeks'}]",4,1 Month,17 Years,ALL,False,Azurity Pharmaceuticals,INDUSTRY,0,40.0,ESTIMATED,2025-09-01T16:18:18.432663,v2_robust,True,True,False,False,True,
NCT00823602,Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH,Comparison Between GnRH Agonist Long Protocol And GnRH Antagonist Protocol In Outcome Of The First Cycle ART,ganirelix,"['ganirelix', 'suprefact']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Infertility,['Infertility'],"['GnRH antagonist', 'GnRH agonist', 'pregnancy rate', 'Ovarian stimulation']",UNKNOWN,,2008-03,2009-01,"[{'measure': 'pregnancy rate', 'timeFrame': '2weeks'}]","[{'measure': 'ovarian stimulation', 'timeFrame': '10days'}]",2,,35 Years,FEMALE,True,Yazd Research & Clinical Center for Infertility,OTHER,0,2.0,ESTIMATED,2025-09-01T16:18:18.432753,v2_robust,True,True,False,False,False,
NCT03314402,"The Tolerance, Pharmacokinetics of Jaktinib in Healthy Volunteers","A Randomized, Double-blind,Dose-escalation Phase 1 Study to Assess the Safety, Tolerance, and Pharmacokinetics of Jaktinib,an Oral JAK2 Inhibitor, in Healthy Volunteers",Jaktinib Dihydrochloride Monohydrate,"['Jaktinib Dihydrochloride Monohydrate', 'PLA', 'Jaktinib', 'placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['JAK2 inhibitor', 'Tolerance', 'Pharmacokinetics', 'Dose-escalated']",COMPLETED,,2017-09-28,2018-09-27,"[{'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'Evaluating Dose-Limiting Toxicities (DLTs) from the individuals taking orally dose-escalated jaktinib', 'timeFrame': 'up to 6 months'}]","[{'measure': 'Maximum Plasma Concentration [Cmax]', 'description': 'The parameter to evaluating the plasma concentration of the oral jaktinib', 'timeFrame': 'up to 120 hours'}, {'measure': 'Area Under the Curve [AUC]', 'description': 'The parameter to evaluating the exposure of the oral jaktinib', 'timeFrame': 'up to 120 hours'}]",3,18 Years,45 Years,ALL,True,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",INDUSTRY,0,126.0,ACTUAL,2025-09-01T16:18:18.432801,v2_robust,True,True,True,False,False,
NCT04622202,Pre-emptive Pregabalin on Attenuating Maternal Anxiety And Stress Response To Intubation During Caesarean Section,The Effects Of Pre-emptive Single Oral Dose Pregabalin on Attenuating Maternal Anxiety And Stress Response To Intubation During Caesarean Section,Pregabalin 150mg,"['multivitamin', 'Pregabalin 150mg', 'Lyrica', 'Placebo']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Anxiety State,"['Anxiety State', 'Sedation']",[],UNKNOWN,,2020-11-15,2021-03-01,"[{'measure': 'preoperative maternal anxiety changes', 'description': 'Anxiety by State-Trait Anxiety Inventory (STAI) questionnaire before drug administration and 60 minutes after giving drug (pre-induction).', 'timeFrame': 'change from baseline at 60 minutes after giving drug preoperative.'}]","[{'measure': 'Number of participant with changes in level of consciousness', 'description': ""changes in level of consciousness of participant by Alert, verbal response, pain response and unresponsive (AVPU) scale 60 minutes after giving drug (pre-induction).\n\nAlert: The patient is aware of the examiner and can respond to the environment around them on their own. The patient can also follow commands, open their eyes spontaneously, and track objects.\n\nVerbally Responsive: The patient's eyes do not open spontaneously. The patient's eyes open only in response to a verbal stimulus directed toward them. The patient is able to react to that verbal stimulus directly and in a meaningful way.\n\nPainfully Responsive: The patient's eyes do not open spontaneously. The patient will only respond to the application of painful stimuli by an examiner. The patient may move, moan, or cry out directly in response to the painful stimuli.\n\nUnresponsive: The patient does not respond spontaneously. The patient does not respond to verbal or painful stimuli."", 'timeFrame': 'at 60 minutes preoperative'}, {'measure': 'Heart rate', 'description': 'Heart rate will be recorded preoperative baseline, 0 (at intubation) 1, 3, 5, 10 and 15 minutes after intubation.', 'timeFrame': 'at baseline, 0 (at intubation) 1, 3, 5, 10 and 15 minutes after intubation.'}, {'measure': 'mean arterial blood pressure', 'description': 'mean arterial blood pressure', 'timeFrame': 'at baseline, 0 (at intubation) 1, 3, 5, 10 and 15 minutes after intubation.'}, {'measure': 'Serum glucose', 'description': 'Serum glucose level will be recorded preoperative and at 10 minutes after intubation.', 'timeFrame': 'preoperative and at 10 minutes after intubation.'}, {'measure': 'cortisol level', 'description': 'cortisol level will be recorded preoperative and at 10 minutes after intubation.', 'timeFrame': 'preoperative and at 10 minutes after intubation.'}, {'measure': 'Baby Apgar score', 'description': 'Apgar score at 1 and 5 min after delivery Apgar Scoring\n\nApgar Sign 2 1 0 Appearance (skin color) Normal color all over (hands and feet are pink) Normal color (but hands and feet are bluish) Bluish-gray or pale all over Pulse (heart rate) Normal (above 100 beats per minute) Below 100 beats per minute Absent (no pulse) Grimace (""reflex irritability"") Pulls away, sneezes, coughs, or cries with stimulation Facial movement only (grimace) with stimulation Absent (no response to stimulation) Activity (muscle tone) Active, spontaneous movement Arms and legs flexed with little movement No movement, ""floppy"" tone Respiration (breathing rate and effort) Normal rate and effort, good cry Slow or irregular breathing, weak cry Absent (no breathing)\n\nA baby who scores a 7 or above on the test is considered in good health.', 'timeFrame': 'at 1 and 5 minutes after delivery'}]",7,21 Years,38 Years,FEMALE,True,Zagazig University,OTHER_GOV,0,74.0,ESTIMATED,2025-09-01T16:18:18.432812,v2_robust,True,True,False,False,False,
NCT04997902,Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC),"A Phase 1/2 Open-label, Biomarker-defined Cohort Trial to Evaluate the Safety, Determine the Recommended Combination Dosing, and Assess Early Antitumor Activity of Tipifarnib and Alpelisib for the Treatment of Adult Participants Who Have HRAS-overexpressing and/or PIK3CA-mutated and/or - Amplified Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",Tipifarnib,"['Tipifarnib', 'Alpelisib', 'BYL719']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,HNSCC,['HNSCC'],"['HRAS', 'PIK3CA', 'PI3K', 'Tipifarnib', 'Alpelisib', 'R/M HNSCC (Recurrent/metastatic Head and Neck Squamous Cell Carcinoma)', 'Head and Neck Cancer', 'SCCHN']",ACTIVE_NOT_RECRUITING,,2021-12-07,2025-12,"[{'measure': 'To determine the recommended dose and regimen and evaluate the safety and tolerability of the combination of tipifarnib and alpelisib', 'description': 'Rate of DLT per dose level and Descriptive statistics of adverse events per the NCI CTCAE v 5.0', 'timeFrame': 'DLTs will be evaluated during the first 28 days (1 cycle) of combination therapy'}]","[{'measure': 'Determine the Objective Response Rate (ORR)', 'description': 'Overall confirmed response rate (CR + PR) and Median duration of response', 'timeFrame': 'Up to approximately 3 years'}, {'measure': 'Disease control rate (DCR)', 'description': 'Disease control rate (CR + PR + SD), Median duration of disease control, Rate of SD, Median duration of SD', 'timeFrame': 'Up to approximately 3 years'}, {'measure': 'Cmax of tipifarnib and alpelisib when administered in combination', 'description': 'Peak drug concentration for single dose and multiple dose', 'timeFrame': 'Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.'}, {'measure': 'Tmax of tipifarnib and alpelisib when administered in combination', 'description': 'Time to reach peak concentration following drug administration for single dose and multiple dose', 'timeFrame': 'Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.'}, {'measure': 'AUC(0-last) of tipifarnib and alpelisib when administered in combination', 'description': 'Area under the concentration-time curve from time zero to time of last measurable concentration for single dose and multiple dose', 'timeFrame': 'Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.'}, {'measure': 'AUC(tau) of tipifarnib and alpelisib when administered in combination', 'description': 'Area under the concentration-time curve during a dosage interval for single dose and multiple dose', 'timeFrame': 'Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.'}, {'measure': 'AUC(0-infinity) of tipifarnib and alpelisib when administered in combination', 'description': 'Area under the concentration-time curve from time zero to infinity for single dose', 'timeFrame': 'Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.'}, {'measure': 'CL/F of tipifarnib and alpelisib when administered in combination', 'description': 'Apparent total clearance of the drug after administration for single dose and multiple dose', 'timeFrame': 'Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.'}, {'measure': 'Vd/F of tipifarnib and alpelisib when administered in combination', 'description': 'Apparent volume of distribution after administration for single dose and multiple dose', 'timeFrame': 'Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.'}, {'measure': 'Half-life of tipifarnib and alpelisib when administered in combination', 'description': 'Time required for the amount of drug in the body to decrease by half for single dose and multiple dose', 'timeFrame': 'Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.'}, {'measure': 'Accumulation ratio of tipifarnib and alpelisib when administered in combination', 'description': 'Ratio of accumulation of a drug after multiple doses compared to a single dose', 'timeFrame': 'Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.'}, {'measure': 'Antitumor activity in terms of PFS and rate of PFS at 6 months', 'description': 'Median PFS and Proportion of participants alive and without progression at 6 months', 'timeFrame': 'Up to approximately 3 years'}, {'measure': 'Overall Survival (OS) and rate of OS at 12 months', 'description': 'Median OS and Proportion of participants alive at 12 months', 'timeFrame': 'Up to approximately 3 years'}]",14,18 Years,,ALL,False,"Kura Oncology, Inc.",INDUSTRY,0,40.0,ESTIMATED,2025-09-01T16:18:18.432847,v2_robust,True,True,False,False,True,
NCT03771053,The Effect of Simvastatin Combined With Ezetimibe in Patients With Stable Angina and Diabetes,Intravascular Ultrasound Evaluation of the Intervention Effect of Simvastatin Combined With Ezetimibe on Coronary Borderline Lesion in Patients With Stable Angina Pectoris and Diabetes Mellitus Compared With Simvastatin Alone,Ezetimibe with simvastatin,"['Ezetimibe with simvastatin', 'Simvastatin']",2,INTERVENTIONAL,['NA'],,,Coronary Heart Disease,['Coronary Heart Disease'],"['Coronary heart disease', 'Atherosclerosis', 'Acute myocardial infarction', 'Coronary intervention']",UNKNOWN,,2018-01-01,2019-12-31,"[{'measure': 'Change from Baseline coronary plaque volume percentage(PAV) at 12 months', 'description': 'PAV=∑（(ESA CSA-lumen CSA)/(ESA CSA)）x100, EEM CSA：cross-sectional area of outer elastic membrane boundary; lumen CSA: cross-sectional area of tube boundary', 'timeFrame': '12 months after PCI'}]","[{'measure': 'Change from Baseline standardized coronary plaque volume(TAV) at 12 months', 'description': 'TAV= (median number of images in ∑ (ESA CSA-lumen CSA) / retracement) x number of images (standardized according to the length of IVUS retracement, To ensure that each individual patient has the same weight)', 'timeFrame': '12 months after PCI'}, {'measure': 'LDL-C', 'description': 'Low density lipoprotein cholesterol (LDL-C)', 'timeFrame': 'follow up in one year'}, {'measure': 'HDL-C', 'description': 'High density lipoprotein cholesterol (HDL-C)', 'timeFrame': 'follow up in one year'}, {'measure': 'TG', 'description': 'Total triglyceride(TG)', 'timeFrame': 'follow up in one year'}, {'measure': 'TC', 'description': 'Total cholesterol (TC)', 'timeFrame': 'follow up in one year'}, {'measure': 'Inflammation marker', 'description': 'hs-CRP', 'timeFrame': 'follow up in one year'}]",7,18 Years,75 Years,ALL,False,Chinese PLA General Hospital,OTHER,0,240.0,ESTIMATED,2025-09-01T16:18:18.432966,v2_robust,True,True,False,False,False,
NCT03067753,Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis,,Monosialoganglioside Ganglioside,"['Methylprednisolone (Steroid Hormone)', 'Prednisolone', 'Monosialoganglioside Ganglioside']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Cerebral Radiation Necrosis,['Cerebral Radiation Necrosis'],[],UNKNOWN,,2016-12,2019-09,"[{'measure': 'Objective response rate', 'description': 'Response Evaluation Criteria in Solid Tumors (RECIST) were used.', 'timeFrame': 'From the first day of treatment, to 3 months after treatment'}]",[],1,18 Years,70 Years,ALL,False,Zhejiang Cancer Hospital,OTHER,0,28.0,ESTIMATED,2025-09-01T16:18:18.432992,v2_robust,True,True,False,False,False,
NCT01683253,Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa,The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy,Levodopa/Carbidopa(200mg/50mg),"['Levodopa/Carbidopa(200mg/50mg)', 'Dopaminergic Agonists']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Impulse Control Disorder,['Impulse Control Disorder'],[],COMPLETED,,2012-11,2014-12,"[{'measure': 'mMIDI(modified Minnesota Impulsive Disorders Interview)', 'description': 'To evaluate the improvement of mMIDI(Korean version) score from the baseline to 12 weeks or LOCF(Last Observation Carried Forward)', 'timeFrame': '12weeks'}]","[{'measure': 'Neuropsychiatric profile', 'description': 'To evaluate the improvement of neuropsychiatric profiles from the baseline to 12 weeks or LOCF\n\n\\* Neuropsychological assessment\n\n* General cognitive status: K-Minimental status exam(K-MMSE)\n* Psychiatric profile:\n\n  * Neuropsychiatric inventory (K-NPI)\n  * Beck depression inventory (BDI)\n  * Barratt impulsiveness scale (BIS)\n  * Beck anxiety inventory (BAI)\n  * State-trait anger expression inventory (STAXI)\n  * Obsessive compulsive inventory (OCI)\n* Evaluation of global change:\n\n  * Patient global impression of improvement (PGI-I)\n  * Clinical global impression of improvement (CGI-I)', 'timeFrame': '12 weeks'}]",2,30 Years,80 Years,ALL,False,Sandoz,INDUSTRY,0,150.0,ACTUAL,2025-09-01T16:18:18.433000,v2_robust,True,True,True,False,False,
NCT03940053,Prevention of Cancer Development and Progression,"The Efficacy of Arginine in Preventing Cancers. A Single Center, Open, Prospective Study",Arginine hydrochloride,['Arginine hydrochloride'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Cancer,['Cancer'],[],UNKNOWN,,2019-05-10,2025-05-10,"[{'measure': 'Incidence', 'description': 'the percentage of patients with cancer from start of treatment to follow-up date of last participant cancers Incidence', 'timeFrame': '60 months'}]","[{'measure': 'tumor markers', 'description': 'the levels of tumor markers in every check point', 'timeFrame': '60 months'}, {'measure': 'Chinese Quality of Life Questionnaire - EORTC QLQ-C30 score', 'description': 'The overall enjoyment of life', 'timeFrame': '60 months'}]",3,40 Years,70 Years,ALL,True,Zujiang YU,OTHER,0,300.0,ESTIMATED,2025-09-01T16:18:18.433024,v2_robust,True,True,False,False,False,
NCT00123253,TH9507 in Patients With HIV-Associated Lipodystrophy,"A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation",TH9507,['TH9507'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,HIV Infections,"['HIV Infections', 'Lipodystrophy']","['HIV', 'Lipodystrophy', 'Abdominal fat accumulation', 'Growth hormone releasing factor/Growth hormone releasing hormone', 'Treatment Experienced']",COMPLETED,,2005-06,2007-04,[{'measure': 'Visceral adipose tissue (VAT)'}],[],1,18 Years,65 Years,ALL,False,Theratechnologies,INDUSTRY,0,412.0,ACTUAL,2025-09-01T16:18:18.433070,v2_robust,True,True,True,False,False,
NCT00003953,Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer,A Phase II Study of Preoperative Dose-Dense Chemotherapy With Sequential Doxorubicin and Docetaxel for Initial Treatment of Operable and Inoperable Stage II-IIIB Breast Cancer,CMF regimen,"['fluorouracil', 'doxorubicin hydrochloride', 'cyclophosphamide', 'methotrexate', 'docetaxel', 'tamoxifen citrate', 'CMF regimen']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],"['stage II breast cancer', 'stage IIIA breast cancer', 'stage IIIB breast cancer']",COMPLETED,,1999-02,2013-01,"[{'measure': 'Determine the clinical response of these patients to treatment', 'description': 'A clinical evaluation of tumor size includes repeat measurements of the palpable tumor in 2 dimensions, repeat mammography, if originally informative, of the affected breast with measurements of the palpable tumor in 2 or 3 dimensions and/or, evaluation of ipsilateral axillary lymph nodes with measurements, if palpable.', 'timeFrame': 'after 3 courses (12 weeks)'}, {'measure': 'Pathological Response', 'description': 'Number of patients with a complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). CR is defined as disappearance of lesions. PR is defined as at least a 50% reduction in the sum of lesions. SD is defined as no significant change and PD is defined as the increase in the size of lesions.', 'timeFrame': 'after surgery at 15 weeks'}]","[{'measure': 'Detection of circulating tumor cells', 'description': 'Detection of circulating tumor cells will be done using a panel of immunocytochemical antibodies directed against breast cancer epithelial cells and IMPATH/BIS laboratories. This assay can detect as few as 1 in 5x105 circulating tumor cells', 'timeFrame': 'after surgery at 15 weeks'}, {'measure': 'Tumor response correlates with HER2/neu expression of the primary tumor.', 'description': 'Pretreatment core needle biopsies will be analyzed for expression of HER2/neu expression using immunohistochemical staining.', 'timeFrame': 'baseline'}]",4,18 Years,,FEMALE,False,Case Comprehensive Cancer Center,OTHER,1,39.0,ACTUAL,2025-09-01T16:18:18.433079,v2_robust,True,True,True,False,False,
NCT03193853,TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer,Phase II Clinical Trial of Treatment With TAK-228 and TAK-117 to Inhibit Homologous Recombination (HR) Followed by Cisplatin and Nab Paclitaxel in Patients With Chemotherapy-pretreated Metastatic Triple Negative Breast Cancer,Tak-228 & Tak-117,"['Cisplatin & Nab Paclitaxel', 'Tak-228 & Tak-117']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Triple Negative Breast Cancer,['Triple Negative Breast Cancer'],[],COMPLETED,,2017-07-18,2022-12-01,"[{'measure': 'Efficacy (Objective Response Rate)', 'description': 'To assess the objective response rate associated with sequential treatment of the oral combination TAK 228 and 117 followed by nab-paclitaxel plus cisplatin in metastatic TNBC. Objective response is measured as prolonged clinical benefit; clinical benefit is defined as progression free survival on study therapy for at least 6 months.', 'timeFrame': 'Through study completion, up to 2 years 8 months'}]","[{'measure': 'Efficacy (Duration of Response)', 'description': 'To assess duration of response associated with sequential treatment of the oral combination Tak 228 and 117 followed by nab-paclitaxel plus cisplatin. Duration of response is measured as prolonged clinical benefit; clinical benefit is defines as progression free survival on study therapy for at least 6 months.', 'timeFrame': 'Through study completion, up to 2 years 8 months'}, {'measure': 'Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0"".', 'description': 'To assess safety associated with sequential treatment of the oral combination Tak 228 and 117 followed by nab-paclitaxel plus cisplatin', 'timeFrame': 'For up to 30 days following last dose, approximately 7 months'}, {'measure': 'Number of Treatment-Emergent Adverse Events (Safety and Tolerability)', 'description': 'To assess safety associated with sequential treatment of the oral combination TAK 228 and TAK 117 followed by nab-paclitaxel plus cisplatin per CTCAE v4.0 criteria.', 'timeFrame': 'For up to 30 days following last dose, approximately 7 months'}]",4,18 Years,,FEMALE,False,Joyce O'Shaughnessy,OTHER,1,12.0,ACTUAL,2025-09-01T16:18:18.433134,v2_robust,True,True,True,False,True,
NCT05332353,Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients,Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients,Bacillus Calmette-Guerin,"['BCG', 'Bacillus Calmette-Guerin']",2,OBSERVATIONAL,[],,,Non-Muscle Invasive Bladder Cancer,['Non-Muscle Invasive Bladder Cancer'],"['Machine Learning', 'BCG Response', 'Prediction', 'Non-Muscle Invasive Bladder Cancer']",UNKNOWN,,2022-04-01,2023-12-01,"[{'measure': 'BCG unresponsiveness', 'description': 'T1/Ta HG recurrence within 6 months of adequate BCG therapy', 'timeFrame': '6 months'}]",[],1,18 Years,,ALL,False,Mansoura University,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:18.433374,v2_robust,False,True,False,False,False,
NCT01485653,Dosage of Mepivacaine in Ultrasound Axillary Block,Effective Low Dosage of Mepivacaine in Ultrasound Guided Axillary Block in Patients Undergoing Distal Upper Extremity Surgery,Mepivacaine,['Mepivacaine'],1,INTERVENTIONAL,['NA'],,,Nerve Block,"['Nerve Block', 'Neuromuscular Blockade', 'Anesthesia']","['Brachial Plexus', 'Mepivacaine', 'Ultrasound', 'Axillary', 'Block']",COMPLETED,,2010-04,2010-09,"[{'measure': 'Successful Block', 'description': 'Definitions of successful block Functional successful block: Sensory score of 0-1 in all 4 territories and motor score of 0-1 in 3 of 4 territories within 30 minutes of needle extraction.\n\nSurgical successful block: no required intraoperative supplemental local anesthetic, light sedation \\<25mcg/kg/min propofol and absence of general endotracheal anesthesia.', 'timeFrame': '30 minutes'}]","[{'measure': 'Time required until onset of sensory blockade.', 'description': 'Onset of Sensory blockade: Examined every 5 minutes following needle extraction using a blunt needle at 4 specific anatomic locations corresponding to radial, ulnar, median, and musculocutaneous distributions and compared with contralateral side using same stimulus.\n\nOnset of Motor Blockade: Examined every 5 minutes following needle extraction. Wrist flexion: median nerve; wrist extension: radial nerve; abduction of 5th finger or straight finger adduction: ulnar nerve; elbow flexion (with forearm supinated): musculocutaneous nerve.', 'timeFrame': '30 minutes'}, {'measure': 'Time taken until Onset of Motor Blockade', 'description': 'Onset of Motor Blockade: Examined every 5 minutes following needle extraction. Wrist flexion: median nerve; wrist extension: radial nerve; abduction of 5th finger or straight finger adduction: ulnar nerve; elbow flexion (with forearm supinated): musculocutaneous nerve.', 'timeFrame': '30 minutes'}]",3,18 Years,80 Years,ALL,True,Wayne State University,OTHER,0,64.0,ACTUAL,2025-09-01T16:18:18.433398,v2_robust,True,True,True,False,False,
NCT00887653,Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy,Changes in Lipid Profiles and Safety of Raltegravir Based Antiretroviral Therapy in HIV-1-infected Patients With Hyperlipidemia While on Current Standard Therapy,raltegravir,"['raltegravir', 'Isentress']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,HIV,"['HIV', 'Hyperlipidemia', 'Hypertriglyceridemia', 'HIV Infections']",[],COMPLETED,,2009-05,2014-04,"[{'measure': 'Change From Baseline Triglycerides', 'description': 'Assess changes from baseline triglycerides at 3 months', 'timeFrame': '3 months'}, {'measure': 'Change From Baseline Triglycerides', 'description': 'Assess changes from baseline triglycerides at 6 months', 'timeFrame': '6 months'}]","[{'measure': 'Proportion of Patients With Plasma Viral Load Below the Limit of Detection', 'description': 'Assess proportion of patients with PVL below limit of detection at end of study.', 'timeFrame': '6 months'}]",3,18 Years,,ALL,False,The Miriam Hospital,OTHER,2,20.0,ACTUAL,2025-09-01T16:18:18.433418,v2_robust,True,True,True,False,False,
NCT00358553,"A Crossover Study Assessing the Pharmacokinetics, Pharmacodynamics, and Safety of Recombinant Human Insulin",,Insulin,['Insulin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],['Human Volunteers'],COMPLETED,,,,[],[],0,18 Years,40 Years,MALE,True,Baxter Healthcare Corporation,INDUSTRY,0,,,2025-09-01T16:18:18.433428,v2_robust,True,True,True,False,False,
NCT04268953,Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production,"A Phase 1, Single-centre, Multiple-dose, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of the AC-SD-03 Formulation of Tricaprilin in Healthy Older Volunteers",Tricaprilin,['Tricaprilin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Alzheimer Disease,['Alzheimer Disease'],[],COMPLETED,,2020-02-27,2020-05-01,"[{'measure': 'Safety and tolerability of multiple-dose administrations of tricaprilin formulated as AC-SD-03 administered using a titration scheme in healthy older volunteers', 'description': 'TEAE incidence rate', 'timeFrame': '32 days'}]","[{'measure': 'Pharmacokinetics (PK) parameters of Total Ketones levels after multiple dose of AC-SD-03 using AUC(0-t)', 'description': 'AUC(0-t) will be calculated from PK concentrations of Total Ketones (B-hydroxybutyrate and Acetoacetate) Levels. AUC (0-t) = Area under the concentration-time curve from 0 to last quantifiable concentration. Summary statistics will be generated for each PK parameter.', 'timeFrame': '28 days'}, {'measure': 'Pharmacokinetics (PK) parameters of Total Ketones levels after multiple dose of AC-SD-03 using Cmax', 'description': 'Cmax will be calculated from PK concentrations of Total Ketones (B-hydroxybutyrate and Acetoacetate) Levels. Cmax = Cmax is maximum concentration, determined directly from individual concentration-time data.Summary statistics will be generated for each PK parameter.', 'timeFrame': '28 days'}]",3,50 Years,,ALL,True,Cerecin,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:18.433441,v2_robust,True,True,True,False,True,
NCT00859937,Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors,Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors,Dasatinib,"['Sprycel', 'BMS-354825', 'Dasatinib']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Malignant Salivary Gland Neoplasm,"['Malignant Salivary Gland Neoplasm', 'Recurrent Salivary Gland Carcinoma', 'Salivary Gland Adenoid Cystic Carcinoma', 'Stage IV Major Salivary Gland Cancer AJCC v7']",[],COMPLETED,,2009-03-16,,"[{'measure': 'Response Rate', 'description': 'Response rate is percentage of the best overall response which recoded from the start of the treatment until diseases progression/recurrence. Response criteria are defined using the international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee: Complete Response, Disappearance of all target lesions; Partial Response, \\>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.', 'timeFrame': 'Up to 2 months'}, {'measure': 'Progression-free Survival', 'description': 'Progression-free survival from start of treatment to the time of disease progression or death from any cause was estimated using the Kaplan-Meier method.', 'timeFrame': 'up to 5 years'}]","[{'measure': 'Overall Survival', 'description': 'Kaplan-Meier curves will be generated and 90% confidence intervals will be derived.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Changes in Laboratory Correlates', 'description': ""Changes in laboratory correlates pre-post therapy will be analyzed using paired t-tests. The association between RET gene rearrangements/mutations and tumor response, as well as the association between germ-line polymorp response, will be analyzed using Fisher's exact test. The correlative and genetic data will also be entered as cova only due to the small sample size) in a Cox regression model of progression-free survival."", 'timeFrame': 'Baseline and 4 weeks'}]",4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,55.0,ACTUAL,2025-09-01T16:18:18.433529,v2_robust,True,True,True,False,False,
NCT00160537,POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis),"A Monocenter, Double-blind, Randomized Trial, With Two Parallel Groups Comparing the Clinical Efficacy of Levocetirizine 5 mg Capsules and Desloratadine 5 mg Capsules Taken Once a Day Over 3 Weeks of Treatment in Adult Subjects Suffering From Seasonal Allergic Rhinitis (SAR) Due to Grass Pollen",Levocetirizine,['Levocetirizine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Seasonal Allergic Rhinitis,['Seasonal Allergic Rhinitis'],"['Seasonal Allergic Rhinitis (SAR), Grass pollen, SAR Symptoms (sneezing, rhinorrhea, nasal / ocular pruritus, nasal congestion)', 'POPULAR, Xyzal, Levocetirizine']",COMPLETED,,2005-05,2005-07,"[{'measure': ""Subjects' satisfaction / dissatisfaction after the first week of treatment.""}]","[{'measure': ""allergic rhinitis symptoms scores over the first week of treatment , subject's satisfaction / dissatisfaction of their choice of treatment after the first week of treatment, time to first feeling of (sufficient) symptom improvement during the first we""}]",2,18 Years,,ALL,,UCB Pharma,INDUSTRY,0,200.0,,2025-09-01T16:18:18.433553,v2_robust,True,True,True,False,False,
NCT01854437,The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients,,Mg Oxide,"['Mg Oxide', '(Mg®, 21st Century®)']",2,OBSERVATIONAL,[],,,Hyperphosphatemia,['Hyperphosphatemia'],"['mg oxide', 'hyperphosphatemia', 'plasma phosphor level']",COMPLETED,,2012-06,2012-12,"[{'measure': 'plasma phosphate level', 'timeFrame': '4 week'}]",[],1,18 Years,80 Years,ALL,True,Shiraz University of Medical Sciences,OTHER,0,42.0,ACTUAL,2025-09-01T16:18:18.433582,v2_robust,False,True,True,False,False,
NCT01542437,"Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer","Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2",BIBW 2992,"['BIBW 2992', 'Afatinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-Small Cell Lung Cancer,"['Non-Small Cell Lung Cancer', 'EGFR', 'HER-2']",['Non-Small Cell Lung Cancer'],COMPLETED,,2012-01,2017-06,"[{'measure': 'Overall response', 'description': ""Is assigned to each subject the best objective response according to the investigator's decision (according to RECIST criteria). This is defined as the best response recorded from the start of treatment until progression / recurrence of disease. For patients with response status partial (PR) or complete response (CR), changes in tumor measurements must be confirmed by repeated assessments to be made not less than 4 weeks after it first reached the response criteria The CT will be made every two months to assess response to treatment. The objective response will be summarized descriptively."", 'timeFrame': 'from the start of consumption until at least 6 months after stopping BIBW 2992 or when all patients have died.'}, {'measure': 'Progression Free Survival', 'description': 'Is defined as the time from start of treatment until the date of the first documented evidence of progression (RECIST criteria) or the date of death for any reason in the absence of disease progression (EP). For patients who have died or progressed at the time of final analysis, use the date of last contact.', 'timeFrame': 'from the start of consumption until at least 6 months after stopping BIBW 2992 or when all patients have died.'}, {'measure': 'Overall survival', 'description': 'Overall survival will be determined from the date of commencement of treatment to date of death, regardless of the cause of death. In patients who did not die at the time of final analysis will use the date of last contact.', 'timeFrame': 'from the start of consumption until at least 6 months after stopping BIBW 2992 or when all patients have died.'}]","[{'measure': 'Evaluation of the HER-2 gene copy number and amplification', 'description': 'Assessing the number of copies of the HER-2 gene by FISH', 'timeFrame': 'Baseline'}, {'measure': 'DNA Extraction and Mutational Analysis of EGFR and HER-2', 'description': 'Tumor samples were fixed in formalin and embedded in paraffin, used for histologic diagnosis of patients will be obtained from the Departments of Pathology participating institutes.', 'timeFrame': 'Baseline'}, {'measure': 'Toxicity evaluation', 'description': 'adverse effect from CTCAE', 'timeFrame': 'from the start of consumption until at least 6 months after stopping BIBW 2992 or when all patients have died.'}, {'measure': 'Determination of plasma HGF pre and post-treatment concentration', 'description': 'Plasma samples were collected before the start of treatment with afatinib and after 2 months of treatment. HGF plasma levels were determined using ELISA, which was per-formed according to Quantikine human HGF immunoassay (DHG00; R\\&D System, Minneapolis, MN, USA). All assays were performed in duplicate. Color intensity was measured at 450 nm with a spectrophotometric plate reader. HGF concentrations were determined by comparison with standard curves.', 'timeFrame': 'Baseline and after 2 months of treatment.'}]",7,18 Years,90 Years,ALL,False,Instituto Nacional de Cancerologia de Mexico,OTHER,0,66.0,ACTUAL,2025-09-01T16:18:18.433621,v2_robust,True,True,True,False,True,
NCT02530437,"Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer","A Phase 1B/2 Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction",Carboplatin,"['Blastocarb', 'Taxol Konzentrat', 'Carboplatinum', 'Taladegib', 'Paraplatin', 'Carboplatino', 'Paraplatine', 'Ribocarbo', 'Bristaxol', 'Ercar', 'Paclitaxel', 'Novoplatinum', 'Carbotec', 'Carboplat', 'Asotax', 'Carboplatin', 'Carbosol', 'Carbosin', 'Taxol', 'LY2940680', 'Anzatax', 'LY-2940680', 'Platinwas', 'Nealorin', 'Displata', 'CBDCA', 'Praxel', 'Benzamide, 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)-', 'JM-8', 'Paraplatin AQ', 'Carboplatin Hexal']",31,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Gastroesophageal Junction Adenocarcinoma,"['Gastroesophageal Junction Adenocarcinoma', 'Stage IB Esophageal Adenocarcinoma AJCC v7', 'Stage II Esophageal Adenocarcinoma AJCC v7', 'Stage IIA Esophageal Adenocarcinoma AJCC v7', 'Stage IIB Esophageal Adenocarcinoma AJCC v7', 'Stage IIIA Esophageal Adenocarcinoma AJCC v7', 'Stage IIIB Esophageal Adenocarcinoma AJCC v7']",[],TERMINATED,The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was available. The sponsor made a decision to stop development of this drug Taladegib.,2017-03-07,2022-01-07,"[{'measure': 'Safety of Taladegib When Given in Combination With Paclitaxel, Carboplatin, and Radiation Therapy Defined by Dose-limiting Toxicities (Phase IB)', 'description': 'The safety data will be summarized using frequencies and percentages by adverse event category, grade and attributions.', 'timeFrame': 'Up to 5 weeks'}, {'measure': 'Pathologic Complete Response Rate (Phase II)', 'description': 'A pathologic complete response (pathCR) rate of at least 35% (\\>= 40% is desirable) will be of interest. The pathCR rate in each of the treatment step will be estimated, along with the 95% confidence interval.', 'timeFrame': 'Up to 4 years and 10 months'}]","[{'measure': 'Change in Biomarker Expression Levels of Primary and Secondary Resistance', 'description': 'A linear mixed effect model will be used to assess the change of biomarkers over time. The outcome variable will be biomarker expression level and the covariates will include time, treatment step and time by treatment interaction. The biomarker expression may be log-transformed prior to fit the model in order to satisfy the normality assumption. Also, a logistic regression model will be used for the binary outcome of pathCR, using treatment step, baseline biomarker and the change of biomarker between baseline and at surgery as covariates.', 'timeFrame': 'Baseline to the time of surgery'}, {'measure': 'Relapse-free Survival', 'description': 'Kaplan-Meier method will be used to estimate the probabilities of relapse-free survival.', 'timeFrame': 'Up to 4 years and 10 months'}, {'measure': 'Overall Survival', 'description': 'Kaplan-Meier method will be used to estimate the probabilities of overall survival.', 'timeFrame': 'Up to 4 years and 10 months'}]",5,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,7.0,ACTUAL,2025-09-01T16:18:18.433659,v2_robust,True,True,False,True,True,The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was available. The sponsor made a decision to stop development of this drug Taladegib.
NCT00306137,Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung Cancer or Esophageal Cancer","Trasylol (Aprotinin, BAYA0128)","['Trasylol (Aprotinin, BAYA0128)', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Blood Loss, Surgical","['Blood Loss, Surgical']",[],TERMINATED,,2005-12,2007-03,"[{'measure': 'Percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period', 'timeFrame': 'Up to the end of follow up visit (4 to 8 weeks)'}]","[{'measure': 'Number of units of blood or packed red cells transfused', 'timeFrame': 'Up to the end of follow up visit (4 to 8 weeks)'}, {'measure': 'Number of units transfused per patient', 'timeFrame': 'Up to the end of follow up visit (4 to 8 weeks)'}, {'measure': 'Intra-operative blood loss', 'timeFrame': 'Intra-operative'}, {'measure': 'Drainage volume', 'timeFrame': 'Until removal of drains'}, {'measure': 'Transfusion of platelets, colloids and plasma', 'timeFrame': 'Up to the end of follow up visit (4 to 8 weeks)'}, {'measure': 'Change from pre-operative to post-operative hemoglobin concentration', 'timeFrame': 'At day 3 or earlyer prior to transfusion'}, {'measure': ""Surgeon's assessment of obscurement of operative field by bleeding"", 'timeFrame': 'Up to the end of follow up visit (4 to 8 weeks)'}, {'measure': 'Blood markers of inflammation and coagulation', 'timeFrame': 'Up to the end of follow up visit (4 to 8 weeks)'}, {'measure': 'Time to discontinuation of mechanical ventilation', 'timeFrame': 'Until removal of mechanical ventilation'}, {'measure': 'Health related quality of life measurements', 'timeFrame': 'Up to the end of follow up visit (4 to 8 weeks)'}]",11,18 Years,,ALL,False,Bayer,INDUSTRY,0,104.0,ACTUAL,2025-09-01T16:18:18.433699,v2_robust,True,True,False,True,False,
NCT03241745,A Study of Nivolumab in Selected Uterine Cancer Patients,Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer,Nivolumab,['Nivolumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Uterine Cancer,"['Uterine Cancer', 'Endometrial Carcinoma', 'Carcinosarcoma', 'Leiomyosarcoma', 'Undifferentiated Sarcoma', 'High Grade Endometrial Stromal Sarcoma', 'Clear Cell Carcinoma']","['Nivolumab', '17-180']",COMPLETED,,2017-08-03,2024-04-01,"[{'measure': 'Progression-Free Survival', 'description': 'will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)', 'timeFrame': 'at 24 weeks'}]",[],1,18 Years,,FEMALE,False,Memorial Sloan Kettering Cancer Center,OTHER,1,35.0,ACTUAL,2025-09-01T16:18:18.433826,v2_robust,True,True,True,False,False,
NCT03665545,Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma,Pembrolizumab in Association With the Multipeptide Vaccine IMA950 Adjuvanted With Poly-ICLC for Relapsing Glioblastoma: a Randomized Phase I/ II Trial,IMA950/Poly-ICLC,"['IMA950/Poly-ICLC and pembrolizumab', 'IMA950/Poly-ICLC']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Glioblastoma Multiforme,"['Glioblastoma Multiforme', 'Glioblastoma, Adult', 'Glioma of Brain', 'Glioblastoma Multiforme of Brain']",['glioblastoma'],COMPLETED,,2018-10-25,2024-04-24,"[{'measure': 'Incidence of Treatment-Emergent Adverse Events', 'description': 'To assess tolerability and safety of IMA950 adjuvanted with Poly-ICLC when given together with pembrolizumab, using CTCAE v.4.03', 'timeFrame': 'From the time of treatment randomization through 30 days following cessation of treatment'}]","[{'measure': 'Progression-free survival at 6, 9, 12 months', 'description': 'To estimate 6, 9 and 12-month progression-free survival (PFS) using gadolinium-enhanced MRI and clinical assessment according to revised iRANO criteria', 'timeFrame': 'through study completion, an average of 3 years'}, {'measure': 'Overall Survival', 'description': 'To estimate OS, defined as the time between the date of study entry and the date of death due to any cause. Subjects who have not died at the time of last known follow-up will be censored', 'timeFrame': 'through study completion, an average of 3 years'}, {'measure': 'Patient-reported Quality of life', 'description': 'Quality of life patient-reported outcomes (EORTC QLQ-C30 questionnaire)', 'timeFrame': 'through study completion, an average of 3 years'}]",4,18 Years,,ALL,False,"University Hospital, Geneva",OTHER,0,18.0,ACTUAL,2025-09-01T16:18:18.433836,v2_robust,True,True,True,False,True,
NCT00468845,Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy,"A Multiple Dose, Randomized, Double-Blind Multicenter Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Treatment Of Patients With Post-Surgical Pain From Hysterectomy",pregabalin (Lyrica),"['pregabalin (Lyrica)', 'matched placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Pain, Postoperative","['Pain, Postoperative']","['pain after hysterectomy', 'amount of opioids used']",COMPLETED,,2007-06,2010-10,"[{'measure': 'Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)', 'description': 'Modified Brief Pain Inventory - Short Form (m-BPI-sf): participant rated 11-point Likert rating scale ranged from 0 (no pain) to 10 (worst pain imaginable).\n\nLeast Square (LS) Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': 'Day 2 (24 hours post surgery [PS])'}]","[{'measure': 'Current Pain - Pain With Movement Caused by Sitting', 'description': 'Participant sat upright from supine position, followed by 120 second (sec) rest period, during which participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': 'Day 1 (day of surgery), up to 7 days PS, Discharge, 2 and 4 weeks PS'}, {'measure': 'Current Pain - Pain With Movement Caused by Peak Expiratory (PEF) Test', 'description': 'Current pain with movement caused by peak expiratory flow (PEF) test as reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': 'Day 1, up to 7 days PS, 2 and 4 weeks PS'}, {'measure': 'Area Under the Curve (AUC) Pain - Pain With Movement Caused by Sitting', 'description': 'Time-normalized AUC of pain with movement caused by sitting reported by participants. Participant sat upright from supine position, followed by a 120sec rest period, during which the participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': '48 +/- 4 hours PS'}, {'measure': 'Area Under the Curve (AUC) Pain - Pain With Movement Caused by Peak Expiratory Flow (PEF) Test', 'description': 'Time-normalized AUC of pain reported by participants with movement caused by PEF test. Pain reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': '48 +/- 4 hours PS'}, {'measure': 'Current Pain at Rest', 'description': 'Pain reported by participants at rest (numeric rating scale (NRS) - Current Pain) on an 11 point Likert scale 0 (no pain) - 10 (worst pain). Pain at rest during the hospital stay was assessed just before each Pain with Movement assessment. Assessment performed 3 times each day of hospital stay, with 1 of daily assessments at 24 (+/- 2 ) hour intervals from end of surgery. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': '8, 16, 24, 32, 40, 48 hours PS'}, {'measure': 'Area Under the Curve (AUC) of Pain at Rest During the First Two Days of Hospital Stay', 'description': 'Time-normalized AUC of pain reported by participants on 11 point Likert scale 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': '48 +/- 4 hours PS'}, {'measure': 'Total Cumulative Dose of Opioids Following Surgery', 'description': 'Total cumulative dose was calculated as milligram (mg) of morphine equivalent and included opioids administered by any route. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': '24, 48 Hours PS, Discharge (day 3 up to day 7 PS)'}, {'measure': 'Integrated Analgesic Score', 'description': 'The integrated analgesic score (a combination of opioid use and either worst pain, or pain at rest, or pain caused by sitting, or pain caused by forced expiration as defined by Silverman et al 1993) was the sum of percent differences from mean rank for pain and opioids and ranged from -200 to 200 where lower values represent improvement. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': '0-24, 24-48, 48-72 hours PS'}, {'measure': 'Non-opioid Rescue Medication - Paracetamol', 'description': 'The amounts of non-opioid rescue medications, paracetamol, used by the participants during the study, including anti-emetic medications.', 'timeFrame': '24, 48, 72 hours PS, Discharge (day 3 up to day 7 PS), Week 1, 2, 3, 4 PS,'}, {'measure': 'Anxiety Before and After Surgery', 'description': 'Participant anxiety reported on Visual Anxiety Scale (VAS), 0 (not at all anxious) to 100 (extremely anxious). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata', 'timeFrame': 'Surgery day before first dose and 1 hour after first dose, Day 1, 2, 3, 4, 5 PS and Discharge (day 3 up to day 7 PS)'}, {'measure': 'Non-opioid Rescue Medication - Ibuprofen', 'description': 'The amounts of non-opioid rescue medications, ibuprofen, used by the participants during the study, including anti-emetic medications.', 'timeFrame': '24, 48, 72 hours PS, Discharge (day 3 up to day 7 PS), Week 1, 2, 3, 4 PS'}, {'measure': 'Percent Change From Baseline in Peak Expiratory Flow', 'description': 'Change from baseline= PEF at x hours minus PEF at baseline; possible values ranged from 0-900 liters/minute (higher values indicated better lung function). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': 'Baseline, every 8 hours (up to 232 hours) PS, and Discharge (Day 3-7 PS flexible)'}, {'measure': 'Timed Up-and-Go (TUG)', 'description': 'Functional mobility test performed once a day at 24 hour intervals from surgery after the pain with movement assessment. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': 'Day 1, 2, 3, 4, 5 PS and Discharge (day 3 up to day 7 PS)'}, {'measure': 'Average Daily Pain', 'description': 'Post-discharge average pain as measured in daily participant diaries NRS an 11 point Likert scale ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': 'Day 2, 3, 4, 5, 6, 7, PS; week 2, 3, 4 PS'}, {'measure': 'Worst Daily Pain', 'description': 'Post-discharge worst pain as measured in daily participant diaries NRS an 11 point Likert scale that ranged from 0 (no pain) to 10 (pain as bad as you can imagine). LS Means from ANOVA model with terms of treatment, pooled center, salpingo-oophorectomy strata and baseline worst pain score.', 'timeFrame': 'Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS'}, {'measure': 'Sleep Interference', 'description': 'Sleep interference post surgery measured daily in participant diaries; NRS of how pain interfered with sleep during the last 24 hours, ranged from 0 (does not interfere) to 10 (completely interferes). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': 'Daily post hospital discharge ( Day 2-7 PS), Week 2, 3, 4 PS'}, {'measure': 'Brief Pain Inventory-Short Form (m-BPI-sf): Pain Interference Index Scores', 'description': 'm-BPI-sf: participant-rated 11 point Likert rating scale ranging from 0 (does not interfere) to 10 (completely interferes) with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': 'Baseline, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS'}, {'measure': 'Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores', 'description': 'm-BPI-sf: participant rated 11-point Likert rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level).\n\nLS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': 'Baseline, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS'}, {'measure': 'Participant Satisfaction With Study Medication - Surgery Day', 'description': 'Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.', 'timeFrame': 'Day 1'}, {'measure': 'Participant Satisfaction With Study Medication - Day 1 PS', 'description': 'Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.', 'timeFrame': 'Day 1 PS'}, {'measure': 'Participant Satisfaction With Study Medication - Day 2 PS', 'description': 'Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.', 'timeFrame': 'Day 2 PS'}, {'measure': 'Participant Satisfaction With Study Medication - Day 3 PS', 'description': 'Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.', 'timeFrame': 'Day 3 PS'}, {'measure': 'Participant Satisfaction With Study Medication - Day 4 PS', 'description': 'Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.', 'timeFrame': 'Day 4 PS'}, {'measure': 'Participant Satisfaction With Study Medication - Day 5 PS', 'description': 'Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.', 'timeFrame': 'Day 5 PS'}, {'measure': 'Participant Satisfaction With Study Medication - Discharge', 'description': 'Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.', 'timeFrame': 'Discharge (day 3 up to day 7 PS)'}, {'measure': 'Participant Satisfaction With Study Medication - Day 7 PS', 'description': 'Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.', 'timeFrame': 'Day 7 PS'}, {'measure': 'Participant Satisfaction With Study Medication - Day 14 PS', 'description': 'Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.', 'timeFrame': 'Day 14 PS'}, {'measure': 'Participant Satisfaction With Study Medication - Day 28 PS', 'description': 'Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.', 'timeFrame': 'Day 28 PS'}, {'measure': 'Pain Treatment Satisfaction Scale (PTSS): Satisfaction With Current Pain Medication', 'description': 'Satisfaction with current pain medication ranged from 0 (worst possible response) to100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': 'Discharge (day 3 up to day 7 PS), Day 28 PS'}, {'measure': 'Pain Treatment Satisfaction Scale (PTSS): Impact of Current Pain Medication', 'description': 'Impact of current pain medication response scale: 0 (worst possible response) to 100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': 'Discharge (day 3 up to day 7 PS), Day 28 PS'}, {'measure': 'Quality of Life Using EuroQol (EQ-5D) Health State Profile', 'description': 'Participant rated questionnaire assessed current health for 6 domains: mobility/self-care/ usual activities/pain/discomfort/anxiety and depression. Scoring developed by EuroQol Group assigned a utility value for each domain in the profile. Scores ranged from 1 better health (no problems) to 3 worst health (eg, ""confined to bed""). Score transformed and resulted in a total score range -0.594 to 1.000; higher score=better health state. Health profile scores estimated using Dolan computational algorithms 1997 and 2001. LS Means adjusted for treatment/pooled center/salpingo-oophorectomy strata.', 'timeFrame': 'Discharge (day 3 up to day 7 PS) and day 28 PS'}, {'measure': 'Time to Meet Hospital Discharge Criteria', 'description': 'Mean time from end of surgery to meet protocol defined hospital discharge criteria: participant no longer received parental opioids, was able to dress and mobilize without assistance, and had normal intake of food and fluids.', 'timeFrame': 'Day 1 up to Day 7 PS'}, {'measure': 'Time to Actual Discharge', 'description': 'Mean time from end of surgery to actual hospital discharge. Participant was expected to remain at the hospital for a minimum of 2 days following surgery.', 'timeFrame': 'Day 1 up to Day 7 PS'}, {'measure': 'Incidence of Chronic Post-operative Pain', 'description': 'Chronic post-operative pain as a result of abdominal hysterectomy as reported by participants on PS questionaire of pain within last 24 hours in area affected by surgery.', 'timeFrame': '3 and 6 Months PS'}, {'measure': 'Total Clinically Meaningful Event (CME) Score', 'description': 'Total CME score calculated by summing the number of Clinically Meaningful Events (CMEs) across symptoms. CME for each symptom will be defined using the Opioid-Related Symptom Distress Scale (OR-SDS) a participant rated scale of symptoms within the last 24 hours. Total CME score could range from 0 to 9. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.', 'timeFrame': 'Surgery Day, Day 1, 2, 3, 4, 5 PS, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS'}]",36,25 Years,70 Years,FEMALE,False,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,0,501.0,ACTUAL,2025-09-01T16:18:18.433912,v2_robust,True,True,True,False,False,
NCT05479045,A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients,A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients,Toripalimab-tpzi,"['Toripalimab-tpzi', 'LOQTORZI']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Cancer Stage IV,"['Ovarian Cancer Stage IV', 'Ovarian Cancer Stage III', 'Ovarian Cancer Stage 3']",[],NOT_YET_RECRUITING,,2026-01,2027-11,"[{'measure': 'Median Progression Free Survival', 'timeFrame': '2 years'}]","[{'measure': 'Median Overall Survival', 'description': 'per RECIST v1.1 and mRECIST v1.1', 'timeFrame': '2 years'}, {'measure': 'Overall Response Rate', 'description': 'based on irRECIST', 'timeFrame': '2 years'}, {'measure': 'Duration of Response', 'description': 'per RECIST v1.1 and mRECIST v1.1', 'timeFrame': '2 years'}, {'measure': 'Disease Control Rate', 'description': 'based on irRECIST', 'timeFrame': '2 years'}, {'measure': 'Incidence of Adverse Events (AE)', 'description': 'Safety and tolerability will be assessed by calculating the rates and frequencies of all AEs, serious adverse events (SAE), and any toxicities according to CTCAE v5.0', 'timeFrame': '2 years'}]",6,18 Years,,FEMALE,False,Georgetown University,OTHER,1,24.0,ESTIMATED,2025-09-01T16:18:18.434038,v2_robust,True,True,False,False,True,
NCT00650845,Renal Safety Evaluation After Dotarem®-Enhanced MRI,Renal Safety Evaluation After Dotarem®-Enhanced MRI Compared With Non-enhanced MRI in Patients at High Risk of Developing Contrast Medium Induced Nephropathy,Dotarem®-enhanced MRI,"['Gadoteric acid', 'Dotarem®-enhanced MRI', 'Gadoterate meglumine']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Renal Insufficiency,['Renal Insufficiency'],"['contrast-induced nephropathy, creatinemia']",COMPLETED,,2008-01,2011-08,"[{'measure': 'Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis Set Population.', 'description': 'Comparing the number of patients experiencing an increase of creatinine of at least 25% over baseline levels after Dotarem®-enhanced MRI and after non-enhanced MRI in patients with at least a moderate renal insufficiency.', 'timeFrame': 'baseline pre MRI and 3 days post MRI'}, {'measure': 'Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of at Least 25% Over Baseline Levels, in the Per Protocol Population.', 'description': 'Comparing the number of patients experiencing an increase of creatinine of at least 25% over baseline levels after Dotarem®-enhanced MRI and after non-enhanced MRI in patients with at least a moderate renal insufficiency.', 'timeFrame': 'Baseline pre MRI and 3 days post MRI'}]","[{'measure': 'Percent Change of Serum Creatinine Level From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population.', 'description': 'Serum creatinine levels were measured at baseline and at 72±24 hours after examination. The percentage of change in creatinemia from baseline was calculated for both the Dotarem® and the non-enhanced groups.', 'timeFrame': 'Baseline pre MRI and 3 days post MRI'}, {'measure': 'Percent Change of Serum Creatinine Level Variation From Baseline to 72±24 Hours After Examination, in the Per Protocol Population', 'description': 'Serum creatinine levels were measured at baseline and at 72±24 hours after examination. The percentage of change in creatinemia from baseline was calculated for both the Dotarem® and the non-enhanced groups.', 'timeFrame': 'Baseline pre MRI and 3 days post MRI'}, {'measure': 'Percent Change of Estimated Glomerular Filtration Rate (eGFR) Values From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population', 'description': 'eGFR was assessed using creatinemia and the Modification of Diet in Renal Disease (MDRD) study equation. eGFR were evaluated in terms of mean difference between the pre- and post-MRI procedure. The eGFR variation was expressed as a percentage of change from baseline values.', 'timeFrame': 'Baseline pre MRI and 3 days post MRI'}, {'measure': 'eGFR Values Variation Between Baseline and 72±24 Hours After Examination, in the Per Protocol Population', 'description': 'eGFR (estimated Glomerular Filtration Rate) was assessed using creatinemia and the Modification of Diet in Renal Disease (MDRD) study equation. eGFR were evaluated in terms of mean difference between the pre- and post-MRI procedure. The eGFR variation was expressed as a percentage of change from baseline values.', 'timeFrame': 'Baseline pre MRI and 3 days post MRI'}]",6,18 Years,,ALL,False,Guerbet,INDUSTRY,0,135.0,ACTUAL,2025-09-01T16:18:18.434084,v2_robust,True,True,True,False,False,
NCT06573645,A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL,A Phase III Randomized Controlled Study Comparing High-dose Rituximab (500 mg/m²) Combined With CHOP Regimen Versus Standard-dose Rituximab (375 mg/m²) Combined With CHOP Regimen in Male Patients With Newly Diagnosed Advanced Diffuse Large B-cell Lymphoma,Rituximab,['Rituximab'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,"Lymphoma, Large B-Cell, Diffuse","['Lymphoma, Large B-Cell, Diffuse']","['lymphoma', 'Diffuse large B cell lymphoma', 'High doses rituximab']",NOT_YET_RECRUITING,,2024-08-23,2027-07-12,"[{'measure': 'MODIFIED-PFS', 'description': 'To investigate the preliminary anti-tumor efficacy', 'timeFrame': 'From the date of enrollment until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 48 months'}]","[{'measure': 'Overall survival (OS)', 'description': 'To investigate the preliminary anti-tumor efficacy', 'timeFrame': 'From the date of enrollment until the date of death from ant cause, assessed up to 48 months'}, {'measure': 'Complete response rate (CRR)', 'description': 'To investigate the preliminary anti-tumor efficacy', 'timeFrame': 'Up to 8 cycles (each cycle is 21 days)'}, {'measure': 'Objective response rate (ORR)', 'description': 'To investigate the preliminary anti-tumor efficacy', 'timeFrame': 'Up to 8 cycles (each cycle is 21 days)'}]",4,18 Years,75 Years,MALE,False,Xia Yi,OTHER,0,428.0,ESTIMATED,2025-09-01T16:18:18.434213,v2_robust,True,True,False,False,False,
NCT00846872,"Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance","Effect of Continuous Subcutaneous GHRP-3 Infusion at 2 Dose Levels on the Physiological Secretion of the GH-IGF-I System, Blood Pressure, Glucose, Inflammatory Markers and Endothelial Function in Subjects With Insulin Resistance",GHRP-3 low dose,"['Saline', '5% mannitol', 'GHRP-3 low dose', 'GHRP-3 high dose', 'Fourth generation growth hormone secretagogue', 'Formerly coded as 1485']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Insulin Resistance,"['Insulin Resistance', 'Endothelial Dysfunction']","['GHRP-3', 'Insulin Resistance', 'Markers of inflammation', 'Endothelial Dysfunction', 'Flow Mediated Dilation', 'GH/IGF-1 axis', 'Post menopausal']",WITHDRAWN,Inadequate subject recruitment,2008-07,2012-03,"[{'measure': 'Determine the relative effects of 0.1µg/kg/h and 0.5µg/kg/h GHRP-3 as compared to placebo in inducing physiological secretion of the GH-IGF-I system after continuous sc delivery in healthy older men and women with insulin resistance', 'timeFrame': '6 months'}]","[{'measure': 'Determine the relative interrelated effects of 0.1 and 0.5µg/kg/h GHRP-3 infusion and placebo on various hormonal and non hormonal aspects of insulin resistance.', 'timeFrame': '6 months'}]",2,45 Years,85 Years,ALL,True,Tulane University Health Sciences Center,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:18.434228,v2_robust,True,True,False,True,False,Inadequate subject recruitment
NCT04030572,Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies,"Pilot Study to Assess the Safety, Tolerability, and Feasibility of Administering Clonidine as a Pharmacological Challenge in Future Imaging Studies of Cerebrospinal Fluid Kinetics",Clonidine Pill,"['Clonidine Pill', 'On-Drug']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Neuro-Degenerative Disease,"['Neuro-Degenerative Disease', 'Cancer']",[],TERMINATED,Not logistically feasible during the COVID pandemic,2019-12-10,2020-03-17,"[{'measure': 'Number of subjects experiencing adverse events related to drug-induced changes in hemodynamic function.', 'description': 'clinically significant drop in blood pressure or pulse', 'timeFrame': 'Day 2 or Day 8 compared to Day (-7) through Day 1 during drug-free lead-in'}]","[{'measure': 'Change in Total Sleep Duration', 'description': 'Time interval between falling asleep and waking up as estimated by a wearable sleep tracking device', 'timeFrame': 'Day 2 and Day 8 on drug and Day 16 washout compared to Day (-7) through Day 1 during drug-free lead-in'}, {'measure': 'Change in Deep Sleep Time', 'description': 'amount of time estimated to be in deep sleep versus light sleep by a wearable sleep tracking device', 'timeFrame': 'Day 2 and Day 8 on drug and Day 16 washout compared to Day (-7) through Day 1 during drug-free lead-in'}]",3,18 Years,89 Years,ALL,True,Weill Medical College of Cornell University,OTHER,0,3.0,ACTUAL,2025-09-01T16:18:18.434291,v2_robust,True,True,False,True,True,Not logistically feasible during the COVID pandemic
NCT05681572,Effect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia,""" Effect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia "" The pediaPREM Study.",Midazolam,"['Midazolam', 'Dexmedetomidine', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Anesthesia,['Anesthesia'],"['children premedication', 'anesthesia', 'children perioperative experience', 'anxiety', 'sedation']",RECRUITING,,2023-04-18,2027-10-18,"[{'measure': 'EVANpedia Score', 'description': 'To evaluate patient experience of the perioperative and post-operative period', 'timeFrame': 'from the day of surgery up to the day one after surgery'}]","[{'measure': 'VAS-anxiety Scores', 'description': 'To evaluate the perioperative level of anxiety thanks to the Visual Analogue Scale (VAS)', 'timeFrame': 'from preoperative period up to 6 postoperative month'}, {'measure': 'Postoperative waking delay', 'description': 'Time to wake up after surgery (minutes) to evaluate the delay emergence from anesthesia', 'timeFrame': 'from the end of the surgery up to the exit of the recovery room'}, {'measure': 'Modified Brice questionnaire Score', 'description': 'To evaluate postoperative amnesia after anesthesia', 'timeFrame': 'from the day of surgery up to 1 day'}, {'measure': 'Post Hospitalization Behavior Scores', 'description': 'To evaluate changes of behavioral (appetite, sleep, sociability) after surgery', 'timeFrame': '15 postoperative days'}, {'measure': 'quality of life', 'description': 'to evaluate the impact of the perioperative experience on the long-term experience', 'timeFrame': '6 postoperative months'}, {'measure': 'neuropathic pain', 'description': 'to evaluate the percentage of patients with long-term neuropathic pain', 'timeFrame': '6 postoperative month'}, {'measure': 'FPS-r scores', 'description': 'To evaluate the Postoperative level of pain thanks to the Faces Pain Scale-revised (FPS-r)', 'timeFrame': 'from the end of the surgery up to 6 post-operative month'}, {'measure': 'Quality of life PedsQL', 'description': ""The quality of life will be measured by PedsQL in order to evaluate the impact of the perioperative experience on the long-term experience. The 23 questions cover 4 different domains: physical functioning (8 items), emotional functioning (5 items), social functioning (5 items) and academic functioning (5 items).\n\nThe parent questionnaire assesses parents' perceptions of their child's health-related quality of life. On the PedsQL Generic Core Scales, for ease of interpretability, items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life)."", 'timeFrame': 'Up to 6 months post-operatively'}]",9,7 Years,18 Years,ALL,False,"University Hospital, Montpellier",OTHER,0,1000.0,ESTIMATED,2025-09-01T16:18:18.434299,v2_robust,True,True,False,False,False,
NCT03721172,Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy,"A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Mild to Moderate Plaque Psoriasis",Apremilast,['Apremilast'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Psoriasis,['Psoriasis'],"['Phase 3', 'Double-Blind', 'Efficacy', 'Safety', 'Apremilast', 'Otezla', 'CC-10004', 'Plaque Psoriasis', 'Mild', 'Moderate', 'Scalp', 'Nail', 'Itch']",COMPLETED,,2019-03-11,2020-07-24,"[{'measure': 'Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase', 'description': 'The sPGA is a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 =severe. Scores incorporate an assessment by the Investigator of the severity of the 3 primary signs of the disease: erythema, scaling and plaque elevation.\n\nAn sPGA response is defined as sPGA score of clear (0) or almost clear (1) and with at least a 2-point reduction from baseline at Week 16.', 'timeFrame': 'Baseline and Week 16 of the placebo-controlled phase'}]","[{'measure': 'Percentage of Participants With a ≥ 75 Percent (%) Improvement From Baseline in Affected Body Surface Area (BSA) at Week 16', 'description': 'The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant\'s hand. The surface area of the whole body is made up of approximately 100 palms or ""handprints"" (each entire palmar surface or ""handprint"" equates to approximately 1% of total body surface area).', 'timeFrame': 'Baseline and Week 16 of the placebo-controlled phase'}, {'measure': 'Change From Baseline in Percentage of Affected BSA at Week 16', 'description': 'The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant\'s hand. The surface area of the whole body is made up of approximately 100 palms or ""handprints"" (each entire palmar surface or ""handprint"" equates to approximately 1% of total body surface area).\n\nA negative change from baseline indicates a reduction of affected BSA.', 'timeFrame': 'Baseline and Week 16 of the placebo-controlled phase'}, {'measure': 'Change From Baseline in Total Psoriasis Area Severity Index (PASI) Score at Week 16', 'description': 'The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.\n\nPASI scores range from 0 to 72, with higher scores reflecting greater disease severity.\n\nA negative change from baseline indicates an improvement of disease symptoms.', 'timeFrame': 'Baseline and Week 16 of the placebo-controlled phase'}, {'measure': 'Percentage of Participants Who Achieved BSA ≤ 3% for Participants With Baseline Affected BSA > 3% at Week 16', 'description': 'The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant\'s hand. The surface area of the whole body is made up of approximately 100 palms or ""handprints"" (each entire palmar surface or ""handprint"" equates to approximately 1% of total body surface area).', 'timeFrame': 'Baseline and Week 16 of the placebo-controlled phase'}, {'measure': 'Percentage of Participants With ≥ 4-point Reduction From Baseline in Whole Body Itch Numeric Rating Scale (NRS) Score at Week 16 Who Had Baseline Whole Body Itch NRS ≥ 4', 'description': 'The whole body itch NRS is a self-reported measure where participants were asked to assess whole body itch and select a number on a scale of 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch. A reduction in score from baseline represents an improvement in symptoms.', 'timeFrame': 'Baseline and Week 16 of the placebo-controlled phase'}, {'measure': 'Percentage of Participants With a Scalp Physician Global Assessment (ScPGA) Response at Week 16 Among Participants With Baseline scPGA Score ≥ 2 at Week 16', 'description': ""The ScPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an Investigator's assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation of the overall scalp.\n\nAn ScPGA response is defined as and ScPGA score clear (0) or almost clear (1) with at least a 2-point reduction from baseline among participants with a baseline ScPGA score ≥ 2."", 'timeFrame': 'Baseline and Week 16 of the placebo-controlled phase'}, {'measure': 'Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16', 'description': 'The DLQI is a 10 item questionnaire dealing with the participant\'s skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from 0 (not at all) to 3 (very much). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant\'s skin prevented them from working or studying (Yes or No), and if ""No,"" then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being 0 (not at all), 1 (a little) and 2 (a lot).\n\nTotal scores have a possible range of 0 to 30, with 30 corresponding to the worst health-related quality of life, and 0 corresponding to the best score.\n\nA negative change from baseline indicates an improvement in health-related quality of life scores.', 'timeFrame': 'Baseline and Week 16 of the placebo-controlled phase'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'description': ""An adverse event (AE) is An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A TEAE is any AE that occurs following administration of study treatment.\n\nFrequency of TEAEs was assessed as well as severity and treatment relatedness.\n\nA TEAE was considered severe based on the Investigator's assessment. A TEAE could be severe if it was serious or non-serious, had symptoms causing discomfort or pain, requiring medical or surgical attention or intervention, interfered with activities of daily life and if drug therapy was required."", 'timeFrame': 'Placebo: Day 1 to Week 16; Apremilast Day 1 to a maximum of Week 32 (plus 4 week safety follow-up)'}]",9,18 Years,,ALL,False,Amgen,INDUSTRY,0,595.0,ACTUAL,2025-09-01T16:18:18.434361,v2_robust,True,True,True,False,True,
NCT06483672,Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases,"Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases, a Prospective Phase II Single-arm Clinical Study",Furmonertinib,"['AST2818', 'Anlotinib', 'No other intervention names', 'Furmonertinib']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Adenocarcinoma of Lung Metastatic to Brain,['Adenocarcinoma of Lung Metastatic to Brain'],"['Adenocarcinoma of Lung', 'Brain metastasis', 'EGFR mutation']",NOT_YET_RECRUITING,,2024-07,2027-12-31,"[{'measure': 'Central Nervous System Objective Response Rate (CNS ORR)', 'description': 'Proportion of subjects whose CNS tumors are assessed as complete response(CR) or partial response(PR) according to RANO-BM.', 'timeFrame': 'Approximately 12 weeks after the last patient begin study treatment'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'Proportion of subjects whose tumors are assessed as complete response(CR) or partial response(PR) according to RECIST 1.1.', 'timeFrame': 'Approximately 12 weeks after the last patient begin study treatment'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Proportion of subjects whose tumors are assessed as CR, PR or stable disease (SD) according to RECIST 1.1.', 'timeFrame': 'Approximately 12 weeks after the last patient begin study treatment'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'The time from the first dose of the study drugs to the progression of the disease or death for any reason according to RECIST 1.1', 'timeFrame': 'Approximately 18 months after the first patient begin study treatment'}, {'measure': 'Overall survival (OS)', 'description': 'The time from the first dose of the study drugs to the death for any reason according to RECIST 1.1', 'timeFrame': 'Approximately 24 months after the last patient begin study treatment'}, {'measure': 'Central Nervous System Disease Control Rate (CNS DCR)', 'description': 'Proportion of subjects whose CNS tumors are assessed as CR, PR or stable disease (SD) according to RANO-BM.', 'timeFrame': 'Approximately 12 weeks after the last patient begin study treatment'}, {'measure': 'Central Nervous System Progression Free Survival (PFS)', 'description': 'The time from the first dose of the study drugs to the progression of the CNS disease or death for any reason according to RECIST 1.1', 'timeFrame': 'Approximately 18 months after the first patient begin study treatment'}, {'measure': 'Adverse Events (AEs)', 'description': 'The number of patients with adverse events and the severity according to CTCAE v5.0', 'timeFrame': 'rom the start of study drug to 28 days after the last dose of study drug'}]",8,18 Years,,ALL,False,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",OTHER,0,27.0,ESTIMATED,2025-09-01T16:18:18.434446,v2_robust,True,True,False,False,True,
NCT03432572,Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets,Pilot Study: Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets,Pyridium,"['Pyridium', 'Group B', 'Riboflavin', 'Group A', 'Thiamine', 'Group C']",6,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Ureteral Injury,['Ureteral Injury'],[],COMPLETED,,2018-06-27,2020-06-30,"[{'measure': 'urine discoloration on cystoscopy', 'description': 'To determine if oral pyridium and vitamin B riboflavin administration prior to gynecologic procedures are effective and safe alternatives for evaluating ureteral patency at the time of cystoscopy.', 'timeFrame': 'through study completion, an average of 1 year'}]",[],1,21 Years,75 Years,FEMALE,True,Texas Tech University Health Sciences Center,OTHER,0,120.0,ACTUAL,2025-09-01T16:18:18.434471,v2_robust,True,True,True,False,False,
NCT00669695,Systemic Inflammation and Obstructive Sleep Apnea Syndrome: Effect of Atorvastatin,Systemic Inflammation and Obstructive Sleep Apnea Syndrome: Effect of Atorvastatin,Atorvastatin treatment,"['Atorvastatin treatment', 'statin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Obstructive Sleep Apnea Syndrome,['Obstructive Sleep Apnea Syndrome'],"['statins', 'cardiovascular risk', 'Obstructive sleep apnea syndrome (OSAS) patients']",TERMINATED,Interim analysis performed without efficient results,2008-05,2013-02,"[{'measure': 'The primary endpoint is the percent of peripheral arterial tone (PAT) improvement in comparison with the baseline situation.', 'timeFrame': 'after 3 months of Atorvastatin treatment.'}]","[{'measure': 'Evaluation of the inflammation occurring during OSAS.', 'timeFrame': 'after 3 months of Atorvastatin or placebo treatment.'}, {'measure': 'Evaluation of the insulin-resistance associated to OSAS.', 'timeFrame': 'after 3 months of Atorvastatin or placebo treatment.'}, {'measure': 'Evaluation of the hypercholesterolemia associated to OSAS.', 'timeFrame': 'after 3 months of Atorvastatin or placebo treatment.'}, {'measure': 'Evaluation of the effect of continuous positive airway pressure (CPAP) + Atorvastatin association on the previously cited parameters, in comparison with effect of Atorvastatin, CPAP and placebo.', 'timeFrame': 'after 6 months of treatments'}, {'measure': 'Measurement of the CPAP efficiency in comparison with sham CPAP in patients receiving the placebo.', 'timeFrame': 'after 3 months of treatment.'}]",6,18 Years,65 Years,ALL,False,"University Hospital, Grenoble",OTHER,0,54.0,ACTUAL,2025-09-01T16:18:18.434554,v2_robust,True,True,False,True,False,Interim analysis performed without efficient results
NCT06792695,A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer,"A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)",Volrustomig,"['Volrustomig', 'Bevacizumab', 'FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)', 'MEDI5752']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Colorectal Cancer,['Metastatic Colorectal Cancer'],"['Metastatic disease', 'Immunotherapy', 'Liver metastasis', 'Mismatch-repair-proficient', 'Antibody targeting', 'Colorectal Cancer', 'CANTOR']",RECRUITING,,2025-03-12,2028-01-11,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS is defined as the time from randomization until progression per Response Evaluation Criteria in Solid Tumours, Version 1.1 (RECIST 1.1) or death due to any cause.', 'timeFrame': 'Approximately 3 years'}, {'measure': 'Number of Participants with Adverse Events (AEs)', 'description': 'Number of participants who received at least one dose of study treatment will be assessed.', 'timeFrame': 'Approximately 3 years'}]","[{'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from randomization until the date of death due to any cause.', 'timeFrame': 'Approximately 3 years'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'ORR is defined as the proportion of participants who have a confirmed complete response or confirmed partial response as per RECIST 1.1.', 'timeFrame': 'Approximately 3 years'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'DCR is defined as the percentage of participants who have a confirmed CR or PR or who have SD per RECIST 1.1 after randomization.', 'timeFrame': 'Approximately 3 years'}, {'measure': 'Duration of Response (DOR)', 'description': 'DoR is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 or death due to any cause.', 'timeFrame': 'Approximately 3 years'}, {'measure': 'Time to second progression or death (PFS2)', 'description': 'PFS2 is defined as the time from randomization to the earliest of the progression event, after first subsequent therapy, or death.', 'timeFrame': 'Approximately 3 years'}, {'measure': 'Maximum Observed Concentration (Cmax)', 'description': 'Concentration of novel study intervention in serum and PK parameters as data allow (such as peak and trough concentrations) will be assessed.', 'timeFrame': 'Approximately 3 years'}, {'measure': 'Observed lowest concentration before the next dose is administered (Ctrough)', 'description': 'Concentration of novel study intervention in serum and PK parameters as data allow (such as peak and trough concentrations) will be assessed.', 'timeFrame': 'Approximately 3 years'}, {'measure': 'Number of patients with positive Antidrug Antibodies (ADAs)', 'description': 'The immunogenicity (ADAs) of novel study intervention in participants with CRC in the absence of liver metastases is investigated.', 'timeFrame': 'Approximately 3 years'}]",10,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,1,120.0,ESTIMATED,2025-09-01T16:18:18.434571,v2_robust,True,True,False,False,True,
NCT03748095,Population Pharmacokinetic Modeling to Optimize the Dosage of the Piperacillin / Tazobactam Combination in Patients With Sepsis in Intensive Care,Population Pharmacokinetic Modeling to Optimize the Dosage of the Piperacillin / Tazobactam Combination in Patients With Sepsis in Intensive Care,pipéracilline/tazobactam,['pipéracilline/tazobactam'],1,OBSERVATIONAL,[],,,Resuscitation Patients With Sepsis,['Resuscitation Patients With Sepsis'],[],UNKNOWN,,2019-03-12,2024-06-15,"[{'measure': 'The objective is to develop a Bayesian estimator of the area under the blood concentration curves of the piperacillin / tazobactam combination in resuscitation patients with sepsis.', 'description': 'The primary endpoint of this study is the ability of the pharmacokinetic model developed to predict the AUC of the piperacillin / tazobactam combination at 24 hours after initiation of antibiotic therapy.', 'timeFrame': '24hours'}]",[],1,18 Years,,ALL,False,"University Hospital, Rouen",OTHER,0,90.0,ESTIMATED,2025-09-01T16:18:18.434581,v2_robust,False,True,False,False,False,
NCT01857895,Feasibility Study of Exenatide by Continuous Subcutaneous Infusion,An Open-Label Exploratory Study to Investigate the Feasibility of Administering Exenatide by Continuous Subcutaneous Infusion to Healthy Subjects,Exenatide,['Exenatide'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Obesity,['Obesity'],"['Nausea', 'subcutaneous infusion', 'exenatide']",COMPLETED,,2013-05-16,2013-11-01,"[{'measure': 'Characterization of interruptions or deviations from prescribed exenatide infusion in Part A', 'description': 'To investigate the feasibility of administering exenatide via continuous subcutaneous infusion', 'timeFrame': '2 days'}, {'measure': 'Characterization of interruptions or deviations from prescribed exenatide infusion in Part B', 'description': 'To investigate the feasibility of administering exenatide via continuous subcutaneous infusion', 'timeFrame': '8 days'}, {'measure': 'Infusion rate adjustments when nausea/vomiting occurs in Part B', 'description': 'To investigate the feasibility of administering exenatide via continuous subcutaneous infusion. Infusion rate adjustment will be done to achieve tolerable infusion rate when nausea/vomiting occurs', 'timeFrame': '8 days'}, {'measure': 'Number of participants with adverse events (AEs) in Part A', 'description': 'AEs will be collected from the Day -1 and until the follow-up contact. AE data will be collected to evaluate the ability to monitor and maintain acceptable safety', 'timeFrame': '17 days'}, {'measure': 'Number of participants with AEs in Part B', 'description': 'AEs will be collected from the Day -1 and until the follow-up contact. AE data will be collected to evaluate the ability to monitor and maintain acceptable safety', 'timeFrame': '23 days'}, {'measure': 'Laboratory parameter assessment in Part A', 'description': 'Laboratory parameters include: hematology, clinical chemistry, and urinalysis', 'timeFrame': '17 days'}, {'measure': 'Laboratory parameter assessment in Part B', 'description': 'Laboratory parameters include: hematology, clinical chemistry, and urinalysis', 'timeFrame': '23 days'}, {'measure': 'Vital sign assessment in Part A', 'description': 'Vital signs measurement include: systolic and diastolic blood pressure, and pulse rate', 'timeFrame': '17 days'}, {'measure': 'Vital sign assessment in Part B', 'description': 'Vital signs measurement include: systolic and diastolic blood pressure, and pulse rate', 'timeFrame': '23 days'}]","[{'measure': 'Pharmacokinetic (PK) profile of exenatide in Part A', 'description': 'PK parameters include: area under concentration time curve from time 0 to 24 hours (AUC0 to24), maximum observed concentration from time 0 to 24 hours (Cmax0 to 24), and average concentration from time 0 to 24 hours (Cavg0 to 24) versus time', 'timeFrame': 'PK samples will be collected at pre-dose, and at 0.5, 1, 2, 4, 6, 10, 14, 24, and 26 hours post dose.'}, {'measure': 'Pharmacokinetic (PK) profile of exenatide in Part B', 'description': 'PK parameters include: AUC0-24, Cmax0 to 24, and Cavg0 to 24 versus time for each of 7 days and AUC0 to 168, Cmax0 to 168, and Cavg0 to 168 versus time over entire infusion period.', 'timeFrame': '8 days'}]",11,18 Years,60 Years,ALL,True,GlaxoSmithKline,INDUSTRY,1,10.0,ACTUAL,2025-09-01T16:18:19.656905,v2_robust,True,True,True,False,True,
NCT04590495,The Effects of Cannabidiol on the Driving Ability of Healthy Adults,The Effects of Cannabidiol on the Driving Ability of Healthy Adults: a Clinical Trial,300 mg Cannabidiol (CBD) oil,"['300 mg Cannabidiol (CBD) oil', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Driving Performance,"['Driving Performance', 'Cognitive Impairment', 'Sedation Complication', 'Mood']",[],COMPLETED,,2021-04-01,2021-12-01,"[{'measure': 'Driving Performance - Percent of Time Spent Out of Lane', 'description': 'From driving simulation. A greater percentage of time spent driving out of lane indicates worse performance. Min=0 max=100%', 'timeFrame': '1.5 hour post intervention'}, {'measure': 'Driving Performance - Number of Collisions.', 'description': 'From driving simulation. A greater number of collisions indicate worse performance. Min=0 max=infinity', 'timeFrame': '1.5 hour post intervention'}, {'measure': 'Driving Performance - Brake Reaction Time', 'description': 'Mean reaction time to stimuli from driving simulation. Longer reaction times indicate worst performance. Min=0 max=infinity', 'timeFrame': '1.5 hour post intervention'}, {'measure': 'Driving Performance - Lateral Position in Lane', 'description': 'Mean standard deviation of lateral position in lane under consistent speed from driving simulation. Larger standard deviations in lane position indicate worse performance. Min=0 max=infinity', 'timeFrame': '1.5 hour post intervention'}, {'measure': 'Driving Performance-percent of Time Spent Driving Above Speed Limit', 'description': 'From driving simulation. This is the percent of drive time that the driver spent driving above the speed limit. Greater percentage indicates worse performance.', 'timeFrame': '1.5 hour post intervention'}]","[{'measure': 'Change in Baseline VAMS for Mental Sedation', 'description': 'Visual Analog Mood Scale (VAMS). Mental sedation: sum of scores from questions 1, 4, 11, 13 on VAMS - higher scores indicate more mental sedation. Total min=0 Total max=400', 'timeFrame': '4 hours after baseline'}, {'measure': 'Change in Baseline VAMS--Physical Sedation', 'description': 'Visual Analog Mood Scale (VAMS). Physical sedation: sum of scores from questions 3, 5, 6, 16 on VAMS - higher scores indicate more physical sedation. Total min=0 Total max=400', 'timeFrame': '4 hours after baseline'}, {'measure': 'Change in Baseline SSS', 'description': 'Stanford Sleepiness Scale (SSS). Self-reported sleepiness, The SSS is a Likert-type scale which assess mental and physical sedation and sleepiness, respectively, at that moment and time. SSS only consists of 1 question that is scaled from 1 to 7, with 7 being a higher or worse score (i.e. more sleepy and sedated)', 'timeFrame': '4 hours after baseline'}, {'measure': 'Change in Baseline TMT Part A', 'description': 'Trail Making Test (TMT). Time to accurately complete Part A . The TMT measures executive function and consists of two parts; the first part requires participants to connect numbers in ascending order, while the second part requires individuals to connect numbers and letters in sequence. The test is scored by the time it takes to accurately complete each test. Increases in time correlate with greater impairment.', 'timeFrame': '4 hours after baseline'}, {'measure': 'Change in Baseline TMT Part B', 'description': 'Trail Making Test (TMT). Time to accurately complete Part B. The TMT measures executive function and consists of two parts; the first part requires participants to connect numbers in ascending order, while the second part requires individuals to connect numbers and letters in sequence. The test is scored by the time it takes to accurately complete each test. Increases in time correlate with greater impairment.', 'timeFrame': '4 hours after baseline'}, {'measure': 'Change in Baseline DSST', 'description': 'Digital Symbol Substitution Test (DSST). Number of correct symbols completed within 60 seconds. The test is scored by the degree of completion and accuracy over a timed 60 second period. More accurate completion (i.e. higher the score) indicates better cognitive functioning. Min=0 Max=90', 'timeFrame': '4 hours after baseline'}, {'measure': 'Change in Baseline PVT', 'description': 'Psychomotor Vigilance Test (PVT). Mean reaction time (in milliseconds) when responding to a stimuli that appears on a computer screen. Longer reaction time means worse vigilance. Min=0 max=infinity', 'timeFrame': '4 hours after baseline'}, {'measure': 'Change in Baseline SRT for Sound #1', 'description': 'Simple Reaction Time test (SRT). Mean reaction time to stimuli that appears on a computer screen. Longer reaction times mean a decrease in reaction time. Min=0 max=infinity. Two separate sounds were emitted. Data were obtained for participants reaction to each separate sound', 'timeFrame': '4 hours after baseline'}, {'measure': 'Change in Baseline SRT--sound #2', 'description': 'Simple Reaction Time test (SRT). Mean reaction time to stimuli that appears on a computer screen. Longer reaction times mean a decrease in reaction time. Min=0 max=infinity. Two separate sounds were emitted. Data were obtained for participants reaction to each separate sound', 'timeFrame': '4 hours after baseline'}]",14,18 Years,30 Years,ALL,True,West Virginia University,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:19.656929,v2_robust,True,True,True,False,False,
NCT02331095,Statin Use in Patients With Acute VTE,A Pilot Study of Using Statins in Patients With Acute Venous Thromboembolism (VTE),Atorvastatin,"['Atorvastatin', 'warfarin or rivaroxaban', 'Lipitor', 'Anticoagulation Therapy']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Venous Thromboembolism,['Venous Thromboembolism'],[],TERMINATED,Low recruitment,2015-01,2020-05-20,"[{'measure': 'The Reduction of Endogenous Thrombin Potential', 'description': 'Determine the reduction of endogenous thrombin potential measured by Thrombin Generation Assay (TGA) at 3 months in the ""anticoagulation +atorvastatin"" arm as compared to the ""anticoagulation"" arm.', 'timeFrame': '3 Months'}, {'measure': 'The Reduction of Peak Thrombin Concentration', 'description': 'Determine the reduction of thrombin peak concentration measured by Thrombin Generation Assay (TGA) at 3 months in the ""anticoagulation +atorvastatin"" arm as compared to the ""anticoagulation"" arm.', 'timeFrame': '3 Months'}]","[{'measure': 'The Composite Rate of Recurrent Venous Thromboembolism (VTE) and VTE Related Mortality', 'description': 'Recurrent PE was defined as new filling defect(s) seen on CT angiogram or a new high-probability ventilation-perfusion lung scan (22, 23). Recurrent DVT was defined as new uncompressible segments seen on vascular Doppler ultrasonography in a previously uninvolved limb, clearly extending from the prior thrombosis, or a new venous segment in a previously involved limb.', 'timeFrame': '3 months and 9 months'}, {'measure': 'The Rate of Arterial Thrombotic Events', 'description': 'Arterial thromboembolism was defined a new myocardial infarction (based on typical electrocardiographic findings and/or elevation of cardiac enzymes) or cerebral vascular accident (based on clinical syndrome of development of focal or global loss of brain function thought to be vascular in origin, confirmed by appropriate standard imaging studies).', 'timeFrame': '3 months and 9 months'}, {'measure': 'The Rate of Residual (Chronic) Vein Obstruction by Doppler Ultrasound', 'description': 'Residual venous obstruction was assed by Doppler Ultrasonography. Residual chronic DVT (to any degree) was reported.', 'timeFrame': '3 Months'}, {'measure': 'The Reduction of Clinical Post-thrombotic Syndrome (PTS), as Objectively Evaluated With Villalta Scoring System', 'description': 'The Villata score for Post-Thrombotic Syndrome (PTS) stratifies the severity of post-thrombotic syndrome in lower extremity DVT. The score contains a combination of 5 subjective symptoms as reported by the patient (cramps, itching, pins and needles, heaviness, and pain) and 6 objective signs measured by a provider (edema, skin induration, hyperpigmentation, prominent veins on legs, redness, and tenderness on calf compression). Each sign is scaled from 0 (no or minimal) to 3 (severe) with a total score ranged from 0 to 33. Higher scores represent more severe disease.', 'timeFrame': '3 Months'}, {'measure': 'The Rate of Major, Non-major, and All Hemorrhages Defined by the International Society on Thrombosis and Haemostasis (ISTH) Criteria', 'description': 'Major bleeding events were defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria, with overt bleeding in critical organs (e.g. central nervous system, retroperitoneum), a \\>2 gram/dL drop in hemoglobin from baseline, or requiring at least two units of packed red blood cell transfusion meeting the criteria for major bleeding. Clinically relevant, non-major bleeding (CRNMB) events were defined as any other bleeding events reported by patients but not otherwise meeting the above listed criteria for major bleeding.', 'timeFrame': '3 months and 9 months'}, {'measure': 'Change in the Levels of D-Dimer at 3 Months', 'timeFrame': '3 Months'}, {'measure': 'Change in the Levels of C-Reactive Protein at 3 Months', 'description': 'C-Reactive (CRP) was measured using high sensitivity.', 'timeFrame': '3 Months'}, {'measure': 'Change in Low-Density Lipoproteins (LDL) at 3 Months', 'timeFrame': '3 Months'}, {'measure': 'Change in Triglyceride Levels at 3 Months', 'timeFrame': '3 Months'}]",11,18 Years,,ALL,False,Ohio State University,OTHER,0,21.0,ACTUAL,2025-09-01T16:18:19.657123,v2_robust,True,True,False,True,False,Low recruitment
NCT03487939,Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer,"Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer：an Open-label, Single-arm, Multicenter Phase II Study",FOLFOXIRI,"['Irinotecan', '5-Fluorouracil', 'FOLFOXIRI', 'Oxaliplatin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Colorectal Neoplasms,"['Colorectal Neoplasms', 'Drug Therapy']",[],UNKNOWN,,2018-05-01,2021-10-01,"[{'measure': 'The ratio of tumor downstaging to stage 0 and stage I', 'description': 'Tumor downstaging from stage II or III to pathologic complete response (stage 0) and stage I', 'timeFrame': '2 years'}]","[{'measure': 'Tumor regression grade (TRG)', 'description': 'The level of tumor regression under pathological examination', 'timeFrame': '2 years'}, {'measure': 'Disease free survival', 'description': 'Estimated from the date of surgery to the date of recurrence.', 'timeFrame': '3 years'}, {'measure': 'Overall survival time', 'description': 'Estimated from the date of enrollment to death from any cause.', 'timeFrame': '3 years'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'The grade of toxicity will be assessed using the NCI-CTCAE version 4.0.', 'timeFrame': '3 years'}, {'measure': 'ctDNA assessment and relation to clinical outcome', 'description': 'The relationship between ctDNA and survival will be evaluated.', 'timeFrame': '3 years'}, {'measure': 'SUVmax assessment and relation to clinical outcome', 'description': 'Tumor metabolic response through FDG-PET examination before and after 4 cycles of neoadjuvant FOLFOXIRI chemotherapy', 'timeFrame': 'At the beginning of Cycle 1 and the end of Cycle 4 (each cycle is 14 days)'}, {'measure': 'Quality of life (QLQ C30)', 'description': 'Scores according to EORTC QLQ-C30 scoring manual', 'timeFrame': 'Every 2 weeks after the first treatment until 3 years'}]",8,18 Years,75 Years,ALL,False,"China Medical University, China",OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:19.657211,v2_robust,True,True,False,False,True,
NCT02428439,Identification of Genetic Markers and Predictors of Antidepressant-induced Suicidality in Youth Depression,Genetic Markers and Predictors of Antidepressant-induced Suicidality in Youth Depression,bupropion or lamotrigine,"['Lamictal', 'bupropion or lamotrigine', 'Wellbutrin']",3,OBSERVATIONAL,[],,,Depression,"['Depression', 'Suicidal Ideation']","['genetic markers', 'predictors', 'Antidepressive Agents', 'Suicidal Ideation', 'Adolescent']",UNKNOWN,,2015-04,2020-06-30,"[{'measure': 'Evaluation of Suicidal ideation and behavior', 'description': 'Using Columbia-Suicide Severity Rating Scale(C-SSRS)', 'timeFrame': '8 weeks'}]","[{'measure': 'Evaluation of treatment effect of antidepressants(CDRS)', 'description': ""A composite measure consisting of Children's Depression Rating scale(CDRS). Modeled after the Hamilton Rating Scale for Depression, the CDRS is a clinical interview tool designed for assessing 6-12 year-olds, and it has also been used successfully for adolescents."", 'timeFrame': '8 weeks'}, {'measure': 'Evaluation of treatment effect of antidepressants (YMRS)', 'description': 'A composite measure consisting of Young Mania Rating Scale(YMRS). The YMRS is an 11-item scale used to assess the severity of mania in children and adolescents ages 5-17.The YMRS has been used in clinical practice since 1978. Ratings are based on child/adolescent self-reporting and clinician observation. This instrument does not assess depressed mood.', 'timeFrame': '8 weeks'}, {'measure': 'Evaluation of treatment effect of antidepressants(P-GBI)', 'description': 'The P-GBI is adapted from the General Behavior Inventory, and allows parents to rate depressive, hypomanic, manic, and alternating mood symptoms in their children and adolescents ages 5-17.', 'timeFrame': '8 weeks'}, {'measure': 'Evaluation of treatment effect of antidepressants(CGI-S)', 'description': 'The Clinical Global Impression rating scales(CGI-S) are commonly used measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders.', 'timeFrame': '8 weeks'}, {'measure': 'Genome wide association analysis', 'description': 'KNIH Biobank Array', 'timeFrame': '8 weeks'}]",6,11 Years,18 Years,ALL,False,Asan Medical Center,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:19.657282,v2_robust,False,True,False,False,False,
NCT07057739,Fentanyl and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided Superficial Cervical Plexus Block in Thyroid Surgeries,Fentanyl and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided Superficial Cervical Plexus Block in Thyroid Surgeries,Superficial cervical plexus block,"['Superficial cervical plexus block', 'Bupivacaine 0.25% + Fentanyl', 'Superficial cervical plexus block + Fentanyl', 'Superficial cervical plexus block + Dexmedetomidine', 'Bupivacaine 0.25% + Dexmedetomidine', 'Bupivacaine 0.25% + Saline']",6,INTERVENTIONAL,['NA'],,,Fentanyl,"['Fentanyl', 'Dexmedetomidine', 'Adjuvants', 'Bupivacaine', 'Ultrasound', 'Superficial Cervical Plexus Block', 'Thyroid Surgeries']",[],COMPLETED,,2024-06-30,2025-05-30,"[{'measure': 'Pain degree', 'description': 'Postoperative pain was assessed using a 10-point Visual Analog Scale (VAS), where 0 represents no pain and 10 indicates the worst imaginable pain. It was assessed at 0, 2, 4, 6, 8, 12, 18, and 24 hours post-surgery.', 'timeFrame': '24 hours postoperatively'}]","[{'measure': 'Duration of Sensory Block', 'description': 'Time from performance of the superficial cervical plexus block to the complete resolution of sensory blockade was assessed.', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Time to First Rescue Analgesia', 'description': 'Time from end of surgery to the administration of the first dose of rescue analgesia, triggered by VAS score ≥3.', 'timeFrame': '48 hours postoperatively'}, {'measure': 'Total Opioid Consumption', 'description': 'Cumulative dose of opioid analgesics (pethidine in mg) administered during the first 48 hours postoperatively.', 'timeFrame': '48 hours postoperatively'}, {'measure': 'Mean arterial pressure (MAP)', 'description': 'Serial measurement of mean arterial pressure (MAP, mmHg) at baseline, intraoperatively every 30 minutes, and postoperatively at 0, 2, 4, 6, 8, 12, and 24 hours.', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Heart rate', 'description': 'Serial measurement of heart rate (beats per minute) at baseline, intraoperatively every 30 minutes, and postoperatively at 0, 2, 4, 6, 8, 12, and 24 hours.', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Incidence of Adverse Events', 'description': ""Incidence of adverse events including but not limited to Horner's syndrome, local anesthetic systemic toxicity (LAST), phrenic nerve block, bradycardia, hypotension, hematoma, nausea, vomiting, respiratory discomfort, and failed block was recorded."", 'timeFrame': '48 hours postoperatively'}]",7,20 Years,65 Years,ALL,False,Kafrelsheikh University,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:19.657392,v2_robust,True,True,True,False,True,
NCT04209439,Analgesic Effect of Erector Spinae Plane Block for Renal Colic Pain,Erector Spinae Plane Block Versus Intravenous Dexketoprofen-trometamol for Treatment of Reno-ureteral Colic: a Randomized Prospective Study,30 ml %0.25 bupivacaine,"['30 ml %0.25 bupivacaine', 'Dexketoprofen-trometamol']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Renal Colic,['Renal Colic'],[],COMPLETED,,2019-01-01,2020-01-28,"[{'measure': 'Number of analgesic consumption', 'description': 'Fentanyl', 'timeFrame': '1 hour'}]","[{'measure': 'Numeric Rating Scale', 'description': 'A NRS involves asking the patient to rate his or her pain from 0 to 10 (11 point scale) with the understanding that 0 is equal to no pain and 10 is equal to worst possible pain. NRS score will be recorded after intervention at 5.,10.,15.,30.,45. and 60. minute', 'timeFrame': '1 hour'}]",2,18 Years,65 Years,ALL,False,Ataturk University,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:19.657639,v2_robust,True,True,True,False,False,
NCT00980239,"HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver",A Multi-arm Phase I Trial of Hepatic Arterial Infusion of Irinotecan With 1) Systemic Bevacizumab 2) Systemic Bevacizumab and Oxaliplatin 3) Systemic Bevacizumab and Cetuximab in Patients With Advanced Cancers Metastatic to the Liver,Irinotecan,"['Erbitux', 'rhuMAb-VEGF', 'Oxaliplatin', 'Irinotecan', 'Eloxatin', 'CPT-11', 'C225', 'Cetuximab', 'Anti-VEGF monoclonal antibody', 'IMC-C225', 'Camptosar', 'Bevacizumab', 'Avastin']",13,INTERVENTIONAL,['PHASE1'],PHASE1,,Liver Cancer,"['Liver Cancer', 'Advanced Cancer']","['Solid Tumors', 'Liver', 'hepatic arterial infusion', 'HAI', 'Bevacizumab', 'Avastin', 'Cetuximab', 'Erbitux', 'Irinotecan', 'Camptosar', 'Oxaliplatin', 'Eloxatin']",COMPLETED,,2009-09,2015-08,"[{'measure': 'Maximum Tolerated Doses (MTDs)', 'description': 'MTD is defined as the highest dose level at which ≥ 33% of patients have a DLT if \\>3 patients are treated at that dose level or \\> 33% have a DLT if ≤3 patients have been treated.', 'timeFrame': 'Evaulated with each 28 day cycle'}, {'measure': 'Dose-limiting toxicities (DLTs)', 'description': 'DLT defined as any grade 3 or 4 non-hematologic toxicity defined in NCI CTC v3.0, even if expected and believed related to study medications (except nausea and vomiting responsive to appropriate regimens or alopecia), any grade 4 hematologic toxicity lasting 2 weeks or longer (as defined by the NCI-CTCAE), despite supportive care; any grade 4 nausea or vomiting \\> 5 days despite maximum anti-nausea regimens, and any other grade 3 non-hematologic toxicity including symptoms/signs of vascular leak or cytokine release syndrome; or any severe or life-threatening complication or abnormality not defined in the NCI-CTCAE that is attributable to the therapy.', 'timeFrame': 'Evaulated with each 28 day cycle'}]",[],2,,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,115.0,ACTUAL,2025-09-01T16:18:19.657652,v2_robust,True,True,True,False,False,
NCT03168139,Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer,"A Two-part, Open-label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in Metastatic Colorectal and Pancreatic Cancer",Olaptesed pegol - Monotherapy,"['NOX-A12', 'NOX-A12, Keytruda, MK-3475', 'Olaptesed pegol - Monotherapy', 'Olaptesed pegol + Pembrolizumab - Combination Therapy']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Metastatic Colorectal Cancer,"['Metastatic Colorectal Cancer', 'Metastatic Pancreatic Cancer']","['Metastatic colorectal cancer', 'Metastatic pancreatic cancer', 'NOX-A12', 'Olaptesed pegol', 'Spiegelmer', 'Pembrolizumab', 'PD-1 inhibitor', 'Stromal cell-derived factor-1 (SDF-1)', 'CXCL12', 'Tumor microenvironment', 'Immunotherapy', 'Checkpoint inhibition']",COMPLETED,,2017-04-18,2020-03-25,"[{'measure': 'Monotherapy: Pharmacodynamics', 'description': 'Evaluation of changes within the tumor microenvironment induced by CXCL12 inhibition with olaptesed pegol by comparing pre- and post-treatment biopsy specimens', 'timeFrame': 'up to 14 days'}, {'measure': 'Combination Therapy: Safety - adverse events, vital signs, ECG, hematology & safety laboratory', 'description': 'Safety and tolerability of olaptesed pegol in combination with pembrolizumab will be evaluated by assessing adverse events, vital signs (pulse rate, blood pressure), 12-lead ECG, hematology (full blood count including platelets and differential count), safety laboratory including thyroid function tests', 'timeFrame': 'up to 24 months'}]","[{'measure': 'Monotherapy: Safety', 'description': 'Assessment of safety and tolerability of olaptesed pegol in patients with metastatic (stage IV) colorectal and pancreatic cancer (adverse events, vital signs (pulse rate, blood pressure), 12-lead ECG, hematology (full blood count including platelets and differential count), safety laboratory)', 'timeFrame': 'up to 14 days'}, {'measure': 'Monotherapy: Pharmacodynamics', 'description': 'Investigation of changes in the cytokine/chemokine signature within the tumor microenvironment and in the peripheral blood induced by CXCL12 inhibition with olaptesed pegol by comparing the pre- and post-treatment samples', 'timeFrame': 'up to 14 days'}, {'measure': 'Combination Therapy: Disease control rate (DCR)', 'description': 'DCR will be calculated as the proportion of patients with best overall response to treatment with olaptesed pegol in combination with pembrolizumab of complete response (CR), partial response (PR) or stable disease (SD).\n\nTreatment responses will be assessed according to the current guidelines of the RECIST 1.1 and irRECIST.', 'timeFrame': 'up to 24 months'}, {'measure': 'Combination Therapy: Efficacy - time to event analyses', 'description': 'Efficacy of treatment with olaptesed pegol in combination with pembrolizumab (PFS and OS)', 'timeFrame': 'up to 24 months'}]",6,18 Years,,ALL,False,TME Pharma AG,INDUSTRY,1,20.0,ACTUAL,2025-09-01T16:18:19.657685,v2_robust,True,True,True,False,True,
NCT05225077,Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients,Effect of Short-term Dapagliflozin on Renal Function After Heart Catheterization or Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease,Dapagliflozin 10 MG [Farxiga],['Dapagliflozin 10 MG [Farxiga]'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,"Renal Insufficiency, Chronic","['Renal Insufficiency, Chronic', 'Cardiac Catheterization', 'Percutaneous Coronary Intervention']","['Sodium-Glucose Transporter 2 Inhibitors', 'Dapaglifozin', 'Chronic kidney disease']",UNKNOWN,,2022-01-01,2023-12-31,"[{'measure': 'Incidence of contrast induced nephropathy', 'description': 'Serum creatinine (Scr) elevation of \\>25% or \\>0.5 mg/dl (44 μmol/l) from baseline within 48 hours', 'timeFrame': '48 hours'}]",[],1,20 Years,80 Years,ALL,True,Dong-A University,OTHER,0,600.0,ESTIMATED,2025-09-01T16:18:19.657750,v2_robust,True,True,False,False,False,
NCT04459377,Ketamine Analgesia in Third Molar Surgery,"An Analysis of Ketamine Analgesia in Third Molar Surgery -Effects, Safety and Influence on Inflammatory Biomarkers in Plasma",S-Ketamine,"['Sodium Chloride 0.9% Inj', 'S-Ketamine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Pain,"['Pain', 'Postoperative']","['Ketamine', 'Postoperative', 'Pain management', 'Third molar']",COMPLETED,,2017-02-14,2022-09-30,"[{'measure': 'Pain (VAS)', 'description': 'Postoperative pain measured by Visual analog scale (VAS). From minimum 0mm to maximum 100mm. 0mm is no pain and 100mm is worst pain imaginable. Changes in Visual Analog Scale value from preoperatively to 4 hours postoperatively', 'timeFrame': '4 hours postoperatively'}]","[{'measure': 'Safety (Oxygen saturation)', 'description': 'Change in oxygen saturation measured by pulseoximeter %. Intra individually and between the groups. From start to completion of the ketamine infusion.', 'timeFrame': 'Up to 2 hours.'}]",2,18 Years,44 Years,ALL,False,"Dalarna County Council, Sweden",OTHER,2,168.0,ACTUAL,2025-09-01T16:18:19.657771,v2_robust,True,True,True,False,True,
NCT05630677,A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.,"An Open-Label, Five-Period Study in Healthy Subjects to Investigate the Relative Bioavailability of AZD5055 Film-Coated Tablet Versus AZD5055 Oral Suspension Formulation, the Absolute Oral Bioavailability of AZD5055 and to Evaluate the Effect of Food and an Acid Reducing Agent on the Pharmacokinetics of AZD5055.",AZD5055 solution for infusion,"['Rabeprazole, Delayed-release tablet', 'AZD5055 solution for infusion', 'AZD5055 oral suspension', 'AZD5055 film-coated tablet']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['Acid Reducing Agent', 'Bioavailability', 'Healthy subjects', 'pH-dependent solubility', 'Food Effect']",COMPLETED,,2022-11-04,2023-02-09,"[{'measure': 'Area under concentration time curve from time 0 to infinity (AUCinf)', 'description': '* To estimate the relative bioavailability of AZD5055 film-coated tablet formulation versus AZD5055 oral suspension formulation.\n* To estimate the absolute bioavailability of AZD5055 oral suspension and AZD5055 film-coated tablet formulation.\n* To assess the effect of the acid reducing agent, rabeprazole, on the PK of AZD5055 alone and in combination with acid reducing agent.\n* To assess the effect of the acid reducing agent, rabeprazole, on the PK of AZD5055, when AZD5055 is administered.', 'timeFrame': 'Day 1-6, 8-10, 13-15, 17-19'}, {'measure': 'Area under the concentration time curve from time 0 to the last quantifiable concentration (AUClast)', 'description': '* To estimate the relative bioavailability of AZD5055 film-coated tablet formulation versus AZD5055 oral suspension formulation.\n* To estimate the absolute bioavailability of AZD5055 oral suspension and AZD5055 film-coated tablet formulation.\n* To assess the effect of food on the pharmacokinetic (PK) parameters of AZD5055 in the fed and fasted state.\n* To assess the effect of the acid reducing agent, rabeprazole, on the PK of AZD5055 alone and in combination with acid reducing agent.\n* To assess the effect of the acid reducing agent, rabeprazole, on the PK of AZD5055, when AZD5055 is administered in fasted and fed state.', 'timeFrame': 'Day 1-6, 8-10, 13-15, 17-19'}, {'measure': 'Maximum observed concentration (Cmax)', 'description': '* To estimate the relative bioavailability of AZD5055 film-coated tablet formulation versus AZD5055 oral suspension formulation.\n* To estimate the absolute bioavailability of AZD5055 oral suspension and AZD5055 film-coated tablet formulation.\n* To assess the effect of food on the pharmacokinetic (PK) parameters of AZD5055 in the fed and fasted state.\n* To assess the effect of the acid reducing agent, rabeprazole, on the PK of AZD5055 alone and in combination with acid reducing agent.\n* To assess the effect of the acid reducing agent, rabeprazole, on the PK of AZD5055, when AZD5055 is administered in fasted and fed state.', 'timeFrame': 'Day 1-6, 8-10, 13-15, 17-19'}]",[],3,18 Years,55 Years,ALL,True,AstraZeneca,INDUSTRY,1,21.0,ACTUAL,2025-09-01T16:18:19.657783,v2_robust,True,True,True,False,False,
NCT00630877,Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin,"A Randomized, Double-blind, Parallel, Multicenter, Placebo-controlled, Prospective Study to Evaluate the Functionality of the Flushing ASsessment Tool (FAST) in Subjects Administered Niaspan® Plus Acetylsalicylic Acid (ASA), Niaspan® Plus ASA Placebo or Niaspan® Placebo Plus ASA Placebo Daily for Six Weeks",Niacin extended-release (NER),"['Aspirin (ASA)', 'ABT-919', 'Niaspan', 'acetylsalicylic acid', 'Aspirin (ASA) placebo', 'Niacin extended-release (NER) placebo', 'Niacin extended-release (NER)']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Dyslipidemia,['Dyslipidemia'],[],COMPLETED,,2008-02,2008-06,"[{'measure': 'Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score', 'description': 'Test-retest reliability of the mean flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe.', 'timeFrame': 'Week 1 to Week 2'}, {'measure': 'FAST Test-retest Reliability--maximum Flushing Severity Score', 'description': 'Test-retest reliability of the maximum flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe.', 'timeFrame': 'Week 1 to Week 2'}, {'measure': 'FAST Cross-sectional Construct Validity--mean Flushing Severity Score', 'description': 'The relationship between mean flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome.', 'timeFrame': 'Week 1'}, {'measure': 'FAST Cross-sectional Construct Validity--maximum Flushing Severity Score', 'description': 'The relationship between maximum flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome.', 'timeFrame': 'Week 1'}, {'measure': 'FAST Longitudinal Construct Validity--mean Flushing Severity Score', 'description': 'The relationship between the change in mean flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start).', 'timeFrame': 'Week 1 to Week 2'}, {'measure': 'FAST Longitudinal Construct Validity--maximum Flushing Severity Score', 'description': 'The relationship between the change in maximum flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start).', 'timeFrame': 'Week 1 to Week 2'}, {'measure': 'FAST Responsiveness--mean Flushing Severity Score', 'description': 'The change in mean flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in mean flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened.', 'timeFrame': 'Study start to Day 43'}, {'measure': 'FAST Responsiveness--maximum Flushing Severity Score', 'description': 'The change in maximum flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in maximum flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened.', 'timeFrame': 'Study start to Day 43'}]","[{'measure': 'Maximum Severity of Flushing Events Overall During the Study', 'description': 'The severity of flushing events was assessed as none, mild, moderate, severe, or very severe using the FAST. The maximum severity of flushing events overall during the study was compared among treatment groups.', 'timeFrame': 'Week 1 to Week 6'}]",9,18 Years,,ALL,False,Abbott,INDUSTRY,0,276.0,ACTUAL,2025-09-01T16:18:19.657886,v2_robust,True,True,True,False,False,
NCT00001277,Studies of Elevated Parathyroid Activity,Studies of Hyperparathyroidism and Related Disorders,68Ga-Dotatate,"['68Ga-Dotatate', '18F-DOPA']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hyperparathyroidism,"['Hyperparathyroidism', 'Hypercalcemia', 'Parathyroid Neoplasm', 'Multiple Endocrine Neoplasia', 'MEN1']","['Hypoglycemia', 'Genetics', 'Hyperparathyroidism']",COMPLETED,,1993-12-15,2020-12-23,"[{'measure': 'Type of Hyperparathyroidism', 'description': 'The purpose of this study is to understand the causes of primary hyperparathyroidism, to evaluate and improve methods for diagnosis and treatment, and to provide insight into the mechanisms of normal parathyroid function. Hereditary causes of primary hyperparathyroidism will be characterized. Patients were categorized as follows:\n\n1. MEN1: Diagnosed by demonstration of a germline variant in MEN1 gene or one of the following: a) two of three primary MEN1 manifestations b) one primary MEN1 manifestation with a family member with MEN1.\n2. Other familial: Non-MEN1 patients who had a positive family history of hyperparathyroidism suspicious for underlying germline predisposition syndrome.\n3. Sporadic: Patients who did not have a positive family history of hyperparathyroidism.\n4. Unknown: No data to help categorize the patients in any of the above categories.', 'timeFrame': 'First year'}, {'measure': 'Organs With Identified Lesions', 'description': 'For each organ, agreement between 68Ga-DOTATATE and 18F-DOPA', 'timeFrame': 'Days 1-6'}, {'measure': 'Number of Lesions Identified', 'description': 'The total number of lesions identified by each imaging modality', 'timeFrame': 'Days 1-6'}]",[],3,2 Months,,ALL,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,0,1553.0,ACTUAL,2025-09-01T16:18:19.657948,v2_robust,True,True,True,False,False,
NCT00955877,Extended-release Epidural Morphine for Acute Post-operative Analgesia Following Selective Dorsal Rhizotomy in Children,"Randomized, Double-Blinded Placebo Controlled Trial of Epidural, Sustained-relief Morphine for Acute Post-operative Analgesia Following Selective Dorsal Rhizotomy in Children",Extended-release Epidural morphine (EREM) 80,"['Control: Saline', 'Extended-release Epidural Morphine (EREM) 120', 'Extended-release Epidural morphine (EREM) 80', 'DepoDur']",4,INTERVENTIONAL,['NA'],,,Spastic Cerebral Palsy,['Spastic Cerebral Palsy'],"['extended-release epidural morphine', 'DepoDur', 'Spastic Cerebral Palsy']",TERMINATED,The manufacturer decided to stop drug production.,2010-03,2015-01,"[{'measure': 'Adequacy of Analgesia as Judged by Age-adjusted Pain Scales', 'description': 'Mean and standard deviation for standardized, age-appropriate pain scales (per patient per day) 48hrs post surgery. As is standard of care at St. Louis Children\'s Hospital, pain level was scored based on age using the ""Face, Legs, Activity, Cry, Consolability"" (FLACC) for participants aged 0-3, the FACES scale on participants between the age of 3 and 5, numeric pain rating scale (NRS) on participants between the age of 5 and 8 years, or the Individualized Numeric Rating Scale (INRS) for participants greater than or equal to 8 years of age. All four of the scales were ranged from 0-10 scores, with 0 being no pain at all, and 10 being extreme pain. Each patient had two scores given, one at 24hrs and one at 48hrs post surgery. The output was reported as an average of all scores for all patients within each group.', 'timeFrame': '48 hour post-operative period'}, {'measure': 'Quantity of Fentanyl Administered', 'description': 'Mean and standard deviation of total quantity of fentanyl administered (per patient per day) 48hrs post surgery.', 'timeFrame': '48 hour post-operative period'}]","[{'measure': 'Number of Participants With Respiratory Depression Within 48hrs Post op', 'description': 'Number of participants with respiratory depression within 48hrs post operation', 'timeFrame': '48 hour post-operative period'}, {'measure': 'Number of Participants With Hemodynamic Instability 48hrs Post op', 'description': 'Number of Participants with Hemodynamic Instability 48hrs post operation', 'timeFrame': '48 hour post-operative period'}, {'measure': 'Number of Participants With CSF Leaks Within 6 Months Post op.', 'description': 'Number of participants with CSF leaks within 6 months post operation.', 'timeFrame': '6 month post-operative period'}, {'measure': 'Number of Participants That Had Urine Retention for 48hrs Post Foley Catheter Removal.', 'description': 'Number of participants that had urine retention for 48hrs post foley catheter removal.', 'timeFrame': 'After the Foley catheter has been removed on post-operative day #1 for a 48 hour follow-up period'}, {'measure': 'Number of Participants With Nausea and/or Vomiting 48hrs Post op.', 'description': 'Number of participants with nausea and or vomiting 48hr post surgery', 'timeFrame': '48 hour post-operative period'}, {'measure': 'Number of Participants With Pruritis Within 48hrs Post op', 'description': 'Number of participants with pruritis within 48hrs post operation', 'timeFrame': '48 hour post-operative period'}, {'measure': 'Number of Participants That Were Given Codeine 48hr Post Surgery', 'description': 'Number of participants that were given codeine 48hr post surgery', 'timeFrame': '48hr post surgery'}, {'measure': 'Number of Participants That Were Given Zofran 48hr Post Surgery', 'description': 'Number of participants that were given Zofran 48hr post surgery', 'timeFrame': '48hr post surgery'}, {'measure': 'Number of Participants That Were Bradycardia Within 48hr Post Surgery', 'description': 'Number of participants that were bradycardia within 48hr post surgery', 'timeFrame': '48hr post surgery'}]",11,2 Years,12 Years,ALL,False,Washington University School of Medicine,OTHER,0,13.0,ACTUAL,2025-09-01T16:18:19.657971,v2_robust,True,True,False,True,False,The manufacturer decided to stop drug production.
NCT06309277,A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD,"A Two-Part Controlled Clinical Study to Evaluate Safety, Tolerability, Response, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of GM-1020 in Patients With Major Depressive Disorder",GM-1020,['GM-1020'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Major Depressive Disorder,['Major Depressive Disorder'],['MDD'],RECRUITING,,2024-02-01,2024-07,"[{'measure': 'Incidence of treatment emergent adverse events', 'description': ""Clinical monitoring of safety data from AE reporting, 12-lead ECG, vital signs, clinical laboratory evaluations, emergence of suicidal thoughts and ideations (Columbia-Suicidal Severity Rating Scale) and sedation (Modified Observer's Assessment of Alertness and Sedation)."", 'timeFrame': 'Baseline, Day 42'}]","[{'measure': 'Montgomery-Åsberg Depression Rating Scale (MADRS) Change from baseline to 72 hours', 'description': 'MADRS total score, sum of 10 item scores (each on a 0 (best value) to 6 (worst value)scale), assesses the severity of depressive symptoms on a continuous scale from 0 (the best) to 60 (the worst).', 'timeFrame': 'Baseline, 72 hours'}]",2,18 Years,65 Years,ALL,False,Gilgamesh Pharmaceuticals,INDUSTRY,0,30.0,ESTIMATED,2025-09-01T16:18:19.658006,v2_robust,True,True,False,False,True,
NCT02547675,Rociletinib (CO-1686) USA Expanded Access Program,An Expanded Access Protocol of Oral Rociletinib (CO-1686) as Epidermal Growth Factor Receptor (EGFR)-Directed Therapy for Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation,Rociletinib,"['Rociletinib', 'CO-1686']",2,EXPANDED_ACCESS,[],,,Non-small Cell Lung Cancer,['Non-small Cell Lung Cancer'],[],NO_LONGER_AVAILABLE,,,,[],[],0,18 Years,,ALL,,"Clovis Oncology, Inc.",INDUSTRY,0,,,2025-09-01T16:18:19.658015,v2_robust,False,True,False,False,False,
NCT06565975,Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France,"RELION Study: Characteristics and Outcomes of the Patient Population With Acute Myeloid Leukemia in Remission, Treated With Oral Azacitidine Maintenance in France",Oral azacitidine,['Oral azacitidine'],1,OBSERVATIONAL,[],,,Acute Myeloid Leukemia (AML),['Acute Myeloid Leukemia (AML)'],['Acute myeloid leukemia (AML)'],ACTIVE_NOT_RECRUITING,,2023-05-23,2024-10-31,"[{'measure': 'Participant real-world relapse-free survival (rw-RFS)', 'timeFrame': 'Up to date of documented relapse or death assessed up to 41 months'}, {'measure': 'Participant overall survival (OS)', 'timeFrame': 'Up to date of documented death assessed up to 41 months'}, {'measure': 'Participant relapsed-free survival (RFS)', 'timeFrame': 'From date of achieved complete remission up to 41 months'}, {'measure': 'Participant overall survival (OS) from the time of complete remission achievement', 'timeFrame': 'From date of achieved complete remission up to 41 months'}, {'measure': 'Participant relapse rate', 'timeFrame': '6 and 12 months'}, {'measure': 'Time to treatment discontinuation (TTD)', 'timeFrame': 'Up to 41 months'}]","[{'measure': 'Participant baseline demographics', 'timeFrame': 'Baseline'}, {'measure': 'Type of acute myeloid (AML)', 'description': 'AML types include: de novo, or secondary AML (therapy-related AML, or secondary to a myeloid disorder)', 'timeFrame': 'Baseline'}, {'measure': 'Participant cytogenetic abnomalities', 'timeFrame': 'Baseline'}, {'measure': 'Participant gene mutation status', 'timeFrame': 'Baseline'}, {'measure': 'Participant cytogenetic and mutational risk category', 'timeFrame': 'Baseline'}, {'measure': 'Participant acute myeloid (AML) classification as per World Health Organization', 'timeFrame': 'Baseline'}, {'measure': 'Participant bone marrow blast percentage', 'timeFrame': 'Baseline'}, {'measure': 'Participant hemoglobin levels', 'timeFrame': 'Baseline'}, {'measure': 'Participant blood test results', 'timeFrame': 'Baseline'}, {'measure': 'Participant Eastern Cooperative Oncology Group or Karnofsky score', 'timeFrame': 'Baseline'}, {'measure': 'Participant diagnosis history of other hematological disorders', 'timeFrame': 'Baseline'}, {'measure': 'Participant treatment history', 'timeFrame': 'Baseline'}, {'measure': 'Minimal residual disease status (MRD)', 'timeFrame': 'Baseline'}, {'measure': 'Reason for stem cell transplant ineligibility post initial frontline treatment', 'timeFrame': 'Baseline'}, {'measure': 'Participant response type at the initiation of maintenance therapy', 'description': 'Response types include: complete remission (CR), incomplete blood count recovery (Cri) or CR with partial hematology recovery (CRh)', 'timeFrame': 'Up to 41 months'}, {'measure': 'First versus subsequent remission at the time of initiation of treatment with oral azacitidine', 'timeFrame': 'Baseline'}, {'measure': 'Criteria to define complete remission (CR), incomplete blood count recovery (Cri), and CR with partial hematology recovery (CRh) at time of initiation of oral azacitidine', 'timeFrame': 'Baseline'}, {'measure': 'Oral azacitidine treatment regimen', 'timeFrame': 'Up to 41 months'}, {'measure': 'Concomitant support treatment received with oral azacitidine', 'timeFrame': 'Up to 41 months'}, {'measure': 'Duration of oral azacitidine treatment', 'timeFrame': 'Up to 41 months'}, {'measure': 'Reason for oral azacitidine treatment discontinuation', 'timeFrame': 'Up to 41 months'}, {'measure': 'Treatments/procedures following oral azacitidine cessation', 'timeFrame': 'Up to 41 months'}, {'measure': 'Participant adverse events (AEs)', 'timeFrame': 'Up to 41 months'}]",29,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,112.0,ACTUAL,2025-09-01T16:18:19.658056,v2_robust,False,True,False,False,True,
NCT02577575,Adult Oxytocin Study,The Effects of Oxytocin on Social Cognition in Patients With Schizophrenia,Oxytocin,"['Syntocinon', 'Saline Nasal Spray', 'Placebo', 'Oxytocin']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Schizophrenia,"['Schizophrenia', 'Oxytocin', 'Social Cognition']","['Oxytocin', 'Syntocinon', 'Social Cognition', 'Schizophrenia']",COMPLETED,,2010-08,2015-11,"[{'measure': 'Improvement in social cognition task performance', 'description': ""The outcome will be the number of tasks that improve on the oxytocin day compared to the placebo day in a panel of tasks designed to measure the subject's level of social cognition. Participants will complete social cognition tasks, which include the Auction Task, Devil's Task, Ultimatum Task, Verbal Prosody, Effort Expenditure for Rewards Task (EEfRT), and Passive Viewing Eyetracking."", 'timeFrame': '2-days at least 1-week apart'}]","[{'measure': 'Pre-morbid IQ Questionnaire (AmNART)', 'description': 'The American National Adult Reading Test (AMNART) is an instrument used to estimate premorbid verbal intelligence quotient (IQ) in adults. Participants are shown 45 words one at a time and are asked to read the word aloud. The scorer then writes 0 if the participant read the word incorrectly or 1 if the pronunciation is correct.', 'timeFrame': '1 day'}, {'measure': 'Experiences in Close Relationships-Relationship Structures (ECR-RS) Questionnaire', 'description': 'The ECR is used to evaluate the construct of adult attachment. The scale involves 36 itemized statements split into four parts, each part referring to a different attachment figure. Participants rank each item using a 7-point likert scale.', 'timeFrame': '1 day'}, {'measure': 'Childhood Trauma Questionnaire (CTQ)', 'description': ""The CTQ is a brief survey of 6 early traumatic experiences, including death, divorce, violence, sexual abuse, illness or other. The scale determines and assesses an individual's understanding of their childhood trauma, if applicable."", 'timeFrame': '1 day'}, {'measure': 'Emotional Quotient Scale (EQS)', 'description': 'The EQ is a 60-item self-report questionnaire that is designed to measure empathy in adults. Participants use a 4 item likert scale to record their responses (1=definitely agree, 4= definitely disagree).', 'timeFrame': '1 day'}, {'measure': 'Kinsey Scale', 'description': ""The Kinsey scale attempts to describe a person's sexual orientation using a scale from 0 (i.e. heterosexual) to 6 (i.e. homosexual)."", 'timeFrame': '1 day'}, {'measure': 'Change in Working Memory capacity', 'description': ""This task determines a participant's working memory capacity using the University of Maryland Letter Number Span Assessment. This asks 24 questions of increasing working memory difficulty and the total correct is calculated. Investigators will measure the change in the total correct between oxytocin and placebo days."", 'timeFrame': '2-days at least 1-week apart'}, {'measure': 'Change in Auditory Perception correctness', 'description': 'The Sound Sweeps task determines auditory perception ability by measuring changes in pitches to sounds. Investigators will measure the change in the total correct responses between oxytocin and placebo days.', 'timeFrame': '2-days at least 1-week apart'}, {'measure': 'Change in Auditory Perception reaction time', 'description': 'The Sound Sweeps task determines auditory perception ability by measuring changes in pitches to sounds. Investigators will measure the change in the reaction time between oxytocin and placebo days.', 'timeFrame': '2-days at least 1-week apart'}]",9,18 Years,65 Years,ALL,True,"University of California, San Francisco",OTHER,1,120.0,ACTUAL,2025-09-01T16:18:19.658194,v2_robust,True,True,True,False,False,
NCT01198275,n-3 Polyunsaturated Fatty Acids (PUFAs) in the Prevention of Atrial Fibrillation,N-3 Polyunsaturated Fatty Acids (n-3 PUFAs) in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion. A Prospective Randomized Study.,n-3 PUFAs,"['n-3 PUFAs', 'Amiodarone', 'RASS inhibitors and/or RAS blockers', 'Placebo', 'OMACOR', 'renin-angiotensin-aldosterone system inhibitor']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Atrial Fibrillation,['Atrial Fibrillation'],['PUFA atrial fibrillation'],COMPLETED,,2006-01,2008-05,"[{'measure': 'Probability of Maintenance of Sinus Rhythm at One-year Follow up.(Number of Patients Who Maintained Sinus Rhythm)', 'description': 'Sinus Rhythm maintenance means no Atrial Fibrillation recurrence at one-year follow up. Patients with successful electrical cardioversion (DCCV)underwent weekly clinical and electrocardiographic controls for the first three weeks following cardioversion. Subsequently, follow up visits with performance of clinical evaluation, ECG, and a 24-hour Holter monitoring were performed at 1, 3, 6 and 12 months after DCCV.', 'timeFrame': 'one year'}]","[{'measure': 'The Mean Time to a First Recurrence of AF and the Rate of AF Recurrence', 'description': 'The mean time to a first recurrence of AF; and the rate of AF recurrence at 1, 3 and 6 months.', 'timeFrame': '1, 3 and 6 months'}]",2,18 Years,80 Years,ALL,False,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,OTHER,0,199.0,ACTUAL,2025-09-01T16:18:19.658231,v2_robust,True,True,True,False,False,
NCT05527275,A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma,"A Multicenter, Single-arm, Prospective Phase I/II Trial of Mitoxantrone Hydrochloride Liposome Injection Combined With Chidamide in Relapsed or Refractory Peripheral T-cell Lymphoma",Mitoxantrone liposome combine with Chidamide,['Mitoxantrone liposome combine with Chidamide'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Relapsed and Refractory Peripheral T-cell Lymphoma,['Relapsed and Refractory Peripheral T-cell Lymphoma'],[],UNKNOWN,,2022-10-01,2024-12-01,"[{'measure': 'RP2D', 'description': 'Phase II recommended dose', 'timeFrame': '24 months'}, {'measure': 'ORR', 'description': 'Objective remission rate', 'timeFrame': '24 months'}]","[{'measure': 'MTD', 'description': 'Maximum tolerated dose', 'timeFrame': '24 months'}, {'measure': 'DLT', 'description': 'Dose-limiting toxicity', 'timeFrame': '24 months'}, {'measure': 'DOR', 'description': 'Duration of remission time', 'timeFrame': '24 months'}]",5,18 Years,70 Years,ALL,False,Sun Yat-sen University,OTHER,0,78.0,ESTIMATED,2025-09-01T16:18:19.658295,v2_robust,True,True,False,False,False,
NCT00382057,Testosterone Effects on Men With the Metabolic Syndrome,Effect of Increasing Testosterone Levels on Insulin Sensitivity in Men With the Metabolic Syndrome,Testosterone,"['Testosterone', 'Anastrozole', 'Goserelin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Metabolic Syndrome,['Metabolic Syndrome'],"['Testosterone', 'Insulin resistance', 'Insulin sensitivity', 'Metabolic disorders']",WITHDRAWN,,2006-05,2011-03,"[{'measure': 'insulin sensitivity'}, {'measure': 'muscle and body fat distribution'}, {'measure': 'VO2 max'}, {'measure': 'resting metabolic rate'}, {'measure': 'muscle biopsy analysis'}]",[],5,50 Years,75 Years,MALE,False,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,0,72.0,ESTIMATED,2025-09-01T16:18:19.658371,v2_robust,True,True,False,True,False,
NCT01224457,Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients.,Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients.,Phenobarbital,['Phenobarbital'],1,INTERVENTIONAL,['NA'],,,Neonatal Seizure,['Neonatal Seizure'],[],COMPLETED,,2008-05,2010-05,"[{'measure': 'pb drug concentration', 'description': 'pb drug concentration, CYP2C9/CYP2C19 polymorphism', 'timeFrame': '48 hours after administering phenobarbital'}]",[],1,,1 Year,ALL,False,Yonsei University,OTHER,0,52.0,ACTUAL,2025-09-01T16:18:19.658469,v2_robust,True,True,True,False,False,
NCT05892757,Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers,A Phase 1 Lactation Study in Healthy Adult Lactating Female Subjects One to Six Months Post-Partum to Evaluate the Pharmacokinetics and Safety of Ubrogepant and Atogepant,Atogepant,"['Ubrogepant', 'Atogepant', 'QULIPTA', 'UBRELVY']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['Healthy Volunteers', 'Atogepant', 'Ubrogepant']",COMPLETED,,2023-07-11,2024-02-22,"[{'measure': 'Number of Participants Experiencing Adverse Events', 'description': 'An adverse event is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.', 'timeFrame': 'Up to Day 30'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of Atogepant', 'description': 'Cmax of Atogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax)of Ubrogepant', 'description': 'Cmax of Ubrogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Time to Cmax (Tmax) of Atogepant', 'description': 'Tmax of Atogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Time to Cmax (Tmax) of Ubrogepant', 'description': 'Tmax of Ubrogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Apparent Terminal Phase Elimination Rate Constant (β) of Atogepant', 'description': 'Apparent terminal phase elimination rate constant of Atogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Apparent Terminal Phase Elimination Rate Constant (β) of Ubrogepant', 'description': 'Apparent terminal phase elimination rate constant of Ubrogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Terminal Phase Elimination Half-life (t1/2) of Atogepant', 'description': 'T1/2 of Atogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Terminal Phase Elimination Half-life (t1/2) of Ubrogepant', 'description': 'T1/2 of Ubrogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of Atogepant', 'description': 'AUCt of Atogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'AUCt of Ubrogepant', 'description': 'AUCt of Ubrogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'AUC From Time 0 to the Time Infinity (AUCinf) of Atogepant', 'description': 'AUCinf of Atogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'AUCinf of Ubrogepant', 'description': 'AUCinf of Ubrogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Maximum Observed Breast Milk Concentration (CMAX) of Atogepant', 'description': 'CMAX of Atogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Maximum Observed Breast Milk Concentration (CMAX) of Ubrogepant', 'description': 'CMAX of Ubrogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Time to Maximum Observed Breast Milk Concentration (TMAX) of Atogepant', 'description': 'TMAX of Atogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Time to Maximum Observed Breast Milk Concentration (TMAX) of Ubrogepant', 'description': 'TMAX of Ubrogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Area Under the Milk Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCLST) of Atogepant', 'description': 'AUCLST of Atogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Area Under the Milk Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCLST) of Ubrogepant', 'description': 'AUCLST of Ubrogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Area Under the Milk Concentration-Time Curve (AUC) From Time 0 to Infinity (AUCINF) of Atogepant', 'description': 'AUCINF of Atogepant', 'timeFrame': 'Up to Day 2'}, {'measure': 'Area Under the Milk Concentration-Time Curve (AUC) From Time 0 to Infinity (AUCINF) of Ubrogepant', 'description': 'AUCINF of Ubrogepant', 'timeFrame': 'Up to Day 2'}]",[],21,18 Years,45 Years,FEMALE,False,AbbVie,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:19.658478,v2_robust,True,True,True,False,True,
NCT02655757,Effect of Sitagliptin on Progression of Coronary Intermediate Lesion,Effect of Sitagliptin on Progression of Coronary Intermediate Lesion in Patients With Coronary Heart Disease Complicated With Type 2 Diabetes,Sitagliptin,"['Sitagliptin', 'Placebo', 'JANUVIA']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Atherosclerosis,"['Atherosclerosis', 'Type 2 Diabetes Mellitus']",[],COMPLETED,,2015-12,2017-03-10,"[{'measure': 'Changes in late lumen loss of target lesion', 'description': 'A coronary intermediate lesion in Patients with coronary heart disease complicated with Type 2 Diabetes was measure with 3D QCA(3D Quantitative Coronary Angiography). To measure the changes in target lumen at 12 months.', 'timeFrame': 'Changes from baseline in late lumen loss of target lesion at 12 months'}]","[{'measure': 'Incidence rate of MACE', 'description': 'MACE include composite of death, myocardial infarction, or target-vessel revascularization.', 'timeFrame': 'Incidence rate of MACE from baseline to 12 months'}]",2,18 Years,80 Years,ALL,False,Li Bo,OTHER,0,120.0,ACTUAL,2025-09-01T16:18:19.658556,v2_robust,True,True,True,False,False,
NCT06794957,A Study of AL8326 in Non-Small Cell Lung Cancer,"A Single-Arm, Open, Phase Ib Study Evaluating the Safety, Preliminary Efficacy of AL8326 in the Treatment of Non-Small Cell Lung Cancer",AL8326 tablets,"['AL8326 tablets', 'AL8326']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Non-small Cell Lung Cancer,['Non-small Cell Lung Cancer'],[],ACTIVE_NOT_RECRUITING,,2022-05-19,2027-12,"[{'measure': 'Objective remission rate (ORR)', 'description': 'The proportion of subjects achieving complete remission (CR) and partial remission (PR) with optimal efficacy according to RECIST 1.1.', 'timeFrame': 'Every 2 cycles,up to 24 months (each cycle is 28 days)'}]","[{'measure': 'Duration of remission (DOR)', 'description': 'The time between the start of the first assessment of the tumor as CR or PR and The first assessment of disease progression (PD) or death from any cause.', 'timeFrame': 'Every 2 cycles,up to 24 months (each cycle is 28 days)'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'The proportion of subjects achieving complete remission (CR), partial remission (PR) and stable disease (SD).', 'timeFrame': 'Every 2 cycles,up to 24 months (each cycle is 28 days)'}, {'measure': 'Duration of Disease Control (DDC)', 'description': 'The time from the first assessment of the tumor as CR, PR, or SD to the first assessment of disease progression (PD) or death from any cause.', 'timeFrame': 'Every 2 cycles,up to 24 months (each cycle is 28 days)'}, {'measure': 'Progression Free Survival (PFS)', 'description': ""The period of time between the start of the subject's first dose of medication and the first observation of disease progression (based on imaging) or the occurrence of death due to any cause."", 'timeFrame': 'Every 2 cycles,up to 24 months (each cycle is 28 days)'}, {'measure': 'Overall Survival (OS)', 'description': 'Defined as the time between the date of first dose and death from any cause. Subjects who are alive as of the date of analysis will use and the date they last achieved survival as the cutoff time.', 'timeFrame': 'Cycle 1 Day 1 up to 24 months(each cycle is 28 days)'}, {'measure': 'Plasma Concentration', 'description': 'PK samples of some subjects treated with study drugs will be collected for pharmacokinetic analysis in this study.', 'timeFrame': 'Cycle 1 Day 1，Cycle 1 Day14，Cycle 1 Day 28 (each cycle is 28 days)'}]",7,18 Years,,ALL,False,"Advenchen Laboratories, LLC",INDUSTRY,0,158.0,ESTIMATED,2025-09-01T16:18:19.658568,v2_robust,True,True,False,False,False,
NCT06759857,FHND9041 Versus Afatinib for Non-small Cell Lung Cancer,"A Randomized, Open, Positives Parallel-controlled, Multicenter Phase III to Evaluate the Efficacy and Safety of FHND9041 Versus Afatinib in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer",FHND9041,"['FHND9041', 'Afatinib']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Non Small Cell Lung Cancer,['Non Small Cell Lung Cancer'],"['FHND9041', 'phase Ⅲ']",ENROLLING_BY_INVITATION,,2021-08-01,2025-05-01,"[{'measure': 'Progression-Free Survival (PFS)', 'description': 'The time from randomization to the first documented disease progression ( assessed by investigators) or death due to any cause, whichever occurs first.', 'timeFrame': '24 months'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'The proportion of participants with confirmed complete response (CR) or partial response (PR)', 'timeFrame': '24 months'}, {'measure': 'Overall Survival (OS)', 'description': 'The time from randomization to death due to any cause.', 'timeFrame': '36 months'}, {'measure': 'Duration of Response (DoR)', 'description': 'The time from the first documented CR or PR to the first documented disease progression or death, whichever occurs first.', 'timeFrame': '24 months'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'The proportion of participants with confirmed CR, PR, or stable disease (SD) for at least 6 weeks', 'timeFrame': '24 months'}, {'measure': 'Depth of Response (DepOR)', 'description': 'The maximum percentage change in the sum of target lesion diameters from baseline', 'timeFrame': '24 months'}, {'measure': 'European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 ( EQRTC-C30)', 'description': 'Change from baseline in quality of life (QoL) scores using the EQRTC-C30 questionnaire. The scale ranges from 0 to 100, where higher scores indicate better quality of life.', 'timeFrame': '24 months'}, {'measure': 'European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer Module 13(LC13)', 'description': 'Change from baseline in quality of life (QoL) scores using the LC13 questionnaire. The scale ranges from 0 to 100, where higher scores indicate better quality of life.', 'timeFrame': '36 months'}, {'measure': 'Lung Cancer Symptom Scale(LCSS)', 'description': 'Change from baseline in quality of life (QoL) scores using the LCSS questionnaire. The scale ranges from 0 to 100, where higher scores indicate better quality of life.', 'timeFrame': '36 months'}]",9,18 Months,,ALL,False,"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.",INDUSTRY,0,350.0,ESTIMATED,2025-09-01T16:18:19.658622,v2_robust,True,True,False,False,False,
NCT04006457,Long-Term PF-06651600 for the Treatment of Alopecia Areata,"A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA",PF-06651600,['PF-06651600'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Alopecia Areata,['Alopecia Areata'],"['Alopecia', 'Alopecia Areata', 'Alopecia totalis', 'Alopecia universalis', 'Hair loss', 'JAK inhibitor', 'PF-06651600', 'Ritlecitinib']",ACTIVE_NOT_RECRUITING,,2019-07-18,2026-01-23,"[{'measure': 'Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent if the event had start date on or after the first dosing date of this study.', 'timeFrame': 'From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)'}, {'measure': 'Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until Follow-up Visit', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.', 'timeFrame': 'From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)'}, {'measure': 'Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit', 'description': 'Vital signs including blood pressure included systolic blood pressure (SBP) \\[Millimeters of mercury, mmHg\\]) and diastolic blood pressure (DBP) and pulse rate \\[beats per minute (bpm)\\] were measured using an automated device in a sitting position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Criteria for vital sign abnormalities included: SBP\\<90mmHg, DBP\\<50 mmHg and pulse rate\\<40mmHg.', 'timeFrame': 'From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)'}, {'measure': 'Main Study: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values Until Follow-up Visit', 'description': 'Criteria for laboratory abnormalities included:Hemoglobin, Hematocrit, Erythrocytes (\\<0.8\\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \\<0.8\\*LLN or \\>1.5\\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\\>1.2\\*ULN), Prothrombin Time(\\>1.1\\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\\>3.0\\*ULN); Albumin, Urate (\\<0.8\\*LLN and \\>1.2\\*ULN; Urea Nitrogen,Creatinine Cholesterol \\>1.3\\*ULN; Cholesterol \\<0.8\\*LLN or \\>1.2\\*LLN, Triglycerides,Potassium,Calcium \\< 0.9x LLN \\& \\> 1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \\>=1; Leukocyte Erythrocytes, Leukocytes \\>=20; Epithelial Cells\\>=6, Hyaline Cast\\>1; Bacteria\\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.', 'timeFrame': 'From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)'}, {'measure': 'Vaccine Sub-study: Percentage of Participants With Tetanus Booster Response', 'description': 'Booster response to tetanus toxoid was defined as: \\>=4-fold rise in anti-tetanus toxoid immunoglobulin G (IgG) antibody concentration at Month 1 if the pre-vaccination concentration was \\<=2.7 International Units per milliliter (IU/mL); OR \\>=2-fold rise in anti-tetanus toxoid IgG antibody concentration if the pre-vaccination concentration was \\>2.7 IU/mL. Two-sided 95% confidence interval (CI) was based on Clopper-Pearson exact method.', 'timeFrame': 'Month 1'}]","[{'measure': 'Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until End of Study', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent if the event had start date on or after the first dosing date of this study.', 'timeFrame': 'From start of study intervention (Day 1) until end of study'}, {'measure': 'Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until End of Study', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.', 'timeFrame': 'From start of study intervention (Day 1) until end of study'}, {'measure': 'Main Study: Number of Participants With Clinically Significant Abnormalities in Vital Signs Until End of Study', 'description': 'Vital signs including blood pressure (systolic and diastolic blood pressure \\[Millimeters of mercury, mmHg\\]) and pulse rate (beats per minute \\[bpm\\]) were measured using an automated device in a sitting position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Clinically significant abnormalities will be determined by investigator.', 'timeFrame': 'From start of study intervention (Day 1) until end of study'}, {'measure': 'Main Study: Number of Participants With Clinically Significant Laboratory Abnormalities Until End of Study', 'description': 'Following laboratory parameters were assessed: Hemoglobin, Hematocrit, Erythrocytes Erythrocyte (ery.) corpuscular volume, Ery. Mean Corpuscular hemoglobin concentration, Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils, Monocytes, Prothrombin Time, Bilirubin, Direct Bilirubin, Indirect Bilirubin, Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase; Albumin, Urate; Urea Nitrogen, Creatinine, Cholesterol, Triglycerides, Potassium, Calcium, Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite, Leukocyte Erythrocytes, Leukocytes; Epithelial Cells, Hyaline Cast, Bacteria. Clinically significant abnormalities will be determined by investigator.', 'timeFrame': 'From start of study intervention (Day 1) until end of study'}, {'measure': 'Main Study: Percentage of Participants Achieving Response Based on Severity of Alopecia Tool (SALT) Overall Score <=10 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36', 'description': 'SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). In this outcome measure, percentage of participants with SALT overall score \\<= 10 were reported. 95% CI was calculated based on normal approximation.', 'timeFrame': 'At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36'}, {'measure': 'Main Study: Percentage of Participants Achieving Response Based on Alopecia Areata (AA) SALT Score <=10 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36', 'description': 'SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), with lower score indicating less hair loss. 95% CI was calculated based on normal approximation.', 'timeFrame': 'At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36'}, {'measure': 'Main Study: Percentage of Participants Achieving Response Based on SALT Overall Score <= 20 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36', 'description': 'SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). In this outcome measure, percentage of participants with SALT overall score \\<=20 were reported. 95% CI was calculated based on normal approximation.', 'timeFrame': 'At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36'}, {'measure': 'Main Study: Percentage of Participants Achieving Response Based on AA SALT Score <=20 at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36', 'description': 'SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), with lower score indicating less hair loss. 95% CI was calculated based on normal approximation.', 'timeFrame': 'At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36'}, {'measure': 'Main Study: Change From Baseline in SALT Overall Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36', 'description': 'SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing division of scalp hair into four quadrants (back, top of scalp, right side and left side), with each of four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score is sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.', 'timeFrame': 'Baseline, At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36'}, {'measure': 'Main Study: Change From Baseline in AA SALT Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36', 'description': 'SALT=quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into 4 quadrants (back, top of scalp, right side and left side), with each given an accurate determination of percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss). SALT AA Score = SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), lower score= less hair loss. Baseline (Roll-over participants: Day 1 from Study B7931005 or B7981015; De novo participants: Day 1 from Study B7981032).', 'timeFrame': 'Baseline, At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36'}, {'measure': 'Main Study: Percentage of Participants Achieving Atleast 75% Improvement in Overall SALT Score From Baseline at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36', 'description': 'SALT is a quantitative assessment of AA severity based on the scalp terminal hair loss. A visual aid was utilized showing the division of the scalp hair into four quadrants (back, top of scalp, right side and left side), with each of the four quadrants given an accurate determination of the percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. The SALT overall score included any hair loss regardless of etiology (e.g., including scalp hair loss due to both androgenetic alopecia and AA). An Overall SALT 75 response was a 75% or greater reduction from baseline in SALT score.', 'timeFrame': 'At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36'}, {'measure': 'Main Study: Percentage of Participants Achieving Atleast 75% Improvement in AA SALT Score From Baseline at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36', 'description': 'SALT=quantitative assessment of AA severity based on scalp terminal hair loss. Scalp hair was divided into four quadrants (back, top of scalp, right side and left side), with each given an accurate determination of percentage of scalp surface area covered, representing 24%, 40%, 18%, and 18% of the total scalp surface area, respectively. Percentage of hair loss in these areas is multiplied by percent surface area of scalp in that area. SALT score=sum of percentage of hair loss in all areas and ranged from 0 (no hair loss) to 100 (complete scalp hair loss) with lower score indicating less hair loss. SALT AA Score= SALT overall score minus SALT AGA score, where SALT overall score included any hair loss regardless of etiology and SALT AGA score included scalp hair loss only due to androgenetic alopecia. SALT AA score ranged from 0 (no hair loss) to 100 (complete scalp hair loss), where lower score=less hair loss. SALT 75 response= 75% or greater reduction from baseline in AA SALT score.', 'timeFrame': 'At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32 and 36'}, {'measure': 'Main Study: Percentage of Participants Achieving Atleast 2-Grade Improvement From Baseline or Absolute Score of 3 in the Eyebrow Assessment (EBA) at Months 1, 3, 6, 12, 18, 24 and 36 in Participants Without Normal EBA Score at Baseline', 'description': 'EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where 0= no eyebrow, 1=minimal eyebrow, 2=moderate eyebrow and 3= normal eyebrow. Higher scores represent lesser loss of eyebrow hair. 95% CI was based on normal approximation.', 'timeFrame': 'At Months 1, 3, 6, 12, 18, 24 and 36'}, {'measure': 'Main Study: Percentage of Participants Achieving Atleast 2-Grade Improvement From Baseline or Absolute Score of 3 in the Eyelash Assessment (ELA) at Months 1, 3, 6, 12, 18, 24 and 36 in Participants Without Normal ELA Score at Baseline', 'description': 'ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where 0=no eyelash, 1=minimal eyelash, 2=moderate eyelash and 3=normal eyelash. Higher scores represent lesser loss of eyelash hair.', 'timeFrame': 'At Months 1, 3, 6, 12, 18, 24 and 36'}, {'measure': ""Main Study: Percentage of Participants Achieving Patient's Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Months 1, 3, 6, 9, 12, 18, 24 and 36"", 'description': ""PGI-C is a self-administered single item questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. Participants were required to select their response on a 7-point scale ranging from 1 (greatly worsened), 2=moderately worsened, 3=slightly worsened, 4=not changed, 5= slightly improved, 6=moderately improved, 7 (greatly improved). 95% CI was based on normal approximation."", 'timeFrame': 'At Months 1, 3, 6, 9, 12, 18, 24 and 36'}, {'measure': 'Main Study: Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Months 1, 3, 6, 9, 12, 18, 24 and 36: Emotional Symptoms and Activity Limitations', 'description': ""AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 5-8 assessed emotional symptoms with responses scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations with responses scored from 0='not at all' to 4='completely'. AAPPO emotional symptoms sub score was calculated as mean of items 5-8 and ranged from 0 (never) to 4 (always), where higher scores indicated more emotional symptoms. AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032."", 'timeFrame': 'Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36'}, {'measure': 'Main Study: Percentage of Participants With Response Based on Hair Loss Improvement From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Months 1, 3, 6, 9, 12, 18, 24 and 36, Among Participants With Score >=2 at Baseline', 'description': ""AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss from the scalp, eyebrows, eyelashes and body using a 5 point scale that ranged from 0 ='no hair loss' and 4='complete hair loss'. In this outcome measure, percentage of participants with AAPPO domain scores of 0 = no hair loss or 1 = a little hair loss, among participants with score \\>=2 at baseline are reported."", 'timeFrame': 'Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36'}, {'measure': 'Main Study: Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Months 1, 3, 6, 9, 12, 18, 24 and 36', 'description': 'HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The depression subscale comprised of 7 items with score ranging from 0 (no presence of depression) to 3 (severe feeling of depression). Total depression subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of depression symptoms. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.', 'timeFrame': 'Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36'}, {'measure': 'Main Study: Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Months 1, 3, 6, 9, 12, 18, 24 and 36', 'description': 'HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The anxiety subscale comprised of 7 items with score ranging from 0 (no anxiety) to 3 (severe anxiety). Total anxiety subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of anxiety symptoms. For roll-over participants originating from Study B7931005 or B7981015, baseline is day 1 from Study B7931005 or B7981015. For de novo participants, baseline is day 1 from Study B7981032.', 'timeFrame': 'Baseline, At Months 1, 3, 6, 9, 12, 18, 24 and 36'}, {'measure': 'Main Study: Percentage of Participants With Improvement on HADS Depression Score at Months 1, 3, 6, 9, 12, 18, 24 and 36', 'description': 'HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The depression subscale comprised of 7 items with score ranging from 0 (no presence of depression) to 3 (severe feeling of depression). Total depression subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of depression symptoms. Improvement on HADS depression score was considered as achieving a ""normal"" depression subscale score indicative of an absence of depression. Among adults, a HADS-D score of 0-7 was considered ""normal""; for adolescents, a HADS-D score of 0-6 was considered ""normal"". 95% CI was calculated based on normal approximation.', 'timeFrame': 'At Months 1, 3, 6, 9, 12, 18, 24 and 36'}, {'measure': 'Main Study: Percentage of Participants With Improvement on HADS Anxiety Score At Months 1, 3, 6, 9, 12, 18, 24 and 36', 'description': 'HADS is a validated 14-item questionnaire used to assess states of anxiety and depression over the past week. The HADS consisted of 2 subscales, one for anxiety (HADS-A) and one for depression (HADS-D). The anxiety subscale comprised of 7 items with score ranging from 0 (no anxiety) to 3 (severe anxiety). Total anxiety subscale score was calculated as the sum of 7 items and ranged from 0 to 21; higher score indicating greater severity of anxiety symptoms. Improvement on HADS anxiety score was considered as achieving a ""normal"" anxiety subscale score indicative of an absence of anxiety. Among adults, a HADS-A score of 0-7 was considered ""normal""; for adolescents, a HADS-A score of 0-8 was considered ""normal"". 95% CI was calculated based on normal approximation.', 'timeFrame': 'At Months 1, 3, 6, 9, 12, 18, 24 and 36'}, {'measure': 'Vaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=1.0 International Units Per Milliliter (IU/mL) at Month 1-Tdap Vaccination', 'description': 'Percentage of participants with anti-tetanus antibody level \\>=1.0 IU/mL at Month 1 were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.', 'timeFrame': 'Month 1'}, {'measure': 'Vaccine Sub-study: Percentage of Participants With Anti-tetanus Antibody Level >=0.1 IU/mL at Month 1-Tdap Vaccination', 'description': 'Percentage of participants with anti-tetanus antibody level \\>=0.1 IU/mL at Month 1 were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.', 'timeFrame': 'Month 1'}, {'measure': 'Vaccine Sub-study: Percentage of Participants With >=4 Times Increase in Anti-tetanus Antibody Level From Baseline at Month 1-Tdap Vaccination', 'description': 'Percentage of participants with \\>=4 times increase in anti-tetanus antibody level from baseline were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.', 'timeFrame': 'Month 1'}, {'measure': 'Vaccine Sub-study: Geometric Mean Fold Change in Anti-tetanus Levels Above Baseline Values at Month 1-Tdap Vaccination', 'description': 'Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Fold change was defined as the ratio of the post-baseline result to the baseline result. The assay results below the LLOQ were set to 0.5 \\* LLOQ except when pre-vaccination assay results is \\< LLOQ while postvaccination result is \\>= LLOQ, in which case the pre-vaccination value will be set to LLOQ.', 'timeFrame': 'From Baseline (pre-vaccination on Day 1) to Month 1'}, {'measure': 'Vaccine Sub-study: Geometric Mean Concentrations (GMCs) of Anti-tetanus Antibody Levels at Month 1-Tdap Vaccination', 'description': 'Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Assay results below the LLOQ were set to 0.5\\* LLOQ.', 'timeFrame': 'Month 1'}, {'measure': 'Vaccine Sub-study: Percentage of Participants With Human Serum Bactericidal Activity (hSBA) Titer >=1:8 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination', 'description': 'Percentage of participants with hSBA titer \\>=1.8 at 1 month post vaccination for serogroup C were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.', 'timeFrame': 'Month 1'}, {'measure': 'Vaccine Sub-study: Percentage of Participants With hSBA Titer >=1:4 at Month 1 Post-vaccination for Serogroup C-Meningococcal ACWY Vaccination', 'description': 'Percentage of participants with hSBA titer \\>=1.4 at 1 month post vaccination for serogroup C were reported in this outcome measure. Two-sided 95% CI was based on Clopper-Pearson exact method.', 'timeFrame': 'Month 1'}, {'measure': 'Vaccine Sub-study: Geometric Mean Titers (GMT) of Antibodies for Serogroup C at Baseline and Month 1-Meningococcal ACWY Vaccination', 'description': 'Geometric mean and 95% CI were calculated by exponentiating the mean logarithm of the observed data and the corresponding CIs. Assay results below the LLOQ were set to 0.5\\* LLOQ.', 'timeFrame': 'Baseline (pre-vaccination on Day 1) and Month 1'}, {'measure': 'Vaccine Sub-study: Number of Participants With SAEs', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; other important medical events.', 'timeFrame': 'From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)'}, {'measure': 'Vaccine Sub-study: Number of Participants With AEs', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.', 'timeFrame': 'From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)'}, {'measure': 'Vaccine Sub-study: Number of Participants With AEs Leading to Discontinuation', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs leading to discontinuation included participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study or that action taken with study treatment was drug withdrawn.', 'timeFrame': 'From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)'}]",37,12 Years,,ALL,False,Pfizer,INDUSTRY,0,1052.0,ACTUAL,2025-09-01T16:18:19.658704,v2_robust,True,True,False,False,True,
NCT06932757,Adjuvant Quisinostat in High-Risk Uveal Melanoma,Phase 2 Trial of Adjuvant Quisinostat in High-Risk Uveal Melanoma,Quisinostat,['Quisinostat'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Uveal Melanoma,['Uveal Melanoma'],[],RECRUITING,,2025-05-27,2030-05-27,"[{'measure': 'Distant metastasis-free survival (DMFS) Rate', 'description': 'The distant metastasis-free survival (DMFS) rate among participants will be reported. DMFS is defined as the elapsed time in months from the date of study entry until the appearance of distant metastases or death, whichever occurs first. Participants who have not had an event will be censored at the date of last disease assessment documenting the patient was free of disease metastases. DMFS will be assessed from start of treatment according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.', 'timeFrame': 'Up to 36 months'}]","[{'measure': 'Progression-free Survival (PFS)', 'description': 'PFS is defined as the elapsed time in months from the date of study entry until disease progression, which will include both local/regional recurrences and distant metastatic disease recurrences or death, whichever occurs first. Alive patients who have not had an event will be censored at the date of last disease assessment documenting that the patient was free of progression. PFS will be assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Overall Survival (OS)', 'description': 'Overall survival (OS) is defined as the elapsed time in months from start of study entry to death. OS will be determined to date of death from any cause. Surviving patients will be censored at the date of last contact.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Identification of Site of First Recurrence As Measured By Percentage', 'description': 'Identification of the most common site of first recurrence (SFR) among participants will be reported as a percentage. SFR is defined as the anatomical location of the first documented recurrent lesion and further subcategorized as hepatic and extra-hepatic.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Number of Participants Experiencing Treatment Emergent Adverse Events (AEs)', 'description': 'The number of participants experiencing treatment-emergent adverse events (AEs), including treatment-related adverse events (AEs) will be reported. AEs will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, per physician discretion.', 'timeFrame': 'Up to 13 months'}, {'measure': 'Number of Participants Experiencing Treatment Emergent Serious Adverse Events (SAEs)', 'description': 'The number of participants experiencing treatment-emergent adverse events (SAEs), including treatment-related serious adverse events (SAEs) will be reported. SAEs will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, per physician discretion.', 'timeFrame': 'Up to 13 months'}]",6,19 Years,,ALL,False,University of Miami,OTHER,2,63.0,ESTIMATED,2025-09-01T16:18:19.658714,v2_robust,True,True,False,False,True,
NCT04012957,Desidustat in the Treatment of Anemia in CKD,"A Phase 3, Multicenter, Multi-country, Open-label, Randomized, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Desidustat Versus Darbepoetin for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) Who Are Not on Dialysis",Desidustat Oral Tablet,"['Darbepoetin Alfa', 'Desidustat Oral Tablet']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Kidney Disease Stage 3,"['Chronic Kidney Disease Stage 3', 'Anemia', 'Chronic Kidney Disease Stage 4', 'Chronic Kidney Disease Stage 5']",['DREAM-ND'],COMPLETED,,2019-07-20,2021-08-25,"[{'measure': 'Hemoglobin level', 'description': 'Change in Hb levels from baseline', 'timeFrame': '24 weeks'}]","[{'measure': 'Hemoglobin Response', 'description': 'No. of subjects with Hb response', 'timeFrame': '24 weeks'}, {'measure': 'Hemoglobin target range', 'description': 'Time to achieve target range Hb level', 'timeFrame': '24 weeks'}]",3,18 Years,80 Years,ALL,False,Zydus Lifesciences Limited,INDUSTRY,0,588.0,ACTUAL,2025-09-01T16:18:19.658752,v2_robust,True,True,True,False,False,
NCT01812057,Dexamethasone for Post-cesarean Delivery Pain,Dexamethasone as an Analgesic Adjunct for Post-cesarean Delivery Pain Relief,Dexamethasone,"['Sodium Chloride 0.9%', 'Dexamethasone', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pain, Postoperative","['Pain, Postoperative', 'Postoperative Nausea and Vomiting']","['Anesthesia', 'Cesarean Section', 'Pain, Postoperative', 'Postoperative Nausea and Vomiting', 'Dexamethasone', 'Injections, Spinal', 'morphine']",COMPLETED,,2012-12,2016-09-21,"[{'measure': 'Morphine Consumption at 24 Hours Post-op', 'description': 'The primary outcome will be the cumulative morphine consumption at 24 h in the two study groups. All postoperative opioids were converted to IV morphine equivalents using the following conversion factors: 100 micrograms IV = 10 mg IV morphine, 20 mg oxycodone po = 10 mg IV Morphine', 'timeFrame': '24 hours from admission to Postanesthesia care unit (PACU)'}]","[{'measure': 'Pain Scores Between the Groups at 2 Hours.', 'description': 'Pain scores were measured using a numeric rating scale with a range from 0 to 10, with 0 meaning no pain and 10 indicating the most severe pain.', 'timeFrame': '2 hours from admission to postanesthesia care unit (PACU)'}, {'measure': 'Time to Administration of First Rescue Analgesic Request Between the Groups.', 'description': 'Time in minutes from admission to PACU to the first request by the patient for oral oxycodone (analgesia) administration for pain', 'timeFrame': 'PACU admission to discharge from PACU an average of 2 hours'}, {'measure': 'Cumulative Opioid Consumption at 48 Hours Between the Groups', 'description': 'The secondary outcome was the cumulative morphine consumption at 48 h in the two study groups. All postoperative opioids were converted to IV morphine equivalents using the following conversion factors: 100 micrograms IV = 10 mg IV morphine, 20 mg oxycodone po = 10 mg IV Morphine', 'timeFrame': 'Admission to PACU through 48 hours'}, {'measure': 'Pain Scores Between the Groups at 24 Hours.', 'description': 'Pain scores were measured using a numeric rating scale with a range from 0 to 10, with 0 meaning no pain and 10 indicating the most severe pain.', 'timeFrame': '24 hours from PACU admission'}, {'measure': 'Pain Scores Between the Groups at 48 Hours.', 'description': 'Pain scores were measured using a numeric rating scale with a range from 0 to 10, with 0 meaning no pain and 10 indicating the most severe pain.', 'timeFrame': '48 hours from PACU Admission'}, {'measure': 'Cumulative Opioid Consumption at 24 Hours Between MTS Groups', 'description': 'Mechanical temporal summation (MTS) was assessed using A 180 g Von Frey Filament was applied to the volar aspect of the dominant forearm, and subjects were asked to rate pain scores (NRS 0-100, 0 = no pain and 100= worst pain possible) after the 1st and 11th tap. A difference \\< 1 was recorded as MTS negative, and a difference \\> or = 1 was recorded as MTS positive.', 'timeFrame': '24 hours from admission to Postanesthesia care unit (PACU)'}, {'measure': 'Incidence of Chronic Persistent Pain at 8 Weeks', 'description': 'Patients answered a questionnaire at 8 weeks to determine whether they still had persistent surgical site pain 8 weeks following surgery', 'timeFrame': '8 weeks from the day of surgery'}, {'measure': 'Incidence of Chronic Persistent Pain at 6 Months', 'description': 'Patients answered a questionnaire at 6 months to determine whether they still had persistent surgical site pain 6 months following surgery', 'timeFrame': '6 months from the day of surgery'}, {'measure': 'Pain Scores Between MTS Groups', 'description': 'Mechanical temporal summation (MTS) was assessed using A 180 g Von Frey Filament was applied to the volar aspect of the dominant forearm, and subjects were asked to rate pain scores (NRS 0-100, 0=no pain and 100=worst pain possible) after the 1st and 11th tap. A difference \\< 1 was recorded as MTS negative, and a difference \\> or = 1 was recorded as MTS positive.', 'timeFrame': '24 hours after PACU admission'}, {'measure': 'Incidence of Intraoperative Nausea and Vomiting (IONV) and Need for Rescue Antiemetics.', 'description': 'Incidence of intraoperative nausea and vomiting and need for rescue antiemetics were recorded during surgery. Patient who reported a nausea score on a 11 point NRS where 0=no nausea and 10 = the worse nausea possible. Patients who retched or vomited were reported to have vomited. Patients receiving any antiemetic during surgery were recorded as those requesting ( needing) rescue antiemetic.', 'timeFrame': 'From spinal anesthesia placement to end of surgery, approximately 70 minutes'}, {'measure': 'Incidence of Intraoperative Pruritus', 'description': 'pruritus was defined as patients reporting a pruritus score of greater than o on a numerical rating scale with o=no pruritus and 10= worst pruritus', 'timeFrame': 'From spinal anesthesia placement to end of surgery, approximately 70 minutes'}, {'measure': 'Incidence of Postoperative Pruritus', 'description': 'Incidence of postoperative pruritus was calculated based on their postoperative pruritus scores measured at 2 hours, 24 hours and 48 hours. Median of the scores recorded at three time points was calculated.\n\nIf median score \\>0 then patient experienced postoperative pruritus.', 'timeFrame': '48 hours from admission to PACU'}, {'measure': 'Need for Intraoperative Analgesic Supplementation', 'description': 'Need for intraoperative analgesic supplementation was determined by patients who required intraoperative analgesics for pain', 'timeFrame': 'From spinal anesthesia placement to end of surgery, approximately 70 minutes'}, {'measure': 'Incidence of Post-operative Nausea and Vomiting (PONV) and Need for Rescue Antiemetics', 'description': 'Patients who had experienced Postoperative nausea either reported postoperative nausea scores at 2, 24 and 48 hours from \\>0, reported an episode of vomiting or received an antiemetic were recorded as experiencing PONV.\n\nPatients who received at least one rescue antiemetic postoperatively were recorded as requiring a rescue antiemetic', 'timeFrame': '2, 24 and 48 hours from PACU admission'}, {'measure': 'Incidence of Wound Complications', 'description': 'Patients were assessed for signs of surgical wound inspection by the obstetric team following surgery', 'timeFrame': '24 hours from PACU admission'}, {'measure': 'Blood Pressure Measurements Obtained by the Standard of Care Non-invasive Blood Pressure Monitor Compared With the Continuous Noninvasive Arterial Pressure (CNAP)', 'timeFrame': 'Intraoperatively'}]",17,18 Years,,FEMALE,False,Duke University,OTHER,0,53.0,ACTUAL,2025-09-01T16:18:19.658785,v2_robust,True,True,True,False,False,
NCT02315157,Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma,Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma,Bendamustine,"['Treakisym', 'SDX-105', 'Ribomustin', 'Treanda', 'Levact', 'Bendamustine']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Multiple Myeloma,"['Multiple Myeloma', 'Plasma Cell Leukemia']",['Partial Response'],WITHDRAWN,Withdrawn by PI,,,"[{'measure': 'Maximum tolerated dose of bendamustine', 'description': 'Defined as the dose where no more than 1 out of 6 patients experience dose-limiting toxicities. Toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.', 'timeFrame': '2 days'}]","[{'measure': 'Incidence of toxicity (NCI CTCAE version 4.0)', 'description': 'Graded according to NCI CTCAE version 4.0', 'timeFrame': 'Up to 92 days following the last administration of study treatment'}]",2,18 Years,80 Years,ALL,False,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:19.658855,v2_robust,True,True,False,True,True,Withdrawn by PI
NCT03713801,Impact of Metformin on Immunity,Metformin and Vaccine Response in Older Adults,Metformin,"['Placebo oral tablet', 'Placebo', 'Glucophage', 'Metformin']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Aging,"['Aging', 'Vaccine Response Impaired']",[],COMPLETED,,2019-01-14,2024-07-16,"[{'measure': 'Change in antibody responses to PCV13', 'description': 'The primary outcome will be antibody responses to PCV13. Antibody levels of each of the 13 different serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) will be compared between the pre-treatment values and the post treatment values.', 'timeFrame': 'Change from 4 weeks to 8 weeks'}]","[{'measure': 'Measure of immunophenotypes', 'description': 'The distribution of immunophenotypes will be presented descriptively at each time point for each treatment group. To determine which immunophenotypes differed between MET and placebo groups, changes will be determined using within-patient cell count ratios for each measured phenotype between baseline and 6-weeks of study drug treatment and between baseline and the 30 days after PCV13.', 'timeFrame': 'Baseline, 4 weeks and 8 weeks'}]",2,63 Years,90 Years,ALL,True,The University of Texas Health Science Center at San Antonio,OTHER,0,18.0,ACTUAL,2025-09-01T16:18:19.658997,v2_robust,True,True,True,False,False,
NCT00235001,Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension,"A Multicenter, Open, Phase IV, 24-Hour Ambulatory Blood Pressure Monitoring Study of the Efficacy and Safety of Tarka in Patients With Arterial Hypertension",trandolapril/verapamil,"['trandolapril/verapamil', 'ABT-TARKA', 'Tarka']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,['Hypertension'],"['Hypertension', 'Tarka']",COMPLETED,,2004-06,,"[{'measure': 'Change in blood pressure from baseline/blood pressure control', 'timeFrame': 'Baseline to 3 months of Tx'}]","[{'measure': 'Absolute BP reduction from baseline, safety', 'timeFrame': 'Baseline to 3 months of Tx'}]",2,18 Years,75 Years,ALL,False,Abbott,INDUSTRY,0,120.0,ACTUAL,2025-09-01T16:18:19.659011,v2_robust,True,True,True,False,True,
NCT02619201,Antiemetic Efficacy of Ondansetron Versus Metoclopramide,Comparison of Efficacy of Ondansetron Versus Metoclopramide for Vomiting in Children With Acute Gastroenteritis: Randomized Controlled Clinical Trial,Ondansetron,"['MT', 'Ondansetron', 'OD', 'metoclopramide']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Acute Gastroenteritis,"['Acute Gastroenteritis', 'Vomiting']","['vomiting in children', 'ondansetron', 'metoclopramide', 'antiemetics']",UNKNOWN,,2015-11,2016-11,"[{'measure': 'Cumulative rate of vomiting after cessation of drug administration', 'timeFrame': '4 hours'}]",[],1,1 Year,5 Years,ALL,False,Hospital General Naval de Alta Especialidad - Escuela Medico Naval,OTHER_GOV,0,250.0,ESTIMATED,2025-09-01T16:18:19.659146,v2_robust,True,True,False,False,False,
NCT07089901,Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment,Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment,transdermal nicotine replacement therapy,"['NRT, nicotine patch', 'transdermal nicotine replacement therapy']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Smoking,['Smoking'],[],NOT_YET_RECRUITING,,2025-11-01,2030-07-14,"[{'measure': 'Average number of days to smoking relapse', 'description': 'Participants will self-report smoking from quit date to the 6-month follow-up visit. Days to relapse will be defined as the first of seven consecutive days of smoking.', 'timeFrame': 'From quit date to 6-month follow-up (about 6.5 months)'}]","[{'measure': 'Number of participants who self-report 7-day point prevalence abstinence', 'description': '7-day point prevalence abstinence is defined as no smoking in the prior 7 days.', 'timeFrame': '1-month follow-up (around 1.5 months after beginning treatment)'}, {'measure': 'Number of participants who self-report 7-day point prevalence abstinence', 'description': '7-day point prevalence abstinence is defined as no smoking in the prior 7 days.', 'timeFrame': '3-month follow-up (around 3.5 months after beginning treatment)'}, {'measure': 'Number of participants who self-report 7-day point prevalence abstinence', 'description': '7-day point prevalence abstinence is defined as no smoking in the prior 7 days.', 'timeFrame': '6-month follow-up (around 6.5 months after beginning treatment)'}]",4,21 Years,,ALL,False,Duke University,OTHER,1,600.0,ESTIMATED,2025-09-01T16:18:19.659154,v2_robust,True,True,False,False,False,
NCT06816901,Measuring Lactation Initiation After Early Postpartum Injectable Progestin (DMPA) Use Among Women in Dhanusha District of Nepal: A Pilot Study,Measuring Lactation Initiation After Early Postpartum Injectable Progestin (DMPA) Use Among Women in Dhanusha District of Nepal: A Pilot Study,Depo Medroxyprogesterone acetate,"['Injectable contraception', 'Depo Medroxyprogesterone acetate', 'DMPA']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Postpartum Contraception,"['Postpartum Contraception', 'Depot Medroxyprogesterone Acetate', 'Lactation', 'DMPA']","['Depo', 'Injectable contaception', 'postpartum', 'contraception', 'family planning', 'DMPA']",NOT_YET_RECRUITING,,2025-03,2026-03,"[{'measure': 'Enrollment feasibility', 'description': 'The ability of project staff to consent and enroll 40 individuals who are willing to participate in this pilot study within 12 weeks.', 'timeFrame': '12 weeks'}]","[{'measure': 'Time to lactogensis', 'description': 'Amount of time (in hours) from birth to lactogenesis', 'timeFrame': '148 hours'}, {'measure': 'Exclusive lactation', 'description': 'Proportion of participants who report exclusive lactation without supplementation', 'timeFrame': '12 weeks'}, {'measure': 'DMPA Continuation', 'description': 'The proportion of participants who use DMPA continuously for 12 weeks and return for a second dose', 'timeFrame': '12 weeks'}, {'measure': 'Change in infant weight', 'description': 'Infant weight in grams will be compared over 4 weeks', 'timeFrame': 'Birth to 4 weeks'}, {'measure': 'Change in infant length', 'description': 'Infant length in millimeters will be compared over 4 weeks', 'timeFrame': 'Birth to 4 weeks'}, {'measure': 'Change in infant head circumference', 'description': ""The maximum diameter through the infant's glabella and occiput is found and measured with a tape measure and recorded to the nearest millimeter and compared over 4 weeks"", 'timeFrame': 'Birth to 4 weeks'}]",7,18 Years,,FEMALE,True,"University of California, San Diego",OTHER,1,40.0,ESTIMATED,2025-09-01T16:18:19.659240,v2_robust,True,True,False,False,False,
NCT06268301,A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults,"A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants",Budesonide,"['TAK-721', 'Budesonide']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],['Drug therapy'],COMPLETED,,2023-02-06,2023-02-20,"[{'measure': 'Maximum Observed Concentration (Cmax) of BOS', 'timeFrame': 'Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1'}, {'measure': 'Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of BOS', 'timeFrame': 'Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1'}, {'measure': 'Area Under the Concentration-time Curve From Time 0 to Infinity (AUC∞) of BOS', 'timeFrame': 'Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1'}]","[{'measure': 'Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE), Serious Adverse Events (SAE), and Death', 'description': 'An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. An SAE was defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that may require an intervention to prevent above items and expose the participant to danger.', 'timeFrame': 'From first dose of study drug up to the end of study (EOS) (Up to 15 days)'}, {'measure': 'Number of Participants With Clinically Significant Abnormal Vital Sign Values Reported as Adverse Events', 'description': 'Vital signs included body temperature, respiratory rate, blood pressure, and pulse rate evaluations.', 'timeFrame': 'From first dose of study drug up to EOS (Up to 15 days)'}, {'measure': 'Number of Participants With Clinically Significant Abnormal Clinical Laboratory Values Reported as Adverse Events', 'description': 'Clinical laboratory parameters included hematology, clinical chemistry, serum immunoglobulin and urinalysis tests.', 'timeFrame': 'From first dose of study drug up to EOS (Up to 15 days)'}, {'measure': 'Area Under the Concentration-time Curve From Time 0 to 12 Hours (AUC0-12) of BOS', 'timeFrame': 'Periods 1 and 2: Pre-dose and at multiple timepoints (up to 12 hours) post-dose on Day 1'}, {'measure': 'Area Under the Curve From the Last Quantifiable Concentration to Infinity Expressed as a Percentage of AUC∞ (AUCextrap%) of BOS', 'timeFrame': 'Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1'}, {'measure': 'Time to First Occurrence of Cmax (Tmax) of BOS', 'timeFrame': 'Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1'}, {'measure': 'Lag Time to First Quantifiable Concentration (Tlag) of BOS', 'timeFrame': 'Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1'}, {'measure': 'Terminal Disposition Phase Half-life (t1/2z) of BOS', 'timeFrame': 'Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1'}, {'measure': 'Terminal Disposition Phase Rate Constant (λz) of BOS', 'timeFrame': 'Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1'}, {'measure': 'Apparent Clearance (CL/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS', 'timeFrame': 'Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1'}, {'measure': 'Apparent Volume of Distribution During the Terminal Disposition Phase (Vz/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS', 'timeFrame': 'Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1'}]",14,19 Years,55 Years,ALL,True,Takeda,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:19.659267,v2_robust,True,True,True,False,True,
NCT00449501,A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects,"A Two-week, Randomised, Double-blind Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects (≥ 18 Years) With Mild to Moderate Asthma, Receiving SYMBICORT® pMDI 80/4.5 μg x 2 Actuations Twice Daily or Budesonide HFA pMDI 80 μg x 2 Act. Twice Daily",Budesonide/formoterol pMDI,"['Budesonide HFA pMDI', 'Budesonide/formoterol pMDI', 'Symbicort']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Asthma,['Asthma'],"['Mild Asthma', 'Moderate Asthma']",COMPLETED,,2007-03,2007-11,[{'measure': 'To determine whether subjects respond similarly to the Onset of Effect Questionnaire items 2 and 5 when administered post-dose versus pre-dose and does that difference favour a bronchodilator treatment group over a non-bronchodilator treatment group'}],"[{'measure': ""To determine if there is an association between the immediate physiological response to medication and the responses to OEQ items 2 and 5 and to determine what subjects mean when they say they feel their asthma maintenance medication 'working right away""}]",2,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,134.0,ACTUAL,2025-09-01T16:18:19.659294,v2_robust,True,True,True,False,False,
NCT02768701,Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer,Phase II Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer,Pembrolizumab,"['Pembrolizumab', 'Keytruda', 'Cyclophosphamide', 'Neosar', 'Cytoxan']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Triple Negative Breast Cancer,['Triple Negative Breast Cancer'],"['Pembrolizumab', 'cyclophosphamide']",COMPLETED,,2016-10-18,2023-05-01,"[{'measure': 'The Progression Free Survival (PFS)', 'description': 'PFS is defined as the time from day1 of the study treatment until disease progression or death. Disease progression is defined as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST)1.1 based on computerized tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) images or assessment of the physician.\n\nRECIST v.1.1: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), no response or less response than Partial or Progressive; or Progressive Disease (PD), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Quantification of the Change in Regulatory T Cells (Tregs) During the Study Treatment.', 'description': 'Regulatory T cells (Tregs) are counted before the treatment start and during the treatment. Methods: Blood Sample collection.', 'timeFrame': 'Up to 2 years'}]","[{'measure': 'Overall Response Rate (ORR)', 'description': 'ORR is defined as the percentage of patients with \\[compete response (CR) + partial response (PR)\\] per RECIST1.1 based on computerized tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) images.\n\nRECIST v.1.1: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions;', 'timeFrame': 'Up to 2 years'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR is defined as the time from documentation of tumor response by RECIST1.1 \\[(CR) + (PR)\\] to disease progression by RECIST 1.1. It will be measured from when the time measurement criteria are first met for complete response or partial response (whichever status is recorded first) until the first date of progressive disease or death. Patients who neither progress nor die will be censored on the date of their last tumor assessment.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'DCR is defined as the percentage of participants, who achieve \\[compete response (CR) + partial response (PR) and stable disease (SD) per RECIST1.1. If best response is SD, then it must last more than 6 months to be included in calculation of DCR, to be considered to have received clinical benefit from the treatment regimen.\n\nRECIST v.1.1: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), no response or less response than Partial or Progressive; or Progressive Disease (PD), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from D1 of study treatment to death from any cause.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Treatment Associated Toxicity', 'description': 'Treatment Associated Toxicity is defined as the number of participants with Grade 3-4 adverse events associated with study treatment.\n\nAdverse Events were classified and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.4 based on changes in laboratory parameters, vital signs, and other safety assessments per standard of care.', 'timeFrame': 'Up to 3 years'}]",7,18 Years,,ALL,False,UNC Lineberger Comprehensive Cancer Center,OTHER,1,40.0,ACTUAL,2025-09-01T16:18:19.659405,v2_robust,True,True,True,False,True,
NCT01107912,Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease,A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly Versus Non-Elderly Aspirin-Treated Subjects With Stable Coronary Artery Disease,prasugrel,"['LY640315', 'prasugrel', 'clopidogrel', 'Efient', 'CS747', 'Effient']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Coronary Artery Disease,['Coronary Artery Disease'],['Platelet function'],COMPLETED,,2010-03,2011-10,"[{'measure': 'Change in Maximum Platelet Aggregation (MPA) to 20 Micromoles (μM) Adenosine Diphosphate (ADP) as Measured by Light Transmission Aggregometry (LTA) From Baseline to 12 Days of Therapy in the First Treatment Period', 'description': 'Maximum Platelet Aggregation (MPA) to 20 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). Lower MPA values reflect stronger platelet inhibition, whereas higher MPA values reflect weaker inhibition.', 'timeFrame': 'Baseline, 12 days'}]","[{'measure': 'Change in Vasodilator-associated Stimulated Phosphoprotein (VASP) From Baseline to 12 Days of Therapy', 'description': 'Vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation levels, expressed as the platelet reactivity index (PRI), reflect the degree of thienopyridine-mediated P2Y12 receptor inhibition. A lower PRI reflects stronger inhibition of P2Y12, whereas a higher PRI reflects weaker inhibition of P2Y12.', 'timeFrame': 'Baseline, Day 12'}, {'measure': 'Change in VerifyNow P2Y12 Reaction Units (PRU) From Baseline to 12 Days of Therapy', 'description': 'The Accumetrics VerifyNow® P2Y12 assay measures platelet aggregation in whole blood and is reported in P2Y12 reaction units (PRU). PRU report the extent of P2Y12 receptor-mediated platelet aggregation calculated as a function of the rate and extent of platelet aggregation in the presence of adenosine phosphate ADP. A lower PRU reflects stronger inhibition of P2Y12, whereas a higher PRU reflects weaker inhibition of P2Y12.', 'timeFrame': 'Baseline, Day 12'}, {'measure': 'Active Metabolite Blood Levels to Drug Exposure as Measured by Pharmacokinetics (PK) Through 4 Hours After Dosing', 'description': 'A descriptive pharmacokinetic-pharmacodynamic (PK-PD) analysis comparing prasugrel and clopidogrel active metabolite exposures to MPA in response to 20 µM ADP (by LTA) was conducted as originally intended; however, the graphic output from that analysis is not possible here. Therefore, the PK portion is presented here as AUC and the PD portion is presented in Secondary Outcome Measure #5. AUC was calculated through the last scheduled sampling time of 4 hours \\[AUC (0-4)\\] or through the sampling time of the last quantifiable concentration prior to 4 hours. AUC values were denoted AUC(0-tlast) in both instances.', 'timeFrame': 'Baseline up to 4 hours post-dose'}, {'measure': 'Change From Baseline in Maximum Platelet Aggregation (MPA) as Measured by Light Transmission Aggregometry (LTA) From Baseline at Day 12 of Therapy', 'description': 'Maximum Platelet Aggregation (MPA) to 20 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA reflects stronger platelet inhibition, whereas a higher MPA reflects weaker inhibition.', 'timeFrame': 'Baseline, Day 12'}]",5,45 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,1,155.0,ACTUAL,2025-09-01T16:18:19.659779,v2_robust,True,True,True,False,False,
NCT00816712,A Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (MK-0000-064),"A Randomized, Single-Blind, Placebo-Controlled, Single-dose, Parallel Design Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (FSR)","Comparator: Testosterone 300 mg, intramuscular injection","['Comparator: Testosterone 100 mg, Intramuscular injection', 'Comparator: Testosterone 300 mg, intramuscular injection', 'Comparator: Placebo given by Intramuscular Injection']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Muscle Anabolism,['Muscle Anabolism'],['Males with low-normal serum total testosterone levels.'],COMPLETED,,2008-01,2008-12,"[{'measure': 'Thigh (vastus lateralis) muscle protein fractional synthetic rate one week after dosing with testosterone.', 'timeFrame': 'One week'}]","[{'measure': 'Variability in the muscle fractional synthetic rate measurements.', 'timeFrame': 'One week'}]",2,60 Years,70 Years,MALE,True,Merck Sharp & Dohme LLC,INDUSTRY,0,28.0,ACTUAL,2025-09-01T16:18:19.659843,v2_robust,True,True,True,False,False,
NCT05401812,Glucocorticoid Therapy for Acute Respiratory Distress Syndrome,A Factorial Trial of Glucocorticoid Therapy in Acute Respiratory Distress Syndrome: Optimizing Dosing Regimen and Developing Biomarker-guided Treatment,Intravenous glucocorticoid therapy,['Intravenous glucocorticoid therapy'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Respiratory Distress Syndrome,['Acute Respiratory Distress Syndrome'],"['Acute Respiratory Distress Syndrome', 'Corticosteroid', 'Glucocorticoid']",WITHDRAWN,Difficult enrollment,2022-07-01,2024-04-30,"[{'measure': 'Ventilator-free survival', 'description': 'Ventilator-free survival between control and intervention arms', 'timeFrame': '28 days'}]","[{'measure': 'Glucocorticoid dose and ventilator-free survival', 'description': 'Ventilator-free survival between low-dose and moderate-dose glucocorticoid groups', 'timeFrame': '28 days'}, {'measure': 'Glucocorticoid treatment duration and ventilator-free survival', 'description': 'Ventilator-free survival between long treatment duration and short treatment duration groups', 'timeFrame': '28 days'}, {'measure': 'ICU mortality', 'description': 'Between-group difference in mortality at ICU discharge', 'timeFrame': 'Length of ICU stay up to 28 days'}, {'measure': 'Hospital mortality', 'description': 'Between-group difference in mortality at hospital discharge', 'timeFrame': 'Length of hospital stay up to 60 days'}, {'measure': '60-day mortality', 'description': 'Between-group difference in mortality by day 60', 'timeFrame': '60 days'}, {'measure': 'Oxygenation on day 7', 'description': 'Proportion of patients with a P/F ratio \\> 200 mmHg on day 7', 'timeFrame': '7 days'}, {'measure': 'Rapid oxygenation improvement', 'description': 'Change in P/F ratios between day 1 and day 3', 'timeFrame': '3 days'}, {'measure': 'Successful liberation from mechanical ventilation', 'description': 'Median time to successful liberation from mechanical ventilation', 'timeFrame': 'Up to 60 days'}, {'measure': 'Lymphocytopenia', 'description': 'Proportion of lymphocytopenia on day 7', 'timeFrame': '7 days'}, {'measure': 'Blood glucose level', 'description': 'Peak blood glucose level during treatment', 'timeFrame': '10 days'}, {'measure': 'Hyperglycemia', 'description': 'Proportion of patients with hyperglycemia during treatment', 'timeFrame': '10 days'}]",12,20 Years,,ALL,False,National Taiwan University Hospital,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:19.659852,v2_robust,True,True,False,True,False,Difficult enrollment
NCT00844012,Continuous Postoperative Use of Low-Dose Combined Oral Contraceptivesfor for Endometriosis-Related Chronic Pelvic Pain,Continuous Versus Cyclic Postoperative Use of Low-Dose Combined Oral Contraceptive Belara® for the Treatment of Endometriosis-Related Chronic Pelvic Pain: a Randomized Controlled Trial.,"Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)","['Cyclic OC (clormadinone acetate plus ethinil-estradiol)', 'Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Endometriosis,"['Endometriosis', 'Chronic Pelvic Pain']",[],UNKNOWN,,2009-05,2010-07,"[{'measure': 'Recurrence of pelvic pain', 'timeFrame': '12 months'}]","[{'measure': 'Metabolic effects', 'timeFrame': '12 months'}, {'measure': 'Ovarian effects', 'timeFrame': '12 months'}, {'measure': 'Endometrial effects', 'timeFrame': '12 months'}, {'measure': 'Bleedings characteristics', 'timeFrame': '12 months'}, {'measure': 'Protocol adherence', 'timeFrame': '12 months'}, {'measure': 'Satisfaction rate', 'timeFrame': '12 months'}, {'measure': 'Adverse events', 'timeFrame': '12 months'}, {'measure': 'Effects on cognitive function and mood', 'timeFrame': '12 months'}, {'measure': 'Quality of life', 'timeFrame': '12 months'}]",10,18 Years,40 Years,FEMALE,False,University Magna Graecia,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:19.659880,v2_robust,True,True,False,False,True,
NCT02450812,Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany,URANIS -Data Collection in Urological Centers During Treatment With Ra-223 Dichloride (Xofigo) Within the Framework of a Non-interventional Study Assessing Overall Survival (OS) and Effectiveness Predictors of Ra-223 Dichloride Treated mCRPC Patients in a Real Life Setting in Germany.,"Radium-223-dichloride (Xofigo, BAY88-8223)","['Radium-223-dichloride (Xofigo, BAY88-8223)']",1,OBSERVATIONAL,[],,,"Prostatic Neoplasms, Castration-Resistant","['Prostatic Neoplasms, Castration-Resistant']",['mCRPC'],COMPLETED,,2015-05-28,2020-09-17,"[{'measure': 'Overall survival (OS)', 'timeFrame': 'Up to 60 months'}]","[{'measure': 'Evaluation of symptomatic skeletal event free survival (SSE-FS) of mCRPC patients', 'timeFrame': 'Up to 60 months'}, {'measure': 'Estimation of the incidence of pathological fractures.', 'timeFrame': 'Up to 60 months'}, {'measure': 'Time to next tumor treatment(s) (TTNT)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Incidence of treatment-emergent adverse events (TEAE)', 'timeFrame': 'Up to 30 days after last administration of Radium-223'}, {'measure': 'Quality of life as patient reported outcome estimated using Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire', 'description': ""The FACT-P questionnaire version 4 is a 39-item questionnaire consisting of five domains; 'Physical well-being', 'Social/Family well-being', 'Emotional well-being', 'Functional well-being' and 'Additional concerns' (consisting of items relating specifically to prostate cancer and/or its treatment) and uses a 0-4 Likert-scale."", 'timeFrame': 'Up to 60 months'}, {'measure': 'Activities of daily living assessed according to the Katz-Index', 'timeFrame': 'Up to 7 months'}, {'measure': 'Body function assessed in dimensions of ""mobility"", ""self-care"" and ""domestic life"" using the Medical Oncology Status in Europe Survey (MOSES) questionnaire', 'timeFrame': 'Up to 7 months'}, {'measure': 'Estimation of the non-pathological fractures', 'timeFrame': 'Up to 60 months'}, {'measure': 'Estimation of the bone associated events', 'timeFrame': 'Up to 60 months'}]",10,18 Years,,MALE,False,Bayer,INDUSTRY,0,86.0,ACTUAL,2025-09-01T16:18:19.659905,v2_robust,False,True,True,False,True,
NCT00092612,Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED),"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.","MK0653, ezetimibe","['Comparator: ezetimibe, placebo', 'MK0653, ezetimibe']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypercholesterolemia,"['Hypercholesterolemia', 'Coronary Disease']",['Elevated Cholesterol'],COMPLETED,,2003-05,2004-06,"[{'measure': 'Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatment'}]",[{'measure': 'Safety and tolerability.'}],2,18 Years,,ALL,False,Organon and Co,INDUSTRY,0,372.0,ACTUAL,2025-09-01T16:18:19.659966,v2_robust,True,True,True,False,True,
NCT04101812,"Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer","A Non-randomized, Prospective Clinical Study of Pegylated Liposomal Doxorubicin and PD-1 in the Second-line Treatment of Relapse or Metastatic Muscle Invasive Bladder Cancer",pegylated liposomal doxorubicin (PLD),"['pegylated liposomal doxorubicin (PLD)', 'Doxorubicin Hydrochloride Liposome Injection', 'PD-1']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Muscle Invasive Bladder Cancer,['Muscle Invasive Bladder Cancer'],[],UNKNOWN,,2019-09-17,2021-05-31,"[{'measure': 'Disease control rate', 'description': 'Disease control rate defined as confirmed complete response or partial response or stable disease under RECIST 1.0 criteria.', 'timeFrame': 'at least 10 months'}, {'measure': 'Objective response rate', 'description': 'Objective response rate defined as confirmed complete response or partial response under RECIST 1.0 criteria.', 'timeFrame': 'at least 10 months'}]","[{'measure': 'Progression free survival', 'description': 'Progression-free survival estimated using Kaplan-Meier methods is defined as the time from registration to the earlier of death or disease progression.', 'timeFrame': 'at least 10 months'}, {'measure': 'Overall survival', 'description': 'Overall survival estimated using Kaplan-Meier methods is defined as the time from treatment initiation to death by any cause', 'timeFrame': 'at least 10 months'}]",4,18 Years,75 Years,ALL,False,Tianjin Medical University Second Hospital,OTHER,1,60.0,ESTIMATED,2025-09-01T16:18:19.660023,v2_robust,True,True,False,False,False,
NCT04952012,The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes,The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes,LT4,['LT4'],1,OBSERVATIONAL,[],,,"Thyroiditis, Autoimmune","['Thyroiditis, Autoimmune']",[],UNKNOWN,,2020-11-30,2022-11-30,"[{'measure': 'Incidence rate of pregnancy complications in women with or without thyroid antibodies', 'timeFrame': '1 year'}]",[],1,18 Years,45 Years,FEMALE,True,"Second Affiliated Hospital, School of Medicine, Zhejiang University",OTHER,3,4000.0,ESTIMATED,2025-09-01T16:18:19.660037,v2_robust,False,True,False,False,False,
NCT01864681,Combination of Metformin With Gefitinib to Treat NSCLC,"A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gefitinib and Metformin in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer",Gefitinib and Metformin,"['Gefitinib and placebo', 'Gefitinib and Metformin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,NSCLC,"['NSCLC', 'EGFR Gene Amplification', 'Advanced Cancer', 'Stage IIIB NSCLC', 'Stage IV NSCLC']","['NSCLC', 'TKIs', 'Metformin', 'PFS', 'overall survival', 'IL-6']",COMPLETED,,2013-05,2018-06-04,"[{'measure': 'PFS', 'description': 'One year progression-free survival (PFS) of the patients.', 'timeFrame': '1 year'}]","[{'measure': 'Response to therapy and overall survival', 'description': 'The response to therapy and overall survival of the patients.', 'timeFrame': '2 years'}]",2,18 Years,75 Years,ALL,False,Daping Hospital and the Research Institute of Surgery of the Third Military Medical University,OTHER,0,224.0,ACTUAL,2025-09-01T16:18:19.660117,v2_robust,True,True,True,False,False,
NCT02228681,Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,"A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma",Everolimus,"['Tamoxifen', 'Nolvadex®', 'Everolimus', 'Medroxyprogesterone Acetate', 'Femara®', 'RAD001', 'Letrozole']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,"Advanced, Persistent, or Recurrent Endometrial Cancer","['Advanced, Persistent, or Recurrent Endometrial Cancer']",[],COMPLETED,,2015-05-21,2024-08-22,"[{'measure': 'Frequency of Response', 'description': 'A confirmed complete or partial response as defined by RECIST 1.1 was considered a response. ""Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death , up to 3 years.'}]","[{'measure': 'Median Progression-free Survival', 'description': ""Progression-free Survival is defined as the duration alive from study entry until progression is documented, or death; whichever comes sooner. Progressive disease is defined as at least a 5 mm absolute increase and a 20% relative increase in the sum of measurable target lesions' longest dimensions relative to the smallest sum at baseline or on study or the appearance of new lesions or unequivocal progression of existing non-target lesions."", 'timeFrame': 'Tumor measurements were done at 8 and 16 weeks after initiating treatment and then every 12 weeks and compared with baseline measurements prior to treatment. Measurements are continued until disease progression is documented or death.'}, {'measure': 'Frequency and Severity of CTCAE (Common Toxicity Criteria for Adverse Events) Version 4', 'description': 'Maximum grade of physician assessed adverse events graded and categorized using Common Toxicity Criteria for Adverse Events (CTCAE) version 4', 'timeFrame': 'Assessed throughout the treatment period and for 30 days after discontinuation of treatment. Treatment continues until progression of disease.'}, {'measure': 'Median Survival', 'description': 'Survival is defined as the duration alive from study entry until death.', 'timeFrame': 'Following treatment discontinuation, patients are followed quarterly for 2 years, semi-annually for 3 more years, annually thereafter.'}]",4,18 Years,,FEMALE,False,GOG Foundation,NETWORK,1,74.0,ACTUAL,2025-09-01T16:18:19.660129,v2_robust,True,True,True,False,True,
NCT00954681,Study of Quetiapine Treatment for Cannabis Dependence,Open-Label Pilot Study of Quetiapine Treatment for Cannabis Dependence,quetiapine,"['quetiapine', 'Seroquel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cannabis Dependence,['Cannabis Dependence'],"['Cannabis', 'quetiapine']",COMPLETED,,2009-08,2010-08,"[{'measure': 'Maximum Tolerated Dose of Quetiapine', 'description': 'Mean maximum tolerated dose of quetiapine', 'timeFrame': 'assesssed daily during 8 weeks of study, mean maximum tolerated dose reported'}]",[],1,18 Years,65 Years,ALL,False,New York State Psychiatric Institute,OTHER,1,15.0,ACTUAL,2025-09-01T16:18:19.660192,v2_robust,True,True,True,False,False,
NCT05923281,A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance,"A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance-Multicenter, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Statin Intolerant Hypercholesterolemia-",K-877 0.2 mg/day (once daily),"['K-877 0.2 mg/day (once daily)', 'Pemafibrate 0.4mg/day (once daily)', 'K-877 0.4 mg/day (once daily)', 'Placebo (once daily)', 'Pemafibrate 0.2mg/day (once daily)']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypercholesterolemia,['Hypercholesterolemia'],[],ACTIVE_NOT_RECRUITING,,2023-05-01,2024-10-31,"[{'measure': 'Percent change from baseline in LDL-C (formula F).', 'description': 'Percent change = (measured value at each time point - baseline value) / baseline value', 'timeFrame': '4, 8, and 12 weeks after administration'}]","[{'measure': 'Efficacy: % change from baseline in fasting serum LDL-C (mg/dL)(Direct)', 'timeFrame': '4, 8, and 12 week after administration'}, {'measure': 'Efficacy: % change from baseline in fasting serum HDL-C (mg/dL)', 'timeFrame': '4, 8, and 12 week after administration'}, {'measure': 'Efficacy: % change from baseline in fasting serum non HDL-C (mg/dL)', 'timeFrame': '4, 8, and 12 week after administration'}, {'measure': 'Efficacy: % change from baseline in fasting serum TG (mg/dL)', 'timeFrame': '4, 8, and 12 week after administration'}, {'measure': 'Efficacy: % change from baseline in fasting serum LDL-C（formula F）/HDL-C', 'timeFrame': '4, 8, and 12 week after administration'}, {'measure': 'Efficacy: % change from baseline in fasting serum non HDL-C/HDL-C', 'timeFrame': '4, 8, and 12 week after administration'}]",7,18 Years,,ALL,False,"Kowa Company, Ltd.",INDUSTRY,0,60.0,ESTIMATED,2025-09-01T16:18:19.660202,v2_robust,True,True,False,False,False,
NCT01028781,Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis,Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis,Thalidomide,"['Thalomid', 'Thalidomide']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Endometriosis,['Endometriosis'],[],TERMINATED,Difficulty finding eligible participants and lack of funding.,2006-10,2009-08,"[{'measure': 'pain report', 'timeFrame': '6 months'}]",[],1,18 Years,,FEMALE,False,"University of North Carolina, Chapel Hill",OTHER,1,9.0,ACTUAL,2025-09-01T16:18:19.660244,v2_robust,True,True,False,True,False,Difficulty finding eligible participants and lack of funding.
NCT02983981,Topical Psoriasis Study for Patients Receiving Biologic Therapy,"An Open-Label, Observational Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) BID in Psoriasis Patients Being Treated With Biologic Agents",Topicort Topical Spray,['Topicort Topical Spray'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Psoriasis,['Psoriasis'],[],COMPLETED,,2016-03,2016-10,"[{'measure': 'Psoriasis Severity', 'description': ""Physician's Global Assessment x Percentage of Body Surface Area (scale scores 0-400 where 0 is best psoriasis 400 is worst possible psoriasis) Body surface area calculated as 1 of patient's palm is 1%."", 'timeFrame': '16 weeks'}]","[{'measure': 'Psoriasis Severity', 'description': ""Physician's Global Assessment Scores Scales 0-4 with 0 as no psoriasis and 4 is severe psoriasis"", 'timeFrame': '16 weeks'}, {'measure': 'Psoriasis Severity', 'description': ""Psoriasis severity measured as Body Surface area measured as 1 of patient's palm is equal to 1% body surface area."", 'timeFrame': '16 weeks'}, {'measure': 'Dermatology Life Quality Index', 'description': 'calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.', 'timeFrame': '16 weeks'}]",4,18 Years,,ALL,False,Psoriasis Treatment Center of Central New Jersey,OTHER,1,20.0,ACTUAL,2025-09-01T16:18:19.660314,v2_robust,True,True,True,False,False,
NCT01344681,Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases,"A Randomized Phase II, Multi-center, Non-inferiority Clinical Trial for Efficacy and Safety of Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases",Micafungin sodium,"['Itraconazole', 'Mycamine®', 'Micafungin sodium', 'Sporanox®']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Febrile Neutropenia,"['Febrile Neutropenia', 'Hematological Diseases']",[],COMPLETED,,2011-06,2014-03,"[{'measure': 'Responses to therapy', 'description': ""1. definition of 'treatment success': (5 Items to meet all your success)\n\n   * Within 7 days after stopping study medication if there is no fungal infection\n   * 7 days after stopping study medication if you are alive\n   * Neutropenia period of serious adverse events or lack of effective medication is not stopped\n   * If fever during neutropenia (temperature \\<37.5 ℃)\n   * Treatment until the end of the existing fungal infection is treated completely or partially\n2. definition of 'treatment failure': - If you failed any of 5 Items in 'treatment success'"", 'timeFrame': '7 days after stopping study medication'}]",[],1,18 Years,65 Years,ALL,False,Yonsei University,OTHER,0,153.0,ACTUAL,2025-09-01T16:18:19.660348,v2_robust,True,True,True,False,True,
NCT01478581,Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma,"A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma",PCI-32765,"['PCI-32765', 'Ibrutinib', 'Dexamethasone']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,['Multiple Myeloma'],"['PCI-32765', 'Multiple Myeloma', 'Relapsed Refractory Multiple Myeloma', ""Bruton's Tyrosine Kinase""]",COMPLETED,,2012-03,2018-08,"[{'measure': 'The Clinical Benefit Response (CBR)', 'description': 'The clinical benefit response (CBR) rate, defined as the proportion of subjects who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), or minimal response (MR) as assessed by the modified International Myeloma Working Group (IMWG) response criteria', 'timeFrame': 'From the date of first study treatment until disease progression per IMWG, up to 60 months'}]","[{'measure': 'To Evaluate the Efficacy of PCI-32765 by Assessing ORR', 'description': 'The objective response rate, defined as the proportion of subjects who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR), as assessed by the modified International Myeloma Working Group (IMWG) response criteria.', 'timeFrame': 'From the date of first study treatment until disease progression per IMWG, up to 60 months'}, {'measure': 'Pharmacokinetics (PK). (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Maximum Observed Plasma Concentration (Cmax)', 'description': 'Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Maximum observed plasma concentration of ibrutinib during the dosing interval on Day 8.', 'timeFrame': 'Procedure was performed up to 60 weeks.'}, {'measure': 'Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Time to Maximum Observed Plasma Concentration (Tmax).', 'description': 'Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Time to corresponding maximum observed plasma concentration of ibrutinib during the dosing interval on Day 8.', 'timeFrame': 'Procedure was performed up to 60 weeks.'}, {'measure': 'Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h).', 'description': 'Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Ibrutinib AUC0-24h calculated using linear trapezoidal summation after dosing from time 0 to 24 hours on Day 8.', 'timeFrame': 'Procedure was performed up to 60 weeks.'}, {'measure': 'Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Terminal Elimination Half-life (t1/2,Term).', 'description': 'Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Ibrutinib terminal elimination half-life associated with the terminal slope (λz) of the semi-logarithmic plasma concentration-time curve, calculated as 0.693/λz on Day 8.', 'timeFrame': 'Procedure was performed up to 60 weeks.'}, {'measure': 'Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Accumulation Ratio for AUC0-24h (Acc. Ratio AUC0-24h)', 'description': 'Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Acc. Ratio calculated as Day 8 ibrutinib AUC0-24h/ Day 1 ibrutinib AUC0-24h.', 'timeFrame': 'Procedure was performed up to 60 weeks.'}, {'measure': 'Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for Cmax (M/P Cmax)', 'description': 'Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Calculated as (PCI-45227 Cmax/PCI-45227 molecular weight)/(ibrutinib Cmax/ibrutinib molecular weight) on Day 8.', 'timeFrame': 'Procedure was performed up to 60 weeks.'}, {'measure': 'Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for AUC0-24h (M/P AUC0-24h)', 'description': 'Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Calculated as (PCI-45227 AUC0-24h/PCI-45227 molecular weight)/(ibrutinib AUC0-24h/ibrutinib molecular weight) on Day 8.', 'timeFrame': 'Procedure was performed up to 60 weeks.'}, {'measure': 'Duration of Clinical Benefit Response (DCB)', 'description': 'DCB is defined as the time from first observation of response to the time of disease progression.', 'timeFrame': 'From the date of first study treatment until disease progression per IMWG, up to 60 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'The time interval between the date of initial documentation of a response and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects not progressed/died. The censoring date is the last adequate tumor assessment date.', 'timeFrame': 'up to 3 Years'}]",11,18 Years,,ALL,False,Pharmacyclics LLC.,INDUSTRY,0,92.0,ACTUAL,2025-09-01T16:18:19.660463,v2_robust,True,True,True,False,False,
NCT03529019,Nutrition in Patient With Critical Limb Ischemia,Perioperative Nutritional Optimization in Patients With Critical Limb Ischemia,Ensure Surgery Immunonutrition Shake,"['Ensure Enlive Advanced Nutrition Shake', 'Ensure Surgery Immunonutrition Shake']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Critical Limb Ischemia,"['Critical Limb Ischemia', 'Malnutrition', 'Nutritional Supplements']",['Enhanced Recovery After Surgery Protocol'],RECRUITING,,2018-10-02,2025-12,"[{'measure': 'Change in serum albumin levels', 'description': 'Albumin is a carbohydrate-free protein, which constitutes 55% to 65% of total plasma protein. Albumin results can reflect the nutritional status of the body and other problems with the kidney or liver. A normal albumin range is 3.4 to 5.4 g/dL. Albumin levels will be tested on blood samples on each participant obtained at baseline and 30 days after nutritional supplementation. Lower albumin levels are associated with malnutrition', 'timeFrame': 'baseline and 30 days'}, {'measure': 'Change in prealbumin levels', 'description': 'Prealbumin is a protein produced by the liver and levels can reflect nutritional status. Normal results for a prealbumin blood test for adults are 15 to 36 milligrams per deciliter (mg/dL). Prealbumin levels will be tested on blood samples on each participant obtained at baseline and 30 days after nutritional supplementation. Lower levels of prealbumin are associated with malnutrition.', 'timeFrame': 'baseline and 30 days'}, {'measure': 'Change in transferrin levels', 'description': 'Transferrin is the main protein in the blood that binds to iron and transports it throughout the body. The normal range for transferrin is 170 to 370 mg/dl. Transferrin levels will be tested on blood samples on each participant obtained at baseline and 30 days after nutritional supplementation. Transferrin levels rise with iron deficiency and fall in cases of iron overload.', 'timeFrame': 'baseline and 30 days'}, {'measure': 'Change in C-reactive protein levels', 'description': 'C-reactive protein (CRP) is a substance produced by the liver that increases in the presence of inflammation in the body. C-reactive protein levels will be tested on blood samples on each participant obtained at baseline and 30 days after nutritional supplementation. Lower levels are favorable.', 'timeFrame': 'baseline and 30 days'}]","[{'measure': 'Change in Hand grip strength', 'description': 'A hand dynamometer will be used to measure hand grip strength. Higher values are favorable.', 'timeFrame': 'baseline and 30 days'}]",5,18 Years,99 Years,ALL,False,Boston Medical Center,OTHER,2,30.0,ESTIMATED,2025-09-01T16:18:19.660551,v2_robust,True,True,False,False,False,
NCT05599919,Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19,"A Randomized, Double-blind, Parallel Arm, Multicenter Study To Evaluate The Efficacy And Safety Of Nitric Oxide Nasal Spray Combined With Standard Supportive Care In Adult Non-hospitalized Patients With COVID-19.",Nitric Oxide,"['Nitric Oxide', 'Nasal Spray']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,SARS-CoV-2 Infection,['SARS-CoV-2 Infection'],[],COMPLETED,,2021-11-01,2022-02-02,"[{'measure': 'The primary objective of this study is to evaluate the efficacy of Nitric Oxide Nasal Spray combined with standard supportive care compared with standard supportive care alone in adult subjects with COVID-19 not requiring hospitalization', 'description': 'Change from baseline in log viral load', 'timeFrame': '8 days'}]","[{'measure': 'The secondary objective is to evaluate the safety and tolerability of Nitric Oxide Nasal Spray combined with standard supportive care compared with standard supportive care alone in adult subjects with COVID-19 not requiring hospitalization.', 'description': 'Number of adverse events, pain, discomfort or discontinuations of treatment', 'timeFrame': '18 days'}]",2,18 Years,65 Years,ALL,True,Sanotize Research and Development corp.,INDUSTRY,1,306.0,ACTUAL,2025-09-01T16:18:19.660627,v2_robust,True,True,True,False,True,
NCT05794919,Bioequivalence Study of Calcium Hydroxybenzene Sulphonate Dispersible Tablets in Chinese Healthy Volunteers,Bioequivalence Study of Calcium Hydroxybenzene Sulphonate Dispersible Tablets and Calcium Hydroxybenzene Sulfonate Tablets (Doxium®) Under Fed Conditions in Chinese Healthy Volunteers,Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g,"['Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g', 'Calcium Hydroxybenzene Sulfonate Tablets（Doxium®) 250mg']",2,INTERVENTIONAL,['NA'],,,Bioequivalence Study,['Bioequivalence Study'],[],UNKNOWN,,2023-03-20,2023-12,"[{'measure': 'Bioequivalence based on Cmax', 'description': 'Cmax - Maximum Observed Concentration in Plasma', 'timeFrame': 'Pharmacokinetic plasma samples collected over 36 hour period'}, {'measure': 'Bioequivalence based on AUC 0-t', 'description': 'Area Under the Concentration-time Curve From Time Zero to Time of Last', 'timeFrame': 'Pharmacokinetic plasma samples collected over 36 hour period'}, {'measure': 'Bioequivalence based on AUC 0-∞', 'description': 'Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)', 'timeFrame': 'Pharmacokinetic plasma samples collected over 36 hour period'}]",[],3,18 Years,55 Years,ALL,True,Beijing Tongren Hospital,OTHER,1,56.0,ESTIMATED,2025-09-01T16:18:19.660638,v2_robust,True,True,False,False,False,
NCT06485219,A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma,"An Open-Label, Multicenter Phase IIa Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Purinostat Mesylate for Injection for the Treatment of Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma",11.2 mg/m2 Purinostat Mesylate,"['15 mg/m2 Purinostat Mesylate', '11.2 mg/m2 Purinostat Mesylate']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),"['Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)', 'Cutaneous T-cell Lymphoma (CTCL)']",[],RECRUITING,,2024-04-14,2025-12-22,"[{'measure': 'Objective remission rate (ORR)', 'description': 'Defined as the proportion of subjects with an overall efficacy response of complete remission (CR) or partial remission (PR) after at least one post-baseline evaluation during the trial period', 'timeFrame': 'Evaluated every two cycles (Each cycle is 21 days)'}]","[{'measure': 'Complete Remission Rate (CRR)', 'description': 'Defined as the proportion of subjects with an overall efficacy response of CR after at least one post-baseline evaluation during the trial;', 'timeFrame': 'Evaluated every two cycles (Each cycle is 21 days)'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Defined as the proportion of subjects with an overall efficacy response of CR, PR, and stable disease (SD) after at least one post-baseline evaluation during the trial;', 'timeFrame': 'Evaluated every two cycles (Each cycle is 21 days)'}, {'measure': 'Duration of remission (DOR)', 'description': 'Duration of first remission (PR or CR) to disease progression or death;', 'timeFrame': 'Evaluated every two cycles (Each cycle is 21 days)'}, {'measure': 'Time to Tumor Remission (TTR)', 'description': 'Time from first dose to the onset of remission', 'timeFrame': 'Evaluated every two cycles (Each cycle is 21 days)'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'Defined as the time from the first administration of the drug to disease progression or death (whichever occurs first).', 'timeFrame': 'Week 96'}, {'measure': 'Overall Survival (OS)', 'description': 'Defined as the time from the first administration of the drug to death (due to any cause).', 'timeFrame': 'Week 96'}]",7,18 Years,,ALL,False,"Chengdu Zenitar Biomedical Technology Co., Ltd",INDUSTRY,0,50.0,ESTIMATED,2025-09-01T16:18:19.660657,v2_robust,True,True,False,False,False,
NCT02782819,A Comparison of Crystalloid Alone Versus Crystalloid Plus Colloid in Shock Resuscitation,A Randomized Controlled Trial of Crystalloid Alone Versus Crystalloid Plus Colloid in Shock Resuscitation,Isotonic crystalloid solution resuscitation,"['Colloid plus', 'Colloid solution resuscitation', 'Crystalloid', 'Isotonic crystalloid solution resuscitation']",4,INTERVENTIONAL,['NA'],,,Hypotension and Shock,['Hypotension and Shock'],"['Shock resuscitation', 'colloid', 'crystalloid']",UNKNOWN,,2014-09,2018-11,"[{'measure': 'Proportion of patients who had shock reversal', 'description': 'Shock reversal was defined by mean arterial blood pressure \\> 65 mmHg plus lactate clearance more than 10%', 'timeFrame': '6 hours after initial resuscitation'}]","[{'measure': 'Mortality rate', 'description': 'Dead from any causes within 28 days after enrollment', 'timeFrame': '28 days'}, {'measure': 'Hospital mortality', 'description': 'Dead from any causes during hospital admission', 'timeFrame': '90 days'}, {'measure': 'Total fluid resuscitation within 24 hours', 'description': 'Total volume of fluid resuscitation the patient received within 24 hours after enrollment', 'timeFrame': '24 hours'}, {'measure': 'Renal replacement therapy', 'description': 'Patient who required acute renal replacement therapy during admission', 'timeFrame': '28 days'}]",5,18 Years,,ALL,False,Mahidol University,OTHER,1,320.0,ESTIMATED,2025-09-01T16:18:19.660716,v2_robust,True,True,False,False,False,
NCT01053819,Can We Miss Pigmented Lesions in Psoriasis Patients?,Can We Miss Pigmented Lesions in Psoriasis Patients?,etanercept,"['etanercept', 'Enbrel']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Psoriasis,"['Psoriasis', 'Melanoma', 'Non-melanoma Skin Cancer']","['psoriasis', 'melanoma', 'non-melanoma skin cancer', 'etanercept', 'Enbrel']",COMPLETED,,2007-09,2012-04,"[{'measure': 'The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques.', 'timeFrame': 'Patients will complete study within 6 months.'}]","[{'measure': 'A Secondary Objective Will be to Evaluate the Identified Pigmented Lesions for Suspicious Criteria', 'description': 'The data for this Outcome was not collected and due to the length of time, the records have been destroyed.', 'timeFrame': 'Patients will complete the study within 6 months'}]",2,19 Years,,ALL,True,University of Alabama at Birmingham,OTHER,1,6.0,ACTUAL,2025-09-01T16:18:19.660731,v2_robust,True,True,True,False,False,
NCT02507219,Study of Ibuprofen Effects on Brain Function,"Placebo-controlled, Dose-response Study of Ibuprofen Effects on Brain Function",Ibuprofen,"['Ibuprofen', 'Placebo']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Major Depressive Disorder,['Major Depressive Disorder'],[],COMPLETED,,2015-07,2015-10,"[{'measure': 'Dose-dependent Differences in the BOLD Response to fMRI Tasks in the Amygdala', 'description': 'Change in amygdala activation following administration of placebo, 200mg of ibuprofen or 600mg of ibuprofen', 'timeFrame': '3-6 weeks'}]",[],1,18 Years,55 Years,ALL,True,"Laureate Institute for Brain Research, Inc.",OTHER,1,24.0,ACTUAL,2025-09-01T16:18:19.660769,v2_robust,True,True,True,False,False,
NCT02726919,Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy,Prospective Open Label Evaluation of Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy: A Pilot Study,Clobazam,"['Onfi', 'Clobazam']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Epilepsy,['Epilepsy'],"['focal epilepsy', 'clobazam']",UNKNOWN,,2015-02,2018-06,"[{'measure': 'seizure freedom', 'description': 'seizure freedom for 3 months of maintenance treatment with the highest tolerated clobazam dose', 'timeFrame': '12 weeks'}]","[{'measure': '>75% seizure frequency reduction and median seizure frequency reduction for the whole treatment duration', 'description': 'Secondary outcome measures will include \\>75% seizure frequency reduction and median seizure frequency reduction for the whole treatment duration and for the maintenance treatment period, comparing seizure frequency per 28 day periods during treatment vs. baseline.', 'timeFrame': '16 weeks'}, {'measure': 'median seizure frequency reduction for the whole treatment duration', 'description': 'median seizure frequency reduction for the whole treatment duration', 'timeFrame': '16 weeks'}, {'measure': 'comparing seizure frequency per 28 day periods during treatment vs. baseline', 'description': 'comparing seizure frequency per 28 day periods during treatment vs. baseline', 'timeFrame': '16 weeks'}, {'measure': 'quality of life questionnaire (QOLIE-31-P) scores', 'timeFrame': '16 weeks'}]",5,18 Years,65 Years,ALL,False,Pavel Klein,OTHER,1,20.0,ESTIMATED,2025-09-01T16:18:19.660778,v2_robust,True,True,False,False,False,
NCT00038519,Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor,"An Open Label, Phase II Study of Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra (Lopinavir/Ritonavir) as Their Second Protease Inhibitor.",Amprenavir/ritonavir,"['Amprenavir/ritonavir', 'Saquinavir/ritonavir']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,HIV Infections,['HIV Infections'],"['treatment experienced', 'HIV']",COMPLETED,,2001-04,,[{'measure': 'Proportion of subjects with plasma HIV RNA levels below the limit of quantification (400 copies/mL) at week 24 and the time until loss of virologic response through week 48'}],[],1,18 Years,,ALL,False,Abbott,INDUSTRY,0,16.0,,2025-09-01T16:18:19.660795,v2_robust,True,True,True,False,False,
NCT06121830,Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD),"A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-erosive Gastroesophageal Reflux Disease",DWP14012 20mg,"['DWP14012 40mg', 'DWP14012 20mg', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-erosive Reflux Disease,"['Non-erosive Reflux Disease', 'Non-Erosive Gastro-Esophageal Reflux Disease', 'Non-Erosive Esophageal Reflux Disease']",['NERD'],RECRUITING,,2023-08-31,2025-03,"[{'measure': 'Percentage of heartburn-free days for 4 weeks (daytime/nighttime)', 'timeFrame': '4 Weeks'}]","[{'measure': 'Percentage of major symptom-free (heartburn, acid regurgitation, or heartburn/acid regurgitation) days for 2 and 4 weeks (daytime/nighttime, daytime and nighttime)', 'timeFrame': '4 Weeks'}]",2,19 Years,75 Years,ALL,False,Daewoong Pharmaceutical Co. LTD.,INDUSTRY,0,324.0,ESTIMATED,2025-09-01T16:18:19.660805,v2_robust,True,True,False,False,False,
NCT00045630,"S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium","A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Urothelial Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin With Molecular Correlates",carboplatin,"['paclitaxel', 'gemcitabine hydrochloride', 'carboplatin', 'Taxol', 'gemcitabine']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Bladder Cancer,"['Bladder Cancer', 'Transitional Cell Cancer of the Renal Pelvis and Ureter', 'Urethral Cancer']","['anterior urethral cancer', 'localized transitional cell cancer of the renal pelvis and ureter', 'posterior urethral cancer', 'stage II bladder cancer', 'stage III bladder cancer', 'transitional cell carcinoma of the bladder', 'urethral cancer associated with invasive bladder cancer', 'regional transitional cell cancer of the renal pelvis and ureter']",COMPLETED,,2003-01,2011-12,"[{'measure': 'Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy', 'description': 'Pathologic complete response (CR) is defined as absence of viable tumor in the TURBT specimen. Stable/No Response is defined as at least some disease evaluation tests were done (same tests as baseline) and status does not qualify for CR or Progression. Progression is defined as one or more of the following must occur: unequivocal progression of disease in the opinion of the treating physician. Appearance of any new lesion/site. Death due to disease without documented progression or symptomatic deterioration.', 'timeFrame': 'up to 12 weeks after registration (assessed within 8 weeks after completion of 3 cycles of chemotherapy )'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Overall survival is defined from the date of registration to date of death from any cause', 'timeFrame': '0-2 years'}, {'measure': 'Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug', 'description': 'Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 2.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal.', 'timeFrame': 'Patients were assessed for adverse events at weeks 1, 2, 4, 5, 7, 8, and following surgery'}]",3,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,1,77.0,ACTUAL,2025-09-01T16:18:19.661038,v2_robust,True,True,True,False,True,
NCT06961630,Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction,A Pilot Randomized Trial of Post-Operative Biomarker-Guided Precision Medicine With Rivaroxaban and Atorvastatin for Cardiovascular Risk-Reduction,Rivaroxaban,"['Atorvastatin', 'Rivaroxaban']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Myocardial Injury After Noncardiac Surgery,['Myocardial Injury After Noncardiac Surgery'],[],NOT_YET_RECRUITING,,2025-06-01,2027-03-31,"[{'measure': 'Percentage of pills taken at Month 6', 'description': 'Treatment adherence will be assessed by pill count and patient self report.', 'timeFrame': 'Month 6'}]","[{'measure': 'Percentage of Quality of Life (QOL) questionnaires completed at Month 6', 'description': 'Two QOL questionnaires (Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10) and EuroQol 5 Dimension (EQ5D)) will be administered at baseline, 2-month follow-up visit, and the 6-month follow-up visit.', 'timeFrame': 'Month 6'}]",2,45 Years,,ALL,False,NYU Langone Health,OTHER,1,50.0,ESTIMATED,2025-09-01T16:18:19.661058,v2_robust,True,True,False,False,False,
NCT02802930,Test the Phototoxicity of Sunscreen Products,"A Randomized Study to Assess the Potential for Phototoxicity of SPF 50 Y65 110, SPF 50 Y51 002 and SPF 15 V27-104 in Human Subjects",SPF 50 Y65 110 (BAY987519),"['SPF 50 Y65 110 (BAY987519)', 'SPF 50 Y51 002 (BAY987519)', 'SPF 15 V27 104 (BAY987519)', 'Sodium chloride [NaCl]']",4,INTERVENTIONAL,['NA'],,,Sunscreen Agents,['Sunscreen Agents'],[],COMPLETED,,2015-04-20,2015-04-26,"[{'measure': 'Skin irritation', 'description': 'Skin irritation was rated on a scale from 0-7 where 0 is no evidence of irritation and 7 is strong reaction spreading beyond test site', 'timeFrame': 'up to 1 week'}]","[{'measure': 'Number of adverse event as a measure of safety and tolerability', 'timeFrame': 'up to 1 week'}]",2,18 Years,65 Years,ALL,True,Bayer,INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:19.661095,v2_robust,True,True,True,False,True,
NCT06886230,Ondansetron vs. Dexamethasone for Postoperative Nausea,"Assessing The Safety and Efficacy of Ondansetron, Dexamethasone, and Their Combined Regimen in Managing Post Operative Nausea and Vomiting: A Randomized Controlled Trial",Placebo (Normal Saline),"['Saline Injection', 'Ondem', 'Dexasone', 'Placebo (Normal Saline)', 'Zofran', 'Emeset', 'Ondansetron (Zofran)', 'Dexamethasone', 'Inert Solution', 'Decadron']",10,INTERVENTIONAL,['PHASE4'],PHASE4,,Postoperative Nausea and Vomiting (PONV),['Postoperative Nausea and Vomiting (PONV)'],"['nausea', 'vomiting', 'PONV', 'randomized controlled trial', 'ondansetron', 'dexamethasone']",COMPLETED,,2025-03-20,2025-06-11,"[{'measure': 'Incidence of Postoperative Nausea and Vomiting (PONV)', 'description': 'Defined as the presence of nausea and/or vomiting at any assessment time point (recovery, 2, 4, 6, 12, and 24 hours postoperatively).\n\nComparison of postoperative nausea and vomiting incidence between the Ondansetron-Dexamethasone and Ondansetron groups.\n\nThe need for rescue antiemetic administration as an indicator of postoperative nausea and vomiting severity.', 'timeFrame': '24 hours'}]","[{'measure': 'Severity of Postoperative Nausea and Vomiting (Postoperative Nausea and Vomiting Impact Scale Score)', 'description': 'Assessment of the frequency, severity, and impact of nausea and vomiting on daily activities and quality of life.\n\nMeasured using patient-reported responses to the Postoperative Nausea and Vomiting Impact Scale.\n\nScoring Range: 0 to 6 Minimum Score (0): No impact of nausea or vomiting Maximum Score (6): Severe impact on daily activities Interpretation: Higher scores indicate a worse outcome, with greater severity and impact of PONV.', 'timeFrame': '24 hours'}, {'measure': 'Postoperative Pain Scores (Visual Analog Scale Score)', 'description': 'Pain intensity recorded at recovery, 2, 6 and 24 hours postoperatively using the Visual Analog Scale. A 10-point scale ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicate greater pain severity.\n\nComparison of pain levels between the two groups to determine any analgesic effects of dexamethasone.', 'timeFrame': '24 hours'}, {'measure': 'Need for Rescue Medication', 'description': 'Frequency and timing of rescue antiemetic administration in both groups. Determines the effectiveness of the interventions in controlling postoperative nausea and vomiting.', 'timeFrame': '24 hours'}, {'measure': 'Adverse Effects of Medications', 'description': 'Frequency of ondansetron-related side effects: headache, dizziness, constipation, diarrhea, fatigue, allergic reactions.\n\nFrequency of dexamethasone-related side effects: increased appetite, insomnia, mood changes, fluid retention, hypertension, hyperglycemia.', 'timeFrame': '24 hours'}, {'measure': 'Satisfaction with Postoperative Nausea and Vomiting Management', 'description': 'Patient-reported satisfaction levels with nausea and vomiting management, measured using the satisfaction scale in the questionnaire.\n\nEach response is scored on a 5-point Likert scale, where:\n\n1. = Very dissatisfied (minimum score)\n2. = Somewhat dissatisfied\n3. = Neutral\n4. = Somewhat satisfied\n5. = Very satisfied (maximum score) The total score ranges from 5 (minimum satisfaction) to 25 (maximum satisfaction), with higher scores indicating better patient satisfaction.', 'timeFrame': '24 hours'}, {'measure': 'Apfel Score: Risk Assessment for Postoperative Nausea and Vomiting (PONV)', 'description': 'Apfel Score Components (Each Risk Factor = 1 Point) Female gender → (Yes = 1 point, No = 0 points) History of postoperative nausea and vomiting or motion sickness → (Yes = 1 point, No = 0 points) Non-smoker → (Yes = 1 point, No = 0 points) Planned use of postoperative opioid analgesia → (Yes = 1 point, No = 0 points) Higher Apfel Scores indicate an increased risk of postoperative nausea and vomiting.', 'timeFrame': '24 hours'}, {'measure': 'Heart Rate', 'description': 'Heart rate (beats per minute) will be continuously monitored and recorded at predefined intraoperative and postoperative time points to assess hemodynamic stability and detect potential bradycardia or tachycardia.', 'timeFrame': '24 hours'}, {'measure': 'Blood Pressure', 'description': 'Systolic and diastolic blood pressure (measured in mmHg) will be recorded at regular intraoperative and postoperative intervals to monitor hemodynamic stability and detect episodes of hypotension or hypertension.', 'timeFrame': '24 hours'}, {'measure': 'Respiratory Rate', 'description': 'Respiratory rate (measured in breaths per minute) will be monitored intraoperatively and postoperatively to evaluate respiratory function and detect potential respiratory depression or distress.', 'timeFrame': '24 hours'}, {'measure': 'Oxygen Saturation', 'description': 'Oxygen saturation levels (SpO₂, measured as a percentage) will be continuously monitored throughout the intraoperative and postoperative periods to assess respiratory function and detect hypoxia.', 'timeFrame': '24 hours'}]",11,18 Years,65 Years,ALL,False,Hafiz Muhammad Hamza,OTHER,1,105.0,ACTUAL,2025-09-01T16:18:19.661129,v2_robust,True,True,True,False,True,
NCT03315130,Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis",zilucoplan (RA101495),"['zilucoplan (RA101495)', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Generalized Myasthenia Gravis,['Generalized Myasthenia Gravis'],[],COMPLETED,,2017-10-11,2020-11-19,"[{'measure': 'Main Portion: Change From Baseline to Week 12 in Quantitative Myasthenia Gravis (QMG) Score', 'description': 'The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for myasthenia gravis (MG). The scale consists of 13 individual assessments, each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the individual scores with a range of 0-39. Higher scores are representative of more severe impairment.', 'timeFrame': 'From Baseline to Week 12'}]","[{'measure': 'Main Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Scale', 'description': 'The MG-ADL is a brief 8-item survey designed to evaluate MG symptom severity. The scale consists of 8 items each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the 8 individual scores with range of 0-24. Higher scores are associated with more severe symptoms of MG.', 'timeFrame': 'From Baseline to Week 12'}, {'measure': 'Main Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life 15r (MG-QOL15r) Survey', 'description': ""The MG-QOL15r is a 15-item survey that was designed to assess quality of life in participants with MG. The survey consisted of 15 questions and the corresponding responses were each scored on a 0-2 point scale (0=Not much at all, 1=Somewhat, 2=Very Much). The total score is the sum of the 15 individual item scores with a range of 0-30. Higher scores indicate more severe impact of the disease on aspects of the participant's life."", 'timeFrame': 'From Baseline to Week 12'}, {'measure': 'Main Portion: Change From Baseline to Week 12 in the MG Composite Scale Total Score', 'description': 'The MG Composite is a 10-item scale that has been used to measure the clinical status of participants with MG, in order to evaluate treatment response. It consists of 10 items which included ptosis (score range=0 to 3), double vision on lateral gaze left/right/both (score range=0 to 4), eye closure (score range=0 to 2), talking (score range=0 to 6), chewing (score range=0 to 6), swallowing (score range=0 to 6), breathing (score range=0 to 9), neck flexion or extension (score range=0 to 4), shoulder abduction (score range=0 to 5) and hip flexion (score range= 0 to 5). The total score is the sum of the 10 individual scores with a range of 0-50. Higher scores in the MG Composite indicate more severe impairment due to the disease.', 'timeFrame': 'From Baseline to Week 12'}, {'measure': 'Main Portion: Percentage of Participants With >= 3-point Reduction in QMG Total Score at Week 12', 'description': 'The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consists of 13 individual assessments, each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the individual scores with a range of 0-39. Higher scores are representative of more severe impairment.', 'timeFrame': 'Week 12'}, {'measure': 'Main Portion: Percentage of Participants Who Required Rescue Therapy Over the 12-week Treatment Period', 'description': 'Percentage of participants who used at least 1 dose of rescue medication were reported.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Main Portion: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in death, life-threatening, significant or persistent disability/incapacity, congenital anomaly/birth defect, important medical event, initial inpatient hospitalization or prolongation of hospitalization.', 'timeFrame': 'From Baseline to Week 12'}, {'measure': 'Main Portion: Change From Baseline in Sheep Red Blood Cell (sRBC) Lysis Assay at Week 12 (Pre-dose)', 'description': 'A BioTek ELx800 automated microplate reader is used to measure the optical density at 415 nanometer (nm) of human plasma samples to calculate the percent lysis of sheep erythrocytes that has occurred as a result of total complement activity. The measure of complement activity is determined by the degree of hemolysis of the erythrocytes.', 'timeFrame': 'Baseline and Week 12 (Pre-dose)'}, {'measure': 'Main Portion: Change From Baseline in C5 Levels at Week 12 (Pre-dose)', 'description': 'Blood samples were collected from participants to assess Complement Component 5C levels.', 'timeFrame': 'Baseline and Week 12 (Pre-dose)'}, {'measure': 'Main Portion: Plasma Concentration of RA101495 and Its Major Metabolites', 'description': 'RA102758 and RA103488 are the metabolites of RA101495.', 'timeFrame': '1, 3 and 6 hours postdose on Day 1; Pre-dose on Week 1, 2, 4, 8 and 12'}, {'measure': 'Main Portion: Maximum Plasma Concentration (Cmax) on Day 1', 'description': 'Cmax is defined as the maximum observed plasma concentration.', 'timeFrame': 'Pre-dose, 1, 3 and 6 hours postdose on Day 1'}, {'measure': 'Main Portion: Time Corresponding to Cmax (Tmax) on Day 1', 'description': 'Tmax is defined as the time to observe maximum plasma concentration.', 'timeFrame': 'Pre-dose, 1, 3 and 6 hours postdose on Day 1'}, {'measure': 'Main Portion: Metabolites (RA102758 and RA103488) to Parent Ratio', 'description': 'RA102758 and RA103488 are the metabolites of RA101495.', 'timeFrame': 'Pre-dose, 1, 3 and 6 hours postdose on Day 1; Pre-dose on Week 1, 2, 4, 8 and 12'}]",13,18 Years,85 Years,ALL,False,Ra Pharmaceuticals,INDUSTRY,0,45.0,ACTUAL,2025-09-01T16:18:19.661252,v2_robust,True,True,True,False,True,
NCT02652728,Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy,Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy,Enalapril Orodispersible Minitablet,"['Enalapril Orodispersible Minitablet', 'Enalapril ODMT']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Heart Failure,"['Heart Failure', 'Dilated Cardiomyopathy']",[],UNKNOWN,,2016-01,2017-06,"[{'measure': 'Area under the Curve (AUC) of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure', 'description': 'Area under the Curve (AUC) of enalapril and enalaprilat are measured at first dose or at any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy (1 month to less than 12 years); descriptive pharmacokinetic investigation', 'timeFrame': '0 hours to 12 hours'}, {'measure': 'Maximum Concentration (Cmax) of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure', 'description': 'Maximum Concentration (Cmax) of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy (1 month to less than 12 years); descriptive pharmacokinetic investigation', 'timeFrame': '0 hours to 12 hours'}, {'measure': 'Time to Maximum Concentration (Tmax) of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure', 'description': 'Time to Maximum Concentration (Tmax) of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy (1 month to less than 12 years); descriptive pharmacokinetic investigation', 'timeFrame': '0 hours to 12 hours'}]","[{'measure': 'AUC of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure of two age-subsets', 'description': 'AUC of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy in the age subsets 1 month to less than 1 year and 1 year to less than 12 years; descriptive pharmacokinetic investigation', 'timeFrame': '0 hours to 12 hours'}, {'measure': 'Cmax of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure of two age-subsets', 'description': 'Cmax of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy in the age subsets 1 month to less than 1 year and 1 year to less than 12 years; descriptive pharmacokinetic investigation', 'timeFrame': '0 hours to 12 hours'}, {'measure': 'Tmax of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure of two age-subsets', 'description': 'Tmax of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy in the age subsets 1 month to less than 1 year and 1 year to less than 12 years; descriptive pharmacokinetic investigation', 'timeFrame': '0 hours to 12 hours'}, {'measure': 'Renin', 'description': 'Renin as marker of the renin-angiotensin-aldosterone system at each study visit up to the end of treatment at 8 weeks; exploratory pharmacodynamic investigation', 'timeFrame': 'Pre-dose, 4 h post first dose, pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42) up to Last Visit (day 56)'}, {'measure': 'Angiotensin 1', 'description': 'Angiotensin 1 as marker of the renin-angiotensin-aldosterone system at each study visit up to the end of treatment at 8 weeks; exploratory pharmacodynamic investigation', 'timeFrame': 'Pre-dose, 4 h post first dose, pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42) up to Last Visit after 8 (day 56)'}, {'measure': 'Aldosterone', 'description': 'Aldosterone as marker of the renin-angiotensin-aldosterone system at every study visit up to the end of treatment at 8 weeks; exploratory pharmacodynamic investigation', 'timeFrame': 'Pre-dose, 4 h post first dose, pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42) up to Last Visit (day 56)'}, {'measure': 'Plasma Renin Activity', 'description': 'Plasma Renin Activity as marker of the renin-angiotensin-aldosterone system at each study visit up to the end of treatment at 8 weeks; exploratory pharmacodynamic investigation', 'timeFrame': 'Pre-dose, 4 h post first dose, pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42) up to Last Visit (day 56)'}, {'measure': 'Brain natriuretic peptides (BNP)', 'description': 'Brain natriuretic peptides measurement as indicator of disease severity measured at every visit up to the end of treatment at 8 weeks', 'timeFrame': 'At Screening Visit and then pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42), at Last Visit (day 56)'}, {'measure': 'Acceptability of the ODMTs', 'description': 'Acceptability assessment according to an age-appropriate scale', 'timeFrame': 'Assessment time points: at Initial Dose, at one Study Control Visit (at days 14, 28 or 42), at Last Visit (day 56)'}, {'measure': 'Palatability of the ODMTs', 'description': 'Palatability assessment according to an age-appropriate scale', 'timeFrame': 'Assessment time points: at Initial Dose, at one Study Control Visit (at days 14, 28 or 42), at Last Visit (day 56)'}, {'measure': 'Blood pressure', 'description': 'Safety monitoring parameter to decide on next dose prescription level', 'timeFrame': 'Pre-dose at each Visit, over 8 hours at Initial Dose Visit, over 4 hours at First Titration Visit (day 3 to 7), over 2 hours after all other Titration Visits, pre-dose at all Study Control Visits (at days 14, 28 and 42), at Last Visit (day 56)'}, {'measure': 'Serum potassium', 'description': 'Renal monitoring parameter to decide on next dose prescription level', 'timeFrame': 'Pre-dose at each Visit: Screening Visit, Initial Dose Visit, all Titration Visits, all Study Control Visits (day 14,28, 42) up to Last Visit (day 56)'}, {'measure': 'Blood urea nitrogen (BUN)', 'description': 'Renal monitoring parameter to decide on next dose prescription level', 'timeFrame': 'Pre-dose at each Visit: Screening Visit, Initial Dose Visit, all Titration Visits, all Study Control Visits (day 14,28, 42) up to Last Visit (day 56)'}, {'measure': 'Creatinine', 'description': 'Renal monitoring parameter to decide on next dose prescription level', 'timeFrame': 'Pre-dose at each Visit: Screening Visit, Initial Dose Visit, all Titration Visits, all Study Control Visits (day 14,28, 42) up to Last Visit (day 56)'}, {'measure': 'Micro-albuminuria', 'description': 'Renal monitoring parameter to decide on next dose prescription level', 'timeFrame': 'Pre-dose at each Visit: Screening Visit, Initial Dose Visit, all Titration Visits, all Study Control Visits (day 14,28, 42) up to Last Visit (day 56)'}, {'measure': 'Shortening fraction', 'description': 'Shortening Fraction in echocardiography', 'timeFrame': 'Assessment time points: at Screening Visit and at Last Visit (day 56)'}, {'measure': 'Number of patients experiencing rehospitalisation due to heart failure', 'description': 'Number of patients experiencing rehospitalisation due to heart failure including the need for heart transplantation or the institution of mechanical circulatory support', 'timeFrame': 'During 8 weeks of treatment'}, {'measure': 'Death due to worsening of the underlying disease', 'description': 'Death due to worsening of the underlying disease', 'timeFrame': 'During 8 weeks of treatment'}]",21,1 Month,11 Years,ALL,False,Ethicare GmbH,INDUSTRY,0,50.0,ESTIMATED,2025-09-01T16:18:19.661320,v2_robust,True,True,False,False,True,
NCT00896428,Effects of Gallopamil in Severe Asthma,Effects of Gallopamil on Bronchial Smooth Muscle Remodelling in Severe Asthma: a Double Blind Study.,Methoxyverapamil (gallopamil),"['Methoxyverapamil (gallopamil)', 'Placebo.']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Asthma,['Asthma'],"['Asthma', 'gallopamil', 'airway remodelling', 'smooth muscle']",COMPLETED,,2009-12,2012-11,"[{'measure': 'Bronchial smooth muscle remodelling assessed by optic microscopy.', 'timeFrame': 'Before and after 12 months treatment.'}]","[{'measure': 'Bronchial smooth muscle remodelling assessed by electron microscopy', 'timeFrame': 'Before and after 12 months treatment.'}, {'measure': 'Bronchial smooth muscle mitochondrial number and activity assessed in vitro', 'timeFrame': 'Before and after 12 months treatment.'}, {'measure': 'Bronchial thickness assessed by 3D analysis of computed tomography', 'timeFrame': 'Before and after 12 months treatment.'}, {'measure': 'Asthma control using asthma control questionnaire, inflammation monitoring, number of hospitalizations, number of emergency visits, number of unplanned medical visits.', 'timeFrame': 'Once per month for 12 months.'}]",5,18 Years,,ALL,False,"University Hospital, Bordeaux",OTHER,0,31.0,ACTUAL,2025-09-01T16:18:19.661365,v2_robust,True,True,True,False,False,
NCT01862328,"Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors","A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors",MLN4924,"['Paclitaxel', 'Pevonedistat', 'Carboplatin', 'Gemcitabine', 'MLN4924', 'Docetaxel']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumors,['Solid Tumors'],"['MLN4924', 'Solid Tumors']",COMPLETED,,2013-06-10,2018-05-21,"[{'measure': 'Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'Baseline up to 30 days after the last dose of study drug (up to 5 years)'}, {'measure': 'Number of Participants With TEAEs Related to Clinically Significant Laboratory Evaluation Findings', 'timeFrame': 'Baseline up to 30 days after the last dose of study drug (up to 5 years)'}, {'measure': 'Number of Participants With TEAEs Related to Clinically Significant Vital Sign Findings', 'timeFrame': 'Baseline up to 30 days after the last dose of study drug (up to 5 years)'}]","[{'measure': 'Percentage of Participants With Objective Response', 'description': 'Percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: complete disappearance of all target lesions and non-target disease, with exception of nodal disease; all nodes, both target and non-target, must decrease to normal (short axis less than \\[\\<\\] 10 millimeter \\[mm\\]); no new lesions. PR: greater than or equal to (\\>=) 30 percent (%) decrease under baseline of sum of diameters of all target lesions; short axis was used in sum for target nodes, while longest diameter was used in sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions.', 'timeFrame': 'Screening, Cycle 2 Days 15 (Arm 1, 2a, and 2) and 22 (Arm 3) then every other Cycle thereafter up to 30 days after the last dose of study drug (up to 5 years) (Cycle Length = 21 days [Arm 1, 2a, and 2] and 28 days [Arm 3])'}, {'measure': 'Duration of Response', 'description': 'Duration of response: time from the date of first documented response per the investigator response assessment (CR or PR) to the date of PD or the date of last disease assessment if the participant discontinued the study before PD using RECIST 1.1 CR: complete disappearance of all target lesions and non-target disease, with exception of nodal disease; all nodes, both target and non-target, must decrease to normal (short axis \\<10 mm); no new lesions. PR: \\>=30% decrease under baseline of sum of diameters of all target lesions; short axis was used in sum for target nodes, while longest diameter was used in sum for all other target lesions; no unequivocal progression of non-target disease; no new lesions. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in sum of diameters of target lesions, taking as reference smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.', 'timeFrame': 'From the date of first documented response (CR or PR) to the date of first documented PD or the date of last disease assessment if the participants discontinued the study before PD (up to 5 years)'}, {'measure': 'Dose-escalation Phase: Plasma Concentrations-time Data of MLN4924', 'timeFrame': 'Cycle 1 Day 1 pre-dose and at multiple time points (up to 20 hours) post-dose (Cycle Length=21 days [Arm 1 and 2] and 28 days [Arm 3])'}, {'measure': 'MTD Expansion Phase: Plasma Concentrations-time Data of MLN4924', 'description': 'The number of participants analyzed includes only those participants who had data available for this measure.', 'timeFrame': 'Cycle 1 Days 1 and 5 pre-dose and at multiple time points (up to 20 hours) post-dose (Cycle Length=21 days [Arm 1 and 2])'}]",7,18 Years,,ALL,False,"Millennium Pharmaceuticals, Inc.",INDUSTRY,0,64.0,ACTUAL,2025-09-01T16:18:19.661380,v2_robust,True,True,True,False,True,
NCT01227928,"Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women","A Study to Evaluate Efficacy and Safety of Pazopanib Monotherapy in Asian Women Who Have Not Progressed After First-line Chemotherapy for Advanced Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma - An Extension Study to VEG110655",Pazopanib,"['Pazopanib', 'Placebo comparator']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Neoplasms, Ovarian","['Neoplasms, Ovarian']","['tyrosine kinase inhibitors', 'Primary Peritoneal Carcinoma', 'primary peritoneal cancer', 'ovarian cancer', 'Fallopian Tube Cancer', 'gynecologic cancer', 'anti-angiogenesis', 'pazopanib']",COMPLETED,,2010-09,2014-01,"[{'measure': 'Progression-free Survival (PFS)', 'description': ""PFS is defined as the time interval between randomization and evidence of progressive disease (PD), as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, or death, whichever occurred first. A visit-based analysis approach to determine participants' dates of progression was applied in the analysis method. PD is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Participants who were alive and had not progressed at the time of analysis were censored at the date associated with the last visit with adequate assessment."", 'timeFrame': 'From randomization until evidence of progressive disease or death, whichever occurred first (average of 15.2 months)'}]","[{'measure': 'Overall Survival', 'description': 'Overall survival is defined as the time interval from the date of randomization to the date of death due to any cause.', 'timeFrame': 'From randomization until death due to any cause (average of 29.4 months)'}, {'measure': 'PFS by Gynaecologic Cancer Intergroup (GCIG) Criteria', 'description': 'PFS by GCIG criteria is defined as the time from the randomization date to the earliest date of disease progression (PD) per GCIG criteria or death due to any cause. Per GCIG criteria, an objective progression is defined as the earliest event of either tumor progression based on RECIST v1.0 or confirmed CA-125 progression. A participant is counted as ""Progressed per RECIST"" if the radiological PD per RECIST occurred prior to or on the same day as CA-125 progression. A participant is counted as ""Progressed per CA-125"" if the radiological PD occurred after CA-125 progression. Per RECIST, PD is defined as at least a 20% increase in the sum of the LD of target lesions, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Participants who were alive and had not progressed at the time of analysis were censored at the date associated with the last visit with adequate assessment.', 'timeFrame': 'From randomization to the earliest date of disease progression per GCIG criteria or death due to any cause (average of 15.2 months)'}, {'measure': 'Number of Participants With Any Dose Reduction or Any Dose Interruption', 'description': 'Dose interruptions or reductions may have been required following potential drug-related toxicities. As a general rule, if dose reduction of investigational product (IP) was necessary, the dose should have been reduced stepwise by 200 mg at each step, and the participant should have been monitored for 10 to 14 days. If toxicity recurred or worsened during this monitoring time, the IP could have been interrupted and/or the dose of IP further decreased, with continued monitoring for an additional 10 to 14 days, and so on. The cut off for these data was October 12, 2012.', 'timeFrame': 'From Week 1 until the end of the treatment period (up to Study Week 108)'}, {'measure': 'Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)', 'description': 'An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalizaton or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. See the non-serious AE/SAE module for a list of specific events.', 'timeFrame': 'From Week 1 until the end of the treatment period (up to Study Week 108)'}, {'measure': 'Number of Participants With Any On-therapy AE and Any AE Related to Study Treatment', 'description': 'An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. On-therapy AEs were those reported from the first day that randomized study drug was received to 28 days after the last dose of randomized study drug, and within 28 days of dose interruption. Relatedness was assessed by the Investigator.', 'timeFrame': 'From Week 1 until the end of the treatment period (up to Study Week 108)'}, {'measure': 'Number of Participants With Any Grade 3 or 4 AE', 'description': 'An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. The NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0 was used to grade AEs per the following scale to assess severity: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling AE; Grade 5, death related to AE.', 'timeFrame': 'From Week 1 until the end of the treatment period (up to Study Week 108)'}, {'measure': 'Number of Participants With the Indicated On-therapy Grade 3-5 AEs', 'description': 'An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. On-therapy AEs were those reported from the first day that randomized study drug was received to 28 days after the last dose of randomized study drug, and within 28 days of dose interruption. The NCI-CTCAE Version 3.0 was used to grade AEs per the following scale to assess severity: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling AE; Grade 5, death related to AE. ALT=alanine aminotransferase; AST=aspartate aminotransferase.', 'timeFrame': 'From Week 1 until the end of the treatment period (up to Study Week 108)'}, {'measure': 'Number of Participants With AEs Leading to Permanent Discontinuation of Study Treatment, Dose Interruption, and Dose Reduction', 'description': 'An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Dose interruptions or reductions may have been required following potential drug-related toxicities. As a general rule, if dose reduction of investigational product (IP) was necessary, the dose should have been reduced stepwise by 200 mg at each step, and the participant should have been monitored for 10 to 14 days. If toxicity recurred or worsened during this monitoring time, the IP could have been interrupted and/or the dose of IP further decreased, with continued monitoring for an additional 10 to 14 days, and so on.', 'timeFrame': 'From Week 1 until the end of the treatment period (up to Study Week 108)'}, {'measure': 'Number of Participants With Any SAE, Any SAE Related to Study Treatment, and Any Fatal SAE', 'description': 'An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalizaton or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. See the non-serious AE/SAE module for a list of specific events. Relatedness was assessed by the Investigator.', 'timeFrame': 'From Week 1 until the end of the treatment period (up to Study Week 108)'}, {'measure': 'Number of Participants With the Indicated Worst-case On-therapy Blood Pressure Shifts From Baseline', 'description': 'Systolic blood pressure (SBP) and Diatolic blood pressure (DBP) are measured in millimeters of mercury (mmHg). A participant could have been counted in more than one shift category. Participants who experienced shifts in both SBP and DBP are represented under each individual parameter. A worst-case on-therapy shift is defined as the worst shift that occurred at any time during the treatment period.', 'timeFrame': 'From Week 1 until the end of the treatment period (up to Study Week 108)'}, {'measure': ""Number of Participants With the Indicated Worst-case On-therapy Shift From Baseline in Bazett's Corrected QT Interval (QTc)"", 'description': ""12-lead ECGs were obtained at the scheduled visits. A worst-case on-therapy shift is defined as the worst shift that occurred at any time during the treatment period. The QTc is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. In general, the faster the heart rate the shorter the QTc. If a QTc \\>=500 milliseconds (msec) was noted on a scheduled or unscheduled electrocardiogram (ECG), then two additional ECGs should have been obtained within 5 minutes to confirm the abnormality. The average QTc was determined from the three ECG tracings by manual evaluation and was used to determine continued eligibility."", 'timeFrame': 'From Week 1 until the end of the treatment period (up to Study Week 108)'}, {'measure': 'Number of Participants With the Indicated Worst-case On-therapy Hematology Parameter Grade Shifts From Baseline Grade', 'description': 'Grade shifts from Baseline were assessed as any grade increase (AGI), increase to Grade (G) 3 (ITG3), and increase to Grade 4 (ITG4). Toxicities were graded according to the National Cancer Institute common toxicity criteria (NCI-Common Toxicity Criteria for Adverse Events), version 4.0. Grade refers to the severity of the toxicity. The CTCAE displays Grades (G) 1 through 5 with unique clinical descriptions of severity for each toxicity based on the following general guideline: G1, mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; G2, moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL); G3, severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL; G4, Life-threatening consequences; urgent intervention indicated.; G5, death related to AE.', 'timeFrame': 'From Week 1 until the end of the treatment period (up to Study Week 108)'}, {'measure': 'Number of Participants With the Indicated Worst-case On-therapy Chemistry Parameter Grade Shifts From Baseline Grade', 'description': 'Grade shifts from Baseline were assessed as any grade increase (AGI), increase to Grade (G) 3 (ITG3), and increase to Grade 4 (ITG4). Toxicities were graded according to the National Cancer Institute common toxicity criteria (NCI-Common Toxicity Criteria for Adverse Events), version 4.0. Grade refers to the severity of the toxicity. The CTCAE displays Grades (G) 1 through 5 with unique clinical descriptions of severity for each toxicity based on the following general guideline: G1, mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; G2, moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL); G3, severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL; G4, Life-threatening consequences; urgent intervention indicated.; G5, death related to AE.', 'timeFrame': 'From Week 1 until the end of the treatment period (up to Study Week 108)'}, {'measure': 'Number of Participants With the Indicated Worst-case Eastern Cooperative Oncology Group (ECOG) Performance Status Shifts From Baseline Grades of 0, 1, and 2', 'description': ""The ECOG performance status scales and criteria are used by doctors and researchers to assess how a participant's disease is progressing, assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. Grade 0, fully active, able to carry on all pre-disease performance without restriction. Grade 1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. Grade 2, ambulatory and capable of all selfcare, but unable to carry out any work activities; up and about more than 50% of waking hours. Grade 3, capable of only limited selfcare; confined to bed or chair more than 50% of waking hours. Grade 4, completely disabled; cannot carry on any selfcare; totally confined to bed or chair. Grade 5, dead."", 'timeFrame': 'From Week 1 until the end of the treatment period (up to Study Week 108)'}]",15,18 Years,,FEMALE,False,GlaxoSmithKline,INDUSTRY,0,145.0,ACTUAL,2025-09-01T16:18:19.661517,v2_robust,True,True,True,False,True,
NCT02486328,The Effect of Different Sedation Regimes on Cognitive Function in Lower Gastrointestinal System Endoscopy,The Effect of Different Sedation Regimes Administered by Anesthesiologists or Endoscopists on Cognitive Functions in Lower Gastrointestinal System Endoscopy,Midazolam,"['Diprivan', 'Meperidine', 'Midazolam', 'Versed', 'Remifentanil', 'Demerol', 'Propofol', 'Ultiva']",8,INTERVENTIONAL,['PHASE4'],PHASE4,,Gastrointestinal Dysfunction,"['Gastrointestinal Dysfunction', 'Alteration of Cognitive Function']","['Cognitive dysfunction', 'Colonoscopy', 'Sedation']",COMPLETED,,2015-05,2015-06,"[{'measure': 'Change in Cognitive Function', 'description': 'As measured by Trieger Dot Test. The test does not have an upper limit; the time taken to complete the test is added to the number of dots missed by the patient and a result is obtained. The lowest score possible is 0. Higher values represent worse outcomes.', 'timeFrame': 'Baseline and 5, 15, 30 minutes after the procedure'}, {'measure': 'Change in Cognitive Function', 'description': 'As measured by Digit Symbol Substitution Test. Scale range 0-9. No cut-off value. Higher results represent better outcomes', 'timeFrame': 'Baseline and 5, 15, 30 minutes after the procedure'}]","[{'measure': 'Change in Visual Analogue Scale Scores From the Baseline', 'description': 'Pain as measured by Visual Analogue Scale. Range 1-10. No cut-off value, Higher results represent worse outcomes', 'timeFrame': 'Baseline and 5, 15, 30 minutes after the procedure'}, {'measure': 'Heart Rate', 'description': 'Heart rate as measured in beats per minute', 'timeFrame': 'Baseline and 1,2,3,5,10,15 and 20 minutes'}, {'measure': 'Mean Arterial Pressure', 'description': 'mean arterial blood pressure as measured in mmHg', 'timeFrame': 'Baseline and 1,2,3,5,10,15 and 20 minutes'}, {'measure': 'Peripheral Oxygen Saturation', 'description': 'peripheral oxygen saturation as measured by pulse oximeter. Units are percentages, Scale range 0-100.', 'timeFrame': 'Baseline and 1,2,3,5,10,15 and 20 minutes'}]",6,18 Years,65 Years,ALL,False,Ufuk University,OTHER,0,103.0,ACTUAL,2025-09-01T16:18:19.661564,v2_robust,True,True,True,False,False,
NCT01424228,Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years,"A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Quality of Life, Safety and Tolerability of Long-term Treatment (24 Weeks) With Prucalopride in Subjects Aged ≥18 Years With Chronic Constipation",placebo,"['prucalopride', 'placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Constipation,['Constipation'],"['Long term', 'Constipation', 'Digestive signs and symptoms']",COMPLETED,,2011-04-06,2012-12-19,"[{'measure': 'The Percentage of Subjects With an Average of ≥3 Spontaneous Complete Bowel Movements (SCBM) Per Week Over the 24 Week Treatment Period', 'description': 'Spontaneous Bowel Movements defined as a bowel movement that is not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.', 'timeFrame': 'Over 24 week treatment period'}]","[{'measure': 'Percentage of Subjects With an Increase of ≥1 Spontaneous Complete Bowel Movement (SCBM) Per Week Up to 24 Weeks', 'timeFrame': 'Over 24 week treatment period'}, {'measure': 'Average Number of Spontaneous Complete Bowel Movements (SCBM) Per Week Up to 24 Weeks', 'timeFrame': 'Over 24 week treatment period'}, {'measure': 'Change From Baseline in Spontaneous Complete Bowel Movements Per Week at Up to 24 Weeks', 'timeFrame': 'Baseline and Over 24 week treatment period'}, {'measure': 'Percent of Subjects With an Average Weekly Frequency of at Least 3 SCBM by Week', 'timeFrame': 'Over 24 week treatment period'}, {'measure': 'Percent of Subjects With an Average Weekly Frequency of at Least 3 SCBM by 4-Week Treatment Period', 'timeFrame': 'Over 24 week treatment period'}, {'measure': 'Change From Baseline in Average Consistency Per SCBM at Up to 24 Weeks', 'description': 'Consistency measured using the 7-point Bristol scale where 1-2 indicate constipation (=hard/very hard), 3-4 are ideal stools (=normal), and 5-7 tending toward diarrhea.', 'timeFrame': 'Baseline and Over 24 week treatment period'}, {'measure': 'Change From Baseline in Percent SCBM With a Consistency of Normal and Hard/Very Hard at Up to 24 Weeks', 'timeFrame': 'Baseline and Over 24 week treatment period'}, {'measure': 'Change From Baseline in Straining Per SCBM at Up to 24 Weeks', 'description': 'Straining was evaluated on a 5-point scale (0=none, 1=mild, 2=moderate, 3=severe, or 4=very severe)', 'timeFrame': 'Baseline and Over 24 week treatment period'}, {'measure': 'Change From Baseline in Percent SCBM With No Straining and Severe/Very Severe Straining at Up to 24 Weeks', 'timeFrame': 'Baseline and Over 24 week treatment period'}, {'measure': 'Change From Baseline in Percent SBM With Sensation of Complete Evacuation at Up to 24 Weeks', 'timeFrame': 'Baseline and Over 24 week treatment period'}, {'measure': 'Time to First SCBM After Investigational Product Intake on Day 1 and Day 28', 'timeFrame': 'Day 1 and 28'}, {'measure': 'Change From Baseline in the Number of Bisacodyl Tablets Taken Per Week at Up to 24 Weeks', 'timeFrame': 'Baseline and Over 24 week treatment period'}, {'measure': 'Change From Baseline in the Number of Days With Rescue Medication Taken Per Week at Up to 24 Weeks', 'description': 'Rescue medications include laxatives and enemas.', 'timeFrame': 'Baseline and Over 24 week treatment period'}, {'measure': 'Change From Baseline in the Patient Assessment of Constipation - Symptom (PAC-SYM) Questionnaire Score at Up to the Final On Treatment Assessment Value', 'description': 'The PAC-SYM is a validated 12-item questionnaire for the evaluation of severity of symptoms of constipation in subjects with constipation. Items are rated on a 5-point Likert scale: 0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe. Total score ranges from 0 to 48. Lower scores indicate improvement in symptoms. A 1-point improvement in PAC-SYM total score was considered clinically meaningful.', 'timeFrame': 'Baseline and Over 24 week treatment period'}, {'measure': 'Change From Baseline in the Patient Assessment of Constipation - Quality of Life (PAC-QOL) Score at Up to the Final On Treatment Assessment Value', 'description': 'The PAC-QOL is a validated 28-item questionnaire for the evaluation of quality of life in subjects with constipation. Items are rated on a 5-point Likert scale: 0=not at all/none of the time, 1=a little bit/a little bit of the time, 2=moderately/some of the time, 3=quite a bit/most of the time, 4=extremely/all of the time. Total score ranges from 0-112. Lower scores indicate improvement in symptoms. A 1-point improvement in PAC-QOL total score was considered clinically meaningful.', 'timeFrame': 'Baseline and Over 24 week treatment period'}, {'measure': 'Change From Baseline in the Short Form-36 Health Survey (SF-36) Score at Up to the Final On Treatment Assessment Value', 'description': 'The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.', 'timeFrame': 'Baseline and Over 24 week treatment period'}]",17,18 Years,,ALL,False,Shire,INDUSTRY,0,364.0,ACTUAL,2025-09-01T16:18:19.661584,v2_robust,True,True,True,False,False,
NCT04376528,Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy,Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Duo to Nonresponse to Standard Therapy,Cyclosporin A,"['Cyclosporin A', 'Mycophenolate Mofetil']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Hepatitis, Autoimmune","['Hepatitis, Autoimmune', 'Primary Biliary Cholangitis', 'Immunosuppression']",[],UNKNOWN,,2021-06-16,2021-12-30,"[{'measure': 'Biochemical remission', 'description': 'The percentage of patients in biochemical remission, defined as normalization of serum ALT and IgG levels after 24 weeks of treatment, per treatment group.', 'timeFrame': 'up to 6 months'}]","[{'measure': 'Partial remission', 'description': 'Partial remission, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) serum levels \\>1x Upper Limit of Normal (ULN) and \\<2x ULN', 'timeFrame': 'up to 6 months'}, {'measure': 'Minimal response', 'description': 'Minimal response, defined as decrease of ALT or AST serum levels but still \\>2x ULN', 'timeFrame': 'up to 6 months'}, {'measure': 'Treatment failure', 'description': 'defined as no improvement or increase of ALT or AST serum levels', 'timeFrame': 'up to 6 months'}, {'measure': 'Changes in liver stiffness', 'description': 'liver stiffness will be measured by shear-wave elastography', 'timeFrame': 'up to 6 months'}, {'measure': 'Side-effects', 'description': 'Drug related side-effects', 'timeFrame': 'up to 6 months'}]",6,18 Years,70 Years,ALL,False,West China Hospital,OTHER,0,89.0,ESTIMATED,2025-09-01T16:18:19.661674,v2_robust,True,True,False,False,False,
NCT00297128,Preoperative Chemoradiation With Capecitabine and Cetuximab,Preoperative Chemoradiation With Capecitabine and Cetuximab Within a Multidisciplinary Therapeutic Approach in Patients With Operable T3-T4 Rectal Cancer: a Phase II Study,Capecitabine,"['Cetuximab', 'Xeloda', 'Capecitabine', 'Erbitux']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Rectal Cancer,['Rectal Cancer'],"['pilot study', 'rectal', 'cancer', 'phase II', 'preoperative', 'chemoradiation', 'capecitabine', 'cetuximab', 'operable', 'T4', 'ABCSG', 'TAKO', 'R03', '96', '06']",COMPLETED,,2005-10,2011-11,"[{'measure': 'feasibility and tolerance of preoperative therapy with Cetuximab in combination with Capecitabine and radiotherapy for patients with locally advanced operable rectal carcinoma', 'timeFrame': 'descriptive evaluation'}]","[{'measure': 'collection of response rate (T-downstaging, pCR), correlation of responsiveness with EGFR-status', 'timeFrame': 'description evaluation'}]",2,18 Years,80 Years,ALL,False,Austrian Breast & Colorectal Cancer Study Group,NETWORK,2,31.0,ACTUAL,2025-09-01T16:18:19.661748,v2_robust,True,True,True,False,False,
NCT07104565,Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders,"A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders",INCA000585,['INCA000585'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Immune Thrombocytopenia,['Immune Thrombocytopenia'],"['primary warm autoimmune hemolytic anemia', 'primary immune thrombocytopenia', 'anti-CD19 monoclonal antibody']",NOT_YET_RECRUITING,,2025-10-15,2028-03-09,"[{'measure': 'Number of participants with Treatment-emergent Adverse Events (TEAEs)', 'description': 'Defined as any adverse event, either reported for the first time or worsening of a pre-existing event after the first dose of study drug up to 90 days after the last dose of study drug.', 'timeFrame': 'Up to 52 weeks'}, {'measure': 'Stable platelet response', 'description': 'Defined as platelet count ≥ 50 × 109/L in the absence of clinically significant bleeding or rescue therapy at ≥ 2 consecutive assessments any time after Day 56 until Week 48 in participants with primary ITP.', 'timeFrame': 'After Day 56 up to Week 48'}, {'measure': 'Stable hemoglobin response', 'description': 'Defined as hemoglobin ≥ 10 g/dL and a ≥ 2 g/dL increase from baseline in the absence of rescue therapy at ≥ 2 consecutive assessments any time after Day 56 until Week 48 in participants with primary wAIHA.', 'timeFrame': 'After Day 56 up to Week 48'}]","[{'measure': 'Complete Response (CR)', 'description': 'Defined as platelet count ≥ 100 × 109/L at Week 24 in the absence of clinically significant bleeding or rescue therapy in participants with primary ITP.', 'timeFrame': 'Week 24'}, {'measure': 'CR (complete remission)', 'description': 'Defined as platelet count ≥ 100 × 109/L at Week 48 in the absence of clinically significant bleeding or rescue therapy in participants with primary ITP.', 'timeFrame': 'Week 48'}, {'measure': 'Partial Response (PR)', 'description': 'Defined as platelet count ≥ 30 × 109/L and at least a 2-fold increase of baseline platelet count at Week 24 in the absence of clinically significant bleeding or rescue therapy in participants with primary ITP.', 'timeFrame': 'Week 24'}, {'measure': 'Duration of stable platelet response', 'description': 'Defined as time from start of stable platelet response to loss of platelet response (\\< 50 × 109/L), clinically significant bleeding, need for rescue therapy, or death, whichever occurs first in participants with primary ITP.', 'timeFrame': 'Up to Week 48'}, {'measure': 'Duration of CR', 'description': 'Defined as time from the start of CR to loss of CR (platelet count \\< 100 × 109/L), clinically significant bleeding, need for rescue therapy, or death, whichever occurs first in participants with primary ITP.', 'timeFrame': 'Up to Week 48'}, {'measure': 'Duration of response', 'description': 'Defined as time from the date of the first response (PR or CR) to the loss of response (platelet count \\< 30 × 109/L or a less than a 2-fold increase of baseline platelet count), clinically significant bleeding, need for rescue therapy, or death, whichever occurs first in participants with primary ITP.', 'timeFrame': 'Up to Week 48'}, {'measure': 'CR', 'description': 'Defined as hemoglobin ≥ 12 g/dL and normalization of hemolytic markers (unconjugated bilirubin, LDH, haptoglobin, and reticulocytes) at Week 24 in the absence of rescue therapy in participants with primary wAIHA.', 'timeFrame': 'Week 24'}, {'measure': 'CR (Complete remission)', 'description': 'Defined as hemoglobin ≥ 12 g/dL and normalization of hemolytic markers (unconjugated bilirubin, LDH, haptoglobin, and reticulocytes) at Week 48 in the absence of rescue therapy in participants with primary wAIHA.', 'timeFrame': 'Week 48'}, {'measure': 'PR', 'description': 'Defined as hemoglobin ≥ 10 g/dL and a ≥ 2 g/dL increase from baseline at Week 24 in the absence of rescue therapy in participants with primary wAIHA.', 'timeFrame': 'Week 24'}, {'measure': 'Duration of stable hemoglobin response', 'description': 'Defined as time from start of stable hemoglobin response to loss of stable hemoglobin response (\\< 10 g/dL or a \\< 2 g/dL increase from baseline), need for rescue therapy, or death, whichever occurs first in participants with primary wAIHA.', 'timeFrame': 'Up to Week 48'}, {'measure': 'Duration of CR', 'description': 'Defined as time from start of CR to loss of CR (hemoglobin \\< 12 g/dL or abnormal hemolytic markers \\[unconjugated bilirubin, LDH, haptoglobin, and reticulocytes\\]), need for rescue therapy, or death, whichever occurs first in participants with primary wAIHA.', 'timeFrame': 'Up to Week 48'}, {'measure': 'Duration of response', 'description': 'Defined as time from the date of the first response (PR or CR) to the loss of response (hemoglobin \\< 10 g/dL), need for rescue therapy, or death, whichever occurs first in participants with primary wAIHA.', 'timeFrame': 'Up to Week 48'}, {'measure': 'Serum concentrations of tafasitamab', 'description': 'Serum concentrations of tafasitamab at each assessed timepoint.', 'timeFrame': 'Up to Week 48'}, {'measure': 'Change from baseline in serum antidrug antibody levels', 'timeFrame': 'Up to Week 48'}]",17,18 Years,,ALL,False,Incyte Corporation,INDUSTRY,0,56.0,ESTIMATED,2025-09-01T16:18:19.661758,v2_robust,True,True,False,False,True,
NCT06870565,Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma,A Multicenter Randomized Study Comparing Paclitaxel and Platinum-based Concurrent Chemoradiotherapy With Short-term Adjuvant Chemotherapy Versus Platinum-based Monotherapy Concurrent Chemoradiotherapy in Patients With Postoperative Cervical Gastric-type Adenocarcinoma With High-risk Factors for Recurrence.,paclitaxel and platinum,"['paclitaxel and platinum', 'platinum']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Gastric-type Endocervical Adenocarcinoma,"['Gastric-type Endocervical Adenocarcinoma', 'Cervical Cancer']",[],NOT_YET_RECRUITING,,2025-03,2030-12,"[{'measure': '2-year progression-free survival (PFS)', 'timeFrame': '2 year'}]","[{'measure': 'Disease failure pattern', 'description': 'The pattern of disease failure will be assessed by the site and number of recurrences or distant metastases.', 'timeFrame': '2 year'}, {'measure': 'Overall survival rate', 'timeFrame': '2 year'}, {'measure': 'Incidence of acute/chronic toxicity', 'timeFrame': '2 year'}, {'measure': 'Quality of life assessment', 'description': ""Quality of life assessment (time node: 2 years). The patients'quality of life will be assessed using the Quality of Life Questionnaire-Core 30 (QLQ-C30) scale."", 'timeFrame': '2 year'}]",5,18 Years,65 Years,FEMALE,False,Women's Hospital School Of Medicine Zhejiang University,OTHER,0,238.0,ESTIMATED,2025-09-01T16:18:19.661835,v2_robust,True,True,False,False,False,
NCT02915965,"A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma","A Phase II Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma",DCX,['DCX'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Stage II and III Esophageal Squamous Cell Carcinoma,['Stage II and III Esophageal Squamous Cell Carcinoma'],[],UNKNOWN,,2016-10,,"[{'measure': 'overall survival rate', 'timeFrame': '2 years'}]","[{'measure': 'Pathologic response rate', 'description': 'Pathologic response rate is defined as tumor regression score', 'timeFrame': '2 years'}, {'measure': 'Disease-free survival', 'timeFrame': '2 years'}, {'measure': 'Incidence of adverse event based on CTCAE 4.0', 'description': 'Incidence of adverse event in patients during treatment period graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03', 'timeFrame': '2 years'}]",4,18 Years,70 Years,ALL,False,Sun Yat-sen University,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:19.661867,v2_robust,True,True,False,False,True,
NCT01600365,Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus,"""Prospective, Interventional, Randomized, Double-masked With the Use of Ganciclovir Gel 0.3% for Treatment of Conjunctivitis Caused by Adenovirus.""",Ophthalmic gel (placebo),"['artificial tears', 'Ganciclovir', 'Ophthalmic gel (placebo)', 'ganciclovir gel']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Conjunctivitis,"['Conjunctivitis', 'Adenovirus.']","['Conjunctivitis', 'adenovirus.']",UNKNOWN,,2012-05,2012-06,"[{'measure': 'time to regression of the ocular symptomatology', 'description': 'Time to regression of ocular symptomatology compared to the baseline, as determined by clinical evaluation (biomicroscopy) performed on V1, V2 and V3, based on scale of absent, mild, moderate and severe.', 'timeFrame': '10 days'}]","[{'measure': 'Development of sub-epithelial infiltrates', 'description': 'Development of sub-epithelial infiltrates,incidence for the study duration and severity at each follow-up visit (based on scale of absent, mild, moderate and severe)', 'timeFrame': '10 days'}, {'measure': 'Degree of Bulbar conjunctival Injection', 'description': 'Degree of bulbar conjunctival injection at each follow-up visit, based on the scale of mild, moderate and severe', 'timeFrame': '10 days'}, {'measure': 'Involvement of the second eye', 'description': 'Involvement of the second eye - incidence for the study duration and severity at each follow-up visit, as determined by the clinical evaluation (biomicroscopy)', 'timeFrame': '10 days'}, {'measure': 'Patient Dairy - intensity of ocular pain', 'description': 'intensity of ocular pain selected by the patient on the ""Patient Dairy"" based on the visual analogue scale (VAS)on each follow-up visit (absent, mild, moderate, severe)', 'timeFrame': '10 days'}]",5,18 Years,65 Years,ALL,False,Adapt Produtos Oftalmológicos Ltda.,INDUSTRY,0,22.0,ESTIMATED,2025-09-01T16:18:19.661879,v2_robust,True,True,False,False,False,
NCT05130567,A Study of LP-128 Capsules in Healthy Subjects,"A Randomized Study of LP-128 Capsules vs. Placebo to Evaluate Safety, Tolerability and Pharmacokinetics in Healthy Subjects",LP-128 capsules,"['LP-128 capsules', 'NWP-1080']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Hepatitis b,['Chronic Hepatitis b'],[],ACTIVE_NOT_RECRUITING,,2021-11-19,2026-12-30,"[{'measure': 'Area under the plasma concentration-time curve (AUC) of LP-128', 'description': 'Plasma samples were collected at different points for pharmacokinetic analysis', 'timeFrame': 'Up to 4 and 17 days in Single-dose group and Multi-dose group, respectively'}, {'measure': 'Apparent terminal phase half-life (T1/2) of LP-128', 'description': 'Plasma samples were collected at different points for pharmacokinetic analysis', 'timeFrame': 'Up to 4 and 17 days in Single-dose group and Multi-dose group, respectively'}, {'measure': 'Maximum observed plasma concentration (Cmax) of LP-128', 'description': 'Plasma samples were collected at different points for pharmacokinetic analysis', 'timeFrame': 'Up to 4 and 17 days in Single-dose group and Multi-dose group, respectively'}, {'measure': 'Adverse events of LP-128', 'description': 'The incidence and severity of adverse events as assessed by NCI CTCAE v5.0.', 'timeFrame': 'Up to 28 days'}]","[{'measure': 'Excretion of LP-128 in urine', 'description': 'Urine samples will be collected at different points for pharmacokinetic analysis', 'timeFrame': 'Up to 4 days'}, {'measure': 'Excretion of LP-128 in feces', 'description': 'feces samples will be collected at different points for pharmacokinetic analysis', 'timeFrame': 'Up to 4 days'}]",6,18 Years,55 Years,ALL,True,Guangzhou Lupeng Pharmaceutical Company LTD.,INDUSTRY,0,104.0,ESTIMATED,2025-09-01T16:18:19.662003,v2_robust,True,True,False,False,True,
NCT00453167,Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer,A Phase II Study of Weekly Paclitaxel and Gemcitabine as Second-line Therapy in Patients With Metastatic or Recurrence Small Cell Lung Cancer,Paclitaxel,"['Gemcitabine', 'Paclitaxel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Cancer,['Lung Cancer'],"['Small cell lung cancer', 'second-line therapy']",COMPLETED,,2005-12,2010-03,"[{'measure': 'To evaluate the response rate of paclitaxel plus gemcitabine', 'timeFrame': 'the ratio between the number of responders and number of patients assessable for tumor response'}]","[{'measure': 'To access the toxicity', 'timeFrame': 'the first day of the treatment to 30 days after the last dose of study drug'}, {'measure': 'To estimate the time to progression', 'timeFrame': 'the first day of treatment to the date that disease progression is reported'}, {'measure': 'To examine the association between genotypes of paclitaxel biotransformation and the pharmacokinetics /', 'timeFrame': 'before the first treatment date, each response evaluation until disease progression'}, {'measure': 'To estimate the overall survival', 'timeFrame': 'the first day of treatment to death date'}]",5,18 Years,,ALL,False,"National Cancer Center, Korea",OTHER_GOV,0,35.0,ACTUAL,2025-09-01T16:18:19.662087,v2_robust,True,True,True,False,False,
NCT01996267,"Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2",Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study,PTC+Pertuzumab,"['Pertuzumab; 420 mg (loading dose 840 mg); day 1', 'PTC+Pertuzumab', 'Carboplatin; AUC=6; day 1', 'Cyclophosphamide 500 mg/m2; day 1', 'Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1', 'Fluorouracil; 500 mg/m2; day 1', 'Trastuzumab; 6 mg/kg (loading dose 8 mg/kg)', 'FEC-T+Pertuzumab', 'Paclitaxel; 80 mg/m2; day 1,8', 'Epirubicine; 90 mg/m2; day 1']",10,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,"['Breast Cancer', 'HER2 Positive']","['neoadjuvant', 'breast cancer', 'HER2 positive']",ACTIVE_NOT_RECRUITING,,2013-12,2030-12,"[{'measure': 'Number of patients with pathological complete response', 'description': 'To compare the efficacy of six cycles neoadjuvant PTC plus pertuzumab preceded by either three cycles of FEC-T plus pertuzumab or three cycles of PTC plus pertuzumab in HER2 positive breast cancer', 'timeFrame': 'at week 30'}]","[{'measure': 'Number of patients with grade >2 adverse events as a measure of safety and tolerability', 'description': 'to describe the safety of the various regimens toxicity is compared between the two arms', 'timeFrame': 'up to week 35'}, {'measure': 'identify prognostic and predictive biomarkers for pCR', 'description': 'To identify prognostic and predictive biomarkers for pCR after neoadjuvant treatment', 'timeFrame': 'within one year after end of treatment'}]",3,18 Years,,ALL,False,The Netherlands Cancer Institute,OTHER,2,437.0,ACTUAL,2025-09-01T16:18:19.662114,v2_robust,True,True,False,False,True,
NCT03683667,Protein Plus: Improving Infant Growth Through Diet and Enteric Health,"Efficacy of Supplemental Protein, Delivered Alone or in Combination With Treatment for Enteric Pathogens, to Prevent Growth Faltering in Bangladeshi Infants",Azithromycin Oral Product,"['Azithromycin Oral Product', 'Placebos', 'Azithrocin']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Stunting,"['Stunting', 'Malnutrition; Protein', 'Enteric Pathogens', 'Campylobacter Infections']","['linear growth', 'infant feeding', 'environmental enteric dysfunction']",COMPLETED,,2018-09-23,2020-03-24,"[{'measure': 'Length-for-age Z-score (LAZ) at 12 months of age', 'timeFrame': '12 months'}]","[{'measure': 'Nutrient biomarkers', 'description': 'Serum essential, conditionally essential amino acids and choline (by metabolomic analysis); retinol and tocopherols (HPLC); vitamin B12 (microbiological assay); zinc (AAS); ferritin and thyroglobulin (ELISA)', 'timeFrame': '6 and 12 months'}, {'measure': 'Growth hormone and stress axes biomarkers', 'description': 'Serum insulin-like growth factor 1 (IGF-1), IGF binding protein 3, cortisol, by ELISA', 'timeFrame': '6 and 12 months'}, {'measure': 'Enteropathogen burden', 'description': 'Campylobacter, enterotoxigenic Escherichia coli (ETEC), enteroaggregative Escherichia coli (EAEC), enteropathogenic Escherichia coli (EPEC), Shigella and Cryptosporidium, by quantitative polymerase chain reaction (qPCR)', 'timeFrame': '6, 6.5, 9, 9.5, 12, 15, and 18 months'}, {'measure': 'Gut microbiota composition', 'description': 'Microbial diversity and abundance, by 16S ribosomal RNA sequencing', 'timeFrame': '6, 6.5, 9, 9.5, 12, 15, and 18 months'}, {'measure': 'Environmental enteric dysfunction biomarkers', 'description': 'Stool myeloperoxidase and intestinal fatty acid-binding protein concentrations and plasma Endogenous endotoxin-core antibody (EndoCAb), by ELISA', 'timeFrame': '6 and 12 months'}, {'measure': 'Inflammatory biomarkers', 'description': 'Plasma alpha-1 acid glycoprotein, C-reactive protein and interleukin-6, by ELISA; stool inflammatory cytokines, by ELISA', 'timeFrame': '6 and 12 months'}, {'measure': 'Bone biomarkers', 'description': 'Plasma collagen type X and N-Terminal Pro-C-Type Natriuretic Peptide (NT-ProCNP), by ELISA', 'timeFrame': '6 and 12 months'}, {'measure': 'Morbidity incidence', 'description': 'Incident diarrhea/dysentery or respiratory infection, based on weekly recalls', 'timeFrame': '6-12 months'}, {'measure': 'Body composition', 'description': 'Fat mass by bioelectrical impedence', 'timeFrame': '6, 9, 12, 15, and 18 months'}, {'measure': 'Antibiotic resistance', 'description': 'Resistance of commensal E. coli (stool) or S. pneumoniae (nasopharyngeal swab) to panel of antibiotics, by culture', 'timeFrame': '6, 9, 12, 15, and 18 months'}]",11,3 Months,6 Months,ALL,False,Johns Hopkins Bloomberg School of Public Health,OTHER,2,5283.0,ACTUAL,2025-09-01T16:18:19.662140,v2_robust,True,True,True,False,False,
NCT03684967,Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC,An Open-label Single Arm Multi-center Phase II Study to Assess Fruquintinib in High Risk Patients With Advanced Non-squamous Non-small Cell Lung Cancer,Fruquintinib,['Fruquintinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Cancer,['Lung Cancer'],[],WITHDRAWN,the study stopped because the company's strategy.,2018-05-08,2019-09-06,"[{'measure': 'Disease Control Rate (DCR)', 'description': 'Tumor assessment will be performed using radiography method at the first 4th week and 8th week after the first dose, or until the occurrence of progressive disease (PD), using RECIST v 1.1.', 'timeFrame': 'from the first dose until progressive disease or End of Therapy (EOT) due to any cause, whichever came first, assessed up to 8 weeks.'}, {'measure': 'Safety and tolerance evaluated by incidence, severity and outcomes of AEs', 'description': 'Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 4.03', 'timeFrame': 'from the first dose to 30 days post the last dose'}]","[{'measure': 'Objective response rate (ORR)', 'description': 'Tumor assessment will be performed using radiography method at the first 4th week and 8th week after the first dose, then every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1.', 'timeFrame': 'from the first dose until progressive disease or EOT due to any cause, whichever came first, assessed up to 1 year'}, {'measure': 'Duration of Response (DOR)', 'description': 'Tumor assessment will be performed using radiography method at the first 4th week and 8th week after the first dose, then every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1.', 'timeFrame': 'from the first dose until progressive disease or EOT due to any cause, whichever came first, assessed up to 1 year'}, {'measure': 'Progression free survival (PFS)', 'description': 'Tumor assessment will be performed using radiography method at the first 4th week and 8th week after the first dose, then every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1.', 'timeFrame': 'from the first dose until progressive disease or EOT due to any cause, whichever came first, assessed up to 1 year'}, {'measure': 'Overall survival (OS)', 'description': 'Every two months follow up after EOT observation period at 30 days after the last medication', 'timeFrame': 'from the first dose until death due to any cause, assessed up to 3 year'}, {'measure': 'Quality of Life (QoL)', 'description': 'The change of QoL will be assessed by the EORTC Quality of Life Questionnaire Core-30 (QLQ-C30) plus QLQ-Lung Cancer 13-item (LC13) ( LC13 is a supplementary module plus QLQ-C30 as one complete measure) every 4 weeks. A descriptive statistics analysis will be used to look at QoL over the time course.', 'timeFrame': 'from the first dose to 30 days post the last dose'}]",7,18 Years,,ALL,False,Hutchison Medipharma Limited,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:19.662259,v2_robust,True,True,False,True,True,the study stopped because the company's strategy.
NCT00470067,"Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer",A Multi-center Phase II Study of Doxil®/Carboplatin in Patients With Advanced or Recurrent Endometrial Carcinoma,carboplatin,"['carboplatin', 'pegylated liposomal doxorubicin hydrochloride']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Endometrial Cancer,['Endometrial Cancer'],"['recurrent endometrial carcinoma', 'stage III endometrial carcinoma', 'stage IV endometrial carcinoma']",TERMINATED,Due to low accrual,2007-02,2009-12,"[{'measure': 'Response (Complete and Partial)', 'description': 'Response Rate', 'timeFrame': 'Every 28 days'}]",[],1,18 Years,,FEMALE,False,Roswell Park Cancer Institute,OTHER,0,9.0,ACTUAL,2025-09-01T16:18:19.662284,v2_robust,True,True,False,True,False,Due to low accrual
NCT05287100,To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation.,To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation,Midodrine Oral Tablet,['Midodrine Oral Tablet'],1,INTERVENTIONAL,['NA'],,,"Cirrhosis, Liver","['Cirrhosis, Liver']",[],COMPLETED,,2022-01-01,2023-05-30,"[{'measure': 'Complications between the two groups', 'description': '• To compare incidence of complications (Acute kidney injury, New onset ascites or increase in grade of ascites, Spontaneous bacterial peritonitis, Hyponatremia, Hepatic encephalopathy) of cirrhosis in patients receiving midodrine (at a dose of 0.25 - 0.5mg/kg/day) and standard medical therapy versus standard medical therapy alone for 6 months', 'timeFrame': '6 months'}]","[{'measure': '• Frequency of development of new onset ascites or increase in grade of ascites by 6 months', 'timeFrame': '6 months'}, {'measure': 'Change in serum sodium from baseline to 6 months', 'timeFrame': '6 months'}, {'measure': 'Change in Mean arterial pressure (MAP) at 1 week and then 2 weekly till the end of the study', 'timeFrame': '6 months'}, {'measure': 'Plasma renin activity at baseline, at 12 weeks and 24 weeks', 'timeFrame': '6 months'}, {'measure': 'Frequency of development of SBP over 6 months', 'timeFrame': '6 months'}, {'measure': 'Change in eGFR from baseline to 6 months', 'timeFrame': '6 months'}, {'measure': 'Frequency of developing AKI by 6 months', 'timeFrame': '6 months'}, {'measure': 'Frequency of development of Hepatic encephalopathy by 6 months', 'timeFrame': '6 months'}, {'measure': 'Proportion of patients developing hypertension at 6 months', 'timeFrame': '6 months'}, {'measure': 'Frequency of development of drug related adverse effects by 6 months', 'timeFrame': '6 months'}, {'measure': 'Requirement of albumin infusion in 2 groups', 'timeFrame': '6 months'}, {'measure': 'Transplant free survival', 'timeFrame': '6 months'}]",13,10 Days,18 Years,ALL,False,"Institute of Liver and Biliary Sciences, India",OTHER,0,35.0,ACTUAL,2025-09-01T16:18:19.662368,v2_robust,True,True,True,False,True,
NCT00435500,Fluoride Varnish in the Prevention of Dental Caries in Aboriginal and Non-aboriginal Children,Fluoride Varnish in the Prevention of Dental Caries in Aboriginal and Non-aboriginal Children,Fluoride varnish,['Fluoride varnish'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Dental Caries,['Dental Caries'],"['Dental caries, topical fluorides']",UNKNOWN,,2003-06,2006-01,[{'measure': 'Reduction in the 2-year caries increment (dmfs/DMFS index); final follow-up at 24 months.'}],[{'measure': '(1) Need for dental treatment under general anaesthesia at 24 months; (2) score on an oral-health-related quality of life scale at 24 months; (3) the annualized cost of fluoride varnish treatment per child'}],2,6 Months,71 Months,ALL,True,University of Toronto,OTHER,2,1320.0,,2025-09-01T16:18:19.662435,v2_robust,True,True,False,False,False,
NCT01290900,"A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers","A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of a Single Dose of Intravenous Ceftazidime NXL104 (3000/2000 mg) or Ceftaroline Fosamil NXL104 (1500/2000 mg), Compared With Placebo, Using Open-label Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers",NXL104,"['Ceftaroline', 'Moxifloxacin', 'NXL104', 'Ceftazidime', 'Placebo Infusion']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Male Volunteers,['Healthy Male Volunteers'],"['NXL104', 'CAZ104', 'Ceftazidime', 'CXL104', 'Ceftaroline', 'Healthy Male Volunteers', 'Phase 1', 'OT', 'Single Dose Study']",COMPLETED,,2011-02,2011-05,"[{'measure': 'To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).', 'timeFrame': '12-lead dECG will be performed pre-dose'}, {'measure': 'To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).', 'timeFrame': '12-lead dECG at 30 min after starting dosing.'}, {'measure': 'To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).', 'timeFrame': '12-lead dECG at 60 min after starting dosing.'}, {'measure': 'To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).', 'timeFrame': '12-lead dECG at 90 min after starting dosing.'}, {'measure': 'To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).', 'timeFrame': '12-lead dECG at 2 hour after starting dosing.'}, {'measure': 'To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).', 'timeFrame': '12-lead dECG at 3 hour after starting dosing.'}, {'measure': 'To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).', 'timeFrame': '12-lead dECG at 4 hour after starting dosing.'}, {'measure': 'To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).', 'timeFrame': '12-lead dECG at 6 hour after starting dosing.'}, {'measure': 'To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).', 'timeFrame': '12-lead dECG at 8 hour after starting dosing.'}, {'measure': 'To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).', 'timeFrame': '12-lead dECG at 12 hour after starting dosing.'}, {'measure': 'To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).', 'timeFrame': '12-lead dECG at 24 hour after starting dosing.'}]","[{'measure': 'To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).', 'timeFrame': '12-lead dECG will be performed pre-dose'}, {'measure': 'To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).', 'timeFrame': '12-lead dECG at 30 min after starting dosing.'}, {'measure': 'To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).', 'timeFrame': '12-lead dECG at 60 min after starting dosing.'}, {'measure': 'To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).', 'timeFrame': '12-lead dECG at 90 min after starting dosing.'}, {'measure': 'To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).', 'timeFrame': '12-lead dECG at 2 hour after starting dosing.'}, {'measure': 'To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).', 'timeFrame': '12-lead dECG at 3 hour after starting dosing.'}, {'measure': 'To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).', 'timeFrame': '12-lead dECG at 4 hour after starting dosing.'}, {'measure': 'To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).', 'timeFrame': '12-lead dECG at 6 hour after starting dosing.'}, {'measure': 'To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).', 'timeFrame': '12-lead dECG at 8 hour after starting dosing.'}, {'measure': 'To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).', 'timeFrame': '12-lead dECG at 12 hour after starting dosing.'}, {'measure': 'To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).', 'timeFrame': '12-lead dECG at 24 hour after starting dosing.'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken pre-dose'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken at 30 min after starting dosing'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken at 60 min after starting dosing'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken at 75 min after starting dosing'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken at 90 min after starting dosing'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken at 2 hour after starting dosing'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken at 3 hour after starting dosing'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken at 4 hour after starting dosing'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken at 6 hour after starting dosing'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken at 8 hour after starting dosing'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken at 12 hour after starting dosing'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken at 18 hour after starting dosing'}, {'measure': 'To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.', 'timeFrame': 'Blood samples will be taken at 24 hour after starting dosing.'}]",35,18 Years,45 Years,MALE,True,Pfizer,INDUSTRY,0,54.0,ACTUAL,2025-09-01T16:18:19.662464,v2_robust,True,True,True,False,False,
NCT04130100,Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis,To Evaluate the Safety and Efficacy of Dental Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis Using Sodium Hyaluronate as a Parallel Control.,Sodium Hyaluronate,"['3', 'Sodium Hyaluronate']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Knee Osteoarthritis,['Knee Osteoarthritis'],[],UNKNOWN,,2019-04-04,2021-12-30,"[{'measure': ""Kellgren and Lawrence's rating"", 'description': 'X-ray imaging was used to evaluate the degree of improvement in knee joint structure', 'timeFrame': '12 month'}, {'measure': 'WOMAC score', 'description': 'WOMAC score decreased', 'timeFrame': '12 month'}]","[{'measure': 'Volume of femoral surface of knee joint on MRI', 'description': 'Changes of volume of lateral femoral condylar, medial femoral condylar, lateral tibial condylar, medial tibial condylar and posterior patellar articular surfaces on MRI', 'timeFrame': '12 month'}, {'measure': 'relaxation time of femoral surface of knee joint on MRI', 'description': 'Changes of relaxation time (T1 condylar, T2 condylar, T2\\*) of lateral femoral condylar, medial femoral condylar, lateral tibial condylar, medial tibial condylar and posterior patellar articular surfaces on MRI', 'timeFrame': '12 month'}]",4,40 Years,70 Years,ALL,False,"CAR-T (Shanghai) Biotechnology Co., Ltd.",INDUSTRY,0,60.0,ESTIMATED,2025-09-01T16:18:19.662539,v2_robust,True,True,False,False,False,
NCT06483100,Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance,Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance,Elrantamab,['Elrantamab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,['Multiple Myeloma'],"['Maintenance', 'Stem cell transplant', 'Immunotherapy']",RECRUITING,,2024-12-20,2031-12-31,"[{'measure': 'Progression-free survival (PFS)', 'description': 'Progression-free survival (PFS) is defined as time to progression or death.', 'timeFrame': 'Through completion of follow-up (up to 5 years)'}, {'measure': 'Proportion of patients achieving MRD negativity at the 10^-5 threshold per the clonoSEQ assay', 'timeFrame': 'Through completion of end of study visit (up to 36 months)'}]","[{'measure': 'Event-free survival (EFS)', 'description': 'Composite of progression, death, or treatment intolerance (discontinuation due to toxicity)', 'timeFrame': 'Through completion of follow-up (up to 5 years)'}, {'measure': 'Time to next therapy', 'description': 'Time to next therapy (TTNT) is defined as the time to initiation of subsequent anti-myeloma therapy (excluding standard-of-care maintenance).', 'timeFrame': 'Through completion of follow-up (up to 5 years)'}, {'measure': 'Maximum depth of response by IMWG criteria', 'timeFrame': 'Through completion of end of study visit (up to 36 months)'}, {'measure': 'Proportion of patients achieving sustained MRD-negativity at the 10^-5 threshold per the clonoSEQ assay for at least 12 months', 'description': 'MRD negativity per the clonoSEQ assay will be defined as less than 1 myeloma cell per 10\\^6 bone marrow cells evaluated (i.e. \\<10-6)', 'timeFrame': 'Through completion of end of study visit (up to 36 months)'}, {'measure': 'Proportion of patients discontinuing therapy per MRD-guided protocol', 'timeFrame': 'Through completion of treatment (up to 36 months)'}, {'measure': 'Time on treatment during study period', 'timeFrame': 'Through completion of treatment (up to 36 months)'}, {'measure': 'Incidence and severity of treatment-related adverse events by CTCAE v5', 'timeFrame': 'From start of treatment through 90 days after completion of treatment (up to 39 months)'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS) is defined as time to death.', 'timeFrame': 'Through completion of follow-up (up to 5 years)'}, {'measure': 'Proportion of patients resuming therapy per MRD-guided protocol', 'timeFrame': 'Through completion of treatment (up to 36 months)'}]",11,18 Years,,ALL,False,Washington University School of Medicine,OTHER,3,65.0,ESTIMATED,2025-09-01T16:18:19.662554,v2_robust,True,True,False,False,True,
NCT03380000,Effect of Beetroot Juice on Blood Pressure Regulation in Post Menopausal Women,Acute Blood Pressure-lowering Effects of Beetroot Juice in Postmenopausal Women With and Without Hypertension,Beetroot juice,"['Beet-It Organic placebo', 'Beet-It Organic Shot', 'Beetroot juice', 'Beetroot juice placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Postmenopausal Women,['Postmenopausal Women'],"['Dietary nitrate supplementation', 'Beetroot juice']",COMPLETED,,2014-09-12,2020-01,"[{'measure': 'Resting Aortic Blood Pressures', 'description': 'Aortic Blood pressures were measured in the arm (cuff) and estimated in the aorta (radial artery tonometry).', 'timeFrame': 'Resting systolic blood pressure at 90 minutes after beetroot juice ingestion'}]","[{'measure': 'Blood Measures of Nitrate Absorption and Conversion', 'description': 'Venous blood will be withdrawn (venipuncture) for determination of plasma nitrate and nitrite.', 'timeFrame': 'Change from baseline measures of plasma nitrate and nitrite at 90 minutes and at approximately 6 hours'}, {'measure': 'Resting Arterial Stiffness/Wave Properties', 'description': 'Carotid to femoral artery pulse wave velocity will be assessed using arterial tonometry.', 'timeFrame': 'Change from baseline resting pulse wave velocity at 90 minutes after beet root juice ingestion'}, {'measure': 'Handgrip Exercise Blood Pressure Responses (Relative Change From Baseline)', 'description': 'Beat-to-beat blood pressure (finger cuff) will be assessed at rest and during handgrip exercise to volitional fatigue.', 'timeFrame': 'Approximately 180 minutes after ingestion of beetroot juice'}, {'measure': 'Peak Rate of Perceived Exertion Scores During Handgrip Exercise', 'description': 'The Borg Rating of Perceived Exertion Scale (RPE) was used to assess exercise intensity during handgrip exercise. The RPE scale ranges from a minimum of 6 (no exertion at all) to a maximum of 20 (maximal exertion) units on a scale.', 'timeFrame': 'Approximately 90 minutes after ingestion of beetroot juice'}, {'measure': 'Handgrip Exercise Tolerance', 'description': 'Time to fatigue (seconds) was assessed during a progressive blood flow restricted handgrip exercise protocol.', 'timeFrame': 'Approximately 90 minutes after ingestion of beetroot juice'}]",6,55 Years,80 Years,FEMALE,True,Penn State University,OTHER,0,16.0,ACTUAL,2025-09-01T16:18:19.662596,v2_robust,True,True,True,False,False,
NCT05868200,Anti-Inflammatory Efficacy of Ginger Containing Dentifrice in the Control of Biofilm Induced Gingivitis,Anti-Inflammatory Efficacy of Ginger Containing Dentifrice in the Control of Biofilm Induced Gingivitis: a 3 Months Randomized Parallel Clinical Trial,Capitano zenzero toothpaste,"['Ginger toothpaste', 'Colgate total toothpaste', 'Capitano zenzero toothpaste']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Gingivitis,['Gingivitis'],[],COMPLETED,,2022-02-12,2022-06-21,"[{'measure': 'Change in Gingival index', 'description': 'Subjects will undergo the measurement of gingival index according to Loe \\& Silness, designed to assess the severity and quality of gingival inflammation in an individual or population. The gingival inflammation is assessed on the basis of color, consistency and bleeding on probing. The gingiva surrounding the tooth is assessed at four sites: mesio-facial papilla, facial marginal gingiva, disto-facial papilla and lingual marginal gingiva. Data will be collected based on four possible clinical conditions:\n\n0=Normal gingiva1=Mild Inflammation-Slight change in color, Slight odema. No bleeding on probing2=Moderate inflammation-redness,odema and glazing. Bleeding on probing 3=Sever inflammation-marked redness and edema.Ulceration.Tendency to spontaneous bleeding.', 'timeFrame': '0 ,3 months'}, {'measure': 'Mean relative changes in Interleukin 1 beta level in salivary Fluid.', 'description': 'Mean relative changes in Interleukin 1 beta level in salivary fluid after brushing with different comparators from baseline at 3 months.', 'timeFrame': '0 ,3 months'}, {'measure': 'Mean relative changes in superoxide dismutase SOD level in salivary Fluid.', 'description': 'Mean relative changes in superoxide dismutase SOD level in salivary fluid after brushing with different comparators from baseline at 3 months.', 'timeFrame': '0 ,3 months'}]","[{'measure': 'Changes in BOP score', 'description': 'For recording BOP score, the periodontal probe was inserted with gentle force into the sulcus/pocket until minimal resistance was felt. The probing force presumably was ranging between 20 to 25g. The examination started from the distal surface of the right upper 7 moving mesially to measure all the existing teeth. For each tooth, 6 surfaces were examined; the surface that displayed bleeding on probing was scored 1 and the surface with no bleeding was scored 0', 'timeFrame': '0 ,3 months'}, {'measure': 'Mean amount plaque between different comparators.', 'description': 'Mean amount plaque between different comparators as anti-plaque agent after brushing with different comparators using means of modified quigely hein plaque index\\[ Turesky ,1970\\]', 'timeFrame': '0 ,3 months'}]",5,20 Years,35 Years,ALL,True,University of Baghdad,OTHER,0,80.0,ACTUAL,2025-09-01T16:18:19.662618,v2_robust,True,True,True,False,False,
NCT01671800,Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating,"Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis Associated Symptomatic Sweating, or Residual Limb Hyperhidrosis in Amputees",Botulinum Type B,"['Myobloc', 'Botulinum Type B', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Hyperhidrosis,['Hyperhidrosis'],"['Hyperhidrosis', 'Botulinum Toxin', 'Amputation', 'Phantom limb pain']",COMPLETED,,2008-09,2012-12,"[{'measure': 'Amount of sweating', 'description': 'The amount of sweating will be assessed via gravimetry, which is an accepted method for determining sweating in a particular area. This method involves covering the area of the residual limb in question with filter paper for five minutes. After five minutes, the filter paper is removed and weighed. The weight of the dry filter paper is subtracted to give the approximate weight of the sweat produced. This study will use the total weight of sweat produced as a method of objectively quantifying the amount of sweating in the residual limb. Gravimetry will be used as a measure of change from pre-treatment to post-treatment.', 'timeFrame': 'one month after initial injection'}]",[],1,18 Years,50 Years,ALL,True,Henry M. Jackson Foundation for the Advancement of Military Medicine,OTHER,1,20.0,ACTUAL,2025-09-01T16:18:19.662775,v2_robust,True,True,True,False,False,
NCT03602300,A Phase 1 Bioequivalence Study of a Test Tablet Formulation of Ravidasvir With the Reference Tablet Formulation of Ravidasvir Study,"A Phase 1, Open-Label, Four-Period, Two-Sequence, Two-Treatment, Single Dose, Randomized, Crossover Bioequivalence Study of a Test Tablet Formulation of Ravidasvir With the Reference Tablet Formulation of Ravidasvir in Healthy Adult Volunteers Under Fasting Conditions",Ravidasvir test formulation produced by Doppel,"['Ravidasvir reference formulation produced by EEPI', 'Ravidasvir test formulation produced by Doppel']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Bioequivalence Study,['Bioequivalence Study'],[],COMPLETED,,2018-06-05,2018-08-17,"[{'measure': 'RDV Plasma CMax when administered as a single 200 mg oral dose of the test versus reference product', 'description': 'Plasma RDV Cmax will be calculated based on plasma RDV concentrations at pre-dose (time 0 hours) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, and 48 hours post-dose', 'timeFrame': 'Measurement within 48 hours post-dose'}, {'measure': 'RDV area under the plasma concentration-time curve from time of intake until infinity (AUC0-∞) when administered as a single 200 mg oral dose of the test versus reference product', 'description': 'Area under the plasma concentration-time curve from time of intake until infinity (AUC0-∞) will be calculated based on plasma RDV concentrations at pre-dose (time 0 hours) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, and 48 hours post-dose.', 'timeFrame': 'Measurement within 48 hours post-dose'}, {'measure': 'RDV area under the plasma concentration-time curve from time of intake until the last quantifiable concentration (AUC0-t) when administered as a single 200 mg oral dose of the test versus reference product', 'description': 'Area under the plasma concentration-time curve from time of intake until the last quantifiable concentration (AUC0-t) will be calculated based on plasma RDV concentrations at pre-dose (time 0 hours) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, and 48 hours post-dose.', 'timeFrame': 'Measurement within 48 hours post-dose'}]","[{'measure': 'RDV maximum plasma concentration (tmax) when administered as a single 200 mg oral dose of the test versus reference product', 'description': 'RDV maximum plasma concentration (tmax) will be calculated based on plasma RDV concentrations at pre-dose (time 0 hours) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, and 48 hours post-dose.', 'timeFrame': 'Measurement within 48 hours post-dose'}, {'measure': 'RDV mean residence time (MRT) when administered as a single 200 mg oral dose of the test versus reference product', 'description': 'RDV mean residence time (MRT) will be calculated based on plasma RDV concentrations at pre-dose (time 0 hours) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, and 48 hours post-dose.', 'timeFrame': 'Measurement within 48 hours post-dose'}, {'measure': 'RDV elimination rate constant (λz) when administered as a single 200 mg oral dose of the test versus reference product', 'description': 'RDV elimination rate constant (λz) will be calculated based on plasma RDV concentrations at pre-dose (time 0 hours) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, and 48 hours post-dose.', 'timeFrame': 'Measurement within 48 hours post-dose'}, {'measure': 'RDV elimination half-life (t1/2, estimated based on λz), when administered as a single 200 mg oral dose of the test versus reference product', 'description': 'RDV elimination half-life (t1/2, estimated based on λz) will be calculated based on plasma RDV concentrations at pre-dose (time 0 hours) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, and 48 hours post-dose.', 'timeFrame': 'Measurement within 48 hours post-dose'}, {'measure': 'RDV apparent volume of distribution when administered as a single 200 mg oral dose of the test versus reference product', 'description': 'RDV apparent volume of distribution will be calculated based on plasma RDV concentrations at pre-dose (time 0 hours) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, and 48 hours post-dose.', 'timeFrame': 'Measurement within 48 hours post-dose'}, {'measure': 'RDV terminal phase (Vz/F) when administered as a single 200 mg oral dose of the test versus reference product', 'description': 'RDV terminal phase (Vz/F) will be calculated based on plasma RDV concentrations at pre-dose (time 0 hours) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, and 48 hours post-dose.', 'timeFrame': 'Measurement within 48 hours post-dose'}, {'measure': 'RDV apparent clearance (CL/F) when administered as a single 200 mg oral dose of the test versus reference product', 'description': 'RDV apparent clearance (CL/F) will be calculated based on plasma RDV concentrations at pre-dose (time 0 hours) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, and 48 hours post-dose.', 'timeFrame': 'Measurement within 48 hours post-dose'}, {'measure': 'RDV safety (Incidence of treatment-related adverse events as assessed by CTCAE v4.03) when administered as a single 200 mg oral dose of the test versus reference product', 'description': 'Safety will be assessed by monitoring clinical adverse events (AEs) incidence', 'timeFrame': 'From 1st patient consent until last patient completes the post-study safety assessment over a total period of 60 days'}, {'measure': 'RDV tolerability (Incidence of treatment-related adverse events as assessed by CTCAE v4.03) when administered as a single 200 mg oral dose of the test versus reference product', 'description': 'Tolerability will be assessed by monitoring clinical adverse events (AEs) incidence', 'timeFrame': 'From 1st patient consent until last patient completes the post-study safety assessment over a total period of 60 days'}]",12,18 Years,55 Years,ALL,True,Drugs for Neglected Diseases,OTHER,0,37.0,ACTUAL,2025-09-01T16:18:19.662809,v2_robust,True,True,True,False,True,
NCT01432600,Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide,Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma,Pomalidomide,"['Decadron®', 'Pomalidomide', 'CC-4047, POMALYST®', 'Cyclophosphamide', 'Dexamethasone', 'Cytoxan']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Myeloma,['Myeloma'],"['Multiple Myeloma', 'Relapsed', 'Refractory', 'Corticosteroids']",COMPLETED,,2011-11,2016-08,"[{'measure': 'Phase I - Maximum Tolerated Dose (MTD)', 'description': 'The maximum tolerated dose of oral weekly cyclophosphamide in milligrams (mg), in combination with pomalidomide and dexamethasone. Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows: Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg. The period for assessment of Dose Limiting Toxicity (DLT) is the first cycle (28 days). The following toxicities will be considered dose limiting if encountered only in the phase I portion of the study: Febrile neutropenia; Grade 3 or 4 non-hematologic toxicity related to treatment with pomalidomide or cyclophosphamide; Participants must have received optimal symptomatic treatment for Grade 3 or 4 nausea, vomiting, or diarrhea to be considered a DLT; Grade 4 transaminitis; Grade 3 transaminitis must be present for ≥ 7 days to be considered a DLT; Grade 4 thrombocytopenia for 7 or more days; Grade 4 neutropenia for 7 or more days.', 'timeFrame': '28 Days'}, {'measure': 'Phase II - Overall Response Rate (ORR)', 'description': 'Overall response, Minimal Remission (MR) or better per treatment arm, using the uniform response criteria by the International Myeloma Working Group (IMWG) of pomalidomide in combination with high dose dexamethasone with or without cyclophosphamide in participants with relapsed and refractory myeloma. In addition, Minimal response was incorporated in those response criteria as this is a valid endpoint in patients with relapsed or refractory myeloma. MR: 25-49% reduction in serum paraprotein and a 50-89% reduction in urine light chain excretion; A 25-49% reduction in the size of soft tissue plasmacytoma must be demonstrated is applicable.', 'timeFrame': '36 Months'}]","[{'measure': 'Phase II - Median Progression Free Survival (PFS)', 'description': 'Progression free survival per treatment arm. Progressive Disease (PD) requires one of the following, increase of greater than or equal to 25% from baseline in: Serum M-component; Urine M-component; The difference between involved and uninvolved sFLC levels; The size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia.', 'timeFrame': '36 Months'}, {'measure': 'Phase II - Median Overall Survival (OS)', 'description': 'Overall survival per treatment arm. Overall survival is defined as the time from start of treatment to death of any cause.', 'timeFrame': '36 Months'}, {'measure': 'Phase II - Occurrence of Possibly Related Adverse Events (AEs)', 'description': 'Phase II: Participants with Grade 3 or 4 adverse events at least possibly related to the study treatment in 5% of participants in the Phase 2 portion, by AE category, assessed by the National Cancer Institute Common Terminology Criteria (NCI CTC) version 4.0.', 'timeFrame': 'Up to 48 Months'}]",5,18 Years,,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,80.0,ACTUAL,2025-09-01T16:18:19.662867,v2_robust,True,True,True,False,True,
NCT00833300,Haloperidol vs Olanzapine for the Management of ICU Delirium,Haloperidol vs Olanzapine for the Management of ICU Delirium: A Randomized Clinical Trial,Haloperidol,"['PMS-Olanzapine', 'Haldol', 'Haloperidol', 'Olanzapine', 'Novo-Olanzapine', 'Zyprexa Zydis', 'Zyprexa']",7,INTERVENTIONAL,['NA'],,,Delirium,"['Delirium', 'Agitation']","['Delirium', 'Agitation', 'Intensive Care', 'Critical Care', 'Antipsychotics', 'Olanzapine', 'Haloperidol']",TERMINATED,,2008-06,2011-11,"[{'measure': 'Resolution of delirium as indicated by an Intensive Care Delirium Screening Checklist score of less than 4', 'timeFrame': 'Every 24 hours'}]","[{'measure': 'Delirium free days (i.e. time from resolution of delirium to ICU discharge)', 'timeFrame': 'Every 24 hours'}, {'measure': 'Incidence of treatment failure at 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Requirement for rescue medication', 'timeFrame': 'Every 24 hours'}, {'measure': 'Type of rescue medication', 'timeFrame': 'Every 24 hours'}, {'measure': 'Mortality', 'timeFrame': 'Time of death'}, {'measure': 'If on mechanical ventilation at time delirium develops, duration of mechanical ventilation', 'timeFrame': 'Every 24 hours'}]",7,18 Years,,ALL,False,Richard Hall,OTHER,1,200.0,ESTIMATED,2025-09-01T16:18:19.662918,v2_robust,True,True,False,True,False,
NCT04563000,Impact of Vitamin C on Biomarkers of Neurologic Injury in Survivors of Cardiac Arrest,Impact of Vitamin C on Biomarkers of Neurologic Injury in Patients With Return of Spontaneous Circulation After Out-of-Hospital Cardiac Arrest,Vitamin C,"['Vitamin C', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Heart Arrest, Out-Of-Hospital","['Heart Arrest, Out-Of-Hospital', 'Biomarkers', 'Oxidative Stress', 'Neurological Injury']","['vitamin C', 'biomarkers', 'brain injury', 'cardiac arrest']",UNKNOWN,,2020-10-01,2022-12-31,"[{'measure': 'Biomarkers of neurological injury', 'description': 'Serum levels of protein S-100b and neuron-specific enolase.', 'timeFrame': '5th day'}]","[{'measure': 'Brain imaging (CT and MRI)', 'description': 'Unconscious survivors will have first brain imaging on the 3rd day, if still unconscious, second imaging around the 10th day. Imaging results will be descriptive (normal or pathological with signs of global ischemic injury: generalised edema, reduced grey and white matter differentiation, obliteration of the sulci). Second image will be compared to the first.', 'timeFrame': '3rd-10th day'}, {'measure': 'Electroencephalography (EEG)', 'description': 'Unconscious survivors will have first EEG on the 3rd day, if still unconscious, second imaging around the 10th day. EEG results will be descriptive (normal or pathological with background suppression with or without periods of bursts, with or without response to external stimulus and similar patterns). Second EEG will be compared to the first.', 'timeFrame': '3rd-10th day'}, {'measure': 'Evaluation of pupils', 'description': 'Pupils size, reactivity and symmetry on admission and during hospitalisation will be observed daily.', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Evaluation of involuntary movements', 'description': 'The presence of involuntary movements will be observed daily.', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Evaluation of GCS', 'description': 'Level of consciousness will be determined daily with Glasgow Coma Scale (GCS).', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Evaluation of FOUR', 'description': 'Level of consciousness will be determined daily with Full Outline of UnResponsiveness (FOUR) score.', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Cerebral Performance Category', 'description': 'Cerebral Performance Category (CPC) at discharge will be recorded.', 'timeFrame': 'from admission till discharge from ICU or death (whatever comes first)'}, {'measure': 'Left ventricular ejection fraction', 'description': 'Left ventricular ejection fraction (first, last, best, worst), determined by ultrasound will be noted.', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Arrhythmias', 'description': 'Presence of arrhythmias and the need for treating them will be recorded.', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Evaluation of heart failure', 'description': 'Clinical evaluation of heart failure according to Killip-Kimball classification will be performed (worst result).', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Serum troponin level', 'description': 'Serum troponin levels will be determined (on admission, minimal, maximal).', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Serum Brain natriuretic peptide', 'description': 'Serum brain natriuretic peptide levels will be determined (on admission, minimal, maximal).', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Vasopressor and/or inotrope need', 'description': 'The need for vasopressors and inotropes will be noted, along with the name of the substance, maximal dosage and duration.', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Mechanical ventilation', 'description': 'Days and hours of mechanical ventilation will be noted.', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Kidney failure', 'description': 'The need for renal replacement therapy (and consecutive day of such therapy) will be recorded.', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Serum urea levels', 'description': 'Serum levels of urea will be recorded (on admission, minimal, maximal).', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Serum creatinine levels', 'description': 'Serum creatinine levels will be recorded (on admission, minimal, maximal).', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Serum C-reactive protein levels', 'description': 'Serum C-reactive protein levels will be determined (on admission, minimal, maximal).', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}, {'measure': 'Serum procalcitonin levels', 'description': 'Serum procalcitonin levels will be determined (on admission, minimal, maximal).', 'timeFrame': 'from admission until 14 days or till discharge from ICU or death (whatever comes first)'}]",20,18 Years,,ALL,False,University Medical Centre Maribor,OTHER,0,150.0,ESTIMATED,2025-09-01T16:18:19.662983,v2_robust,True,True,False,False,False,
NCT00088400,Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors,"A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme",TransMID,['TransMID'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Glioblastoma,['Glioblastoma'],"['Transferrin', 'Brain Tumor', 'Convection', 'Immunotherapy', 'Targeted Protein Toxin', 'Glioblastoma Multiforme', 'GBM']",COMPLETED,,2004-07,2005-11,[],[],0,,,ALL,False,National Institute of Neurological Disorders and Stroke (NINDS),NIH,0,30.0,,2025-09-01T16:18:19.663054,v2_robust,True,True,True,False,False,
NCT06966700,"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer",Rescue Medication,"['Olaparib', 'Paclitaxel', 'ADRIAMYCIN®', 'Carboplatin', 'Onxol', 'Capecitabine', 'Doxorubicin', 'Rescue Medication', 'Cytophosphane', 'Ellence®', 'Paraplatin', 'Cyclophosphamide', 'Taxol', 'Epirubicin', 'LYNPARZA®', 'Xeloda®']",16,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Neoplasms,"['Breast Neoplasms', 'Triple Negative Breast Neoplasms', 'HR Low-Positive/HER2-Negative Breast Neoplasms']","['Programmed Cell Death-1 (PD1, PD-1)', 'Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)', 'Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)']",RECRUITING,,2025-06-30,2035-02-04,"[{'measure': 'Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive Surgery', 'description': 'pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy per current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.', 'timeFrame': 'Up to approximately 30 weeks'}, {'measure': 'Event-Free Survival (EFS)', 'description': 'EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to approximately 92 months'}]","[{'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from randomization to death due to any cause.', 'timeFrame': 'Up to approximately 115 months'}, {'measure': 'Percentage of Participants with pCR with No Ductal Carcinoma in Situ (pCR-no DCIS) at the Time of Definitive Surgery', 'description': 'pCR-no ductal carcinoma in situ (DCIS) (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy per current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.', 'timeFrame': 'Up to approximately 30 weeks'}, {'measure': 'Percentage of Participants with pCR at the Time of Definitive Surgery (High-risk, early-stage, TNBC subset)', 'description': 'pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy per current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery. The pCR will be presented for the subset of participants who enrolled with high-risk, early-stage, TNBC.', 'timeFrame': 'Up to approximately 30 weeks'}, {'measure': 'Event-Free Survival (EFS) (High-risk, early-stage, TNBC subset)', 'description': 'EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first. The EFS will be presented for the subset of participants who enrolled with high-risk, early-stage, TNBC.', 'timeFrame': 'Up to approximately 92 months'}, {'measure': 'Overall Survival (OS) (High-risk, early-stage, TNBC subset)', 'description': 'OS is defined as the time from randomization to death due to any cause.', 'timeFrame': 'Up to approximately 115 months'}, {'measure': 'Distant Progression or Distant Recurrence-Free Survival (DPDRFS)', 'description': 'DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed by investigator, or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to approximately 92 months'}, {'measure': 'Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status-Quality of Life Score', 'description': 'The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to Item 30 (""""How would you rate your overall quality of life during the past week?"") is scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function. The change from baseline in EORTC QLQ-C30 Item 30 score will be reported.', 'timeFrame': 'Baseline and up to approximately 3 years'}, {'measure': 'Change from Baseline in EORTC QLQ-C30 Physical Functioning Score', 'description': 'The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning.', 'timeFrame': 'Baseline and up to approximately 3 years'}, {'measure': 'Change from Baseline in EORTC QLQ-C30 Role Functioning Score', 'description': 'The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning.', 'timeFrame': 'Baseline and up to approximately 3 years'}, {'measure': 'Change from Baseline in EORTC QLQ-C30 Fatigue Score', 'description': 'The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their fatigue are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function.', 'timeFrame': 'Baseline and up to approximately 3 years'}, {'measure': 'Change from Baseline in EORTC QLQ Breast Cancer 42 (BR42) Systemic Therapy Side Effects Score', 'description': 'The EORTC QLQ-BR42 is a 42-item questionnaire to assess the overall quality of life of breast cancer patients. Participant responses to questions about their systemic therapy side effects are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a lower level of side effects.', 'timeFrame': 'Baseline and up to approximately 3 years'}, {'measure': 'Number of Participants Who Experience One or More Adverse Events (AEs)', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.', 'timeFrame': 'Up to approximately 67 weeks'}, {'measure': 'Number of Participants Who Discontinue Study Treatment Due to an AE', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.', 'timeFrame': 'Up to approximately 54 weeks'}]",15,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,2400.0,ESTIMATED,2025-09-01T16:18:19.663091,v2_robust,True,True,False,False,True,
NCT01340300,Exercise and Metformin in Colorectal and Breast Cancer Survivors,Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors,Metformin,"['Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet', 'Metformin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Colorectal Cancer,"['Colorectal Cancer', 'Breast Cancer']","['Colorectal', 'Breast', 'Insulin', 'Exercise']",COMPLETED,,2011-05,2017-12,"[{'measure': 'Change in Fasting Insulin Level', 'description': 'Determine whether supervised exercise training alone and metformin, either alone or in combination can decrease fasting insulin level from baseline to 3 months in patients who completed standard therapy for stage I-III colorectal or breast cancer. Fasting insulin levels in blood will be drawn at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.', 'timeFrame': '0 and 3 months (change between 0 and 3 months)'}]","[{'measure': 'Changes in Other Insulin-Related Biomarkers', 'description': 'Markers related to insulin and insulin-like growth factors (including insulin-like growth factor 1 \\[IGF-1\\], IGF binding protein-1 \\[IGFBP-1\\], IGF binding protein-3 \\[IGFBP-3\\], leptin) will be measured by a blood draw at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.', 'timeFrame': '0 and 3 months (change between 0 and 3 months)'}, {'measure': 'Change in Fasting Glucose Level', 'description': 'Determine whether supervised exercise training alone and metformin, either alone or in combination can decrease fasting Glucose level from baseline to 3 months in patients who completed standard therapy for stage I-III colorectal or breast cancer. Fasting Glucose levels in blood will be drawn at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.', 'timeFrame': '0 and 3 months (change between 0 and 3 months)'}]",3,18 Years,,ALL,False,Dana-Farber Cancer Institute,OTHER,0,139.0,ACTUAL,2025-09-01T16:18:19.663149,v2_robust,True,True,True,False,False,
NCT01427907,Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients,"Randomized,Multi-center,Phase IV, 2-arm,Open-Label,Cross-over Study to Demonstrate the Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients",Calcium acetate oral solution (COS),"['Phoslyra', 'Sevelamer carbonate', 'Calcium acetate oral solution (COS)', 'Renvela']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Kidney Disease,['Chronic Kidney Disease'],['Serum phosphorus levels'],COMPLETED,,2011-09,2012-07,"[{'measure': 'Serum Phosphorus Levels', 'description': 'The average phosphorus level of non-missing laboratory assessments from the last two weeks of each treatment period for each subject', 'timeFrame': '2 weeks'}]",[],1,18 Years,,ALL,False,Fresenius Medical Care North America,INDUSTRY,0,38.0,ACTUAL,2025-09-01T16:18:19.663208,v2_robust,True,True,True,False,False,
NCT01145807,TDT 067 Onychomycosis Study,"A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients With Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of TDT 067 for 48 Weeks",TDT067,"['Transfersome', 'TDT067', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Onychomycosis,['Onychomycosis'],['Distal Subungual Toenail Onychomycosis'],UNKNOWN,,2010-04,2012-08,"[{'measure': 'Cure Rate', 'description': 'To compare complete cure rates for onychomycosis at Week 52 for TDT 067 versus non-Transfersome placebo.\n\nIf the comparison between TDT 067 and non-Transfersome placebo is statistically significant in favor of TDT 067, the following additional primary efficacy objective:\n\nTo compare onychomycosis cure rates at Week 52 for TDT 067 versus Transfersome vehicle', 'timeFrame': '52 Weeks'}]","[{'measure': 'Cure Rate 48', 'description': 'Compare onychomycosis complete cure rates at Wk 48 for TDT 067 versus non Transfersome® placebo and Transfersome® vehicle\n\nCompare effective treatment rates at Wk 48 for TDT 067 versus non Transfersome® placebo and Transfersome® vehicle\n\nCompare mycological cure rates at Wk 48 for TDT 067 versus non Transfersome® placebo and Transfersome® vehicle\n\nCompare complete cure rates at Wk 48 effective treatment rates at Wks 48, and mycological cure rates at Wks 48 for Transfersome® vehicle versus non Transfersome® placebo', 'timeFrame': '48 Weeks'}, {'measure': 'Cure Rate 52', 'description': 'Compare onychomycosis complete cure rates at Wk 52 for TDT 067 versus non Transfersome® placebo and Transfersome® vehicle\n\nCompare effective treatment rates at Wk 52 for TDT 067 versus non Transfersome® placebo and Transfersome® vehicle\n\nCompare mycological cure rates at Wk 52 for TDT 067 versus non Transfersome® placebo and Transfersome® vehicle\n\nCompare complete cure rates at Wk 52 effective treatment rates at Wk 52 and mycological cure rates at Wk 52 for Transfersome® vehicle versus non Transfersome® placebo', 'timeFrame': '52 Weeks'}, {'measure': 'Cure Rate 60', 'description': 'Compare onychomycosis complete cure rates at Wk 60 for TDT 067 versus non Transfersome® placebo and Transfersome® vehicle\n\nCompare effective treatment rates at Wk 60 for TDT 067 versus non Transfersome® placebo and Transfersome® vehicle\n\nCompare mycological cure rates at Wk 60 for TDT 067 versus non Transfersome® placebo and Transfersome® vehicle\n\nCompare complete cure rates at Wk 60, effective treatment rates at Wk 60, and mycological cure rates at Wk 60 for Transfersome® vehicle versus non Transfersome® placebo', 'timeFrame': '60 Weeks'}]",4,18 Years,75 Years,ALL,False,Celtic Pharma Development Services,INDUSTRY,1,738.0,ESTIMATED,2025-09-01T16:18:19.663218,v2_robust,True,True,False,False,False,
NCT05543707,PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19,"A Phase 2 Double-blind, Randomized Study to Evaluate the Antiviral Activity, Safety, and Efficacy of Orally Administered PBI-0451(Pomotrelvir) Compared With Placebo in Nonhospitalized Symptomatic Adults With COVID-19",PBI-0451 (Pomotrelvir),"['Active', 'PBI-0451 (Pomotrelvir)', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,COVID-19,['COVID-19'],"['COVID', 'SARS-CoV-2', 'Coronavirus']",TERMINATED,Interim analysis concluded primary endpoint was not met,2022-09-21,2023-04-14,"[{'measure': 'Virologic Efficacy of PBI-0451 (Pomotrelvir)', 'description': 'The primary efficacy endpoint was the proportion of participants below LOD for infectious SARS-CoV-2 on Day 3 by IVA from MT nasal swabs for the mITTV analysis set.', 'timeFrame': 'Day 3'}]","[{'measure': 'Safety and Tolerability of PBI-0451(Pomotrelvir)', 'description': 'Number of treatment-emergent adverse events (AEs), serious adverse events (SAEs), discontinuations due to AEs, and Grade 3 or 4 laboratory abnormalities', 'timeFrame': 'Day 1-28'}, {'measure': 'Clinical Efficacy of PBI-0451(Pomotrelvir) Versus Placebo Through Study Day 28', 'description': 'Number of Pomotrelvir treated participants with sustained symptom resolution through Day 28 versus untreated Placebo participants', 'timeFrame': 'Day 1 - 28'}, {'measure': 'Effect of PBI-0451(Pomotrelvir) on SARS-CoV-2', 'description': 'Presence of SARS-CoV-2 virus, viral RNA or viral antigen based on IVA, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), and rapid antigen test (RAT), as specified in the Clinical Virology Analysis Plan (CVAP)', 'timeFrame': 'Day 1-28'}, {'measure': 'Clinical Efficacy of PBI-0451(Pomotrelvir) Versus Placebo Through Study Day 1-28', 'description': 'The median number of days to sustained resolution of of all 14 COVID-19 symptoms for the PBI-0451 vs Placebo groups through Day 28.', 'timeFrame': 'Day 1-28'}]",5,18 Years,64 Years,ALL,False,"Pardes Biosciences, Inc.",INDUSTRY,0,242.0,ACTUAL,2025-09-01T16:18:19.663391,v2_robust,True,True,False,True,True,Interim analysis concluded primary endpoint was not met
NCT06293807,Immediate Post-Operative Anesthesia With Either Lidocaine or Bupivacaine,Immediate Post-Operative Anesthesia With Either Lidocaine or Bupivacaine: A Short-term Clinical Response,"Xylocaine 2 % with 1:100,000 epinephrine","['Xylocaine 2 % with 1:100,000 epinephrine', 'Marcaine', 'Lidocaine', 'Bupivicaine 0.5% with 1:200,000 epinephrine']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Periodontal Diseases,['Periodontal Diseases'],"['Flap debridement', 'Flap osseous', 'Tooth extractions', 'Guided Tissue Regeneration', 'IV sedation', 'Local anesthesia']",COMPLETED,,2022-06-06,2023-04-16,"[{'measure': 'Change in pain using Visual Analog Scale (VAS)', 'description': 'Pain response recorded using a 20 point visual Analog Scale. The VAS scale is a straight line scale scored from 0-20 with 0 indicating the least amount of pain and 20 the worst pain ever experienced.', 'timeFrame': 'Baseline to 48 hours'}, {'measure': 'Number of Ibuprofen administered', 'description': 'Additive number of ibuprofen taken over monitoring period', 'timeFrame': 'Baseline to 48 hours'}, {'measure': 'Number of Tylenol administered', 'description': 'Additive number of acetaminophen taken over monitoring period', 'timeFrame': 'Baseline to 48 hours'}]","[{'measure': 'Arch Response', 'description': 'Difference in pain response based upon arch', 'timeFrame': 'Baseline to 48 hours'}, {'measure': 'Number of teeth', 'description': 'Difference in pain response based upon number of teeth per surgical site', 'timeFrame': 'Baseline to 48 hours'}, {'measure': 'Type of procedure', 'description': 'Difference in pain response based upon type of procedure', 'timeFrame': 'Baseline to 48 hours'}, {'measure': 'Gender of patient', 'description': 'Difference in pain response based upon gender of participant', 'timeFrame': 'Baseline to 48 hours'}, {'measure': 'Age of patient', 'description': 'Difference in pain response based upon age of participant', 'timeFrame': 'Baseline to 48 hours'}]",8,18 Years,,ALL,True,The University of Texas Health Science Center at San Antonio,OTHER,0,72.0,ACTUAL,2025-09-01T16:18:19.663489,v2_robust,True,True,True,False,False,
NCT06371807,Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab,"Immunogenicity Profile of Neoadjuvant Keytruda in Combination With Anthracycline Versus Carboplatin/PAclitaxel Containing Chemotherapy Regimen for The Treatment of Early-stage, TILs-Positive, Triple-Negative Breast CanceR",Pembrolizumab injection,"['Paclitaxel', 'Pembrolizumab injection', 'Carboplatin', 'Cyclophosphamide', 'Doxorubicin or Epirubicin']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Early Breast Cancer,"['Early Breast Cancer', 'Triple Negative Breast Cancer']",[],NOT_YET_RECRUITING,,2024-07,2026-12,"[{'measure': 'Detect immunologic activation signal and the immunologically defined most suitable patient population for the synergistic interaction between pembrolizumab and chemotherapy backbone', 'description': 'Compare signals of immunological activation or a more favorable immunological context beetween T cell subpopulations and transcriptional changes of T cell populations infiltrating tumors at baseline and C2D1', 'timeFrame': 'At the end of cycle 1 (each cycle is 28 days)'}, {'measure': 'Rate of pCR', 'description': 'Compare the rate of pCR in subjects with locally advanced TNBC with TILs ≥ 10% in arm A and arm B at cycle 4', 'timeFrame': '6 months to one year after subject inclusion'}, {'measure': 'Primary translational endpoint', 'description': 'Quantification of number of T cells per mm2 with different phenotypes using fate bifurcation as defined as the proportion of TILs with the phenotype T-bet(hi) PD1(mid) CD8+.', 'timeFrame': '6 months to one year after subject inclusion'}]","[{'measure': 'Changes in the immunogenic phenotype', 'description': 'Determine changes in the immunogenic phenotype by longitudinally evaluating RNA-based gene expression signatures (e.g., tumor inflammation signature expression of granzyme A \\[GZMA\\] and perforin 1 at baseline and at C2D1.', 'timeFrame': '6 months to one year after subject inclusion'}, {'measure': 'Incidence of treatment relatred Adverse events', 'description': 'Describe the safety and tolerability of the combinations of pembrolizumab plus chemotherapy (either EC/AC or paclitaxel + carboplatin) in the Neoadjuvant and Adjuvant setting throught the CTCAE version 5.0 adverse event evaluation', 'timeFrame': '6 months to one year after subject inclusion'}]",5,18 Years,100 Years,ALL,False,Fundacao Champalimaud,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:19.663558,v2_robust,True,True,False,False,True,
NCT04966507,Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention,A Randomized Crossover Study to Evaluate the Efficacy of Antibacterial Mouthwash in Preventing Pharyngeal Gonorrhea Among a High Risk Population,Listerine Antiseptic Mouthwash Product,"['Biotene Mouthwash', 'Active Mouthwash', 'Placebo Mouthwash', 'Listerine Antiseptic Mouthwash Product']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Gonorrhea,['Gonorrhea'],[],ACTIVE_NOT_RECRUITING,,2022-02-17,2025-12,"[{'measure': 'Adherence and acceptability of mouthwash use', 'description': 'This outcome will be assessed using self-reported questionnaire data and will include mouthwash use in terms of number of days used, amount of mouthwash used, number of times per day, duration of gargling/rinsing; reasons for not using mouthwash, and overall experience.', 'timeFrame': 'This outcome will be measured at 12-weeks post intervention.'}, {'measure': 'Adherence and acceptability of mouthwash use', 'description': 'This outcome will be assessed using self-reported questionnaire data and will include mouthwash use in terms of number of days used, amount of mouthwash used, number of times per day, duration of gargling/rinsing; reasons for not using mouthwash, and overall experience.', 'timeFrame': 'This outcome will be measured at 24-weeks post intervention.'}, {'measure': 'Laboratory identified pharyngeal gonorrhea', 'description': 'Pharyngeal swabs will be collected for gonorrhea testing using Nucleic acid amplification testing (NAAT) with Aptima Combo 2 (GenProbe, San Diego, CA). Additionally, all participants will be asked to provide consent to access medical records in order to verify any pharyngeal gonorrhea diagnoses made during the study period but resulting from testing conducted outside of the study.', 'timeFrame': 'This outcome will be measured at 12-weeks post intervention.'}, {'measure': 'Laboratory identified pharyngeal gonorrhea', 'description': 'Pharyngeal swabs will be collected for gonorrhea testing using Nucleic acid amplification testing (NAAT) with Aptima Combo 2 (GenProbe, San Diego, CA). Additionally, all participants will be asked to provide consent to access medical records in order to verify any pharyngeal gonorrhea diagnoses made during the study period but resulting from testing conducted outside of the study.', 'timeFrame': 'This outcome will be measured at 24-weeks post intervention.'}]",[],4,18 Years,45 Years,MALE,False,"University of California, Los Angeles",OTHER,1,100.0,ESTIMATED,2025-09-01T16:18:19.663624,v2_robust,True,True,False,False,False,
NCT05651607,Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa,Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa,Cannabidiol,"['Cannabidiol', 'Epidyolex']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hereditary Epidermolysis Bullosa,['Hereditary Epidermolysis Bullosa'],"['hereditary epidermolysis bullosa', 'Cannabidiol', 'Prutitus', 'Pilot Study']",COMPLETED,,2023-07-06,2023-11-17,"[{'measure': 'Clinically significant decrease of pruritus Visual Analog Scale (VAS) scores', 'description': 'Loss of at least 2 points on the mean pruritus VAS scores recorded on D27, D28 and D29 compared to the mean pruritus scores recorded on D-3, D-2 and D-1 (D0 = inclusion and start of treatment). The Visual Analogue Scale (VAS) is a scale consisting of a 10cm long line and a single question. The scale is scored in a range of 0-10 with 10 representing worst imaginable pruritus.', 'timeFrame': 'Day 30'}]","[{'measure': 'Change of pruritus Visual Analog Scale scores', 'description': 'Change of the mean pruritus VAS scores recorded on D27, D28 and D29 compared to the mean pruritus VAS scores on D-3, D-2 and D-1 . The scale is scored in a range of 0-10 with 10 representing worst imaginable pruritus.', 'timeFrame': 'Day 30'}, {'measure': 'Evaluation of tolerance of Cannabidiol', 'description': 'Serious and non-serious side effects', 'timeFrame': 'Day 48'}, {'measure': 'Clinically significant decrease of chronic pain scores', 'description': 'Loss of at least 2 points on the mean pain scores (VAS or FLACC according to the age of patient) recorded on D27, D28 and D29 compared to the mean pain scores recorded on D-3, D-2 and D-1 (D0 = inclusion and start of treatment). The Face, Legs, Activity, Cry, Consolability (FLACC) scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 10 representing severe pain.\n\nThe Visual Analogue Scale (VAS) is a scale consisting of a 10cm long line and a single question. The scale is scored in a range of 0-10 with 10 representing worst imaginable pain.', 'timeFrame': 'Day 30'}, {'measure': 'Change of chronic pain scores', 'description': 'Change of the mean pain scores (Visual Analogue Scale or Face, Legs, Activity, Cry, Consolability scale according to the age of patient) recorded on D27, D28 and D29 compared to the mean pain scores on D-3, D-2 and D-1 The Face, Legs, Activity, Cry, Consolability (FLACC) scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 10 representing severe pain.\n\nThe Visual Analogue Scale (VAS) is a scale consisting of a 10cm long line and a single question. The scale is scored in a range of 0-10 with 10 representing worst imaginable pain.', 'timeFrame': 'Day 30'}, {'measure': 'Change of pruritus Visual Analog Scale score during cares', 'description': 'Change of the mean of maximum pruritus VAS scores recorded during the last two cares before D30 compared to the mean of maximum pruritus VAS scores recorded during the last two cares before D0. The Visual Analogue Scale (VAS) is a scale consisting of a 10cm long line and a single question. The scale is scored in a range of 0-10 with 10 representing worst imaginable pruritus.', 'timeFrame': 'Day 30'}, {'measure': 'Change of acute pain score during cares', 'description': 'Change of the mean of maximum acute pain scores (VAS or FLACC according to the age of patient) recorded during the last two cares before D30 compared to the mean of maximum acute pain scores recorded during the last two cares before D0. The Face, Legs, Activity, Cry, Consolability (FLACC) scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 10 representing severe pain.\n\nThe Visual Analogue Scale (VAS) is a scale consisting of a 10cm long line and a single question. The scale is scored in a range of 0-10 with 10 representing worst imaginable pain.', 'timeFrame': 'Day 30'}, {'measure': 'Change of quality of sleep', 'description': 'Quality of sleep measured by the patient or his family on a scale of 0 to 10, with 10 representing excellent sleep quality, at D30 compared to D0', 'timeFrame': 'Day 30'}, {'measure': 'Change of quality of life', 'description': ""Quality of life measured by the patient or his family via the Dermatology Life Quality Index (DLQI child) at D30 compared to D0.\n\nThe Dermatology Life Quality Index (DLQI child) is scored in a range of 0-30 with 30 representing extremely important effect on the patient's quality life."", 'timeFrame': 'Day 30'}, {'measure': 'Systemic passage of CANNABIDIOL', 'description': 'Systemic passage measured at D30 by blood test 4 hours after the morning intake and before the midday intake of CANNABIDIOL.', 'timeFrame': 'Day 30'}, {'measure': 'Acceptability of CANNABIDIOL', 'description': 'Measure of acceptability: difficulty of ingesting, difficulty of using the syringe, taste', 'timeFrame': 'Day 30'}]",11,2 Years,17 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,3,10.0,ACTUAL,2025-09-01T16:18:19.663671,v2_robust,True,True,True,False,False,
NCT02798107,Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients,Safety of Potential Paediatric Patients Treated With Idarucizumab: a Non-internventional Chart Review Study,idarucizumab,['idarucizumab'],1,OBSERVATIONAL,[],,,Hemorrhage,['Hemorrhage'],[],WITHDRAWN,No recruitment,2019-05-20,2019-05-24,"[{'measure': 'Safety outcomes until hospital discharge * Incidence of thromboembolic events (ie. obstruction of a blood vessel by the formation of a thrombus - e.g. ischemic stroke, MI, DVT, PE) after administration', 'timeFrame': 'Up to 33 months'}, {'measure': 'Safety outcomes until hospital discharge * Incidence of hypersensitivity/anaphylactic reactions', 'timeFrame': 'Up to 33 months'}, {'measure': 'Safety outcomes until hospital discharge * Incidence of AE, SAE, ADR, SADR reporting', 'timeFrame': 'Up to 33 months'}, {'measure': 'Safety outcomes until hospital discharge * Cause of death and in-hospital mortality rate', 'timeFrame': 'Up to 33 months'}]","[{'measure': 'Comparison of patient characteristics of paediatric patients with & without outcome events * Incidence of thromboembolic events (ie. obstruction of a blood vessel by the formation of a thrombus - e.g. ischemic stroke, MI, DVT, PE) after administration', 'timeFrame': 'Up to 33 months'}, {'measure': 'Comparison of patient characteristics of paediatric patients with & without outcome events * Incidence of hypersensitivity/anaphylactic reactions', 'timeFrame': 'Up to 33 months'}, {'measure': 'Comparison of patient characteristics of paediatric patients with & without outcome events * Incidence of AE, SAE, ADR, SADR reporting', 'timeFrame': 'Up to 33 months'}, {'measure': 'Comparison of patient characteristics of paediatric patients with & without outcome events * Cause of death and in-hospital mortality rate', 'timeFrame': 'Up to 33 months'}]",8,,17 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:19.663766,v2_robust,False,True,False,True,True,No recruitment
NCT05743907,Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control,"A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control",DA-2811,"['DA-2811', 'Forxiga']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetes Mellitus,['Diabetes Mellitus'],[],COMPLETED,,2023-04-25,2025-03-10,"[{'measure': 'HbA1c(%)', 'timeFrame': 'Change from baseline at 24 weeks'}]",[],1,19 Years,,ALL,False,"Dong-A ST Co., Ltd.",INDUSTRY,0,231.0,ACTUAL,2025-09-01T16:18:19.663774,v2_robust,True,True,True,False,False,
NCT02979392,Phase I Study of TENPA in Advanced Solid Cancer,"A Prospective, Open-label, Dose Escalation (Part A), Cohort Expansion (Part B) Phase I Study to Investigate the Safety and to Determine Maximum Tolerated Dose and Recommended Phase 2 Dose of TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) in Patients With Advanced Solid Tumor",TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel),['TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumor,['Advanced Solid Tumor'],[],TERMINATED,,2016-05-02,2019-07-04,"[{'measure': 'Dose limiting toxicity (DLT)', 'timeFrame': 'at least one cycle of treatment (3 weeks)'}, {'measure': 'Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)', 'timeFrame': 'at least one cycle of treatment (3 weeks)'}]","[{'measure': 'Maximum Plasma Concentration [Cmax]', 'timeFrame': '3 weeks'}, {'measure': 'Area Under the Curve [AUC]', 'timeFrame': '3 weeks'}, {'measure': 'Response rate (RR)', 'timeFrame': '6 weeks'}, {'measure': 'Progression-free survival (PFS)', 'timeFrame': '6 weeks'}]",6,20 Years,,ALL,False,Yung-Jue Bang,OTHER,0,19.0,ACTUAL,2025-09-01T16:18:19.663787,v2_robust,True,True,False,True,False,
NCT01840592,Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib,Phase II Study of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib,Sorafenib,"['Sorafenib', 'Doxorubicin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],"['Liver', 'Sorafenib', 'Doxorubicin', '12-259']",ACTIVE_NOT_RECRUITING,,2013-04,2026-04,"[{'measure': 'overall survival', 'timeFrame': '6 months'}]","[{'measure': 'median time to progression', 'timeFrame': '2 years'}, {'measure': 'median progression free survival', 'timeFrame': '2 years'}, {'measure': 'median overall survival', 'timeFrame': '2 years'}, {'measure': 'toxicity', 'description': 'Toxicity rate will be reported by type and severity according to the NCI common toxicity criteria version 4 and descriptive statistics will be provided.', 'timeFrame': '2 years'}]",5,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,2,30.0,ACTUAL,2025-09-01T16:18:19.663800,v2_robust,True,True,False,False,False,
NCT00437892,Statins to Reduce D-dimer Levels in Patients With Venous Thrombosis,The Effect of Statins on D-dimer Levels in Patients With a Previous Venous Thromboembolic Event,atorvastatin,['atorvastatin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Venous Thromboembolism,"['Venous Thromboembolism', 'Hypercholesterolemia']","['Statins', 'secondary prevention', 'venous thromboembolism', 'd-dimer']",TERMINATED,Competitive trials and slow recruitment rate,2007-05,2011-05,"[{'measure': 'proportion of patients with elevated D-dimer at day 90', 'timeFrame': '3 months'}]","[{'measure': 'proportion of patients with elevated D-dimer levels at Day 30;', 'timeFrame': '1 month'}, {'measure': 'proportion of patients with elevated D-dimer levels at Day 0 and subsequent normalization of D-dimer levels at Day 30 and Day 90;', 'timeFrame': '3 months'}, {'measure': 'proportion of patients with recurrent VTE', 'timeFrame': '3 months'}]",4,18 Years,,ALL,False,Università degli Studi dell'Insubria,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:19.663813,v2_robust,True,True,False,True,False,Competitive trials and slow recruitment rate
NCT05783492,INK Feasibility Study,Intranasal Ketamine for Procedural Sedation: a Feasibility Cohort Study,Intranasal ketamine,['Intranasal ketamine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Procedural Sedation,['Procedural Sedation'],['ketamine'],WITHDRAWN,Lack of availability of drug,2024-01-01,2024-04-30,"[{'measure': 'Adequacy of sedation', 'description': 'Dartmouth Operative Conditions Scale (DOCS) score between -2 and +2 for the duration of the closed reduction AND, (ii) No additional IV ketamine is given during closed reduction for the purpose of sedation, AND (iii) The patient did not actively resist, cry, or require physical restraint for completion of the closed reduction.', 'timeFrame': '1 hour'}]","[{'measure': 'Length of stay', 'description': 'Defined as the time recorded in the medical record between triage and discharge in minutes', 'timeFrame': '1 hour'}, {'measure': 'Onset of sedation', 'description': 'This will be defined as the time interval from administration of the first pair of IN sprays to the time when a first DOCS score of between -2 and +2 is achieved post-intervention (minutes)', 'timeFrame': '1 hour'}, {'measure': 'Duration of sedation', 'description': 'This will be defined as the duration of time between the first DOCS score between -2 to +2 post-intervention to the last DOCS score between -2 and +2 post-closed reduction (minutes).', 'timeFrame': '1 hour'}, {'measure': 'Adverse effects', 'description': 'Research nurses will be trained on the recognition and definition of expected and unexpected AEs. AEs will be determined from the medical record and recorded on REDCap. Expected AEs are based on the Quebec guidelines and other practice guidelines. Unpleasant recovery reactions will be recorded by the research nurse using REDCap.', 'timeFrame': '1 hour'}]",5,7 Years,17 Years,ALL,False,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:19.663824,v2_robust,True,True,False,True,True,Lack of availability of drug
NCT02325492,Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study,Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study,Aramchol,"['Placebo', 'Aramchol']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Gallstones,['Gallstones'],"['bariatric surgery', 'NASH', 'ARAMCHOL']",TERMINATED,Protocol redesign,2014-10,2015-10,"[{'measure': 'Complete dissolution of existing gallstones proven by repeated US examined gallbladder', 'description': 'Change from baseline measured by US scan', 'timeFrame': 'At baseline and week 12'}]","[{'measure': 'Decrease of more than a 50% in number of stones. (change from baseline)', 'description': 'change from baseline measured by US scan', 'timeFrame': 'At baseline and week 12'}, {'measure': 'Prevention of formation of new gallstones during the study period', 'description': 'change from baseline measured by US scan', 'timeFrame': 'At baseline and week 12'}, {'measure': 'Dissolution of sludge.', 'description': 'change from baseline measured by US scan', 'timeFrame': 'At baseline and week 12'}]",4,18 Years,75 Years,ALL,False,Galmed Pharmaceuticals Ltd,INDUSTRY,0,10.0,ACTUAL,2025-09-01T16:18:19.663844,v2_robust,True,True,False,True,False,Protocol redesign
NCT00033592,Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking,Phase III Trial Comparing Nicotine Inhaler Versus Bupropion Versus Nicotine Inhaler Plus Bupropion For Smoking Cessation Efficacy And Relapse Prevention,bupropion hydrochloride,"['bupropion hydrochloride', 'nicotine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Lung Cancer,['Lung Cancer'],"['non-small cell lung cancer', 'small cell lung cancer']",COMPLETED,,2002-02,2006-07,"[{'measure': 'Prevention in relapse', 'timeFrame': 'Up to 6 months'}]","[{'measure': 'Reduction in the rate of relapse', 'timeFrame': 'Up to 6 months'}]",2,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,1708.0,ACTUAL,2025-09-01T16:18:19.663955,v2_robust,True,True,True,False,False,
NCT04864392,"Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis","A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis",LNA043 Dosing Regimen A,"['LNA043', 'LNA043 Dosing Regimen A', 'LNA043 Dosing Regimen D', 'Placebo', 'LNA043 Dosing Regimen C', 'LNA043 Dosing Regimen B']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Osteoarthritis,['Osteoarthritis'],"['LNA043', 'knee', 'arthritis', 'OA', 'knees']",TERMINATED,Study early terminated due to lack of effect (did not meet primary/key secondary endpoints). This decision was not linked to safety concerns,2021-05-31,2025-05-29,"[{'measure': 'Change from baseline in the cartilage thickness of the medial compartment of the knee as assessed by imaging.', 'description': 'To evaluate cartilage thickness changes', 'timeFrame': 'Week 0 to Week 104'}]","[{'measure': 'Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index pain scale. The scale (5 questions) ranges from 0 to 50. Higher score indicates a worse outcome.', 'description': 'To evaluate changes from baseline in OA pain', 'timeFrame': 'Week 0 to Week 104'}, {'measure': 'Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index function scale. The scale (17 questions) ranges from 0 to 170. Higher scores indicates a worse outcome.', 'description': 'To evaluate changes from baseline in physical function', 'timeFrame': 'Week 0 to Week 104'}, {'measure': 'Change from baseline in the cartilage thickness of the knee as assessed by imaging.', 'description': 'To evaluate changes from baseline the cartilage structure', 'timeFrame': 'Week 0 to Week 104'}, {'measure': 'Change from baseline in the Osteoarthritis Research Society International physical performance-based assessment of 40-meter (4×10m) fast-paced walk test', 'description': 'To evaluate changes from baseline in physical function', 'timeFrame': 'Week 0 to Week 104'}, {'measure': 'Change from baseline in the Osteoarthritis Research Society International physical performance-based assessments 30-second chair stand test', 'description': 'To evaluate changes from baseline in physical function', 'timeFrame': 'Week 0 to Week 104'}, {'measure': 'Change from baseline in the Osteoarthritis Research Society International physical performance-based assessment of 6-minute walking test', 'description': 'To evaluate changes from baseline in physical function', 'timeFrame': 'Weeek 0 to Week 104'}, {'measure': 'Proportion of participants demonstrating structural progression', 'description': 'To evaluate structural progression', 'timeFrame': 'Week 0 to Week 104'}, {'measure': 'Assessing percentage of participants with adverse events and serious adverse events', 'description': 'To evaluate safety and tolerability of the various LNA043 regimens', 'timeFrame': 'Week 0 to Week 104'}]",9,40 Years,75 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,582.0,ACTUAL,2025-09-01T16:18:19.663985,v2_robust,True,True,False,True,True,Study early terminated due to lack of effect (did not meet primary/key secondary endpoints). This decision was not linked to safety concerns
NCT01785992,A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.,A Phase II Study to Assess the Safety and Efficacy of the Steroid Sulfa-tase Inhibitor Irosustat When Added to an Aromatase Inhibitor in ER Positive Locally Advanced or Metastatic Breast Cancer Patients.,Irosustat,"['667 Coumate', 'BN83495', 'STX64', 'Irosustat']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Locally Advanced Breast Cancer,"['Locally Advanced Breast Cancer', 'Metastatic Breast Cancer']","['Oestrogen receptor', 'Locally advanced', 'Metastatic', 'Breast cancer', 'Sulfatase inhibitor']",COMPLETED,,2012-10,2014-12,"[{'measure': 'Clinical benefit defined as complete response / partial response plus stable disease for at least 6 months (RECIST v1.1).', 'timeFrame': 'Patients will be followed up until disease progression, an expected average of 6 months'}]","[{'measure': 'Duration of clinical benefit as defined by the number of days from start of study drug to the first evidence of disease progression or death due to any cause (RECIST v1.1).', 'timeFrame': 'Patients will be followed up until disease progression, an expected average of 6 months'}, {'measure': 'Progression Free Survival defined as time from randomisation to first evidence of disease progression or death due to any cause (RECIST v1.1).', 'timeFrame': 'Patients will be followed up until disease progression, an expected average of 6 months'}, {'measure': 'Safety and tolerability as assessed by the collection of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE v 4.03).', 'timeFrame': 'Patients will be followed up until disease progression, an expected average of 6 months'}, {'measure': 'To measure alterations in circulating steroid hormones and correlation of these measures with clinical outcome.', 'timeFrame': '0,1,2,3,4,5,6,9,12 months after study entry'}, {'measure': 'Objective response rate as defined by complete response and partial response (RECIST v1.1)', 'timeFrame': 'Patients will be followed up until disease progression, an expected average of 6 months'}]",6,25 Years,,FEMALE,False,Imperial College London,OTHER,1,27.0,ACTUAL,2025-09-01T16:18:19.664053,v2_robust,True,True,True,False,True,
NCT02962492,An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes,An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes,Exenatide/Exenatide extended release,"['Exenatide/Exenatide extended release', 'Farxiga', 'Placebo for both active drugs', 'Placebo', 'Dapagliflozin', 'Bydureon']",6,INTERVENTIONAL,['NA'],,,Evaluate Ketogenic Stress,['Evaluate Ketogenic Stress'],"['Dapagliflozin', 'Ketogenesis', 'Type 1 Diabetes', 'DKA', 'ketones', 'exenatide/Bydureon']",COMPLETED,,2016-11-01,2021-10-24,"[{'measure': 'Change in Beta-hydroxybutyrate Levels in Blood', 'description': 'Beta-hydroxybutyrate (BHB) was measured in blood during the acute stress conditions in all the groups after single dose intervention at baseline (0 Week) and at 12 weeks of treatment. The magnitude of change at each of these visits was calculated from each visit baseline (0 hr) and the difference between the change at 12 weeks was compared to the change at 0 week and reported as: Change at week 12 - change at week 0.', 'timeFrame': '12 weeks'}]","[{'measure': 'Change in HbA1c Following Treatment', 'description': 'Hemoglobin A1c (HbA1c) was measured in basal conditions in all the groups at week 0 and week 12 of treatment. The change in HbA1c from baseline at 12 weeks is calculated as: HbA1c at week 12 - HbA1c at week 0.', 'timeFrame': '12 weeks'}, {'measure': 'Change in Urinary Beta-hydroxybutyrate (BHB) After 12 Weeks of Treatment', 'description': 'Beta-hydroxybutyrate (BHB) was measured in urine during the acute stress conditions in all the groups after single dose intervention at baseline (0 Week) and at 12 weeks of treatment. The magnitude of change at each of these visits was calculated from each visit baseline (0 hr) and the difference between the change at 12 weeks was compared to the change at 0 week and reported as: Change at week 12 - change at week 0.', 'timeFrame': '12 weeks'}, {'measure': 'Change in Plasma Glucagon', 'description': 'change in basal plasma glucagon after 12 weeks of dapagliflozin and Bydureon or combination of both treatments compared to baseline', 'timeFrame': '12 weeks'}, {'measure': 'Change in Total Insulin Dose', 'description': 'change in total (basal or long acting and short acting) insulin daily dose calculated as daily units/Kg body weight at 12 weeks from baseline (0 week). Long acting or basal insulin dose (in units of insulin) plus short acting (meal) insulin doses administered through the day and reported by patients in patients logs or from insulin pumps are added and divided by body weight in Kg. The reported total insulin dose/Kg represents the average of last 3-7 days before the visit.', 'timeFrame': '12 weeks'}]",5,18 Years,65 Years,ALL,False,University at Buffalo,OTHER,1,70.0,ACTUAL,2025-09-01T16:18:19.664108,v2_robust,True,True,True,False,False,
NCT05487092,Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy,Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy,Letrozole,['Letrozole'],1,INTERVENTIONAL,['NA'],,,Endometriotic Cyst of Ovary,['Endometriotic Cyst of Ovary'],"['endometriotic cyst', 'recurrence', 'letrozole', 'combined oral contraceptive pills']",RECRUITING,,2022-12-01,2027-06-30,"[{'measure': 'Recurrence of endometrioma', 'description': 'the presence of ovarian cysts with the typical sonographic criteria of endometriomas and a diameter of ≥30 mm after previous complete ovarian cystectomy, to be measured by a transvaginal or transrectal ultrasound transducer', 'timeFrame': '12 months'}]","[{'measure': 'Endometriosis Health Profile Questionnaire (EHP-30) score', 'description': ""a validated disease-specific health related quality of life patient self-reported scale for endometriosis used to measure the effects that endometriosis can have on the women's lives and the effectiveness of medical and surgical therapies for endometriosis on their quality of life"", 'timeFrame': '6 months, 12 months, 24 months'}, {'measure': 'Non-menstrual pelvic pain (chronic pelvic pain, deep dyspareunia) and dysmenorrhoea measured by a 10cm visual analogue pain scale (VAS)', 'description': '0-100', 'timeFrame': '6 months, 12 months, 24 months'}, {'measure': 'Menstrual regularity', 'description': 'menstrual chart', 'timeFrame': '6 months, 12 months, 24 months'}, {'measure': 'Use of additional analgesics', 'timeFrame': '6 months, 12 months, 24 months'}, {'measure': 'Side effects/ adverse events', 'description': 'Number of women with side effects/ adverse events', 'timeFrame': '6 months, 12 months, 24 months'}, {'measure': 'Need for further surgery for endometriosis', 'description': 'Number of women who required further surgery for endometriosis', 'timeFrame': '6 months, 12 months, 24 months'}]",7,18 Years,45 Years,FEMALE,False,The University of Hong Kong,OTHER,4,194.0,ESTIMATED,2025-09-01T16:18:19.664131,v2_robust,True,True,False,False,True,
NCT01128192,Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers,"Phase 2, Double-Blind, Randomized, Single Center Trial to Assess the Mechanism(s) Responsible for the Effect of the Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers. Version #2 05/09/2009",pasireotide,"['SOM230', 'pasireotide']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hyperglycemia,['Hyperglycemia'],[],COMPLETED,,2009-08,2010-04,"[{'measure': 'Change in Insulin Basal Level', 'description': 'Change from Day 2 and Day 9 of insulin basal levels (2-step hyperglycemic clamp test with arginine stimulation)', 'timeFrame': '-30 min and -15 min on Day 2 and Day 9'}, {'measure': 'Change in Area Under the Curve (AUC) of Plasma Insulin Level 0-10mins, 10-180mins, 0-180mins During Hyperglycemic Clamp', 'description': 'Blood samples were taken at -30 min, -15 min, 0 min, 15 min, 30 min, 45 min, 60 min, 75 min, 90 min, 105 min, 120 min, 135 min, 150 min, 165 min, 180 min to assess the plasma insulin levels during Hyperglycemic Clamp (2-step hyperglycemic clamp test with arginine stimulation). The mean change in plasma insulin levels from Day 2 to Day 9 were calculated as Values on Day 9 - Values on Day 2.', 'timeFrame': '0-10 mins, 10-180 mins, 0-180 mins (Day 2 and Day 9)'}, {'measure': 'Change in Basal Endogenous Glucose Production (EGP)', 'description': 'Change from Day 3 and Day 10 of Basal EGP (Hyperinsulinemic-Euglycemic Clamp)', 'timeFrame': 'Day 3 and Day 10'}, {'measure': 'Change in Low Dose % Endogenous Glucose Production (EGP) Inhibition', 'description': 'Change from Day 3 and Day 10 of low dose % EGP Inhibition (Hyperinsulinemic-Euglycemic Clamp)', 'timeFrame': 'Day 3 and Day 10'}, {'measure': 'Change in High Dose % Endogenous Glucose Production (EGP) Inhibition', 'description': 'Change from Day 3 and Day 10 of high dose % EGP Inhibition (Hyperinsulinemic-Euglycemic Clamp)', 'timeFrame': 'Day 3 and Day 10'}, {'measure': 'Change in Low-Dose Glucose Disposal Rate (GDR)', 'description': 'Change from Day 3 and Day 10 in Low-Dose Glucose Disposal Rate (GDR) during Hyperinsulinemic-Euglycemic Clamp.', 'timeFrame': 'Day 3 and Day 10'}, {'measure': 'Change in High-Dose Glucose Disposal Rate (GDR)', 'description': 'Change from Day 3 and Day 10 in High-Dose Glucose Disposal Rate (GDR) during Hyperinsulinemic-Euglycemic Clamp.', 'timeFrame': 'Day 3 and Day 10'}]","[{'measure': 'Change in Fasting Plasma Glucose Level', 'description': 'An Oral Glucose Tolerance Test was performed at Day 1 (baseline) and Day 8 (post-treatment). Samples were taken at\n\n-30 min to assess the fasting plasma glucose level. The mean change in fasting plasma glucose level from Day 1 to Day 8 was assessed.', 'timeFrame': '-30 minutes on Day 1 and -30 minutes on Day 8'}, {'measure': 'Change in Area Under the Curve (AUC) of Plasma Glucose 0-30mins, 30-180mins, 0-180mins During Oral Glucose Tolerance Test (OGTT)', 'description': 'Blood samples were taken at -30 min, 0 min, 30 min, 60 min, 90 min, 120 min, 150 min, 180 min to assess the plasma glucose level. The mean change in plasma glucose level from Day 1 to Day 8 were calculated as Values on Day 8 - Values on Day 1.', 'timeFrame': '0-30 mins, 30-180 mins, 0-180 mins (Day 1 and Day 8)'}, {'measure': 'Change Fasting Plasma Insulin Level', 'description': 'An Oral Glucose Tolerance Test was performed at Day 1 (baseline) and Day 8 (post-treatment). Samples were taken at -30 min to assess the fasting plasma insulin level. The mean change in fasting plasma insulin level from Day 1 to Day 8 was assessed.', 'timeFrame': '-30 minutes on Day 1 and -30 minutes on Day 8'}, {'measure': 'Change in Area Under the Curve (AUC) of Plasma Insulin 0-30mins, 30-180mins, 0-180mins During Oral Glucose Tolerance Test (OGTT)', 'description': 'Blood samples were taken at -30 min, 0 min, 30 min, 60 min, 90 min, 120 min, 150 min, 180 min to assess the plasma insulin level. The mean change in plasma insulin level from Day 1 to Day 8 were calculated as Values on Day 8 - Values on Day 1', 'timeFrame': '0-30 mins, 30-180 mins, 0-180 mins (Day 1 and Day 8)'}]",11,18 Years,50 Years,MALE,True,"Robert R. Henry, MD",OTHER,1,45.0,ACTUAL,2025-09-01T16:18:19.664157,v2_robust,True,True,True,False,False,
NCT05245292,3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803),"An Open Label, Single Arm Study of the Safety and Antiretroviral Activity of Two Long-acting Broadly Neutralizing Antibodies Plus an IL-15 Superagonist in ART-treated Adults Living With HIV During Analytical Treatment Interruption",3BNC117-LS,"['10-1074-LS', 'monoclonal antibody', 'IL-15 superagonist complex', 'broadly neutralizing antibody', 'N803', '3BNC117-LS']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Human Immunodeficiency Virus,['Human Immunodeficiency Virus'],"['3BNC117-LS', '10-1074-LS', 'Broadly Neutralizing Antibody', 'N-803', 'IL-15 superagonist complex']",ACTIVE_NOT_RECRUITING,,2022-12-07,2025-12-31,"[{'measure': 'Treatment-related Grade 3 adverse events and serious adverse events', 'description': 'The number of participants with treatment-related solicited and unsolicited grade 3 and serious adverse events (including confirmed laboratory abnormalities), or premature study treatment discontinuation due to an adverse event (regardless of grade).', 'timeFrame': '72 weeks'}, {'measure': 'Any serious adverse events', 'description': 'The number of participants with serious adverse events, regardless of relationship to 3BNC117-LS, 10-1074-LS and N-803.', 'timeFrame': '72 weeks'}, {'measure': 'Dosing completion', 'description': 'The proportion of participants who complete dosing with 3BNC117-LS, 10-1074-LS and N-803.', 'timeFrame': '24 weeks'}, {'measure': 'Viral rebound before or at week 24 post withdrawing ART', 'description': 'The number of participants experiencing viral rebound, defined as confirmed HIV-1 RNA \\>200 copies/mL at or prior to week 24 of ART discontinuation.', 'timeFrame': '24 weeks'}, {'measure': 'ART not restarted by weeks 60 and 72', 'description': 'The proportion of participants who do not meet ART restart criteria by weeks 60 and 72.', 'timeFrame': '72 weeks'}, {'measure': 'ART not restarted when bNABs below threshold', 'description': 'The proportion of participants who do not meet ART restart criteria for 12 or more weeks after bNAbs are below a threshold of 10 mcg/ml.', 'timeFrame': '72 weeks'}]","[{'measure': 'Treatment-related Grade 2 adverse events', 'description': 'The number of participants with treatment-related solicited and unsolicited grade 2 adverse events.', 'timeFrame': '72 weeks'}, {'measure': 'Viral rebound through Step 2', 'description': 'The number of participants experiencing viral rebound, defined as confirmed HIV-1 RNA \\>200 copies/mL, through Step 2 of the study.', 'timeFrame': '72 weeks'}, {'measure': 'Time from ART withdrawal to re-initiating ART', 'description': 'Time from ART withdrawal to virologic or immunologic criteria (i.e. viral load, CD4 cell count, or development of severe acute retroviral syndrome) to reinitiate ART.', 'timeFrame': '72 weeks'}, {'measure': 'Viral rebound determined by Monogram assay', 'description': 'Time to viral rebound (confirmed HIV-1 RNA \\>200 copies/mL) across different 3BNC117-LS and 10-1074-LS IC90s cut points determined by the Monogram PhenoSense assay.', 'timeFrame': '72 weeks'}, {'measure': 'Size of latent HIV-1 reservoir', 'description': 'Size of the latent HIV-1 reservoir, measured by IPDA and/or other appropriate assay, before, during (Step 1) and after dosing with 3BNC117-LS, 10-1074-LS and N-803 (Step 2), and after antibody concentrations have declined below a therapeutic threshold.', 'timeFrame': '72 weeks'}, {'measure': 'Changes in HIV-1 specific T Cell immune responses', 'description': 'Changes in HIV-1 specific T cell immune responses in peripheral blood, measured by ELISPOT, before, during (Step 1) and after dosing with 3BNC117-LS, 10-1074-LS and N-803 (Step 2), and after antibody concentrations have declined below a therapeutic threshold.', 'timeFrame': '72 weeks'}, {'measure': 'Half-life of 3BNC117-LS and 10-1074-LS', 'description': 'Half-life of 3BNC117-LS and 10-1074-LS, when administered in combination with N-803 to individuals with HIV during ART interruption.', 'timeFrame': '72 weeks'}, {'measure': 'Anti-drug antibodies (ADA)', 'description': 'The proportion of individuals with treatment-induced ADA against each bNAb or N-803 and magnitude of the response.', 'timeFrame': '72 weeks'}]",14,18 Years,70 Years,ALL,False,Rockefeller University,OTHER,3,28.0,ACTUAL,2025-09-01T16:18:19.664196,v2_robust,True,True,False,False,True,
NCT00159692,Amlodipine Diabetic Hypertension Efficacy Response Trial,"A Multi-Center, Randomized, Double-Blind, Double-Dummy Study Evaluating The Safety and Efficacy Of The Addition Of Amlodipine To Quinapril Or Losartan In The Treatment Of Diabetic Hypertensive Subjects",Amlodipine,['Amlodipine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,['Hypertension'],[],COMPLETED,,2003-03,2005-08,"[{'measure': 'The percentage of subjects that reach the JNC diabetic hypertensive BP goal of <130/80 will be assessed at Week 0 (Visit 2-Randomization), Week 5 (Visit 3), Week 9 (Visit 4), Week 15 (Visit 5) and Week 20 (Visit 6 - Final Evaluation).'}]","[{'measure': 'Percentage of subjects at SBP goal of <130 mmHg and DBP goal of <80mmHg; change from baseline blood pressures (SBP and DBP); percentage of subjects with SBP >160mmHg and/or DBP >100mmHg at Visits 2, 3, 4, 5, 6.'}]",2,30 Years,75 Years,ALL,False,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,0,739.0,ACTUAL,2025-09-01T16:18:19.664223,v2_robust,True,True,True,False,False,
NCT01489592,Effect of Curcumin on Iron Metabolism in Healthy Volunteer,Effect of Curcumin on Iron Metabolism in Healthy Volunteer,curcuma longa,['curcuma longa'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2011-10,2012-03,"[{'measure': 'Maximal variation of serum hepcidin level after oral administration of curcumin', 'timeFrame': 'within 48 hours after administration of curcumin'}]","[{'measure': 'Plasmatic iron bioavailability', 'description': 'Iron, ferritin, transferrin, transferrin saturation', 'timeFrame': '30min, 1H, 2H, 3H, 4H, 6H, 8H, 12H, 24H et 48H'}, {'measure': ""Evaluation of the inhibitory activity of volunteers's serum on hepcidin expression by hepatocytes"", 'description': 'In vitro:\n\n* the coculture model that we previously developed to analyze endogenous hepcidin expression, and\n* human hepatic cells line (HepG2) stimulated or not by IL-6 which governs the STAT3 pathway, transfected with gene reporter constructs containing hepcidin promoter.', 'timeFrame': '30min, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h'}]",3,18 Years,35 Years,MALE,True,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,0,18.0,ACTUAL,2025-09-01T16:18:19.664395,v2_robust,True,True,True,False,False,
NCT03535792,Nalbuphine Versus Fentanyl As Additives To Bupivacaine In Spinal Anaesthesia For Internal FixationI Of Tibia,The Efficacy Of Nalbuphine Versus Fentanyl As Additives To Bupivacaine In Spinal Anaesthesia For Internal FixationI Of Tibia,Fentanyl/Hyperbaric bupivacaine,"['Spinal Nalbuphine/Hyperbaric bupivacaine', 'Nalbuphine/Hyperbaric bupivacaine', 'Fentanyl/Hyperbaric bupivacaine', 'Spinal Fentanyl/Hyperbaric bupivacaine']",4,INTERVENTIONAL,['NA'],,,"Pain, Postoperative","['Pain, Postoperative']",[],COMPLETED,,2017-11-04,2018-08-20,"[{'measure': 'Pain Postoperative', 'description': 'VAS 0-10', 'timeFrame': '24 hours'}]",[],1,18 Years,50 Years,ALL,False,University of Alexandria,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:19.664410,v2_robust,True,True,True,False,False,
NCT00384592,PPI Sequencing Study,A Study to Assess the Effectiveness of Esomeprazole 40 mg Once Daily in Subjects With Continuing Gastroesophageal Reflux Disease (GORD) Symptoms Following Treatment Wit a Previous Full Dose Proton Pump Inhibitor (PPI),Esomeprazole,['Esomeprazole'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Gastro-Oesophageal Reflux Disease,['Gastro-Oesophageal Reflux Disease'],"['heartburn', 'reflux', 'proton pump inhibitor', 'GERD', 'GORD']",COMPLETED,,2006-09,2007-05,"[{'measure': 'The primary objective of this study is to assess the change in the frequency of heartburn from baseline value at entry to the end of the study, after 8-weeks treatment with esomeprazole 40mg compared to previous full dose treatment with a PPI daily'}]","[{'measure': 'Change in frequency and severity of heartburn, epigastric pain and acid regurgitation after 4 and 8 weeks treatment from baseline value at study entry'}, {'measure': 'Change in symptom control from baseline to 4 and 8 weeks using QOL questionnaires'}]",3,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,100.0,,2025-09-01T16:18:19.664418,v2_robust,True,True,True,False,False,
NCT02459236,A Study of Intermittent Doses of CERC-301 in MDD,"A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment",CERC-301,"['CERC-301', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Major Depressive Disorder,['Major Depressive Disorder'],[],COMPLETED,,2015-06,2016-12,"[{'measure': 'Change in Bech-6 from baseline', 'description': 'To evaluate the antidepressant effect of CERC-301 (12 or 20 mg) compared to placebo averaged between 2 and 4 days post-treatment with study drug assessed by the 6-item unidimensional subset (Bech-6) of the 17-item Hamilton Depression Rating Scale (HDRS-17)', 'timeFrame': 'average of 2 and 4 days post-treatment'}]","[{'measure': 'Change from baseline in Santen-7', 'description': 'To evaluate the antidepressant effect of a single dose of CERC-301 (12 or 20 mg) compared to placebo averaged between 2 and 4 days post-treatment with study drug assessed by the 7-item unidimensional subset of the HDRS-17, the Santen-7', 'timeFrame': 'averaged between 2 and 4 days post treatment'}, {'measure': 'Change from baseline in HDRS-17', 'description': 'To evaluate the antidepressant effect of a single dose of CERC-301 (12 or 20 mg) compared to placebo averaged between 2 and 4 days post-treatment with study drug assessed by the HDRS-17', 'timeFrame': 'averaged between 2 and 4 days post treatment'}, {'measure': 'Change from baseline in Bech-6', 'description': 'To evaluate the antidepressant effect of CERC-301 at 2, 4, 7 days after each dose, and 14 days after last dose of study drug treatment assessed by the Bech-6.', 'timeFrame': '2, 4, 7 days after each dose, and 14 days after last dose of study drug treatment'}, {'measure': 'Change from baseline in Santen-7', 'description': 'To evaluate the antidepressant effect of CERC-301 at 2, 4, 7 days after each dose, and 14 days after last dose of study drug treatment assessed by the Santen-7.', 'timeFrame': '2, 4, 7 days after each dose, and 14 days after last dose of study drug treatment'}, {'measure': 'Change from baseline in HDRS-17', 'description': 'To evaluate the antidepressant effect of CERC-301 at 2, 4, 7 days after each dose, and 14 days after last dose of study drug treatment assessed by the HDRS-17.', 'timeFrame': '2, 4, 7 days after each dose, and 14 days after last dose of study drug treatment'}, {'measure': 'Change from baseline in CUDOS-A', 'description': 'To evaluate the antidepressant effect of CERC-301 at 2, 4, 7 days after each dose, and 14 days after last dose of study drug treatment assessed by the Clinically Useful Depression Outcome Scale-Anxiety (CUDOS-A).', 'timeFrame': '2, 4, 7 days after each dose, and 14 days after last dose of study drug treatment'}, {'measure': 'Change from baseline in SHAPS-SR', 'description': 'To evaluate the antidepressant effect of CERC-301 at 2, 4, 7 days after each dose, and 14 days after last dose of study drug treatment assessed by the Snaith-Hamilton Pleasure Scale Self Report (SHAPS-SR)', 'timeFrame': '2, 4, 7 days after each dose, and 14 days after last dose of study drug treatment'}, {'measure': 'Change from baseline in QIDS-SR', 'description': 'To evaluate the antidepressant effect of CERC-301 at 7 days after each dose and 14 days after last dose of study drug treatment assessed by the Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR)', 'timeFrame': '7 days after each dose and 14 days after last dose of study drug treatment'}, {'measure': 'Change from baseline in CGI-I', 'description': 'To evaluate the antidepressant effect of CERC-301 at 7 days after each dose and 14 days after last dose of study drug treatment assessed by the Clinical Global Impression-Improvement (CGI-I)', 'timeFrame': '7 days after each dose and 14 days after last dose of study drug treatment'}, {'measure': 'Change from baseline in CGI-S', 'description': 'To evaluate the antidepressant effect of CERC-301 at 7 days after each dose and 14 days after last dose of study drug treatment assessed by the Clinical Global Impression -Severity (CGI-S)', 'timeFrame': '7 days after each dose and 14 days after last dose of study drug treatment'}]",11,18 Years,65 Years,ALL,False,"Avalo Therapeutics, Inc.",INDUSTRY,0,115.0,ACTUAL,2025-09-01T16:18:19.664474,v2_robust,True,True,True,False,False,
NCT02572336,"A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA","Phase II Study to Assess the Safety, Imaging, Pharmacodynamic and Clinical Outcomes of Acute Ischemic Stroke Subjects Treated With tPA and THR-18",THR-18,"['THR-18', 'Tissue Plasminogen Activator (tPA)', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Ischemic Stroke,['Ischemic Stroke'],[],UNKNOWN,,2015-10,2016-04,"[{'measure': 'physical examination', 'timeFrame': '30 days after administration'}, {'measure': 'ASPECTS score', 'timeFrame': '2 days after administration'}, {'measure': 'ECASS-II bleeding grades', 'timeFrame': '2 days after administration'}, {'measure': 'Severity of cerebral edema per computerized tomography according to the IST-3 grades', 'timeFrame': '2 days after administration'}, {'measure': 'Final infarct volume per computerized tomography', 'timeFrame': '30 days after administration'}, {'measure': 'Neurological deficits per the NIH stroke scale', 'timeFrame': '30 days after administration'}, {'measure': 'Functional capacity per the modified Rankin Score', 'timeFrame': '30 days after administration'}, {'measure': 'Change in blood levels of matrix metalloproteinase 9', 'timeFrame': '3 days after administration'}, {'measure': 'heart rate', 'timeFrame': '30 days after administration'}, {'measure': 'blood pressure', 'timeFrame': '30 days after administartion'}, {'measure': 'electrocardiogram', 'timeFrame': '30 days after administration'}, {'measure': 'persons with adverse events', 'timeFrame': '30 days after administration'}]",[],12,18 Years,80 Years,ALL,False,D-Pharm Ltd.,INDUSTRY,0,40.0,ESTIMATED,2025-09-01T16:18:19.664515,v2_robust,True,True,False,False,True,
NCT01978236,"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites","An Open-Label, Multicentre, Corollary Study of Pre-Operative Therapy With Dabrafenib and the Combination of Dabrafenib With Trametinib in Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain",Dabrafenib 150 mg,"['Dabrafenib 150 mg', 'Trametinib 2.0 mg']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Melanoma and Brain Metastases,['Melanoma and Brain Metastases'],"['BRAF V600E mutation', 'brain metastases', 'BRAF V600K mutation', 'Metastatic melanoma', 'BRAF inhibitor', 'brain neoplasms', 'GSK2118436']",TERMINATED,This study was terminated due to the limited enrollment.,2014-04-08,2017-04-26,"[{'measure': 'Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib in Peripheral Blood (Plasma)', 'description': 'Blood samples for pharmacokinetic analysis of dabrafenib and its active metabolites, including hydroxy-, carboxy-, and desmethyl-dabrafenib were collected on day of surgical resection of the brain metastasis(es), Two samples were collected before surgery and 2 samples after surgery with one hour gap in between. Upon collection blood was placed on wet ice. Plasma was isolated within 60 minutes of collection and frozen at -20 degree celsius.', 'timeFrame': 'Pre-surgery and post-surgery on Day 15'}, {'measure': 'Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib in Parenchymal Brain Metastases', 'description': 'Concentrations of dabrafenib, its metabolites, hydroxy-, carboxy, and desmethyl-dabrafenib, and possibly other drug-related species were quantified in the pharmacokinetic tissue sample by an investigative Liquid chromatography- mass spectrometry (LC-MS)/MS method. The spatial distribution of dabrafenib, its metabolites, hydroxy-, carboxy, and desmethyl-dabrafenib and possibly other drug-related species in the tissue samples were determined using an investigative matrix assisted laser desorption ionization (MALDI) analysis method. Parenchymal brain metastases and extracranial metastases using MALDI imaging was not determined for all participants (completed by GSK for the first two participants enrolled)', 'timeFrame': 'Day 15'}, {'measure': 'Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib) and Trametinib (Cohort B Only) in CSF Samples.', 'description': 'Blood samples for pharmacokinetic analysis of dabrafenib and its active metabolites, including hydroxy-, carboxy-, and desmethyl-dabrafenib and trametinib (as appropriate), were planned but not collected.', 'timeFrame': 'Pre-surgery and post-surgery on Day 15'}]","[{'measure': 'Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib) in Cerebrospinal Fluid (CSF) Samples', 'description': 'Concentrations of dabrafenib, its metabolites hydroxy-, carboxy- and desmethyl-dabrafenib) and trametinib in CSF (in participants who agree for optional collection of CSF at the time of brain tumor resection). Optional collection of CSF was obtained in the operating room on the day of brain metastasis resection. CSF samples for only one participant were collected and analyzed.', 'timeFrame': 'Day 15'}, {'measure': 'Number of Participants With Changes in Mitogen-activated Protein Kinase (MAPK) Pathway Markers', 'description': 'Changes in MAPK pathway markers in paired extracranial biopsies taken pre-treatment, during craniotomy, and at disease progression, and changes in markers between post-operative intracranial and extracranial biopsies was planned but not performed as the study was terminated due to low enrollment.', 'timeFrame': 'Up to Day 15'}, {'measure': 'Number of Participants With Changes in Radiographic Tumors', 'description': 'Changes in the radiographic characteristics of the tumors were planned to be compared to (1) levels of dabrafenib, its metabolites and trametinib (where appropriate) in the brain metastases, plasma, and CSF, and (2) MAPK pathway activation status in tumors at the time of surgery. Results were planned to be compared to the analysis of early clinical responses in extracranial metastases, as determined by the Positron emission tomography (PET-CT) imaging. This analysis was planned but not performed as the study was terminated due to low enrollment', 'timeFrame': 'Up to 2 years'}, {'measure': 'Percent Change From Baseline to Pre-surgery in the Sum of the Longest Diameters (SLD) of Intracranial Target Lesions', 'description': 'The change from Baseline to the pre-surgery intracranial disease assessment in the SLD of intracranial target lesions was planned to be calculated as a percentage change from the baseline SLD. It was planned to be reported for the V600E and V600K analysis populations for each cohort and also aggregately if appropriate. This analysis was planned but not performed as the study was terminated due to low enrollment.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Maximum Percent Change From Baseline in the SLD of Unresected Intracranial Target Lesions', 'description': 'The maximum change from Baseline in the SLD of unresected intracranial target lesions was planned to be calculated as a percentage change from the baseline SLD. It was planned to be reported for the V600E and V600K analysis populations for each cohort and also aggregately if appropriate. This analysis was planned but not performed as the study was terminated due to low enrollment.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Percentage of Participants With Overall Extracranial Response Rate in Unresected Lesions', 'description': ""Overall Extracranial Response Rate was defined as the percentage of participants with Complete response (CR) or Partial response (PR) at anytime as per modified Response Evaluation Criteria in Solid Tumors (RECIST). The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence and is determined programmatically based on the investigator's assessment of response at each time point. Overall Extracranial Response Rate was planned but not analyzed as the study was terminated due to low enrollment."", 'timeFrame': 'Approximately 2 years or death whichever occurs first'}, {'measure': 'Percentage of Participants With Overall Survival', 'description': 'Overall survival, defined as the time from first dose of study treatment to death for any reason, was planned to summarize using Kaplan-Meier quartile estimates along with two sided 95% confidence intervals. But were not performed as the study was terminated due to low enrollment.', 'timeFrame': 'Approximately 2 years or death whichever occurs first'}, {'measure': 'Number of Participants With Abnormal Vital Signs', 'description': 'Vital sign measurements including temperature, respiratory rate, systolic and diastolic blood pressure, and pulse rate were planned to be performed but were neither summarized nor listed as the study was terminated.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Number of Participants With Abnormal Physical Examinations', 'description': 'A complete physical examination was planned which included assessments of the head, eyes, ears, nose, throat, skin, thyroid, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes, and extremities. Height and weight was also planned to be measured and recorded. A complete physical exam including a thorough genitourinary examination for female participants, inspection of the head and neck region, and digital rectal examination for both male and female participants was planned to be performed at Screening, and Month 12 or at discontinuation if discontinuation occurs prior to Month 12. If the participants had a genitourinary and rectal exam within 6 months of screening, these assessments need not to be repeated at screening. But data for physical examinations were not summarized and listed as the study was terminated.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Number of Participants With Abnormal 12-lead Electrocardiograms (ECG)', 'description': '112-lead ECGs were planned to be obtained at screening during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals. At each assessment a 12-lead ECG was planned to be performed by qualified personnel at the site after at least a five-minute rest with the participants in a semi-recumbent or supine position. But data for 12-lead ECGs were not summarized and listed as the study was terminated.', 'timeFrame': 'Screening'}, {'measure': 'Number of Participants With Abnormal Echocardiogram (ECHO)', 'description': 'ECHO include an evaluation for Left ventricular ejection fraction (LVEF) and both right- and left-sided valvular lesions. ECHO was planned to be performed at screening, Week 8 and every 16 weeks till discontinuation. data for ECHO was not summarized and listed as the study was terminated.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Number of Participants With Abnormal Clinical Laboratory Assessments', 'description': 'Laboratory assessments included parameters like Hematology, Standard Chemistry, Coagulation, Serum Pregnancy. Assessment of these parameters were planned to be performed by the central laboratory on screening, Day prior to surgery, Every 4 weeks after restart and Discontinuation, but were not analyzed as the study was terminated due to low enrollment.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)', 'description': 'AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AE were collected from the time the first dose of study treatment is administered until 30 days following discontinuation of study treatment regardless of initiation of a new cancer therapy using Medical Dictionary for Regulatory Activities (MedDRA)', 'timeFrame': 'Up to 2 years'}]",16,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:19.664535,v2_robust,True,True,False,True,True,This study was terminated due to the limited enrollment.
NCT04342936,Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma,"A Randomized,Open-label Phase III Study of Camrelizumab (SHR-1210) vs. Investigator's Choice of Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)",Camrelizumab,"[""Investigator's choice of Chemotherapy"", 'SHR-1210', 'Camrelizumab']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Classical Hodgkin Lymphoma,['Classical Hodgkin Lymphoma'],[],UNKNOWN,,2020-07-17,2023-12-01,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'Time from randomisation to radiologically confirmed progressive disease', 'timeFrame': 'anticipated 16 months'}]",[],1,18 Years,,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,56.0,ESTIMATED,2025-09-01T16:18:19.664631,v2_robust,True,True,False,False,False,
NCT03386136,Therapeutic Oxygen for Gastrointestinal Atony (TOGA),Therapeutic Oxygen for Gastrointestinal Atony (TOGA): Pilot Trial - Management of Acute Colonic Pseudo-Obstruction With Oxygen Supplementation,100% Oxygen,['100% Oxygen'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Ileus,"['Ileus', 'Ogilvie Syndrome', 'Small Bowel Obstruction']","['bowel ischemia', 'bowel perforation']",COMPLETED,,2018-01-25,2019-10-17,"[{'measure': 'Changes in Diameter of Colon', 'description': 'X-ray of kidney, ureter and bladder (KUB) to determine maximal cecal diameter, maximal mid-transverse colon diameter, maximal mid-sigmoid colon diameter.', 'timeFrame': '6 - 24 hours'}, {'measure': 'Changes in Diameter of the Small Bowel', 'description': 'X-ray of kidney, ureter and bladder (KUB) to determine maximal cecal diameter, maximal mid-transverse colon diameter, maximal mid-sigmoid colon diameter.', 'timeFrame': '6 - 24 hours'}]","[{'measure': 'Demonstrates No Resolution of Ileus', 'description': 'A second treatment with TOGA will be offered.', 'timeFrame': '24 - 30 hours after initial TOGA'}, {'measure': 'Worsening of Ileus', 'description': 'Worsening of ileus after initial treatment but not requiring surgical or endoscopic intervention, will be offered a second treatment of TOGA.', 'timeFrame': '24 - 30 hours after initial TOGA'}, {'measure': 'Need for endoscopic or surgical intervention', 'description': 'Worsening of ileus after initial treatment, requiring surgical or endoscopic intervention', 'timeFrame': '24 - 30 hours after initial TOGA'}, {'measure': 'Length of Hospital Stay', 'description': 'Length of stay, measured at the end of hospitalization', 'timeFrame': 'up to 100 weeks'}, {'measure': 'Patient Complaints', 'description': 'Recording of patient perception/tolerance \\[daily\\] of TOGA.', 'timeFrame': 'Up to 48 hours'}, {'measure': 'Patient Pain Measurement', 'description': 'Patient pain measurement determined subjectively through a visual analogue scale (VAS) scale of 0 (no pain) to 10 (worst pain imaginable) taken before and after TOGA treatment.', 'timeFrame': 'Up to 48 hours'}, {'measure': 'Medication Measurement', 'description': 'Documenting medication requirements for patients exposed to TOGA.(past 24 hours on a scale of 0 (no pain) to 10 (worst pain imaginable)', 'timeFrame': '24 hours before through 24 hours after TOGA'}]",9,18 Years,100 Years,ALL,False,University of Florida,OTHER,0,17.0,ACTUAL,2025-09-01T16:18:19.664639,v2_robust,True,True,True,False,False,
NCT00363636,A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL),"A Phase III, Randomized, Double-Blind Study of Galiximab in Combination With Rituximab Compared With Rituximab in Combination With Placebo for the Treatment of Subjects With Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma",Galiximab in combination with rituximab,"['Galiximab in combination with rituximab', 'Rituximab in combination with placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Lymphoma, Non-Hodgkin's","[""Lymphoma, Non-Hodgkin's""]","['relapsed', 'NHL', 'pharmacokinetics', 'antibody', 'safety', 'galiximab', 'efficacy', 'rituximab', 'refractory']",TERMINATED,Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.,2006-09,2010-04,"[{'measure': 'To assess efficacy as measured by progression free survival (PFS), and determine whether rituximab plus galiximab compared to rituximab plus placebo may extend PFS.', 'timeFrame': 'The duration of this study is approx 4 years'}]","[{'measure': 'Secondary efficacy measures include: event-free survival, time to progression, duration of response, complete response rate, and overall survival.', 'timeFrame': 'The duration of this study is approx 4 years'}, {'measure': 'Safety measures include: adverse event rates, clinical laboratory results, development of anti-galiximab and human anti-chimeric antibodies.', 'timeFrame': 'The duration of this study is approx 4 years'}, {'measure': 'Pharmacokinetics', 'timeFrame': 'The duration of this study is approx 4 years'}, {'measure': 'Quality of Life using both the Functional Assessment of Cancer Therapy-Lymphoma (FACT-lym) and the EQ-5D (EuroQoL) instruments', 'timeFrame': 'The duration of this study is approx 4 years'}]",5,18 Years,,ALL,False,Biogen,INDUSTRY,0,340.0,ACTUAL,2025-09-01T16:18:19.664683,v2_robust,True,True,False,True,True,Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.
NCT05467436,Evaluation of Pharmacogenomics Testing to Precision Prescriptions in Periodontal Patients,Evaluation of Pharmacogenomics Testing to Precision Prescriptions in Periodontal Patients,"Local anesthetics, IV sedation drugs and analgesics.","['Local anesthetics, IV sedation drugs and analgesics.']",1,INTERVENTIONAL,['PHASE4'],PHASE4,,Oral Surgeries,['Oral Surgeries'],"['Pharmacogenomics', 'Precision prescriptions']",UNKNOWN,,2020-01-01,2023-07-01,"[{'measure': 'Change in subject-reported post-surgery pain levels', 'description': ""Patient 's assessment of the pain on a scale of 0-10 in the first week after the surgery"", 'timeFrame': 'Average of pain ratings, recorded after each surgery in the first week after the surgery. Patient will receive 1 call every 2 days to report his/her pain scale. Patient will receive a total of 3 calls in the 1st week after surgery.'}, {'measure': 'Changes in post-surgery complications related to medications', 'description': 'Post-operative complication will be classified for 6 grades.', 'timeFrame': 'Post-operative complication will be assessed 2-4 weeks after the surgery'}]","[{'measure': 'Changes in post-surgery sedation assessment', 'description': 'Evaluated using Riker Sedation-Agitation Scale', 'timeFrame': 'Evaluated by the surgeon at the same day of the surgery where sedation performed'}]",3,18 Years,,ALL,False,Augusta University,OTHER,0,35.0,ESTIMATED,2025-09-01T16:18:19.664695,v2_robust,True,True,False,False,False,
NCT00249236,A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder,The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder,"Risperidone, oral tablets","['Risperidone, oral tablets']",1,INTERVENTIONAL,['PHASE3'],PHASE3,,Bipolar Disorder,"['Bipolar Disorder', 'Manic Episode']","['risperidone', 'antipsychotic agents', 'bipolar disorders', 'manic episode']",COMPLETED,,2001-03,2001-12,[{'measure': 'Change in Young Mania Rating Scale (YMRS) total score from baseline to end of treatment.'}],"[{'measure': 'Change from baseline to end of treatment in Clinical Global Impression-Severity of Illness (CGI-S) scale, Global Assessment Scale (GAS), and Positive and Negative Syndrome Scale (PANSS) total score; incidence of adverse events throughout study.'}]",2,18 Years,,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,291.0,ACTUAL,2025-09-01T16:18:19.664709,v2_robust,True,True,True,False,True,
NCT00337636,Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL),A Phase I Study of the Safety and Preliminary Effectiveness of Human CNS Stem Cells (HuCNS-SC) in Patients With Neuronal Ceroid Lipofuscinosis Caused by Palmitoyl Protein Thioesterase 1 (PPT1) or Tripeptidyl Peptidase 1 (TPP-I) Deficiency,Medication to suppress the immune system,['Medication to suppress the immune system'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Neuronal Ceroid Lipofuscinosis,['Neuronal Ceroid Lipofuscinosis'],"['NCL', 'INCL', 'LINCL', 'Batten disease', 'Infantile Neuronal Ceroid Lipofuscinosis (INCL)', 'Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)']",COMPLETED,,2006-05,2009-09,"[{'measure': 'Safety', 'timeFrame': 'one year post transpant'}]","[{'measure': 'Preliminary efficacy', 'timeFrame': 'one year post transplant'}]",2,18 Months,12 Years,ALL,False,"StemCells, Inc.",INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:19.664718,v2_robust,True,True,True,False,True,
NCT00463736,Magnesium Sulfate Versus Placebo for Tocolysis in PPROM,Magnesium Sulfate Versus Placebo for Tocolysis in Preterm Premature Rupture of Membranes,Magnesium sulfate,['Magnesium sulfate'],1,INTERVENTIONAL,['NA'],,,Preterm Premature Rupture of Membranes,['Preterm Premature Rupture of Membranes'],"['short term tocolysis', 'preterm premature rupture of membranes']",TERMINATED,enrollment proceeding too slowly,2007-04,2010-03,"[{'measure': 'hours of latency to delivery', 'description': 'from start of study drug to delivery', 'timeFrame': '0 hours to > 168 hours'}]","[{'measure': 'maternal postpartum length of stay', 'description': 'from start of study drug to delivery', 'timeFrame': '0 hours to > 168 hours'}, {'measure': 'maternal infection rates', 'description': 'from start of study drug to maternal discharge from hospital', 'timeFrame': '0 hours to > 168 hours'}, {'measure': 'neonatal ventilator days', 'description': 'from delivery to 28 days of life', 'timeFrame': '0 to 28 days'}, {'measure': 'neonatal early onset infection', 'description': 'from delivery to 28 days of life', 'timeFrame': '0 to 28 days'}, {'measure': 'neonatal length of stay', 'description': 'from delivery to 28 days of life', 'timeFrame': '0 to 28 days'}]",6,18 Years,45 Years,FEMALE,True,Regional Obstetrical Consultants,OTHER,0,4.0,ACTUAL,2025-09-01T16:18:19.664725,v2_robust,True,True,False,True,False,enrollment proceeding too slowly
NCT02444936,ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors,A Pilot Study Using a Randomized Design to Evaluate the Immunologic Efficacy and Safety of ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors,ZOSTAVAX,"['Voster vaccine live', 'ZOSTAVAX']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Shingles,['Shingles'],"['solid tumor', 'chemotherapy', 'vaccine']",UNKNOWN,,2015-05-01,2018-05-01,"[{'measure': 'Measuring the Efficacy of ZOSTAVAX in Chemotherapy Patients (Changes in ZOSTAVAX-specific IFN-gamma Spot Forming Units Will be Measured by ELISPOT)', 'description': 'To examine the cellular immunologic efficacy as measured by IFN-gamma assays of ZOSTAVAX given to individuals with solid organ tumors at least 14 days prior to initiation of chemotherapy or surgery and then chemotherapy. Changes in ZOSTAVAX-specific IFN-gamma spot forming units will be measured by ELISPOT.', 'timeFrame': '3 years'}, {'measure': 'Measuring the Safety of ZOSTAVAX Given to Chemotherapy Patients (Vaccine Report Card (VRC) to Document Injection-site Adverse Experiences, Systemic Clinical Adverse Experiences (AEs), Concomitant Medications, and Oral Temperatures', 'description': 'To asses the safety of ZOSTAVAX given to subjects that will receive chemotherapy or surgery and then chemotherapy for solid organ tumor at least 14 days after vaccination. Safety and tolerability data will be collected for all subjects throughout the study. Each subject will be given a Vaccine Report Card (VRC) to document injection-site adverse experiences, systemic clinical adverse experiences (AEs), concomitant medications, and oral temperatures (only if feeling feverish) noted during the 14-day post-vaccination period. Participants will be asked to notify the study personnel immediately if any unexpected or serious adverse experience (SAE) occurs. At all study visits subjects will be asked about any unreported SAEs. All AEs and SAEs will be recorded on an AE/SAE case report form and relationship to study vaccine will be determined by the site investigator.', 'timeFrame': '3 years'}]",[],2,50 Years,,ALL,False,Louis Stokes VA Medical Center,FED,1,22.0,ACTUAL,2025-09-01T16:18:19.664740,v2_robust,True,True,False,False,True,
NCT00615836,"An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving (""Melt"") Formulation of Desmopressin for the Treatment of Nocturia in Adults","A Multi-Center Extension Study Investigating the Long Term Efficacy and Safety of a Fast-Dissolving (""Melt"") Formulation of Desmopressin for the Treatment of Nocturia in Adults",Desmopressin Melt,"['Desmopressin Melt', 'Nocturin®', 'Minirin® Melt', 'FE992026']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Nocturia,['Nocturia'],[],COMPLETED,,2007-12,2010-05,"[{'measure': 'Change From Baseline in Mean Number of Nocturnal Voids', 'description': 'Participants completed a voiding diary for 3 consecutive 24-hour periods prior to the study visit in which they recorded each nocturnal urination (void). The mean number of voids per night was the average number of voids from the 3-day diary. Baseline refers to Baseline of Study CS29 and the number of weeks represents the total exposure to study drug.\n\nParticipants in the 10μg arm are included only until the time of dose escalation.', 'timeFrame': 'Baseline of Study CS29 and Weeks 8, 12, 20, 28, 52-56, 72-76, and 92-96.'}, {'measure': 'Percentage of Participants With a Greater Than 33% Reduction in the Mean Number of Nocturnal Voids', 'description': 'Percentage of participants with \\>33% reduction from Baseline in the mean number of nocturnal urinations per night, calculated from the 3-day voiding diary completed prior to each study visit.\n\nParticipants in the 10μg arm are included only until the time of dose escalation.', 'timeFrame': 'Baseline of Study CS29 and Weeks 8, 12, 20, 28, 52-56, 72-76, and 92-96.'}, {'measure': 'Change From Baseline in Initial Period of Undisturbed Sleep', 'description': 'Participants completed a sleep diary on 3 consecutive mornings prior to each study visit, from which the initial period of undisturbed sleep was calculated and averaged for the 3 days. The Initial Period of Undisturbed Sleep is the time elapsed from bedtime to either first void or morning arising minus the minutes it took to fall asleep. Baseline refers to Baseline of Study CS29 and the number of weeks represents the total exposure to study drug.\n\nParticipants in the 10μg arm are included only until the time of dose escalation.', 'timeFrame': 'Baseline of Study CS29 and Weeks 8, 12, 20, 28, 52-56, 72-76, and 92-96.'}]","[{'measure': 'Change From Baseline in Total Sleep Time', 'description': 'Participants completed a sleep diary on 3 consecutive mornings prior to each study visit, from which the total sleep time was calculated and averaged for the 3 days. Baseline refers to Baseline of Study CS29 and the number of weeks represents the total exposure to study drug.\n\nParticipants in the 10μg arm are included only until the time of dose escalation.', 'timeFrame': 'Baseline of Study CS29 and Weeks 8, 12, 20, 28, 52-56, 72-76, and 92-96.'}, {'measure': 'Change From Baseline in International Consultation on Incontinence Modular Questionnaire - Nocturia (ICIQ-N) Nighttime Urination Bother Score', 'description': 'The ICIQ-N is a self-administered 4-item questionnaire designed to assess the frequency and bother of daytime and nighttime urination. To assess nighttime urination bother, participants were asked to rate the degree of bother of nighttime urination by answering the question ""Night time urination: How much does this bother you?"" on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate greater bother.\n\nParticipants in the 10μg arm are included only until the time of dose escalation.', 'timeFrame': 'Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)'}, {'measure': 'Change From Baseline in Nocturia Quality of Life (NQoL) Overall Score', 'description': 'The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question (which is not included in the overall score). The 12 core items are scored on a 0 to 4 scale, and the overall score is calculated by transforming the raw score into a 0-100 scale with higher numbers indicating better impact on quality of life.\n\nParticipants in the 10μg arm are included only until the time of dose escalation.', 'timeFrame': 'Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)'}, {'measure': 'Change From Baseline in NQoL Bother/Concern Domain Score', 'description': 'The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The 12 core items are scored on a 0 to 4 scale with higher numbers indicating a better quality of life. The bother/concern domain summary score is calculated by transforming the raw score into a 0-100 scale with higher numbers indicating a better impact on quality of life.\n\nParticipants in the 10μg arm are included only until the time of dose escalation.', 'timeFrame': 'Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)'}, {'measure': 'Change From Baseline in Nocturia Quality of Life (NQoL) Sleep/Energy Domain Score', 'description': 'The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The 12 core items are scored on a 0 to 4 scale with higher numbers indicating a better quality of life. The sleep/energy domain summary score is calculated by transforming the raw score into a 0-100 scale with higher numbers indicating a better impact on quality of life.\n\nParticipants in the 10μg arm are included only until the time of dose escalation.', 'timeFrame': 'Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)'}, {'measure': 'Change From Baseline in the Nocturia Quality of Life (NQoL) Global Quality of Life Score', 'description': 'The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The global QoL question is scored on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate better impact on quality of life.\n\nParticipants in the 10μg arm are included only until the time of dose escalation.', 'timeFrame': 'Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)'}, {'measure': 'Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Global Score', 'description': 'The PSQI is a self-administered 19-item questionnaire designed to assess sleep quality and disturbances. The 19 individual items are scored on an evenly weighted 0 to 3 scale and generate 7 component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these 7 components yields 1 global score ranging from 0 to 21. Higher numbers indicate greater sleep disturbance.\n\nParticipants in the 10μg arm are included only until the time of dose escalation.', 'timeFrame': 'Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)'}, {'measure': 'Change From Baseline in the Short Form-12, Version 2 (SF-12v2) Mental Component Summary Score', 'description': 'The SF-12v2 was used to measure the impact of nocturia and lack of sleep on general quality of life. The SF-12 consists of 12 questions spanning 8 domains: physical functioning, role function-physical, role function-emotional, bodily pain, general health, vitality, social functioning, and mental health. These scales are combined to create 2 summary measures: the Physical Health Summary and Mental Health Summary. The Mental Health Summary score ranges from 0 to 100, where higher numbers indicate better quality of life.\n\nParticipants in the 10μg arm are included only until the time of dose escalation.', 'timeFrame': 'Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)'}, {'measure': 'Change From Baseline in the Short Form-12, Version 2 (SF-12v2) Physical Component Summary Score', 'description': 'The SF-12v2 was used to measure the impact of nocturia and lack of sleep on general quality of life. The SF-12 consists of 12 questions spanning 8 domains: physical functioning, role function-physical, role function-emotional, bodily pain, general health, vitality, social functioning, and mental health. These scales are combined to create 2 summary measures: the Physical Health Summary and Mental Health Summary. The Physical Health Summary score ranges from 0 to 100, where higher numbers indicate better quality of life.\n\nParticipants in the 10μg arm are included only until the time of dose escalation.', 'timeFrame': 'Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)'}, {'measure': 'Participants With Treatment-Emergent Adverse Events (AEs)', 'description': ""An AE was any untoward medical occurrence that did not necessarily have a causal relationship with the study drug. An adverse drug reaction (ADR) was an AE evaluated by the Investigator as being probably or possibly causally related to treatment with the study drug.\n\nA serious AE (SAE) was any event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect or was an important medical event that could have jeopardized the patient's safety or required medical or surgical intervention to prevent 1 of the outcomes listed above. The intensity of an AE was defined as severe if it resulted in the inability to work or perform usual activities."", 'timeFrame': 'From first dose of study drug in Study CS29 until the end of study CS31 (up to 35 months).'}]",13,18 Years,,ALL,False,Ferring Pharmaceuticals,INDUSTRY,0,554.0,ACTUAL,2025-09-01T16:18:19.664756,v2_robust,True,True,True,False,True,
NCT06992336,Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy,"A Phase II, Open-label, Randomized Trial to Compare Anlotinib and Immunotherapy and Capecitabine Versus Investigator's Choice Therapy in High Risk ctDNA Positive, Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","Anlotinib ,","['Benmelstobart', 'Capecitabine', 'Anlotinib ,']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],[],RECRUITING,,2025-04-10,2036-01-01,"[{'measure': 'iDFS', 'description': 'invasive disease free survival', 'timeFrame': 'from randomization to any of the following events: local or distant relapse; contralateral breast caner, death of any cause，assessed up to 36 months.'}]","[{'measure': 'dDFS', 'description': 'distant disease free survival', 'timeFrame': 'from randomization to any of the following events: distant relapse; contralateral breast caner, death of any cause，assessed up to 36 months'}, {'measure': 'OS', 'description': 'overall survival', 'timeFrame': 'from randomization to any of the following events: death of any cause，assessed up to 120 months'}, {'measure': 'ctDNA clearance', 'description': 'the rate of patients whose ctDNA are positive after surgery and turns negative after boost therapy', 'timeFrame': 'From the time when post-operative ctDNA is tested to be positive to the time surveillence ctDNA turns negative, assessed up to 60 months'}]",4,18 Years,70 Years,FEMALE,False,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,OTHER,0,411.0,ESTIMATED,2025-09-01T16:18:19.664945,v2_robust,True,True,False,False,False,
NCT02268136,Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL,"A Single-blind, Placebo-controlled, Parallel Group, Single Increasing Dose Tolerance Study in Healthy Male Volunteers After Intravenous Administration of BIII 890 CL (Dosage: 0.5 mg/h - 80 mg/h), Infusion Time 1 Hour.",BIII 890 CL,"['Placebo', 'BIII 890 CL']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],TERMINATED,,1999-04,,"[{'measure': 'Number of subjects with clinically relevant changes in vital signs', 'timeFrame': 'up to 8 days after drug administration'}, {'measure': 'Number of subjects with adverse events', 'timeFrame': 'up to 8 days after drug administration'}, {'measure': 'Number of subjects with clinically relevant changes in electrocardiogram', 'timeFrame': 'up to 8 days after drug administration'}, {'measure': 'Number of subjects with clinically relevant changes in pharmaco electroencephalogram (EEG)', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Number of subjects with clinically relevant changes in laboratory parameters', 'timeFrame': 'up to 8 days after drug administration'}]","[{'measure': 'Maximum plasma concentration (Cmax)', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Time to reach Cmax (tmax)', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Terminal half-life (t1/2)', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Area under the plasma concentration-time curve (AUC) for several time points', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Mean residence time (MRT)', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Plasma clearance (CL)', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Volume of distribution (Vz)', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Amount of the analyte excreted in urine (Ae)', 'timeFrame': 'up to 24 hours after drug administration'}]",13,21 Years,50 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,76.0,ACTUAL,2025-09-01T16:18:19.665025,v2_robust,True,True,False,True,True,
NCT06296836,Effect of Continuing Versus Holding Metformin During Hospitalizations.,"Effect of Continuing Versus Holding Metformin During Hospitalizations to Internal Medicine on Glucose Control, Acidosis, Abdominal Symptoms, Length of Stay, and Mortality.",Metformin,"['Glucophage', 'Metformin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],RECRUITING,,2025-01-21,2026-06-30,"[{'measure': 'Mean glucose levels', 'description': 'Average of daily glucose levels during hospitalization', 'timeFrame': 'During hospitalization'}]","[{'measure': 'Incidence of hyperglycemia greater than 300 mg/dl.', 'description': 'Glucose \\> 300', 'timeFrame': 'During hospitalization'}, {'measure': 'Incidence of hypoglycemia (Glu = 54 - 70).', 'description': 'Glu = 54 - 70', 'timeFrame': 'During hospitalization'}, {'measure': 'Incidence of moderate hypoglycemia (Glu < 54)', 'description': 'Glu \\< 54', 'timeFrame': 'During hospitalization'}, {'measure': 'Incidence of severe hypoglycemia (Glu < 54 with symptoms)', 'description': 'Glu \\< 54 with symptoms', 'timeFrame': 'During hospitalization'}, {'measure': 'Mean lactic acid levels.', 'description': 'Mean lactic acid levels', 'timeFrame': 'During hospitalization'}, {'measure': 'Incidence of lactic acid levels greater than 2.0.', 'description': 'Lactic acid \\> 2.0', 'timeFrame': 'During hospitalization'}, {'measure': 'Mean anion gap.', 'description': 'Mean anion gap, a calculated value', 'timeFrame': 'During hospitalization'}, {'measure': 'Incidence of anion gap > 11', 'description': 'Anion Gap \\> 11', 'timeFrame': 'During hospitalization'}, {'measure': 'Incidence of elevated lactic acid level or anion gap.', 'description': 'Lactic acid \\> 2.0 or Anion Gap \\> 11', 'timeFrame': 'During hospitalization'}, {'measure': 'Incidence of inadvertently not continuing metformin on discharge', 'description': 'Transitions of care', 'timeFrame': 'At discharge'}, {'measure': 'GI adverse effects', 'description': 'GI side effects after discharge', 'timeFrame': 'Within 3 days of discharge'}, {'measure': 'Mortality', 'description': 'Mortality as determined via chart search and follow up phone call', 'timeFrame': '30 +/- 3 days after discharge'}]",13,18 Years,110 Years,ALL,False,University of Illinois at Chicago,OTHER,0,300.0,ESTIMATED,2025-09-01T16:18:19.665034,v2_robust,True,True,False,False,True,
NCT03317236,Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.,"Bioequivalence Study of Quetiapine in Healthy Volunteers, After Administering a Single Dose of the Test Extended Release Formulation, Kemoter XR With Respect to the Reference Product, Etiasel XR ® From AstraZeneca S.A.",Quetiapine,['Quetiapine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Healthy,['Healthy'],"['Bioequivalence', 'Quetiapine']",COMPLETED,,2017-03-13,2017-10-01,"[{'measure': 'Cmax', 'description': 'Maximum plasma concentration', 'timeFrame': '36 hours'}, {'measure': 'AUC', 'description': 'Area under curve', 'timeFrame': '36 hours'}]",[],2,18 Years,55 Years,ALL,True,Laboratorio Elea Phoenix S.A.,INDUSTRY,1,24.0,ACTUAL,2025-09-01T16:18:19.665058,v2_robust,True,True,True,False,False,
NCT05977036,BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer,BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer,CDK4/6 + Endocrine therapy,['CDK4/6 + Endocrine therapy'],1,INTERVENTIONAL,['NA'],,,Metastatic Breast Cancer,"['Metastatic Breast Cancer', 'Unresectable Breast Cancer']","['ER+ HER2- metastatic breast cancer', 'biomarkers', 'thymidine kinase']",RECRUITING,,2024-09-25,2034-09-30,"[{'measure': 'Progression-free survival (PFS) in patients who remain on CKD4/6i (patients with suppressed TKa levels at cycle 1 day 15)', 'description': '. PFS in patients with suppressed TKa levels is defined as from the start date of receiving CDK4/6i to the end date of CDK4/6i or last date on CDK4/6i if the treatment on CDK4/6i is still ongoing or date of death if death occurs on treatment.', 'timeFrame': 'Through completion of follow-up (estimated to be 7 years)'}, {'measure': 'Clinical benefit rate (CBR) in patients who remain on CDK4/6i', 'description': 'CBR is defined as total number (or percentage) of patients who achieved a complete response, partial response, or had stable disease for 6 months or more.', 'timeFrame': 'Through completion of follow-up (estimated to be 7 years)'}, {'measure': 'Progression-free survival (PFS) in patients who switch to an alternate therapy (patients with unsuppressed TKa levels at cycle 1 day 15)', 'description': 'PFS in patients with unsuppressed TKa levels is defined as from the start date of receiving CDK4/6i to the end date of next-line therapy or last date on next-line if the treatment on next-line therapy is still ongoing or date of death if death occurs on treatment.', 'timeFrame': 'Through completion of follow-up (estimated to be 7 years)'}]","[{'measure': 'Feasibility (compliance rate) in patients with suppressed TKa level at cycle 1 day 15', 'description': '-Feasibility defined as compliance rate:\n\n\\*\\*Patients with suppressed TKa at C1D15, C2D1, C4D1 and 24 weeks: compliance is defined as this subset of physicians and patients who delay restaging scans from 24 weeks to 36 weeks.', 'timeFrame': 'At 36 weeks'}, {'measure': 'Feasibility (compliance rate) in patients with unsuppressed TKa level at cycle 1 day 15', 'description': '-Feasibility defined as compliance rate:\n\n\\*\\*Patients with unsuppressed TKa at C1D15: compliance is defined as subset of physicians and patients following protocol recommendation to switch to next line of treatment.', 'timeFrame': 'At Cycle 1 Day 15'}, {'measure': 'Baseline TKa level to predict overall survival (OS) on first-line CDK4/6i', 'description': 'OS is defined as from the start date of receiving CDK4/6i to the date of death or date of last follow up.', 'timeFrame': 'Through completion of follow-up (estimated to be 7 years)'}, {'measure': 'Baseline TKa level to predict overall survival (OS) on later lines of therapy', 'description': 'OS is defined as from the start date of receiving CDK4/6i to the date of death or date of last follow up.', 'timeFrame': 'Through completion of follow-up (estimated to be 7 years)'}, {'measure': 'Cycle 1 day 15 TKa level to predict overall survival (OS) on first-line CDK4/6i', 'description': 'OS is defined as from the start date of receiving CDK4/6i to the date of death or date of last follow up.', 'timeFrame': 'Through completion of follow-up (estimated to be 7 years)'}, {'measure': 'Cycle 1 day 15 TKa level to predict overall survival (OS) on later lines of therapy', 'description': 'OS is defined as from the start date of receiving CDK4/6i to the date of death or date of last follow up.', 'timeFrame': 'Through completion of follow-up (estimated to be 7 years)'}, {'measure': 'Cycle 2 day 1 TKa level to predict overall survival (OS) on first-line CDK4/6i', 'description': 'OS is defined as from the start date of receiving CDK4/6i to the date of death or date of last follow up.', 'timeFrame': 'Through completion of follow-up (estimated to be 7 years)'}, {'measure': 'Cycle 2 day 1 TKa level to predict overall survival (OS) on later lines of therapy', 'description': 'OS is defined as from the start date of receiving CDK4/6i to the date of death or date of last follow up.', 'timeFrame': 'Through completion of follow-up (estimated to be 7 years)'}, {'measure': 'Number of patients with TKa suppressed at cycle 1 day 15 who have stable disease on subsequent disease assessments', 'timeFrame': 'Through 2 years'}]",12,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,65.0,ESTIMATED,2025-09-01T16:18:19.665126,v2_robust,True,True,False,False,False,
NCT03165136,Hydroxychloroquine for Prevention of Recurrent Miscarriage.,"Prévention Des Fausses Couches Spontanées Répétées Par Hydroxychloroquine. Essai thérapeutique Multicentrique, randomisé, en Double Insu, Contre Placebo",Hydroxychloroquine,"['Placebo', 'Hydroxychloroquine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Recurrent Miscarriage,"['Recurrent Miscarriage', 'First Trimester Abortion']","['Unexplained Recurrent Miscarriage', 'First trimester abortion', 'Hydroxychloroquine', 'Antiphospholipid antibody']",ACTIVE_NOT_RECRUITING,,2017-12-04,2026-02-01,"[{'measure': 'A live and viable birth', 'description': 'In case of preterm and/or low birth weight, we define the viability by the decision to transfer the newborn to a neonatal intensive care unit', 'timeFrame': 'At delivery'}]","[{'measure': 'a live and viable birth (for the subgroup analyses)', 'timeFrame': 'At delivery'}, {'measure': 'occurrence of pregnancy complications (Recurrent Miscarriage-any other premature termination of pregnancy-placental vascular disease)', 'timeFrame': 'Since the beginning of pregnancy up to delivery'}, {'measure': 'gestation time (in weeks of amenorrhea) at delivery,', 'timeFrame': 'At delivery up'}, {'measure': 'birth weight (in grams) at delivery', 'timeFrame': 'At delivery'}, {'measure': 'survival of the newborn', 'timeFrame': 'At 28 days of the newborn'}, {'measure': 'psychomotor development of the child (normal/abnormal)', 'timeFrame': 'at 6 months of age'}, {'measure': 'psychomotor development of the child (normal/abnormal)', 'timeFrame': 'at 12 months of age'}, {'measure': 'height (in centimeters)', 'timeFrame': 'at 6 months of age'}, {'measure': 'height (in centimeters)', 'timeFrame': 'at 12 months of age'}, {'measure': 'weight (in grams)', 'timeFrame': 'at 6 months of age'}, {'measure': 'weight (in grams)', 'timeFrame': 'at 12 months of age'}, {'measure': 'Cranial perimeter (in centimeters)', 'timeFrame': 'at 6 months of age'}, {'measure': 'Cranial perimeter (in centimeters)', 'timeFrame': 'at 12 months of age'}]",14,18 Years,38 Years,FEMALE,False,"University Hospital, Brest",OTHER,0,300.0,ESTIMATED,2025-09-01T16:18:19.665163,v2_robust,True,True,False,False,False,
NCT06682611,Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.,"An, Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.",SYHA1813,"['Etoposide', 'Paclitaxel', 'SYHA1813', 'Carboplatin', 'Everolimus', 'Cisplatin', 'Regorafenib', 'HB1801', 'SG001']",9,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Unresectable Locally Advanced or Metastatic Solid Tumors,['Unresectable Locally Advanced or Metastatic Solid Tumors'],[],NOT_YET_RECRUITING,,2024-11-13,2027-11-13,"[{'measure': 'DLT', 'description': 'Safety run-in stage，Dose-limiting toxicity (DLT) will be assessed according to NCI-CTCAE v5.0.', 'timeFrame': 'Up to approximately 2years'}, {'measure': 'Frequency and severity of TEAE and SAE', 'description': 'Safety run-in stage', 'timeFrame': 'Up to approximately 2years'}, {'measure': 'ORR', 'description': 'Cohorts 1-6, Objective response rate (ORR) as evaluated by Investigator (RECIST1.1)', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'PFS', 'description': 'Cohorts 7-8, Progression-free survival (PFS) as evaluated by Investigator (RECIST1.1)', 'timeFrame': 'Up to approximately 2years'}]","[{'measure': 'OS', 'description': 'Overall survival', 'timeFrame': 'Up to approximately 2years'}, {'measure': 'DoR', 'description': 'Duration of response', 'timeFrame': 'Up to approximately 2years'}, {'measure': 'DCR', 'description': 'Disease control rate', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Frequency and severity of TEAE and SAE', 'description': 'Safety', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Plasma Concentration', 'description': 'Concentration of SYHA1813/SG001/HB1801 in serum', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Immunogenicity', 'description': 'Incidence of SG001 Anti-drug antibody (ADA) and neutralizing antibody (Nab) (if applicable)', 'timeFrame': 'Up to approximately 2 years'}]",10,18 Years,,ALL,False,"Shanghai Runshi Pharmaceutical Technology Co., Ltd",INDUSTRY,0,380.0,ESTIMATED,2025-09-01T16:18:19.665213,v2_robust,True,True,False,False,True,
NCT02223611,Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection,Phase ⅡTrial of S1 Capsule Plus Cisplatin Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage Ⅱ-ⅢA Non-small Cell Lung Cancer (NSCLC) After Complete Resection,S1 capsule,"['S1 capsule', 'S1: Gimeracil and oteracil porassium capsules', 'Vinorelbine: Navelbine,vinorelbine bitartrate injection', 'Vinorelbine', 'Cisplatin: Cisplatin for injection']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-small Cell Lung Cancer Stage Ⅱ,"['Non-small Cell Lung Cancer Stage Ⅱ', 'Non-small Cell Lung Cancer Stage ⅢA']",['Stage Ⅱ-ⅢA NSCLC S1 capsule Completely resection'],UNKNOWN,,2014-12,2018-12,"[{'measure': 'Disease free survival rate', 'timeFrame': '2 years'}]","[{'measure': 'Disease free survival', 'description': 'The period from the date of enrollment to the date on which the recurrence was first confirmed. For patients who died before disease progression from any cause, death was attributed to recurrence.', 'timeFrame': '4 years'}, {'measure': 'Overall survival', 'description': 'The period from the date of enrollment to the date of death from any cause.', 'timeFrame': '4 years'}, {'measure': 'Number of Participants with Adverse Events as a Measure of Safety and Tolerability', 'description': 'The incidences of adverse events were calculated according to the National Cancer Institute Cancer Common Toxicity Criteria, version 4.0.', 'timeFrame': 'Participants will be followed for the duration of hospital stay, an expected average of 3 weeks.'}, {'measure': 'Quality of life (QOL)', 'description': 'QOL was assessed with the lung cancer subscale of the Functional Assessment of Cancer Therapy-Lung (FACT-L) and Lung Cancer Symptom Scale(LCSS).', 'timeFrame': 'Participants will be followed for the duration of hospital stay, an expected average of 3 weeks.'}]",5,18 Years,75 Years,ALL,False,Hebei Medical University Fourth Hospital,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:19.665223,v2_robust,True,True,False,False,True,
NCT00381511,Deferment of Imaging for Pulmonary Embolism,Objective Assessment of Pulmonary Embolism Can be Deferred Without Increased Risk,low molecular weight heparin,['low molecular weight heparin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Pulmonary Embolism,['Pulmonary Embolism'],"['pulmonary embolism,', 'deferred diagnosis,', 'protective anticoagulation', 'anticoagulants']",COMPLETED,,1999-01,2004-04,"[{'measure': 'Recurrent venous thromboembolism'}, {'measure': 'major bleeding'}, {'measure': 'death'}]",[],3,18 Years,,ALL,False,Azienda Ospedaliera Universitaria Policlinico,OTHER,0,300.0,,2025-09-01T16:18:19.665304,v2_robust,True,True,True,False,False,
NCT01312311,Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer,Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer,"Docetaxel, Cisplatin","['Docetaxel, Cisplatin']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Nasopharyngeal Cancer,['Nasopharyngeal Cancer'],"['nasopharyngeal cancer', 'weekly docetaxel', 'cisplatin']",UNKNOWN,,2006-07,,"[{'measure': 'objective response rate', 'timeFrame': '6 months after the enrollment of the last patients'}]","[{'measure': 'number of patients with adverse events', 'timeFrame': 'simultaneously when the analysis of primary endpoint'}]",2,18 Years,,ALL,False,Samsung Medical Center,OTHER,0,51.0,ESTIMATED,2025-09-01T16:18:19.665385,v2_robust,True,True,False,False,True,
NCT05370911,Effects of Repeated Psilocybin Dosing in OCD,"Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study",Psilocybin,['Psilocybin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Obsessive-Compulsive Disorder,['Obsessive-Compulsive Disorder'],['Psilocybin'],RECRUITING,,2023-07-20,2027-07,"[{'measure': 'Change in Yale-Brown Obsessive-Compulsive Scale-Second Edition (Y-BOCS-II) Severity Scale total score from baseline at 4 days post-second dose', 'description': 'Clinician-administered assessment of severity of OCD symptoms over the past seven days. The most prominent obsessions and compulsions are rated on the Severity Scale from 0 to 4. Total Y-BOCS-II scores range from 0 to 40, with higher scores indicating greater severity of OCD symptoms.', 'timeFrame': 'Baseline & 4 days post-second dose'}]","[{'measure': 'Change in Montgomery-Asberg Depression Scale (MADRS) total score from baseline at 4 days post-second dose', 'description': 'Clinician-administered assessment of severity of depressive symptoms over past month. Total scores range from 0 to 60, with higher scores indicating greater severity of depressive symptoms.', 'timeFrame': 'Baseline & 4 days post-second dose'}, {'measure': 'Change in Dimensional Obsessive-Compulsive Scale (DOCS) total score from baseline at 4 days post-second dose', 'description': 'Self-report measure of various OCD symptoms over the modified time frame of the past week. Total scores range from 0 to 140, with higher scores indicating greater severity of OCD symptoms.', 'timeFrame': 'Baseline & 4 days post-second dose'}, {'measure': 'Change in Obsessive Beliefs Questionnaire-44 (OBQ-44) total score from baseline at 4 days post-second dose', 'description': 'Self-report measure of various obsessive beliefs implicated in OCD in general. Total scores range from 44 to 308, with higher scores indicating greater severity of obsessive beliefs.', 'timeFrame': 'Baseline & 4 days post-second dose'}, {'measure': 'Change in Acceptance and Action Questionnaire for Obsessions and Compulsions (AAQ-OC) total score from baseline at 4 days post-second dose', 'description': 'Self-report measure of experiential avoidance and psychological flexibility in the context of OCD symptoms in general. Total scores range from 13 to 91, with higher scores indicating greater psychological inflexibility.', 'timeFrame': 'Baseline & 4 days post-second dose'}, {'measure': 'Change in Tolerance of Uncontrollability Questionnaire (TOUQ) total score from baseline at 4 days post-second dose', 'description': 'Self-report measure of ability to tolerate uncontrollability (or inversely need for control) in general. Total scores range from 19 to 133, with higher scores indicating greater tolerance of uncontrollability.', 'timeFrame': 'Baseline & 4 days post-second dose'}, {'measure': 'Change in White Bear Suppression Inventory (WBSI) total score from baseline at 4 days post-second dose', 'description': 'Self-report measure of thought suppression tendencies in general. Total scores range from 15 to 75, with higher scores indicating stronger thought suppression tendencies.', 'timeFrame': 'Baseline & 4 days post-second dose'}, {'measure': 'Change in Difficulties in Emotion Regulation Scale (DERS) total score from baseline at 4 days post-second dose', 'description': 'Self-report measure of emotion regulation difficulties in general. Total scores range from 36 to 180, with higher scores indicating greater difficulties with regulating emotions.', 'timeFrame': 'Baseline & 4 days post-second dose'}, {'measure': 'Change in Southampton Mindfulness Questionnaire (SMQ) total score from baseline at 4 days post-second dose', 'description': 'Self-report measure of trait mindfulness in regards to distressing thoughts and images. Total scores range from 0 to 96, with higher scores indicating greater trait mindfulness.', 'timeFrame': 'Baseline & 4 days post-second dose'}, {'measure': 'Toronto Mindfulness Scale (TMS)', 'description': 'Self-report measure of state mindfulness during dosing session. Total scores range from 0 to 52, with higher scores indicating greater state mindfulness.', 'timeFrame': 'Up to 3 weeks for immediate treatment condition, and up to 10 weeks for waitlist condition'}, {'measure': 'Set, Setting, and Intentions (SSI) Scale', 'description': 'Self-report measure of set, setting, and clarity of intentions just prior to dosing session. Total mean scores range from 0 to 100 (after reverse-scoring two items), with higher scores indicating greater preparedness for the dosing session.', 'timeFrame': 'Up to 3 weeks for immediate treatment condition, and up to 10 weeks for waitlist condition'}, {'measure': 'Mystical Experience Questionnaire (MEQ)', 'description': 'Self-report measure of acute mystical experiences during dosing. Total mean scores range from 0 to 5, with higher scores indicating greater mystical experiences.', 'timeFrame': 'Up to 3 weeks for immediate treatment condition, and up to 10 weeks for waitlist condition'}, {'measure': 'Psychological Insight Questionnaire (PIQ)', 'description': 'Self-report measure of acute psychological insights during dosing. Total mean scores range from 0 to 5, with higher scores indicating greater insightful experiences.', 'timeFrame': 'Up to 3 weeks for immediate treatment condition, and up to 10 weeks for waitlist condition'}, {'measure': 'Challenging Experience Questionnaire (CEQ)', 'description': 'Self-report measure of acute challenging experiences during dosing. Total mean transformed scores range from 0 to 1, with higher scores indicating greater challenging experiences.', 'timeFrame': 'Up to 3 weeks for immediate treatment condition, and up to 10 weeks for waitlist condition'}, {'measure': 'Ego Dissolution Inventory (EDI)', 'description': 'Self-report measure of acute experiences of ego dissolution during dosing. Total mean scores range from 0 to 100, with higher scores indicating greater ego dissolution.', 'timeFrame': 'Up to 3 weeks for immediate treatment condition, and up to 10 weeks for waitlist condition'}, {'measure': 'Emotional Breakthrough Inventory (EBI)', 'description': 'Self-report measure of different experiences of emotional breakthroughs during dosing. Total mean scores range from 0 to 100, with higher scores indicating greater emotional breakthrough.', 'timeFrame': 'Up to 3 weeks for immediate treatment condition, and up to 10 weeks for waitlist condition'}, {'measure': 'Change in Self-Compassion Scale (SCS) total mean score from baseline at 4 days post-second dose', 'description': 'Self-report measure of self-compassion in general. Total mean scores range from 1 to 5 (after reverse-scoring 13 items), with higher scores indicating greater self-compassion.', 'timeFrame': 'Baseline & 4 days post-second dose'}, {'measure': 'Change in Ten-Item Personality Inventory (TIPI) total score from baseline at 4 days post-second dose', 'description': 'Brief self-report measure of Big Five personality dimensions. Total scores range from 10 to 70 (after reverse-scoring 5 items), with higher scores indicating more positive personality traits.', 'timeFrame': 'Screening, 4 days and 12 months post-second dose'}, {'measure': 'Change in Persisting Effects Questionnaire (PEQ) subscale scores from 4 weeks post-second dose at 12 months post-second dose', 'description': 'Self-report measure of persisting effects from dosing in general. Subscale scores range from a minimum of 0 to a maximum of 5 to 85, with higher scores indicating greater positive or negative persisting changes since dosing.', 'timeFrame': '4 weeks post-second dose & 12 months post-second dose'}, {'measure': 'Change in Alcohol Use Disorders Identification Test (AUDIT) total score from baseline at 4 weeks post-second dose', 'description': 'Self-report measure of alcohol use severity. Total scores range from 0 to 40, with higher scores indicating greater alcohol use severity.', 'timeFrame': 'Baseline & 4 weeks post-second dose'}, {'measure': 'Change in Drug Use Disorders Identification Test (DUDIT) total score from baseline at 4 weeks post-second dose', 'description': 'Self-report measure of illicit substance use. Total scores range from 0 to 44, with higher scores indicating greater illicit substance use severity.', 'timeFrame': 'Baseline & 4 weeks post-second dose'}, {'measure': 'Change in Fagerstrom Test for Nicotine Dependence (FTND) total score from baseline at 4 weeks post-second dose', 'description': 'Self-report measure of nicotine use. Total scores range from 0 to 10, with higher scores indicating greater nicotine use severity.', 'timeFrame': 'Baseline & 4 weeks post-second dose'}, {'measure': 'Change in World Health Organization Disability Assessment Scale, v2.0 (WHODAS-2.0) 12-item, self-administered version total score from baseline at 4 days post-second dose', 'description': 'Self-report measure of symptom-related functional impairment in general. Total scores range from 12 to 60, with higher scores indicating greater functional impairment.', 'timeFrame': 'Baseline & 4 weeks post-second dose'}, {'measure': 'Change in Quality of Life Enjoyment & Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) percentage maximum score from baseline at 4 days post-second dose', 'description': 'Self-report measure of life satisfaction over the past week. Percentage maximum scores range from 0% to 100%, with higher percentages indicating greater life satisfaction.', 'timeFrame': 'Baseline & 4 weeks post-second dose'}, {'measure': 'Writing task', 'description': 'Online writing task in which participants describe their perceptions of their OCD symptoms with a short written essay', 'timeFrame': 'Baseline & 4 days post-second dose'}, {'measure': 'Columbia Suicide Severity and Risk Scale (C-SSRS) Since Last Visit version', 'description': 'Clinician-administered assessment of suicidal ideation and behaviors since the last study visit', 'timeFrame': 'Every study visit through study completion, an average of 12 months and 3 weeks for immediate treatment condition, and an average of 12 months and 10 weeks for waitlist condition'}, {'measure': 'Theoretical Orientation Profile Scale-Revised (TOPS-R)', 'description': 'Clinician-reported measure of theoretical orientation over 11 subscales, each corresponding to a different theoretical orientation. Subscale scores range from 1 to 30, with higher scores indicating greater affiliation with a particular theoretical orientation.', 'timeFrame': 'Baseline'}, {'measure': 'Working Alliance Inventory-Short Revised (WAI-SR)', 'description': 'Self-report measure of perceived working alliance with study clinicians. Total scores range from 0 to 60, with higher scores indicating stronger perceived working alliance.', 'timeFrame': 'Up to 4 days post-second dose'}, {'measure': 'Change in Symptom Provocation Task (SPT) ratings from baseline at 4 days post-second dose', 'description': 'Behavioral measure of OCD symptoms when provoked with idiosyncratic questions. Scores for compulsive urges range from 0-10 in terms of VAS ratings, with higher VAS ratings indicating greater compulsive urges.', 'timeFrame': 'Baseline & 4 days post-second dose'}, {'measure': 'Stanford Expectations of Treatment Scale (SETS)', 'description': 'Self-report measure of treatment expectancy over 2 subscales, corresponding to positive and negative expectancy. Subscale scores range from 7 to 21, with higher scores indicating more positive or negative expectancy.', 'timeFrame': 'Baseline'}]",30,18 Years,65 Years,ALL,False,Yale University,OTHER,1,30.0,ESTIMATED,2025-09-01T16:18:19.665438,v2_robust,True,True,False,False,False,
NCT06193811,A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood,"Relative Bioavailability of Two Different Tablet Formulations of BI 685509 and Investigation of the Effects of Food and Esomeprazole on the Pharmacokinetics of BI 685509 Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Four-way Crossover Trial)",Avenciguat (BI 685509) (intended commercial formulation (iCF)),"['Avenciguat (BI 685509) (intended commercial formulation (iCF))', 'esomeprazole', 'Avenciguat (BI 685509) (trial formulation 2 (TF2))']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2024-01-16,2024-03-14,"[{'measure': 'Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)', 'timeFrame': 'Up to 4 days'}, {'measure': 'Maximum measured concentration of the analyte in plasma (Cmax)', 'timeFrame': 'Up to 4 days'}]","[{'measure': 'Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)', 'timeFrame': 'Up to 4 days'}]",3,18 Years,55 Years,ALL,True,Boehringer Ingelheim,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:19.665533,v2_robust,True,True,True,False,False,
NCT00003111,Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer,Phase II Clinical and Laboratory Study of Irinotecan/Cisplatin Chemotherapy Followed by Surgery in Stage III NSCLC,carboplatin,"['irinotecan hydrochloride', 'cisplatin', 'paclitaxel', 'carboplatin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Cancer,['Lung Cancer'],['stage IIIA non-small cell lung cancer'],COMPLETED,,1997-04,2004-04,[],[],0,18 Years,,ALL,False,Yale University,OTHER,1,10.0,ACTUAL,2025-09-01T16:18:19.665549,v2_robust,True,True,True,False,False,
NCT03428711,Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis,Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis,Mesoglycan Oral Tablet,"['Prisma', 'Placebo Oral Tablet', 'Mesoglycan Oral Tablet', 'placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Superficial Venous Thrombosis of Leg, Secondary Prevention","['Superficial Venous Thrombosis of Leg, Secondary Prevention']","['Superficial Venous Thrombosis of Leg', 'secondary prevention', 'prophylaxis']",COMPLETED,,2018-03-26,2024-12-31,"[{'measure': 'Cumulative thrombosis recurrence', 'description': 'Cumulative occurrence of the first event, with instrumental confirmation, occurring during the study treatment between: recurrence or extension of, asymptomatic or symptomatic, SVT, new DVT (proximal asymptomatic or symptomatic / symptomatic isolated distal), pulmonary embolism (fatal or symptomatic non-fatal).', 'timeFrame': '12 months'}]","[{'measure': 'Cumulative thrombosis recurrence with distal', 'description': 'Cumulative occurrence of the first event between: recurrence or extension of, asymptomatic or symptomatic, SVT, new proximal / distal DVT (asymptomatic or symptomatic), pulmonary embolism (fatal or symptomatic non-fatal)', 'timeFrame': '12 months'}, {'measure': 'Symptoms', 'description': 'variation during the follow-up of the ""revised Venous Clinical Severity Score"" (rVCSS); min-max scale value 0-30; higher value represent a worse severity outcome.', 'timeFrame': '12 months'}, {'measure': 'VEINES-QOL/ Sym score', 'description': 'variation during the follow-up of the ""Venous Insufficiency Epidemiological and Economic Study"" (VEINES)-QOL/ Sym scores;\n\nsubscale QOL: a venous disease-specific measure of quality of life; min-max scale value 0-100; higher value represent a better quality of life outcome.\n\nsubscale Sym: a venous disease-specific measure of symptoms ; min-max scale value 0-100; higher value represent a better symptomatic outcome.', 'timeFrame': '12 months'}]",4,18 Years,90 Years,ALL,False,Quovadis Associazione,OTHER,1,560.0,ACTUAL,2025-09-01T16:18:19.665556,v2_robust,True,True,True,False,False,
NCT02473211,SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients,Efficacy and Safety of Sofosbuvir Plus Daclatasvir in Chinese Treatment-experienced Patients With Chronic Genotype 1b HCV Infection,Sofosbuvir,"['Daclatasvir', 'Sofosbuvir', 'GS-7977', 'BMS-790052']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Chronic Hepatitis C Infection,['Chronic Hepatitis C Infection'],[],COMPLETED,,2015-01,2018-03-15,"[{'measure': 'Proportion of participants with sustained virologic response 12 weeks after the end of treatment (SVR12)', 'description': 'SVR12 is defined as HCV RNA \\< the lower limit of quantitation (LLOQ) (15 IU/ml) 12 weeks following the last dose of study drug', 'timeFrame': 'Post treatment Week 12'}]",[],1,18 Years,,ALL,False,Humanity and Health Research Centre,OTHER,1,106.0,ACTUAL,2025-09-01T16:18:19.665723,v2_robust,True,True,True,False,False,
NCT07013071,Hemodynamic Effects of Different Vasoconstrictors in Mandibular Exodontia,The Effect of Different Vasoconstrictive Agents on Hemodynamics Among Patients Undergoing Simple Mandibular Exodontia: A Triple-Blind Randomized Controlled Trial,"2% Mepivacaine with 1:100,000 epinephrine","['2% Mepivacaine with 1:55,000 Epinephrine Bitartrate', '2% Mepivacaine with 1:100,000 epinephrine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hemodynamics,"['Hemodynamics', 'Pain', 'ASA I-II Requiring Simple Dental Extraction of a Mandibular Tooth']","['Mepivacaine 2% with vasoconstrictor', 'Hemodynamic effects of vasoconstrictors', 'Epinephrine vs epinephrine bitartrate', 'Pain control during dental extraction', 'Blood pressure and heart rate during dental procedures']",COMPLETED,,2024-02-10,2024-05-20,"[{'measure': 'Change in Systolic and Diastolic Blood Pressure', 'description': 'To compare changes in systolic and diastolic blood pressure between the two groups (epinephrine vs. epinephrine bitartrate) at three time points: before administration of local anesthesia, 3 minutes after administration (intraoperative), and postoperatively following simple mandibular tooth extraction.', 'timeFrame': 'Measured preoperatively, 3 minutes post-anesthesia (intraoperative), and immediately after the procedure (postoperative).'}, {'measure': 'Change in Heart Rate', 'description': 'To evaluate changes in heart rate between the two intervention groups across the same three time points to assess the hemodynamic impact of the vasoconstrictors used.', 'timeFrame': 'Measured preoperatively, 3 minutes post-anesthesia (intraoperative), and immediately after the procedure (postoperative).'}]","[{'measure': 'Pain Score Using Visual Analogue Scale (VAS)', 'description': 'To compare pain perception during and after the dental procedure between the two groups using a 10-point Visual Analogue Scale (VAS). Patients reported pain at 30-minute intervals throughout the procedure and at the end of treatment. The minimum value on the VAS is 0 and the maximum is 10.', 'timeFrame': 'Assessed every 30 minutes during the procedure and once at the completion of the extraction.'}]",3,18 Years,,ALL,True,King Abdulaziz University,OTHER,0,52.0,ACTUAL,2025-09-01T16:18:19.665732,v2_robust,True,True,True,False,False,
NCT04481971,A Comparison of Two Different Single Doses of Prednisolone on Endodontic Inter-appointment Pain,Comparative Evaluation of the Effectiveness of Premedication With Two Different Single Doses of Prednisolone on Inter-appointment Pain in Symptomatic Patients With Irreversible Pulpitis: a Double-blind Randomized Controlled Clinical Trial,Prednisolone,"['Prednisolone', 'lactose in capsules gelatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Endodontics,"['Endodontics', 'Pain']",[],UNKNOWN,,2020-08-09,2020-12-31,"[{'measure': 'Change in post-operative pain', 'description': 'Questionnaire (visual analogue scale)', 'timeFrame': 'Change from baseline pain and pain at 4, 12, 24, and 48 hours after initiation of therapy'}]",[],1,18 Years,45 Years,ALL,True,King Saud University,OTHER,0,72.0,ESTIMATED,2025-09-01T16:18:19.665820,v2_robust,True,True,False,False,False,
NCT02821871,"the Food Effect Pharmacokinetic, Material Balance and Metabolite Identification of SP2086 in Healthy Volunteers",,SP2086,['SP2086'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Type 2 Diabetes,['Type 2 Diabetes'],[],UNKNOWN,,2016-03,2016-09,"[{'measure': 'The maximum plasma concentration (Cmax) of SP2086', 'description': ""Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086"", 'timeFrame': 'up to Day 12'}, {'measure': 'The maximum plasma concentration (Cmax) of SP2086 acid', 'description': ""Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086."", 'timeFrame': 'up to Day 12'}, {'measure': 'The area under the plasma concentration-time curve (AUC) of SP2086', 'description': ""AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086."", 'timeFrame': 'up to Day 12'}, {'measure': 'The area under the plasma concentration-time curve (AUC) of SP2086 acid', 'description': ""AUC (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086."", 'timeFrame': 'up to Day 12'}, {'measure': 'Cumulative percentage drainage of SP2086 in urine', 'timeFrame': 'up to Day 12'}, {'measure': 'Cumulative percentage drainage of SP2086 in fecal', 'timeFrame': 'up to Day 12'}]","[{'measure': 'The number of volunteers with adverse events as a measure of safety and tolerability', 'timeFrame': 'up to Day 12'}]",7,18 Years,45 Years,MALE,True,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,24.0,ESTIMATED,2025-09-01T16:18:19.665835,v2_robust,True,True,False,False,True,
NCT02695771,The Bladder Instillation Comparison Study,"A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)",Mitomycin C,"['Mitomycin C', 'Gemzar, Novaplus', 'Gemcitabine', 'Mutamycin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Urinary Bladder Neoplasms,['Urinary Bladder Neoplasms'],"['bladder tumors', 'urinary tumors', 'non-muscle invasive bladder tumors', 'NMIBC']",COMPLETED,,2016-04-19,2021-10-22,"[{'measure': 'Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03', 'description': 'The NCI CTCAE Version 4.03 grades adverse events as follows: grade 3 include severe but non-life-threatening consequences that result in hospitalization and/or interventions, including elective radiologic or operative interventions; grade 4 events include life-threatening consequences, such as those requiring urgent reoperation; and grade 5 events result in treatment-related death.', 'timeFrame': 'Two years'}]","[{'measure': 'Freedom From Bladder Stones/Dystrophic Calcification', 'description': 'The secondary endpoint for this study will be the number of subjects who did not experience dystrophic calcification or bladder calculi measured by the number of patients with Grade 3 through Grade 5 Adverse Events that are related to study arm, graded according to NCI CTCAE Version 4.03.Version 4.03', 'timeFrame': 'Two years'}]",2,18 Years,,ALL,False,Spectrum Health Hospitals,OTHER,0,101.0,ACTUAL,2025-09-01T16:18:19.665910,v2_robust,True,True,True,False,True,
NCT04886271,Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors,A Multicenter Phase II Clinical Study of Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors,HX009,['HX009'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Solid Tumor,['Advanced Solid Tumor'],[],UNKNOWN,,2021-05-12,2023-02-10,"[{'measure': 'Objective response rate (ORR) of patients with solid tumors treated with HX009 assessed by the Independent Review Committee (IRC)', 'description': 'The ORR is defined as the percentage of participants in the analysis population who had a confirmed Complete Response or Partial Response using RECIST 1.1 criteria.', 'timeFrame': 'Approximately 1 year'}]","[{'measure': 'Objective response rate(ORR) of patients with solid tumors treated with HX009 per Investigator Assessment', 'description': 'The ORR is defined as the percentage of participants in the analysis population who had a confirmed Complete Response or Partial Response using RECIST 1.1 criteria.', 'timeFrame': 'Approximately 1 year'}, {'measure': 'Duration of response (DoR) of patients with solid tumors treated with HX009', 'description': 'The DoR is defined as the time from the first recorded response (CR or PR) to the first recorded tumor progression or death due to any cause.', 'timeFrame': 'Approximately 1 year'}, {'measure': 'Disease control rate (DCR) of patients with solid tumors treated with HX009', 'description': 'The DCR is defined as the percentage of participants in the analysis population who had a confirmed Complete Response, or Partial Response, or Stable Disease using RECIST 1.1 criteria.', 'timeFrame': 'Approximately 1 year'}, {'measure': 'Progression-free survival (PFS) of patients with solid tumors treated with HX009', 'description': 'PFS is defined as the time from the start of the first dose and the first documented disease progression using RECIST 1.1 criteria or death of any cause.', 'timeFrame': 'Approximately 1 year'}, {'measure': 'Overall survival (OS) of patients with solid tumors treated with HX009', 'description': 'OS is defined as the time between the start of the first dose and death of any cause.', 'timeFrame': 'Approximately 1 year'}, {'measure': 'Incidence of treatment-related adverse events in patients with advanced solid tumors treated with HX009', 'description': 'Adverse events (AEs) related to HX009 as determined by the investigator are recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0).', 'timeFrame': 'AEs will be collected from the start of the study treatment up to 90 days after the last dose.'}, {'measure': 'Severity of treatment-related adverse events in patients with advanced solid tumors treated with HX009', 'description': 'Adverse events (AEs) related to HX009 as determined by the investigator are recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0).', 'timeFrame': 'AEs will be collected from the start of the study treatment up to 90 days after the last dose.'}, {'measure': 'Number of patients having detectable anti-drug antibody (ADA) of HX009', 'description': 'Detection of ADA is a measure of immunogenicity of HX009', 'timeFrame': 'Approximately 1 year'}, {'measure': 'Number of patients having detectable neutralizing antibody (Nab) of HX009', 'description': 'Detection of Nab is a measure of immunogenicity of HX009', 'timeFrame': 'Approximately 1 year'}, {'measure': 'Elimination half-life (t1/2β) of HX009 in patients with advanced solid tumors', 'description': 'Key pharmacokinetic parameter', 'timeFrame': 'Approximately 1 year'}, {'measure': 'Mean residence time in the body (MRT) of HX009 in patients with advanced solid tumors', 'description': 'Key pharmacokinetic parameter', 'timeFrame': 'Approximately 1 year'}, {'measure': 'Area under the concentration-time curve (AUC0-t) of HX009 in patients with advanced solid tumors', 'description': 'Key pharmacokinetic parameter', 'timeFrame': 'Approximately 1 year'}, {'measure': 'Peak plasma concentration (Cmax) of HX009 in patients with advanced solid tumors', 'description': 'Key pharmacokinetic parameter', 'timeFrame': 'Approximately 1 year'}, {'measure': 'Time to peak plasma concentration (Tmax) of HX009 in patients with advanced solid tumors', 'description': 'Key pharmacokinetic parameter', 'timeFrame': 'Approximately 1 year'}]",15,18 Years,75 Years,ALL,False,Waterstone Hanxbio Pty Ltd,INDUSTRY,0,210.0,ESTIMATED,2025-09-01T16:18:19.666086,v2_robust,True,True,False,False,True,
NCT06238544,Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria,"An Open Label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria",HRS-5965 tablets,"['HRS-5965 Capsules', 'HRS-5965 tablets']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Paroxysmal Nocturnal Hemoglobinuria,['Paroxysmal Nocturnal Hemoglobinuria'],[],RECRUITING,,2024-02-06,2027-12,"[{'measure': 'Incidence and severity of adverse events.', 'timeFrame': 'Every six months,for about 3 years'}]","[{'measure': 'Proportion of participants achieving sustained hemoglobin levels ≥ 12 g/dL in the absence of red blood cell transfusions was assessed every half a year during treatment..', 'timeFrame': 'Every six months ,for about 3 years'}, {'measure': 'Proportion of participants who remain free from transfusions was assessed every half a year during treatment..', 'timeFrame': 'Every six months,for about 3 years'}, {'measure': 'Rate of breakthrough hemolysis was assessed every half a year during treatment', 'timeFrame': 'Every six months,for about 3 years'}, {'measure': 'Proportion of participants with Major Adverse Vascular Events MAVEs.', 'timeFrame': 'Every six months,for about 3 years'}, {'measure': 'Plasma concentration of HRS-5965.', 'timeFrame': 'Start of Treatment to end of study，for about 3 years'}]",6,18 Years,,ALL,False,"Chengdu Suncadia Medicine Co., Ltd.",INDUSTRY,0,120.0,ESTIMATED,2025-09-01T16:18:19.666129,v2_robust,True,True,False,False,True,
NCT03691844,AMZ001 for the Treatment of Knee Osteoarthritis Symptoms,"A Placebo-controlled, Double-blind, Randomized, Trial of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms",AMZ001,"['active comparator', 'Comparator', 'AMZ001', 'Placebo']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,"Osteoarthritis, Knee","['Osteoarthritis, Knee']",['AMZ001'],COMPLETED,,2018-10-04,2019-07-09,"[{'measure': 'WOMAC Pain Sub-score', 'description': 'Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-score (questions 1-5; score 0 \\[no pain\\]-50 \\[extreme pain\\]) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.', 'timeFrame': 'baseline, week 4'}]","[{'measure': 'WOMAC Total Score and WOMAC Function and Stiffness', 'description': 'Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) total score and WOMAC function (degree of difficulty experienced in performing daily activities - 17 questions score 0-170) and stiffness (the degree and timing of joint stiffness - 2 questions score 0-20). The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.', 'timeFrame': 'baseline, week 4'}, {'measure': 'WOMAC Pain Weight-bearing Score and Non-weight-bearing Score', 'description': 'Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) pain weight-bearing score (questions 1,2, \\& 5; score 0-30) and non-weight-bearing score (questions 3\\&4; score 0-20) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.', 'timeFrame': 'baseline, week 4'}, {'measure': 'ICOAP Scores', 'description': 'Change from baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) scores (score 0 \\[no pain\\]- 4 \\[extreme pain\\]). ICOAP scores were normalized to a 0-100 point scale, where 0 is no pain and higher scores indicate greater pain.', 'timeFrame': 'baseline, week 4'}, {'measure': 'Physical Function', 'description': 'Change in baseline in physical function assessed by the chair-stand test. The test measures the maximum number of chair stand repetitions possible in a 30-second period with out using the arms. Where 0 is no repetition completed and higher numbers corresponds to greater repetitions and physical function.', 'timeFrame': 'baseline, week 4'}, {'measure': 'Proportion of Responders as Per OMERACT-OARSI Criteria', 'description': 'Outcome Measures in Rheumatology- Osteoarthritis Research Society International (OMERACT-OARSI) response involves changes that are deemed to be clinically relevant in three domains: pain, function, and PGA (Patient Global Assessment). For each of these domains, ranges are defined for absolute and percent changes from baseline that correspond to ""high improvement"" and ""moderate improvement"". OMERACT-OARSI response is defined as either high improvement in at least 1 of WOMAC pain and function scores OR moderate improvement in at least 2 of WOMAC pain scores, WOMAC function score or Patient Global Assessment (PGA)', 'timeFrame': 'week 4'}, {'measure': 'Total Dose of Rescue Medication', 'description': 'Total dose of rescue medication calculated as the average gram use/day, based on pill counts.', 'timeFrame': 'weeks 1 through 4'}, {'measure': 'Time Between Baseline and First Use of Rescue Medication', 'description': 'Time between baseline and first use of rescue medication.', 'timeFrame': 'weeks 1 through 4'}, {'measure': 'WOMAC Pain Sub-score (Dose Comparison)', 'description': 'Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-score (questions 1-5; score 0 \\[no pain\\]-50 \\[extreme pain\\]) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.', 'timeFrame': 'baseline, week 4'}, {'measure': 'ICOAP Scores (Dose Comparison)', 'description': 'Change from baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) scores (score 0 \\[no pain\\]- 4 \\[extreme pain\\]). ICOAP scores were normalized to a 0-100 point scale, where 0 is no pain and higher scores indicate greater pain.', 'timeFrame': 'baseline, week 4'}, {'measure': 'WOMAC Pain Weight-bearing Score and Non-weight-bearing Score (Dose Comparison)', 'description': 'Changes from baseline in Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) pain weight-bearing score (questions 1,2, \\& 5; score 0-30) and non-weight-bearing score (questions 3\\&4; score 0-20) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.', 'timeFrame': 'baseline, week 4'}, {'measure': 'Physical Function (Dose Comparison)', 'description': 'Change in baseline assessed by the chair-stand test. The test measures the maximum number of chair stand repetitions possible in a 30-second period with out using the arms. Where 0 is no repetition completed and higher numbers corresponds to greater repetitions and physical function.', 'timeFrame': 'baseline, week 4'}, {'measure': 'WOMAC Total Score and WOMAC Function and Stiffness (Dose Comparison)', 'description': 'Change from baseline in Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) total score and WOMAC function (degree of difficulty experienced in performing daily activities - 17 questions score 0-170) and stiffness (the degree and timing of joint stiffness - 2 questions score 0-20). The WOMAC scores were normalized to a 0-100 point scale for data analysis, where 0 is no pain and higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.', 'timeFrame': 'baseline, week 4'}, {'measure': 'Impact of Osteoarthritis on Daily Living (PGA Score)', 'description': 'Change from baseline in Impact of OA daily living assessed using Patient Global Assessment (PGA) score. PGA is scored on a 11-point scale from 0 (none) to 10 (extreme), where higher scores represents a higher level of disease activity or worse health.', 'timeFrame': 'baseline, week 4'}, {'measure': 'Work Productivity', 'description': 'Change from baseline in work productivity and activity assessed by the Work Productivity and Active Impairment (WPAI scores 0-100% in four different categories: absenteeism, presenteeism, work productivity loss, and activity impairment). Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.', 'timeFrame': 'baseline, week 4'}, {'measure': 'Change in Quality of Life: EQ5D VAS Score', 'description': 'The EuroQol-5 Domain (EQ-5D) is a standardized generic measure of health-related quality of life. The visual analog scale (VAS) is scored on a 0-100 scale, where 0 is ""the worst health you can imagine"" and 100, ""the best health you can imagine"".', 'timeFrame': 'baseline, week 4'}]",16,40 Years,85 Years,ALL,False,Amzell,INDUSTRY,0,444.0,ACTUAL,2025-09-01T16:18:19.666158,v2_robust,True,True,True,False,False,
NCT05294744,Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32),Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32),N-acetylcysteine,['N-acetylcysteine'],1,INTERVENTIONAL,['NA'],,,Alcoholic Hepatitis,['Alcoholic Hepatitis'],[],UNKNOWN,,2022-04,2023-07,"[{'measure': 'Number of Participants with all-cause mortality at 6 months.', 'description': 'Main result variable.', 'timeFrame': '6 months.'}]","[{'measure': 'Number of participants with complications: infections, ascites, gastrointestinal bleeding, renal failure, hepatic encephalopathy, need for MARSH or orthotopic liver transplantation.', 'description': 'Security variable.', 'timeFrame': '3 months'}]",2,18 Years,75 Years,ALL,False,Bioaraba Health Research Institute,NETWORK,0,390.0,ESTIMATED,2025-09-01T16:18:19.666221,v2_robust,True,True,False,False,False,
NCT00694044,"Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects","A Randomized, Investigator and Subject Blind, Sponsor Open Parallel Group Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pro-Cognitive Effects of Varenicline, Under Various Titration Schemes, in Healthy Elderly Non-Smoking Subjects",varenicline,"['Placebo', 'Champix, Chantix', 'varenicline']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,"['Healthy', 'Non-Smoking']","['Safety, Tolerability, Pharmacokinetics, Cognition']",COMPLETED,,2008-04,2008-06,"[{'measure': 'Tolerability and safety (adverse events, electrocardiogram, vital signs, clinical safety labs, self reported nausea visual analogue scales)', 'timeFrame': '21 days'}, {'measure': 'Steady state pharmacokinetics', 'timeFrame': '21 days'}, {'measure': 'Effects on cognition (computerized battery of cognitive tests)', 'timeFrame': '21 days'}]","[{'measure': 'No secondary outcomes.', 'timeFrame': 'Time frame n/a'}]",4,65 Years,85 Years,ALL,True,Pfizer,INDUSTRY,0,50.0,ACTUAL,2025-09-01T16:18:19.666262,v2_robust,True,True,True,False,True,
NCT03394144,Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies,"A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD9150 Monotherapy and AZD9150 in Combination With Durvalumab in Japanese Patients With Advanced Solid Malignancies","AZD9150, Durvalumab","['AZD9150, Durvalumab']",1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Malignancies,['Advanced Solid Malignancies'],[],COMPLETED,,2018-01-30,2019-04-12,"[{'measure': 'Safety and tolerability in terms of adverse events', 'description': 'Number of subjects with adverse events as a measure of safety and tolerability including changes in vital signs, electrocardiograms (ECGs), safety and laboratory parameters', 'timeFrame': 'From obtaining the first informed consent until 28 days after the last dose (AZD9150). In patients with Durvalumab until 90 days after the last dose (Durvalumab). Expected to be for up to 12 months.'}]","[{'measure': 'Maximum plasma concentration (Cmax)', 'description': 'Pharmacokinetics (PK) parameters will be derived using standard non-compartmental methods.', 'timeFrame': 'From obtaining the first informed consent until 28 days after the last dose (AZD9150). In patients with Durvalumab for 90 days for the last dose (Durvalumab). Expected to be for up to 12 months.'}, {'measure': 'Overall response rate', 'description': 'Defined as the proportion of subjects who achieve a response.', 'timeFrame': 'Assessed at every even numbered cycle with RECIST until disease progression. Expected to be for up to 12 months.'}, {'measure': 'Duration of Response', 'description': 'Defined as the interval from the first documentation of response to the earlier of the first documentation of definitive disease progression or death from any cause.', 'timeFrame': 'Assessed at every even numbered cycle with RECIST until disease progression. Expected to be for up to 12 months.'}, {'measure': 'Area under the plasma concentration-time curve (AUC)', 'description': 'PK parameters will be derived using standard non-compartmental methods.', 'timeFrame': 'From obtaining the first informed consent until 28 days after the last dose (AZD9150). In patients with Durvalumab for 90 days for the last dose (Durvalumab). Expected to be for up to 12 months.'}]",5,20 Years,120 Years,ALL,False,AstraZeneca,INDUSTRY,0,11.0,ACTUAL,2025-09-01T16:18:19.666289,v2_robust,True,True,True,False,True,
NCT05702944,The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma,A Pilot Study for Randomized Controlled Trial on the Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma,Phenoxybenzamine,['Phenoxybenzamine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Pheochromocytoma,"['Pheochromocytoma', 'Paraganglioma', 'Adrenalectomy; Status', 'Adrenergics Causing Adverse Effects in Therapeutic Use']",[],RECRUITING,,2023-01-18,2027-12-31,"[{'measure': 'The effect and safety of omitting preoperative alpha blockade during surgery', 'description': 'Percentage of time during the surgery with systolic blood pressure \\> 160mmHg or average blood pressure \\< 60mmHg', 'timeFrame': 'during surgery'}]","[{'measure': 'The effect and safety of omitting preoperative alpha blockade during surgery', 'description': '1. Percentage of the surgery time greater than 100 times per pulse minute\n2. Average systolic/diastolic blood pressure in millimeters of mercury and pulse in beats each minutes during surgery\n3. Types and amount of antihypertensive drugs in mg per day during surgery\n4. Types and amount of vasopressor drugs in mg per day during surgery', 'timeFrame': 'during surgery'}, {'measure': 'The effect and safety of omitting preoperative alpha blockade before surgery', 'description': '1. The number of times systolic blood pressure more than 130 mmHg and diastolic blood pressure more than 80mmHg in the preoperative ward\n2. The number of times of pulse rate per minute more than 80 times in the preoperative ward', 'timeFrame': '3 days, 2 days, 1 day before surgery'}, {'measure': 'The effect and safety of omitting preoperative alpha blockade after surgery', 'description': '1. The number of times of average blood pressure less than 60mmHg in postoperative ward\n2. Average blood pressure in postoperative ward\n3. Types and amount of antihypertensive drugs in mg per day after surgery\n4. Types and amount of vasopressor drugs in mg per day after surgery', 'timeFrame': '1 day, 2 day, 2 weeks, 3 months after surgery'}]",4,19 Years,70 Years,ALL,False,Seoul National University Hospital,OTHER,0,24.0,ESTIMATED,2025-09-01T16:18:19.666379,v2_robust,True,True,False,False,True,
NCT06147544,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.","A Single Center, Randomized, Double Blind, Placebo Controlled, Multiple Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.",PB-718,"['PB-718', 'Placebo']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Obesity,['Obesity'],[],COMPLETED,,2023-07-06,2024-04-16,"[{'measure': 'Incidence of Treatment-Emergent Adverse Events', 'timeFrame': 'From the first dosing (Day 1 ) of study drug until completion of the post treatment follow-up visit (20 weeks for cohort 1 and cohort 2 or 26 weeks for cohort 3)'}]","[{'measure': 'Pharmacokinetic profile', 'description': 'Cmax', 'timeFrame': 'From the first dose (Day 1 ) of study drug until week 12 (for cohort 1 and cohort 2) or week 18(for cohort 3)'}, {'measure': 'Pharmacokinetic profile', 'description': 'Tmax', 'timeFrame': 'From the first dose (Day 1 ) of study drug until week 12(for cohort 1 and cohort 2) or week 18(for cohort 3)'}, {'measure': 'Pharmacokinetic profile', 'description': 'Area under the concentration-time curve over dosing interval(AUC0-tau）', 'timeFrame': 'From the first dose (Day 1 ) of study drug until week 12(for cohort 1 and cohort 2) or week 18(for cohort 3)'}, {'measure': 'Pharmacokinetic profile', 'description': 'Area under the concentration-time curve from time zero to the time of the last quantifiable concentration（AUC0-last）', 'timeFrame': 'From the first dose (Day 1 ) of study drug until week 12(for cohort 1 and cohort2) or week 18(for cohort 3)'}, {'measure': 'Pharmacokinetic profile', 'description': 't1/2', 'timeFrame': 'From the first dose (Day 1 ) of study drug until week 12(for cohort 1 and cohort 2) or week 18(for cohort3)'}, {'measure': 'Proportion of participants with ≥5% weight loss', 'timeFrame': 'week 12 (for cohort 1 and cohort2) or week 18(for cohort 3)'}, {'measure': 'Change in body weight from baseline', 'timeFrame': 'Week12(for cohort 1 and cohort 2) or week 18(for cohort 3)'}, {'measure': 'Change in Fasting Plasma Glucose(FPG) from baseline', 'timeFrame': 'week 12(for cohort 1 and cohort 2) or week 18(for cohort 3)'}]",9,18 Years,60 Years,ALL,True,"PegBio Co., Ltd.",OTHER,0,36.0,ACTUAL,2025-09-01T16:18:19.666422,v2_robust,True,True,True,False,True,
NCT00865644,Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1,Pilot Study of Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1,Imiquimod 5% Cream,['Imiquimod 5% Cream'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Neurofibromatosis Type 1,"['Neurofibromatosis Type 1', 'Cutaneous Neurofibromas']",['imiquimod 5% cream'],COMPLETED,,2009-03,2013-12,"[{'measure': 'To determine the effect of topical imiquimod 5% cream on tumor volume of cutaneous neurofibromas in adult subjects with neurofibromatosis 1', 'timeFrame': '2 years'}]","[{'measure': 'To correlate the inflammatory infiltrate adjacent to treated lesions during treatment with tumor response and to determine the number of circulating Tregs in this patient population', 'timeFrame': '2 years'}]",2,18 Years,,ALL,False,Massachusetts General Hospital,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:19.666596,v2_robust,True,True,True,False,False,
NCT04545944,Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants,"An Open-Label, Fixed Sequence, Clinical Drug Interaction Study to Evaluate the Time-Dependent Inhibition Potential of Vonoprazan on a Sensitive CYP3A4 Substrate, Midazolam, in Healthy Volunteers",Vonoprazan,"['Vonoprazan', 'Midazolam']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['vonoprazan', 'midazolam']",COMPLETED,,2020-09-15,2020-11-25,"[{'measure': 'Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Midazolam', 'description': 'AUC0-t was measured for midazolam alone on Day 1 and for midazolam administered with vonoprazan on Day 9.', 'timeFrame': 'Day 1 (midazolam alone): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose; Day 9 (midazolam and vonoprazan): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Midazolam', 'description': 'AUC0-inf was measured for midazolam alone on Day 1 and for midazolam administered with vonoprazan on Day 9.', 'timeFrame': 'Day 1 (midazolam alone): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose; Day 9 (midazolam and vonoprazan): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of Midazolam', 'description': 'Cmax was measured for midazolam alone on Day 1 and for midazolam administered with vonoprazan on Day 9.', 'timeFrame': 'Day 1 (midazolam alone): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose; Day 9 (midazolam and vonoprazan): Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose'}]",[],3,18 Years,45 Years,ALL,True,"Phathom Pharmaceuticals, Inc.",INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:19.666630,v2_robust,True,True,True,False,False,
NCT03576144,This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.,"Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhaled Doses of BI 1265162 in Healthy Male Subjects in a Randomised, Double Blind, Placebo-controlled Trial",BI 1265162,"['Placebo', 'BI 1265162']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2018-07-11,2018-12-06,"[{'measure': 'Percentage of Participants With Drug-related Adverse Events (AEs)', 'description': 'Percentage of participants with drug-related adverse events (AEs).', 'timeFrame': 'From first drug administration until 2 days after last drug administration, up to 10 days.'}]","[{'measure': 'Area Under the Concentration-time Curve of the BI 1265162 in Plasma Over the Time Interval of 0 to 12 Hour (h) After Administration of the First Dose (AUC0-12)', 'description': 'Area under the concentration-time curve of the BI 1265162 in plasma over the time interval of 0 to 12 hour (h) after administration of the first dose (AUC0-12).', 'timeFrame': 'Pharmacokinetic samples were taken within 1:30 hour:minute (h:m) before dosing and 0:02, 0:05, 0:10, 0:15, 0:20 , 0:40, 1:00, 2:00, 4:00, 8:00 and 12:00 h:m after dosing on day 1.'}, {'measure': 'Maximum Measured Concentration of the BI 1265162 in Plasma After Administration of the First Dose (Cmax)', 'description': 'Maximum measured concentration of the BI 1265162 in plasma after administration of the first dose (Cmax).', 'timeFrame': 'Pharmacokinetic samples were taken within 1:30 hour: minute (h:m) before dosing and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 8:00, 12:00 and 24:00 h:m after dosing on day 1.'}, {'measure': 'Area Under the Concentration-time Curve of the BI 1265162 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss)', 'description': 'Area under the concentration-time curve of the BI 1265162 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss).', 'timeFrame': 'Pharmacokinetic samples were taken 0:05 hour: minute (h:m) before dosing and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 8:00 and 12:00 h:m after last dosing on day 8.'}, {'measure': 'Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax,ss)', 'description': 'Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss).', 'timeFrame': 'Pharmacokinetic samples were taken 0:05 hour: minute (h:m) before dosing and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 8:00 and 12:00 h:m after last dosing on day 8.'}]",5,18 Years,45 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,50.0,ACTUAL,2025-09-01T16:18:19.666647,v2_robust,True,True,True,False,True,
NCT06964334,The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection,The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection,Lansoprazole,"['clarithromycin', 'Lansoprazole', 'amoxicillin', 'vitamin D']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Helicobacter Pylori Infection,['Helicobacter Pylori Infection'],[],NOT_YET_RECRUITING,,2025-06-01,2026-08-01,"[{'measure': 'cure rate after treatment', 'description': 'compare cure rate between two groups', 'timeFrame': '3 months'}]",[],1,1 Year,18 Years,ALL,False,Assiut University,OTHER,0,70.0,ESTIMATED,2025-09-01T16:18:19.666688,v2_robust,True,True,False,False,False,
NCT03549234,Erector Spinae Versus Paravertebral Nerve Blocks for Breast Surgery,"A Randomized, Subject-Masked, Active-Controlled, Parallel-Arm Clinical Trial Comparing Erector Spinae and Paravertebral Nerve Blocks",Erector Spinae (single injection),"['Paravertebral (single injection)', 'Erector Spinae (single injection)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Breast Surgery,['Breast Surgery'],"['Regional anesthesia', 'Paravertebral', 'Erector spinae', 'Nerve block']",COMPLETED,,2018-07-12,2019-05-08,"[{'measure': 'Numeric Rating Scale Pain Scores', 'description': 'Range scale minimum 0, maximum 10. Lower pain scores are considered a better outcome, higher pain scores are considered a worse outcome.', 'timeFrame': '1 day (PACU pain scores)'}, {'measure': 'OR and PACU Opioid Consumption', 'description': 'This outcome measure reflects the total amount of opioid administered in the operating room and recovery room perioperatively. Specific time points are not applicable since operating room and recovery room times differ among subjects.', 'timeFrame': 'up to 1 day, in the OR and PACU'}]",[],2,18 Years,,ALL,False,"University of California, San Diego",OTHER,0,100.0,ACTUAL,2025-09-01T16:18:19.666707,v2_robust,True,True,True,False,False,
NCT03358134,Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis,Mechanism of Action Study of Anti-IL17 Treatment in Spondyloarthritis: Impact on Cellular and Molecular Pathways of Synovial Inflammation and Tissue Remodeling,Secukinumab,"['AIN457', 'Secukinumab']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Spondylarthropathies,['Spondylarthropathies'],"['Peripheral Spondylarthropathies', 'Psoriatic arthritis', 'Reactive arthritis']",COMPLETED,,2014-03,2017-10,"[{'measure': 'Biological changes induced by therapy on target tissue (synovium)', 'description': 'Molecular changes of the synovium as measured by expression of several cytokines/chemokines by quantitative polymerase chain reaction (qPCR) as measured by a change in cytokine expression between baseline and week 12.', 'timeFrame': 'week 0 and week 12'}, {'measure': 'Changes of cellular infiltrate in the target tissue (synovium)', 'description': 'Changes in cell count measured by immunohistochemistry (on a 0-4 semi-quantitative analysis scale)', 'timeFrame': 'week 0 and week 12'}]","[{'measure': 'Adverse events', 'description': 'Number of patients with adverse events as a measure of safety and tolerability', 'timeFrame': 'between day0 and 2 yrs of treatment'}, {'measure': 'Vessel wall inflammation', 'description': 'Changes in Fludeoxyglucose (FDG18) PET/CT uptake in the vessel walls of the carotic arteries and aorta as measured by CT values', 'timeFrame': 'week 0 and week 12'}]",4,18 Years,70 Years,ALL,False,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),OTHER,1,20.0,ACTUAL,2025-09-01T16:18:19.666828,v2_robust,True,True,True,False,True,
NCT06660134,Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF,Strict Weight Management and Glycemic Control Based on Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment VS. Conventional Antidiabetic Drugs for Ablation Outcomes in Overweight or Obese Patients with Type 2 Diabetes and Atrial Fibrillation,Glucagon-like peptide-1 receptor agonists (GLP 1 RA),['Glucagon-like peptide-1 receptor agonists (GLP 1 RA)'],1,INTERVENTIONAL,['NA'],,,Type 2 Diabetes Mellitus (T2DM),"['Type 2 Diabetes Mellitus (T2DM)', 'Atrial Fibrillation (AF)']","['Catheter ablation', 'Glucagon-like Peptide-1 receptor agonist', 'Atrial fibrillation', 'overweight', 'obesity']",COMPLETED,,2021-08-01,2024-01-10,"[{'measure': 'Atrial fibrillation (AF), atrial flutter (AFL), or atrial tachycardia events lasting ≥30 seconds occurring from the end of a 3-month blanking period post-procedure up to 12 months of follow-up.', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}]","[{'measure': 'Changes in Body Mass Index (BMI) from baseline to 12 months.', 'description': 'Combine weight and height, and report the Body Mass Index (BMI) in units of kilograms per square meter (kg/m²).', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3 month blanking period'}, {'measure': 'Quality of life assessments.', 'description': 'The quality of life and cardiac function of the subjects were assessed using the World Health Organization Quality of Life (WHOQOL-100) questionnaire.', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}, {'measure': 'Complications associated with AF ablation and serious adverse events (such as rehospitalizations, cardiovascular rehospitalizations) occurring during the study period.', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}, {'measure': 'Quality of life assessments', 'description': 'Quality of life assessments were conducted within at least 12 months of follow-up using measures such as the AF6.', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}, {'measure': 'Quality of life assessments', 'description': 'Quality of life assessments were conducted using the AFEQT (Atrial Fibrillation Effect on Quality of Life) questionnaire.', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}, {'measure': 'Psychological distress', 'description': 'Psychological distress was assessed using the HADS (Hospital Anxiety and Depression Scale).', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}, {'measure': 'Functional status', 'description': 'Functional status was assessed using the CCS-SAF (Canadian Cardiovascular Society - Self-Assessed Functioning scale).', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3 month blanking period'}, {'measure': 'quality of life', 'description': 'The quality of life and cardiac function of the subjects were assessed using the New York Heart Association (NYHA) functional classification.', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}]",9,18 Years,,ALL,False,Shanghai Chest Hospital,OTHER,3,174.0,ACTUAL,2025-09-01T16:18:19.666927,v2_robust,True,True,True,False,True,
NCT01950234,ACTH in Progressive Forms of MS,Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel),ACTH,"['Acthar gel', 'ACTH', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Secondary Progressive Multiple Sclerosis,"['Secondary Progressive Multiple Sclerosis', 'Primary Progressive Multiple Sclerosis', 'Progressive Relapsing Multiple Sclerosis']",[],TERMINATED,The funding source discontinued financial support for the study.,2014-04-17,2022-12-31,"[{'measure': 'Proportion of Patients Exhibiting a 20% Worsening in T25FW at 36 Months', 'timeFrame': 'Month 36'}]","[{'measure': 'Safety and Tolerability of ACTH: Menstrual Changes [Female]', 'description': 'Count of participants self reporting at any time throuhgout the study noticing any changes in menstrual cycle or period.', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: DEXA Scans', 'description': ""The number is a T-score. There is no maximum or minimum value. Mean change in average of 5 DEXA scan values dual-energy x-ray absorptiometry; measures bone mineral density. Higher numbers are better.\n\nA DEXA T-score has a mean of 0 and standard deviation of 1, meaning that a T-score represents how many standard deviations a person's bone density is away from the average bone density of a healthy young adult, with a score of 0 indicating average bone density. Higher scores are better, indicating better bone density. A T-score of -1 to +1 is considered normal bone density, a score between -1 and -2.5 indicates osteopenia (low bone mass), and a score of -2.5 or lower indicates osteoporosis."", 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Bruising', 'description': 'Count of participants self reporting at any time throuhgout the study that they bruise more easily', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Swelling Ankles', 'description': 'Count of participants self reporting at any time throuhgout the study that have noticed swelling in their ankles', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Hair Loss', 'description': 'Count of participants self reporting at any time throuhgout the study that have noticed losing more hair', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Acne', 'description': 'Count of participants self reporting at any time throuhgout the study that have noticed in increase in acne', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Insomnia', 'description': 'Count of participants self reporting at any time throuhgout the study that they have been having trouble sleeping', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Mood Change', 'description': 'Count of participants self reporting at any time throuhgout the study that they have noticed changes in mood', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: GI Upset', 'description': 'Count of participants self reporting at any time throuhgout the study that they have had upset stomach, indigestion, diarrhea, or bloating', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Fatigue', 'description': 'Count of participants self reporting at any time throuhgout the study that noticed feeling tired or worn out', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Unpleasant Taste', 'description': 'Count of participants self reporting at any time throuhgout the study noticing a metallic taste in their mouth', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Blurred Vision', 'description': 'Count of participants self reporting at any time throuhgout the study noticing any blurred vision', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Moon Facies', 'description': 'New physician assessed moon facies over study duration', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Skin Thinning', 'description': 'New physician assessed skin thinning over study duration', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Hirsuitism', 'description': 'New physician assessed hirsuitism over study duration', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Bruising', 'description': 'New physician assessed bruising over study duration', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Ankle Swelling', 'description': 'New physician assessed ankle swelling over study duration', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Hair Loss', 'description': 'Any new physician assessed hair loss over study duration', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Cataracts', 'description': 'New physician assessed cataracts over study duration', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Myopathy', 'description': 'New physician assessed myopathy over study duration', 'timeFrame': 'Month 36'}, {'measure': 'Safety and Tolerability of ACTH: Change in Hemoglobin A1c', 'description': 'Change in hemoglobin A1c', 'timeFrame': 'Month 36'}]",22,18 Years,,ALL,False,University of Minnesota,OTHER,1,59.0,ACTUAL,2025-09-01T16:18:19.667093,v2_robust,True,True,False,True,True,The funding source discontinued financial support for the study.
NCT01499134,Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure,Effect of Nebivolol Compared With Metoprolol in Hypertensive Patients With Peripheral Arterial Disease,nebivolol,"['Bystolic', 'Metoprolol succinate', 'Toprol XL', 'nebivolol']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Peripheral Artery Disease,"['Peripheral Artery Disease', 'Hypertension']",[],COMPLETED,,2011-08,2014-06,"[{'measure': 'Peak Walking Time (PWT)', 'description': 'Change in peak walking time (PWT) is measured in seconds. The PWT is defined as when walking on a treadmill cannot continue due to maximal leg pain, resulting in the discontinuation of the treadmill test.', 'timeFrame': 'Baseline PWT is measured at the time of enrollment and again at the final study visit at 26 weeks.'}]","[{'measure': 'Ankle-brachial Index (ABI)', 'description': 'Change in measurement of Ankle-brachial index (ABI). The ABI is the ratio of the blood pressure measured in the lower legs to the blood pressure measured in the arms.', 'timeFrame': 'Baseline ABI is measured at the time of enrollment and again at the final study visit at 26 weeks'}, {'measure': 'Claudication Onset Time (COT)', 'description': 'Change in measurement of claudication onset time (COT). The COT is defined as the time when a patient first experienced pain walking during a treadmill test.', 'timeFrame': 'Baseline COT is measured at the time of enrollment and again at the final study visit at 26 weeks.'}, {'measure': 'Walking Impairment Questionnaire (WIQ) - Change Calf Pain', 'description': 'Change in calf pain as captured by the Walking Impairment Questionnaire (WIQ). A 5 point Likert scale scoring ranges from 1) No Difficulty, 2) Slight Difficulty, 3) Some Difficulty, 4) Much Difficulty, and 5) Great Difficulty. The scores are determined by dividing the score by the maximum possible score and then multiplying by 100. The score ranges from 0-100 with lower scores indicating greater pain.', 'timeFrame': 'Baseline WIQ is completed at the time of enrollment and again at the final study visit at 26 weeks.'}, {'measure': 'Walking Impairment Questionnaire (WIQ) - Change in Buttock Pain', 'description': 'Change in buttock pain as captured by the Walking Impairment Questionnaire (WIQ). A 5 point Likert scale scoring ranges from 1) No Difficulty, 2) Slight Difficulty, 3) Some Difficulty, 4) Much Difficulty, and 5) Great Difficulty. The scores are determined by dividing the score by the maximum possible score and then multiplying by 100. The score ranges from 0-100 with lower scores indicating greater pain.', 'timeFrame': 'Baseline WIQ is completed at the time of enrollment and again at the final study visit at 26 weeks.'}, {'measure': 'Walking Impairment Questionnaire (WIQ) - Change in WIQ Distance Score', 'description': 'Change in distance score as captured by the Walking Impairment Questionnaire (WIQ) distance score subscale. The degree of difficulty in the walking of specific distances is ranked on a 0 to 4 Likert scale, in which 0 represents the inability to walk the distance and 4 represents no difficulty. A Likert scale is an ordinal scale of consecutive, equidistant, numerical values (ie, 0 to 4). The distances assessed in the WIQ range from walking indoors around the home to walking 5 blocks (1500 feet). The items on the subscale are weighted according to the difficulty of walking. The distance score is determined by dividing the total weighted score by the greatest possible weighted score and multiplying by 100. Scores range from 0-100.', 'timeFrame': 'Baseline WIQ is completed at the time of enrollment and again at the final study visit at 26 weeks.'}, {'measure': 'Walking Impairment Questionnaire (WIQ) - Change in WIQ Speed Score', 'description': 'Change in speed score as captured by the Walking Impairment Questionnaire (WIQ) speed score subscale. In the walking speed component, the degree of difficulty walking is ranked on a 0 to 4 scale where speed is assessed for each of the following speeds: at the following speeds: 1, slowly; 2, average speed; 3, quickly; or 4, running or jogging 1 block. Zero represents the inability to walk the specified speed, and 4 represents no difficulty. The items on the subscale are weighted according to the difficulty of the task. The speed score is determined by dividing the total weighted score by the greatest possible weighted score and multiplying by 100. Scores range from 0-100.', 'timeFrame': 'Baseline WIQ is completed at the time of enrollment and again at the final study visit at 26 weeks.'}, {'measure': 'Walking Impairment Questionnaire (WIQ) - Change in WIQ Stairs Score', 'description': 'Change in stairs score as captured by the Walking Impairment Questionnaire (WIQ) stairs subscale. This scale item asks the subject to describe the degree of difficulty climbing one, two, or three flights of stairs in the past week. A flight of stairs is defined as 14 steps. A 5 point Likert scale scoring ranges from 1) No Difficulty, 2) Slight Difficulty, 3) Some Difficulty, 4) Much Difficulty, 5) Unable to Do, or 6) Didn Do for Other Reasons. The items on the subscale are weighted according to the difficulty of the task. The stairs score is determined by dividing the total weighted score by the greatest possible weighted score and multiplying by 100. Scores range from 0-100.', 'timeFrame': 'Baseline WIQ is completed at the time of enrollment and again at the final study visit at 26 weeks.'}]",8,18 Years,,ALL,False,Thomas Jefferson University,OTHER,1,17.0,ACTUAL,2025-09-01T16:18:19.667103,v2_robust,True,True,True,False,False,
NCT00486564,Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma,A Phase I Trial of Nifurtimox for Relapsed or Refractory Neuroblastoma,Nifurtimox,['Nifurtimox'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Neuroblastoma,['Neuroblastoma'],"['Treatment', 'Refractory or Relapsed']",COMPLETED,,2006-11,2009-06,"[{'measure': 'Test the safety of nifurtimox in children with relapsed or refractory neuroblastoma alone and in combination with cyclophosphamide and topotecan.', 'timeFrame': '3 months'}]","[{'measure': 'To evaluate the pharmacokinetic profile of nifurtimox alone and in combination with cyclophosphamide and topotecan.', 'timeFrame': '3 months'}, {'measure': 'To determine the response rate to treatment with nifurtimox combined with cyclophosphamide/topotecan', 'timeFrame': '3 months'}]",3,,21 Years,ALL,False,University of Vermont,OTHER,1,20.0,ESTIMATED,2025-09-01T16:18:19.667164,v2_robust,True,True,True,False,True,
NCT05020964,Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib,Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib,Trastuzumab and Pyrotinib,['Trastuzumab and Pyrotinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Breast Cancer,['Advanced Breast Cancer'],[],UNKNOWN,,2021-08-20,2023-09-01,"[{'measure': 'objective response rate(ORR)', 'description': 'The ORR will be defined as the proportion of patients in the Efficacy Evaluable patient Set who achieve complete response (CR) and partial response (PR)', 'timeFrame': 'up to 1 year after the last patient enrolled'}]","[{'measure': 'Progression free survival(PFS)', 'description': 'PFS will be defined as the time from first dose of study drug until documentation of disease progression or death from any cause', 'timeFrame': 'up to 1 year after the last patient enrolled'}, {'measure': 'Incidence and Severity of adverse events', 'description': 'hematologic, hepatotoxicity, Incidence of hypertension, Incidence of proteinuria', 'timeFrame': 'approximately 1.5 years'}]",3,18 Years,75 Years,FEMALE,False,Chinese Academy of Medical Sciences,OTHER,0,68.0,ESTIMATED,2025-09-01T16:18:19.667171,v2_robust,True,True,False,False,True,
NCT06151964,A Trial to Learn How Safe AZD9550 is in People With or Without Type 2 Diabetes Who Are Overweight or Obese,"A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD9550 in Overweight and Obese Participants With or Without Type 2 Diabetes Mellitus",AZD9550,"['Placebo', 'AZD9550']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Non-alcoholic Steatohepatitis (NASH),['Non-alcoholic Steatohepatitis (NASH)'],"['AZD9550', 'Non-alcoholic Fatty Liver Disease', 'Non-alcoholic Steatohepatitis', 'Overweight', 'Obese', 'Obesity', 'Diabetes Mellitus, Type 2', 'Liver Glycogen', 'Adipose Tissue', 'Glucose', '3-Hydroxybutyric Acid', 'Subcutaneous Fat', 'Liver fat', 'Magnetic Resonance Imaging', 'Magnetic Resonance Spectroscopy', 'Weight Loss', 'Mixed Meal Tolerance Test']",ACTIVE_NOT_RECRUITING,,2023-09-29,2026-10-01,"[{'measure': 'Number and percentage of participants with any AE, SAEs, AEs leading to discontinuation of study intervention, AEs with outcome of death, and AEs leading to withdrawal from study.', 'timeFrame': 'Day - 35 to Day 205'}, {'measure': 'Number and percentage of participants with clinically significant changes from baseline in Vital Sign Parameters.', 'timeFrame': 'Day - 35 to Day 205'}, {'measure': 'Number and percentage of participants with clinically significant changes in ECG parameters.', 'timeFrame': 'Day - 35 to Day 205'}, {'measure': 'Number and percentage of participants with clinically significant changes from baseline in Clinical Laboratory Parameters', 'timeFrame': 'Day - 35 to Day 205'}, {'measure': 'Area Under Concentration-Time Curve of AZD9550 following repeat weekly SC doses', 'description': '* AUC from 0 to the time of the last measured concentration (AUClast) at first dose and last dose\n* AUC over a dosing interval (AUCtau) at first dose and last dose', 'timeFrame': 'Day 1 to Day 65'}, {'measure': 'Maximum observed concentration of AZD9550 following repeat weekly SC doses', 'description': '• Cmax at first dose and last dose', 'timeFrame': 'Day 1 to Day 65'}, {'measure': 'Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC doses', 'description': '• t1/2λz at first dose and last dose', 'timeFrame': 'Day 1 to Day 65'}, {'measure': 'Time to maximum observed concentration of AZD9550 following repeat weekly SC doses', 'description': '• tmax at first dose and last dose', 'timeFrame': 'Day 1 to Day 65'}, {'measure': 'Apparent oral clearance of AZD9550 following repeat weekly SC doses', 'description': '• CL/F at first dose and last dose', 'timeFrame': 'Day 1 to Day 65'}, {'measure': 'Apparent volume of distribution of AZD9550 following repeat weekly SC doses', 'description': '• Vz/F at first dose and last dose', 'timeFrame': 'Day 1 to Day 65'}, {'measure': 'Ratio for AUC of AZD9550 following repeat weekly SC doses', 'description': '• Rac AUCtau at last dose', 'timeFrame': 'Day 1 to Day 65'}, {'measure': 'Ratio for Cmax of AZD9550 following repeat weekly SC doses', 'description': '• Rac Cmax at last dose', 'timeFrame': 'Day 1 to Day 65'}]","[{'measure': 'PD effect of AZD9550 on fasting glucose compared to placebo', 'description': '• Absolute change in fasting glucose', 'timeFrame': 'From baseline to Week 4'}, {'measure': 'PD effect of AZD9550 on fasting lipid profile compared to placebo', 'description': '• Absolute and percentage change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, and BHB', 'timeFrame': 'From baseline to Week 4'}, {'measure': 'Absolute and percentage change in body weight from baseline', 'timeFrame': 'From baseline to Week 4'}, {'measure': 'Incidence of anti-AZD9550 antibodies', 'description': '• Incidence of ADA to AZD9550', 'timeFrame': 'From Day 1 to Day 65'}, {'measure': 'Absolute change in percentage body fat from baseline', 'timeFrame': 'From baseline to Week 4'}, {'measure': 'PD effect of AZD9550 on fasting glucose compared to placebo', 'description': '• Absolute change in fasting glucose', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'PD effect of AZD9550 on fasting lipid profile compared to placebo', 'description': '• Absolute and percentage change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglyceride, and BHB', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'Effect of AZD9550 on hepatic fat fraction versus placebo at Week 5', 'description': '* Change in hepatic fat fraction as measured by MRI-PDFF\n* Percent change in hepatic fat fraction as measured by MRI-PDFF', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'PD effect of AZD9550 on glucose metabolism following an MMTT compared to placebo', 'description': '* Percent change in glucose AUC(0-4h) measured by MMTT\n* Percent change in insulin AUC(0-4h) measured by MMTT\n* Percent change in c-peptide AUC(0-4h) measured by MMTT', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'Area Under concentration-time Curve of AZD9550 following repeat weekly SC doses', 'description': '* AUC from 0 to the time of the last measured concentration (AUClast) at the last dose\n* AUC over a dosing interval (AUCtau) at first dose and last dose', 'timeFrame': 'Day 1 to Day 72'}, {'measure': 'Incidence of anti-AZD9550 antibodies', 'description': '• Incidence of ADA to AZD9550', 'timeFrame': 'Day 1 to Day 72'}, {'measure': 'PD effect of AZD9550 on fasting glucose compared to placebo', 'description': '• Absolute change in fasting glucose', 'timeFrame': 'From baseline to Week 24'}, {'measure': 'PD effect of AZD9550 on fasting lipid profile compared to placebo', 'description': '• Absolute and percentage change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, and BHB', 'timeFrame': 'From baseline to Week 24'}, {'measure': 'The effect of AZD9550 on hepatic fat fraction versus placebo after 13 and 24 weeks of treatment', 'description': '* Change in hepatic fat fraction as measured by MRI-PDFF\n* Percent change in hepatic fat fraction as measured by MRI-PDFF', 'timeFrame': 'From baseline to Weeks 13 and 24'}, {'measure': 'Effects of AZD9550 compared to placebo on body weight', 'description': '* Change in body weight\n* Percent change in body weight\n* Proportion of participants achieving ≥ 5% body weight loss\n* Proportion of participants achieving ≥ 10% body weight loss\n* Absolute change in percentage body fat', 'timeFrame': 'From baseline to Week 24'}, {'measure': 'Change in daily (24 hours) average glucose levels as measured by CGM', 'timeFrame': 'From baseline to Day 176'}, {'measure': 'Change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS', 'timeFrame': 'From baseline to Weeks 13 and 24'}, {'measure': 'Area Under concentration-time Curve of AZD9550 following repeat weekly SC doses', 'description': '* AUC from 0 to the time of the last measured concentration (AUClast) at the first doses of each dose level and the last dose of MTD\n* AUC over a dosing interval (AUCtau) at the first doses of each dose level and the last dose of MTD', 'timeFrame': 'Day 1 to Day 169'}, {'measure': 'Incidence of anti-AZD9550 antibodies', 'description': '• Incidence of ADA to AZD9550', 'timeFrame': 'Day 1 to Day 205'}, {'measure': 'Change in daily (24 hours) average glucose levels as measured by CGM', 'timeFrame': 'From baseline to Weeks 1, 2, 3, 4, 5, and 6, and during 14 days post last dose'}, {'measure': 'Change in 7-day average glucose levels as measured by CGM', 'timeFrame': 'From baseline to Weeks 1, 2, 3, 4, 5, and 6 and during 14 days post last dose'}, {'measure': 'Change in coefficient of variation of glucose levels as measured by CGM over 7 days', 'timeFrame': 'From baseline to Weeks 1, 2, 3, 4, 5, and 6, and during 14 days post last dose'}, {'measure': 'Change in percentage time spent in hyperglycaemia (> 140 mg/dL), normoglycaemia (70 -140 mg/dL), and clinically significant hypoglycaemia (< 54 mg/dL) as measured by CGM over 24 hours', 'timeFrame': 'From baseline to Weeks 1, 2, 3, 4, 5, and 6, and during 14 days post last dose'}, {'measure': 'Change in percentage time spent in hyperglycaemia (> 140 mg/dL), normoglycaemia (70 -140 mg/dL), and clinically significant hypoglycaemia (< 54 mg/dL) as measured by CGM over 7 days', 'timeFrame': 'From baseline to Weeks 1, 2, 3, 4, 5, and 6, and during 14 days post last dose'}, {'measure': 'Change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'Percentage change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'Change in fasting hepatic glycogen concentration unadjusted for liver volume as measured by MRS', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'Percentage change in fasting hepatic glycogen concentration unadjusted for liver volume as measured by MRS', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'Change in liver volume as measured by MRI', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'Absolute change in body weight', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'Percent change in body weight', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'Proportion of participants achieving ≥ 5% body weight loss', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'Proportion of participants achieving ≥ 10% body weight loss', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'Change in 7-day average glucose levels as measured by CGM', 'timeFrame': 'From baseline to Day 176'}, {'measure': 'Change in coefficient of variation of glucose levels as measured by CGM over 7 days', 'timeFrame': 'From baseline to Day 176 and during 14 days post last dose'}, {'measure': 'Change in percentage time spent in hyperglycaemia (> 140 mg/dL), normoglycaemia (70 -140 mg/dL), and clinically significant hypoglycaemia (< 54 mg/dL) as measured by CGM over 24 hours', 'timeFrame': 'From baseline to Day 176'}, {'measure': 'Change in percentage time spent in hyperglycaemia (> 140 mg/dL), normoglycaemia (70 -140 mg/dL), and clinically significant hypoglycaemia (< 54 mg/dL) as measured by CGM over 7 days', 'timeFrame': 'From baseline to Day 176 and during 14 days post last dose'}, {'measure': 'Percentage change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS', 'timeFrame': 'From baseline to Weeks 13 and 24'}, {'measure': 'Change in fasting hepatic glycogen concentration unadjusted for liver volume as measured by MRS', 'timeFrame': 'From baseline to Weeks 13 and 24'}, {'measure': 'Percentage change in fasting hepatic glycogen concentration unadjusted for liver volume as measured by MRS', 'timeFrame': 'From baseline to Weeks 13 and 24'}, {'measure': 'Change in liver volume, visceral and SC fat as measured by MRI', 'timeFrame': 'From baseline to Weeks 13 and 24'}, {'measure': 'Anti-AZD9550 antibody titre among participants with positive serum antibodies to AZD9550', 'description': '• Titre of ADA to AZD9550', 'timeFrame': 'From Day 1 to 65'}, {'measure': 'Maximum observed concentration of AZD9550 following repeat weekly SC doses', 'description': '• Cmax at the last dose', 'timeFrame': 'Day to Day 72'}, {'measure': 'Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC doses', 'description': '• t1/2λz at the last dose', 'timeFrame': 'Day 1 to Day 72'}, {'measure': 'Time to maximum observed concentration of AZD9550 following repeat weekly SC doses', 'description': '• tmax at the last dose', 'timeFrame': 'Day 1 to Day 72'}, {'measure': 'Apparent oral clearance of AZD9550 following repeat weekly SC doses', 'description': '• CL/F at the last dose', 'timeFrame': 'Day 1 to day 72'}, {'measure': 'Apparent volume of distribution of AZD9550 following repeat weekly SC doses', 'description': '• Vz/F at the last dose', 'timeFrame': 'Day 1 to Day 72'}, {'measure': 'Anti-AZD9550 antibody titre among participants with positive serum antibodies to AZD9550', 'description': '• Titre of ADA to AZD9550', 'timeFrame': 'Day 1 to Day 72'}, {'measure': 'Maximum observed concentration of AZD9550 following repeat weekly SC doses', 'description': '• Cmax at the first doses of each dose level and the last dose of MTD', 'timeFrame': 'Day 1 to Day 169'}, {'measure': 'Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC doses', 'description': '• t1/2λz at the first doses of each dose level and the last dose of MTD', 'timeFrame': 'Day 1 to Day 169'}, {'measure': 'Time to maximum observed concentration of AZD9550 following repeat weekly SC doses', 'description': '• tmax at the first doses of each dose level and the last dose of MTD', 'timeFrame': 'Day 1 to Day 169'}, {'measure': 'Apparent oral clearance of AZD9550 following repeat weekly SC doses', 'description': '• CL/F at the first doses of each dose level and the last dose of MTD', 'timeFrame': 'Day 1 to Day 169'}, {'measure': 'Apparent volume of distribution of AZD9550 following repeat weekly SC doses', 'description': '• Vz/F at the first doses of each dose level and the last dose of MTD', 'timeFrame': 'Day 1 to day 169'}, {'measure': 'Anti-AZD9550 antibody titre among participants with positive serum antibodies to AZD9550', 'description': '• Titre of ADA to AZD9550', 'timeFrame': 'Day 1 to Day 205'}, {'measure': 'Change in visceral and subcutaneous fat as measured by MRI', 'timeFrame': 'From baseline to week 5'}, {'measure': 'PD effect of AZD9550 on glucose metabolism compared to placebo', 'description': '• Percent change in fasting glucose, fasting insulin, fasting c-peptide, and HbA1c', 'timeFrame': 'From baseline to Week 4'}, {'measure': 'PD effect of AZD9550 on glucose metabolism compared to placebo', 'description': '• Percent change in fasting glucose, fasting insulin, fasting c-peptide, and HbA1c', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'PD effect of AZD9550 on glucose metabolism compared to placebo', 'description': '• Percent change in fasting glucose, fasting insulin, fasting c-peptide, and HbA1c', 'timeFrame': 'From baseline to Week 24'}, {'measure': 'PD effect of AZD9550 on fasting insulin compared to placebo', 'description': '• Absolute change in fasting insulin', 'timeFrame': 'From baseline to Week 4'}, {'measure': 'PD effect of AZD9550 on fasting c-peptide compared to placebo', 'description': '• Absolute change in fasting c-peptide', 'timeFrame': 'From baseline to Week 4'}, {'measure': 'PD effect of AZD9550 on fasting insulin compared to placebo', 'description': '• Absolute change in fasting insulin', 'timeFrame': 'From baseline to Week 24'}, {'measure': 'PD effect of AZD9550 on fasting c-peptide compared to placebo', 'description': '• Absolute change in fasting c-peptide', 'timeFrame': 'From baseline to Week 24'}, {'measure': 'PD effect of AZD9550 on fasting insulin compared to placebo', 'description': '• Absolute change in fasting insulin', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'PD effect of AZD9550 on fasting c-peptide compared to placebo', 'description': '• Absolute change in fasting c-peptide', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'Absolute change in percentage body fat', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'PD effect of AZD9550 on glucose metabolism following an MMTT compared to placebo', 'description': '* Percent change in glucose AUC(0-4h) measured by MMTT\n* Percent change in insulin AUC(0-4h) measured by MMTT\n* Percent change in c-peptide AUC(0-4h) measured by MMTT\n* Absolute change in fasting glucose, fasting insulin, and fasting c-peptide\n* Percent change in fasting glucose, fasting insulin, and fasting c-peptide', 'timeFrame': 'From baseline to Week 13 and Week 24'}, {'measure': 'PD effect of AZD9550 on fasting lipid profile compared to placebo', 'description': 'Absolute and percentage change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, and HB', 'timeFrame': 'From baseline to week 24'}, {'measure': 'PD effect of AZD9550 on HbA1c compared to placebo', 'description': 'Absolute change in HbA1c', 'timeFrame': 'From baseline to Week 4'}, {'measure': 'PD effect of AZD9550 on HbA1c compared to placebo', 'description': 'Absolute change in HbA1c', 'timeFrame': 'From baseline to Week 5'}, {'measure': 'PD effect of AZD9550 on HbA1c compared to placebo', 'description': 'Absolute change in HbA1c', 'timeFrame': 'From baseline to Week 24'}]",82,18 Years,65 Years,ALL,False,AstraZeneca,INDUSTRY,0,88.0,ACTUAL,2025-09-01T16:18:19.667304,v2_robust,True,True,False,False,False,
NCT02823964,EASY: Extended Access to Sollpura Over Years,An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis,Liprotamase,"['Sollpura', 'Liprotamase']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Exocrine Pancreatic Insufficiency,"['Exocrine Pancreatic Insufficiency', 'Cystic Fibrosis']","['exocrine pancreatic insufficiency', 'cystic fibrosis', 'pancreatic enzyme replacement therapy']",COMPLETED,,2016-09,2018-03,"[{'measure': 'Safety, as Measured by Number of Participants With Adverse Events Including Clinical or Laboratory Abnormalities', 'description': 'Descriptive analysis', 'timeFrame': '12 months'}]",[],1,7 Years,,ALL,False,Anthera Pharmaceuticals,INDUSTRY,0,25.0,ACTUAL,2025-09-01T16:18:19.667683,v2_robust,True,True,True,False,True,
NCT05485909,Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM,"A Single-arm, Single-center Phase II Clinical Study of Regorafenib and Toripalimab Combined With Radiofrequency Ablation (RFA) in Patients With Colorectal Cancer Liver Metastases",Regorafenib and Toripalimab Combination,['Regorafenib and Toripalimab Combination'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Colorectal Cancer Liver Metastases,['Colorectal Cancer Liver Metastases'],[],UNKNOWN,,2022-07-25,2024-06-30,"[{'measure': 'Objective response rate (ORR)', 'description': 'The ratio of patients who are evaluated as CR or PR', 'timeFrame': '2 years'}]","[{'measure': 'Progression free survival (PFS)', 'description': 'Time from first dose to first documented disease progression or death from any cause (whichever occurs first)', 'timeFrame': '2 years'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS) was defined as the time (days) from randomization to death due to any cause.', 'timeFrame': '2 years'}, {'measure': 'Disease control rate (DCR)', 'description': 'Defined as the proportion of patients whose tumors shrink or remain stable for a certain period of time, including CR, PR and SD', 'timeFrame': '2 years'}, {'measure': 'Duration of response (DOR)', 'description': 'defined as the time between the first assessment of a tumor as PR or CR and the first assessment as PD or any cause of death', 'timeFrame': '2 years.'}, {'measure': 'Time to disease progression (TTP)', 'description': 'Time from first dose to first documented disease progression', 'timeFrame': '2 years'}]",6,18 Years,,ALL,False,Sun Yat-sen University,OTHER,0,32.0,ESTIMATED,2025-09-01T16:18:19.667777,v2_robust,True,True,False,False,False,
NCT07095309,Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer,"Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II/III Colorectal Cancer",Artesunate,"['Artesunate matching Placebo', 'Artesunate']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Stage II/III Colon Cancer,"['Stage II/III Colon Cancer', 'Bowel Cancer']","['artesunate', 'colorectal', 'drug repurposing', 'antimalarial']",NOT_YET_RECRUITING,,2025-08-15,2033-07-31,"[{'measure': 'Recurrence-Free Survival (RFS) at 2 Years Post-Randomisation Assessed by Radiological and Clinical Evaluation', 'description': 'RFS is defined as the time from randomisation to the first documented recurrence of colorectal cancer (local or distant) or death from any cause, whichever occurs first. Recurrence will be assessed using standard CT scans of the chest, abdomen, and pelvis, clinical examination and measuring carcinoembryonic antigen (CEA). Confirmation of recurrence may include histological evidence where clinically indicated. Unit of Measure: Months', 'timeFrame': '2 years following study randomisation.'}]","[{'measure': 'Recurrence-Free Survival at 5 Years Post-Randomisation Assessed by Radiological and Clinical Evaluation', 'description': 'RFS is defined as the time from randomisation to the first documented recurrence of colorectal cancer (local or distant) or death from any cause, whichever occurs first. Recurrence will be assessed using standard CT scans of the chest, abdomen, and pelvis, clinical examination and CEA . Histological confirmation of recurrence will be obtained where clinically indicated. Unit of Measure: Months', 'timeFrame': '5 years from study randomisation'}, {'measure': 'Overall Survival (OS) at 2 and 5 Years Post-Randomisation', 'description': 'Survival status will be determined through clinical follow-up, hospital records, and national death registries where available. Unit of Measure: Months', 'timeFrame': '2 years and 5 years following study randomisation.'}, {'measure': 'Colon Cancer-Specific Mortality at 2 and 5 Years Post-Randomisation', 'timeFrame': '2 years and 5 years following study randomisation.'}, {'measure': 'Incidence of Artesunate-Related Toxicity Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0', 'description': 'The number of participants experiencing adverse events considered related to artesunate will be recorded and graded using the CTCAE.\n\nUnit of Measure:\n\nNumber of participants with at least one artesunate-related adverse event, by CTCAE grade.', 'timeFrame': 'Assessment at Day 7 following initiation of study intervention (artesunate or matching placebo).'}, {'measure': 'Incidence of Artesunate-Related Toxicity Assessed by Common Terminology CTCAE v5.0', 'description': 'The number of participants experiencing adverse events considered related to artesunate will be recorded and graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Causality will be assessed by the site investigator and confirmed by the clinical trial safety team. Adverse events will be coded and reported by type and severity.', 'timeFrame': 'Assessment at Day 14 following initiation of study intervention (artesunate or matching placebo).'}, {'measure': 'Incidence of Artesunate-Related Toxicity Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0', 'description': 'The number of participants experiencing adverse events considered related to artesunate will be recorded and graded using the CTCAE. Causality will be assessed by the site investigator and confirmed by the clinical trial safety team. Adverse events will be coded and reported by type and severity.\n\nUnit of Measure:\n\nNumber of participants with at least one artesunate-related adverse event, by CTCAE grade.', 'timeFrame': 'Assessment at Day 42 following initiation of study intervention (artesunate or matching placebo).'}, {'measure': 'Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0', 'description': 'The number and proportion of participants experiencing any adverse events (AEs), regardless of causality, will be recorded and graded using the CTCAE.\n\nUnit of Measure:\n\nNumber of participants with at least one adverse event, categorised by CTCAE grade.', 'timeFrame': 'Assessment at Day 7 following administration of study intervention (artesunate or matching placebo).'}, {'measure': 'Incidence Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Day 14', 'description': 'The number and proportion of participants experiencing any adverse events (AEs), regardless of causality, will be recorded and graded using the CTCAE.\n\nUnit of Measure:\n\nNumber of participants with at least one adverse event, categorised by CTCAE grade.', 'timeFrame': 'Assessment at Day 14 following study intervention'}, {'measure': 'Incidence of adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0', 'description': 'The number and proportion of participants experiencing any adverse events (AEs), regardless of causality, will be recorded and graded using the CTCAE.\n\nUnit of Measure:\n\nNumber of participants with at least one adverse event, categorised by CTCAE grade.', 'timeFrame': 'Assessment at Day 42 following study intervention'}, {'measure': 'Pathological assessment of tumour regression post intervention', 'description': 'Tumour regression will be assessed by histopathological examination of the surgical resection specimen. The assessment will include:\n\n* Degree of tumour regression in the primary tumour bed\n* Presence of tumour involvement at the resection margins\n* Evidence of tumour invasion into the serosa (pT4a) and lymph node involvement (number and proportion of positive lymph nodes).\n* Histopathological evaluation\n\nUnit of Measure:\n\nNumber and proportion of participants with positive lymph nodes, serosal involvement, and positive resection margins.', 'timeFrame': 'Post surgical pathology review (following Day 14 of study intervention)'}, {'measure': 'Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires at Baseline', 'description': 'Quality of life will be assessed using validated, self-administered questionnaires:\n\n1. EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30)\n2. EORTC QLQ-CR29 (Colorectal Cancer-Specific Module)\n\nThese instruments evaluate global health status/QoL, functional scales (physical, role, emotional, cognitive, social), and symptom scales. Scores for each scale range from 0 to 100. For functional and global health status scales, higher scores indicate better QoL. For symptom scales, higher scores indicate worse symptoms.\n\nUnit of Measure:\n\nMean scores for each scale/domain of the EORTC QLQ-C30 and QLQ-CR29 questionnaires.', 'timeFrame': 'Assessment at Day 1 of study intervention (baseline assessment)'}, {'measure': 'Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires', 'description': 'Quality of life will be assessed using validated, self-administered questionnaires:\n\n1. EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30)\n2. EORTC QLQ-CR29 (Colorectal Cancer-Specific Module)\n\nThese instruments evaluate global health status/QoL, functional scales (physical, role, emotional, cognitive, social), and symptom scales. Scores for each scale range from 0 to 100. For functional and global health status scales, higher scores indicate better QoL. For symptom scales, higher scores indicate worse symptoms.\n\nUnit of Measure:\n\nMean scores for each scale/domain of the EORTC QLQ-C30 and QLQ-CR29 questionnaires.', 'timeFrame': 'Assessment at Day 7 of study intervention'}, {'measure': 'Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires post intervention', 'description': 'Quality of life will be assessed using validated, self-administered questionnaires: 1. EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) 2. EORTC QLQ-CR29 (Colorectal Cancer-Specific Module) These instruments evaluate global health status/QoL, functional scales (physical, role, emotional, cognitive, social), and symptom scales. Scores for each scale range from 0 to 100. For functional and global health status scales, higher scores indicate better QoL. For symptom scales, higher scores indicate worse symptoms. Unit of Measure: Mean scores for each scale/domain of the EORTC QLQ-C30 and QLQ-CR29 questionnaires.', 'timeFrame': 'Assessment at Day 14 of study intervention'}, {'measure': 'Incidence of Surgery-Related Adverse Events Assessed by CTCAE v5.0', 'description': 'The number and proportion of participants experiencing surgery-related adverse events (AEs) will be recorded. Events will be graded using the CTCAE version 5.0, with severity classified from Grade 1 (mild) to Grade 5 (death related to AE). Events of interest include, but are not limited to, surgical site infection, anastomotic leak, wound dehiscence, postoperative bleeding, and thromboembolic events.\n\nUnit of Measure:\n\nNumber of participants with at least one surgery-related AE, categorised by CTCAE grade.', 'timeFrame': 'From time of surgery up to 3 months post surgery'}, {'measure': 'Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy', 'description': 'Carcinoembryonic Antigen (CEA) levels will be measured in blood samples and their predictive value for response to artesunate therapy. he predictive value will be evaluated by correlating CEA with pathological tumour regression grade and recurrence-free survival.\n\nUnit of Measure:\n\nChange in serum CEA levels (ng/mL)', 'timeFrame': 'Day 1 of study intervention (baseline assessment).'}, {'measure': 'Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy', 'description': 'Carcinoembryonic Antigen (CEA) levels will be measured in blood samples and their predictive value for response to artesunate therapy. he predictive value will be evaluated by correlating CEA with pathological tumour regression grade and recurrence-free survival.\n\nUnit of Measure:\n\nChange in serum CEA levels (ng/mL)', 'timeFrame': 'Assessment at Day 7 of study intervention'}, {'measure': 'Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy', 'description': 'Carcinoembryonic Antigen (CEA) levels will be measured in blood samples and their predictive value for response to artesunate therapy. he predictive value will be evaluated by correlating CEA with pathological tumour regression grade and recurrence-free survival.\n\nUnit of Measure:\n\nChange in serum CEA levels (ng/mL)', 'timeFrame': 'Assessment at Day 14 of study intervention'}, {'measure': 'Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy', 'description': 'Carcinoembryonic Antigen (CEA) levels will be measured in blood samples and their predictive value for response to artesunate therapy. he predictive value will be evaluated by correlating CEA with pathological tumour regression grade and recurrence-free survival.\n\nUnit of Measure:\n\nChange in serum CEA levels (ng/mL)', 'timeFrame': 'Assessment at Day 42 of study intervention'}, {'measure': 'Immunohistochemical analyses of paraffin-embedded tumour sections to assess Kirsten rat sarcoma viral oncogene homolog (Kras) mutation status', 'description': 'KRAS mutation status will be assessed in tumour tissue sections obtained from pre-intervention (diagnostic biopsy, Day 0) and post-intervention (surgical resection, Day 15) samples. Immunohistochemistry (IHC) will be performed. Comparisons will be made to evaluate changes in mutation status and association with response to artesunate therapy.\n\nUnit of Measure:\n\nNumber and proportion (%) of participants with KRAS mutant tumours at each time point.', 'timeFrame': 'Pre and post intervention tumour samples from patients (Day 0 and Day 15)'}, {'measure': 'Immunohistochemical analyses of paraffin-embedded tumour sections to assess Mismatch Repair (MMR) status', 'description': 'Mismatch Repair (MMR) status will be assessed in tumour tissue sections obtained from pre-intervention (diagnostic biopsy, Day 0) and post-intervention (surgical resection, Day 15) samples. Immunohistochemistry (IHC) will be performed.\n\nUnit of Measure:\n\nNumber and proportion (%) of participants with MMR-deficient tumours at each time p', 'timeFrame': 'Pre and post intervention tumour samples from patients (Day 0 and Day 15)'}, {'measure': 'Immunohistochemical analyses of paraffin-embedded tumour for v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation status', 'description': 'Number of patients with BRAF mutant tumours', 'timeFrame': 'Pre and post intervention tumour samples from patients (Day 0 and Day 15)'}, {'measure': 'Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor (PDGF) expression', 'description': 'Number of patients whose tumours show PDGF upregulation/downregulation following treatment intervention', 'timeFrame': 'Pre and post intervention tumour samples from patients (Day 0 and Day 15)'}, {'measure': 'Immunohistochemical analyses of paraffin-embedded tumour for Vascular endothelial Growth Factor (VEGF) expression', 'description': 'Number of patients whose tumours show VEGF upregulation/downregulation following study intervention', 'timeFrame': 'Pre and post intervention tumour samples from patients (Day 0 and Day 15)'}, {'measure': 'Immunohistochemical analyses of paraffin-embedded tumour on Vascular endothelial Growth Factor Receptor (VEGFR) expression', 'description': 'Number of patients whose tumours show VEGFR upregulation/downregulation following study intervention', 'timeFrame': 'Pre and post intervention tumour samples from patients (Day 0 and Day 15)'}, {'measure': 'Determination of proliferative activity (Ki-67 staining, Cluster of Differentiation 31 protein (CD31) staining)', 'description': 'Number of patients whose tumours show an increase or reduction in proliferation markers Ki67 and CD31 following study intervention', 'timeFrame': 'Pre and post intervention tumour samples from patients (Day 0 and Day 15)'}, {'measure': 'Determination of activation of the Deoxyribonucleic acid damage response (DDR) pathway', 'description': 'Number of patients whose tumour samples show activation of the DDR pathway following study intervention', 'timeFrame': 'Pre and post intervention tumour samples from patients (Day 0 and Day 15)'}, {'measure': 'Wnt/β-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins)', 'description': 'Number of patients who show an increase or a decrease in expression of proteins involved in the Wnt/β-catenin proliferation pathway (e.g. c-myc and cyclinD1 proteins) following study intervention', 'timeFrame': 'Pre and post intervention tumour samples from patients (Day 0 and Day 15)'}]",28,18 Years,,ALL,False,Metanoic Health Ltd.,INDUSTRY,1,120.0,ESTIMATED,2025-09-01T16:18:19.667842,v2_robust,True,True,False,False,True,
NCT04184609,Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes,Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes,Albuterol,"['Albuterol', 'Ventolin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Asthma in Children,"['Asthma in Children', 'Dyspnea; Asthmatic', 'Obesity, Childhood']","['Pediatric', 'Breathlessness', 'Ventilatory Constraints', 'Exercise']",WITHDRAWN,Funding ran out before participants were enrolled.,2023-07-01,2023-11-03,"[{'measure': 'Expiratory flow limitation', 'description': 'Units: % of tidal volume, measured as overlap between exercise tidal flow volume loop and maximal expiratory flow volume loop', 'timeFrame': 'up to 2 hours during the intervention (exercise)'}, {'measure': 'Dynamic hyperinflation', 'description': 'Units: % of total lung capacity, measured as change in end-expiratory lung volume from rest to exercise', 'timeFrame': 'up to 2 hours during the intervention (exercise)'}, {'measure': 'Forced expiratory volume in 1 s', 'description': 'Units: Litres, measured with spirometry', 'timeFrame': 'Pre to 30 min post exercise'}, {'measure': 'Peripheral airway reactivity (R5-R20)', 'description': 'Units: % change from pre to post exercise, measured with impulse oscillometry', 'timeFrame': 'Pre to 30 min post exercise'}]","[{'measure': 'Rating of perceived breathlessness', 'description': 'Borg 0 - 10 scale', 'timeFrame': 'up to 2 hours during the intervention (exercise)'}]",5,9 Years,17 Years,ALL,False,Ohio State University,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:19.667904,v2_robust,True,True,False,True,False,Funding ran out before participants were enrolled.
NCT02489409,Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer,"EndostarTM Injection Combined With Gemcitabine+Platinum (GP)/Navelbine+Platinum (NP)/Gemcitabine+Xeloda (GX)/Navelbine+Xeloda (NX) in Treatment of Recurrent Metastatic Breast Cancer: A Randomized, Opened and Controlled Clinical Study",EndostarTM Injection,"['ECX', 'Navelbine', 'NVB', 'EndostarTM Injection', 'Platinum', 'DDP', 'GEM', 'Gemcitabine', 'Xeloda Tablets:', 'Endostatin']",10,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Neoplasms,['Breast Neoplasms'],[],UNKNOWN,,2015-10,2018-07,"[{'measure': 'response rate', 'description': 'response rate that defined as the total ratio of study subjects with complete response, complete response unconfirmed and partial response after treatment. ORR=(CR+ CRu+ PR)cases/total cases×100%.', 'timeFrame': '2 years'}]","[{'measure': 'clinical benefit rate', 'description': 'clinical benefit rate that defined as the total ratio of study subjects with complete response，partial response and stable disease more than 24 months after treatment.', 'timeFrame': '2 years'}, {'measure': 'progression-free survival', 'description': 'Progression-free survival (PFS) defined as the ratio of study subjects who had disease progression or died from the start of randomization.', 'timeFrame': '2 years'}, {'measure': 'median survival time', 'description': 'median survival time defined as the corresponding survival time when the cumulative survival rate is 50%.', 'timeFrame': '2 years'}, {'measure': 'overall survival', 'description': 'overall survival rate (OS) that defined as the ratio of study subjects who survived after randomization', 'timeFrame': '2 years'}, {'measure': 'adverse responses', 'description': 'adverse responses that defined as the evaluated by rates of all adverse reactions caused by Recombinant Human Endostatin and the changes of all indexes before and after treatment', 'timeFrame': '2 years'}]",6,18 Years,70 Years,FEMALE,False,Xinjiang Medical University,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:19.667946,v2_robust,True,True,False,False,True,
NCT04891809,Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM,Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650),Isatuximab-Irfc 20 MG/ML [Sarclisa],"['Lenalidomide', 'Isatuximab-Irfc 20 MG/ML [Sarclisa]', 'Dexamethasone Oral']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Newly Diagnosed Multiple Myeloma,['Newly Diagnosed Multiple Myeloma'],"['Myeloma', 'Isatuximab', 'Lenalidomide', 'Dexamethasone', 'Elderly', 'age ≥70']",ACTIVE_NOT_RECRUITING,,2021-10-20,2028-12,"[{'measure': 'Proportion of patients with MRD (minimal residual disease) negativity (defined by NGF [next generation flow] at 10^-5) after end of induction treatment in the two arms.', 'description': 'To demonstrate the benefit of isatuximab in combination with lenalidomide and low-dose dexamethasone followed by isatuximab and lenalidomide maintenance therapy in changing the proportion of patients with MRD negativity as compared to lenalidomide and low-dose dexamethasone followed by lenalidomide maintenance treatment in patients with newly diagnosed multiple myeloma (NDMM).', 'timeFrame': 'After 8 months of induction treatment (8 cycles, each cyle is 28 days)'}]","[{'measure': 'Percentage of patients with response to study treatment', 'description': 'Effect of treatment on Overall Response Rate (ORR) including patients with Partial Response (PR), Very Good Partial Response (VGPR) and Complete Response (CR) as per International Myeloma Working Group (IMWG) criteria in each arm.', 'timeFrame': 'After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)'}, {'measure': 'Progression-free Survival', 'description': 'Effectiveness of treatments on Progression-free survival (PFS)', 'timeFrame': 'After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)'}, {'measure': 'Overall Survival', 'description': 'Effectiveness of treatments on Overall Survival (OS)', 'timeFrame': 'After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)'}, {'measure': 'Effectiveness of treatments on MRD negativity', 'description': 'To evaluate the proportion of patients with MRD negativity (defined by NGF \\[next generation flow\\] at 10\\^-5) after 12 months (13 cycles) of maintenance treatment.', 'timeFrame': 'After 20 months (8 months of induction treatment and 12 months of maintenance treatemnent)'}, {'measure': 'Effectiveness of treatments on preventing progressive disease', 'description': 'To evaluate the Time to Progression (TTP) in each arm.', 'timeFrame': 'After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)'}, {'measure': 'Progression-free Survival in different high-risk cytogenetic populations', 'description': 'Effectiveness of treatment on PFS in high risk cytogenetic populations defined as patients carrying a) del(17p), t(4;14), t(14;16) in each arm and b) the same aberrations plus amp1q21.', 'timeFrame': 'After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)'}, {'measure': 'Duration of response', 'description': 'Length of time between response and progression or death.', 'timeFrame': 'After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)'}, {'measure': 'Incidence of treatment-emergent adverse events (Safety and tolerability)', 'description': 'Number of participants with treatment-emergent adverse events as assessed by NCI-CTCAE Version 5.0.', 'timeFrame': 'After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)'}, {'measure': 'Changes in quality of life (QoL) using general questionnaire European Organization for Research and Treatment of Cancer (EORTC) Quality of life questionnaire (QLQ) Core 30 (C 30) (EORTC-QLQ-C30)', 'description': 'Changes in quality of life will be analyzed by using the cancer patient-specific questionnaire EORTC-QLQ-C30.', 'timeFrame': 'After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)'}, {'measure': 'Changes of general health status using questionnaire EQ (EuroQol) 5 dimension (5D) 5 level (5L) (EQ-5D-5L)', 'description': 'Changes in general health status will be analyzed by using the questionnaires EQ-5D-5L. QoL.', 'timeFrame': 'After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)'}, {'measure': 'Changes in quality of life (QoL) using multiple myeloma specific questionnaire EORTC-QLQ Myeloma (MY) 20 (EORTC-QLQ-MY20)', 'description': 'Changes in quality of life will be analyzed by using the multiple myeloma-specific questionnaire EORTC-QLQ-MY20.', 'timeFrame': 'After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)'}, {'measure': 'Progression-free survival after second line therapy', 'description': 'Influence of potential second line therapy on Progression-free Survival', 'timeFrame': 'After end of study treatment until 12 months of follow up as a minimum (until LPLV)'}]",13,70 Years,,ALL,False,Arbeitsgemeinschaft medikamentoese Tumortherapie,OTHER,5,198.0,ESTIMATED,2025-09-01T16:18:19.668024,v2_robust,True,True,False,False,True,
NCT02029209,To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer,,Anlotinib,"['Anlotinib', 'Placebo Capsule']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Non-small Cell Lung Cancer,['Non-small Cell Lung Cancer'],[],UNKNOWN,,2013-12,2017-03,"[{'measure': 'Number of circulating endothelial cell subsets（ total CECs 、 aCECs、apopCECs, etc.)', 'description': 'To detect number of circulating endothelial cell subsets（ total CECs 、aCECs、apopCECs, etc.) by Flow Cytometry;', 'timeFrame': 'Different time points before and after treatment of anlotinib,an expected average of 3 weeks'}, {'measure': 'The strength of intratumoral blood perfusion index (BV, BF, PS and MTT) .', 'description': 'To detect the strength of intratumoral blood perfusion index(BV, BF, PS and MTT) by CT perfusion imaging.', 'timeFrame': 'Different time points before and after treatment of anlotinib,an expected average of 3 weeks'}]",[],2,18 Years,70 Years,ALL,False,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",INDUSTRY,1,110.0,ESTIMATED,2025-09-01T16:18:19.668086,v2_robust,True,True,False,False,False,
NCT00772499,Vascular Improvement With Olmesartan Medoxomil Study,Vascular Improvement With Olmesartan Medoxomil Study,olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure,"['olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure', 'atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,['Hypertension'],[],COMPLETED,,2002-11,2005-07,"[{'measure': 'Subcutaneous gluteal fat arteriole measurements prior to and after 52 weeks of therapy', 'timeFrame': '52 weeks'}]","[{'measure': 'Results of vascular function tests', 'timeFrame': '12 weeks'}, {'measure': 'Results of vascular function tests', 'timeFrame': '28 weeks'}, {'measure': 'Results of vascular function tests', 'timeFrame': '52 weeks'}, {'measure': 'Measurement of serum lipid and markers of atherosclerosis', 'timeFrame': '12 weeks'}, {'measure': 'Measurement of serum lipid and markers of atherosclerosis', 'timeFrame': '28 weeks'}, {'measure': 'Measurement of serum lipid and markers of atherosclerosis', 'timeFrame': '52 weeks'}, {'measure': 'Retinal arteriole measurements', 'timeFrame': '52 weeks'}, {'measure': 'Calculation of insulin sensitivity measurement', 'timeFrame': '12 Weeks'}, {'measure': 'Calculation of insulin sensitivity measurement', 'timeFrame': '28 weeks'}, {'measure': 'Calculation of insulin sensitivity measurement', 'timeFrame': '52 weeks'}, {'measure': '24 hour urine creatinine and thromboxane B2 measurements', 'timeFrame': '12 weeks'}, {'measure': 'Calculation of albumin-to-creatinine ratio and sodium-to-creatinine ratio', 'timeFrame': '12 weeks'}, {'measure': 'Calculation of albumin-to-creatinine ratio and sodium-to-creatinine ratio', 'timeFrame': '28 weeks'}, {'measure': 'Calculation of albumin-to-creatinine ratio and sodium-to-creatinine ratio', 'timeFrame': '52 weeks'}]",15,18 Years,75 Years,ALL,False,Daiichi Sankyo,INDUSTRY,0,100.0,ACTUAL,2025-09-01T16:18:19.668121,v2_robust,True,True,True,False,False,
NCT03451799,Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma,IIT2016-17-HU-KETORADTMZ: A Phase 1 Study of a 4-month Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Newly/Recently Diagnosed Glioblastoma,Standard-of-care Temozolomide,['Standard-of-care Temozolomide'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,GBM,"['GBM', 'Glioblastoma']","['Glioblastoma', 'Ketogenic diet', 'Keto diet', 'GBM']",ACTIVE_NOT_RECRUITING,,2018-04-13,2026-05,"[{'measure': 'Safety of the intervention', 'description': 'Proportion of participants experiencing a 10% decrease in weight or body mass index AND have a BMI \\<18.5 within one month from initiation of the ketogenic diet.', 'timeFrame': 'Four Months'}, {'measure': 'Safety of the intervention', 'description': 'Number of related adverse events based on CTCAE v.5.', 'timeFrame': 'Four months'}]","[{'measure': 'Feasibility of the intervention', 'description': 'Proportion of enrolled patients able to maintain blood ketone levels \\>0.3 mM for over 50% of days on study starting 2 weeks after initiation of the ketogenic diet.', 'timeFrame': 'Four Months'}, {'measure': 'Overall Survival', 'description': 'Time (in months) from initiation of the ketogenic diet to date of death', 'timeFrame': 'Sixty months'}, {'measure': 'Time-to-progression', 'description': 'Time (in months) from baseline to progressive disease over study duration (estimated 4 months)\n\n\\- measured by RANO criteria (standard of care brain MRI)', 'timeFrame': 'Four Months'}, {'measure': 'Quality of Life (two months)', 'description': 'Mean change in overall Quality of Life from baseline to two months.\n\n-Quality of Life measured using EORTC QLQ-C30 global score', 'timeFrame': 'Two months'}, {'measure': 'Quality of Life (four months)', 'description': 'Mean change in overall Quality of Life from baseline to four months.\n\n-Quality of Life measured using EORTC QLQ-C30 global score', 'timeFrame': 'Four months'}, {'measure': 'Cognitive function (Hopkins Verbal Learning Test-Revised)', 'description': 'Mean change in cognitive function from initiation of ketogenic diet to four months.\n\n-measured using Hopkins Verbal learning Test-Revised', 'timeFrame': 'Four months'}, {'measure': 'Cognitive function (Trail Making Test)', 'description': 'Mean change in cognitive function from initiation of ketogenic diet to four months.\n\n-measured using Trail Making Test', 'timeFrame': 'Four months'}, {'measure': 'Cognitive function (Controlled Word Association Test)', 'description': 'Mean change in cognitive function from initiation of ketogenic diet to four months.\n\n-measured using Controlled Word Association Test', 'timeFrame': 'Four months'}, {'measure': 'Cognitive function (Montreal Cognitive Assessment)', 'description': 'Mean change in cognitive function from initiation of ketogenic diet to four months.\n\n-measured using Montreal Cognitive Assessment', 'timeFrame': 'Four months'}]",11,18 Years,,ALL,False,Jethro Hu,OTHER,0,21.0,ACTUAL,2025-09-01T16:18:19.668142,v2_robust,True,True,False,False,True,
NCT00707499,A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158,"A Single-Dose, Phase I, Dosimetry, Biodistribution, and Safety Trial of BMS 747158 in Healthy Subjects",BMS747158,['BMS747158'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2007-09,2008-06,"[{'measure': 'Dosimetry analysis following whole body imaging after resting injection', 'timeFrame': 'Imaging takes place 0 - 310 minutes post injection'}]","[{'measure': 'Safety analysis following vital signs, ECGs, EEG, neuro and physical exams, telephone and visit follow up, and blood draws for chemistry and hematology post injection of BMS747158 at rest', 'timeFrame': 'Screening (14 days prior to dosing) through 14 days post dose administration'}]",2,18 Years,40 Years,ALL,True,Lantheus Medical Imaging,INDUSTRY,0,13.0,ACTUAL,2025-09-01T16:18:19.668182,v2_robust,True,True,True,False,True,
NCT00541099,Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,Evaluation of Bevacizumab and Weekly Docetaxel in Elderly (≥ 75 Years) Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),docetaxel,"['TAXOTERE®', 'docetaxel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Cancer,['Lung Cancer'],"['stage IIIA non-small cell lung cancer', 'stage IIIB non-small cell lung cancer', 'stage IV non-small cell lung cancer']",COMPLETED,,2008-01,2013-01,"[{'measure': 'Survival', 'timeFrame': '6 months when treated with combination of Avastin and weekly docetaxel'}]","[{'measure': 'Progression-free Survival', 'description': 'Progression-free survival in months via the Kaplan-Meier method', 'timeFrame': '6 months when treated with combination of Avastin and weekly docetaxel'}, {'measure': 'Overall Survival', 'description': 'Overall survival using Kaplan-Meier method.', 'timeFrame': '4 weeks after removal from study or until death'}, {'measure': 'Response Rate', 'timeFrame': 'Every 8 weeks'}, {'measure': 'Toxicity According to NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0', 'description': 'Toxicity: using the highest grade of each toxicity experienced by each patient according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.', 'timeFrame': '1st and 2nd week of each 21 day cycle, up to six cycles.'}]",5,75 Years,120 Years,ALL,False,Barbara Ann Karmanos Cancer Institute,OTHER,1,11.0,ACTUAL,2025-09-01T16:18:19.668228,v2_robust,True,True,True,False,True,
NCT00658099,Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®,Change in Weight on Insulin Detemir (Levemir®) or Isophane (NPH) Insulin (Insulatard®) in Patients With Type 2 Diabetes Mellitus,insulin detemir,"['insulin detemir', 'insulin NPH']",2,OBSERVATIONAL,[],,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],COMPLETED,,2007-11,2008-06,"[{'measure': 'Change in weight', 'timeFrame': 'after 6 months of treatment'}]","[{'measure': 'The effect on metabolic control assessed by the changes in glycaemic parameters: HbA1c and blood glucose values', 'timeFrame': 'after 6 months of treatment'}, {'measure': 'The incidence of hypoglycaemic events', 'timeFrame': 'after 6 months of treatment'}, {'measure': 'Safety parameters by collecting (serious) adverse drug reactions, pregnancies and technical complaints.', 'timeFrame': 'after 6 months of treatment'}, {'measure': 'The general well-being by using the WHO-5 well-being questionnaire.', 'timeFrame': 'after 6 months of treatment'}, {'measure': 'The treatment satisfaction of subjects treated with insulin detemir or NPH insulin by using insulin treatment satisfaction questionnaire', 'timeFrame': 'after 6 months of treatment'}, {'measure': 'The satisfaction of physicians who treat the subjects with either insulin detemir or NPH insulin by using 4 questions, which are included in CRF, at the final visit.', 'timeFrame': 'after 6 months of treatment'}]",7,,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,699.0,ACTUAL,2025-09-01T16:18:19.668254,v2_robust,False,True,True,False,True,
NCT01258699,"A Study Comparing the Pharmacokinetics of BK-C-0701 320mg, 480mg and Thiocacid HR Tab 600mg in Healthy Adult Male Subjects","A Study Comparing the Pharmacokinetics of BK-C-0701 320mg, 480mg and Thiocacid HR Tab 600mg in Healthy Adult Male Subjects",Thiocacid HR Tab 600mg,"['BK-C-0701 320mg', 'Thiocacid HR Tab 600mg', 'BK-C-0701 480mg']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Adult Male,['Healthy Adult Male'],[],COMPLETED,,2009-08,,[],[],0,20 Years,45 Years,MALE,True,Bukwang Pharmaceutical,INDUSTRY,0,30.0,ESTIMATED,2025-09-01T16:18:19.668282,v2_robust,True,True,True,False,False,
NCT03801499,Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma,"Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma: a Single-arm, Phase 2 Trial",Lenvatinib,['Lenvatinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Intrahepatic Cholangiocarcinoma,['Intrahepatic Cholangiocarcinoma'],"['Intrahepatic Cholangiocarcinoma', 'Lenvatinib']",WITHDRAWN,Protocol modification,2018-09-01,2019-12,"[{'measure': 'overall survival (OS)', 'description': 'OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.', 'timeFrame': '12 months'}]","[{'measure': 'progression free survival (PFS)', 'description': 'PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first.', 'timeFrame': '12 months'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference to the baseline sum of the diameters of target lesions.', 'timeFrame': '12 months'}, {'measure': 'Adverse Events', 'description': 'Number of adverse events. Postoperative adverse events were graded based on CTCAE v4.03', 'timeFrame': '12 months'}]",4,18 Years,75 Years,ALL,False,Sun Yat-sen University,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:19.668302,v2_robust,True,True,False,True,True,Protocol modification
NCT02364999,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF- 06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL -CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER.",Bevacizumab-Pfizer,"['Carboplatin', 'Paclitaxel', 'Bevacizumab-EU', 'Bevacizumab-Pfizer']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-Small Cell Lung Cancer,['Non-Small Cell Lung Cancer'],[],COMPLETED,,2015-04,2017-12,"[{'measure': 'Objective Response Rate (ORR) by Week 19', 'description': 'ORR refers to percentage of participants who achieved complete response (CR) or partial response (PR) by Week 19 of the study in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 which was subsequently confirmed by Week 25. A participant achieved CR if both target and non-target lesions achieved CR, no new lesions; achieved PR if target lesions achieved CR or PR, non-target lesions were assessed as non-CR/non-PD (progressive disease), indeterminate or missing, and no new lesions. For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes must decrease to normal size); PR: \\>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target lesions, CR: disappearance of all non-target lesions and normalization of tumor marker levels and all lymph nodes must be normal in size; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits.', 'timeFrame': '25 weeks'}]","[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events', 'description': 'AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. Treatment-emergent AEs (TEAEs) were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. Severity was graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.', 'timeFrame': '55 weeks'}, {'measure': 'Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)', 'description': 'Laboratory evaluation included hematology (hemoglobin, white blood cells, platelets and absolute neutrophil count), blood chemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, serum or plasma creatinine, sodium, potassium, total calcium, magnesium, blood urea nitrogen or urea, and albumin ), coagulation (international normalized ratio for prothrombin time and activated partial thromboplastin time) and urinalysis (dipstick followed by a quantitative urine protein analysis for results of 2+ or greater).', 'timeFrame': '55 weeks'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR was defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. DOR was based on the Brookmeyer and Crowley method.', 'timeFrame': '55 weeks'}, {'measure': 'Progression Free Survival Rate at 55 Weeks', 'description': 'This outcome measure refers to the possibility of being progression free at 55 weeks since start of study treatment, estimated from the Kaplan-Meier curve using the product-limit method.', 'timeFrame': '55 weeks'}, {'measure': 'Survival Rate at 55 Weeks', 'description': 'This outcome measure refers to the possibility of being alive at 55 weeks since start of study treatment, estimated from the Kaplan-Meier curve using the product-limit method.', 'timeFrame': '55 weeks'}, {'measure': 'Serum Concentration of Bevacizumab up to 1 Year', 'timeFrame': 'Pre-dose from Cycle 1 to Cycle 17, 2.5 hours post-dose in Cycle 1, and 1.5 hours post-dose in Cycle 5'}, {'measure': 'Number of Participants With Anti-Drug Antibody (ADA)', 'description': 'ADA assay was performed using a sensitive, specific, and semi-quantitative electrochemiluminescent (ECL) method, which used biotinylated- and ruthenium-labeled PF-06439535 as reagents. Samples with ADA titer greater than or equal to (\\>=) 2.29 were considered positive.', 'timeFrame': '55 weeks'}, {'measure': 'Number of Participants With Neutralizing Antibody (NAb)', 'description': 'Only samples that were confirmed positive for ADA were further tested for NAb. The NAb analysis was conducted using a single validated quasi-quantitative enzyme-linked immunosorbent assay (ELISA) that utilized PF-06439535 as a reagent. Samples with NAb titer \\>=1.70 were considered positive.', 'timeFrame': '55 weeks'}]",9,18 Years,,ALL,False,Pfizer,INDUSTRY,0,719.0,ACTUAL,2025-09-01T16:18:19.668338,v2_robust,True,True,True,False,True,
NCT05322499,Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer,Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Second-line or Above Therapy for Advanced Esophageal Squamous Cell Cancer Previously Treated With First-line Immunotherapy,Camrelizumab,"['Paclitaxel', 'Irinotecan', 'SHR-1210', 'Camrelizumab', 'Docetaxel', 'Anlotinib', 'Paclitaxel-albumin']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Stage IV Esophagus Squamous Cell Carcinoma,['Stage IV Esophagus Squamous Cell Carcinoma'],[],UNKNOWN,,2022-04-15,2025-04-15,"[{'measure': 'Objective response rate (ORR)', 'description': 'ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1', 'timeFrame': 'Up to 24 month'}]","[{'measure': 'Duration of response (DoR)', 'description': 'DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to 24 month'}, {'measure': 'Disease control rate (DCR)', 'description': 'DCR is defined as the percentage of participants in the analysis population who have a CR, PR or stable disease (SD) per RECIST 1.1.', 'timeFrame': 'Up to 24 month'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Progression-free survival is defined as the duration from date of enrollment to the first occurrence of progression of disease or death from any cause', 'timeFrame': 'Up to 24 month'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival is defined as the duration from date of enrollment to the date of death from any cause.', 'timeFrame': 'Up to 24 month'}]",5,18 Years,75 Years,ALL,False,Zhejiang Cancer Hospital,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:19.668367,v2_robust,True,True,False,False,False,
NCT05040932,Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy,"A First-In-Human, Multicenter, Open-Label, Phase I Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of YH004 As A Single Agent And Combination With Toripalimab In Subjects With Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma",YH004,['YH004'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Cancer,['Cancer'],"['Eucure', 'YH004', 'anti-4-1BB', 'Toripalimab', 'anti-PD-1']",COMPLETED,,2021-12-07,2023-07-16,"[{'measure': 'Treatment-emergent adverse events (TEAEs) including determination of DLTs and serious AEs (SAEs)', 'description': 'Adverse events will be assessed, and severity will be assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0', 'timeFrame': 'up to 24 months'}, {'measure': 'Maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D)', 'description': 'The MTD and/or RP2D will be determined based on TEAEs', 'timeFrame': 'up to 24 months'}]",[],2,18 Years,80 Years,ALL,False,"Eucure (Beijing) Biopharma Co., Ltd",INDUSTRY,0,8.0,ACTUAL,2025-09-01T16:18:19.668541,v2_robust,True,True,True,False,True,
NCT00243932,Clinical Trial of High Dose CoQ10 in ALS,Clinical Trial of High Dose CoQ10 in ALS,coenzyme Q10,"['Coenzyme Q 10', 'CoQ10', 'coenzyme Q10', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Amyotrophic Lateral Sclerosis,"['Amyotrophic Lateral Sclerosis', ""Lou Gehrig's Disease""]","['amyotrophic lateral sclerosis', 'ALS', ""Lou Gehrig's disease"", 'CoQ10', 'coenzyme Q10', 'antioxidants', 'free radicals', 'mitochondrial dysfunction']",COMPLETED,,2005-04,2008-03,"[{'measure': 'Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.', 'description': 'The ALSFRSr, a questionnaire-based scale assessing daily living function ranging from 48 (best score) to 0 (worst), was administered to the patient, or to a proxy if the patient could not communicate effectively. Decline was defined as ALSFRSr at baseline minus ALSFRSr at month 9. Thus a positive value indicates worsening.', 'timeFrame': '9 months'}]","[{'measure': 'Change in Fatigue Severity Scale', 'description': 'The change over 9 months in fatigue severity scale. A 9-item scale measuring the impact of fatigue. Scores range from 7 (strongly disagree)-63 (strongly agree) with higher scores indicating a worse outcome.', 'timeFrame': '9 months'}, {'measure': 'Change in Forced Vital Capacity', 'description': 'The change over 9 months in forced vital capacity is the volume (liters) of gas that can be exhaled by maximum voluntary effort following deep inspiration. The best of three trials will be recorded. The result is recorded as percentage of predicted for age, height and weight.', 'timeFrame': '9 months'}, {'measure': 'Change in Short Form (SF)-36 Score (Physical)', 'description': 'The change over 9 months in SF-36 score, which is a quality of life measure. Scores range from 0-100 with a higher score indicating a better outcome.', 'timeFrame': '9 months'}, {'measure': 'Change in Short Form (SF)-36 Score (Mental)', 'description': 'The change over 9 months in SF-36 score, which is a quality of life measure. Scores range from 0-100 with a higher score indicating a better outcome.', 'timeFrame': '9 months'}]",5,21 Years,85 Years,ALL,False,Columbia University,OTHER,1,185.0,ACTUAL,2025-09-01T16:18:19.668595,v2_robust,True,True,True,False,False,
NCT06476132,Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients,"Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients: A Randomized, Multicenter, Double Blind, Placebo-Controlled Trial (CTOT-47)",Belumosudil,"['Belumosudil', 'Placebo for Belumosudil']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Transplant,['Lung Transplant'],"['Lung Transplant', 'Belumosudil', 'CLAD', 'Acute Rejection', 'Lymphocytic Bronchiolitis', 'Organizing Pneumonia', 'Acute Lung Injury']",RECRUITING,,2025-03-12,2027-06-30,"[{'measure': 'Time from randomization to the first occurrence of probable or definite CLAD (per ISHLT 2019 standard defined criteria), lung retransplant, or death', 'description': 'Probable CLAD is defined as a \\>= 20% decline in Forced Expiratory Volume in 1 Second (FEV1) compared to the baseline value on 2 measurements taken at least 3 weeks apart and after exclusion or adequate treatment of potential secondary causes of allograft dysfunction.\n\nThe baseline FEV1 value is defined as the average of the 2 best posttransplant FEV1s taken at least 3 weeks apart', 'timeFrame': 'From randomization until study completion - scheduled assessments: minimum of 1 year, maximum of 3 years'}]","[{'measure': 'Time from randomization to first occurrence of probable or definite CLAD (per ISHLT 2019 standard defined criteria) or lung retransplant', 'description': 'Definite CLAD is a sustained decline in pulmonary function as defined by a persistent decline in lung function meeting the definition of probable CLAD but sustained for a duration of at least 3 months', 'timeFrame': 'From randomization until study completion - scheduled assessments: minimum of 1 year, maximum of 3 years'}, {'measure': 'Time from randomization to death', 'timeFrame': 'From date of randomization until the date of death, through study completion; participants are scheduled to be assessed for a minimum of 1 year up to a maximum of 3 years'}, {'measure': 'Time from randomization to first occurrence of the specific CLAD phenotypes of Restrictive Allograft Syndrome (RAS), Bronchiolitis Obliterans Syndrome (BOS), mixed, or undefined', 'timeFrame': 'From date of randomization until study completion - scheduled assessments: minimum of 1 year, maximum of 3 years'}, {'measure': 'Frequency of Acute Rejection (AR)', 'timeFrame': 'Number of AR events occurring from date of randomization until date of end of treatment visit, an average of 1 year'}, {'measure': 'Frequency of Lymphocytic Bronchiolitis (LB)', 'timeFrame': 'Number of LB events occurring from date of randomization until date of end of treatment visit, an average of 1 year.'}, {'measure': 'Frequency of Organizing Pneumonia (OP)', 'timeFrame': 'Number of OP events occurring from date of randomization until date of end of treatment visit, an average of 1 year.'}, {'measure': 'Frequency of Acute Lung Injury (ALI)', 'timeFrame': 'Number of ALI events occurring from date of randomization until date of end of treatment visit, an average of 1 year.'}, {'measure': 'Rate of change in lung function measures (forced expiratory volume [FEV1] and forced vital capacity [FVC])', 'timeFrame': 'Rate of change occurring from date of randomization until date of end of treatment visit, an average of 1 year.'}]",9,12 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,234.0,ESTIMATED,2025-09-01T16:18:19.668638,v2_robust,True,True,False,False,False,
NCT00034632,Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095),"Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections",Posaconazole oral suspension,['Posaconazole oral suspension'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Mycoses,['Mycoses'],"['Aspergillosis, Candidiasis, Cryptococcosis, Phaeohyphomycosis', 'Invasive Fungal Infections']",COMPLETED,,2001-04,2007-03,[],[],0,13 Years,65 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,,,2025-09-01T16:18:19.668714,v2_robust,True,True,True,False,False,
NCT00931632,Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants,Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth,Inhaled Nitric Oxide,"['Nitrogen gas', 'INOmax', 'Placebo', 'Inhaled Nitric Oxide']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Bronchopulmonary Dysplasia,['Bronchopulmonary Dysplasia'],"['Bronchopulmonary Dysplasia, BPD']",COMPLETED,,2009-11,2014-05,"[{'measure': 'Survival Without BPD at 36 Weeks', 'timeFrame': 'Baseline, 36 weeks PMA'}]","[{'measure': 'Days of Airway Pressure Support - Intent-to-treat Population', 'description': 'Airway pressure support includes conventional mechanical ventilation, conventional, high frequency oscillatory ventilation, jet, continuous positive airway pressure, and other.', 'timeFrame': 'Through hospital discharge, an average of 105 days for placebo and 108 days for INO'}, {'measure': 'Length of Birth Hospitalization', 'timeFrame': 'Through hospital discharge, an average of 105 days for placebo and 108 days for INO'}, {'measure': 'Number and Percentage of Participants With Use of Postnatal Corticosteroids for Bronchopulmonary Dysplasia', 'timeFrame': 'Through hospital discharge, an average of 105 days for placebo and 108 days for INO'}, {'measure': 'Number and Percentage of Participants With Use of Postnatal Corticosteroids for Any Medical Reason', 'timeFrame': 'Through hospital discharge, an average of 105 days for placebo and 108 days for INO'}, {'measure': 'Systemic Use of Postnatal Corticosteroids for Any Medical Reason', 'timeFrame': 'Through hospital discharge, an average of 105 days for placebo and 108 days for INO'}, {'measure': 'Number of Days of Oxygen Use', 'timeFrame': 'Through hospital discharge, an average of 105 days for placebo and 108 days for INO'}, {'measure': 'Severity of Bronchopulmonary Dysplasia', 'description': 'Severity of bronchopulmonary dysplasia defined by the fraction of inspired O2 concentration (FiO2) requirement.', 'timeFrame': '36 weeks'}]",8,5 Days,14 Days,ALL,False,Mallinckrodt,INDUSTRY,0,451.0,ACTUAL,2025-09-01T16:18:19.668745,v2_robust,True,True,True,False,False,
NCT00546832,Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II,The Efficacy and Safety of TDS-943 in the Treatment of Osteoarthritis of the Knee: Pivotal Study II,TDS-943 (topical diclofenac sodium 4% spray),"['TDS-943 (topical diclofenac sodium 4% spray)', 'celecoxib']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Osteoarthritis,['Osteoarthritis'],[],COMPLETED,,2007-10,2008-11,"[{'measure': 'Change from baseline in the WOMAC Composite Pain Score', 'timeFrame': '30 days'}]","[{'measure': ""Change from baseline in the WOMAC Composite Stiffness and Composite Function Scores, Change from Baseline in the Subject's Global Assessment of Arthritic Condition, Change from baseline in the Subject's Assessment of OA Pain, %OMERACT-OARSI responders"", 'timeFrame': '30 days'}]",2,40 Years,,ALL,False,Mika Pharma GmbH,INDUSTRY,0,650.0,ACTUAL,2025-09-01T16:18:19.668776,v2_robust,True,True,True,False,False,
NCT04899232,Antithrombin III in Infectious Disease Caused by COVID-19,Antithrombin III (AT3) in Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)/ Coronavirus Disease of 2019 (COVID-19),Antithrombin III,"['Antithrombin III', 'Thrombate III']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Antithrombin III Deficiency,"['Antithrombin III Deficiency', 'Covid19']",[],TERMINATED,There are fewer potential patients and an early conclusion of the study would be beneficial in an attempt to finish in a reasonable time and keep the cohorts homogenous.,2021-07-06,2022-03-31,"[{'measure': 'Change in ISTH DIC Score', 'description': 'As measured by the International Society of Thrombosis and Haemostasis Disseminated Intravascular Coagulation scale (ISTH DIC) which has a total score ranging from 0-8 with a score of 5 and higher indicating overt DIC.', 'timeFrame': 'Baseline, Day 9'}]","[{'measure': 'Change in D-Dimer Levels', 'description': 'D-Dimer levels assessed from blood samples will be evaluated in mcg/ml D-Dimer Units (DDU)', 'timeFrame': 'Baseline, Day 9'}, {'measure': 'Change in Fibrinogen Levels', 'description': 'Fibrinogen levels assessed from blood samples will be evaluated in mg/dL.', 'timeFrame': 'Baseline, Day 9'}, {'measure': 'Change in Prothrombin Time', 'description': 'Prothrombin time assessed from blood samples will be evaluated in seconds.', 'timeFrame': 'Baseline, Day 9'}, {'measure': 'Length of Hospital Stay', 'description': 'Length of Hospital Stay reported in days.', 'timeFrame': 'Up to 60 days'}, {'measure': 'Mortality Rate', 'description': 'The number of participants with reported death.', 'timeFrame': 'Up to 60 days'}, {'measure': 'Pulmonary Function', 'description': 'Pulmonary Function will be reported as the mean days the participant was on any of the following: mechanical ventilation and/or Extracorporeal Membrane Oxygenation (ECMO) use.', 'timeFrame': 'Up to 60 days'}, {'measure': 'Change in SOFA Scores', 'description': 'Sequential Organ Failure Assessment (SOFA) is scored from 0-4 with the higher score indicating more organ failure.', 'timeFrame': 'Baseline, Day9'}, {'measure': 'Change in SOFA Respiratory Sub Score', 'description': 'SOFA Respiratory Sub Score is scored from 0-4 with the higher score indicating worse organ failure.', 'timeFrame': 'Baseline, Day 9'}, {'measure': 'Number of Events of Venous Thromboembolism', 'description': 'Number of events of venous thromboembolisms from admission to hospital discharge.', 'timeFrame': 'Up to 60 days'}, {'measure': 'Number of Events of Major Bleeding', 'description': 'Number of events of major bleeding from admission to hospital discharge.', 'timeFrame': 'Up to 60 days'}]",11,18 Years,,ALL,False,Enrique Ginzburg,OTHER,1,52.0,ACTUAL,2025-09-01T16:18:19.668818,v2_robust,True,True,False,True,False,There are fewer potential patients and an early conclusion of the study would be beneficial in an attempt to finish in a reasonable time and keep the cohorts homogenous.
NCT04728932,LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients,LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients,Levosimendan,"['Placebo of Levosimendan', 'Levosimendan']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Cardiogenic Shock,"['Cardiogenic Shock', 'Extracorporeal Membrane Oxygenation Complication']",['LEVOSIMENDAN'],COMPLETED,,2021-08-27,2024-11-09,"[{'measure': 'Time to successful ECMO weaning within the 30 days following randomization', 'timeFrame': 'Day 30'}]","[{'measure': 'Mortality', 'timeFrame': 'Day 30, Day 60'}, {'measure': 'Total duration of ECMO support', 'timeFrame': 'Between inclusion and Day 30/Day 60'}, {'measure': 'Number of ECMO-free days', 'timeFrame': 'Between inclusion and Day 30/Day 60'}, {'measure': 'Duration of ICU stay', 'timeFrame': 'Between inclusion and Day 60'}, {'measure': 'Duration of hospitalization stay', 'timeFrame': 'Between inclusion and Day 60'}, {'measure': 'Major adverse cardiovascular events', 'description': 'defined as death, cardiac transplant, escalation to permanent left ventricular assist device, stroke, dialysis, re-hospitalization for heart failure', 'timeFrame': 'Day 30, Day 60'}, {'measure': 'Time to improvement in hemodynamic parameters', 'timeFrame': 'Between inclusion and Day 60'}, {'measure': 'Time to hemodynamic stabilization', 'timeFrame': 'Between inclusion and Day 60'}, {'measure': 'Days with organ failure asessed by sequential organ failure assessment', 'timeFrame': 'Between inclusion and Day 30'}, {'measure': 'Duration of hemodynamic support with catecholamines', 'timeFrame': 'Between inclusion and Day 30/Day 60'}, {'measure': 'Number of days alive without hemodynamic support', 'timeFrame': 'Between inclusion and Day 30/Day 60'}, {'measure': 'Duration of mechanical ventilation', 'timeFrame': 'Between inclusion and Day 30/Day 60'}, {'measure': 'Number of days alive without mechanical ventilation', 'timeFrame': 'Between inclusion and Day 30/Day 60'}, {'measure': 'Left ventricular function assessed with echocardiography', 'timeFrame': 'Day 30'}, {'measure': 'Incidence of adverse drug reactions', 'timeFrame': 'Between inclusion and Day 60'}]",16,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,206.0,ACTUAL,2025-09-01T16:18:19.668847,v2_robust,True,True,True,False,True,
NCT05971732,The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF),"The Effects of Ferric Derisomaltose Administered Before Hospital Discharge in Stabilised Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life: a Randomised, Parallel-group, Double-blind, Placebo Controlled Trial (COREVIVE-HFrEF)",Ferric derisomaltose,"['Ferric derisomaltose', 'Normal saline', 'Placebo', 'Monofer', 'Iron (III) isomaltoside 1000']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Heart Failure With Reduced Ejection Fraction,"['Heart Failure With Reduced Ejection Fraction', 'Iron Deficiency', 'Acute Heart Failure']","['Exercise capacity', 'Quality of life', 'Acute Heart Failure']",RECRUITING,,2023-08-01,2025-08-01,"[{'measure': 'Change in 6-minute walking distance', 'description': 'The difference of 6-minute walking distance in meters from baseline to day3 after IV iron injection.', 'timeFrame': 'Up to 3 days'}]","[{'measure': 'Change From Baseline in 6-minute walking distance', 'description': 'The difference of 6-minute walking distance in meters from baseline at 2 weeks, 4weeks after IV iron injection.', 'timeFrame': 'At 2 weeks, 4weeks after IV iron injection'}, {'measure': 'Change From Baseline in the KCCQ Clinical Summary Score', 'description': ""KCCQ was a 23-item, self-administered questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. KCCQ-clinical summary score was average of domains- physical limitation and total symptoms (average of symptom frequency and symptom burden), and transformed to a single score which ranged from 0 (worst) -100 (the best possible status), where the higher score reflected better health status."", 'timeFrame': 'At 2 weeks, 4weeks after IV iron injection'}, {'measure': 'Change From Baseline in the EQ-5D-5L Questionnaire Indexed Value', 'description': 'EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels The EQ 5D questionnaire consists of a health descriptive system for participants to self-classify and rate their health status on the day of administration.\n\nThe descriptive system includes 5 items/dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are coded from 1 (best state) to 5 (worst state).', 'timeFrame': 'At 3 days, 2weeks, 4weeks after IV iron injection'}, {'measure': 'Change From Baseline in NYHA Functional Class', 'description': 'NYHA = New York Heart Association\n\nNYHA functional class was assessed as Class I, II, III, IV:\n\nClass I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.\n\nClass II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.\n\nClass III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity. Comfortable only at rest.\n\nClass IV - Severe limitations. Experiences symptoms even while at rest.\n\nLower response categories are better for score NYHA.', 'timeFrame': 'At 3 days, 2weeks, 4weeks after IV iron injection'}, {'measure': 'Change From Baseline in PGA quality of life questionnaire', 'description': 'PGA:Patient Global Assessment\n\nPGA questionnaire consists of a health descriptive system for participants to self-reported and rate their medical condition after participate this study.\n\nThe descriptive system includes 7 choices：has much improved, has (moderately) improved, has a little improved, is unchanged, is a little worse, is (moderately) worse, is much worse, which are coded from 1 (best state) to 7 (worst state).', 'timeFrame': 'At 3 days, 2weeks, 4weeks after IV iron injection'}, {'measure': 'Change From Baseline in Concentration of hemoglobin (Hb)', 'description': 'Hemoglobin (Hb) is a commonly used clinical test for assessing anaemia, with units of g/L.', 'timeFrame': 'At 3 days, 2weeks, 4weeks after IV iron injection'}, {'measure': 'Change From Baseline in proportion of reticulocyte (Ret%)', 'description': 'The reticulocyte ratio is often used to reflect the hematopoiesis of the bone marrow erythrocyte with units of percentage(%).', 'timeFrame': 'At 3 days, 2weeks, 4weeks after IV iron injection'}, {'measure': 'Change From Baseline in Concentration of ferritin', 'description': 'To assess the effect of ferric derisomaltose vs. placebo on change in ferritin from baseline to 3 days, 2weeks and 4weeks', 'timeFrame': 'At 3 days, 2weeks, 4weeks after IV iron injection'}, {'measure': 'Change From Baseline in concentration of transferrin saturation', 'description': 'To assess the effect of ferric derisomaltose vs. placebo on change in transferrin saturation from baseline to 3 days, 2weeks and 4weeks', 'timeFrame': 'At 3 days, 2weeks, 4weeks after IV iron injection'}, {'measure': 'Change From Baseline in Concentration of serum transferrin receptors (sTfR)', 'description': 'To assess the effect of ferric derisomaltose vs. placebo on change in serum transferrin receptors (sTfR) from baseline to 3 days, 2weeks and 4weeks', 'timeFrame': 'At 3 days, 2weeks, 4weeks after IV iron injection'}, {'measure': 'Change From Baseline in Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)', 'description': 'To assess the effect of ferric derisomaltose vs. placebo on change in NT-proBNP from baseline to 3 days, 2weeks and 4weeks', 'timeFrame': 'At 3 days, 2weeks, 4weeks after IV iron injection'}, {'measure': 'Change From Baseline in Left Ventricular Systolic Function', 'description': 'Left ventricular ejection fraction is assessed by two-dimensional directed M-mode echocardiography.', 'timeFrame': 'At 2weeks, 4weeks after IV iron injection'}, {'measure': 'Change From Baseline in Left Ventricular End-Diastolic Diameter', 'description': 'Left ventricular end-diastolic diameter is assessed by two-dimensional directed M-mode echocardiography.', 'timeFrame': 'At 2weeks, 4weeks after IV iron injection'}]",14,18 Years,,ALL,False,China-Japan Friendship Hospital,OTHER,0,146.0,ESTIMATED,2025-09-01T16:18:19.668863,v2_robust,True,True,False,False,False,
NCT00003332,Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer,Phase I/II Study of Induction Chemotherapy With Gemcitabine and Cisplatin Followed by Combined Chemo-radiation and/or Surgical Resection for Locally Advanced Pancreatic Cancer,cisplatin,"['cisplatin', 'gemcitabine hydrochloride']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Pancreatic Cancer,['Pancreatic Cancer'],"['stage I pancreatic cancer', 'stage II pancreatic cancer', 'stage III pancreatic cancer', 'adenocarcinoma of the pancreas']",COMPLETED,,1997-07,,[],[],0,18 Years,,ALL,False,NYU Langone Health,OTHER,1,36.0,ESTIMATED,2025-09-01T16:18:19.668946,v2_robust,True,True,True,False,False,
NCT06383598,PD-L1 Specific 68Ga-THP-PD-L1-3 Probe for PET Imaging in Solid Tumors,PD-L1 Specific 68Ga-THP-PD-L1-3 Probe for PET Imaging in Solid Tumors,18F-FDG,['18F-FDG'],1,INTERVENTIONAL,['NA'],,,Solid Tumor,['Solid Tumor'],[],RECRUITING,,2024-04-01,2026-12-31,"[{'measure': 'Standardized uptake value（SUV）', 'description': 'The uptake of the tracer （68Ga-THP-PD-L1-3) in solid tumor lesions or suspected tumor lesions by measuring SUV on PET/CT.', 'timeFrame': '2 years'}]",[],1,18 Years,70 Years,ALL,False,Hua Zhu,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:19.669114,v2_robust,True,True,False,False,False,
NCT03433898,This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer,"An Open Label, Phase I Study of BI 754091 Monotherapy and Combination Therapy of BI 754091 and BI 754111 in Asian Patients With Advanced Solid Tumours",BI 754091,"['BI 754091', 'BI 754111']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Neoplasms,['Neoplasms'],[],COMPLETED,,2018-02-23,2023-07-20,"[{'measure': 'Part I: Maximum tolerated dose (MTD) of BI 754091', 'timeFrame': 'Up to 9 months'}, {'measure': 'Part I: Number of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period (first cycle of treatment)', 'timeFrame': 'Up to 3 weeks'}, {'measure': 'Part II: MTD of the BI 754091 plus BI 754111 combination', 'timeFrame': 'Up to 9 months'}, {'measure': 'Part II: Number of patients experiencing DLTs during the MTD evaluation period (first cycle of treatment)', 'timeFrame': 'Up to 3 weeks'}, {'measure': 'Part III: Objective response (OR) - confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumours (RECIST) Version 1.1 as assessed by the Investigator', 'timeFrame': 'Up to 12 months'}]","[{'measure': 'Part I: Cmax: maximum measured concentration of BI 754091 in plasma', 'timeFrame': 'Up to 3 weeks'}, {'measure': 'Part I: AUC0-504: area under the concentration-time curve of BI 754091 in plasma', 'timeFrame': 'Up to 3 weeks'}, {'measure': 'Part II: Cmax: maximum measured concentration of BI 754091 and BI 754111 in plasma', 'timeFrame': 'Up to 3 weeks'}, {'measure': 'Part II: AUC0-504: area under the concentration-time curve of BI 754091 and BI 754111 in plasma', 'timeFrame': 'Up to 3 weeks'}, {'measure': 'Part III: Duration of response', 'description': 'Defined as the duration from the date of first documented PR or CR according to RECIST Version 1.1 as assessed by the Investigator to the date of progressive disease (PD) or death', 'timeFrame': 'Up to 18 months'}, {'measure': 'Part III: Disease control', 'description': 'CR, PR, or stable disease (SD) according to RECIST Version 1.1 as assessed by the Investigator', 'timeFrame': 'Up to 12 months'}, {'measure': 'Part I - Objective response (OR)', 'timeFrame': 'Up to 12 months'}, {'measure': 'Part II - Objective response (OR)', 'timeFrame': 'Up to 12 months'}]",13,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,146.0,ACTUAL,2025-09-01T16:18:19.669145,v2_robust,True,True,True,False,False,
NCT01931098,Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab,A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab,topotecan,"['Votrient', 'topotecan', 'pazopanib', 'Hycamtin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Glioblastoma,"['Glioblastoma', 'Glioblastoma Multiforme', 'Gliosarcoma', 'Brain Neoplasms', 'Central Nervous System Neoplasms']",['Brain Tumors'],COMPLETED,,2015-12-10,2019-09-12,"[{'measure': 'Proportion of Patients That Have Progressive Survival (PFS) at Six Months From Patient Registration for Bevacizumab Naive Patients and PFS at 3 Months for Patients With Prior Bevacizumab Treatment', 'description': 'PFS was evaluated using the Kaplan-Meier product-limit survival curve methodology. For participants with no prior bevacizumab exposure, PFS is defined as 2 or more participants who are progression free at 6 months. For participants with prior bevacizumab exposure, PFS is defined as 1 or more participants who are progression free at 3 months. Progression is a 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) or clear worsening of evaluable disease or the appearance of any new lesions.', 'timeFrame': 'six months from patient registration for bevacizumab naive patients, and 3 months from patient registration for patients with prior bevacizumab treatment'}]","[{'measure': 'Overall Survival', 'description': 'OS was evaluated using the Kaplan-Meier product-limit survival curve methodology and is defined as the time from date of registration to date of death due to any cause.', 'timeFrame': 'From date of registration to date of death due to any cause, up to 5 years.'}, {'measure': 'Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle', 'description': 'Responders and Non-Responders symptom presence and severity were assessed by the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) questionnaire using an scale of (0-10); 0 being not present and 10 being the worst, and Responders were defined as patients with stable disease (SD) and partial response (PR) as their best response, and Non-responders were defined as patients with disease progression (PD) as their best response. Partial response is greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesion. Progressive disease is a 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease). And stable disease does not qualify for complete response, partial response or progression.', 'timeFrame': 'Baseline, and Cycles 1-6'}, {'measure': 'Mean Symptom Interference Score Between Responders and Non-responders at Baseline and by Cycle', 'description': ""Responders and Non-Responders symptom interference was assessed by the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) questionnaire that determined how much general activity, mood, work inside and outside the home, relations with other people, walking and enjoying life interfered with a participant's life rated on an scale (0-10); 0 being not present and 10 being the worst. Responders were defined as patients with stable disease (SD) and partial response (PR) as their best response, and Non-responders were defined as patients with disease progression (PD) as their best response. Partial response is greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesion. Progressive disease is a 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease). And stable disease does not qualify for complete response, partial response or progression."", 'timeFrame': 'Baseline, and Cycles 1-6'}, {'measure': 'Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)', 'description': 'Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.', 'timeFrame': 'Date treatment consent signed to date off study, approximately 20 months and 18 days for the first Arm/Group, and 28 months and 23 days for the second Arm/Group.'}]",5,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,35.0,ACTUAL,2025-09-01T16:18:19.669239,v2_robust,True,True,True,False,True,
NCT02048098,Misoprostol for Second Trimester Termination of Pregnancy,A Comparison Between Vaginal Misoprostol vs. Buccal Misoprostol For Second Trimester Termination of Pregnancy,Vaginal misoprostol,"['Buccal misoprostol', 'Cytotec', 'Vaginal misoprostol']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Abortion, Induced","['Abortion, Induced']","['misoprostol', 'Labor, Induced', 'Pregnancy Trimester, Second', 'Abortion, Induced']",COMPLETED,,2014-01,2014-12,"[{'measure': 'Induction to fetal expulsion interval', 'description': 'Time elapsed between administration of the first misoprostol dose until expulsion of the fetus', 'timeFrame': '15 minutes after fetus delivered'}]","[{'measure': 'Delivery within 24 hours', 'timeFrame': '24 hour'}, {'measure': 'Delivery within 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Use of additional interventions', 'description': 'the patients who did not delivered within 48 hours will considered as failed induction and will be offered another method of induction/delivery or to continue same protocol.', 'timeFrame': 'One week'}, {'measure': 'Expected pain before induction and perceived (actual) pain after abortion completed', 'description': 'Expected and perceived pain will be measured by VAS', 'timeFrame': 'within 1 hour after randomisation and after 12 hour after complete abortion/placenta removed'}, {'measure': 'Rate of complete abortion', 'timeFrame': '12 hour after fetus and placenta removed'}]",6,16 Years,45 Years,FEMALE,True,Ataturk University,OTHER,0,130.0,ACTUAL,2025-09-01T16:18:19.669289,v2_robust,True,True,True,False,False,
NCT00525798,A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D,"A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D",SMC021 Oral calcitonin,"['SMC021 Placebo', 'SMC021 Oral calcitonin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Osteoporosis,['Osteoporosis'],"['Osteoporosis, oral salmon calcitonin, treatment, efficacy, tolerability']",COMPLETED,,2007-03,2011-11,"[{'measure': 'Number of Patients With New Vertebral Fractures', 'description': 'The primary variable was the occurrence or not of a new vertebral fracture during the 3 year observation period. New vertebral fractures were identified from an assessment of x-ray of the lateral spine through time (at baseline and at yearly intervals thereafter).\n\nThe outcome is the number of new vertebral fractures from baseline to 36 months.', 'timeFrame': 'From baseline to month 36'}]","[{'measure': 'Number of Patients With Non-vertebral Fractures', 'description': ""The secondary outcome was the occurrence or not of a non-vertebral fracture during the 3 year observation period. Non-vertebral fractures of interest were: hip fractures, forearm fractures, humurus fractures, rib fractures and clavicular fractures.\n\nAny new non-vertebral fractures while on-study were recorded. A copy of radiographs confirming the fracture, as well as a copy of the radiologist's report was to be obtained. A copy of the emergency room discharge letter or a hospital discharge letter was also obtained."", 'timeFrame': 'From baseline to month 36'}]",2,55 Years,85 Years,FEMALE,False,Nordic Bioscience A/S,INDUSTRY,1,4665.0,ACTUAL,2025-09-01T16:18:19.669314,v2_robust,True,True,True,False,False,
NCT05890898,Virtual Reality vs Nitrous Oxide in Pediatric Dentistry,Virtual Reality: An Interventional Study Comparing the Use of Virtual Reality to Nitrous Oxide for Analgesia During Dental Procedures on Pediatric Patients,Nitrous Oxide,['Nitrous Oxide'],1,INTERVENTIONAL,['NA'],,,Pediatric Dentistry,['Pediatric Dentistry'],[],ACTIVE_NOT_RECRUITING,,2023-09-19,2025-06,"[{'measure': 'Rate of effectiveness virtual reality goggles reduce pain', 'description': 'To determine whether the use of distraction via virtual reality headset can be as effective as nitrous oxide for purposes of anxiolysis and analgesia during dental treatment. The FLACC scale will be used to help measure this outcome.\n\nPatients will be observed during injection and assessed by the operator using the Faces, Legs, Arms, Crying Consolability (FLACC) scale. Each category will be rated from 0 to 2. Zero indicating normal positions and no sign of discomfort and 2 indicating discomfort in movements or unable to console/comfort.', 'timeFrame': '12 months'}, {'measure': 'Rate of effectiveness virtual reality goggles reduce pain', 'description': ""To determine whether the use of distraction via virtual reality headset can be as effective as nitrous oxide for purposes of anxiolysis and analgesia during dental treatment. The WongBaker scale will be used to help measure this outcome.\n\nPatients will rate their pain using the Wong-Baker FACES Pain Scale by indicating which face best depicts the pain they are experiencing. Each face has a corresponding number: 0 = doesn't hurt at all to 10 = hurts as much as you can imagine."", 'timeFrame': '12 months'}]","[{'measure': 'Rate of effectiveness of virtual reality distraction to nitrous oxide', 'description': 'To determine if there is a difference in the effectiveness between the use of the standard nitrous oxide and VR distraction. The Houpt scales will be used to help measure this outcome.\n\nPatients will be observed during the procedure using the Houpt Behavioral Scale. Each category is scored on the 0-2 scale which results in a total score of 0-10. Assessment of Behavioral Score: 0 = Relaxed and comfortable, 1-3 = Mild discomfort, 4-6 = Moderate pain, 7-10 = Severe discomfort/pain.', 'timeFrame': '12 months'}]",3,4 Years,12 Years,ALL,False,Geisinger Clinic,OTHER,0,62.0,ESTIMATED,2025-09-01T16:18:19.669332,v2_robust,True,True,False,False,False,
NCT04278898,Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose,Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: a Single-dose Challenge Study,N-Acetylcysteine,['N-Acetylcysteine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Autism Spectrum Disorder,['Autism Spectrum Disorder'],"['Magnetic Resonance Imaging', 'N-acetylcysteine', 'Restricted and Repetitive Behaviors', 'electroencephalography']",RECRUITING,,2021-02-12,2027-01,"[{'measure': 'Change in glutamatergic neurometabolites (Glx) measured by proton spectroscopy Magnetic Resonance Imaging (MRI)', 'timeFrame': '1 hour after single dose'}]","[{'measure': 'Change in Gamma band amplitude and synchronization measured by electroencephalography', 'timeFrame': '1 hour after single dose'}]",2,3 Years,12 Years,ALL,False,Stanford University,OTHER,1,24.0,ESTIMATED,2025-09-01T16:18:19.669383,v2_robust,True,True,False,False,False,
NCT06613698,A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease,"A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)",GSK4532990,"['GSK4532990', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Liver Diseases, Alcoholic","['Liver Diseases, Alcoholic']","['GSK4532990', 'Alcohol-related liver disease', 'Steatohepatitis']",RECRUITING,,2024-09-27,2027-08-23,"[{'measure': 'Number of participants with adverse events (AEs) and serious adverse events (SAEs)', 'timeFrame': 'Up to 8 weeks'}, {'measure': 'Number of participants with potentially clinically relevant changes in electrocardiogram (ECG), vital signs, and clinical laboratory tests', 'timeFrame': 'Up to 8 weeks'}, {'measure': 'Change from baseline in Liver Stiffness measurement (LSM) reduction using FibroScan® at Week 28 (kiloPascal)', 'description': 'Liver stiffness will be measured by vibration-controlled transient elastography (VCTE) using the FibroScan® device.', 'timeFrame': 'Baseline (Day 1) and up to Week 28'}, {'measure': 'Change from baseline in model for end-stage liver disease (MELD) score reduction at Week 28', 'description': 'MELD is a scoring system for assessing the severity of chronic liver disease. MELD scores range between 6 and 40, with 40 being the most severe.', 'timeFrame': 'Baseline (Day 1) and up to Week 28'}]","[{'measure': 'Maximum plasma concentration (Cmax) of GSK4532990', 'timeFrame': 'Up to Day 4'}, {'measure': 'Area Under the Curve from Time 0 to t [AUC (0-t)] of GSK4532990', 'timeFrame': 'Up to Day 4'}, {'measure': 'Area Under the Curve from Time 0 to 24 hours [AUC (0-24)] of GSK4532990', 'timeFrame': 'Up to 24 hours'}, {'measure': 'Plasma half-life (t1/2) of GSK4532990', 'timeFrame': 'Up to Day 4'}, {'measure': 'Apparent clearance (CL/F) of GSK4532990', 'timeFrame': 'Up to Day 4'}, {'measure': 'Time to maximum concentration (tmax) of GSK4532990', 'timeFrame': 'Up to Day 4'}, {'measure': 'Apparent terminal phase volume of distribution (Vz/F) of GSK4532990', 'timeFrame': 'Up to Day 4'}, {'measure': 'Change from baseline in serum AST at Week 28', 'timeFrame': 'Baseline (Day 1), and at Week28'}, {'measure': 'Change from baseline in Enhanced Liver Fibrosis (ELF™) score at Week 28', 'description': 'The ELF™ score will be calculated using a published algorithm combining the values of a set of extracellular matrix markers, including tissue inhibitor of metalloproteinases-1 (TIMP-1), type III procollagen (PIIINP), and hyaluronic acid (HA). The ELF™ score is used as a prognostic marker for disease progression. ELF™ score will range between 4.5 to 14.7. A higher ELF™ score will predict worse prognosis', 'timeFrame': 'Baseline (Day 1), and at Week 28'}, {'measure': 'Area under the concentration-time curve from time zero (pre-dose) to the last quantifiable concentration (AUC0-t) of GSK4532990', 'timeFrame': 'Up to Day 3'}, {'measure': 'Maximum observed plasma concentration (Cmax) of GSK4532990', 'timeFrame': 'Up to Day 3'}]",15,18 Years,65 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,393.0,ESTIMATED,2025-09-01T16:18:19.669393,v2_robust,True,True,False,False,True,
NCT00690898,Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma,"Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma",Lanreotide autogel 120 mg,['Lanreotide autogel 120 mg'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Acromegaly,['Acromegaly'],[],COMPLETED,,2008-05,2012-02,"[{'measure': 'Percentage of Patients With Relevant Reduction in Pituitary Tumour Volume (as Measured by MRI) From Baseline Volume (Visit 1) to Week 48 (After 12 Injections at Visit 5)', 'description': 'A blinded, centrally assessed evaluation of all MRIs was performed. A 20% reduction from the volume at Visit 1 was considered to be clinically relevant.', 'timeFrame': 'Week 1 and Week 48'}]","[{'measure': 'Number of Patients With at Least a 20% Reduction in Tumour Volume From Baseline Volume (Visit 1) to Week 12 (Visit 3) and Week 24 (Visit 4).', 'timeFrame': 'Baseline (week 1) to week 12 and week 24'}, {'measure': 'Percent Variation From Baseline to Visit 3, 4 and 5 (Week 12, 24, and 48) of IGF-1 Levels', 'timeFrame': 'Week 12, 24, and 48'}, {'measure': 'Percent Variation From Baseline to Visit 3, 4 and 5 (Week 12, 24, and 48) of Serum GH Levels.', 'timeFrame': 'Week 12, 24, and 48'}, {'measure': 'Change From Baseline to Visit 3, 4 and 5 (Week 12, 24, and 48) of Prolactin Levels', 'timeFrame': 'Week 12, 24 and 48'}, {'measure': 'Percentage of Patients With Improved, Unchanged or Worsened Clinical Signs of Acromegaly (Arthralgia) From Baseline', 'description': 'The status of clinical signs of acromegaly assessed by an acromegaly symptoms questionnaire (paper form) completed by the patient at each study visit. The scoring for each clinical sign of acromegaly on the questionnaire is from 0 (no symptom) to 8 (severe, incapacitating symptom). The variation (or no variation) in scores indicate whether the clinical sign of acromegaly had improved, worsened or was unchanged.', 'timeFrame': 'Week 12, 24 and 48'}, {'measure': 'Percentage of Patients With Improved, Unchanged or Worsened Clinical Signs of Acromegaly (Excessive Perspiration) From Baseline', 'description': 'The status of clinical signs of acromegaly assessed by an acromegaly symptoms questionnaire (paper form) completed by the patient at each study visit. The scoring for each clinical sign of acromegaly on the questionnaire is from 0 (no symptom) to 8 (severe, incapacitating symptom). The variation (or no variation) in scores indicate whether the clinical sign of acromegaly had improved, worsened or was unchanged.', 'timeFrame': 'Week 12, 24 and 48'}, {'measure': 'Percentage of Patients With Improved, Unchanged or Worsened Clinical Signs of Acromegaly (Fatigue) From Baseline', 'description': 'The status of clinical signs of acromegaly assessed by an acromegaly symptoms questionnaire (paper form) completed by the patient at each study visit. The scoring for each clinical sign of acromegaly on the questionnaire is from 0 (no symptom) to 8 (severe, incapacitating symptom). The variation (or no variation) in scores indicate whether the clinical sign of acromegaly had improved, worsened or was unchanged.', 'timeFrame': 'Week 12, 24 and 48'}, {'measure': 'Percentage of Patients With Improved, Unchanged or Worsened Clinical Signs of Acromegaly (Headache) From Baseline', 'description': 'The status of clinical signs of acromegaly assessed by an acromegaly symptoms questionnaire (paper form) completed by the patient at each study visit. The scoring for each clinical sign of acromegaly on the questionnaire is from 0 (no symptom) to 8 (severe, incapacitating symptom). The variation (or no variation) in scores indicate whether the clinical sign of acromegaly had improved, worsened or was unchanged.', 'timeFrame': 'Week 12, 24 and 48'}, {'measure': 'Percentage of Patients With Improved, Unchanged or Worsened Clinical Signs of Acromegaly (Soft Tissue Swelling) From Baseline', 'description': 'The status of clinical signs of acromegaly assessed by an acromegaly symptoms questionnaire (paper form) completed by the patient at each study visit. The scoring for each clinical sign of acromegaly on the questionnaire is from 0 (no symptom) to 8 (severe, incapacitating symptom). The variation (or no variation) in scores indicate whether the clinical sign of acromegaly had improved, worsened or was unchanged.', 'timeFrame': 'Week 12, 24 and 48'}, {'measure': 'Changes in the Global Acromegaly Quality of Life Assessment (AcroQoL) From Baseline', 'description': 'Acromegaly Quality of Life Assessment (AcroQoL) questionnaire response scores range from 0 to 100. Higher scores indicate best possible Quality of Life.', 'timeFrame': 'Week 12, 24 and 48'}]",11,18 Years,75 Years,ALL,False,Ipsen,INDUSTRY,0,108.0,ACTUAL,2025-09-01T16:18:19.669400,v2_robust,True,True,True,False,False,
NCT00003198,Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors,A Phase I Dose-Escalation Study of Topotecan and Ifosfamide in Patients With Refractory Non-Hematologic Malignancies.,ifosfamide,"['topotecan hydrochloride', 'ifosfamide']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Unspecified Adult Solid Tumor, Protocol Specific","['Unspecified Adult Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific']",COMPLETED,,1997-11,2000-05,[],[],0,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,,,2025-09-01T16:18:19.669452,v2_robust,True,True,True,False,False,
NCT01477463,Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers,Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers,Vitamin D3,"['25-hydroxy D3', 'inactive tablet and 25-hydroxy D3', 'Vitamin D3', 'placebo and vitamin D']",4,INTERVENTIONAL,['NA'],,,"Melanoma, Skin","['Melanoma, Skin']",['quality of life'],COMPLETED,,2012-09,2014-05,"[{'measure': 'Number of Genes That Showed Changes in Expression After Vitamin D Treatment', 'description': 'Normal cells have a complex series of molecular signals that allow communication between cells and to the cell nucleus. These signals work together to control one or more cell functions, such as cell division or cell death. Abnormal signaling activity caused by changes in gene expression can lead to cancer. An understanding of abnormal signaling, both in the tumor and in normal tissues, may lead to new therapies in cancer patients. We wish to identify changes in molecular signaling that occur in the development of melanoma that might be suppressed in benign nevi (moles) in response to vitamin D supplementation.', 'timeFrame': '2 years'}, {'measure': 'Number of Genes Differentialy Regulated in Melanoma That Showed Changes in Expression After Vitamin D Treatment', 'description': 'We utilized a prior gene expression study that compared malignant melanoma cells to benign nevi (moles) and identified over 2300 genes that were differentially regulated in melanoma compared to benign nevi. There were approximately 270 genes in our data set that showed changes in expression after vitamin D treatment. We wish to identify overlap between these two groups.', 'timeFrame': '2 years'}]","[{'measure': 'Vitamin D Toxicity', 'description': 'serum 25(OH)D for', 'timeFrame': '2 years'}, {'measure': 'Incidence of Hypercalcemia for Vitamin D Toxicity', 'description': 'Calcium levels', 'timeFrame': '2 years'}]",4,18 Years,75 Years,FEMALE,False,Stanford University,OTHER,2,24.0,ACTUAL,2025-09-01T16:18:19.669567,v2_robust,True,True,True,False,False,
NCT02746263,Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe Pain,"A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Repeated Dose, Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe Pain in Combination With Patient-Controlled Analgesia With Morphine in Adults Following Elective Total Knee Arthroplasty",IV acetaminophen,"['Ofirmev', 'IV acetaminophen', 'Oral acetaminophen', 'Morphine', 'Acetaminophen (APAP)']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,"Acute Pain, Postoperative","['Acute Pain, Postoperative']",['Elective total knee arthroplasty'],TERMINATED,Business decision because enrollment was slower than expected,2016-04-27,2016-05-05,"[{'measure': 'Pain Intensity on a Numerical Pain Scale (NPS) for 18 Hours', 'description': 'Participants rate intensity of their pain on a Numerical Pain Scale (NPS) from 0-10, wherein 0=no pain (better) and 10=most intense pain (worse). The highest possible score is 10.', 'timeFrame': '18 hours'}]",[],1,50 Years,90 Years,ALL,False,Mallinckrodt,INDUSTRY,0,1.0,ACTUAL,2025-09-01T16:18:19.669623,v2_robust,True,True,False,True,False,Business decision because enrollment was slower than expected
NCT05618587,Effect of Lithium Therapy on Long COVID Symptoms,Effect of Low-dose Lithium Therapy on Long COVID Symptoms: a Randomized Controlled Trial.,Lithium,"['Lithium', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Long COVID,['Long COVID'],"['lithium, long COVID']",COMPLETED,,2022-11-28,2023-07-21,"[{'measure': 'Fatigue Severity Scale', 'description': '7-item questionnaire assessing fatigue severity. Score range 1-49 with higher values signifying worse outcome', 'timeFrame': 'Change from baseline to day 21'}, {'measure': 'Brain Fog Severity Scale', 'description': '7-item questionnaire assessing brain fog severity. Score range 1-49 with higher values signifying worse outcome', 'timeFrame': 'Change from baseline to day 21'}]","[{'measure': 'Patient Global Impression of Change (PGIC)', 'description': 'Change in symptoms on 7-point scale. Single-item scale. Score range 1-7 with higher values signifying better outcome', 'timeFrame': 'Day 21'}, {'measure': 'Well-Being Scale', 'description': 'Sense of well-being over past week on 10-point scale. Score range 0-10 with higher values signifying better outcome.', 'timeFrame': 'Change from baseline to day 21'}, {'measure': 'Short Form-12 Health Survey (1-week Modification)', 'description': 'Quality of life assessment over past week, PCS-subscale. 12-item quality of life scale. Score range 0-100 for both the Physical Component Score and the Mental Component Score with higher values signifying better outcomes.', 'timeFrame': 'Change from baseline to day 21'}, {'measure': 'Desire to Continue Therapy', 'description': 'Single Yes/No question. Single-item scale. Score range 1-2 with higher value signifying better outcome. Reported as % of respondents recording ""yes"".', 'timeFrame': 'Day 21'}, {'measure': 'Generalized Anxiety Disorder-2 Scale', 'description': '2-item questionnaire assessing anxiety frequency over the past week. 2-item scale. Score range 0-6 with higher values signifying worse outcome', 'timeFrame': 'Change from baseline to day 21'}, {'measure': 'Headache and Body Pain Bother Scale', 'description': '2-item questionnaire assessing frequency of headaches and body pain over the past week, Headache score. 2-item scale. Score range 2-10 with higher values signifying worse outcome', 'timeFrame': 'Change from baseline to day 21'}, {'measure': 'Insomnia Severity Index', 'description': '7-item questionnaire assessing insomnia severity over the past week. 7-item scale. Score range 0-28 with higher values signifying worse outcome.', 'timeFrame': 'Change from baseline to day 21'}, {'measure': 'Sense of Smell and Taste Change Scale', 'description': 'Subjective change from baseline on a 7-point scale (score range: 1-7) with higher scores indicating better outcomes. Scores of 1 and 7 indicate sense of smell and taste were ""very much worse"" or ""very much improved"", respectively, since the start of study treatment.', 'timeFrame': 'Day 21'}, {'measure': 'Digit Symbol Substitution Test', 'description': 'Validated cognitive test. Score range 0-100 with higher scores indicating a better outcome.', 'timeFrame': 'Change from baseline to day 21'}, {'measure': 'Delayed Recall Test', 'description': 'Validated cognitive test. Score range 0-5 with higher scores indicating better outcomes.', 'timeFrame': 'Change from baseline to day 21'}]",12,18 Years,80 Years,ALL,False,State University of New York at Buffalo,OTHER,1,52.0,ACTUAL,2025-09-01T16:18:19.669644,v2_robust,True,True,True,False,False,
NCT01515787,PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery,A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT),FOLFOX (chemotherapy),['FOLFOX (chemotherapy)'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Colorectal Cancer,['Colorectal Cancer'],"['stage IIA rectal cancer', 'stage IIIA rectal cancer', 'stage IIIB rectal cancer']",ACTIVE_NOT_RECRUITING,,2012-06-12,2024-06-30,"[{'measure': 'Pelvic R0 Resection Rate', 'description': 'Number of Participants with Pelvic R0 Resection', 'timeFrame': 'Up to 5 years'}, {'measure': 'DFS', 'description': 'Disease-free Survival (DFS): The distribution of DFS by group will be estimated using the method of Kaplan-Meier. 5 year disease free rates by treatment group with confidence intervals based on Kaplan-Meier curves will be reported. Log-rank test will be used to compare DFS between two treatment groups. Hazard ratio with confidence interval will be estimated based on Cox proportional hazard model. The Cox proportional hazard model will be used for multivariate analysis.', 'timeFrame': 'Up to 5 years'}]","[{'measure': 'Pathologic Complete Response', 'description': ""Pathologic Complete Response (pCR): The pCR rate is defined as number of patients who achieve pCR divided by total number of patients included in the analysis population (see definition in Section 16.3.3.1) in each group. Patients who didn't undergo surgery will be classified as non-pCR. Point estimate and confidence interval (according to approach of Duffy and Santner) will be calculated by treatment groups. Chi-square test will be used to compare the pCR rates between groups."", 'timeFrame': 'Up to 8 years'}, {'measure': 'Overall Survival', 'description': 'Overall Survival (OS): OS is defined as time from randomization to the date of death due to all causes. The distribution of OS by group will be estimated using the method of Kaplan-Meier. Five year survival rates by treatment group with confidence intervals based on Kaplan-Meier curves will be reported. Logrank test will be used to compare OS between two treatment groups. Hazard ratio with confidence interval will be estimated based on Cox proportional hazard model. The Cox proportional hazard model will be used for multivariate analysis.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Rates of Receiving Pre- or Post-operative 5FUCMT', 'description': 'Rates of Receiving 5FUCMT: For selective group patients, the proportion of patients who received 1) pre-operative 5FUCMT, 2) post-operative 5FUCMT, 3) either pre or post-operative 5FUCMT, and confidence intervals (according to approach of Duffy and Santner) will be reported.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Local Recurrence (TLR):', 'description': 'Time to Local Recurrence (TLR): The distribution of TLR by group will be estimated using the method of Kaplan-Meier. 5 year local recurrence free rates by treatment group with confidence intervals based on Kaplan-Meier curves will be reported. The comparison of the cumulative incidence of local recurrence between groups, treating distant recurrence and death as competing risks using the test of Gray (Annals of Statistics, 1988) will be conducted.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Neoadjuvant Rectal Score', 'description': 'neoadjuvant rectal (NAR) score =\\[5 \\* pN - 3(cT - pT) + 12\\]\\^2/9.61. cT is an element of the set {1, 2, 3, 4}, pT is in {0, 1, 2, 3, 4}, and pN is in {0, 1, 2}. cT clinical tumor stage, pT pathologic tumor stage, pN pathologic nodal stage. Low (NAR \\<8), intermediate (NAR = 8-16), and high (NAR \\>16). Low is better and high is worse.', 'timeFrame': 'Up to 5 years'}]",7,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,2,1194.0,ACTUAL,2025-09-01T16:18:19.669741,v2_robust,True,True,False,False,False,
NCT02240693,Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo,"A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease",BI 409306,"['BI 409306', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Alzheimer Disease,['Alzheimer Disease'],[],COMPLETED,,2015-01-15,2017-10-09,"[{'measure': 'Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment.', 'description': 'Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Change from baseline will be calculated as the post-baseline composite z-score minus the pre-treatment z-score, such that a positive change indicates an improvement from baseline', 'timeFrame': 'Baseline and 12 weeks'}, {'measure': 'Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907)', 'description': 'Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Change from baseline will be calculated as the post-baseline composite z-score minus the pre-treatment z-score, such that a positive change indicates an improvement from baseline', 'timeFrame': 'Baseline and 12 weeks'}]","[{'measure': ""Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment"", 'description': ""Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) is a rating scale used to assess basic and instrumental activities of daily living. In the full version of the scale, 23 items are rated by the investigator using information supplied by the caregiver.\n\nEach item has a score range varying from 0-3 to 0-5. The sum score can range from 0 to 78. Higher scores indicate better function.\n\nLeast Squares Mean is actually an adjusted mean change from baseline."", 'timeFrame': 'Baseline and 12 weeks'}, {'measure': 'Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment', 'description': 'The CDR-SB is obtained through semi-structured interviews of patients and informants, and cognitive functioning was rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care.\n\nEach domain was rated on a 5-point scale of functioning as follows: 0-no impairment; 0.5-questionable impairment; 1-mild impairment; 2-moderate impairment and 3-severe impairment. Only personal care was scored on a 4-point scale without a 0.5 rating available. The higher the score, the greater the severity of dementia. Least Squares Mean is actually an adjusted mean change from baseline.', 'timeFrame': 'Baseline and 12 weeks'}, {'measure': ""Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment"", 'description': ""Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog11) is an 11-item cognitive subscale that objectively measures memory, language, orientation, and praxis with a total score range of 0 to 70. The greater the dysfunction, the greater the score. Least Squares Mean is actually an adjusted mean change from baseline."", 'timeFrame': 'Baseline and 12 weeks'}]",5,55 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,128.0,ACTUAL,2025-09-01T16:18:19.669986,v2_robust,True,True,True,False,False,
NCT04125121,Neuroplasticity Induced by General Anaesthesia,Neuroplasticity Induced by General Anaesthesia,Sevoflurane-propofol,"['Propofol-sevoflurane', 'Sevoflurane-propofol']",2,INTERVENTIONAL,['NA'],,,Healthy Volunteers,"['Healthy Volunteers', 'General Anaesthesia', 'Neuroplasticity']","['Neuroplasticity', 'Neuroplastic changes', 'General anaesthesia', 'Magnetic resonance imaging', 'Sevoflurane', 'Propofol', 'Healthy volunteers', 'Consciousness', 'Cognitive', 'Fatigue']",COMPLETED,,2019-09-26,2021-08-13,"[{'measure': 'Changes in T1w3D', 'description': 'Volume and morphology of selected brain regions and anatomical structures as recorded by T1w3D anatomy MRI.', 'timeFrame': '8 days'}, {'measure': 'Changes in DTI', 'description': 'White matter microstructure as measured using Diffusion Tensor Imaging (DTI)', 'timeFrame': '8 days'}]","[{'measure': 'Changes in rsfMRI', 'description': 'Differences in resting state functional MRI induced by general anaesthesia', 'timeFrame': '8 days'}, {'measure': 'Changes in fatigue', 'description': 'Differences in severity and characteristics of fatigue related to general anaesthesia, as measured by Multidimensional Fatigue Inventory (MFI-20, a scale of 0-5 in each of 20 questions, with higher scores indicating more fatigue).', 'timeFrame': '8 days'}, {'measure': 'Cognitive performance', 'description': 'Changes in cognitive function related to general anaesthesia, measured with a combination of Test of Attentional Performance, Paced Auditory Serial Addition Test and Conners Continuous Performance Test.', 'timeFrame': '8 days'}]",5,18 Years,35 Years,ALL,True,Signe Sloth Madsen,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:19.670057,v2_robust,True,True,True,False,False,
NCT05321121,Dexmedotomidine for Acute Pain Control in Patients With Multiple Rib FracturesRandomized Controlled Trial,Dexmedotomidine for Acute Pain Control in Patients With Multiple Rib Fractures,Dexmedetomidine,['Dexmedetomidine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Rib Fractures,"['Rib Fractures', 'Pain, Acute']","['Rib Fracture', 'Pain', 'Dexmedotomidine']",COMPLETED,,2021-11-12,2023-10-21,"[{'measure': 'Evaluation of Pain', 'description': 'Numerical pain score (NPS): a score of 1-10 that will be recorded by the nurse in charge of the patients as standard of care.', 'timeFrame': 'through study completion of index hospitalization (up to 6 months)'}, {'measure': 'Use of morphine and morphine equivalents.', 'description': '2\\. Oral morphine equivalents (OME) - A study team member will do a chart review and collect morphine used by the patients.', 'timeFrame': 'through study completion of index hospitalization (up to 6 months)'}]","[{'measure': 'Epidural administration', 'description': 'Epidural use - patients that fail pain management will be offered an epidural', 'timeFrame': 'through study completion of index hospitalization (up to 6 months)'}, {'measure': 'Time in the hospital', 'description': 'ICU length of stay - number of days in the ICU Hospital length of stay - number of days admitted to the acute care hospital', 'timeFrame': 'through study completion of index hospitalization (up to 6 months)'}, {'measure': 'Respiratory complications', 'description': 'Respiratory complications - include events such as unplanned intubation, pneumonia, pneumothorax and incentive spirometry', 'timeFrame': 'through study completion of index hospitalization (up to 6 months)'}, {'measure': 'Mortality', 'description': 'Mortality - in-hospital mortality rate and 30-day mortality', 'timeFrame': 'through study completion of index hospitalization (up to 6 months)'}]",6,18 Years,,ALL,False,"University of California, Irvine",OTHER,0,41.0,ACTUAL,2025-09-01T16:18:19.670074,v2_robust,True,True,True,False,False,
NCT02119221,Copanlisib Mass Balance Study,"Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics After Single Intravenous Administration of 12 mg [14C]Copanlisib (BAY 80-6946) in Healthy Male Subjects",Copanlisib (BAY80-6946),['Copanlisib (BAY80-6946)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2014-02,2014-10,"[{'measure': 'Pharmacokinetics of copanlisib in plasma by maximum concentration (Cmax)', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve from the first time point (t=0) extrapolated to infinity (AUC)', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve to the last data point above the lower limit of quantitation (AUC(0-tlast))', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of total radioactivity in plasma by Cmax', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of total radioactivity in plasma by AUC', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of total radioactivity in plasma by AUC(0-tlast)', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of total radioactivity in whole blood by Cmax', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of total radioactivity in whole blood by AUC', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of total radioactivity in whole blood by AUC(0-tlast)', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Radioactivity excreted in urine as a percentage of the dose (AE,ur)', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Radioactivity excreted in feces as a percentage of the dose (AE,fec)', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Metabolite profile in plasma', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Metabolite profile in urine', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Metabolite profile in feces', 'timeFrame': 'Multiple time points up to 336 hours'}]","[{'measure': 'Number of participants with adverse events as a measure of safety and tolerability', 'timeFrame': 'Until 30 days after study drug administration'}]",15,45 Years,65 Years,MALE,True,Bayer,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:19.670111,v2_robust,True,True,True,False,True,
NCT04221321,Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult Volunteers,"An Open-label, Randomized, Multiple-dose, Replicated Crossover Study to Evaluate Drug-drug Interaction Following Co-administration of Tegoprazan or RAPA114 With Atorvastatin in Healthy Adults",Atorvastatin 40 mg,"['K-CAB', 'Tegoprazan 50 mg', 'RAPA114', 'Atorvastatin 40 mg', 'Lipitor']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2020-01-07,2020-04-20,"[{'measure': 'AUCτ of atorvastatin', 'description': 'Area under the plasma drug concentration-time curve at steady state', 'timeFrame': 'Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period'}, {'measure': 'Css,max of atorvastatin', 'description': 'Maximum concentration of drug in plasma of atorvastatin at steady state', 'timeFrame': 'Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period'}]","[{'measure': 'Tss,max of atorvastatin', 'description': 'Time to Cmax at steady state', 'timeFrame': 'Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period'}, {'measure': 'AUCτ of 2-OH atorvastatin', 'description': 'Area under the plasma drug concentration-time curve at steady state', 'timeFrame': 'Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period'}, {'measure': 'Css,max of 2-OH atorvastatin', 'description': 'Maximum concentration of drug in plasma of 2-OH atorvastatin at steady state', 'timeFrame': 'Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period'}, {'measure': 'metabolic ratio', 'description': 'AUCτ of 2-OH atorvastatin / AUCτ of atorvastatin', 'timeFrame': 'Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period'}]",6,19 Years,55 Years,MALE,True,HK inno.N Corporation,INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:19.670152,v2_robust,True,True,True,False,False,
NCT01958021,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer,"A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease",Ribociclib,"['Ribociclib', 'LEE011', 'Placebo', 'Letrozole']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,"Advanced, Metastatic Breast Cancer","['Advanced, Metastatic Breast Cancer']","['HR-positive', 'HER2-negative', 'Advanced breast cancer', 'LEE011', 'Letrozole', 'CDK', 'CDK4', 'CDK6', 'CDK4/6', 'Phase III', 'ER-positive', 'PR-positive', 'Postmenopausal']",COMPLETED,,2013-12-17,2023-03-16,"[{'measure': 'Progression Free Survival (PFS) by Investigator Assessment', 'description': 'PFS was defined as the period starting from the date of randomization to the date of the first documented progression or death caused by any reason. In cases where patients did not experience an event, the PFS was censored at the date of the last adequate tumor assessment. Clinical deterioration without objective radiological evidence was not considered as documented disease progression.PFS was assessed by investigator assessment according to RECIST 1.1. The Kaplan-Meier method was used to estimate PFS, and the median PFS, along with 95% confidence intervals, was reported for each treatment group. A stratified Cox regression model was used to estimate the hazard ratio of PFS, along with 95% confidence interval', 'timeFrame': 'Up to 23 months'}]","[{'measure': 'Overall Survival (OS)', 'description': ""OS was defined as the time from the date of randomization to the date of death from any cause. In cases where the patient's death was not recorded, the OS value was censored at the date of the last known patient's survival status.OS was estimated using the Kaplan-Meier method. As per protocol, the final OS analysis was conducted after approximately 400 deaths were documented.\n\nThe median OS, along with 95% confidence intervals, was reported for each treatment group.The distribution of OS between the two treatment arms was compared using a log-rank test at one-sided cumulative 2.5% level of significance. A stratified Cox regression was used to estimate the OS hazard ratio and the associated 95% CI."", 'timeFrame': 'Up to approximately 87 months'}, {'measure': 'Overall Response Rate (ORR) by Investigator Assessment', 'description': 'ORR is the percentage of participants with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1 as per investigator assessment. . CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.', 'timeFrame': 'Up to 23 months'}, {'measure': 'Clinical Benefit Rate (CBR) by Investigator Assessment', 'description': 'Percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) lasting 24 weeks or longer as defined in RECIST 1.1 as per investigator assessment. CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters; SD = Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease: PD = At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20% the sum must also demonstrate an absolute increase of at least 5 mm.', 'timeFrame': 'Up to 23 months'}, {'measure': 'Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) by at Least One Category of the Score', 'description': 'ECOG PS categorized patients based on their ability to perform daily activities and self-care, with scores ranging from 0 to 5. A score of 0 indicated no restrictions in activity, while higher scores indicated increasing limitations. Time to definitive deterioration was defined as the time from the date of randomization to the date of the event, defined as experiencing an increase in ECOG PS by at least one category from the baseline or death. A deterioration was considered definitive if no improvements in the ECOG PS were observed at a subsequent time. The Kaplan-Meier method was used to estimate the distribution, and the median time to definitive deterioration, along with 95% confidence intervals, was reported for each treatment group. Patients receiving any further therapy prior to definitive worsening were censored at their date of last assessment prior to start of therapy. Patients that had not worsened at the data cutoff point were censored at the date of last assessment.', 'timeFrame': 'From baseline up to 23 months'}, {'measure': ""Time to Definitive 10% Deterioration in the Global Health Status/Quality of Life (GHS/QoL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)"", 'description': 'The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, 1 GHS/QoL scale, and 6 single items. GHS/QoL scale score ranges between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.The time to definitive 10% deterioration is defined as the time from the date of randomization to the date of event, which is defined as at least 10% relative to baseline worsening of the QoL score (without further improvement above the threshold) or death due to any cause. The Kaplan-Meier method was used to estimate the distribution, and the median time to definitive 10% deterioration, along with 95% confidence intervals, was reported for each treatment group. If a patient had not had an event, time to deterioration was censored at the date of the last adequate QoL evaluation.', 'timeFrame': 'From baseline up to 23 months'}, {'measure': 'Change From Baseline in the GHS/QoL Scale Score of the EORTC QLQ-C30', 'description': 'The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, 1 GHS/QoL scale, and 6 single items. GHS/QoL scale score ranges between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.The change from baseline in the GHS/QoL score was assesed. A positive change from baseline indicated improvement.\n\nFor subjects who discontinued treatment earlier and without disease progression, post-treatment efficacy follow-up visits occurred every 8 weeks after End of treatment (EOT) during the initial 18 months since start of treatment, followed by visits every 12 weeks until disease progression or end of study.', 'timeFrame': 'Baseline, every 2 cycles for 18 months, then every 3 cycles until last dose; at EOT (within 15 days from last dose);every 8 or 12 weeks post-treatment until progression (post-treatment efficacy visits), assessed up to 23 months. Cycle=28 days'}]",7,18 Years,100 Years,FEMALE,False,Novartis Pharmaceuticals,INDUSTRY,0,668.0,ACTUAL,2025-09-01T16:18:19.670191,v2_robust,True,True,True,False,False,
NCT00310921,A Randomized Study of Cervical Priming With Misoprostol Prior to Elective First Trimester Pregnancy Termination,"A Randomized Study of Cervical Priming With Misoprostol Prior to Elective First Trimester Pregnancy Termination: Effects on Pain, Ease of Procedure and Complications",Misoprostol,['Misoprostol'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Abortion, Therapeutic","['Abortion, Therapeutic']",[],COMPLETED,,2001-05,2006-05,[{'measure': 'The first assessment will be a Visual Box Scale (VBS) for pain administered while the patient is undergoing the abortion procedure.'}],"[{'measure': ""After the procedure the physician will estimate the patient's pain using a VBS. The physician will also estimate the ease of the procedure using a different VBS.""}]",2,,,FEMALE,True,Kaiser Permanente,OTHER,0,200.0,,2025-09-01T16:18:19.670321,v2_robust,True,True,True,False,False,
NCT01670721,Colorectal Cancer Metastatic,"A Multicenter, Single Arm, Open Label Clinical Trial Evaluating Safety and Health Related Quality of Life of Aflibercept in Combination With Irinotecan/5-FU Chemotherapy (FOLFIRI) in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen",AFLIBERCEPT,"['Irinotecan', 'Fluorouracil', 'Leucovorin', 'AFLIBERCEPT', 'AVE0005']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Colorectal Cancer Metastatic,['Colorectal Cancer Metastatic'],[],COMPLETED,,2012-08,2015-06,"[{'measure': 'Percentage of Participants With Adverse Events (AEs)', 'description': 'Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period. On-treatment period was defined as the time from the first dose of treatment to 30 days after the last dose of treatment (either Aflibercept or FOLFIRI). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.', 'timeFrame': 'Baseline upto 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure:723 days)'}]","[{'measure': 'Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)', 'description': ""EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \\& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \\& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \\& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant."", 'timeFrame': 'Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)'}, {'measure': 'Change From Baseline in HRQL European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score', 'description': 'EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \\& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state.', 'timeFrame': 'Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)'}, {'measure': 'Change From Baseline in HRQL EQ-5D-3L VAS Score', 'description': ""EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state. Baseline corresponded to last evaluable assessment before treatment administration."", 'timeFrame': 'Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)'}]",4,18 Years,,ALL,False,Sanofi,INDUSTRY,1,175.0,ACTUAL,2025-09-01T16:18:19.670333,v2_robust,True,True,True,False,True,
NCT02363621,Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME,Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs. Aflibercept in Patients With Diabetic Macular Edema,Ranibizumab 0.3 mg,"['Eylea', 'Aflibercept 2.0 mg', 'Lucentis', 'Ranibizumab 0.3 mg']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Diabetic Macular Edema,['Diabetic Macular Edema'],[],COMPLETED,,2015-01,2017-10,"[{'measure': 'Number of Participants With Intraocular Inflammation', 'description': 'Number of participants with intraocular inflammation as seen on slide lamp and dilated fundus exam.', 'timeFrame': '24 to 48 hours (visit #1)'}, {'measure': 'Number of Participants With Intraocular Inflammation', 'description': 'Number of Participants With Intraocular Inflammation as seen on slit lamp and dilated fundus exam', 'timeFrame': '5 to 7 days (visit #2)'}]","[{'measure': 'Number of Participants With Post Injection Pain Above 0 on a 11 Point Pain Scale.', 'description': 'Pain score rated on a 11 point numerical rating from 0-10 administered to each patient verbally at visit #1 and visit #2.\n\n0 = no pain 10 = severe pain', 'timeFrame': '24 to 48 hours visit #1 and 5 to 7 days visit #2'}]",3,21 Years,,ALL,True,Arshad Khanani,OTHER,1,101.0,ACTUAL,2025-09-01T16:18:19.670367,v2_robust,True,True,True,False,False,
NCT00860821,A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS),"A Randomised, Double-blind, Placebo-controlled, Two-way Crossover, Single-centre Methodologhy Study in Healthy Subjects to Evaluate the Effect of Oral Dosing With AZD8309 on Cells and Inflammatory Biomarkers in Nasal Lavage and Blood After Nasal Challenge With Lipopolysaccharide (LPS).",AZD8309,['AZD8309'],1,INTERVENTIONAL,['NA'],,,Healthy,['Healthy'],"['Healthy subjects', 'LPS', 'Effect', 'Intranasally']",COMPLETED,,2009-03,2009-10,"[{'measure': 'Neutrophil numbers in nasal lavage', 'timeFrame': '3 times each in the end of two treatment periods'}]","[{'measure': 'Cells and inflammatory biomarkers in nasal lavage', 'timeFrame': '3 times in the end of the two treatment periods'}, {'measure': 'Cells and inflammatory biomarkers in blood', 'timeFrame': '2 times in the beginning and 5 times in the end of the two treatment periods'}]",3,18 Years,50 Years,ALL,True,AstraZeneca,INDUSTRY,0,20.0,ESTIMATED,2025-09-01T16:18:19.670458,v2_robust,True,True,True,False,False,
NCT00095121,Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B,"A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents (Age 2 to Less Than 18) With Chronic Hepatitis B",Placebo (PLB),"['Placebo (PLB)', 'Adefovir Dipivoxil (ADV)', 'Lamivudine']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Hepatitis B,['Chronic Hepatitis B'],"['Hepatitis B', 'Children', 'Pediatric', 'Adefovir Dipivoxil']",COMPLETED,,2004-06,2010-04,"[{'measure': 'Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 1000 Copies/mL (Polymerase Chain Reaction [PCR]-Based Assay) and Normal Alanine Aminotransferase (ALT) at Week 48 (Missing = Failure)', 'description': 'In the absence of biopsy data from these pediatric participants, this endpoint enables assessments of drug effect on viral replication and the underlying degree of inflammation in the liver.', 'timeFrame': 'Week 48'}]","[{'measure': 'Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Baseline)', 'description': 'The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV \\[ADV-ADV group\\] and Week 48 for those originally randomized to placebo \\[PLB-ADV group\\]).', 'timeFrame': 'ADV baseline'}, {'measure': 'Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment - Missing = Failure) (ADV Week 192)', 'description': 'Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192).', 'timeFrame': 'ADV Week 192'}, {'measure': 'Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 240)', 'timeFrame': 'ADV Week 240'}, {'measure': 'Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Baseline)', 'description': 'The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV \\[ADV-ADV group\\] and Week 48 for those originally randomized to placebo \\[PLB-ADV group\\]).', 'timeFrame': 'ADV baseline'}, {'measure': 'Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 192)', 'description': 'Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192).', 'timeFrame': 'ADV Week 192'}, {'measure': 'Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 240)', 'timeFrame': 'ADV Week 240'}, {'measure': 'Adefovir (ADV) Baseline Serum HBV DNA', 'description': 'The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV \\[ADV-ADV group\\] and Week 48 for those originally randomized to placebo \\[PLB-ADV group\\]).', 'timeFrame': 'ADV baseline'}, {'measure': 'Change From ADV Baseline to ADV Week 192 for Serum HBV DNA', 'description': 'Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192).', 'timeFrame': 'ADV baseline to ADV 192 weeks'}, {'measure': 'Change From ADV Baseline to ADV Week 240 for Serum HBV DNA', 'timeFrame': 'ADV baseline to ADV 240 weeks'}, {'measure': 'ADV Baseline ALT', 'description': 'The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV \\[ADV-ADV group\\] and Week 48 for those originally randomized to placebo \\[PLB-ADV group\\]).', 'timeFrame': 'ADV baseline'}, {'measure': 'Change From ADV Baseline to ADV Week 192 for ALT', 'description': 'Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192).', 'timeFrame': 'ADV baseline to ADV 192 weeks'}, {'measure': 'Change From ADV Baseline to ADV Week 240 for ALT', 'timeFrame': 'ADV baseline to ADV 240 weeks'}, {'measure': 'Percentage of Participants With Normal ALT at Adefovir Baseline (Missing = Failure)', 'description': 'The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV \\[ADV-ADV group\\] and Week 48 for those originally randomized to placebo \\[PLB-ADV group\\]). Normal ALT: 0-1 year old = \\<=54 U/L; females 1-88 years old and males 1-10 years old = 8-34 U/L; males 10-88 years old = 8-43 U/L.', 'timeFrame': 'ADV baseline'}, {'measure': 'Percentage of Participants With Normal ALT at ADV Week 192 (Missing = Failure)', 'description': 'Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192). Normal ALT: 0-1 year old = \\<=54 U/L; females 1-88 years old and males 1-10 years old = 8-34 U/L; males 10-88 years old = 8-43 U/L.', 'timeFrame': 'ADV Week 192'}, {'measure': 'Percentage of Participants With Normal ALT at ADV Week 240 (Missing = Failure)', 'description': 'Normal ALT: 0-1 year old = \\<=54 U/L; females 1-88 years old and males 1-10 years old = 8-34 U/L; males 10-88 years old = 8-43 U/L.', 'timeFrame': 'ADV Week 240'}, {'measure': 'Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss or Seroconversion by End of Blinded Treatment (Study Week 48; Randomized and Treated Analysis Set)', 'description': 'HBeAg loss is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- post baseline. HBeAg seroconversion is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- and hepatitis B e antibody + (anti-HBe+) post baseline.', 'timeFrame': 'Study Week 0 to Study Week 48 (double-blind period)'}, {'measure': 'Percentage of Participants With HBeAg Loss or Seroconversion by ADV Week 192 (Open Label Analysis Set, Participants Who Were HBeAg Positive at ADV Baseline; Missing = Excluded)', 'description': 'ADV baseline = 1st ADV-dose day = Week 0 for ADV-ADV group and Week 48 for PLB-ADV group. ADV week = windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192). HBeAg loss is defined per individual participant as HBeAg+ at ADV baseline and HBeAg- post baseline. HBeAg seroconversion is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- and anti-HBe+ post baseline.', 'timeFrame': 'ADV baseline to ADV Week 192'}, {'measure': 'Percentage of Participants With HBeAg Loss or Seroconversion by ADV Week 240 (Open Label Analysis Set, Participants Who Were HBeAg Positive at ADV Baseline; Missing = Excluded)', 'description': 'Per protocol, participants could discontinue study medication due to HBeAg seroconversion and remain in the study in order to evaluate the durability of seroconversion. HBeAg loss is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- post baseline. HBeAg seroconversion is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- and anti-HBe+ post baseline.', 'timeFrame': 'ADV baseline to ADV Week 240'}, {'measure': 'Cumulative Summary of Participants With HBV Genotypic Changes From Baseline (Resistance Surveillance)', 'description': 'Resistance surveillance was conducted annually for all participants who remained on treatment and had HBV DNA concentrations greater than or equal to the level of detection (\\>= 169 copies/mL) by PCR. The last on-ADV sample for all participants in the study was analyzed in the cumulative Week 240 resistance surveillance analysis.', 'timeFrame': '240 weeks'}, {'measure': 'Cumulative Summary of Participants With HBV Genotypic Changes From Baseline (Resistance Surveillance) for Subjects Who Received Combination ADV + Lamivudine Therapy', 'description': 'Resistance surveillance was conducted at Week 240/last on-treatment study visit for all participants who had HBV DNA concentrations greater than or equal to the level of detection (\\>= 169 copies/mL) by PCR while on combination ADV + lamivudine treatment.', 'timeFrame': '240 weeks'}, {'measure': 'Percentage of Participants With Durable HBeAg Seroconversion', 'description': 'A participant was defined to have durable HBeAg seroconversion only if she/he remained in a seroconverted state (HBeAg-, hepatitis B e antibody + \\[anti-HBe+\\]) from the date that she/he first seroconverted through and including her/his last study visit. This endpoint could only be assessed for participants who (HBeAg-) seroconverted on-treatment and subsequently discontinued open-label dosing.', 'timeFrame': '240 weeks'}]",22,2 Years,17 Years,ALL,False,Gilead Sciences,INDUSTRY,0,173.0,ACTUAL,2025-09-01T16:18:19.670530,v2_robust,True,True,True,False,False,
NCT02489214,Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer,A Phase 1B Study of Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer,donafenib tosilate tablets,"['CM4307', 'donafenib tosilate tablets']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Gastric Cancer,['Gastric Cancer'],['donafenib'],TERMINATED,Corporate policy adjustments,2016-05-16,2019-06-13,"[{'measure': 'Number of Participants with Adverse Events', 'description': 'patients with adverse events/all patients\\*100%', 'timeFrame': '54 weeks'}]","[{'measure': 'Tumor response', 'description': 'complete response and partial response patients/all patients\\*100%', 'timeFrame': '54 weeks'}, {'measure': 'Progression-free survival time', 'description': 'median progress-free survival time', 'timeFrame': '54 weeks'}]",3,18 Years,75 Years,ALL,False,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",INDUSTRY,0,13.0,ACTUAL,2025-09-01T16:18:19.670623,v2_robust,True,True,False,True,True,Corporate policy adjustments
NCT02732314,Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis,Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis,Investigational OTC Cream,"['0.05% Desonide Cream', 'Actavis', 'Investigational OTC Cream']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,"Dermatitis, Atopic","['Dermatitis, Atopic', 'Eczema']",[],COMPLETED,,2016-03,2016-06,"[{'measure': 'SCORAD (Severity Scoring of Atopic Dermatitis)', 'description': 'Dermatologic assessment and scoring of atopic dermatitis lesion severity', 'timeFrame': 'Change from Baseline at Week 12'}]","[{'measure': 'SCORAD (Severity Scoring of Atopic Dermatitis)', 'description': 'Dermatologic assessment and scoring of atopic dermatitis lesion severity', 'timeFrame': 'Change from Baseline at Week 2'}, {'measure': 'SCORAD (Severity Scoring of Atopic Dermatitis)', 'description': 'Dermatologic assessment and scoring of atopic dermatitis lesion severity', 'timeFrame': 'Change from Baseline at Week 4'}, {'measure': 'SCORAD (Severity Scoring of Atopic Dermatitis)', 'description': 'Dermatologic assessment and scoring of atopic dermatitis lesion severity', 'timeFrame': 'Change from Baseline at Week 8'}]",4,12 Years,65 Years,ALL,False,Procter & Gamble Beauty,INDUSTRY,0,53.0,ACTUAL,2025-09-01T16:18:19.670656,v2_robust,True,True,True,False,False,
NCT07139314,Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2,Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation: a Randomised Controlled Trial,Early anticoagulation,"['Delayed anticoagulation', 'Early anticoagulation']",2,INTERVENTIONAL,['NA'],,,Ischemic Stroke,"['Ischemic Stroke', 'Atrial Fibrillation']","['Endovascular therapy', 'Direct oral anticoagulation', 'Therapy initiation', 'Hemorrhagic transformation', 'Randomized Controlled Trial', 'Stroke']",RECRUITING,,2025-08-26,2026-08-31,"[{'measure': 'Composite outcome of recurrent ischemic stroke, symptomatic intracranial hemorrhage, and all-cause death', 'timeFrame': '90 days'}]","[{'measure': 'Incidence of recurrent ischemic stroke', 'timeFrame': '90 days'}, {'measure': 'Incidence of venous thromboembolism', 'timeFrame': '90 days'}, {'measure': 'Incidence of systemic embolism', 'timeFrame': '90 days'}, {'measure': 'Incidence of myocardial infarction', 'timeFrame': '90 days'}, {'measure': 'Proportion of patients achieving mRS 0-2 at 90 Days', 'description': 'The modified Rankin scale (range, 0 \\[no symptoms\\] to 6 \\[death\\])', 'timeFrame': '90 days'}, {'measure': 'Proportion of patients achieving mRS 0-3 at 90 Days', 'description': 'The modified Rankin scale (range, 0 \\[no symptoms\\] to 6 \\[death\\])', 'timeFrame': '90 days'}, {'measure': 'Length of hospital stay for stroke-related care', 'timeFrame': '90 days'}, {'measure': 'Quality of life at 90 days assessed by EuroQol 5 Dimensions 5 level questionnaire [EQ-5D-5L]', 'description': 'The EQ-5D-5L includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.', 'timeFrame': '90 days'}, {'measure': 'Incidence of vascular death', 'timeFrame': '90 days'}, {'measure': 'All-cause mortality', 'timeFrame': '90 days'}, {'measure': 'Incidence of symptomatic intracranial hemorrhage (sICH)', 'timeFrame': '90 days'}, {'measure': 'Incidence of major extracranial bleeding', 'timeFrame': '90 days'}]",13,18 Years,,ALL,False,Capital Medical University,OTHER,0,240.0,ESTIMATED,2025-09-01T16:18:19.670790,v2_robust,True,True,False,False,False,
NCT02049814,Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes,"A Randomized, Open-label, Non-inferiority Study to Compare the Efficacy and Safety of Voglibose and Acarbose in Patients With Type 2 Diabetes Mellitus With Poor Control of Metformin",Metformin,"['Voglibose', 'Glucobay, Precose, Prandase', 'Basen', 'Acarbose', 'Glucophage', 'Metformin']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],['Drug therapy'],COMPLETED,,2014-05-09,2016-06-28,"[{'measure': 'Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12', 'description': 'The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline.', 'timeFrame': 'Baseline, Week 12'}]","[{'measure': 'Change From Baseline in HbA1c at Week 6', 'description': 'The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 6 relative to baseline.', 'timeFrame': 'Baseline and Week 6'}, {'measure': 'Change From Baseline in Fasting Blood Glucose Over Time', 'description': 'The change between the fasting blood glucose value collected at weeks 6 and 12 or final visit relative to baseline.', 'timeFrame': 'Baseline, Weeks 6 and 12'}, {'measure': 'Change From Baseline in Postprandial Plasma Glucose (PPG) Over Time', 'description': 'The change between the value of glucose after 1 and 2 hours of meal, measured by the meal tolerance test collected at Weeks 6 and 12 or relative to baseline.', 'timeFrame': '1 and 2 hours after meal at Baseline, Weeks 6 and 12'}, {'measure': 'Change From Baseline in Fasting Insulin at Week 12', 'description': 'The change between the fasting insulin value collected at week 12 or final visit relative to baseline.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in Postprandial Serum Insulin at Week 12', 'description': 'The change from Baseline in postprandial serum insulin, after 1 and 2 hours of meal collected at Week 12 relative to baseline.', 'timeFrame': '1 and 2 hours after meal at Baseline and Week 12'}, {'measure': 'Change From Baseline in Fasting Glucagon at Week 12', 'description': 'The change between the fasting glucagon value collected at week 12 or final visit relative to baseline.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in Postprandial Serum Glucagon at Week 12', 'description': 'The change from Baseline in postprandial serum glucagon, after 1 and 2 hours of meal collected at Week 12 relative to baseline.', 'timeFrame': '1 and 2 hours after meal at Baseline and Week 12'}, {'measure': 'Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance (HOMA IR) at Week 12', 'description': 'The change between the value of HOMA-IR collected at Week 12 and HOMA-IR collected at Baseline. HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \\* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater insulin resistance.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in Insulin Homeostatic Model Assessment Beta Cell Function (HOMA β) at Week 12', 'description': 'The change between the value of HOMA-beta cell function collected at Week 12 and HOMA-beta cell function collected at Baseline. The homeostatic model assessment estimates steady state beta cell function as a percentage of a normal reference population (%B). HOMA %B = 20 \\* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in Body Weight Over Time', 'description': 'The change between body weight at weeks 2, 6 and 12 or relative to baseline.', 'timeFrame': 'Baseline, Weeks 2, 6 and 12'}]",11,18 Years,75 Years,ALL,False,Takeda,INDUSTRY,0,494.0,ACTUAL,2025-09-01T16:18:19.670899,v2_robust,True,True,True,False,False,
NCT00967616,Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy,"Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy",CS7017,"['Irinotecan', 'Leucovorin', 'irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)', '5-fluorouracil', 'CS7017', '5-FU']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Colorectal Cancer,"['Colorectal Cancer', 'Neoplasms, Colorectal']","['metastatic', 'colon', 'rectum', 'combination', 'chemotherapy']",COMPLETED,,2009-09,2013-04,"[{'measure': 'Percentage of Participants With Progression-Free Survival at 16 Weeks After Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer', 'description': 'Progression-free survival (PFS) was defined as the time from randomization until the first objective evidence of disease progression or death from any cause.', 'timeFrame': 'Baseline to 16 weeks postdose'}]","[{'measure': 'Median Overall Progression-Free Survival Following Administration of CS-7017 in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer', 'description': 'Progression-free survival (PFS) was defined as the time from randomization until the first objective evidence of disease progression or death from any cause.', 'timeFrame': 'Baseline to approximately 3 years postdose'}, {'measure': 'Median Overall Progression-Free Survival: Sensitivity Analysis Including Clinical Progression After Administration of CS-7017 and Irinotecan, Leucovorin, and 5-Fluorouracil After Failure of First-line Therapy of Metastatic Colorectal Cancer', 'description': 'Progression-free survival (PFS) was defined as the time from randomization to the date of the first objective documentation of progressive disease (PD) or death resulting from any cause, whichever came first. The sensitivity analysis included clinical progression as an event.', 'timeFrame': 'Baseline to approximately 3 years postdose'}, {'measure': 'Best Overall Response and Objective Response Rate Following Administration of CS-7017 in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer', 'description': 'As per Response Evaluation Criteria for Solid Tumors v1.0, best overall response was characterized as confirmed complete response (CR) defined as disappearance of all target lesions, confirmed partial response (PR) defined as ≥30% decrease from baseline, stable disease (SD) defined as neither progressive disease (PD) nor PR, and PD defined as ≥20% increase from smallest sum of longest diameter recorded since treatment started. Objective response rate (ORR) was defined as CR + PR. If there is no tumor assessment after the first dose of study drug, the best overall response is classified as Inevaluable.', 'timeFrame': 'Baseline to approximately 3 years postdose'}, {'measure': 'Treatment-Emergent Adverse Events Occurring in ≥10% of Participants Following Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer', 'description': 'An adverse event (AE) \\>30 days after last dose of study drug was not included as a treatment-emergent adverse events (TEAE) unless considered related to treatment.', 'timeFrame': 'Baseline to 30 days post last dose, up to approximately 3 years'}]",5,18 Years,,ALL,False,Daiichi Sankyo,INDUSTRY,0,100.0,ACTUAL,2025-09-01T16:18:19.671012,v2_robust,True,True,True,False,True,
NCT00987116,Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis,Comparison of Two Tapering Strategies of Prednisone in Patients With Generalised Myasthenia Gravis Treated With Prednisone and Azathioprine: a Single-blind Randomised Controlled Multicenter Study,Prednisone - Azathioprine,['Prednisone - Azathioprine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Myasthenia Gravis,['Myasthenia Gravis'],"['Myasthenia gravis', 'Steroids side effects', 'Comparison of strategies for tapering steroids', 'Generalized MG corresponding to grade III, IV or V of MGFA']",COMPLETED,,2009-06,2017-09,"[{'measure': 'Proportion of patients who have reach minimal manifestation state (according to MGFA criteria) and are not treated with prednisone after 12 months of treatment and have not relapsed during the next 3 months.', 'timeFrame': '15 months'}]","[{'measure': 'Cumulative dose of prednisone at twelve months', 'timeFrame': '15 MONTHS'}, {'measure': 'Proportion of patients having reached minimal manifestation state 12 months', 'timeFrame': '15 MONTHS'}, {'measure': 'Time for reaching the improvement or minimal manifestation state (MGFA criteria)', 'timeFrame': '15 MONTHS'}, {'measure': 'Frequency of exacerbations within the first 15 months after randomization', 'timeFrame': '15 MONTHS'}, {'measure': 'Frequency of treatment by IvIg or plasma exchange within the first 15 months after randomization', 'timeFrame': '15 MONTHS'}, {'measure': 'Frequency and type of complications related to prednisone.', 'timeFrame': '15 MONTHS'}, {'measure': 'Frequency and type of complications of azathioprine', 'timeFrame': '15 MONTHS'}]",8,18 Years,80 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,118.0,ACTUAL,2025-09-01T16:18:19.671065,v2_robust,True,True,True,False,False,
NCT02743806,Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease,Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn's Disease,Vedolizumab,"['Vedolizumab', 'Entyvio', 'MLN0002', 'Kynteles']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,"Colitis, Ulcerative","['Colitis, Ulcerative', 'Crohn Disease']",['Drug Therapy'],TERMINATED,Early Completed - Alternative Source of Drug Available,2016-08-01,2023-01-03,"[{'measure': 'Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the study drug. A SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires participant hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect or is an important medical event. Percentages are rounded off to the nearest decimal point.', 'timeFrame': 'From first dose of study drug in this XAP study through 18 weeks after the last dose of study drug (up to 6.3 years)'}, {'measure': 'Percentage of Participants With Adverse Events of Special Interest (AESIs)', 'description': 'An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the study drug. AESIs included serious infections (opportunistic infections, such as progressive multifocal leukoencephalopathy \\[PML\\]), malignancies, liver injury, infusion-related hypersensitivity reactions, and injection site reactions. Percentages are rounded off to the nearest decimal point.', 'timeFrame': 'From first dose of study drug in this XAP study through 18 weeks after the last dose of study drug (up to 6.3 years)'}]",[],2,18 Years,90 Years,ALL,False,Takeda,INDUSTRY,0,331.0,ACTUAL,2025-09-01T16:18:19.671143,v2_robust,True,True,False,True,True,Early Completed - Alternative Source of Drug Available
NCT01504906,Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor,"A Single-Center,Open-Label,Randomized,3-Treatment,3-Period Cross-Over Study to Investigate the Potential Effect of Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Ticagrelor and the Effect of Ticagrelor on the Pharmacokinetics, Safety, and Tolerability of Cyclosporine",cyclosporine,"['ticagrelor', 'cyclosporine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Phase 1', 'Healthy male volunteers', 'pharmacokinetics', 'cyclosporine', 'ticagrelor', 'Bioavailability (plasma AUC, Cmax, plasma AUC0-t, t1/2λz, tmax)']",COMPLETED,,2012-01,2012-06,"[{'measure': 'Description of the pharmacokinetic (PK) profile for Ticagrelor and its metabolite AR-C124910XX in terms of maximum concentration (Cmax),time to maximum concentration (tmax) and area under the concentration curve from time zero to infinity (AUC)', 'description': 'PK samples will be collected postdose at visits 2,3 and 4', 'timeFrame': 'PK samples will be collected postdose 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, and 48 hours'}, {'measure': 'Description of the PK profile for Ticagrelor and its metabolite AR-C124910XX in terms of area under the concentration-time curve from time zero to the last measurable concentration (AUC(0-t)),terminal half-life (t1/2)', 'description': 'PK samples will be collected postdose at visit 2,3 and 4', 'timeFrame': 'PK samples will be collected postdose 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, and 48 hours'}, {'measure': 'Description of the PK profile for AR-C124910XX : ticagrelor in terms of ratios for Cmax, AUC(0-t), and AUC', 'description': 'PK samples will be collected postdose at visit 2,3 and 4', 'timeFrame': 'PK samples will be collected postdose 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, and 48 hours'}, {'measure': 'Description of the PK profile for Cyclosporine in terms of Cmax, AUC(0-t), AUC, tmax and t1/2', 'description': 'PK samples will be collected postdose at visit 2,3 and 4', 'timeFrame': 'PK samples will be collected postdose 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, and 48 hours'}]","[{'measure': 'Description of the safety profile in terms of adverse events, blood pressure, pulse, temperature, ECG (Electrocardiogram), physical examination, and safety laboratory variables', 'timeFrame': 'Baseline up to 45 days'}]",5,18 Years,45 Years,MALE,True,AstraZeneca,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:19.671157,v2_robust,True,True,True,False,True,
NCT00034606,Comparing 3 Schedules of Alimta Plus Gemzar,,Pemetrexed (Alimta) in combination with gemcitabine (Gemzar),['Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Carcinoma, Non-Small-Cell Lung","['Carcinoma, Non-Small-Cell Lung', 'Lung Neoplasms', 'Neoplasms']","['Lung cancer', 'cancer', 'neoplasm', 'non-small', 'chemotherapy']",COMPLETED,,,,[],[],0,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,,,2025-09-01T16:18:19.671194,v2_robust,True,True,True,False,False,
NCT05103306,Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy,Long-term Effectiveness and Safety of Empagliflozin-based Quadruple Oral Antidiabetic Agents Therapy Compared to Basal Insulin-based Combination Therapy in Patients With Type 2 Diabetes,Empagliflozin 25 MG,"['Basal insulin', 'Empagliflozin 25 MG', 'INS']",3,OBSERVATIONAL,[],,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']","['Type 2 diabetes mellitus', 'Sodium-glucose co-transporter 2 inhibitor', 'Empagliflozin', 'Insulin glargine', 'Insulin degludec']",UNKNOWN,,2017-01,2022-12,"[{'measure': 'Changes in HbA1c From Baseline to months 36', 'description': 'Changes in HbA1c From Baseline to months 36 (3-year)', 'timeFrame': 'Baseline, month 36 (3-year)'}]","[{'measure': 'Achievement of target HbA1c', 'description': 'Percentage of Patients Who Achieved Glycemic Target of HbA1c at month 36', 'timeFrame': 'Baseline, month 36'}, {'measure': 'Changes in HbA1c', 'description': 'Changes in HbA1c From Baseline to each time frame', 'timeFrame': 'Baseline, month 3, 6, 12, 18, 24, 30'}, {'measure': 'Changes in FPG', 'description': 'Changes in fasting plasma glucose level from baseline to each month', 'timeFrame': 'Baseline, month 3, 6, 12, 18, 24, 30, 36'}, {'measure': 'Changes in lipid profiles', 'description': 'Changes in total cholesterol, triglyceride, HDL-cholesterol and LDL cholesterol from baseline to month 36', 'timeFrame': 'Baseline, month 36'}, {'measure': 'Changes in body weight', 'description': 'Changes in body weight from baseline to month 36', 'timeFrame': 'Baseline, month 36'}, {'measure': 'Changes in blood pressure', 'description': 'Changes in systolic and diastolic blood pressure from baseline to month 36', 'timeFrame': 'Baseline, month 36'}, {'measure': 'Percentage of patients with hypoglycemic episodes', 'description': 'All episodes consistent with hypoglycemia with or without a confirmatory blood glucose reading were collected.', 'timeFrame': 'Baseline, month 36'}, {'measure': 'Percentage of patients with at least 1 episode of genitourinary tract infections', 'description': 'Percentage of Patients With At Least 1 Episode of Genitourinary Tract Infections', 'timeFrame': 'Baseline, month 36'}]",9,18 Years,80 Years,ALL,False,Chungbuk National University Hospital,OTHER,0,300.0,ESTIMATED,2025-09-01T16:18:19.671201,v2_robust,False,True,False,False,False,
NCT05555706,Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer,A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel in First-line Treatment for Patients With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer,B013+Nab-Paclitaxel,['B013+Nab-Paclitaxel'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Triple Negative Breast Cancer (TNBC),['Triple Negative Breast Cancer (TNBC)'],[],COMPLETED,,2022-12-06,2024-09-30,"[{'measure': 'Objective response rate (ORR)(phase Ⅱ)', 'description': 'tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1.', 'timeFrame': 'Baseline up to approximately 18 months'}, {'measure': 'Progression-free survival (PFS)(IRC) (phase Ⅲ)', 'description': 'from the start date of study treatment to the date of progression disease or death , whichever occurred first.', 'timeFrame': 'Baseline up to approximately 18 months'}]","[{'measure': 'Disease control rate (DCR)', 'description': 'DCR was defined as the percentage of patients who have achieved complete response, partial response and stable disease', 'timeFrame': '18 months'}, {'measure': 'Duration of remission (DOR)', 'description': 'DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause', 'timeFrame': '18 months'}, {'measure': 'Time to Response (TTR)', 'description': 'Defined as the interval from the start of study therapy to the first documentation of an objective response', 'timeFrame': '18 months'}, {'measure': 'Overall Survival (OS)', 'description': 'Determination of the overall survival times of all patients', 'timeFrame': '3years'}, {'measure': 'Drug concentration in plasma', 'description': 'Determination of drug concentration in plasma of all patients', 'timeFrame': '18 months'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events', 'description': 'Adverse event type, incidence, duration, correlation with study drug', 'timeFrame': '3years'}]",8,18 Years,75 Years,ALL,False,"Shanghai Jiaolian Drug Research and Development Co., Ltd",INDUSTRY,1,62.0,ACTUAL,2025-09-01T16:18:19.671228,v2_robust,True,True,True,False,True,
NCT05341206,"Evaluation the Effects of Herbal Gargle for Chemoradiotherapy-induced Oral Mucositis of Head & Neck Cancer, a Pilot Study.","Evaluation the Effects of Herbal Gargle for Chemoradiotherapy-induced Oral Mucositis of Head & Neck Cancer, a Pilot Study.",Herbal gargle,['Herbal gargle'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Head and Neck Neoplasms,"['Head and Neck Neoplasms', 'Chemoradiotherapy', 'Stomatitis and Ulceration']","['Medicine, Chinese Traditional', 'Head and Neck Neoplasms', 'Chemoradiotherapy', 'Stomatitis and Ulceration']",NOT_YET_RECRUITING,,2022-04-15,2025-12-31,"[{'measure': 'Change of CTCAE 4.0', 'description': 'CTCAE is used to describe the severity of oral mucositis for patients receiving cancer therapy.', 'timeFrame': 'change from baseline and every week for 8 weeks.'}]","[{'measure': 'Change of EORTC QLQ-C30', 'description': ""European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire score, EORTC QLQ-C30, is used to measure cancer patients' physical, psychological and social functions."", 'timeFrame': 'change from baseline at 4 weeks and 8 weeks post treatment.'}, {'measure': 'Change of EORTC QLQ-H&N35', 'description': 'European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-head \\& neck, EORTC QLQ-H\\&N35, is used for assessing the health-related quality of life for head-and-neck cancer patients.', 'timeFrame': 'change from baseline at 4 weeks and 8 weeks post treatment.'}, {'measure': 'Change of VAS of pain of oral mucositis', 'description': 'Visual Analogue Scale, VAS, is used to to measure the intensity of pain of oral mucositis.', 'timeFrame': 'change from baseline and everyday for 8 weeks.'}, {'measure': 'Change of body weight', 'description': 'The oral mucositis caused by chemoradiotherapy will influence food intake. Monitor body weight provides objective evaluation of nutrition status.', 'timeFrame': 'change from baseline and every week for 8 weeks.'}, {'measure': 'Change of opioid use', 'description': 'Opioid analgesics is often prescribed for alleviating pain from oral mucositis. Monitor opioid use provides other evaluation for severity of pain and wound healing.', 'timeFrame': 'change from baseline and every week for 8 weeks.'}, {'measure': 'Change of albumin', 'description': 'Albumin has been used as maker of nutrition status.', 'timeFrame': 'change from baseline at 4 weeks and 8 weeks post treatment.'}, {'measure': 'Change of CRP', 'description': 'C-reactive protein is used to monitor severity of oral mucositis.', 'timeFrame': 'change from baseline and every week for 8 weeks.'}, {'measure': 'Change of common aerobic culture', 'description': 'Aerobic culture is used to monitor the change of bacteria flora before and after Herbal gargle treatment.', 'timeFrame': 'change from baseline and every week for 8 weeks.'}]",9,20 Years,,ALL,False,Chang Gung Memorial Hospital,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:19.671322,v2_robust,True,True,False,False,False,
NCT05567406,"Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy","A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Participants With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy",Belumosudil,"['Belumosudil', 'Rezurock', 'KD025', 'SAR445761']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Graft Versus Host Disease,['Chronic Graft Versus Host Disease'],[],RECRUITING,,2025-06-16,2026-08-31,"[{'measure': 'Number of participants with treatment emergent adverse events and serious adverse events', 'description': 'Safety will be assessed by monitoring adverse events, physical Examinations, clinical laboratory evaluations, vital sign measurements, and ECG parameters.', 'timeFrame': 'Up to approximately 48 months'}, {'measure': 'Number of participants with clinically significant laboratory abnormalities', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Change from baseline in systolic and diastolic blood pressure', 'timeFrame': 'Baseline; up to approximately 12 months'}, {'measure': 'Change from baseline in heart rate', 'timeFrame': 'Baseline; up to approximately 12 months'}, {'measure': ""Change from baseline in corrected QT interval using Fridericia's formula (QTc[F])"", 'timeFrame': 'Baseline; up to approximately 12 months'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'The ORR is defined as the proportion of participants meeting the overall response criteria assessment of Complete Response (CR) or Partial Response (PR) as defined by the 2014 NIH Consensus Development Project on Clinical Trials in cGVHD at any post-baseline response assessment.', 'timeFrame': 'Up to approximately 12 months'}]","[{'measure': 'Duration of Response (DOR)', 'description': 'Assessments of DOR includes\n\n* The time from first response to progression, death, or new systemic therapy for cGVHD\n* Time from initial response to start of additional systemic cGVHD therapy or death', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Change from baseline in the Lee Symptom Scale Score: Number of participants with a ≥ 7-point reduction', 'description': ""Changes in symptom burden/bother will be assessed using the Lee Symptom Scale, a symptom scale designed for individuals with chronic Graft Versus Host Disease (cGVHD). The questionnaire asks participants to indicate the degree of bother that they experienced due to symptoms in seven domains potentially affected by cGVHD (skin, eyes, mouth, breathing, eating and digestion, energy, and emotional distress). The response will be determined based on clinician's assessment."", 'timeFrame': 'Baseline; up to approximately 12 months'}, {'measure': 'Change from baseline in the Lee Symptom Scale Score: Number of participants with a ≥ 7-point reduction on 2 consecutive assessments', 'description': ""Changes in symptom burden/bother will be assessed using the Lee Symptom Scale, a symptom scale designed for individuals with chronic Graft Versus Host Disease (cGVHD). The questionnaire asks participants to indicate the degree of bother that they experienced due to symptoms in seven domains potentially affected by cGVHD (skin, eyes, mouth, breathing, eating and digestion, energy, and emotional distress). The response will be determined based on clinician's assessment."", 'timeFrame': 'Baseline; up to approximately 12 months'}, {'measure': 'Change from baseline in the Lee Symptom Scale Score: Duration of a ≥ 7 point reduction', 'description': ""Changes in symptom burden/bother will be assessed using the Lee Symptom Scale, a symptom scale designed for individuals with chronic Graft Versus Host Disease (cGVHD). The questionnaire asks participants to indicate the degree of bother that they experienced due to symptoms in seven domains potentially affected by cGVHD (skin, eyes, mouth, breathing, eating and digestion, energy, and emotional distress). The response will be determined based on clinician's assessment."", 'timeFrame': 'Baseline; up to approximately 12 months'}, {'measure': 'Response rate by organ system', 'description': 'The response rate for the nine individual organs (skin, eyes, mouth, esophagus, upper GI, lower GI, liver, lungs, and joints and fascia) will be assessed by the clinician.', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Time to Response (TTR)', 'description': 'TTR defined as the time from the first dose of belumosudil to the first documented cGVHD response.', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Time to Next Treatment (TTNT)', 'description': 'TTNT defined as the time from the first dose of belumosudil to the start of additional systemic cGVHD therapy.', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Number of participants who have a best response of PR and CR', 'description': 'CR is defined as resolution of all manifestations of cGVHD in each organ or site. PR is defined as Improvement in at least 1 organ or site without progression in any other organ or site.', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Change from baseline in corticosteroid dose', 'description': 'The prednisone equivalent dose of corticosteroids (mg/kg/day) during the study will be analyzed. The change in systemic corticosteroid dose over time will be determined.', 'timeFrame': 'Baseline; up to approximately 12 months'}, {'measure': 'Change from baseline in calcineurin inhibitor dose', 'description': 'The change in calcineurin inhibitor dose over time will be determined.', 'timeFrame': 'Baseline; up to approximately 12 months'}, {'measure': 'Failure-free survival (FFS)', 'description': 'FFS defined as the absence of new cGVHD systemic therapy, non-relapse mortality and recurrent malignancy. Median FFS (from first dose of belumosudil) will be analyzed.', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Overall survival (OS)', 'description': 'OS defined as time from first dose of belumosudil to the date of death due to any cause.', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Change from baseline in cGVHD global severity rating using the Clinician-Reported Global cGVHD Activity Assessment', 'description': 'Patient-reported outcome', 'timeFrame': 'Baseline; up to approximately 12 months'}, {'measure': 'Change from baseline in symptom activity as based on cGVHD Activity Assessment Patient Self-Report', 'description': 'Patient-reported outcome', 'timeFrame': 'Baseline; up to approximately 12 months'}, {'measure': 'Plasma belumosudil concentrations', 'timeFrame': 'Day 1 of Cycles 2, 3, 5, and 7 (1 Cycle = 28 days)'}]",21,12 Years,,ALL,False,"Kadmon, a Sanofi Company",INDUSTRY,0,36.0,ESTIMATED,2025-09-01T16:18:19.671417,v2_robust,True,True,False,False,True,
NCT02399306,Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma,"A Prospective, Multicenter, Randomized Controlled Study to Compare Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma",Enteral nutrition,['Enteral nutrition'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Esophageal Squamous Cell Carcinoma,"['Esophageal Squamous Cell Carcinoma', 'Enteral Nutrition Therapy', 'Chemoradiotherapy']",[],COMPLETED,,2014-09,2017-10,"[{'measure': 'Body Weight Change from baseline to the end of treatment', 'description': 'Body weight change from baseline to the end of treatment = body weight at the end of treatment - baseline body weight.', 'timeFrame': 'up to 1 month after the treatment'}]","[{'measure': 'Maximum Body Weight Change during treatment', 'description': 'Maximum body weight change during treatment= the lowest body weight during treatment - baseline body weight.', 'timeFrame': 'up to 1 month after the treatment'}, {'measure': 'Blood biochemical examination', 'description': 'albumin, haemoglobin,et al', 'timeFrame': 'up to 1 month after the treatment'}, {'measure': 'Grade 3-5 toxicity', 'description': 'Grade 3-5 adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 andthe criteria of the Radiation Therapy Oncology Group ，such as esophagitis、pneumonitis 、hematologic toxicity and infection rate', 'timeFrame': 'up to 1 month after the treatment'}, {'measure': 'Completion rate of chemoradiotherapy', 'description': 'The proportion of people who complete all treatment as required', 'timeFrame': 'up to 1 month after the treatment'}, {'measure': 'short-term effect', 'description': 'objective remission rate', 'timeFrame': 'up to 1 month after the treatment'}, {'measure': 'Overall Survival', 'description': 'overall survival', 'timeFrame': 'at least 2 years'}]",7,18 Years,75 Years,ALL,False,Sichuan Cancer Hospital and Research Institute,OTHER,7,222.0,ACTUAL,2025-09-01T16:18:19.671444,v2_robust,True,True,True,False,True,
NCT04405206,Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer,"Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for MRI Stratified Low-risk Rectal Cancer: a Multi-center, Prospective, Single-arm Phase II Trial.",Oxaliplatin,"['Capecitabine', 'Oxaliplatin', 'Cape', 'OXA']",4,OBSERVATIONAL,[],,,Rectum Cancer,['Rectum Cancer'],['rectum cancer'],UNKNOWN,,2020-05-25,2023-12-30,"[{'measure': 'OPR(organ preservation rate)', 'description': 'Proportion of patients who achieved cCR or near cCR after neoadjuvant treatment and received watch and wait approach or local excision', 'timeFrame': '3 year'}]","[{'measure': 'NR-DFS(Non-regrowth disease free survival)', 'description': 'Within 3 years after receiving the neoadjuvant treatment, the time patient in status free of death, local recurrence after radical resection or distant metastasis.', 'timeFrame': '3 year'}, {'measure': 'SFS(stoma-free survival)', 'description': 'Within 3 years after receiving the neoadjuvant treatment, the time patient in status free of stoma', 'timeFrame': '3 year'}]",3,18 Years,85 Years,ALL,False,Peking University Cancer Hospital & Institute,OTHER,0,54.0,ESTIMATED,2025-09-01T16:18:19.671464,v2_robust,False,True,False,False,False,
NCT00255606,Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer,A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer Patients - PROSTY Trial,docetaxel,"['prednisone', 'docetaxel']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Prostate Cancer,['Prostate Cancer'],"['adenocarcinoma of the prostate', 'stage IV prostate cancer', 'recurrent prostate cancer']",COMPLETED,,2005-08,2010-08,[{'measure': 'Time to treatment failure (TTF)'}],"[{'measure': 'Quality of life every 6 weeks until TTF'}, {'measure': 'Safety'}, {'measure': 'Overall survival'}, {'measure': 'Response rate'}, {'measure': 'Use of epoetin beta'}]",6,18 Years,,MALE,False,Tampere University,OTHER,0,360.0,ESTIMATED,2025-09-01T16:18:19.671509,v2_robust,True,True,True,False,True,
NCT03609606,"A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects","An Open-label, Randomized, Multiple-dose Crossover Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects","D013, D326 and D337","['CKD-386 Reference2', 'CKD-386 Test', 'D013', 'D326 and D337', 'CKD-386 Reference1', 'D013, D326 and D337']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Dyslipidemias,"['Dyslipidemias', 'Hypertension']","['Dyslipidemia', 'Hypertension', 'CKD-386', 'Drug-Drug Interaction']",COMPLETED,,2018-08-09,2018-09-27,"[{'measure': 'AUCtau(area under the plasma concentration-time curve for a dosing interval at steady state)', 'description': '* Part A: Pharmacokinetic parameter of D013 after multiple dosing\n* Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing', 'timeFrame': '0(predose)~24 hours at Day7 and Day28'}, {'measure': 'Cmax,ss(Maximum plasma concentration of the drug at steady state)', 'description': '* Part A: Pharmacokinetic parameter of D013 after multiple dosing\n* Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing', 'timeFrame': '0(predose)~24 hours at Day7 and Day28'}]","[{'measure': 'Cmin,ss(Minimum concentration of the drug in plasma at steady state)', 'description': '* Part A: Pharmacokinetic parameter of D013 after multiple dosing\n* Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing', 'timeFrame': '0(predose)~24 hours at Day7 and Day28'}, {'measure': 'Tmax,ss(Time to maximum plasma concentration at steady state)', 'description': '* Part A: Pharmacokinetic parameter of D013 after multiple dosing\n* Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing', 'timeFrame': '0(predose)~24 hours at Day7 and Day28'}, {'measure': 't1/2(Terminal elimination half-life)', 'description': '* Part A: Pharmacokinetic parameter of D013 after multiple dosing\n* Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing', 'timeFrame': '0(predose)~24 hours at Day7 and Day28'}, {'measure': 'CLss/F(Apparent total body clearance of the drug from plasma at steady state)', 'description': '* Part A: Pharmacokinetic parameter of D013 after multiple dosing\n* Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing', 'timeFrame': '0(predose)~24 hours at Day7 and Day28'}, {'measure': 'Vd,ss/F(Apparent volume of distribution at steady state)', 'description': '* Part A: Pharmacokinetic parameter of D013 after multiple dosing\n* Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing', 'timeFrame': '0(predose)~24 hours at Day7 and Day28'}, {'measure': 'PTF(Peak-to-trough fluctuation)', 'description': '* Part A: Pharmacokinetic parameter of D013 after multiple dosing\n* Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing', 'timeFrame': '0(predose)~24 hours at Day7 and Day28'}]",8,20 Years,45 Years,MALE,True,Chong Kun Dang Pharmaceutical,INDUSTRY,0,69.0,ACTUAL,2025-09-01T16:18:19.671518,v2_robust,True,True,True,False,False,
NCT05755204,A Pharmacist-run PrEP Program for Women,"A Pharmacist-run, Community-based PrEP Program for High-risk Women-the OPTIMIZE Study",LA-CAB,"['Truvada', 'Apretude', 'LA-CAB', 'TDF/FTC']",4,OBSERVATIONAL,[],,,HIV Prevention,['HIV Prevention'],[],TERMINATED,This protocol was early terminated on 10/15/2024 due to low enrollment,2023-06-21,2024-10-15,"[{'measure': 'Uptake of LA-CAB vs. TDF/FTC for PrEP', 'description': 'proportion of women who initiate LA-CAB vs. TDF/FTC for PrEP', 'timeFrame': '48 weeks'}, {'measure': 'Persistence on LA-CAB vs. TDF/FTC for PrEP', 'description': 'proportion of women who remain on LA-CAB vs. TDF/FTC for PrEP', 'timeFrame': '48 weeks'}]","[{'measure': 'Persistence on LA-CAB vs. TDF/FTC for PrEP', 'description': 'proportion of women who remain on LA-CAB vs. TDF/FTC for PrEP', 'timeFrame': '24 weeks'}, {'measure': 'Uptake of LA-CAB vs. TDF/FTC for PrEP', 'description': 'proportion of women who initiate LA-CAB vs. TDF/FTC for PrEP', 'timeFrame': '24 weeks'}, {'measure': 'HIV incidence', 'description': 'proportion of women with new HIV infections (will be stratified by intervention group)', 'timeFrame': '24 weeks'}, {'measure': 'HIV incidence', 'description': 'proportion of women with new HIV infections (will be stratified by intervention group)', 'timeFrame': '48 weeks'}, {'measure': 'Awareness of and willingness to initiate PrEP', 'description': 'Proportion of participants who are aware of LA-CAB and daily oral TDF/FTC (based on responses to PrEP awareness and willingness survey)', 'timeFrame': 'Baseline'}, {'measure': 'Preference for chosen PrEP modality', 'description': 'Proportion of participants who elect to initiate LA-CAB vs. daily oral TDF/FTC for PrEP and reasons why (based on responses to PrEP preference survey)', 'timeFrame': 'Baseline and time of PrEP modality switch'}, {'measure': 'Safety and tolerability of LA-CAB vs. TDF/FTC for PrEP', 'description': 'Incidence and severity of AEs and laboratory abnormalities, Investigator assessment of causality of AEs and laboratory abnormalities (drug-relatedness), Proportion of subjects who discontinue PrEP medications due to Aes', 'timeFrame': '24 weeks'}, {'measure': 'Safety and tolerability of LA-CAB vs. TDF/FTC for PrEP', 'description': 'Incidence and severity of AEs and laboratory abnormalities, Investigator assessment of causality of AEs and laboratory abnormalities (drug-relatedness), Proportion of subjects who discontinue PrEP medications due to Aes', 'timeFrame': '48 weeks'}, {'measure': 'PrEP satisfaction', 'description': 'Proportion of participants who are satisfied with their chosen PrEP modality (based on responses to PrEP satisfaction survey)', 'timeFrame': '24 weeks'}, {'measure': 'PrEP satisfaction', 'description': 'Proportion of participants who are satisfied with their chosen PrEP modality (based on responses to PrEP satisfaction survey)', 'timeFrame': '48 weeks'}, {'measure': 'PrEP Adherence', 'description': 'Proportion of participants with 100% adherence (target adherence defined as ""within window, on-time LA-CAB injection"") to LA-CAB vs. at least 6/7 weekly doses of TDF/FTC', 'timeFrame': '24 weeks'}, {'measure': 'PrEP Adherence', 'description': 'Proportion of participants with 100% adherence (target adherence defined as ""within window, on-time LA-CAB injection"") to LA-CAB vs. at least 6/7 weekly doses of TDF/FTC', 'timeFrame': '48 weeks'}, {'measure': 'Bacterial STI incidence', 'description': 'Proportion of participants with new STIs (based on proportion with positive results for chlamydia, gonorrhea, trichomonas, and syphilis)', 'timeFrame': '24 weeks'}, {'measure': 'Bacterial STI incidence', 'description': 'Proportion of participants with new STIs (based on proportion with positive results for chlamydia, gonorrhea, trichomonas, and syphilis)', 'timeFrame': '48 weeks'}, {'measure': 'Treatment-emergent resistance among those who acquire HIV infection', 'description': 'Proportion of participants with treatment-emergent resistance associated mutations (RAMs) on LA-CAB vs. daily oral TDF/FTC', 'timeFrame': '24 weeks'}, {'measure': 'Treatment-emergent resistance among those who acquire HIV infection', 'description': 'Proportion of participants with treatment-emergent resistance associated mutations (RAMs) on LA-CAB vs. daily oral TDF/FTC', 'timeFrame': '48 weeks'}]",18,18 Years,65 Years,FEMALE,True,Orlando Immunology Center,OTHER,0,2.0,ACTUAL,2025-09-01T16:18:19.671543,v2_robust,False,True,False,True,True,This protocol was early terminated on 10/15/2024 due to low enrollment
NCT00089804,Study of LJP 394 in Lupus Patients With History of Renal Disease,"A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300 mg and 900 mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease",abetimus sodium (LJP 394) and/or placebo solution,"['abetimus sodium (LJP 394) and/or placebo solution', 'Phosphate-buffered saline', 'Placebo, normal saline', 'abetimus sodium (LJP 394)']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,"Lupus Erythematosus, Systemic","['Lupus Erythematosus, Systemic', 'Lupus Nephritis']","['Lupus', 'Nephritis', 'Kidney', 'SLE', 'Systemic Lupus Erythematosus', 'Nephritis, Lupus']",TERMINATED,Interim efficacy analysis indicated it would be futile to continue study.,2004-10,2009-02,"[{'measure': 'To determine whether abetimus sodium is more effective than placebo in delaying the time to renal flare in SLE patients with a history of SLE renal disease. Weekly administration with a 52-week treatment duration.', 'timeFrame': 'Time to event (12 months fixed treatment duration)'}]","[{'measure': 'To determine whether treatment with abetimus sodium is more effective than placebo in delaying the time to Major SLE flare; and to determine whether treatment with abetimus sodium (LJP 394) is more effective than placebo in reducing proteinuria.', 'timeFrame': '12 month fixed treatment duration'}]",2,12 Years,70 Years,ALL,False,La Jolla Pharmaceutical Company,INDUSTRY,0,943.0,ACTUAL,2025-09-01T16:18:19.671618,v2_robust,True,True,False,True,False,Interim efficacy analysis indicated it would be futile to continue study.
NCT03070704,"Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India","A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India",insulin degludec/liraglutide,['insulin degludec/liraglutide'],1,OBSERVATIONAL,[],,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],WITHDRAWN,Request for the study waived by Indian Health Authorities,2017-08-16,2019-08-16,"[{'measure': 'Incidence of treatment emergent Adverse Events (AEs)', 'description': 'Count and % of events', 'timeFrame': 'Year 0-1'}]","[{'measure': 'Number of Serious Adverse Events (SAEs)', 'description': 'Count and % of events', 'timeFrame': 'Year 0-1'}, {'measure': 'Number of Serious Adverse Drug Reactions (SADRs)', 'description': 'Count and % of events', 'timeFrame': 'Year 0-1'}, {'measure': 'Number of Adverse Drug Reactions (ADRs)', 'description': 'Count and % of events', 'timeFrame': 'Year 0-1'}, {'measure': 'Number of confirmed hypoglycaemic episodes', 'description': 'Count of episodes', 'timeFrame': 'Year 0-1'}, {'measure': 'Change from baseline in the level of glycosylated haemoglobin (HbA1c)', 'description': 'Measured in %', 'timeFrame': 'Year 0, Year 1'}, {'measure': 'Change in the level of Fasting Plasma/Blood Glucose (FPG/FBG) from baseline', 'description': 'Measured in mg/dl or other equivalent SI units', 'timeFrame': 'Year 0, Year 1'}, {'measure': 'Percentage of patients achieving the target level of HbA1c below 7%', 'description': 'Measured in %', 'timeFrame': 'Year 1'}, {'measure': 'Change in body weight', 'description': 'Measured in kg and/or %', 'timeFrame': 'Year 0, Year 1'}, {'measure': 'Number of patients withdrawn due to ineffective therapy', 'description': 'Count of withdrawals', 'timeFrame': 'Year 1'}]",10,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:19.671629,v2_robust,False,True,False,True,True,Request for the study waived by Indian Health Authorities
NCT02345304,"Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin","A Study to Investigate the Effects of BI 1181181 on the Pharmacokinetics of Midazolam, Warfarin, Omeprazole and Digoxin in Healthy Male Subjects",Omeprazole,"['Digoxin', 'Midazolam', 'Warfarin', 'BI 1181181', 'Omeprazole']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],WITHDRAWN,,2015-03,2015-05,"[{'measure': 'AUC0-tz (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) of midazolam and omeprazol after each dosing', 'timeFrame': 'up to 24 hours'}, {'measure': 'AUC0-tz (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) of digoxin after each dosing', 'timeFrame': 'up to 96 hours'}, {'measure': 'AUC0-tz (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) of warfarin after each dosing', 'timeFrame': 'up to 120 hours'}, {'measure': 'Cmax (Maximum measured concentration the analyte in plasma) of midazolam and omeprazol after each dosing', 'timeFrame': 'up to 24 hours'}, {'measure': 'Cmax (Maximum measured concentration the analyte in plasma) of digoxin after each dosing', 'timeFrame': 'up to 96 hours'}, {'measure': 'Cmax (Maximum measured concentration the analyte in plasma) of warfarin after each dosing', 'timeFrame': 'up to 120 hours'}]",[],6,18 Years,50 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:19.671682,v2_robust,True,True,False,True,False,
NCT02563704,A Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon,A Randomized Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon,Artesunate,"['Quinine', 'Artesunate']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Malaria,['Malaria'],"['Artesunate', 'Quinine', 'Efficacy', 'Malaria', 'Children', 'Cameroon']",COMPLETED,,2013-09,2014-03,"[{'measure': 'Fever clearance time', 'timeFrame': 'Time (in hours) from the onset of treatment till rectal temperature went down to 37.5°C for at least 24 hour'}, {'measure': 'Coma recovery time', 'timeFrame': 'Time (in hours) from the onset of treatment till the participant was fully conscious with a BCS of 5 or GCS of 15 for an average of 24 hours'}, {'measure': 'Time to sit unsupported', 'timeFrame': 'Time (in hours) from the onset of treatment till when the participant could sit unsupported for an average of 24 hours if the participant was unable to do so on admission'}, {'measure': 'Time to eat and drink', 'timeFrame': 'Time (in hours) from the onset of treatment till when the participant could eat and drink for an average of 24 hours if the participant was unable to do so on admission'}, {'measure': 'Parasite clearance time', 'timeFrame': 'Time (in hours) from the onset of treatment to the time of the first of two successive negative blood smear through hospital discharge, an average of one week'}, {'measure': 'Parasite reduction rate 24 hours after onset of treatment', 'timeFrame': '24 hours from onset of treatment'}]",[],6,3 Months,15 Years,ALL,False,University of Yaounde 1,OTHER,0,238.0,ACTUAL,2025-09-01T16:18:19.671710,v2_robust,True,True,True,False,False,
NCT03646604,"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis","An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis",Upadacitinib (ABT-494),"['ABT-494', 'Upadacitinib (ABT-494)', 'RINVOQ']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Atopic Dermatitis,['Atopic Dermatitis'],"['Upadacitinib', 'ABT-494', 'Atopic Dermatitis', 'RINVOQ']",COMPLETED,,2019-01-31,2024-08-29,"[{'measure': 'Maximum Plasma Concentration (Cmax)', 'description': 'It is defined as the maximum observed plasma concentration (Cmax) for upadacitinib.', 'timeFrame': 'Up to 7 days'}, {'measure': 'Time to Maximum Observed Plasma Concentration (Tmax)', 'description': 'It is defined as the time to maximum plasma concentration (Tmax) of upadacitinib.', 'timeFrame': 'Up to 7 days'}, {'measure': 'Area under the plasma concentration-time curve within a dosing interval (AUCtau)', 'description': 'The area under the plasma concentration-time curve (AUCtau) is a method of measurement of the total exposure of a drug in plasma.', 'timeFrame': 'Up to 7 days'}, {'measure': 'Oral Clearance', 'description': 'Clearance is defined the volume of plasma cleared of the drug per unit time.', 'timeFrame': 'Up to 7 days'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAE)', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug.', 'timeFrame': 'Up to 2 years'}]",[],5,2 Years,12 Years,ALL,False,AbbVie,INDUSTRY,0,35.0,ACTUAL,2025-09-01T16:18:19.671728,v2_robust,True,True,True,False,True,
NCT00986804,Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant,Maintenance Therapy With Decitabine After Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome,Decitabine,"['Dacogen', 'Decitabine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Leukemia, Myeloid, Acute","['Leukemia, Myeloid, Acute', 'Myelodysplastic Syndromes']",[],COMPLETED,,2009-12,2016-02,"[{'measure': 'To determine the maximum tolerated dose and schedule of decitabine when administered as maintenance therapy after alloHSCT performed for AML or high-risk MDS.', 'timeFrame': 'Up to 6 weeks (completion of first cycle)'}]","[{'measure': 'To determine the safety and tolerability of decitabine as maintenance therapy after alloHSCT.', 'timeFrame': 'Up to 30 days after end of study (approximately 46 weeks)'}, {'measure': 'To determine the rates disease relapse', 'timeFrame': 'Every 3 months for 2 years then every 6 months for 3 years'}, {'measure': 'To assess lymphoid and myeloid chimerism while on decitabine maintenance.', 'timeFrame': 'End of cycle 3 (18 weeks)'}, {'measure': 'To determine the incidence of acute GVHD.', 'timeFrame': 'End of study (42 weeks)'}, {'measure': 'To assess immunologic reconstitution after alloHSCT.', 'timeFrame': 'End of study (42 weeks)'}, {'measure': 'To assess changes in gene expression and methylation patterns following decitabine treatment', 'timeFrame': 'End of study (42 weeks)'}, {'measure': 'To assess the effects of decitabine on immune reconstitution post transplant.', 'timeFrame': 'End of study (42 weeks)'}, {'measure': 'To access the frequency of FoxP3+ CD3+/CD4+ and CD3+/CD8+ lymphocytes before and after decitabine treatment.', 'timeFrame': 'End of cycle 3 (18 weeks)'}, {'measure': 'To determine the 1-year disease-free survival', 'timeFrame': '1 year'}, {'measure': 'To determine overall survival.', 'timeFrame': 'Every 3 months for 2 years then every 6 months for 3 years'}, {'measure': 'To determine the incidence of chronic GVHD.', 'timeFrame': 'End of study (42 weeks)'}]",12,18 Years,,ALL,False,Washington University School of Medicine,OTHER,0,24.0,ACTUAL,2025-09-01T16:18:19.671793,v2_robust,True,True,True,False,True,
NCT00248404,NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS),A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase,NB1011,['NB1011'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Tumors,['Tumors'],"['colorectal cancer', 'ovarian cancer', 'lung cancer', 'breast cancer', 'small bowel cancer', 'Advanced, recurrent, or metastatic solid tumors of any type', 'TS overexpression confirmed by fresh biopsy (RTPCR)', 'Suitable for experimental monotherapy']",COMPLETED,,2005-09,2007-12-12,"[{'measure': 'Safety/tolerability of NB1011 infusions'}, {'measure': 'Determination of maximum tolerated dose (MTD)'}]","[{'measure': 'Pharmacokinetics of NB1011 and its metabolite'}, {'measure': 'Clinical activity as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria'}, {'measure': 'Assessment of TS overexpression'}]",5,18 Years,,ALL,False,Kiadis Pharma,INDUSTRY,0,155.0,ESTIMATED,2025-09-01T16:18:19.671858,v2_robust,True,True,True,False,True,
NCT03308604,AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy,Phase I Study of AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer,Polysiloxane Gd-Chelates based nanoparticles (AGuIX),"['Chemotherapy (cisplatin)', 'Polysiloxane Gd-Chelates based nanoparticles (AGuIX)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Gynecologic Cancer,['Gynecologic Cancer'],[],UNKNOWN,,2018-05-17,2024-05,"[{'measure': 'Maximum Tolerated Dose (MTD)', 'timeFrame': 'Day 84 after inclusion'}, {'measure': 'Recommended Phase 2 Dose (RP2D)', 'timeFrame': 'Day 84 after inclusion'}]",[],2,18 Years,70 Years,FEMALE,False,"Gustave Roussy, Cancer Campus, Grand Paris",OTHER,1,18.0,ESTIMATED,2025-09-01T16:18:19.671875,v2_robust,True,True,False,False,False,
NCT00212004,Pioglitazone Protects Diabetes Mellitus (DM) Patients Against Re-Infarction (PPAR Study),The Japan Working Group for the Assessment That the Pioglitazone Protects DM Patients Against Re-Infarction,pioglitazone,['pioglitazone'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetes Mellitus,"['Diabetes Mellitus', 'Myocardial Infarction']","['diabetes mellitus', 'myocardial infarction', 'pioglitazone']",TERMINATED,Limited budget to continue this study,2005-04,2018-04,"[{'measure': 'The time till the first cardiovascular composite endpoint', 'description': 'death from cardiovascular death, and the hospitalization due to nonfatal myocardial infarction, nonfatal unstable angina25, treatment with coronary revascularisation (percutaneous coronary intervention or coronary artery bypass graft) and cerebral infarction.', 'timeFrame': '2 years'}]","[{'measure': 'All cause mortality', 'description': 'death of any cause', 'timeFrame': '2 years'}, {'measure': 'Hospitalization due to nonfatal myocardial infarction', 'description': 'nonfatal myocardial infarction', 'timeFrame': '2 years'}, {'measure': 'Hospitalization due to nonfatal unstable angina', 'description': 'nonfatal unstable angina', 'timeFrame': '2 years'}, {'measure': 'Hospitalization due to treatment with coronary revascularisation (percutaneous coronary intervention or coronary artery bypass graft)', 'description': 'coronary revascularisation', 'timeFrame': '2 years'}, {'measure': 'Hospitalization due to cerebral infarction', 'description': 'cerebral infarction', 'timeFrame': '2 years'}, {'measure': 'The progression of DM', 'description': 'HbA1C levels\\>7.0%', 'timeFrame': '2 years'}, {'measure': 'worsening of renal function', 'description': 'serum creatine levels\\>2.5mg/dL or the increases of serum creatine levels by \\>2mg/dL', 'timeFrame': '2 years'}]",8,20 Years,79 Years,ALL,False,"National Cerebral and Cardiovascular Center, Japan",OTHER,1,630.0,ACTUAL,2025-09-01T16:18:19.671891,v2_robust,True,True,False,True,False,Limited budget to continue this study
NCT00667004,Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease,,ecabet ophthalmic solution,"['ecabet ophthalmic solution', 'placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Dry Eye Disease,['Dry Eye Disease'],[],COMPLETED,,2008-03-22,2008-09-12,"[{'measure': ""Mean Change From Baseline in Lacrimation Assessed by Schirmer's Test"", 'description': ""The Schirmer's test is used determine if tear glands produce enough tears to keep eyes adequately moist. Calibrated strips of a non-toxic filter paper are used. One free end is placed within the lower eyelid. At the conclusion of the test, the paper strip is removed from the lower eyelid and the amount of wetting of the paper strip is measured."", 'timeFrame': '43 days'}]",[],1,18 Years,,ALL,False,Bausch & Lomb Incorporated,INDUSTRY,0,183.0,ACTUAL,2025-09-01T16:18:19.671937,v2_robust,True,True,True,False,False,
NCT02063204,"To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects","An Open Label Comparative Study of the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY 142886) (Hyd Sulfate) Following a Single Oral Dose in Subjects With Renal Impairment and Healthy Subjects",selumetinib,['selumetinib'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumours,['Solid Tumours'],"['Phase I, healthy, pharmacokinetics, renal impairment']",COMPLETED,,2014-03,2014-07,"[{'measure': 'Description of the pharmacokinetic(PK) profile in terms of maximum observed plasma concentration (Cmax)', 'description': 'This will be taken at visit 2 for Healthy volunteers and at visit 2 and 3 for patients with end stage renal disease', 'timeFrame': 'Samples taken at predose, 30min, 1h, 1h30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h,6h,7h,8h,12h,18h,24h,36h,48h and 76h'}, {'measure': 'Description of PK profile in terms of area under plasma concentration-time curve from zero extrapolated to infinity (AUC)', 'description': 'This will be taken at visit 2 for Healthy volunteers and at visit 2 and 3 for patients with end stage renal disease', 'timeFrame': 'Samples taken at predose, 30min, 1h, 1h30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h,6h,7h,8h,12h,18h,24h,36h,48h and 76h'}, {'measure': 'Description of PK profile in terms of area under plasma concentration-time curve to time of last measurable concentration (AUC[0-t]) for selumetinib if AUC is not reportable in more than 80% of subjects', 'description': 'This will be taken at visit 2 for Healthy volunteers and at visit 2 and 3 for patients with end stage renal disease', 'timeFrame': 'Samples taken at predose, 30min, 1h, 1h30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h,6h,7h,8h,12h,18h,24h,36h,48h and 76h'}]","[{'measure': 'Description of the safety profile in terms of adverse events, physical examinations, ophthalmologic assessments, vital signs, clinical laboratory assessments and 12-lead electrocardiograms.', 'timeFrame': 'From screening until follow up. Approximately 6 weeks for healthy volunteers and 8 weeks for renal patients'}, {'measure': 'Description of the PK profile in terms of time to reach maximum observed concentration administration (tmax)', 'description': 'This will be taken at visit 2 for Healthy volunteers and at visit 2 and 3 for patients with end stage renal disease', 'timeFrame': 'Samples taken at predose, 30min, 1h, 1h30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h,6h,7h,8h,12h,18h,24h,36h,48h and 76h'}, {'measure': 'Description of PK profile in terms of area under the plasma concentration time curve from zero to 12 hours postdose (AUC[0-12])', 'description': 'This will be taken at visit 2 for Healthy volunteers and at visit 2 and 3 for patients with end stage renal disease', 'timeFrame': 'Samples taken at predose, 30min, 1h, 1h30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h,6h,7h,8h, and12h'}, {'measure': 'Description of PK profile in terms of terminal rate constant (λz), terminal elimination half-life (t1/2), apparent oral clearance (CL/F)', 'description': 'This will be taken at visit 2 for Healthy volunteers and at visit 2 and 3 for patients with end stage renal disease', 'timeFrame': 'Samples taken at predose, 30min, 1h, 1h30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h,6h,7h,8h,12h,18h,24h,36h,48h and 76h'}, {'measure': 'Description of PK profile in terms of apparent volume of distribution at steady state (Vss/F) and apparent volume of distribution during the terminal phase (Vz/F)', 'description': 'This will be taken at visit 2 for Healthy volunteers and at visit 2 and 3 for patients with end stage renal disease', 'timeFrame': 'Samples taken at predose, 30min, 1h, 1h30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h,6h,7h,8h,12h,18h,24h,36h,48h and 76h'}, {'measure': 'Description of PK profile in terms of mean residence time (MRT) and fraction unbound (fu), free Cmax (Cmax, u), free AUC (AUCu), free AUC(0-t) (AUC[0-t],u) and unbound CL/F (CL/Fu)', 'description': 'This will be taken at visit 2 for Healthy volunteers and at visit 2 and 3 for patients with end stage renal disease', 'timeFrame': 'Samples taken at predose, 30min, 1h, 1h30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h,6h,7h,8h,12h,18h,24h,36h,48h and 76h'}, {'measure': 'Description of PK profile in terms of the amount of drug excreted in urine (Ae) the fraction of dose excreted in urine (fe), renal clearance (CLR) for selumetinib and AUC, Cmax, tmax, t1/2, λz, AUC(0-12) and AUC(0-t)', 'description': 'These collection will be taken on visit 2 for the healthy volunteers and on visit 2 and 3 if the patients can produce urine', 'timeFrame': 'The urine collection intervals will be from -12 to 0 (predose), and 0 to 6, 6 to 12, 12 to 24, 24 to 36, 36 to'}, {'measure': 'Description of the PK profile in terms of the metabolite to parent AUC and Cmax ratios (MRAUC and MRCmax)', 'description': 'These samples will be taken on visit 2 for the healthy volunteers and on both visit 2 and visit 3', 'timeFrame': 'Samples taken at predose, 30min, 1h, 1h30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h,6h,7h,8h,12h,18h,24h,36h,48h and 76h'}, {'measure': 'Description of the PK profile in terms of Ae, fe, and CLR for N-desmethyl selumetinib (and the amide metabolite, if deemed appropriate)', 'timeFrame': 'Samples taken at predose, 30min, 1h, 1h30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h,6h,7h,8h,12h,18h,24h,36h,48h and 76h'}, {'measure': 'Description of the PK profile in terms of time-matched area under the plasma concentration time curve from 1 to 5 hours postdose (AUC[1-5])', 'description': 'This will only be taken at the visit when dose is given 1h before dialyse start', 'timeFrame': 'Sample taken predose, at 1h just before dialyse and at 5h after the end of the dialyse'}, {'measure': 'Description of the PK profile in terms of cumulative amount extracted during dialysis (Ad[1-5]), and dialysis clearance (CLD)', 'description': 'This will only be collected during visit 2 and only on end stage renal disease patients', 'timeFrame': 'Samples taken from dialysate collections over 1 hour intervals throughout the entire (approximately 4 hours) dialysis period ie, 0 to 1, 1 to 2, 2 to 3, 3'}]",14,18 Years,,ALL,True,AstraZeneca,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:19.671953,v2_robust,True,True,True,False,True,
NCT00307684,"Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)",An Open International Multicentre Long-Term Follow Up Study to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder,double blind placebo,"['double blind PR OROS methylphenidate', 'open label PR OROS methylphenidate', 'double blind placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Attention Deficit Disorder With Hyperactivity,['Attention Deficit Disorder With Hyperactivity'],"['Attention Deficit Hyperactivity Disorder', 'Adult', 'Long term safety', 'Efficacy', 'Quality of life']",COMPLETED,,2006-01,2008-07,"[{'measure': 'Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'To evaluate the long term safety and tolerability of PR OROS MPH (18, 36, 54, 72 and 90 mg/day) in adults with Attention Deficit Hyperactivity Disorder (ADHD)', 'timeFrame': 'Treatment duration for OL extended from 52 wks to 72 wks (International Amendment 2) or 108 wks in Germany. Treatment duration for double-blind (DB) randomized withdrawal: 4 weeks'}, {'measure': ""Change From DB Baseline in Conners' Adult ADHD Rating Scale (CAARS) Total Score at DB Endpoint"", 'description': 'To evaluate maintenance of treatment effects of PR OROS MPH vs. placebo as measured on CAARS.\n\nCAARS assesses ADHD symptoms and behaviors in adults. best value: 0 worst value: 54\n\nEndpoint: last available post-baseline assessment.', 'timeFrame': 'DB baseline, DB endpoint'}]","[{'measure': ""Change From OL Baseline to OL Endpoint in Conners' Adult ADHD Rating Scale (CAARS) Total and Subscale Scores"", 'description': 'Long term efficacy of PR OROS MPH as assessed by investigator-rated CAARS total score, hyperactivity/impulsivity subscale score and inattention subscale score.\n\nSubscale scores: best value: 0, worst value: 27', 'timeFrame': 'OL baseline, OL endpoint'}, {'measure': 'Change From OL Baseline in Clinical Global Impression Scale (CGI-S) Score at OL Endpoint', 'description': 'Assessment of the long term effect on overall functioning measured by CGI-S best score: 1 worst score: 7', 'timeFrame': 'OL baseline, OL endpoint'}, {'measure': 'Change From OL Baseline in Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score at OL Endpoint', 'description': 'Quality of life measured by Q-LES-Q best score: 100 worst score: 0', 'timeFrame': 'OL baseline, OL endpoint'}, {'measure': 'Change From DB Baseline to DB Endpoint in CGI-S Score', 'description': ""evaluation of treatment effects as rated by the investigator on the CGI-S scale. CGI-S is used to rate the severity of a subject's illness on a 7- point scale ranging from 1 (not ill) to 7 (extremely severe)."", 'timeFrame': 'DB baseline, DB endpoint'}, {'measure': 'Change From DB Baseline to DB Endpoint in CAARS Self Rated Scale (CAARS-S:S) Total Score', 'description': 'Evaluation of treatment effects as rated by the subjects on the CAARS-S:S. best score: 0 worst score: 104', 'timeFrame': 'DB baseline, DB endpoint'}]",7,18 Years,65 Years,ALL,False,Janssen-Cilag International NV,INDUSTRY,0,155.0,ACTUAL,2025-09-01T16:18:19.671987,v2_robust,True,True,True,False,True,
NCT06303284,Post-surgical Outcomes With Anabolic Agent Use in High-risk Ankle Fractures: A Pilot RCT,Post-surgical Outcomes With Anabolic Agent Use in High-risk Ankle Fractures: A Pilot RCT,subcutaneous Teriparatide injection,"['Teriparatide', 'subcutaneous Teriparatide injection']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Ankle Fractures,['Ankle Fractures'],[],NOT_YET_RECRUITING,,2025-01-01,2027-06-01,"[{'measure': 'Participant recruitment rate', 'description': 'Estimate of the mean monthly recruitment rate across participating sites', 'timeFrame': '2 years'}]","[{'measure': 'Incidence of composite measure of complications', 'description': 'Estimate of composite measure of complication (revision surgery, infection, non-union).', 'timeFrame': '3 month after surgery'}, {'measure': 'Adverse events', 'description': 'Estimate of intervention related adverse events', 'timeFrame': '3 month after surgery'}, {'measure': 'modified Radiological Union Scale for Tibia [RUST] score),', 'description': 'Tool for radiographic assessment of fracture healing', 'timeFrame': '2 week, 4 week, 2 months, 3 months, 4 months, 5 months, 6 months post operative.'}, {'measure': 'Olerud Molander Score', 'description': 'a functional rating scale from 0 (totally impaired) to 100 (completely unimpaired)', 'timeFrame': 'within 48 hours of surgery, 3 month and 6 months after surgery.'}, {'measure': 'EuroQol five dimensions [EQ-5D]', 'description': 'Quality of life measure', 'timeFrame': 'within 48 hours of surgery, 3 month and 6 months after surgery.'}, {'measure': 'short form-12 [SF-12]', 'description': 'Quality of life measure', 'timeFrame': 'within 48 hours of surgery, 3 month and 6 months after surgery.'}, {'measure': 'pain visual analogue score [VAS]', 'description': 'Pain intensity measure', 'timeFrame': 'within 48 hours of surgery, 3 month and 6 months after surgery.'}, {'measure': 'time-to-fracture union', 'description': 'the time between fracture and radiological healing of the fracture', 'timeFrame': '6 month post operative'}, {'measure': '90 day mortality', 'description': 'Mortality rate after 90 days of the surgery', 'timeFrame': '3 month post operative'}, {'measure': 'Bone mineral density', 'description': 'Bone mineral density scan', 'timeFrame': '2 week and 3 month post operative'}, {'measure': 'Total cost and QALYs', 'description': 'Measurement of the incremental cost per QALY gained for the more effective treatment option.', 'timeFrame': '3 month post operative'}]",12,60 Years,,ALL,False,University of Calgary,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:19.672125,v2_robust,True,True,False,False,True,
NCT05878184,Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT),"A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)",SC291,"['Fludarabine', 'Cyclophosphamide', 'SC291']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Non Hodgkin Lymphoma,"['Non Hodgkin Lymphoma', 'Chronic Lymphocytic Leukemia']","['Large B cell lymphoma', 'CAR T Cell Therapy', 'Mantle cell lymphoma', 'Indolent follicular lymphoma', 'Marginal zone lymphoma', 'High-grade B cell lymphoma', 'Primary mediastinal B cell lymphoma', 'Diffuse large B cell lymphoma', ""Non-Hodgkin's Lymphoma"", 'Chronic Lymphocytic Leukemia', 'Allogeneic', 'Hypoimmune', 'CD19']",ACTIVE_NOT_RECRUITING,,2023-05-02,2038-11-04,"[{'measure': 'Evaluate safety and tolerability of SC291', 'description': 'Safety and Tolerability: Proportion of subjects experiencing adverse events and dose-limiting toxicities', 'timeFrame': '24 months'}]","[{'measure': 'Evaluate preliminary anti-tumor activity of SC291', 'description': 'Preliminary anti-tumor activity: Proportion of subjects with an objective response (including partial response or complete response)', 'timeFrame': '24 months'}, {'measure': 'Evaluate cellular kinetics and persistence of SC291', 'description': 'Cellular kinetics-related parameters evaluated by CAR T cell copy number', 'timeFrame': '24 months'}, {'measure': 'Evaluate cellular kinetics and persistence of SC291', 'description': 'Cellular kinetics related peak (Cmax) in peripheral blood', 'timeFrame': '24 months'}, {'measure': 'Evaluate cellular kinetics and persistence of SC291', 'description': 'Area under the concentration time curve (AUC) in peripheral blood', 'timeFrame': '24 months'}, {'measure': 'Evaluate host immunogenicity to SC291', 'description': 'Incidence of anti-CD19-directed CAR antibodies', 'timeFrame': '24 months'}]",6,18 Years,80 Years,ALL,False,Sana Biotechnology,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:19.672196,v2_robust,True,True,False,False,True,
NCT00544284,Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment,A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors,bortezomib,"['bortezomib', 'temozolomide']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Brain and Central Nervous System Tumors,"['Brain and Central Nervous System Tumors', 'Lymphoma', 'Metastatic Cancer', 'Unspecified Adult Solid Tumor, Protocol Specific']","['adult glioblastoma', 'adult anaplastic astrocytoma', 'adult giant cell glioblastoma', 'recurrent adult brain tumor', 'adult gliosarcoma', 'adult mixed glioma', 'adult anaplastic oligodendroglioma', 'primary central nervous system lymphoma', 'adult diffuse astrocytoma', 'adult brain stem glioma', 'adult central nervous system germ cell tumor', 'adult choroid plexus tumor', 'adult craniopharyngioma', 'adult ependymoblastoma', 'adult medulloblastoma', 'adult supratentorial primitive neuroectodermal tumor (PNET)', 'adult anaplastic ependymoma', 'adult ependymoma', 'adult myxopapillary ependymoma', 'adult subependymoma', 'adult anaplastic meningioma', 'adult melanocytic lesion', 'adult meningeal hemangiopericytoma', 'adult grade I meningioma', 'adult grade II meningioma', 'adult grade III meningioma', 'adult papillary meningioma', 'adult oligodendroglioma', 'adult pineoblastoma', 'adult pineocytoma', 'tumors metastatic to brain', 'unspecified adult solid tumor, protocol specific', 'adult pilocytic astrocytoma', 'adult subependymal giant cell astrocytoma']",COMPLETED,,2005-01,2012-01,"[{'measure': 'Dose-limiting toxicity and maximum tolerated dose', 'timeFrame': '28 days'}]","[{'measure': 'Pharmacokinetics', 'timeFrame': 'Day 9'}, {'measure': 'Confirmed complete or partial response', 'timeFrame': '6 months'}, {'measure': 'Percentage of patients with 6-month progression-free survival', 'timeFrame': '6 months'}]",4,18 Years,,ALL,False,City of Hope Medical Center,OTHER,1,25.0,ACTUAL,2025-09-01T16:18:19.672215,v2_robust,True,True,True,False,False,
NCT04968184,Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD),A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD,Placebo,"['KBP-5074', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Kidney Diseases,['Chronic Kidney Diseases'],"['Stage 3b/4 chronic kidney disease', 'Hypertension', 'Uncontrolled Hypertension', 'Blood pressure', 'Mineralocorticoid Receptor Antagonist', 'Randomized withdrawal']",TERMINATED,Interim futility analysis showed primary endpoint not achieved,2021-11-05,2024-07-10,"[{'measure': 'Change in seated trough cuff SBP from baseline to Week 12', 'description': 'Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, will be evaluated.', 'timeFrame': 'From baseline to Week 12'}, {'measure': 'Change in seated trough cuff SBP from Week 48 to Week 52', 'description': 'Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, will be evaluated.', 'timeFrame': 'Week 48 to Week 52'}]","[{'measure': 'Change in seated trough cuff SBP from baseline to Week 24', 'description': 'Efficacy and durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP, will be evaluated.', 'timeFrame': 'From baseline to Week 24'}, {'measure': 'Changes in seated trough cuff diastolic blood pressure (DBP) from baseline to Week 12 and Week 24', 'description': 'Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, will be evaluated.', 'timeFrame': 'From baseline to Week 12 and Week 24'}, {'measure': 'Changes in seated trough cuff SBP and DBP from baseline to Week 48', 'description': 'Effect of KBP-5074 on SBP and DBP by assessing change in seated trough cuff SBP and DBP, will be evaluated.', 'timeFrame': 'From baseline to Week 48'}, {'measure': 'Changes in urinary albumin: creatinine ratio (UACR) from baseline to Week 12 and Week 24 for participants with UACR ≥30 mg/g at baseline', 'description': 'Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline, will be evaluated.', 'timeFrame': 'From baseline to Week 12 and Week 24'}, {'measure': 'Percentage changes in UACR from baseline to Week 12 and Week 24 for participants with UACR ≥30 mg/g at baseline', 'description': 'Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g at baseline, will be evaluated.', 'timeFrame': 'From baseline to Week 12 and Week 24'}, {'measure': 'Changes in UACR from baseline to Week 12, Week 24, and Week 48', 'description': 'Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \\<300 mg/g) at baseline, will be evaluated.', 'timeFrame': 'From baseline to Week 12, Week 24, and Week 48'}, {'measure': 'Percentage changes in UACR from baseline to Week 12, Week 24, and Week 48', 'description': 'Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \\<300 mg/g) at baseline, will be evaluated.', 'timeFrame': 'From baseline to Week 12, Week 24, and Week 48'}, {'measure': 'Change in seated trough cuff DBP from Week 48 to Week 52', 'description': 'Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, will be evaluated.', 'timeFrame': 'Week 48 to Week 52'}, {'measure': 'Change in UACR from Week 48 to Week 52', 'description': 'Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g, macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \\<300 mg/g) at baseline, will be evaluated.', 'timeFrame': 'Week 48 to Week 52'}, {'measure': 'Percentage change in UACR from Week 48 to Week 52', 'description': 'Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g, macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \\<300 mg/g) at baseline, will be evaluated.', 'timeFrame': 'Week 48 to Week 52'}, {'measure': 'Number of participants with adverse events (AEs) and serious adverse events (SAEs)', 'description': 'The safety and tolerability of KBP-5074,will be evaluated.', 'timeFrame': 'Screening (Week -6 to -2) until EOS (Week 56) or Unscheduled visit or end of treatment or early termination'}]",13,18 Years,,ALL,False,KBP Biosciences,INDUSTRY,0,652.0,ACTUAL,2025-09-01T16:18:19.672284,v2_robust,True,True,False,True,True,Interim futility analysis showed primary endpoint not achieved
NCT00251784,Healthy Volunteer Study of Sildenafil Effects Upon Vision,"A Double-Blind, Randomised, Placebo Controlled Healthy Volunteer Study to Investigate the Nature and Origin of the Disturbance of Vision Induced by Single Oral Doses of Sildenafil",Sildenafil,['Sildenafil'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Blindness,['Blindness'],[],COMPLETED,,2002-02,2003-06,[],[],0,18 Years,,MALE,True,University of Cambridge,OTHER,0,,,2025-09-01T16:18:19.672357,v2_robust,True,True,True,False,False,
NCT05832684,Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy,A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of ZVS101e Administered as a Single Monocular Subretinal Injection in Subjects With Bietti's Crystalline Dystrophy (BCD),ZVS101e,"['ZVS101e', 'rAAV8-hCYP4V2', 'AAV8-hCYP4V2', 'rAAV2/8-hCYP4V2']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Bietti's Crystalline Dystrophy,"[""Bietti's Crystalline Dystrophy""]",[],ACTIVE_NOT_RECRUITING,,2023-02-20,2028-12,"[{'measure': 'Incidence of ocular and systemic adverse events (AEs) after ZVS101e treatment', 'description': 'An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a product; the event will not need to have a causal relationship with the treatment.', 'timeFrame': 'Up to day 180'}, {'measure': 'Incidence of ocular and systemic serious adverse events (SAEs) after ZVS101e treatment', 'description': ""A serious adverse event (SAE) is any untoward medical occurrence at any dose that leading to the following:\n\nResults in death; Life-threatening, refers to an event in which the patient is at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe; Significant or permanent disability/incapacity, where disability refers to a serious disruption and damage of a person's ability to perform normal life functions; Requires inpatient hospitalization or prolongation of existing hospitalization; Congenital anomaly or birth defect; Other medically important events."", 'timeFrame': 'Up to day 180'}, {'measure': 'Mean change from baseline in BCVA (LogMAR)', 'description': 'BCVA of both eyes will be assessed using the early treatment of diabetic retinopathy study (ETDRS) chart.', 'timeFrame': 'Up to day 180'}]","[{'measure': 'Change from Baseline in visual field', 'description': 'Visual field will be assessed by Humphrey perimetry, changes in retinal light sensitivity will be analyzed.', 'timeFrame': 'Up to day 180'}, {'measure': 'Change from Baseline in contrast sensitivity', 'description': 'Change from baseline in contrast sensitivity at all spatial frequency will be measured using the CSV-1000E instrument.', 'timeFrame': 'Up to day 180'}, {'measure': 'Change from Baseline in microperimetry', 'description': 'Microperimetry will be measured using MP-3，changes in retinal sensitivity (dB) will be analyzed.', 'timeFrame': 'Up to day 180'}, {'measure': 'Change from Baseline in mfERG', 'description': 'The measurement will be performed based on the standards of international society for clinical electrophysiology of vision (ISCEV). Response Amplitude Density will be analyzed.', 'timeFrame': 'Up to day 180'}, {'measure': 'Change from Baseline in retinal thickness', 'description': 'Retinal thickness will be assessed for both eyes using OCT.', 'timeFrame': 'Up to day 180'}, {'measure': 'Change from Baseline in NEI VFQ-25 total score', 'description': 'National eye institute 25-item visual function questionnaire (NEI VFQ-25) consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively.', 'timeFrame': 'Up to day 180'}, {'measure': 'Change from Baseline in color vision', 'description': ""Subjects' color vision was classified and graded by having them identify the pictures within Color Vision Examination Plates."", 'timeFrame': 'Up to day 180'}]",10,18 Years,,ALL,False,"Chigenovo Co., Ltd",NETWORK,0,24.0,ESTIMATED,2025-09-01T16:18:19.672364,v2_robust,True,True,False,False,True,
NCT04104984,Detection of Preterm Labour by Cervical Length,Antenatal Management Based on Transvaginal Ultrasound Cervical Length Screening for Preventing Preterm Birth,Progesterone Vaginal Suppository,"['Progesterone Vaginal Suppository', 'Tocolytic Agents']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Preterm Labour,['Preterm Labour'],[],UNKNOWN,,2020-02-15,2021-11-15,"[{'measure': 'preterm birth, defined as delivery before 37 weeks 0 days of gestation', 'description': 'determine number of patients with preterm birth under 37 week gastational age and trying to prevent early diagnosed conditions from 922 patient diagnosed with short cervix', 'timeFrame': 'baseline'}]","[{'measure': 'Mean GA at delivery', 'description': 'detection of Mean gastational age at delivery', 'timeFrame': 'baseline'}, {'measure': 'Birth Wight less than 2500 grams.', 'description': 'determine number of infants born from patients with short cervix and undergo management and record Birth Wight less than 2500 grams.', 'timeFrame': 'baseline'}, {'measure': 'Birth Wight ( mean +SD) in grams', 'description': 'detection of Birth Wight ( mean +SD) in grams', 'timeFrame': 'baseline'}, {'measure': 'compliance to medication.', 'description': 'determine if the 466 of study group patient taking the medication regularly as progesterone vaginal suppository by questioning the patient.', 'timeFrame': 'baseline'}, {'measure': 'side effect related to intervention either progesterone or cercalage', 'description': 'detection and record the side effect related to intervention either progesterone or cercalage by questioning the patient', 'timeFrame': 'baseline'}, {'measure': 'Mode of delivery', 'description': 'recording which patients deliver normal vaginal delivery or by cesarean section', 'timeFrame': 'baseline'}, {'measure': 'perinatal mortality.', 'description': ""record the numbers of perinatal death who's mothers undergo treatment during pregnancy of overall 922 patients"", 'timeFrame': 'baseline'}, {'measure': 'Neonatal morbidity', 'description': 'record infants born to mother of study group and study group after birth with any morbidity like respiratory distress syndrome,necrotizing enterocolities,jaundice .', 'timeFrame': 'baseline'}, {'measure': 'admission to Neonatal intensive care unit', 'description': 'determine which infant born will be admitted to the intensive care unit after delivery and record numbers of infants .', 'timeFrame': 'baseline'}, {'measure': 'Maternal morbidity', 'description': 'record Maternal morbidity like maternal haemorrhage , maternal infection ,maternal medication from 922 patients with short cervix.', 'timeFrame': 'baseline'}]",11,16 Years,45 Years,FEMALE,True,Assiut University,OTHER,0,966.0,ESTIMATED,2025-09-01T16:18:19.672448,v2_robust,True,True,False,False,False,
NCT05988684,Effect of Metformin on Carotid Atherosclerosis for Non-diabetic Patients With PsA (CAMPA Study),Effect of Metformin on Carotid Atherosclerosis for Non-diabetic Patients With Psoriatic Arthritis - a Pilot Randomized Controlled Trial,Metformin,"['Glucophage', 'Metformin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,PsA (Psoriatic Arthritis),['PsA (Psoriatic Arthritis)'],[],RECRUITING,,2023-08-30,2025-10,"[{'measure': 'Difference in the proportion of subjects with carotid plaque progression between the metformin group and control group', 'description': 'Carotid plaques will be assessed at baseline and 12 months using a high-resolution B mode ultrasound machine (Philips EPIQ7) by a single experienced sonographer blinded to all clinical information using a 30-MHz linear vascular probe (Philips L12-3 broadband linear array transducer). Plaque progression is defined as an incident plaque in a segment without plaque before or an increase in number of plaque.\n\nThe primary outcome will be analyzed using multivariate logistic regression model. In univariate analysis, potential covariates including age, sex, traditional cardiovascular risk factor, disease activity and use of statin or biologic or targeted synthetic disease modifying anti-rheumatic drugs would be included. Variables which are significantly different between the two groups in the univariate analyses and are biologically plausible will be adjusted in the multivariate logistic regression model to confirm the metformin treatment effect.', 'timeFrame': '1 year'}]","[{'measure': 'Changes in mean carotid intima-media thickness (CIMT) between the two groups', 'description': 'The CIMT will be measured offline in the distal common carotid artery, bulb, and proximal internal carotid artery using dedicated software (Philips Xcelera Cardiology Enterprise Viewer Client 4). The mean and maximal IMT values of 6 arterial segments will be calculated for further analysis.\n\nThe secondary outcomes on other carotid and coronary atherosclerosis parameters, multivariate linear regression or logistic regression model similar to the primary outcome analysis would be used with adjustment for covariates.', 'timeFrame': '1 year'}, {'measure': 'Changes in carotid total plaque area (TPA) between the two groups', 'description': 'For TPA, the plane for measurement of each plaque will be chosen by reviewing the video of the scan to find the largest extent of plaque as seen on the longitudinal view. TPA will be recorded as the sum of the areas of all plaques in the right and left carotid arteries. Reading of the ultrasound scans obtained at baseline and follow-up will be performed concurrently by a single reader who is aware of the temporal order of the images but is blinded to all clinical data.\n\nThe secondary outcomes on other carotid and coronary atherosclerosis parameters, multivariate linear regression or logistic regression model similar to the primary outcome analysis would be used with adjustment for covariates.', 'timeFrame': '1 year'}, {'measure': 'Changes in coronary artery calcification (CAC) score', 'description': 'Coronary computer tomography angiogram (CCTA) scans will be performed at baseline and 12 months with 256-rows dual source multi-detector CT (Siemens Somatom Drive). CAC will be quantified by the Agatston method (normal = 0, higher = worse score). The images will be analyzed by an experienced radiologist blinded to all clinical data.\n\nThe secondary outcomes on other carotid and coronary atherosclerosis parameters, multivariate linear regression or logistic regression model similar to the primary outcome analysis would be used with adjustment for covariates.', 'timeFrame': '1 year'}, {'measure': 'Changes in coronary plaque volume', 'description': 'CCTA scans will be performed at baseline and 12 months with 256-rows dual source multi-detector computer tomography (CT) (Siemens Somatom Drive). Coronary arteries will be standardized to the American Heart Association 15-segment model. Non-calcified plaque volumes will be measured (CardIQ Xpress 2.0 Reveal, General Electic). The images will be analyzed by an experienced radiologist blinded to all clinical data.\n\nThe secondary outcomes on other carotid and coronary atherosclerosis parameters, multivariate linear regression or logistic regression model similar to the primary outcome analysis would be used with adjustment for covariates.', 'timeFrame': '1 year'}, {'measure': 'Changes in coronary stenosis level', 'description': 'CCTA scans will be performed at baseline and 12 months with 256-rows dual source multi-detector computer tomography (CT) (Siemens Somatom Drive). Coronary arteries will be standardized to the American Heart Association 15-segment model. Lesions rendering over 50% stenosis of the lumen will be considered as obstructive. For multiple plaques, the most stenotic one will be recorded. The images will be analyzed by an experienced radiologist blinded to all clinical data.\n\nThe secondary outcomes on other carotid and coronary atherosclerosis parameters, multivariate linear regression or logistic regression model similar to the primary outcome analysis would be used with adjustment for covariates.', 'timeFrame': '1 year'}, {'measure': 'Changes in anthropometric measurements', 'description': ""The patients' body mass index (BMI) will be checked at baseline and after 1 year.\n\nMann-Whitney U test will be used to evaluate the differences between the metformin and the placebo group at baseline as well as after 1 year."", 'timeFrame': '1 year'}, {'measure': 'Changes in sugar levels', 'description': ""The patients' fasting blood glucose will be checked at baseline and after 1 year.\n\nMann-Whitney U test will be used to evaluate the differences between the metformin and the placebo group at baseline as well as after 1 year."", 'timeFrame': '1 year'}, {'measure': 'Changes in insulin resistance', 'description': ""The patients' Hba1c will be checked at baseline and after 1 year.\n\nMann-Whitney U test will be used to evaluate the differences between the metformin and the placebo group at baseline as well as after 1 year."", 'timeFrame': '1 year'}, {'measure': 'Changes in cholesterol level in terms of cholesterol ratio (total cholesterol/high density lipoprotein)', 'description': ""The patients' lipid profile will be checked at baseline and after 1 year.\n\nMann-Whitney U test will be used to evaluate the differences between the metformin and the placebo group at baseline as well as after 1 year."", 'timeFrame': '1 year'}, {'measure': 'Occurrence of adverse events', 'description': 'All adverse events will be reported and recorded.\n\nOccurrence of adverse effects will be compared by Chi-square test or fisher exact test.', 'timeFrame': '1 year'}, {'measure': 'PsA disease activity control in terms of minimal disease activity (MDA) achievement', 'description': ""The MDA criteria assess 7 domains: number of tender joints (0-68), number of swollen joints (0-66), visual analogue scale (VAS) for pain (0-100 mm, 100 mm=most pain), VAS for patient's global assessment (0-100 mm, 100 mm=worst score), tender entheseal point and Psoriasis Area and Severity Index(PASI)/body surface area(BSA). Functional disability is assessed by the Health Assessment Questionnaire (HAQ) (0-3=most functional disability). The MDA criteria have the following cutoffs: tender joint count ≤1, swollen joint count ≤1, enthesitis count ≤1, PASI ≤1 (or BSA ≤3%), function score ≤0.5 (measured by the HAQ), patient's global assessment ≤20 and patient-reported pain ≤15 on a 100-mm VAS. If 5 of the 7 cutoffs for these domains are met, then the patient is classified as having MDA.\n\nChi-square test or fisher exact test will be used to evaluate the differences in proportion of patients with MDA between the metformin and the placebo group at 1 year."", 'timeFrame': '1 year'}]",12,18 Years,,ALL,False,Chinese University of Hong Kong,OTHER,0,24.0,ESTIMATED,2025-09-01T16:18:19.672576,v2_robust,True,True,False,False,True,
NCT06073184,Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium,Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (WE-FiERCE),Mounjaro,"['Mirena', 'Tirzepatide', 'Progestin-releasing intra-uterine device (pIUD)', 'Mounjaro']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Endometrial Cancer,"['Endometrial Cancer', 'Atypical Hyperplasia']","['Tirzepatide', 'pIUD']",NOT_YET_RECRUITING,,2025-08,2032-02,"[{'measure': 'Assessment of Complete Pathologic Response', 'description': 'Proportion of patients (%) who achieve pathological complete response at 48 weeks after initiation of pIUD and tirzepatide.', 'timeFrame': '48 weeks'}]","[{'measure': 'Assessment of Safety and Tolerability', 'description': 'Adverse events during treatment period', 'timeFrame': '48 weeks'}, {'measure': 'Assessment of Feasibility', 'description': 'Rate of accrual; Patient compliance; Retention', 'timeFrame': '2.5 years'}, {'measure': 'Assessment of Secondary Oncologic Outcomes', 'description': 'Time to achieve complete response; Duration of response; Recurrence rate; Time to recurrence; Progression/persistence rate', 'timeFrame': '6 years'}, {'measure': 'Assessment of Reproductive Outcomes', 'description': 'Rate of pregnancy; Live birth; Miscarriage; Pregnancy complications', 'timeFrame': '6 years'}, {'measure': 'Assessment of Patient Reported Outcomes', 'description': 'Quality of Life; Psychological functioning and fertility concerns after cancer diagnosis', 'timeFrame': '48 weeks'}, {'measure': 'Assessment of Metabolic Outcomes', 'description': 'Weight; BMI; Waist/hip circumference; Serum biomarkers of obesity and insulin resistance', 'timeFrame': '48 weeks'}]",7,18 Years,41 Years,FEMALE,False,"University Health Network, Toronto",OTHER,0,71.0,ESTIMATED,2025-09-01T16:18:19.672657,v2_robust,True,True,False,False,True,
NCT04305184,A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP),"A Phase 1/2, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of ASP0598 Otic Solution Following Topical Application Into the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)",ASP0598,['ASP0598'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Chronic Tympanic Membrane Perforation,['Chronic Tympanic Membrane Perforation'],['ASP0598'],TERMINATED,Lack of Efficacy,2020-09-10,2023-01-24,"[{'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs) in SAD', 'description': 'An adverse event (AE) is any untoward medical occurrence in a participant administered an investigational product (IP), and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of IP whether or not considered related to the IP. A TEAE is defined as an AE observed after starting administration of the study drug through end of study visit.', 'timeFrame': 'From first dose up to day 57'}, {'measure': 'Number of Participants With AE of Special Interest as Cholesteatoma or Ear Neoplasm in SAD', 'description': 'An AE is any untoward medical occurrence in a participant administered an IP, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of IP whether or not considered related to the IP. Number of participants with cholesteatoma or ear neoplasm is reported.', 'timeFrame': 'From first dose up to day 57'}, {'measure': 'Number of Participants With AE of Special Interest as Ototoxic Symptoms (Tinnitus, Sensorineural Hearing Loss, Dizziness) in SAD', 'description': 'An AE is any untoward medical occurrence in a participant administered an IP, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of IP whether or not considered related to the IP. Number of participants with any ototoxic symptoms (tinnitus, sensorineural hearing loss, dizziness) is reported.', 'timeFrame': 'From first dose up to day 57'}, {'measure': 'Number of Participants With AE of Special Interest as Otitis Media or Otitis Externa in SAD', 'description': 'An AE is any untoward medical occurrence in a participant administered an IP, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of IP whether or not considered related to the IP. Number of participants with otitis media or otitis externa is reported.', 'timeFrame': 'From first dose up to day 57'}, {'measure': 'Change From Baseline in Bone Conduction Hearing at 1, 2, 4 kHz by Pure Tone Audiometry at Week 8/EOS in SAD', 'description': 'PTA was a behavioral and quantitative hearing test to assess hearing. Pure tone air conduction and bone conduction tests were used to determine whether there was any unilateral or bilateral hearing loss, what type of hearing loss was present, which frequencies were impacted, and the magnitude of the hearing loss.', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Change From Baseline in TVAS at Week 8/EOS in SAD', 'description': 'TVAS was used by participants to rate their tinnitus at baseline and week 8. The scale was a numeric scale and ranged from 0 (not at all strong or loud) to 10 (extremely strong or loud). A lower value indicates less level of discomfort. For the change from baseline, a negative value indicates improvement (less level of discomfort).', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Number of Participants With TEAEs in MAD', 'description': 'An AE is any untoward medical occurrence in a participant administered an IP, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of IP whether or not considered related to the IP. A TEAE is defined as an AE observed after starting administration of the study drug through end of study visit.', 'timeFrame': 'From first dose up to day 85'}, {'measure': 'Number of Participants With AE Special Interest as Cholesteatoma or Ear Neoplasm in MAD', 'description': 'An AE is any untoward medical occurrence in a participant administered an IP, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of IP whether or not considered related to the IP. Number of participants with cholesteatoma or ear neoplasm is reported.', 'timeFrame': 'From first dose up to day 85'}, {'measure': 'Number of Participants With AE of Special Interest as Ototoxic Symptoms (Tinnitus, Sensorineural Hearing Loss, Dizziness) in MAD', 'description': 'An AE is any untoward medical occurrence in a participant administered an IP, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of IP whether or not considered related to the IP. Number of participants with any Ototoxic symptoms (tinnitus, sensorineural hearing loss, dizziness) is reported', 'timeFrame': 'From first dose up to day 85'}, {'measure': 'Number of Participants With AE of Special Interest as Otitis Media or Otitis Externa in MAD', 'description': 'An AE is any untoward medical occurrence in a participant administered an IP, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of IP whether or not considered related to the IP. Number of participants with otitis media or otitis externa is reported.', 'timeFrame': 'From first dose up to day 85'}, {'measure': 'Change From Baseline in Bone Conduction Hearing at 1, 2, 4 kHz by Pure Tone Audiometry at Week 12/EOS in MAD', 'description': 'PTA was a behavioral and quantitative hearing test to assess hearing. Pure tone air conduction and bone conduction tests were used to determine whether there was any unilateral or bilateral hearing loss, what type of hearing loss was present, which frequencies were impacted, and the magnitude of the hearing loss.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Change From Baseline in TVAS at Week 12/EOS in MAD', 'description': 'TVAS was used by participants to rate their tinnitus at baseline and week 12. The scale was a numeric scale and ranged from 0 (not at all strong or loud) to 10 (extremely strong or loud). A lower value indicates less level of discomfort. For the change from baseline, a negative value indicates improvement (less level of discomfort).', 'timeFrame': 'Baseline and week 12'}]","[{'measure': 'Number of Participants With Complete Closure of Tympanic Membrane Perforation (TMP) at Week 8 for SAD', 'description': 'Tympanic membrane perforation is a hole in the thin membrane that separates the ear canal from the middle ear. TMP closure is defined as microscopic TMP closure without presence of pin hole.', 'timeFrame': 'Week 8'}, {'measure': 'Number of Participants With Complete Closure of TMP at Week 12 for Dose Expansion', 'description': 'Tympanic membrane perforation is a hole in the thin membrane that separates the ear canal from the middle ear. TMP closure is defined as microscopic TMP closure without presence of pin hole.', 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline in the Ratio of TMP Size Per Total Area of Tympanic Membrane at Week 8 for SAD', 'description': 'Ratio of TMP size per total area of tympanic membrane calculation was performed by central imaging vendor and measured in percentage.', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Change From Baseline in the Ratio of TMP Size Per Total Area of Tympanic Membrane at Week 12 for Dose Expansion', 'description': 'Ratio of TMP size per total area of tympanic membrane calculation was performed by central imaging vendor and was measured by percentage.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Change From Baseline in TMP Size at Week 8 for SAD', 'description': 'TMP size calculation was be performed by central imaging vendor.', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Change From Baseline in TMP Size at Week 12 for Dose Expansion', 'description': 'TMP size calculation was be performed by central imaging vendor.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Number of Participants With Complete Closure of TMP at Week 12 for MAD', 'description': 'Tympanic membrane perforation is a hole in the thin membrane that separates the ear canal from the middle ear. TMP closure is defined as microscopic TMP closure without presence of pin hole.', 'timeFrame': 'Week 12'}, {'measure': 'Number of Participants With Complete Closure of TMP at Week 16 for Dose Expansion', 'description': 'Tympanic membrane perforation is a hole in the thin membrane that separates the ear canal from the middle ear. TMP closure is defined as microscopic TMP closure without presence of pin hole.', 'timeFrame': 'Week 16'}, {'measure': 'Change From Baseline in the Ratio of TMP Size Per Total Area of Tympanic Membrane at Week 12 for MAD', 'description': 'Ratio of TMP size per total area of tympanic membrane calculation was performed by central imaging vendor and measured in percentage.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Change From Baseline in the Ratio of TMP Size Per Total Area of Tympanic Membrane at Week 16 for Dose Expansion', 'description': 'Ratio of TMP size per total area of tympanic membrane calculation was performed by central imaging vendor and measured in percentage.', 'timeFrame': 'Baseline and week 16'}, {'measure': 'Change From Baseline in TMP Size at Week 12 for MAD', 'description': 'TMP size calculation was be performed by central imaging vendor.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Change From Baseline in TMP Size at Week 16 for Dose Expansion', 'description': 'TMP size calculation was be performed by central imaging vendor.', 'timeFrame': 'Baseline and week 16'}]",24,18 Years,75 Years,ALL,False,"Astellas Pharma Global Development, Inc.",INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:19.672667,v2_robust,True,True,False,True,True,Lack of Efficacy
NCT03580733,Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis,Prospective Multicentre Randomized Double-blind Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis,caspofungin antifungal therapy,['caspofungin antifungal therapy'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,ICU Yeast Intra-abdominal Infection,['ICU Yeast Intra-abdominal Infection'],"['ICU', 'yeast intra abdominal infection', 'candidiasis', 'ß-D-glucan', 'caspofungin']",RECRUITING,,2019-01-01,2024-12-04,"[{'measure': 'failure rate after the beginning of treatment', 'description': '28-day failure rate after the beginning of treatment', 'timeFrame': '28 days'}]","[{'measure': 'mortality', 'description': '28 and 90-day mortality rate', 'timeFrame': '28 and 90 days'}, {'measure': 'success rate at the end of treatment', 'description': 'success rate at the end of treatment', 'timeFrame': '8 days'}, {'measure': 'slope of ß-D-glucan concentrations', 'description': 'slope of ß-D-glucan concentrations', 'timeFrame': '8 days'}, {'measure': 'mortality', 'description': '28- 28 day mortality for subgroup analysis', 'timeFrame': '28 days'}]",5,18 Years,,ALL,False,"Centre Hospitalier Universitaire, Amiens",OTHER,0,448.0,ESTIMATED,2025-09-01T16:18:19.672870,v2_robust,True,True,False,False,False,
NCT01361633,The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly,The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly,d-cycloserine,"['Sugar Pill', 'd-cycloserine', 'Placebo', 'Seromycin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Treatment,"['Treatment', 'Placebo']","['d-cycloserine', 'geriatric', 'neuropsychology', 'cognition', 'cognitive-enhancer', 'aging', 'neuropsychological functioning']",COMPLETED,,2008-01,2009-02,"[{'measure': 'California Verbal Learning Test-II (CLVT-II)', 'description': 'The CLVT-II is an assessment of verbal learning and memory which measures recall and recognition scores, encoding strategies, learning rates and error types. A list learning task with 16 words from 4 semantic categories are read over a series of 5 list presentations. Recall is assessed after learning and at a 20-minute delay. Software produces a report that computes raw and standardized scores. Our dependent variable was the age adjusted t-score for total number of words recalled after 5 trials. A higher score indicated better recall. The maximum possible score was 80 and a minimum was 0.', 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without patient follow up. Scores for the experimental and control group were compared.'}]","[{'measure': 'Continuous Performance Test', 'description': 'Sustained attention was assessed using the Penn version of the Continuous Performance Test. During the CPT the participant responds to a target stimulus (e.g., the letter ""A""), while inhibiting responding to distractor stimuli. Reaction time to correct targets (true positives) was used as the dependent variable. Faster reaction times indicate better performance.', 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without further patient follow-up'}, {'measure': 'Controlled Oral Word Association Test', 'description': 'The Controlled Oral Word Association Test is a measure of the ability to orally generate words to a phonemic cue within a 60-second time interval. Age and education-adjusted t-scores were used as the dependent variable. A T-score of 50 is equal to the mean, with a standard deviation of 10 points. A higher T-score is a more favorable outcome.', 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without further patient follow-up'}, {'measure': 'Wisconsin Card Sort Test', 'description': 'The Wisconsin Card Sorting Test is a test of rule-learning and conceptual flexibility. The participant is required to learn to sort a series of cards according to one of three principles (color, form or number) based on response feedback. The age-adjusted t-score for total number of errors was used as a dependent variable. A T-score of 50 is equal to the mean, with a standard deviation of 10 points. A higher T-score is a more favorable outcome.', 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without further patient follow-up'}, {'measure': 'Trails B', 'description': 'Trails B is a measure of cognitive flexibility. The participant alternates sequencing between numbers and letters. An age and education-adjusted t-score for time to complete the exercise was used as the dependent variable. A T-score of 50 is equal to the mean, with a standard deviation of 10 points. A higher T-score is a more favorable outcome.', 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without further patient follow-up'}, {'measure': 'Stroop', 'description': 'The Stroop Color Word Test is a measure of selective attention and cognitive flexibility. This measure consists of three conditions: word reading, color naming and color-word naming. The interference score (t-score) was used as the dependent variable. A T-score of 50 is equal to the mean, with a standard deviation of 10 points. Higher t-scores represent a more favorable outcome.', 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without further patient follow-up'}, {'measure': 'Implicit Memory Task', 'description': ""Participants were presented with 32 stimulus words: 16 neutral and 16 threatening words. After a filler task (crossing out 8's on a sheet of randomized numbers) participants completed a response sheet including the stems for the 32 words presented to participants (primed words) along with stems for the 32 unprimed words. Participants were instructed to write down the first word that came to mind that completes each word stem. The priming effect was determined using the difference score between the correct number of stem completions for primed versus unprimed words. This is a value determined for each participant using the following equation: correct number of stem completions for primed word minus the correct number of stem completions for unprimed words. A larger difference score indicates a stronger implicit memory."", 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without further patient follow-up'}]",7,60 Years,,ALL,True,Hartford Hospital,OTHER,0,51.0,ACTUAL,2025-09-01T16:18:19.672888,v2_robust,True,True,True,False,False,
NCT00735852,Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women,"A Prospective Single Centre, Single Arm, Open Label Study of the Long Term Use of a LHRA Agonist (Decapeptyl SR, 11.25mg) in Combination With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women",Decapeptyl SR 11.25mg,"['Triptorelin acetate', 'Decapeptyl SR 11.25mg']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Endometriosis,['Endometriosis'],"['endometriosis', 'chronic cyclical pelvic pain']",COMPLETED,,2008-12,2016-05,"[{'measure': 'To assess the impact of treatment with Decapeptyl SR plus Livial on CCPP throughout the 24 month treatment period', 'timeFrame': 'baseline, month 12, month 24 and month 30'}]","[{'measure': 'To asses effect of Decapeptyl SR on pain, disability, overall health status and quality of life', 'timeFrame': 'baseline and 3 monthly until study end'}]",2,18 Years,45 Years,FEMALE,False,Sheffield Teaching Hospitals NHS Foundation Trust,OTHER,1,31.0,ACTUAL,2025-09-01T16:18:19.672986,v2_robust,True,True,True,False,False,
NCT00821652,"Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination","Phase I Randomized, Double-blind, Placebo-controlled Study of Topical Resiquimod as an Adjuvant for NY-ESO1 Protein+Montanide Vaccination in Patients With Tumors That Often Express NY-ESO-1",NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod,"['NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo', 'NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Tumors,['Tumors'],"['Tumor', 'NY-ESO-1 expression', 'Tumors that often express NY-ESO-1.']",COMPLETED,,2009-02,2014-12,"[{'measure': 'The primary objectives of the study are to define the safety and immunogenicity of vaccination with NY-ESO-1 protein emulsified in Montanide® ISA-51 VG when given with or without the topical TLR 7/8 agonist resiquimod.', 'timeFrame': 'Blood samples are obtained at baseline, 1 week after each vaccination, and at follow-up 1visit.'}]","[{'measure': 'To document tumor response by RECIST criteria if applicable. Skin section analysis of resiquimod/placebo treated site for immune cell infiltration and gene expression analysis. Investigation of polymorphisms for TLR7/8 through germline SNP analysis', 'timeFrame': 'Skin biopsies will be obtained after the last vaccination cycle. Clinical hematology and biochemistry measurements will be taken at baseline, one week after the second vaccination and two to four weeks after the fourth vaccination'}]",2,18 Years,,ALL,False,Nina Bhardwaj,OTHER,1,26.0,ACTUAL,2025-09-01T16:18:19.673013,v2_robust,True,True,True,False,True,
NCT05005052,Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities,Efficacy and Safety of Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities: A Randomized Placebo-Controlled Double-Blind Clinical Trial,Vessel,"['Vessel', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Venous Disease,"['Chronic Venous Disease', 'Chronic Insufficiency Venous']","['sulodexide', 'venoactive drug', 'venous disease', 'randomized', 'blinded', 'CEAP', 'ultrasonography', 'angiology', 'conservative treatment', 'quality of life', 'productivity loss', 'EQ-5D', 'CIVIQ-20']",UNKNOWN,,2021-11-25,2023-12,"[{'measure': 'Revised Venous Clinical Severity Score (rVCSS)', 'description': 'A minimal decrease in rVCSS score by 4 points will be considered a clinically significant response to treatment.', 'timeFrame': '24 weeks of treatment'}]","[{'measure': 'Revised Venous Clinical Severity Score (rVCSS)', 'description': 'A minimal decrease in rVCSS score by 4 points will be considered a clinically significant response to treatment.', 'timeFrame': '4, 8 and 12 weeks of treatment'}, {'measure': 'Volume in lower limb', 'description': 'The decrease of lower limb volume of at least 30 mL will be determined using water displacement leg volumetry and will be considered a clinically significant response to treatment.', 'timeFrame': '4, 8, 12 and 24 weeks of treatment'}, {'measure': 'Visual Analogue Scale (VAS)', 'description': 'Decrease in mean pain on Visual Analogue Scale.', 'timeFrame': '4, 8, 12 and 24 weeks of treatment'}, {'measure': 'Work Productivity and Activity Impairment (WPAI questionnaire)', 'description': 'Increase in mean work productivity in WPAI questionnaire.', 'timeFrame': '8 and 24 weeks of treatment'}, {'measure': 'EQ-5D questionnaire', 'description': 'Increase in the mean generic quality of life in EQ-5D questionnaire.', 'timeFrame': '8 and 24 weeks of treatment'}, {'measure': 'Chronic Venous Insufficiency Quality of Life (CIVIQ-20 questionnaire)', 'description': 'Increase in the mean disease-specific quality of life in CIVIQ-20 questionnaire.', 'timeFrame': '8 and 24 weeks of treatment'}, {'measure': 'Mean time of clinically significant worsening rVCSS', 'description': 'Mean time of worsening the rVCSS score since study initiation of at least 4 points. The difference will be visualized using Kaplan-Meier estimates and tested using Cox proportional-hazards models.', 'timeFrame': '4, 8, 12 and 24 weeks of treatment'}, {'measure': 'Compression therapy initiation', 'description': 'Mean time of duration of initiation of compression therapy since study initiation. The difference will be visualized using Kaplan-Meier estimates and tested using Cox proportional-hazards models.', 'timeFrame': '4, 8, 12 and 24 weeks of treatment'}]",9,18 Years,,ALL,False,Value Outcomes Ltd.,OTHER,1,290.0,ESTIMATED,2025-09-01T16:18:19.673048,v2_robust,True,True,False,False,False,
NCT03134352,Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema,"A Multi-center, Randomized, Double-blind, Parallel, Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Fugan Ointment (ZL-3101) in Subjects With Subacute Eczema",ZL-3101,"['Placebo', 'ZL-3101', 'Fugan ointment']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Eczema,['Eczema'],['subacute'],COMPLETED,,2017-04-26,2018-09-10,"[{'measure': 'Eczema Area and Severity Index (EASI) score changes from baseline to day 21', 'description': 'To evaluate efficacy of Fugan ointment applied to involved skin of subjects with mild to moderate subacute eczema', 'timeFrame': '21 days'}]",[],1,18 Years,65 Years,ALL,False,Zai Lab Pty. Ltd.,INDUSTRY,0,290.0,ACTUAL,2025-09-01T16:18:19.673344,v2_robust,True,True,True,False,False,
NCT00371852,Topic Compatibility Dermacyd Wipes - Lactoserum - Hygiene,Safety Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability and Dermical Sensibility) of Dermacyd Wipes,lactoserum,['lactoserum'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Hygiene,['Hygiene'],[],COMPLETED,,2006-05,,"[{'measure': 'Score evaluation of the cutaneous reaction, preconized by International Contact Dermatitis Research Group (ICDRG)'}]",[],1,18 Years,60 Years,ALL,True,Sanofi,INDUSTRY,0,50.0,,2025-09-01T16:18:19.673352,v2_robust,True,True,True,False,False,
NCT00819052,Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients,"An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regiment to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID Based Program",Nevirapine XR,"['Nevirapine XR', 'Nevirapine IR']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,HIV Infections,['HIV Infections'],[],COMPLETED,,2008-12,2012-01,"[{'measure': 'Comparison of Virologic Response at Week 24 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population', 'description': 'Primary endpoint was the number of patients with a sustained virologic response through week 24', 'timeFrame': 'week 24'}]","[{'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 2', 'timeFrame': 'week 2'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 4', 'timeFrame': 'week 4'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 8', 'timeFrame': 'week 8'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 12', 'timeFrame': 'week 12'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 24', 'timeFrame': 'week 24'}, {'measure': 'Kaplan-Meier Estimates of the Proportions of Patients Without Loss of Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population', 'timeFrame': 'week 0 to 24'}, {'measure': 'Summary of CD4 Count (Cells/Cubic Millimeter) at Baseline, Full Analysis Set Population', 'timeFrame': 'week 0'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 2, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 2'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 4, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 4'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 8, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 8'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 12, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 12'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 24, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 24'}, {'measure': 'Comparison of CD4 Count (Cells/Cubic Millimeter) Change From Baseline at Week 24, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 24'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 48', 'timeFrame': 'week 48'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 60', 'timeFrame': 'week 60'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 72', 'timeFrame': 'week 72'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 84', 'timeFrame': 'week 84'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 96', 'timeFrame': 'week 96'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 108', 'timeFrame': 'week 108'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 120', 'timeFrame': 'week 120'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 132', 'timeFrame': 'week 132'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 144', 'timeFrame': 'week 144'}, {'measure': 'Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population', 'description': 'Endpoint was the number of patients with a sustained virologic response at their last available visit', 'timeFrame': 'last available visit, up to 144 weeks'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 48, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 48'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 60, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 60'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 72, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 72'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 84, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 84'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 96, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 96'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 108, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 108'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 120, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 120'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 132, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 132'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 144, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, week 144'}, {'measure': 'Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Last Available Visit, Observed Cases, Full Analysis Set Population', 'timeFrame': 'baseline, last available visit (up to 144 weeks)'}, {'measure': 'Proportion of Virologic Response (Viral Load <400 Copies/mL) Trough Week 144', 'description': 'Endpoint was the number of patients with a sustained virologic response through week 144', 'timeFrame': 'week 144'}, {'measure': 'Change From Baseline in VL (HIV-1 Viral Load) at Each Visit', 'timeFrame': 'week 48, 60, 72, 84, 96, 108, 120, 132, 144, last available visit'}, {'measure': 'Changes in Safety Parameters Related to Treatment', 'description': 'Occurence of investigations related to treatment', 'timeFrame': 'until week 144'}, {'measure': 'Occurence of Rashes', 'description': 'drug-related rashes by severity', 'timeFrame': '144 weeks'}, {'measure': 'Occurence of Hepatic Events', 'timeFrame': '144 weeks'}, {'measure': 'New AIDS or AIDS-related Progression Event or Death', 'timeFrame': '144 weeks'}, {'measure': 'Time to Loss of Virologic Response', 'description': 'Kaplan-Meier Estimates of time to loss of virologic response defined as the time between the start of treatment and the time of treatment failure, up to and including the time when the last patient was on treatment for 48 weeks.', 'timeFrame': '48 weeks'}, {'measure': 'Genotypic Resistance Associated With Virologic Failure', 'description': 'Genotypic resistance associated with virologic failure.\n\nThis endpoint was not analysed due to lack of data.', 'timeFrame': '48 weeks'}, {'measure': 'Trough Plasma Concentration', 'description': 'Trough plasma concentrations of Nevirapine at steady state after multiple oral administrations of Nevirapine treatments from day 1 (visit 2) to week 48 (visit 9).', 'timeFrame': 'Day 1 to week 48'}]",43,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,445.0,ACTUAL,2025-09-01T16:18:19.673368,v2_robust,True,True,True,False,True,
NCT01509547,Varenicline for Adolescent Smoking Cessation,A Randomized Controlled Trial of Varenicline for Adolescent Smoking Cessation,Varenicline,"['Varenicline', 'Chantix', 'placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Nicotine Dependence,['Nicotine Dependence'],[],COMPLETED,,2012-08,2018-01-26,"[{'measure': 'Number of Participants With Cotinine-confirmed 7-day Point Prevalence Abstinence at the End of Treatment', 'description': 'Self-reported 7-day cigarette abstinence, confirmed by urine corinne ≤50 ng/mL at the end-of-treatment (week 12) visit', 'timeFrame': '7 days at end of treatment'}, {'measure': 'Number of Participants Experiencing Treatment-emergent Adverse Events', 'description': 'Clinician-collected adverse events (regardless of relatedness to medication) occurring at any point after randomization and initiation of treatment.', 'timeFrame': '26 weeks (12 weeks of treatment plus full post-treatment follow-up)'}]","[{'measure': 'Percentage of Visits With Abstinence During Treatment', 'description': 'Self-reported between-visit abstinence at weekly visits during treatment (reported as percentage of total possible visits across all participants at which participants self-reported abstinence). Missing data were imputed to non-abstinence.', 'timeFrame': '12 weeks (all of active treatment)'}, {'measure': 'Percentage of Post-treatment Visits With Abstinence', 'description': 'Self-reported abstinence at post-treatment follow-up visits (reported as percentage of total possible post-treatment follow-up visits at which abstinence in the prior week was self-reported). Missing data were imputed to non-abstinence.', 'timeFrame': 'One week abstinence at the Week 16 and Week 26 post-treatment follow-up visits'}, {'measure': 'Number of Participants Achieving 7+ Days Abstinence at Any Point During Treatment', 'description': 'Number of participants achieving 7+ days of self-reported abstinence at any point during active treatment', 'timeFrame': '12 weeks of active treatment'}]",5,14 Years,21 Years,ALL,False,Medical University of South Carolina,OTHER,0,157.0,ACTUAL,2025-09-01T16:18:19.673435,v2_robust,True,True,True,False,True,
NCT02783547,Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome,"A Phase 1, Open Label, Multicentre Clinical Trial of SyB C-1101 in Combination With Azacytidine in Patients With Myelodysplastic Syndrome",SyB C-1101 and Azacytidine,['SyB C-1101 and Azacytidine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Myelodysplastic Syndrome,['Myelodysplastic Syndrome'],[],WITHDRAWN,The trial was withdrawn due to problems with the manufacture of the investigational drug.,2015-12,2017-06,"[{'measure': 'Number of dose-limiting toxicity (DLT) in patients administered with specified (level 1 or 2) dosage of SyB C-1101 in Cycle 1 and the descriptions of DLT', 'description': 'Incidence rate of DLT and its binomial proportion confidence interval at the 90% level\n\ndefinition of DLT are as below: 1) Non-hematotoxicity of grade 3 or above with the exception of fever 2) fever of grade 2 or above uncontrolled by antipyretics', 'timeFrame': 'Up to 19 months'}]","[{'measure': 'Serious Adverse Events', 'timeFrame': 'Up to 19 months'}, {'measure': 'Adverse Events, not including Serious Adverse Events', 'timeFrame': 'Up to 19 months'}, {'measure': 'Change in laboratory values', 'timeFrame': 'Up to 19 months'}, {'measure': 'Total efficacy in hematologic remission rate', 'description': 'Ratio of patients scored as complete remission (CR), partial remission (PR) or marrow CR) according to the International Working Group (IWG) response criteria in myelodysplasia, 2006 (in each response criteria, responses must last at least 4 weeks):\n\n\\< CR\\>\n\n* Bone marrow: ≤5% myeloblasts with normal maturation of all cell lines.\n* Persistent dysplasia will be noted.\n* Peripheral blood:\n\nHgb ≥ 11 g/dL Platelets ≥ 100 × 109/L Neutrophils ≥ 1.0 × 109/L† Blasts 0% \\< PR \\>\n\nAll CR criteria if abnormal before treatment except:\n\n* Bone marrow blasts decreased by ≥ 50% over pretreatment but still \\> 5%\n* Cellularity and morphology not relevant \\<marrow CR\\>\n* Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment\n* Peripheral blood: if hematological improvement (HI) responses, they will be noted in addition to marrow CR.', 'timeFrame': 'Up to 19 months'}, {'measure': 'Total efficacy in hematologic improvement rate', 'description': 'Ratio of patients with hematologic improvement(erythroid, platelet or neutrophil) according to the International Working Group (IWG) response criteria in myelodysplasia, 2006 (in each response criteria, responses must last at least 8 weeks):\n\n\\< Erythroid response (pretreatment, \\<11 g/dL) \\>\n\n1. Hgb increase by ≥1.5 g/dL.\n2. Relevant reduction of units of red blood cell (RBC) transfusions by an absolute number of at least 4 RBC transfusions/8 wk compared with the pretreatment transfusion number in the previous 8 wk. Only RBC transfusions given for a Hgb of ≤9.0 g/dL pretreatment will count in the RBC transfusion response evaluation.\n\n\\< Platelet response (pretreatment, \\<100 × 109/L) \\>\n\n1. Absolute increase of ≥30 × 109/L for patients starting with \\>20 × 109/L platelets\n2. Increase from \\<20 × 109/L to \\>20 × 109/L and by at least 100%\n\n\\< Neutrophil response (pretreatment, \\<1.0 × 109/L) \\> At least 100% increase and an absolute increase \\>0.5 × 109/L', 'timeFrame': 'Up to 19 months'}, {'measure': 'Cytogenetic response rate', 'description': 'Ratio of patients scored as complete cytogenetic response or partial cytogenetic response) according to the International Working Group (IWG) response criteria in myelodysplasia, 2006 (in each response criteria, responses must last at least 4 weeks):\n\n\\< Cytogenetic response \\> Complete: Disappearance of the chromosomal abnormality without appearance of new ones.\n\nPartial: At least 50% reduction of the chromosomal abnormality.', 'timeFrame': 'Up to 19 months'}, {'measure': 'Peak plasma concentration (Cmax)', 'timeFrame': 'Up to 19 months'}, {'measure': 'Time to maximum drug concentration time (tmax)', 'timeFrame': 'Up to 19 months'}, {'measure': 'Area under the plasma concentration-time curve (AUC)', 'timeFrame': 'Up to 19 months'}, {'measure': 'Elimination half-life (t1/2)', 'timeFrame': 'Up to 19 months'}]",11,20 Years,,ALL,False,SymBio Pharmaceuticals,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:19.673458,v2_robust,True,True,False,True,True,The trial was withdrawn due to problems with the manufacture of the investigational drug.
NCT06322147,Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer,"Doublet or Triplet Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF Wild Type Unresectable Liver Metastasis Right-sided Colon Cancer With Curative Intent：Multi-center, Ambispective Observational Trial",Doublet or triplet chemotherapy combined with cetuximab,['Doublet or triplet chemotherapy combined with cetuximab'],1,OBSERVATIONAL,[],,,Colon Cancer,['Colon Cancer'],[],RECRUITING,,2023-06-01,2025-12-30,"[{'measure': 'R0 resection rate', 'description': 'R0 resection rate upon conversion treatment with chemotherapy plus cetuximab', 'timeFrame': '1 year'}]","[{'measure': 'Objective response rate', 'description': 'CR + PR rate according to RECIST', 'timeFrame': '1 year'}, {'measure': 'Reported adverse events', 'description': 'Number of patients with adverse events and severity according to NCI CTC 4.0', 'timeFrame': '1 year'}, {'measure': 'Progression free survival', 'description': 'Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first.', 'timeFrame': '2 year'}, {'measure': 'no evidence of disease', 'description': 'the percentage of patients who had a curative liver treatment following protocol treatment', 'timeFrame': '1 year'}, {'measure': 'depth of response', 'description': 'DOR means that the period from the day when either CR or PR is first confirmed until the day of documented PD or the day of death due to all causes, whichever occurs earlier.', 'timeFrame': '1 year'}, {'measure': 'Early Tumor Shrinkage', 'description': 'Early tumor shrinkage assessed by Response rate at week 8', 'timeFrame': '1 year'}]",7,18 Years,75 Years,ALL,,Qilu Hospital of Shandong University,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:19.673471,v2_robust,False,True,False,False,True,
NCT06402747,Clopidogrel Versus Cilostazol on Vessels,Comparing Clopidogrel and Cilostazol in Type 2 Diabetes Patients With Carotid Atherosclerosis,Clopidogrel,"['Cilostazol', 'Platless Tab.', 'Cilostan CR Tab. 200mg', 'Clopidogrel']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes,"['Type 2 Diabetes', 'Atherosclerosis']",[],RECRUITING,,2024-04-16,2027-12-31,"[{'measure': 'Changes of carotid intima-media thickness', 'description': 'mm', 'timeFrame': '52 weeks'}]","[{'measure': 'Changes of circulation', 'description': 'measured by ankle brachial index and laser doppler', 'timeFrame': '52 weeks'}, {'measure': 'Changes of HbA1c', 'timeFrame': '26 and 52 weeks'}, {'measure': 'Changes of glucose', 'description': 'mg/dL', 'timeFrame': '26 and 52 weeks'}, {'measure': 'Changes of body weight', 'description': 'kg', 'timeFrame': '26 and 52 weeks'}, {'measure': 'Changes of whole body fat', 'description': 'measured by bioelectrical impedance analysis', 'timeFrame': '26 and 52 weeks'}, {'measure': 'Changes of blood pressures', 'description': 'systolic, diastolic (mmHg)', 'timeFrame': '26 and 52 weeks'}, {'measure': 'Changes of lipids', 'description': 'total cholesterol, triglycerides, LDLc, HDLc (mg/dL)', 'timeFrame': '26 and 52 weeks'}, {'measure': 'Changes of peripheral pain or ischemic symptoms', 'description': 'measured by questionnaires (visual analogue scale: 100)', 'timeFrame': '26 and 52 weeks'}, {'measure': 'Changes of laboratory values related to blood clot', 'description': 'prothrombin time, activated partial thromboplastin time', 'timeFrame': '26 and 52 weeks'}]",10,19 Years,,ALL,False,Seoul National University Bundang Hospital,OTHER,1,120.0,ESTIMATED,2025-09-01T16:18:19.673491,v2_robust,True,True,False,False,False,
NCT04747847,Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease,Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease,Atorvastatin and anakinra,['Atorvastatin and anakinra'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Kawasaki Disease,['Kawasaki Disease'],[],ACTIVE_NOT_RECRUITING,,2017-10-09,2025-04,"[{'measure': 'Number of participants with treatment-related adverse events', 'description': 'The number of participants with adverse events related to study drugs will be assessed and reported', 'timeFrame': '6 weeks'}]",[],1,1 Year,17 Years,ALL,False,"University of California, San Diego",OTHER,1,10.0,ESTIMATED,2025-09-01T16:18:19.673522,v2_robust,True,True,False,False,True,
NCT03164447,UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients,"A Multicenter, Single-Arm, 24-Week Study of UB-421 in Combination With Optimized Background Therapy (OBT) Regimen in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection",Optimized background therapy (OBT),['Optimized background therapy (OBT)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV-1 Infection,['HIV-1 Infection'],[],UNKNOWN,,2023-12,2024-05,"[{'measure': 'Effectiveness by Viral Load Log10 Change from Baseline', 'timeFrame': '2 weeks'}]","[{'measure': 'Number of participants with treatment-related adverse events', 'timeFrame': '35 weeks'}, {'measure': 'Peak concentration of UB-421', 'timeFrame': '35 weeks'}, {'measure': 'Trough concentration of UB-421', 'timeFrame': '35 weeks'}]",4,18 Years,,ALL,False,United BioPharma,INDUSTRY,0,10.0,ESTIMATED,2025-09-01T16:18:19.673529,v2_robust,True,True,False,False,True,
NCT07062549,Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell,First-in-Human Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma,111In-XYIMSR-01,['111In-XYIMSR-01'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Renal Cell Carcinoma (Kidney Cancer),['Renal Cell Carcinoma (Kidney Cancer)'],[],RECRUITING,,2022-01-26,2029-07,"[{'measure': 'Number of adverse events', 'description': 'To evaluate the safety, tolerability, and feasibility of SPECT/CT imaging with 111In-XYIMSR-01 measured by all adverse events according to CTCAE version 5.', 'timeFrame': 'From enrollment to the end of treatment at 1 week'}]","[{'measure': 'Biodistribution assessed by SPECT/CT images', 'description': 'To determine the biodistribution and radiation dosimetry of 111In-XYIMSR-01', 'timeFrame': 'From enrollment to the end of treatment at 1 week'}, {'measure': 'Radiation Dosimetry assessed by SPECT/CT images', 'description': 'To determine radiation dosimetry of 111In-XYIMSR-01', 'timeFrame': 'From enrollment to the end of treatment at 1 week'}, {'measure': 'Total Radioactivity Concentration of 111In-XYIMSR-01 in Plasma Over Time', 'description': 'To quantify the total radioactivity (expressed in counts per minute \\[CPM\\]) in plasma samples at specified time points following injection of 111In-XYIMSR-01', 'timeFrame': 'From enrollment to the end of treatment at 1 week'}, {'measure': 'Number of lesions detected', 'description': 'Investigating the role of 111In-XYIMSR-01 SPECT/CT as a diagnostic assessment tool in comparison to conventional imaging. To compare the number of lesions detected with 111In-XYIMSR-01 SPECT/CT in comparison to conventional imaging all imaging modalities', 'timeFrame': 'From enrollment to the end of treatment at 1 week'}]",5,18 Years,,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,0,6.0,ESTIMATED,2025-09-01T16:18:19.673562,v2_robust,True,True,False,False,True,
NCT00878449,A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer,A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer,ABT-263,"['ABT-263', 'etoposide/cisplatin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumors,['Solid Tumors'],[],COMPLETED,,2009-10,2011-07,"[{'measure': 'Assess the safety profile of ABT-263 when administered in combination with etoposide/cisplatin in subjects with Cancer.', 'timeFrame': 'Weekly'}, {'measure': 'Characterize the pharmacokinetics of ABT-263 when administered in combination with etoposide/cisplatin .', 'timeFrame': 'Weekly'}, {'measure': 'Determine the maximum tolerable dose (MTD) of ABT-263 when administered in combination with etoposide/cisplatin.', 'timeFrame': 'Weekly'}, {'measure': 'Determine the recommended Phase 2 dose (RPTD) of ABT-263 when administered in combination with etoposide/cisplatin.', 'timeFrame': 'Weekly'}]","[{'measure': 'Evaluate preliminary data regarding progression free survival (PFS).', 'timeFrame': 'Bi-monthly'}, {'measure': 'Evaluate preliminary data regarding objective response rate (ORR).', 'timeFrame': 'Bi-monthly'}, {'measure': 'Evaluate preliminary data regarding time to tumor progression (TTP).', 'timeFrame': 'Bi-monthly'}, {'measure': 'Evaluate preliminary data regarding overall survival (OS).', 'timeFrame': 'Bi-monthly'}, {'measure': 'Evaluate preliminary data regarding duration of overall response.', 'timeFrame': 'Bi-monthly'}, {'measure': 'Evaluate preliminary data regarding Eastern Cooperative Oncology Group (ECOG) performance status.', 'timeFrame': 'Bi-monthly'}, {'measure': 'Evaluate biomarkers', 'description': 'Define the relationship between disease state (related to patient selection and monitoring), B-Cell Lymphoma 2 (Bcl-2) family protein expression, and potential response to the proposed therapy ABT-263 and etoposide/cisplatin.', 'timeFrame': 'Bi-monthly'}]",11,18 Years,,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,1,12.0,ACTUAL,2025-09-01T16:18:19.673593,v2_robust,True,True,True,False,True,
NCT02619149,Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis,Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis,Piperacillin-tazobactam combination product,"['Saline solution', 'Piperacillin-tazobactam combination product', 'Piperacillin-Tazobactam']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Cholecystitis, Acute","['Cholecystitis, Acute']",[],COMPLETED,,2009-03,2018-01,"[{'measure': 'Proportion of positive bacterial cultures', 'description': 'Proportion of patients with bacterial growth in the bile, assessed by culture from the bile assembled perioperatively.', 'timeFrame': '5 days'}]","[{'measure': 'Postoperative hospital stay', 'timeFrame': '5-10 days'}, {'measure': 'Health-related quality of life', 'description': 'Health-related quality of Life measured with SF-3', 'timeFrame': 'One month'}, {'measure': 'Postoperative pain as measured by the McGill Pain Questionnaire', 'description': 'Level of pain as measured by the McGill Pain Questionnaire', 'timeFrame': '3 days'}, {'measure': 'Levels of C-reactive Protein postoperatively', 'description': 'CRP levels measured daily in the postoperative period', 'timeFrame': '3 days'}, {'measure': 'Surgical site infections', 'description': 'Abscesses or superficial wound infections requiring drainage or antibiotic treatment', 'timeFrame': '5-10 days'}, {'measure': 'Infectious complications other than surgical site infections', 'timeFrame': '5-10 days'}]",7,18 Years,,ALL,False,Karolinska Institutet,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:19.673616,v2_robust,True,True,True,False,False,
NCT03761849,A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease",RO7234292,"['Tominersen', 'RO7234292', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Huntingtons Disease,['Huntingtons Disease'],"['HD, RG6042, intrathecal, ASO, antisense oligonucleotide']",COMPLETED,,2019-01-23,2022-03-24,"[{'measure': ""Change From Baseline in the Composite Unified Huntington's Disease Rating Scale (cUHDRS) Score-Z Score"", 'description': ""cUHDRS includes the Total Functional Capacity (range, 0-13; higher score means better functioning), Total Motor Score (range, 0-124; higher score means worse motor severity), Symbol Digit Modality Test (range, 0-110, correctly paired numbers-symbols in 90 seconds; higher score means better cognitive performance), and Stroop Word Reading (range, 0-no max value, correctly read colour words in 45 seconds; higher score means better cognitive performance) scores. A z-score for each test is calculated, which alone can be used to describe relationship between an individual's test score and the mean score of a target population. A z-score of 0 is the mean, and ±1 is 1 standard deviation from the mean. For cUHDRS, z-scores of each test are summed, whereby a higher cUHDRS score is better (score of -3.06-no max value) and a change of ≥1.2 is a meaningful worsening, shown to track functional decline."", 'timeFrame': 'Weeks 21 for ODC and 69 for NDC'}, {'measure': 'Change From Baseline in the Total Functional Capacity (TFC) Score', 'description': 'Total Functional Capacity (TFC) Scores are reported at Weeks 21 and 69. Total Functional Capacity Score ranges from 0 to 13, with a higher score representing better functioning.', 'timeFrame': 'Weeks 21 for ODC and 69 for NDC'}]","[{'measure': 'Change From Baseline in Total Motor Score (TMS)', 'description': 'The TMS score is the sum of the individual motor ratings obtained from administration of the 31-item motor assessment. The score ranges from 0 to 124, with a higher score representing more severe impairment.', 'timeFrame': 'Weeks 21 for ODC and 69 for NDC'}, {'measure': ""Change From Baseline in Symbol Digit Modalities Test (SDMT) Scores' Least Squares Mean Values"", 'description': 'Symbol Digit Modality Test -SDMT test measures the number of items correctly paired maximum of 110 correct pairs in 90 seconds, more correctly paired items representing less impairment.\n\nThe differences in LS mean ( +/-SE) change from baseline SDMT score between the active groups compared with the placebo group at Weeks 21 and 69 were reported. A negative change from baseline in the SDMT indicates disease progression.\n\nThe Least Square Mean values of Symbol Digit Modality Test Scores are reported below.\n\nThe minimum range for the SDMT scale is 0, indicating highest severity. A max number is not possible as it is a time based task, based on the number of correct answers within a set time frame. There are no validated SDMT score thresholds to indicate the level of HD symptom severity.', 'timeFrame': 'Weeks 21 for ODC and 69 NDC'}, {'measure': ""Change From Baseline in Stroop Word Reading (SWR) Test Scores' Least Squares Mean Values"", 'description': 'Stroop Word Reading-SWR number of words and colors read correctly is counted, with a higher score indicating better cognitive performance scores. There is no upper limit for SWR as it is a time based task. The lower limit (worst possible) however is 0; higher score is better meaning less severity.\n\nThe differences in LS mean ( +/-SE) change from baseline SWR score between the active groups compared with the placebo group at Weeks 21 and 69 were reported. A negative change from baseline in the SWR indicates disease progression.\n\nThe Least Square Mean values of Stroop Word Reading (SWR) Test Scores are reported below.', 'timeFrame': 'Weeks 21 for ODC and 69 for NDC'}, {'measure': ""Change From Baseline in the Clinical Global Impression, Severity Scale (CGI-S) Scores' Least Squares Mean Values"", 'description': 'The CGI-S is a single-item measure of current global severity and is completed by the clinician at specified clinic visits. The CGI-S is assessed using an 11-point numeric rating scale (NRS), where higher scores indicate greater severity. Only NDC participants data were reported, all other data were not available.\n\nCGI-S) Scores range from 0 (not at all severe) to 10 (Extremely severe); lower score is better meaning less severity.', 'timeFrame': 'Week 69 for NDC Only'}, {'measure': 'Percentage of Patients With a Decrease From Baseline of >=1 Point on the Total Functional Capacity (TFC) Score', 'description': 'Only NDC participant data are available and reported. Total Functional Capacity-TFC score ranges from 0 to 13, with a higher score representing better functioning.\n\nIn this outcome measure, participants with 1 or higher point score decrease from the Baseline TFC Total Score was considered. The Percentage of these participants with such a change was calculated.', 'timeFrame': 'Week 69 for NDC only'}, {'measure': ""Percentage of Patients With a Decline From Baseline of >=1.2 Points on the Composite Unified Huntington's Disease Rating Scale-cUHDRS Score"", 'description': ""Only NDC participant data are available and reported. The cUHDRS is comprised of the sum scores of the subscales, score ranges and severities mentioned in the Outcome Measure Description 1 (please see above).\n\nIn this outcome measure, participants with 1.2 or higher point score decrease from the Baseline Composite Unified Huntington's Disease Rating Scale- cUHDRS Total Score was considered. The Percentage of these participants with such a change was calculated.\n\ncUHDRS lowest (worst) score possible value is -3.06 but no upper limit as it involves SWR; higher score is better meaning less severity."", 'timeFrame': 'Week 69 for NDC Only'}, {'measure': 'Percentage of Patients With an Unchanged or Improved Score on the Clinical Global Impression, Change Scale Score', 'description': 'The Clinical Global Impression, Change - CGI-C Scale is a single-item measure of change in global status scale and total scores are summed and reported. The CGI-C has 7 response options: ""very much worse,"" ""much worse,"" ""minimally worse,"" ""no change,"" ""minimally improved,"" ""much improved,"" and ""very much improved."" ""Yes"", ""No"" responses collected and total scores are summed and reported below. Percentage of participants who have unchanged or improved scores from the Baseline CGI-C Scores are calculated and reported here.\n\nTotal CGI-C scores range from 1 (Very much improved) to 7 (Very much worse); lower score is better meaning less severity. Only NDC Arms data were available. Minimum and maximum values are 1 and 7 respectively.', 'timeFrame': 'Weeks 53 and 69 NDC only'}, {'measure': 'Percentage of Participants With Adverse Events', 'timeFrame': 'Up to 117 Weeks (29 months)'}, {'measure': 'Change From Baseline in Montreal Cognitive Assessment (MoCA)', 'description': 'ODC Week 21 and NDC Week 69 data were reportable. Total MOCA scores are reported. The MoCA is a patient-completed assessment used to detect cognitive impairment. It contains a series of basic assessments, including attention and visuospatial tasks. The total score ranges from 0-30, where lower scores indicate greater impairment.', 'timeFrame': 'Up to Week 21 for ODC, Up to Week 69 for NDC'}, {'measure': 'Percentage of Participants With Suicidal Ideation or Behavior, as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score', 'description': 'SI-Suicidal Idealation. For ODC, only Treatment Emergent Suicide-Related Events Based on the Columbia-Suicide Severity Rating Scale (CSSRS) are reported. Four constructs are measured: severity of ideation, intensity of ideation, behavior, and lethality of actual suicide attempts. Binary (yes/no) data are collected for 10 categories, and composite endpoints based on the categories are followed over time to monitor patient safety (Posner et al. 2011). It maps to the Columbia-Classification Algorithm for Suicide Assessment and meets the criteria listed in the U.S. FDA draft guidance for assessment of suicidality in clinical trials (FDA 2012). The higher scores indicate higher severity', 'timeFrame': 'For ODC at 13th Month, for NDC at Week 101'}, {'measure': 'Concentration of RO7234292 in Plasma', 'description': 'Concentration of tominersen in plasma reported', 'timeFrame': 'Week 21 for ODC and Week 69 for NDC'}, {'measure': 'Trough Concentration of RO7234292 in Cerebrospinal Fluid (CSF)', 'description': 'Tominersen concentrations in cerebrospinal fluid', 'timeFrame': 'Week 21 for ODC and Week 69 for NDC'}, {'measure': 'Incidence of Anti-Drug Antibodies (ADAs).', 'description': 'Data at Weeks 21 and 69 for Old Design and New Design Cohorts are reported respectively. All other timepoints were not evaluable and not meaningful.', 'timeFrame': 'Week 21 for ODC and Week 69 for NDC'}, {'measure': 'Titer and Antibody Subtype, Determined if ADAs Are Identified', 'description': ""Titer and Antibody Subtype was not analyzed and there is not data to report due to participants' discontinuation"", 'timeFrame': 'Week 21 for ODC and Week 69 for NDC'}, {'measure': 'Change From Baseline in CSF mHTT Protein Level', 'description': 'Data to be reported within 12 months after the primary completion.', 'timeFrame': 'Baseline, Week 101'}, {'measure': 'Change From Baseline in Whole and Regional Brain Volumes, as Detrmined by Structural Magnetic Resonance Imaging (MRI)', 'description': 'Data reported only for ODC Arms. Analysis of Percent Change from Baseline in Volumetric MRI / BSI at 3 Months reported. Analysis performed using analysis of covariance with covariates of CAP, CAG, Age at Baseline and treatment included.\n\nAnalysis of Change from Baseline in: Caudate Volume (mL)', 'timeFrame': 'Week 13 for ODC'}, {'measure': 'Change From Baseline in CSF Neurofilament Light Chain (NfL) Proteint Level', 'timeFrame': 'Week 21 for ODC, Weeks 21 and 69 for NDC'}]",19,25 Years,65 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,899.0,ACTUAL,2025-09-01T16:18:19.673650,v2_robust,True,True,True,False,True,
NCT02966249,"Dexmetomidine Intrathecally and Intravenously Additionally to Spinal Anaesthesia, in Total Knee Arthroplasty","Comparison of Dexmetomidine's Efficacy as an Adjuvant to Intrathecal Levobupivacaine and Intravenous Administration Additionally to Spinal Anaesthesia, In Total Knee Arthroplasty",Levobupivacaine,"[""Ringer's Lactate solution intravenously"", 'LB', 'Normal Saline added intrathecally', 'DEX', 'R/L', 'Dexmetomidine intravenously', 'Dexmetomidine intrathecally', 'N/S', 'Levobupivacaine', 'Normal Saline intrathecally']",10,INTERVENTIONAL,['PHASE4'],PHASE4,,Neuromuscular Block,['Neuromuscular Block'],"['dexmetomidine, intrathecally, intavenously,anesthesia']",UNKNOWN,,2016-10,2017-09,"[{'measure': ""Onset and duration of sensory block using the ' pin-prick ' method,in total knee athroplasty, using DEX as an adjuvant to intrathecal Levobuvicaine and iv administration additionally to spinal anesthesia with Levobuvicaine"", 'description': ""By using a hypodermic needle at 2 min interval, we will assess the 'pin-prick' sensation from T12 to S1 The onset of sensory block will be tested by 'pin-prick method' using a hypodermic needle at 2 minutes interval. The time of onset will be taken from the time of injection of drug into subarachnoid space to loss of pinprick sensation to T12 level. We study 90 patients(ASAI-II) devided in 3 groups and we measure the highest level of sensory block, time for two dermatomal segments regression of sensory level, duration of sensory blockade taken as time from onset to time of return of pinprick sensation to S1 (heel) dermatomal area will be noted."", 'timeFrame': 'The time of onset will be taken from the time of injection of drug intrathecally to loss of pinprick sensation to T12 within 30 min. Duration of sensory blockade will be measured as time from onset to time of return of piniprick sensation to S1 level.'}, {'measure': 'Onset and duration of motor block using the Modified Bromage Scale, in total knee athroplasty, using DEX as an adjuvant to intrathecal Levobuvicaine and iv administration additionally to spinal anesthesia with Levobuvicaine', 'description': 'By using the Modified Bromage Scale we will assess the onset and duration of motor block. Grade 0 : Full flexion of knees and feet. Grade 1: Just able to flex knees, full flexion of feet. Grade 2: Unable to flex knees, but some flexion of feet possible. Grade 3; Unable to move legs or feet.', 'timeFrame': ""Onset time will be taken from the time of injection of drug intrathecally to the patient's inability to lift the extended leg within 30 min. The duration will be taken from time of injection of drug to the patient's ability to lift the extended leg.""}, {'measure': 'Duration of post-operative analgesia using the Visual Analogue Scale (VAS), in total knee arthroplasty, using DEX as an adjuvant to intrathecal Levobuvicaine and iv administration additionally to spinal anesthesia with Levobuvicaine', 'description': ""VAS is a scale from 0 to 10, with 0 indicating 'no pain' and 10 indicating the most severe pain, that somebody has experienced. Rescue analgesics will be given to the patients when VAS\\>3, which will be the cut-off point of our study."", 'timeFrame': 'We will record the post-operative analgesia using the Visual Analogue Scale (VAS) at the end of the surgery and 3, 6, 12,24 hours after the end of the surgeryn and at the end of the surgery. an interval of 3, 6 ,and 12 h after surgery'}]","[{'measure': 'Hemodynamic stability of DEX, used as an adjuvant to intrathecal Levobupivacaine and intravenous administration additionally to spinal anesthesia, in total knee arthroplasy', 'description': 'We will record SAP intra-operatively', 'timeFrame': 'SAP will be recorded at the time of the spinal injection, 10, 20, 30,45, 60 min after spinal injection and at the end of the surgery.'}, {'measure': 'Hemodynamic stability of DEX, used as an adjuvant to intrathecal Levobupivacaine and intravenous administration additionally to spinal anesthesia, in total knee arthroplasy', 'description': 'We will record DAP intra-operatively', 'timeFrame': 'DAP will be recorded will be recorded at the time of the spinal injection, 10, 20, 30,45, 60 min after spinal injection and at the end of the surgery.'}, {'measure': 'Hemodynamic stability of DEX, used as an adjuvant to intrathecal Levobupivacaine and intravenous administration additionally to spinal anesthesia, in total knee arthroplasy', 'description': 'We will record HR intra-operatively', 'timeFrame': 'HR will be recorded will be recorded at the time of the spinal injection, 10, 20, 30,45, 60 min after spinal injection and at the end of the surgery.'}, {'measure': 'Adverse effects of DEX, used as an adjuvant to intrathecal Levobupivacaine and intravenous administration additionally to spinal anaesthesia with Levobupivacaine, in total knee arthroplasy', 'description': 'We will record adverse effects like nausea, vomitting and shivering.', 'timeFrame': 'Adverse effects will be recorded will be recorded at the time of the spinal injection, 15, 30, 60 min after spinal injection, at the end of the surgery and 3, 6, 12, 24 hours after the end of the surgery'}, {'measure': 'Sedation will be assessed with the Ramsay Sedation Scale, in total knee arthroplasty, by using DEX as an adjuvant to intrathecal Levobupivacaine and intravenous administration additionally to spinal anesthesia with Levobuvicaine', 'description': 'The Ramay Sedation Scale is : If awake : Ramsay 1 Anxious, agitated, restless Ramsay 2 Co-operative, oriented,tranquil, Ramsay 3 Responsive to commands only. If asleep: Ramsey 4 Brisk response to light glabellar tap or loud auditory stimulus Ramsey 5 Sluggish response to light glabellar tap or loud auditory stimulus Ramsey 6 No response to light glabellar tap or loud auditory stimulus', 'timeFrame': 'Sedation scores will be assessed will be recorded at the time of the spinal injection, 10, 20, 30,45, 60 min after spinal injection, at the end of the surgery and 30 minutes after the end of the surgery'}]",8,18 Years,85 Years,ALL,False,KAT General Hospital,OTHER,0,90.0,ESTIMATED,2025-09-01T16:18:19.673765,v2_robust,True,True,False,False,True,
NCT05704049,A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma,"A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)",Isatuximab,"['Dexamethasone IV', 'Diphenhydramine', 'Kyprolis', 'Acetaminophen', 'Montelukast', 'Isatuximab', 'Carfilzomib', 'Dexamethasone', 'Methylprednisolone']",9,INTERVENTIONAL,['PHASE2'],PHASE2,,Relapsed/Refractory Multiple Myeloma,['Relapsed/Refractory Multiple Myeloma'],[],RECRUITING,,2023-04-05,2028-05-12,"[{'measure': 'Overall response rate (ORR) - Cohorts 1 to 3', 'description': 'ORR defined as the proportion of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to the 2016 International Myeloma Working Group (IMWG) criteria assessed by Independent Review Committee (IRC).', 'timeFrame': '6 months after the Last Participant In (LPI) i.e., approximately 16 months'}, {'measure': 'Maximum observed concentration (Cmax) over Cycle 1- Cohorts 4 to 5', 'timeFrame': 'Cycle 1 (28 days)'}, {'measure': 'Cumulative area under the curve over the first 4 weeks (AUC4weeks) of isatuximab treatment- Cohorts 4 to 5', 'timeFrame': 'Cycle 1 (28 days)'}]","[{'measure': 'Proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6', 'description': 'Patient preference for method of administration defined as the proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6 using the patient experience and satisfaction questionnaire version 2 (PESQ v2).', 'timeFrame': '6 months from LPI i.e., approximately 16 months'}, {'measure': 'Incidence rate of infusion reactions (IRs)', 'timeFrame': 'From the signing of the informed consent to 30 days following the last administration of any study treatment i.e., up to approximately 45 months'}, {'measure': 'Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and changes in laboratory parameters', 'timeFrame': 'From the signing of the informed consent to 30 days following the last administration of any study treatment i.e., up to approximately 45 months'}, {'measure': 'Incidence rate of injection site reactions (ISRs)', 'timeFrame': '18 months after LPI i.e., approximately 28 months'}, {'measure': 'PK concentration: trough plasma concentration (Ctrough)', 'description': 'Blood samples will be collected for measurement of isatuximab concentrations.', 'timeFrame': 'Cycle 2 Day 1 and Cycle 6 Day 1 (1 Cycle = 28 days)'}, {'measure': 'Overall response rate (ORR)', 'description': 'Proportion of participants with sCR, CR, VGPR, and PR according to the 2016 IMWG criteria assessed by investigator.', 'timeFrame': '6 months after the Last Participant In (LPI) i.e., approximately 16 months'}, {'measure': 'Duration of response (DOR)', 'description': 'DOR defined as time from date of first IRC-determined response for participants achieving PR or better to first documentation of progressive disease (PD) determined by IRC or death, whichever occurred first, for Cohorts 1 to 3. For Cohorts 4-5, the time from date of first investigator determined response for participants achieving PR or better to first documentation of progressive disease (PD) determined by investigator or death, whichever occurred first.', 'timeFrame': '6 months after the Last Participant In (LPI) i.e., approximately 16 months'}, {'measure': 'Time to first response (TT1R)', 'description': 'TT1R defined as time from first investigational medicinal product (IMP) administration or randomization to first IRC determined response (PR or better) that is subsequently confirmed, for Cohorts 1 to 3. For cohorts 4-5, the time from first IMP administration or randomization to first investigator determined response (PR or better) that is subsequently confirmed.', 'timeFrame': '6 months after the Last Participant In (LPI) i.e., approximately 16 months'}, {'measure': 'Time to best response (TTBR)', 'description': 'TTBR defined as time from first IMP administration or randomization to first occurrence of IRC determined best response (PR or better) that is subsequently confirmed, for Cohorts 1 to 3. For cohorts 4-5, the time from first IMP administration or randomization to first occurrence of investigator determined best response (PR or better) that is subsequently confirmed.', 'timeFrame': '6 months after the Last Participant In (LPI) i.e., approximately 16 months'}, {'measure': 'Progression free survival (PFS)', 'description': 'PFS defined as time from the date of first IMP administration or randomization to the date of first documentation of PD as determined by IRC for Cohorts 1 to 3 and by Investigator for all cohorts, or the date of death from any cause, whichever comes first.', 'timeFrame': '18 months after LPI i.e., approximately 28 months'}, {'measure': 'Overall survival (OS)', 'description': 'OS defined as time from the date of first IMP administration or randomization to death from any cause.', 'timeFrame': '18 months after LPI i.e., approximately 28 months'}, {'measure': 'Incidence of participants with anti-drug antibodies (ADA) against isatuximab', 'timeFrame': 'From Cycle 1 Day 1 to follow-up (90 days from last administration) i.e., approximately 13 months (1 Cycle = 28 days)'}, {'measure': 'Patient Expectations Questionnaire at Baseline (PEQ-BL v2) with isatuximab administered subcutaneously', 'description': 'PEQ-BL v2 is a participant assessed questionnaire. It will be completed at baseline prior to study treatment administration or other study related procedures. This questionnaire has been designed to assess the expectations of the participants regarding both the treatment (side effects, worth taking) and the administration method (confidence, comfortability, pain, side effects, potential time-savings), as well as to understand previous treatment experience from the participant (experience with injection methods for oncology medication).', 'timeFrame': 'Baseline'}, {'measure': 'Patient experience and satisfaction questionnaires (PESQ v2) with isatuximab administered subcutaneously', 'description': 'PESQ v2 is a participant assessed questionnaire. It has been designed to follow up on participant experience and satisfaction regarding the treatment (side effects, worth taking and overall satisfaction) and the administration method (confidence, comfortability, pain, side effects, potential time-savings and overall satisfaction). The PESQ v2 includes items to assess preference on subcutaneous injection method. This questionnaire has been developed using industry standard for instrument development and has been debriefed and adapted based on qualitative interviews with oncology patients. The more general treatment expectations instrument (v1) was further adapted and debriefed with patients to assess manual and OBDS subcutaneous delivery (v2). The PESQ v2 contains a total of 9 items. There are 6 items that are administered for the duration of treatment, and 3 preference items administered only after patient experience of both manual and OBDS.', 'timeFrame': '18 months after LPI i.e., approximately 28 months'}, {'measure': 'Health state utility assessed using Health Resource Utilization and Productivity Questionnaire (HRUPQ)', 'description': 'Medical resource utilization and participant productivity will be collected from participants through a specific questionnaire developed by Sanofi for cohorts 1,2, 3, and 5. The data collected include number, nature (emergency or routine) and duration of hospitalizations, emergency room visits and outpatient medical encounters and employment history.', 'timeFrame': '18 months after LPI i.e., approximately 28 months'}, {'measure': 'Health Related Quality of Life (HRQL)', 'description': 'HRQL is assessed for cohorts 1, 2, and 3 using the European Organization for Research and Treatment of Cancer (EORTC) myeloma module with 20 items (QLQ-MY20) and EORTC quality of life questionnaire with 30 questions (QLQ-C30); a total of 50 items. The EORTC QLQ-C30 provides a comprehensive assessment of the principal HRQL dimensions identified as relevant by cancer patients. The EORTC QLQ-MY20 is to be used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impact HRQL in participants with MM.', 'timeFrame': '18 months after LPI i.e., approximately 28 months'}, {'measure': 'European Quality of Life Group questionnaire with 5 dimensions and 5 levels per dimension (EQ-5D-5L)', 'description': ""Health status is assessed for cohorts 1, 2, and 3, using the EQ-5D-5L, a standardized measure of health status that provides a simple, generic measure of health utility, and consists of 2 sections: descriptive and VAS. The descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The VAS records the respondent's self-rated health on a 20 cm vertical VAS with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. This information can be used as a quantitative measure of health as judged by the individual respondents."", 'timeFrame': '18 months after LPI i.e., approximately 28 months'}]",20,18 Years,,ALL,False,Sanofi,INDUSTRY,0,118.0,ESTIMATED,2025-09-01T16:18:19.673845,v2_robust,True,True,False,False,True,
NCT04285749,Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas,Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas,Fluvastatin,['Fluvastatin'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Malignant Melanoma,['Malignant Melanoma'],[],WITHDRAWN,PI moving to new institution prior to study activation,2020-11-06,2021-04-01,"[{'measure': 'Genetic profile shift in melanoma transcriptome', 'description': 'The study team will report which of the 28 genes had significant expression changes. A 2-fold change in the appropriate direction with a p-value of at least 0.05 will be considered significant for potential therapeutic value. P-values will be corrected for the false discovery rate using the Benjamini-Hochberg procedure. Fluvastatin successful in shifting the genetic profile in a therapeutic manner if at least half of the 28 genes have significant expression changes', 'timeFrame': 'Two weeks'}]","[{'measure': 'Number of patients who convert from Class 2 to Class 1', 'description': 'Number of patients who convert from Class 2 to Class 1 profile on retesting', 'timeFrame': 'Two weeks'}]",2,18 Years,99 Years,ALL,False,Case Comprehensive Cancer Center,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:19.673923,v2_robust,True,True,False,True,False,PI moving to new institution prior to study activation
NCT05362149,"An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings","DEAR: Use of Darolutamide, Enzalutamide and Apalutamide in the Real-world for Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)","Darolutamide (Nubeqa, BAY1841788)","['Darolutamide (Nubeqa, BAY1841788)', 'Apalutamide', 'Enzalutamide']",3,OBSERVATIONAL,[],,,Non-metastatic Castration-resistant Prostate Cancer,['Non-metastatic Castration-resistant Prostate Cancer'],[],COMPLETED,,2022-04-04,2023-06-30,"[{'measure': 'Composite event of treatment discontinuation/progression', 'timeFrame': 'Retrospective analysis from 01-Aug-2019 to 31-Mar-2022'}]","[{'measure': 'Time to Composite event of discontinuation/progression', 'timeFrame': 'Retrospective analysis from 01-Aug-2019 to 31-Mar-2022'}, {'measure': 'Treatment Discontinuation (non-composite event) of index treatment', 'timeFrame': 'Retrospective analysis from 01-Aug-2019 to 31-Mar-2022'}, {'measure': 'Time to treatment discontinuation (days) (non-composite event) of each treatment cohort', 'description': 'Time from index date (first SGARI initiation) to the date medication was discontinued. Patients will be censored if they discontinued from study for any reason other than death or disease progression, e.g., lost to follow-up or end of study period or if patients had their care transferred, or were admitted to hospice.', 'timeFrame': 'Retrospective analysis from 01-Aug-2019 to 31-Mar-2022'}, {'measure': 'Reason for discontinuation of each treatment cohort', 'description': 'Reasons for discontinuation (if available) will be ascertained from patient charts summarized by SGARI group using frequencies and percentages, and will be grouped into the following categories: AE-related; Cost-related; Metastatic disease; Death; Other; Unknown.', 'timeFrame': 'Retrospective analysis from 01-Aug-2019 to 31-Mar-2022'}, {'measure': 'Proportion of patients switching to another SGARI therapy of each treatment cohort', 'description': 'Switching will be defined as switching from one SGARI to another, within 60 days from date of discontinuation of the first SGARI. If the structured data or patient charts indicate that another SGARI was prescribed, then the patient would be considered to have discontinued on the previous treatment.', 'timeFrame': 'Retrospective analysis from 01-Aug-2019 to 31-Mar-2022'}, {'measure': 'Dose changes during the follow-up period of each treatment cohort', 'description': 'All dose reductions or increases prescribed during the follow-up period will be recorded.', 'timeFrame': 'Retrospective analysis from 01-Aug-2019 to 31-Mar-2022'}, {'measure': 'Dose intensity during the follow-up period of each treatment cohort', 'description': 'Dose intensity will be estimated as the ratio of the actual dose given throughout the follow-up period, divided by the amount that should have been prescribed according to the initial dose.', 'timeFrame': 'Retrospective analysis from 01-Aug-2019 to 31-Mar-2022'}, {'measure': 'Frequency of all types of AEs of each treatment cohort', 'description': 'AEs during the index treatment will be identified from patient charts and supplemented with diagnosis codes from structured data. Frequency of all AEs, frequency of AEs of special interest (falls, fractures, rash, cognitive disorders, hypertension and fatigue) and of AEs leading to discontinuation will be described.', 'timeFrame': 'Retrospective analysis from 01-Aug-2019 to 31-Mar-2022'}]",9,18 Years,,MALE,False,Bayer,INDUSTRY,0,870.0,ACTUAL,2025-09-01T16:18:19.673936,v2_robust,False,True,True,False,False,
NCT06498349,Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl,A Randomized Controlled Trial of Bilateral Subthalamic Stimulation in Patients With Parkinson's Disease and Impulse Control Disorders,best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations,['best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations'],1,INTERVENTIONAL,['NA'],,,Parkinson Disease,"['Parkinson Disease', 'Impulse Control Disorders']",[],RECRUITING,,2024-09-05,2028-07-15,"[{'measure': ""Ardouin Scale of Behaviour in Parkinson's Disease (ASBPD)"", 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups with respect to the hyperdopaminergic sub-score', 'timeFrame': '12 months'}]","[{'measure': 'Questionnaire for Impulsive-Compulsive Disorders in Parkinson Disease Rating Scale (QUIP RS)', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Starkstein-Apathy-Scale (SAS)', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Hospital Anxiety and Depression Scale (HADS)', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Beck Depression Inventory (BDI)', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'suicidal item 9 of the BDI', 'description': 'safety focus on suicidal item 9 of the BDI with reference to the question for the last 2 months', 'timeFrame': '12 months'}, {'measure': 'Neuropsychiatric-fluctuations scale (NFS)', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Young mania rating scale (YMRS)', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Quality of life (PDQ-39) measured by Parkinson Disease Questionaire-39 Summary Index', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Zarit Burden Interview ( ZIB) for the change of burden assessment in caregivers using the brief version', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': ""MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (parts I-IV med on/med off and stim on/stim off; if applicable"", 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Marconi Dyskinesia Rating Scale', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Levodopa-equivalent/dopamine-agonist dosage (LEDD) and other medication', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Pittsburgh Sleep Quality Index (PSQI)', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Safety weight monitoring (BMI control)', 'description': 'Difference of change from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Montreal Cognitive Assessment (MoCA)', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Clinical Global Impression (CGI-S, Severity) (CGI-C, Change)', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Patient Global Impression (PGI-S, Severity) (PGI-C, Change)', 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': ""Parkinson's disease Dysarthria Compound Score (PD-DCS) (Speech assessment)"", 'description': 'Difference of change (improvement) from baseline to follow-up between the two treatment groups', 'timeFrame': '12 months'}, {'measure': 'Adverse events', 'description': 'Reporting and analysis of adverse events: Frequency, type and severity of therapy related relevant adverse events of medication or DBS', 'timeFrame': '12 months'}, {'measure': ""Parkinson's disease Dysarthria Compound Score (PD-DCS)"", 'description': ""An intra-group comparison will be performed between the individual patient's safety speech outcome of Parkinson's disease Dysarthria Compound Score (PD-DCS) The PD-DCS is a speech acoustic summary measure of the main speech affected domains in PD, namely monopitch, monoloudness, imprecise consonants, inappropriate silences, harsh/breathy voice, and speech timing abnormalities. Acoustic proxy measures of these perceptual speech domains can be extracted from speech using modern acoustic speech analysis."", 'timeFrame': '12 months'}]",21,18 Years,70 Years,ALL,False,University of Kiel,OTHER,6,60.0,ESTIMATED,2025-09-01T16:18:19.674020,v2_robust,True,True,False,False,True,
NCT00446849,Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC),"A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC)",MMX Mesalamine,"['Lialda', 'MMX Mesalamine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Ulcerative Colitis,['Ulcerative Colitis'],"['ulcerative colitis', 'compliance', 'mesalamine', 'clinical study', 'clinical trial', 'clinical research', 'maintenance', 'long term', 'uc study', 'uc trial', 'uc research', 'open label', 'once a day', 'once', 'daily', 'daily dosing', 'simple', 'oral']",COMPLETED,,2007-05-01,2009-08-17,"[{'measure': 'Clinical Recurrence of Ulcerative Colitis (UC) During the Maintenance Phase at 6 Months', 'description': ""Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding."", 'timeFrame': '6 months'}]","[{'measure': 'Clinical Recurrence of UC During the Maintenance Phase at 12 Months', 'description': ""Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding."", 'timeFrame': '12 Months'}, {'measure': 'Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 6 Months', 'description': ""Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. Compliance is a subject's adherence to a recommended course of treatment and for this study is calculated: \\[(Sum of days' supplies dispensed) divided by (Sum of days in all refill intervals)\\] x 100."", 'timeFrame': '6 Months'}, {'measure': 'Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 12 Months', 'description': ""Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. Compliance is a subject's adherence to a recommended course of treatment and for this study is calculated: (Sum of days' supplies dispensed) divided by (Sum of days in all refill intervals) x 100."", 'timeFrame': '12 months'}, {'measure': 'Quiescent UC During the Maintenance Phase at 12 Months', 'description': 'Quiescent UC is defined as scores of 0 for both rectal bleeding and bowel movements. Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Bowel movements are assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day).', 'timeFrame': '12 Months'}, {'measure': 'Endoscopic Remission of UC During the Maintenance Phase at 12 Months', 'description': 'Endoscopic remission is defined as an endoscopy score of less than or equal to 1. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal \\[intact vascular pattern; no friability or granulation\\], 1 = mild \\[erythema; decreased vascular pattern; minimal granularity\\], 2 = moderate \\[marked erythema; granularity; friability; absent vascular pattern; bleeding with minimal trauma; no ulcerations\\], 3 = severe \\[ulceration; spontaneous bleeding\\].', 'timeFrame': '12 Months'}]",6,18 Years,,ALL,False,Shire,INDUSTRY,0,290.0,ACTUAL,2025-09-01T16:18:19.674036,v2_robust,True,True,True,False,False,
NCT03510338,Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products,A Pharmacoscintigraphic Clinical Study to Evaluate a Biphasic Release Sildenafil Formulation (With Immediate and Sustained Release Components) Compared to a Marketed Sildenafil Product in Fed and Fasted States,Sublingual sildenafil,"['Oral sildenafil', 'Viagra', 'Sublingual sildenafil', 'N4S001']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Erectile Dysfunction,['Erectile Dysfunction'],[],COMPLETED,,2018-05-08,2018-06-13,"[{'measure': 'Sildenafil plasma concentrations', 'description': 'Measure sildenafil and its main metabolite in plasma and compare pharmacokinetic profiles with that of a marketed sildenafil product in fed and fasted states', 'timeFrame': '24 hours'}]","[{'measure': 'Extent of dispersion', 'description': 'Quantification of extent of dispersion of the immediate release portion of the radiolabelled N4S001 tablet in the oral cavity using gamma scintigraphy', 'timeFrame': '1 hour'}, {'measure': 'Visualisation of kinetics', 'description': 'Quantification the kinetics in the oral cavity of the immediate release portion of the radiolabelled N4S001 tablet using gamma scintigraphy', 'timeFrame': '1 hour'}, {'measure': 'Change in oral examination findings post-dose', 'description': 'Assess changes in the oral cavity following dosing of the N4S001 tablet', 'timeFrame': '1 hour'}, {'measure': 'Blood pressure', 'description': 'Systolic \\& diastolic measurements will be used to assess the effects of the N4S001 tablet compared with the marketed sildenafil product', 'timeFrame': '24 hours'}, {'measure': 'Heart Rate', 'description': 'Measurements will be used to assess the effects of the N4S001 tablet compared with the marketed sildenafil product', 'timeFrame': '24 hours'}, {'measure': 'Questionnaire', 'description': 'Assessment of taste acceptability using a 7-point categorical scale', 'timeFrame': '1 hour'}]",7,18 Years,65 Years,MALE,True,N4 Pharma UK Ltd.,INDUSTRY,1,12.0,ACTUAL,2025-09-01T16:18:19.674251,v2_robust,True,True,True,False,False,
NCT05166538,Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass,"Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass: Prospective, Randomized Controlled Trial",Ticagrelor,"['brilinta', 'Ticagrelor', 'plavix', 'Clopidogrel']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Multi Vessel Coronary Artery Disease,['Multi Vessel Coronary Artery Disease'],"['Antiplatelets', 'Coronary artery bypass surgery']",UNKNOWN,,2022-02-01,2023-12,"[{'measure': 'Early graft patency', 'description': 'graft occlusion rate diagnosed by CT exam, at follow-up angiography, grafts were evaluated by use of the usual definition of patency and were assessed for FitzGibbon patency with the A, B, and O classification system in which FitzGibbon A is an excellent/unimpaired graft, Bis an impaired graft with a stenosis \\>50% reducing the caliber of the graft to \\<50% of the target artery diameter, and O is a completely occluded graft.', 'timeFrame': '1 year after OPCAB'}]","[{'measure': 'degree of resistance', 'description': 'Platelet reactivity was assayed using the VeriofyNowP2Y12 assay (Accumetrics Inc, San Diego, CA) which is a cartridge-based assay that specifically measures the direct effects of clopidogrel on the platelet P2Y12 receptor. The results are expressed as P2Y12 reaction units (PRUs) for clopidogrel. The cut-off PRU value was 188 PRU and the details were described previous study.', 'timeFrame': '7 day after surgery'}, {'measure': 'Number of patients with resistance with clopidogrel as assessed by VeriofyNowP2Y12 assay', 'description': 'The cut-off PRU value was 188 PRU', 'timeFrame': '7 day after surgery'}, {'measure': 'Mediastinal Bleeding', 'description': 'total drainage counts (ml) from median tubes', 'timeFrame': 'up to 4 weeks'}, {'measure': 'Total hospital day from admission to discharge', 'timeFrame': 'up to 4 weeks'}, {'measure': 'rate of postoperative stroke of myocardial infarction', 'timeFrame': 'Participants will be followed during 1 years from operation'}, {'measure': 'rate of postoperative morbidity/ mortality', 'timeFrame': 'Participants will be followed during 5 years from operation'}]",7,19 Years,85 Years,ALL,False,Yonsei University,OTHER,0,204.0,ESTIMATED,2025-09-01T16:18:19.674495,v2_robust,True,True,False,False,False,
NCT00032838,Effects of Stress Hormones on Emotion and Cognition,The Effects of Cortisol and Norepinephrine Modulation on Emotional and Nonemotional Processing,Yohimbine,['Yohimbine'],1,OBSERVATIONAL,[],,,Healthy,['Healthy'],"['Hydrocortisone', 'Yohimbine', 'Cognition', 'Norepinephrine', 'Cortisol', 'Emotion', 'Healthy Volunteer', 'HV', 'Normal Control']",COMPLETED,,2002-03,2006-01,[],[],0,,,ALL,True,National Institute of Mental Health (NIMH),NIH,0,170.0,,2025-09-01T16:18:19.674518,v2_robust,False,True,True,False,False,
NCT00366938,Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).,"A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator",Lumiracoxib,['Lumiracoxib'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,"Osteoarthritis, Knee","['Osteoarthritis, Knee']","['Osteoarthritis, lumiracoxib, celecoxib, Cox-2']",COMPLETED,,2003-09,,"[{'measure': 'Overall OA pain intensity in the target knee using a 0-100 mm Visual Analogue Scale (VAS), at week 13.'}, {'measure': ""Patient's global assessment of disease activity using a 0-100 mm VAS, at week 13.""}, {'measure': ""Patient's functional status using Western Ontario and McMaster Universities Arthritis Index (WOMAC©) total score, at week 13.""}]","[{'measure': 'Overall OA pain intensity in the target knee using 0-100 mm VAS, at weeks 2, 4, 8.'}, {'measure': ""Patient's global assessment of disease activity using 0-100 mm VAS, at weeks 2, 4, 8.""}, {'measure': ""Patient's functional status using WOMAC© Likert 3.1 sub-scale scores and total score, at weeks 2, 8, 13.""}, {'measure': ""Patient's health status using the Short Form-36 (SF-36), at week 13.""}, {'measure': ""Physician's global assessment of disease activity using 0-100 mm VAS, at weeks 2, 4, 8.""}]",8,18 Years,,ALL,,Novartis,INDUSTRY,0,1464.0,,2025-09-01T16:18:19.674524,v2_robust,True,True,True,False,False,
NCT00607438,A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer,A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer,Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane),"['Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)', 'Abraxane', 'Sorafenib (Nexavar)', 'Nexavar']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],['Locally Advanced or Metastatic'],TERMINATED,Low accrual,2007-09,2009-05,"[{'measure': 'To evaluate the progression-free survival (PFS)and duration of response of the combination of weekly Abraxane and continuous Nexavar as first-line treatment for patients with locally advanced or metastatic breast cancer.', 'timeFrame': 'Survival every 3 months for two years starting from the end of study date. Duration of response every 8 weeks while on treatment.'}]","[{'measure': 'To evaluate the response rate.', 'timeFrame': 'Every 8 weeks while on study treatment.'}, {'measure': 'Evaluate the 1 and 2 year survival rate.', 'timeFrame': 'Every 3 months for 2 years starting from the end of therapy visit date'}, {'measure': 'Evaluate the toxicities of the combination of Abraxane and Nexavar', 'timeFrame': 'At each clinic visit or if reported by subject.'}]",4,18 Years,,ALL,False,Veeda Oncology,OTHER,2,16.0,ACTUAL,2025-09-01T16:18:19.674604,v2_robust,True,True,False,True,False,Low accrual
NCT01393158,Apremilast for Atopic Dermatitis - A Pilot Study in Adults,A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults,Apremilast,"['Otezla', 'Apremilast']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Atopic Dermatitis,['Atopic Dermatitis'],[],COMPLETED,,2009-05,2011-07,"[{'measure': 'Change in EASI Scores', 'description': ""The eczema area and severity index (EASI) is a composite score measuring physical signs of atopic dermatitis. The scale ranges from 0-72. The components measuring severity are four signs/symptoms of atopic dermatitis: erythema, population, excoriation and lichenification on a scale of 0-3 for each body of the four body regions (head/neck, trunk, arms, legs). The component measuring area is a body surface area measurement of each region. The area and severity of each body region is weighted based on size of region which are added together for the complete score. The score for each patient's with scores between 0 and 7 are considered mild ,between 7 and 21 are considered moderate, and greater than 21 are considered severe. In this study the change in EASI score between baseline and month three (end of study) in the 20 mg arm and month six in the 30 mg arm, baseline EASI score was subtracted from month 3 or month 6 score in the 30mg arm,and calculated as a final outcome data point."", 'timeFrame': 'Mean change in EASI score measured at Baseline and Month 3, (if on 20mg arm) or Baseline and Month 6 (if on 30mg arm)'}]","[{'measure': 'Number of Participants in Each IGA Category', 'description': 'The investigator global assessment scale is a gestalt global assessment made by an investigator describing the overall disease severity of the patient. It is a categorical scale that includes 0-clear, 1-almost clear, 2-mild,3- moderate, 4-severe, and 5-very severe. The reduction in IGA score from baseline to month three (end of study) in the 20mg arm and month six (end of study) in the 30mg arm was evaluated for efficacy.', 'timeFrame': 'Mean change in IGA score measured at Baseline and Month 3, (if on 20mg arm) or Baseline and Month 6 (if on 30mg arm)'}, {'measure': 'Change in Pruritus (Visual Analog Scale) Score', 'description': ""The pruritus visual analog scale (VAS) is a 10 cm (100 mm) visual analog scale that measures up patient's itch severity with 10 (100 mm) representing the worst imaginable and 0 representing no itch. This is a validated scale with a change of three from baseline to month three in the 20mg arm (end of study) and month six in the 30mg arm (end of study) being clinically relevant."", 'timeFrame': 'Mean change in Pruritus (Visual Analog Scale) score measured at Baseline and Month 3, (if on 20mg arm) or Baseline and Month 6 (if on 30mg arm)'}, {'measure': 'Change In DLQI Scores', 'description': 'The dermatology life quality index (DLQI) is a validated quality-of-life scale that measures the impact of skin disease. It is a 10 question instrument. Scores of 0 over 0-1 means there is no effect on the patient\'s life. Scores between 2 and 5 represent a small effect on patient\'s life. Scores between 6 and 10 correspond to a moderate effect on patient\'s life. Scores between 11 and 20 correspond to a very large effect on the patient\'s life. And scores between 21 and 30 correspond to an extremely large effect on patient\'s life. The range of the scale between 0 and 30 for the added total of the patient\'s responses. Each question can be answered on a scale of 0-""not at all"", 1-""a little"", 2-"" a lot"", 3- ""very much"" with some questions having the option of ""not relevant"". The difference in DLQI score from baseline to month three (end of study) in the 20mg arm and month six (end of study) in the 30mg arm was evaluated for efficacy.', 'timeFrame': 'Mean change in DLQI scores measured at Baseline and Month 3, (if on 20mg arm) or Baseline and Month 6 (if on 30mg arm)'}]",4,18 Years,,ALL,False,Oregon Health and Science University,OTHER,1,16.0,ACTUAL,2025-09-01T16:18:19.674730,v2_robust,True,True,True,False,False,
NCT00216658,"Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -","Open Label Study to Confirm Effectiveness, Safety and Pharmacokinetics of Fentanyl Transdermal Matrix Patch, in Japanese Patients With Cancer Pain Who Have Had a Minimum Amount of Morphine Therapy, Such as Equal to Less Than 45 mg/Day of Oral Morphine or Oxycodone Equal to Less Than 30 mg/Day.",fentanyl,['fentanyl'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Pain, Intractable","['Pain, Intractable']","['Fentanyl', 'Cancer pain', 'Japanese patients']",COMPLETED,,2004-12,2005-09,"[{'measure': ""Patient's global assessments of pain""}]","[{'measure': ""Physician's global assessments, pain intensity (Visual Analog Scale: VAS), pain intensity (categorical scale), total pain duration per day, and dose of rescue medication, Adverse events, laboratory values, and vital signs. Pharmacokinetics""}]",2,20 Years,,ALL,False,Janssen Pharmaceutical K.K.,INDUSTRY,0,87.0,ACTUAL,2025-09-01T16:18:19.674809,v2_robust,True,True,True,False,True,
NCT07110558,Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma,"A Single-arm, Phase II Trial of Radiotherapy Without Prophylactic Neck Irradiation in Combination With Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab for Nasopharyngeal Carcinoma",PD-1 antibody (Toripalimab),"['Cisplatin', 'PD-1 antibody (Toripalimab)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Nasopharyngeal Cancinoma (NPC),['Nasopharyngeal Cancinoma (NPC)'],"['nasopharyngeal carcinoma', 'radiotherapy', 'immunotherapy']",NOT_YET_RECRUITING,,2025-08-15,2032-08-14,"[{'measure': 'Regional relapse-free survival (RRFS)', 'description': 'Defined as the time from registration to documented nodal relapse or non-cancer-specific death.', 'timeFrame': '2 years'}]","[{'measure': 'Progress-free survival (PFS)', 'description': 'Defined as the time from registration to documented disease progression or non-cancer-specific death.', 'timeFrame': '2 years'}, {'measure': 'Overall Survival (OS)', 'description': 'Defined as the time from registration to death from any cause.', 'timeFrame': '2 years'}, {'measure': 'Locoregional Relapse-Free Survival (LRRFS)', 'description': 'Defined as the time from registration to documented locoregional recurrence or non-cancer-specific death.', 'timeFrame': '2 years'}, {'measure': 'Distant Metastasis-Free Survival (DMFS)', 'description': 'Defined from registration to documented distant metastasis or noncancer-specific death.', 'timeFrame': '2 years'}, {'measure': 'Objective Response Rate （ORR）', 'description': 'An objective response is defined as either a confirmed CR or a PR, as determined by the investigator using RECIST v1.1Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI).', 'timeFrame': 'After the completion of the neoadjuvant PD-1 antibody and chemoradiotherapy treatment'}, {'measure': 'Incidence rate of acute and late adverse events (AEs)', 'description': 'Analysis of adverse events (AEs) are based on treatment-related AEs (trAEs) and immune-related AEs (irAEs), and all-grade AEs and grade 3-4 AEs. Acute AEs are evaluated by investigators according to the Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE 5.0). Late radiation toxicities were assessed using the Radiation Therapy Oncology Group (RTOG) and European Organisation for Research and Treatment of Cancer (EORTC).', 'timeFrame': '2 years'}, {'measure': 'Change of QoL (quality of life)', 'description': 'QoL scores were assessed by using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTCQLQ-C30) and Quality-of-Life Head and Neck 35 items (QLQ-H\\&N35) before neoadjuvant PD-1 antibody, before radiotherapy, at the end of radiotherapy, at 6 months after radiotherapy and 12 months after radiotherapy.', 'timeFrame': '1 year'}]",8,18 Years,70 Years,ALL,False,Sun Yat-sen University,OTHER,0,59.0,ESTIMATED,2025-09-01T16:18:19.674819,v2_robust,True,True,False,False,True,
NCT01468558,Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole,A Phase I Evaluation of the Effect of Ketoconazole on the Pharmacokinetics and Safety of Dihydroergotamine Mesylate (DHE) Delivered by Oral Inhalation (MAP0004) in Healthy Volunteers Compared to DHE Delivered Intravenously (DHE 45®),MAP0004,"['IV DHE', 'Nizoral®', 'Ketoconazole', 'MAP0004', 'D.H.E.45®']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],['Drug Drug Interaction Study in Normal Healthy Volunteers'],COMPLETED,,2010-07,2010-08,"[{'measure': 'Cmax of Dihydroergotamine After MAP0004, MAP0004 Co-administered With Ketoconazole, and IV DHE Administration', 'description': 'The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Dihydroergotamine is reported in picograms per milliliter (pg/ml).', 'timeFrame': '48 hours'}, {'measure': 'AUC(0-48) of Dihydroergotamine After MAP0004, MAP0004 Co-administered With Ketoconazole, and IV DHE Administration', 'description': 'The AUC(0-48) is the area under the plot of plasma concentration of drug against time after drug administration. Dihydroergotamine AUC(0-48) is reported in picograms times hour per milliliter (pg\\*h/ml).', 'timeFrame': '48 hours'}]",[],2,18 Years,45 Years,ALL,True,Allergan,INDUSTRY,1,24.0,ACTUAL,2025-09-01T16:18:19.674847,v2_robust,True,True,True,False,False,
NCT02669758,A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia,"A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia",ALKS 3831,['ALKS 3831'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Schizophrenia,['Schizophrenia'],"['Alkermes', 'ALKS 3831', 'Samidorphan', 'Schizophrenia', 'Safety']",COMPLETED,,2016-01-20,2018-06-29,"[{'measure': 'Number of Participants With Adverse Events (AEs)', 'timeFrame': 'Up to 52 weeks'}]",[],1,18 Years,70 Years,ALL,False,"Alkermes, Inc.",INDUSTRY,0,281.0,ACTUAL,2025-09-01T16:18:19.674859,v2_robust,True,True,True,False,True,
NCT03306758,The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Gout,The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Gout,Sodium Bicarbonate,['Sodium Bicarbonate'],1,INTERVENTIONAL,['NA'],,,Asymptomatic Hyperuricemia,"['Asymptomatic Hyperuricemia', 'Gout']",[],UNKNOWN,,2017-11-01,2018-09-30,"[{'measure': 'Serum uric acid', 'description': 'Change from baseline serum levels of uric acid at 1 month', 'timeFrame': '1 month after randomization'}]","[{'measure': 'Fraction excretion of uric acid', 'description': 'Change from baseline fraction excretion of uric acid at 1 month', 'timeFrame': '1 month after randomization'}]",2,18 Years,65 Years,ALL,False,Shanghai Zhongshan Hospital,OTHER,0,104.0,ESTIMATED,2025-09-01T16:18:19.674866,v2_robust,True,True,False,False,False,
NCT06525948,Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA,Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of Transfusion-dependent Non-severe Aplastic Anaemia (TD-NSAA),rhTPO,"['Cyclosporin A', 'rhTPO']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Aplastic Anemia,"['Aplastic Anemia', 'Transfusion-dependent Anemia']",[],NOT_YET_RECRUITING,,2024-07-30,2025-12-30,"[{'measure': 'ORR', 'description': 'Overall Response Rate (ORR): meets the criteria for CR and PR.', 'timeFrame': '3 months'}, {'measure': 'CRR', 'description': 'Complete Response Rate (CRR)：ANC\\>1.5×10\\^9/L，Hb\\>100g/L，PLT\\>100×10\\^9/L；', 'timeFrame': '3 months'}]","[{'measure': 'ORR', 'description': 'Overall Response Rate (ORR): meets the criteria for CR and PR.', 'timeFrame': '6 months'}, {'measure': 'CRR', 'description': 'Complete Response Rate (CRR)：ANC\\>1.5×10\\^9/L，Hb\\>100g/L，PLT\\>100×10\\^9/L；', 'timeFrame': '6 months'}, {'measure': 'Time for platelet count to recover to ≥20 x 10^9/L with a 1-fold increase in absolute value', 'description': 'Time for platelet count to recover to ≥20 x 10\\^9/L with a 1-fold increase in absolute', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Proportion of patients with adverse events', 'description': 'safety event', 'timeFrame': 'through study completion, an average of 1 year'}]",6,18 Years,,ALL,False,Peking Union Medical College Hospital,OTHER,0,54.0,ESTIMATED,2025-09-01T16:18:19.675215,v2_robust,True,True,False,False,True,
NCT03491748,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants","A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ETX0282 Administered in Healthy Subjects",ETX0282,"['ETX0282', 'Cefpodoxime proxetil', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['Pharmacokinetics', 'ETX0282', 'Single Ascending Dose', 'Multiple Ascending Doses', 'ETX1317', 'Cefpodoxime Proxetil', 'Cefpodoxime', 'Enterobacteriaceae Infections']",COMPLETED,,2018-03-16,2019-09-11,"[{'measure': 'Number of participants with any non-serious adverse event', 'timeFrame': 'Up to 14 days after the last dose of study drug (Study Day [SD] 210)'}, {'measure': 'Number of participants with any serious adverse event', 'timeFrame': 'Up to 14 days after the last dose of study drug (SD 210)'}, {'measure': 'Number of participants with an adverse event of the indicated causality and severity', 'timeFrame': 'Up to 14 days after the last dose of study drug (SD 210)'}, {'measure': 'Part A: Number of participants with abnormal, clinically significant hematology, clinical chemistry, and urinalysis laboratory values at the indicated time points', 'timeFrame': 'Screening (Day -1) up to Day 15±2 (Follow-up)'}, {'measure': 'Part B: Number of participants with abnormal, clinically significant hematology, clinical chemistry, and urinalysis laboratory values at the indicated time points', 'timeFrame': 'Screening (Day -1; SD 44) up to Day 18±2 (SD 62±2; Follow-up)'}, {'measure': 'Part C: Number of participants with abnormal, clinically significant hematology, clinical chemistry, and urinalysis laboratory values at the indicated time points', 'timeFrame': 'Screening (Day -1; SD 91) up to Day 22±2 (SD 113±2; Follow-up)'}, {'measure': 'Part D: Number of participants with abnormal, clinically significant hematology, clinical chemistry, and urinalysis laboratory values at the indicated time points', 'timeFrame': 'Screening (Day -1; SD 142) up to Day 21±2 (SD 163±2; Follow-up)'}, {'measure': 'Part G: Number of participants with abnormal, clinically significant hematology, clinical chemistry, and urinalysis laboratory values at the indicated time points', 'timeFrame': 'Screening (Day -1; SD 192) up to Day 18±2 (SD 210±2; Follow-up)'}, {'measure': 'Part A: Number of participants with abnormal, clinically significant vital sign values at the indicated time points', 'timeFrame': 'Screening (Day -1) up to Day 15±2 (Follow-up)'}, {'measure': 'Part B: Number of participants with abnormal, clinically significant vital sign values at the indicated time points', 'timeFrame': 'Screening (Day -1; SD 44) up to Day 18±2 (SD 62±2; Follow-up)'}, {'measure': 'Part C: Number of participants with abnormal, clinically significant vital sign values at the indicated time points', 'timeFrame': 'Screening (Day -1; SD 91) up to Day 22±2 (SD 113±2; Follow-up)'}, {'measure': 'Part D: Number of participants with abnormal, clinically significant vital sign values at the indicated time points', 'timeFrame': 'Screening (Day -1; SD 142) up to Day 21±2 (SD 163±2; Follow-up)'}, {'measure': 'Part G: Number of participants with abnormal, clinically significant vital sign values at the indicated time points', 'timeFrame': 'Screening (Day -1; SD 192) up to Day 18±2 (SD 210±2; Follow-up)'}, {'measure': 'Part A: Number of participants with abnormal, clinically significant electrocardiogram values at the indicated time points', 'timeFrame': 'Screening (Day -1) up to Day 15±2 (Follow-up)'}, {'measure': 'Part B: Number of participants with abnormal, clinically significant electrocardiogram values at the indicated time points', 'timeFrame': 'Screening (Day -1; SD 44) up to Day 18±2 (SD 62±2; Follow-up)'}, {'measure': 'Part C: Number of participants with abnormal, clinically significant electrocardiogram values at the indicated time points', 'timeFrame': 'Screening (Day -1; SD 91) up to Day 22±2 (SD 113±2; Follow-up)'}, {'measure': 'Part D: Number of participants with abnormal, clinically significant electrocardiogram values at the indicated time points', 'timeFrame': 'Screening (Day -1; SD 142) up to Day 21±2 (SD 163±2; Follow-up)'}, {'measure': 'Part G: Number of participants with abnormal, clinically significant electrocardiogram values at the indicated time points', 'timeFrame': 'Screening (Day -1; SD 192) up to Day 18±2 (SD 210±2; Follow-up)'}, {'measure': 'Part A: Mean peak plasma concentration (Cmax) of ETX0282 and ETX1317 in blood in Cohorts 1 to 5', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean plasma concentration at time t (Ct) of ETX0282 and ETX1317 in blood in Cohorts 1 to 5', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean time to peak plasma concentration (Tmax) of ETX0282 and ETX1317 in blood in Cohorts 1 to 5', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean area under the concentration-time curve from time 0 to 24 hours (AUC0-24) of ETX0282 and ETX1317 in blood in Cohorts 1 to 5', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), and 24 (Day 2) hours postdose'}, {'measure': 'Part A: Mean area under the concentration-time curve from time 0 to the last time point evaluated (AUC0-t) of ETX0282 and ETX1317 in blood in Cohorts 1 to 5', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean area under the concentration-time curve from time 0 and extrapolated to infinity (AUC0-∞) of ETX0282 and ETX1317 in blood in Cohorts 1 to 5', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean elimination rate constant (Kel) of ETX0282 and ETX1317 in blood in Cohorts 1 to 5', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean elimination half-life (t½) of ETX0282 and ETX1317 in blood in Cohorts 1 to 5', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean clearance (CL) of ETX0282 and ETX1317 in blood in Cohorts 1 to 5', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean volume of distribution (Vdss) of ETX0282 and ETX1317 in blood in Cohorts 1 to 5', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean cumulative excretion of unchanged ETX0282 and ETX1317 in urine (Ae) in Cohorts 1 to 5', 'timeFrame': 'Prior to dosing (-6 to 0 hours; Day 1); 0 to 8 (Day 1), 8 to 24 (Day 2), 24 to 48 (Day 3), and 48 to 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean urinary clearance (CLR) of ETX0282 and ETX1317 in Cohorts 1 to 5', 'timeFrame': 'Prior to dosing (-6 to 0 hours; Day 1); 0 to 8 (Day 1), 8 to 24 (Day 2), 24 to 48 (Day 3), and 48 to 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean fraction of the administered dose of ETX0282 and ETX1317 that is excreted unchanged in the urine (fe) in Cohorts 1 to 5', 'timeFrame': 'Prior to dosing (-6 to 0 hours; Day 1); 0 to 8 (Day 1), 8 to 24 (Day 2), 24 to 48 (Day 3), and 48 to 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean dose proportionality of ETX0282 and ETX1317 in Cohorts 1 to 5', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part C: Mean Cmax of ETX0282 and ETX1317 in blood', 'description': 'min, minutes', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part C: Mean Ct of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part C: Mean Tmax of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part C: Mean AUC0-24 of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part C: Mean AUC0-t of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part C: Mean AUC0-∞ of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part C: Mean AUC from time 0 to the end of the dosing period (AUC0-tau) of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part C: Mean accumulation ratio (R0) of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part C: Mean Kel of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part C: Mean t½ of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part C: Mean CL of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part C: Mean Vdss of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part C: Mean Ae of ETX0282 and ETX1317', 'timeFrame': 'Days 1-4 and 8-11 (SDs 92-95 and 99-102): prior to dosing (-6 to 0 hours; first and last doses) and at 0-8, 8-24, 24-48, and 48-72 hours post first and last dose'}, {'measure': 'Part C: Mean CLR of ETX0282 and ETX1317', 'timeFrame': 'Days 1-4 and 8-11 (SDs 92-95 and 99-102): prior to dosing (-6 to 0 hours; first and last doses) and at 0-8, 8-24, 24-48, and 48-72 hours post first and last dose'}, {'measure': 'Part C: Mean fe of ETX0282 and ETX1317', 'timeFrame': 'Days 1-4 and 8-11 (SDs 92-95 and 99-102): prior to dosing (-6 to 0 hours; first and last doses) and at 0-8, 8-24, 24-48, and 48-72 hours post first and last dose'}, {'measure': 'Part C: Mean dose proportionality of ETX0282 and ETX1317', 'timeFrame': 'Days 1-3, 5, and 8 (SDs 92-94, 96, and 99): predose (30 min); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours post first dose; at troughs of Days 3, 5, and 8 (SDs 94, 96, and 99); at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post last dose'}, {'measure': 'Part D: Mean Cmax of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean Ct of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean Tmax of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean AUC0-24 of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose'}, {'measure': 'Part D: Mean AUC0-t of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean AUC0-∞ of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean Kel of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean t½ of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean CL of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean Vdss of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean Ae of ETX0282 and ETX1317', 'timeFrame': 'Days 1-10 (SDs 143-152): prior to dosing (-6 to 0 hours) and at 0-8, 8-24, 24-48, and 48-72 hours postdose'}, {'measure': 'Part D: Mean CLR of ETX0282 and ETX1317', 'timeFrame': 'Days 1-10 (SDs 143-152): prior to dosing (-6 to 0 hours) and at 0-8, 8-24, 24-48, and 48-72 hours postdose'}, {'measure': 'Part D: Mean fe of ETX0282 and ETX1317', 'timeFrame': 'Days 1-10 (SDs 143-152): prior to dosing (-6 to 0 hours) and at 0-8, 8-24, 24-48, and 48-72 hours postdose'}, {'measure': 'Part D: Mean dose proportionality of ETX0282 and ETX1317', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean Cmax of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean Ct of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean Tmax of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean AUC0-24 of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose'}, {'measure': 'Part D: Mean AUC0-t of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean AUC0-∞ of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean Kel of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean t½ of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean CL of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean Vdss of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part D: Mean Ae of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): prior to dosing (-6 to 0 hours) and at 0-8, 8-24, 24-48, and 48-72 hours postdose'}, {'measure': 'Part D: Mean CLR of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): prior to dosing (-6 to 0 hours) and at 0-8, 8-24, 24-48, and 48-72 hours postdose'}, {'measure': 'Part D: Mean fe of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): prior to dosing (-6 to 0 hours) and at 0-8, 8-24, 24-48, and 48-72 hours postdose'}, {'measure': 'Part D: Mean dose proportionality of cefpodoxime proxetil and cefpodoxime following administration of cefpodoxime proxetil as a single oral dose either alone or in combination with ETX0282', 'timeFrame': 'Days 1-10 (SDs 143-152): predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part G: Mean Cmax of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean Ct of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean Tmax of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean AUC0-24 of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean AUC0-t of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean AUC0-∞ of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean AUC0-tau of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean R0 of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean Kel of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean t½ of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean CL of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean Vdss of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean Ae of ETX0282 and ETX1317', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean CLR of ETX0282 and ETX1317', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean fe of ETX0282 and ETX1317', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}, {'measure': 'Part G: Mean dose proportionality of ETX0282 and ETX1317', 'timeFrame': 'Days 1 and 4 (SDs 193 and 196): 30 minutes predose; 0.25, 0.5, 0.75, 1, 1.5, 2 (predose prior to subsequent dose), 2.5, 3, 4 (predose prior to subsequent dose), 7, 8, 12, and 16 hours postdose. Days 2 and 5 (SDs 194 and 197): 24 hours postdose'}]","[{'measure': 'Number of elderly participants with any non-serious adverse event', 'timeFrame': 'Up to 14 days after the last dose of study drug (SD 210)'}, {'measure': 'Number of elderly participants with any serious adverse event', 'timeFrame': 'Up to 14 days after the last dose of study drug (SD 210)'}, {'measure': 'Number of elderly participants with an adverse event of the indicated causality and severity', 'timeFrame': 'Up to 14 days after the last dose of study drug (SD 210)'}, {'measure': 'Part A: Number of elderly participants with abnormal, clinically significant hematology, clinical chemistry, and urinalysis laboratory values at the indicated time points', 'timeFrame': 'Screening (Day -1); Days 2, 3, 4, 7, and 15±2 (Follow-up)'}, {'measure': 'Part A: Number of elderly participants with abnormal, clinically significant vital sign values at the indicated time points', 'timeFrame': 'Screening (Day -1); Days 2, 3, 4, 7, and 15±2 (Follow-up)'}, {'measure': 'Part A: Number of elderly participants with abnormal, clinically significant electrocardiogram values at the indicated time points', 'timeFrame': 'Screening (Day -1); Days 1-7; Day 15±2 (Follow-up)'}, {'measure': 'Number of participants who received concomitant medications', 'description': 'Concomitant medications will be coded using the World Health Organization Drug Dictionary. The incidence of participants taking each medication by Anatomical Therapeutic Chemical second and fourth level categories (pharmacological or therapeutic group) will be presented.', 'timeFrame': 'Up to 14 days after the last dose of study drug (SD 210)'}, {'measure': 'Part A: Mean Cmax of ETX0282 and ETX1317 in blood of elderly participants (Cohort 6)', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean Ct of ETX0282 and ETX1317 in blood of elderly participants (Cohort 6)', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean Tmax of ETX0282 and ETX1317 in blood of elderly participants (Cohort 6)', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean AUC0-24 of ETX0282 and ETX1317 in blood of elderly participants (Cohort 6)', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), and 24 (Day 2) hours postdose'}, {'measure': 'Part A: Mean AUC0-t of ETX0282 and ETX1317 in blood of elderly participants (Cohort 6)', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean AUC0-∞ of ETX0282 and ETX1317 in blood of elderly participants (Cohort 6)', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean Kel of ETX0282 and ETX1317 in blood of elderly participants (Cohort 6)', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean t½ of ETX0282 and ETX1317 in blood of elderly participants (Cohort 6)', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean CL of ETX0282 and ETX1317 in blood of elderly participants (Cohort 6)', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean Vdss of ETX0282 and ETX1317 in blood of elderly participants (Cohort 6)', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean Ae of ETX0282 and ETX1317 for elderly participants (Cohort 6)', 'timeFrame': 'Prior to dosing (-6 to 0 hours; Day 1); 0 to 8 (Day 1), 8 to 24 (Day 2), 24 to 48 (Day 3), and 48 to 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean CLR of ETX0282 and ETX1317 in urine for elderly participants (Cohort 6)', 'timeFrame': 'Prior to dosing (-6 to 0 hours; Day 1); 0 to 8 (Day 1), 8 to 24 (Day 2), 24 to 48 (Day 3), and 48 to 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean fe of ETX0282 and ETX1317 for elderly participants (Cohort 6)', 'timeFrame': 'Prior to dosing (-6 to 0 hours; Day 1); 0 to 8 (Day 1), 8 to 24 (Day 2), 24 to 48 (Day 3), and 48 to 72 (Day 4) hours postdose'}, {'measure': 'Part A: Mean dose proportionality of ETX0282 and ETX1317 for elderly participants (Cohort 6)', 'timeFrame': 'Predose (0); 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 (Day 1), 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours postdose'}, {'measure': 'Part B: Mean Cmax of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-7 (SDs 45-51): predose (0), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part B: Mean Ct of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-7 (SDs 45-51): predose (0), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part B: Mean Tmax of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-7 (SDs 45-51): predose (0), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part B: Mean AUC0-24 of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-7 (SDs 45-51): predose (0), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 16, and 24 hours postdose'}, {'measure': 'Part B: Mean AUC0-t of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-7 (SDs 45-51): predose (0), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part B: Mean AUC0-∞ of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-7 (SDs 45-51): predose (0), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part B: Mean Kel of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-7 (SDs 45-51): predose (0), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part B: Mean t½ of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-7 (SDs 45-51): predose (0), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part B: Mean CL of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-7 (SDs 45-51): predose (0), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part B: Mean Vdss of ETX0282 and ETX1317 in blood', 'timeFrame': 'Days 1-7 (SDs 45-51): predose (0), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 16, 24, 48, and 72 hours postdose'}, {'measure': 'Part B: Mean Ae of ETX0282 and ETX1317', 'timeFrame': 'Days 1-7 (SDs 45-51): prior to dosing (-6 to 0 hours) and at 0-8, 8-24, 24-48, and 48-72 hours postdose'}, {'measure': 'Part B: Mean CLR of ETX0282 and ETX1317', 'timeFrame': 'Days 1-7 (SDs 45-51): prior to dosing (-6 to 0 hours) and at 0-8, 8-24, 24-48, and 48-72 hours postdose'}, {'measure': 'Part B: Mean fe of ETX0282 and ETX1317', 'timeFrame': 'Days 1-7 (SDs 45-51): prior to dosing (-6 to 0 hours) and at 0-8, 8-24, 24-48, and 48-72 hours postdose'}, {'measure': 'Part B: Mean dose proportionality of ETX0282 and ETX1317', 'timeFrame': 'Days 1-7 (SDs 45-51): predose (0), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 16, 24, 48, and 72 hours postdose'}]",127,18 Years,,ALL,True,Entasis Therapeutics,INDUSTRY,0,99.0,ACTUAL,2025-09-01T16:18:19.675269,v2_robust,True,True,True,False,True,
NCT00103948,"The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment","An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment",Aricept,['Aricept'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Cognitive Impairment,['Cognitive Impairment'],[],COMPLETED,,2005-02,2007-02,[{'measure': 'Cognitive function.'}],[],1,25 Years,70 Years,ALL,False,Eisai Limited,INDUSTRY,0,165.0,ACTUAL,2025-09-01T16:18:19.675367,v2_robust,True,True,True,False,False,
NCT04362748,Study of AMG 256 in Adult Subjects With Advanced Solid Tumors,"A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors",AMG 256,['AMG 256'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],[],COMPLETED,,2020-09-15,2023-09-21,"[{'measure': 'Number of Participants with Dose Limiting Toxicities (DLTs)', 'timeFrame': '28 days'}, {'measure': 'Number of Participants with Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'Up to 2.5 Years'}, {'measure': 'Number of Participants with Treatment-Related Adverse Events', 'timeFrame': 'Up to 2.5 Years'}, {'measure': 'Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Sign Measurement', 'timeFrame': 'Up to 2 Years'}, {'measure': 'Number of Participants Who Experience a Clinically Significant Change from Baseline in Clinical Laboratory Tests', 'timeFrame': 'Up to 2 Years'}, {'measure': 'Maximum Tolerated Dose (MTD) of AMG 256', 'timeFrame': '28 days'}, {'measure': 'Recommended Phase 2 Dose (RP2D) of AMG 256', 'timeFrame': '28 days'}]","[{'measure': 'Maximum Observed Plasma Concentration (Cmax) of AMG 256', 'timeFrame': 'Up to 2.5 Years'}, {'measure': 'Time to Achieve Cmax (Tmax) of AMG 256', 'timeFrame': 'Up to 2.5 Years'}, {'measure': 'Area Under the Plasma Concentration-time Curve (AUC) of AMG 256', 'timeFrame': 'Up to 2.5 Years'}, {'measure': 'Objective Response (OR)', 'timeFrame': 'Up to 2.5 Years'}, {'measure': 'Duration of Response (DOR)', 'timeFrame': 'Up to 2.5 Years'}, {'measure': 'Progression-Free Survival (PFS)', 'timeFrame': 'Up to 1 Year'}, {'measure': 'Disease Control Rate (DCR)', 'timeFrame': 'Up to 2.5 Years'}, {'measure': 'Duration of Stable Disease', 'timeFrame': 'Up to 2.5 Years'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'Up to 2 Years'}, {'measure': 'Number of Participants with anti-AMG 256 Antibodies', 'timeFrame': 'Up to 2.5 Years'}]",17,18 Years,100 Years,ALL,False,Amgen,INDUSTRY,0,34.0,ACTUAL,2025-09-01T16:18:19.675411,v2_robust,True,True,True,False,True,
NCT03564548,Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain,"Inhaled PPP001 Versus Immediate-release Oral Opioids for the Management of Breakthrough Pain in Cancer Subjects: a Randomized, Open Label, Crossover, Comparison Study",PPP001,"['Morphine sulfate or Hydromorphone or Oxycodone', 'PPP001']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cancer,"['Cancer', 'Breakthrough Cancer Pain']",[],UNKNOWN,,2021-05-26,2022-04,"[{'measure': 'Time weighted Sum of Pain Intensity Differences from 0 to 30 minutes (SPID30).', 'description': 'SPID30 score after PPP001 administration or immediate-release oral opioids (morphine sulfate or hydromorphone or oxycodone) administration. The SPID30 calculation is based on a 100 mm pain intensity VAS were 0 mm is the minimum and 100 mm the maximum with higher score representing a worse outcome.', 'timeFrame': 'change between 0 min (before starting treatment) and 30 minutes after dosing'}]","[{'measure': 'SPID at 10, 15, and 60 minutes', 'description': 'SPID score after PPP001 administration or immediate-release oral opioids (morphine sulfate or hydromorphone or oxycodone) administration. The SPID calculation is based on a 100 mm pain intensity VAS were 0 mm is the minimum and 100 mm the maximum with higher score representing a worse outcome.', 'timeFrame': '10, 15, and 60 minutes after dosing'}, {'measure': 'Pain intensity difference (PID)', 'description': 'PID score after PPP001 administration or immediate-release oral opioids (morphine sulfate or hydromorphone or oxycodone) administration. The PID calculation is based on a 100 mm pain intensity VAS were 0 mm is the minimum and 100 mm the maximum with higher score representing a worse outcome.', 'timeFrame': '5, 10, 15, 30 and 60 minutes after dosing'}, {'measure': 'Pain relief at 5, 10, 15, 30 and 60 minutes', 'description': 'Subjective pain relief evaluated with a self-administered scale. The pain relief is measured with a five-point scale (0 = none to 4 = complete relief) with a higher score representing a better outcome.', 'timeFrame': '5, 10, 15, 30 and 60 minutes after dosing'}]",4,18 Years,,ALL,False,Tetra Bio-Pharma,INDUSTRY,1,20.0,ESTIMATED,2025-09-01T16:18:19.675420,v2_robust,True,True,False,False,False,
NCT01357655,Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923),"An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).",Dasatinib,"['BMS-833923', 'Sprycel®', 'Dasatinib']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Leukemia,['Leukemia'],"['Myelogenous', 'Chronic', 'BCR-ABL Positive']",TERMINATED,"No participants enrolled in this trial could receive the SMO antagonist as a recommended phase 2 dose was not determined by a different, concurrently-run trial.",2011-09,2016-01,"[{'measure': 'Number of Participants With Major Molecular Response', 'description': 'Major molecular response (MMR) was assessed using BCR-ABL transcript levels measured by real-time quantitative polymerase chain reaction (qPCR). MMR was defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value). Number of participants with MMR by timepoint are cumulative.', 'timeFrame': 'Baseline up to 12 months'}]","[{'measure': 'Complete Molecular Response at Any Time', 'timeFrame': 'Baseline to End of study (approximately 48 months)'}, {'measure': 'Progression-free Survival, Measured by the Time From Start of Treatment to Progression or Death', 'timeFrame': 'Baseline to End of study (approximately 48 months)'}, {'measure': 'Event-free Survival, Measured by the Time From Start of Treatment to Progression, Death or Treatment Discontinuation', 'timeFrame': 'Baseline to End of study (approximately 48 months)'}, {'measure': 'Transformation-free Survival Measured by the Time From Start of Treatment to Criteria for Accelerated or Blast Phase CML Are Met and Death', 'timeFrame': 'Baseline to End of study (approximately 48 months)'}, {'measure': 'Number of Participants Experiencing Serious Adverse Events (SAE), Drug-Related Adverse Event (AE), AE Leading to Discontinuation, and Death', 'description': 'AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=having certain, probable, possible, or missing relationship to study drug.', 'timeFrame': 'From date of first dose of study treatment up to the date of the last dose plus 30 days (approximately 49 months)'}]",6,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,70.0,ACTUAL,2025-09-01T16:18:19.675598,v2_robust,True,True,False,True,True,"No participants enrolled in this trial could receive the SMO antagonist as a recommended phase 2 dose was not determined by a different, concurrently-run trial."
NCT03654755,Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis,"A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis",ASN002,['ASN002'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Atopic Dermatitis,['Atopic Dermatitis'],['eczema'],TERMINATED,Phase 2 study results,2018-09-29,2019-10-29,"[{'measure': 'Change From Baseline in Eczema Area Severity Index (EASI) Score', 'description': 'The Eczema Area and Severity Index (EASI) is a composite score ranging from 0 to 72, the higher the value the worse the disease, that takes into account the degree of erythema, induration/infiltration (papules), excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percentage of BSA involved for each body region and for the proportion of the body region to the whole body.\n\nDue to early termination of the study, all efficacy analyses were descriptive in nature', 'timeFrame': '3 Months'}]","[{'measure': 'Number of Participants Achieving an Investigator Global Assessment (IGA) Scale of Clear (0) or Almost Clear (1)', 'description': 'The IGA is a global assessment of the current state of the disease. It is a 5-point (0-4) morphological assessment of overall disease severity. The IGA is selected using descriptors that best describe the overall appearance of the lesions at any given point. Signs like inflammation, redness, oozing, and crusting are evaluated. The 0 is the least severe and 4 is the most severe.\n\nDue to early termination of the study, all efficacy analyses were descriptive in nature.', 'timeFrame': '3 months'}, {'measure': 'Change From Baseline in 5-D Pruritus (Itch) Scale', 'description': 'The 5-D Pruritus Scale is a validated questionnaire used in clinical trials to assess the degree, duration, direction, disability, and distribution of the itch to rate the their symptoms over the preceding 2-week period. Each symptoms is scored on a scale of 1 to 5, with 5 being the most affected. The total score of 5-D pruritus is a sum of the 5 scores to provide a total score range from 5 (best) to 25 (worst).\n\nDue to early termination of the study, all efficacy analyses were descriptive in nature', 'timeFrame': '3 months'}, {'measure': 'Change From Baseline in Pruritus (Itch) Numeric Rating Scale (NRS)', 'description': 'Intensity of itch will be measured using an NRS to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where ""0"" represents ""no itching"" and ""10"" represents ""worst itching imaginable"" Due to early termination of the study, all efficacy analyses were descriptive in nature', 'timeFrame': '3 months'}, {'measure': 'Change From Baseline in Patient-Oriented Eczema Measure (POEM)', 'description': 'POEM developed by Charman et al. is a self-assessment of disease severity by the participant. The POEM includes 7 questions to evaluate the number of days the signs and symptoms of eczema over the last week. The answer to each question is categorized by the frequency of the sign or symptom from no days to 7 days. Each question is scored from 0 to 4 and the sum of the questions if the POEM score. The score ranges from 0 to 28 with 0 being the least frequency and 28 showing that all the signs and symptoms occur every day. Therefore, the higher the score, the more severe the eczema. Due to early termination of the study, all efficacy analyses were descriptive in nature', 'timeFrame': '3 months'}]",5,18 Years,75 Years,ALL,False,Asana BioSciences,INDUSTRY,0,162.0,ACTUAL,2025-09-01T16:18:19.675636,v2_robust,True,True,False,True,False,Phase 2 study results
NCT00298155,Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer,Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer,goserelin with dutasteride,"['goserelin with bicalutamide and dutasteride', 'goserelin with dutasteride', 'goserelin with bicalutamide and dutasteride and ketoconazole']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Cancer,"['Cancer', 'Prostate Neoplasms']",[],COMPLETED,,2006-07,2014-01,"[{'measure': 'Prostate Tissue DHT', 'description': 'Tissue dihydrotesterone (DHT)', 'timeFrame': 'After 12 weeks of neoadjuvant androgen deprivation'}]","[{'measure': 'To Determine the Effects of Different Modes of Androgen Deprivation on Serum DHT', 'description': 'Serum DHT', 'timeFrame': 'After 12 weeks of neoadjuvant androgen deprivation'}]",2,18 Years,100 Years,MALE,False,University of Washington,OTHER,2,35.0,ACTUAL,2025-09-01T16:18:19.675671,v2_robust,True,True,True,False,False,
NCT06526455,Efficacy and Safety of Vonorasan Versus Esomeprazole in the Treatment of Ulcers After Endoscopic Submucosal Dissection,"Efficacy and Safety of Vonorasan Versus Esomeprazole in the Treatment of Ulcers After Endoscopic Submucosal Dissection (ESD): a Multicentre, Parallel-design, Double-blind, Randomised Controlled Study",Vonoprazan,"['Vonoprazan', 'Esomeprazole']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Ulcers, Gastric","['Ulcers, Gastric']",[],NOT_YET_RECRUITING,,2024-08-01,2029-06-30,"[{'measure': 'Rate of ulcer reduction', 'description': 'Ulcer area = maximum diameter of the ulcer \\* perpendicular line of the maximum diameter (mm2) The rate of ulcer reduction at 2 weeks = \\[(area of the initial ulcer - area of the ulcer at 2 weeks)/area of the initial ulcer\\]\\*100% The rate of ulcer reduction at 8 weeks = \\[ (area of the initial ulcer - area of the ulcer at 8 weeks)/area of the initial ulcer\\]\\*100% Ulcer area = maximum diameter of the ulcer \\* perpendicular line of the maximum diameter (mm2) The rate of ulcer reduction at 2 weeks = \\[(area of the initial ulcer - area of the ulcer at 2 weeks)/area of the initial ulcer\\]\\*100% The rate of ulcer reduction at 8 weeks = \\[ (area of the initial ulcer - area of the ulcer at 8 weeks)/area of the initial ulcer\\]\\*100%', 'timeFrame': '2nd and 8th week post-dose'}]","[{'measure': 'Size of ulcer', 'description': 'Ulcer area = maximum diameter of the ulcer \\* perpendicular line of the maximum diameter (mm2)', 'timeFrame': '2nd and 8th week post-dose'}, {'measure': 'Rate of ulcer healing', 'description': 'Healing rate = number of cases with scarring/total number of cases × 100 per cent', 'timeFrame': '2nd and 8th week post-dose'}, {'measure': 'Rate of bumpy', 'description': 'Rate of bumpy= number of cases that have occurred/total number of cases × 100 per cent', 'timeFrame': '2nd and 8th week post-dose'}, {'measure': 'Quality of ulcer healing', 'description': 'Scoring using the Ulcer Healing Scoring Scale，the highest score is 3 and the lowest is 1, with higher scores indicating better ulcer healing', 'timeFrame': '2nd and 8th week post-dose'}, {'measure': 'Rate of delayed hemorrhage', 'description': 'Rate of delayed hemorrhage=Number of haemorrhages/total', 'timeFrame': '2th week post-dose'}, {'measure': 'Postoperative symptom relief rate', 'description': 'Number of persons in remission/total', 'timeFrame': '2th week post-dose'}]",7,18 Years,70 Years,ALL,False,Shicai Ye,OTHER,4,196.0,ESTIMATED,2025-09-01T16:18:19.675681,v2_robust,True,True,False,False,False,
NCT03240055,The Effects of Spinal Anesthesia on ED50 and BIS50 of Etomidate for the Loss of Consciousness,The Effects of Spinal Anesthesia on ED50 and BIS50 of Etomidate for the Loss of Consciousness,spinal anesthesia,['spinal anesthesia'],1,INTERVENTIONAL,['NA'],,,"Dose-Response Relationship, Drug","['Dose-Response Relationship, Drug']","['spinal anesthesia', 'etomidate', 'median effective dose', 'BIS50']",COMPLETED,,2017-06-01,2017-07-15,"[{'measure': 'Median effective dose (ED50)of etomidate at which 50% of patients lose consciousness', 'description': ""We want to determine Median effective dose (ED50) of etomidate at which 50% of patients lose consciousness in the SE and E group, respectively. It is a value，like 0.105mg/kg. Patients were considered to be loss of consciousness if there Observer's Assessment of Alertness/Sedation (OAA/S) scores were 2,1,or 0."", 'timeFrame': 'After etomidate administration to the lowest BIS value appears，usually about 4 minutes'}, {'measure': 'BIS value (BIS50) of etomidate at which 50% of patients lose consciousness', 'description': ""We want to determine BIS value (BIS50) of etomidate at which 50% of patients lose consciousness in the SE and E group, respectively. It is a unitless value，like 60. Patients were considered to be loss of consciousness if there Observer's Assessment of Alertness/Sedation (OAA/S) scores were 2,1,or 0."", 'timeFrame': 'After etomidate administration to the lowest BIS value appears，usually about 4 minutes'}]","[{'measure': 'The change of Mean Arterial Pressure (MAP)', 'timeFrame': 'Baseline, l min (T1), 2min (T2), 3min (T3), 5min (T5) after administration of etomidate'}, {'measure': 'The change of heart rate (HR)', 'timeFrame': 'Baseline, l min (T1), 2min (T2), 3min (T3), 5min (T5) after administration of etomidate'}]",4,18 Years,65 Years,FEMALE,False,General Hospital of Ningxia Medical University,OTHER,0,54.0,ACTUAL,2025-09-01T16:18:19.675741,v2_robust,True,True,True,False,False,
NCT00136955,Irinotecan Study For Cervical Cancer,"An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan Plus Cisplatin As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix",Irinotecan,['Irinotecan'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Uterine Cervical Neoplasms,['Uterine Cervical Neoplasms'],"['Weekly Irinotecan(60mg/sqm, D1, 8, 15) in combination with Cisplatin (60mg/sqm, D1), Squamous Cell Carcinoma Of The Uterine Cervix']",COMPLETED,,2004-06,2008-05,"[{'measure': 'Response to Treatment Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Evaluable Population)', 'description': 'Tumor response according to RECIST.', 'timeFrame': 'At baseline and every 8 weeks through end of treatment (21-28 days after last administration of study treatment)'}, {'measure': 'Response to Treatment Based on RECIST Criteria (Intent-to-Treat [ITT] Population)', 'description': 'Tumor response according to RECIST.', 'timeFrame': 'At baseline and every 8 weeks through end of treatment (21-28 days after last administration of study treatment)'}]","[{'measure': 'Overall Survival (OS) and Time to Tumor Progression (TTP) (Evaluable Population)', 'description': 'TTP is date of first infusion to first date of documented progression or date of death due to progressive disease or date of further anti-tumor therapy, whichever occurs first. OS is time from date of first infusion to date of death due to any cause or last date patient is known to be alive at date of data cutoff for final analysis.', 'timeFrame': 'Tumor response measurements were made at baseline, according to RECIST criteria. After end of treatment, subject was followed-up every 12 weeks plus or minus 2 weeks.'}, {'measure': 'Overall Survival (OS) and Time to Tumor Progression (ITT Population)', 'description': 'TTP is date of first infusion to first date of documented progression or date of death due to progressive disease or date of further anti-tumor therapy, whichever occurs first. OS is time from date of first infusion to date of death due to any cause or last date patient is known to be alive at date of data cutoff for final analysis.', 'timeFrame': 'Tumor response measurements were made at baseline, according to RECIST criteria. After end of treatment, subject was followed-up every 12 weeks plus or minus 2 weeks.'}]",4,18 Years,75 Years,FEMALE,False,Pfizer,INDUSTRY,0,41.0,ACTUAL,2025-09-01T16:18:19.675803,v2_robust,True,True,True,False,False,
NCT00528255,Pharmacokinetics and Safety of the 100 Mcg Misoprostol Vaginal Insert (MVI 100),"A Multicenter, Open-Label, Phase II Study of the Pharmacokinetics and Safety of the100 Mcg Misoprostol Vaginal Insert (MVI 100) in Women Requiring Cervical Ripening and Induction of Labor",Misoprostol Vaginal Insert (MVI 100),"['Cervical ripener', 'Misoprostol Vaginal Insert (MVI 100)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cervical Ripening,"['Cervical Ripening', 'Induction of Labor']","['cervical ripening', 'induction of labor']",WITHDRAWN,PK portion will be included in a future protocol,,,"[{'measure': 'The levels of misoprostol acid in plasma at time points 0 (baseline), 2, 4, 6, 8, 10 and 14 hours. Not all patients will have all in situ time points as the insert may be removed earlier for safety or efficacy reasons.', 'timeFrame': '24 Hours'}]","[{'measure': '-The levels of misoprostol acid in plasma at time of removal, and 30 and 60 minutes post removal. -Assess all adverse events.', 'timeFrame': '24h'}]",2,18 Years,,FEMALE,True,Ferring Pharmaceuticals,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:19.675823,v2_robust,True,True,False,True,True,PK portion will be included in a future protocol
NCT02961855,Efficacy and Safety of CLIFE1 Gel in Benign Anorectal Surgery,Double-blinded Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of CLIFE1 and CLIFE2 Gels in Benign Anorectal Surgery,"anesthesics plus antiinflammatory, CLIFE1","['lidocaine', 'lidocaine plus diclofenac', 'CLIFE1 topical gel', 'local anesthesics, CLIFE2', 'CLEFE2 topical gel', 'anesthesics plus antiinflammatory, CLIFE1']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Fissure;Anal,"['Fissure;Anal', 'Fistula;Rectal', 'Hemorrhoids']",[],COMPLETED,,2011-01,2013-12,"[{'measure': 'mean level of pain, as assessed by visual analog scale (VAS)', 'timeFrame': '3 days post-surgery'}]","[{'measure': 'Mean level of pain (VAS) at day 3 post-surgery', 'timeFrame': '6 days post-surgery'}, {'measure': 'Level of pain (VAS), assessed by Andersen scale', 'timeFrame': '6 days post-surgery'}, {'measure': 'Pain relief', 'description': 'Question about pain relief in comparison with the last application (scores from 0 to 4).', 'timeFrame': '6 days post-surgery'}, {'measure': 'analgesics use', 'timeFrame': '6 days post-surgery'}, {'measure': 'patient satisfaction', 'description': 'Satisfaction questionnaire about the efficacy of treatment (6 levels)', 'timeFrame': '6 days post-surgery'}, {'measure': 'demographic and clinical characteristics-1', 'description': 'sex', 'timeFrame': 'baseline'}, {'measure': 'demographic and clinical characteristics-2', 'description': 'age', 'timeFrame': 'baseline'}, {'measure': 'safety evaluation as assessed by recording fo adverse events', 'description': 'recording of adverse events', 'timeFrame': '6 days post-surgery'}]",9,18 Years,,ALL,False,Hospital de Viladecans,OTHER,0,120.0,ACTUAL,2025-09-01T16:18:19.675832,v2_robust,True,True,True,False,True,
NCT01101555,Repeat Dose Subcutaneous Rhumatoid Arthritis Efficacy Study,"A Randomised, Single-blind, Placebo-controlled, Study Toevaluate the Safety, Tolerability, Pharmacodynamics Andpharmacokinetics of Repeat Subcutaneous Administration Ofotelixizumab in Subjects With Rheumatoid Arthritis",subcutanious administration,['subcutanious administration'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Arthritis, Rheumatoid","['Arthritis, Rheumatoid']","['Rheumatoid arthritis', 'repeat dose', 'pharmacodynamics', 'pharmacokinetics', 'subcutaneous', 'safety', 'Otelixizumab', 'long term follow up', 'tolerability']",COMPLETED,,2010-05-12,2012-11-29,"[{'measure': 'Adverse Events (AEs)', 'timeFrame': '1 month'}, {'measure': 'Change from baseline and number of subjects outside the normal range for blood pressure, heart rate, temperature, electrocardiography parameters (12-lead)', 'timeFrame': '1 month'}, {'measure': 'Change from baseline in clinical chemistry and haematology parameters', 'timeFrame': '1 month'}, {'measure': 'Epstein-Barr Virus viral load', 'timeFrame': '1 month'}, {'measure': 'Individual absolute and percentage circulating peripheral T lymphocytes and CD4+ and CD8+ subset counts', 'timeFrame': '1 month'}, {'measure': 'Saturation of CD3 antigen on peripheral blood T cells', 'timeFrame': '1 month'}]","[{'measure': 'Individual serum concentrations of otelixizumab and data permitting summary PK parameters', 'timeFrame': '1 month'}, {'measure': 'Serum levels of anti-otelixizumab binding antibodies. Where binding antibodies are detected, proportion which are anti-otelixizumab neutralising antibodies.', 'timeFrame': '1 month'}]",8,18 Years,75 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,28.0,ACTUAL,2025-09-01T16:18:19.675867,v2_robust,True,True,True,False,True,
NCT07090655,A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous and Intravenous Injections of Budoprutug (TNT119) in Normal Healthy Volunteers",Budoprutug,"['TNT119', 'Budoprutug', 'Placebo']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['healthy', 'volunteer']",RECRUITING,,2025-08-11,2026-06,"[{'measure': 'Safety and Tolerability of Single Ascending Doses of budoprutug in Healthy Participants', 'description': 'Incidence of treatment-emergent adverse events', 'timeFrame': 'Day 57'}, {'measure': 'Incidence of infusion-related reactions (IRRs) for IV administration', 'description': 'Number of infusion-related reactions', 'timeFrame': 'Day 57'}, {'measure': 'Incidence of injection site reactions (ISRs) for SC administration', 'description': 'Number of injection site reactions', 'timeFrame': 'Day 57'}]","[{'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'description': 'Measurement of the maximum observed plasma concentration.', 'timeFrame': 'Day 57'}, {'measure': 'Time to Maximum Observed Concentration (Tmax)', 'description': 'Measurement of the time to maximum observed concentration.', 'timeFrame': 'Day 57'}, {'measure': 'Area Under the Curve (AUC)', 'description': 'Measurement of the area under the drug concentration-time curve.', 'timeFrame': 'Day 57'}, {'measure': 'Terminal Half-Life (T1/2)', 'description': 'Measurement of the terminal half-life in days.', 'timeFrame': 'Day 57'}, {'measure': 'Bioavailability (F)', 'description': 'Relative absorption of SC vs IV budoprutug (%).', 'timeFrame': 'Day 57'}]",8,18 Years,50 Years,ALL,True,"Climb Bio, Inc.",INDUSTRY,0,38.0,ESTIMATED,2025-09-01T16:18:19.675874,v2_robust,True,True,False,False,True,
NCT01867255,Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels,Pharmacokinetic Study Comparing Area Under the Curve for a Single Dose of Venlafaxine ER Pre- and Post-gastric Bypass,venlafaxine ER (extended-release) 75 mg,"['Effexor XR 75 mg', 'venlafaxine ER (extended-release) 75 mg']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Bariatric Surgery,"['Bariatric Surgery', 'Gastric Bypass', 'Roux-en-Y Gastric Bypass']","['venlafaxine', 'Effexor', 'antidepressive agent']",COMPLETED,,2013-10,2015-03,"[{'measure': 'Venlafaxine levels pre- and post-gastric bypass', 'description': 'This study will measure and compare venlafaxine and desvenlafaxine levels in participants before, and again 3 to 4 months after, gastric bypass surgery.', 'timeFrame': '3 to 4 months'}]",[],1,18 Years,,ALL,False,Mayo Clinic,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:19.675881,v2_robust,True,True,True,False,False,
NCT04745026,Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder,"An Exploratory, Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder",GWP42003-P,"['GWP42003-P', 'Epidiolex®', 'Placebo', 'CBD-OS', 'cannabidiol']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Autism Spectrum Disorder,['Autism Spectrum Disorder'],"['Cannabidiol oral solution', 'CBD-OS', 'GWP42003-P', 'Children', 'Adolescents']",COMPLETED,,2021-05-31,2023-12-21,"[{'measure': 'Change From Baseline in Aberrant Behavior Checklist (ABC) Subscale Total Scores', 'description': 'The caregiver-assessed ABC was designed to assess the presence and severity of various problem behaviors commonly observed in individuals diagnosed with intellectual and developmental disability. The checklist contains 5 subscales: Irritability (15 items); Social Withdrawal (16 items); Stereotypic Behavior (7 items); Hyperactivity/Noncompliance (16 items); and Inappropriate Speech (4 items). Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). The total score of all items for each subscale range from 0-45 (irritability), 0-48 (social withdrawal and hyperactivity/noncompliance), 0-21 (stereotypic behavior), and 0-12 (inappropriate speech) where higher scores indicate worse clinical outcome. The change from baseline to Week 4, Week 8, and Week 12 is reported with lower scores indicating better clinical outcome.', 'timeFrame': 'Baseline up to Week 12'}, {'measure': 'Change From Baseline in Vineland Adaptive Behavior Scales-3 (VABS-3) Scores', 'description': 'The VABS-3 scales assess what a person does, rather than what he or she can do. The Vineland-3 assesses adaptive behavior in 3 domains: Communication, Daily Living Skills, and Socialization. Each domain is comprised of 3 subdomains: receptive expression and written (communication); personal, domestic and community (daily living skills); Interpersonal relationships, play and leisure and copying skills (socialization). The adaptive behavior composite score is calculated as arithmetic mean of all 3 domain scores. The total score range is 20 to 140, where low scores indicate low (worst) clinical outcome and high scores indicate high (best) clinical outcome. The change from baseline in VABS-3 is being reported with positive values indicating a positive improvement in adaptive behavior.', 'timeFrame': 'Baseline up to Week 12'}, {'measure': 'Number of Patients Per Clinical Global Impression Improvement (CGI-I) Category', 'description': ""The CGI-I is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The clinician is asked: Compared to the patient's condition at admission to the project, how much has the patient changed? This is rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. Higher scores indicate worse clinical outcome. The number of patients in each CGI-I category is reported."", 'timeFrame': 'Day 85'}, {'measure': 'Change From Baseline in Clinical Global Impression Severity (CGI-S) Scores', 'description': ""The CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's experience with patients who have the same diagnosis. The clinician is asked: Considering your total clinical experience with this particular population, how ill is the patient at this time? This is rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill. Higher scores indicate worse outcome. The change from baseline in CGI-S scores is reported and lower mean scores indicate better outcome."", 'timeFrame': 'Baseline up to Week 12'}]","[{'measure': 'Number of Participants Reporting Treatment-emergent Adverse Events', 'description': 'A TEAE is one that started, or worsened in severity or seriousness, following the first dose of IMP. AEs were coded according to the Medical Dictionary for Regulatory Activities v24.0 dictionary.', 'timeFrame': 'Baseline up to Week 12'}, {'measure': 'Mean Change From Baseline in Hematology Clinical Laboratory Levels', 'timeFrame': 'Baseline up to Week 9 (end of taper/withdrawal)'}, {'measure': 'Mean Percentage Change From Baseline in Hematology Clinical Laboratory Levels', 'timeFrame': 'Baseline up to Week 9 (end of taper/withdrawal)'}, {'measure': 'Mean Change From Baseline in Hemoglobin Levels', 'timeFrame': 'Week 9 (end of taper/withdrawal)'}, {'measure': 'Mean Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin Levels', 'timeFrame': 'Week 9 (end of taper/withdrawal)'}, {'measure': 'Mean Change From Baseline in Erythrocyte Mean Corpuscular Volume Levels', 'timeFrame': 'Week 9 (end of taper/withdrawal)'}, {'measure': 'Number of Patients With Clinically Significant Vital Sign Values', 'timeFrame': 'Post-baseline up to 12 weeks'}, {'measure': 'Number of Patients With Clinically Significant Physical Examination Procedure Findings', 'description': 'Number of patients with abnormal physical exam findings are reported.', 'timeFrame': 'Baseline up to Day 85 post-baseline'}, {'measure': 'Number of Patients With Clinically Significant 12-lead Electrocardiogram Findings', 'timeFrame': 'Baseline up to Day 85 post-baseline'}, {'measure': 'Number of Participants Reporting Suicidal Ideation or Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS)', 'description': 'C-SSRS rating scale results since last visit is reported. The presence/absence of any suicidal ideation or behavior is scored based on yes/no responses. The overall number of participants reporting suicidal ideation or behavior is being reported.', 'timeFrame': 'Baseline up to Day 92'}]",14,6 Years,17 Years,ALL,False,Jazz Pharmaceuticals,INDUSTRY,0,103.0,ACTUAL,2025-09-01T16:18:19.675943,v2_robust,True,True,True,False,True,
NCT01908426,Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib,"A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib",Cabozantinib tablets,"['Placebo tablets', 'XL184', 'Cabozantinib tablets']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],"['cabozantinib', 'XL184', 'liver cancer', 'hepatocellular carcinoma', 'tyrosine kinase inhibitor', 'MET kinase', 'vascular endothelial growth factor receptor 2 (VEGFR2)']",COMPLETED,,2013-09-26,2021-01-12,"[{'measure': 'Overall Survival (OS)', 'description': 'The primary analysis of OS is defined as the time from randomization to death from any cause. The analysis was based on a second planned interim analysis prespecified to be performed at approximately the 75% information fraction (ie, at approximately 466 deaths). The data cutoff date for this event-driven analysis in the Intent to Treat (ITT) population was 01 June 2017. Median OS was calculated using the Kaplan-Meier estimates.', 'timeFrame': 'Up to 45 months'}]","[{'measure': 'Progression-Free Survival (PFS)', 'description': 'Duration of PFS is defined as the time of randomization to the earlier of the following events, progressive disease as determined by Investigator (per RECIST 1.0, which is defined by a ≥ 20% increase in the sum of the longest diameter of target lesions from baseline) or death due to any cause. A Kaplan- Meier analysis was performed to estimate the median duration.', 'timeFrame': 'Up to 45 months'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', 'timeFrame': 'ORR is measured by radiologic assessment every 8 weeks after randomization until disease progression or discontinuation of study treatment (up to 45 months)'}]",3,18 Years,,ALL,False,Exelixis,INDUSTRY,0,707.0,ACTUAL,2025-09-01T16:18:19.675979,v2_robust,True,True,True,False,False,
NCT00629226,"Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer",Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer,bortezomib,"['bortezomib', 'cisplatin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Head and Neck Cancer,['Head and Neck Cancer'],"['stage IV squamous cell carcinoma of the hypopharynx', 'stage IV squamous cell carcinoma of the larynx', 'stage IV squamous cell carcinoma of the lip and oral cavity', 'stage IV squamous cell carcinoma of the oropharynx', 'stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity', 'recurrent squamous cell carcinoma of the hypopharynx', 'recurrent squamous cell carcinoma of the larynx', 'recurrent squamous cell carcinoma of the lip and oral cavity', 'recurrent squamous cell carcinoma of the nasopharynx', 'recurrent squamous cell carcinoma of the oropharynx', 'recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity']",COMPLETED,,2007-10,,"[{'measure': 'Dose-limiting toxicities and other toxicities as assessed by NCI CTCAE v3.0'}, {'measure': 'Maximum tolerated dose of bortezomib when administered in combination with cetuximab and radiotherapy with and without cisplatin'}]","[{'measure': 'Objective response rate'}, {'measure': 'Progression-free survival'}, {'measure': 'Overall survival'}, {'measure': 'Pre-to-post-treatment changes in biomarkers'}]",6,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,46.0,ESTIMATED,2025-09-01T16:18:19.676036,v2_robust,True,True,True,False,False,
NCT03953326,HeartPhone Cancer Survivors Trial 2019,Digital Intervention to Promote Physical Activity and Improve Cardiovascular Health Among Cancer Survivors,Acetylcholine,"['L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester', 'Acetylcholine', 'Sodium Nitroprusside']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Breast Cancer,"['Breast Cancer', 'Leukemia', 'Lymphoma']",[],TERMINATED,Futility in recruitment,2019-04-23,2020-12-31,"[{'measure': 'Physical activity volume', 'description': 'Daily step counts over 1-week from Fitbit device', 'timeFrame': '3 month'}]","[{'measure': 'Microvessel function', 'description': 'Skin blood flow during perfusion of endothelium-dependent and independent agonists', 'timeFrame': '3 month'}]",2,18 Years,65 Years,ALL,False,Penn State University,OTHER,0,3.0,ACTUAL,2025-09-01T16:18:19.676048,v2_robust,True,True,False,True,False,Futility in recruitment
NCT00881426,To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions,"Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb (Cefzil) 500 mg Cefprozil Tablets In Healthy Adults Volunteers Under Fasting Conditions",Cefprozil 500 mg Tablets (Sandoz GmbH),"['Cefprozil 500 mg Tablets (Sandoz GmbH)', 'Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],['Antibiotic'],COMPLETED,,2004-03,2004-04,"[{'measure': 'Bioequivalence based on AUC and Cmax', 'timeFrame': '16 days'}]",[],1,20 Years,54 Years,ALL,True,Sandoz,INDUSTRY,0,26.0,ACTUAL,2025-09-01T16:18:19.676202,v2_robust,True,True,True,False,False,
NCT06132178,Psilocybin rTMS for Treatment Resistant Depression,"Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder",Psilocybin,"['Low-dose psilocybin', 'low-dose COMP360', 'Psilocybin', 'COMP360']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Treatment Resistant Depression,"['Treatment Resistant Depression', 'MDD', 'Major Depressive Disorder', 'Recurrent Depression', 'Depression']",[],NOT_YET_RECRUITING,,2025-01-01,2030-12-31,"[{'measure': 'Montgomery Asberg Depression Rating Scale (MADRS)', 'description': 'A ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Scoring ranging from 0 to 60, with higher scores indicating greater depressive symptomology.', 'timeFrame': '12 months'}, {'measure': 'fMRI task-evoked brain activation', 'description': 'A method used in functional magnetic resonance imaging (fMRI) to observe different areas of the brain or other organs, which are found to be active at any given time.', 'timeFrame': 'At both 1 week and 2 weeks'}, {'measure': 'fMRI resting state', 'description': 'A method aimed at examining intrinsic networks in the brain while no task is performed (rest) in order to estimate correlations between brain regions.', 'timeFrame': 'At both 1 week and 2 weeks'}, {'measure': 'EEG functional connectivity change', 'description': 'A method aimed at examining intrinsic networks in the brain to estimate correlations between brain regions.', 'timeFrame': 'At both 1 week and 2 weeks'}]","[{'measure': 'Snaith Hamilton Pleasure Scale (SHAPS)', 'description': 'A self-report measure of anhedonia. Scoring range from 0 to 14, with lower scores indicating less anhedonia.', 'timeFrame': '12 months'}, {'measure': 'Quick Inventory of Depressive Symptom Self-Report (QIDS-SR)', 'description': 'A self report measure of depressive symptoms. Scores range from 0 to 48, with lower scores indicating less symptoms of depression.', 'timeFrame': '12 months'}, {'measure': 'World Health Organization Quality of Life Inventory-Brief subscale (WHO-QL-Brief)', 'description': 'A self-report measure of quality of life with four subscales: Physical Health, Psychological Health, Social Relationships, and Environment. Scores for each range from 4-20, with higher scores indicating better quality of life.', 'timeFrame': '12 months'}, {'measure': 'Beck Depression Inventory II (BDI II)', 'description': 'A self-report measure of positive and negative affect. There are scores for Positive Affect and Negative Affect, each of which is scored from 10-50. Higher scores indicate more of that particular type of affect.', 'timeFrame': '12 months'}, {'measure': 'Anxiety Sensitivity Index 3 (ASI-3)', 'description': 'A self-report measure of anxiety sensitivity. Scores range from 0 to 72, with lower scores indicating less anxiety sensitivity.', 'timeFrame': '12 months'}, {'measure': 'Beck Anxiety Inventory (BAI)', 'description': 'A self report measure of anxiety symptoms. Scores range from 0 to 63, with lower scores indicating less anxiety.', 'timeFrame': '12 months'}, {'measure': 'Mood and Anxiety Symptom Questionnaire 30 item Anhedonic Depression subscale (MASQ-30)', 'description': 'A subscale measure of anhedonic depressive symptoms. Scores range from 10-50, with lower scores indicating less anhedonic depression.', 'timeFrame': '12 months'}, {'measure': 'Mood and Anxiety Symptom Questionnaire 30 item Anxious Arousal subscale (MASQ-30)', 'description': 'A subscale measure of anxious arousal symptoms. Scores range from 10-50, with lower scores indicating less anxious arousal.', 'timeFrame': '12 months'}, {'measure': 'Physicians Health Questionnaire 9 (PHQ-9)', 'description': 'A self-report screener of major depression. Scores range from 0 to 27, with lower scores indicating fewer symptoms of depression.', 'timeFrame': '12 months'}, {'measure': 'Generalized Anxiety Disorder 7 (GAD-7)', 'description': 'A self-report screener of generalized anxiety disorder. Scores range from 0 to 21, with lower scores indicating less symptoms of generalized anxiety.', 'timeFrame': '12 months'}, {'measure': 'Columbia-Suicide Severity Rating Scale (C-SSRS)', 'description': 'Clinician-administered measure of suicidal ideation. Scores range from 0 to 25, with higher scores indicating more severe suicidal ideation.', 'timeFrame': '12 months'}, {'measure': 'Anger Attacks Questionnaire (AAQ)', 'description': 'Self-report measure of anger outbursts. Scores range from 5-25, with higher scores indicating more severe expressions of anger.', 'timeFrame': '12 months'}, {'measure': 'Brief Psychiatric Rating Scale (BPRS)', 'description': 'A tool clinicians or researchers use to measure psychiatric symptoms such as anxiety, depression, and psychoses. Scores range from 18 to 126, with lower scores indicating less severe psychiatric symptoms a score of 18 meaning no symptoms present.', 'timeFrame': '2 weeks'}, {'measure': 'Sheehan Disability Scale (SDS)', 'description': 'Self-report screener that measures impairment in functioning and generates 4 scores: a work disability score, a social life disability score, a family life disability score and a total score. To get a total score add up the 3 individual scores (work: social life: family life). The maximum possible score is 30, meaning more severe impairment from experienced disability.', 'timeFrame': '12 months'}, {'measure': 'Positive and Negative Affect Scale Short Form (PANAS-SF)', 'description': 'Self-Report scale that consists of different words that describe feelings and emotions to measure positive and negative affect. Scores are divided into two categories: 1) can range from 10-50 with higher scores representing higher levels of positive affect and 2) can range from 10-50 with lower scores representing lower levels of negative affect.', 'timeFrame': '12 months'}, {'measure': 'Acceptance and Action Questionnaire II (AAQ II)', 'description': 'Self-report measure that tracks how individuals are applying flexibility skills to their daily lives. 7 item scale with scores ranging from 7-49,with higher scores indicating higher psychological inflexibility, experiential avoidance, and more potential for psychological stress.', 'timeFrame': '12 months'}, {'measure': 'NEO Five Factor Inventory (NEO-FFI)', 'description': 'Self-report measure that assesses subjects for five domains of normal personality: neuroticism, extraversion, conscientiousness, agreeableness, and openness. Each domain is a 12-item scale with scores ranging from 12-60 where the combined scores create a personality profile.', 'timeFrame': '12 months'}, {'measure': 'Emotion Regulation Questionnaire (ERQ)', 'description': ""A 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Assesses cognitive reappraisal (6 items) and expressive suppression (4 items) on a 7-point Likert-type response scale, with higher scores on each scale indicate greater use of the corresponding emotional regulation strategy. Min 10 - max 70."", 'timeFrame': '12 months'}, {'measure': 'UCLA Loneliness Scale 3 (UCLA-LS-3)', 'description': 'Clinician administered scale that comprises 3 questions that measure three dimensions of loneliness: relational connectedness, social connectedness, and self-perceived isolation. Each item is rated on a 3-point scale for a range of 3-9, with higher scores meaning more intense feelings of the 3 dimensions of loneliness.', 'timeFrame': '12 months'}, {'measure': 'Freiberg Mindfulness Inventory (FMI)', 'description': 'Self-report questionnaire for measuring mindfulness. A 14-item scale with scores 14-56 with higher scores meaning a higher degree of mindfulness.', 'timeFrame': '12 months'}, {'measure': 'Discontinuation Emergent Signs and Symptoms Scale', 'description': 'Self-report measure of 43-items that assess changes in symptomology when starting a new treatment. This measures does not correlate scores to an outcome but is used to assess the development of a new symptom or the worsening of an already existing one.', 'timeFrame': '1 week'}]",25,22 Years,65 Years,ALL,False,University of Texas at Austin,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:19.676235,v2_robust,True,True,False,False,False,
NCT06531278,"Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety","Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety",Irinotecan liposome,"['Oxaliplatin', 'Irinotecan liposome', 'Calcium folinate', 'Adebrelimab', 'Fluorouracil']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Pancreatic Cancer Metastatic to Liver,['Pancreatic Cancer Metastatic to Liver'],[],RECRUITING,,2024-07-16,2026-12-31,"[{'measure': 'ORR', 'description': 'The proportion of patients whose tumors shrink to a certain amount for a certain period of time and include cases of complete response (CR) and partial response (PR). Calculated as: (CR cases + PR cases) / FAS × 100 (%); FAS (full analysis set) refers to the case of qualified patients, administered more than one case.\n\nTumor remission rates are calculated according to the RECIST guidelines (version 1.1)', 'timeFrame': 'Up to 1 year after the treatment'}]",[],1,18 Years,75 Years,ALL,False,Jiang Long,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:19.676376,v2_robust,True,True,False,False,False,
NCT01758978,A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet,"A Randomized, Open-Label, 2-Period, Crossover Study to Assess the Bioequivalence of Two 30-mg and One 60-mg Hydrocodone Bitartrate Extended-Release Tablet",a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).,['a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Pain,['Pain'],"['bioequivalence, hydrocodone bitartrate extended-release tablets']",COMPLETED,,2012-12,2013-01,"[{'measure': 'Maximum observed plasma drug concentration (Cmax)', 'description': 'To assess the bioequivalence between 30-mg tablets and one 60-mg tablet of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}, {'measure': 'Area under the plasma drug concentration by time curve AUC 0-∞', 'description': 'To assess bioequivalence between two 30-mg tablets and one 60-mg tablet of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}]","[{'measure': 'Time to maximum observed plasma drug concentration (tmax)', 'description': 'To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}, {'measure': 'AUC from time 0 to 72 hours after study drug administration (AUC0-72)', 'description': 'To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}, {'measure': 'AUC from time 0 to the time of the last measurable drug concentration (AUC0-t)', 'description': 'To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}, {'measure': 'Percentage extrapolation, 100x(AUC0-∞-AUC0-t)/AUC0-∞)', 'description': 'To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}, {'measure': 'Apparent plasma terminal elimination rate constant (λz) and associated elimination half life (t½)', 'description': 'To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}, {'measure': 'Recording of Adverse Events', 'description': 'To characterize the safety of the hydrocodone bitartrate extended-release tablet in healthy naltrexone-blocked subjects.', 'timeFrame': 'From ICF signing to 48-72 hours after discharge from the study center following the last administration of the hydrocodone bitartrate extended-release tablet.'}]",8,18 Years,45 Years,ALL,True,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,0,54.0,ACTUAL,2025-09-01T16:18:19.676416,v2_robust,True,True,True,False,True,
NCT06851078,"Evaluation of Early Administration of Levetiracetam in the Prevention and Treatment Encephalopathy in Septic Shock: Randomized, Double-blind, Placebo-controlled Trial","Evaluation de l'Administration précoce de lévétiracétam Dans la prévention et le Traitement de l'encéphalopathie au Cours du Choc Septique : Essai randomisé, en Double Aveugle, contrôlé Par Placebo",Levetiracetam IV,['Levetiracetam IV'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Septic Shock,['Septic Shock'],[],NOT_YET_RECRUITING,,2025-03-15,2027-06-15,"[{'measure': 'Number of days alive without delirium or coma', 'timeFrame': '14 days after randomization'}]","[{'measure': 'Mortality in intensive care', 'timeFrame': 'At day 28'}, {'measure': 'Mortality in intensive care', 'timeFrame': 'At day 90'}, {'measure': 'Mortality in hospital', 'timeFrame': 'At day 28'}, {'measure': 'Mortality in hospital', 'timeFrame': 'At day 90'}, {'measure': 'Overall survival', 'timeFrame': 'At day 90'}, {'measure': 'Duration of mechanical ventilation', 'timeFrame': 'At day 28'}, {'measure': 'Length of stay in intensive care unit', 'timeFrame': 'Up to day 90'}, {'measure': 'Length of stay in hospital', 'timeFrame': 'Up to day 90'}, {'measure': 'Occurrence of epileptic seizures', 'description': 'From Day 1 to Day 14 (confirmed by EEG or tonic-clonic seizures) and/or occurrence of epileptic abnormalities (periodic epileptic discharges)', 'timeFrame': 'Up to day 14'}, {'measure': 'Time between cessation of sedation and awakening', 'description': 'Defined by spontaneous eye opening, among patients not deceased under sedation', 'timeFrame': 'At day 90'}, {'measure': 'Severity of cognitive impairment', 'description': 'Evaluated by a telephone survey using Telephone MoCA (Montreal Cognitive Assessment). The scores ranges from 0 to 30.\n\nA score of 26 or higher is typically considered normal. A score of 25 or lower may indicate cognitive impairment, such as mild cognitive impairment (MCI) or early-stage dementia.', 'timeFrame': 'At day 90'}, {'measure': 'Severity of anxiety and depression', 'description': 'Assessed with HADS (Hospital Anxiety and Depression Scale) scale Score varies from 0 to 21 for each componant (Anxiety and depression) The higher the score, the more severe the anxiety or depression.', 'timeFrame': 'At day 90'}, {'measure': 'Presence of post-traumatic stress (PTSD)', 'description': 'Assessed by IES-R (Impact of Event Scale Revisited) The total score can range from 0 to 88. Higher scores indicate greater trauma-related distress and a higher likelihood of experiencing PTSD symptoms.', 'timeFrame': 'At day 90'}, {'measure': 'Quality of life scoring', 'description': 'Using EQ-5D-5L. It evaluates five dimensions : mobility, self-care, usual activities, pain/discomfort and anxiety/depression and each dimension has five levels : no problems, slight problems, moderate problems, severe problems and extreme problems. Answers are given on a 5-point scale by domain, the higher the score, the poorer the quality of life.', 'timeFrame': 'At day 90'}, {'measure': 'Autonomy in daily life', 'description': 'Using Katz Index of Independence in Activities of Daily Living (ADL) The score varies from 0 to 6, the lower the score, the more dependent the person.', 'timeFrame': 'At day 90'}]",16,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,280.0,ESTIMATED,2025-09-01T16:18:19.676459,v2_robust,True,True,False,False,False,
NCT07032285,Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas,"Multicenter, Open-Label Phase II Trial of Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas",Cirtuvivint,['Cirtuvivint'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Soft Tissue Sarcoma (STS),['Soft Tissue Sarcoma (STS)'],[],RECRUITING,,2025-01-15,2027-07-30,"[{'measure': 'To evaluate the progression-free survival rate (PFSR) at 3 months.', 'description': 'PFSR-3m (according to central radiology assessment): Efficacy measured by the PFSR at 3 months, which is defined as the percentage of patients who did not experience radiological progression according to RECIST v1.1 or death due to any cause since the date of treatment initiation until month 3 after date of treatment initiation.', 'timeFrame': '3 months'}]",[],1,16 Years,70 Years,ALL,False,Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas,OTHER,1,25.0,ESTIMATED,2025-09-01T16:18:19.676578,v2_robust,True,True,False,False,False,
NCT06405685,Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis,"A Prospective, Single Arm Study of Nimotuzumab Combined With Gemcitabine and Nab-paclitaxel as Conversion Therapy in Pancreatic Cancer With Liver Metastasis",Nimotuzumab,"['h-R3', 'AG', 'Nimotuzumab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Pancreatic Cancer,['Pancreatic Cancer'],[],RECRUITING,,2023-04-27,2025-10-30,"[{'measure': 'R0 resection rate', 'description': 'The Proportion of patients who achieved R0 resection (incisal edge\\>1cm)', 'timeFrame': 'Up to 6 months'}]","[{'measure': 'resection rate', 'description': 'The proportion of patients who underwent surgery.', 'timeFrame': 'Up to 18 months'}, {'measure': 'overall survival (OS)', 'description': 'The time from the beginning of treatment to death due to any cause.', 'timeFrame': 'Up to 18 months'}, {'measure': 'Objective response rate (ORR)', 'description': 'Objective response rate (ORR), including complete response (CR) and partial response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions.', 'timeFrame': 'Up to 18 months'}, {'measure': 'tumor-related markers', 'description': 'To explore the influence of tumor-related markers (such as CA199,EGFR) on prognosis.', 'timeFrame': 'Up to 18 months'}, {'measure': 'adverse events', 'description': 'Frequency and severity of adverse events.', 'timeFrame': 'Up to 30 days after last administration'}]",6,18 Years,75 Years,ALL,False,Tianjin Medical University Cancer Institute and Hospital,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:19.676588,v2_robust,True,True,False,False,True,
NCT00826085,Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall,"A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer.",ThermoDox in combination with Microwave Hyperthermia (heat),['ThermoDox in combination with Microwave Hyperthermia (heat)'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Breast Cancer,['Breast Cancer'],"['Breast Cancer', 'Recurrent Chest Wall Cancer', 'Loco-regional Recurrent Breast Cancer', 'Breast Cancer Recurrence at the Chest Wall']",COMPLETED,,2013-02,2016-06,"[{'measure': 'To determine the bioequivalence of ThermoDox when used with hyperthermia among patients with RCW breast cancer.', 'timeFrame': 'PK collection at Cycle 1 and Cycle 2'}, {'measure': 'To determine efficacy of ThermoDox in combination with Hyperthermia', 'timeFrame': 'Efficacy assessed at Cycle 3, Cycle 5 and End of Treatment'}]","[{'measure': 'To evaluate the safety of ThermoDox in combination with Hyperthermia', 'timeFrame': 'Through 6 treatment Cycles'}]",3,18 Years,,FEMALE,False,Imunon,INDUSTRY,0,17.0,ACTUAL,2025-09-01T16:18:19.676607,v2_robust,True,True,True,False,True,
NCT03544385,Effect of Ocular Hygiene on Scleral Lens Wear,Effect of Ocular Hygiene on Scleral Lens Wear,Ringers Solution,"['Ringers Solution', 'Placebo - Concentrate']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Scleral Contact Lenses,['Scleral Contact Lenses'],[],UNKNOWN,,2018-05-18,2018-10-25,"[{'measure': 'length of scleral lens wear', 'timeFrame': 'one month'}]",[],1,18 Years,85 Years,ALL,True,University of Houston,OTHER,0,24.0,ESTIMATED,2025-09-01T16:18:19.676717,v2_robust,True,True,False,False,False,
NCT05703685,[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET,[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET,Apremilast,"['18F-PF-06445974', 'Apremilast']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Depression,['Depression'],"['PET Imaging', 'Depression', 'Phosphodiesterase-4']",RECRUITING,,2023-06-22,2029-04-11,"[{'measure': 'To measure distribution volume', 'description': 'Target quantification', 'timeFrame': '36 months'}]","[{'measure': 'To determine the optimal length', 'description': 'Target quantification', 'timeFrame': '36 months'}, {'measure': 'To measure whole-brain distribution volume in retest', 'description': 'Target quantification', 'timeFrame': '36 months'}, {'measure': 'measure clinical rating scales and PDE4B binding', 'description': 'Assess the severity of depression', 'timeFrame': '36 months'}]",4,18 Years,70 Years,ALL,True,National Institute of Mental Health (NIMH),NIH,0,108.0,ESTIMATED,2025-09-01T16:18:19.676730,v2_robust,True,True,False,False,False,
NCT03830385,"Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck","Open-Label, Multicenter, Phase Ⅱ Study Of Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin As First-Line Treatment In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck","PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin","['PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Squamous Cell Carcinoma Of The Head And Neck,['Squamous Cell Carcinoma Of The Head And Neck'],[],RECRUITING,,2019-02-15,2026-02-15,"[{'measure': 'overall survival', 'description': 'overall survival', 'timeFrame': '5 years'}]",[],1,18 Years,70 Years,ALL,False,Sun Yat-sen University,OTHER,0,51.0,ESTIMATED,2025-09-01T16:18:19.676780,v2_robust,True,True,False,False,False,
NCT01989585,Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma,"Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)",Dabrafenib,"['GSK 212', 'GSK212', 'GSK 2118436A', 'GSK-2118436', 'MEK Inhibitor GSK1120212', 'GSK-212', 'GSK2118436', 'GSK 2118436', 'JTP-74057', 'GSK 1120212', 'Dabrafenib', 'JTP74057', 'GSK-2118436A', 'BRAF Inhibitor GSK2118436', 'Trametinib', 'GSK-1120212', 'GSK1120212', 'JTP 74057', 'GSK2118436A']",19,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Clinical Stage III Cutaneous Melanoma AJCC v8,"['Clinical Stage III Cutaneous Melanoma AJCC v8', 'Clinical Stage IV Cutaneous Melanoma AJCC v8', 'Malignant Solid Neoplasm', 'Metastatic Melanoma', 'Unresectable Melanoma']",[],ACTIVE_NOT_RECRUITING,,2014-03-24,2025-12-31,"[{'measure': 'Recommended phase II dose of the combination of dabrafenib, trametinib, and navitoclax (Phase I)', 'description': 'Determined by dose-limiting toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events.', 'timeFrame': 'Up to 28 days'}, {'measure': 'Proportion of patients with a complete response (CR) (Phase II)', 'description': 'Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, in the cohort of patients treated with dabrafenib, trametinib, and navitoclax (DTN). The proportion of patients with a best response of CR will be presented with a 95% confidence interval calculated using the method of Atkinson and Brown.', 'timeFrame': 'Up to 4 weeks after last study treatment'}, {'measure': 'Maximal degree of tumor regression (Phase II)', 'description': 'A comparison between the maximal tumor regression for patients treated with DTN and dabrafenib and trametinib (DT) will be conducted using a Wilcoxon rank-sum test.', 'timeFrame': 'Up to 4 weeks after last study treatment'}]","[{'measure': 'Progression free survival (PFS) (Phase II)', 'description': 'PFS will be summarized using the Kaplan-Meier. Log-rank tests will be used to assess for indications of differences between the two treatment modalities.', 'timeFrame': 'Time from start of treatment to time of progression or death, whichever occurs first, assessed for up to 10 years'}, {'measure': 'Overall survival (OS) (Phase II)', 'description': 'OS will be summarized using the Kaplan-Meier. Log-rank tests will be used to assess for indications of differences between the two treatment modalities.', 'timeFrame': 'Up to 10 years'}, {'measure': 'Objective response rate (ORR) (Phase II)', 'description': 'ORRs will be presented with 95% exact, binomial confidence intervals.', 'timeFrame': 'Up to 4 weeks after last study treatment'}]",6,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,75.0,ESTIMATED,2025-09-01T16:18:19.676791,v2_robust,True,True,False,False,True,
NCT02421185,"Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma","A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced Hepatocellular Carcinoma",JNJ-42756493 (erdafitinib),['JNJ-42756493 (erdafitinib)'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Carcinoma, Hepatocellular","['Carcinoma, Hepatocellular']","['Carcinoma, Hepatocellular', 'JNJ 42756493', 'a pan-Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor']",COMPLETED,,2015-05-25,2019-05-16,"[{'measure': 'Part 1:Recommended Phase 2 Dose (RP2D)', 'description': 'RP2D will be determined based on pharmacodynamics, biomarker response or clinical response, as well as the incidence rate and nature of the toxicities observed.', 'timeFrame': 'Up to Part 1 Day 84 (Cycle 3, Day 28) (approximately 84 days)'}, {'measure': 'Number of participants with Objective Response', 'description': 'Objective response based on assessment of confirmed Complete response (CR) or partial response (PR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) for HCC. CR defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of the diameters of the target lesions taking as reference the Baseline sum diameters. Confirmed responses are those that persist on repeat imaging study for at least 4 weeks after initial documentation of response.', 'timeFrame': 'up to Month 12'}]","[{'measure': 'Number of Participants With Adverse Events', 'description': 'An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.', 'timeFrame': 'up to Month 12'}, {'measure': 'Time to Progression (TTP)', 'description': 'Time interval in months between the date of randomization and the date of disease progression or death due to progression, whichever occurred first.', 'timeFrame': 'up to Month 12'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'DCR defined as the proportion of participants with complete response \\[CR\\], partial response \\[PR\\], or stable disease \\[SD\\]), and duration of objective response (DOR).', 'timeFrame': 'up to Month 12'}, {'measure': 'Progression-free Survival', 'description': 'Time from date of randomization to date of first documentation of objective tumor progression or death due to any cause, whichever occurred first.', 'timeFrame': 'up to Month 12'}, {'measure': 'Maximum Observed Plasma Concentration of JNJ-42756493 (erdafitinib)', 'timeFrame': 'Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days)'}, {'measure': 'Time of Maximum Observed Plasma Concentration of JNJ-42756493 (erdafitinib)', 'timeFrame': 'Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days)'}, {'measure': 'Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)', 'description': 'The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption.', 'timeFrame': 'Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days)'}, {'measure': 'Half life of JNJ-42756493 (erdafitinib)', 'timeFrame': 'Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days)'}, {'measure': 'Apparent Volume of Distribution at Steady-State of JNJ-42756493 (erdafitinib)', 'timeFrame': 'Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days)'}, {'measure': 'Total Clearance of JNJ-42756493 (erdafitinib)', 'timeFrame': 'Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days)'}, {'measure': 'Accumulation Index of JNJ-42756493 (erdafitinib)', 'timeFrame': 'Up to Part 2 Day 84 (Cycle 3, Day 28) (approximately 84 days)'}, {'measure': 'Duration of Objective Response (DOR)', 'timeFrame': 'Up to Month 12'}]",14,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,53.0,ACTUAL,2025-09-01T16:18:19.676828,v2_robust,True,True,True,False,True,
NCT01933243,Treatment of Anxiety and Anorexia Nervosa in Adolescents,Treatment of Anxiety and Anorexia Nervosa in Adolescents,Fish oil,"['ProEPA Xtra soft gel capsules', 'Fish oil', 'Eicosapentaenoic acid (2120mg)/ docosahexaenoic acid (600mg)', 'soybean oil placebo capsules', 'Placebo pill']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Anxiety,"['Anxiety', 'Anorexia Nervosa']","['Anxiety', 'Anorexia nervosa', 'Adolescents', 'Fish oil']",COMPLETED,,2013-08,2016-12,"[{'measure': 'Medication Side Effects Score', 'description': 'At 6 and 12 weeks, medication tolerability was assessed via self-report of nine potential side effects (e.g. diarrhea, burping). Participants were asked whether they experienced these side effects ""never, rarely, occasionally, frequently, or very frequently."" Individual responses were assigned a numeric equivalent from 0 to 4, and summed for a total side effect score ranging from 0 to 36. Higher scores indicated greater frequency of side effects and lower medication tolerability.', 'timeFrame': '6 and12 weeks'}]","[{'measure': 'Beck Anxiety Inventory-Trait (BAIT)', 'description': 'The BAIT is a 21-item self-report measure of anxiety severity rated on a 4-point Likert scale (0= rarely or never; 3= almost always). It has shown acceptable reliability and validity in an adolescent psychiatric inpatient population. BAIT scores over 26 indicate severe anxiety, scores 16-25 indicate moderate anxiety, scores 8-15 indicate mild anxiety, and scores 0-7 indicate a minimal level of anxiety. We chose to measure trait anxiety to examine beyond meal-related (state) anxiety.', 'timeFrame': 'Baseline, 6 weeks, and 12 weeks'}]",2,12 Years,21 Years,ALL,False,Andrea Bonny,OTHER,0,24.0,ACTUAL,2025-09-01T16:18:19.676867,v2_robust,True,True,True,False,False,
NCT00152243,A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC),A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of UFT Compared With Surgery Alone for Serosa-negative Advanced Gastric Cancer (NSAS-GC),"UFT (uracil, tegafur)","['UFT (uracil, tegafur)']",1,INTERVENTIONAL,['PHASE3'],PHASE3,,Gastric Cancer,['Gastric Cancer'],['Stomach Cancer'],COMPLETED,,1997-06,2007-08,"[{'measure': 'Overall survival and relapse-free survival', 'timeFrame': 'every course for first three courses, then every other course'}]","[{'measure': 'Adverse events', 'timeFrame': 'any time'}]",2,20 Years,75 Years,ALL,False,"Taiho Pharmaceutical Co., Ltd.",INDUSTRY,0,500.0,ESTIMATED,2025-09-01T16:18:19.676916,v2_robust,True,True,True,False,True,
NCT04884243,"Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction","A Phase 2 Multicenter, Double-masked, Randomized, Vehicle-controlled, Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction",CBT-006,"['not apply', 'CBT-006']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Meibomian Gland Dysfunction,['Meibomian Gland Dysfunction'],[],COMPLETED,,2021-09-05,2023-08-17,"[{'measure': 'IOP of Study Eye Related to Safety', 'description': 'Intraocular Pressure of study eye related to safety', 'timeFrame': '12 weeks'}]",[],1,18 Years,,ALL,False,"Cloudbreak Therapeutics, LLC",INDUSTRY,0,92.0,ACTUAL,2025-09-01T16:18:19.676924,v2_robust,True,True,True,False,True,
NCT05445843,Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.,KontRASt-06: An Open-label Phase II Trial Evaluating the Activity and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.,JDQ443,['JDQ443'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation,['Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation'],"['Lung cancer', 'NSCLC', 'KRAS G12C', 'STK11', 'PD-L1', 'JDQ443']",ACTIVE_NOT_RECRUITING,,2022-10-31,2027-11-30,"[{'measure': 'Overall Response Rate (ORR) as determined by the Investigator in Cohort A', 'description': 'Overall Response Rate (ORR) is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the Investigator in Cohort A', 'timeFrame': 'Up to approximately 24 months'}]","[{'measure': 'Key Secondary Outcome Measure: Overall Response Rate (ORR) as determined by the Investigator in Cohort B', 'description': 'Overall Response Rate (ORR) is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the Investigator in Cohort B', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Number of adverse events and serious adverse events as assessed by CTCAE criteria', 'description': 'An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.\n\nTreatment emergent Adverse Event (TEAEs) in this study were events that started after the first dose of study treatment and until 30 days after the last dose of study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 30 days after the last study treatment.', 'timeFrame': 'Up to approximately 60 months'}, {'measure': 'Maximum concentration (Cmax) of JDQ443 in plasma', 'description': 'Blood samples will be collected for pharmacokinetics characterization.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Time to reach maximum concentration at steady-state (Tmax,ss) of JDQ443 in plasma', 'description': 'Blood samples will be collected for pharmacokinetics characterization.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of JDQ443 in plasma', 'description': 'Blood samples will be collected for pharmacokinetics characterization.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Area Under the Curve From Time Zero to the last measurable concentration sampling time at steady-state (AUClastss) of JDQ443 in plasma', 'description': 'Blood samples will be collected for pharmacokinetics characterization.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Observed concentration at the end of a dosing interval at steady-state (Cmin,ss) of JDQ443 in plasma', 'description': 'Blood samples will be collected for pharmacokinetics characterization.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Total body clearance (CL/F) of JDQ443 from the plasma', 'description': 'Blood samples will be collected for pharmacokinetics characterization.', 'timeFrame': 'Up to approximately 24 months'}]",9,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,96.0,ACTUAL,2025-09-01T16:18:19.676954,v2_robust,True,True,False,False,True,
NCT03510715,An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia,An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia,Alirocumab SAR236553 (REGN727),"['Nicotinic acid', 'Atorvastatin', 'Cholestyramine', 'Simvastatin', 'Fenofibrate', 'Rosuvastatin', 'Lovastatin', 'Pravastatin', 'Alirocumab SAR236553 (REGN727)', 'Omega-3 fatty acids', 'Ezetimibe', 'Fluvastatin']",12,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypercholesterolemia,['Hypercholesterolemia'],"['Pediatrics, Homozygous Familial Hypercholesterolemia, Alirocumab, PCSK9 inhibitor, Low-density Lipoprotein Cholesterol (LDL-C)']",COMPLETED,,2018-08-31,2020-02-17,"[{'measure': 'Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis', 'description': 'Adjusted least square (LS) means and standard errors were obtained from the mixed model analysis with repeated measures (MMRM) to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis).', 'timeFrame': 'Baseline to Week 12'}]","[{'measure': 'Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 12: On-treatment Analysis', 'description': 'Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline on-treatment data from Week 4 to Week 48 (on-treatment Analysis).', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Weeks 24 and 48: ITT Analysis/On-treatment Analysis', 'description': 'Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.', 'timeFrame': 'Baseline to Weeks 24 and 48'}, {'measure': 'Percent Change From Baseline in Apolipoprotein (Apo) B at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis', 'description': 'Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.', 'timeFrame': 'Baseline to Weeks 12, 24 and 48'}, {'measure': 'Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 12, 24 and 48 - ITT Analysis/On-treatment Analysis', 'description': 'Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.', 'timeFrame': 'Baseline to Weeks 12, 24 and 48'}, {'measure': 'Percent Change From Baseline in Total Cholesterol (Total-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis', 'description': 'Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Weeks 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.', 'timeFrame': 'Baseline to Weeks 12, 24 and 48'}, {'measure': 'Percent Change From Baseline in Lipoprotein a (Lp) (a) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis', 'description': 'Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 48 regardless of status on-or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.', 'timeFrame': 'Baseline to Weeks 12, 24 and 48'}, {'measure': 'Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis', 'description': 'Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Weeks 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.', 'timeFrame': 'Baseline to Weeks 12, 24 and 48'}, {'measure': 'Percent Change From Baseline in Fasting Triglycerides (TG) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis', 'description': 'Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.', 'timeFrame': 'Baseline to Weeks 12, 24 and 48'}, {'measure': 'Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis', 'description': 'Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.', 'timeFrame': 'Baseline to Weeks 12, 24 and 48'}, {'measure': 'Percentage of Participants Reporting >=15 Percent (%) Reduction in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis', 'description': 'Adjusted Percentage were obtained from a multiple imputation approach for handling of missing data including all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.', 'timeFrame': 'Baseline to Weeks 12, 24 and 48'}, {'measure': 'Absolute Change From Baseline in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis', 'description': 'Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.', 'timeFrame': 'Baseline to Weeks 12, 24 and 48'}, {'measure': 'Number of Participants With Tanner Staging at Baseline, Weeks 12, 24 and 48', 'description': 'Tanner stage defines physical measurements of development in children and adolescent based on external primary and secondary sex characteristics. Participants were evaluated for pubic hair distribution, breast development (only females) and genital development (only males), and classified in 3 categories as: Prepubescent (defined as a person just before start of the development of adult sexual characteristics), Pubescent (defined as a person at or approaching the age of puberty), Postpubescent (sexually mature or a person who has completed puberty).', 'timeFrame': 'Baseline, Weeks 12, 24 and 48'}]",13,8 Years,17 Years,ALL,False,Sanofi,INDUSTRY,1,18.0,ACTUAL,2025-09-01T16:18:19.677088,v2_robust,True,True,True,False,False,
NCT03463915,Clinical Trial Comparing Two Bladder Instillations for IC/BPS,Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome,Bladder instillation WITH triamcinolone acetonide,"['Bladder instillation WITHOUT triamcinolone acetonide', 'Bladder instillation WITH triamcinolone acetonide']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Interstitial Cystitis,"['Interstitial Cystitis', 'Bladder Pain Syndrome']","['Interstitial cystitis', 'Bladder pain syndrome', 'IC/BPS', 'Women', 'Pelvic pain', 'Urologic pain', 'Bladder instillation', 'Kenalog', 'Steroid']",COMPLETED,,2019-01-25,2020-10-23,"[{'measure': ""Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire"", 'description': 'Total scores range: 0-36 (0= no symptoms to 36= the most severe symptoms)', 'timeFrame': 'Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported'}]","[{'measure': 'Pelvic Pain and Urgency/Frequency (PUF) Questionnaire', 'description': 'Total scores range: 0-35 (0= no symptoms to 35= the most severe symptoms)', 'timeFrame': 'Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported'}, {'measure': 'Overactive Bladder Questionnaire (OAB-q)', 'description': 'Total scores range: 0-100 (higher scores on the symptom-severity scale suggestive of greater severity of symptoms and higher scores on the quality-of-life scale suggestive of better quality of life)', 'timeFrame': 'Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported'}, {'measure': 'Pelvic Floor Distress Inventory (PFDI)', 'description': '20 question self-administered questionnaire on the presence and absence of pelvic floor symptoms. Score ranges from 0 (least distress) to 300 (most distress).', 'timeFrame': 'Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported'}, {'measure': 'Sexual Function Measured by the Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR) Questionnaire', 'description': 'Measures sexual function in women with pelvic floor disorders. Queries about arousal, orgasm, partner-related issues, sexual quality, and desire. The tool also takes into account those who are not sexually active. The questionnaire was used in the study solely to determine if patients had improved dyspareunia (as a categorical variable).', 'timeFrame': 'Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported'}, {'measure': 'Change From Baseline in Treatment Response as Measured by the Visual Analogue Scale (VAS) for Pain', 'description': 'VAS is measured on marking on a 10-centimeter (cm) ruler (measured in cm, 0= no pain and 10= most severe pain possible)', 'timeFrame': 'Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported'}, {'measure': 'Number of Participants With at Least One Adverse Event', 'description': 'Adverse events will only be those determined to be related to the study drug', 'timeFrame': 'End of study (6 weeks)'}]",7,18 Years,,FEMALE,False,"Olivia Cardenas-Trowers, M.D.",OTHER,0,90.0,ACTUAL,2025-09-01T16:18:19.677192,v2_robust,True,True,True,False,True,
NCT03189615,Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects,"Interventional, Open-label, Three-group, Single-dose Study Investigating the Pharmacokinetic Properties of Lu AF35700 in Subjects With Hepatic Impairment (Mild or Moderate) and in Healthy Subjects",Lu AF35700,['Lu AF35700'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Hepatic Impairment,['Hepatic Impairment'],[],COMPLETED,,2017-05-14,2018-04-23,"[{'measure': 'Area under the Lu AF35700 plasma concentration-time curve from zero to infinity (AUC0-inf)', 'description': 'Area under the Lu AF35700 plasma concentration-time curve from zero to infinity (AUC0-inf)', 'timeFrame': 'Predose to day 57 postdose'}, {'measure': 'Maximum observed plasma concentration (Cmax) of Lu AF35700', 'description': 'Maximum observed plasma concentration (Cmax) of Lu AF35700', 'timeFrame': 'Predose to day 57 postdose'}]",[],2,18 Years,70 Years,ALL,True,H. Lundbeck A/S,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:19.677280,v2_robust,True,True,True,False,False,
NCT00507715,Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk,Clinical Trial to Study the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk,Plantago ovata husk,['Plantago ovata husk'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Parkinson's Disease, Idiopathic","[""Parkinson's Disease, Idiopathic""]","[""Parkinson's Disease, Idiopathic"", 'l-dopa levels', 'plantago ovata husk']",COMPLETED,,2006-09,2006-11,"[{'measure': 'To study how the fiber Plantago ovata husk modifies the pharmacokinetics parameters of the absorption and elimination of L-dopa.', 'timeFrame': '14 days'}]","[{'measure': 'To evaluate if the treatment with Plantago ovata husk modifies the biochemical parameters as total cholesterol, HDL y LDL, glycaemia, etc.', 'timeFrame': '14 days'}]",2,60 Years,80 Years,ALL,False,Rottapharm Spain,INDUSTRY,0,18.0,ACTUAL,2025-09-01T16:18:19.677321,v2_robust,True,True,True,False,False,
NCT00369915,The Antidepressant Efficacy of the Anticholinergic Scopolamine,The Antidepressant Efficacy of the Anticholinergic Scopolamine,Scopolamine,['Scopolamine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Unipolar Depression,"['Unipolar Depression', 'Bipolar Depression']","['Cholinergic', 'Unipolar', 'Bipolar', 'Depression', 'Muscarinic', 'Scopolamine', 'Major Depressive Disorder', 'MDD', 'Bipolar Disorder', 'BP']",TERMINATED,,2006-08,2013-01,"[{'measure': 'Change in Depression Severity', 'description': 'The Montgomery-Asberg Depression Rating Scale (MADRS) has a range of scores from 0 to 60 where the highest values indicate the most depression.', 'timeFrame': 'Outcome measures obtained at each of 12 sessions'}]","[{'measure': 'Hamilton Anxiety Rating Scale', 'description': 'The Hamilton Anxiety Rating Scale (HARS) has a range of scores from 0 to 56 where the highest values indicate the most anxiety.', 'timeFrame': 'Each of 12 sessions.'}]",2,18 Years,55 Years,ALL,False,National Institute of Mental Health (NIMH),NIH,0,17.0,ACTUAL,2025-09-01T16:18:19.677370,v2_robust,True,True,False,True,False,
NCT02135315,Intensive Arterial Pressure Control in Acute Coronary Syndrome,One-year Outcome of Intensive Versus Standard Blood Pressure Treatment in Non-ST Elevation Acute Coronary Syndrome: A Randomised Controlled Trial,Isosorbide Dinitrate,"['Isosorbide Dinitrate', 'Risordan']",2,INTERVENTIONAL,['NA'],,,Acute Coronary Syndrome,['Acute Coronary Syndrome'],"['Acute Coronary Syndrome, arterial pressure']",COMPLETED,,2014-03,2020-12-31,"[{'measure': 'mortality', 'description': '1-year death rate', 'timeFrame': '12 months'}, {'measure': 'major cardiovascular events (MACE)', 'description': '1-year MACE rate', 'timeFrame': '12months'}, {'measure': 'combined mortality and MACE rate', 'description': 'combined mortality and MACE rate at one year.', 'timeFrame': '1 year'}]","[{'measure': 'troponin change', 'description': 'troponin change between baseline and 24 hour after', 'timeFrame': '24 hours after baseline measurement'}, {'measure': 'Adverse events', 'description': 'Severe hypotension', 'timeFrame': '24 hours after start of protocol intervention'}]",5,30 Years,100 Years,ALL,False,University of Monastir,OTHER,1,1500.0,ACTUAL,2025-09-01T16:18:19.677398,v2_robust,True,True,True,False,True,
NCT00975715,"Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures","A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy",TRI476,"['Placebo to TRI476', 'TRI476', 'Benzodiazepines']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Partial Onset Seizures,['Partial Onset Seizures'],"['Seizures', 'oxcarbazepine', 'child']",COMPLETED,,2009-09,2012-10,"[{'measure': 'Percent Change in Partial Onset Seizure Frequency Per 28 Days From Baseline to the Double-blind Phase, by Treatment Group', 'description': 'Percent change in partial onset seizure frequency per 28 days during the double-blind phase from the screening phase, was calculated according to the following formula: ""Percent change in partial onset seizure frequency per 28 days from the screening phase"" = (partial onset seizure frequency per 28 days during the double-blind phase - partial onset seizure frequency per 28 days during the screening phase) / partial onset seizure frequency per 28 days during the double-blind phase x 100 ""Partial onset seizure frequency per 28 days"" = Number of partial onset seizures during each phase (screening phase or double-blind phase) / number of days during the screening or double-blind phase × 28.', 'timeFrame': 'screening and 28 days'}]","[{'measure': 'Partial Seizure Frequency Per 28 Days, by Study Period (Every 28 Days) and Treatment Group', 'description': 'Partial onset seizure frequency per 28 days during a period between baseline and Week 4 was measured. Partial onset seizure frequency per 28 days (count/28 days)"" = Number of partial onset seizures during each phase (screening phase or double-blind phase) / Number of days during the phase x 28.', 'timeFrame': 'baseline, 28 days and 56 days'}, {'measure': 'Percent of Participants With Response During Double-blind Phase, by Treatment Group', 'description': 'Responder rate was defined as the percent of participants with an at least 50% reduction in partial onset seizure frequency per 28 days from the screening phase.', 'timeFrame': 'screening to 28 days'}, {'measure': 'Percent Change in Partial Onset Seizure Frequency During the Double-blind Phase by Seizure Type', 'description': 'Percent change in seizure frequency from baseline = 100 (T-B)/B, B=Seizure frequency per 28 days during baseline phase, T=Seizure frequency per 28 days during the double-blind phase. Seizure frequency per 28 days is calculated as: (seizure frequency during the double-blind phase / the number of days the seizure information were provided) x 28. Only patients with both baseline and corresponding post-baseline values are included.', 'timeFrame': '28 days'}, {'measure': 'Number of Participants With Clinical Global Impression of Change (CGIC) at Final Assessment, by Treatment Group', 'description': 'Clinical Global Impression of Change (CGI) is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). CGI-C scores range from 1 (very much improved) through to 7 (very much worse).', 'timeFrame': '56 days'}]",5,4 Years,14 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,99.0,ACTUAL,2025-09-01T16:18:19.677446,v2_robust,True,True,True,False,False,
NCT01968135,Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study,Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study,Combined Oral Contraceptive Pill,"['Combined Oral Contraceptive Pill', 'Placebo Sugar Pill']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Uterine Hemorrhage,"['Uterine Hemorrhage', 'Contraception']",[],COMPLETED,,2013-10,2014-11,"[{'measure': 'Cessation of Vaginal Bleeding', 'description': 'Proportion of women in each group who stopped bleeding during therapy and continued to report no bleeding at the end of the 14-day treatment period.', 'timeFrame': 'At day 3 of 14 day course of study drug'}]","[{'measure': 'Number of Days Until Temporary Interruption of Bleeding During Therapy Occurred', 'timeFrame': 'over the 14 day course of study drug'}, {'measure': 'Number of Days Without Bleeding During Therapy', 'timeFrame': 'Over the 14 day course of study drug'}, {'measure': 'Number of Days to Recurrence of Bleeding After Discontinuation of Therapy', 'timeFrame': 'Up to six months'}]",4,18 Years,44 Years,FEMALE,True,"University of Colorado, Denver",OTHER,0,32.0,ACTUAL,2025-09-01T16:18:19.677481,v2_robust,True,True,True,False,False,
NCT04994535,A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence,"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence",OnabotulinumtoxinA,"['BOTOX', 'Placebo', 'OnabotulinumtoxinA']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Platysma Prominence,['Platysma Prominence'],"['Platysma Prominence', 'OnabotulinumtoxinA', 'BOTOX']",COMPLETED,,2021-08-10,2023-06-14,"[{'measure': 'Number of Participants With Adverse Events', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.', 'timeFrame': 'Enrollment to Day 120'}, {'measure': ""Composite Achievement of Grade 1 or 2 (Minimal or Mild) and at Least a 2-Grade Improvement From Baseline Based on Both Investigator's Assessment Using C-APPS and Participant's Self-Assessment Using P-APPS, at Maximum Contraction at Day 14"", 'description': ""The Clinician Allergan Platysma Prominence Scale (C-APPS) evaluates platysma prominence severity and is a static measurement encompassing the investigator's visual examination of the platysma muscle at maximum contraction, ranging from 1 - Minimal to 5- Extreme.\n\nThe Participant Allergan Platysma Prominence Scale (P-APPS) evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme."", 'timeFrame': 'Day 14'}, {'measure': ""Achievement of at Least a 2-grade Improvement From Baseline Based on the Investigator's Assessment Using C-APPS at Maximum Contraction at Day 14"", 'description': ""The C-APPS evaluates platysma prominence severity and is a static measurement encompassing the investigator's visual examination of the platysma muscle at maximum contraction, ranging from 1 - Minimal to 5- Extreme."", 'timeFrame': 'Day 14'}, {'measure': ""Achievement of at Least a 2-grade Improvement From Baseline Based on the Participant's Self-Assessment Using P-APPS at Maximum Contraction at Day 14"", 'description': 'The P-APPS evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.', 'timeFrame': 'Day 14'}]","[{'measure': ""Percentage of Participants Who Achieved Grade 1 or 2 (Minimal or Mild) According to Investigator's Assessment Using C-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120"", 'description': ""The C-APPS evaluates platysma prominence severity and is a static measurement encompassing the investigator's visual examination of the platysma muscle at maximum contraction, ranging from 1 - Minimal to 5- Extreme."", 'timeFrame': 'Day 14, 30, 60, 90, and 120'}, {'measure': ""Percentage of Participants Who Achieved Grade 1 or 2 (Minimal or Mild) According to Participant's Self-Assessment Using P-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120"", 'description': 'The P-APPS evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.', 'timeFrame': 'Day 14, 30, 60, 90, and 120'}, {'measure': 'Percentage of Participants With Responses of ""Satisfied"" or ""Very Satisfied"" on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction (Follow-up) Item 5 (Effect of Treatment) at Day 14', 'description': 'The ANLFQ: Satisfaction scale assesses how satisfied the participants are with the treatment they received for the appearance of their neck and lower face. Item 5 is a verbal descriptor scale ranging from 1 (Very satisfied) to 5 (Very dissatisfied).', 'timeFrame': 'Day 14'}, {'measure': ""Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the Bother Assessment Scale - Platysma Prominence (BAS-PP) Scale Item 2 (Jawline) at Day 14"", 'description': 'The BAS-PP Scale is a 2-item measure that asks participants to rate how bothered they are by the appearance of their vertical neck bands (Item 1) and jawline (Item 2) where items are rated from 1 (Not at all bothered) to 5 (Extremely bothered).', 'timeFrame': 'Day 14'}, {'measure': ""Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 1 (Vertical Neck Bands) at Day 14"", 'description': 'The BAS-PP Scale is a 2-item measure that asks participants to rate how bothered they are by the appearance of their vertical neck bands (Item 1) and jawline (Item 2) where items are rated from 1 (Not at all bothered) to 5 (Extremely bothered).', 'timeFrame': 'Day 14'}, {'measure': 'Change From Baseline on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Impacts Summary Score at Day 14', 'description': 'The ANLFQ: Impacts scale assesses the psychosocial impact due to the appearance of the neck and lower face. All items are rated on a 5-point Verbal Descriptor Scale ranging from 1 (Never) to 5 (All of the time), with higher summary scores (range: 7-35) indicating greater negative psychosocial impact from the appearance of the neck and lower face. For change from baseline in the ANLFQ: Impacts summary score, positive values indicate worsening and negative values indicate improvement in the psychosocial impact.', 'timeFrame': 'Day 14'}, {'measure': ""Percentage of Participants Who Achieved at Least 1-Grade Improvement From Baseline Based on Investigator's Assessment Using C-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120"", 'description': ""The C-APPS evaluates platysma prominence severity and is a static measurement encompassing the investigator's visual examination of the platysma muscle at maximum contraction, ranging from 1 - Minimal to 5- Extreme."", 'timeFrame': 'Day 14, 30, 60, 90, and 120'}, {'measure': ""Percentage of Participants Who Achieved at Least 1-Grade Improvement From Baseline Based on Participant's Assessment Using P-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120"", 'description': 'The P-APPS evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.', 'timeFrame': 'Day 14, 30, 60, 90, and 120'}, {'measure': ""Percentage of Participants Who Achieved a Rating of Minimal or Mild According to Participant's Assessment Using P-APPS at Maximum Contraction at Days 14"", 'description': 'The P-APPS evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.', 'timeFrame': 'Day 14'}, {'measure': 'Percentage of Participants With Responses of ""Satisfied"" or ""Very Satisfied"" on the ANLFQ: Satisfaction (Follow-up) Item 5 (Effect of Treatment) at Day 14', 'description': 'The ANLFQ: Satisfaction scale assesses how satisfied the participants are with the treatment they received for the appearance of their neck and lower face. Item 5 is a verbal descriptor scale ranging from 1 (Very satisfied) to 5 (Very dissatisfied).', 'timeFrame': 'Day 14'}, {'measure': ""Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 2 (Jawline) at Day 14"", 'description': 'The BAS-PP Scale is a 2-item measure that asks participants to rate how bothered they are by the appearance of their vertical neck bands (Item 1) and jawline (Item 2) where items are rated from 1 (Not at all bothered) to 5 (Extremely bothered).', 'timeFrame': 'Day 14'}, {'measure': 'Change From Baseline on the ANLFQ: Impacts Summary Score at Days 30, 60, and 90', 'description': 'The ANLFQ: Impacts scale assesses the psychosocial impact of the appearance of the neck and lower face. All items are rated on a 5-point Verbal Descriptor Scale ranging from 1 (Never) to 5 (All of the time), with higher scores indicating greater negative impact from the appearance of the neck and lower face.', 'timeFrame': 'Days 30, 60, and 90'}]",16,18 Years,,ALL,False,AbbVie,INDUSTRY,0,426.0,ACTUAL,2025-09-01T16:18:19.677540,v2_robust,True,True,True,False,True,
NCT01155635,Carvedilol Post-intervention Long-term Administration in Large-scale Trial,Carvedilol Post-intervention Long-term Administration in Large-scale Randomized Controlled Trial,Carvedilol,"['Carvedilol', 'No Carvedilol']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Myocardial Infarction,['Myocardial Infarction'],"['Myocardial infarction', 'Adrenergic beta-Antagonists', 'Percutaneous coronary intervention']",COMPLETED,,2010-07,2017-03,"[{'measure': 'All cause mortality', 'description': 'Death from any reason', 'timeFrame': '6-year'}, {'measure': 'Composite of death, myocardial infarction, acute coronary syndrome, heart failure hospitalization', 'timeFrame': '6-year'}]","[{'measure': 'Cardiac death', 'timeFrame': '6-year'}, {'measure': 'Sudden cardiac death', 'timeFrame': '6-year'}, {'measure': 'Cardiovascular death', 'timeFrame': '6-year'}, {'measure': 'Myocardial infarction', 'timeFrame': '6-year'}, {'measure': 'Acute coronary syndrome', 'timeFrame': '6-year'}, {'measure': 'Sustained ventricular tachycardia or ventricular fibrillation', 'timeFrame': '6-year'}, {'measure': 'Heart failure hospitalization', 'timeFrame': '6-year'}, {'measure': 'Stent thrombosis', 'description': 'Stent thrombosis defined by Academic Research Consortium', 'timeFrame': '6-year'}, {'measure': 'Target-vessel revascularization', 'timeFrame': '6-year'}, {'measure': 'Clinically-driven target-lesion revascularization', 'timeFrame': '6-year'}, {'measure': 'Any coronary revascularization', 'timeFrame': '6-year'}, {'measure': 'Any clinically-driven coronary revascularization', 'timeFrame': '6-year'}, {'measure': 'Coronary artery bypass grafting', 'timeFrame': '6-year'}, {'measure': 'Stroke', 'description': 'Any ischemic and hemorrhagic strokes excluding transient ischemic attacks', 'timeFrame': '6-year'}, {'measure': 'Worsening of angina due to coronary spasm', 'timeFrame': '6-year'}, {'measure': 'Bleeding complications', 'description': 'Bleeding complications defined by GUSTO and TIMI definitions', 'timeFrame': '6-year'}, {'measure': 'Composite of death, myocardial infarction, stroke, acute coronary syndrome, heart failure hospitalization, any coronary revascularization', 'timeFrame': '6-year'}, {'measure': 'Composite of cardiac death, myocardial infarction, acute coronary syndrome, heart failure hospitalization', 'timeFrame': '6-year'}, {'measure': 'Composite of cardiovascular death, myocardial infarction, stroke', 'timeFrame': '6-year'}]",21,,,ALL,False,Takeshi Morimoto,OTHER,0,801.0,ACTUAL,2025-09-01T16:18:19.677709,v2_robust,True,True,True,False,False,
NCT01437735,Dose Finding Study for QAW039 in Asthma,"A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.",QAW039,"['Montelukast', 'QAW039', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Asthma,['Asthma'],"['Asthma', 'QAW039']",COMPLETED,,2011-08,2013-11,"[{'measure': 'Change in trough Forced Expiratory Volume in 1 second (FEV1) from baseline to week 12', 'description': 'Forced Expiratory Volume in 1 second (FEV1) (measured in litters), and the trough measurement is taken 24 hours after morning dose on the previous day.', 'timeFrame': 'Baseline and week 12'}]","[{'measure': 'Change in Asthma Control Questionnaire (ACQ) score from baseline to week 12', 'description': 'The Asthma Control Questionnaire (ACQ) is a validated questionnaire consisting of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 assessing the patients Forced Expiratory Volume in 1 second (FEV1) result against the predicted result for a person of similar age and stature. Each item is graded on a scale of 0-6, and a mean score of 1.5 or greater is considered to demonstrate inadequate asthma control in this trial. The minimal important difference that is considered clinically important is a change of 0.5 in the mean score.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Change in Forced Expiratory Volume in 1 second (FEV1) from baseline to weeks 2, 4 and 8.', 'description': 'Forced Expiratory Volume in 1 second (FEV1) (measured in litters), and the measurement is taken 24 hours after the morning dose on the previous day.', 'timeFrame': 'Baseline, week 2, week 4 and week 8'}, {'measure': 'Change in the Asthma Control Questionnaire (ACQ) score from baseline to weeks 2, 4 and 8.', 'description': 'The Asthma Control Questionnaire (ACQ) is a validated questionnaire consisting of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 assessing the patients Forced Expiratory Volume in 1 second (FEV1) result against the predicted result for a person of similar age and stature. Each item is graded on a scale of 0-6, and a mean score of 1.5 or greater is considered to demonstrate inadequate asthma control in this trial. The minimal important difference that is considered clinically important is a change of 0.5 in the mean score.', 'timeFrame': 'Baseline, week 2, week 4 and week 8'}, {'measure': 'Change in the dose response relationship among QAW039 doses with respect to Forced Expiratory Volume in 1 second (FEV1) after 12 weeks treatment.', 'description': 'Forced Expiratory Volume in 1 second (FEV1) (measured in litters), and the measurement is taken 24 hours after the morning dose on the previous day.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Comparison of vital signs, ECG, laboratory tests and adverse events across QAW039 doses and placebo.', 'description': 'Comparisons of vital signs (i.e. systolic and diastolic blood pressure, pulse rate), ECG (e.g. quantitative assessments - heart rate, QTcF, PRS, PR intervals), laboratory tests (haematology, clinical chemistry and urinalysis) and adverse events across QAW039 doses and placebo.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Comparison of efficacy of QAW039 with that of active comparator as an add-on therapy to Inhaled Corticosteroids (ICS)', 'description': 'Forced Expiratory Volume in 1 second (FEV1) measurement taken 24 hours after the morning dose on the previous day. The Asthma Control Questionnaire (ACQ)consisting of 7 items: 5 on system assessment, 1 on rescue bronchodilator use and 1 assessing the patients for FEV1 result against the predicted result for a person of similar age and stature. Each item is graded on a scale of 0-6, and a mean score of 1.5 or greater is considered to demonstrate inadequate asthma control in this trial. The minimal important difference that is considered clinically important is a change of 0.5 in the mean score.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Assess the effect of QAW039 on asthma symptoms as measured by asthma control diary.', 'description': 'The asthma control diary mimics the Asthma Control Questionnaire (ACQ), but is recorded daily by the patient, rather than at each visit. As for the ACQ, the ACD consists of 7 questions.', 'timeFrame': 'Baseline and week 12'}]",8,18 Years,65 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,1043.0,ACTUAL,2025-09-01T16:18:19.677741,v2_robust,True,True,True,False,True,
NCT03824535,18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules,18F-FSPG PET/CT and Integrated Biomarkers for Early Lung Cancer Detection in Patients With Indeterminate Pulmonary Nodules,Fludeoxyglucose F-18,"['Fluorodeoxyglucose F18', 'fludeoxyglucose F 18', 'FDG', 'Fludeoxyglucose F-18', 'Fludeoxyglucose F18', '18-FDG', '(S)-4-(3-18F-fluoropropyl)-L-glutamic Acid', '18F-FSPG', 'BAY94-9392', 'Fluorine-18 2-Fluoro-2-deoxy-D-Glucose', 'Fluorine F 18 L-glutamate Derivative BAY94-9392']",11,INTERVENTIONAL,['PHASE2'],PHASE2,,Cigarette Smoker,"['Cigarette Smoker', 'Current Smoker', 'Former Smoker', 'Multiple Pulmonary Nodules', 'Pulmonary Nodule']",['Indeterminate lung nodule'],COMPLETED,,2019-02-04,2021-07-30,"[{'measure': 'Diagnostic Performance Metrics (Sensitivity, Specificity, PPV, NPV, and Accuracy) of Ultrasonography and Capnography for Malignant Lung Nodules', 'description': 'The diagnostic performance of ultrasonography and capnography in detecting malignant lung nodules was assessed using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. Sensitivity and specificity were calculated to determine the ability to correctly identify malignant and non-malignant nodules, respectively. Results were compared to a predefined threshold of 75%, with all percentages reported as proportions of the total number of nodules analyzed. Confidence intervals were calculated for each metric to ensure precision and reliability in the estimates.', 'timeFrame': 'Through study completion, an average of 2 years and 6 months'}]","[{'measure': 'Improvement in Predictive Accuracy of Lung Nodule Diagnosis Using the C Statistic (Area Under the Curve, AUC)', 'description': 'The predictive accuracy of the lung nodule diagnosis model was assessed using the C statistic, also referred to as the area under the receiver operating characteristic (ROC) curve (AUC). Improved performance was defined as a statistically significant increase (p \\< 0.05) in the C statistic, determined using the DeLong test for comparing correlated ROC curves. The Mann-Whitney U test was also used to compare the distributions of the C statistic between diagnostic methods. Results are reported as the mean C statistic with 95% confidence intervals for each diagnostic method.', 'timeFrame': 'Through study completion, an average of 2 years and 6 months'}]",2,45 Years,,ALL,False,Andrei Iagaru,OTHER,3,15.0,ACTUAL,2025-09-01T16:18:20.949430,v2_robust,True,True,True,False,False,
NCT03597035,Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On,Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On,Spironolactone,"['Veltassa', 'Spironolactone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Type2 Diabetes,"['Type2 Diabetes', 'Hyperkalemia']",[],TERMINATED,The study could not enroll patients owing to the inclusion exclusion criteria,2018-07-17,2020-07-31,"[{'measure': 'Left Ventricular Mass', 'description': 'Change in left ventricular mass from baseline to 12 months.', 'timeFrame': 'Time 0: study baseline, beginning of treatment. Time 1: 12 months follow-up, end of treatment.'}]",[],1,45 Years,,ALL,False,University Hospitals Cleveland Medical Center,OTHER,1,8.0,ACTUAL,2025-09-01T16:18:20.949636,v2_robust,True,True,False,True,False,The study could not enroll patients owing to the inclusion exclusion criteria
NCT00000735,A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC,A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC,Ampligen,['Ampligen'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,HIV Infections,['HIV Infections'],"['Virus Replication', 'T-Lymphocytes', 'Infusions, Intravenous', 'Immunologic Surveillance', 'Acquired Immunodeficiency Syndrome', 'ampligen', 'AIDS-Related Complex', 'Antiviral Agents']",COMPLETED,,,1990-02,[],[],0,12 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,12.0,,2025-09-01T16:18:20.949765,v2_robust,True,True,True,False,False,
NCT02386735,Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD,"Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD - a Randomized, Double-blind, Non-inferiority Study (The ""RECUT""-Trial)",Placebo,"['Prednisone', 'Placebo']",2,INTERVENTIONAL,['NA'],,,"Pulmonary Disease, Chronic Obstructive","['Pulmonary Disease, Chronic Obstructive', 'Adverse Effect of Glucocorticoids and Synthetic Analogues', 'Disease Exacerbation']","['Corticosteroid treatment', 'COPD', 'Primary Health Care', 'Randomized controlled trial']",TERMINATED,"Low recruitment rate, motivation and engagement of participating GPs unfortunately declined over time, as well as the financial resources.",2015-03,2024-07-31,"[{'measure': 'Time to next exacerbation', 'timeFrame': 'Six month follow-up period after index exacerbation.'}]","[{'measure': 'Cumulative glucocorticoid dose', 'timeFrame': 'Six month follow-up period after index exacerbation.'}, {'measure': 'Glucocorticoid side effects and complications', 'timeFrame': 'Six month follow-up period after index exacerbation.'}, {'measure': 'Change in FEV1', 'timeFrame': '7 days follow-up period after index exacerbation.'}, {'measure': 'Hospitalization rate during index exacerbation', 'timeFrame': 'Six month follow-up period after index exacerbation.'}, {'measure': 'Overall mortality', 'timeFrame': 'Six month follow-up period after index exacerbation.'}]",6,40 Years,,ALL,False,Prof. Dr. Jörg Leuppi,OTHER,2,133.0,ACTUAL,2025-09-01T16:18:20.949853,v2_robust,True,True,False,True,False,"Low recruitment rate, motivation and engagement of participating GPs unfortunately declined over time, as well as the financial resources."
NCT00176735,Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer,Pilot Trial of Capecitabine and Radiation Therapy With Pre and Post Combination Chemotherapy in Advanced Pancreatic Cancer,Capecitabine,['Capecitabine'],1,INTERVENTIONAL,['NA'],,,Pancreatic Cancer,['Pancreatic Cancer'],[],TERMINATED,,2001-12,2005-08,[],[],0,18 Years,,ALL,,University of Michigan Rogel Cancer Center,OTHER,0,,,2025-09-01T16:18:20.949880,v2_robust,True,True,False,True,False,
NCT02147808,A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects,"A Phase 1, Open-Label, Single-Center, 2-Period, Single-Sequence Drug-Drug Interaction Study to Evaluate the Effects of Multiple-Dose Telotristat Etiprate on the Pharmacokinetics of Single-Dose Midazolam, a Sensitive P450-3A4 Substrate, in Healthy Male and Female Subjects",Telotristat etiprate,"['Midazolam', 'Telotristat etiprate']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Drug Interactions,['Drug Interactions'],[],COMPLETED,,2014-05,,"[{'measure': 'Midazolam plasma concentration in combination with steady state telotristat etiprate', 'timeFrame': 'Day 9'}]","[{'measure': 'Number of treatment emergent adverse events', 'timeFrame': '12 days'}]",2,18 Years,55 Years,ALL,True,Lexicon Pharmaceuticals,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:20.949952,v2_robust,True,True,True,False,True,
NCT01506908,Provoked Craving Assessment,Evaluation of the Nicotine Mini Lozenge in Relief of Provoked Acute Craving,oral nicotine,"['oral nicotine', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Smoking Dependence,"['Smoking Dependence', 'Smoking']",['craving'],COMPLETED,,2011-09,2011-12,"[{'measure': 'Change From Post-cue Baseline in Nicotine Craving Score at 5 Minutes', 'description': 'Participants completed a nicotine craving assessment consisting of following five items: I have a desire for a cigarette right now, if it were possible I would smoke right now, All I want right now is a cigarette, I have an urge for a cigarette, I crave a cigarette right now. All participants indicated their craving intensity on a pre-drawn 100 mm scale ranging from 0 (disagree) to 100 (agree). At the end of the craving assessment period, mean VAS score was measured.', 'timeFrame': 'Post-cue baseline,5 minutes'}]","[{'measure': 'Change From Post-cue Baseline in Nicotine Craving Score at 1 Minute', 'description': 'Participants completed a nicotine craving assessment consisting of following five items: I have a desire for a cigarette right now, if it were possible I would smoke right now, All I want right now is a cigarette, I have an urge for a cigarette, I crave a cigarette right now. All participants indicated their craving intensity on a pre-drawn 100 mm scale ranging from 0 (disagree) to 100 (agree). At the end of the craving assessment period, mean VAS score was measured.', 'timeFrame': 'Post-cue baseline, 1 minute post treatment administration'}, {'measure': 'Change From Post-cue Baseline in Nicotine Craving Score at 3 Minutes', 'description': 'Participants completed a nicotine craving assessment consisting of following five items: I have a desire for a cigarette right now, if it were possible I would smoke right now, All I want right now is a cigarette, I have an urge for a cigarette, I crave a cigarette right now. All participants indicated their craving intensity on a pre-drawn 100 mm scale ranging from 0 (disagree) to 100 (agree). At the end of the craving assessment period, mean VAS score was measured.', 'timeFrame': 'Post-cue Baseline, 3 minutes post treatment administration'}, {'measure': 'Change From Post-cue Baseline in Nicotine Craving Score at 7 Minutes', 'description': 'Participants completed a nicotine craving assessment consisting of following five items: I have a desire for a cigarette right now, if it were possible I would smoke right now, All I want right now is a cigarette, I have an urge for a cigarette, I crave a cigarette right now. All participants indicated their craving intensity on a pre-drawn 100 mm scale ranging from 0 (disagree) to 100 (agree). At the end of the craving assessment period, mean VAS score was measured.', 'timeFrame': 'Post-Cue Baseline, 7 minutes post treatment administration'}, {'measure': 'Change From Post-cue Baseline in Nicotine Craving Score at 10 Minutes', 'description': 'Participants completed a nicotine craving assessment consisting of following five items: I have a desire for a cigarette right now, if it were possible I would smoke right now, All I want right now is a cigarette, I have an urge for a cigarette, I crave a cigarette right now. All participants indicated their craving intensity on a pre-drawn 100 mm scale ranging from 0 (disagree) to 100 (agree). At the end of the craving assessment period, mean VAS score was measured.', 'timeFrame': 'Post-Cue Baseline, 10 minutes post treatment administration'}, {'measure': 'Number of Participants With Adverse Events (AEs), Treatment Related AEs, and Serious AEs (SAEs)', 'description': 'AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with study treatment/s. Treatment related AE was defined as any AE considered to be possibly, probably or highly probably related to study medication. SAE was defined as any untoward medical occurrence that at any dose results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization results in disability/ incapacity; is a congenital anomaly/ birth defect.', 'timeFrame': 'Baseline to Day 5 post treatment administration'}]",6,18 Years,,ALL,True,GlaxoSmithKline,INDUSTRY,0,323.0,ACTUAL,2025-09-01T16:18:20.949974,v2_robust,True,True,True,False,True,
NCT05256108,Assessment of Abuse Potential of Cebranopadol in Humans,"A Single-dose, Randomized, Double-blind, Placebo- and Active-controlled Crossover Trial to Evaluate the Abuse Potential of Two Doses of Cebranopadol in Adult Nondependent Recreational Opioid Users",Oxycodone 40 mg,"['Qualification Phase/ Treatment Phase', 'Cebranopadol 1000 µg', 'Tramadol 600 mg', 'Placebo', 'Oxycodone 40 mg', 'Treatment Phase', 'Cebranopadol 600 µg']",7,INTERVENTIONAL,['PHASE1'],PHASE1,,Human Abuse Potential,['Human Abuse Potential'],"['pain', 'abuse', 'opioid']",COMPLETED,,2022-03-28,2022-07-12,"[{'measure': 'Drug Liking Visual analog scale (VAS) Emax', 'description': 'The scale is a 0-100-point scale: 0 = ""Strong disliking""; 50 = ""Neither like nor dislike""; 100 = ""Strong liking""', 'timeFrame': 'Treatment Phase: Intervals from predose to 48 hours post-dose'}]","[{'measure': 'VAS rating for Overall Liking', 'description': 'The scale is a 0-100-point scale: 0 = ""Strong Disliking"", 50 = ""Neither Like nor Dislike"", 100 = ""Strong Liking""', 'timeFrame': 'Treatment Phase: Intervals from predose to 48 hours post-dose'}, {'measure': 'VAS rating for Take Drug Again', 'description': 'The scale is a 0-100-point scale: 0 = ""Definitely would not""; 50 = ""Do not care""; 100 = ""Definitely would""', 'timeFrame': 'Treatment Phase: Intervals from predose to 48 hours post-dose'}, {'measure': 'Pupillometry', 'description': 'Data from a series of frames will be used in the calculation, and the final display will show the weighted average and standard deviation of the pupil size. Measurements will be collected under mesopic lighting conditions', 'timeFrame': 'Treatment Phase: Intervals from predose to 48 hours post-dose'}, {'measure': 'Multi-Tasking Test', 'description': 'Formerly known as the Attention Switching Task (AST), is a test of executive function which provides a measure of the ability to use multiple sources of potentially conflicting information to guide behavior.', 'timeFrame': 'Treatment Phase: Intervals from predose to 48 hours post-dose'}]",5,18 Years,55 Years,ALL,True,"Tris Pharma, Inc.",INDUSTRY,0,38.0,ACTUAL,2025-09-01T16:18:20.950119,v2_robust,True,True,True,False,False,
NCT02433808,Neostigmine Reversal And Neuromuscular Recovery,Neostigmine Reversal And Neuromuscular Recovery,Neostigmine Group,['Neostigmine Group'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Residual Neuromuscular Block,['Residual Neuromuscular Block'],[],COMPLETED,,2015-04,2017-04,"[{'measure': 'Change in train-of-four (TOF) ratio', 'description': 'The effect of neostigmine or placebo (saline) on TOF ratios, when given at full neuromuscular recovery, will be assessed', 'timeFrame': '30 minutes after the end of the surgical procedure'}]","[{'measure': 'airway obstruction-presence or absence (yes or no)', 'description': 'Any episodes of airway obstruction will be recorded', 'timeFrame': '30 minutes after the end of the surgical procedure'}, {'measure': 'hypoxemic events (oxygen saturation by pulse oximeter (SpO2) < 94%)', 'description': 'Any hypoxemic events will be recorded', 'timeFrame': '30 minutes after the end of the surgical procedure'}]",3,18 Years,80 Years,ALL,True,Endeavor Health,OTHER,0,120.0,ACTUAL,2025-09-01T16:18:20.950139,v2_robust,True,True,True,False,False,
NCT00871208,Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy,"Randomized, Placebo-Controlled Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids vs. Low-Potency Corticosteroid Mono-therapy",Altabax (R),"['Locoid lipocream (R)', 'Altabax(R)ointment', 'Vehicle and Locoid lipocream (R)', 'Altabax (R)']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Atopic Dermatitis,['Atopic Dermatitis'],"['Atopic Dermatitis', 'pruritus', 'quality of life']",WITHDRAWN,Funding withdrawn,2009-05,2010-05,"[{'measure': 'Superiority of drug to vehicle in reducing Eczema Area and Severity Index (EASI) scores in children with atopic dermatitis', 'timeFrame': 'Each patient will be enrolled for a 4 week trial'}]","[{'measure': 'Improved quality of life with usage of the drug altabax (R) and topical corticosteroids over vehicle and topical corticosteroids for treatment of atopic dermatitis in children with atopic dermatitis.', 'timeFrame': '4 week trial of medication'}]",2,9 Months,17 Years,ALL,True,St. Luke's-Roosevelt Hospital Center,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:20.950181,v2_robust,True,True,False,True,False,Funding withdrawn
NCT06549608,A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada,Patient Characteristics and Treatment Duration of Mavacamten Obstructive HCM Patient Support Program in Canada: A Retrospective Cohort Study,Mavacamten,['Mavacamten'],1,OBSERVATIONAL,[],,,Hypertrophic Cardiomyopathy,['Hypertrophic Cardiomyopathy'],['Hypertrophic cardiomyopathy'],ACTIVE_NOT_RECRUITING,,2024-04-20,2025-04-18,"[{'measure': 'Participant demographics', 'timeFrame': 'Baseline'}, {'measure': 'Participant clinical characteristics', 'timeFrame': 'Baseline'}]","[{'measure': 'Dose regimen of mavacamten treatment', 'timeFrame': 'Every 3-months up to 14 months'}, {'measure': 'Titration patterns of mavacamten treatment', 'timeFrame': 'Up to 14 months'}, {'measure': 'Mavacamten treatment duration', 'timeFrame': 'Up to 14 months'}]",5,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,685.0,ACTUAL,2025-09-01T16:18:20.950202,v2_robust,False,True,False,False,False,
NCT00465608,Propranolol in Post Traumatic Stress Disorder,Reduction of the Traumatic Memory by Reconsolidation Blockade: A Pilot Study,propranolol,"['propranolol', 'betablocker']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Post-Traumatic Stress Disorder,['Post-Traumatic Stress Disorder'],"['adults', 'PTSD', 'trauma', 'AZF', 'propranolol', 'reconsolidation', 'Post traumatic stress disorder', 'chronic form', 'PTSD (Post-Traumatic Stress Disorder)']",COMPLETED,,2007-04,2008-11,"[{'measure': 'PTSD Checklist score', 'timeFrame': '3 months'}]","[{'measure': 'SCID diagnosis', 'timeFrame': '3 months'}]",2,18 Years,65 Years,ALL,False,"University Hospital, Toulouse",OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:20.950243,v2_robust,True,True,True,False,False,
NCT02452008,Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer,Overcoming Drug Resistance in Metastatic Castration-resistant Prostate Cancer With Novel Combination of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide: a Randomized Multi-site Phase II Study,Enzalutamide,"['TGF-β receptor inhibitor', 'XTANDI', 'LY2157299', 'Enzalutamide']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],"['metastatic castration-resistant prostate cancer', 'enzalutamide', 'LY2157299', 'TGF-β receptor inhibitor']",ACTIVE_NOT_RECRUITING,,2016-05-03,2026-05,"[{'measure': 'Progression free survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299 (Arm 1) versus enzalutamide alone (Arm 2) using RECIST 1.1 criteria.', 'timeFrame': '4 years'}]","[{'measure': 'Tumor marker kinetics (PSA) in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299 (Arm 1) versus enzalutamide alone (Arm 2).', 'timeFrame': '4 years'}, {'measure': 'Overall survival (OS) in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299 (Arm 1) versus enzalutamide alone (Arm 2).', 'timeFrame': '4 years'}, {'measure': 'Number of patients experiencing treatment-related toxicities', 'timeFrame': '4 years'}]",4,18 Years,100 Years,MALE,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,2,60.0,ESTIMATED,2025-09-01T16:18:20.950268,v2_robust,True,True,False,False,False,
NCT03965208,Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation,"Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation: an Open Label, Parallel Group Randomized Pilot Study (BIV-ECMO2)",Bivalirudin,"['Bivalirudin', 'Angiomax', 'Unfractionated heparin']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Extracorporeal Membrane Oxygenation Complication,"['Extracorporeal Membrane Oxygenation Complication', 'Anticoagulants']",[],UNKNOWN,,2019-05-23,2020-12-31,"[{'measure': 'Percentage of time in the target anticoagulation range', 'description': 'activated partial thromboplastin time', 'timeFrame': 'From ECMO cannulation (start of ECMO) until patient is decannulated up to 12 weeks'}]","[{'measure': 'Major bleeding events', 'timeFrame': 'From ECMO cannulation (start of ECMO) until patient is decannulated up to 12 weeks'}, {'measure': 'Major clinical thrombotic events', 'timeFrame': 'From ECMO cannulation (start of ECMO) until patient is decannulated up to 12 weeks'}, {'measure': 'Duration of oxygenator use', 'timeFrame': 'From ECMO cannulation (start of ECMO) until patient is decannulated up to 12 weeks'}]",4,18 Years,,ALL,False,Legacy Health System,OTHER,1,34.0,ESTIMATED,2025-09-01T16:18:20.950501,v2_robust,True,True,False,False,False,
NCT00810108,Lopinavir/Ritonavir (Kaletra) PK in Children,Pharmacokinetics of Lopinavir Crushed Versus Whole Tablets in Pediatric Patients,lopinavir/ritonavir (Kaletra®) tablets,"['lopinavir/ritonavir (Kaletra®) tablets', 'Kaletra®']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,HIV/AIDS Treatment,"['HIV/AIDS Treatment', 'HIV Infections']","['HIV/AIDS', 'pediatrics', 'resource-limited settings', 'lopinavir', 'ritonavir', 'Kaletra®', 'antiretroviral treatment', 'crushed tablets', 'treatment experienced']",COMPLETED,,2006-06,2009-05,"[{'measure': 'Lopinavir Area Under the Curve (AUC)', 'description': 'Lopinavir Area Under the Plasma Concentration versus Time Curve (AUC)', 'timeFrame': 'pre-dose, 1,2,4,6,8, and 12 hours post-dose'}]",[],1,6 Years,17 Years,FEMALE,False,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,1,12.0,ACTUAL,2025-09-01T16:18:20.950516,v2_robust,True,True,True,False,False,
NCT04274608,"Intra-gastric Fundal and Body Injection of Botulinum Toxin A for Weight Loss, a Randomized Controlled Trial","Intra-gastric Fundal and Body Injection of Botulinum Toxin A for Weight Loss, a Randomized Controlled Trial",Botulinum toxin type A,['Botulinum toxin type A'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Obesity,"['Obesity', 'Weight Loss']",[],UNKNOWN,,2020-01-01,2022-07,"[{'measure': 'Weight loss', 'description': 'Examine the average weight loss', 'timeFrame': '1 year'}, {'measure': 'Time to weight regain following a single injection of intra-gastric Botox', 'timeFrame': '1 year'}]","[{'measure': 'Gut hormone level', 'description': 'Ghrelin', 'timeFrame': '1 year'}, {'measure': 'Gut hormone level ( Leptin)', 'description': 'Leptin', 'timeFrame': '1 year'}, {'measure': 'Satiety index', 'timeFrame': '1 year'}, {'measure': 'Co-morbidities', 'description': 'Diabetes, hypertension, hyperlipidemia', 'timeFrame': '1 year'}]",6,21 Years,65 Years,ALL,True,Tan Tock Seng Hospital,OTHER,0,18.0,ESTIMATED,2025-09-01T16:18:20.950551,v2_robust,True,True,False,False,False,
NCT02935725,A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males,"A Phase 1, Single-centre, Double-blind, Placebocontrolled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants",Low dose AUT00206 800mg,"['Low dose AUT00206 800mg', 'Ketamine', 'High dose AUT00206 2000 mg', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Schizophrenia,['Schizophrenia'],[],COMPLETED,,2016-10,2017-11,"[{'measure': 'Significant difference in BOLD phMRI signals after dosing with AUT00206 vs placebo', 'timeFrame': '15 Weeks'}]",[],1,18 Years,45 Years,MALE,True,Autifony Therapeutics Limited,INDUSTRY,1,22.0,ACTUAL,2025-09-01T16:18:20.950808,v2_robust,True,True,True,False,False,
NCT01646125,"An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations","A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment",AUY922,"['TAXOTERE', 'AUY922', 'Pemetrexed', 'Docetaxel', 'ALIMTA']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Non Small Cell Lung Cancer (NSCLC),['Advanced Non Small Cell Lung Cancer (NSCLC)'],"['Non-small cell lung carcinoma (NSCLC)', 'treatment of lung cancer after first metastasis', 'lung cancer', 'lung adenocarcinoma', 'Squamous cell lung carcinoma', 'Large-cell lung carcinoma', 'Non small cell lung carcinoma', 'Non small cell lung cancer', 'Non-small cell lung cancer', 'NSCLC', 'Large cell lung carcinoma', 'Large cell lung cancer', 'HSP90', 'AUY922', 'Pemetrexed', 'Docetaxel', 'EGFR TKI', 'EGFR mutations']",TERMINATED,"An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended study termination due to futility.",2012-11-23,2015-11-04,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'Compared PFS between the treatment of AUY922 to comparators Pemetrexed or Docetaxel. Progression-free survival (PFS) based on local investigator assessment per RECIST 1.1 was the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient had not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions', 'timeFrame': '16 months'}]","[{'measure': 'Overall Response Rate (ORR)', 'description': 'ORR was to be compared between treatment arms. The ORR was to be based on local investigator assessment per Response Evaluation Criteria In Solid Tumors Criteria 1.1 (RECIST 1.1). Per this criteria for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.This outcome measure was originally planned to be analyzed up to 24 months. The DMC recommendation at the IA was to stop the study for futility. As a result, collection of all the efficacy assessments was stopped at that time.', 'timeFrame': '16 months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from the date of randomization to date of death due to any cause. If a death has not been observed by the date of analysis cutoff, then OS was to be censored at the last known date patient was alive.', 'timeFrame': 'from randomization until death up to death'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Duration of DCR will be compared between treatment arms. The duration of DCR will be based on local investigator assessment per RECIST 1.1', 'timeFrame': 'baseline, until disease progression up to 24 months'}, {'measure': 'Time to Response (TRR)', 'description': 'TTR was to compare between treatment arms. The TTR was to be based on local investigator assessment per RECIST 1.1', 'timeFrame': 'baseline, until disease progression up to 24 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'The DOR will be compared between treatment arms. The DOR will be based on local investigator assessment per RECIST 1.1', 'timeFrame': 'baseline, until disease progression up to 24 months'}, {'measure': 'Rate of Adverse Events (AEs)', 'description': 'To evaluate safety and tolerability of AUY922 compared to chemotherapy agents pemetrexed or docetaxel.', 'timeFrame': 'baseline, until disease progression up to 24 months'}, {'measure': 'Change in Laboratory Paramenters', 'description': 'Changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), Dose interruptions, reductions and dose intensity.', 'timeFrame': 'baseline, until disease progression up to 24 months'}, {'measure': 'Time to Progression (TTP)', 'description': 'TTP will be compared between treatment arms. The TTP will be based on local investigator assessment per RECIST 1.1', 'timeFrame': 'baseline, until disease progression up to 24 months'}]",9,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,59.0,ACTUAL,2025-09-01T16:18:20.951155,v2_robust,True,True,False,True,True,"An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended study termination due to futility."
NCT03052725,A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma,"An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma",reslizumab,"['CEP38072', 'reslizumab']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Eosinophils, Asthma","['Eosinophils, Asthma']",[],TERMINATED,Parent Studies didn't meet their primary endpoint so study was terminated.,2017-03-10,2018-02-22,"[{'measure': 'Participants With Treatment-Emergent Adverse Events (TEAEs)', 'description': ""An adverse event is any untoward medical occurrence, regardless of whether it has a causal relationship with study treatment. In this study, asthma exacerbations should not be recorded as adverse events unless assessed by the investigator as more severe than the patient's usual disease course. The period for reporting treatment-emergent adverse events was defined as the period after the first dose of study drug was administered until the end of treatment visit. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes."", 'timeFrame': 'Day 1 to up to Day 269; for participants who discontinued early for reasons other than study termination, the timeframe was first dose of study drug to 4 weeks after the last dose of study drug.'}]","[{'measure': 'Participants With Potentially Clinically Significant Abnormal Hematology Values', 'description': 'Participants are included in the counts if the worst study value reaches the following clinically significant levels:\n\nEosinophils (high): \\>=1.5\\*10\\^9/L and increase \\>0 Hematocrit (low): \\>=18 years old: \\<0.32 L/L for females; \\<0.37 L/L for males plus a decrease \\>0 for both or 12 to \\<18 years old: \\<0.30 L/L and a decrease \\>0 for both females and males Hemoglobin (low): \\>=18 years old: \\<=95 g/L and decrease \\>0; 12 to \\<18 years old: \\<=100 g/L and decrease \\>0 Leukocytes (high): \\>=20\\*10\\^9/L and increase \\>0 Leukocytes (low): \\<=3\\*10\\^9/L and decrease \\>0 Neutrophils (low): \\<=1\\*10\\^9/L and decrease \\>0 Platelets (low): \\<=75\\*10\\^9/L and decrease \\>0', 'timeFrame': 'Week 0 (baseline), Weeks 8, 24, 36 plus any unscheduled visits'}, {'measure': 'Participants With Potentially Clinically Significant Abnormal Serum Chemistry Values', 'description': 'Participants are included in the counts if the worst study value reaches the following clinically significant levels:\n\nAlanine Aminotransferase (high): \\>=3\\* upper limit of normal (ULN) and increase \\>0 Aspartate Aminotransferase (high): \\>=3\\* upper limit of normal (ULN) and increase \\>0 Bilirubin (high): \\>=34.2 micromol/L and increase \\>0 Blood Urea Nitrogen (high): \\>=10.71 mmol/L and increase \\>0 Creatine Phosphokinase (high): \\>10\\* ULN and increase \\>0 Creatine Phosphokinase (medium high): \\>=3.1\\*ULN and \\<=10\\*ULN and increase \\>0 Creatinine (high): \\>=177 micromol/L and increase \\>0', 'timeFrame': 'Week 0 (baseline), Weeks 4, 8, 24, 36 plus any unscheduled visits'}, {'measure': ""Participants' Tolerability and Injection Site Reactions by Domain and Worst Overall Severity"", 'description': 'The worst finding for participants in each tolerability and injection site domain from all treatment weeks is summarized. Local tolerability at the injection site was assessed approximately 1 hour after study drug administration.\n\nSeverity was rated on a 4-level scale of none, mild, moderate and severe.', 'timeFrame': 'Weeks 4, 8, 12, 16, 20, 24, 28, and 36'}, {'measure': 'Participants With Potentially Clinically Significant Abnormal Vital Sign Values', 'description': 'Participants are included in the counts if the worst study value reaches the following clinically significant levels:\n\nDiastolic blood pressure (high): \\>100 mmHg and increase \\>=12 for participants \\>=18 years; \\>85 mmHg and increase \\>=12 for participants 12 - \\< 18 years Pulse rate (high): \\>100 beats/minute and increase \\>=12 Respiratory rate (high): \\>24 breaths/minute and increase \\>=10 for participants \\>=18 years \\>20 breaths/minute and increase \\>=10 for participants 12 - \\< 18 years Systolic blood pressure (high): \\>160 mmHg and increase \\>=30 for participants \\>=18 years; \\>130 mmHg and increase \\>=30 for participants 12 - \\< 18 years Temperature (high): \\>38.1 celsius and increase \\>=1.1 Temperature (low): \\<35.8 celsius', 'timeFrame': 'Week 0 (baseline), Weeks 4, 8, 12, 16,20, 24, 28, 32, 36 plus any unscheduled visits'}, {'measure': 'Annualized Rate of Clinical Asthma Exacerbations (CAEs)', 'description': 'Data is included between the first dose of study drug to the end of treatment visit for completed participants, and the first dose of study drug to 4 weeks after the last dose of study drug for patients who discontinued treatment early.\n\nAnnual rate is defined as the number of events/(duration of treatment \\[days\\]/365.25).\n\nParticipants with zero events are included.', 'timeFrame': 'Day 1 to up to Day 269; for participants who discontinued early for reasons other than study termination, the timeframe was first dose of study drug to 4 weeks after the last dose of study drug.'}, {'measure': 'Annualized Rate of Clinical Asthma Exacerbations (CAEs) Requiring Asthma-Specific Hospital Admissions or Emergency Room Visits', 'description': 'Data is included between the first dose of study drug to the end of treatment visit for completed participants, and the first dose of study drug to 4 weeks after the last dose of study drug for patients who discontinued treatment early.\n\nAnnual rate is defined as the number of events/(duration of treatment \\[days\\]/365.25).\n\nParticipants with zero events are included.', 'timeFrame': 'Day 1 to up to Day 269; for participants who discontinued early for reasons other than study termination, the timeframe was first dose of study drug to 4 weeks after the last dose of study drug.'}, {'measure': 'Mean Number of Days of Hospital Stay During the Treatment Period', 'description': 'Participants with no hospitalizations are included.', 'timeFrame': 'Day 1 to up to Day 269; for participants who discontinued early for reasons other than study termination, the timeframe was first dose of study drug to 4 weeks after the last dose of study drug'}, {'measure': 'Mean Number of School/Work Days Missed Due to Asthma During the Treatment Period', 'description': 'Participants with no school or work days missed due to asthma are included in the counts.', 'timeFrame': 'Day 1 to up to Day 269; for participants who discontinued early for reasons other than study termination, the timeframe was first dose of study drug to 4 weeks after the last dose of study drug'}, {'measure': 'Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1): Baseline Values and Change From Baseline Values at Weeks 8, 24 and 36', 'description': 'The FEV1 is the volume of air that can be forcibly exhaled from the lungs in the first second, measured in liters.\n\nPre-bronchodilator spirometry assessments at designated clinic visits (weeks 0, 8, and 24, and 36) should only be performed after withholding short-acting bronchodilators (ie, inhaled short-acting beta-adrenergic agonists and/or short-acting anticholinergics) for at least 6 hours and long-acting bronchodilators ie, inhaled long-acting beta-adrenergic agonists and long acting anticholinergic agents) for at least 12 or 24 hours, according to their labeled dose schedule.', 'timeFrame': 'Week 0 (baseline), Weeks 8, 24, 36'}, {'measure': 'Morning Ambulatory Forced Expiratory Volume in One Second (FEV1): Baseline Values and Change From Baseline Values at Weeks 1, 4, 8, 24 and 36', 'description': 'A weekly average of daily morning ambulatory FEV1 (measured by the handheld spirometry device) was derived using 7-day window intervals. The average was calculated as the sum of all values divided by the number of non-missing assessments. There will be no imputation of missing data. At least 4 of the 7 measurements need to be recorded for a week to be included in the analysis; otherwise the week was treated as missing.', 'timeFrame': 'Week 0 (baseline), Weeks 1, 4, 8, 24, 36'}, {'measure': 'Percent Change From Baseline in Daily Oral Corticosteroid (OCS) Dose During Weeks 16-20 and Weeks 32-36', 'description': 'Daily OCS dose is defined as total OCS dose in a day (accounting for reported dose and dose frequency) and converting the total daily dose to a prednisone-equivalent dose.\n\nBaseline dose is the prescribed OCS dose on the day of first dose of study drug in this study. Dose at Weeks 16-20 and 32-36 is the mean of all daily OCS doses during the week range.\n\nPercent change = 100 \\* (absolute change / baseline dose)', 'timeFrame': 'Week 0 (baseline), Weeks 16-20, Weeks 32-36'}, {'measure': 'Total Inhalations of Reliever Bronchodilator Medication: Baseline Values and Change From Baseline Values at Weeks 1, 4, 8, 24 and 36', 'description': 'Total inhalations of reliever bronchodilator medication (eg, short-acting beta-agonist \\[SABA\\]) measured using weekly averages.\n\nThe average was calculated as the sum of all values divided by the number of non-missing assessments. There was no imputation of missing data. At least 4 of the 7 measurements need to be recorded for a week to be included in the analysis; otherwise the week was treated as missing.', 'timeFrame': 'Baseline (Week 0), Weeks 1, 4, 8, 24, 36'}, {'measure': 'Asthma Control Questionnaire-6 (ACQ-6) Total Score: Baseline Values and Change From Baseline Values at Weeks 8, 24 and 36', 'description': ""The ACQ-6 is a validated asthma assessment tool that has been widely used. There are 6 self-assessment questions. Each item on the ACQ-6 has a possible score ranging from 0 to 6 and the total score is the mean of all responses. The seven-point response scale: 0 = 'totally controlled' and 6 = 'severely uncontrolled.' Negative change from baseline values indicate improved asthma control."", 'timeFrame': 'Baseline (Week 0), Weeks 8, 24, 36'}, {'measure': 'Asthma Quality of Life Questionnaire Administered to Participants Ages 12-70 Years (AQLQ +12) Overall Score: Baseline Values and Change From Baseline Values at Weeks 8, 24 and 36', 'description': 'The AQLQ +12 is a modified version of the standardized AQLQ, which was developed to measure functional impairments experienced by adults ≥17 years of age. The AQLQ +12 is valid for patients 12 to 70 years of age and includes 32 questions in 4 domains (symptoms, activity limitation, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and score each of the questions on a 7-point scale, where 7=not at all limited and 1=totally limited. The overall score of the AQLQ +12 was derived as the average of the 32 questions, thus, the total score ranges from 1 (indicates ""total impairment"") to 7 (indicates ""no impairment"").\n\nPositive change from baseline values indicate improved quality of life.', 'timeFrame': 'Baseline (Week 0), Weeks 8, 24, 36'}, {'measure': 'Participants With Treatment-Emergent Anti-Drug Antibody (ADA) Responses', 'description': 'Treatment-emergent responses were defined as a positive sample post-baseline (negative baseline) OR a titer increase of \\>=4-fold relative to a positive baseline sample.\n\nTwo types of antibody assay were performed, an immunogenicity status assay (ADA) and neutralizing assay (NAb).\n\nThe ADA assay produces a positive or negative result. For samples with a positive result, a neutralizing assay was performed, which also produces a positive or negative result.', 'timeFrame': 'Baseline - date of randomization in the previous study (C38072-AS-30025 or C38072-AS-30027), Weeks 8, 24, 36 or early withdrawal'}, {'measure': 'Participants With Treatment-Emergent Anti-Drug Antibody (ADA) At the End-0f-Study Visit (Week 51)', 'description': 'The endpoint was defined to evaluate immunogenicity after study drug washout since the end of study visit on Week 51 was to be 19 weeks after the final dose of study drug. Due to the early termination of the study no participants had an end of study visit.', 'timeFrame': 'Week 51'}]",17,12 Years,,ALL,False,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,0,391.0,ACTUAL,2025-09-01T16:18:20.951218,v2_robust,True,True,False,True,True,Parent Studies didn't meet their primary endpoint so study was terminated.
NCT02301676,Long Term Postoperative Cognitive Dysfunction in the Elderly Patients,Phase 4 Study of Long Term Postoperative Cognitive Dysfunction After Laparoscopic Cholecystectomy in the Elderly Patients,Sevoflurane,"['sevofrane', 'fresofol', 'Sevoflurane', 'propofol']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Cognitive Impairment,['Cognitive Impairment'],"['Geriatrics; Cognitive impairment; Interviews, Telephone']",UNKNOWN,,2014-12,2016-12,"[{'measure': 'The incidence of long-term postoperative cognitive dysfunction after general anesthesia in elderly patients.', 'description': 'Investigators will assess the postoperative cognitive dysfunction after general anesthesia in elderly patients compare to spouses which have no anesthetic history. Investigators will test participants using the Korean version of TICS and test will be done 1weak, 3months, 6months, 1 year after the surgery.', 'timeFrame': 'two years'}]","[{'measure': 'The difference of incidence in postoperative cognitive dysfunction after general anesthesia according to the anesthetic drugs', 'description': 'Investigators will assess the postoperative cognitive dysfunction (POCD) after general anesthesia (sevoflurane, propofol and dexmedetomidine) and compare the occurrence rate of the POCD in 3 anesthetic methods.', 'timeFrame': 'two years'}]",2,60 Years,,ALL,False,Pusan National University Yangsan Hospital,OTHER,0,190.0,ESTIMATED,2025-09-01T16:18:20.951237,v2_robust,True,True,False,False,False,
NCT03309176,"""Stair Step Study""",Is Endometrial Withdrawal Bleeding Necessary Prior to Ovulation Induction With Clomiphene Citrate? A Randomized Controlled Trial and Feasibility Study,Medroxyprogesterone Acetate 10 MG,"['Provera', 'Medroxyprogesterone Acetate 10 MG']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Ovulation Disorder,['Ovulation Disorder'],[],COMPLETED,,2016-06-21,2018-05-31,"[{'measure': 'Ongoing pregnancy rate per cycle', 'description': 'Ongoing pregnancy is defined as the presence of at least one intra uterine fetus with heartbeat at 8 weeks of gestation', 'timeFrame': 'in case of pregnancy: 8 weeks after the start of each cycle, (maximum of 3 cycles, duration of 1 cycle: 28-35 days)'}, {'measure': 'Time to pregnancy', 'description': 'the time between obtaining informed consent and the presence of a positive pregnancy test after treatment', 'timeFrame': 'duration of 1 cycle: 28-35 days, a maximum of 3 cycles will be performed (pregnancy test will be performed at the end of the cycle if there is no menstruation)'}]","[{'measure': 'Time to ovulation', 'description': 'calculated as 14 days prior to the first day of menstruation or positive pregnancy test', 'timeFrame': '3 cycles of 28-35 days, calculated as 14 days before the start of menstruation or 14 days before a positive pregnancy test'}, {'measure': 'Endometrial thickness on the last day of ultrasonography', 'description': 'measurement of the endometrial thickness on the last day of ultrasound monitoring. This day can differ among cycles, depending on the speed of follicle growth, hence it cannot be further specified.', 'timeFrame': 'maximum of 3 cycles (each 28-35 days)'}, {'measure': 'The incidence of multiple follicle growth on the last day of ultrasonography', 'description': 'This day can differ among cycles, depending on the speed of follicle growth, hence it cannot be further specified.', 'timeFrame': 'maximum of 3 cycles (each 28-35 days)'}, {'measure': 'The incidence of multiple pregnancy', 'description': 'ultrasound performed at 8 weeks of gestation, which is 8 weeks after the start of a treatment cycle', 'timeFrame': 'in case of pregnancy: 8 weeks after the start of a treatment cycle (maximum of 3 cycles; each 28-35 days)'}, {'measure': 'The incidence of treatment failure', 'description': 'treatment failure is defined as no follicle ≥ 14 mm on CD 20 despite using a maximum clomiphene citrate dose of 150 mg in the standard arm. Or no follicle ≥ 14 mm after increasing the clomiphene citrate dose up to 150 mg.', 'timeFrame': 'maximum of 3 cycles (each 28-35 days)'}, {'measure': 'The number of eligible patients', 'description': 'The total number of patients that fits the inclusion criteria.', 'timeFrame': 'Inclusion 16 months, follow-up 3 months.'}, {'measure': 'The number of protocol violations', 'description': 'The total number of protocol violations.', 'timeFrame': 'duration: maximum of 3 cycles (each 28-35 days)'}]",9,18 Years,41 Years,FEMALE,True,Radboud University Medical Center,OTHER,0,42.0,ACTUAL,2025-09-01T16:18:20.951303,v2_robust,True,True,True,False,False,
NCT00490776,Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL),A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor,Panobinostat,"['LBH589', 'Panobinostat']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cutaneous T-Cell Lymphoma,['Cutaneous T-Cell Lymphoma'],"['Cutaneous T-Cell Lymphoma', 'adults', 'Mycosis Fungoides', 'Sézary Syndrome', 'CTCL']",TERMINATED,Recruitment was stopped on 15 June 2009 (early termination date) due to low prevalence of study population and slow accrual.,2007-07-05,2009-09-22,"[{'measure': 'Overall Response Rate (ORR) in Participants With Resistant Cutaneous T-Cell Lymphoma (CTCL) Treated With Oral Panobinostat by Using the Modified Severity-Weighted Assessment Tool (mSWAT)', 'description': 'ORR was defined as the percentage of participants with best overall response (OR) of complete response (CR) or partial response (PR) based on mSWAT score, (OR = CR + PR). mSWAT score represents the product of the percentage total body surface area (%TBSA) involvement of each lesion type (patch, plaque, and tumor or ulceration), multiplied by a weighting factor: modified SWAT score = (patch %TBSA x 1) + (plaque %TBSA x 2) + (tumor or ulcer %TBSA x 4). The sum of these 3 numbers gave the modified SWAT score, on a 0 (no lesions) to 400 (lesions covering all areas) scale. CR based on mSWAT score was defined as the absence of skin disease. PR was defined as ≥ 50% decrease of the modified SWAT score compared to the Baseline score.', 'timeFrame': 'From first dose of study drug up to disease progression or death, (up to approximately 2 years)'}]","[{'measure': ""Response Rate of Participants With Refractory CTCL Using the Physician's Global Assessment of Clinical Condition (PGA)"", 'description': ""Response rate was defined as the percentage of participants with CR or PR based on PGA scale. PGA is a 7-point grading scale for the investigator's assessment of the overall extent of improvement or worsening of the participant's disease as compared to Baseline. CR corresponds to Grade 0 (Completely clear) on PGA scale and was defined as no evidence of disease; 100% improvement. PR corresponds to Grade 2 (marked improvement) on PGA scale and was defined as significant improvement (≥75% - \\<90%); some evidence of disease remains."", 'timeFrame': 'From first dose of study drug up to disease progression or death, (up to approximately 2 years)'}, {'measure': 'Response Rate in Participants With Refractory CTCL Using Modified Skin Score', 'description': 'Response rate was defined as the percentage of participants with CR or PR based on mSWAT skin score. mSWAT score represents the product of the %TBSA involvement of each lesion type (patch, plaque, and tumor or ulceration), multiplied by a weighting factor: mSWAT score = (patch %TBSA x 1) + (plaque %TBSA x 2) + (tumor or ulcer %TBSA x 4). The sum of these 3 numbers gave the modified SWAT score, on a 0 (no lesions) to 400 (lesions covering all areas) scale. CR based on mSWAT score was defined as the absence of skin disease. PR was defined as ≥ 50% decrease of the modified SWAT score compared to the Baseline score.', 'timeFrame': 'From first dose of study drug up to disease progression or death, (up to approximately 2 years)'}, {'measure': 'Responses in Index Lesions in Participants With Refractory CTCL by Lesion Measurements With Photographic Supporting Documentation', 'description': 'Index lesions in each participant were selected as four to six of the prominent lesions amenable to bi-dimensional measurements. The longest diameter and its perpendicular measurement were used to determine the surface area and a weighted sum was determined as: Lesion 1 + lesion 2 + … + lesions 6 = Total sum of weighted score where Lesion 1: cm\\^2 x \\[1 (for patch); 2 (for plaque); 4 (for tumor or ulcer)\\]; Lesion 2: cm\\^2 x \\[1 (for patch); 2 (for plaque); 4 (for tumor or ulcer)\\]; Lesion 6: cm\\^2 x \\[1 (for patch); 2 (for plaque); 4 (for tumor or ulcer)\\]. These lesions were photographed at Baseline and at the time of response determined by either mSWAT or PGA', 'timeFrame': 'From first dose of study drug up to disease progression or death (up to approximately 2 years)'}, {'measure': 'ORR of Participants With Resistant CTCL Treated With Oral Panobinostat by Using the Modified PGA to Assess Skin Disease and the Evaluation of Disease in the Viscera, Lymph Nodes and Blood (Circulating Sézary Syndrome Cells)', 'description': ""ORR was defined as the percentage of participants with best OR of CR or PR based on PGA scale (OR = CR + PR). The PGA is a 7-point grading scale for the investigator's assessment of the overall extent of improvement or worsening of the participant's disease as compared to Baseline. CR corresponds to Grade 0 (completely clear) of PGA scale and was defined as no evidence of disease; 100% improvement. PR corresponds to Grade 2 (marked improvement) of PGA scale and was defined as significant improvement (≥75%-\\<90%); some evidence of disease remains."", 'timeFrame': 'From first dose of study drug up to disease progression or death, (up to approximately 2 years)'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR was defined as the time from first documented evidence of CR or PR until the earliest date of documented progression or death due to any cause among participants who achieved a confirmed CR or PR. The DOR was calculated in two ways. The DOR among responders only included participants who responded to the drug. The overall DOR included non-responders as having a DOR of zero days.', 'timeFrame': 'From first dose of study drug up to disease progression or death, (up to approximately 2 years)'}, {'measure': 'Time to Response (TTR)', 'description': 'TTR was defined as the time from the start of treatment until the first documented evidence of CR or PR among participants who achieved a confirmed CR or PR.', 'timeFrame': 'From first dose of study drug up to study completion (approximately 2 years)'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS was defined as the time from the start of treatment until the earliest date of disease progression or death due to any cause, if sooner.', 'timeFrame': 'From first dose of study drug up to disease progression or death, (up to approximately 2 years)'}]",8,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,9.0,ACTUAL,2025-09-01T16:18:20.951338,v2_robust,True,True,False,True,False,Recruitment was stopped on 15 June 2009 (early termination date) due to low prevalence of study population and slow accrual.
NCT01912976,Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Bowen's Disease,"A Randomized, Intra-individual, Prospective Study Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Ablative Fractional Laser Treatment in Asian Patients With Lower Extremity Bowen's Disease",Er:YAG AFL-PDT,"['Er:YAG AFL-PDT', 'Er:YAG ablative fractional laser-assisted MAL-PDT', 'methyl aminolaevulinate-Photodynamic therapy', 'MAL-PDT']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Bowen's Disease,"[""Bowen's Disease""]","[""Bowen's disease"", 'Er:YAG', 'AFL-assisted', 'MAL-PDT']",COMPLETED,,2011-03,2012-03,"[{'measure': 'Difference the efficacy between Er:YAG AFL-assisted MAL-PDT (Er:YAG AFL-PDT) and standard MAL-PDT.', 'description': 'Lesion response was classified as either complete (complete disappearance of the lesion) or incomplete (incomplete disappearance) on the basis of visual examination and palpation. The response of each lesion was clinically evaluated', 'timeFrame': 'Efficacy was evaluated at 3 months and 12 months after treatment'}]","[{'measure': 'Difference of the cosmetic outcomes between Er:YAG AFL-assisted MAL-PDT (Er:YAG AFL-PDT) and standard MAL-PDT.', 'description': 'It was graded using a 4-point scale: excellent (only slight occurrence of redness or change in pigmentation), good (moderate redness or change in pigmentation), fair (slight-to-moderate scarring, atrophy, or induration), or poor (extensive scarring, atrophy, or induration)', 'timeFrame': 'Cosmetic outcome was assessed by each investigator for all lesions that achieved a complete response at 3 or 12 months'}]",2,18 Years,92 Years,ALL,True,Dong-A University,OTHER,0,21.0,ACTUAL,2025-09-01T16:18:20.951437,v2_robust,True,True,True,False,False,
NCT03766776,Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC),"Anlotinib Hydrochloride Capsules in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Open, Single Arm, Exploratory Clinical Trial.",Anlotinib,['Anlotinib'],1,INTERVENTIONAL,['NA'],,,Cancer of Liver,['Cancer of Liver'],[],UNKNOWN,,2018-12-31,2020-12-31,"[{'measure': 'PFS', 'description': 'Progression free survival', 'timeFrame': '3 month'}]",[],1,18 Years,75 Years,ALL,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:20.951483,v2_robust,True,True,False,False,False,
NCT03069976,"""Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Identification With Antibiotics in Children""",""" Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Modification With Antibiotics in Children""",Metronidazole,"['Flagyl', 'Metronidazole']",2,INTERVENTIONAL,['NA'],,,Primary Sclerosing Cholangitis,"['Primary Sclerosing Cholangitis', 'Autoimmune Hepatitis', 'Overlap Syndrome']",[],COMPLETED,,2016-01,2021-08,"[{'measure': 'Liver function test', 'description': 'AST, ALT, GGT to be measured', 'timeFrame': '14 days'}]","[{'measure': 'Microbiome', 'description': 'Intestinal microflora to be characterized', 'timeFrame': '14 days'}, {'measure': 'Bile acid profile', 'description': 'Bile acids profile to be characterized', 'timeFrame': '14 days'}]",3,3 Years,25 Years,ALL,False,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,OTHER,0,15.0,ACTUAL,2025-09-01T16:18:20.951498,v2_robust,True,True,True,False,False,
NCT07144176,PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers,"An Open-label, Randomized, Fasting, Single-dose, Two-treatment, Two-period, Crossover, Phase 1 Clinical Trial to Compare and Evaluate the Pharmacokinetics and Safety of ""DWJ1511"" and ""DWC202501"" in Healthy Adult Volunteers",DWJ1511,"['DWJ1511', 'DWC202501']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Subjects,['Healthy Subjects'],[],RECRUITING,,2025-09,2025-09,"[{'measure': 'Area under the plasma drug concentration-time curve [AUCt]', 'description': 'Area under the plasma drug concentration-time curve \\[AUCt\\] of DWJ1511 and DWC202501', 'timeFrame': '0-12 Hours'}, {'measure': 'Maximum plasma concentration [Cmax]', 'description': 'Maximum plasma concentration \\[Cmax\\] of DWJ1511 and DWC202501', 'timeFrame': '0-12 Hours'}]","[{'measure': 'Area under the plasma drug concentration-time curve from time 0 to infinity [AUCinf]', 'description': 'Area under the plasma drug concentration-time curve from time 0 to infinity \\[AUCinf\\] of DWJ1511 and DWC202501', 'timeFrame': '0-12 Hours'}]",3,19 Years,64 Years,ALL,True,Daewoong Pharmaceutical Co. LTD.,INDUSTRY,0,60.0,ESTIMATED,2025-09-01T16:18:20.951530,v2_robust,True,True,False,False,False,
NCT01206517,"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)","A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder",Asenapine 2.5 mg,"['Asenapine 5 mg', 'Org 5222', 'Asenapine 10 mg', 'SCH 900274', 'Asenapine 2.5 mg']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Schizophrenia,"['Schizophrenia', 'Bipolar I Disorder']","['asenapine', 'pediatric schizophrenia', 'bipolar I disorder']",COMPLETED,,2010-07-18,2011-08-04,"[{'measure': 'Maximum Plasma Concentration (Cmax) of Asenapine', 'description': 'Cmax is the peak plasma concentration following a dose of the study drug.', 'timeFrame': 'Predose (0 hours) and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 36 and 48 hours after the final asenapine dose (administered on Day 7 for Cohorts 1 and 2; on Day 8 for Cohorts 3b, 3c and 3d; and on Day 12 for Cohort 3a)'}, {'measure': 'Time to Maximum Plasma Concentration (Tmax) of Asenapine', 'description': 'tmax is the time from dosing to maximum plasma drug concentration levels.', 'timeFrame': 'Predose (0 hours) and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 36 and 48 hours after the final asenapine dose (administered on Day 7 for Cohorts 1 and 2; on Day 8 for Cohorts 3b, 3c and 3d; and on Day 12 for Cohort 3a)'}, {'measure': 'Area Under the Plasma Concentration-time Curve From 0 to 12 Hours Post Dose (AUC0-12) of Asenapine', 'description': 'AUC0-12 is the area under the plasma drug-concentration time curve calculated for the 12 hour interval after dosing.', 'timeFrame': 'Predose (0 hours) and 0.5, 1, 1.5, 2, 3, 4, 6 and 12 hours after the final asenapine dose (administered on Day 7 for Cohorts 1 and 2; on Day 8 for Cohorts 3b, 3c and 3d; and on Day 12 for Cohort 3a)'}, {'measure': 'Terminal Phase (Elimination) Half-life (t1/2) of Asenapine', 'description': 'Elimination t1/2 is the time it takes for the concentration of the drug in the body to decrease by half during the elimination phase.', 'timeFrame': 'Predose (0 hours) and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 36 and 48 hours after the final asenapine dose (administered on Day 7 for Cohorts 1 and 2; on Day 8 for Cohorts 3b, 3c and 3d; and on Day 12 for Cohort 3a)'}]",[],4,10 Years,17 Years,ALL,False,Organon and Co,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:20.951574,v2_robust,True,True,True,False,False,
NCT04944017,Ketamine for the Treatment of Depression in Parkinson's Disease,Ketamine for the Treatment of Depression in Parkinson's Disease (KET-PD),Ketamine Infusion,['Ketamine Infusion'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Parkinson's Disease,"[""Parkinson's Disease"", 'Depression']",['Ketamine Treatment'],RECRUITING,,2021-11-23,2025-08,"[{'measure': 'Change in Depression Severity', 'description': 'The primary outcome of depression severity post-treatment will be compared between groups using a linear mixed model with group (ketamine, placebo) included as a between-subjects factor and time (baseline, weeks 1, 2, 3) included as a within-subjects factor. The scale used to measure depression severity is called The Montgomery-Åsberg Depression Rating Scale (MADRS). The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. The overall score ranges from 0 to 60, higher MADRS score indicates more severe depression.', 'timeFrame': 'Baseline, Week 1, Week 2, and Week 3'}]","[{'measure': 'Change in Blood pressure: systolic', 'description': 'Changes in systolic and diastolic blood pressure determined as clinically significant by the Investigator', 'timeFrame': 'Baseline and up to 19 days after last administration of study intervention'}, {'measure': 'Change in Blood pressure: diastolic', 'description': 'Changes in systolic and diastolic blood pressure determined as clinically significant by the Investigator', 'timeFrame': 'Baseline and up to 19 days after last administration of study intervention'}, {'measure': 'Change in Heart rate', 'description': 'Changes in heart rate determined as clinically significant by the Investigator', 'timeFrame': 'Baseline and up to 19 days after last administration of study intervention'}, {'measure': 'Change in Respiration', 'description': 'Changes in respiration determined as clinically significant by the Investigator', 'timeFrame': 'Baseline and up to 19 days after last administration of study intervention'}, {'measure': 'Change in O2 saturation', 'description': 'Changes in O2 saturation determined as clinically significant by the Investigator', 'timeFrame': 'Baseline and up to 19 days after last administration of study intervention'}, {'measure': 'Change in ECG', 'description': 'Changes in ECG indicating a cardiac event such as an arrhythmia or ischemia determined as clinically significant by the Investigator', 'timeFrame': 'Baseline and up to 19 days after last administration of study intervention'}, {'measure': 'Change in CBC with differential', 'description': 'Changes in CBD with differential determined as clinically significant by the Investigator', 'timeFrame': 'Baseline and up to 19 days after last administration of study intervention'}, {'measure': 'Change in complete metabolic panel', 'description': 'Changes in complete metabolic panel determined as clinically significant by the Investigator', 'timeFrame': 'Baseline and up to 19 days after last administration of study intervention'}, {'measure': 'Change in TFTs', 'description': 'Changes in TFTs determined as clinically significant by the Investigator', 'timeFrame': 'Baseline and up to 19 days after last administration of study intervention'}, {'measure': 'Change in routine urinalysis', 'description': 'Changes in routine urinalysis determined as clinically significant by the Investigator', 'timeFrame': 'Baseline and up to 19 days after last administration of study intervention'}, {'measure': 'Adverse events', 'description': 'Assessed by CTCAE v5.0 and the abbreviated version of the SAFTEE-GI and -SI to assess all body systems', 'timeFrame': 'Baseline and up to 32 days after last administration of study intervention'}, {'measure': 'Change in synaptic density', 'description': 'The change in synaptic (SV2A) density (measured using \\[11C\\]UCB-J PET) between baseline and post-intervention scans will be measured across regions of interest', 'timeFrame': 'Baseline, Week 3'}, {'measure': 'Change in network function', 'description': 'The change in network function will be measured by comparing fMRI functional connectivity between baseline and post-intervention scans', 'timeFrame': 'Baseline, Week 3'}]",14,40 Years,80 Years,ALL,False,Yale University,OTHER,1,56.0,ESTIMATED,2025-09-01T16:18:20.951713,v2_robust,True,True,False,False,True,
NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),A Phase 1 Dose-Escalation Study of SCH 900776 in Combination With Cytarabine in Subjects With Acute Leukemias (Protocol No. P05247),MK-8776,"['Generic: ara-C and cytosine arabinoside', 'Cytarabine', 'SCH 900776', 'MK-8776', 'Cytosar-U®']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,"Myelogenous Leukemia, Acute","['Myelogenous Leukemia, Acute', 'Leukemia, Lymphocytic, Acute', 'Leukemia, Lymphoblastic, Acute, Philadelphia-Positive', 'Myelogenous Leukemia, Chronic, Aggressive Phase']",[],TERMINATED,,2009-07-29,2011-06-13,"[{'measure': 'Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)', 'description': 'Toxicity was assessed according to the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v 3.0). DLTs in Cycle 1 consisted of any of the following: 1) Selected Grade 4 drug-related nonhematologic toxicities, 2) Selected Grade 3 drug-related nonhematologic toxicities that do not resolve to ≤ Grade 2 within 48 hours: Neurotoxicity of any duration, Nephrotoxicity of any duration, QT interval corrected by Fridericia (QTcF) prolongation of any duration, 3) Inability to administer Day 10 cytarabine therapy due to ongoing, uncontrolled serious or life-threatening toxicity. The number of participants who experienced a DLT during Cycle 1 is summarized.', 'timeFrame': 'Throughout Cycle 1 (Up to 6 weeks)'}, {'measure': 'Number of Participants Who Experienced an Adverse Event (AE)', 'description': 'An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to this study treatment. The number of participants who experienced an AE is summarized.', 'timeFrame': 'Up to 45 days after last dose of study treatment (Up to 180 days)'}, {'measure': 'Number of Participants Who Discontinued Study Treatment Due to an AE', 'description': 'An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to this study treatment. The number of participants who discontinued study treatment due to an AE is summarized.', 'timeFrame': 'Up to 135 days'}]",[],3,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:20.951851,v2_robust,True,True,False,True,True,
NCT00000117,Intravenous Immunoglobulin Therapy in Optic Neuritis,,Immunoglobulin,['Immunoglobulin'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Optic Neuritis,['Optic Neuritis'],[],COMPLETED,,1995-08,1997-12,[],[],0,,50 Years,ALL,,National Eye Institute (NEI),NIH,0,,,2025-09-01T16:18:20.951872,v2_robust,True,True,True,False,False,
NCT03113617,68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer,68Ga-RM2 PET/CT for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer,Gallium Ga 68-labeled GRPR Antagonist BAY86-7548,"['Gallium Ga 68-labeled GRPR Antagonist BAY86-7548', '68Ga-DOTA-Bombesin Analog BAY86-7548', '(68)Ga-DOTA-4-amino-1-carboxymethylpiperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2', 'BAY 86-7548', 'Ga-68-labeled Bombesin Antagonist BAY 86-7548', 'Gallium Ga68-labeled GRPR Antagonist RM2', '68Ga-DOTA RM2', '[68Ga]RM2', '68Ga-Bombesin Antagonist BAY86-7548', '[68Ga]-labeled Bombesin Analog BAY86-7548']",10,INTERVENTIONAL,['PHASE2'],PHASE2,,Stage II Prostate Adenocarcinoma,"['Stage II Prostate Adenocarcinoma', 'Stage III Prostate Adenocarcinoma', 'Stage IV Prostate Adenocarcinoma']",[],COMPLETED,,2017-04-10,2021-12-19,"[{'measure': 'Sensitivity, Specificity, Positive, and Negative Predictive Value of 68Ga-RM2 PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy', 'description': 'True positive patient is defined as PET positive for regional nodes, pathology at prostatectomy positive for regional nodes or PET positive for regional nodes, pathology negative for regional nodes, imaging after prostatectomy demonstrates node was not removed at surgery, and follow-up biopsy or imaging demonstrates presence of nodal disease. True negative patient is defined as PET negative for regional nodes, pathology at prostatectomy negative for regional nodes. False positive patient is defined as PET positive for regional nodes, pathology at prostatectomy is negative, and imaging after prostatectomy', 'timeFrame': 'week 1 study visit following radiopharmaceutical administration, up to 2 hours to assess'}]","[{'measure': 'Sensitivity, Specificity, Negative and Positive Predictive Value for Detection of Regional Nodal Metastases in Comparison to Cross Sectional Imaging Performed Contemporaneously With the 68Ga-RM2 PET', 'description': 'True positive patient is defined as PET positive for regional nodes, pathology at prostatectomy positive for regional nodes or PET positive for regional nodes, pathology negative for regional nodes, imaging after prostatectomy demonstrates node was not removed at surgery, and follow-up biopsy or imaging demonstrates presence of nodal disease. True negative patient is defined as PET negative for regional nodes, pathology at prostatectomy negative for regional nodes. False positive patient is defined as PET positive for regional nodes, pathology at prostatectomy is negative, and imaging after prostatectomy', 'timeFrame': 'week 1 study visit following radiopharmaceutical administration, up to 2 hours to assess'}]",2,19 Years,,MALE,False,Andrei Iagaru,OTHER,0,44.0,ACTUAL,2025-09-01T16:18:20.951881,v2_robust,True,True,True,False,False,
NCT05154240,"A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Oral Single and Multiple Ascending Doses, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects",INS018_055,"['INS018_055', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Idiopathic Pulmonary Fibrosis,['Idiopathic Pulmonary Fibrosis'],['IPF'],COMPLETED,,2022-02-21,2022-12-02,"[{'measure': 'Number of participants with treatment-related adverse events based on subjective and objective examination', 'description': ""Subjective examination refers to the participant response to standard question to elicit any medically related changes in their well-being.\n\nDescriptive examination refers to laboratory values as reviewed by the investigator, physical examination findings and ECG Changes, or other documents that are relevant to participant safety.\n\nAEs will be classified as:\n\nMild: These events require minimal or no treatment and do not interfere with the subject's daily activities. Moderate: These events result in a low level of inconvenience or require minor therapeutic measures. Moderate events may cause some interference with normal functioning. Severe: These events interrupt a subject's usual daily activity and may require systemic drug therapy or other treatment. Severe events are usually incapacitating."", 'timeFrame': '12 months'}]","[{'measure': 'Maximum Plasma Concentration [Cmax]', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'AUC from time 0 extrapolated to infinity (AUC0-inf)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'AUC from time 0 to the time of the dosing interval (To; AUC0-To)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Accumulation ratio (AR), calculated as AUC0-To (Day 10)/AUC0-To (Day 1)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'AR calculated as Cmax (Day 10)/Cmax (Day 1)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Time to reach Cmax (Tmax)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Pre-dose concentrations on Days 1 through 10 (C trough)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Average concentration on Day 1 and Day 10 (Cav)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Terminal elimination rate constant (Kel)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Terminal elimination half-life (t1/2)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Apparent total body clearance (CL/F)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Peak to trough ratio calculated as Cmax/Ctrough', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Apparent volume of distribution (Vd/F)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Metabolite-to parent ratio based on AUC calculated as AUCmetabolite/AUCparent', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Metabolite-to parent ratio based on Cmax calculated as Cmax, metabolite/Cmax, parent', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Renal clearance (CLr)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}, {'measure': 'Total amount of drug excreted unchanged in urine from 0 to 24 hours after dosing (XU0-24)', 'description': '* To determine the PK of INS018\\_055 following single and multiple oral escalating doses in healthy subjects.\n* To assess the effect of food on the PK of INS018\\_055 following an oral dose.', 'timeFrame': '12 months'}]",19,18 Years,55 Years,ALL,True,InSilico Medicine Hong Kong Limited,INDUSTRY,0,78.0,ACTUAL,2025-09-01T16:18:20.952030,v2_robust,True,True,True,False,True,
NCT00060489,Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression,,SEROQUEL (quetiapine fumarate) Tablets,['SEROQUEL (quetiapine fumarate) Tablets'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Bipolar Disorder,"['Bipolar Disorder', 'Depression, Bipolar']",['Bipolar Depression'],COMPLETED,,2002-09,2003-09,[],[],0,18 Years,65 Years,ALL,False,AstraZeneca,INDUSTRY,0,,,2025-09-01T16:18:20.952151,v2_robust,True,True,True,False,False,
NCT05837689,Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation,Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation,Blinatumomab,['Blinatumomab'],1,OBSERVATIONAL,[],,,"Acute Lymphoblastic Leukemia, Pediatric","['Acute Lymphoblastic Leukemia, Pediatric']",[],UNKNOWN,,2023-04,2023-04,"[{'measure': 'MRD clearance rate (MRD<0.00001%)', 'description': 'The change of MRD will be detected by NGS, with sensitivity of 0.00001% and 0.01%, respectively', 'timeFrame': 'before blinatumomab initiation (baseline), Day 15 of blinatumomab treatment, Day 29 of blinatumomab treatment'}]",[],1,1 Year,18 Years,ALL,False,Xiaojun Xu,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:20.952237,v2_robust,False,True,False,False,False,
NCT04366089,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora,Azithromycin,"['hydroxychloroquine', 'Azithromycin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,COVID,"['COVID', 'SARS-CoV 2', 'Pneumonia, Viral', 'Coronavirus Infection']","['Oxygen-ozone therapy', 'gut microbiota']",UNKNOWN,,2020-03-26,2020-12-31,"[{'measure': 'Delta in the number of patients requiring orotracheal intubation despite treatment', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}]","[{'measure': 'Delta of crude mortality', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'Delta of length of stay for patients in hospital', 'description': 'Comparison between the two groups', 'timeFrame': '90 days'}, {'measure': 'delta in the value of interleukin (IL)-1', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of IL-6', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of IL-10', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of Tumor Necrosis Factor (TNF)-alpha', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of cluster of differentiation (CD)4+ CD38/ Human Leukocyte Antigen-DR isotype (HLA-DR)', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of CD8+ CD38/ HLA-DR', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of fecal calprotectin', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of lipopolysaccharide (LPS)', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of zonulin', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of alpha1-antitrypsin', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}]",13,18 Years,,ALL,False,"Roberto Poscia MD, PhD",OTHER,0,152.0,ESTIMATED,2025-09-01T16:18:20.952491,v2_robust,True,True,False,False,False,
NCT04408989,"A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®.","A Randomized, Double-Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02-SP, MB02-DM (Bevacizumab Biosimilar Drugs) and US-licensed Avastin® in Healthy Male Volunteers",MB02-SP,"['US licenced Avastin®', 'MB02-SP', 'Bevacizumab (US sourced)', 'MB02-DM', 'MB02-DM (Bevacizumab Biosimilar)', 'MB02-SP (Bevacizumab Biosimilar)']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2021-01-11,2021-09-02,"[{'measure': 'Pharmacokinetics (PK) - (AUC[0-∞])', 'description': 'Compare the pharmacokinetic (PK) profiles of the 3 arms (AUC\\[0-∞\\])', 'timeFrame': 'Pre-dose (0 hours),end of infusion, 2, 3, 4, 5, 6, 7, 12, and 24 hours and at Days 3, 4, 5, 6, 7, 8, 10, 14, 21, 28, 42, 56, 78, and 100 post-dose'}, {'measure': 'Pharmacokinetics (PK) - (Cmax)', 'description': 'Compare the pharmacokinetic (PK) profiles of the 3 arms (Cmax)', 'timeFrame': 'Pre-dose (0 hours),end of infusion, 2, 3, 4, 5, 6, 7, 12, and 24 hours and at Days 3, 4, 5, 6, 7, 8, 10, 14, 21, 28, 42, 56, 78, and 100 post-dose'}]","[{'measure': 'Other PK Parameters (Tmax)', 'description': 'Evaluation of all other PK parameters (tmax) tmax = time of maximum observed serum concentration', 'timeFrame': 'Pre-dose (0 hours),end of infusion, 2, 3, 4, 5, 6, 7, 12, and 24 hours and at Days 3, 4, 5, 6, 7, 8, 10, 14, 21, 28, 42, 56, 78, and 100 post-dose'}, {'measure': 'Other PK Parameters (AUC[0 t])', 'description': 'Evaluation of all other PK parameters (AUC\\[0 t\\]) AUC(0-t) = AUC from time zero to the time of last quantifiable concentration', 'timeFrame': 'Pre-dose (0 hours),end of infusion, 2, 3, 4, 5, 6, 7, 12, and 24 hours and at Days 3, 4, 5, 6, 7, 8, 10, 14, 21, 28, 42, 56, 78, and 100 post-dose'}, {'measure': 'Other PK Parameters (CL)', 'description': 'Evaluation of all other PK parameters (CL) CL = total body clearance of drug after intravenous administration', 'timeFrame': 'Pre-dose (0 hours),end of infusion, 2, 3, 4, 5, 6, 7, 12, and 24 hours and at Days 3, 4, 5, 6, 7, 8, 10, 14, 21, 28, 42, 56, 78, and 100 post-dose'}, {'measure': 'Other PK Parameters (t1/2)', 'description': 'Evaluation of all other PK parameters (t1/2) t½ = apparent serum terminal elimination half-life', 'timeFrame': 'Pre-dose (0 hours),end of infusion, 2, 3, 4, 5, 6, 7, 12, and 24 hours and at Days 3, 4, 5, 6, 7, 8, 10, 14, 21, 28, 42, 56, 78, and 100 post-dose'}, {'measure': 'Immunogenicity', 'description': 'Number of participants with anti-bevacizumab antiboides (ADA), including neutralizing antibodies (Nab).\n\nSubjects who tested positive at baseline are not included here.', 'timeFrame': 'Days -1, 14, 28, 56 and 78'}, {'measure': 'Safety (Number of Participants Reporting Treatment-related Adverse Events)', 'description': 'Number of participants who reported Treatment-related Adverse Events using the CTCAE v5.0 criteria', 'timeFrame': 'Day 1 - Day 100'}, {'measure': 'Safety (Treatment-related Adverse Events)', 'description': 'Treatment-related Adverse Events based on the CTCAE v5.0 criteria reported by the study participants', 'timeFrame': 'Day 1 - Day 100'}]",9,18 Years,55 Years,MALE,True,mAbxience Research S.L.,INDUSTRY,0,114.0,ACTUAL,2025-09-01T16:18:20.952519,v2_robust,True,True,True,False,True,
NCT05628389,Phone Enabled Implementation of Cessation Support,Phone Enabled Implementation of Cessation Support,Nicotine Replacement Therapy,['Nicotine Replacement Therapy'],1,INTERVENTIONAL,['NA'],,,Smoking Cessation,['Smoking Cessation'],[],RECRUITING,,2024-03-06,2027-08-31,"[{'measure': '7-day smoking abstinence', 'description': 'Carbon monoxide confirmed-abstinence from smoking in the last 7 days days prior to assessment', 'timeFrame': '6 Months'}]",[],1,18 Years,,ALL,False,University of Florida,OTHER,1,1500.0,ESTIMATED,2025-09-01T16:18:20.952615,v2_robust,True,True,False,False,False,
NCT02599168,Effect of Dexmedetomidine on Propofol Requirement During Anesthesia,The Effect of Dexmedetomidine on Propofol Requirements During Anesthesia Administered by Bispectral Index-Guided Closed-Loop Anesthesia Delivery System: A Randomized Controlled Study,Propofol,"['Placebo (normal saline)', 'Propofol', 'Dexmedetomidine']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Anesthesia,['Anesthesia'],"['dexmedetomidine', 'propofol', 'BIS', 'CLADS']",COMPLETED,,2015-12-05,2017-03-20,"[{'measure': 'Change in Propofol usage in milligrams', 'description': ""Comparison of 'dexmedetomidine' versus 'no dexmedetomidine' administration in decreasing quantitative propofol requirements (measured in milligrams) during closed loop anaesthesia delivery system empowered and Bi-spectral index controlled propofol-based general anaesthesia."", 'timeFrame': 'From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively'}, {'measure': 'Assessment of change in anaesthesia depth using Bi-spectral index score', 'description': 'Comparison of anaesthesia depth adequacy in intervention (with dexmedetomidine) versus control (without dexmedetomidine) using Varvel criteria to assess Bi-spectral index (BIS) score consistency during closed loop anaesthesia delivery system empowered and BIS-controlled propofol-based general anaesthesia', 'timeFrame': 'From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively'}]","[{'measure': 'Change in Intraoperative heart Rate (beats per minute)', 'description': ""Comparison of intraoperative heart rate in the 'intervention' (with dexmedetomidine) versus 'control' (without dexmedetomidine) during closed loop anaesthesia delivery system empowered and Bi-spectral index controlled propofol-based GA"", 'timeFrame': 'From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively'}, {'measure': 'Change in Intraoperative blood pressure - systolic , diastolic, and mean (mmHg)', 'description': ""Comparison of intraoperative blood pressure (systolic , diastolic, and mean) in the 'intervention' (with dexmedetomidine) versus 'control' (without dexmedetomidine) during closed loop anaesthesia delivery system empowered and Bi-spectral index controlled propofol-based GA"", 'timeFrame': 'From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively'}, {'measure': 'Postoperative sedation', 'description': 'Will be assessed using Observer asssesment of Alertness/Sedation Scale (OAAS)', 'timeFrame': 'From the end of anaesthesia till 24-hours, postoperatively'}, {'measure': 'Intraoperative awareness', 'description': 'Will be assessed using modified brice questionnaire', 'timeFrame': 'From the end of anaesthesia till 48-hours, postoperatively'}, {'measure': 'Postoperative nausea and vomiting', 'description': 'Will be assessed using PONV scale', 'timeFrame': 'From the end of anaesthesia till 24-hours, postoperatively'}, {'measure': 'Postoperative Analgeisa', 'description': 'Will be assessed using Visual Analogue Scale (VAS) Score', 'timeFrame': 'From the end of anaesthesia till 24-hours, postoperatively'}]",8,20 Years,65 Years,ALL,False,Dr Nitin Sethi,OTHER,0,80.0,ACTUAL,2025-09-01T16:18:20.952753,v2_robust,True,True,True,False,False,
NCT06516068,A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy,"A Multicenter, Randomized, Open-label Phase II Clinical Study on the Efficacy and Safety of HRS-1893 in Obstructive Hypertrophic Cardiomyopathy Subjects.",HRS-1893,['HRS-1893'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Obstructive Hypertrophic Cardiomyopathy,['Obstructive Hypertrophic Cardiomyopathy'],[],ACTIVE_NOT_RECRUITING,,2024-08-11,2025-08,"[{'measure': ""The subjects' left ventricular outflow tract pressure gradient (Valsalva LVOT-G) was assessed for changes from the baseline after performing the Valsalva maneuver"", 'timeFrame': 'After 12 weeks of HRS-1893 treatment'}]","[{'measure': 'Change in peak oxygen uptake (pVO2) and carbon dioxide ventilation equivalent (VE/VCO2)', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change in LVEF', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change in LVOT-VTI', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change in LV-FS', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change in LV-GLS', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change in Rest LVOT-G', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change in Valsalva LVOT-G', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change in cardiac troponin', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change in NT-proBNP', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Proportion of participants with ≥ 1 class improvement in NYHA Functional Class', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Incidence and severity of any adverse events (AESI, SAE, TRAE, TEAE)', 'timeFrame': 'Through study completion, an average of 68 weeks'}, {'measure': 'plasma concentration of HRS-1893', 'timeFrame': 'Through study completion, an average of 68 weeks'}]",14,18 Years,85 Years,ALL,False,"Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,0,42.0,ACTUAL,2025-09-01T16:18:20.952815,v2_robust,True,True,False,False,True,
NCT02508168,Phase 1 Bioavailability Study of SYR-322MET,"An Open-Label, Single-dose, Randomized, Crossover Study to Determine the Bioavailability and Bioequivalence of Alogliptin 12.5 mg and Metformin 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet Vipdomet (Alogliptin FDC With Metformin) in Russian Healthy Subjects",Alogliptin,"['SYR-322MET', 'Alogliptin', 'Metformin Hydrochloride', 'Vipidia', 'Glucophage']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],['Drug therapy'],COMPLETED,,2016-04,2016-04,"[{'measure': 'AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alogliptin', 'description': '(AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\\[0-tlqc\\]).', 'timeFrame': 'Day 1 predose and at multiple time points (up to 72 hours) post-dose.'}, {'measure': 'Cmax: Maximum Observed Plasma Concentration for Alogliptin', 'description': 'Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.', 'timeFrame': 'Day 1 predose and at multiple time points (up to 72 hours) post-dose.'}, {'measure': 'AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Metformin', 'description': '(AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\\[0-tlqc\\]).', 'timeFrame': 'Day 1 predose and at multiple time points (up to 72 hours) post-dose.'}, {'measure': 'Cmax: Maximum Observed Plasma Concentration for Metformin', 'description': 'Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.', 'timeFrame': 'Day 1 predose and at multiple time points (up to 72 hours) post-dose.'}]","[{'measure': 'Percentage of Participants who Experience at Least one Post-dose Adverse Event (AE)', 'description': 'An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.', 'timeFrame': 'Day 1 of Period 1 up to 30 days after the last dose of study medication (up to 38 days)'}, {'measure': 'Percentage of Participants who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose', 'description': 'Standard safety laboratory values (hematology and chemistry) will be collected throughout study and compared to pre-specified criteria for markedly abnormal values.', 'timeFrame': 'At Day 4 and Day 7 of Period 2'}, {'measure': 'Percentage Of Participants who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose', 'description': 'Vital sign measurements will be collected throughout study and compared to pre-specified criteria for markedly abnormal values.', 'timeFrame': 'Day 1 up to Day 4 of each period'}, {'measure': 'Percentage of Participants who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post Dose', 'description': 'Standard 12-lead ECG measurements will be collected throughout the study and compared to pre-specified criteria for markedly abnormal values.', 'timeFrame': 'At Day 1 and Day 4 of each period'}]",8,18 Years,55 Years,ALL,True,Takeda,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:20.952841,v2_robust,True,True,True,False,True,
NCT04588168,Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma,Multi-parameter Magnetic Resonance Imaging for Early Evaluation of the Efficacy of Neoadjuvant Chemotherapy With Modified GC Regimen for Urothelial Carcinoma,Chemotherapy,"['Chemotherapy', 'Neoadjuvant chemotherapy']",2,INTERVENTIONAL,['NA'],,,Bladder Cancer,['Bladder Cancer'],"['Multiparametric Magnetic Resonance Imaging', 'Bladder Cancer', 'Chemotherapy']",RECRUITING,,2018-01-01,2026-06,"[{'measure': 'Changes from baseline tumor mp-MRI parameters at immediate mp-MRI evaluation.', 'description': 'Using the built-in tools of the MRI imaging system to assess the changes of tumor size between immediate mp-MRI evaluation and baseline mp-MRI evaluation after the use of cisplatin during the first course of modified GC neoadjuvant chemotherapy.', 'timeFrame': 'baseline, during the intervention (Within 24 hours after use of cisplatin of the first course of neoadjuvant chemotherapy(NAC), up to 2 weeks)'}]","[{'measure': 'Changes from baseline tumor mp-MRI parameters after two course of modified GC neoadjuvant chemotherapy.', 'description': 'Using the built-in tools of the MRI imaging system to assess the changes of tumor size conventional mp-MRI evaluation and baseline mp-MRI evaluation after the second course of modified GC neoadjuvant chemotherapy.', 'timeFrame': 'baseline, during the intervention(From the end date of the second course of NAC until one day before the third course of NAC, up to 7 weeks)'}, {'measure': 'Changes from baseline tumor mp-MRI parameters after three course of modified GC neoadjuvant chemotherapy.', 'description': 'Using the built-in tools of the MRI imaging system to assess the changes of tumor size between conventional mp-MRI evaluation and baseline mp-MRI evaluation after the third course of modified GC neoadjuvant chemotherapy.', 'timeFrame': 'baseline, during the intervention(From the end date of the third course of NAC until one day before surgery, up to 10 weeks)'}]",3,18 Years,,ALL,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:20.952865,v2_robust,True,True,False,False,False,
NCT04156568,"A Multicentre, Cohort Study of Screening and Preventive Intervention for Latent Tuberculosis Infection in Children","A Multicentre, Cohort Study of Screening and Preventive Intervention for Latent Tuberculosis Infection in Children",INH、RFT,['INH、RFT'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Children LTBI,['Children LTBI'],"['Children', 'LTBI', 'Intervention']",UNKNOWN,,2018-11-01,2021-12-31,"[{'measure': 'Morbidity', 'description': 'Percentage of latent TB infections converted to active TB', 'timeFrame': 'During the 2 year follow-up study'}, {'measure': 'Proportion of adverse reactions', 'description': 'The incidence of adverse reactions in different treatment regimens', 'timeFrame': 'During the 2 year follow-up study'}, {'measure': 'Proportion of lost to follow-up', 'description': 'The proportion of lost to follow-up in different treatment regimens', 'timeFrame': 'During the 2 year follow-up study'}]",[],3,1 Day,18 Years,ALL,False,Beijing Children's Hospital,OTHER,0,1000.0,ESTIMATED,2025-09-01T16:18:20.952903,v2_robust,True,True,False,False,True,
NCT00185068,An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension,"A Prospective, Open Label, Titration Study to Assess the Efficacy and Safety of Benicar® and Benicar ®HCT in Patients With Stage II Systolic Hypertension",Olmesartan medoxomil,"['Olmesartan medoxomil/hydrochlorothiazide', 'Olmesartan medoxomil', 'Hydrochlorothiazide']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,['Hypertension'],"['Systolic hypertension, Angiotensin receptor blocker']",COMPLETED,,2004-03,2004-10,[{'measure': 'Change in mean trough seated systolic blood pressure compared to the start of the study'}],"[{'measure': '1. Blood pressure changes from baseline at the end of each titration period.'}, {'measure': '2. Percentage of patients responding to therapy'}, {'measure': '3. Percentage of patients achieving various blood pressure target goals'}]",4,18 Years,,ALL,False,Daiichi Sankyo,INDUSTRY,0,110.0,,2025-09-01T16:18:20.952922,v2_robust,True,True,True,False,False,
NCT00528268,Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy,Prospective Phase I/II Study to Evaluate Effects of Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy,Sodium phenylbutyrate,"['NaPB', 'Sodium phenylbutyrate']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Spinal Muscular Atrophy,['Spinal Muscular Atrophy'],"['Spinal Muscular Atrophy', 'SMA', 'Sodium Phenylbutyrate']",COMPLETED,,2007-07,2013-12,"[{'measure': 'Safety and Tolerability of Sodium Phenylbutyrate in Neonates and Infants With SMA', 'description': 'The number of participants able to achieve specific developmental milestones, such as sitting unsupported or walking independently, during the study period.', 'timeFrame': '24 months'}]",[],1,1 Day,6 Months,ALL,False,University of Utah,OTHER,1,22.0,ACTUAL,2025-09-01T16:18:20.952933,v2_robust,True,True,True,False,True,
NCT04952168,Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC,"A Single Arm, Prospective, Open Clinical Study of Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC With EGFR Mutation",Almonertinib,['Almonertinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"NSCLC, Stage III","['NSCLC, Stage III']","['Almonertinib', 'chemoradiotherapy']",UNKNOWN,,2021-06-02,2023-06-02,"[{'measure': '2-year overall survival rate', 'description': 'The 2-year overall survival rate was defined as the rate of death within 2 years', 'timeFrame': '2 years'}]","[{'measure': 'Progression-free survival', 'description': 'From the first treatment to the date of first documentation of disease progression, or death due to any cause', 'timeFrame': '3 years'}, {'measure': 'Overall survival', 'description': 'From the first administration to death from any cause', 'timeFrame': '5 years'}]",3,18 Years,,ALL,False,Yuan Chen,OTHER,0,26.0,ESTIMATED,2025-09-01T16:18:20.953099,v2_robust,True,True,False,False,False,
NCT06847568,"The Investigator Administers Intracoronary Adrenaline Via the Catheter in STEMI Patients During Primary PCI, After Flow Restoration and Before Stenting, and Studies Its Effect in Prevention of No Reflow",Role of Catheter Administered Intracoronary Epinephrine in Prevention of No-Reflow in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention,Adrenaline,"['Adrenaline', 'Epinephrine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,ST Segment Elevation Myocardial Infarction (STEMI),"['ST Segment Elevation Myocardial Infarction (STEMI)', 'No Reflow Phenomenon']","['STEMI', 'No-reflow', 'Adrenaline', 'Prophylaxis']",RECRUITING,,2024-04-01,2026-04-30,"[{'measure': 'No-relow', 'description': 'The primary end points will be improvement in coronary flow, as assessed by TIMI (Thrombolysis in Myocardial Infarction) flow\n\nThrombolysis in Myocardial Infarction risk score (TIMI) flow grading system as following:\n\n* TIMI 0 = No ante-grade flow beyond the point of occlusion.\n* TIMI 1 = Faint ante-grade flow beyond the point of occlusion with incomplete filling of the distal vascular bed.\n* TIMI 2 = Delayed or sluggish ante-grade flow with complete filling of the distal vascular beds.\n* TIMI 3 = Normal flow with complete filling of the distal vascular bed\n\nCoronary no-reflow (CNR) is diagnosed immediately after PCI when post-procedural angiographic TIMI flow is \\< 3', 'timeFrame': '1 year up to 2 years'}, {'measure': 'No-relow', 'description': 'The primary end points will be improvement in coronary flow, as assessed by myocardial blush grade.\n\nMyocardial blush grade (MBG) is defined as:\n\n* MBG 0 = No myocardial blush or contrast density.\n* MBG 1 = Minimal myocardial blush or contrast density.\n* MBG 2 = Moderate myocardial blush or contrast density but less than that obtained during angiography of a contralateral or ipsi-lateral non-infarct-related coronary artery.\n* MBG 3 = Normal myocardial blush or contrast density, comparable with that obtained during angiography of a contralateral or ipsilateral non-infarct-related coronary artery\n\nCoronary no-reflow (CNR) is diagnosed immediately after PCI when post-procedural angiographic MBG is 0 or 1', 'timeFrame': '1 year up to 2 years'}]","[{'measure': 'MACE', 'description': 'Secondary end points will be major adverse cardiac events.', 'timeFrame': '1 year up to 2 years'}]",3,18 Years,,ALL,False,Ain Shams University,OTHER,0,1000.0,ESTIMATED,2025-09-01T16:18:20.953112,v2_robust,True,True,False,False,True,
NCT00968968,Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone,"A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer",Lapatinib,['Lapatinib'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Cancer,['Cancer'],"['carcinoma, breast lump, Pagets disease, breast cancer positive for human epidermal growth factor receptor 2, breast cancer progression, estrogen-receptor']",TERMINATED,,2010-01-20,2018-03-30,"[{'measure': 'Progression-free Survival', 'description': 'Progression-free survival (PFS) with lapatinib plus trastuzumab versus trastuzumab alone.\n\nProgression-free survival (PFS) is defined as the time from randomization to the earliest date of disease progression (with radiological evidence) or death from any cause, or to last contact date up to 21Feb2014.\n\nDisease Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.1), a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum diameters recorded since the treatment started (the sum must have an absolute increase from nadir of 5mm), or an unequivocal progression of existing non-target lesions, or the appearance of new lesions.', 'timeFrame': 'Time from randomization until disease progression or death, approximately 4 years'}]","[{'measure': 'Overall Survival', 'description': 'Overall Survival is defined as the interval of time (in months) between the date of randomization and the date of death due to any cause.', 'timeFrame': 'Time from randomization until death, approximately 4 years'}, {'measure': 'Best Overall Response', 'description': 'The best overall response was the best response from the start of the treatment until disease progression/recurrence and was determined programmatically using investigators assessment of responses of target lesion, non-target lesion and new lesions based on RECIST v1.1. Complete Response (CR) = disappearance of all target lesion and non-target lesions if applicable, and no new lesion; Partial Response (PR) = ≥30% decrease in the sum of the longest diameter of target lesions and non-target lesion was neither complete response nor progressive disease (Non-CR/Non-PD) or not evaluable (NE); SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; PD = ≥ 20% increase from nadir of the target lesions or appearance of new lesion. CR and PR were confirmed responses. Confirmed CR - at least two determinations of CR at least 4 weeks apart before PD; Confirmed PR - at least two determinations of PR or better at least 4 weeks apart before PD.', 'timeFrame': 'approximately 4 years'}, {'measure': 'Clinical Benefit Response Rate (CR, PR or SD ≥24 Weeks)', 'description': 'Clinical Benefit Rate (CBR) was defined as the percentage of patients achieving either a confirmed CR or PR at any time or maintaining SD for at least 24 weeks while on study, according to the investigator assessment of response per RECIST 1.1 criteria.\n\nConfirmed CR - at least two determinations of CR at least 4 weeks apart before PD; Confirmed PR - at least two determinations of PR or better at least 4 weeks apart before PD.', 'timeFrame': 'approximately 4 years'}, {'measure': 'Adverse Event Profile of the Two Treatment Arms', 'timeFrame': 'From first dose of study treatment until 30 days after the last dose of study treatment, approximately 8 years.'}]",5,18 Years,,FEMALE,False,Novartis Pharmaceuticals,INDUSTRY,0,37.0,ACTUAL,2025-09-01T16:18:20.953135,v2_robust,True,True,False,True,True,
NCT00452868,Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain,A Pilot Study of Donepezil Hydrochloride in Pediatric Brain Tumor Survivors After Cranial Irradiation,Donepezil,['Donepezil'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Brain and Central Nervous System Tumors,"['Brain and Central Nervous System Tumors', 'Cognitive/Functional Effects', 'Long-term Effects Secondary to Cancer Therapy in Children', 'Neurotoxicity', 'Psychosocial Effects of Cancer and Its Treatment', 'Radiation Toxicity']","['cognitive/functional effects', 'neurotoxicity', 'long-term effects secondary to cancer therapy in children', 'psychosocial effects of cancer and its treatment', 'radiation toxicity', 'childhood central nervous system germ cell tumor', 'childhood choroid plexus tumor', 'childhood craniopharyngioma', 'childhood grade I meningioma', 'childhood grade II meningioma', 'childhood grade III meningioma', 'childhood spinal cord neoplasm', 'childhood brain stem glioma', 'childhood cerebellar astrocytoma', 'childhood medulloblastoma', 'childhood supratentorial primitive neuroectodermal tumor', 'childhood visual pathway and hypothalamic glioma', 'childhood subependymal giant cell astrocytoma', 'childhood ependymoma', 'childhood cerebral astrocytoma/malignant glioma']",COMPLETED,,2006-06,2010-02,"[{'measure': 'Neurocognitive Function as Measured by the Neurocognitive Battery at 24 Weeks', 'description': 'Delis-Kaplan Executive Function System Tower Total Scaled Score, range is 1-19 with the higher score being a better outcome.', 'timeFrame': '24 weeks'}]",[],1,8 Years,17 Years,ALL,False,Wake Forest University Health Sciences,OTHER,1,14.0,ACTUAL,2025-09-01T16:18:20.953227,v2_robust,True,True,True,False,False,
NCT00216268,Treatment of Japanese Encephalitis,Treatment of Japanese Encephalitis - a Double Blind Placebo Controlled Trial,Ribavirin,['Ribavirin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Japanese Encephalitis,['Japanese Encephalitis'],[],UNKNOWN,,2005-07,2008-05,[{'measure': 'Mortality during hospital stay'}],"[{'measure': 'Sequelae at 3 months'}, {'measure': 'Duration of hospital stay'}, {'measure': 'Days to return to oral feeds'}, {'measure': 'Days to become convulsion free'}, {'measure': 'Days to become afebrile'}]",6,6 Months,12 Years,ALL,False,Indian Council of Medical Research,OTHER_GOV,0,200.0,,2025-09-01T16:18:20.953354,v2_robust,True,True,False,False,False,
NCT02980068,A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction,An Open Label Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction (PH-HFpEF) and Normal Healthy Adults,15N Nitrate,"['15N Nitrate', '14N Sodium Nitrate', '15N Sodium Nitrate', '14N Nitrate']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Pulmonary; Hypertension,"['Pulmonary; Hypertension', 'Heart Failure', 'Preserved Ejection Fraction']",[],COMPLETED,,2017-08-28,2022-02-25,"[{'measure': 'Change in nitrate level in urine', 'description': 'The investigators will examine urine nitrate', 'timeFrame': 'Urine collected approx 0 & 6 hours after drug administration'}, {'measure': 'Change in nitrate level in plasma', 'description': 'The investigators will examine plasma nitrate', 'timeFrame': 'Approx 50cc of blood drawn approx 0, 2, & 6 hours after drug administration'}, {'measure': 'Bacterial content of gut microbiome', 'description': 'Stool will be analyzed for bacterial makeup', 'timeFrame': 'Stool collected before drug administration'}, {'measure': 'Bacterial content of the oral microbiome', 'description': 'Saliva and tongue scraping will be analyzed for bacterial makeup', 'timeFrame': 'Saliva and tongue scraping will occur preceding administration of drug'}, {'measure': 'Change in nitrite level in urine', 'description': 'The investigators will examine urine nitrite', 'timeFrame': 'Urine collected approx 0 & 6 hours after drug administration'}, {'measure': 'Change in nitrite level in plasma', 'description': 'The investigators will examine plasma nitrite', 'timeFrame': 'Approx 50cc of blood drawn approx 0, 2, & 6 hours after drug administration'}]","[{'measure': 'Change in blood pressure', 'timeFrame': 'Frequently over 6 hour study visit'}, {'measure': 'Change in heart rate', 'timeFrame': 'Continuous over 6 hour study visit'}, {'measure': 'Change in respiratory rate', 'timeFrame': 'Continuous over 6 hour study visit'}, {'measure': 'Change in hemoglobin concentration', 'timeFrame': 'Continuous over 6 hour study visit'}]",10,18 Years,,ALL,True,"Gladwin, Mark, MD",INDIV,1,77.0,ACTUAL,2025-09-01T16:18:20.953366,v2_robust,True,True,True,False,False,
NCT04339868,Terlipressin for Refractory Septic Shock,Terlipressin Versus Placebo for Septic Shock Refractory to High Doses Catecholamine Vasopressors: A Randomized-controlled Trial,Terlipressin,"['Terlipressin', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Septic Shock,"['Septic Shock', 'Refractory Shock', 'Norepinephrine Adverse Reaction']",[],UNKNOWN,,2020-04-03,2025-07-31,"[{'measure': 'Achieve target blood pressure with low dose adrenergic agents', 'description': 'Achieve target mean arterial blood pressure 65 millimeter mercury or more with norepinephrine and/or epinephrine dose 0.2 mcg/kg/min or lower', 'timeFrame': '6 hours after initiate study drug'}]","[{'measure': '28 day mortality', 'description': 'Proportion of patient who dead before 28 days after enrollment', 'timeFrame': '28 days'}, {'measure': 'Mean arterial blood pressure', 'description': 'Mean arterial blood pressure after initiate study drug', 'timeFrame': '72 hours'}, {'measure': 'Hospital mortality', 'description': 'Proportion of patient who dead before hospital discharge after enrollment', 'timeFrame': '90 days'}, {'measure': 'ICU mortality', 'description': 'Proportion of patient who dead before ICU discharge after enrollment', 'timeFrame': '90 days'}]",5,18 Years,,ALL,False,Mahidol University,OTHER,0,130.0,ESTIMATED,2025-09-01T16:18:20.953413,v2_robust,True,True,False,False,False,
NCT00935168,Crystalloid Versus Hydroxyethyl Starch Trials,A Multi-centre Randomized Controlled Trial of Fluid Resuscitation With Starch (6%Hydroxyethyl Starch 130/0.4) Compared to Saline (0.9% Sodium Chloride) in Intensive Care Patients on Mortality,6% Hydroxy-ethyl starch (130/0.4),"['Saline', '6% Hydroxy-ethyl starch (130/0.4)', 'Sodium Chloride 0.9%', 'Voluven 6%']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Intensive Care,['Intensive Care'],"['Intensive Care', 'Fluid Resuscitation', 'Saline', 'Hydroxy-ethyl starch']",COMPLETED,,2009-12,2012-09,"[{'measure': 'All cause mortality', 'timeFrame': '90 days'}]","[{'measure': 'Renal failure requiring renal replacement therapy will be assessed using hospital records.', 'timeFrame': 'During intensive care Unit (ICU) stay after randomisation up to 90 days'}, {'measure': 'Other organ failures will be assessed using the Sequential Organ Failure Assessment (SOFA) score which is based on biochemical and bio-physiological parameters recorded in the hospital record.', 'timeFrame': 'During ICU stay after randomisation up to 90 days'}, {'measure': 'ICU, hospital and 28 day mortality', 'timeFrame': 'At 28 days and 6 months after randomisation'}, {'measure': 'Quality of life will be assessed using the EQ-5D questionnaire.', 'timeFrame': '6 months after randomisation'}, {'measure': 'Functional status will be assessed using the Glasgow Outcome score.', 'timeFrame': '6 months after randomisation.'}]",6,18 Years,,ALL,False,The George Institute,OTHER,3,7000.0,ACTUAL,2025-09-01T16:18:20.953428,v2_robust,True,True,True,False,False,
NCT02627950,Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction,Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction,Morphinhydrochloricum,"['Morphin-hameln (manufacturer: hameln pharmaceuticals)', 'Isotonic sodium chloride', 'Ticagrelor', 'MCP-ratiopharm (manufacturer: Ratiopharm)', 'Metoclopramide', 'Morphinhydrochloricum', 'Brilique (manufacturer: AstraZeneca)', 'NaCl (manufacturer: Berlin-Chemie Menarini)']",8,INTERVENTIONAL,['PHASE4'],PHASE4,,Acute Myocardial Infarction,['Acute Myocardial Infarction'],[],COMPLETED,,2015-12,2018-10,"[{'measure': 'Platelet activity 2 hours after administration of loading dose of ticagrelor measured by VerifyNow-P2Y12-test', 'timeFrame': '2 hours'}]","[{'measure': 'Platelet reactivity 0.5, 1, 4, 6 and 24 hours after loading dose of ticagrelor measured by VerifyNow-P2Y12-test', 'timeFrame': '0.5, 1, 4, 6 h and 24 hours'}, {'measure': 'Platelet reactivity 0.5, 1, 2, 4, 6 and 24 hours after loading dose of ticagrelor measured by Vasodilator Stimulated Phosphoprotein-test', 'timeFrame': '0.5, 1, 2, 4, 6 h and 24 hours'}, {'measure': 'Percentage of patients with high on-treatment platelet reactivity 0.5, 1, 2, 4, 6 and 24 hours after loading dose of ticagrelor (measured by VerifyNow-P2Y12-test)', 'timeFrame': '0.5, 1, 2, 4, 6 h and 24 hours'}, {'measure': 'Ticagrelor plasma levels and levels of active serum metabolites after 0.5, 1, 2, 4, 6 and 24 hours', 'timeFrame': '0.5, 1, 2, 4, 6 h and 24 hours'}, {'measure': 'Infarct size measured by delayed enhancement magnetic resonance imaging', 'timeFrame': 'Day 1-4'}, {'measure': 'Microvascular obstruction measured by delayed enhancement magnetic resonance imaging', 'description': 'Cardiac magnetic resonance imaging equivalent of angiographic no-reflow, expressed as percentage of left ventricular mass', 'timeFrame': 'Day 1-4'}]",7,18 Years,,ALL,False,University of Luebeck,OTHER,0,138.0,ACTUAL,2025-09-01T16:18:20.953445,v2_robust,True,True,True,False,False,
NCT05803850,"A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058","A Randomized, Double-blind, Placebo-controlled, Single Ascending Doses (SAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of HNC1058",HNC1058 Capsules,"['HNC1058 Capsules', 'HNC1058 Placebos']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,IPF,['IPF'],[],COMPLETED,,2023-03-28,2024-03-08,"[{'measure': 'Number of subjects with adverse events and concomitant medications', 'description': 'To evaluate the safety and tolerability of HNC1058 in comparison with placebo after a single oral dose in healthy subjects in terms of AEs and CMs.', 'timeFrame': 'Between screening and 7-9 days after the last dose'}]","[{'measure': 'Number of subjects with vital sign measurements', 'description': 'To evaluate the safety and tolerability of HNC1058 in comparison with placebo after a single oral dose in healthy subjects in terms of abnormal vital signs', 'timeFrame': 'Between screening and 7-9 days after the last dose'}, {'measure': 'Number of subjects with clinical laboratory test results', 'description': 'o evaluate the safety and tolerability of HNC1058 in comparison with placebo after a single oral dose in healthy subjects in terms of abnormal clinical laboratory test results', 'timeFrame': 'Between screening and 7-9 days after the last dose'}]",3,18 Years,55 Years,ALL,True,Guangzhou Henovcom Bioscience Co. Ltd.,INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:20.953528,v2_robust,True,True,True,False,True,
NCT01844050,Traditional Chinese Medicine in Individualized Treatment of Patients With Diabetes Symptoms,,Chinese herbal medicine,"['Placebo', 'Chinese herbal medicine']",2,INTERVENTIONAL,['NA'],,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],"['Chinese herbal medicine', 'diabetes symptoms']",COMPLETED,,2008-09,2009-10,"[{'measure': 'Change from Baseline Total score of diabetes symptoms at 4 weeks', 'timeFrame': '0 weeks(baseline), 2 weeks, 4 weeks'}]","[{'measure': 'Change from Baseline Fasting Blood Glucose at 4 weeks', 'timeFrame': '0 weeks(baseline), 2 weeks, 4 weeks'}, {'measure': 'Change from Baseline blood glucose at 2 hours after meal at 4 weeks', 'timeFrame': '0 weeks(baseline), 2 weeks, 4 weeks'}]",3,18 Years,65 Years,ALL,False,Shanghai University of Traditional Chinese Medicine,OTHER,2,120.0,ACTUAL,2025-09-01T16:18:20.953536,v2_robust,True,True,True,False,False,
NCT00061750,Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions,"A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis",ICL670,"['Deferasirox', 'deferoxamine', 'ICL670']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Beta-Thalassemia,['Beta-Thalassemia'],"['Thalassemia, iron overload, deferoxamine, hemosiderosis']",COMPLETED,,2003-05,,[{'measure': 'Demonstrate non-inferiority to deferoxamine in its effects on liver iron content (LIC)'}],"[{'measure': 'Evaluate tolerability profile'}, {'measure': 'Estimate absolute and relative change of LIC and Total body iron excretion'}, {'measure': 'Evaluation relationship between LIC and potential surrogate markers'}, {'measure': 'Evaluate the relationship between pharmacokinetics, pharmacodynamics and safety variable'}]",5,2 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,595.0,ACTUAL,2025-09-01T16:18:20.953547,v2_robust,True,True,True,False,True,
NCT02855450,Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma,"An 8 Week Phase Ib, Monocentric, Randomized, Double-masked, Parallel Groups, Study With a 24 Week Follow-up to Evaluate Safety and Potential Efficacy of a 180 μg/ml rhNGF Eye Drops Solution Vs Vehicle in Patients With Glaucoma",rhNGF,"['cenegermin', 'rhNGF', 'Vehicle', 'placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Glaucoma,['Glaucoma'],[],COMPLETED,,2016-12,2018-05,"[{'measure': 'Incidence of Events as of Primary Safety Outcomes', 'description': ""Unexpected Severe Progression Of Optic Neuropathy (USPON) is a composed parameter which required at least 28 single evaluations; it occurred if the subject answered Yes to any of the following 4 questions on unexpected severe progression:\n\n* Best Corrected Distance Visual Acuity (BCDVA): 'Yes' for at least one treated eye at any Follow-Up Visit after first study drug dose\n* Humphrey Visual Field (HVF): 'Yes' for at least one treated eye in at least one assessment during treatment or follow-up period\n* Electroretinography (ERG): 'Yes' for at least one treated eye at any Follow-Up Visit after first study drug dose\n* Optical Coherence tomography (OCT): 'Yes' for at least one treated eye at any Follow-Up Visit after first study drug dose\n\nIntolerance and allergy to the drug was identified based on preferred term of treatment-emergent adverse events.\n\nURAEs are unexpected related AE affecting ocular function. Local/systemic toxicities were identified via the AE form"", 'timeFrame': 'At day 56/end of treatment'}, {'measure': 'Change From Baseline in Visual Analogue Scale (VAS) Ocular Tolerability Score', 'description': 'A ocular tolerability score was determined using a 100 mm VAS on which 0 meant No symptoms and 100 meant the Worst possible discomfort. The patients subjectively evaluated their ocular symptoms (foreign body sensation, burning or stinging, itching, pain, sticky feeling, blurred vision and photophobia) using the VAS giving the value they were feeling from none to an extreme value.\n\nThe ocular symptoms were evaluated by the patients through the scale. Only ""overall"" values for primary eye and secondary eye are reported here under.\n\nAn eye was considered as Primary eye, if\n\n* the eye was treated and\n* the investigator considered this eye as qualifying eye.\n* If both eyes were considered as qualifying eye, the right eye was chosen.\n\nThe other eye was then considered as Secondary eye, if the eye was treated.', 'timeFrame': 'Change from baseline to days 7, 28 and 56 (Treatment period), and Day 84 (Follow up)'}]",[],2,18 Years,90 Years,ALL,False,Dompé Farmaceutici S.p.A,INDUSTRY,1,60.0,ACTUAL,2025-09-01T16:18:20.953558,v2_robust,True,True,True,False,True,
NCT06358950,A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201),"A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1",ALKS 2680,"['ALKS 2680', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Narcolepsy Type 1,['Narcolepsy Type 1'],"['Narcolepsy', 'Cataplexy', 'Orexin']",COMPLETED,,2024-03-28,2025-07-31,"[{'measure': 'Change in Mean Sleep Latency (MSL) on the Maintenance of Wakefulness Test (MWT) from baseline to Week 6', 'timeFrame': 'Baseline to Week 6'}]","[{'measure': 'Change in Epworth Sleepiness Scale (ESS) from baseline to Week 6', 'description': 'Epsworth Sleepiness Scale is a 4-point scale used to measure excessive sleepiness from 0 (would never doze) to 3 (high chance of ""dozing)', 'timeFrame': 'Baseline to Week 6'}, {'measure': 'Mean weekly cataplexy rate (WCR) as derived by subject cataplexy diary', 'timeFrame': 'Measured at Week 5 and 6'}, {'measure': 'Incidence of adverse events', 'timeFrame': 'Up to 15 Weeks'}]",4,18 Years,70 Years,ALL,False,"Alkermes, Inc.",INDUSTRY,0,92.0,ACTUAL,2025-09-01T16:18:20.953702,v2_robust,True,True,True,False,True,
NCT02243150,"Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1","First-In-Human Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of G1T28-1 in Healthy Male and Female Subjects",G1T28-1 (CDK 4/6 Inhibitor),"['G1T28-1 (CDK 4/6 Inhibitor)', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2014-09,2015-12-18,"[{'measure': 'Adverse Events', 'description': 'All Adverse events, including-clinical laboratory data, vital signs and ECGs will be analyzed in all subjects receiving study drug through 14 days post dose of study drug.', 'timeFrame': 'Up to day 14'}]","[{'measure': 'Pharmacokinetics of G1T28-1 in Plasma: Peak Plasma Concentration (Cmax)', 'description': 'The observed peak plasma concentration determined from the plasma concentration vs. time data', 'timeFrame': 'Day 1, Day 2, Day 3 and Day 4'}, {'measure': 'Pharmacokinetics of G1T28-1 in Plasma: Time to reach the observed peak plasma concentration (tmax)', 'description': 'The time to reach the observed peak plasma concentration from the plasma concentration vs. time data', 'timeFrame': 'Day 1, Day 2, Day 3 and Day 4'}, {'measure': 'Pharmacokinetics of G1T28-1 in Plasma: Area under the plasma concentration -time curve from 0-12 hrs (AUC 0-12)', 'description': 'Area under the plasma concentration-time curve from 0 to 12 hours post dosing, calculated by linear/log trapezoidal method', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetics of G1T28-1 in Plasma: Area under the plasma concentration- time curve from 0 to last (AUC 0-last)', 'description': 'Area under the plasma concentration-time curve from time 0 to time of last measurable concentration calculated by linear/log trapezoidal method', 'timeFrame': 'Day 1, Day 2, Day 3, Day 4'}, {'measure': 'Pharmacokinetics of G1T28-1 in Plasma: Area under the plasma concentration-time curve from time zero to infinity', 'description': 'Area under the concentration time curve from time zero extrapolated to infinity', 'timeFrame': 'Day 1, Day 2, Day 3, Day 4'}, {'measure': 'Pharmacokinetics of G1T28-1 in Plasma: terminal half life (T1/2)', 'description': 'Terminal half-life, defined as 0.693 divided by λzλ', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetics of G1T28-1 in Plasma: Terminal phase rate constant', 'description': 'Determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve.', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetics of G1T28-1 in Plasma: Clearance', 'description': 'Clearance after intravenous administration', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetics of G1T28-1 in Plasma: Volume of distribution', 'description': 'Volume of distribution in the terminal elimination phase', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacodynamics-Whole Blood Ex Vivo Stimulation', 'description': 'Analysis of peripheral blood cell proliferation', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacodynamic - Bone Marrow Analysis', 'description': 'Analysis of hematopoietic stem and progenitor cell (HSPC)', 'timeFrame': 'Day 1'}]",12,18 Years,60 Years,ALL,True,"G1 Therapeutics, Inc.",INDUSTRY,0,53.0,ACTUAL,2025-09-01T16:18:20.953765,v2_robust,True,True,True,False,True,
NCT02034591,Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects,Bioavailability of Apixaban Oral Solution Administered Through a Nasogastric Tube in the Presence of Boost® Plus and Apixaban Administered as Crushed Tablet Through a Nasogastric Tube Relative to Apixaban Oral Solution in Healthy Subjects,Apixaban,"['Apixaban', 'BMS-562247']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Subjects,['Healthy Subjects'],[],COMPLETED,,2011-10,2011-11,"[{'measure': 'Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban', 'description': 'Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)', 'timeFrame': 'Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention'}, {'measure': 'Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban', 'description': 'AUC(INF) is measured in nanogram hours per milliliter (ng\\*h/mL)', 'timeFrame': 'Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention'}, {'measure': 'Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban', 'description': 'AUC(0-T) is measured in nanogram hours per milliliter (ng\\*h/mL)', 'timeFrame': 'Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention'}]","[{'measure': 'Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban', 'description': 'Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)', 'timeFrame': 'Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention'}, {'measure': 'Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban', 'description': 'AUC(INF) is measured in nanogram hours per milliliter (ng\\*h/mL)', 'timeFrame': 'Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention'}, {'measure': 'Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban', 'description': 'AUC(0-T) is measured in nanogram hours per milliliter (ng\\*h/mL)', 'timeFrame': 'Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention'}, {'measure': 'Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths or Discontinuation of Study Drug Due to AEs', 'description': 'AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v15.1) and graded using the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0', 'timeFrame': 'Day 1 to 30 days after last dose of study drug'}, {'measure': 'Number of Participants With Marked Laboratory Abnormalities', 'description': 'Marked laboratory abnormalities were defined as laboratory assessments meeting the following investigator-specified criteria: Leukocytes \\>1.2\\* upper limits of normal (ULN) , Basophils \\>3%, Eosinophils \\>1.5\\*ULN, Blood Urine \\>=2, Red Blood Cell (RBC) Urine \\>=2, White Blood Cell (WBC) Urine \\>=2', 'timeFrame': 'Day 1 to 30 days after last dose of study drug'}]",8,18 Years,45 Years,ALL,True,Bristol-Myers Squibb,INDUSTRY,1,37.0,ACTUAL,2025-09-01T16:18:20.953784,v2_robust,True,True,True,False,True,
NCT01258491,"Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects","Double-blind, Randomized, Placebo-controlled, Single-center, 2 Treatment, 3-way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects",Nicotinic Acids,['Nicotinic Acids'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Subjects,['Healthy Subjects'],[],COMPLETED,,2005-05,2005-12,[],[],0,18 Years,45 Years,ALL,True,Heidelberg University,OTHER,0,18.0,ACTUAL,2025-09-01T16:18:20.953852,v2_robust,True,True,True,False,False,
NCT02996591,Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery.,Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery: A Double-Blinded Randomized Controlled Trial.,"Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed","['Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed']",1,INTERVENTIONAL,['PHASE4'],PHASE4,,Nerve Block,"['Nerve Block', 'General Anesthesia', 'Spinal Anesthesia', 'Pain', 'Postoperative Nausea and Vomiting']","['Nerve Block', 'General Anesthesia', 'Spinal Anesthesia', 'Pain', 'Postoperative Nausea and Vomiting']",COMPLETED,,2017-01,2017-05,"[{'measure': 'Time Until Patient is Ready for Discharge From Post-Anesthesia Care Unit (PACU) to Home.', 'description': 'Modified Aldrete Scoring System and Marshall and Chung Postanesthesia Discharge Scoring System, measured in time until discharge criteria is met (in minutes)', 'timeFrame': 'Duration of stay in recovery room after surgery'}]","[{'measure': 'Numerical Rating Scale (NRS) Pain Scores at 1 Hour Postop', 'description': 'NRS Pain scores at 1 hour after surgery. Rated on a scale of 0 (no pain) to 10 (worst pain imaginable).', 'timeFrame': '1 hour after PACU admission'}, {'measure': 'Numerical Rating Scale Pain Scores at 2 Hours Postop', 'description': 'Numerical rating scale pain score as reported by the patient at 2 hours post-operatively. Rated on a scale of 0 (no pain) to 10 (worst pain imaginable).', 'timeFrame': '2 hours after PACU admission'}, {'measure': 'Numerical Rating Scale Pain Scores on Postoperative Day (POD) 1', 'description': 'Numerical Rating Scale Pain from 0-10. 0 being no pain at all. 10 being the worst pain imaginable.', 'timeFrame': '24 hours after surgery'}, {'measure': 'Postoperative Discomfort and Needs (Post-op Pain, Sore Throat, Back Pain, Nausea, Cold, Hunger, Thirst)', 'description': 'Leiden Perioperative Care Patient Satisfaction questionnaire (LPPSq) score. Performed at 1 hour postoperatively. To what degree did patients have the following symptoms. Rated 1-5, 1 being not at all. 5 being extremely.', 'timeFrame': '1 hour after surgery'}, {'measure': 'Postoperative Discomfort and Needs (Post-op Pain, Sore Throat, Back Pain, Nausea, Cold, Hunger, Thirst)', 'description': 'Rating the Nausea/Vomiting of patients post-operatively.', 'timeFrame': '2 hours after surgery'}, {'measure': 'Postoperative Discomfort and Needs (Post-op Pain, Sore Throat, Back Pain, Nausea, Cold, Hunger, Thirst)', 'description': 'Leiden Perioperative Care Patient Satisfaction questionnaire (LPPSq). From 1-5. 1 being not at all. 5 being extremely.', 'timeFrame': 'Postoperative day 1'}, {'measure': 'Incidence of Post-dural Puncture Headache', 'timeFrame': 'Postoperative day 1 and if present, monitored until resolution'}, {'measure': 'Incidence of Transient Neurologic Symptoms', 'timeFrame': 'Postoperative day 1 and if present, monitored until resolution'}, {'measure': 'Opioid Consumption', 'description': 'Opioid consumption (mg OME) during inpatient stay', 'timeFrame': 'Duration of stay in recovery room after surgery (average 2 hours)'}, {'measure': 'Opioid Consumption Through First Postoperative Day. Measured in mg OME', 'timeFrame': 'Postoperative day 1'}, {'measure': 'Non-opioid Analgesic Consumption', 'description': 'The number of patients who took non-opioid analgesic medication for post-operative pain between hospital discharge and postoperative day 1.', 'timeFrame': 'Hospital discharge to postoperative day 1'}, {'measure': 'Opioid-Related Symptom Distress Scale (ORSDS) Score', 'description': 'Opioid-related symptom distress scale. The ORSDS measures patient opioid-related symptoms on a 4-point scale that evaluates 3 symptom distress dimension (severity, frequency, and bothersomeness) for 12 opioid-related symptoms. Scores range from 0-4, and the mean of the 12 answers is the ORSDS score. Higher values indicate worse opioid-related symptoms.', 'timeFrame': '2 hours after surgery'}, {'measure': 'Cognitive Recovery', 'description': 'Postoperative Quality Recovery Scale Cognitive Domain questionnaire. Asked at 1 hour post-operatively. Either yes (return to pre-operative cognitive function levels) or no (not yet returned to pre-operative function levels)', 'timeFrame': '1 hour after surgery'}, {'measure': 'Incidence of Urinary Catheterization', 'timeFrame': 'Duration of stay in recovery room after surgery (average 2 hours)'}, {'measure': 'Anesthesia-related Postoperative Complications', 'description': 'Measuring any anesthesia-related post-op complications that occured (yes or no)', 'timeFrame': 'Surgery start to postoperative day 1'}, {'measure': 'Assessment of Patient Blinding to Group Assignment', 'description': 'Patients will be asked whether they believe they were in the general anesthesia or spinal anesthesia group. These responses are then validated using the Bang Blinding Index, which either confirms or refutes the validity of the blinding. The scale runs from -1 to 1, with a score of 0 indicating complete blinding, -1 indicating opposite guessing of groups, and 1 indicating a complete lack of blinding.', 'timeFrame': 'Postoperative day 1'}, {'measure': 'Patient Satisfaction', 'description': 'Yes/no if patients would request the same anesthetic that they received', 'timeFrame': 'POD1'}, {'measure': 'Cognitive Recovery at 2 Hours Post-operative', 'description': 'Postoperative Quality Recovery Scale Cognitive Domain questionnaire. Asked at 2 hour post-operatively. Either yes (return to pre-operative cognitive function levels) or no (not yet returned to pre-operative function levels)', 'timeFrame': '2 hours after PACU admission'}, {'measure': 'Cognitive Recovery on POD1', 'description': 'Postoperative Quality Recovery Scale Cognitive Domain questionnaire. Asked on postoperative day 1. Either yes (return to pre-operative cognitive function levels) or no (not yet returned to pre-operative function levels)', 'timeFrame': 'Postoperative day 1'}, {'measure': 'Nausea Intensity', 'description': 'Nausea intensity ranked on NRS score following PACU admission to 2 hours after discharge. Scored from 0-10. 0 Being no nausea, 10 being worst nausea imaginable.', 'timeFrame': '2 hours after PACU admission'}, {'measure': 'Back Pain on POD1', 'description': 'Back pain (yes/no) on POD1', 'timeFrame': 'Postoperative day 1'}]",22,18 Years,75 Years,ALL,False,"Hospital for Special Surgery, New York",OTHER,0,36.0,ACTUAL,2025-09-01T16:18:20.953858,v2_robust,True,True,True,False,False,
NCT04750291,Management of Popeye Sign With Botulinum Toxin After Bicepstenotomy,Management of Popeye Sign With Botulinum Toxin After Tenotomy of the Long Head of the Biceps Tendon: a Double-blinded Randomized Controlled Trial,Botulinum toxin type A,['Botulinum toxin type A'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Popeye Syndrome,['Popeye Syndrome'],"['tenotomy', 'long head of the biceps tendon', 'botulinum toxin']",UNKNOWN,,2021-08-09,2022-12,"[{'measure': 'Pain change', 'description': 'VAS score: Visual Analogue Scale score of 0 to 10 with 0 indicating no pain and 10 the worst pain imaginable', 'timeFrame': '3 months'}, {'measure': 'Disability change', 'description': 'quick DASH: Disabilities of the Arm, Shoulder and Hand 0 (no disability) to 100 (most severe disability)', 'timeFrame': '3 months'}]",[],2,18 Years,65 Years,ALL,False,AZ Delta,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:20.953925,v2_robust,True,True,False,False,False,
NCT01270191,The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients,The Effects of Short-Term Exenatide Therapy on the Beta-Cell Function and Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients,Exenatide,"['Exenatide', 'Byetta', 'NPH insulin', 'Humulin-N']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes,['Type 2 Diabetes'],"['Exenatide, Beta-Cell Function, Glycemic Control', 'in Newly Diagnosed Type 2 Diabetic Patients']",UNKNOWN,,2010-11,2015-12,"[{'measure': 'the time of glycemic remission and remission rate', 'description': 'The primary outcomes are the time of glycemic remission and remission rate at one year after short-term therapy.', 'timeFrame': 'at one year'}, {'measure': 'The time of monotherapy failure and monotherapy failure rate', 'description': 'The primary outcomes at 5 years are long-term glycemic control. After 5 months of intensive therapy, these patients were off medication and follow up in our clinics. When diabetes relapsed, they will be treated with metformin monotherapy. The monotherapy failure is defined as A1C \\>7.0% with metformin 1500 mg per day.', 'timeFrame': '5 years'}]","[{'measure': 'Beta-cell function and insulin sensitivity calculated from OGTT.', 'description': 'The Beta-cell function and insulin sensitivity calculated from OGTT.', 'timeFrame': 'at 6 months'}, {'measure': 'Comparison of A1C change, the proportion of subjects who reached the treatment target', 'description': 'The secondary outcomes are the comparison of A1C change, the proportion of subjects who reached the treatment target (A1C \\<7.0% or \\<6.5%) at 6 months and 12 months.', 'timeFrame': '6-12 months'}, {'measure': 'Comparison of A1C change, the proportion of subjects who reached the treatment target', 'description': 'These subjects will be followed up for 5 years to evaluate their long-term glycemic control. The secondary outcomes are the comparison of A1C change, the proportion of subjects who reached the treatment target (A1C \\<7.0% or \\<6.5%) at 5 years.', 'timeFrame': '5 years'}]",5,30 Years,70 Years,ALL,False,"Taipei Veterans General Hospital, Taiwan",OTHER_GOV,0,160.0,ESTIMATED,2025-09-01T16:18:20.953968,v2_robust,True,True,False,False,False,
NCT02117791,"Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )",Drug Use Investigation of Riociguat for ChronicThromboembolic Pulmonary Hypertension (CTEPH),"Riociguat (ADEMPAS, BAY63-2521)","['Riociguat (ADEMPAS, BAY63-2521)']",1,OBSERVATIONAL,[],,,"Hypertension, Pulmonary","['Hypertension, Pulmonary']","['Riociguat, Adempas, sGC stimulator, CTEPH, Japan, PMS']",COMPLETED,,2014-07-16,2023-09-20,"[{'measure': 'Number of participants with treatment emergent adverse events and adverse drug reactions', 'timeFrame': 'up to 8 years'}]","[{'measure': 'Change from baseline in 6MWD (6-Minute Walking Distance) after 4 and 12 months', 'timeFrame': 'baseline and 4 months, and 12 months'}, {'measure': 'Change from baseline in Pulmonary Vascular Resistance (PVR) after 4 and 12 months', 'timeFrame': 'baseline and 4 months, and 12 months'}, {'measure': 'Change from baseline in TRPG (Tricuspid Regurgitation Pressure Gradient) after 4 and 12 months', 'timeFrame': 'baseline and 4 months, and 12 months'}, {'measure': 'Change from baseline in BNP/NT-pro BNP after 4 and 12 months', 'timeFrame': 'baseline and 4 months, and 12 months'}, {'measure': 'Change from baseline in WHO (World Health Organization) functional class after 4 and 12 months', 'timeFrame': 'baseline and 4 months, and 12 months'}, {'measure': 'Time to Clinical Worsening', 'description': 'The first occurrence of the following events is recorded and will be considered for the calculation of the combined endpoint: • Death (all-cause mortality) • Heart/lung transplantation • Rescue Pulmonary Endarterectomy, Rescue Balloon Pulmonary Angioplasty or Hospitalization due to persistent worsening of Pulmonary Hypertension • Start of new PH specific treatment due to worsening Pulmonary Hypertension. • Persistent decrease in 6MWD due to worsening pulmonary hypertension • Persistent worsening of functional class due to deterioration of Pulmonary Hypertension.', 'timeFrame': 'up to 8 years'}]",7,,,ALL,False,Bayer,INDUSTRY,0,1298.0,ACTUAL,2025-09-01T16:18:20.953989,v2_robust,False,True,True,False,True,
NCT00490191,Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency,Comparison of an Incremental Weight-Based Dose Regimen With an Individualized Dosage Adjusted According to the IGF-I Response in Adults With Growth Hormone Deficiency,Somatropin,['Somatropin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypopituitarism,['Hypopituitarism'],[],COMPLETED,,1999-01,2001-07,"[{'measure': 'Percent change in total fat mass', 'timeFrame': 'Eight months'}]","[{'measure': 'Safety', 'timeFrame': 'Eight months'}]",2,20 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,387.0,ACTUAL,2025-09-01T16:18:20.953996,v2_robust,True,True,True,False,True,
NCT04609891,Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors,"A Single-arm, Multi-center, Open Clinical Study of Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors",Avatrombopag,['Avatrombopag'],1,INTERVENTIONAL,['NA'],,,Thrombocytopenia,['Thrombocytopenia'],"['chemotherapy', 'rh-TPO', 'avatrombopag']",COMPLETED,,2020-05-26,2021-05-16,"[{'measure': 'Proportion of responders', 'description': 'Proportion of patients with platelet count ≥100×10\\^9/L or increase of platelet count ≥50×10\\^9/L or ≥100% from baseline within cycle X after initiation of avatrombopag treatment.Due to chemotherapy induced thrombocytopenia in the X+1 cycle, the dose reduction in chemotherapy of X+2 cycle by ≥15% or chemotherapy delay by ≥4 days.', 'timeFrame': 'up to 2 months'}]","[{'measure': 'Duration of grade Ⅲ and Ⅳ thrombocytopenia after initiation of avatrombopag treatment', 'timeFrame': 'up to 2 months'}, {'measure': 'Time for PLT to recover to ≥75×10^9/L and ≥100×10^9/L after initiation of avatrombopag treatment', 'timeFrame': 'up to 2 months'}, {'measure': 'minimal platelet count', 'timeFrame': 'up to 2 months'}, {'measure': 'Proportion of patients without platelet transfusion', 'timeFrame': 'up to 2 months'}, {'measure': 'Proportion of patients without bleeding', 'timeFrame': 'up to 2 months'}]",6,18 Years,75 Years,ALL,False,Anhui Provincial Cancer Hospital,OTHER,0,74.0,ACTUAL,2025-09-01T16:18:20.954025,v2_robust,True,True,True,False,False,
NCT04215991,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants","An Open-label Study With a Nonrandomized Single-dose Phase in Subjects With Suspected or Confirmed Aerobic Gram-negative Bacterial Infections Followed by a Randomized, Multiple-dose, Active-controlled Phase in Subjects With Suspected or Confirmed Complicated Urinary Tract Infection (cUTI), Hospital-acquired Bacterial Pneumonia (HABP) or Ventilator-associated Bacterial Pneumonia (VABP) to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Subjects 3 Months to < 18 Years of Age",Cefiderocol,"['S-649266', 'Cefiderocol', 'Fetroja', 'Standard of Care']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Gram-negative Bacterial Infections,"['Gram-negative Bacterial Infections', 'Hospital Acquired Bacterial Pneumonia (HABP)', 'Complicated Urinary Tract Infection (cUTI)', 'Ventilator Associated Bacterial Pneumonia (VABP)']",[],COMPLETED,,2020-02-19,2024-09-17,"[{'measure': 'Number of Participants with Adverse Events in the Single Dose Phase', 'timeFrame': '28 days'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of Cefiderocol in the Single Dose Phase', 'timeFrame': 'Day 1, 1 (cohort 2 only), 3, 3.5 (cohort 2 only), 5, and 8 hours after the start of infusion'}, {'measure': 'Area Under the Plasma Concentration Time Curve Extrapolated from Time 0 to Infinity (AUCinf) of Cefiderocol in the Single Dose Phase', 'timeFrame': 'Day 1, 1 (cohort 2 only), 3, 3.5 (cohort 2 only), 5, and 8 hours after the start of infusion'}, {'measure': 'Apparent Terminal Elimination Half-life of Cefiderocol in the Single Dose Phase', 'timeFrame': 'Day 1, 1 (cohort 2 only), 3, 3.5 (cohort 2 only), 5, and 8 hours after the start of infusion'}, {'measure': 'Number of Participants with Adverse Events in the Multiple Dose Phase', 'timeFrame': 'Up to 28 days after last dose (33 to 42 days depending on treatment duration)'}, {'measure': 'Maximum Observed Plasma Concentration of Cefiderocol in the Multiple Dose Phase', 'timeFrame': 'During one of the dosing intervals from Day 5-14, 1 (cohort 2 1 and 2 only), 3, 3.5 (cohorts 1 and 2 only), 5, and 8 hours after the start of infusion'}, {'measure': 'Area Under the Plasma Concentration Time Curve Over the Dosing Interval τ (AUC0-τ) of Cefiderocol in the Multiple Dose Phase', 'timeFrame': 'During one of the dosing intervals from Day 5-14, 1 (cohort 2 1 and 2 only), 3, 3.5 (cohorts 1 and 2 only), 5, and 8 hours after the start of infusion'}, {'measure': 'Apparent Terminal Elimination Half-life of Cefiderocol in the Multiple Dose Phase', 'timeFrame': 'During one of the dosing intervals from Day 5-14, 1 (cohort 2 1 and 2 only), 3, 3.5 (cohorts 1 and 2 only), 5, and 8 hours after the start of infusion'}]",[],8,3 Months,17 Years,ALL,False,Shionogi,INDUSTRY,0,91.0,ACTUAL,2025-09-01T16:18:20.954051,v2_robust,True,True,True,False,True,
NCT05239091,Comparison of the Efficacy of Prolotherapy Injection Therapy & Local Anesthetic Injection Therapy.,Comparison of the Efficacy of Prolotherapy Injection Therapy and Local Anesthetic (Lidocaine) Injection Therapy in Myofascial Pain Syndrome.,Dextrose solution,"['Dextrose solution', 'Lidocain', 'Local anesthetic', 'Dextrose prolotherapy']",4,INTERVENTIONAL,['NA'],,,Myofascial Pain Syndrome of Neck,['Myofascial Pain Syndrome of Neck'],"['Lidocaine', 'dextrose prolotherapy', 'pain']",COMPLETED,,2022-08-01,2022-08-22,"[{'measure': 'Pressure pain threshold', 'description': 'It will be measured by algometer. Its unit is kg/cm2', 'timeFrame': 'Change from baseline pressure pain threshold at 2,4,6 and 8 weeks.'}]","[{'measure': 'Pain intensity', 'description': 'Pain intensity will be evaluated by using a visual analog scale (VAS).The maximum score is 10 points. A higher score indicates a worse pain level', 'timeFrame': 'Change from baseline pain intensity score at 2,4,6 and 8 weeks.'}, {'measure': 'Pain tolerance measurement', 'description': 'A pressure of 2.5 kg/cm2 will be applied to the trigger point using an algometer (WAGNER -FPK20) and patients will be asked to express their pain intensity according to the visual analog scale (VAS) scale. All patients will be informed that VAS is 0 (no pain) and 10 (worst pain imaginable), and will be asked to indicate the point between 0 and 10 that can represent the severity of their pain.', 'timeFrame': 'change from baseline pain tolerance at 2,4,6 and 8 weeks.'}, {'measure': 'SF-36 (Short Form-36) Survey', 'description': 'The scale consists of 36 items and these provide the measurement of 8 dimensions. Instead of giving only a single total score, the scale gives a total score for each subscale separately. Subscales evaluate health on a scale of 0 to 100, with 0 indicating poor health and 100 indicating good health.', 'timeFrame': 'Change from baseline SF-36 Short Form Survey score at 8 week.'}]",4,18 Years,65 Years,ALL,False,Istanbul Physical Medicine Rehabilitation Training and Research Hospital,OTHER_GOV,0,28.0,ACTUAL,2025-09-01T16:18:20.954159,v2_robust,True,True,True,False,False,
NCT05773391,Mechanism Exploration of Anti-HER-2 Small-molecule Tyrosine Kinase Inhibitor-related Diarrhea and Establishment of Prevention and Treatment Model(Measure),A Prospective Phase II Study About Mechanism Exploration of Anti-HER-2 Small-molecule Tyrosine Kinase Inhibitor-related Diarrhea and Establishment of Prevention and Treatment Model in HER2+ Breast Cancer,Take probiotics,['Take probiotics'],1,INTERVENTIONAL,['NA'],,,Breast Cancer,['Breast Cancer'],[],UNKNOWN,,2023-04-12,2024-08,"[{'measure': 'Diarrhea grading', 'description': 'Score according to the diarrhea grading：grading score： 0（None）；1（Increased bowel movements \\< 4 times per day compared to before treatment）； 2（Increased bowel movements 4 to 6 times/day or night compared to before treatment）；3（ Increased number of stools ≥ 7 times/day compared with before treatment, fecal incontinence, severe abdominal pain or fecal incontinence, affecting daily activities and requiring hospitalization）； 4（life-threatening (e.g. circulatory failure））；5（Death）.', 'timeFrame': '28 days'}]","[{'measure': 'Time of the first occurrence of diarrhea', 'description': 'The median time of the first occurrence of diarrhea', 'timeFrame': '28 days'}, {'measure': 'Duration of diarrhea', 'description': 'The median duration of diarrhea', 'timeFrame': '28 days'}, {'measure': 'Time of the first occurrence of grade 3 diarrhea', 'description': 'The median time of the first occurrence of grade 3 diarrhea', 'timeFrame': '28 days'}, {'measure': 'Duration of grade 3 diarrhea', 'description': 'The median duration of grade 3 diarrhea', 'timeFrame': '28 days'}, {'measure': 'Adverse events', 'description': 'Occurrence of other adverse events', 'timeFrame': '28 days'}]",6,18 Years,65 Years,ALL,False,Sun Yat-sen University,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:20.954290,v2_robust,True,True,False,False,True,
NCT03282591,"Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough","A Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough",5 mg Serlopitant Tablets,"['Matching Placebo Tablets', 'VPD-737', '5 mg Serlopitant Tablets']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Refractory Chronic Cough,['Refractory Chronic Cough'],[],COMPLETED,,2017-10-03,2018-09-06,"[{'measure': 'Change in 24-hour Objective Cough Frequency (Log Normalized Percent Change Relative to Placebo)', 'description': 'Change in 24-hour objective cough frequency is total number of cough events during the monitoring period (24-hour interval)/24 (Total duration (in hours) for the monitoring period) which is captured through sound recordings by a custom-built digital recording device (VitaloJAK, Vitalograph, Ltd).', 'timeFrame': 'from Baseline to Day 84'}]","[{'measure': 'Change in Awake Objective Cough Frequency', 'description': 'Awake cough frequency = (total number of cough events during the monitoring period (24-hour interval) the subject is awake)/(Total duration (in hours) for the monitoring period the subject is awake) which is captured by a custom-built digital recording device (VitaloJAK, Vitalograph, Ltd).', 'timeFrame': 'from Baseline to Day 84'}, {'measure': 'Percentage of Participants With ≥ 30% Reduction in 24-hour Objective Cough Frequency', 'description': 'The percentage of participants with ≥ 30% of reduction from baseline in 24-hour cough frequency is the number of participants with ≤-30% change in 24-hour cough frequency divided by the total number of participants with available data. This data is captured by a custom-built digital recording device (VitaloJAK, Vitalograph, Ltd).', 'timeFrame': 'from Baseline to Day 84'}, {'measure': 'Percentage of Participants With ≥30% Reduction in Awake Objective Cough Frequency', 'description': 'The percentage of participants with ≥ 30% of reduction from baseline in the awake cough frequency is the number of participants with ≤30% change in awake cough frequency divided by the total number of participants with available data. This data is captured by a custom-built digital recording device (VitaloJAK, Vitalograph, Ltd).', 'timeFrame': 'from Baseline to Day 84'}, {'measure': 'Change From Baseline in Cough Severity Visual Analog Scale (VAS)', 'description': 'Visual Analog Scale (VAS) 101-point scale ranging from 0 (no cough) to 100 (worst cough). A higher score corresponds to higher cough severity.', 'timeFrame': 'from Baseline to Day 84'}]",5,18 Years,80 Years,ALL,False,Vyne Therapeutics Inc.,INDUSTRY,0,185.0,ACTUAL,2025-09-01T16:18:20.954317,v2_robust,True,True,True,False,False,
NCT00024674,Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days,,SS1(dsFv)-PE38,['SS1(dsFv)-PE38'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Neoplasms,['Neoplasms'],"['SS1(dsFv)-PE38', 'SS1P', 'anti-mesothelin immunotoxin', 'advanced malignancy']",WITHDRAWN,Support withdrawn - Study continued by NCI - see record NCT00006981,2001-02,,[],[],0,18 Years,,ALL,False,INSYS Therapeutics Inc,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:20.954360,v2_robust,True,True,False,True,False,Support withdrawn - Study continued by NCI - see record NCT00006981
NCT04478474,Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients,Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients Following Ganciclovir Prophylaxis Until Day +100,Ganciclovir,"['Ganciclovir', 'allogenic stem cell tranplatation']",2,OBSERVATIONAL,[],,,Cytomegalovirus Infections,['Cytomegalovirus Infections'],[],COMPLETED,,2020-09-15,2022-09-15,"[{'measure': 'Ganciclovir', 'description': 'Ganciclovir will be safe, well tolerated, and effective to prevent CMV viremia and/or decrease in pediatric allogeneic stem cell transplant recipients.', 'timeFrame': 'June 29, 2011 through December 31, 2019'}, {'measure': 'CMV viremia and disease in pediatric allogenic SCT recipients', 'description': 'The primary objective is to determine the incidence of CMV viremia and disease in pediatric allogeneic stem cell transplantation recipients who received ganciclovir prophylaxis up until day +100 by retrospective analysis.', 'timeFrame': 'June 29, 2011 through December 31, 2019'}]",[],2,,26 Years,ALL,False,New York Medical College,OTHER,1,100.0,ACTUAL,2025-09-01T16:18:20.954375,v2_robust,False,True,True,False,False,
NCT01286974,A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.,Disposition of [14C]ABT-869 in Patients With Solid Tumors Following a Single Oral Dose Administration,[14C]linifanib,"['ABT-869, linifanib', '[14C]linifanib']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],[],TERMINATED,"Terminated early, Sponsor Decision",2011-08,2012-09,"[{'measure': 'Pharmacokinetic Profile', 'description': 'Blood samples for the pharmacokinetics (PK) of linifanib will be collected at designated time points.', 'timeFrame': 'Various timepoints from Day 1 through approximately Day 9'}, {'measure': 'Total radioactivity', 'description': 'Blood, urine, and fecal samples for total radioactivity analysis will be collected at designated time points.', 'timeFrame': 'Various timepoints from Day 1 through approximately Day 9'}]","[{'measure': 'Safety (Number of subjects with adverse events and/or dose-limiting toxicities)', 'description': 'Adverse event monitoring, lab test assessments, physical exam and vital signs will be evaluated throughout the study.', 'timeFrame': 'At each treatment visit (daily for first 9 days and then approximately every 4 weeks through end of treatment)'}]",3,18 Years,,MALE,False,Abbott,INDUSTRY,0,3.0,ACTUAL,2025-09-01T16:18:20.954387,v2_robust,True,True,False,True,True,"Terminated early, Sponsor Decision"
NCT01611974,Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients,"A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients",Maribavir,['Maribavir'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Cytomegalovirus (CMV),['Cytomegalovirus (CMV)'],"['transplant', 'treatment', 'resistant', 'CMV', 'refractory', 'cytomegalovirus']",COMPLETED,,2012-07-17,2014-12-05,"[{'measure': 'Number of Participants With Confirmed Undetectable Plasma Cytomegalovirus (CMV) Within 6 Weeks', 'description': 'Blood samples were collected at the study sites, processed to plasma aliquots, and sent to the central laboratory for quantitative CMV DNA polymerase chain reaction (PCR) testing. Plasma samples were assayed for CMV concentration using a qualified PCR method. This method was linear over 200-100,000 viral copies/mL with a lower limit of quantification (LLOQ) of 200 copies/mL. Results below LLOQ were considered undetectable. Confirmed undetectable plasma CMV DNA within 6 weeks was defined as 2 consecutive post-baseline, on-treatment undetectable results separated by \\>/= 5 days (assessed by the central laboratory). Samples were collected on Days 1 and 8, weekly during Weeks 2-6, and once in Weeks 8, 10, 12, 16, 20, 24 (treatment) and Weeks 1, 4, 8, 12 (follow-up). Permissible assessment windows were: Days 8-15 +/- 1 day; Weeks 3-4 +/- 2 days; Weeks 5-6 +/- 3 days; Weeks 8-12 +/- 4 days; Weeks 16-24 +/- 7 days (treatment) and Weeks 1-4 +/- 2 days; Weeks 8-12 +/- 4 days (follow-up).', 'timeFrame': '6 weeks'}, {'measure': 'Number of Participants With a Treatment Emergent Adverse Event (TEAE).', 'description': 'Treatment-emergent adverse events are those events that occurred on or after study drug administration through 7 days after the last dose of study drug, or are events that occurred prior to study drug administration and recurred with increased severity after taking study drug through 7 days after the last dose of study drug.', 'timeFrame': '25 weeks'}]","[{'measure': 'Number of Participants With CMV Recurrence', 'description': 'Blood samples were collected at the study sites, processed to plasma aliquots, and sent to the central laboratory for quantitative CMV DNA polymerase chain reaction (PCR) testing. Plasma samples were assayed for CMV concentration using a qualified PCR method. CMV recurrence was defined as achievement of undetectable plasma CMV DNA at any time after Day 1 in at least 2 consecutive samples separated by at least 5 days, followed by detectable plasma CMV DNA in at least 2 consecutive samples separated by at least 5 days (assessed by the central laboratory). For the analyses of CMV recurrence, the first of 2 consecutive confirmed undetectable plasma CMV DNA results had to be on-treatment. CMV DNA PCR values of ≥200 copies/mL were considered detectable. Participants assessed for recurrence (n= 29, 27, 30) are the subset of the ITT-S who had at least 2 consecutive undetectable plasma CMV DNA results separated by at least 5 days, including early withdrawn qualified subjects.', 'timeFrame': '36 weeks'}, {'measure': 'Time to First Confirmed Undetectable Plasma CMV DNA Within 6 Weeks and at Any Time During The Study', 'description': 'Blood samples were collected at the study sites, processed to plasma aliquots, and sent to the central laboratory for quantitative CMV DNA polymerase chain reaction (PCR) testing. Plasma samples were assayed for CMV concentration using a qualified PCR method. The time to event was defined as the time from first dose of study drug to first undetectable plasma CMV DNA within 6 weeks and at any time during the study, defined as the date of the first of at least 2 consecutive post-baseline, on-treatment undetectable results (\\<200 copies/mL) separated by at least 5 days; as assessed by the central laboratory. The median values are Kaplan-Meier estimates.', 'timeFrame': '6 weeks after start of treatment, within 36 weeks of start of treatment'}, {'measure': 'Time to CMV Recurrence', 'description': 'Blood samples were collected at the study sites, processed to plasma aliquots, and sent to the central laboratory for quantitative CMV DNA polymerase chain reaction (PCR) testing. Plasma samples were assayed for CMV concentration using a qualified PCR method. The time to event was defined as the time of the first of at least 2 consecutive samples, separated by at least 5 days, with detectable plasma CMV DNA after achievement of undetectable plasma CMV DNA in at least 2 consecutive samples, separated by at least 5 days, at any time after Day 1; as assessed by the central laboratory. Participants assessed for recurrence (n= 29, 27, 30) are the subset of the ITT-S who had at least 2 consecutive undetectable plasma CMV DNA results separated by at least 5 days, including early withdrawn qualified subjects. The median values are Kaplan-Meier estimates.', 'timeFrame': '36 weeks'}, {'measure': 'Maximum Concentration (Cmax) of Maribavir', 'description': 'For the subset of participants who had pharmacokinetic (PK) profiling performed, non-compartmental PK analyses were used to determine Cmax, time to Cmax (tmax), time of last non-zero concentration (tlast), area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration (AUClast), and half-life (t½). Values below the LLOQ post-baseline were replaced with a value of 0 ug/mL. Values below the LLOQ at baseline were replaced with zero as it was assumed that subjects had no levels of maribavir at baseline. At the designated timepoints, the PK sample was obtained 2-4 hours after the dose of study drug; for subjects who were inpatients, a pre-dose PK sample also was collected. These samples were not required at Day 8 and Week 4 for subjects who had PK profiles performed on those days.', 'timeFrame': 'pre-dose and 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Day 8 and the Week 4 visit'}, {'measure': 'Time to Maximum Concentration (Tmax) of Maribavir', 'description': 'For the subset of participants who had pharmacokinetic (PK) profiling performed, non-compartmental PK analyses were used to determine Cmax, time to Cmax (tmax), time of last non-zero concentration (tlast), area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration (AUClast), and half-life (t½). Values below the LLOQ post-baseline were replaced with a value of 0 ug/mL. Values below the LLOQ at baseline were replaced with zero as it was assumed that subjects had no levels of maribavir at baseline. At the designated timepoints, the PK sample was obtained 2-4 hours after the dose of study drug; for subjects who were inpatients, a pre-dose PK sample also was collected. These samples were not required at Day 8 and Week 4 for subjects who had PK profiles performed on those days.', 'timeFrame': 'pre-dose and 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Day 8 and the Week 4 visit'}, {'measure': 'Time of Last Non-Zero Concentration (Tlast) of Maribavir', 'description': 'For the subset of participants who had pharmacokinetic (PK) profiling performed, non-compartmental PK analyses were used to determine Cmax, time to Cmax (tmax), time of last non-zero concentration (tlast), area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration (AUClast), and half-life (t½). Values below the LLOQ post-baseline were replaced with a value of 0 ug/mL. Values below the LLOQ at baseline were replaced with zero as it was assumed that subjects had no levels of maribavir at baseline. At the designated timepoints, the PK sample was obtained 2-4 hours after the dose of study drug; for subjects who were inpatients, a pre-dose PK sample also was collected. These samples were not required at Day 8 and Week 4 for subjects who had PK profiles performed on those days.', 'timeFrame': 'pre-dose and 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Day 8 and the Week 4 visit'}, {'measure': 'Area Under The Plasma Concentration Versus Time Curve From The Time of Dosing to The Last Measurable Concentration (AUClast) of Maribavir', 'description': 'For the subset of participants who had pharmacokinetic (PK) profiling performed, non-compartmental PK analyses were used to determine Cmax, time to Cmax (tmax), time of last non-zero concentration (tlast), area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration (AUClast), and half-life (t½). Values below the LLOQ post-baseline were replaced with a value of 0 ug/mL. Values below the LLOQ at baseline were replaced with zero as it was assumed that subjects had no levels of maribavir at baseline. At the designated timepoints, the PK sample was obtained 2-4 hours after the dose of study drug; for subjects who were inpatients, a pre-dose PK sample also was collected. These samples were not required at Day 8 and Week 4 for subjects who had PK profiles performed on those days.', 'timeFrame': 'pre-dose and 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Day 8 and the Week 4 visit'}, {'measure': 'Half-Life (T½) of Maribavir', 'description': 'For the subset of participants who had pharmacokinetic (PK) profiling performed, non-compartmental PK analyses were used to determine Cmax, time to Cmax (tmax), time of last non-zero concentration (tlast), area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration (AUClast), and half-life (t½). Values below the LLOQ post-baseline were replaced with a value of 0 ug/mL. Values below the LLOQ at baseline were replaced with zero as it was assumed that subjects had no levels of maribavir at baseline. At the designated timepoints, the PK sample was obtained 2-4 hours after the dose of study drug; for subjects who were inpatients, a pre-dose PK sample also was collected. These samples were not required at Day 8 and Week 4 for subjects who had PK profiles performed on those days.', 'timeFrame': 'pre-dose and 1, 2, 3, 4, 6, 8, and 12 hours post-dose on Day 8 and the Week 4 visit'}]",10,12 Years,,ALL,False,Shire,INDUSTRY,0,120.0,ACTUAL,2025-09-01T16:18:20.954404,v2_robust,True,True,True,False,True,
NCT06371274,A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.,"Efficacy and Safety Study of Oral All-trans Retinoic Acid Combined With Toripalimab in Patients With Inoperable Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer Who Had Failed Prior Second-line or Higher Standard Therapy.",ATRA,"['Toripalimab', 'ATRA']",2,INTERVENTIONAL,['NA'],,,Triple-negative Breast Cancer,['Triple-negative Breast Cancer'],"['all-trans retinoic acid', 'Toripalimab', 'triple-negative breast cancer', 'efficacy', 'safety']",RECRUITING,,2024-10-10,2026-04-30,"[{'measure': 'Objective Response Rate (ORR)', 'description': 'During the combined therapy, tumor assessment (enhanced CT) is conducted every 2 cycles (6 weeks), and the efficacy is evaluated using the RECIST 1.1 criteria. ORR will be summarized as the proportion of subjects achieving objective tumor responses (complete response or partial response). ORR and its 95% confidence interval will be calculated.', 'timeFrame': 'up to 2 years'}]","[{'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS defined as the time from enrollment until disease progression or death (whichever occurs first).', 'timeFrame': 'up to 2 years'}, {'measure': 'Duration of Response (DOR)', 'description': 'For responders (complete response or partial response), DOR is defined as the time from the earliest date meeting the response criteria to disease progression or death for any reason (whichever occurs first). For subjects who do not experience progression after meeting response criteria and continue to survive, DOR will be censored at the last evaluable tumor assessment date or the last follow-up date for disease progression.', 'timeFrame': 'up to 2 years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time interval between the date of the first dose and the date of death for any reason. Kaplan-Meier methodology will be used to estimate median OS, OS rates, and their 95% confidence intervals at different time points.', 'timeFrame': 'up to 2 years'}]",4,18 Years,,FEMALE,False,First Affiliated Hospital of Zhejiang University,OTHER,2,29.0,ESTIMATED,2025-09-01T16:18:20.954506,v2_robust,True,True,False,False,False,
NCT00005674,Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS],,Creatine,['Creatine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Amyotrophic Lateral Sclerosis,['Amyotrophic Lateral Sclerosis'],[],COMPLETED,,,,[],[],0,18 Years,80 Years,ALL,False,National Center for Research Resources (NCRR),NIH,1,,,2025-09-01T16:18:20.954524,v2_robust,True,True,True,False,False,
NCT05098574,Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder,"A Pilot, Randomized, Placebo-Controlled Trial Evaluating the Treatment of Premenstrual Dysphoric Disorder with Oral Contraceptives in Bipolar Disorder.",Yaz,"['3mg drospirenone/ 0.02mg ethinyl estradiol', 'Yaz', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Premenstrual Dysphoric Disorder,"['Premenstrual Dysphoric Disorder', 'Bipolar Disorder']","['bipolar disorder', 'premenstrual dysphoric disorder']",COMPLETED,,2023-02-03,2024-04-11,"[{'measure': 'Feasibility outcome: treatment compliance', 'description': 'Treatment compliance - assessed via number and percentage of treatment pills taken', 'timeFrame': '12 weeks'}, {'measure': 'Feasibility outcome: retention rates', 'description': 'Retention rates - number and percentage of people who remain in the study once randomized', 'timeFrame': '12 weeks'}, {'measure': 'Feasibility outcome: recruitment rate (monthly)', 'description': 'Recruitment rate (monthly) - number of participants per month', 'timeFrame': '2 years'}, {'measure': 'Feasibility outcome: recruitment capacity', 'description': 'Recruitment capacity - total number of participants randomized and enrolled', 'timeFrame': '2 years'}, {'measure': 'Feasibility outcome: screening rates (monthly)', 'description': 'Screening rates (monthly) - number screened; number enrolled as a percentage of number screened', 'timeFrame': '2 years'}, {'measure': 'Feasibility outcome: duration of assessment process', 'description': 'Duration of assessment process - mean in hours from start to finish for each visit', 'timeFrame': 'Screening'}, {'measure': 'Feasibility outcome: duration of assessment process', 'description': 'Duration of assessment process - mean in hours from start to finish for each visit', 'timeFrame': 'Baseline'}, {'measure': 'Feasibility outcome: duration of assessment process', 'description': 'Duration of assessment process - mean in hours from start to finish for each visit', 'timeFrame': 'Week 4'}, {'measure': 'Feasibility outcome: duration of assessment process', 'description': 'Duration of assessment process - mean in hours from start to finish for each visit', 'timeFrame': 'Week 8'}, {'measure': 'Feasibility outcome: duration of assessment process', 'description': 'Duration of assessment process - mean in hours from start to finish for each visit', 'timeFrame': 'Week 12'}, {'measure': 'Feasibility outcome: safety of use of oral contraceptives in this population', 'description': 'Safety of use of oral contraceptives in this population - adverse events reported, onset of mood episodes (assessed by clinicians)', 'timeFrame': 'Week 4'}, {'measure': 'Feasibility outcome: safety of use of oral contraceptives in this population', 'description': 'Safety of use of oral contraceptives in this population - adverse events reported, onset of mood episodes (assessed by clinicians)', 'timeFrame': 'Week 8'}, {'measure': 'Feasibility outcome: safety of use of oral contraceptives in this population', 'description': 'Safety of use of oral contraceptives in this population - adverse events reported, onset of mood episodes (assessed by clinicians)', 'timeFrame': 'Week 12'}, {'measure': 'Feasibility outcome: tolerability', 'description': 'Tolerability - assessed as percentage dropped out after randomization due to adverse events', 'timeFrame': 'Week 4'}, {'measure': 'Feasibility outcome: tolerability', 'description': 'Tolerability - assessed as percentage dropped out after randomization due to adverse events', 'timeFrame': 'Week 8'}, {'measure': 'Feasibility outcome: tolerability', 'description': 'Tolerability - assessed as percentage dropped out after randomization due to adverse events', 'timeFrame': 'Week 12'}, {'measure': 'Feasibility outcome: response rates', 'description': 'Response rates - response will be defined as 50% decrease from baseline symptom change from late luteal to follicular phase; remission will be defined as number and percentage of responders who no longer need DSM-5 criteria for PMDD', 'timeFrame': 'Week 12'}, {'measure': 'Feasibility outcome: estimated treatment effect', 'description': 'Estimated treatment effect - mean percent change from baseline to post-treatment in percent change on the MAC-PMSS from late luteal to follicular phase', 'timeFrame': 'Week 12'}, {'measure': 'Feasibility outcome: variance of the treatment effect', 'description': 'Variance of the treatment effect - standard deviation of above measure.', 'timeFrame': 'Week 12'}]",[],19,16 Years,45 Years,FEMALE,False,St. Joseph's Healthcare Hamilton,OTHER,2,17.0,ACTUAL,2025-09-01T16:18:20.954557,v2_robust,True,True,True,False,True,
NCT03531918,"Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm","A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm",Cladribine,"['Leustatine', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', 'Aracytine', 'hP67.6-Calicheamicin', 'U 19920', 'Alexan', 'Mitoxantroni Hydrochloridum', 'ARA-cell', 'Gemtuzumab Ozogamicin', 'Cladribine', '.beta.-Cytosine arabinoside', 'Mylotarg', 'CL 232315', '1-.beta.-D-Arabinofuranosylcytosine', 'WR-28453', 'CdA', 'Erpalfa', 'Cytarbel', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', 'Cladribina', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', 'Cytosar', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', 'CHX-3311', 'Dihydroxyanthracenedione Dihydrochloride', 'Udicil', 'Novantrone', 'Ara-C', 'Cytosine Arabinoside', 'Mitoxantrone Dihydrochloride', 'gemtuzumab', 'Aracytidine', 'Mitoxantrone Hydrochloride', 'Cytosine-beta-arabinoside', 'Mitroxone', 'WAY-CMA-676', 'Cytosine-.beta.-arabinoside', 'Cytarabinum', '2CDA', 'U-19920', 'Arabinofuranosylcytosine', 'DHAQ', 'Aracytin', 'DHAD', 'Onkotrone', '2-CdA', 'Starasid', 'Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody', '1.beta.-D-Arabinofuranosylcytosine', 'CDP-771', 'RWJ-26251', 'CMA-676', 'Cytarabine', 'Arabinosylcytosine', 'Tarabine PFS', '1-Beta-D-arabinofuranosylcytosine', 'Neotalem', 'Pralifan', 'Leustat', 'Leustatin', 'Arabine', 'Mitozantrone Hydrochloride', 'Beta-cytosine Arabinoside']",63,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],[],COMPLETED,,2018-09-14,2021-11-01,"[{'measure': 'Maximum Tolerated Dose (MTD) of Gemtuzumab Ozogamicin (GO) When Added to GCLAM (Phase 1)', 'description': 'Defined as the highest dose studied in which the incidence of Dose Limiting Toxicity (DLT) is ≤33% (≤4 of 12 patients experiencing DLT), defined as any Grade 3 non-hematologic toxicity lasting \\>48 hours that results in \\>7-day delay of the subsequent treatment cycle, with the exception of febrile neutropenia or infection or toxicities secondary to febrile neutropenia or infection, or any Grade ≥4 non-hematologic toxicity except febrile neutropenia/infection (or toxicities secondary to febrile neutropenia or infection) unless felt to be a direct consequence of treatment-related toxicity (e.g. intestinal infection following mucosal barrier breakdown), and with the exception of constitutional symptoms if recovery to Grade ≤2 within 14 days. The National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 will be used.', 'timeFrame': 'At time of count recovery, second cycle of treatment, response assessment or removal from protocol (at approximately 1 month).'}, {'measure': 'Event-free Survival (EFS) Rate (Phase 2)', 'description': 'A two-stage design will be used to evaluate the EFS. Patients treated at the maximum tolerated dose (MTD) from the phase 1 portion of the trial will be used in the phase 2 analysis. If censoring occurs, secondary analyses analyzing 6-month or 1-year EFS accounting for censoring will be done, including estimating 6-month or 1-year EFS using the Kaplan-Meier method. The first stage of the two-stage phase 2 design will evaluate 30 patients. If 20 or more of the first 30 patients are alive without event at 6-months after study registration, an additional 30 patients will be enrolled. If 46 or more of the 60 patients treated at the MTD are alive and without event at 6-months after study registration, the study will consider the regimen of interest for further investigation. Patients last known to be alive in CR were censored at date of last contact.', 'timeFrame': 'From the start of study treatment, assessed at 6 months and 1 year'}]","[{'measure': '30-day All-cause Mortality', 'description': 'As a summary of adverse events (captured on trial using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0), 30-day all cause mortality is reported as a percent of patients treated at the MTD/RP2D.\n\nWill be estimated and 95% confidence intervals will be calculated. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.', 'timeFrame': 'Up to 5 years. 30-day all-cause mortality is reported'}, {'measure': 'Relapse-free Survival of GO3 Cohort', 'description': 'RFS was calculated for participants who achieved a complete remission (with or without count recovery; CR or CRi) and measured from the date remission to the first of relapse from CR/CRi or death from any cause. Patients last known to be alive in CR /CRi were censored at date of last contact. Will be estimated using the Kaplan-Meier method. Time to relapse will be estimated using non-parametric estimates of the cumulative incidence curve with death analyzed as a competing event. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.', 'timeFrame': 'Up to 5 years. 2-year RFS reported.'}, {'measure': 'Overall Survival', 'description': 'OS was calculated for all participants and measured from initial trial therapy to death from any cause. Patients last known ot be alive were censored at date of last contact. Will be estimated using the Kaplan-Meier method. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.', 'timeFrame': '3 years and 1 month'}, {'measure': 'Measurable Residual Disease (MRD) Rates and Remission Rates: CR', 'description': 'Will be estimated and 95% confidence intervals will be calculated. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.\n\nComplete response (CR) rate is defined as the frequency of patients achieving CR, which is defined by the European LeukemiaNet 2017 guidelines as bone marrow blasts \\<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC ≥1.0 x 109/L (1000/mL); platelet count ≥100 x 109/L. (100 000/mL). MRD negative (MRDneg) status is defined as negative for leukemic markers by multiparameter flow cytometry.\n\nAplasia was defined as absence of tumoral cells but cellularity not meeting criteria for MLFS.\n\nStatistical significance tests were not performed.', 'timeFrame': '90 days'}, {'measure': 'Measurable Residual Disease (MRD) and Remission Rates: CRi (MRDneg)', 'description': 'Will be estimated and 95% confidence intervals will be calculated. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.\n\nComplete response with incomplete hematologic recovery (CRi) rate is defined as the frequency of patients achieving CRi, which is defined by the European LeukemiaNet 2017 guidelines as all CR criteria except for residual neutropenia (ANC \\<1.0 x 109/L \\[1000/mL\\]) or thrombocytopenia (platelet count \\<100 x 109/L \\[100,000/mL\\]). MRD negative (MRDneg) status is defined as negative for leukemic markers by multiparameter flow cytometry.\n\nAplasia was defined as absence of tumoral cells but cellularity not meeting criteria for MLFS.\n\nStatistical significance tests were not performed.', 'timeFrame': '90 days'}, {'measure': 'Measurable Residual Disease (MRD) and Remission Rates: CR/CRi', 'description': 'Will be estimated and 95% confidence intervals will be calculated. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.\n\nComplete response (CR) + complete response with incomplete hematologic recovery (CRi) rate is defined as the frequency of patients achieving CR or CRi per the European LeukemiaNet 2017 criteria as defined above. MRD negative (MRDneg) status is defined as negative for leukemic markers by multiparameter flow cytometry.\n\nAplasia was defined as absence of tumoral cells but cellularity not meeting criteria for MLFS.\n\nStatistical significance tests were not performed.', 'timeFrame': '90 days'}, {'measure': 'Measurable Residual Disease (MRD) and Remission Rates: MLFS (MRDneg)', 'description': 'Will be estimated and 95% confidence intervals will be calculated. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.\n\nMorphologic leukemia free state (MLFS) rate is defined as the frequency of patients achieving MLFS, which is defined by the European LeukemiaNet guidelines as bone marrow blasts \\<5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required. At least 200 cells should be enumerated or cellularity should be at least 10%. MRD negative (MRDneg) status is defined as negative for leukemic markers by multiparameter flow cytometry.\n\nAplasia was defined as absence of tumoral cells but cellularity not meeting criteria for MLFS.\n\nStatistical significance', 'timeFrame': '90 days'}, {'measure': 'Measurable Residual Disease (MRD) and Remission Rates: Alapasia (MRDneg)', 'description': 'Will be estimated and 95% confidence intervals will be calculated. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.\n\no Aplasia rate is defined in this protocol as frequency of patients without blood count recovery after chemotherapy and bone marrow examination showing hypocellularity not meeting cellularity criteria for morphologic leukemia free state (MLFS). MRD negative (MRDneg) status is defined as negative for leukemic markers by multiparameter flow cytometry.\n\nAplasia was defined as absence of tumoral cells but cellularity not meeting criteria for MLFS.\n\nStatistical significance tests were not performed.', 'timeFrame': '90 days'}]",10,18 Years,,ALL,False,Fred Hutchinson Cancer Center,OTHER,1,66.0,ACTUAL,2025-09-01T16:18:20.954668,v2_robust,True,True,True,False,True,
NCT04339218,Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma,Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in First-line Treatment for Patients With Metastatic Lung Adenocarcinoma: A Randomized Phase III Study,Pembrolizumab,"['Pembrolizumab', 'Carboplatin', 'Pemetrexed']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Lung Adenocarcinoma,"['Lung Adenocarcinoma', 'Cryotherapy Effect']","['Lung adenocarcinoma, immunotherapy, cryoablation']",RECRUITING,,2020-08-28,2028-08-27,"[{'measure': '1-year overall survival rate', 'description': 'Overall survival (OS) is defined as the time interval between the date of randomization and the date of death (from any cause). Patients alive will be censored at the date of last follow-up or last patient contact. One-year OS rates will be compared between arms.', 'timeFrame': '1 year'}]","[{'measure': 'Overall response rate within 6 months as per RECIST v1.1', 'description': 'Overall response rate (ORR) is defined as the rate of patients with complete or partial response (CR, PR) as per RECIST v1.1. According to RECIST v1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.; Overall Response (OR) = CR + PR.', 'timeFrame': 'throughout the treatment period, an expected average of 6 months'}, {'measure': 'Overall response rate at 6 months as per RECIST v1.1', 'description': 'Overall response rate (ORR) is defined as the rate of patients with complete or partial response (CR, PR) as per RECIST v1.1. According to RECIST v1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.; Overall Response (OR) = CR + PR.', 'timeFrame': '6 months'}, {'measure': 'Overall response rate as per RECIST v1.1', 'description': 'Overall response rate (ORR) is defined as the rate of patients with complete or partial response (CR, PR) as per RECIST v1.1. ORR will be assessed across all time points, once all the data for the patient is known. According to RECIST v1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.; Overall Response (OR) = CR + PR.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': 'Duration of overall response', 'description': 'The duration of overall response (DoR) is defined as the time from documentation of tumour response (Complete or partial responses whichever is first recorded) to disease progression, according to RECIST v1.1. Kaplan-Meier Method will be used to estimate DoR.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': 'Best overall response rate as per RECIST v1.1', 'description': 'Best overall response rate (BoR) is defined as rate of patients with the best response across all time points (RECIST v1.1). The best overall response will be determined once all the data for the patient is known.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': '2-year overall survival rate', 'description': 'Overall survival (OS) is defined as the time interval between the date of randomization and the date of death (from any cause). 2-year OS rates will be compared between arms.', 'timeFrame': '2 years'}, {'measure': '1-year progression-free survival rate', 'description': 'Progression-free survival (PFS) is defined as the time interval between the date of randomization and the date of progression (RECIST v1.1) or death (from any cause), whichever occurs first.The analysis of PFS will be based on the censoring process following FDA guidelines. Progression is defined using RECIST v1.1, as a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), or a unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.1-year PFS rates will be compared between arms.', 'timeFrame': '1 year'}, {'measure': '2-year progression-free survival rate', 'description': 'Progression-free survival (PFS) is defined as the time interval between the date of randomization and the date of progression (RECIST v1.1) or death (from any cause), whichever occurs first.The analysis of PFS will be based on the censoring process following FDA guidelines. Progression is defined using RECIST v1.1, as a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), or a unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.2-year PFS rates will be compared between arms.', 'timeFrame': '2 years'}, {'measure': 'Mean scores of each dimension of QLQ-C30 from EORTC quality of life group', 'description': 'Health-related quality of life (HRQoL) will be assessed through EORTC QLQ-C30 (Aaronson et al. J Natl Cancer Inst 1993).The QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. The questionnaire includes one global health status/QoL scale, five functional scales and three symptom scale. Each scale is scored from 0 to 100. A high score on a scale indicate a good outcome for the dimension of QoL.', 'timeFrame': 'at baseline, 3, 6, 9, 12 and 24 months'}, {'measure': 'Time to health-related quality of life score definitive deterioration (targeted dimension of EORTC QLQC30 : global health)', 'description': 'Time until definitive deterioration (TUDD) of HRQoL is defined as the time from the date of randomization to a first deterioration of at least 10 points of HRQoL as compared to the baseline score (Bonnetain et al. Eur J Cancer 2010).', 'timeFrame': 'at baseline, 3, 6, 9, 12 and 24 months'}, {'measure': 'Number of patient receiving a post-progression treatment', 'description': 'Post-progression treatment is defined as the treatment (systemic/local) given after the first progression under cryoablation+pembrolizumab and pemetrexed-carboplatin or pembrolizumab and pemetrexed-carboplatin.', 'timeFrame': 'an average of 6 months'}, {'measure': 'Overall response rate as per iRECIST', 'description': 'Overall response rate (ORR) is defined as the rate of patients with immune complete or partial responses (iCR, iPR) as per iRECIST (Seymour et al. 2017). iCR and iPR can be assigned after iUPD (immune unconfirmed progressive disease) has been documented.', 'timeFrame': 'throughout the treatment period, an expected average of 6 months'}, {'measure': 'Duration of immune overall response', 'description': 'Duration of i-response (iDoR) is defined as the time from the date of the first response iCR/iPR (whichever is first recorded) to the date of PD (iUPD confirmed as iCPD). iDOR is only defined for subjects who have best overall response of iCR or iPR.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': '1-year immune-progression-free survival rate', 'description': 'Immune-progression-free survival (iPFS) is defined as the time interval between the date of randomization and the date of progression (iRECIST) or death (from any cause), whichever occurs first. The event date to be used for calculation of progression-free survival (iPFS) should be the first date at which progression criteria are met (ie, the date of iUPD) provided that iCPD is confirmed at the next assessment. 1-year iPFS rates will be compared between arms.', 'timeFrame': '1 year'}, {'measure': '2-year immune-progression-free survival rate', 'description': 'Immune-progression-free survival (iPFS) is defined as the time interval between the date of randomization and the date of progression (iRECIST) or death (from any cause), whichever occurs first. The event date to be used for calculation of progression-free survival (iPFS) should be the first date at which progression criteria are met (ie, the date of iUPD) provided that iCPD is confirmed at the next assessment. 2-year iPFS rates will be compared between arms.', 'timeFrame': '2 year'}, {'measure': 'Best overall response rate as per iRECIST', 'description': 'Best overall response rate (iBoR) is defined, according to iRECIST, as the rate of patients with the best timepoint response recorded from the start of the study treatment until the end of treatment, taking into account any requirement for confirmation.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': 'Number of immune-related SAEs (CTCAE NCI V5)', 'description': 'Serious Adverse events (SAEs) will be coded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) NCI v5.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': 'Number of immune-related AEs (CTCAE NCI V5)', 'description': 'Adverse events (AEs) will be coded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) NCI v5.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': 'Number of chemotherapy-related SAEs (CTCAE NCI V5)', 'description': 'Serious Adverse events (SAEs) will be coded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) NCI v5.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': 'Number of chemotherapy-related AEs (CTCAE NCI V5)', 'description': 'Adverse events (AEs) will be coded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) NCI v5.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': 'Number of cryoablation-related SAEs (CTCAE NCI V5)', 'description': 'Serious Adverse events (SAEs) will be coded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) NCI v5.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': 'Number of cryoablation-related AEs (CTCAE NCI V5)', 'description': 'Adverse events (AEs) will be coded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) NCI v5.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': 'Number of SAEs related to study procedures (CTCAE NCI V5)', 'description': 'Serious Adverse events (SAEs) will be coded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) NCI v5.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': 'Number of AEs related to study procedures (CTCAE NCI V5)', 'description': 'Adverse events (AEs) will be coded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) NCI v5.', 'timeFrame': 'throughout the treatment period, an expected average of 1 year'}, {'measure': 'Number of hospitalisations in experimental arm only', 'description': 'counts of hospitalisations within 30 days after the cryoablation will be summarized by treatment strategy.', 'timeFrame': 'within 6 weeks + 30 days after first pembrolizumab administration'}, {'measure': 'Percentage of patients that worsen their ECOG score of 1 or more point', 'description': 'Percentage of patients that worsen their ECOG score of 1 or more point at follow-up visits post randomization will be summarized by treatment strategy.', 'timeFrame': 'at follow-up visits post randomization (an average of 2 years)'}]",27,18 Years,,ALL,False,Institut Bergonié,OTHER,0,214.0,ESTIMATED,2025-09-01T16:18:20.954697,v2_robust,True,True,False,False,True,
NCT05819918,Calcifediol in the Treatment of COVID 19,Calcifediol in the Treatment of COVID 19. Modification of Therapeutic Response by Best Available Treatment or Other Treatment or Clinical Variables,Calcifediol,"['Calcifediol', 'Best available therapy']",2,OBSERVATIONAL,[],,,COVID-19,['COVID-19'],[],COMPLETED,,2022-04-01,2023-04-17,"[{'measure': 'Need for ICU admission', 'description': 'Measure the need for ICU admission by differentiating the groups calcifediol yes/no; corticosteroids yes/no.', 'timeFrame': 'from hospitalization till discharge /death'}, {'measure': 'Mortality', 'description': 'Measure mortality by differentiating groups: calcifediol yes/no; corticosteroids yes/no.', 'timeFrame': 'from hospitalization till discharge /death'}, {'measure': 'Composite variable poor prognosis, (ICU&death)', 'description': 'Measure the composite variable poor prognosis, (ICU\\&death) by differentiating the groups calcifediol yes/no; corticosteroids yes/no.', 'timeFrame': 'from hospitalization till discharge /death'}]","[{'measure': 'clinical variables that calcifediol response', 'description': 'To detect clinical variables that may modify the response to calcifediol.', 'timeFrame': 'from hospitalization till discharge /death'}, {'measure': 'drug modifying calcifediol response', 'description': 'To detect clinical variables that may modify the response to calcifediol.', 'timeFrame': 'from hospitalization till discharge /death'}]",5,18 Years,,ALL,,Maimónides Biomedical Research Institute of Córdoba,OTHER,0,728.0,ACTUAL,2025-09-01T16:18:20.954855,v2_robust,False,True,True,False,False,
NCT04213118,Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence,"An Open, Single Arm,Multicenter Clinical Trial of Anlotinib Combined With Transcatheter Arterial Chemoembolization for Adjuvant Therapy in Patients With High Risk of Recurrence After Resection of Advanced Hepatocellular Carcinoma",Anlotinib Hydrochloride,['Anlotinib Hydrochloride'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Hepatocellular Carcinoma,"['Hepatocellular Carcinoma', 'TACE', 'Anlotinib']",[],UNKNOWN,,2020-04-23,2023-09,"[{'measure': 'Disease free survival', 'description': 'The period from resection surgery to recurrence of HCC', 'timeFrame': 'From randomization to recurrence of HCC or death (up to 1year)'}]","[{'measure': '1-year DFS Rate', 'description': 'One year ratio of DFS', 'timeFrame': 'From randomization to recurrence of HCC or death (up to 1year)'}, {'measure': 'Time to recurrence', 'description': 'The period from resection surgery to recurrence of HCC', 'timeFrame': 'From randomization to recurrence of HCC(up to 1year)'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events Safety and Tolerability', 'description': 'Any adverse effects occur during the use of anlotinib', 'timeFrame': 'Up to 30 day safety follow-up visit'}]",4,18 Years,75 Years,ALL,False,First Affiliated Hospital Xi'an Jiaotong University,OTHER,1,30.0,ESTIMATED,2025-09-01T16:18:20.954872,v2_robust,True,True,False,False,True,
NCT00382018,S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo,A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment,chemotherapy,['chemotherapy'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],"['recurrent breast cancer', 'stage IV breast cancer']",COMPLETED,,2006-10,2017-07-11,"[{'measure': 'Overall Survival', 'description': 'From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.', 'timeFrame': 'Every 3 months until progression then every 6 months for 5 years or until death'}, {'measure': 'Progression-free Survival', 'description': 'Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions', 'timeFrame': 'every 3 months until progression. From date of registration to date of first documentation of progressive disease, death due to any cause or symptomatic deterioration, whichever occurs first, assessed up to five years.'}, {'measure': 'Progression Free Survival', 'description': 'From date of registration to date of first documentation of progressive disease, death due to any cause or symptomatic deterioration, whichever occurs first. Patients last known to be alive and progression-free are censored at date of last contact.', 'timeFrame': 'every 3 months until progression'}]","[{'measure': 'Number of Patients With Adverse Events That Are Related to Study Drugs', 'description': 'Adverse Events (AEs) are reported by CTCAE Version 3.0. Only adverse events that are possibly, probably or definitely related to study drug are reported.', 'timeFrame': 'Toxicity assessment was evaluated after 3 weeks, 6 weeks, and every 6 weeks thereafter until progression'}]",4,18 Years,,FEMALE,False,SWOG Cancer Research Network,NETWORK,2,624.0,ACTUAL,2025-09-01T16:18:20.954983,v2_robust,True,True,True,False,True,
NCT04900818,Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors,A Phase 1 Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors,TJ033721 (givastomig),"['TJ033721 (givastomig)', 'TJ033721 (givastomig) , nivolumab, chemotherapy']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumor,"['Solid Tumor', 'Advanced Cancer', 'Metastatic Cancer', 'Gastric Cancer', 'Gastroesophageal Junction Carcinoma', 'Esophageal Adenocarcinoma']",[],RECRUITING,,2021-06-29,2026-12,"[{'measure': 'Dose-limiting toxicities (DLTs)', 'timeFrame': '28 days'}, {'measure': 'Incidence and severity of AEs', 'description': 'The CTCAE criteria will be used to assess adverse events on this trial.', 'timeFrame': 'Up to 100 days post last dose'}, {'measure': 'Maximum tolerated or administered dose (MTD, MAD)', 'description': 'Based on DLT definitions', 'timeFrame': '28 Days'}]","[{'measure': 'Pharmacokinetic (PK) Parameters: AUC∞', 'description': 'Area under the curve from time zero extrapolated to infinity (AUC∞)', 'timeFrame': 'Up to 100 days post last dose'}, {'measure': 'Pharmacokinetic (PK) Parameters: AUCt', 'description': 'AUC from time zero to the time of the last quantifiable concentration (AUC0-t)', 'timeFrame': 'up to 100 days post last dose'}, {'measure': 'Pharmacokinetic (PK) Parameters: Cmax', 'description': 'Maximum observed concentration', 'timeFrame': 'up to 100 days post last dose'}, {'measure': 'Pharmacokinetic Parameters: Tmax', 'description': 'Time of peak concentration (Tmax)', 'timeFrame': 'up to 100 days post last dose'}, {'measure': 'Pharmacokinetic Parameters: T1/2', 'description': 'Investigational Product (IP) half-life (T1/2)', 'timeFrame': 'up to 100 days post last dose'}]",8,18 Years,,ALL,False,I-Mab Biopharma US Limited,INDUSTRY,1,168.0,ESTIMATED,2025-09-01T16:18:20.955012,v2_robust,True,True,False,False,True,
NCT05145218,A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer,"A Multicenter, Randomized, Open, Parallel Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Injection Combined With Androtinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment in the Treatment of Recurrent Platinum-resistant Ovarian Cancer",Anlotinib Hydrochloride Capsules,"['TQB2450 injection', 'Anlotinib Hydrochloride Capsules', 'Paclitaxel injection']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Recurrent Platinum-resistant Ovarian Cancer,['Recurrent Platinum-resistant Ovarian Cancer'],[],UNKNOWN,,2021-09-28,2024-12,"[{'measure': 'Disease progression-free survival(PFS) evaluated by Independent Review Committee(IRC)', 'description': 'The period from the first use of the drug to disease progression or death (whichever occurs first);', 'timeFrame': 'Baseline up to two years'}, {'measure': 'Overall survival (OS)', 'description': 'The preriod from the first use of the drug to death from all causes. For subjects who are still alive at the last follow-up, the OS will be counted as data censored based on the last follow-up. For subjects who are lost follow-up, the OS will be counted as data cesored based on the last confirmed survival time before being lost to follow-up.', 'timeFrame': 'Baseline up to two years'}]","[{'measure': 'Disease PFS evaluated by investigators', 'description': 'The period from the first use of the drug to disease progression or death (whichever occurs first)', 'timeFrame': 'Baseline up to two years'}, {'measure': 'PFS rate of 6 months: including PFS rate of 6 months evaluated by IRC and investigators;', 'description': 'The proportion of subjects reaching 6 months from firstly- recorded objective tumor response (complete remission(CR) or partial remission(PR)) to firstly-recorded objective tumor progression or death due to any cause (whichever occurred first) .', 'timeFrame': 'Baseline up to six months'}, {'measure': 'Objective response rate (ORR) evaluated by IRC and investigators', 'description': ', the proportion of subjects whose tumors are evaluated as complete remission(CR) and partial remission(PR) by IRC and investigators. It is recorded from the first use of the drug to disease progression or initiation of a new anticancer treatment.', 'timeFrame': 'Baseline up to two years'}, {'measure': 'Duration of response (DOR)', 'description': 'The period from firstly-recorded objective tumor response (CR or PR) to firstly-recorded objective tumor progression or death due to any cause (whichever occurs first) .', 'timeFrame': 'Baseline up to two years'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Proportion of subjects whose tumors shrink or remain stable for a certain period, including complete remission（CR）, partial remission（PR） and stable disease（SD）;', 'timeFrame': 'Baseline up to two years'}, {'measure': 'OS rate of 12 months', 'description': 'The proportion of subjects who survive for 12 months after the first dose', 'timeFrame': 'Baseline up to one year'}, {'measure': 'Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)，as well as abnormal laboratory examination indicators.', 'description': 'The proportion of AEs and SAEs recorded afte signing the informed consent form(ICF).', 'timeFrame': 'Baseline up to two years'}]",9,18 Years,75 Years,FEMALE,False,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",INDUSTRY,0,405.0,ESTIMATED,2025-09-01T16:18:20.955022,v2_robust,True,True,False,False,True,
NCT04431518,Pharmacokinetics of JULUCA in Hemodialysis,The Steady-State Pharmacokinetics (PK) of Dolutegravir/Rilpivirine Fixed Dose Combination (FDC) in Patients With End Stage Renal Disease (ESRD) Requiring Hemodialysis (HD),JULUCA 50Mg-25Mg Tablet,['JULUCA 50Mg-25Mg Tablet'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,HIV/AIDS,"['HIV/AIDS', 'ESRD']","['HIV', 'ESRD', 'Hemodialysis', 'Pharmacokinetics']",COMPLETED,,2021-04-23,2023-07-31,"[{'measure': 'Dolutegravir (DTG) Ctau', 'description': 'Steady-state plasma Ctau for dolutegravir at the intensive study visit, which occurred between days 11 and 14', 'timeFrame': '0 to 24 hours post-dose on the intensive study visit'}, {'measure': 'Rilpivirine (RPV) Ctau', 'description': 'Steady-state plasma Ctau for rilpivirine at the intensive study visit, which occurred between days 11 and 14', 'timeFrame': '0 to 24 hours post-dose on the intensive study visit'}]","[{'measure': 'Safety of DTG', 'description': 'The attributable grade 3 or 4 adverse events associated with use of DTG will be assessed during the study. Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Grade 3 indicates a severe event, and Grade 4 indicates a potentially life-threatening event.', 'timeFrame': '30 days'}, {'measure': 'DTG AUC', 'description': 'Steady-state plasma AUC for dolutegravir at the intensive study visit, which occurred between days 11 and 14', 'timeFrame': '0 to 24 hours post-dose on the intensive study visit'}, {'measure': 'DTG Cmax', 'description': 'Steady-state plasma Cmax for dolutegravir at the intensive study visit, which occurred between days 11 and 14', 'timeFrame': '0 to 24 hours post-dose on the intensive study visit'}]",5,18 Years,65 Years,ALL,True,Indiana University,OTHER,0,8.0,ACTUAL,2025-09-01T16:18:20.955075,v2_robust,True,True,True,False,True,
NCT03933618,Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function,"A Randomized Double Blinded Placebo Controlled Trial Between Anastrozole and Clomiphene to Evaluate Improvement in Hypogonadal Symptoms and Erectile Function Using ADAM, IIEF and EHS Validated Scales",Anastrozole 1mg,"['Clomiphene Citrate 25mg', 'Anastrozole 1mg', 'Placebo - Cap']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,"Hypogonadism, Male","['Hypogonadism, Male']",[],COMPLETED,,2015-04-02,2017-03-08,"[{'measure': 'IIEF (International Index of Erectile Function) Score - Screen', 'description': '15 item self reported erectile function. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75', 'timeFrame': 'At baseline'}, {'measure': 'IIEF (International Index of Erectile Function) Score - Week 8', 'description': '15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75', 'timeFrame': 'Week 8'}, {'measure': 'IIEF (International Index of Erectile Function) Score - Week 16', 'description': '15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75', 'timeFrame': 'Week 16'}, {'measure': 'IIEF (International Index of Erectile Function) Score - Week 24', 'description': '15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75', 'timeFrame': 'Week 24'}]","[{'measure': 'Normalized Testosterone - Screen', 'description': 'Normalized at \\>350ng/dl', 'timeFrame': 'Baseline'}, {'measure': 'Normalized Testosterone - Week 8', 'description': 'Normalized at \\>350ng/dl', 'timeFrame': 'Week 8'}, {'measure': 'Normalized Testosterone - Week 16', 'description': 'Normalized at \\>350ng/dl', 'timeFrame': 'Week 16'}, {'measure': 'Normalized Testosterone - Week 24', 'description': 'Normalized at \\>350ng/dl', 'timeFrame': 'Week 24'}, {'measure': 'ADAM (Androgen Deficiency in the Aging Male) Score - Screen', 'description': 'Self reported quantification of hypogonadism. 10 ""yes"" or ""no"" questions.\n\nA positive (yes) questionnaire result is defined as a ""yes or 1"" and a negative (no) questionnaire result is defined as a ""no or 0"" to question 1 or question 7 or any 3 other questions.\n\nYes (1) represents a better outcome than No (1)\n\nIn Data Entry:\n\nYes - 1 No - 0', 'timeFrame': 'Baseline'}, {'measure': 'ADAM (Androgen Deficiency in the Aging Male) Score - Week 8', 'description': 'Self reported quantification of hypogonadism. 10 ""yes"" or ""no"" questions.\n\nA positive (yes) questionnaire result is defined as a ""yes or 1"" and a negative (no) questionnaire result is defined as a ""no or 0"" to question 1 or question 7 or any 3 other questions.\n\nYes (1) represents a better outcome than No (1)\n\nIn Data Entry:\n\nYes - 1 No - 0', 'timeFrame': 'Week 8'}, {'measure': 'ADAM (Androgen Deficiency in the Aging Male) Score - Week 16', 'description': 'Self reported quantification of hypogonadism. 10 ""yes"" or ""no"" questions.\n\nA positive (yes) questionnaire result is defined as a ""yes or 1"" and a negative (no) questionnaire result is defined as a ""no or 0"" to question 1 or question 7 or any 3 other questions.\n\nYes (1) represents a better outcome than No (1)\n\nIn Data Entry:\n\nYes - 1 No - 0', 'timeFrame': 'Week 16'}, {'measure': 'ADAM (Androgen Deficiency in the Aging Male) Score - Week 24', 'description': 'Self reported quantification of hypogonadism. 10 ""yes"" or ""no"" questions.\n\nA positive (yes) questionnaire result is defined as a ""yes or 1"" and a negative (no) questionnaire result is defined as a ""no or 0"" to question 1 or question 7 or any 3 other questions.\n\nYes (1) represents a better outcome than No (1)\n\nIn Data Entry:\n\nYes - 1 No - 0', 'timeFrame': 'Week 24'}, {'measure': 'EHS (Erectile Hardness Score) - Screen', 'description': 'Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid', 'timeFrame': 'Baseline'}, {'measure': 'EHS (Erectile Hardness Score) - Week 8', 'description': 'Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid', 'timeFrame': 'Week 8'}, {'measure': 'EHS (Erectile Hardness Score) - Week 16', 'description': 'Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid', 'timeFrame': 'Week 16'}, {'measure': 'EHS (Erectile Hardness Score) - Week 24', 'description': 'Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid', 'timeFrame': 'Week 24'}, {'measure': 'LH - Screen', 'description': 'Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods.', 'timeFrame': 'Baseline'}, {'measure': 'LH - Week 8', 'description': 'Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods.', 'timeFrame': 'Week 8'}, {'measure': 'LH - Week 16', 'description': 'Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods.', 'timeFrame': 'Week 16'}, {'measure': 'LH - Week 24', 'description': 'Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods.', 'timeFrame': 'Week 24'}, {'measure': 'FSH - Screen', 'description': 'Lab Values for follicle stimulating hormone', 'timeFrame': 'Baseline'}, {'measure': 'FSH - Week 8', 'description': 'Lab Values for follicle stimulating hormone', 'timeFrame': 'Week 8'}, {'measure': 'FSH - Week 16', 'description': 'Lab Values for follicle stimulating hormone', 'timeFrame': 'Week 16'}, {'measure': 'FSH - Week 24', 'description': 'Lab Values for follicle stimulating hormone', 'timeFrame': 'Week 24'}, {'measure': 'Free Testosterone - Screen', 'description': 'Measure of Free Testosterone', 'timeFrame': 'Baseline'}, {'measure': 'Free Testosterone - Week 8', 'description': 'Measure of Free Testosterone', 'timeFrame': 'Week 8'}, {'measure': 'Free Testosterone - Week 16', 'description': 'Measure of Free Testosterone', 'timeFrame': 'Week 16'}, {'measure': 'Free Testosterone - Week 24', 'description': 'Measure of Free Testosterone', 'timeFrame': 'Week 24'}, {'measure': 'Estradiol - Screen', 'description': 'Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24', 'timeFrame': 'Baseline'}, {'measure': 'Estradiol - Week 8', 'description': 'Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was \\<5', 'timeFrame': 'Week 8'}, {'measure': 'Estradiol - Week 16', 'description': 'Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was \\<5', 'timeFrame': 'Week 16'}, {'measure': 'Estradiol - Week 24', 'description': 'Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was \\<5', 'timeFrame': 'Week 24'}, {'measure': 'SHBG - Screen', 'description': 'Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24', 'timeFrame': 'Baseline'}, {'measure': 'SHBG - Week 8', 'description': 'Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24', 'timeFrame': 'Week 8'}, {'measure': 'SHBG - Week 16', 'description': 'Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24', 'timeFrame': 'Week 16'}, {'measure': 'SHBG - Week 24', 'description': 'Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24', 'timeFrame': 'Week 24'}, {'measure': 'SEP #1-3 Cumulative - Screen', 'description': 'Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.\n\n0-3: cumulative score from SEP questions 1, 2, and 3\n\nHigher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0', 'timeFrame': 'Baseline'}, {'measure': 'SEP #1-3 Cumulative - Week 8', 'description': 'Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.\n\n0-3: cumulative score from SEP questions 1, 2, and 3\n\nHigher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0', 'timeFrame': 'Week 8'}, {'measure': 'SEP #1-3 Cumulative - Week 16', 'description': 'Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.\n\n0-3: cumulative score from SEP questions 1, 2, and 3\n\nHigher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0', 'timeFrame': 'Week 16'}, {'measure': 'SEP #1-3 Cumulative - Week 24', 'description': 'Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.\n\n0-3: cumulative score from SEP questions 1, 2, and 3\n\nHigher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0', 'timeFrame': 'Week 24'}]",40,18 Years,70 Years,MALE,False,Albany Medical College,OTHER,1,24.0,ACTUAL,2025-09-01T16:18:20.955093,v2_robust,True,True,True,False,False,
NCT03510390,Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation,Metformin in Head and Neck Squamous Cell Carcinoma: A Window of Opportunity Study to Assess the Effect on Tissue Oxygenation,Metformin,['Metformin'],1,INTERVENTIONAL,['NA'],,,Head and Neck Cancer,"['Head and Neck Cancer', 'Oral Cavity Squamous Cell Carcinoma']","['head and neck cancer', 'tissue hypoxia', 'metformin']",COMPLETED,,2018-06-13,2021-11-15,"[{'measure': 'Metformin dependent changes in gene expression', 'description': 'Metformin induced changes in gene expression between samples taken before and after the intervention, analyzed by RNAseq, with special attention to hypoxia responsive genes:\n\n* Hypoxia inducible factor 1 (HIF1) and co-transcription factors (ARNT, COPS5, HIF1A, HIFAN, HIF3a, HNF4A, NCOA1, PER1)\n* HIF interactors (APEX1, EGLN1, EGLN2, NFKB1, P4HA1, P4HB, TP53)\n* Markers of Angiogenesis (ADROA2B, ANGPTL4, ANXA2, BTG1, EGR1, EDN1, EPO, F3, GPI, HMOX1, JMJD6, LOX, MMP9, PGF, PLAU, SERPINE1, VEGFA)\n\nAdditionally, metformin induced changes in HIF1A, Ki67, cleaved caspase 3, CAIX, p-mTOR and p-AKT will be assessed by immunohistochemistry', 'timeFrame': 'Baseline and two weeks'}]","[{'measure': 'Hypoxia dependent changes in MRI', 'description': 'Diffusion-weighted MRI and blood oxygen level dependent imaging (BOLD) will be obtained before and after the Intervention and compared. Alterations will be correlated to changes in gene Expression.', 'timeFrame': 'baseline and two weeks'}]",2,18 Years,,ALL,False,"Insel Gruppe AG, University Hospital Bern",OTHER,2,17.0,ACTUAL,2025-09-01T16:18:20.955216,v2_robust,True,True,True,False,False,
NCT06807190,General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus,"A Multi-centre, Prospective, Open Label, Non-interventional, Single-armed, 52 Weeks Post-marketing Study to Investigate Safety and Clinical Parameters of Awiqli Once Weekly in Patients With Diabetes Mellitus Under Real-world Clinical Practice Setting in Japan",Insulin Icodec,"['Awiqli', 'Insulin Icodec']",2,OBSERVATIONAL,[],,,"Diabetes Mellitus, Type 1","['Diabetes Mellitus, Type 1']",[],RECRUITING,,2025-04-15,2028-01-31,"[{'measure': 'Number of Adverse Reactions (ARs)', 'description': 'Measured as number of events.', 'timeFrame': 'From baseline (week 0) to end of study (week 52)'}]","[{'measure': 'Number of Adverse Events (AEs)', 'description': 'Measured as number of events.', 'timeFrame': 'From baseline (week 0) to end of study (week 52)'}, {'measure': 'Number of Serious Adverse Events (SAEs)', 'description': 'Measured as number of events.', 'timeFrame': 'From baseline (week 0) to end of study (week 52)'}, {'measure': 'Number of Serious Adverse Reactions (SARs)', 'description': 'Measured as number of events.', 'timeFrame': 'From baseline (week 0) to end of study (week 52)'}, {'measure': 'Change in Glycosylated Haemoglobin (HbA1c)', 'description': 'Measured as percentage (%) point of HbA1c.', 'timeFrame': 'From baseline (week 0) to end of study (week 52)'}, {'measure': 'Change in Fasting Plasma Glucose (FPG)', 'description': 'Measured as milligrams per decilitre (mg/dL).', 'timeFrame': 'From baseline (week 0) to end of study (week 52)'}, {'measure': 'Change in Diabetes Therapy-Related Quality Of Life (DTR-QOL)', 'description': 'DTR-QOL is a Japanese questionnaire assessing the influence of diabetes treatment on the individual health related quality of life on 4 domains: ""burden on social activities and daily activities"", ""anxiety and dissatisfaction with treatment"", ""hypoglycaemia"" and ""satisfaction with treatment"". DTR-QOL contains 29 questions and the response scale is a 7-point scale (1: strongly agree to 7: strongly disagree). The score of each item will be reversed so that ""7: strongly disagree"" represents the highest/desirable QOL. The total score, after simple addition of the item scores, is converted to 0 to 100 (best-case response is 100; worst case response is 0).', 'timeFrame': 'From baseline (week 0) to end of study (week 52)'}]",7,,,ALL,,Novo Nordisk A/S,INDUSTRY,0,630.0,ESTIMATED,2025-09-01T16:18:20.955234,v2_robust,False,True,False,False,True,
NCT01921790,Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma,"An Open-Label, Uncontrolled, Single Centered Phase Ⅱ Study of Avastin Combined With Gemcitabine, Oxaliplatin, Pegaspargase and Dexamethasone (Avastin+ GemAOD) As First-Line Treatment in Patients With Untreated NK/T Cell Lymphoma",Gemcitabine,"['Gemcitabine', 'Pegaspargase', 'Oxaliplatin', 'Dexamethasone']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Extranodal NK/T-cell Lymphoma, Nasal Type","['Extranodal NK/T-cell Lymphoma, Nasal Type']","['Avastin+ GemAOD', 'first line chemotherapy', 'NK/T-cell Lymphoma']",UNKNOWN,,2013-08,2020-08,"[{'measure': 'Overall Response Rate(ORR)', 'description': '21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles', 'timeFrame': 'every 6 weeks,up to completion of treatment(approximately 6 months)'}]","[{'measure': 'Progress Free Survival(PFS)', 'timeFrame': 'up to end of follow-up-phase (approximately 5 years)'}, {'measure': 'Overall Survival(OS)', 'timeFrame': 'up to the date of death (approximately 5 years)'}, {'measure': 'The tolerance and the side effects of the treatment', 'description': '21 days(3 weeks) for one cycle,Toxicity was evaluated every cycle', 'timeFrame': 'every 3 weeks,up to completion of treatment(approximately 6 months)'}]",4,18 Years,80 Years,ALL,False,Sun Yat-sen University,OTHER,2,30.0,ESTIMATED,2025-09-01T16:18:20.955242,v2_robust,True,True,False,False,False,
NCT00443690,Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms, Diuresis, Renal Function, and Clinical Outcomes in Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring Intravenous Therapy",rolofylline,"['rolofylline', 'MK7418', 'KW-3902IV', 'Comparator: Placebo (unspecified)']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,"Heart Failure, Congestive","['Heart Failure, Congestive']","['heart failure', 'diuretic', 'renal impairment', 'renal function']",COMPLETED,,2007-08,2009-01,"[{'measure': 'Effect on heart failure signs and symptoms', 'timeFrame': 'through day 7'}, {'measure': 'Effect on renal function', 'timeFrame': 'through Day 7'}]",[],2,18 Years,,ALL,False,"NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",INDUSTRY,1,480.0,ESTIMATED,2025-09-01T16:18:20.955320,v2_robust,True,True,True,False,False,
NCT00403390,Generic vs. Name-Brand Levothyroxine,Generic vs. Name-Brand Levothyroxine: Assessment of Bioequivalence Using TSH as a Marker in Children With Permanent Hypothyroidism,Brand Name Levothyroxine (Synthroid),"['Brand Name Levothyroxine (Synthroid)', 'Generic formulation of Levothyroxine', 'No other names', 'Levothyroxine']",4,INTERVENTIONAL,['NA'],,,Congenital Hypothyroidism,"['Congenital Hypothyroidism', 'Hypothyroidism']",[],COMPLETED,,2006-11,2010-03,"[{'measure': 'Thyroid Stimulating Hormone as Primary Endpoint Measured at Initiation of Study, After 8 Weeks of One Drug, and Then 8 Weeks After the Second Drug.', 'timeFrame': '3 points over 16 weeks'}]",[],1,3 Years,18 Years,ALL,True,Boston Children's Hospital,OTHER,0,34.0,ACTUAL,2025-09-01T16:18:20.955329,v2_robust,True,True,True,False,False,
NCT02846090,Dexmedetomidine as an Additive to Local Anaesthesia to Decrease Intraocular Pressure in Glaucoma Surgery,Dexmedetomidine as an Additive to Local Anaesthesia to Decrease Intraocular Pressure in Glaucoma Surgery,Dexmedetomidine to reduce the IOP,"['Dexmedetomidine to reduce the IOP', 'reduction of OCULAR HYPERTENSION']",2,INTERVENTIONAL,['NA'],,,Glaucoma,['Glaucoma'],[],UNKNOWN,,2016-08,2017-01,"[{'measure': 'IOP before the block, after the message and before the surgical incision, after the end of the surgery', 'description': 'IOP before the block, after the message and before the surgical incision, after the end of the surgery', 'timeFrame': 'one hour'}]","[{'measure': 'Onset of the block', 'description': 'the time elapsed between the end of the block and the complete anaesthesia and complete or partial akainesia', 'timeFrame': '2 min'}]",2,25 Years,80 Years,ALL,False,Cairo University,OTHER,0,105.0,ESTIMATED,2025-09-01T16:18:20.955337,v2_robust,True,True,False,False,False,
NCT00175890,A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age",Levetiracetam,"['Levetiracetam', 'Keppra']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Epilepsy, Partial","['Epilepsy, Partial']","['Partial Onset Seizure', 'levetiracetam', 'Video Electroencephalogram', 'Keppra']",COMPLETED,,2004-10,2007-01,"[{'measure': 'Responder Rate for total partial onset seizures as computed from the 48-hour Evaluation video-EEG (post-baseline) and the 48-hour Selection video-EEG (baseline)', 'description': 'Responder Rate is defined as the number of subjects with a ≥ 50 % reduction from baseline in their Average Daily Frequency (ADF) for partial onset seizures divided by the total number of subjects. If a subject had \\< 24 hours of usable Evaluation video-EEG time (including zero time available) and withdrawal from the study with reasons linked to lack or loss of efficacy, the subject was counted as a non-responder.', 'timeFrame': '48-hours in Evaluation Period and 48-hours in Selection Period'}]","[{'measure': 'Responder rate for total seizures (all types) as computed from the 48-hour Evaluation video-EEG (post-baseline) and the 48-hour Selection video-EEG (baseline)', 'description': 'Responder Rate is defined as the number of subjects with a ≥ 50 % reduction from baseline in their Average Daily Frequency (ADF) for all seizure types divided by the total number of subjects. Subjects who withdrew or dropped out before the first 24 hours Evaluation video-EEG with reasons linked to lack of efficacy were considered as non-responders. All (total) seizures were defined as the total of Type I (partial onset) + Type II (Primary generalized) + Type III (unclassified epileptic).', 'timeFrame': '48-hours in Evaluation Period and 48-hours in Selection Period'}, {'measure': 'Percent reduction in Average Daily Frequency (ADF) of partial onset seizures recorded on the 48-hour Evaluation video-EEG compared to those recorded on the 48-hour Selection video-EEG', 'description': 'A positive value in Percent reduction from Selection Period to Evaluation Period indicates an improvement.', 'timeFrame': '48-hours in Evaluation Period and 48-hours in Selection Period'}, {'measure': 'Percent reduction in Average Daily Frequency (ADF) of total seizures (all types) recorded on the 48-hour Evaluation video-EEG compared to those recorded on the 48-hour Selection video-EEG', 'description': 'A positive value in Percent reduction from Selection Period to Evaluation Period indicates an improvement. All (total) seizures were defined as the total of Type I (partial onset) + Type II (Primary generalized) + Type III (unclassified epileptic).', 'timeFrame': '48-hours in Evaluation Period and 48-hours in Selection Period'}, {'measure': 'Absolute reduction in Average Daily Frequency (ADF) of partial onset seizures recorded on the 48-hour Evaluation video-EEG compared to those recorded on the 48-hour Selection video-EEG', 'description': 'A positive value in Absolute reduction from Selection Period to Evaluation Period indicates an improvement.', 'timeFrame': '48-hours in Evaluation Period and 48-hours in Selection Period'}, {'measure': 'Absolute reduction in Average Daily Frequency (ADF) of total seizures (all types) recorded on the 48-hour Evaluation video-EEG compared to those recorded on the 48-hour Selection video-EEG', 'description': 'A positive value in Absolute reduction from Selection Period to Evaluation Period indicates an improvement. All (total) seizures were defined as the total of Type I (partial onset) + Type II (Primary generalized) + Type III (unclassified epileptic).', 'timeFrame': '48-hours in Evaluation Period and 48-hours in Selection Period'}, {'measure': 'Percent reduction in Average Daily Frequency (ADF) of electro-clinical partial onset seizures recorded on the 48-hour Evaluation video-EEG compared to those recorded on the 48-hour Selection video-EEG for children 1 month to less than 6 months old', 'description': 'A positive value in Percent reduction from Selection Period to Evaluation Period indicates an improvement. For children 1 month to less than 6 months old, partial onset seizure counts were based on electroclinical seizures plus electrographic seizures.', 'timeFrame': '48-hours in Evaluation Period and 48-hours in Selection Period'}, {'measure': 'Percentage of drop-outs for any reasons during the study', 'timeFrame': 'During the study (up to 20 days)'}, {'measure': 'Percentage of drop-outs due to lack of efficacy during the study', 'timeFrame': 'During the study (up to 20 days)'}, {'measure': 'Percentage of drop-outs before 24 hours of Evaluation video-EEG for reasons other than lack or loss of efficacy', 'timeFrame': 'During the study (up to 20 days)'}, {'measure': 'Time to Exit (TTE) during the Evaluation Period', 'description': 'For early termination subjects in the Evaluation period the TTE is the time to discontinuing the study for any reason. TTE was defined as the day of study discontinuation - the day of randomization + 1. For completed subjects, the TTE was censored on Day 6.', 'timeFrame': 'During Evaluation Period (Day 1 to Day 6)'}]",11,1 Month,4 Years,ALL,False,UCB Pharma,INDUSTRY,0,116.0,ACTUAL,2025-09-01T16:18:20.955470,v2_robust,True,True,True,False,False,
NCT04517890,Transdermal Lidocaine Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System,Clinical Outcomes of Transdermal Lidocaine Administration Prior to Levonorgestrel Releasing Intrauterine System Insertion in Women Delivered Only by Elective Cesarean Section: a Randomized Double Blinded Clinical Trial,lidocaine patch,"['Placebo Comparator', 'lidocaine patch', 'Sham patch', 'Experimental']",4,INTERVENTIONAL,['NA'],,,IUCD Complication,['IUCD Complication'],[],UNKNOWN,,2020-09-01,2021-09-01,"[{'measure': 'The difference in pain scores during intrauterine device insertion', 'description': 'The difference in pain scores during intrauterine device insertion using visual analog scale from 0 to 10', 'timeFrame': '10 minutes'}]","[{'measure': 'duration of IUD insertion', 'description': 'duration of IUD insertion measured in minutes', 'timeFrame': '15 minutes'}]",2,18 Years,45 Years,FEMALE,False,Aswan University Hospital,OTHER,0,200.0,ESTIMATED,2025-09-01T16:18:20.955692,v2_robust,True,True,False,False,False,
NCT06278090,Impact of Ursodeoxycholic Acid Treatment on the Gallbladder Polyp Evolution,Impact of Ursodeoxycholic Acid Treatment on the Gallbladder Polyp Evolution. Prospective Cohort Study,Ursodeoxycholic Acid Only Product,"['Ursodeoxycholic Acid Only Product', 'Ursobilane, Ursochol']",2,OBSERVATIONAL,[],,,Gallbladder Polyp,['Gallbladder Polyp'],"['Gallbladder polyp', 'Ursodeoxycholic acid']",RECRUITING,,2024-03-01,2026-07,"[{'measure': 'Reducing gallbladder polyp size by 2mm or more', 'description': 'Reducing the polyp size by 2mm or more, at the usual ultrasonographic controls at 6 and 12 months.', 'timeFrame': '6 and 12 months'}]","[{'measure': 'Modification of the expected follow up', 'description': 'Depending on the polyp size, physicians could either discontinue the follow up (decreasing to \\<5mm or disappearing) or indicate surgery (according to the current guidelines). Deviation from the usual evolution of the polyp size, comparing both groups, that leads to alteration of the possible follow up (termination of the follow up when polyp size reduces to \\<5mm or indication of surgery when polyp size increases by 2mm or reaches 10mm) will be studied.', 'timeFrame': '12 months'}]",2,18 Years,,ALL,False,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz,OTHER,0,36.0,ESTIMATED,2025-09-01T16:18:20.955702,v2_robust,False,True,False,False,False,
NCT01348490,"Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)","An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis, and Post-Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50 × 10^9/L to 100 × 10^9/L",Ruxolitinib,"['Ruxolitinib', 'INCB018424']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,MPN (Myeloproliferative Neoplasms),['MPN (Myeloproliferative Neoplasms)'],"['PMF', 'PPV-MF', 'PET-MF']",COMPLETED,,2011-06-15,2018-12-19,"[{'measure': 'Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose', 'description': 'Magnetic resonance imaging (MRI) of the upper and lower abdomen and pelvis was performed to assess spleen volumes. Computed tomography (CT) scan was performed if participant was not a candidate for MRI or if MRI was not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percent Change From Baseline in Total Symptom Score (TSS) as Measured by the Modified Myelofibrosis Symptom Assessment Form (MFSAF) V2.0 Diary at Week 24 by Final Titrated Dose', 'description': 'Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAE)', 'description': 'TEAE was defined as adverse events that began or worsened from baseline after the first administration of the study drug.\n\nParticipants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.', 'timeFrame': 'Up to Week 156'}, {'measure': 'Percentage of Participants With New Onset Grade 4 Thrombocytopenia Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE V4.03)', 'description': 'Participants with platelet count between 50 and 100 × 10\\^9/L at the screening and/or baseline visit were enrolled in the study. Thrombocytopenia is defined as a condition with low blood platelet count. Grade 4 thrombocytopenia was platelet count \\< 25 × 10\\^9/L.\n\nParticipants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.', 'timeFrame': 'Up to Week 156'}, {'measure': 'Percentage of Participants With New Onset Grade 2 or Higher Hemorrhage as Assessed by CTCAE V4.03', 'description': 'Hemorrhages were defined as any lower level terms by MedDRA included in the Standardized MedDRA Query (SMQ) for hemorrhage terms.\n\nParticipants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.', 'timeFrame': 'Up to Week 156'}]","[{'measure': 'Percent Change in Spleen Volume at Week 24 Compared to Baseline', 'description': 'MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant was not a candidate for MRI, or if MRI was not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percent Change in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline', 'description': 'Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms..', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percentage of Participants With ≥ 35% Reduction in Spleen Volume at Week 24 Compared to Baseline', 'description': 'MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant is not a candidate for MRI, or if MRI is not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percentage of Participants With ≥10% Reduction in Spleen Volume at Week 24 Compared to Baseline', 'description': 'MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant is not a candidate for MRI, or if MRI is not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percentage of Participants With ≥ 50% Improvement in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline', 'description': 'Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Change in Spleen Length Measured by Palpation', 'description': 'Measurement of spleen length below the left costal margin was measured by palpation at each study visit. Investigators were provided with a soft centimeter ruler so that palpable spleen length was measured in centimeters and not in finger breadths. The edge of the spleen was determined by palpation, and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.', 'timeFrame': 'Up to Week 156'}, {'measure': 'Percent Change From Baseline in Spleen Length Measured by Palpation', 'description': 'Measurement of spleen length below the left costal margin was measured by palpation at each study visit. Investigators were provided with a soft centimeter ruler so that palpable spleen length was measured in centimeters and not in finger breadths. The edge of the spleen was determined by palpation, and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.', 'timeFrame': 'Up to Week 156'}, {'measure': 'Patient Global Impression of Change (PGIC) Score at Each Visit', 'description': ""Symptoms of myelofibrosis were assessed using the PGIC questionnaire. Using the questionnaire, patients rated the overall sense of treatment effect on their symptoms on a scale of 1 (very much improved)- 7(very much worse). The specific wording was: Since the start of the treatment you've received in this study, your myelofibrosis symptoms are: 1) Very much improved, 2) Much improved, 3) Minimally improved, 4) No change, 5) Minimally worse, 6) Much worse, 7) Very much worse. A higher score indicates worse symptoms."", 'timeFrame': 'Up to Week 156'}]",13,18 Years,,ALL,False,Incyte Corporation,INDUSTRY,0,66.0,ACTUAL,2025-09-01T16:18:20.955717,v2_robust,True,True,True,False,True,
NCT04826497,Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction,Effects of Nicorandil on Cardiac Sympathetic Nerve Activity and Distribution in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention,nicorandil,"['Control Group', 'Placebo（normal saline）', 'nicorandil', 'Experiment Group']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Coronary Heart Disease,['Coronary Heart Disease'],"['nicorandil', 'primary percutaneous coronary intervention', 'acute ST segment elevation myocardial infarction', 'cardiac sympathetic nerve']",UNKNOWN,,2021-04,2022-02,"[{'measure': 'Comparison of the delayed heart/mediastinum count (H/M) ratio', 'description': 'The delayed heart/mediastinum count (H/M) ratio was determined from 123I-meta-iodobenzylguanidine (MIBG) images', 'timeFrame': '10 days after primary PCI'}]","[{'measure': 'The total defect score (TDS)', 'description': 'The total defect score was determined from 123I-meta-iodobenzylguanidine (MIBG) images', 'timeFrame': '10 days after primary PCI'}, {'measure': 'Rate of slow re-flow/no-reflow phenomenon', 'description': 'TIMI myocardial perfusion grade (TMPG) of the final coronary flow in the culprit artery', 'timeFrame': '5 minutes after primary PCI'}, {'measure': 'Rate fo complete ST-segment resolution', 'description': 'ST-segment resolution \\>50 percent in ECG', 'timeFrame': '2 hours after primary PCI'}, {'measure': 'Rate of unplanned hospitalization for heart failure', 'description': 'Rate of unplanned hospitalization for heart failure', 'timeFrame': '6 months after primary PCI'}, {'measure': 'The washout rate (WR)', 'description': 'The washout rate (WR) were determined from 123I-meta-iodobenzylguanidine (MIBG) images', 'timeFrame': '10 days after primary PCI'}, {'measure': 'The total defect score (TDS)', 'description': 'The total defect score was determined from 99mTc-pyrophosphate scintigraphy', 'timeFrame': '7 days after primary PCI'}]",7,20 Years,80 Years,ALL,False,Xuzhou Central Hospital,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:20.955751,v2_robust,True,True,False,False,False,
NCT04145297,Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas,A Phase I Trial of Ulixertinib (BVD-523) and Hydroxychloroquine in Patients with Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas,Ulixertinib,"['Ulixertinib', 'BVD-523', 'Hydroxychloroquine']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Gastrointestinal Neoplasms,['Gastrointestinal Neoplasms'],[],COMPLETED,,2020-03-17,2022-08-18,"[{'measure': 'Recommended phase 2 dose of ulixertinib in combination with a fixed dose of hydroxychloroquine in subjects with advanced, RAS, non-V600 BRAF, ERK or MEK mutated gastrointestinal malignancies', 'description': 'The incidence of DLTs during the defined DLT period', 'timeFrame': 'the day of the first dose, cycle one day one, to cycle one day 28 (Cycle=28 days)'}]","[{'measure': 'Safety and tolerability of ulixertinib and hydroxychloroquine in the study population: adverse events (AEs) and serious adverse events (SAEs)', 'description': 'The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment', 'timeFrame': 'Any patient who has taken at least one dose of both ulixertinib and hydroxychloroquine will be evaluable for toxicity. Assessment will be completed through safety follow-up visit at 60 days after the end of treatment visit.'}, {'measure': 'Efficacy of ulixertinib and hydroxychloroquine in the study population: Objective response rate (PR and CR)', 'description': 'Objective response rate (PR and CR) will be described', 'timeFrame': 'Patients will be evaluable for response once they have completed the first cycle of treatment and completed the C2D1 CT Scan.Assessment will be completed through safety follow-up visit at 60 days after the end of treatment visit.'}]",3,18 Years,,ALL,False,University of Utah,OTHER,1,16.0,ACTUAL,2025-09-01T16:18:20.955772,v2_robust,True,True,True,False,True,
NCT06286397,Topical Anti-Androgens in Pilonidal Sinus Disease,Topical Anti-Androgens in Pilonidal Sinus Disease,1% Clascoterone,"['1% Clascoterone', 'Vehicle Cream']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Pilonidal Disease,"['Pilonidal Disease', 'Pilonidal Disease of Natal Cleft', 'Pilonidal Sinus', 'Pilonidal Cyst']","['Pilonidal Cyst', 'Pilonidal Sinus', 'Clascoterone', 'Androgen']",RECRUITING,,2025-01-10,2028-01-01,"[{'measure': 'Physician-Assessed Disease Severity Assessment', 'description': 'To objectively evaluate PSD, the investigators will obtain physical measurements of disease extent (left to right, cranial to caudal) and obtain disease photographs at baseline and weeks 4, 8, and 12. Photographs will be collected, deidentified, and provided to two colorectal surgeons for scoring. Surgeons will be asked to compare each timepoint to baseline and rate the PSD severity as significantly worsened, mildly worsened, unchanged, mildly improved, or significantly improved. Discrepant evaluations between surgeons will be referred to a third blinded surgeon. Data will be collated and analyzed in two fashions: as a 6-point ordinal outcome and collapsed into a dichotomous outcome with severely worsened to no change as a negative outcome and improvement as a positive outcome.', 'timeFrame': 'From enrollment to the end of treatment at 12 weeks'}, {'measure': 'Dermatology Life Quality Index', 'description': 'Randomized subjects will be administered the Dermatology Life Quality Index (DLQI) at baseline and at 4, 8, and 12 weeks. The DLQI is a 10-question survey scored from 0-30 that has been applied widely across multiple dermatologic conditions and covers a range of potential quality of life impacts over a weekly basis. Specifically, the DLQI inquires about the impact of skin disease on symptoms (Example: ""Over the past week, how itchy, painful, or stinging has your skin been?""), daily activities, leisure, work and school, and personal relationships, as well as a question of impact of treatment (""Over the last week, how much of a problem has the treatment of your skin been?""). Subjects respond Very much, A lot, A little, or Not at all for descending scores of 3 to zero. A score at or above 10 is considered a significant impact on quality of life.', 'timeFrame': 'From enrollment to the conclusion of treatment at 12 weeks'}]","[{'measure': 'Subcutaneous Inflammation', 'description': 'The investigators anticipate that a large portion of subjects will ultimately undergo surgery. Those that undergo surgery within 4 weeks will be selected. At surgery, blinded investigators will measure the excisional defect. The investigators will then follow patients with chart review in the electronic medical record for 8 weeks postoperatively to assess for immediate wound complications. A full thickness representative sample of the excised pilonidal cyst will analyzed including: antibodies against CD3, CD4, CD8, CD68, and D79. Investigators will assess the specimens for hyperkeratosis, and follicular hyperplasia.', 'timeFrame': 'From 12 weeks to 16 weeks after enrollment, only in patients who undergo surgery'}]",3,18 Years,,ALL,False,University of Pennsylvania,OTHER,0,75.0,ESTIMATED,2025-09-01T16:18:20.955948,v2_robust,True,True,False,False,False,
NCT00051597,A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies,A Phase I/II Multi-Dose Study of SGN-30 in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies,SGN-30 (monoclonal antibody),['SGN-30 (monoclonal antibody)'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Hodgkin Disease,"['Hodgkin Disease', 'Lymphoma, Large-Cell', 'Sarcoma, Kaposi', 'Lymphoma, T-Cell, Cutaneous', 'Lymphoma, B-Cell']",[],COMPLETED,,,2003-08,[],[],0,18 Years,,ALL,False,Seagen Inc.,INDUSTRY,0,70.0,,2025-09-01T16:18:20.955988,v2_robust,True,True,True,False,False,
NCT01182597,Oral Versus IV Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis,Oral Versus Intravenous Proton Pump Inhibitor Treatment in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis: a Prospective Randomized Comparative Study,Pantoprazole (Pantoloc),"['Pantoprazole (Pantoloc)', 'Lansoprazole (Takepron OD)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Peptic Ulcers,['Peptic Ulcers'],['Oral PPI treatment has similar benefit as proton pump inhibitor infusion in patient with bleeding ulcers after combined endoscopic hemostasis'],UNKNOWN,,2010-08,,"[{'measure': 'Clinical rebleeding', 'description': 'Clinical rebleeding defines:\n\n1. Hematemesis, fresh blood in the NG tube aspirate\n2. Hematochezia/melena after a normal stool\n3. Decrease in Hb \\>= 2 g/dL or an increase in Hb \\< 1 g/dL during 24 hrs, despite \\>=2 units of blood transfused during 24 hours\n4. SBP \\<= 90 mm Hg or HR \\>= 110 beats/min AND melena/hematemesis', 'timeFrame': '30 days'}]","[{'measure': 'Blood transfusion', 'timeFrame': '30 day'}, {'measure': 'Need of surgery', 'timeFrame': '30 days'}, {'measure': 'Lengths of hospital stay', 'timeFrame': '30 days'}, {'measure': 'Mortality rate', 'timeFrame': '30 days'}]",5,18 Years,,ALL,False,National Taiwan University Hospital,OTHER,0,190.0,ESTIMATED,2025-09-01T16:18:20.956043,v2_robust,True,True,False,False,False,
NCT00106197,Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression,Treatment Prediction in Adolescent and Adult Depression,Bupropion,['Bupropion'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Depression,['Depression'],"['Sleep, REM', 'Antidepressant', 'Adolescent', 'Cortisol']",UNKNOWN,,2004-06,2014-03,"[{'measure': 'Reduction in depressive symptoms', 'timeFrame': 'Measured at Week 8 and Month 6 post-treatment'}]","[{'measure': 'Improvement in quality of life', 'timeFrame': 'Measured at Week 8 and Month 6 post-treatment'}]",2,12 Years,50 Years,ALL,False,Uma Rao,OTHER,1,130.0,ESTIMATED,2025-09-01T16:18:20.956168,v2_robust,True,True,False,False,False,
NCT03545997,Montelukast for Patients With Obstructive Sleep Apnea Syndrome,Impact of Blocked Cysteinyl Leukotriene Pathway on Endothelial Function in Patients With Obstructive Sleep Apnea Syndrome: Multicenter Randomized Placebo Controlled Crossover Trial,Montelukast 10mg,"['Montelukast 10mg', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Sleep Apnea, Obstructive","['Sleep Apnea, Obstructive']","['Montelukast', 'leukotriene pathway', 'endothelial function', 'flux-mediated dilation']",TERMINATED,lack of recruitment,2019-11-29,2020-03-20,"[{'measure': 'Change in FMD of the brachial artery between the beginning and end of each treatment period (Montelukast and placebo), expressed as absolute value (FMD unit is %) and measured in a standardized manner.', 'timeFrame': 'before and after 3 months treatment'}]","[{'measure': 'Concentrations of urinary LTE4 at the beginning and end of each treatment period', 'timeFrame': 'before and after 3 months the two periods of treatment'}, {'measure': '24h ambulatory blood pressure (systolic and diastolic) measurement', 'timeFrame': 'before and after 3 months of the two periods of treatment, and 15 days after the last period'}, {'measure': 'Polysomnography at inclusion and at the end of each treatment period', 'timeFrame': 'inclusion and at the end of the two periods of treatment'}, {'measure': 'Plasma concentration of Montelukast measured by HPLC-MS at the end of the Montelukast treatment period', 'timeFrame': 'at the end of Montelukast treatment period'}, {'measure': 'Collection of adverse events', 'timeFrame': 'from inclusion to 15 days after the last period of treatment'}, {'measure': 'Comparison of Cardiovascular Events occurence (myocardial infarction, Stroke, Cardiovascular Death) between the two periods', 'timeFrame': 'from inclusion to 15 days after the last period of treatment'}, {'measure': 'Concentrations of plasma CRPus at baseline and at the beginning and end of each treatment period', 'timeFrame': 'before and after 3 months the two periods of treatment'}]",8,45 Years,75 Years,ALL,False,"University Hospital, Grenoble",OTHER,2,1.0,ACTUAL,2025-09-01T16:18:20.956178,v2_robust,True,True,False,True,True,lack of recruitment
NCT02815397,DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma,DA-EPOCH-RM: A Phase II Study Evaluating the Efficacy and Safety of Metformin in Combination With Standard Induction Therapy (DA-EPOCH-R) for Previously Untreated C-myc+ Diffuse Large B-Cell Lymphoma,Metformin,"['Glumetza, Fortamet, Glucophage, Riomet', 'Metformin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Diffuse Large B-Cell Lymphoma,['Diffuse Large B-Cell Lymphoma'],['Double Hit DLBCL'],TERMINATED,Poor accrual,2016-02,2016-07,"[{'measure': 'Evaluation of Impact of Metformin on 18 Month Progression-free Survival', 'description': 'Progression-free survival determined by CT scans at 18 months', 'timeFrame': '18 month'}]","[{'measure': 'Effect of Metformin Overall Response Rate', 'description': 'Evaluation of the effect of the addition of metformin to induction chemotherapy on overall response rates', 'timeFrame': '3 years'}, {'measure': 'Effect of Metformin Overall Survival', 'description': 'Evaluation of the addition of metformin to standard induction therapy on 18 month overall survival', 'timeFrame': '18 months'}, {'measure': 'Safety Profile With Addition of Metformin Evaluated by Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v.4.0', 'description': 'Describe the safety profile observed by measuring fasting glucose and anion gap weekly through cycle 6.', 'timeFrame': '18 months'}]",4,18 Years,,ALL,False,Rush University Medical Center,OTHER,1,2.0,ACTUAL,2025-09-01T16:18:20.956208,v2_robust,True,True,False,True,True,Poor accrual
NCT00193297,Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma,A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma,Topotecan,"['Paclitaxel', 'Carboplatin', 'Topotecan']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovary Cancer,['Ovary Cancer'],['Ovary Cancer'],COMPLETED,,2002-02,2006-06,[{'measure': 'Overall response rate'}],[{'measure': 'Overall toxicity'}],2,18 Years,,FEMALE,False,"SCRI Development Innovations, LLC",OTHER,1,50.0,,2025-09-01T16:18:20.956235,v2_robust,True,True,True,False,False,
NCT01514110,Gastric Cancer RAD001 Study,Phase I/II Study of Paclitaxel / Carboplatin / RAD001 as First Line Therapy for Advanced Adenocarcinoma of the Stomach,RAD001,"['RAD001', 'RAD001 with Paclitaxel 175 mg/m2 and carboplatin (AUC=5) on Day 1, every 3 weeks until PD']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Gastric Cancer,['Gastric Cancer'],[],COMPLETED,,2008-01-23,2019-03-06,"[{'measure': 'to determine the Maximum tolerated dose and dose limiting toxicity of RAD001 in combination with paclitaxel and carboplatin', 'timeFrame': '2 years'}]","[{'measure': 'Toxicity of combination Paclitaxel/carboplatin/RAD001 in advanced adenocarcinoma of the stomach and gastroesophageal junction', 'timeFrame': '2 Years'}]",2,18 Years,,ALL,False,Chinese University of Hong Kong,OTHER,0,35.0,ACTUAL,2025-09-01T16:18:20.956306,v2_robust,True,True,True,False,False,
NCT01489410,Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma,Prospective Study Comparing Lipiodol Plus Ethanol Solution Compared With Drug-Eluting Beads for Trans-arterial Chemoembolization of Liver in Treatment of Hepatocellular Carcinoma,Drug-Eluting Beads (DEB) with Doxorubicin,"['Drug-Eluting Beads (DEB) with Doxorubicin', 'Lipiodol Ethanol Mixture', 'LEM', 'Doxorubicin']",4,INTERVENTIONAL,['NA'],,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],[],WITHDRAWN,Insufficient staff,2012-10,2014-03,"[{'measure': 'Number of Patients with Post-Embolization Syndrome', 'description': 'Count of patients with post-embolizaation syndrome reported which includes fatigue, anorexia, nausea, fever.', 'timeFrame': 'Week 6 Post Intervention'}]","[{'measure': 'Patients with Encephalopathy After Embolization', 'description': 'Count of patients who had encephalopathy after embolization.', 'timeFrame': 'Week 6 Post Intervention'}, {'measure': 'Changes in Quality of Life', 'description': 'Changes (noted as a score of 0 \\[not at all\\] to 4 \\[very much\\]; total score ranges from 1-180) in the different aspects of the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) quality of life questionnaire (a 45-item self-report instrument designed to measure health-related quality of life in patients with hepatobiliary cancers).', 'timeFrame': 'Baseline and Week 6 After Intervention'}, {'measure': 'Comparison of Liver Function Tests Results', 'description': 'List of results for alpha-fetoprotein (AFP), albumin (Alb), alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALKP), blood urea nitrogen (BUN), creatinine (Cr), glomerular filtration rate (GFR), Bilirubin (T, D), platelets (Plt), international normalized ratio (INR - prothrombin time), Child-Pugh score.', 'timeFrame': 'Day 0 and Week 6 Post Intervention'}, {'measure': 'Imaging Response', 'description': 'Determined by European Association for the Study of the Liver (EASL) criteria a set of non-invasive criteria for HCC in cirrhotic patients. The diagnosis is established if two imaging modalities (US, CT, magnetic resonance imaging (MRI)) show a coincidental nodule with arterial hypervascularization regardless of AFP levels, or if a single modality shows a lesion when the AFP levels are more than 400 ng/ml. Histologic diagnosis is required if the patient is non-cirrhotic or if the lesions are smaller than 2 cm.', 'timeFrame': 'Week 6 Post Intervention'}, {'measure': 'Number of Patients with Successful Liver Transplant', 'timeFrame': 'Week 6 After Intervention'}, {'measure': 'Overall Survival', 'description': 'Determined by date of death or date censored.', 'timeFrame': 'Week 6 After Intervention'}]",7,18 Years,,ALL,False,University of Minnesota,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:20.956391,v2_robust,True,True,False,True,False,Insufficient staff
NCT06975410,Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors,"A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors",YH32364,['YH32364'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,EGFR Overexpression,"['EGFR Overexpression', 'Locally Advanced Solid Tumor', 'Metastatic Solid Tumor']","['YH32364', 'EGFR/4-1BB bispecific antibody', 'Solid tumor', 'Head and neck squamous cell carcinoma (HNSCC)', 'Non-small cell lung cancer (NSCLC)', 'Esophageal squamous cell carcinoma (ESCC)', 'Biliary tract cancer (BTC)', 'Uterine cervical cancer', 'Vulvar cancer', 'Urothelial cancer']",RECRUITING,,2025-06-12,2029-12,"[{'measure': 'Treatment-emergent adverse events (TEAEs) including dose limiting toxicities (DLTs)', 'description': 'To assess the safety and tolerability of YH32364 in order to determine maximum tolerated dose (MTD) and select doses for dose optimization', 'timeFrame': 'Study Day 1 to Study Day 28 (during the DLTs evaluation period)'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'To assess the ORR of YH32364 at the recommended dose (RD) according to RECIST v1.1 by Investigator assessment', 'timeFrame': 'through dose expansion part completion, approximately 1.5 year'}]","[{'measure': 'Area under the serum concentration-time curve from time 0 to the last quantifiable concentration (AUClast)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'AUC from time 0 to infinity (AUCinf)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Maximum observed serum concentration (Cmax)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Time to reach Cmax (Tmax)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Apparent terminal elimination half-life (t1/2)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Total clearance (CL)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Volume of distribution (Vd)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Volume of distribution at steady state (Vss)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'AUC during dosing interval at steady state (AUCtau)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Cmax at steady state (Cmax,ss)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Time to reach Cmax,ss (Tmax,ss)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Accumulation ratio (Rac)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Trough (predose) serum concentration on Cycle 4 (Ctrough)', 'description': 'To characterize the pharmacokinetics (PK) of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Presence and characterization of YH32364 ADA including neutralizing antibodies', 'description': 'To explore the immunogenicity of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Titer of YH32364 ADA', 'description': 'To explore the immunogenicity of YH32364', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment', 'timeFrame': 'through dose escalation part completion, approximately 1 year'}, {'measure': 'Duration of Response (DoR)', 'description': 'To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Depth of Response', 'description': 'To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Time to Response', 'description': 'To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'Progression-free survival (PFS)', 'description': 'To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment', 'timeFrame': 'through study completion, approximately 2.5 year'}, {'measure': 'TEAEs', 'description': 'To assess the safety and tolerability of YH32364', 'timeFrame': 'through dose expansion part completion, approximately 1.5 year'}, {'measure': 'Overall Survival (OS)', 'description': 'To assess the overall survival of YH32364 at the RD', 'timeFrame': 'through dose expansion part completion, approximately 1.5 year'}]",25,18 Years,,ALL,False,Yuhan Corporation,INDUSTRY,0,80.0,ESTIMATED,2025-09-01T16:18:20.956418,v2_robust,True,True,False,False,True,
NCT03607110,Comparison of Efficacy of Anesthesia Administered by Endoscopist or Anesthesiologist on Colonoscopy,Comparison of Ketamine-propofol Sedation Protocols With Fentanyl-propofol Administered by Endoscopist or Anesthesiologist at Colonoscopy,Ketamine,"['Ketamine', 'fentanyl']",2,OBSERVATIONAL,[],,,Colonoscopy,"['Colonoscopy', 'Ketamine', 'Fentanyl']",[],COMPLETED,,2018-03-01,2018-06-01,"[{'measure': 'pain level - VAS SCALE', 'description': 'Pain level assessed by VAS', 'timeFrame': 'during the operation'}, {'measure': 'patient satisfaction - Patient satisfaction Scale', 'description': 'patient satisfaction assessed by with satisfaction score of 4 points-scale (1 very good, 2 good, 3 not bad, 4 bad)', 'timeFrame': 'during the operation'}]","[{'measure': 'operation time', 'description': 'duration of operation time will be asssessed as min.', 'timeFrame': 'during the operation'}, {'measure': 'side effects questionnaire', 'description': 'Cardio pulmonary side effects (Hypotension, Bradycardia, Desaturation) and other side effects (Nausea and Vomiting, Headache)', 'timeFrame': 'during the operation'}]",4,18 Years,75 Years,ALL,False,Selda KAYAALTI,OTHER_GOV,0,120.0,ACTUAL,2025-09-01T16:18:20.956483,v2_robust,False,True,True,False,False,
NCT00004310,Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder,,Clomipramine,['Clomipramine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Obsessive-Compulsive Disorder,['Obsessive-Compulsive Disorder'],"['anxiety disorder', 'disease-related problem/condition', 'neurologic and psychiatric disorders', 'obsessive compulsive disorder', 'oncologic disorders', 'rare disease']",UNKNOWN,,1999-10,,[],[],0,18 Years,55 Years,ALL,False,National Center for Research Resources (NCRR),NIH,1,76.0,,2025-09-01T16:18:20.956582,v2_robust,True,True,False,False,False,
NCT00242710,Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women,"A Double-Blind, Randomized, Placebo- And Active-Controlled Efficacy And Safety Study Of Bazedoxifene/Conjugated Estrogens Combinations For Prevention Of Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women",Bazedoxifene/Conjugated Estrogen,"['CE 0.45 mg/MPA 1.5mg', 'Bazedoxifene/Conjugated Estrogen']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Endometrial Hyperplasia,"['Endometrial Hyperplasia', 'Osteoporosis']","['Endometrium', 'Uterus', 'Menopause']",COMPLETED,,2005-09,2008-09,"[{'measure': 'Percentage of Participants With Hyperplasia at Screening', 'description': 'Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.', 'timeFrame': 'Screening'}, {'measure': 'Percentage of Participants With Hyperplasia at Month 12', 'description': 'Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.', 'timeFrame': 'Month 12'}, {'measure': 'Bone Mineral Density (BMD) of Lumbar Spine at Screening', 'description': 'BMD measurements of the anteroposterior lumbar spine were acquired by dual-energy x-ray absorptiometry (DXA), twice during screening in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.', 'timeFrame': 'Screening'}, {'measure': 'Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12', 'description': 'BMD measurements of the anteroposterior lumbar spine were acquired by DXA, twice at Month 12 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.', 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Bone Mineral Density (BMD) of Total Hip at Screening', 'description': 'BMD measurements of the total hip were acquired by DXA, twice during screening in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.', 'timeFrame': 'Screening'}, {'measure': 'Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 12', 'description': 'BMD measurements of the total hip were acquired by DXA, twice at Month 12 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.', 'timeFrame': 'Baseline, Month 12'}]","[{'measure': 'Percentage of Days With Breast Pain', 'description': 'Percentage of days with breast pain in each 4-week period (for example, Week 1 to 4, 5 to 8) calculated as the number of days on which a participants reported breast pain divided by total number of days with data recorded multiplied by 100. Data was collected every day after randomization up to Year 1 and was analyzed in 4 weeks intervals. Data for screening was not analyzed since data were collected only for 7 days at screening which was not considered comparable to 4-week post-baseline data.', 'timeFrame': 'Screening, Week 1 to 4, 5 to 8, 9 to 12, 13 to 16, 17 to 20, 21 to 24, 25 to 28, 29 to 32, 33 to 36, 37 to 40, 41 to 44, 45 to 48, 49 to 52'}, {'measure': 'Percentage of Participants With Uterine Bleeding or Spotting', 'description': 'Data was collected every day after randomization up to Year 1 and was analyzed in 4 weeks intervals. Data for screening was not analyzed since data were collected only for 7 days at screening which was not considered comparable to 4-week post-baseline data.', 'timeFrame': 'Screening, Week 1 to 4, 5 to 8, 9 to 12, 13 to 16, 17 to 20, 21 to 24, 25 to 28, 29 to 32, 33 to 36, 37 to 40, 41 to 44, 45 to 48, 49 to 52'}, {'measure': 'Percentage of Participants With Hyperplasia at Month 24', 'description': 'Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.', 'timeFrame': 'Month 24'}, {'measure': 'Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 24', 'description': 'BMD measurements of the anteroposterior lumbar spine were acquired by DXA, twice at Month 24 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.', 'timeFrame': 'Baseline, Month 24'}, {'measure': 'Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 24', 'description': 'BMD measurements of the total hip were acquired by DXA, twice at Month 24 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.', 'timeFrame': 'Baseline, Month 24'}]",11,40 Years,65 Years,FEMALE,False,Pfizer,INDUSTRY,0,1083.0,ACTUAL,2025-09-01T16:18:20.956589,v2_robust,True,True,True,False,False,
NCT02171910,Doxapram as an Additive to Propofol Sedation in Sedation for ERCP,Doxapram as an Additive to Propofol Sedation in Sedation for Endoscopic Retrograde Cholangiopancreatography,Doxapram,"['Dopram', 'Respiram', 'Doxapram', 'Placebo', 'Stimulex']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Sedation,"['Sedation', 'Hypoxia']","['Cholangiopancreatography, Endoscopic Retrograde', 'Sedation']",COMPLETED,,2016-10,2016-12,"[{'measure': 'Change in arterial oxygenation', 'description': 'Hypoxemia, oxygen saturation by pulse oximetry (SpO2 \\<90%), considered as a significant change', 'timeFrame': 'values recorded before the procedure, during the procedure at 5 min intervals and at the end of the procedure, on arrival at the recovery room and at 5 min, 10 min, and after that at 10 min intervals until discharge to ward'}]","[{'measure': 'change in systolic arterial pressure', 'description': 'A drop of systolic arterial pressure to \\<90 mmHg is considered significant', 'timeFrame': 'values recorded before the procedure, during the procedure at 5 min intervals and at the end of the procedure, on arrival at the recovery room and at 5 min, 10 min, and after that at 10 min intervals until discharge to ward'}, {'measure': 'Pulse (heartbeats/minute)', 'timeFrame': 'values recorded before the procedure, during the procedure at 5 min intervals and at the end of the procedure, on arrival at the recovery room and at 5 min, 10 min, and after that at 10 min intervals until discharge to ward'}, {'measure': 'breathing rate (breaths/minute)', 'timeFrame': 'values recorded before the procedure, during the procedure at 5 min intervals and at the end of the procedure'}]",4,18 Years,75 Years,ALL,False,Helsinki University Central Hospital,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:20.956639,v2_robust,True,True,True,False,False,
NCT02265510,"An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies","A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies",INCB052793,"['nab-paclitaxel', 'bortezomib', 'Velcade®', 'INCB052793', 'azacitidine', 'INCB050465', 'pomalidomide', 'Gemzar®', 'Vidaza®', 'dexamethasone', 'Carfilzomib', 'Abraxane®', 'gemcitabine', 'itacitinib', 'INCB039110', 'Kyprolis®', 'Pomalyst®', 'lenalidomide', 'Revlimid®']",19,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Solid Tumors,"['Solid Tumors', 'Advanced Malignancies', 'Metastatic Cancer']",[],TERMINATED,,2014-09-10,2019-02-27,"[{'measure': 'Phase 1a and 1b: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)', 'description': 'An AE is any untoward medical occurrence in a subject administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization. A TEAE was defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study drug and within 30 days of the last dose of study drug.', 'timeFrame': 'From first dose of study drug up to 30 days after last dose of study drug (Up to approximately 3.4 years)'}, {'measure': 'Phase 2: Objective Response Rate (ORR) in Hematological Malignancies', 'description': 'ORR is defined as the proportion of participants who achieved complete response (CR), CR with incomplete hematologic recovery (CRi), partial response (PR), or hematologic improvement (HI), using the IWG response criteria.', 'timeFrame': 'Baseline through end of study (Up to approximately 4.5 years)'}]","[{'measure': ""Phase 1A and 1B: Percentage of Participants With Response as Determined by Investigator's Assessment"", 'description': ""Response rate is defined as the percentage of participants who achieved best overall response (BOR) as determined by IWG response criteria of investigator's assessment. A participant was considered an objective responder based on the following- Solid tumors: participant had a best overall response (BOR) of CR or PR, Lymphoma: participant had a BOR of complete radiologic response/complete metabolic response or partial remission/partial metabolic response, AML: participant had a BOR of CR, CRi, morphological leukemia-free state (MLFS), or PR, MDS: participant had a BOR of CR, PR, or marrow CR, MDS/myeloproliferative neoplasm (MPN): participant had a BOR of CR, PR, or marrow response, MM: participant had a BOR of stringent CR, CR, very good PR, PR, or MR. Subjects are combined by tumor type for this analysis."", 'timeFrame': 'Baseline through end of study (Up to approximately 4.5 years)'}, {'measure': 'Phase 2: Number of Participants With at Least One TEAE and SAE', 'description': 'An AE is any untoward medical occurrence in a subject administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization. A TEAE was defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study drug and within 30 days of the last dose of study drug.', 'timeFrame': 'From first dose of study drug up to 30 days after last dose of study drug (Up to approximately 1.3 years)'}, {'measure': 'Phase 1a, 1b, and Phase 2: Cmax: Maximum Observed Plasma Concentration for INCB052793', 'description': 'Cmax is defined as the maximum observed plasma concentration measured at steady state (Day 15). For PK analyses subjects in TGA and TGB are combined by dosage group because only 3 subjects were enrolled in each dose group in TGB and 4 subject for first dose in TGB 50 mg.', 'timeFrame': 'Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2'}, {'measure': 'Phase 1a, 1b, and Phase 2: Tmax: Time to Maximum Plasma Concentration for INCB052793', 'description': 'Tmax is the time to maximum (peak) observed plasma drug concentration. Summary of Steady-State, Day 15, was evaluated by dosing regimen. For PK analyses subjects in TGA and TGB are combined by dosage group because only 3 subjects were enrolled in each dose group in TGB and 4 subject for first dose in TGB 50 mg.', 'timeFrame': 'Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2'}, {'measure': 'Phase 1a, 1b, and Phase 2: AUC0-τ: Area Under the Plasma Concentration-time Curve Over Dosing Interval for INCB052793', 'description': 'AUC0-τ is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t measured at steady state (Day 15). For PK analyses subjects in TGA and TGB are combined by dosage group because only 3 subjects were enrolled in each dose group in TGB and 4 subject for first dose in TGB 50 mg.', 'timeFrame': 'Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2'}, {'measure': 'Phase 1a, 1b, and Phase 2: Cmax: Maximum Observed Plasma Concentration of Itacitinib', 'description': 'Cmax is defined as the maximum observed plasma concentration measured at steady state (Day 15).', 'timeFrame': 'Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2'}, {'measure': 'Phase 1a, 1b, and Phase 2: Tmax: Time to Maximum Plasma Concentration for Itacitinib', 'description': 'Tmax is the time to maximum (peak) observed plasma drug concentration.', 'timeFrame': 'Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2'}, {'measure': 'Phase 1a, 1b, and Phase 2: AUC0-τ: Area Under the Plasma Concentration-time Curve Over Dosing Interval for Itacitinib', 'description': 'AUC0-τ is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t measured at steady state (Day 15).', 'timeFrame': 'Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2'}, {'measure': 'Phase 1a, Part 2: Cmax: Maximum Observed Plasma Concentration for INCB052793', 'description': 'Cmax is defined as the maximum observed plasma concentration measured at Day 1.', 'timeFrame': 'Cycle 1, Day 1'}, {'measure': 'Phase 1a, Part 2: Tmax: Time to Maximum Plasma Concentration for INCB052793', 'description': 'Tmax is the time to maximum (peak) observed plasma drug concentration.', 'timeFrame': 'Cycle 1, Day 1'}, {'measure': 'Phase 1a, Part 2: AUC[0-t]: Area Under the Plasma Concentration-Time Curve From Time 0 To the Last Measurable Concentration at Time t', 'description': 'AUC0-t is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t.', 'timeFrame': 'Cycle 1, Day 1'}, {'measure': 'Phase 1a, Part 2: Cmax: Maximum Observed Plasma Concentration for INCB052793', 'description': 'Cmax is defined as the maximum observed plasma concentration measured at steady state (Day 15).', 'timeFrame': 'Cycle 1, Day 15'}, {'measure': 'Phase 1a, Part 2: Cmin: Minimum Observed Plasma Concentration Over the Dose Interval', 'description': 'Minimum observed plasma concentration measured at steady state (Day 15).', 'timeFrame': 'Cycle 1, Day 15'}, {'measure': 'Phase 1a, Part 2: Tmax: Time to Maximum Plasma Concentration for INCB052793', 'description': 'Tmax is the time to maximum (peak) observed plasma drug concentration.', 'timeFrame': 'Cycle 1, Day 15'}, {'measure': 'Phase 1a, Part 2: AUC[0-t]: Area Under the Plasma Concentration-Time Curve From Time 0 To the Last Measurable Concentration at Time', 'description': 'AUC0-t is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t measured at steady state (Day 15).', 'timeFrame': 'Cycle 1, Day 15'}, {'measure': 'Phase 1a, Part 2: AUC0-τ: Area Under the Plasma Concentration-time Curve Over Dosing Interval for INCB052793', 'description': 'AUC0-τ is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t.', 'timeFrame': 'Cycle 1, Day 15'}, {'measure': 'Phase 1a, Part 2: Cmax: Maximum Observed Plasma Concentration for INCB052793', 'description': 'Cmax is defined as the maximum observed plasma concentration measured at cycle 2 Day 1.', 'timeFrame': 'Cycle 2, Day 1'}, {'measure': 'Phase 1a, Part 2: Cmin: Minimum Observed Plasma Concentration Over the Dose Interval', 'description': 'Cmin is defined as the minimal observed plasma concentration measured at cycle 2 Day 1', 'timeFrame': 'Cycle 2, Day 1'}, {'measure': 'Phase 1a, Part 2: Tmax: Time to Maximum Plasma Concentration for INCB052793', 'description': 'Tmax is the time to maximum (peak) observed plasma drug concentration.', 'timeFrame': 'Cycle 2, Day 1'}, {'measure': 'Phase 1a, Part 2: AUC[0-t]: Area Under the Plasma Concentration-Time Curve From Time 0 To the Last Measurable Concentration at Time', 'description': 'AUC0-t is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t.', 'timeFrame': 'Cycle 2, Day 1'}, {'measure': 'Phase 1a, Part 2: AUC0-τ: Area Under the Plasma Concentration-time Curve Over Dosing Interval for INCB052793', 'description': 'AUC0-τ is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t.', 'timeFrame': 'Cycle 2, Day 1'}]",23,18 Years,,ALL,False,Incyte Corporation,INDUSTRY,0,83.0,ACTUAL,2025-09-01T16:18:20.956684,v2_robust,True,True,False,True,True,
NCT01049113,Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia,"Phase 1, Dose Escalation Study To Assess the Safety, Pharmacokinetics and Activity of 2-Hour Continuous Intravenous Dosing of ON 013105 Administered Weekly in Patients With Relapsed/Refractory Lymphoma and Acute Lymphoid Leukemia",ON 013105,"['ON 013105', 'briciclib']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Lymphoma,"['Lymphoma', 'Acute Lymphocytic Leukemia']","['Lymphoma', 'B-cell Acute Lymphocytic Leukemia', 'ALL']",TERMINATED,Lack of available clinical drug supply,2009-11,2015-12,"[{'measure': 'Safety based on adverse events, hematology and chemical laboratory values, urinalysis, coagulation, ECG, vital signs, physical examination.', 'timeFrame': '2 years'}]","[{'measure': 'Tumor response (according to Cheson, B.D., et al., Revised Response Criteria for Malignant Lymphoma, J Clin Oncol 2007. 25: p. 579-86).', 'timeFrame': '2 years'}, {'measure': 'Non-compartmental pharmacokinetic analysis of drug concentrations in plasma including area under concentration time curve, half-life, clearance.', 'timeFrame': 'Day 1 of first cycle'}]",3,18 Years,,ALL,False,"Traws Pharma, Inc.",INDUSTRY,0,7.0,ACTUAL,2025-09-01T16:18:20.956799,v2_robust,True,True,False,True,True,Lack of available clinical drug supply
NCT03140813,An Initial Study of AZD7325 in Adults With Fragile X Syndrome,"An Initial Double-Blind, Placebo-Controlled Two-Dose Crossover Study of AZD7325 in Adults With Fragile X Syndrome",AZD7325 (High-Dose),"['Placebo oral capsule', 'AZD7325 (Low-Dose)', 'AZD7325 (High-Dose)']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Fragile X Syndrome,['Fragile X Syndrome'],[],COMPLETED,,2018-01-16,2020-06-18,"[{'measure': 'Amyloid Precursor Protein (APP)', 'description': 'Short-term treatment of peripheral APP dysregulation by correcting elevated levels', 'timeFrame': 'Through end of study, approximately 12 weeks'}]","[{'measure': 'Change in the Social Withdrawal subscale score of the Aberrant Behavior Checklist (ABC)', 'description': 'The ABC is the gold standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials.', 'timeFrame': 'Through end of study, approximately 12 weeks'}, {'measure': 'Change in the Pediatric Anxiety Rating Scale (PARS)', 'description': 'The PARS is the gold standard parent/caregiver reported anxiety outcome measure for use in Fragile X Syndrome clinical trials.', 'timeFrame': 'Through end of study, approximately 12 weeks'}]",3,18 Years,50 Years,ALL,False,"Children's Hospital Medical Center, Cincinnati",OTHER,0,15.0,ACTUAL,2025-09-01T16:18:20.956864,v2_robust,True,True,True,False,False,
NCT03064113,Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease",Placebo,"['Ipratropium 500 μg', 'Placebo', 'TD-4208 700 μg', 'TD-4208 350 μg', 'Revefenacin']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,"Chronic Obstructive Pulmonary Disease, COPD","['Chronic Obstructive Pulmonary Disease, COPD']","['Chronic Obstructive Pulmonary Disease, COPD']",COMPLETED,,2011-05,2011-10,"[{'measure': 'Peak Forced Expiratory Volume in One Second (FEV1) Relative to Baseline', 'timeFrame': 'From predose to 25 hours postdose'}]","[{'measure': 'Area Under the FEV1 vs. Time Curve, Time-matched Difference From Placebo', 'timeFrame': '12 hr and 24 hr'}, {'measure': 'Area Under the FEV1 vs. Peak FEV1, Time-matched Difference From Placebo', 'timeFrame': '12 hr and 24 hr'}, {'measure': 'Peak Expiratory Flow Rate (PEFR) From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1', 'timeFrame': '12hr and 24hr'}, {'measure': 'Forced Expiratory Flow From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1', 'timeFrame': '12hr and 24hr'}, {'measure': 'Forced Vital Capacity (FVC)', 'timeFrame': 'From predose to 25 hours postdose'}, {'measure': 'Area Under the Forced Vital Capacity (FVC) vs. Time Curve', 'timeFrame': '0-24 hours'}]",7,40 Years,75 Years,ALL,False,Mylan Inc.,INDUSTRY,1,32.0,ACTUAL,2025-09-01T16:18:20.956952,v2_robust,True,True,True,False,False,
NCT01413360,The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients,Phase 4 Study of High Dose Vitamin C in Chronic Hepatitis Patients,High dose vitamin C,"['Koreaeundan Vitamin C 1000', 'High dose vitamin C']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Hepatitis,"['Chronic Hepatitis', 'Chronic Hepatitis C', 'Chronic Alcoholic Hepatitis']",[],COMPLETED,,2011-08,2014-12,"[{'measure': 'The Change in Serum Alanine Aminotransferase Level From Baseline to 12 Weeks', 'description': 'Serum alanine aminotransferase (ALT) level after 12 weeks of high dose vitamin C administration and Baseline serum ALT level', 'timeFrame': 'Baseline and 12 weeks'}]","[{'measure': 'The Change in Serum Interleukin 22 Level From Baseline to 12 Weeks', 'description': 'Serum interleukin 22(IL-22)level after 12 weeks of high vitamin C administration and Baseline IL-22 level', 'timeFrame': 'Baseline and 12 weeks'}]",2,18 Years,80 Years,ALL,False,Seoul National University Hospital,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:20.957016,v2_robust,True,True,True,False,False,
NCT04083560,A Comparison of Two Different Doses of Maternal B12 Supplementation in Improving Infant B12 Deficiency and Neurodevelopment,A Comparison of Two Different Doses of Maternal B12 Supplementation in Improving Infant B12 Deficiency and Neurodevelopment,Vit B12,['Vit B12'],1,INTERVENTIONAL,['NA'],,,Vitamin B 12 Deficiency,['Vitamin B 12 Deficiency'],[],COMPLETED,,2018-09-26,2022-09-25,"[{'measure': 'Infant neurodevelopment', 'description': 'Developmental Assessment Scale for Indian Infant (modified Bayleys scale) measured as average of motor and mental scores', 'timeFrame': '9 Month of infant age'}]","[{'measure': 'Biochemical B12 status of mother', 'description': 'Change in B12 status of mother between first and third trimester', 'timeFrame': 'At recruitment'}, {'measure': 'Biochemical B12 status of infant', 'description': 'Biochemical B12 status of infant at nine months postpartum', 'timeFrame': '9 months of infant age'}]",3,18 Years,35 Years,FEMALE,True,Sitaram Bhartia Institute of Science and Research,OTHER,3,708.0,ACTUAL,2025-09-01T16:18:20.957026,v2_robust,True,True,True,False,False,
NCT00456560,AV650 Drug-Drug Interaction Study,"A Phase I, Randomized, Two-Period, Single-Center Study to Assess the Effect of CYP2D6 and CYP2C19 Inhibitors on a Single Oral Dose of AV650 (300 mg) in Healthy Subjects",AV650,"['Fluvoxamine', 'Paroxetine', 'AV650']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2007-04,2007-05,[{'measure': 'Pharmacokinetics of AV650'}],"[{'measure': 'Safety and tolerability of AV650'}, {'measure': 'Genetic contribution, if any, to AV650 metabolism'}]",3,18 Years,65 Years,ALL,True,Avigen,INDUSTRY,0,30.0,ESTIMATED,2025-09-01T16:18:20.957265,v2_robust,True,True,True,False,True,
NCT05528120,Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects,Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects,VC004 Capsules,['VC004 Capsules'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion,['Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion'],['healthy subjects'],COMPLETED,,2022-10-20,2022-11-23,"[{'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'timeFrame': 'Day1-Day8'}, {'measure': 'Peak time(Tmax)', 'timeFrame': 'Day1-Day8'}, {'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC）', 'timeFrame': 'Day1-Day8'}]",[],3,18 Years,45 Years,ALL,True,"Jiangsu vcare pharmaceutical technology co., LTD",INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:20.957319,v2_robust,True,True,True,False,False,
NCT01615120,Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer,"Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy",GTx-758 125 mg,"['GTx-758 125 mg', 'GTx-758 250 mg']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],[],COMPLETED,,2012-08-14,2016-11-09,"[{'measure': 'Decline in Serum PSA', 'description': 'The percentage of subjects with a 50% decline from baseline in serum PSA (confirmed by a second serum PSA assessment 30 days later) by Day 90 (with follow up confirmation by Day 120)', 'timeFrame': '120 days'}]",[],1,18 Years,,MALE,False,GTx,INDUSTRY,0,77.0,ACTUAL,2025-09-01T16:18:20.957417,v2_robust,True,True,True,False,False,
NCT03704220,Anti-thrombotic Monotherapy With the HeartMate 3 LVAS,Safety and Feasibility of Anti-thrombotic Monotherapy With the HeartMate 3 LVAS: A Single Center Prospective Controlled Study,Warfarin,['Warfarin'],1,INTERVENTIONAL,['NA'],,,Heart Failure,"['Heart Failure', 'Cardiovascular Diseases']","['Single anti-thrombotic therapy', 'Mechanical circulatory support']",UNKNOWN,,2018-08-16,2021-12,"[{'measure': 'survival free rate of thromboembolic events', 'description': 'Determination of survival free of thromboembolic events (i.e. pump thrombosis or any ischemic stroke) using only a single antithrombotic therapy with Acetylsalicylic Acid.', 'timeFrame': '90 days'}]","[{'measure': 'Adverse Events', 'description': 'Adverse events rates per INTERMACS definitions.', 'timeFrame': '90 days'}]",2,18 Years,,ALL,False,Institute for Clinical and Experimental Medicine,OTHER_GOV,1,10.0,ESTIMATED,2025-09-01T16:18:20.957426,v2_robust,True,True,False,False,True,
NCT00542620,Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial,"A Randomised, Multicentric, Open Labelled, Parallel Group Trial With Insulin Aspart and Insulin Detemir, Investigating the Glycaemic Effect and Profile in Children With Type 1 Diabetes, of Two Separate Levemir® + NovoRapid® Injections and Extemporaneous Mixing - The Paediatric MIXING Trial",insulin detemir,"['insulin detemir', 'insulin aspart']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 1']",[],COMPLETED,,2007-09,2009-03,"[{'measure': 'Glycosylated Haemoglobin A1c (HbA1c)', 'description': 'Measured for the Per Protocol (PP) set', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Glycosylated Haemoglobin A1c (HbA1c)', 'description': 'Measured for the ITT (Intention-to-Treat) set', 'timeFrame': 'Week 0 and Week 8'}]","[{'measure': 'Fructosamine', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Self-measured Plasma Glucose Profile (Before Breakfast)', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Self-measured Plasma Glucose Profile (After Breakfast)', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Self-measured Plasma Glucose Profile (Before Dinner)', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Self-measured Plasma Glucose Profile (After Dinner)', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Cmax of Free Insulin', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2 hours (hrs), T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Tmax of Free Insulin', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to the Time of the Last Measured Level of Free Insulin', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to Infinity of Free Insulin', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Terminal Phase Elimination Half-life (T½) - Parameter of Free Insulin', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Cmax of Insulin Detemir', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Tmax of Insulin Detemir', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to the Time of the Last Measured Level of Insulin Detemir', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to Infinity of Insulin Detemir', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Terminal Phase Elimination Half-life (T½) - Parameter of Insulin Detemir', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Cmax of Insulin Aspart', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Tmax of Insulin Aspart', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to the Time of the Last Measured Level of Insulin Aspart', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to Infinity of Insulin Aspart', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Pharmacokinetics: Terminal Phase Elimination Half-life (T½) - Parameter of Insulin Aspart', 'description': 'The observed peak drug concentration at time (T): T0, T0.5hour (hr), T1hr, T1.5hr, T2hrs, T2.5hrs, T3hrs, T3.5hrs, T4hrs', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Weight Z Score', 'description': 'Z score of weight. To estimate the growth of children, standardised mean weight values were calculated for each month of age and for each sex', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Body Mass Index (BMI) Z Score', 'description': 'Z score of BMI index. To estimate the growth of children, standardised mean BMI values were calculated for each month of age and for each sex', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Incidence of Hypoglycaemic Episodes - All Episodes', 'description': ""Number of hypoglycaemic episodes from Week 0 to Week 8, defined as self-measurement plasma glucose less than 56 mg/dL (3.1 mmol/L). Classified as major, minor or symptoms only. Major if unable to treat her/himself (given the age of the study population, the definition of major hypoglycemia was to be adapted through the investigator's judgment). Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L (56 mg/dL). Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L."", 'timeFrame': 'Weeks 0-8'}, {'measure': 'Incidence of Hypoglycaemic Episodes - Glycaemia Below 0.56 g/L', 'description': 'Number of minor hypoglycaemic episodes from Week 0 to Week 8, defined as self-measurement plasma glucose below 3.1 mmol/L (56 mg/dL) and the child is able to treat her/himself.', 'timeFrame': 'Weeks 0-8'}, {'measure': 'Incidence of Hypoglycaemic Episodes - Glycaemia Above or Equal to 0.56 g/L', 'description': 'Number of ""symptoms only"" hypoglycaemic episodes from Week 0 to Week 8, defined as self-measurement plasma glucose higher than or equal to 3.1 mmol/L (56 mg/dL) or no plasma glucose measurement and the child is able to treat her/himself.', 'timeFrame': 'Weeks 0-8'}, {'measure': 'Percentage of Children Assessing Insulin Therapy Injection Pain as ""Sad Face""', 'description': 'Via a paper diary, the children perceived insulin therapy injection pain by using a four-grade facial visual analogue scale (VAS): very sad face, sad face, happy face or very happy face.', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Percentage of Children Assessing Insulin Therapy Injection Pain as ""Happy Face""', 'description': 'Via a paper diary, the children perceived insulin therapy injection pain by using a four-grade facial visual analogue scale (VAS): very sad face, sad face, happy face or very happy face.', 'timeFrame': 'Week 0 and week 8'}, {'measure': 'Percentage of Children Assessing Insulin Therapy Injection Pain as ""Very Happy Face""', 'description': 'Via a paper diary, the children perceived insulin therapy injection pain by using a four-grade facial visual analogue scale (VAS): very sad face, sad face, happy face or very happy face.', 'timeFrame': 'Week 0 and Week 8'}]",30,6 Years,18 Years,ALL,False,Novo Nordisk A/S,INDUSTRY,0,25.0,ACTUAL,2025-09-01T16:18:20.957436,v2_robust,True,True,True,False,False,
NCT00446420,"Cognitive Impairment Following Sedation for Colonoscopy With Propofol, Midazolam and Fentanyl Combinations","Cognitive Impairment Following Sedation for Colonoscopy With Propofol, Midazolam and Fentanyl Combinations","Propofol, midazolam, fentanyl","['Diprivan', 'Propofol, midazolam, fentanyl', 'Sublimase', 'Versed']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Cognitive Impairment,['Cognitive Impairment'],[],COMPLETED,,2007-02,2008-02,"[{'measure': 'Cognitive impairment at hospital discharge after elective outpatient colonoscopy', 'timeFrame': 'Before discharge from daycare facility'}]","[{'measure': 'Dreaming during sedation, intraoperative operating conditions and complications, satisfaction with care', 'timeFrame': 'Before discharge from daycare facility'}]",2,18 Years,,ALL,False,Melbourne Health,OTHER,0,200.0,ACTUAL,2025-09-01T16:18:20.957568,v2_robust,True,True,True,False,False,
NCT03011320,An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery,"An Exploratory, Open-label Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Cytoreductive Surgery",EC1456,"['99mTc-Etarfolatide', 'folate (vitamin B-9) and tubulysin B hydrazide small molecule conjugate', 'etarfolatide', 'EC1456', 'EC20']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Ovary Cancer,['Ovary Cancer'],"['ovarian cancer', 'specimen collection']",COMPLETED,,2017-01-24,2018-08-28,"[{'measure': 'To assess tumor penetration of EC1456 in frozen tissue', 'description': 'Measure and characterize intratumoral levels of EC1456, and metabolites, by liquid chromatography-tandem mass spectrometry (LC-MS/MS). All results will be descriptive and exploratory.', 'timeFrame': '18 months'}]","[{'measure': 'To assess tumor penetration EC1456 in formalin fixed tissue samples (intratumoral levels of EC1456 in tissue blocks using anti-tubulysin IHC testing)', 'description': 'Measurement and characterization of intratumoral levels of EC1456 in the tissue blocks and assess if there is detectable penetration of the drug into the tumor using anti-tubulysin immunohistochemistry (IHC) testing. All results will be descriptive and exploratory.', 'timeFrame': '18 months'}, {'measure': 'To assess correlation of tumor penetration of EC1456 with tumor uptake of 99m-Tc etarfolatide in SPECT or SPECT/CT scan', 'description': 'Using the measures of tumor penetration, see if the SPECT or SPECT/CT scan correlates with etarfolatide update in the 99m-TC etarfolatide SPECT or SPECT/CT scans. All results will be descriptive and exploratory.', 'timeFrame': '18 month'}]",3,18 Years,,FEMALE,False,Endocyte,INDUSTRY,0,3.0,ACTUAL,2025-09-01T16:18:20.957586,v2_robust,True,True,True,False,False,
NCT02465320,"COL-1077 (Lidocaine Bioadhesive Gel, 10%) in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy","A Muticenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single-Dose of COL-1077 in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy",COL-1077,"['COL-1077', 'bioadhesive gel', 'Placebo', 'lidocaine bioadhesive gel, 10%']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Endometrial Biopsy,['Endometrial Biopsy'],[],COMPLETED,,2015-05,2016-07,"[{'measure': 'Pain Intensity recorded on the 11-point Numerical Pain Rating Scale (NPRS)', 'timeFrame': 'at the time of endometrial biopsy'}]","[{'measure': 'Pain intensity (using 11-point NPRS)', 'timeFrame': 'at the time of tenaculum placement, at the time of insertion of the pipelle, 1 minute following tenaculum removal, 5, 15, 30 and 60 minutes & 2, 6, 8, & 24 hours post-endometrial biopsy'}, {'measure': 'Time-Weighted Average Pain Intensity (TWAPI)', 'timeFrame': 'time of tenaculum placement until 2 hours post-endometrial biopsy'}, {'measure': 'Sum Pain Intensity Difference (SPID)', 'timeFrame': 'time of tenaculum placement until 2 & 8 hours post-endometrial biopsy'}, {'measure': 'Rescue medication usage', 'description': 'For those who used rescue medication, time to first dose of rescue medication \\& total number of rescue doses used will be determined', 'timeFrame': 'up to 24 hours post-endometrial biopsy'}, {'measure': 'Proportion of responders vs. non-responders to COL-1077.', 'timeFrame': 'up to 24 hours post-endometrial biopsy'}]",6,40 Years,75 Years,FEMALE,False,"Juniper Pharmaceuticals, Inc.",INDUSTRY,0,187.0,ACTUAL,2025-09-01T16:18:20.957603,v2_robust,True,True,True,False,False,
NCT01950182,Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer,"A Multicentre, Randomized Study of Trastuzumab Combined With Chemotherapy or Endocrine Therapy as the First Line Treatment for Patients With Metastatic Luminal B2 Breast Cancer Subtype",Endocrine therapy combined with trastuzumab,"['Endocrine therapy combined with trastuzumab', 'Tamoxifen', 'Chemotherapy combined with trastuzumab', 'trastuzumab', 'Capecitabine', 'Gemcitabine', 'Vinorelbine', 'aromatase inhibitors']",8,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],"['Luminal B2 subtype', 'First line treatment']",COMPLETED,,2013-09-16,2020-05-31,"[{'measure': 'progression-free survival (PFS)', 'description': 'The interim analysis and the final analysis are expected ot occur 18 and 36 months after the end of recruitment.', 'timeFrame': '36 months'}]",[],1,18 Years,75 Years,FEMALE,False,Sun Yat-sen University,OTHER,0,392.0,ACTUAL,2025-09-01T16:18:20.957663,v2_robust,True,True,True,False,False,
NCT01730482,"A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)","A Phase 1 Study to Investigate the Absorption, Metabolism and Excretion of [14C] AT1001 (Migalastat Hydrochloride) Following a Single Oral Administration in Healthy Volunteers (AT1001-014)",[14C] AT1001,['[14C] AT1001'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Fabry Disease,['Fabry Disease'],"['excretion', 'healthy volunteer', 'migalastat hydrochloride', 'AT1001', 'pharmacokinetics', 'Fabry disease']",COMPLETED,,2011-08,2011-09,"[{'measure': 'Recovery of total radioactivity in urine', 'description': 'Urine will be collected: pre-dose (-12-0 hours), 0-12 and 12-24 hours on Day 1, 24-hourly on Days 2-10; the last sample will be collected on Day 11. Total radioactivity excreted in urine will be calculated for the entire collection period. The excretion rate will be calculated from total radioactivity collected in urine, divided by the duration of collection. The percentage of dose excreted in urine will be calculated from the total amount excreted in urine divided by the dose administered, multiplied by 100.', 'timeFrame': 'Days 1 to 11'}, {'measure': 'Recovery of total radioactivity in feces', 'description': 'Feces will be collected: predose (-24 to 0 hours); all bowel movements post-dose will be collected on Days 1 to 10; the last sample will be collected on Day 11. Total radioactivity excreted in feces will be calculated for the entire collection period. The excretion rate will be calculated from total radioactivity collected in feces, divided by the duration of collection. The percentage of dose excreted in feces will be calculated from the total amount excreted in feces divided by the dose administered, multiplied by 100.', 'timeFrame': 'Days 1 to 11'}, {'measure': 'Presence of radioactivity in expired air', 'description': 'Expired air will be collected: pre-dose and at 2, 4, 6 and 24 hours after dosing. Each subject will blow into a measured volume of sodium hydroxide solution containing phenolphthalein, until an indicator changes color, showing that the sodium hydroxide is saturated. This sodium hydroxide solution will be analysed for radioactive content. If radioactivity is detected the total amount in expired air during the collection period will be calculated.', 'timeFrame': 'Day 1'}, {'measure': 'Plasma AT1001 pharmacokinetic parameters', 'description': 'Blood samples will be collected: Pre-dose, at 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216 and 240 hours after dosing. Non-compartmental pharmacokinetic parameters will be calculated for plasma AT1001: area under the drug concentration-time curve (AUC) from time zero to the time of the last measurable concentration, AUC from time zero to infinity, maximum observed drug concentration, time of the maximum drug concentration, apparent terminal elimination rate constant and apparent elimination half life.', 'timeFrame': 'Days 1 to 10'}, {'measure': 'Plasma total radioactivity pharmacokinetic parameters', 'description': 'Blood samples will be collected: Pre-dose, at 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216 and 240 hours after dosing. Non-compartmental pharmacokinetic parameters will be calculated for plasma radioactivity: area under the drug concentration-time curve (AUC) from time zero to the time of the last measurable concentration, AUC from time zero to infinity, maximum observed drug concentration, time of the maximum drug concentration, apparent terminal elimination rate constant and apparent elimination half life.', 'timeFrame': 'Days 1 to 10'}]","[{'measure': 'Number of subjects with adverse events as a measure of safety and tolerability', 'description': 'Adverse events (AEs) will be collected from the start of Investigation Product and until the follow-up visit.', 'timeFrame': 'Day 1 to Day 29'}, {'measure': 'Measure of clinical laboratory test values to access safety and tolerability', 'description': 'Clinical laboratory tests will include hematology, coagulation tests, clinical chemistry, urinalysis, drug and toxicology screen, Hepatitis A and HIV screen.', 'timeFrame': 'Upto 8 weeks'}, {'measure': 'Physical examination to access safety and tolerability', 'description': 'Physical examination results will be categorized as normal, abnormal clinically significant, or abnormal not clinically significant', 'timeFrame': 'Upto 8 weeks'}, {'measure': 'Measure of vital signs to access safety and tolerability', 'description': 'Vital sign measurements will include pulse, respiratory rate, blood pressure, and oral temperature). Subjects should be in a supine position for at least 5 minutes prior to taking measurements.', 'timeFrame': 'Upto 8 weeks'}, {'measure': 'Measure of ECG to access safety and tolerability', 'description': ""Electrocardiograph (ECG) is a machine that measures the electrical activity of the heart and records changes in the hearts' rhythm. All subjects will undergo ECG testing."", 'timeFrame': 'Upto 8 weeks'}, {'measure': 'The blood to plasma ratio of total radioactivity', 'description': 'The ratio of plasma to blood radioactivity will be calculated at 2, 4, 6 and 24 hours after administration of AT1001.', 'timeFrame': 'Day 1'}, {'measure': 'Characterization of metabolites in plasma, urine, duodenal bile and fecal homogenates', 'description': 'An Entero-Test capsule will be ingested to collect duodenal bile and will be removed after sample collection. Metabolite elucidation and identification will be performed in the collected plasma, urine doudenal bile, and fecal samples, if feasible, under a separate study. Results will be summarized in a separate report.', 'timeFrame': 'Day -1 to Day 11'}]",12,30 Years,55 Years,MALE,True,Amicus Therapeutics,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:20.957671,v2_robust,True,True,True,False,True,
NCT00566982,A Clinical Study to Evaluate the Safety of Ospemifene,"Efficacy and Long-Term Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing 60 MG Oral Daily Dose of Ospemifene With Placebo",Ospemifene 60 mg,"['Osphena®', 'Ospemifene 60 mg', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Atrophy,"['Atrophy', 'Vaginal Diseases']","['Urogenital atrophy', 'Menopausal symptoms', 'Vulvar and vaginal atrophy in postmenopausal women', 'Vaginal atrophy']",COMPLETED,,2007-10,2009-07,"[{'measure': 'Mean Change From Baseline in Percentage of Parabasal Cells in Maturation Index of Vaginal Smear', 'timeFrame': '12 weeks'}, {'measure': 'Mean Change From Baseline in Percentage of Superficial Cells in Maturation Index of Vaginal Smear', 'timeFrame': '12 weeks'}, {'measure': 'Mean Change From Baseline in Vaginal pH', 'timeFrame': '12 weeks'}]","[{'measure': 'Change From Baseline in Estradiol Levels', 'timeFrame': '52 weeks'}, {'measure': 'Change From Baseline in Luteinizing Hormone Levels', 'timeFrame': '52 weeks'}, {'measure': 'Change From Baseline in Follicle Stimulating Hormone Levels', 'timeFrame': '52 weeks'}, {'measure': 'Change From Baseline in Sex Hormone Binding Globulin Levels', 'timeFrame': '52 weeks'}, {'measure': 'Visual Evaluation of the Vagina (Baseline & Week 52)', 'timeFrame': '52 weeks'}]",8,40 Years,80 Years,FEMALE,False,Shionogi,INDUSTRY,2,426.0,ACTUAL,2025-09-01T16:18:20.957826,v2_robust,True,True,True,False,False,
NCT00420082,"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber","A Randomized, Double-Blind, 4 Way Cross-over, Placebo Controlled Trial to Evaluate the Onset of Action of Bilastine 20 mg vs. Placebo, Cetirizine 10 mg, and Fexofenadine 120 mg in the Vienna Challenge Chamber",Bilastine,"['Fexofenadine', 'Cetirizine', 'Placebo', 'Zyrtec', 'Allegra', 'Bilastine']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Seasonal Allergic Rhinitis,['Seasonal Allergic Rhinitis'],"['Rhinitis', 'Seasonal', 'Allergic', 'Pollen allergy', 'Environmental Exposure Chamber', 'Challenge Chamber']",COMPLETED,,2006-10,2006-12,[{'measure': 'Onset of action and action duration'}],"[{'measure': 'Nasal and ocular symptom scores'}, {'measure': 'Nasal airflow resistance'}, {'measure': 'Nasal secretion weight'}, {'measure': 'FEV1'}, {'measure': 'Routine safety parameters (vital signs, ECGs, clinical laboratory tests)'}]",6,18 Years,55 Years,ALL,False,"Faes Farma, S.A.",INDUSTRY,0,75.0,ACTUAL,2025-09-01T16:18:20.958073,v2_robust,True,True,True,False,True,
NCT01919424,Comparison of the Methacholine PC20 Between the Trudell Aeroeclipse* II Ban Nebulizer and the Wright Nebulizer,Comparison of the Methacholine PC20 Between the Trudell Aeroeclipse* II Ban Nebulizer and the Wright Nebulizer,Methacholine Chloride,['Methacholine Chloride'],1,INTERVENTIONAL,['NA'],,,Asthma,['Asthma'],[],COMPLETED,,2011-04,2013-10,"[{'measure': 'Methacholine PC20 of two different aerosol systems', 'description': 'To compare the methacholine PC20 of a modern delivery aerosol system, the Trudell AeroEclipse\\*II BAN nebulizer, to that of the current ""gold standard"", the English-Wright nebulizer. FEV1 is measured by spirometry following inhalation of increasing concentrations of methacholine. The PC20 is a calculated value of the amount of methacholine required to cause a 20% fall in the subject\'s FEV1.', 'timeFrame': '2 weeks'}]",[],1,18 Years,65 Years,ALL,False,McMaster University,OTHER,0,46.0,ACTUAL,2025-09-01T16:18:20.958107,v2_robust,True,True,True,False,False,
NCT05299424,A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma,"A Multi-center, Open-label, Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Multiple Myeloma",CM336_group 1,"['CM336_group 9', 'CM336_group 3b', 'CM336_group 1', 'CM336_group 4a', 'CM336_group 3a', 'CM336_group 8b', 'CM336_group 6b', 'CM336_group 6a', 'CM336_group 8a', 'CM336_RP2D', 'CM336_group 2b', 'CM336_group 7', 'CM336_group 4b', 'CM336_group 2a', 'CM336_group 5']",15,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Multiple Myeloma,['Multiple Myeloma'],[],RECRUITING,,2022-08-09,2026-12,"[{'measure': 'Dose-limiting toxicities (DLTs)', 'description': 'Dose-limiting toxicities (DLTs)', 'timeFrame': '21 days after the first dose'}, {'measure': 'Adverse events (AEs)', 'description': 'Adverse events (AEs), including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.', 'timeFrame': 'Up to 4.5 years'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'Assessed according to International Myeloma Working Group (IMWG) response criteria.', 'timeFrame': 'up to 4.5 years'}]",[],3,18 Years,,ALL,False,Keymed Biosciences Co.Ltd,INDUSTRY,0,48.0,ESTIMATED,2025-09-01T16:18:20.958129,v2_robust,True,True,False,False,True,
NCT04146324,An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia,A Prospective Observational Study in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma in Australia,nivolumab,['nivolumab'],1,OBSERVATIONAL,[],,,Melanoma,['Melanoma'],"['Adjuvant', 'nivolumab']",COMPLETED,,2019-12-12,2024-05-31,"[{'measure': 'Percentage of Participants with Relapse-Free Survival (RFS)', 'description': 'The time between the date of randomisation and the date of first recurrence, new primary melanoma, or death due to any cause, whichever occurred first.', 'timeFrame': 'Up to 5 years post treatment initiation with adjuvant nivolumab therapy'}]","[{'measure': 'Percentage of Participants with Distant Metastasis-Free Survival (DMFS)', 'timeFrame': 'Up to 5 years post treatment initiation with adjuvant nivolumab therapy'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'Up to 5 years post treatment initiation with adjuvant nivolumab therapy'}, {'measure': 'Description of sociodemographic profile of participants', 'timeFrame': 'At treatment initiation with adjuvant nivolumab therapy'}, {'measure': 'Description of clinical characteristics of participants', 'timeFrame': 'At treatment initiation with adjuvant nivolumab therapy'}, {'measure': 'Prior medical history of participants', 'timeFrame': 'At treatment initiation with adjuvant nivolumab therapy'}, {'measure': 'Description of nivolumab pattern of use', 'timeFrame': 'At treatment initiation with adjuvant nivolumab therapy'}, {'measure': 'Health-related quality of life (HRQOL) of participants as assessed by European Quality of Life Five Dimensional Scale (EuroQOL-5D/EQ-5D)', 'timeFrame': 'Up to 5 years post treatment initiation with adjuvant nivolumab therapy'}, {'measure': 'HRQOL of participants as assessed by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ C-30)', 'timeFrame': 'Up to 5 years post treatment initiation with adjuvant nivolumab therapy'}, {'measure': 'HRQOL of participants as assessed by Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire', 'timeFrame': 'Up to 5 years post treatment initiation with adjuvant nivolumab therapy'}, {'measure': ""Participants' socioeconomic status as assessed by their highest education level"", 'timeFrame': 'At treatment initiation with adjuvant nivolumab therapy'}, {'measure': 'Description of care received as assessed by Healthcare Resource Utlization', 'timeFrame': 'During, and up to 5 years post discontinuation of nivolumab use'}, {'measure': 'Number of participants experiencing immune-related Adverse Events (AEs)', 'timeFrame': 'Up to 5 years post treatment initiation with adjuvant nivolumab therapy'}, {'measure': 'Number of participants experiencing non-immune-related AEs', 'timeFrame': 'Up to 5 years post treatment initiation with adjuvant nivolumab therapy'}]",14,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,150.0,ACTUAL,2025-09-01T16:18:20.958165,v2_robust,False,True,True,False,True,
NCT03522324,Pain Research: Innovative Strategies With Marijuana,"An Observational Study of the Effects of Edible Cannabis and Its Constituent Cannabinoids on Pain, Inflammation, and Cognition",Cannabis Edible,['Cannabis Edible'],1,OBSERVATIONAL,[],,,Chronic Pain,"['Chronic Pain', 'Chronic Low Back Pain', 'Cannabis Use']","['Cannabis', 'Pain', 'Cytokines', 'Inflammation', 'Cognition']",COMPLETED,,2018-06-01,2023-10-12,"[{'measure': 'Pain Interference: Roland Morris Disability Questionnaire (RMDQ)', 'description': 'The Roland Morris Disability Questionnaire assesses self-rated physical disability caused by low back pain. Scores range from 0 to 24, with higher scores indicating more pain interference.', 'timeFrame': 'Change over two time points over 2 weeks: Baseline (before 2 weeks of edible use), Pre-Administration (after 2 weeks of use and before acute administration) using the total RMDQ score (0-24).'}, {'measure': 'Inflammation: Circulating Levels of Cytokines', 'description': 'Tests levels of recent inflammation (panel of inflammatory markers) before and after cannabis use. Higher numbers indicate higher levels of circulating pro-inflammatory cytokines. Results are in pg/mL and are separated by the three cytokines: IL-1b, IL-6, and IL-10.', 'timeFrame': 'Change over two time points over 2 weeks: Baseline (before 2 weeks of edible use) and Pre-Administration (after 2 weeks of use and before acute administration).'}, {'measure': 'Flanker Inhibitory Control Attention Task (FICA) & International Shopping List Task (ISLT)', 'description': 'Co-outcomes testing cognitive impairment in the domains of immediate and delayed recall (ISLT) and attention and inhibitory control (FICA). Cognitive outcomes are measured in standard scores (e.g. Range of \\>70 to \\>140 (Mean of 100 and SD of 15) with higher scores indicating better performance) and can be averaged to reflect a Standard score of overall cognitive function.', 'timeFrame': 'Change over two time points over 2 weeks: Baseline (before 2 weeks of edible use), Pre-Administration (after 2 weeks of use and before acute administration).'}, {'measure': 'Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)', 'description': 'Subjective report of cognitive function using the Perceived Cognitive Impairments subscale of the Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog). Possible scores range from 0-80 where higher scores are associated with higher levels of perceived impairment.', 'timeFrame': 'Change over two time points over 2 weeks: Baseline (before 2 weeks of edible use), Pre-Administration (after 2 weeks of use and before acute administration).'}]","[{'measure': 'Pain Intensity: Current Pain Using NIH Pain Intensity Scale.', 'description': 'Test effects of cannabinoids on pain using the NIH Pain intensity scale for ""current pain"" (on a scale from 0-10 with 10 being the worst).', 'timeFrame': 'Change over 2 weeks'}, {'measure': 'Health & Wellbeing', 'description': 'Self-report measure across primary domains of diet, assessment of sleep quality, and health-related well-being. Each domain was assessed with the following single items:\n\nDiet: ""In general, how healthy is your overall diet? Would you say"" (response options 0- excellent; 1- very good; 2- good; 3- fair; 4- poor) Sleep Quality: ""During the past 2 weeks, how would you rate your sleep quality overall?"" (response options 0- very good; 1- fairly good; 2- fairly bad; 3- very bad"") Health Related Wellbeing: ""In general, how would you describe your health?"" (response options 0- excellent; 1- very good; 2- good; 3- fair; 4- poor)', 'timeFrame': 'Change over 2 weeks'}, {'measure': 'Pittsburgh Sleep Quality Assessment (PSQI)', 'description': 'The Pittsburgh Sleep Quality Assessment (PSQI) is a self-report assessment of sleep quality.9 self-reported items belongs to one of seven subcategories: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Scores for each question range from 0 to 3, with higher scores indicating more acute sleep disturbances (Scores range from 0 to 21 overall, with scores greater than 5 suggesting significant sleep difficulties).', 'timeFrame': 'Change over 4 weeks'}, {'measure': 'Motor Function', 'description': 'Motor control assessed via dynamic sway and proprioception. Motor outcomes were aggregated to reflect a Z-score of overall motor function. Scores reported below are sum of Motor Battery Balance z-scores (Eyes Open, Eyes Closed, and Head Back). Higher scores correspond to worse balance- there is not a maximum score.', 'timeFrame': 'Change over 2 weeks'}, {'measure': 'Depression and Stress', 'description': 'The DASS21 is a 21-item scale that measures self-reported change in anxiety, depression, and stress symptoms. Participants are asked to use 4-point severity/frequency scales (higher values indicate greater severity) to rate the extent to which they have experienced each state. For this aim, the Depression and Stress subscales were used.\n\nDepression subscale score range 0-21 Normal (0 to 4), Mild (5 to 6), Moderate, (7 to 10), Severe (11 to 13), Extremely Severe (14 and above) Stress subscale score range 0-33 Normal (0 to 14), Mild (15 to 18), Moderate, (19 to 25), Severe (26 to 33)', 'timeFrame': 'Change over 2 weeks'}, {'measure': 'Acute Cognitive Impairment: Flanker Inhibitory Control Attention Task (FICA) and International Shopping List Task (ISLT).', 'description': 'Co-outcomes testing cognitive impairment after acute use of cannabis in the domains of immediate and delayed recall (ISLT) and and attention and inhibitory control (FICA). Cognitive outcomes are measured in standard scores (e.g. Range of \\<70 to \\>140 (Mean of 100 and SD of 15) with higher scores indicating better performance) and can be averaged to reflect a Standard score of overall cognitive function.', 'timeFrame': '2 Weeks'}, {'measure': 'Patient Global Impression of Change: Global Impression of Change Scale (PGIC).', 'description': 'Patient Global Impression of Change Scale (PGIC) measures self-reported change on a 1-7 scale (i.e. from 1 (very much worse) to 7 (very much improved) in pain. Changes in this measure will be tested in relation to THC and CBD blood levels. Scale possible score range 1-7, with higher scores indicating the largest amount of possible change. Importantly, it is a subjective self-assessment of change and is only measured at the 2 week timepoint.', 'timeFrame': 'Change over 2 week primary exposure period.'}]",11,21 Years,70 Years,ALL,False,"University of Colorado, Boulder",OTHER,2,268.0,ACTUAL,2025-09-01T16:18:20.958220,v2_robust,False,True,True,False,False,
NCT00404924,ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures,A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI),ZD6474 (vandetanib),"['ZD6474 (vandetanib)', 'ZACTIMA™']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-Small-Cell Lung Carcinoma,['Non-Small-Cell Lung Carcinoma'],"['Non-Small-Cell Lung Carcinoma', 'Adenocarcinoma', 'Squamous Cell Carcinoma', 'Large Cell Carcinoma']",COMPLETED,,2006-11,2014-11,"[{'measure': 'Overall Survival (OS)', 'description': 'Overall Survival (OS) is defined as the time from date of randomization until death. Any blinded/unknown patient which have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie, their status must be known at the censored date and should not be lost to follow up or unknown).', 'timeFrame': 'Time to death in months'}]","[{'measure': 'Progression-Free Survival (PFS)', 'description': 'Median time (in months) from randomisation until objective disease progression (determined by RECIST assessments) or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment', 'timeFrame': 'RECIST tumour assessments carried out every 8 weeks from randomisation until objective disease progression'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria.\n\nThe categories for best objective response are CR, PR, stable disease (SD)\\>= 8 weeks, progressive disease (PD) or NE.', 'timeFrame': 'Each patient was assessed for objective response from the sequence of RECIST scan data up to data cut off. RECIST tumour assessments carried out every 8 weeks from randomisation until objective disease progression.'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Disease control rate is defined as the number of patients who achieved disease control at 8 weeks following randomisation. Disease control at 8 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) \\>= 8 weeks', 'timeFrame': 'RECIST tumour assessments carried out every 8 weeks from randomisation until objective disease progression'}, {'measure': 'Duration of Response (DoR)', 'description': 'Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment)', 'timeFrame': 'RECIST tumour assessments carried out every 8 weeks from randomisation until objective disease progression'}, {'measure': 'Time to Deterioration of Disease-related Symptoms (TDS) by Questionnaire - the Lung Cancer Subscale (LCS) a Selection of the FACT-L Focusing on Symptoms of Lung Cancer Plus Pain and Fatigue (LCS-PF)', 'description': ""Time to deterioration in symptoms is defined as the interval from the date of randomization to the first assessment of 'worsened' with no visit assessment of 'improved' within the next 28 days. Where assessment is by a selection of questions from the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire."", 'timeFrame': 'Disease-related symptom assessments are to be administered at screening (within 7 days before the first dose of study medication) and every 4 weeks thereafter, at discontinuation of study treatment and at the 30-day follow-up visit'}]",6,18 Years,,ALL,False,"Genzyme, a Sanofi Company",INDUSTRY,0,1140.0,ACTUAL,2025-09-01T16:18:20.958340,v2_robust,True,True,True,False,False,
NCT01181024,"A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1","A Single Ascending Dose Tolerability and Pharmacokinetic Study of RO5303253 With a Pilot Food-effect Investigation in Healthy Subjects and Exploratory Pharmacokinetic, Pharmacodynamic, and Safety Assessments in Chronic Hepatitis C Genotype 1 Patients Following 5 Days of Oral Administration",Placebo,"['RO5303253', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Hepatitis C, Chronic, Healthy Volunteer","['Hepatitis C, Chronic, Healthy Volunteer']",[],COMPLETED,,2010-04,2010-10,"[{'measure': 'Safety and tolerability: Adverse events, laboratory parameters, ECG, blood pressure', 'timeFrame': 'approximately 6 months'}, {'measure': 'Pharmacokinetics: Plasma and urine concentrations of RO5303253 and its main metabolite RO1080713', 'timeFrame': 'approximately 6 months'}]","[{'measure': 'Effect of food intake on pharmacokinetics in healthy volunteers', 'timeFrame': 'Days 1-4'}, {'measure': 'Pharmacodynamics (viral responses) and drug resistance profiling in chronic hepatitis C patients', 'timeFrame': 'From baseline to Day 15'}]",4,18 Years,60 Years,ALL,True,Hoffmann-La Roche,INDUSTRY,0,82.0,ACTUAL,2025-09-01T16:18:20.958378,v2_robust,True,True,True,False,True,
NCT06960824,Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence,Real-word Study of the de NOVO Use of Once-daily Extended-release tacrolimuS (LCPT) in Kidney Transplantation Using an ARTificial Intelligence Prognostic System: a Multicenter Prospective Ob-servational Study,Life-Cycle Pharma Tacrolimus,['Life-Cycle Pharma Tacrolimus'],1,OBSERVATIONAL,[],,,Chronic Renal Disease,['Chronic Renal Disease'],[],NOT_YET_RECRUITING,,2025-05,2027-12-31,"[{'measure': 'Incidence of Biopsy Proven Acute Rejection', 'description': 'The primary endpoint is the incidence of Biopsy Proven Acute Rejection between the Life-Cycle Pharma Tacrolimus cohort and the control groups of the transplant reference cohort.', 'timeFrame': '12 months'}]",[],1,18 Years,,ALL,False,Chiesi SAS,INDUSTRY,0,165.0,ESTIMATED,2025-09-01T16:18:20.958522,v2_robust,False,True,False,False,False,
NCT01489124,The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia,The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia,Imipenem,"['Imipenem (Tienam)', 'Imipenem']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Ventilator-Associated Pneumonia,['Ventilator-Associated Pneumonia'],"['Infection', 'Imipenem', 'Ventilator-Associated Pneumonia', 'pharmacokinetic', 'pharmacodynamic']",COMPLETED,,2008-01,2009-01,"[{'measure': 'Efficacy of imipenem administration by a 0.5 h and 2 h infusion', 'description': 'Concentration of imipenem in plasma will be simulated in Monte Carlo technique (Computer model) to get PK/PD index (40%T\\>MIC) and reported to % PTA (Probability Target Attainment) and %CFR (Cumulative Fraction Response).', 'timeFrame': 'At 0, 0.5, 1, 2, 3, 4, 5 and 6 hours after 4th dose of imipenem.'}]",[],1,18 Years,,ALL,False,Sutep Jaruratanasirikul,OTHER,1,9.0,ACTUAL,2025-09-01T16:18:20.958539,v2_robust,True,True,True,False,False,
NCT00157924,Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093),"A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe (+) Simvastatin Versus Atorvastatin in Hypercholesterolemic Patients With Diabetes Mellitus or Metabolic Syndrome",simvastatin (+) ezetimibe,"['Lipitor®', 'atorvastatin', 'simvastatin (+) ezetimibe', 'Vytorin®', 'MK0653A']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypercholesterolemia,['Hypercholesterolemia'],[],COMPLETED,,2005-11,2007-09,"[{'measure': 'LDL-C lowering efficacy', 'timeFrame': '6 weeks'}]","[{'measure': 'Safety', 'timeFrame': '6 weeks'}]",2,18 Years,,ALL,False,Organon and Co,INDUSTRY,0,190.0,ACTUAL,2025-09-01T16:18:20.958729,v2_robust,True,True,True,False,True,
NCT02586623,Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension,RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy,Droxidopa capsules,"['Northera', 'Placebo capsules', 'Placebo', 'Droxidopa capsules']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Symptomatic Neurogenic Orthostatic Hypotension,['Symptomatic Neurogenic Orthostatic Hypotension'],"[""Parkinson's Disease"", 'Multiple System Atrophy', 'Pure Autonomic Failure', 'Primary Autonomic Failure', 'Dopamine Beta Hydroxylase Deficiency']",COMPLETED,,2016-02-11,2022-09-09,"[{'measure': 'Time To Intervention', 'description': 'Kaplan-Meier estimates are presented for time to treatment intervention. The estimates represent the quartiles of the survival time, where 50% corresponds to the median time to need for treatment intervention.\n\nNeed for intervention is defined as meeting ANY of the following criteria during the Double-Blind Treatment Period:\n\n* OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) AND lack of efficacy as judged by the investigator; OR\n* OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) at 2 consecutive visits; OR\n* OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) at the visit before early discontinuation; OR\n* participant stops IMP or withdraws from study for patient-reported lack of efficacy.', 'timeFrame': 'Randomization (Day 0) up to Week 12'}]","[{'measure': 'Number of Participants Who Needed Intervention During the 12-week Double-Blind Treatment Period', 'description': 'Need for intervention is defined as meeting ANY of the following criteria during the Double-Blind Treatment Period:\n\n* OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) AND lack of efficacy as judged by the investigator; OR\n* OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) at 2 consecutive visits; OR\n* OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) at the visit before early discontinuation; OR\n* participant stops IMP or withdraws from study for patient-reported lack of efficacy.', 'timeFrame': 'Randomization (Day 0) up to Week 12'}, {'measure': 'Time To All-cause Discontinuation', 'description': 'Kaplan-Meier estimates are presented for time to all-cause discontinuation. The estimates represent the quartiles of the survival time, where 50% corresponds to the median time to discontinuation. Time to all-cause discontinuation was defined as the time from randomization to withdrawal or last contact date.', 'timeFrame': 'Randomization (Day 0) up to Week 12'}, {'measure': 'Change From Randomization To All Post-randomization Visits in Orthostatic Hypotension Symptom Assessment (OHSA) Item #1 Score', 'description': 'The OHSA scale was designed to rate symptoms occurring specifically as a result of low blood pressure (BP), on average, over the past week using an 11-point scale (0 to 10), with more severe symptoms scoring higher. A score of zero indicates that the symptom was not experienced, and 10 is the worst possible. The scale was used to assess six symptoms: 1) Dizziness, lightheadedness, feeling faint, or feeling like you might black out, 2) problems with vision, 3) weakness, 4) fatigue, 5) trouble concentrating, and 6) head/neck discomfort. Scores for each activity and a composite score for all six activities were tabulated. A mean negative change from baseline means that symptoms have improved. A mean positive change from baseline means that symptoms have gotten worse.', 'timeFrame': 'Randomization (Day 0); Weeks 2 to 12'}, {'measure': 'Change From Randomization To All Post-randomization Visits in Orthostatic Hypotension Questionnaire (OHQ) Composite Score', 'description': 'The OHQ composite score was a mean of the OHSA composite and the Orthostatic Hypotension Daily Activity Scale (OHDAS) composite scores. The OHDAS was designed as a measure of quality of life. It uses an 11-point scale to assess whether orthostatic hypotension (OH) ""interfered"" with four types of activities: 1) standing for a short time, 2) standing for a long time, 3) walking for a short time, and 4) walking for a long time. A zero rating means that over the preceding week the activity was performed with no interference and a 10 rating means that orthostatic hypotension completely interfered with the activity. Scores for each activity and a composite score for all four activities were tabulated. A mean negative change from baseline means that symptoms have improved. A mean positive change from baseline means that symptoms have gotten worse.', 'timeFrame': 'Randomization (Day 0); Weeks 2 to 12'}, {'measure': 'Clinician-rated Clinical Global Impressions - Severity (CGI-S)', 'description': ""The CGI-S was developed to provide global measures of the severity of a participant's clinical condition during clinical studies. The CGI-S was utilized by both the clinician and the participant to provide an impression of the participant's current state of OH. The severity of the participant's current illness was rated by the clinician on a 7-point scale ranging from 1 (normal, no OH) to 7 (among those patients most extremely ill with OH)."", 'timeFrame': 'Weeks 2 to 12'}, {'measure': 'Participant-rated CGI-S', 'description': ""The CGI-S was developed to provide global measures of the severity of a participant's clinical condition during clinical studies. The CGI-S was utilized by both the clinician and the participant to provide an impression of the participant's current state of OH. The severity of the participant's current illness was rated by the participant on a 7-point scale ranging from 1 (normal, no OH) to 7 (most extremely ill with OH)."", 'timeFrame': 'Weeks 2 to 12'}]",7,18 Years,,ALL,False,H. Lundbeck A/S,INDUSTRY,0,453.0,ACTUAL,2025-09-01T16:18:20.958738,v2_robust,True,True,True,False,False,
NCT03023423,A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer,"A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer",Atezolizumab,"['Daratumumab', 'Atezolizumab', 'JNJ-54767414']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Carcinoma, Non-Small-Cell Lung","['Carcinoma, Non-Small-Cell Lung']",[],COMPLETED,,2016-12-23,2019-09-26,"[{'measure': 'Percentage of Participants With Overall Response Rate (ORR)', 'description': ""ORR was defined as the percentage of participants with partial response (PR) or complete response (CR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Criteria for CR: Disappearance of all target lesions; all lymph nodes must be of non-pathological in size (less than \\[\\<\\]10 millimeter \\[mm\\] short axis; normalization of tumor marker level. Criteria for PR: greater than or equal to (\\>=)30 percent (%) decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Overall Response (OR) = CR + PR. The outcome measure (OM) was planned to be reported for participants based on their initial assignment to Randomized Phase: Atezolizumab'."", 'timeFrame': 'Up to 1.5 years'}]","[{'measure': 'Number of Participants With Adverse Events', 'description': ""An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Crossover participants were counted twice (in 'Randomized Phase: Atezo arm' and in 'Randomized Phase: Atezo Crossed Over to Dara + Atezo') for safety analysis. For cross-over participants, AEs after initiation of cross-over treatment were summarized separately in the crossover arm, however, AEs occurred before crossover treatment were included in 'Randomized Phase: Atezolizumab arm'."", 'timeFrame': 'Up to 1.5 years'}, {'measure': 'Duration of Response (DoR)', 'description': 'Duration of response was defined as duration from date of initial documentation of disease response to date of first objectively documented evidence of recurrence or progressive disease (PD) or death, whichever occurred first. PD: Sum of diameters increased by \\>=20% and \\>=5 millimeter (mm) from nadir (including baseline if it was smallest sum). Participants with measurable disease: for ""unequivocal progression"" based on non-target disease, overall level of substantial worsening that merits discontinuation of therapy (if target disease was stable disease \\[SD\\]/PR). Participants without measurable disease: for ""unequivocal progression"" of non-target disease, increase in overall tumor burden comparable to increase required for PD of measurable disease. Appearance of 1/ more new lesions or unequivocal progression of non-target lesion was also considered as PD. The OM was planned to be reported for participants based on their initial assignment to \'Randomized Phase: Atezolizumab\'.', 'timeFrame': 'Up to 1.5 years'}, {'measure': 'Clinical Benefit Rate', 'description': ""Clinical benefit rate was defined as percentage of participants who achieved disease control (CR, PR, or SD). RECIST 1.1 Criteria for CR: Disappearance of all target lesions; all lymph nodes of non-pathological in size (\\<10 mm short axis); normalization of tumor marker level. Criteria for PR: \\>=30 % decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Criteria for SD: \\<30% decrease in sum of diameters of all target lesions compared with baseline and \\<20% increase compared with nadir, in absence of new lesions or unequivocal progression of nontarget lesions. The OM was planned to be reported for participants based on their initial assignment to 'Randomized Phase: Atezolizumab'."", 'timeFrame': 'Up to 1.5 years'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS was defined as the duration from the date of randomization until the first documented disease progression (PD) or death, whichever occurred first. PD: Sum of diameters increased by \\>=20% and \\>=5 millimeter (mm) from nadir (including baseline if it was smallest sum). Participants with measurable disease: for ""unequivocal progression"" based on non-target disease, overall level of substantial worsening that merits discontinuation of therapy (if target disease was stable disease \\[SD\\]/PR). Participants without measurable disease: for ""unequivocal progression"" of non-target disease, increase in overall tumor burden comparable to increase required for PD of measurable disease. Appearance of 1/ more new lesions or unequivocal progression of non-target lesion was also considered as PD. The OM was planned to be reported for participants based on their initial assignment to \'Randomized Phase: Atezolizumab\'.', 'timeFrame': 'Up to 1.5 years'}, {'measure': 'Overall Survival (OS)', 'description': ""Overall Survival was defined as the duration from the date of randomization to the date of participant's death due to any cause. The OM was planned to be reported for participants based on their initial assignment to 'Randomized Phase: Atezolizumab'."", 'timeFrame': 'Up to 1.5 years'}, {'measure': 'Daratumumab Serum Concentration', 'description': ""Daratumumab serum concentrations were reported. Each cycle was of 21-days. The OM was planned to be reported for participants based on their initial assignment to 'Randomized Phase: Atezolizumab'."", 'timeFrame': 'Cycle 1 Day 1 (C1D1):predose and postdose; C2D1 and C3D1:predose; C3D15: predose and postdose; C4D1: predose and postdose; C8D1: predose and postdose; C12D1: predose; end of treatment (37 days after last dose); and post last dose (up to 1.5 years)'}, {'measure': 'Atezolizumab Serum Concentration', 'description': ""Atezolizumab serum concentrations were reported. Each cycle was of 21-days. The OM was planned to be reported for participants based on their initial assignment to 'Randomized Phase: Atezolizumab'."", 'timeFrame': 'C1D1:predose and postdose; C1D2:predose and postdose; C2D1, C3D1:predose; C3D15:predose and postdose; C4D1:predose and postdose; C8D1:predose and postdose; C12D1:predose; end of treatment (37 days after last dose); and post last dose (up to 1.5 years)'}, {'measure': 'Number of Participants With Anti-Daratumumab Antibodies', 'description': ""Number of participants with antibodies to daratumumab (tested using a validated immunoassay method) were reported. The OM was planned to be reported for participants based on their initial assignment to 'Randomized Phase: Atezolizumab'."", 'timeFrame': 'Up to 1.5 years'}, {'measure': 'Number of Participants With Anti-Atezolizumab Antibodies', 'description': ""Number of participants with antibodies to atezolizumab (tested using a validated immunoassay method) were reported. The OM was planned to be reported for participants based on their initial assignment to 'Randomized Phase: Atezolizumab'."", 'timeFrame': 'Up to 1.5 years'}]",10,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,1,100.0,ACTUAL,2025-09-01T16:18:20.958806,v2_robust,True,True,True,False,True,
NCT06634823,Efficacy of Intramuscular Steroid Injection for Chronic Cough.,Prospective Placebo-Controlled Trial of Intramuscular Steroid Administration for the Treatment of Unexplained Chronic Cough,Triamcinolone Acetonide Injectable Suspension,"['Saline injection', 'Triamcinolone Acetonide Injectable Suspension']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Chronic Cough (CC),"['Chronic Cough (CC)', 'Laryngeal Disease', 'Coughing']","['Throat', 'Chronic cough', 'Neurogenic cough', 'Unexplained cough']",RECRUITING,,2024-12-02,2026-06-30,"[{'measure': 'Leicester Cough Questionnaire', 'description': 'The primary outcome for which this study is powered is the change in mean Leicester Cough Questionnaire (LCQ) scores, both global and specific domains (physical, psychological, and social) from baseline to 1-4 weeks post-treatment. This score will be 19-133, with higher score indicating better outcomes.', 'timeFrame': '4 weeks'}]","[{'measure': 'Visual Analog Scale', 'description': 'Visual analog scale for symptom severity. This will be reported as a percentage (ratio of X marked spot to total line).', 'timeFrame': '4 weeks'}, {'measure': 'Dichotomous yes/no to symptom improvement', 'description': 'Yes/No response to cough improvement', 'timeFrame': '4 weeks'}]",3,18 Years,,ALL,False,Medical University of South Carolina,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:20.958826,v2_robust,True,True,False,False,False,
NCT03335423,Inter- and Intra-individual Variations in Metformin Pharmacokinetics - The Importance of Genes and Drug Interactions,Inter- and Intra-individual Variations in Metformin Pharmacokinetics - The Importance of Genes and Drug Interactions,Oral metformin,"['Oral codeine and intravenous metformin', 'Oral metformin', 'Intravenous metformin', 'Oral codeine and oral metformin']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Metformin,"['Metformin', 'Organic Cation Transporter 1', 'Codeine']",[],COMPLETED,,2018-03-01,2020-06-13,"[{'measure': 'Metformin AUC', 'description': 'Outcomes of part 1: Variation in metformin AUC in a large cohort of healthy volunteers after a single dose of metformin', 'timeFrame': 'blood samples will be collected after 3 and 10 hours for each subject (N=300) after oral metformin ingestion. Urine is collected for 24 hours.'}, {'measure': 'Metformin AUC', 'description': 'Outcome of part 3; differences in AUC for metformin when given alone and together with codeine', 'timeFrame': 'Blood samples will be drawn in each of the 4 arms from ingestion of the drug/drugs and for 24 hours at suitable times. Urine is collected after ingestion of metformin for 24 hours.'}]","[{'measure': 'Codeine AUC', 'description': 'secondary outcome of part 3: differences in codeine AUC when codeine is given alone and together with metformin', 'timeFrame': 'Blood samples are collected for 6 hours after ingestion of the first codeine pill. Blood samples are also collected and measured for codeine, morphing, M3G,M6G for 6 hours after both oral and intravenous metformin'}, {'measure': 'Lactate AUC', 'description': 'Secondary outcome of part 3: differences in lactate AUC after metformin is given orally and intravenously', 'timeFrame': 'Blood samples for lactate will be drawn in each arm after metformin ingestion for 24 hours at suitable times'}]",4,18 Years,65 Years,ALL,True,University of Southern Denmark,OTHER,0,228.0,ACTUAL,2025-09-01T16:18:20.958848,v2_robust,True,True,True,False,False,
NCT06736223,"Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function","A Multicentric, Open-label, Non-randomized Study to Evaluate the Pharmacokinetic, Safety and Tolerability of ITF2357 Given as an Oral Single 50 mg Dose in Participants With Chronic Hepatic Impairment Relative to Matched Participants With Normal Hepatic Function",ITF2357,"['ITF2357', 'Givinostat', 'Givinostat hydrochloride Monohydrate']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Hepatic Impairment,['Hepatic Impairment'],['Hepatic impairment'],RECRUITING,,2025-05-28,2025-08,"[{'measure': 'Maximum plasma concentration observed (Cmax) of ITF2357', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Area under the plasma concentration versus time curve to the real time tlast (AUClast) of ITF2357', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Area under the plasma concentration versus time curve extrapolated to infinity (AUC0-inf) of ITF2357', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}]","[{'measure': 'Time to reach Cmax (tmax) of ITF2357', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Apparent terminal half-life (t1/2) of ITF2357', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Apparent total plasma clearance from plasma (CL/F) of ITF2357', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Apparent volume of distribution (Vz/F) of ITF2357', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Maximum plasma concentration observed (Cmax) of ITF2357 metabolites', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Area under the plasma concentration versus time curve to the real time tlast (AUClast) of ITF2357 metabolites', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Area under the plasma concentration versus time curve extrapolated to infinity (AUC0-inf) of ITF2357 metabolites', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Time to reach Cmax (tmax) of ITF2357 metabolites', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Apparent terminal half-life (t1/2) of ITF2357 metabolites', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Unbound fraction (fu) of ITF2357 and its metabolites', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Unbound area under the plasma concentration time curve (AUCu) of ITF2357 and its metabolites', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Unbound maximum plasma concentration observed (Cmax,u) of ITF2357 and its metabolites', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Unbound apparent total plasma clearance (CL/Fu) of ITF2357', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': 'Unbound apparent volume of distribution (Vz/Fu) of ITF2357', 'timeFrame': 'Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose'}, {'measure': ""Electrocardiogram QT interval corrected according to Fredericia's formula (ECG QTcF)"", 'timeFrame': 'From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)'}, {'measure': 'Incidence of Treatment Emergent Adverse Events (TEAEs)', 'description': 'Treatment Emergent Adverse Event is defined as any untoward medical occurrence (including an abnormal laboratory finding, symptom or a disease) in a participant administered the pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment', 'timeFrame': 'From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)'}, {'measure': 'Severity of Treatment Emergent Adverse Events (TEAEs)', 'description': 'Treatment Emergent Adverse Event is defined as any untoward medical occurrence (including an abnormal laboratory finding, symptom or a disease) in a participant administered the pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment', 'timeFrame': 'From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)'}]",20,18 Years,75 Years,ALL,True,Italfarmaco,INDUSTRY,1,24.0,ESTIMATED,2025-09-01T16:18:20.958866,v2_robust,True,True,False,False,True,
NCT01129323,Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia,Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia,"Cyclophosphamide, Fludarabine, Rabbit ATG","['Cyclophosphamide, Fludarabine, Rabbit ATG']",1,INTERVENTIONAL,['NA'],,,Severe Aplastic Anemia,['Severe Aplastic Anemia'],"['Anemia, Severe, Aplastic, Reduced-Intensity, Allogeneic, Stem, Cell, Transplantation']",WITHDRAWN,This study did not accrue any subjects and due to this will be closed.,2009-11,,"[{'measure': 'Engraftment rate', 'timeFrame': 'Day 42 after allogeneic transplant'}]","[{'measure': 'Relapse', 'timeFrame': 'Days 180, 365 and yearly post transplant'}, {'measure': 'Development of Graft vs. Host Disease', 'timeFrame': 'Days 180, 365 and yearly post transplant'}, {'measure': 'Evaluation of the occurrence of secondary malignancies', 'timeFrame': 'Days 180, 365 and yearly post transplant'}, {'measure': 'Overall survival', 'timeFrame': 'Days 180, 365 and yearly post transplant'}, {'measure': 'Evaluation of treatment feasibility', 'timeFrame': 'Days 180, 365 and yearly post transplant'}, {'measure': 'Evaluation of toxicities', 'timeFrame': 'Days 180, 365 and yearly post transplant'}]",7,,21 Years,ALL,False,City of Hope Medical Center,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:20.958913,v2_robust,True,True,False,True,False,This study did not accrue any subjects and due to this will be closed.
NCT03240523,A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids,"A Randomized, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids",Vilaprisan (BAY1002670),['Vilaprisan (BAY1002670)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Uterine Fibroids,['Uterine Fibroids'],[],TERMINATED,"Due to a change in the development program, the study was closed prematurely.",2017-07-31,2021-10-25,"[{'measure': 'Amenorrhea (yes/no)', 'description': 'Defined as menstrual blood loss (MBL) \\< 2 mL based on the menstrual pictogram (MP) during last 28 days.\n\nFor the primary analysis of the primary variable, the amenorrhea rates after 12 weeks of treatment in Groups A1, A2 and A3 will be compared to the rate from Group B.', 'timeFrame': 'At 3 months (at the end of treatment perid 1)'}]","[{'measure': 'Total volume of menstrual blood loss', 'description': 'Assessed by menstrual pictogram (MP). Volume of menstrual blood loss will be normalized by 28 days.', 'timeFrame': 'After approximately 1 year in subgroup 1 and after approximately 2 years in subgroup 2'}, {'measure': 'Number of bleeding days', 'description': 'From day 1 of the first treatment period until the day before the next treatment period after the last treatment period would start again normalized to 28 days.', 'timeFrame': 'After approximately 1 year in subgroup 1 and after approximately 2 years in subgroup 2'}, {'measure': 'Amenorrhea (yes/no)', 'description': 'Defined as menstrual blood loss (MBL) \\< 2 mL based on the menstrual pictogram (MP) during last 28 days of the treatment period.', 'timeFrame': 'At 6 months, at 12 months, at 15 months, at 18 months, at 21 months and at 24 months'}, {'measure': 'Absence of bleeding (spotting allowed)', 'description': 'Absence of bleeding defined as no bleeding (spotting allowed) during the last 28 days of the treatment; based on the UF-DBD (Uterine Fibroid Daily Symptom Diary).', 'timeFrame': 'Up to 24 months'}, {'measure': 'Time to onset of controlled bleeding', 'description': 'Onset of controlled bleeding is defined by the first day, for which the menstrual blood loss (assessed by MP) for all subsequent 28-day periods up to the end of the treatment period is less than 80.00 mL.', 'timeFrame': 'Quarterly up to 24 months'}, {'measure': 'HMB (Heavy Menstrual Bleeding) responder rate', 'description': 'Percentage of subjects with blood loss \\< 80.00 mL per 28 days and 50% reduction compared to baseline \\[assessed by MP\\]', 'timeFrame': 'By treatment period up to 24 months'}, {'measure': 'Percent change in volume of largest fibroid compared to baseline', 'description': 'Measured by MRI (magnetic resonance imaging).', 'timeFrame': 'At baseline, at 12 months and at 24 months'}, {'measure': 'Endometrial histology', 'description': 'E.g., benign endometrium, presence or absence of hyperplasia or malignancy', 'timeFrame': 'Up to 24 months'}, {'measure': 'Endometrial thickness', 'timeFrame': 'Up to 24 months'}]",10,18 Years,,FEMALE,False,Bayer,INDUSTRY,0,766.0,ACTUAL,2025-09-01T16:18:20.958928,v2_robust,True,True,False,True,False,"Due to a change in the development program, the study was closed prematurely."
NCT05750823,A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo,"An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo",Ruxolitinib Cream,"['Ruxolitinib Cream', 'Opzelura']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Nonsegmental Vitiligo With Genital Involvement,['Nonsegmental Vitiligo With Genital Involvement'],"['Vitiligo', 'Genital Vitiligo', 'INCB18424', 'Ruxolitinib Cream']",COMPLETED,,2023-04-11,2025-03-06,"[{'measure': 'Proportion of participants achieving a genital Vitiligo Noticeable Score (VNS) of 4 or 5', 'description': 'Vitiligo Noticeable Score (VNS) is a patient-reported outcome measure on a scale of 1-5, 1- more noticeable, 4 - a lot less noticeable, and 5- no longer noticeable', 'timeFrame': 'Week 48'}]","[{'measure': 'Number of Participants with Treatment Emergent Adverse Events (TEAEs)', 'description': 'Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.', 'timeFrame': '52 weeks'}, {'measure': 'Proportion of participants achieving Genital- Physician Global Vitiligo Assessment (PhGVA)', 'description': 'The severity of total body vitiligo will be assessed by the physician using the PhGVA on a scale of 0-4, 0 being clear to 4 being severe disease', 'timeFrame': 'Week 48'}, {'measure': 'Change from baseline in affected Body Surface Area BSA in the genital region', 'description': 'The BSA depigmented by vitiligo will be estimated at each visit.', 'timeFrame': 'Week 24 and 48'}, {'measure': 'Proportion of participants achieving T-VASI50/75/90', 'description': '≥ 50%/75%/90% improvement in total body Vitiligo Area Scoring Index', 'timeFrame': 'Week 24 and 48'}, {'measure': 'Proportion of participants achieving a genital Vitiligo Noticeable Score (VNS) of 4 or 5', 'description': 'Vitiligo Noticeable Score (VNS) is a patient-reported outcome measure on a scale of 1-5, 1- more noticeable, 4 - a lot less noticeable, and 5- no longer noticeable', 'timeFrame': 'Week 24'}, {'measure': 'Proportion of participants in each category of the color-matching question', 'description': 'Participants will answer how well the color of the treated skin matches the normal skin on a scale of 1-5, 1 being excellent to 5 being very poor.', 'timeFrame': 'Week 24 and 48'}]",7,18 Years,,ALL,False,Incyte Corporation,INDUSTRY,0,49.0,ACTUAL,2025-09-01T16:18:20.958959,v2_robust,True,True,True,False,True,
NCT03907423,Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin,Effects of Rosuvastatin on Markers of Atherosclerosis in Diabetic Patients Treated With Glimepiride/Metformin Combination,Rosuvastatin10 mg tablet,"['Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral', 'Rosuvastatin10 mg tablet', 'Placebo Oral Tablet']",3,INTERVENTIONAL,['NA'],,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",['T2DM.'],COMPLETED,,2019-04-01,2021-01-31,"[{'measure': 'serum levels of fetuin A', 'description': 'Fetuin-A has a diagnostic potential as a biomarker for liver dysfunction, cardiovascular diseases and disorders associated with metabolic syndrome.', 'timeFrame': 'three months'}, {'measure': 'serum levels of Sortilin', 'description': 'Sortilin is involved in lipid metabolism, promotes the development of atherosclerosis, and possibly becomes a potential therapeutic target for atherosclerosis treatment.', 'timeFrame': 'three months'}]",[],2,21 Years,65 Years,ALL,False,Rehab Werida,OTHER,0,70.0,ACTUAL,2025-09-01T16:18:20.958970,v2_robust,True,True,True,False,False,
NCT03239223,Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection,"A Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Subjects With Cervical High Grade Squamous Intreaepithelial Lesions (cHSIL)",ABI-1968,['ABI-1968'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,HSIL,"['HSIL', 'HSIL of Cervix', 'High-Grade Squamous Intraepithelial Lesions', 'High-grade Cervical Intraepithelial Neoplasia', 'Human Papilloma Virus', 'Cervical Cancer', 'Cervical Intraepithelial Neoplasia', 'Cervical Neoplasm', 'Cervical Dysplasia', 'CIN']",[],COMPLETED,,2018-01-01,2018-10-30,"[{'measure': 'Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of cHSIL', 'description': 'Number of participants with Adverse Events related to treatment to determine MTD', 'timeFrame': '85 Days'}]","[{'measure': 'Systemic exposure to Topical ABI-1968 Cream following topical application to the cervix.', 'description': 'Plasma concentrations of ABI-1968 over time to determine systemic exposure', 'timeFrame': '85 Days'}, {'measure': 'Histopathology of areas with biopsy-proven disease following multiple doses of Topical ABI-1968 Cream.', 'description': 'Number of subjects with complete and or partial regression of cHSIL by Colposcopy and histopathology to determine change and impact over 4 weekly doses', 'timeFrame': '85 Days'}]",3,25 Years,50 Years,FEMALE,False,Antiva Biosciences,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:20.958981,v2_robust,True,True,True,False,True,
NCT01432223,Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab,Phase II Study of Primary Chemotherapy With Anthracycline-based Regimen Followed by Nab-paclitaxel and Trastuzumab in Patients With HER2 Positive Breast Cancer,Nab-paclitaxel,"['Nab-paclitaxel', 'Abraxane']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,"['Breast Cancer', 'HER-2 Positive Breast Cancer', 'Effects of Chemotherapy']","['Trastuzumab', 'Neoadjuvant chemotherapy', 'Primary chemotherapy']",COMPLETED,,2011-09,2014-05,"[{'measure': 'To evaluate the pathological complete response rate', 'timeFrame': '1 year from last patient enrolled'}]","[{'measure': 'Disease free survival', 'timeFrame': '5 years from the last patient enrolled'}, {'measure': 'Overall response rate', 'timeFrame': 'After the protocol therapy'}, {'measure': 'Pathological response rate', 'timeFrame': 'After the protocol therapy'}, {'measure': 'Breast-conserving surgery rate', 'timeFrame': 'After the protocol therapy'}, {'measure': 'Safety', 'timeFrame': 'Within the protocol thepapy'}]",6,20 Years,70 Years,FEMALE,False,Osaka Medical College,OTHER,0,46.0,ACTUAL,2025-09-01T16:18:20.959052,v2_robust,True,True,True,False,True,
NCT00670423,"A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation","A Phase I Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation",Tacrolimus,"['Rapamune®', 'Bortezomib', 'Velcade®', 'Sirolimus', 'Prograf®', 'Tacrolimus']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Graft vs Host Disease,"['Graft vs Host Disease', 'Peripheral Blood Stem Cell Transplantation', 'Transplantation, Homologous']","['Tacrolimus', 'Sirolimus', 'Bortezomib', 'Acute Graft Versus Host Disease', 'Allogeneic Peripheral Blood Stem Cell Transplantation']",COMPLETED,,2008-05-16,2013-10-16,"[{'measure': 'To evaluate the maximum tolerated dose (MTD) of bortezomib in combination with tacrolimus and sirolimus as GVHD prophylaxis in patients undergoing myeloablative allogeneic peripheral blood stem cell transplantation.', 'timeFrame': 'Baseline through end of study'}]","[{'measure': 'To assess the toxicity of bortezomib', 'timeFrame': 'Baseline through end of study'}, {'measure': 'To describe engraftment', 'timeFrame': 'Baseline through end of study'}, {'measure': 'To describe the incidence of acute and chronic GVHD', 'timeFrame': 'Baseline through end of study'}]",4,18 Years,,ALL,False,Jennifer E. Schwartz,OTHER,1,27.0,ACTUAL,2025-09-01T16:18:20.959066,v2_robust,True,True,True,False,False,
NCT01147523,Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease,The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study,Spironolactone/Vitamin E,"['Spironolactone/Vitamin E', 'Aldactone tab 25', 'Eviol caps 100']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Fatty Liver,"['Fatty Liver', 'Steatohepatitis']","['nonalcoholic fatty liver disease', 'nonalcoholic steatohepatitis', 'adipokines', 'spironolactone', 'vitamin E', 'adiponectin', 'visfatin', 'leptin', 'resistin', 'TNF-alpha', 'IL-6', 'IL-1']",COMPLETED,,2010-01,2011-12,"[{'measure': 'Serum adipocytokines levels', 'description': 'Adiponectin; visfatin; leptin; resistin; omentin; vaspin; RBP4; TNF-alpha, IL-6; IL-1', 'timeFrame': '52 weeks'}]","[{'measure': 'Serum homocysteine levels', 'description': 'Homocysteine; vitamin B12; folate', 'timeFrame': '52 weeks'}, {'measure': 'Liver histology', 'description': 'Repeat biopsy, if patients provide their consent', 'timeFrame': '52 weeks'}, {'measure': 'Insulin resistance', 'description': 'Serum insulin; serum glucose; HOMA and QUICKI indexes', 'timeFrame': '52 weeks'}, {'measure': 'Hormonal profile', 'description': 'DHEAS; testosterone; estradiol; TSH; free T4; cortisol (serum levels)', 'timeFrame': '52 weeks'}, {'measure': 'Serum biochemistry', 'description': 'ALT; AST; ggt; Potassium; Sodium; urea; creatinin; cholesterol; triglycerides; HDL; LDL', 'timeFrame': '52 weeks'}, {'measure': 'Reactive Oxygen Metabolites (ROMs)', 'description': 'Serum dROMs leves', 'timeFrame': '52 weeks'}]",7,18 Years,75 Years,ALL,False,Aristotle University Of Thessaloniki,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:20.959078,v2_robust,True,True,True,False,False,
NCT00554723,CHInese Medicine NeuroAid Efficacy on Stroke Recovery,"A Double Blind, Placebo Controlled, Randomized, Multicenter Study to Investigate CHInese Medicine NeuroAid Efficacy on Stroke Recovery",NeuroAid,"['Danqi Piantan Jiaonang (In China)', 'NeuroAid matched Placebo', 'NeuroAid']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Cerebral Infarction,"['Cerebral Infarction', 'Stroke']","['Stroke', 'Cerebral infarct', 'Recovery', 'Double blind', 'Randomized', 'Placebo', 'Traditional Chinese Medicine', 'Neuroaid']",COMPLETED,,2007-05,2012-08,"[{'measure': 'Distribution modified Rankin Scale grades for all randomized subjects', 'timeFrame': '3 months'}]","[{'measure': 'NIHSS, Barthel Index, MMSE', 'timeFrame': '3 months'}]",2,18 Years,,ALL,False,CHIMES Society,OTHER,1,1100.0,ACTUAL,2025-09-01T16:18:20.959116,v2_robust,True,True,True,False,False,
NCT01052623,Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT),"Status of the Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis in Relation to Growth Failure, Body Weight and Neuroprotection in Children With Ataxia Telangiectasia","Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate","['Progynova 21 mite', 'Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate', 'Catapressan', 'Growth hormone', 'L-Arginin_hydrochlorid-einmolar', 'NutropinAq']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Ataxia Telangiectasia,"['Ataxia Telangiectasia', 'Growth Failure']","['GH/IGF-1', 'Ataxia telangiectasia (AT)', 'IGF-1 Generation Test', 'Growth hormone']",UNKNOWN,,2010-01,2012-09,"[{'measure': 'To evaluate the GH increase after Arginine Provocation Test', 'timeFrame': 'at minute 0, 30, 60, 90 und 120 after infusion'}]","[{'measure': 'The GH increase after Clonidine Provocation Test. To evaluate the safety and efficacy of the IGF-1 generation test. To correlate GH/IgF-1 deficiency to BMI To correlate GH/IgF-1 deficiency to MRI findings', 'timeFrame': 'at minute 0, 30, 60, 90 und 120 after dosing of Clonidin. IgF-1 generation test after 5 days.'}]",2,3 Years,18 Years,ALL,False,Johann Wolfgang Goethe University Hospital,OTHER,0,24.0,ESTIMATED,2025-09-01T16:18:20.959126,v2_robust,True,True,False,False,True,
NCT06712823,An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894,"An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894",atumelnant (CRN04894),['atumelnant (CRN04894)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Congenital Adrenal Hyperplasia,"['Congenital Adrenal Hyperplasia', 'Classic Congenital Adrenal Hyperplasia']","['Congenital Adrenal Hyperplasia', 'CAH', 'CRN04894', 'atumelnant']",RECRUITING,,2025-02-25,2027-11,"[{'measure': 'Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation', 'timeFrame': 'Week 108'}, {'measure': 'Incidence of glucocorticoid (GC) deficiency / adrenal insufficiency and adrenal crisis', 'timeFrame': 'Week 108'}, {'measure': 'Incidence of hospitalizations related to congenital adrenal hyperplasia (CAH)', 'timeFrame': 'Week 108'}, {'measure': 'Change from baseline in morning (before 11:00 AM) serum androstenedione (A4) over time', 'timeFrame': 'Week 108'}]","[{'measure': 'Change from baseline in morning (before 11:00 AM) serum 17-hydroxyprogesterone (17-OHP) over time', 'timeFrame': 'Week 108'}, {'measure': 'Change from baseline in daily glucocorticoid (GC) dose (hydrocortisone [HC] mg equivalents) over time', 'timeFrame': 'Week 108'}]",6,16 Years,,ALL,False,Crinetics Pharmaceuticals Inc.,INDUSTRY,0,150.0,ESTIMATED,2025-09-01T16:18:20.959135,v2_robust,True,True,False,False,True,
NCT04804059,A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males,"An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-APX001 in Healthy Male Subjects After Oral and Intravenous Dosing",[14C]-APX001 Oral Solution,"['[14C]-APX001 Solution for Infusion', '[14C]-APX001 Oral Solution']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Fungal Infection,['Fungal Infection'],[],COMPLETED,,2018-08-17,2018-09-26,"[{'measure': 'Mass balance recovery as measured by mass unit equiv/g after a single oral or single intravenous (IV) dose of carbon-14 (14C)-labelled APX001 ([14C]-APX001).', 'timeFrame': '3 weeks'}, {'measure': 'Profiling of metabolites of [14C]-APX001 in plasma and excreta.', 'description': 'Plasma, urine and feces samples from subjects dosed with \\[14C\\]-APX001 were analyzed using high resolution, accurate mass liquid chromatography tandem mass spectrometry (LC-MS/MS) with in-line fraction collection and off-line counting to obtain \\[14C\\]-radiochromatographic profiles and provide information on the nature of the radioactive components present, including chemical structure identification.', 'timeFrame': '3 weeks'}]","[{'measure': 'Elimination pathway of [14C]-APX001 following a single oral or single IV dose of [14C]-APX001.', 'description': 'Amount of radioactivity recovered from urine and feces over time was measured by liquid scintillation counting (LSC) and expressed as a percentage of administered radioactivity.', 'timeFrame': '3 weeks'}, {'measure': 'Extent of distribution of total radioactivity into blood cells following a single oral or single IV dose of [14C]-APX001.', 'description': 'Amount of radioactivity in whole blood over time was quantified by LSC and expressed in ng equivalents free drug/g.', 'timeFrame': '3 weeks'}]",4,30 Years,65 Years,MALE,True,Basilea Pharmaceutica,INDUSTRY,0,10.0,ACTUAL,2025-09-01T16:18:20.959195,v2_robust,True,True,True,False,False,
NCT02306759,Ketamine For Acute Treatment of Pain in Emergency Department,Ketamine For Acute Treatment of Pain in Emergency Department,Ketamine,"['Ketamine', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Pain,['Pain'],"['analgesia', 'ketamine', 'pain']",COMPLETED,,2015-01,2015-11,"[{'measure': 'Change From Baseline of Pain as Described by Numeric Rating Scale (NRS) [Minimum:0, Maximum 10] at 15 Minutes', 'description': 'Change from Baseline of Pain as described by Numeric Rating Scale (NRS) \\[minimum:0, maximum 10\\] at 15 minutes. Lower values indicate worst outcomes while higher values indicate better outcomes.', 'timeFrame': '15 minutes after administration of study intervention'}]","[{'measure': 'Number of Participants With Adverse Events', 'description': 'Incidence or number of participants with adverse events.', 'timeFrame': 'during the study period'}, {'measure': 'Patient Satisfaction of Pain Control Based on a Likert Scale', 'description': 'Patient satisfaction of pain control based on a Likert Scale at the end of study completion, an average of 90 minutes. Scores reported out of scale of 10, 10 being most satisfied and 1 being least satisfied.', 'timeFrame': 'At the end of study period'}, {'measure': 'Mean Consumption of Rescue Analgesia', 'timeFrame': 'at designated intervals during study period (0, 15, 30, 45, 60, 75, 90, 105, 120 minutes)'}, {'measure': 'ED Length of Stay (Minutes)', 'description': 'ED Length of stay (minutes) throughout study period', 'timeFrame': 'throughout study completion'}]",5,18 Years,80 Years,ALL,False,The Brooklyn Hospital Center,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:20.959243,v2_robust,True,True,True,False,True,
NCT00085059,Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma,Early Phase II Study On BNCT In Metastatic Malignant Melanoma Using The Boron Carrier BPA,boronophenylalanine-fructose complex,['boronophenylalanine-fructose complex'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Melanoma (Skin),['Melanoma (Skin)'],"['stage IV melanoma', 'recurrent melanoma']",TERMINATED,low accrual,2004-04,,[{'measure': 'Best response to treatment as measured by RECIST every 8 weeks at completion of study treatment'}],"[{'measure': 'Overall survival as measured every 8 weeks at completion of study treatment'}, {'measure': 'Duration of local response as measured by Kaplan Meier every 8 weeks after completion of study treatment'}, {'measure': 'Time to local progression measured every 8 weeks after completion of study treatment'}, {'measure': 'Acute toxicity as measured by Common Toxicity Criteria AE v 3.0 1- 6 weeks after completion of treatment'}, {'measure': 'Late toxicity as measured by RTOG and EORTC week 6 and thereafter upon completion of study treatment'}]",6,18 Years,,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,4.0,ACTUAL,2025-09-01T16:18:20.959283,v2_robust,True,True,False,True,False,low accrual
NCT02648659,The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients,The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in Helicobacter Pylori Patients,Ilaprazole,"['Ilaprazole', 'Clarithromycin', 'Noltec®', 'Amoxicillin', 'Pamoxin®', 'Clafaxin®', 'Flasinyl®', 'Metronidazole']",8,INTERVENTIONAL,['PHASE4'],PHASE4,,Peptic Ulcer,['Peptic Ulcer'],[],COMPLETED,,2016-03-02,2017-02-14,"[{'measure': 'Eradication rate after tailored therapy assessed by urea breath test', 'description': 'After completion of 14days tailored therapy, the participants will be followed at 4-6 weeks with urea breath test (UBT). The eradication rate will be assessed by the result of UBT.', 'timeFrame': 'Test at 4 -6 weeks after completion of medication'}]","[{'measure': 'Number of participants with treatment-related adverse events as assessed by questionnaire', 'description': 'During the medication of tailored therapy, the participants will be asked to check the compliance and adverse events with diary and questionnaire.', 'timeFrame': 'Questionnaire and diary during medication for 14days'}]",2,20 Years,80 Years,ALL,False,Kyungpook National University Hospital,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:20.959300,v2_robust,True,True,True,False,True,
NCT02142959,RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE,"A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis",Omaveloxolone Lotion 0.5%,"['RTA 408 Lotion 0.5%', 'Vehicle Lotion', 'Omaveloxolone Lotion 0.5%', 'RTA 408 Lotion 3%', 'Omaveloxolone Lotion 3%']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],"['RTA 408', 'RTA 408 Lotion', 'Breast cancer', 'Radiation therapy', 'Radiation dermatitis', 'Oxidative stress', 'Inflammation', 'omaveloxolone']",COMPLETED,,2014-06-30,2015-04-30,"[{'measure': 'Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy to the Breast Following Topical Application of Omaveloxolone Lotion or Lotion Vehicle', 'description': 'CTCAE Radiation dermatitis scoring:\n\nGrade 0 = No radiation dermatitis; Grade 1 = Faint erythema or dry desquamation; Grade 2 = Moderate to brisk erythema, patchy moist desquamation, mostly confined to skin folds and creases, moderate edema; Grade 3 = Moist desquamation in areas other than skin folds and creases, bleeding induced by minor trauma or abrasion; Grade 4 = Life-threatening consequences, skin necrosis or ulceration of full thickness dermis, spontaneous bleeding from involved site, skin graft indicated; Grade 5 = Death', 'timeFrame': 'Day 1 of radiation treatment through the last day of radiation treatment (maximum of 19 weeks), time averaged effect on radiation dermatitis reported'}]",[],1,18 Years,75 Years,FEMALE,False,Biogen,INDUSTRY,1,187.0,ACTUAL,2025-09-01T16:18:20.959444,v2_robust,True,True,True,False,True,
NCT01470859,The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease,a Pilot Follow-up Study of Investigating the Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Chinese Patients With Early Parkinson's Disease,pramipexole,"['pramipexole', 'Sinemet CR', 'Sifrol', ""Sinemet CR 250' (Levodopa 200mg, and 50mg carbidopa)""]",4,INTERVENTIONAL,['NA'],,,Idiopathic Parkinson's Disease,"[""Idiopathic Parkinson's Disease""]","[""De Novo parkinson's disease"", 'initial treatment', 'pramipexole', 'Levodopa', ""Parkinson's disease-related spatial covariance pattern""]",COMPLETED,,2011-12,2014-08,"[{'measure': 'Longitudinal Change of Brain Network Activity', 'description': ""The brain network activity is evaluated by Parkinson's disease-related spatial covariance pattern(PDRP) value (Z score).\n\nThe change of brain network activity is calculated by the PDRP value (Z score) at V5 - the PDRP value (Z score) at V1."", 'timeFrame': 'twice, baseline and 1 year after baseline'}]","[{'measure': ""Unified Parkinson's Disease Rating Score (UPDRS II, III)"", 'description': 'baseline (1st visit, V1), completion of dosage titration within 10 weeks after baseline (2nd visit, V2), 1 year after baseline (final visit, V5) UPDRS II score 0-52 (13 items); UPDRS III score 0-56 (14 items); The more scores,the more severe; the two scales were evaluated separately.', 'timeFrame': 'three times: baseline, 10 weeks, 1 year'}, {'measure': ""Parkinson's Disease Questionnaire (PDQ39)"", 'description': 'The PDQ39 score was assessed at baseline (1st visit, V1) and 1 year after baseline (final visit, V5).\n\nPDQ39 score ranges from 0-156 (0-4 each item); the more score, the more severe.', 'timeFrame': 'twice baseline and 1 year'}, {'measure': 'Hoehn&Yahr (H&Y) Staging', 'description': ""The Hoehn and Yahr scale is a commonly used scale for describing how the symptoms of Parkinson's disease progress and the disease stages. Bigger numbers indicate more symptoms and disease progression. H\\&Y stage range from 0-5; the greater, the more severe.\n\nThe H\\&Y stages of patients were evaluated at baseline (1st visit, V1), and 1 year after baseline (final visit, V5)."", 'timeFrame': 'twice baseline and 1 year'}, {'measure': 'Patients With Clinical Improvement as Evaluated by Global Impression Scale (CGI).', 'description': 'Patients with a score \\<= 2 (very much or much improved in relation to baseline) are considered as clinically improved.\n\nThe numbers of participants with clinical improvement are reported here. The completion of dosage titration within 10 weeks after baseline (visit 2) and 1 year after baseline (final visit)', 'timeFrame': 'twice, at 10 weeks(V2) and 1 year(V5)'}]",5,30 Years,75 Years,ALL,False,Huashan Hospital,OTHER,1,30.0,ACTUAL,2025-09-01T16:18:20.959473,v2_robust,True,True,True,False,False,
NCT03471559,Cannabidiol - an in Vivo Innovative Drug Delivery Study,Cannabidiol as a Medication for Neuropsychiatric and Other Medical Conditions - an in Vivo Innovative Drug Delivery Study,Cannabidiol,['Cannabidiol'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Pharmacokinetics, Bioavailability","['Pharmacokinetics, Bioavailability']",[],TERMINATED,"Two step study, step two was not feasible based on results from phase one.",2018-12-10,2019-08-29,"[{'measure': 'Pharmacokinetic profile of single dose - area under the curve (AUC(0-t)), AUC(0-∞))', 'description': 'reference formulation compared to new formulation', 'timeFrame': '36 hours'}, {'measure': 'Pharmacokinetic profile of single dose - residual area', 'description': 'reference formulation compared to new formulation', 'timeFrame': '36 hours'}, {'measure': 'Pharmacokinetic profile of single dose - maximum concentration (Cmax)', 'description': 'reference formulation compared to new formulation', 'timeFrame': '36 hours'}, {'measure': 'Pharmacokinetic profile of single dose - time to reach Cmax (tmax)', 'description': 'reference formulation compared to new formulation', 'timeFrame': '36 hours'}, {'measure': 'Pharmacokinetic profile of single dose - elimination half life (t1/2)', 'description': 'reference formulation compared to new formulation', 'timeFrame': '36 hours'}, {'measure': 'Pharmacokinetic profile of single dose - elimination rate constant (λz)', 'description': 'reference formulation compared to new formulation', 'timeFrame': '36 hours'}, {'measure': 'Pharmacokinetic profile of multiple dosing - area under the curve (AUC(τ))', 'description': 'reference formulation compared to new formulation', 'timeFrame': '9 days'}, {'measure': 'Pharmacokinetic profile of multiple dosing - maximum concentration (Cmax,ss)', 'description': 'reference formulation compared to new formulation', 'timeFrame': '9 days'}, {'measure': 'Pharmacokinetic profile of multiple dosing - time to reach Cmax (tmax,ss)', 'description': 'reference formulation compared to new formulation', 'timeFrame': '9 days'}, {'measure': 'Pharmacokinetic profile of multiple dosing - elimination half life (t1/2,ss (τ=12h))', 'description': 'reference formulation compared to new formulation', 'timeFrame': '9 days'}, {'measure': 'Pharmacokinetic profile of multiple dosing - steady state accumulation ratio', 'description': 'reference formulation compared to new formulation', 'timeFrame': '9 days'}]","[{'measure': 'Regular laboratory testing', 'description': 'standard laboratory blood tests', 'timeFrame': '36h or 9 days'}, {'measure': 'Electrocardiography - QTc time', 'timeFrame': '36 hours or 9 days'}, {'measure': 'Vital signs - body temperature', 'timeFrame': '36 hours or 9 days'}, {'measure': 'Vital signs - blood pressure', 'description': 'Systolic and diastolic blood pressure reported in millimetres of mercury (mmHg)', 'timeFrame': '36 hours or 9 days'}, {'measure': 'Vital signs - pulse rate', 'timeFrame': '36 hours or 9 days'}]",16,18 Years,85 Years,ALL,True,"Central Institute of Mental Health, Mannheim",OTHER,0,8.0,ACTUAL,2025-09-01T16:18:20.959514,v2_robust,True,True,False,True,False,"Two step study, step two was not feasible based on results from phase one."
NCT04845659,Avatrombopaq In Patients With Cirrhosis,Treatment With Avatrombopaq in Patients With Cirrhosis Undergoing Small Invasive Procedure: A Prospective Case Series,Doptelet Pill,['Doptelet Pill'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Thrombocytopenia; Drugs,"['Thrombocytopenia; Drugs', 'Cirrhosis, Liver', 'Procedural Bleeding']","['Cirrhosis', 'Thrombocytopenia']",UNKNOWN,,2021-06-01,2022-06-01,"[{'measure': 'Adverse Events', 'description': 'Mortality, bleedning, blood clots, readmission, reoperation', 'timeFrame': '3 months postprocedural'}]",[],1,18 Years,80 Years,ALL,False,Hvidovre University Hospital,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:20.959643,v2_robust,True,True,False,False,True,
NCT00009659,Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause,"Biologic Activity of a Selective Progesterone Receptor Modulator, CDB-2914, in Post-Menopausal Women",CDB 2914,['CDB 2914'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Postmenopause,['Postmenopause'],"['Endometrium', 'Estrogen', 'Antihormone', 'Menopause', 'Progesterone', 'Postmenopausal Women', 'Hormone Replacement']",COMPLETED,,2001-01,2001-12,[],[],0,,,FEMALE,True,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,0,58.0,,2025-09-01T16:18:20.959650,v2_robust,True,True,True,False,False,
NCT02751359,"Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers","Characterization of the Analgesic Effects of Oral CBD in Healthy, Normal Volunteers",Cannabidiol,"['Cannabidiol', 'CBD', 'Placebo']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Pain,['Pain'],[],COMPLETED,,2016-07,2020-04,"[{'measure': 'Analgesia: Change From Baseline in Pain Tolerance and Threshold as Measured by the Cold Pressor Test', 'description': 'Time to first feel pain (""Pain threshold"" measured in seconds) during the Cold Pressor Test and withdraw the hand from the cold water (""Pain Tolerance"" measured in seconds). Changes in threshold from baseline were averaged across study sessions for each CBD dose.', 'timeFrame': 'Baseline, 60 minutes, 120 minutes 180 minutes, 240 minutes, 300 minutes and 360 minutes after each dose'}]","[{'measure': 'Subjective Drug Effects Related to Abuse Liability as Measured by Visual Analog Scales', 'description': ""Participants rate the strength of their desire to take again, drug liking, good effect and bad effect. Each item was presented and the participant was asked to rate his / her rating on a scale anchored by 'Not At All' (0 mm) to 'Extremely' (100 mm). The average of all timepoints is reported for each category."", 'timeFrame': '30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes, 270 minutes, 300 minutes, 330 minutes, 360 minutes'}]",2,21 Years,50 Years,ALL,True,"University of California, Los Angeles",OTHER,1,18.0,ACTUAL,2025-09-01T16:18:20.959666,v2_robust,True,True,True,False,False,
NCT03852459,Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS,"A Randomized, Double-Blind,Vehicle-Controlled Study to Determine the Efficacy and Safety of AP0302 in the Treatment of Delayed Onset Muscle Soreness (DOMS)",S-Ibuprofen,"['Vehicle', 'S-Ibuprofen']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Pain, Acute","['Pain, Acute']",[],COMPLETED,,2018-01-12,2019-04-11,"[{'measure': 'Sum of the Time-weighted Differences From Baseline in Pain Intensity With Movement(SPIDMOVE) Over 24 Hours Post Time Zero', 'description': 'The primary efficacy outcome is the sum of the time-weighted differences from baseline in muscle pain/soreness with movement over 0-24 hours post T0 (SPIDMOVE 0-24h), that is the area under the differences from baseline pain/soreness intensity difference curve. The pain intensity differences (PIDs) with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 pain score with movement from the pain score with movement at time point Ti. Positive and higher scores indicate greater reduction in pain. Measured by Pain Intensity Numerical Rating Scale (PI-NRS) where 0 = no pain and 10 = worst possible pain at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of investigational product (IP).', 'timeFrame': '0-24 hours.'}]","[{'measure': 'SPIDMOVE Over the Following Intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 24-48, 0-36, 36-48 and 0-48 Hours Post-T0.', 'description': 'Sum of the time-weighted differences from baseline in pain intensity with movement (SPIDMOVE) over the following intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-28, 36-48, and 0-48 hours post-T0, that is the area under the differences from baseline pain/soreness intensity difference curve. The PIDs with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 pain score with movement from the pain score with movement at time point Ti. Positive and higher scores indicate greater reduction in pain. Measured by Pain Intensity Numerical Rating Scale (PI-NRS) where 0 = no pain and 10 = worst possible pain at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of IP.', 'timeFrame': 'From 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-28,36-48, and 0-48 hours post-T0. Time point i included 1, 2, 3, 4, 5, 6 (pre-dose), 7, 8, 9, 10, 11, 12 (pre-dose), 16, 18 (pre-dose), 20, and 24 (pre-dose) hours after the first dose.'}, {'measure': 'Sum of Time Weighted Differences From Baseline in Muscle Stiffness (SSID) With Movement Over the Interval', 'description': 'Sum of the time-weighted differences from baseline in muscle stiffness with movement (SSIDMOVE) over the following intervals: 0-6, 6-12, 0-12, 12-24, 0-24, 24-36, 24-48, 0-36, 36-48, and 0-48 hours post-T0, that is the area under the differences from baseline stiffness difference curve. The muscle Stiffness Intensity Differences (SIDs) with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 stiffness score with movement from the stiffness score with movement at time point Ti. Positive and higher scores indicate greater reduction in stiffness. Measured by Muscle Stiffness Numerical Rating Scale (NRS) where 0 = No Stiffness and 10 = Worst Possible Stiffness at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of IP.', 'timeFrame': '0-6, 6-12, 0-12, 12-24, 24-36, 24-48, 0-36, 36-48, and 0-48 post T0'}, {'measure': 'Total Relief With Movement (TOTPAR) 0-6 Hours Post Time Zero', 'description': 'Total relief with movement (TOTPAR) 0-6 hours post time zero\n\nTOTPAR was calculated as the sum of pain relief at time point i (PR i) times the weight for each PR i, where i referred to each pain relief scheduled assessment time point between A and B (not including B). The higher the number the better pain relief.\n\nCategorical Relief Rating Scale: Subjects rated relief from starting pain with movement using a 5-point categorical relief scale ""0=no relief,"" ""1=a little relief,"" ""2=some relief,"" ""3=a lot of relief,"" or ""4=complete relief"" at 1, 2, 3, 4, 5, and 6 hours post-initial IP dose and immediately prior to a subsequent dose of IP if one occurred prior to 6 hours.', 'timeFrame': '0-6 hours'}, {'measure': 'Subject Global Assessment of Study Medication Assessed at Approximately 48 Hours Post Time Zero', 'description': 'Global assessment of efficacy will be assessed at approximately 48 hours post-T0 (or upon early termination if the subject withdraws prior to the 48-hour assessment).\n\nSubject Global Assessment Using Original 5 Categories as 0=poor, 1=fair, 2=good, 3=very good, 4=excellent. In addition, the 5 categories were dichotomized into 2 categories (good/very good/excellent versus poor/fair). The proportion of good, very good, and excellent ratings were calculated for each treatment.', 'timeFrame': '48 hours post time zero'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'description': 'TEAE was defined as an adverse event that was new or worsened in severity after the first dose of study drug. A treatment-related TEAE was defined as a TEAE that was at least possibly related to the administration of study drug or was missing the relationship assessment. If a TEAE was recorded on multiple occasions, only the highest severity was presented.', 'timeFrame': 'Up to Day 7'}]",6,18 Years,55 Years,ALL,True,"Aponia Laboratories, Inc.",INDUSTRY,0,251.0,ACTUAL,2025-09-01T16:18:20.959684,v2_robust,True,True,True,False,True,
NCT02828059,Continuous Wound Infiltration for Diminution of Post-surgery Pain After Caesarean Section,Continuous Wound Infiltration for Diminution of Post-surgery Pain After Caesarean Section (Dip-Caesar),Ropivacaine,"['ReadyFusor', 'Ropivacaine']",2,OBSERVATIONAL,[],,,Pain,['Pain'],['Caesarean section'],WITHDRAWN,changed drug approval,2016-08,2016-08,"[{'measure': 'Maximal perceived pain intensity 24 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '24 hours'}]","[{'measure': 'Perceived pain at rest over 12 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '12 hours'}, {'measure': 'Perceived pain at mobilization over 12 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '12 hours'}, {'measure': 'Perceived pain at rest over 24 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '24 hours'}, {'measure': 'Perceived pain at mobilization over 24 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '24 hours'}, {'measure': 'Perceived pain at rest over 48 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '48 hours'}, {'measure': 'Perceived pain at mobilization over 48 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '48 hours'}, {'measure': 'Opioid demand over 12 h after surgery', 'description': 'Cumulative dosis of Piritramide administered on demand over 12 hours', 'timeFrame': '12 hours'}, {'measure': 'Opioid demand over 24 h after surgery', 'description': 'Cumulative dosis of Piritramide administered on demand over 24 hours', 'timeFrame': '24 hours'}, {'measure': 'Opioid demand over 48 h after surgery', 'description': 'Cumulative dosis of Piritramide administered on demand over 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Satisfaction with pain management 24 h after surgery', 'description': 'Subjectively rated degree of satisfaction with analgesia by 10-point numeric Rating scale', 'timeFrame': '24 hours'}]",11,18 Years,,FEMALE,False,Jena University Hospital,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:20.959733,v2_robust,False,True,False,True,False,changed drug approval
NCT02257359,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers","A Phase 1, Open Label, Ascending Cohort, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban and Its Metabolite in Healthy Female Volunteers Following Administration of Epelsiban",Epelsiban,['Epelsiban'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Embryo Transfer,['Embryo Transfer'],"['Epelsiban', 'Healthy Female Volunteers', 'Safety', 'Tolerability', 'Oxytocin', 'Pharmacokinetics']",COMPLETED,,2014-12-18,2015-01-29,"[{'measure': 'Composite pharmacokinetic parameters of epelsiban and its metabolite (GSK2395448)', 'description': 'Pharmacokinetic parameters including area under the plasma drug (and metabolite) concentration versus time curve (AUC\\[0-t\\], AUC\\[0- infinity\\], AUC\\[0-tau\\]), maximum observed concentration (Cmax), time to maximum observed plasma drug (and metabolite) concentration (tmax), and terminal half-life (t1/2), as data permit, will be analyzed. Blood samples for pharmacokinetic analysis will be collected on Day 1 (Morning pre-dose and 0.5hour(hr), 1 hr, 4 hr, 6hr, 8 hr, 12 hr post morning dose; evening pre-dose and 12.5 hr, 13 hr post morning dose) and Day 2 (16 hr and 24 hr post Day 1 morning dose).', 'timeFrame': 'Up to Day 2'}, {'measure': 'Number of subjects with Adverse events (AEs)', 'description': 'An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.', 'timeFrame': 'Up to Day 12'}, {'measure': 'Assessment of clinical observations', 'timeFrame': 'Up to Day 12'}, {'measure': 'Assessment of hematology parameters', 'description': 'Hematology parameters include complete blood count with red blood cell indices, white blood cell count differential, hemoglobin, hematocrit and platelet count.', 'timeFrame': 'Up to Day 12'}, {'measure': 'Assessment of clinical chemistry parameters', 'description': 'Clinical chemistry parameters includes glucose, blood urea, creatinine, sodium, potassium, calcium, total protein, albumin, total bilirubin, direct bilirubin, alkaline phosphatase, alanine aminotransferase and aspartate aminotransferase.', 'timeFrame': 'Up to Day 12'}, {'measure': 'Assessment of urinalysis by dipstick', 'description': 'Urinalysis includes specific gravity, pH, glucose, protein, blood and ketones by dipstick. If blood or protein is abnormal microscopic examination will be done.', 'timeFrame': 'Up to Day 12'}, {'measure': 'Assessment of vital sign measurements', 'description': 'Vital sign measurements will include temperature, systolic and diastolic blood pressure and heart rate.', 'timeFrame': 'Up to Day 12'}, {'measure': 'Assessment of 12-lead electrocardiogram (ECG)', 'description': 'Triplicate 12-lead ECGs will be obtained at each timepoint during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.', 'timeFrame': 'Up to Day 12'}, {'measure': 'Assessment of physical examination findings', 'description': 'A physical examination will include, at a minimum, assessment of the cardiovascular, respiratory, gastrointestinal and neurological systems. Height and weight will also be measured', 'timeFrame': 'Up to Day 12'}]",[],9,18 Years,55 Years,FEMALE,True,GlaxoSmithKline,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:20.959797,v2_robust,True,True,True,False,True,
NCT05641480,Technical R&D and Demonstration of Intelligent Medical Care in Alzheimer's Disease's Management,Technical R&D and Demonstration of Intelligent Medical Care in Alzheimer's Disease's Management,Donepezil hydrochloride tablets or carpalatine bitartrate tablets,['Donepezil hydrochloride tablets or carpalatine bitartrate tablets'],1,INTERVENTIONAL,['NA'],,,Alzheimer Disease,"['Alzheimer Disease', 'Subjective Cognitive Decline', 'Mild Cognitive Impairment', 'Mild Dementia']","[""Alzheimer's Disease"", 'Subjective Cognitive Decline', 'Mild Cognitive Impairment', 'Mild Dementia']",RECRUITING,,2022-06-03,2025-12-09,"[{'measure': 'AD-seeds protein analyzer（Developed by Professor Jia Jianping of Capital Medical University of China）', 'description': ""The area under curve is used to show the ability of the AD-seeds-detector to diagnose AD. The value of area under curve is higher, then the ability of the AD-seeds-detector to diagnose AD is stronger.AD-seeds protein analyzer is an antibody-free and cost-efective approach for measuring blood biomarkers. It's a newly developed instrument to distinguish Alzheimer's disease (AD) from other forms of dementia.It examines amyloid in the blood. Alzheimer's disease is usually not discovered until the late stage, and early detection and intervention are of great significance to improve the treatment effect of the disease."", 'timeFrame': 'Change from Baseline Aβ level at 6 months'}, {'measure': 'Or adopting Serum Aβ level is detected', 'description': 'A certain amount of fasting venous blood is collected from participants before and after treatment, and the supernatant is collected by low-speed centrifugation at a certain temperature. The serum Aβ level is detected by enzyme-linked immunosorbent assay (ELISA)', 'timeFrame': 'Change from Baseline Aβ level at 6 months'}]","[{'measure': 'Electrocardiogram（ECG）', 'description': 'ECG QT Interval.（Security Index）', 'timeFrame': 'Change from Baseline at 6 months（Week -1~0 day, week 24 ± 3 days）'}, {'measure': 'Change of total MMSE score from baseline', 'description': 'MMSE score are commonly used for estimating the severity of cognitive impairment with maximum score of 30. The questions in this scale included orientation to time, orientation to place, attention and calculation, recall of three words and visual construction.It can comprehensively, accurately and rapidly reflect the degree of mental state and cognitive impairment of the subjects. To provide scientific basis for clinical psychological diagnosis, treatment and neuropsychological research.', 'timeFrame': 'Change from Baseline at 6 months（FIve times：Week -1~0 day，Week 4 ± 2 days，week 8 ± 2 days，week 12 ± 3 days，week 24 ± 3 days）'}, {'measure': 'Montreal Cognitive Assessment Scale (MoCA) Score', 'description': 'MoCA is an assessment tool used for rapid screening of abnormal cognitive function, including 11 examination items in 8 cognitive fields, with a total score of 30 points, among which a score ≥26 is considered as normal cognitive function. Its high sensitivity, covering important cognitive fields, short test time, suitable for clinical application. The MoCA scores of the two groups are recorded before and after treatment.', 'timeFrame': 'Change from Baseline at 6 months（FIve times：Week -1~0 day，Week 4 ± 2 days，week 8 ± 2 days，week 12 ± 3 days，week 24 ± 3 days）'}, {'measure': 'Disease conversion rate A', 'description': 'The disease conversion rate is calculated to evaluate the application effect of this model in elderly people with cognitive dysfunction.The number of stable dementia cases is calculated according to the diagnostic criteria of dementia symptom staging.', 'timeFrame': 'Baseline，6 months'}, {'measure': 'Disease conversion rate B', 'description': 'According to the diagnostic criteria of dementia symptom staging, the number of participants turned to normal is calculated.', 'timeFrame': 'Baseline，6 months'}, {'measure': 'Disease conversion rate C', 'description': 'According to the diagnostic criteria of dementia symptom staging, the number of disease conversion cases is calculated.', 'timeFrame': 'Baseline，6 months'}, {'measure': 'Disease conversion rate D', 'description': ""The conversion of SCD to MCI/ Alzheimer's disease is calculated according to the diagnostic criteria of dementia symptom staging."", 'timeFrame': 'Baseline，6 months'}, {'measure': 'Disease conversion rate E', 'description': ""According to the diagnostic criteria of dementia symptom staging, MCI is converted to Alzheimer's disease."", 'timeFrame': 'Baseline，6 months'}, {'measure': 'Disease conversion rate F', 'description': 'According to the diagnostic criteria of dementia symptom staging, the conversion rate of mild dementia to moderate to severe dementia is calculated.', 'timeFrame': 'Baseline，6 months'}]",11,55 Years,75 Years,ALL,True,Shaanxi Hospital of Traditional Chinese Medicine,OTHER,0,150.0,ESTIMATED,2025-09-01T16:18:20.959827,v2_robust,True,True,False,False,False,
NCT00796380,Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases,Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases,Xingnaojing,['Xingnaojing'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Convulsive Diseases,['Convulsive Diseases'],[],UNKNOWN,,2008-12,2010-07,"[{'measure': 'Antipyretic rate , Frequency of convulsive episodes ,', 'timeFrame': 'one year'}, {'measure': 'Frequency of convulsive episodes', 'timeFrame': '1 year'}]",[],2,1 Month,18 Years,ALL,False,Shenzhen Children's Hospital,OTHER_GOV,0,1.0,ESTIMATED,2025-09-01T16:18:20.959914,v2_robust,True,True,False,False,False,
NCT02968680,Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma,Pilot Translational Study of Sonazoid-Enhanced Ultrasonography for Sentinel Lymph Node Mapping in Cutaneous Melanoma,Sonazoid,"['Contrast ultrasound microvascular perfusion imaging', 'Sonazoid']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Cutaneous Melanoma,"['Cutaneous Melanoma', 'Melanoma']",[],TERMINATED,Insufficient accrual,2017-04-26,2020-01-09,"[{'measure': 'Percent of patients with SLN identified by sonazoid-US alone or both sonazoid-US and conventional methods', 'description': 'Analyzed using descriptive comparison.', 'timeFrame': 'Up to 1 year'}]",[],1,19 Years,,ALL,False,University of Southern California,OTHER,1,5.0,ACTUAL,2025-09-01T16:18:20.959944,v2_robust,True,True,False,True,False,Insufficient accrual
NCT00535379,"SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme","SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-arm Phase II Clinical Trial Including Ranslational Research Studies",Sunitinib,"['SUTENT', 'Sunitinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Glioblastoma Multiforme,['Glioblastoma Multiforme'],"['glioblastoma multiforme', 'sunitinib', 'recurrent', 'progressive']",UNKNOWN,,2007-10,2011-01,"[{'measure': 'Progression-free survival rate at 6 months', 'timeFrame': '6 months after tumor progression'}, {'measure': 'Median time to tumor progression', 'timeFrame': 'Time to tumor progression'}]","[{'measure': 'Overall survival', 'timeFrame': 'Time from study inclusion to death'}, {'measure': 'Overall survival rate at 12 months', 'timeFrame': '12 months after tumor progression'}]",4,18 Years,,ALL,False,Medical University Innsbruck,OTHER,1,70.0,ESTIMATED,2025-09-01T16:18:20.960350,v2_robust,True,True,False,False,False,
NCT00389779,DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension,"A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo (Protocol DAR-312)",Darusentan,"['Darusentan Placebo', 'LU 135252', 'Guanfacine', 'Darusentan']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypertension,['Hypertension'],[],COMPLETED,,2006-09,2009-08,"[{'measure': 'Change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry', 'timeFrame': 'Baseline to Week 14'}]","[{'measure': 'Percentage of subjects reaching systolic blood pressure goal after 14 weeks of treatment', 'timeFrame': 'Week 14'}, {'measure': 'Change from baseline in mean 24-hour systolic and diastolic blood pressure measured by ambulatory blood pressure monitoring (ABPM)', 'timeFrame': 'Baseline to Week 14'}, {'measure': 'Change from baseline in estimated glomerular filtration rate (eGFR)', 'timeFrame': 'Baseline to Week 14'}]",4,35 Years,80 Years,ALL,False,Gilead Sciences,INDUSTRY,0,849.0,ACTUAL,2025-09-01T16:18:20.960393,v2_robust,True,True,True,False,False,
NCT03105479,Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD),"A Prospective, Multicenter Study to Investigate the Pharmacokinetics, Safety, and Efficacy of Cadazolid Versus Vancomycin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea",Cadazolid,"['ACT-179811', 'Cadazolid', 'Vancomycin capsule', 'Vancomycin solution']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Clostridium Difficile Infection,['Clostridium Difficile Infection'],"['vancomycin', 'children', 'cadazolid', 'clostridium difficile associated diarrhea']",TERMINATED,"Study suspended in October 2017 and terminated April 17, 2018 after decision to discontinue the study drug development",2017-04-14,2018-04-17,"[{'measure': 'Clinical Cure Rate During Part B', 'description': 'This is the percentage of participants in part B reported as with a clinical cure. Clinical Cure is defined as: • \\<3 unformed bowel movement (UBM) per day (or no water diarrhea if subjects \\< 2 years of age), for at least 2 consecutive days between first dose of study treatment up to end of treatment (EOT) (inclusive) AND • Subject remains well up to EOT + 2 days (inclusive) based on investigator judgment AND • No need for additional antimicrobial treatment active against Clostridium difficile-associated diarrhea (CDAD) between first dose of study treatment up to EOT + 2 days (inclusive). percentage of subjects with a clinical cure', 'timeFrame': 'Day 10 (End of Treatment) + 2 days'}, {'measure': 'Maximal Plasma Concentration (Cmax) of Cadazolid During Part A', 'description': 'Blood samples are collected at different timepoints on Day 10 for the determination of cadazolid Cmax after 10 days of treatment.', 'timeFrame': 'Day 10 (End of Treatment)'}, {'measure': 'Time to Reach Cmax (Tmax) of Cadazolid During Part A', 'description': 'Blood samples are collected at different timepoints to determine the time when the maximal plasma concentration of cadazolid is reached.', 'timeFrame': 'Day 10 (End of Treatment)'}, {'measure': 'Area Under the Plasma Concentration Time Curve (AUC) of Cadazolid During Part A', 'description': 'Blood samples are collected at different timepoints for the determination of the cadazolid AUC over one dosing interval (0-12h) on Day 10.', 'timeFrame': 'Day 10 (End of Treatment)'}, {'measure': 'Fecal Concentrations of Cadazolid During Part A', 'description': 'A fecal sample is collected as the end-of-treatment visit in all participants in Part A.', 'timeFrame': 'Day 10 (End of Treatment)'}]","[{'measure': 'Clinical Cure Rate During Part A', 'description': 'This is the percentage of participants in Part A reported as with a clinical cure. Clinical Cure is defined as: • \\<3 unformed bowel movement (UBM) per day (or no water diarrhea if subjects \\< 2 years of age), for at least 2 consecutive days between first dose of study treatment up to end of treatment (EOT) (inclusive) AND • Subject remains well up to EOT + 2 days (inclusive) based on investigator judgment AND • No need for additional antimicrobial treatment active against Clostridium difficile-associated diarrhea (CDAD) between first dose of study treatment up to EOT + 2 days (inclusive).', 'timeFrame': 'Day 10 (End of Treatment) + 2 days'}, {'measure': 'Sustained Clinical Cure Rate During Part A and Part B', 'description': 'This is the percentage of participants in Parts A and B reported as with sustained clinical cure. Sustained clinical cure is defined as • Clinical Cure and no Recurrence until 30 days after the last study drug intake (end of study).', 'timeFrame': 'Day 40 (on average)'}, {'measure': 'Recurrence Rate During Part A and Part B', 'description': 'This is the percentage of participants in Parts A and B assessed as having a recurrence out of subjects meeting the criteria for Clinical Cure. Recurrence is defined as: • Clinical Cure AND New episode of diarrhea with ≥ 3 UBMs (or watery diarrhea if subject \\< 2 years) on any day between EOT + 3 days and end of study AND • Stool test showing positive C. difficile (as defined in Inclusion Criterion 4), AND •Antimicrobial treatment active against CDAD started between EOT + 3 days and end of study.', 'timeFrame': 'Day 40 (on average)'}, {'measure': 'Time to Recurrence in Part B', 'description': 'This it the time (in days) elapsed between the last dose of study drug and the onset day of new episode of diarrhea reported as Kaplan-Meier estimates (KM estimates)', 'timeFrame': 'Day 40 (on average)'}, {'measure': 'Time to Resolution of Diarrhea in Part B', 'description': 'This is the time (in days) elapsed between the first dose of study treatment and the resolution of diarrhea and reported as Kaplan-Meier estimates (KM estimates). The date of resolution of Diarrhea (ROD) is defined as the date of the first day of the 2 consecutive days on treatment with \\< 3 UBM (or no watery diarrhea for subjects \\< 2 years of age). Time to ROD is the time (in days) elapsed between the first dose of study treatment and the ROD', 'timeFrame': 'Day 10'}, {'measure': 'Adverse Events Leading to Premature Discontinuation of Study Treatment', 'description': 'Number of participants who prematurely discontinued the study treatment due to an adverse event', 'timeFrame': 'Up to Day 10'}, {'measure': 'Marked Abnormalities in Clinical Laboratory Parameters', 'description': 'Number of participants with any marked abnormalities in laboratory parameters up to 7 days after end of treatment', 'timeFrame': 'Day 17 (on average)'}, {'measure': 'Marked Abnormalities in Vital Signs', 'description': 'Number of subjects with any treatment-emergent abnormalities in vital signs (up to 7 days after end of treatment)', 'timeFrame': 'Day 17 (on average)'}, {'measure': 'Treatment-emergent Adverse Events (TEAES)', 'description': 'Number of subjects with any TEAEs. A TEAE is any adverse event temporally associated with the use of study treatment (from study treatment initiation until 7 days after study treatment discontinuation) whether or not considered by the investigator as related to study treatment.', 'timeFrame': 'Day 17 (on average)'}]",14,,18 Years,ALL,False,Actelion,INDUSTRY,0,1.0,ACTUAL,2025-09-01T16:18:20.960411,v2_robust,True,True,False,True,True,"Study suspended in October 2017 and terminated April 17, 2018 after decision to discontinue the study drug development"
NCT00020579,MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma,"A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas",entinostat,['entinostat'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Cancer,['Cancer'],"['stage IV cutaneous T-cell non-Hodgkin lymphoma', 'recurrent cutaneous T-cell non-Hodgkin lymphoma', 'small intestine lymphoma', 'stage IV grade 1 follicular lymphoma', 'stage IV grade 2 follicular lymphoma', 'stage IV grade 3 follicular lymphoma', 'stage IV adult diffuse small cleaved cell lymphoma', 'stage IV adult diffuse mixed cell lymphoma', 'stage IV adult diffuse large cell lymphoma', 'stage IV adult immunoblastic large cell lymphoma', 'stage IV adult lymphoblastic lymphoma', 'stage IV adult Burkitt lymphoma', 'recurrent grade 1 follicular lymphoma', 'recurrent grade 2 follicular lymphoma', 'recurrent grade 3 follicular lymphoma', 'recurrent adult diffuse small cleaved cell lymphoma', 'recurrent adult diffuse mixed cell lymphoma', 'recurrent adult diffuse large cell lymphoma', 'recurrent adult immunoblastic large cell lymphoma', 'recurrent adult lymphoblastic lymphoma', 'recurrent adult Burkitt lymphoma', 'stage IV adult T-cell leukemia/lymphoma', 'recurrent adult T-cell leukemia/lymphoma', 'primary central nervous system non-Hodgkin lymphoma', 'intraocular lymphoma', 'stage IV mantle cell lymphoma', 'recurrent mantle cell lymphoma', 'angioimmunoblastic T-cell lymphoma', 'anaplastic large cell lymphoma', 'stage IV mycosis fungoides/Sezary syndrome', 'recurrent mycosis fungoides/Sezary syndrome', 'recurrent marginal zone lymphoma', 'recurrent small lymphocytic lymphoma', 'stage IV small lymphocytic lymphoma', 'stage IV marginal zone lymphoma', 'extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue', 'nodal marginal zone B-cell lymphoma', 'splenic marginal zone lymphoma', 'male breast cancer', 'stage IIIA breast cancer', 'stage IIIB breast cancer', 'stage IIIC breast cancer', 'stage IV breast cancer', 'recurrent pancreatic cancer', 'stage III pancreatic cancer', 'recurrent colon cancer', 'stage III colon cancer', 'stage IV colon cancer', 'recurrent rectal cancer', 'stage III rectal cancer', 'stage IV rectal cancer', 'recurrent ovarian epithelial cancer', 'recurrent ovarian germ cell tumor', 'stage III ovarian epithelial cancer', 'stage III ovarian germ cell tumor', 'stage IV ovarian epithelial cancer', 'stage IV ovarian germ cell tumor', 'recurrent malignant testicular germ cell tumor', 'stage III malignant testicular germ cell tumor', 'recurrent cervical cancer', 'stage III cervical cancer', 'stage IVA cervical cancer', 'stage IVB cervical cancer', 'recurrent endometrial carcinoma', 'stage III endometrial carcinoma', 'stage IV endometrial carcinoma', 'fallopian tube cancer', 'primary peritoneal cavity cancer', 'recurrent uterine sarcoma', 'stage III uterine sarcoma', 'stage IV uterine sarcoma', 'recurrent vaginal cancer', 'stage III vaginal cancer', 'stage IVA vaginal cancer', 'stage IVB vaginal cancer', 'recurrent vulvar cancer', 'stage III vulvar cancer', 'stage IV vulvar cancer', 'recurrent anal cancer', 'stage IIIA anal cancer', 'stage IIIB anal cancer', 'stage IV anal cancer', 'recurrent esophageal cancer', 'stage III esophageal cancer', 'stage IV esophageal cancer', 'recurrent gastric cancer', 'stage III gastric cancer', 'stage IV gastric cancer', 'recurrent extrahepatic bile duct cancer', 'unresectable extrahepatic bile duct cancer', 'advanced adult primary liver cancer', 'localized unresectable adult primary liver cancer', 'recurrent adult primary liver cancer', 'recurrent squamous cell carcinoma of the larynx', 'recurrent verrucous carcinoma of the larynx', 'stage III squamous cell carcinoma of the larynx', 'stage III verrucous carcinoma of the larynx', 'stage IV squamous cell carcinoma of the larynx', 'stage IV verrucous carcinoma of the larynx', 'recurrent basal cell carcinoma of the lip', 'recurrent squamous cell carcinoma of the lip and oral cavity', 'stage III basal cell carcinoma of the lip', 'stage III squamous cell carcinoma of the lip and oral cavity', 'stage IV basal cell carcinoma of the lip', 'stage IV squamous cell carcinoma of the lip and oral cavity', 'recurrent lymphoepithelioma of the oropharynx', 'recurrent squamous cell carcinoma of the oropharynx', 'stage III lymphoepithelioma of the oropharynx', 'stage III squamous cell carcinoma of the oropharynx', 'stage IV lymphoepithelioma of the oropharynx', 'stage IV squamous cell carcinoma of the oropharynx', 'recurrent lymphoepithelioma of the nasopharynx', 'recurrent squamous cell carcinoma of the nasopharynx', 'stage III lymphoepithelioma of the nasopharynx', 'stage III squamous cell carcinoma of the nasopharynx', 'stage IV lymphoepithelioma of the nasopharynx', 'stage IV squamous cell carcinoma of the nasopharynx', 'recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity', 'recurrent inverted papilloma of the paranasal sinus and nasal cavity', 'recurrent midline lethal granuloma of the paranasal sinus and nasal cavity', 'recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity', 'stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity', 'stage III inverted papilloma of the paranasal sinus and nasal cavity', 'stage III midline lethal granuloma of the paranasal sinus and nasal cavity', 'stage III squamous cell carcinoma of the paranasal sinus and nasal cavity', 'stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity', 'stage IV inverted papilloma of the paranasal sinus and nasal cavity', 'stage IV midline lethal granuloma of the paranasal sinus and nasal cavity', 'stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity', 'metastatic parathyroid cancer', 'recurrent parathyroid cancer', 'recurrent salivary gland cancer', 'stage III salivary gland cancer', 'stage IV salivary gland cancer', 'recurrent bladder cancer', 'recurrent gallbladder cancer', 'stage III bladder cancer', 'stage IV bladder cancer', 'unresectable gallbladder cancer', 'recurrent renal cell cancer', 'stage III renal cell cancer', 'stage IV renal cell cancer', 'stage III Wilms tumor', 'stage IV Wilms tumor', 'stage V Wilms tumor', 'metastatic transitional cell cancer of the renal pelvis and ureter', 'recurrent transitional cell cancer of the renal pelvis and ureter', 'regional transitional cell cancer of the renal pelvis and ureter', 'anterior urethral cancer', 'posterior urethral cancer', 'recurrent urethral cancer', 'recurrent penile cancer', 'stage III penile cancer', 'stage IV penile cancer', 'recurrent prostate cancer', 'stage III prostate cancer', 'stage IV prostate cancer', 'metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor', 'recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor', 'metastatic osteosarcoma', 'recurrent osteosarcoma', 'recurrent adult soft tissue sarcoma', 'stage III adult soft tissue sarcoma', 'stage IV adult soft tissue sarcoma', 'classic Kaposi sarcoma', 'AIDS-related Kaposi sarcoma', 'recurrent Kaposi sarcoma', 'stage III cutaneous T-cell non-Hodgkin lymphoma', 'ciliary body and choroid melanoma, medium/large size', 'ciliary body and choroid melanoma, small size', 'extraocular extension melanoma', 'iris melanoma', 'recurrent intraocular melanoma', 'recurrent melanoma', 'stage III melanoma', 'stage IV melanoma', 'extensive stage small cell lung cancer', 'recurrent non-small cell lung cancer', 'recurrent small cell lung cancer', 'stage IIIA non-small cell lung cancer', 'stage IIIB non-small cell lung cancer', 'stage IV non-small cell lung cancer', 'recurrent thymoma and thymic carcinoma', 'advanced malignant mesothelioma', 'recurrent malignant mesothelioma', 'recurrent adrenocortical carcinoma', 'stage III adrenocortical carcinoma', 'stage IV adrenocortical carcinoma', 'metastatic gastrointestinal carcinoid tumor', 'recurrent gastrointestinal carcinoid tumor', 'regional gastrointestinal carcinoid tumor', 'desmoid tumor', 'newly diagnosed carcinoma of unknown primary', 'recurrent carcinoma of unknown primary', 'undifferentiated carcinoma of unknown primary', 'carcinoma of the appendix', 'recurrent metastatic squamous neck cancer with occult primary', 'untreated metastatic squamous neck cancer with occult primary', 'recurrent pituitary tumor', 'adult anaplastic astrocytoma', 'adult astrocytic tumors', 'adult diffuse astrocytoma', 'adult pilocytic astrocytoma', 'adult anaplastic oligodendroglioma', 'adult brain stem glioma', 'adult oligodendroglioma', 'adult mixed glioma', 'adult central nervous system germ cell tumor', 'adult choroid plexus tumor', 'adult craniopharyngioma', 'adult anaplastic ependymoma', 'adult subependymoma', 'adult medulloblastoma', 'adult supratentorial primitive neuroectodermal tumor (PNET)', 'adult ependymoblastoma', 'adult ependymoma', 'adult myxopapillary ependymoma', 'adult anaplastic meningioma', 'adult meningeal hemangiopericytoma', 'adult meningioma', 'adult papillary meningioma', 'adult grade I meningioma', 'adult grade II meningioma', 'adult grade III meningioma', 'adult pineal parenchymal tumor', 'recurrent adult brain tumor', 'stage IV pancreatic cancer', 'stage III thymoma', 'stage IVA thymoma', 'stage IVB thymoma']",COMPLETED,,2001-03,2008-10,"[{'measure': 'Dose-limiting toxicities and maximum tolerated dose'}, {'measure': 'Pharmacology and pharmacokinetics'}]","[{'measure': 'Acetylation of histones in peripheral blood'}, {'measure': 'Tumor response by CT scan every 12 weeks'}]",4,18 Years,,ALL,False,National Institutes of Health Clinical Center (CC),NIH,1,75.0,ESTIMATED,2025-09-01T16:18:20.960487,v2_robust,True,True,True,False,False,
NCT00435279,A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia,"A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-existing Insomnia",Eszopiclone,"['Eszopiclone', 'Effexor', 'Venlafaxine', 'Placebo', 'Lunesta']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Major Depressive Disorder,"['Major Depressive Disorder', 'Insomnia']","['Insomnia', 'Depression', 'Major Depressive Disorder']",COMPLETED,,2007-06,2009-07,"[{'measure': 'The primary endpoint is the change from baseline in HAM-D-17 total score at Week 8.', 'timeFrame': 'Week 8'}]","[{'measure': 'The key secondary endpoint is the change from baseline in the mean subjective Total Sleep Time (TST) during Week 1.', 'timeFrame': 'Week 1'}]",2,18 Years,64 Years,ALL,False,"Sumitomo Pharma America, Inc.",INDUSTRY,0,678.0,ACTUAL,2025-09-01T16:18:20.960498,v2_robust,True,True,True,False,False,
NCT01670279,Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder,"A Phase 1, Multicenter, Randomized, Double-blind, Sequential Cohort, Placebo-controlled Trial to Assess the Safety and Tolerability of Ascending Multiple Oral Doses of Brexpiprazole as Adjunctive Therapy in the Treatment of Elderly Subjects With Major Depressive Disorder",Brexpiprazole,"['Brexpiprazole', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Major Depressive Disorder,['Major Depressive Disorder'],['Major Depressive Disorder (MDD)'],COMPLETED,,2012-07,2013-05,"[{'measure': 'Number of Participants Who Tolerated Brexpiprazole', 'description': 'Safety and tolerability of brexpiprazole was noted to be primary outcome measure. Brexpiprazole was judged to be tolerated if at least 6 out of 8 (75%) of the participants in a test cohort tolerated the dose after 14 days of QD dosing at the end of the fixed dose phase based on the blinded data. Dose toleration was defined as follows: during the course of the trial, the participants did not experience any moderate or severe adverse events (AEs) or potentially clinically relevant changes from Baseline in laboratory values, vital signs, electrocardiogram (ECG) tracings, Columbia-Suicide Severity Rating Scale (C-SSRS), or extrapyramidal symptom (EPS) ratings, which were assessed as possibly related to the study drug, and would have warranted a dose decrease or discontinuation of the study drug. The safety and tolerability of brexpiprazole was defined by parameters: AEs, laboratory values, vital signs, ECG, C-SSRS, or EPS ratings, the results of each of the parameters reported separately.', 'timeFrame': '45 Days'}, {'measure': 'Number of AEs Reported.', 'description': 'The AEs were one of the primary parameters to measure the safety and tolerability of individual participants. The AEs were captured for all participants from the time the ICF was signed until the end of the trial. AEs were measured throughout the 14-day titration and 28-day fixed dose phase until follow-up (30 \\[±2\\] days after last dose of study medication).', 'timeFrame': 'Throughout the study, up to 119 days'}, {'measure': 'Incidence of Laboratory Values of Potential Clinical Significance', 'description': 'The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.', 'timeFrame': 'Titration Day 7, Fixed dose Day 14 and 28 and Last Visit'}, {'measure': 'Incidence of Vital Signs of Potential Clinical Significance', 'description': 'The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria.', 'timeFrame': 'Baseline, Titration Day 1, 2, 7, 8, Fixed Days 1, 2, 14, 15, 28, 29, Early Termination and Last Visit.'}, {'measure': 'Incidence of ECG Evaluations of Potential Clinical Significance', 'description': 'The measurement of ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, and QTcF that were identified based on pre-defined criteria.', 'timeFrame': 'Titratrion Day 1 and 7, Fixed dose Day 1, 14, 28, Early Termination'}, {'measure': 'Incidence of Physical Examination Evaluation of Potential Clinical Significance', 'description': 'The physical examination evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.', 'timeFrame': 'Physical examination was performed at Screening, check-in, and discharge'}, {'measure': 'Mean Change From Baseline to Study Completion in Simpson-Angus Scale (SAS) Total Score', 'description': 'EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40.', 'timeFrame': 'End of Titration, Day 15, Day 29, Early Termination and Last visit'}, {'measure': 'Mean Change From Baseline to Study Completion in Barnes Akathisia Global Score', 'description': 'EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The Barnes Akathisia Rating Scale was an EPS rating scale. The Barnes Akathisia Rating Scale was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia).', 'timeFrame': 'End of Titration, Day 15, Day 29, Early Termination and Last visit'}, {'measure': 'Mean Change From Baseline to Study Completion in Abnormal Involuntary Movement Scale (AIMS) Rating Score.', 'description': 'EPS was one of the primary parameters to measure the safety and tolerability of individual participants. The AIMS Scale was an EPS rating scale. The AIMS is a 12 item scale. The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28.', 'timeFrame': 'End of Titration, Day 15, Day 29, Early Termination and Last visit'}, {'measure': 'Change From Baseline to Study Completion in C-SSRS Score.', 'description': 'The C-SSRS was one of the primary parameters to measure the safety and tolerability of individual participants. Suicidality was monitored during the trial using the C-SSRS. This scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicide events and suicidal ideation and a post-baseline evaluation that focuses on suicidality since the last trial visit.', 'timeFrame': 'Baseline, End of Titration, Fixed dose Day 14 and 28, Day 15 and 29, Early Termination, Last Visit'}]",[],10,70 Years,85 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,1,18.0,ACTUAL,2025-09-01T16:18:20.960508,v2_robust,True,True,True,False,True,
NCT05796479,A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants,"A 2-part, Open Label, Phase 1 Study to Investigate the Pharmacokinetics, Safety and Tolerability of Two Different Amlitelimab Drug Products After Administration of a Single Subcutaneous Dose in Healthy Adult Participants",Amlitelimab DP1,"['Amlitelimab DP1', 'Amlitelimab DP2']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2022-04-28,2023-05-22,"[{'measure': 'Part 1: Maximum Plasma concentration observed (Cmax )', 'description': 'Cmax after administration of a single SC dose of amlitelimab DP 1', 'timeFrame': 'From Day1 up to Day92 (end of study [EOS])'}, {'measure': 'Part 1: Area under the curve from the time of dosing to the last measurable concentration (AUClast)', 'description': 'AUClast after administration of a single SC dose of amlitelimab DP 1', 'timeFrame': 'From Day1 up to Day92 (EOS)'}, {'measure': 'Part 1: Area under the plasma concentration versus time curve extrapolated to infinity (AUC)', 'description': 'AUC after administration of a single SC dose of amlitelimab DP 1', 'timeFrame': 'From Day1 up to Day92 (EOS)'}, {'measure': 'Part 2: Cmax of two different amlitelimab DPs (DP1 and DP2)', 'description': 'Cmax after administration of a single SC dose of amlitelimab DP 1 and DP2', 'timeFrame': 'From Day1 up to Day92 (EOS)'}, {'measure': 'Part 2: AUClast of two different amlitelimab DPs (DP1 and DP2)', 'description': 'AUClast after administration of a single SC dose of amlitelimab DP1 and DP 2', 'timeFrame': 'From Day1 up to Day92 (EOS)'}, {'measure': 'Part 2: AUC of two different amlitelimab DPs (DP1 and DP2)', 'description': 'AUC after administration of a single SC dose of amlitelimab DP1 and DP 2', 'timeFrame': 'From Day1 up to Day92 (EOS)'}]","[{'measure': 'Part 1 and Part 2: Incidence of adverse events (AE)/treatment-emergent adverse events (TEAEs)', 'description': 'Incidence of AEs and TEAEs after administration of amlitelimab will be reported.', 'timeFrame': 'From the signing of the informed consent form (ICF) up to Day92 EOS visit'}]",7,18 Years,55 Years,ALL,True,Sanofi,INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:20.960535,v2_robust,True,True,True,False,True,
NCT00950079,Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography,Preventive Strategies of REnal Insufficiency in Patients With Diabetes Undergoing InterVENTion or Arteriography(PREVENT Trial),Sodium bicarbonate,"['Sodium bicarbonate', 'saline']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Contrast Induced Nephropathy,['Contrast Induced Nephropathy'],"['sodium bicarbonate', 'diabetes mellitus', 'coronary angiography or intervention']",UNKNOWN,,2008-02,2010-01,"[{'measure': 'Incidence of contrast-induced nephropathy', 'timeFrame': '24 and 48 hours after angiography or intervention'}]","[{'measure': 'all-cause mortality', 'timeFrame': '30 days after index angiography'}, {'measure': 'stroke', 'timeFrame': '30 days after index angiography'}, {'measure': 'Dialysis', 'timeFrame': '30 days after index angiography'}, {'measure': 'Myocardial infarction', 'timeFrame': '30 days after index angiography'}, {'measure': 'all-cause mortality', 'timeFrame': '30 days to 6 months after index angiography'}, {'measure': 'stroke', 'timeFrame': '30 days to 6 months after index angiography'}, {'measure': 'dialysis', 'timeFrame': '30 days to 6 months after index angiography'}, {'measure': 'myocardial infarction', 'timeFrame': '30 days to 6 months after index angiography'}]",9,18 Years,,ALL,False,"CardioVascular Research Foundation, Korea",OTHER,0,368.0,ESTIMATED,2025-09-01T16:18:20.960555,v2_robust,True,True,False,False,False,
NCT03855579,Levosimendan Versus Milrinone in Off Pump CABG Surgery,Levosimendan Versus Milrinone to Support Hemodynamics During Off Pump Coronary Artery Bypass Grafting Surgery in Patients With Poor Ejection Fraction,Levosimendan,"['Milrinone', 'Levosimendan']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hemodynamics,['Hemodynamics'],"['Levosimendan', 'Milrinone', 'Off-pump', 'Coronary']",UNKNOWN,,2019-03-06,2019-09-10,"[{'measure': 'Mean blood pressure', 'timeFrame': 'Intraoperative'}, {'measure': 'Consumption of other inotropes', 'timeFrame': 'Intraoperative'}]",[],2,30 Years,80 Years,ALL,False,Assiut University,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:20.960570,v2_robust,True,True,False,False,False,
NCT06091579,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants","A Phase 1, Randomized, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Healthy Volunteers",Treprostinil Palmitil Inhalation Powder,"['INS1009', 'Treprostinil Palmitil Inhalation Powder', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2020-09-17,2021-01-12,"[{'measure': 'Parts A and B: Number of Participants who Experienced an Adverse Event (AE)', 'description': 'Safety and tolerability of single and multiple doses of treprostinil inhalation powder will be determined in healthy participants.', 'timeFrame': 'Up to Day 31 in Part A and Day 37 in Part B'}]","[{'measure': 'Parts A and B: Area Under the Plasma Concentration Versus Time Curve (AUC) of Treprostinil', 'description': 'Pharmacokinetics of treprostinil following a single and multiple doses will be assessed in healthy participants.', 'timeFrame': 'Part A: Predose and at multiple time points postdose up to Day 4; Part B: Predose and at multiple time points postdose up to Day 10'}, {'measure': 'Parts A and B: Area Under the Plasma Concentration Versus Time Curve (AUC) of Treprostinil Palmitil', 'description': 'Pharmacokinetics of treprostinil palmitil following a single and multiple doses will be assessed in healthy participants.', 'timeFrame': 'Part A: Predose and at multiple time points postdose up to Day 4; Part B: Predose and at multiple time points postdose up to Day 10'}]",3,18 Years,45 Years,ALL,True,Insmed Incorporated,INDUSTRY,0,42.0,ACTUAL,2025-09-01T16:18:20.960580,v2_robust,True,True,True,False,True,
NCT02836496,Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES),"Study 200622: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Adolescent and Adult Subjects With Severe Hypereosinophilic Syndrome",Mepolizumab 300 mg,"['Mepolizumab 300 mg', 'Placebo matching OCS capsules', 'Placebo matching mepolizumab', 'Active OCS capsules (5 mg prednisolone or prednisone)']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypereosinophilic Syndrome,['Hypereosinophilic Syndrome'],"['Safety', 'Mepolizumab', 'Hypereosinophilic syndrome', 'HES flare', 'Efficacy']",COMPLETED,,2017-03-07,2019-08-08,"[{'measure': 'Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study During the 32-Week Study Treatment Period', 'description': 'Percentage of participants who experienced \\>=1 HES flare during the 32-Week treatment period or who withdrew from the study has been presented. A HES flare is defined as a HES related clinical manifestation based on a physician-documented change in clinical signs or symptoms which resulted in need for an increase in the maintenance Oral Corticosteroid (OCS) dose by at least 10 mg per day for 5 days or an increase in or addition of any cytotoxic or immunosuppressive HES therapy. HES flare is also defined as receipt of two or more courses of blinded active OCS during the treatment period. Intent-to-treat (ITT) Population comprises of all randomized participants. This population was based on the treatment to which the participants were randomized. Any participant who received a treatment randomization number were considered to be randomized.', 'timeFrame': 'Up to Week 32'}]","[{'measure': 'Percentage of Participants Who Experienced a HES Flare or Who Withdrew From the Study During Week 20 Through Week 32', 'description': 'HES flare during Week 20 through Week 32 was defined as a HES flare starting or ongoing on or after the date of the Week 20 visit up to and including the date of the Week 32 visit. Percentage of participants who experienced \\>=1 HES flare during Week 20 through Week 32 or who withdrew from the study has been presented.', 'timeFrame': 'Week 20 to Week 32'}, {'measure': 'Time to First HES Flare', 'description': 'The time to first HES flare was calculated as (onset date of first HES flare minus date of first dose of study treatment) plus 1. Probability of first flare (by week 4, 8, 12, 16, 20, 24, 28, and 32) and corresponding 95% CI have been presented, calculated using the Kaplan-Meier method.', 'timeFrame': 'Weeks 4, 8, 12, 16, 20, 24, 28 and 32'}, {'measure': 'Number of HES Flares Per Participant Per Year', 'description': 'The rate of HES flares for each participant was calculated as the number of observed HES flares divided by the time (expressed in years) between randomization and either the week 32 visit date if available, or the study withdrawal date. Negative binomial generalized linear model including Baseline OCS dose, region, treatment and observed time (offset variable). Wilcoxon test stratified by Baseline OCS (0-\\<=20mg/day, \\>20mg/day prednisone or equivalent) and region. Adjusted mean and 95% CI rate/year has been presented.', 'timeFrame': 'Up to Week 32'}, {'measure': 'Number of Participants With Change From Baseline in Fatigue Severity Based on Brief Fatigue Inventory (BFI) in Item 3 (Worst Level of Fatigue During Past 24 Hours) at Week 32 by Category', 'description': 'The change from Baseline in fatigue severity (worst level of fatigue during past 24 hours) at Week 32 was calculated using the mean of the 7 daily assessments of BFI item 3 up to and including the date of the Week 32 visit as the Week 32 assessment, and the mean of the 7 daily assessments of BFI item 3 up to but not including the date of first dose of study treatment as the Baseline assessment. Wilcoxon Rank Sum test stratified by Baseline fatigue severity (""severe"" defined as BFI item 3\\>=7 and ""not severe"" defined as BFI item 3\\<7), Baseline OCS (0-\\<=20mg/day and \\>20mg/day prednisone or equivalent) and region. Participants with missing change from Baseline at Week 32 were included in the worst category (\\>=4 point increase).', 'timeFrame': 'Baseline (Week 0) and at Week 32'}]",5,12 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,108.0,ACTUAL,2025-09-01T16:18:20.960688,v2_robust,True,True,True,False,False,
NCT02523196,Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG),Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG),"HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)","['HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)', 'HQ-SHUNT']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Liver Disease,['Liver Disease'],"['Hepatic Venous Pressure Gradient (HVPG) testing', 'HepQuant-SHUNT', 'Liver Function']",COMPLETED,,2016-03,2017-02-23,"[{'measure': 'Results of HepQuant SHUNT Test: Elimination Rate (IV Phase 1 Only; Min-1)', 'description': 'Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG ≥6 mmHg) and without (HVPG \\<6 mmHg) portal hypertension.', 'timeFrame': 'Up to 90 minutes'}, {'measure': 'Results of HepQuant SHUNT Test: Systemic Clearance', 'description': 'Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG ≥6 mmHg) and without (HVPG \\<6 mmHg) portal hypertension. Systemic Clearance (13C-CA; ml min-1)', 'timeFrame': 'Up to 90 minutes'}, {'measure': 'Results of HepQuant SHUNT Test: Apparent Portal Clearance', 'description': 'Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG ≥6 mmHg) and without (HVPG \\<6 mmHg) portal hypertension.', 'timeFrame': 'Up to 90 minutes'}, {'measure': 'Results of HepQuant SHUNT Test: Systemic Hepatic Filtration Rate', 'description': 'Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG ≥6 mmHg) and without (HVPG \\<6 mmHg) portal hypertension.', 'timeFrame': 'Up to 90 minutes'}, {'measure': 'Results of HepQuant SHUNT Test: Portal Hepatic Filtration Rate', 'description': 'Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG ≥6 mmHg) and without (HVPG \\<6 mmHg) portal hypertension.', 'timeFrame': 'Up to 90 minutes'}, {'measure': 'Results of HepQuant SHUNT Test: SHUNT', 'description': 'Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG ≥6 mmHg) and without (HVPG \\<6 mmHg) portal hypertension.\n\nSHUNT% is The percent of the oral dose of cholate that escapes hepatic extraction', 'timeFrame': 'Up to 90 minutes'}, {'measure': 'Results of HepQuant SHUNT Test: DSI Score', 'description': 'Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG ≥6 mmHg) and without (HVPG \\<6 mmHg) portal hypertension.\n\nDSI range is from 0 to 50. 0 implies no disease; 50 implies severe end-stage disease.', 'timeFrame': 'Up to 90 minutes'}, {'measure': 'Results of HepQuant SHUNT Test: STAT', 'description': 'Compare HepQuant STAT test from HQ-SHUNT for defining patients with (HVPG ≥6 mmHg) and without (HVPG \\<6 mmHg) portal hypertension. HepQuant STAT is a simple ""drink and draw"" blood-based clearance test that quantifies hepatic impairment from early through late stages of disease.', 'timeFrame': '60 minutes'}]","[{'measure': 'Survey Patients on Their Experience of Having Both HQ-SHUNT and HVPG Procedures.', 'description': 'Overall experience and willingness to repeat 0-10 Scale 0 being no pain, 10 being severe pain 0 being no discomfort, 10 being severe discomfort 0 being no interference with daily life, 10 being unable to carry on activities 0 being very negative experience, 10 being very positive experience 0 being definitely not wanting to have the test again, 10 being very willing to have the test again', 'timeFrame': 'Immediately post HepQuant SHUNT test (Baseline up to Day 60)'}, {'measure': 'Hours for Test', 'description': 'Number of hours it took for subjects to complete each test', 'timeFrame': 'Baseline, up to Day 60'}]",10,18 Years,75 Years,ALL,False,"University of Colorado, Denver",OTHER,0,20.0,ACTUAL,2025-09-01T16:18:20.960729,v2_robust,True,True,True,False,False,
NCT00177996,Pharmacotherapy in Depression With Panic Spectrum,Pharmacotherapy in Depression With Panic Spectrum,sertraline hydrochloride,"['sertraline hydrochloride low versus high dose titration', 'sertraline hydrochloride']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Major Depression,['Major Depression'],"['depression', 'anxiety']",COMPLETED,,2001-10,2007-01,"[{'measure': 'Somatic Symptoms Scale (SSC)', 'description': 'Scale to evaluate somatic and panic like symptoms', 'timeFrame': '1 week'}]","[{'measure': 'Hamilton Rating Scale For Depression- 25 item (HRSD 25)', 'description': 'scale to evaluate depressive symptoms', 'timeFrame': '1 week'}, {'measure': 'Global Assessment of Functioning (GAF)', 'description': 'scale to evaluate ability to function', 'timeFrame': 'past week'}]",3,18 Years,60 Years,ALL,False,University of Pittsburgh,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:20.960794,v2_robust,True,True,True,False,False,
NCT02525796,Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism,Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism,eplerenone,"['eplerenone', 'Cinacalcet', 'amiloride', 'Placebo']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Primary Hyperparathyroidism,['Primary Hyperparathyroidism'],[],COMPLETED,,2016-01,2021-10-02,"[{'measure': 'Change in Parathyroid Hormone Levels', 'description': 'Change in circulating PTH levels before and after 4 weeks of double-blinded intervention when compared to placebo', 'timeFrame': 'Change in circulating PTH levels before and after 4 weeks of double-blinded monotherapy intervention when compared to placebo (PTH at 4 weeks minus PTH at baseline)'}]","[{'measure': 'Change in Calcium Levels', 'description': 'Change in serum calcium levels before and after intervention when compared to placebo', 'timeFrame': 'Change in serum calcium levels before and after 4 weeks of double-blinded monotherapy intervention when compared to placebo (calcium at 4 weeks minus calcium at baseline)'}]",2,18 Years,80 Years,ALL,False,Brigham and Women's Hospital,OTHER,0,69.0,ACTUAL,2025-09-01T16:18:20.960814,v2_robust,True,True,True,False,False,
NCT03915496,Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE MECHANISM OF ACTION OF ABROCITINIB MONOTHERAPY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS",PF-04965842 200 mg,"['PF-04965842 200 mg', 'Placebo', 'PF-04965842 100 mg']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Atopic Dermatitis,['Atopic Dermatitis'],"['atopic dermatitis', 'atopic eczema', 'eczema', 'JAK', 'janus kinase']",COMPLETED,,2020-06-18,2021-11-16,"[{'measure': 'Fold-Change From Baseline in Atopic Dermatitis Biomarkers in Lesional and Non-lesional Skin at Week 12', 'description': 'Mean fold-changes from baseline at Week 12 in the biomarkers for general inflammation (Matrix Metallopeptidase \\[MMP\\]12), hyperplasia (Keratin \\[KRT\\]16), Th2 immune response (C-C motif chemokine ligand \\[CCL\\]17, CCL18, CCL26), and Th22 immune response (S100 calcium binding protein A \\[S100A\\]8, S100A9, S100A12), in lesional (LS) and non-lesional (NL) skin tissues, respectively. Expression levels from RT-PCR are normalized to the housekeeping gene RPLP0 by negatively transforming the Ct values to -dCt.', 'timeFrame': 'Baseline, Week 12'}]","[{'measure': 'Fold-Change From Baseline in Cellular (T-cell and Dendritic Cell) Inflammation Markers at Week 12', 'description': 'Mean fold-changes from baseline in immunohistochemistry analysis in lesional skin endpoints at Week 12 are presented. Fold-changes are computed by obtaining the antilog of log2 fold-changes, retaining the sign for log2 fold-change.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Fold-Change From Baseline in Epidermal Hyperplasia Markers in Skin Biopsies and Skin Thickness at Week 12', 'description': 'Mean fold-changes from baseline in hyperplasia markers in skin biopsies at Week 12 are presented. Fold-changes are computed by obtaining the antilog of log2 fold-changes, retaining the sign for log2 fold-change.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Fold-Change From Baseline in Blood Biomarkers for Inflammation and Immune Response at Week 12', 'description': 'OLINK Proteomics Microassay was used to analyze biomarkers in serum to assess the effect of abrocitinib on the blood biomarkers. Mean fold-changes at Week 12 from baseline are listed. Baseline is defined as the last observation on or prior to day of first dose (Day 1).', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percent-Change From Baseline in T-cell Lymphocyte Subset Populations at Week 12', 'description': 'Mean percent changes from baseline at Week 12 in T-cell lymphocyte subset populations (CD3+ T cells, CD4+ T cells, CD8+ T cells, NK cells, B cells) are presented. Baseline is defined as the last observation on or prior to day of first dose (Day 1).', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Response Based on at Least 4 Points Improvement in the Severity of Peak Pruritus Numerical Rating Scale (NRS) From Baseline and Changes From Baseline in Immunohistochemistry (IHC) and Gene Expression Biomarkers in Lesional Skin', 'description': 'PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms ""no itch"" (0) and ""worst itch imaginable"" (10). Participants who withdrew from the study were counted as non-responder. Spearman correlation coefficient was calculated to assess the relationship between PP-NRS CFB and fold CFB of IHC and gene expression biomarkers.', 'timeFrame': 'Baseline, Week 12'}, {'measure': ""Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' or 'Almost Clear' and >=2 Points Improvement From Baseline at Week 2, 4, 8 and 12"", 'description': 'The IGA of AD is scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, and 12'}, {'measure': 'Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline Week 2, 4, 8 and 12', 'description': 'The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.', 'timeFrame': 'Baseline, Week 2, 4, 8, and 12'}, {'measure': 'Percentage of Participants With >=4 Points at Baseline and Achieving >=4 Points Improvement From Baseline in Numeric Rating Scale for Severity of Pruritus (PP-NRS) at Weeks 2, 4, 8 and 12', 'description': 'PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms ""no itch"" (0) and ""worst itch imaginable"" (10). Higher scores indicated worse itch. Participants who withdrew from the study were counted as non-responder.', 'timeFrame': 'Baseline, Week 2, 4, 8, 12'}, {'measure': 'Percentage of Participants Achieving EASI Response ≥ 90% Improvement From Baseline at Week 2, 4, 8 and 12', 'description': 'The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.', 'timeFrame': 'Baseline to Week 2, 4, 8 and 12'}, {'measure': 'Percentage of Participants Achieving EASI Response ≥ 50% Improvement From Baseline at Week 2, 4, 8 and 12', 'description': 'The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.', 'timeFrame': 'Baseline to Week 2, 4, 8 and 12'}, {'measure': 'Percent Change From Baseline in Percentage Body Surface Area (BSA) at Week 2, 4, 8 and 12', 'description': 'BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.', 'timeFrame': 'Baseline and Week 2, 4, 8 and 12'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'description': 'An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.', 'timeFrame': 'Baseline to 16 weeks'}, {'measure': 'Number of Participants With Serious Adverse Events (SAEs)', 'description': 'A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.', 'timeFrame': 'Baseline to 16 weeks'}, {'measure': 'Number of Participants Who Discontinued From the Study Due to TEAEs', 'description': 'An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.', 'timeFrame': 'Baseline to 16 weeks'}, {'measure': 'Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)', 'description': 'Laboratory tests included hematology (including coagulation panel), clinical chemistry, lipid profile panel, and routine urinalysis. LLN is lower limit of normal. ULN is upper limit of normal.', 'timeFrame': 'Baseline to 16 weeks'}]",16,18 Years,,ALL,False,Pfizer,INDUSTRY,0,46.0,ACTUAL,2025-09-01T16:18:20.960860,v2_robust,True,True,True,False,True,
NCT00109096,Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy,"A Randomized, Double-Blind Phase 2 Study of Two Doses of Pemetrexed in the Treatment of Platinum-Resistant, Epithelial Ovarian or Primary Peritoneal Cancer",Pemetrexed,['Pemetrexed'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Neoplasms,"['Ovarian Neoplasms', 'Primary Peritoneal Cancer']",[],COMPLETED,,2005-06,2007-03,"[{'measure': 'To assess the anti-tumor activity, as measured by tumor response rate (proportion of patients with complete or partial response, of 500 mg/m2 vs. 900 mg/m2 of pemetrexed therapy administered every 21 days'}]","[{'measure': 'Time to response'}, {'measure': 'Duration of response'}, {'measure': 'Time to objective progressive disease (TtPD)'}, {'measure': 'Time to treatment failure (TtTF)'}, {'measure': 'Objective PFS'}, {'measure': 'OS'}, {'measure': 'To assess safety and toxicity profile of two doses of pemetrexed in patients with ovarian cancer'}]",8,18 Years,,FEMALE,False,Eli Lilly and Company,INDUSTRY,0,100.0,ESTIMATED,2025-09-01T16:18:20.960946,v2_robust,True,True,True,False,True,
NCT06173596,"A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults","A Phase 1 Study to Evaluate the Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole, and Carbamazepine in Healthy Adult Participants",ALXN2080,"['Carbamazepine (AxMP)', 'ALXN2080', 'Itraconazole', 'Fluconazole (AxMP)']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['ALXN2080', 'itraconazole', 'Fluconazole', 'carbamazepine']",COMPLETED,,2024-01-10,2024-05-16,"[{'measure': 'Maximum Observed Plasma Concentration (Cmax) of ALXN2080', 'timeFrame': 'Day 1 up to Day 24'}, {'measure': 'Area Under the Curve From Time 0 to the Time of Last Measurable Concentration (AUC0-last) of ALXN2080', 'timeFrame': 'Day 1 up to Day 24'}]","[{'measure': 'Cmax of Itraconazole', 'timeFrame': 'Day 4 up to Day 6'}, {'measure': 'Area under the Curve for the Defined Interval Between Doses AUC(tau) of Itraconazole', 'timeFrame': 'Day 4 up to Day 6'}, {'measure': 'Cmax of Fluconazole', 'timeFrame': 'Day 2 up to Day 5'}, {'measure': 'AUC(tau) of Fluconazole', 'timeFrame': 'Day 2 up to Day 5'}, {'measure': 'Cmax of Carbamazepine', 'timeFrame': 'Day 2 up to Day 20'}, {'measure': 'AUC(tau) of Carbamazepine', 'timeFrame': 'Day 2 up to Day 20'}, {'measure': 'Number of Participants with Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'Baseline up to Day 34'}]",9,18 Years,55 Years,ALL,True,"Alexion Pharmaceuticals, Inc.",INDUSTRY,0,60.0,ACTUAL,2025-09-01T16:18:20.960972,v2_robust,True,True,True,False,True,
NCT02222896,Preoperative Chlorhexidine Gluconate (CHG) Cloth on Healthy Subjects,Assessment of the Antimicrobial Efficacy of 2% CHG Cloth Preoperative Skin Preparation,Chlorhexidine Gluconate,"['CHG', 'CHG 2%', 'Chlorhexidine Gluconate', 'DynaHex-2']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Surgery,['Surgery'],['Preoperative surgical skin preparation'],COMPLETED,,2014-08,2015-05,"[{'measure': 'Percent Responder Rates (%) of Bacterial Reduction on the Abdomen and Groin', 'description': 'Percent of abdomen and groin sites that showed response (achieve a 2-Log and 3-Log reduction) respectively of bacterial flora from baseline.\n\nNote: the number of participants in each treatment group (abdomen and/or groin) can vary depending on whether participants achieved qualifying microbial levels.', 'timeFrame': '10 minutes, 6 hours, 8 hours'}]",[],1,16 Years,,ALL,True,Medline Industries,INDUSTRY,0,347.0,ACTUAL,2025-09-01T16:18:20.960989,v2_robust,True,True,True,False,False,
NCT05507996,Recombinant Adeno-associated Virus Administration for Patients With Menkes Syndrome,An Investigator-initiated Trial Evaluating the Efficacy and Safety of Recombinant Adeno-associated Virus Administration in Patients With Menkes Syndrome,Recombinant adeno-associated virus administration,['Recombinant adeno-associated virus administration'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Menkes Syndrome,['Menkes Syndrome'],"['gene therpy', 'adeno-associated virus']",TERMINATED,The PI decides to stop.,2022-08-18,2022-11-23,"[{'measure': 'Monitoring the disease course or vital signs to assess the efficacy of the investigational medical product', 'description': 'Based on studies of the natural history of Menkes syndrome, which shows that patients have a life span of fewer than three years, this study will evaluate the endpoint of life of patients with the investigational medical product infusion. The endpoint of life is defined as death or the need for ventilatory support (device dependence of at least 16 hours per day for more than 14 days).', 'timeFrame': 'Up to the end of life after infusion or 12 months after the age of 3 years'}, {'measure': 'Incidence of adverse events(AE) after the investigational medical product infusion', 'description': 'The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included. Description, time, classification, and outcome of AE events resulted from the investigational medical product, delivery method, or emergency measures will be recorded in the case report form.', 'timeFrame': 'Up to 12 months after the investigational medical product infusion'}]","[{'measure': 'Developmental behavior assessment', 'description': ""CHOP INTEND was developed to be used on children from 3 months to over four years, although it is not limited to this age range. It was developed by looking at babies with SMA Type 1 and infants with other similar conditions, such as Menkes syndrome. There are 16 parts, and the scale scores infants on how well they can perform certain movements or what the physiotherapist sees while watching the child. Each one is scored from 0 to 4, with 0 being no response/ability to perform the movement and 4 being 'complete response' (being able to perform the task). The total possible score is 64.\n\nThe Developmental Behavior Scale for Children aged 0-6 years (WS/T 580-2017) released by the Ministry of Health of China is used to monitor and evaluate the development improvement of patients in gross motor, fine motor, language, adaptive ability, and social behavior. The scale applies to children aged 0-6 years, with 8-10 test items in each group, totaling 261."", 'timeFrame': 'At baseline and 3, 6, 9, 12 months after infusion'}, {'measure': 'Weight', 'description': 'Record weight of patients in kilograms', 'timeFrame': 'At baseline and 3, 6, 9, 12 months after infusion'}, {'measure': 'Height', 'description': 'Record height of patients in meters', 'timeFrame': 'At baseline and 3, 6, 9, 12 months after infusion'}, {'measure': 'Head circumference', 'description': 'Record head circumference of patients in centimeters', 'timeFrame': 'At baseline and 3, 6, 9, 12 months after infusion'}]",6,,,ALL,False,Kunming Hope of Health Hospital,OTHER,0,1.0,ACTUAL,2025-09-01T16:18:20.961120,v2_robust,True,True,False,True,True,The PI decides to stop.
NCT05587296,"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Induced by Adjuvant Endocrine Therapy, Over 52 Weeks and Optionally for an Additional up to 2.5 Years in Women With Hormone-receptor Positive Breast Cancer:",Elinzanetant (BAY3427080),"['Elinzanetant (BAY3427080)', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","['Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer', 'Hot Flashes']",[],ACTIVE_NOT_RECRUITING,,2022-10-14,2027-06-25,"[{'measure': 'Mean change in frequency of moderate to severe hot flash (HF) from baseline to Week 4 (assessed by hot flash daily diary [HFDD])', 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Mean change in frequency of moderate to severe HF from baseline to Week 12 (assessed by HFDD)', 'timeFrame': 'Baseline to Week 12'}]","[{'measure': 'Mean change in severity of moderate to severe HF from baseline to Week 4 (assessed by HFDD).', 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Mean change in severity of moderate to severe HF from baseline to Week 12 (assessed by HFDD)', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Mean change in frequency of moderate to severe HF from baseline to Week 1 (assessed by HFDD)', 'timeFrame': 'Baseline to Week 1'}, {'measure': 'Mean change in frequency of moderate to severe HF from baseline over time (assessed by HFDD)', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Mean change in patient-reported outcomes measurement information system sleep disturbance short form 8b (PROMIS SD SF 8b) total score from baseline to Week 12', 'description': 'The PROMIS SD SF 8b includes 8 items assessing sleep disturbance over the past 7 days. Items assess sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Participants respond to the items on a 5-point scale from not at all, never or very poor to very much, always or very good. Four of the items are scored reversely. Total scores range from 8 to 40, with higher scores indicating greater severity of sleep disturbance', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Mean change in menopause specific quality of life scale (MENQOL) total score from baseline to Week 12', 'description': ""The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: VMS, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicates if they have experienced the symptom (yes/no). If participants select yes, participants rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother."", 'timeFrame': 'Baseline to Week 12'}]",8,18 Years,70 Years,FEMALE,False,Bayer,INDUSTRY,0,473.0,ACTUAL,2025-09-01T16:18:20.961135,v2_robust,True,True,False,False,False,
NCT00006262,Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer,A Phase 2 Study of BMY-27557-14 (a Rebeccamycin Analog) in Patients With Ovarian Cancer,becatecarin,['becatecarin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Cancer,['Ovarian Cancer'],"['stage III ovarian epithelial cancer', 'stage IV ovarian epithelial cancer', 'recurrent ovarian epithelial cancer']",TERMINATED,Unable to accrue patients to the study.,2000-07,2001-09,[],[],0,21 Years,,FEMALE,False,Northwestern University,OTHER,1,,,2025-09-01T16:18:20.961271,v2_robust,True,True,False,True,False,Unable to accrue patients to the study.
NCT03468062,The Effect of Dexmedetomidine on Postoperative Quality of Recovery,The Effect of Preoperative Intravenous Dexmedetomidine on Postoperative Quality of Recovery: Randomized Study,Dexmedetomidine,"['Dexmedetomidine', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,The Effect of Dexmedetomidine on Postoperative Quality of Recovery,['The Effect of Dexmedetomidine on Postoperative Quality of Recovery'],[],UNKNOWN,,2018-05-09,2019-08-31,"[{'measure': 'Quality of recovery questionnaire', 'description': 'The Quality of Recovery questionnaire (QoR-40) is a tool used to assess the quality of recovery after surgery through questions pertaining to 40 items related to 5 domains. It has been validated as a global and reliable measurement tool.', 'timeFrame': 'postoperative first day'}]",[],1,20 Years,75 Years,ALL,False,Kyungmi Kim,OTHER,0,90.0,ESTIMATED,2025-09-01T16:18:20.961278,v2_robust,True,True,False,False,False,
NCT02689362,Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2),"A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Clinical Trial for the Validation of Optimum Dose and Preliminary Evaluation of Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus",Evogliptin,"['Sitagliptin', 'Placebo Evogliptin', 'Placebo Sitagliptin', 'Evogliptin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",['Diabetes Mellitus Type 2'],COMPLETED,,2017-08-08,2018-08-09,"[{'measure': 'Absolute variation of the values obtained in the baseline for the HbA1c', 'timeFrame': '12 weeks after the start of the treatment'}]","[{'measure': 'Absolute variation of the values obtained in the baseline for the parameter, fasting blood glucose.', 'timeFrame': '12 weeks after the start of the treatment'}, {'measure': 'Absolute variation of the values obtained in the baseline for the parameter, body weight.', 'timeFrame': '12 weeks after the start of the treatment'}]",3,20 Years,75 Years,ALL,False,Eurofarma Laboratorios S.A.,INDUSTRY,0,146.0,ACTUAL,2025-09-01T16:18:20.961312,v2_robust,True,True,True,False,False,
NCT00598962,Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease,"Open, Noncomparative Trial of Multidrug Regimens Containing Azithromycin and Rifabutin Administered Three Times Per Week for the Treatment of M. Avium Complex (MAC) Lung Disease",Azithromycin,"['Zithromax', 'Azithromycin', 'mycobutin/', 'Rifabutin/rifampin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Mycobacterium Avium Complex,['Mycobacterium Avium Complex'],['MAC'],COMPLETED,,1994-12,2017-05-18,"[{'measure': 'Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures', 'description': 'neg cultures X3 ( sputum conversion)', 'timeFrame': '6 months'}]","[{'measure': 'Microbiological cultures', 'description': 'neg culture 1 yr on treatment', 'timeFrame': '1yr'}]",2,18 Years,,ALL,False,The University of Texas Health Science Center at Tyler,OTHER,1,58.0,ACTUAL,2025-09-01T16:18:20.961388,v2_robust,True,True,True,False,False,
NCT06966362,Varenicline for Smoking Reduction in Veterans Not Ready To Quit,Varenicline for Smoking Reduction in Veterans Unwilling to Quit,Motivation-Phase Varenicline,"['Chantix', 'Nicorette, Nicoderm', 'Motivation-Phase Varenicline', 'Nicorette', 'Cessation-Phase Varenicline', 'Motivation-Phase Nicotine Mini-Lozenge', 'Cessation-Phase Combination Nicotine Replacement Therapy (NRT)']",7,INTERVENTIONAL,['PHASE4'],PHASE4,,Veterans,"['Veterans', 'Tobacco Use Disorder', 'Cigarette Smoking', 'Tobacco Dependence']","['Varenicline', 'Tobacco use disorder', 'Veterans', 'Quit attempts', 'Cigarette smoking', 'Motivation phase treatment', 'Nicotine replacement therapy', 'Smoking reduction', 'Smoking abstinence']",NOT_YET_RECRUITING,,2025-12-01,2030-09-30,"[{'measure': 'Biochemically confirmed 7-day point-prevalence abstinence', 'description': 'Participants who report 7-day point-prevalence abstinence from cigarettes at the 12 month follow-up will mailed a saliva collection kit that will test cotinine and anabasine to validate self-reported abstinence from combusted tobacco.', 'timeFrame': '12 months post-study entry'}]","[{'measure': '7-day point prevalence abstinence', 'description': 'Participants who report 7-day point-prevalence abstinence from cigarettes at the 6 month follow-up will mailed a saliva collection kit that will test cotinine and anabasine to validate self-reported abstinence from combusted tobacco.', 'timeFrame': '6 months post-study entry'}, {'measure': 'Making a quit attempt lasting 24 hours', 'description': 'Making a quit attempt lasting at least 24 hours by 6 and 12 months; coded as binary (0 or 1).', 'timeFrame': '6 and 12 months post-study entry'}, {'measure': 'Cessation treatment entry', 'description': 'Entering cessation treatment; coded as binary (0 or 1)', 'timeFrame': '6 months post-study entry'}]",4,21 Years,,ALL,False,VA Office of Research and Development,FED,0,400.0,ESTIMATED,2025-09-01T16:18:20.961476,v2_robust,True,True,False,False,False,
NCT05792462,Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders,Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders,Baricitinib,['Baricitinib'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,NMO Spectrum Disorder,['NMO Spectrum Disorder'],[],RECRUITING,,2023-04-15,2025-12-30,"[{'measure': 'The number of attacks', 'description': 'An acute attack was defined as a new neurological worsening lasting for at least 24 hours and occurring more than 30 days after the previous attack', 'timeFrame': 'From baseline to one year after'}]","[{'measure': 'Changes in EDSS', 'description': 'The Expanded Disability Status Scale (EDSS) is a rating system that is frequently used for classifying and standardizing the severity and progression. EDSS ranges from 0 to 10.', 'timeFrame': 'Changes in EDSS from baseline to 52 weeks'}, {'measure': 'Changes in the number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Optic nerve,brain and spinal cord Magnetic Resonance Imaging (MRI)', 'description': 'The total number of new and/or enlarging T2 lesions for all participants was calculated as the sum of the individual number of lesions at Weeks 12, 24, and 52', 'timeFrame': 'From baseline to 52 weeks'}, {'measure': 'Changes in peripheral blood B cell subsets', 'description': 'Compare peripheral blood plasma cells before and one year after initial intervention', 'timeFrame': 'From baseline to 52 weeks'}, {'measure': 'Changes in serum AQP4 antibodies', 'description': 'Compare serum AQP4-ab titers before and one year after initial intervention', 'timeFrame': 'From baseline to 52 weeks'}, {'measure': 'Incidence of treatment-emergent adverse events [safety and tolerability]', 'description': 'Adverse events related to belimumab are recorded', 'timeFrame': 'From baseline to 52 weeks'}]",6,18 Years,85 Years,ALL,False,Tianjin Medical University General Hospital,OTHER,2,12.0,ESTIMATED,2025-09-01T16:18:20.961491,v2_robust,True,True,False,False,True,
NCT03240562,Ultrasound-guided Block for Thoracic Surgery Pain,Ultrasound-guided Serratus Anterior Plane Block for Thoracic Surgery Pain?,patient controlled analgesia,['patient controlled analgesia'],1,INTERVENTIONAL,['NA'],,,Postoperative Pain,"['Postoperative Pain', 'Thoracic Cancer']","['serratus anterior plane block', 'ultrasound-guided', 'regional anesthesia', 'thoracic surgery', 'postoperative pain']",COMPLETED,,2017-08-03,2017-12-30,"[{'measure': 'opioid consumption', 'description': 'the dose of PCA and residual opioid', 'timeFrame': 'the first 24hour in postoperative phase'}]","[{'measure': 'postoperative pain scale', 'description': 'numeric rating scale', 'timeFrame': 'intraoperative(immediately after surgery), postoperative 6 ,12, 24 hour'}, {'measure': 'opioid consumption', 'description': 'the dose of PCA and residual opioid', 'timeFrame': 'the first 6,12 hour in postoperative phase'}]",3,20 Years,80 Years,ALL,False,Samsung Medical Center,OTHER,0,89.0,ACTUAL,2025-09-01T16:18:20.961510,v2_robust,True,True,True,False,False,
NCT00600262,Intravitreal Bevacizumab for Diabetic Retinopathy,Efficacy of Intravitreal Bevacizumab for Severe Nonproliferative and Proliferative Diabetic Retinopathy.,intravitreal bevacizumab,['intravitreal bevacizumab'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Severe Nonproliferative,"['Severe Nonproliferative', 'Proliferative Diabetic Retinopathy', 'Active Photocoagulated Diabetic Retinopathy']","['severe nonproliferative', 'proliferative diabetic retinopathy', 'active photocoagulated diabetic retinopathy', 'intravitreal bevacizumab']",TERMINATED,Undefined,2005-12,2006-06,[],[],0,,,ALL,False,Asociación para Evitar la Ceguera en México,OTHER,0,,,2025-09-01T16:18:20.961566,v2_robust,True,True,False,True,False,Undefined
NCT05729646,Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma,"Perioperative S-1 Plus Oxaliplatin Combined With Toripalimab or Toripalimab Monotherapy Versus S-1 Plus Oxaliplatin for Treatment of dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Randomized Controlled Study",Toripalimab,"['Toripalimab', 'Oxaliplatin', 'S1']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Adenocarcinoma of the Stomach,"['Adenocarcinoma of the Stomach', 'Adenocarcinoma of Esophagogastric Junction', 'Mismatch Repair Deficiency']","['Gastric Adenocarcinoma', 'Esophagogastric Junction Adenocarcinoma', 'Perioperative Chemotherapy', 'Toripalimab']",RECRUITING,,2023-05-31,2029-02-28,"[{'measure': 'Rate of major pathological response (MPR)', 'description': 'Percentage of patients with MPR referring to the total number of patients with surgery, as evaluated centrally by a reference pathologist.', 'timeFrame': 'From enrollment to surgery after pre-operative treatment (up to approximately 36 months)'}]","[{'measure': 'Overall Survival', 'description': 'The duration of overall survival (OS) was defined as the time interval from randomization to the last follow-up or death from any cause.', 'timeFrame': 'From randomization to the last follow-up or death from any cause (up to approximately 72 months)'}, {'measure': 'Progression-free survival', 'description': 'Progression-free survival (PFS) was defined as the time from randomization to the last follow-up or the time of disease progression or relapse or death from any cause.', 'timeFrame': 'From randomization to the last follow-up or the time of disease progression or relapse or death from any cause (up to approximately 72 months)'}, {'measure': 'The incidences and types of adverse events (AE) and severe adverse events (SAE)', 'description': 'The incidences and severity of adverse events that occur during treatment will be evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.3', 'timeFrame': 'From enrollment to 90-day after the last dose administration (up to approximately 39 months)'}]",4,18 Years,80 Years,ALL,False,Yu jiren,OTHER,0,90.0,ESTIMATED,2025-09-01T16:18:20.961702,v2_robust,True,True,False,False,True,
NCT05327946,A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated,"An Open-label, Phase I Dose Escalation Followed by Dose Expansion Trial in Patients With Advanced Solid Tumours to Investigate Safety, Pharmacokinetics, and Efficacy and to Select the Dose for Further Development of BI 770371 in Combination With Ezabenlimab",BI 770371,"['ezabenlimab', 'BI 770371']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumors,['Solid Tumors'],[],ACTIVE_NOT_RECRUITING,,2022-05-17,2026-09-30,"[{'measure': 'Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period in monotherapy', 'timeFrame': '21 days'}, {'measure': 'Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period in combination therapy', 'timeFrame': '21 days'}]","[{'measure': 'Occurrence of Adverse Events (AEs) during the on-treatment period in monotherapy', 'timeFrame': 'up to 2 years'}, {'measure': 'Occurrence of Adverse Events (AEs) during the on-treatment period in combination therapy', 'timeFrame': 'up to 2 years'}, {'measure': 'Occurrence of Dose Limiting Toxicities (DLTs) during the on-treatment period in monotherapy', 'timeFrame': 'up to 2 years'}, {'measure': 'Occurrence of Dose Limiting Toxicities (DLTs) during the on-treatment period in combination therapy', 'timeFrame': 'up to 2 years'}]",6,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:20.961721,v2_robust,True,True,False,False,True,
NCT00603746,A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.,"A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily Compared With Placebo for 8 Weeks in Adolescent an",GW685698X,['GW685698X'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Asthma,['Asthma'],"['Adolescents', 'Adults', 'Asthma', 'Pharmacokinetics', 'Pharmacogenetics', 'GW685698X']",COMPLETED,,2007-12-01,2008-09-20,"[{'measure': 'Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8', 'description': 'Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcibly exhaled from the lungs in one second. Pre-dose and pre-rescue bronchodilator (albuterol/salbutamol) trough FEV1 (the measurement of FEV1 performed at the end of the dosing interval) was measured electronically by spirometry in the evening at the Baseline (BL) through Week 8 clinic visits. The highest of 3 technically acceptable measurements was recorded. The Visit 3 FEV1 assessment was used as the Baseline value. Change from Baseline in trough FEV1 was calculated as the value at Week 8 minus the value at Baseline. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline trough FEV1, country, sex, age, and treatment group.', 'timeFrame': 'Baseline and Week 8'}]","[{'measure': 'Mean Change From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Averaged Over the 8-week Treatment Period', 'description': 'PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is defined as the maximal rate (speed) that a person can exhale during a short maximal expiratory effort after a full inspiration. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. The best of three attempts was recorded by the participants in a daily diary. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily evening PEF over the 8-week treatment period minus the value at Baseline. The analysis was performed using an ANCOVA model with covariates of Baseline trough evening PEF, country, sex, age, and treatment group.', 'timeFrame': 'From Baseline up to Week 8'}, {'measure': 'Mean Change From Baseline in Daily Morning PEF Averaged Over the 8-week Treatment Period', 'description': 'PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is defined as the maximal rate (speed) that a person can exhale during a short maximal expiratory effort after a full inspiration. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. The best of three attempts was recorded by the participants in a daily diary. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily morning PEF over the 8-week treatment period minus the value at Baseline. The analysis was performed using an ANCOVA model with covariates of Baseline trough morning PEF, country, sex, age, and treatment group.', 'timeFrame': 'From Baseline up to Week 8'}, {'measure': 'Mean Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 8-week Treatment Period', 'description': ""Asthma symptoms were recorded in a daily dairy by the participants every day in the morning and evening before taking any rescue or study medication and before PEF measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered as symptom-free. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 8-week Treatment Period minus the value at Baseline. The analysis was performed using an ANCOVA model with covariates of Baseline, country, sex, age, and treatment group."", 'timeFrame': 'From Baseline up to Week 8'}, {'measure': 'Mean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 8-week Treatment Period', 'description': ""The number of inhalations of rescue albuterol/salbutamol inhalation aerosol used during the day and night was recorded by the participants in a daily diary. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue-free. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 8-week Treatment Period minus the value at Baseline. The analysis was performed using an ANCOVA model with covariates of Baseline, country, sex, age, and treatment group."", 'timeFrame': 'From Baseline up to Week 8'}, {'measure': 'Number Participants Who Withdrew Due to Lack of Efficacy During the 8-week Treatment Period', 'description': 'The number of participants whose primary reason for withdrawal was lack of efficacy was analyzed.', 'timeFrame': 'From the first dose of the study medication up to Week 8/Early Withdrawal'}, {'measure': 'Number of Participants With Any On-treatment Adverse Event or Serious Adverse Event Throughout the 8-week Treatment Period', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; or is a congenital anomaly/birth defect. Medical or scientific judgment should have been exercised in other situations. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \\>=3%) and SAEs.', 'timeFrame': 'From the first dose of the study medication up to Week 8/Early Withdrawal'}, {'measure': 'Number of Participants With Clinical/Visual Evidence of Oropharyngeal Candidiasis', 'description': 'A detailed oropharyngeal examination for visual evidence of oral candidiasis was performed.', 'timeFrame': 'From Baseline up to Week 8/Early Withdrawal'}, {'measure': 'Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils in the Blood at Baseline and Week 8', 'description': 'Blood samples were collected for the measurement of the percentage of basophils, eosinophils, lymphocytes, monocytes, and total neutrophils in the blood at Baseline (BL) and Week 8 (W8). The Baseline value was the measurement taken at screening (Visit 1).', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Hematocrit at Baseline and Week 8', 'description': 'Blood samples were collected for the measurement of hematocrit at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Hemoglobin at Baseline and Week 8', 'description': 'Blood samples were collected for the measurement of hemoglobin at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Platelet Count and White Blood Cell Count at Baseline and Week 8', 'description': 'Blood samples were collected for determining the platelet count and white blood cell (WBC) count at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Red Blood Cell Count at Baseline and Week 8', 'description': 'Blood samples were collected for determining the red blood cell count at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit1).', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Clinical Chemistry Parameters of Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH) at Baseline and Week 8', 'description': 'Blood samples were collected for the measurement of ALT, ALP, AST, GGT, and LDH at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Clinical Chemistry Parameters of Albumin and Total Protein at Baseline and Week 8', 'description': 'Blood samples were collected for the measurement of albumin and total protein at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Clinical Chemistry Parameters of Calcium, Carbon Dioxide Content/Bicarbonate, Chloride, Cholesterol, Glucose, Phosphorus Inorganic, Potassium, Sodium, and Urea at Baseline and Week 8', 'description': 'Blood samples were collected for the measurement of calcium, carbon dioxide content/bicarbonate (CO2/BI), chloride, cholesterol, glucose, phosphorus inorganic (PI), potassium, sodium, and urea at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Clinical Chemistry Parameters of Creatinine, Direct Bilirubin, Total Bilirubin, and Uric Acid at Baseline and Week 8', 'description': 'Blood samples were collected for the measurement of creatinine, direct bilirubin (DBIL), total bilirubin (TBIL), and uric acid at Baseline and Week 8. The Baseline value was the measurement taken at screening (Visit 1).', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Number of Participants With the Indicated Result for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 8/Withdrawal', 'description': 'Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cells (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner; results for urinalysis parameters can be read as 1+, 2+, 3+, Large, Moderate, Negative (Neg), Small, and Trace. For UG, the result can be read as Neg, Trace, Trace or 1/10 grams per deciliter (G/dL), 1+ or 1/4 G/dL, 2+ or 1/2 G/dL, 3+ or 1 G/dL, 4+ or 2 or more G/dL, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had 1+, 2+, 3+, Large, Moderate, Neg, Small, or Trace levels at Baseline (BL) and Week 8 (W8)/Early Withdrawal (EW). The Baseline value was the measurement taken at screening (Visit 1).', 'timeFrame': 'Baseline and Week 8/Early Withdrawal'}, {'measure': 'Urine Specific Gravity at Baseline and Week 8/Early Withdrawal', 'description': 'Urine samples were collected for the measurement of urine specific gravity by dipstick method at Baseline and at Week 8/Early Withdrawal. The Baseline value was the measurement taken at screening (Visit 1). Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance. Normal urine has a specific gravity between 1.010 and 1.020.', 'timeFrame': 'Baseline and Week 8/Early Withdrawal'}, {'measure': 'Urine pH at Baseline and Week 8/Early Withdrawal', 'description': 'Urine samples were collected for the measurement of urine pH by dipstick method at Baseline and at Week 8/Early Withdrawal. The Baseline value was the measurement taken at screening (Visit 1). Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).', 'timeFrame': 'Baseline and Week 8/Early Withdrawal'}, {'measure': '24-hour Urinary Cortisol Excretion at Baseline and Week 8', 'description': 'A 24-hour urine sample was collected for the measurement of 24-hour urinary cortisol excretion at the following scheduled time points: within 7 days prior to Study Visit 3 (Baseline; Week 0) and Study Visit 8 (Week 8). The Baseline value for 24-hour urinary cortisol was taken from Visit 3.', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 8', 'description': 'Change from Baseline was calculated as the Week 8 value minus the Baseline value.', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Change From Baseline in Heart Rate at Week 8', 'description': 'Change from Baseline was calculated as the Week 8 value minus the Baseline value.', 'timeFrame': 'Baseline and Week 8'}]",23,12 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,627.0,ACTUAL,2025-09-01T16:18:20.961745,v2_robust,True,True,True,False,True,
NCT06024746,A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF),"Combined Efficacy and Safety of an Early, Intensive, Management Strategy with Finerenone and SGLT2 Inhibitor in Patients Hospitalized with Heart Failure (CONFIRMATION-HF)",Finerenone,"['Empagliflozin', 'Finerenone']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Heart Failure,['Heart Failure'],"['Heart Failure', 'Hospitalized']",RECRUITING,,2024-07-09,2026-08,"[{'measure': 'Clinical benefit', 'description': 'Hierarchical composite of the following:\n\n* Time to all-cause mortality\n* Number of total HF events\n* Time to first HF event\n* Difference of 5 points or greater on the Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS) assessed by the win-ratio method', 'timeFrame': '6 months'}, {'measure': 'Number of serious adverse events (AEs).', 'description': '\\- Serious AEs (excluding efficacy endpoints).', 'timeFrame': '6 months'}, {'measure': 'Number of adverse events leading to discontinuation of study drug.', 'description': '\\- AEs leading to discontinuation of finerenone or empagliflozin.', 'timeFrame': '6 months'}]","[{'measure': 'Time to first death from any cause or HF event.', 'description': 'Time to first occurrence of all-cause mortality or HF event (hospitalization for HF or urgent visit due to HF)', 'timeFrame': '6 months'}, {'measure': 'Mean change from baseline to 6 months in the Total Symptom Score of the Kansas City Cardiomyopathy Questionnaire (KCCQ-TSS).', 'timeFrame': '6 months'}, {'measure': 'Number of HF events from baseline to Day 90.', 'description': '\\- Total (first and recurrent) HF events.', 'timeFrame': '90 days'}]",6,18 Years,,ALL,False,Colorado Prevention Center,OTHER,2,1500.0,ESTIMATED,2025-09-01T16:18:20.961807,v2_robust,True,True,False,False,True,
NCT06822946,Zhibitai Capsules for the Treatment of Primary Hyperlipidemia,"Zhibitai Capsules for the Treatment of Primary Hyperlipidemia (tan Yu Hu Jie, Qi Xue Bu Li Zheng) a Randomized, Double-blind, Parallel Controlled, Multicenter, Phase II Clinical Trial",zhibitai capsule,['zhibitai capsule'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Primary Hyperlipidemia,['Primary Hyperlipidemia'],"['zhibitai', 'primary hyperlipidemia']",NOT_YET_RECRUITING,,2025-02-14,2026-04-30,"[{'measure': 'The percentage and absolute changes in serum low-density lipoprotein cholesterol (LDL-C) from baseline after 4, 8, and 12 weeks of treatment', 'timeFrame': 'From enrollment to the end of treatment at 4, 8,12 weeks'}]","[{'measure': 'The proportion of ASCVD low-risk subjects with LDL-C < 3.4 mmol/L after 12 weeks of treatment', 'timeFrame': 'From enrollment to the end of treatment at 12 weeks'}, {'measure': 'The proportion of ASCVD medium- and high-risk subjects with LDL-C < 2.6 mmol/L after 12 weeks of treatment', 'timeFrame': 'From enrollment to the end of treatment at 12 weeks'}]",3,18 Years,75 Years,ALL,False,Chengdu Diao Jiuhong Pharmaceutical Factory,INDUSTRY,0,192.0,ESTIMATED,2025-09-01T16:18:20.961852,v2_robust,True,True,False,False,False,
NCT01136746,Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin,Randomized Clinical Trial of Subcutaneous Analog Basal Bolus Therapy Versus Sliding Scale Human Regular Insulin in the Hospital Management of Hyperglycemia in Non-Critically Ill Patients Without Known History of Diabetes: The HMH Trial,Human regular insulin,"['Humulin R', 'Human regular insulin', 'Insulin lispro', 'Lantus', 'LY275585', 'LY041001', 'Humalog', 'Insulin glargine']",8,INTERVENTIONAL,['PHASE3'],PHASE3,,Hyperglycemia,['Hyperglycemia'],"['Hyperglycemia', 'Diabetes', 'Hospital', 'Diabetic']",TERMINATED,Low enrollment,2011-03,2011-11,"[{'measure': 'Mean Plasma Glucose (MPG) Throughout Hospital Study Period', 'description': 'Overall MPG is derived as the mean of plasma glucose (PG) readings from Day/Visit 1 to Day/Visit 10.', 'timeFrame': 'Throughout hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period', 'description': 'Results are reported as the percentage of total number of capillary plasma glucose measurements within the range of 71 to 179 mg/dL for each treatment arm.', 'timeFrame': 'Throughout hospital study period (1 to 10 days post-randomization)'}]","[{'measure': 'Mean Plasma Glucose (MPG) by Hospital Day', 'description': 'The intent was to report results up to Day 10; however, due to low enrollment, mean and standard deviations are only reported up to Day 7.', 'timeFrame': 'Day 1 up to day 7 of hospital study period'}, {'measure': 'Percentage of Plasma Glucose Measurements Within Range 71 to 179 mg/dL by Hospital Day', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Day 1 up to day 10 of hospital study period'}, {'measure': 'Percentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL Throughout Hospital Study Period', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Percentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL by Hospital Day', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Day 1 up to day 10 of hospital study period'}, {'measure': 'Mean Fasting Plasma Glucose (FPG) by Hospital Day', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Day 1 up to day 10 of hospital study period'}, {'measure': 'Mean FPG Throughout Hospital Study Period', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Percentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL Throughout the Hospital Study Period', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout the hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Percentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL by Hospital Day', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Day 1 up to day 10 of hospital study period'}, {'measure': 'Percentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL Throughout the Hospital Study Period', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout the hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Percentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL by Hospital Day', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Day 1 up to day 10 of hospital study period'}, {'measure': 'Percentage of Capillary PG Measurements >240 mg/dL Throughout the Hospital Study Period', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout the hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Percentage of Capillary PG Measurements >240 mg/dL by Hospital Day', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Day 1 up to day 10 of hospital study period'}, {'measure': 'Total Daily Dose (TDD) of Insulin (Units) Throughout the Hospital Study Period', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout the hospital study period (1 to 10 days post-randomization)'}, {'measure': 'TDD of Insulin (Units/kg) Throughout the Hospital Study Period', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout the hospital study period (1 to 10 days post-randomization)'}, {'measure': 'TDD of Insulin (Units) by Hospital Day', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Day 1 up to day 10 of hospital study period'}, {'measure': 'TDD of Insulin (Units/kg) by Hospital Day', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Day 1 up to day 10 of hospital study period'}, {'measure': 'Length of Hospital Stay Post-randomization Throughout the Hospital Study Period', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout the hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, Throughout Hospital Study Period', 'description': 'Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \\<40 mg/dL (Umpierrez et al. 2007; Moghissi et al. 2009; Umpierrez et al. 2009), even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose.', 'timeFrame': 'Throughout hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Number of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), Throughout Hospital Study Period', 'description': 'Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \\<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, by Hospital Day', 'description': 'Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \\<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Day 1 up to day 10 of hospital study period'}, {'measure': 'Number of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), by Hospital Day', 'description': 'Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \\<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Day 1 up to day 10 of hospital study period'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events Throughout Hospital Study Period', 'description': 'Treatment-emergent adverse event - any untoward medical occurrence that either occurred or worsened at any time after treatment baseline and which did not necessarily have a causal relationship with this treatment. A summary of adverse events is located in the Reported Adverse Event Module.', 'timeFrame': 'Throughout hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Percentage of Participants Requiring Intensive Care Unit Transfer', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Percentage of Participants With Deterioration of Renal Function Throughout the Hospital Study Period', 'description': 'Deterioration of renal function was defined by an increase in serum creatinine by \\>0.5 milligrams per deciliter (mg/dL). Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Percentage of Participants With Documented Nosocomial Infections', 'description': 'Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout hospital study period (1 to 10 days post-randomization)'}, {'measure': 'Number of Participants With Major Adverse Cardiovascular Events (MACE)', 'description': 'MACE was defined as the composite of all-cause death, nonfatal myocardial infarction (MI), or nonfatal stroke. Due to low enrollment, this outcome measure was not analyzed.', 'timeFrame': 'Throughout hospital study period (1 to 10 days post-randomization)'}]",28,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:20.961866,v2_robust,True,True,False,True,True,Low enrollment
NCT00881946,Repeat Dose Safety Study for Compound to Treat Hematologic Cancer,"A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 in Subjects With Any Hematologic Malignancy",GSK21110183,['GSK21110183'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Hematologic Malignancies,['Hematologic Malignancies'],"['chronic lymphocytic leukemia', 'aggressive lymphoma', ""non-Hodgkin's lymphoma"", ""Hodgkin's lymphoma"", 'chronic myelogenous leukemia', 'multiple myeloma', 'acute lymphoblastic leukemia', 'acute myeloid leukemia']",COMPLETED,,2009-07,2012-03,"[{'measure': 'Physical exam', 'timeFrame': 'Screening, Days -3, 8, At the start of each additional Cycle'}, {'measure': 'Electrocardiogram (ECG)', 'timeFrame': 'Days -3, -2, -1, 8, 15, At the start of each additional Cycle'}, {'measure': 'Vital signs', 'timeFrame': 'Screening, Days -3, -2, -1, 8, 15, At the start of each additional Cycle'}, {'measure': 'Transthoracic Echocardiogram (TTE)/Multiple Gated Acquisition (MUGA) Scans', 'timeFrame': 'Screening, Additionally as needed'}, {'measure': 'Clinical Laboratory assessments', 'timeFrame': 'Screening, Days -3, 1, 8, 15, At the start of each additional Cycle'}, {'measure': 'ECOG Peformance Status', 'timeFrame': 'Screening, Days -3, 8, At the start of each additional Cycle'}, {'measure': 'PK - Maximum observed plasma concentraion (Cmax)', 'timeFrame': 'Days -3, -2, -1, 8, 15'}, {'measure': 'PK - time to Cmax [tmax] (Maximum observed plasma concentration)', 'timeFrame': 'Days -3, -2, -1, 8, 15'}, {'measure': 'PK - Area under the plasma concentration-time curve (AUC(0-t))', 'timeFrame': 'Days -3, -2, -1, 8, 15'}, {'measure': 'PK - Apparent terminal phase elimination rate constant', 'timeFrame': 'Days -3, -2, -1, 8, 15'}, {'measure': 'PK - Apparent terminal phase half-life (t1/2)', 'timeFrame': 'Days -3, -2, -1, 8, 15'}, {'measure': 'PK - oral clearance (CL/F)', 'timeFrame': 'Days -3, -2, -1, 8, 15'}]","[{'measure': 'Metabolite Profiling', 'timeFrame': 'Days -3, 8'}]",13,18 Years,,ALL,False,Accenture,INDUSTRY,0,73.0,ACTUAL,2025-09-01T16:18:20.962050,v2_robust,True,True,True,False,False,
NCT00004446,Study of Fluoxetine in Patients With Depersonalization Disorder,,fluoxetine,['fluoxetine'],1,INTERVENTIONAL,['NA'],,,Depersonalization Disorder,['Depersonalization Disorder'],"['depersonalization disorder', 'neurologic and psychiatric disorders', 'rare disease']",COMPLETED,,1998-04,,[],[],0,18 Years,65 Years,ALL,False,National Institute of Mental Health (NIMH),NIH,1,80.0,,2025-09-01T16:18:20.962071,v2_robust,True,True,True,False,False,
